10091617	0	(S1 (NP (NP (NP (JJ Doc_10091617_0_10_Chemical-induced) (NN Doc_10091617_19_39_Disease)) (PP (IN in) (NP (NNP Doc_10091617_43_62_Disease)))) (: :) (NP (NP (DT a) (JJ longitudinal) (NN study)) (PP (IN on) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug) (NN withdrawal)))))) (. .)))
10091617	1	(S1 (S (NP (DT The) (NNP United) (NNP Kingdom) (NNP Doc_10091617_151_170_Disease) (NNP Research) (NNP Group) (PRN (-LRB- -LRB-) (NP (NNP UKPDRG)) (-RRB- -RRB-)) (NN trial)) (VP (VBD found) (NP (NP (DT an) (VBN increased) (NN mortality)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (NNP Doc_10091617_247_266_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10091617_268_270_Disease)) (-RRB- -RRB-)) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (CD 10) (NNS mg)) (ADJP (JJ Doc_10091617_300_310_Chemical) (PP (IN per) (NP (NN day)))))))))) (CC and) (NP (NNP Doc_10091617_323_329_Chemical))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (VP (VBG taking) (NP (NP (NNP Doc_10091617_357_363_Chemical)) (ADVP (RB alone)))))))) (. .)))
10091617	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_10091617_408_418_Chemical)) (CC and) (NP (NNP Doc_10091617_423_429_Chemical))))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ selective) (NN Doc_10091617_460_492_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN abolished) (PP (IN by) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_10091617_530_540_Chemical)))))))))))))))) (. .)))
10091617	3	(S1 (S (NP (NP (DT This) (JJ unwanted) (NN effect)) (PP (IN on) (NP (JJ postural) (NN blood) (NN pressure)))) (VP (AUX was) (RB not) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (JJ underlying) (JJ autonomic) (NN failure))))) (. .)))
10091617	4	(S1 (S (NP (NP (DT The) (NNS aims)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX were) (S (VP (VP (TO to) (VP (VB confirm) (NP (NP (PRP$ our) (JJ previous) (NNS findings)) (PP (IN in) (NP (NP (DT a) (JJ separate) (NN cohort)) (PP (IN of) (NP (NNS patients)))))))) (CC and) (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN time) (NN course)) (PP (IN of) (NP (NP (DT the) (JJ cardiovascular) (NNS consequences)) (PP (IN of) (S (VP (VBG stopping) (NP (NNP Doc_10091617_816_826_Chemical)) (PP (IN in) (NP (DT the) (NN expectation) (SBAR (IN that) (S (NP (DT this)) (VP (MD might) (VP (VB shed) (NP (NN light)) (PP (IN on) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (DT the) (NN drug)) (VP (VBZ causes) (NP (NN Doc_10091617_916_939_Disease)))))))))))))))))))))))) (. .)))
10091617	5	(S1 (S (NP (NP (DT The) (JJ cardiovascular) (NNS responses)) (PP (TO to) (NP (NP (NN standing)) (CC and) (NP (NN head-up) (NN tilt))))) (VP (AUX were) (VP (VBN studied) (ADVP (RB repeatedly)) (UCP (PP (IN in) (NP (NP (JJ Doc_10091617_1035_1037_Disease) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_10091617_1057_1067_Chemical))))) (CC and) (SBAR (IN as) (S (NP (DT the) (NN drug)) (VP (AUX was) (VP (VBN withdrawn)))))))) (. .)))
10091617	6	(S1 (S (NP (JJ Head-up) (NN tilt)) (VP (VBD caused) (NP (NP (NN Doc_10091617_1128_1160_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN marked) (PP (IN in) (NP (NP (QP (CD six) (IN of) (CD 20)) (JJ Doc_10091617_1191_1193_Disease) (NNS patients)) (PP (IN on) (NP (NNP Doc_10091617_1206_1216_Chemical))) (, ,) (SBAR (WHNP (CD one) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (VBD lost) (NP (NN consciousness)) (PP (IN with) (NP (JJ unrecordable) (NN blood) (NNS pressures)))))))))))))) (. .)))
10091617	7	(S1 (S (NP (NP (DT A) (JJR lesser) (NN degree)) (PP (IN of) (NP (NNP Doc_10091617_1303_1326_Disease)))) (VP (VBD occurred) (PP (IN with) (NP (NN standing)))) (. .)))
10091617	8	(S1 (S (NP (NN Doc_10091617_1351_1374_Disease)) (VP (AUX was) (VP (VP (VBN ameliorated) (NP (CD 4) (NNS days)) (PP (IN after) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_10091617_1418_1428_Chemical)))))) (CC and) (VP (ADVP (RB totally)) (VBN abolished) (PP (NP (CD 7) (NNS days)) (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))))) (. .)))
10091617	9	(S1 (S (NP (NN Stopping) (NN Doc_10091617_1502_1512_Chemical)) (ADVP (RB also)) (ADVP (RB significantly)) (VP (VBP Doc_10091617_1532_1589_Disease) (NP (ADJP (JJ consistent) (PP (IN with) (NP (DT a) (ADJP (RB previously) (VBN undescribed)) (NN supine) (NN pressor)))) (NN action))) (. .)))
10091617	10	(S1 (S (NP (DT This) (NN study)) (VP (VBZ confirms) (NP (NP (PRP$ our) (JJ previous) (NN finding)) (SBAR (WHNP (IN that)) (S (NP (NP (NNP Doc_10091617_1712_1722_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_10091617_1743_1749_Chemical)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJ selective) (NN Doc_10091617_1779_1802_Disease))))))))) (. .)))
10091617	11	(S1 (S (NP (NP (DT The) (NNS possibilities)) (SBAR (WHNP (IN that)) (S (NP (DT these) (JJ cardiovascular) (NNS findings)) (VP (MD might) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (PP (IN of) (NP (NP (JJ non-selective) (NN inhibition)) (PP (IN of) (NP (JJ monoamine) (NN oxidase))))) (CC or) (PP (IN of) (NP (NP (NNP Doc_10091617_1932_1943_Chemical)) (CC and) (NP (NNP Doc_10091617_1948_1962_Chemical))))))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
1009330	0	(S1 (NP (NP (JJ Further) (NNS studies)) (PP (IN on) (NP (NP (NNS effects)) (PP (IN of) (NP (NN irrigation) (NNS solutions))) (PP (IN on) (NP (NN rat) (NNS bladders))))) (. .)))
1009330	1	(S1 (S (NP (NP (JJ Further) (NNS studies)) (PP (IN on) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ certain) (NN irrigating) (NNS fluids))))) (PP (IN on) (NP (DT the) (NN rat) (NN bladder))) (PP (IN for) (NP (CD 18) (NNS hours)))) (VP (AUX are) (VP (VBN reported))) (. .)))
1009330	2	(S1 (S (NP (DT The) (NNS results)) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (DT the) (NN degradation) (NN product) (NN Doc_1009330_226_242_Chemical)) (VP (AUX is) (RB not) (NP (NP (DT a) (JJ significant) (NN factor)) (PP (IN in) (NP (JJ Doc_1009330_274_299_Chemical) (JJ associated) (NN erosive) (NNP Doc_1009330_319_327_Disease))))))))) (. .)))
1009330	3	(S1 (S (NP (NP (DT A) (JJ high) (NN percentage)) (PP (IN of) (NP (JJ Doc_1009330_350_359_Chemical-Doc_1009330_360_368_Chemical) (CC and) (JJ Doc_1009330_373_388_Chemical) (NNS irrigations)))) (VP (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (JJ erosive) (NN Doc_1009330_430_438_Disease))))) (CC and) (VP (VBD suggested) (NP (NP (DT a) (JJ possible) (NN complication)) (PP (IN with) (NP (JJ human) (NN usage)))))) (. .)))
1009330	4	(S1 (S (S (NP (NN Doc_1009330_495_506_Chemical) (NNS irrigations)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN of) (NP (JJ erosive) (NN Doc_1009330_565_573_Disease))))))))) (CC but) (S (NP (JJ further) (NNS studies)) (VP (MD would) (VP (AUX have) (S (VP (TO to) (VP (AUX be) (VP (VBN performed) (SBAR (IN before) (S (NP (PRP it)) (VP (MD could) (VP (AUX be) (VP (VBN recommended) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (JJ urological) (NNS procedures))))))))))))))))) (. .)))
10193204	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (NNP Doc_10193204_11_22_Chemical)) (CC and) (NP (NNP Doc_10193204_27_40_Chemical)))) (PP (IN on) (NP (NP (JJ experimental) (NNP Doc_10193204_57_67_Disease)) (PP (IN in) (NP (NP (NNS mice)) (CC and) (NP (JJ human) (NN Doc_10193204_86_106_Disease)))))) (. .)))
10193204	1	(S1 (S (NP (NP (NP (NNP Doc_10193204_108_119_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193204_121_124_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_10193204_130_143_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193204_145_148_Chemical)) (-RRB- -RRB-)))) (VP (AUX are) (NP (NP (CD two) (ADJP (RB naturally) (VBG occurring)) (NNS analogues)) (PP (IN with) (NP (DT a) (JJ Doc_10193204_195_216_Chemical) (NN structure))))) (. .)))
10193204	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_10193204_291_294_Chemical) (CC and) (NNP Doc_10193204_299_302_Chemical))) (PP (IN on) (NP (NP (NP (DT the) (JJ experimental) (NNP Doc_10193204_323_333_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NN collagen)) (CC plus) (NP (NP (NNP Doc_10193204_359_370_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193204_372_374_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (NNS mice))))) (, ,) (CC and) (NP (NP (NNP Doc_10193204_389_409_Disease) (CC and) (NNP Doc_10193204_414_431_Disease)) (PP (IN in) (NP (NN vitro)))))))))))) (. .)))
10193204	3	(S1 (S (PP (IN In) (NP (NP (DT the)) (PP (IN in) (NP (NN vivo) (NN study))))) (, ,) (NP (NP (DT the) (NN administration)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (, ,) (NP (CD i.p.)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_10193204_503_506_Chemical) (CC and) (NNP Doc_10193204_511_514_Chemical)) (PP (IN in) (NP (NNS mice)))))) (VP (VBD showed) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NNP Doc_10193204_548_558_Disease)))) (PP (IN by) (NP (NP (CD 55) (NN %)) (CC and) (NP (CD 35) (NN %)))) (, ,) (ADVP (RB respectively)) (, ,) (SBAR (IN while) (S (NP (NP (NNP Doc_10193204_595_615_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10193204_617_620_Chemical)) (, ,) (NP (CD 50) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-)) (, ,) (NP (DT a) (JJ positive) (NN control)) (, ,)) (VP (VBD showed) (NP (QP (RB only) (CD 30)) (NN %) (NN inhibition)))))) (. .)))
10193204	4	(S1 (S (PP (IN In) (NP (NP (DT the) (NN vitro) (NN human) (NN Doc_10193204_706_727_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NNS agonists)) (VP (VBN used) (PP (IN in) (NP (NNS tests))))))))) (, ,) (NP (NP (NNP Doc_10193204_767_770_Chemical)) (CC and) (NP (NNP Doc_10193204_775_778_Chemical))) (VP (VBD showed) (NP (DT the) (NNS inhibitions) (NN dose)) (ADVP (RB dependently))) (. .)))
10193204	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT neither) (NNP Doc_10193204_841_844_Chemical) (CC nor) (NNP Doc_10193204_849_852_Chemical)) (VP (VBD showed) (NP (DT any) (JJ anticoagulation) (NNS activities)) (PP (IN in) (NP (NP (DT the) (NN measurement)) (PP (IN of) (S (NP (NP (DT the) (VBN activated) (JJ partial) (NN thromboplastin) (NN time)) (PRN (-LRB- -LRB-) (NP (NNP APTT)) (-RRB- -RRB-)) (, ,) (NP (NP (NN prothrombin) (NN time)) (PRN (-LRB- -LRB-) (NP (NNP PT)) (-RRB- -RRB-)) (CC and) (NP (NN thrombin) (NN time))) (PRN (-LRB- -LRB-) (NP (NNP TT)) (-RRB- -RRB-))) (VP (VBG using) (NP (JJ human-citrated) (NN plasma)))))))) (. .)))
10193204	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN antithrombosis)) (PP (IN of) (NP (NP (NNP Doc_10193204_1082_1085_Chemical)) (CC and) (NP (NNP Doc_10193204_1090_1093_Chemical)))) (PP (IN in) (NP (NNS mice)))) (VP (MD may) (VP (AUX be) (ADJP (RB mainly) (JJ related) (PP (TO to) (NP (DT the) (JJ antiplatelet) (NN aggregation) (NNS activities))))))))) (. .)))
10342929	0	(S1 (FRAG (NP (NP (NN Doc_10342929_0_10_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_10342929_18_32_Chemical))))) (: :) (S (UCP (ADJP (JJ common)) (CC and) (VP (ADVP (RB inadequately)) (VBN diagnosed)))) (. .)))
10342929	1	(S1 (S (NP (NP (DT The) (VBN estimated) (NN incidence)) (PP (IN of) (NP (NNP Doc_10342929_96_106_Disease))) (PP (IN during) (NP (JJ Doc_10342929_114_159_Chemical) (NN treatment)))) (VP (AUX is) (PP (IN between) (NP (CD 1) (CC and) (CD 7))) (PP (IN per) (NP (CD thousand) (NNS patients)))) (. .)))
10342929	2	(S1 (S (NP (DT This) (ADJP (RB potentially) (JJ serious)) (JJ adverse) (NN effect)) (VP (AUX is) (ADVP (RB often)) (VP (VBN preceded) (PP (IN by) (NP (NP (JJ minor) (NNS manifestations)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB serve) (PP (IN as) (NP (DT a) (NN warning))))))))))) (. .)))
10365197	0	(S1 (NP (NP (JJ Doc_10365197_0_7_Chemical-induced) (NNP Doc_10365197_16_29_Disease)) (: :) (NP (NP (NP (JJ prevalence) (NNS rates)) (CC and) (NP (JJ Doc_10365197_52_63_Disease) (NNS symptoms))) (PP (IN in) (NP (DT an) (NN outpatient) (JJ Doc_10365197_90_97_Chemical-dependent) (NN sample)))) (. .)))
10365197	1	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ attempts) (S (VP (TO to) (VP (VP (VB examine)) (CC and) (VP (VB compare) (SBAR (S (NP (NP (NN prevalence) (NNS rates)) (CC and) (NP (NP (NN symptom) (NNS patterns)) (PP (IN of) (NP (NP (NNP DSM) (JJ substance-induced) (CC and) (JJ other) (NNP Doc_10365197_232_246_Disease.) (CD 243) (JJ Doc_10365197_252_259_Chemical-dependent) (NNS outpatients)) (PP (IN with) (NP (NP (NP (NNP Doc_10365197_287_294_Chemical-induced) (NNP Doc_10365197_303_316_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10365197_318_322_Disease)) (-RRB- -RRB-))) (, ,) (NP (JJ other) (NNP Doc_10365197_331_345_Disease)) (, ,) (CC or) (NP (DT no) (NNP Doc_10365197_353_366_Disease)))))))) (VP (AUX were) (VP (VBN compared) (PP (IN on) (NP (NP (NNS measures)) (PP (IN of) (NP (NNP Doc_10365197_396_407_Disease) (NNS symptoms)))))))))))))) (. .)))
10365197	2	(S1 (S (NP (NP (DT The) (NN prevalence) (NN rate)) (PP (IN for) (NP (NNP Doc_10365197_442_446_Disease)))) (VP (AUX was) (NP (CD 12) (NN %)) (PP (IN at) (NP (NN baseline)))) (. .)))
10365197	3	(S1 (S (NP (NP (NN Introduction)) (PP (IN of) (NP (NP (DT the) (JJ DSM-IV) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10365197_508_512_Disease)))))) (VP (AUX did) (RB not) (VP (ADVP (RB substantially)) (VB affect) (NP (NP (NNS rates)) (PP (IN of) (NP (DT the) (JJ other) (NN Doc_10365197_561_581_Disease)))))) (. .)))
10365197	4	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_10365197_597_601_Disease)))) (VP (AUX had) (NP (NP (NN symptom) (NN severity) (NNS levels)) (PP (IN between) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNS patients)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (DT a) (NN Doc_10365197_675_688_Disease)))))))))) (. .)))
10365197	5	(S1 (S (NP (DT These) (NNS findings)) (VP (VP (VBP suggest) (NP (NP (DT some) (NN validity)) (PP (IN for) (NP (NP (DT the) (JJ new) (JJ DSM-IV) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10365197_759_763_Disease))))))) (, ,) (CONJP (CC but) (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (PRP it)) (VP (VBZ requires) (NP (NP (JJ further) (NN specification)) (CC and) (NP (NN replication)))))))) (. .)))
10406016	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ Doc_10406016_10_18_Chemical) (NN treatment))) (PP (IN on) (NP (NP (JJ collagenase-induced) (NN Doc_10406016_52_76_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
10406016	1	(S1 (S (NP (JJ Inflammatory) (NNS cells)) (VP (AUX are) (VP (VBN postulated) (S (VP (TO to) (VP (VB mediate) (NP (NP (DT some)) (PP (IN of) (NP (DT the) (JJ Doc_10406016_143_155_Disease) (JJ following) (NN Doc_10406016_166_181_Disease))))))))) (. .)))
10406016	2	(S1 (S (NP (NN Doc_10406016_183_207_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (RBR more)) (NP (NNP Doc_10406016_232_244_Disease))) (PP (IN than) (NP (NNP Doc_10406016_250_265_Disease))))))) (. .)))
10406016	3	(S1 (S (NP (PRP We)) (VP (VBD tested) (NP (NP (DT the) (JJ sulfated) (NN polysaccharide) (NN Doc_10406016_305_313_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (JJ inflammatory) (NNP Doc_10406016_362_374_Disease))))) (, ,) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_10406016_394_418_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (NN injection)) (PP (IN of) (NP (JJ bacterial) (NN collagenase))) (PP (IN into) (NP (DT the) (JJ caudate) (NN nucleus))))))))))))))) (. .)))
10406016	4	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (CD seven) (NN day) (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NNP Doc_10406016_548_556_Chemical))) (PRN (-LRB- -LRB-) (ADJP (NP (CD 30) (NNS micrograms)) (JJ h-1)) (-RRB- -RRB-))) (CC or) (NP (NN vehicle)))))) (. .)))
10406016	5	(S1 (S (NP (DT The) (NNP Doc_10406016_593_601_Disease)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NN vivo))) (PP (IN by) (NP (JJ magnetic) (NN resonance) (NN imaging))))) (. .)))
10406016	6	(S1 (S (NP (NP (NN Motor) (NN behavior)) (, ,) (NP (NN passive) (NN avoidance)) (, ,) (CC and) (NP (JJ skilled) (NN forelimb) (NN function))) (VP (AUX were) (VP (VBN tested) (ADVP (RB repeatedly)) (PP (IN for) (NP (CD six) (NNS weeks))))) (. .)))
10406016	7	(S1 (S (NP (JJ Doc_10406016_757_765_Chemical-treated) (NNS rats)) (VP (VP (VBD exhibited) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NNP Doc_10406016_801_824_Disease)) (CC and) (NP (NNP Doc_10406016_829_841_Disease)))))) (, ,) (VP (AUX had) (NP (JJR larger) (NN Doc_10406016_854_863_Disease))) (, ,) (CC and) (VP (VBD tended) (S (VP (TO to) (VP (AUX have) (ADJP (RBR less) (JJ Doc_10406016_889_901_Disease)) (PP (IN in) (NP (NP (DT the) (NN vicinity)) (PP (IN of) (NP (DT the) (NNP Doc_10406016_925_933_Disease))))) (PP (IN after) (NP (CD three) (NNS days)))))))) (. .)))
10406016	8	(S1 (S (NP (PRP They)) (VP (VBD showed) (NP (NP (NP (ADJP (RB significantly) (JJR more)) (JJ rapid) (NN improvement)) (PP (IN of) (NP (NN motor) (NN function))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN week)) (VP (VBG following) (NP (NNP Doc_10406016_1047_1057_Disease)))))) (CC and) (NP (JJR better) (NN memory) (NN retention))) (PP (IN in) (NP (DT the) (JJ passive) (NN avoidance) (NN test)))) (. .)))
10406016	9	(S1 (S (NP (NP (NP (JJ Acute) (NN Doc_10406016_1123_1141_Disease)) (CC and) (NP (JJ eventual) (NN Doc_10406016_1155_1168_Disease))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (ADJP (JJ adjacent) (PP (TO to) (NP (DT the) (NNP Doc_10406016_1201_1209_Disease))))))) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
10406016	10	(S1 (S (NP (NP (NN Investigation)) (PP (IN of) (NP (NP (JJR more) (JJ specific) (NN anti-inflammatory) (NNS agents)) (CC and) (NP (VBG hemodiluting) (NNS agents))))) (VP (AUX are) (VP (VBN warranted) (PP (IN in) (NP (NNP Doc_10406016_1346_1370_Disease))))) (. .)))
10457883	0	(S1 (NP (NP (NN Recurarization)) (PP (IN in) (NP (DT the) (NN recovery) (NN room))) (. .)))
10457883	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NN recurarization))) (PP (IN in) (NP (DT the) (NN recovery) (NN room)))) (VP (AUX is) (VP (VBN reported))) (. .)))
10457883	2	(S1 (S (NP (NP (NN Accumulation)) (PP (IN of) (NP (NNP Doc_10457883_112_122_Chemical))) (PP (IN in) (NP (DT the) (JJ intravenous) (NN line)))) (VP (VBD led) (PP (TO to) (NP (NN recurarization))) (PP (IN after) (S (VP (VBG flushing) (NP (NP (DT the) (NN line)) (PP (IN in) (NP (DT the) (NN recovery) (NN room)))))))) (. .)))
10457883	3	(S1 (S (NP (NP (DT A) (NN Doc_10457883_217_235_Disease)) (PP (IN with) (NP (NP (JJ severe) (NNP Doc_10457883_248_260_Disease)) (CC and) (NP (NNP Doc_10457883_265_276_Disease))))) (VP (VBD occurred)) (. .)))
10457883	4	(S1 (S (NP (NP (NP (NP (NNS Circumstances)) (VP (VBG leading) (PP (TO to) (NP (DT this) (NN event))))) (CC and) (NP (NP (DT the) (NNS mechanisms)) (VP (VBG enabling) (NP (NP (DT a) (NN Doc_10457883_353_375_Disease)) (SBAR (S (VP (TO to) (VP (VB occur))))))))) (, ,) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ small) (NN dose)) (PP (IN of) (NP (NN relaxant))))))) (, ,)) (VP (AUX are) (VP (VBN discussed))) (. .)))
10520387	0	(S1 (NP (NP (DT The) (JJ haemodynamic) (NNS effects)) (PP (IN of) (NP (NNP Doc_10520387_28_36_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NNP Doc_10520387_57_66_Chemical)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP ASA) (NNS groups) (QP (CD 3) (CC and) (CD 4))) (-RRB- -RRB-)))))))) (. .)))
10520387	1	(S1 (S (NP (NP (DT The) (VBN marked) (ADJP (JJ vasodilator) (CC and) (JJ negative)) (JJ inotropic) (NNS effects)) (PP (IN of) (NP (NNP Doc_10520387_166_174_Chemical)))) (VP (AUX are) (NP (NP (NNS disadvantages)) (PP (IN in) (NP (JJ frail) (JJ elderly) (NNS patients))))) (. .)))
10520387	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (S (VP (VBG adding) (NP (NP (JJ different) (NNS doses)) (PP (IN of) (NP (NNP Doc_10520387_289_298_Chemical)))) (PP (TO to) (NP (NNP Doc_10520387_302_310_Chemical))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB obtund) (NP (DT the) (JJ Doc_10520387_334_345_Disease) (NN response))))))))))) (. .)))
10520387	3	(S1 (S (NP (NP (DT The) (JJ haemodynamic) (NNS effects)) (PP (IN of) (S (VP (VBG adding) (NP (NP (CD 15) (, ,) (CD 20) (CC or) (CD 25) (NNS mg)) (PP (IN of) (NP (NNP Doc_10520387_410_419_Chemical)))) (PP (TO to) (NP (NP (QP (CD 200) (CD mg))) (PP (IN of) (NP (NNP Doc_10520387_433_441_Chemical))))))))) (VP (AUX were) (VP (VBN compared) (S (VP (TO to) (VP (VB control) (PP (IN in) (NP (NP (CD 40) (NNP ASA) (CD 3/4) (NNS patients)) (PP (IN over) (NP (NP (CD 60) (NNS years)) (VP (VBG presenting) (PP (IN for) (NP (JJ genito-urinary) (NN surgery))))))))))))) (. .)))
10520387	4	(S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NNP Doc_10520387_559_568_Chemical))) (PP (TO to) (NP (NNP Doc_10520387_572_580_Chemical)))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ effective) (NN method)) (PP (IN of) (S (VP (VBG obtunding) (NP (NP (DT the) (JJ Doc_10520387_632_643_Disease) (NN response)) (PP (TO to) (NP (NNP Doc_10520387_656_664_Chemical)))) (PP (IN at) (NP (NP (DT all) (NNS doses)) (VP (VBN used) (PP (IN in) (NP (DT this) (NN study)))))))))))))) (. .)))
10520387	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ marked) (NN Doc_10520387_714_725_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_10520387_753_762_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_10520387_783_791_Chemical))))))))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NNS patients))))) (, ,) (S (ADVP (RB occasionally)) (VP (VBG reaching) (NP (JJ high) (NNS levels)) (PP (IN in) (NP (JJ individual) (NNS patients)))))) (. .)))
10520387	6	(S1 (S (PP (JJ Due) (TO to) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (DT this) (NNP Doc_10520387_912_923_Disease) (VBG inducing) (NN Doc_10520387_933_952_Disease))))) (, ,) (NP (PRP we)) (VP (MD would) (RB not) (VP (VB recommend) (NP (NP (DT the) (NN use)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNS Doc_10520387_1019_1028_Chemical/Doc_10520387_1029_1037_Chemical/mixtures)) (VP (VBN studied))))))))))) (. .)))
10526274	0	(S1 (S (NP (NP (NNP Doc_10526274_0_11_Chemical) (CC plus) (NNP Doc_10526274_17_28_Chemical)) (PP (IN in) (NP (NNP Doc_10526274_32_60_Disease) (NNS patients)))) (VP (VBP age) (NP (NP (CD 70) (NNS years) (QP (CC or) (JJR older))) (CC or) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (ADVP (RB cannot)) (VP (VBP receive) (NP (NNP Doc_10526274_123_132_Chemical)))))))) (. .)))
10526274	1	(S1 (NP (NNP Oncopaz) (NNP Cooperative) (NNP Group) (. .)))
10526274	2	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (NNP Doc_10526274_200_228_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10526274_230_235_Disease)) (-RRB- -RRB-))))) (VP (AUX is) (ADJP (JJ high)) (PP (IN among) (NP (JJ elderly) (NNS patients)))))) (, ,) (NP (JJ few) (NNS data)) (VP (AUX are) (ADJP (JJ available)) (PP (VBG regarding) (NP (NP (DT the) (NN efficacy) (CC and) (NN Doc_10526274_319_327_Disease)) (PP (IN of) (NP (NN chemotherapy))) (PP (IN in) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NNS patients)))))))) (. .)))
10526274	3	(S1 (S (NP (JJ Recent) (NNS reports)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ single) (NN agent) (NN therapy)) (PP (IN with) (NP (NP (NP (NNP Doc_10526274_426_437_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10526274_439_442_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_10526274_447_458_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10526274_460_463_Chemical)) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB obtain) (NP (NP (DT a) (NN response) (NN rate)) (PP (IN of) (NP (CD 20-30) (NN %)))) (PP (IN in) (NP (JJ elderly) (NNS patients))) (, ,) (PP (IN with) (NP (NP (NP (JJ acceptable) (NN Doc_10526274_539_547_Disease) (CC and) (NN improvement)) (PP (IN in) (NP (NNS symptoms)))) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))))))))))) (. .)))
10526274	4	(S1 (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (NP (NP (DT the) (NN efficacy) (CC and) (NN Doc_10526274_635_643_Disease)) (PP (IN of) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_10526274_666_669_Chemical)) (CC and) (NP (NNP Doc_10526274_674_677_Chemical)))))) (PP (IN in) (NP (NP (NP (JJ elderly) (NNS patients)) (PP (IN with) (NP (JJ advanced) (NNP Doc_10526274_712_717_Disease)))) (CC or) (NP (NP (DT those)) (PP (IN with) (NP (NP (DT some) (NN contraindication)) (PP (TO to) (S (VP (VBG receiving) (NP (NNP Doc_10526274_767_776_Chemical))))))))))) (VP (AUX were) (VP (VBN assessed))) (. .)))
10526274	5	(S1 (S (S (NP (NP (JJ Forty-nine) (NNS patients)) (PP (IN with) (NP (JJ advanced) (NNP Doc_10526274_835_840_Disease)))) (VP (AUX were) (VP (VBN included) (, ,) (SBAR (WHNP (CD 38) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX were) (NP (NN age)) (PP (IN >/=) (NP (CD 70) (NNS years))))))))) (CC and) (S (NP (CD 11)) (VP (AUX were) (UCP (NP (NP (NN age) (CD <)) (NP (CD 70) (NNS years))) (CC but) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT some) (NN contraindication)) (PP (TO to) (S (VP (VBG receiving) (NP (NNP Doc_10526274_963_972_Chemical)))))))))))) (. .)))
10526274	6	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (ADJP (JJ evaluable) (PP (IN for) (NP (NP (NN response)) (CC and) (NP (NN Doc_10526274_1019_1027_Disease)))))) (. .)))
10526274	7	(S1 (S (NP (NN Treatment)) (VP (AUX was) (VP (VBN comprised) (PP (IN of) (NP (NP (NP (NNP Doc_10526274_1056_1059_Chemical)) (, ,) (NP (NP (CD 25) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (, ,) (CC plus) (NP (NNP Doc_10526274_1078_1081_Chemical))) (, ,) (NP (NP (CD 1000) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (, ,) (NP (NP (DT both)) (PP (IN on) (NP (NNPS Days) (CD 1) (, ,) (CD 8)))) (, ,)) (CC and) (NP (NP (CD 15)) (NP (DT every) (CD 28) (NNS days))))))) (. .)))
10526274	8	(S1 (S (NP (NNS Patients)) (VP (VBD received) (NP (NP (DT a) (NN minimum)) (PP (IN of) (NP (CD three) (NNS courses)))) (SBAR (IN unless) (S (NP (JJ progressive) (NN disease)) (VP (AUX was) (VP (VBN detected)))))) (. .)))
10526274	9	(S1 (S (NP (QP (CD One) (CD hundred)) (JJ sixty-five) (NNS courses)) (VP (AUX were) (VP (VBN administered) (, ,) (PP (IN with) (NP (NP (DT a) (NN median)) (PP (IN of) (S (VP (VBG 3.) (NP (NP (CD 6) (NNS courses)) (PP (IN per) (NP (NN patient))))))))))) (. .)))
10526274	10	(S1 (S (NP (DT The) (JJ overall) (NN response) (NN rate)) (VP (AUX was) (NP (NP (CD 26) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %) (NN confidence) (NN interval)) (, ,) (NP (CD 15-41) (NN %))) (-RRB- -RRB-)))) (. .)))
10526274	11	(S1 (S (NP (NP (NP (NP (CD Two) (NNS patients)) (VP (VBN attained) (NP (DT a) (JJ complete) (NN response)))) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 11) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-)))) (VP (VBD achieved) (NP (DT a) (JJ partial) (NN response))) (. .)))
10526274	12	(S1 (S (NP (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group) (NN performance) (NN status)) (VP (VBD improved) (PP (IN in) (NP (NP (CD 35) (NN %)) (PP (IN of) (NP (NP (DT those) (NNS patients)) (PP (IN with) (NP (NP (DT an) (JJ initial) (NN value)) (VP (VBD >) (NP (CD 0))))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN relief)) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD 1)) (NN symptom)) (PP (IN without) (NP (NP (VBG worsening)) (PP (IN of) (NP (JJ other) (NNS symptoms)))))))) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (CD 27) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 55) (NN %)) (-RRB- -RRB-))))))))) (. .)))
10526274	13	(S1 (S (S (NP (NP (DT The) (JJ median) (NN time)) (PP (TO to) (NP (NN progression)))) (VP (AUX was) (NP (CD 16) (NNS weeks)))) (CC and) (S (NP (DT the) (JJ 1-year) (NN survival) (NN rate)) (VP (AUX was) (NP (CD 33) (NN %)))) (. .)))
10526274	14	(S1 (S (NP (NN Doc_10526274_1795_1803_Disease)) (VP (AUX was) (ADJP (JJ mild))) (. .)))
10526274	15	(S1 (S (S (NP (NP (CD Six) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP World) (NNP Health) (NNP Organization) (NNP Grade) (NN 3-4) (NNP Doc_10526274_1873_1884_Disease)))) (, ,) (S (NP (NP (CD 2) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Grade) (NN 3-4) (NNP Doc_10526274_1916_1932_Disease)))) (, ,) (CC and) (S (NP (NP (CD 2) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Grade) (CD 3)) (NP (NNP Doc_10526274_1966_1979_Disease)))) (. .)))
10526274	16	(S1 (S (NP (NP (CD Three) (NNS patients)) (PP (IN with) (NP (JJ severe) (NNP Doc_10526274_2008_2019_Disease))) (PRN (-LRB- -LRB-) (NP (CD 6) (NN %)) (-RRB- -RRB-))) (VP (VBD died) (PP (IN of) (NP (NNP Doc_10526274_2033_2039_Disease)))) (. .)))
10526274	17	(S1 (S (NP (NP (DT The) (JJ median) (NN age)) (PP (IN of) (NP (NP (DT those) (NNS patients)) (VP (VBG developing) (NP (NNP Grade) (NN 3-4) (NNP Doc_10526274_2095_2106_Disease)))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (VBG remaining) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 75) (NNS years)) (CC vs.) (NP (CD 72) (NNS years))) (: ;) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.047)))) (-RRB- -RRB-)))))))) (. .)))
10526274	18	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_10526274_2236_2239_Chemical)) (CC and) (NP (NNP Doc_10526274_2244_2247_Chemical))))) (VP (AUX is) (ADJP (ADJP (RB moderately) (JJ active)) (CC and) (ADJP (RB well) (JJ tolerated))) (PP (IN except) (PP (IN in) (NP (NP (NNS patients)) (SBAR (S (NP (NN age)) (VP (VBZ >/=) (NP (CD 75) (NNS years))))))))) (. .)))
10526274	19	(S1 (S (NP (DT This) (NN age) (NN group)) (VP (AUX had) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_10526274_2365_2381_Disease))))) (. .)))
10526274	20	(S1 (S (ADVP (RB Therefore)) (NP (NP (DT the) (JJ prophylactic) (NN use)) (PP (IN of) (NP (JJ granulocyte-colony) (JJ stimulating) (NN factor)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN with) (NP (DT this) (NN treatment)))))) (. .)))
10526274	21	(S1 (S (NP (NP (JJ New) (JJ chemotherapy) (NNS combinations)) (PP (IN with) (NP (NP (JJR higher) (NN activity)) (CC and) (NP (JJR lower) (NN Doc_10526274_2558_2566_Disease))))) (VP (AUX are) (VP (VBN needed) (PP (IN for) (NP (NP (JJ elderly) (NNS patients)) (PP (IN with) (NP (JJ advanced) (NN Doc_10526274_2613_2618_Disease))))))) (. .)))
10579464	0	(S1 (NP (NP (NP (DT A) (JJ selective) (NNP Doc_10579464_12_20_Chemical) (NNP D4) (NN receptor) (NN antagonist)) (, ,) (NP (NNP Doc_10579464_45_52_Chemical))) (: :) (NP (DT a) (JJ preclinical) (NN neuropharmacological) (NN profile)) (. .)))
10579464	1	(S1 (S (NP (NP (NNP Doc_10579464_98_105_Chemical)) (, ,) (NP (NNP Doc_10579464_107_212_Chemical)) (, ,)) (VP (AUX has) (NP (NP (DT a) (JJ high) (NN affinity)) (PP (IN for) (NP (JJ human) (VBN cloned) (JJ Doc_10579464_251_259_Chemical) (CD D4.2) (, ,) (CD D4.4) (CC and) (CD D4.7) (NNS receptors)))) (, ,) (PP (IN with) (NP (NP (JJ Ki) (NNS values)) (PP (IN of) (NP (NP (CD 0.5)) (, ,) (NP (CD 0.9)) (CC and) (NP (CD 2.7) (NN nM)) (, ,) (ADVP (RB respectively))))))) (. .)))
10579464	2	(S1 (S (NP (NNP Doc_10579464_344_351_Chemical)) (VP (AUX is) (ADVP (RB over)) (ADVP (RB 20,000fold)) (ADJP (RBR more) (JJ potent)) (PP (IN at) (NP (DT the) (NNP Doc_10579464_390_398_Chemical) (CD D4.2) (NN receptor))) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ human) (VBN cloned) (NNP Doc_10579464_444_452_Chemical) (NNP D2L) (NN receptor))))) (. .)))
10579464	3	(S1 (S (NP (NNP Doc_10579464_467_474_Chemical)) (VP (AUX has) (NP (JJ negligible) (NN affinity)) (PP (IN for) (NP (NP (DT the) (JJ human) (VBN cloned) (NNP Doc_10579464_520_528_Chemical) (NNP D3) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP Ki=39) (CD nM)) (-RRB- -RRB-)))) (, ,) (S (VP (VP (VB rat) (NP (NP (NNP Doc_10579464_557_566_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_10579464_568_572_Chemical) (-RRB- -RRB-)) (JJ 2A) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP Ki=180) (CD nM)) (-RRB- -RRB-)))) (CC and) (VP (VB rat) (NP (NP (JJ alpha1) (NN adrenoceptor)) (PRN (-LRB- -LRB-) (NP (CD Ki=237) (NNS nM)) (-RRB- -RRB-))))))) (. .)))
10579464	4	(S1 (S (NP (NNP Doc_10579464_639_646_Chemical) (CC and) (NNP Doc_10579464_651_660_Chemical)) (VP (VBD antagonized) (NP (NP (NN locomotor) (NN Doc_10579464_683_696_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_10579464_708_723_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10579464_725_728_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNS mice)))))) (. .)))
10579464	5	(S1 (S (NP (NP (NNP Doc_10579464_739_746_Chemical)) (CC and) (NP (NNP Doc_10579464_751_760_Chemical))) (VP (VBD antagonized) (NP (JJ Doc_10579464_773_776_Chemical-induced) (JJ stereotyped) (NN behavior)) (PP (IN in) (NP (NNS mice))) (, ,) (SBAR (IN although) (S (NP (PRP$ their) (NNS effects)) (VP (AUX did) (RB not) (VP (VB exceed) (NP (ADJP (CD 50) (NN %)) (NN inhibition)))))) (, ,) (PP (ADVP (RB even)) (IN at) (NP (NP (DT the) (JJS highest) (NN dose)) (VP (VBN given))))) (. .)))
10579464	6	(S1 (S (NP (NP (NNP Doc_10579464_901_908_Chemical)) (CC and) (NP (NNP Doc_10579464_913_922_Chemical))) (VP (ADVP (RB significantly)) (VBN induced) (NP (NNP Doc_10579464_945_954_Disease)) (PP (IN in) (NP (NNS rats))) (, ,) (SBAR (IN although) (S (NP (PRP$ their) (NNS effects)) (VP (AUX did) (RB not) (VP (VB exceed) (NP (ADJP (CD 50) (NN %)) (NN induction)) (ADVP (RB even)) (PP (IN at) (NP (NP (DT the) (JJS highest) (NN dose)) (VP (VBN given))))))))) (. .)))
10579464	7	(S1 (S (NP (NP (NNP Doc_10579464_1048_1055_Chemical)) (CC and) (NP (NNP Doc_10579464_1060_1069_Chemical))) (VP (ADVP (RB significantly)) (VBD reversed) (NP (NP (DT the) (NN disruption)) (PP (IN of) (NP (NP (JJ prepulse) (NN inhibition)) (PRN (-LRB- -LRB-) (NP (NNP PPI)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_10579464_1157_1168_Chemical)))))))) (. .)))
10579464	8	(S1 (S (NP (NP (NNP Doc_10579464_1170_1177_Chemical) (CC and) (NNP Doc_10579464_1182_1191_Chemical)) (VP (ADVP (RB significantly)) (VBN shortened) (NP (NP (DT the) (NNP Doc_10579464_1220_1233_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10579464_1235_1238_Chemical)) (-RRB- -RRB-))))) (VP (VBD -induced) (NP (NP (JJ prolonged) (NN swimming) (NN latency)) (PP (IN in) (NP (NNS rats)))) (PP (IN in) (NP (DT a) (NN water) (NN maze) (NN task)))) (. .)))
10579464	9	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_10579464_1333_1340_Chemical)) (VP (MD may) (VP (AUX have) (NP (JJ unique) (JJ antipsychotic) (NNS activities)) (PP (IN without) (NP (NP (DT the) (NN liability)) (PP (IN of) (NP (NP (NN motor) (NN side) (NNS effects)) (ADJP (JJ typical) (PP (IN of) (NP (JJ classical) (NNS antipsychotics))))))))))))) (. .)))
10669626	0	(S1 (S (NP (JJ Doc_10669626_0_8_Chemical-induced) (NN Doc_10669626_17_37_Disease)) (VP (AUX is) (VP (VBN accelerated) (PP (IN by) (NP (NP (NN growth)) (CC and) (NP (NN Doc_10669626_67_76_Chemical)))))) (. .)))
10669626	1	(S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (NN growth)) (CC and) (NP (JJ Doc_10669626_126_135_Chemical) (NN treatment))) (VP (VB enhance) (S (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NNP Doc_10669626_168_188_Disease)) (PP (IN in) (NP (NNS rats)))))) (VP (VBN given) (NP (NP (JJ sufficient) (NNS doses)) (PP (IN of) (NP (NNP Doc_10669626_223_231_Chemical)))) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NN gamma-carboxylation)) (PP (IN of) (NP (NP (NNP matrix) (NNP Gla) (NN protein)) (, ,) (NP (NP (DT a) (JJ Doc_10669626_288_301_Disease) (NN inhibitor)) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (VP (VBN expressed) (PP (IN by) (NP (NP (JJ smooth) (NN muscle) (NNS cells)) (CC and) (NP (NP (NNS macrophages)) (PP (IN in) (NP (DT the) (NN artery) (NN wall)))))))))))))))))))))))) (. .)))
10669626	2	(S1 (S (NP (NP (DT The) (JJ first) (NN series)) (PP (IN of) (NP (NNS experiments)))) (VP (VBD examined) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (NN age)) (CC and) (NP (NN growth) (NN status)))) (PP (IN on) (NP (NP (NNP Doc_10669626_476_496_Disease)) (PP (IN in) (NP (JJ Doc_10669626_500_508_Chemical-treated) (NNS rats))))))) (. .)))
10669626	3	(S1 (S (NP (NP (NN Treatment)) (PP (IN for) (NP (NP (CD 2) (NNS weeks)) (PP (IN with) (NP (NNP Doc_10669626_550_558_Chemical)))))) (VP (VBD caused) (NP (NP (NP (JJ massive) (JJ focal) (JJ Doc_10669626_580_607_Disease) (NNS media)) (PP (IN in) (NP (JJ 20-day-old) (NNS rats)))) (CC and) (NP (NP (ADJP (RBR less) (JJ extensive)) (JJ focal) (NN Doc_10669626_658_671_Disease)) (PP (IN in) (NP (JJ 42-day-old) (NNS rats)))))) (. .)))
10669626	4	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (DT no) (NN Doc_10669626_708_728_Disease)) (VP (MD could) (VP (AUX be) (VP (VBN detected) (PP (IN in) (NP (JJ 10-month-old) (NN adult) (NNS rats))) (PP (ADVP (RB even)) (IN after) (NP (NP (CD 4) (NNS weeks)) (PP (IN of) (NP (JJ Doc_10669626_796_804_Chemical) (NN treatment)))))))) (. .)))
10669626	5	(S1 (S (S (VP (TO To) (VP (ADVP (RB directly)) (VB examine) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (NN growth))) (PP (TO to) (NP (NNP Doc_10669626_864_872_Chemical-induced) (NNP Doc_10669626_881_901_Disease))) (PP (IN in) (NP (NP (NNS animals)) (PP (IN of) (NP (DT the) (JJ same) (NN age))))))))) (, ,) (NP (JJ 20-day-old) (NNS rats)) (VP (AUX were) (VP (VBN fed) (PP (IN for) (NP (NP (CD 2) (NNS weeks)) (CC either) (NP (DT an) (NN ad) (NN libitum)))) (NP (NP (NN diet)) (CC or) (NP (NP (DT a) (JJ 6-g/d) (JJ restricted) (NN diet)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ maintains) (NP (NN weight))) (CC but) (VP (VBZ prevents) (NP (NN growth)))))))))) (. .)))
10669626	6	(S1 (S (NP (NP (JJ Concurrent) (NN treatment)) (PP (IN of) (NP (DT both) (JJ dietary) (NNS groups))) (PP (IN with) (NP (NNP Doc_10669626_1112_1120_Chemical)))) (VP (VP (VBD produced) (NP (JJ massive) (JJ focal) (NN Doc_10669626_1144_1171_Disease) (NNS media)) (PP (IN in) (NP (DT the) (NN ad) (JJ libitum-fed) (NNS rats)))) (CC but) (VP (NP (DT no) (JJ detectable) (NN Doc_10669626_1223_1243_Disease)) (PP (IN in) (NP (DT the) (JJ restricted-diet) (, ,) (JJ growth-inhibited) (NN group))))) (. .)))
10669626	7	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN explanation)) (PP (IN for) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NNP Doc_10669626_1345_1365_Disease)) (CC and) (NP (NN growth) (NN status) (NN cannot))))))) (VP (AUX be) (VP (VBN determined) (PP (IN from) (NP (DT the) (JJ present) (NN study))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN relationship)) (PP (IN between) (NP (NP (JJR higher) (NN serum) (NN Doc_10669626_1475_1484_Chemical)) (CC and) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_10669626_1507_1527_Disease))))))) (, ,) (PP (IN with) (NP (NP (ADJP (NP (CD 30) (NN %)) (JJR higher)) (NNS levels)) (PP (IN of) (NP (JJ serum) (NNP Doc_10669626_1561_1570_Chemical))) (PP (IN in) (NP (NP (JJ young) (, ,) (ADJP (NN ad) (JJ libitum-fed)) (NNS rats)) (PP (VBN compared) (PP (IN with) (NP (NP (DT either)) (PP (IN of) (NP (NP (NP (DT the) (NNS groups)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADJP (JJ resistant) (PP (TO to) (NP (JJ Doc_10669626_1658_1666_Chemical-induced) (NNP Doc_10669626_1675_1695_Disease)))))))) (, ,) (NP (NNS ie)) (, ,) (NP (DT the) (JJ 10-month-old) (NNS rats)) (CC and) (NP (DT the) (JJ restricted-diet) (, ,) (JJ growth-inhibited) (JJ young) (NNS rats)))))))))))) (. .)))
10669626	8	(S1 (S (NP (DT This) (NN observation)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (VBN increased) (NN susceptibility)) (PP (TO to) (NP (NNP Doc_10669626_1836_1844_Chemical-induced) (NNP Doc_10669626_1853_1873_Disease)))) (VP (MD could) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (JJR higher) (NN serum) (JJ Doc_10669626_1907_1916_Chemical) (NNS levels))))))))) (. .)))
10669626	9	(S1 (S (NP (NP (DT The) (JJ second) (NN set)) (PP (IN of) (NP (NNS experiments)))) (VP (VBD examined) (NP (NP (DT the) (JJ possible) (NN synergy)) (PP (IN between) (NP (NP (NP (NNP Doc_10669626_1993_2002_Chemical)) (CC and) (NP (NNP Doc_10669626_2007_2015_Chemical))) (PP (IN in) (NP (NNP Doc_10669626_2019_2039_Disease))))))) (. .)))
10669626	10	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NNP Doc_10669626_2055_2064_Chemical)))) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NNP Doc_10669626_2084_2111_Disease) (NNS media)) (PP (IN in) (NP (QP (RB as) (JJ little) (IN as) (CD 3) (TO to) (CD 4)) (NNS days)))))))) (. .)))
10669626	11	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (DT the) (NNP Doc_10669626_2165_2174_Chemical) (NN antagonist) (NN Doc_10669626_2186_2194_Chemical)))) (VP (AUX are) (ADVP (RB also)) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NNP Doc_10669626_2219_2246_Disease) (NNS media))))) (, ,) (UCP (CC but) (PP (IN at) (NP (NP (NN treatment) (NNS times)) (PP (IN of) (NP (CD 2) (NNS weeks))))) (CC or) (ADVP (ADVP (RB longer)) (CC yet) (ADVP (RB not) (IN at) (NP (CD 1) (NN week))))))) (. .)))
10669626	12	(S1 (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBD investigated) (NP (NP (DT the) (NN synergy)) (PP (IN between) (NP (DT these) (CD 2) (NNS treatments))))) (CC and) (VP (VBD found) (SBAR (IN that) (S (NP (JJ concurrent) (NNP Doc_10669626_2420_2428_Chemical) (NN administration)) (ADVP (RB dramatically)) (VP (VBD increased) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NNP Doc_10669626_2481_2494_Disease)))) (PP (IN in) (NP (NP (DT the) (NNS media)) (PP (IN of) (NP (JJ Doc_10669626_2511_2520_Chemical-treated) (NNS rats))))) (PP (IN at) (NP (QP (CD 3) (CC and) (CD 4)) (NNS days)))))))) (. .)))
10669626	13	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ close) (NN parallel)) (PP (IN between) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ Doc_10669626_2600_2609_Chemical) (NN dose))) (PP (IN on) (NP (NNP Doc_10669626_2618_2638_Disease)))) (CC and) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ Doc_10669626_2657_2666_Chemical) (NN dose))) (PP (IN on) (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (NP (NNP serum) (NNP Doc_10669626_2698_2705_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_10669626_2727_2736_Chemical)) (VP (MD may) (VP (VB induce) (NP (NNP Doc_10669626_2748_2768_Disease)) (PP (IN through) (NP (NP (PRP$ its) (NN effect)) (PP (IN on) (NP (JJ serum) (NNP Doc_10669626_2797_2804_Chemical))))))))))))))))))))) (. .)))
10669626	14	(S1 (S (SBAR (IN Because) (S (NP (JJ Doc_10669626_2814_2822_Chemical) (NN treatment)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN elevation)) (PP (IN in) (NP (JJ serum) (NNP Doc_10669626_2873_2880_Chemical))) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_10669626_2893_2902_Chemical)))))))))) (, ,) (NP (NP (DT the) (NN synergy)) (PP (IN between) (NP (NNP Doc_10669626_2924_2932_Chemical) (CC and) (NNP Doc_10669626_2937_2946_Chemical)))) (VP (AUX is) (ADVP (RB probably)) (VP (ADVP (RBS best)) (VBN explained) (PP (IN by) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_10669626_2997_3005_Chemical)) (VP (VBZ inhibits) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NNP matrix) (NNP Gla) (NN protein)))) (PP (IN as) (NP (DT a) (NNP Doc_10669626_3055_3068_Disease) (NN inhibitor)))))))))) (. .)))
10669626	15	(S1 (S (S (NP (NP (JJ High) (NNS levels)) (PP (IN of) (NP (NNP matrix) (NNP Gla) (NN protein)))) (VP (AUX are) (VP (VBN found) (PP (IN at) (NP (NP (NNS sites)) (PP (IN of) (NP (NNP Doc_10669626_3136_3156_Disease))))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_10669626_3178_3187_Chemical)) (CC plus) (NP (NNP Doc_10669626_3193_3201_Chemical)))))))))) (, ,) (CC and) (S (NP (NN chemical) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (NN protein) (SBAR (IN that) (S (VP (VBN accumulated))))) (VP (AUX was) (ADVP (RB indeed)) (RB not) (ADJP (JJ Doc_10669626_3281_3299_Chemical))))))) (. .)))
10669626	16	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP indicate) (SBAR (IN that) (S (SBAR (IN although) (S (NP (NP (DT the) (JJ Doc_10669626_3347_3369_Chemical) (NNS residues)) (PP (IN of) (NP (NNP matrix) (NNP Gla) (NN protein)))) (VP (AUX are) (ADVP (RB apparently)) (VP (VBN required) (PP (IN for) (NP (PRP$ its) (NN function))) (PP (IN as) (NP (DT a) (JJ Doc_10669626_3447_3460_Disease) (NN inhibitor))))))) (, ,) (NP (PRP they)) (VP (AUX are) (RB not) (VP (VBN required) (PP (IN for) (NP (NP (PRP$ its) (NN accumulation)) (PP (IN at) (NP (JJ Doc_10669626_3518_3531_Disease) (NNS sites)))))))))) (. .)))
10683478	0	(S1 (S (NP (NN Test) (NNS conditions)) (VP (VBP influence) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NP (DT a) (NN drug) (NN challenge)) (PP (IN in) (NP (NNS rodents))))))) (. .)))
10683478	1	(S1 (S (NP (DT These) (NNS studies)) (VP (AUX were) (VP (VBN conducted) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN differential) (NN response)) (PP (TO to) (NP (NP (DT a) (NN drug) (NN challenge)) (PP (IN under) (NP (NP (JJ varied) (JJ experimental) (NN test) (NNS conditions)) (VP (ADVP (RB routinely)) (VBN employed) (S (VP (TO to) (VP (VB study) (NP (NP (JJ drug-induced) (JJ behavioral) (CC and) (JJ neurophysiological) (NNS responses)) (PP (IN in) (NP (NNS rodents)))))))))))))))))) (. .)))
10683478	2	(S1 (S (NP (NP (NNP Doc_10683478_296_307_Chemical)) (, ,) (NP (DT a) (JJ nonselective) (NN Doc_10683478_324_340_Chemical)) (, ,)) (VP (AUX was) (VP (VBN selected) (PP (JJ due) (TO to) (NP (NP (PRP$ its) (JJ biphasic) (JJ behavioral) (NNS effects)) (, ,) (NP (PRP$ its) (NN ability) (S (VP (VP (TO to) (VP (VB induce) (NP (NNP Doc_10683478_417_428_Disease)))) (, ,) (CC and) (VP (TO to) (VP (VB produce) (NP (NP (JJ distinct) (NNS changes)) (PP (TO to) (NP (NP (JJ Doc_10683478_465_473_Chemical) (NN turnover)) (PP (IN in) (NP (DT the) (JJ rodent) (NN brain))))))))))))))) (. .)))
10683478	3	(S1 (S (PP (IN From) (NP (JJ such) (NNS experiments))) (NP (EX there)) (VP (AUX is) (NP (NN evidence) (SBAR (IN that) (S (NP (NP (NP (NN characterization)) (CC and) (NP (NN detection))) (PP (IN of) (NP (JJ Doc_10683478_583_594_Chemical-induced) (NN activity))) (PP (IN in) (NP (NNS rodents)))) (ADVP (RB critically)) (VP (VBZ depends) (PP (IN upon) (NP (NP (DT the) (NN test) (NNS conditions)) (VP (VBN employed))))))))) (. .)))
10683478	4	(S1 (S (PP (IN In) (NP (NNS rats))) (, ,) (NP (NP (NN detection)) (PP (IN of) (NP (NNP Doc_10683478_699_710_Chemical-induced) (NNP Doc_10683478_719_732_Disease)))) (VP (AUX was) (VP (VBN facilitated) (PP (IN by) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (NN acclimatization))) (PP (TO to) (NP (DT the) (NN test) (NNS conditions))))))) (. .)))
10683478	5	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN test) (NNS conditions)) (VP (MD can) (VP (VB impact) (PP (IN upon) (NP (NP (JJ other) (JJ physiological) (NNS responses)) (PP (TO to) (NP (NNP Doc_10683478_879_890_Chemical))) (PP (JJ such) (IN as) (NP (JJ drug-induced) (NNP Doc_10683478_912_923_Disease))))))) (. .)))
10683478	6	(S1 (S (PP (IN In) (NP (NNS mice))) (, ,) (NP (NNP Doc_10683478_934_945_Chemical)) (VP (VBD produced) (NP (ADJP (RB qualitatively) (JJ different)) (NNS responses)) (PP (IN under) (NP (JJ novel) (NNS conditions))) (SBAR (WHADVP (WRB when)) (S (VP (VBD compared) (PP (TO to) (NP (NP (DT those) (NNS behaviors)) (VP (VBN elicited) (PP (IN in) (NP (DT the) (NN home) (NN test) (NN cage)))))))))) (. .)))
10683478	7	(S1 (S (NP (JJ Drug-induced) (JJ gross) (NN activity) (NNS counts)) (VP (AUX were) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ novel) (JJ exploratory) (NN box) (RB only))) (, ,) (SBAR (IN while) (S (NP (NP (NNS measures)) (PP (IN of) (NP (JJ stereotypic) (NN behavior)))) (VP (AUX were) (ADJP (JJ similar) (PP (IN in) (NP (DT both))))))))) (. .)))
10683478	8	(S1 (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (JJ Doc_10683478_1236_1247_Chemical-induced) (NN locomotion)) (VP (AUX was) (ADJP (RBR more) (JJ prominent)) (PP (IN in) (NP (DT the) (JJ novel) (JJ exploratory) (NN box)))) (. .)))
10683478	9	(S1 (S (NP (NP (JJ Doc_10683478_1316_1324_Chemical) (NN turnover) (NNS ratios)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_10683478_1342_1347_Chemical)) (: :) (NP (NP (NNP Doc_10683478_1348_1350_Chemical)) (CC and) (NP (NNP Doc_10683478_1355_1358_Chemical))) (: :) (NP (NNP Doc_10683478_1359_1361_Chemical))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJR lower)) (PP (IN in) (NP (NP (DT those) (NNS animals)) (VP (VBN exposed) (PP (TO to) (NP (DT the) (JJ exploratory) (NN box)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (PRP$ their) (NN home) (NN cage) (NNS counterparts))))))))))) (. .)))
10683478	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ Doc_10683478_1490_1501_Chemical-induced) (NNS reductions)) (PP (IN in) (NP (JJ striatal) (JJ Doc_10683478_1533_1541_Chemical) (NN turnover)))) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (DT both) (NN novel) (CC and) (NN home) (NN cage) (NNS environments))))) (. .)))
10683478	11	(S1 (S (NP (NP (DT The) (NNS implications)) (PP (IN of) (NP (DT these) (NNS findings)))) (VP (AUX are) (VP (VBN discussed) (PP (IN with) (NP (JJ particular) (NN emphasis))) (PP (IN upon) (S (VP (VBG conducting) (NP (JJ psychopharmacological) (NN challenge) (NNS tests)) (PP (IN in) (NP (NNS rodents)))))))) (. .)))
10704919	0	(S1 (S (NP (NP (NN Doc_10704919_0_9_Disease)) (PP (IN of) (NP (NP (JJ human) (NNS erythrocytes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10704919_43_52_Chemical))))))) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (NP (NN disruption)) (PP (IN of) (NP (NN membrane) (NN structure))))))) (. .)))
10704919	1	(S1 (S (NP (NP (NP (NNP Doc_10704919_101_110_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10704919_112_115_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ antiestrogenic) (NN drug)) (VP (ADVP (RBS most) (RB widely)) (VBN prescribed) (PP (IN in) (NP (NP (DT the) (NN chemotherapy)) (PP (IN of) (NP (NNP Doc_10704919_188_201_Disease))))))) (, ,)) (VP (VBZ induces) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ normal) (JJ discoid) (NN shape)) (PP (IN of) (NP (NP (NNS erythrocytes)) (CC and) (NP (NNP Doc_10704919_263_279_Disease)))))))) (. .)))
10704919	2	(S1 (S (NP (DT This) (NN work)) (VP (VBZ evaluates) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_10704919_316_319_Chemical))) (PP (IN on) (NP (VBN isolated) (JJ human) (NNS erythrocytes)))) (, ,) (S (VP (VBG attempting) (S (VP (TO to) (VP (VB identify) (NP (NP (DT the) (VBG underlying) (NNS mechanisms)) (PP (IN on) (NP (NP (JJ Doc_10704919_404_407_Chemical-induced) (NN Doc_10704919_416_432_Disease)) (CC and) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NNS biomembranes))) (PP (IN in) (NP (PRP$ its) (JJ cytostatic) (NN action) (NNS mechanisms))))))))))))) (. .)))
10704919	3	(S1 (S (NP (NN Doc_10704919_506_509_Chemical)) (VP (VBZ induces) (NP (NP (NN Doc_10704919_518_527_Disease)) (PP (IN of) (NP (NNS erythrocytes)))) (PP (IN as) (NP (NP (DT a) (NN function)) (PP (IN of) (NP (NN concentration)))))) (. .)))
10704919	4	(S1 (S (S (NP (NP (DT The) (NN extension)) (PP (IN of) (NP (NNP Doc_10704919_593_602_Disease)))) (VP (AUX is) (ADJP (JJ variable) (PP (IN with) (NP (JJ erythrocyte) (NNS samples)))))) (, ,) (CC but) (S (NP (CD 12.5) (NN microM) (NN Doc_10704919_657_660_Chemical)) (VP (VBZ induces) (NP (NP (JJ total) (NN Doc_10704919_675_684_Disease)) (PP (IN of) (NP (DT all) (VBN tested) (NNS suspensions)))))) (. .)))
10704919	5	(S1 (S (PP (IN Despite) (S (VP (VBG inducing) (NP (JJ extensive) (NN erythrocyte) (NN lysis))))) (, ,) (NP (NNP Doc_10704919_758_761_Chemical)) (VP (AUX does) (RB not) (VP (VB shift) (NP (NP (DT the) (JJ osmotic) (NN fragility) (NNS curves)) (PP (IN of) (NP (NNS erythrocytes)))))) (. .)))
10704919	6	(S1 (S (NP (NP (DT The) (JJ Doc_10704919_827_836_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_10704919_847_850_Chemical)))) (VP (AUX is) (VP (VBN prevented) (PP (IN by) (NP (NP (NP (JJ low) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_10704919_889_905_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10704919_907_914_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_10704919_920_944_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_10704919_946_955_Chemical) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (VP (VBN inactivated) (NP (JJ functional) (NNP Doc_10704919_981_989_Chemical))) (-RRB- -RRB-))) (VP (VBG indicating) (SBAR (IN that) (S (NP (NNP Doc_10704919_1007_1010_Chemical-induced) (NNP Doc_10704919_1019_1028_Disease)) (VP (AUX is) (RB not) (VP (VBN related) (S (VP (TO to) (VP (VB oxidative) (NP (JJ membrane) (NN damage)))))))))))))) (. .)))
10704919	7	(S1 (S (NP (DT This)) (VP (AUX was) (ADVP (RB further)) (VP (VP (VBN evidenced) (PP (IN by) (NP (NP (NN absence)) (PP (IN of) (NP (NP (JJ Doc_10704919_1115_1121_Chemical) (NN consumption)) (CC and) (NP (NN hemoglobin) (NN oxidation))))))) (CC both) (VP (VBN determined) (PP (IN in) (NP (NP (NN parallel)) (PP (IN with) (NP (NNP Doc_10704919_1192_1195_Chemical-induced) (NNP Doc_10704919_1204_1213_Disease)))))))) (. .)))
10704919	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP it)) (VP (AUX was) (VP (VBN observed) (SBAR (IN that) (S (NP (NNP Doc_10704919_1249_1252_Chemical)) (VP (VBZ inhibits) (NP (NP (DT the) (NN peroxidation)) (PP (IN of) (NP (NP (JJ human) (NNS erythrocytes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10704919_1312_1316_Chemical))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG ruling) (PP (IN out) (NP (JJ Doc_10704919_1334_1337_Chemical-induced) (NN cell) (NN oxidative) (NN stress)))))))))) (. .)))
10704919	9	(S1 (S (NP (NP (NN Doc_10704919_1369_1378_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_10704919_1389_1392_Chemical))))) (VP (AUX was) (RB not) (VP (VBN preceded) (PP (IN by) (NP (NP (DT the) (NN leakage)) (PP (IN of) (NP (NP (NNP Doc_10704919_1428_1429_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)))) (PP (IN from) (NP (DT the) (NNS cells))))) (, ,) (S (ADVP (RB also)) (VP (VBG excluding) (NP (NP (DT a) (JJ colloid-osmotic) (NN type) (NN mechanism)) (PP (IN of) (NP (NNP Doc_10704919_1500_1509_Disease)))))) (, ,) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (JJ osmotic) (NN fragility) (NNS curves)))))))) (. .)))
10704919	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_10704919_1574_1577_Chemical)) (VP (VBZ induces) (NP (NP (NN release)) (PP (IN of) (NP (NP (JJ peripheral) (NNS proteins)) (PP (IN of) (NP (NP (NN membrane-cytoskeleton) (CC and) (NN cytosol) (NNS proteins)) (VP (ADVP (RB essentially)) (VBN bound) (S (VP (TO to) (VP (VB band) (NP (CD 3)))))))))))) (. .)))
10704919	11	(S1 (S (CC Either) (NP (NP (NNP Doc_10704919_1699_1706_Chemical)) (CC or) (NP (NNP Doc_10704919_1710_1719_Chemical))) (VP (VP (VBZ increases) (NP (NN membrane) (NN packing))) (CC and) (VP (VBZ prevents) (NP (JJ Doc_10704919_1760_1763_Chemical) (NN partition)) (PP (IN into) (NP (NN model) (NNS membranes))))) (. .)))
10704919	12	(S1 (S (NP (DT These) (NNS effects)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (DT the) (NN protection)) (PP (IN from) (NP (NNP Doc_10704919_1843_1852_Disease))) (PP (IN by) (NP (NNP Doc_10704919_1856_1867_Chemical)))) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (NP (DT a) (VBN decreased) (JJ Doc_10704919_1894_1897_Chemical) (NN incorporation)) (PP (IN in) (NP (JJ condensed) (NNS membranes)))))))) (CC and) (S (NP (NP (DT the) (JJ structural) (NN damage)) (PP (IN of) (NP (DT the) (JJ erythrocyte) (NN membrane)))) (VP (AUX is) (ADVP (RB consequently)) (VP (VBN avoided))))))) (. .)))
10704919	13	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NNP Doc_10704919_2025_2028_Chemical-induced) (NNP Doc_10704919_2037_2046_Disease)) (VP (VBZ results) (PP (IN from) (NP (NP (DT a) (JJ structural) (NN perturbation)) (PP (IN of) (NP (JJ red) (NN cell) (NN membrane))))) (, ,) (PP (VBG leading) (PP (TO to) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN framework)) (PP (IN of) (NP (DT the) (JJ erythrocyte) (NN membrane)))))) (CC and) (NP (NP (PRP$ its) (NN cytoskeleton)) (VP (VBN caused) (PP (IN by) (NP (NP (PRP$ its) (JJ high) (NN partition)) (PP (IN in) (NP (DT the) (NN membrane))))))))))) (. .)))
10704919	14	(S1 (S (NP (DT These) (NNS defects)) (VP (VBP explain) (NP (NP (NP (DT the) (JJ abnormal) (NN erythrocyte) (NN shape)) (CC and) (NP (VBN decreased) (JJ mechanical) (NN stability))) (VP (VBN promoted) (PP (IN by) (NP (NNP Doc_10704919_2339_2342_Chemical))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NNP Doc_10704919_2357_2373_Disease)))))) (. .)))
10704919	15	(S1 (S (ADVP (RB Additionally)) (, ,) (SBAR (IN since) (S (NP (NN membrane) (NN leakage)) (VP (AUX is) (NP (NP (DT a) (JJ final) (NN stage)) (PP (IN of) (NP (NN cytotoxicity))))))) (, ,) (NP (NP (DT the) (NN disruption)) (PP (IN of) (NP (NP (DT the) (JJ structural) (NNS characteristics)) (PP (IN of) (NP (NNS biomembranes))) (PP (IN by) (NP (NNP Doc_10704919_2514_2517_Chemical)))))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (JJ multiple) (NNS mechanisms)) (PP (IN of) (NP (PRP$ its) (NN anticancer) (NN action))))))) (. .)))
10706004	0	(S1 (S (NP (NP (NNS Changes)) (PP (IN of) (NP (NP (NNP Doc_10706004_11_17_Chemical) (CC and) (NNP Doc_10706004_22_25_Chemical) (NNS affinities)) (PP (IN of) (NP (DT the) (JJ cardiac) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_53_55_Chemical)) (, ,) (NP (NNP Doc_10706004_56_57_Chemical)) (-RRB- -RRB-)) (NN -ATPase))))) (PP (IN during) (CC and) (IN after) (NP (NNP Doc_10706004_83_95_Chemical)))) (VP (VBP deficient) (NP (NN Doc_10706004_106_118_Disease))) (. .)))
10706004	1	(S1 (S (PP (IN In) (NP (DT the) (JJ cardiovascular) (NN system))) (, ,) (NP (NNP Doc_10706004_150_152_Chemical)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS functions))))))))) (. .)))
10706004	2	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NNP Doc_10706004_224_226_Chemical) (NN synthesis) (VBZ induces)))) (VP (VBD sustained) (NP (NN Doc_10706004_255_267_Disease))) (. .)))
10706004	3	(S1 (S (PP (IN In) (NP (NP (JJ several) (NNS models)) (PP (IN of) (NP (NNP Doc_10706004_290_302_Disease))))) (, ,) (NP (NP (NN elevation)) (PP (IN of) (NP (JJ intracellular) (JJ Doc_10706004_331_337_Chemical) (NN level)))) (VP (AUX was) (VP (VBN documented) (PP (IN in) (NP (JJ cardiac) (NN tissue))))) (. .)))
10706004	4	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (JJ molecular) (NN basis)) (PP (IN of) (NP (NP (NNS disturbances)) (PP (IN in) (NP (NP (JJ transmembraneous) (NN transport)) (PP (IN of) (NP (NNP Doc_10706004_457_459_Chemical+))))))))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (JJ cardiac) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_498_500_Chemical)) (, ,) (NP (NNP Doc_10706004_501_502_Chemical)) (-RRB- -RRB-)) (NN -ATPase))) (PP (TO to) (NP (NP (NNP Doc_10706004_514_516_Chemical-deficient) (NNP Doc_10706004_527_539_Disease)) (VP (VBN induced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NP (JJ Doc_10706004_559_561_Chemical-synthase) (NN inhibition)) (PP (IN with) (NP (NP (CD 40) (NN mg/kg/day)) (NP (NP (NNP Doc_10706004_600_634_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_636_642_Chemical)) (-RRB- -RRB-))))))) (PP (IN for) (NP (QP (CD 4) (CD four)) (NNS weeks)))))))) (. .)))
10706004	5	(S1 (S (PP (IN After) (NP (NP (JJ 4-week) (NN administration)) (PP (IN of) (NP (NNP Doc_10706004_693_699_Chemical))))) (, ,) (NP (NP (DT the) (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN SBP)) (-RRB- -RRB-))) (VP (VBN increased) (PP (IN by) (NP (CD 36) (NN %)))) (. .)))
10706004	6	(S1 (S (PP (NP (CD Two) (NNS weeks)) (IN after) (S (VP (VBG terminating) (NP (DT the) (NN treatment))))) (, ,) (NP (DT the) (NNS SBP)) (VP (VBD recovered) (S (VP (TO to) (VP (VB control) (NP (NN value)))))) (. .)))
10706004	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBG activating) (NP (DT the) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_853_855_Chemical)) (, ,) (NP (NNP Doc_10706004_856_857_Chemical)) (-RRB- -RRB-)) (NN -ATPase)) (PP (IN with) (NP (PRP$ its) (JJ substrate) (NN Doc_10706004_885_888_Chemical)))))) (, ,) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (UCP (NNP Km) (CC and) (NNP Vmax)) (NNS values)))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (JJ Doc_10706004_940_942_Chemical-deficient) (NNS rats))))) (. .)))
10706004	8	(S1 (S (PP (IN During) (NP (NP (NN activation)) (PP (IN with) (NP (NNP Doc_10706004_982_984_Chemical+))))) (, ,) (NP (DT the) (NNP Vmax)) (VP (VBD remained) (ADJP (JJ unchanged)) (, ,) (ADVP (RB however)) (SBAR (S (NP (NP (DT the) (NNP Doc_10706004_1028_1029_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1030_1032_Chemical)) (-RRB- -RRB-))) (VP (VBD increased) (PP (IN by) (NP (CD 50) (NN %))) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (JJ profound) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN affinity)) (PP (IN of) (NP (NP (DT the) (JJ Doc_10706004_1106_1108_Chemical+-binding) (NN site)) (PP (IN in) (NP (JJ Doc_10706004_1126_1128_Chemical-deficient) (NNS rats)))))))))))))) (. .)))
10706004	9	(S1 (S (PP (IN After) (NP (NP (NN recovery)) (PP (IN from) (NP (NNP Doc_10706004_1165_1177_Disease))))) (, ,) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1196_1198_Chemical)) (, ,) (NP (NNP Doc_10706004_1199_1200_Chemical)) (-RRB- -RRB-)) (NN -ATPase)))) (VP (VBD increased) (, ,) (PP (JJ due) (TO to) (NP (NP (JJR higher) (NN affinity)) (PP (IN of) (NP (DT the) (JJ Doc_10706004_1250_1253_Chemical-binding) (NN site))))) (, ,) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN from) (NP (NP (DT the) (VBN lowered) (JJ Km) (NN value)) (PP (IN for) (NP (NNP Doc_10706004_1310_1313_Chemical))))))))) (. .)))
10706004	10	(S1 (S (NP (NP (DT The) (NNP Doc_10706004_1319_1320_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1321_1323_Chemical)) (-RRB- -RRB-)) (NN value)) (PP (IN for) (NP (NNP Doc_10706004_1335_1337_Chemical+)))) (VP (VBD returned) (S (VP (TO to) (VP (VB control) (NP (NN value)))))) (. .)))
10706004	11	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NNP Doc_10706004_1380_1382_Chemical-synthase)))) (VP (VBN induced) (NP (NP (DT a) (JJ reversible) (NN Doc_10706004_1413_1425_Disease)) (VP (VBN accompanied) (PP (IN by) (NP (NNP Doc_10706004_1441_1450_Disease) (NNP Doc_10706004_1451_1453_Chemical+-extrusion))))) (PP (IN from) (NP (JJ cardiac) (NNS cells))) (PP (IN as) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (NP (JJ deteriorated) (JJ Doc_10706004_1517_1519_Chemical+-binding) (NNS properties)) (PP (IN of) (NP (DT the) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1548_1550_Chemical)) (, ,) (NP (NNP Doc_10706004_1551_1552_Chemical)) (-RRB- -RRB-)) (NN -ATPase)))))))) (. .)))
10706004	12	(S1 (S (PP (IN After) (NP (NP (NN recovery)) (PP (IN of) (NP (NN blood) (NN pressure))) (PP (TO to) (NP (NN control) (NNS values))))) (, ,) (NP (NP (DT the) (NN extrusion)) (PP (IN of) (NP (NNP Doc_10706004_1631_1633_Chemical+))) (PP (IN from) (NP (JJ cardiac) (NNS cells)))) (VP (AUX was) (VP (VBN normalized) (, ,) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN by) (NP (NP (NN restoration)) (PP (IN of) (NP (DT the) (PRN (-LRB- -LRB-) (NP (NNP Doc_10706004_1705_1707_Chemical)) (, ,) (NP (NNP Doc_10706004_1708_1709_Chemical)) (-RRB- -RRB-)) (JJ -ATPase) (NN activity)))))))))) (. .)))
10721819	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (JJ long-term) (NN pretreatment)) (PP (IN with) (NP (NNP Doc_10721819_39_52_Chemical))))) (PP (IN on) (NP (NP (NNP Doc_10721819_56_69_Chemical-induced) (NNP Doc_10721819_78_89_Disease)) (PP (IN in) (NP (JJ conscious) (NNS rats))))) (. .)))
10721819	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (PP (IN that) (NP (NP (JJ Doc_10721819_132_145_Chemical-induced) (NNP Doc_10721819_154_165_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD persisted) (SBAR (S (S (PP (IN after) (NP (NN adrenalectomy))) (, ,) (VP (AUX is) (PRN (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-)) (VP (VBN mediated) (PP (IN by) (NP (JJ central) (NNP Doc_10721819_231_239_Chemical) (NNP D2) (NN receptor) (NN activation)))))) (CC and) (S (NP (-LRB- -LRB-) (NNP ii) (-RRB- -RRB-)) (VP (VBN reduced) (PP (IN by) (NP (JJ 5-day) (JJ Doc_10721819_289_302_Chemical) (NN pretreatment))))))) (, ,) (S (VP (VBG supporting) (ADVP (RB therefore)) (SBAR (S (NP (NP (DT the) (NN hypothesis)) (PP (IN that) (NP (DT this) (NN effect)))) (VP (AUX is) (ADJP (JJ dependent) (PP (IN on) (NP (NP (JJ sympathetic) (NN outflow)) (PP (TO to) (NP (DT the) (NN heart)))))))))))))))))))) (. .)))
10721819	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB examine) (SBAR (IN whether) (S (NP (NP (JJ prolonged) (NN pretreatment)) (PP (IN with) (NP (NNP Doc_10721819_492_505_Chemical)))) (VP (MD could) (VP (VB abolish) (NP (NP (JJ Doc_10721819_520_533_Chemical-induced) (NN Doc_10721819_542_553_Disease)) (PP (IN in) (NP (JJ conscious) (NNS rats))))))))))))) (. .)))
10721819	3	(S1 (S (NP (NP (JJ Doc_10721819_573_586_Chemical) (NN pretreatment)) (PP (IN for) (NP (CD 15) (NNS days)))) (VP (VBD caused) (NP (NN Doc_10721819_619_638_Disease)) (PP (IN without) (S (VP (VBG affecting) (NP (NP (NN baseline) (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))))))) (. .)))
10721819	4	(S1 (S (PP (IN In) (NP (NN control) (NNS rats))) (, ,) (NP (NP (JJ intravenous) (NNP Doc_10721819_726_739_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 150) (NN microg/kg)) (-RRB- -RRB-))) (VP (VBN induced) (S (ADJP (JJ significant) (NP (NP (NNP Doc_10721819_776_787_Disease)) (CC and) (NP (NNP Doc_10721819_792_803_Disease)))))) (. .)))
10721819	5	(S1 (S (NP (JJ Doc_10721819_805_818_Chemical-induced) (NNP Doc_10721819_827_838_Disease)) (VP (AUX was) (ADJP (JJ unaffected) (PP (IN by) (NP (JJ Doc_10721819_857_870_Chemical) (NN pretreatment)))) (, ,) (SBAR (IN while) (S (NP (NNP Doc_10721819_891_902_Disease)) (VP (AUX was) (VP (VBN reversed) (PP (TO to) (NP (JJ significant) (NNP Doc_10721819_931_942_Disease))) (, ,) (NP (NP (DT an) (NN effect)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADVP (RB partly)) (VP (VBN reduced) (PP (IN by) (S (VP (VBG i.v.) (NP (NP (NNP Doc_10721819_986_997_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/kg)) (-RRB- -RRB-)))))))))))))))) (. .)))
10721819	6	(S1 (S (NP (CC Neither) (NP (JJ cardiac) (NN vagal)) (CC nor) (NP (JJ sympathetic) (NN tone))) (VP (AUX was) (VP (VBN altered) (PP (IN by) (NP (JJ Doc_10721819_1069_1082_Chemical) (NN pretreatment))))) (. .)))
10721819	7	(S1 (S (PP (IN In) (NP (NP (JJ isolated) (JJ perfused) (NN heart) (NNS preparations)) (PP (IN from) (NP (JJ Doc_10721819_1142_1155_Chemical-pretreated) (NNS rats))))) (, ,) (NP (NP (DT the) (JJ Doc_10721819_1177_1190_Chemical-induced) (JJ maximal) (NN increase)) (PP (IN in) (NP (JJ left) (JJ ventricular) (NN systolic) (NN pressure)))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (JJ saline-pretreated) (NNS rats)) (PRN (-LRB- -LRB-) (S (NP (NP (DT the) (CD EC50)) (PP (IN of) (NP (NP (DT the) (JJ Doc_10721819_1335_1348_Chemical-induced) (NN increase)) (PP (IN in) (NP (JJ left) (JJ ventricular) (NN systolic) (NN pressure)))))) (VP (AUX was) (VP (VBN enhanced) (S (ADJP (RB approximately) (JJ 22-fold)))))) (-RRB- -RRB-))))))) (. .)))
10721819	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (JJ 15-day) (JJ Doc_10721819_1472_1485_Chemical) (NN pretreatment)) (VP (CONJP (RB not) (RB only)) (VP (VBD abolished) (CC but) (VBD reversed) (NP (JJ Doc_10721819_1531_1544_Chemical-induced) (NN Doc_10721819_1553_1564_Disease)) (PP (TO to) (NP (NP (NNP Doc_10721819_1568_1579_Disease)) (, ,) (NP (NP (DT an) (NN effect)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADVP (RB mainly)) (VP (VBN related) (PP (TO to) (NP (JJ further) (JJ cardiac) (NN beta-adrenoceptor) (NN desensitization))))))))))) (CONJP (RB rather) (IN than)) (PP (TO to) (NP (NP (NN impairment)) (PP (IN of) (NP (NP (JJ autonomic) (NN regulation)) (PP (IN of) (NP (DT the) (NN heart))))))))))) (. .)))
10721819	9	(S1 (S (NP (PRP They)) (VP (VBP suggest) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (JJ normal) (JJ conscious) (NNS rats))) (, ,) (NP (NP (DT the) (JJ central) (NN Doc_10721819_1788_1799_Disease)) (PP (IN of) (NP (NNP Doc_10721819_1803_1816_Chemical)))) (VP (VBZ appears) (S (VP (VP (TO to) (VP (VB predominate))) (CC and) (VP (TO to) (VP (NN mask) (NP (NP (DT the) (NN Doc_10721819_1856_1867_Disease)) (PP (IN of) (NP (DT this) (NN agonist))) (PP (IN at) (NP (JJ peripheral) (NNP Doc_10721819_1898_1906_Chemical) (NNP D2) (NNS receptors)))))))))))) (. .)))
10737864	0	(S1 (NP (NP (DT A) (JJ developmental) (NN analysis)) (PP (IN of) (NP (NP (NP (NNP Doc_10737864_28_37_Chemical) (POS 's)) (NNS effects)) (PP (IN on) (NP (NP (JJ cardiac) (NN rate) (CC and) (NN ultrasound) (NN production)) (PP (IN in) (NP (NN infant) (NNS rats))))))) (. .)))
10737864	1	(S1 (S (PP (IN Under) (NP (JJ controlled) (NNS conditions))) (, ,) (NP (NN infant) (NNS rats)) (VP (VBP emit) (NP (JJ ultrasonic) (NNS vocalizations)) (PP (PP (IN during) (NP (JJ extreme) (JJ cold) (NN exposure))) (CC and) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT the) (NN alpha) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NN adrenoceptor) (NN agonist)) (, ,) (NP (NNP Doc_10737864_269_278_Chemical)))))))) (. .)))
10737864	2	(S1 (S (NP (JJ Previous) (NNS investigations)) (VP (AUX have) (VP (VBN determined) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_10737864_341_350_Chemical))))) (, ,) (NP (NN ultrasound) (NN production)) (VP (VP (VBZ increases) (PRT (RP through)) (NP (DT the) (JJ 2nd-week) (NN postpartum))) (CC and) (VP (VBZ decreases) (ADVP (RB thereafter)))))))) (. .)))
10737864	3	(S1 (S (S (VP (VP (VBN Given) (NP (DT that) (JJ sympathetic) (JJ neural) (NN dominance) (NNS exhibits)) (NP (DT a) (JJ similar) (NN developmental) (NN pattern))) (, ,) (CC and) (VP (VBN given) (SBAR (IN that) (S (NP (NNP Doc_10737864_539_548_Chemical)) (VP (VBZ induces) (NP (NP (JJ sympathetic) (NN withdrawal)) (CC and) (NP (NNP Doc_10737864_584_595_Disease))))))))) (, ,) (NP (PRP we)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (NP (NNP Doc_10737864_618_627_Chemical) (POS 's)) (JJ developmental) (NNS effects)) (PP (IN on) (NP (NP (JJ cardiac) (NN rate)) (CC and) (NP (NN ultrasound) (NN production))))) (VP (MD would) (VP (VB mirror) (NP (DT each) (JJ other))))))) (. .)))
10737864	4	(S1 (S (ADVP (RB Therefore)) (, ,) (PP (IN in) (NP (DT the) (JJ present) (NN experiment))) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_10737864_772_781_Chemical) (NN administration))) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/kg)) (-RRB- -RRB-)) (PP (IN on) (NP (JJ cardiac) (NN rate) (CC and) (NN ultrasound) (NN production)))) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (NP (NN 2-)) (, ,) (NP (NN 8-)) (, ,) (NP (NN 15-)) (, ,) (CC and) (NP (JJ 20-day-old) (NNS rats)))))) (. .)))
10737864	5	(S1 (S (NP (NP (JJ Age-related) (NNS changes)) (PP (IN in) (NP (NN ultrasound) (NN production)))) (VP (VBD corresponded) (PP (IN with) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ cardiovascular) (NNS variables)) (, ,) (PP (VBG including) (NP (NP (NN baseline) (JJ cardiac) (NN rate)) (CC and) (NP (JJ Doc_10737864_1038_1047_Chemical-induced) (NN Doc_10737864_1056_1067_Disease))))))))) (. .)))
10737864	6	(S1 (S (NP (DT This) (NN experiment)) (VP (AUX is) (VP (VBN discussed) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NN ultrasound) (NN production)) (VP (AUX is) (NP (NP (DT the) (JJ acoustic) (NN by-product)) (PP (IN of) (NP (NP (DT a) (JJ physiological) (NN maneuver)) (SBAR (WHNP (WDT that)) (S (VP (VBZ compensates) (PP (IN for) (NP (NP (NP (NNP Doc_10737864_1231_1240_Chemical) (POS 's)) (JJ detrimental) (NNS effects)) (PP (IN on) (NP (JJ cardiovascular) (NN function)))))))))))))))))))) (. .)))
10739826	0	(S1 (FRAG (NP (NN Recurrent) (NN use)) (PP (IN of) (NP (NP (JJR newer) (NN Doc_10739826_23_42_Chemical)) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_10739826_59_81_Disease)))))) (. .)))
10739826	1	(S1 (NP (NP (DT The) (JJ epidemiological) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBD assessed) (SBAR (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_10739826_137_159_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10739826_161_164_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (NP (JJR newer) (NNP Doc_10739826_188_207_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10739826_209_211_Chemical)) (-RRB- -RRB-)))))) (VP (AUX did) (RB not) (VP (VB distinguish) (PP (IN between) (NP (NP (NP (NNS patterns)) (PP (IN of) (NP (JJ Doc_10739826_253_255_Chemical) (NN use)))) (, ,) (ADVP (RB namely)) (NP (JJ first-time) (NNS users)) (, ,) (NP (NNS repeaters)) (CC and) (NP (NNS switchers))))))))))) (. .)))
10739826	2	(S1 (S (NP (NP (NNS Data)) (PP (IN from) (NP (DT a) (JJ Transnational) (NN case-control) (NN study)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_10739826_388_391_Disease))) (PP (IN for) (NP (NP (DT the) (JJ latter) (NNS patterns)) (PP (IN of) (NP (NN use))))))))) (, ,) (SBAR (IN while) (S (VP (VBG accounting) (PP (IN for) (NP (NP (NN duration)) (PP (IN of) (NP (NN use)))))))))) (. .)))
10739826	3	(S1 (S (PP (IN Over) (NP (DT the) (NN period) (CD 1993-1996))) (, ,) (NP (NP (CD 551) (NNS cases)) (PP (IN of) (NP (NNP Doc_10739826_502_505_Disease)))) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (NP (NNP Germany)) (CC and) (NP (DT the) (NNP UK)))) (PP (IN along) (PP (IN with) (NP (CD 2066) (NNS controls)))))) (. .)))
10739826	4	(S1 (S (NP (NP (NNS Totals)) (PP (IN of) (NP (NP (CD 128) (NNS cases)) (CC and) (NP (CD 650) (NNS controls))))) (VP (AUX were) (VP (VBN analysed) (PP (IN for) (NP (NP (NN repeat) (NN use)) (CC and) (NP (NP (NP (CD 135) (NNS cases)) (CC and) (NP (CD 622) (NNS controls))) (PP (IN for) (NP (VBG switching) (NNS patterns)))))))) (. .)))
10739826	5	(S1 (S (NP (NP (DT The) (JJ adjusted) (NN rate) (NN ratio)) (PP (IN of) (NP (NNP Doc_10739826_718_721_Disease))) (PP (IN for) (NP (NP (NN repeat) (NNS users)) (PP (IN of) (NP (JJ third) (NN generation))))) (NP (NNP Doc_10739826_759_761_Chemical))) (VP (AUX was) (NP (NP (CD 0.6)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI:0.3-1.2)) (-RRB- -RRB-)) (ADJP (JJ relative) (PP (TO to) (NP (NP (NN repeat) (NNS users)) (PP (IN of) (NP (JJ second) (NN generation) (NNS pills))) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (AUX was) (NP (NP (CD 1.3)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI:0.7-2.4)) (-RRB- -RRB-))) (PP (IN for) (NP (NP (NNS switchers)) (PP (IN from) (NP (NP (ADJP (JJ second) (TO to) (JJ third)) (NN generation) (NNS pills)) (ADJP (JJ relative) (PP (TO to) (NP (NP (NNS switchers)) (PP (PP (IN from) (NP (JJ third))) (PP (TO to) (NP (JJ second) (NN generation) (NNS pills))))))))))))))))))) (. .)))
10739826	6	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (ADJP (JJ second) (CC and) (JJ third)) (NN generation) (NNS agents)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (NP (JJ equivalent) (NNS risks)) (PP (IN of) (NP (NNP Doc_10739826_1081_1084_Disease))))) (SBAR (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ same) (NN agent)) (VP (AUX is) (VP (VBN used) (ADVP (RB repeatedly)) (PP (IN after) (NP (NN interruption) (NNS periods))))))) (CC or) (SBAR (WHADVP (WRB when)) (S (NP (NNS users)) (VP (AUX are) (VP (VBN switched) (PP (IN between) (NP (NP (DT the) (CD two) (NNS generations)) (PP (IN of) (NP (NNS pills))))))))))))))) (. .)))
10739826	7	(S1 (S (NP (DT These) (NNS analyses)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJR higher) (NN risk)) (VP (VBN observed) (PP (IN for) (NP (NP (DT the) (JJR newer) (NN Doc_10739826_1283_1285_Chemical)) (PP (IN in) (NP (JJ other) (NNS studies))))))) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ inadequate) (NNS comparisons)) (PP (IN of) (NP (NN pill) (NNS users))) (PP (IN with) (NP (NP (JJ different) (NNS patterns)) (PP (IN of) (NP (NN pill) (NN use))))))))))))) (. .)))
10743446	0	(S1 (S (NP (NP (NN Differential) (NNS effects)) (PP (IN of) (NP (NP (ADJP (RB systemically) (VBN administered)) (NNP Doc_10743446_50_58_Chemical)) (CC and) (NP (NNP Doc_10743446_63_72_Chemical)))) (PP (IN on) (NP (ADJP (JJ dynamic) (CC and) (JJ static)) (NNP Doc_10743446_95_107_Disease)))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intradermal) (NN Doc_10743446_131_140_Chemical)) (PP (IN in) (NP (NNS humans)))))) (. .)))
10743446	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ systemic) (NN administration)) (PP (IN of) (NP (NNP Doc_10743446_210_218_Chemical) (CC and) (NNP Doc_10743446_223_232_Chemical))))) (PP (IN on) (NP (NP (JJ brush-evoked) (-LRB- -LRB-) (JJ dynamic) (-RRB- -RRB-) (NNP Doc_10743446_259_263_Disease)) (CC and) (NP (JJ punctate-evoked) (-LRB- -LRB-) (JJ static) (-RRB- -RRB-) (NNP Doc_10743446_293_305_Disease) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10743446_317_326_Chemical)))))))))) (. .)))
10743446	2	(S1 (S (PP (IN In) (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (, ,) (JJ crossover) (NN study))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (CD 12) (NNS volunteers)) (PP (IN in) (NP (CD three) (NNS experiments)))) (. .)))
10743446	3	(S1 (S (NP (JJ Doc_10743446_443_452_Chemical) (CD 100) (NNS micrograms)) (VP (AUX was) (VP (VBN injected) (ADVP (RB intradermally)) (PP (IN on) (NP (NP (DT the) (JJ volar) (NN forearm)) (VP (VBN followed) (PP (IN by) (NP (NP (DT an) (JJ i.v.) (NN infusion)) (PP (IN of) (NP (NP (NP (NNP Doc_10743446_548_556_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ bolus) (CD 0.1) (ADJP (RB mg) (JJ kg-1) (PP (IN over) (NP (NP (CD 10) (NN min)) (VP (VBN followed) (PP (IN by) (NP (NP (NN infusion)) (PP (IN of) (NP (CD 7) (NNS micrograms))))))))) (JJ kg-1) (NN min-1)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_10743446_638_647_Chemical) (CD 5) (NN mg) (NN kg-1)) (CC or) (NP (NP (NN saline)) (PP (IN for) (NP (CD 50) (NN min)))))))))))))) (. .)))
10743446	4	(S1 (S (NP (NN Infusion)) (VP (VBD started) (NP (CD 15) (NN min)) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NNP Doc_10743446_723_732_Chemical)))))) (. .)))
10743446	5	(S1 (S (S (NP (DT The) (JJ following)) (VP (AUX were) (VP (VBN measured)))) (: :) (S (NP (NP (JJ spontaneous) (NN Doc_10743446_775_779_Disease)) (, ,) (NP (NNP Doc_10743446_781_785_Disease))) (VP (VBN evoked) (PP (IN by) (NP (NP (NP (NN punctate) (CC and) (NN brush) (NNS stimuli)) (PRN (-LRB- -LRB-) (NP (NNP VAS)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNS areas)) (PP (IN of) (NP (ADJP (JJ brush-evoked) (CC and) (JJ punctate-evoked)) (NNP Doc_10743446_876_888_Disease)))))))) (. .)))
10743446	6	(S1 (S (S (NP (NN Doc_10743446_890_898_Chemical)) (VP (VBD reduced) (NP (NP (PDT both) (DT the) (NN area)) (PP (IN of) (NP (ADJP (JJ brush-evoked) (CC and) (JJ punctate-evoked)) (NN Doc_10743446_957_969_Disease)))) (ADVP (RB significantly)))) (CC and) (S (NP (PRP it)) (VP (VBD tended) (S (VP (TO to) (VP (VB reduce) (NP (JJ brush-evoked) (NN Doc_10743446_1021_1025_Disease))))))) (. .)))
10743446	7	(S1 (S (NP (NN Doc_10743446_1027_1036_Chemical)) (VP (VBD reduced) (NP (NP (DT the) (NN area)) (PP (IN of) (NP (JJ punctate-evoked) (NN Doc_10743446_1073_1085_Disease)))) (ADVP (RB significantly))) (. .)))
10743446	8	(S1 (S (NP (PRP It)) (VP (VP (VBD tended) (S (VP (TO to) (VP (VB reduce) (NP (NP (NN VAS) (NNS scores)) (PP (IN of) (NP (JJ spontaneous) (NN Doc_10743446_1147_1151_Disease)))))))) (CC but) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (JJ evoked) (NNP Doc_10743446_1180_1184_Disease)))))) (. .)))
10743446	9	(S1 (S (NP (NP (DT The) (NN differential) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_10743446_1214_1222_Chemical)) (CC and) (NP (NNP Doc_10743446_1227_1236_Chemical)))) (PP (IN on) (NP (NP (JJ static)) (CC and) (NP (JJ dynamic) (NNP Doc_10743446_1259_1271_Disease))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (CD two) (NNS types)) (PP (IN of) (NP (NNP Doc_10743446_1302_1314_Disease)))) (VP (VP (AUX are) (VP (VBN mediated) (PP (IN by) (NP (JJ separate) (NNS mechanisms))))) (CC and) (VP (AUX have) (NP (DT a) (JJ distinct) (NN pharmacology))))))) (. .)))
10791295	0	(S1 (NP (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_10791295_15_26_Chemical-induced) (NNP Doc_10791295_35_54_Disease)))) (: :) (NP (NP (NN comparison)) (PP (IN of) (NP (NN adult) (ADJP (JJ male) (CC and) (JJ female)) (NN Wistar) (NNS rats)))) (. .)))
10791295	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NP (NNP Doc_10791295_124_135_Chemical-induced) (PRN (-LRB- -LRB-) (NP (NP (CD 1.0) (JJ mg/kg) (NNP s.c.)) (ADJP (RB once) (JJ daily))) (-RRB- -RRB-)) (NNP Doc_10791295_172_191_Disease)) (PP (IN of) (NP (NP (JJ adult) (ADJP (JJ male) (CC and) (JJ female)) (JJ Wistar) (NNS rats)) (VP (VBN obtained) (PP (IN from) (NP (DT the) (JJ same) (NN breeder))))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (CD two) (JJ consecutive) (NNS sets))))) (. .)))
10791295	2	(S1 (S (PP (IN In) (NP (JJ male) (NNS animals))) (, ,) (NP (VBN repeated) (JJ Doc_10791295_323_334_Chemical) (NN treatment)) (VP (VBN induced) (NP (NP (DT a) (JJ gradual) (NN development)) (PP (IN of) (NP (NNP Doc_10791295_378_397_Disease)))) (SBAR (IN as) (S (VP (VP (VBN evidenced) (PP (IN by) (NP (NP (DT the) (VBN increased) (NN intensity)) (PP (IN of) (NP (NNP Doc_10791295_441_455_Disease)))))) (CC and) (VP (VBN shortened) (NP (NN latency)) (PP (IN before) (NP (NP (DT the) (JJ first) (NN attack)) (PP (IN toward) (NP (DT the) (NN opponent)))))))))) (. .)))
10791295	3	(S1 (S (PP (IN In) (NP (JJ female) (NNS rats))) (, ,) (NP (NP (RB only) (DT a) (JJ weak) (NN tendency)) (PP (IN toward) (NP (NNP Doc_10791295_567_581_Disease)))) (VP (AUX was) (VP (VBN found))) (. .)))
10791295	4	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT the) (JJ present) (NN study)) (VP (VP (VBZ demonstrates) (NP (NN gender) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (JJ Doc_10791295_684_695_Chemical-induced) (NN Doc_10791295_704_723_Disease)))))) (CC and) (VP (VBZ indicates) (SBAR (IN that) (S (NP (DT the) (JJ female) (NNS rats)) (VP (AUX do) (RB not) (VP (VB fill) (NP (NP (DT the) (JJ validation) (NNS criteria)) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (DT this) (NN method)))))))))))) (. .)))
10807237	0	(S1 (NP (NP (NP (NN Doc_10807237_0_22_Disease)) (CC and) (NP (NN Doc_10807237_27_40_Disease))) (: :) (NP (NP (NN analysis)) (PP (IN of) (NP (JJ prognostic) (NNS indicators)))) (. .)))
10807237	1	(S1 (S (NP (NP (DT The) (NN outcome)) (PP (IN of) (NP (NNP Doc_10807237_103_126_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_10807237_143_156_Disease))))) (VP (AUX is) (ADVP (RB reportedly)) (ADJP (JJ poor))) (. .)))
10807237	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT no) (NN study)) (PP (IN in) (NP (DT the) (NN literature)))) (VP (AUX has) (VP (VBN reported) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT a) (JJ statistical) (NN model)) (SBAR (S (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NNS variables)) (SBAR (WHNP (WDT that)) (S (VP (VBP influence) (NP (NN outcome))))))))))))))) (. .)))
10807237	3	(S1 (S (NP (NP (DT A) (NN review)) (PP (IN of) (NP (NNS admissions)))) (PP (IN during) (NP (DT a) (JJ 6-year) (NN period))) (VP (VBD revealed) (NP (NP (CD 14) (NNS patients)) (PP (IN with) (NP (NNP Doc_10807237_387_394_Chemical-related) (NNP Doc_10807237_403_412_Disease))))) (. .)))
10807237	4	(S1 (S (NP (DT This) (NN group)) (VP (AUX was) (PP (VBN compared) (PP (IN with) (NP (NP (NP (DT a) (NN control) (NN group)) (PP (IN of) (NP (NP (CD 135) (NNS patients)) (PP (IN with) (NP (NNP Doc_10807237_480_498_Disease)))))) (CC and) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NNP Doc_10807237_517_530_Disease)))))))) (. .)))
10807237	5	(S1 (S (PP (NP (NN Age)) (IN at) (NP (NN presentation))) (, ,) (NP (NP (NN time)) (PP (IN of) (NP (NN ictus))) (PP (IN after) (NP (NP (NN intoxication)) (, ,) (NP (NP (NNP Hunt) (CC and) (NNP Hess) (NN grade)) (PP (IN of) (NP (NNP Doc_10807237_610_633_Disease)))) (, ,) (NP (NP (NN size)) (PP (IN of) (NP (DT the) (NNP Doc_10807237_647_655_Disease)))) (, ,) (NP (NP (NN location)) (PP (IN of) (NP (DT the) (NNP Doc_10807237_673_681_Disease)))) (, ,) (CC and) (NP (DT the) (NNP Glasgow) (NN Outcome) (NN Scale) (NN score))))) (VP (VP (AUX were) (VP (VBN assessed))) (CC and) (VP (VBN compared))) (. .)))
10807237	6	(S1 (S (NP (NP (DT The) (NNS patients)) (PP (IN in) (NP (DT the) (NN study) (NN group)))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR younger)) (PP (IN than) (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.002))) (-RRB- -RRB-))) (. .)))
10807237	7	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (NN study) (NN group))))) (, ,) (NP (DT all) (NNP Doc_10807237_903_912_Disease)) (VP (AUX were) (VP (VBN located) (PP (IN in) (NP (DT the) (NNP anterior) (NN circulation))))) (. .)))
10807237	8	(S1 (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (DT these) (NNP Doc_10807237_977_986_Disease)))) (VP (AUX were) (ADJP (ADJP (JJR smaller)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (NN control) (NN group)))))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 8) (CD +/-)) (QP (CD 6.08) (CD mm) (CC versus) (CD 11)) (JJ +/-) (CD 5.4) (NNS mm)) (: ;) (NP (NNP P) (SYM =) (CD 0.05))) (-RRB- -RRB-))) (. .)))
10807237	9	(S1 (S (NP (NP (DT The) (NNS differences)) (PP (IN in) (NP (NP (NN mortality)) (CC and) (NP (NN morbidity)))) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))) (VP (AUX were) (RB not) (ADJP (JJ significant))) (. .)))
10807237	10	(S1 (S (NP (NP (NP (NP (NN Hunt)) (CC and) (NP (NNP Hess) (NN grade))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.005))) (-RRB- -RRB-))) (CC and) (NP (NP (NN age)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.007))) (-RRB- -RRB-)))) (VP (AUX were) (NP (NP (JJ significant) (NNS predictors)) (PP (IN of) (NP (NP (NN outcome)) (PP (IN for) (NP (NP (DT the) (NNS patients)) (PP (IN with) (NP (NNP Doc_10807237_1281_1288_Chemical-related) (NNP Doc_10807237_1297_1306_Disease))))))))) (. .)))
10807237	11	(S1 (S (NP (JJ Doc_10807237_1320_1327_Chemical) (NN use)) (VP (VBD predisposed) (NP (NNP Doc_10807237_1344_1362_Disease)) (PP (PP (IN at) (NP (DT a) (ADJP (RB significantly) (JJR earlier)) (NN age))) (CC and) (PP (IN in) (NP (ADJP (RB much) (JJR smaller)) (NN Doc_10807237_1414_1423_Disease))))) (. .)))
10807237	12	(S1 (S (ADVP (JJ Contrary) (PP (TO to) (NP (DT the) (VBN published) (NN literature)))) (, ,) (NP (DT this) (NN group)) (VP (AUX did) (ADVP (RB reasonably)) (ADVP (RB well)) (PP (IN with) (NP (JJ aggressive) (NN management)))) (. .)))
10835440	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_10835440_22_32_Chemical))) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN outcome)))) (PP (IN after) (NP (NNP Doc_10835440_69_81_Disease))) (. .)))
10835440	1	(S1 (NP (NP (NP (NN BACKGROUND)) (CC AND) (NP (NN PURPOSE))) (: :) (S (NP (NP (DT The) (JJ Intravenous) (NNP Doc_10835440_123_133_Chemical) (NNP West) (NNP European) (NNP Doc_10835440_148_154_Disease) (NNP Trial)) (PRN (-LRB- -LRB-) (NP (NNP INWEST)) (-RRB- -RRB-))) (VP (VBD found) (NP (NP (DT a) (NN correlation)) (PP (IN between) (NP (NP (NP (NNP Doc_10835440_198_208_Chemical-induced) (NNP Doc_10835440_217_244_Disease)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (CC and) (NP (NP (DT an) (JJ unfavorable) (NN outcome)) (PP (IN in) (NP (NNP Doc_10835440_280_292_Disease))))))))) (. .)))
10835440	2	(S1 (S (NP (PRP We)) (VP (VBD sought) (S (VP (VP (TO to) (VP (VB confirm) (NP (NP (DT this) (NN correlation)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NN adjustment)) (PP (IN for) (NP (JJ prognostic) (NNS variables))))))))) (CC and) (VP (TO to) (VP (VB investigate) (NP (NP (NN outcome)) (PP (IN in) (NP (NP (NNS subgroups)) (PP (IN with) (NP (NP (VBG increasing) (NNS levels)) (PP (IN of) (NP (NNP Doc_10835440_451_463_Disease))))))))))))) (. .)))
10835440	3	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (DT a) (JJ clinical) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10835440_512_527_Disease))))) (PRN (-LRB- -LRB-) (PP (IN within) (NP (CD 24) (NNS hours))) (-RRB- -RRB-))) (VP (AUX were) (ADVP (RB consecutively)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD n=100)) (-RRB- -RRB-)) (, ,) (NP (QP (CD 1) (CD mg/h)) (PRN (-LRB- -LRB-) (NP (NN low-dose)) (-RRB- -RRB-)) (NNP Doc_10835440_621_631_Chemical)) (PRN (-LRB- -LRB-) (NP (CD n=101)) (-RRB- -RRB-)) (, ,) (CC or) (NP (NP (QP (CD 2) (CD mg/h)) (PRN (-LRB- -LRB-) (NP (NN high-dose)) (-RRB- -RRB-)) (NNP Doc_10835440_663_673_Chemical)) (PRN (-LRB- -LRB-) (NP (CD n=94)) (-RRB- -RRB-))))))))) (. .)))
10835440	4	(S1 (S (NP (NP (DT The) (NN correlation)) (PP (IN between) (NP (NP (NP (JJ average) (NNP BP) (NN change)) (PP (IN during) (NP (DT the) (JJ first) (CD 2) (NNS days)))) (CC and) (NP (NP (DT the) (NN outcome)) (PP (IN at) (NP (NN day) (CD 21))))))) (VP (AUX was) (VP (VBN analyzed))) (. .)))
10835440	5	(S1 (S (NP (QP (CD Two) (CD hundred)) (JJ sixty-five) (NNS patients)) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (NP (DT this) (NN analysis)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD n=92)) (, ,) (NP (CD 93)) (, ,) (CC and) (NP (CD 80))) (PP (IN for) (NP (NP (NN placebo)) (, ,) (NP (JJ low) (NN dose)) (, ,) (CC and) (NP (JJ high) (NN dose)) (, ,) (ADVP (RB respectively))))) (-RRB- -RRB-)))))) (. .)))
10835440	6	(S1 (S (NP (JJ Doc_10835440_931_941_Chemical) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NNP Doc_10835440_992_1016_Disease)) (PRN (-LRB- -LRB-) (NP (NNP SBP)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ diastolic) (NNP BP)) (PRN (-LRB- -LRB-) (NP (NNP DBP)) (-RRB- -RRB-))))) (PP (IN from) (NP (NN baseline))) (PP (VBN compared) (PP (IN with) (NP (NN placebo)))) (PP (IN during) (NP (DT the) (JJ first) (JJ few) (NNS days)))) (. .)))
10835440	7	(S1 (S (PP (IN In) (NP (NN multivariate) (NN analysis))) (, ,) (NP (NP (DT a) (JJ significant) (NN correlation)) (PP (IN between) (NP (NP (NNP Doc_10835440_1169_1182_Disease) (CC and) (VBG worsening)) (PP (IN of) (NP (DT the) (JJ neurological) (NN score)))))) (VP (AUX was) (VP (VBN found) (PP (IN for) (NP (NP (DT the) (JJ high-dose) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD beta=0.49)) (, ,) (NP (NNP P=0.) (CD 048))) (-RRB- -RRB-)))))) (. .)))
10835440	8	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (DT a) (NN Doc_10835440_1296_1309_Disease)) (PP (IN of) (NP (NP (QP (CD >) (CC or) (CD =20)) (NN %)) (PP (IN in) (NP (DT the) (JJ high-dose) (NN group)))))))) (VP (AUX had) (NP (NP (DT a) (ADJP (RB significantly) (VBN increased))) (VP (VBN adjusted) (PP (CC OR) (PP (IN for) (NP (NP (NP (DT the) (NN compound) (NN outcome)) (NP (JJ variable) (NNP Doc_10835440_1422_1427_Disease))) (CC or) (NP (NP (NN dependency)) (-LRB- -LRB-) (NP (NNP Barthel) (NNP Index) (CD <60)) (-RRB- -RRB-)))) (PRN (-LRB- -LRB-) (NP (NP (CD n/N=25/26)) (, ,) (CC OR) (NP (QP (CD 10.) (CD 16))) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.02) (TO to) (CD 101.74)))) (-RRB- -RRB-)) (CC and) (NP (NP (NNP Doc_10835440_1512_1517_Disease)) (ADVP (RB alone)))) (PRN (-LRB- -LRB-) (S (NP (NP (CD n/N=9/26)) (, ,) (CC OR) (NP (CD 4.336)) (, ,) (NP (CD 95) (NN %))) (VP (VBG CI) (NP (QP (CD 1.131) (CD 16.619))))) (-RRB- -RRB-)) (PP (VBN compared) (PP (IN with) (NP (NP (DT all) (NN placebo) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD n/N=62/92) (CC and) (CD 14/92)) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))))))) (. .)))
10835440	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN correlation)) (PP (IN between) (S (VP (VBG SBP) (NP (NP (NN change)) (CC and) (NP (NN outcome)))))))) (. .)))
10835440	10	(S1 (S (NP (NP (NN DBP)) (, ,) (CONJP (CC but) (RB not)) (NP (NN SBP)) (, ,) (NP (NN reduction))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ neurological) (VBG worsening)) (PP (IN after) (NP (NP (DT the) (JJ intravenous) (NN administration)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_10835440_1829_1839_Chemical))) (PP (IN after) (NP (NNP Doc_10835440_1846_1858_Disease))))))))) (. .)))
10835440	11	(S1 (S (PP (IN For) (NP (JJ low-dose) (NNP Doc_10835440_1873_1883_Chemical))) (, ,) (NP (DT the) (NNS results)) (VP (AUX were) (RB not) (ADJP (JJ conclusive))) (. .)))
10835440	12	(S1 (S (NP (DT These) (NNS results)) (VP (AUX do) (RB not) (VP (VB confirm) (CC or) (VB exclude) (NP (NP (DT a) (JJ neuroprotective) (NN property)) (PP (IN of) (NP (NNP Doc_10835440_1988_1998_Chemical)))))) (. .)))
1085609	0	(S1 (NP (NP (JJ Neonatal) (JJ Doc_1085609_9_19_Chemical) (JJ responsive) (NN Doc_1085609_31_42_Disease)) (ADJP (JJ due) (PP (TO to) (NP (JJ Doc_1085609_50_59_Chemical) (NN therapy)))) (. .)))
1085609	1	(S1 (S (NP (NP (DT A) (JJ 17-day-old) (NN infant)) (PP (IN on) (S (NP (NNP Doc_1085609_92_101_Chemical) (NN therapy) (CD 13)) (VP (VBG mg/kg) (ADVP (RB daily)) (PP (IN from) (NP (NN birth))) (PP (IN because) (IN of) (NP (JJ maternal) (NNP Doc_1085609_156_168_Disease))))))) (VP (AUX was) (VP (VBN admitted) (PP (IN after) (NP (NP (CD 4) (NNS days)) (PP (IN of) (NP (NNP Doc_1085609_198_209_Disease))))))) (. .)))
1085609	2	(S1 (S (NP (NP (DT No) (JJ underlying) (NN infective)) (CC or) (NP (JJ biochemical) (NN cause))) (VP (MD could) (VP (AUX be) (VP (VBN found)))) (. .)))
1085609	3	(S1 (S (NP (DT The) (NNP Doc_1085609_276_280_Disease)) (VP (VBD ceased) (PP (IN within) (NP (NP (CD 4) (NNS hours)) (PP (IN of) (S (VP (VBG administering) (NP (JJ intramuscular) (NNP Doc_1085609_334_344_Chemical))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT an) (NN aetiology)) (PP (IN of) (NP (JJ Doc_1085609_373_383_Chemical) (NN deficiency))) (ADJP (JJ secondary) (PP (TO to) (NP (JJ Doc_1085609_408_417_Chemical) (NN medication)))))))) (. .)))
10901305	0	(S1 (NP (NP (JJ Doc_10901305_0_8_Chemical) (NN sedation)) (PP (IN for) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (NNS children) (POS 's)) (NNP Doc_10901305_50_59_Disease))) (PP (IN in) (NP (DT the) (NN emergency) (NN department))))) (. .)))
10901305	1	(S1 (S (NP (EX There)) (ADVP (RB recently)) (VP (AUX has) (VP (AUX been) (NP (NP (DT a) (NN resurgence)) (PP (IN in) (NP (NP (DT the) (NN utilization)) (PP (IN of) (NP (NP (NNP Doc_10901305_160_168_Chemical)) (, ,) (NP (NP (DT a) (JJ unique) (NN anesthetic)) (, ,) (PP (IN for) (NP (NP (JJ emergency-department) (NNS procedures)) (VP (VBG requiring) (NP (NN sedation))))))))))))) (. .)))
10901305	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NNP Doc_10901305_322_330_Chemical))) (PP (IN for) (NP (NN sedation))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NP (NNS children) (POS 's)) (NNP Doc_10901305_375_384_Disease)) (PP (IN in) (NP (DT the) (NN emergency) (NN department)))))))))))) (. .)))
10901305	3	(S1 (S (NP (NP (QP (CD One) (CD hundred) (CC and) (CD fourteen)) (NNS children)) (PRN (-LRB- -LRB-) (NP (NP (JJ average) (NN age)) (, ,) (NP (CD 5.3) (NNS years))) (: ;) (NP (NP (NN range)) (, ,) (NP (NP (NP (CD twelve) (NNS months)) (PP (TO to) (NP (CD ten) (NNS years)))) (CC and) (NP (CD ten) (NNS months)))) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (VBN closed) (NN reduction)) (PP (IN of) (NP (NP (DT an) (VBN isolated) (NNP Doc_10901305_578_586_Disease)) (CC or) (NP (NNP Doc_10901305_590_601_Disease))))) (PP (IN in) (NP (NP (DT the) (NN emergency) (NN department)) (PP (IN at) (NP (DT a) (JJ level-I) (JJ Doc_10901305_643_649_Disease) (NN center))))))))) (VP (AUX were) (ADVP (RB prospectively)) (VP (VBN evaluated))) (. .)))
10901305	4	(S1 (S (NP (NNP Doc_10901305_687_709_Chemical)) (VP (AUX was) (VP (VP (VBN administered) (ADVP (RB intravenously)) (PRN (-LRB- -LRB-) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD two) (NNS milligrams)) (PP (IN per) (NP (NP (NN kilogram)) (PP (IN of) (NP (NN body) (NN weight))))))))) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NN ninety-nine)) (PP (IN of) (NP (DT the) (NNS patients)))))) (CC and) (ADVP (RB intramuscularly)) (-LRB- -LRB-) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD four) (NNS milligrams)) (PP (IN per) (NP (NP (NN kilogram)) (PP (IN of) (NP (NN body) (NN weight))))))))) (-RRB- -RRB-) (PP (IN in) (NP (DT the) (JJ other) (NNS fifteen))))) (. .)))
10901305	5	(S1 (S (S (NP (NP (DT A) (JJ board-certified) (NN emergency) (NN physician)) (ADJP (JJ skilled) (PP (IN in) (NP (JJ airway) (NN management))))) (VP (VBD supervised) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NN anesthetic)))))) (, ,) (CC and) (S (NP (DT the) (NNS patients)) (VP (AUX were) (VP (VBN monitored) (PP (IN by) (NP (DT a) (JJ registered) (NN nurse)))))) (. .)))
10901305	6	(S1 (S (NP (NP (DT Any) (NN Doc_10901305_1102_1106_Disease)) (PP (IN during) (NP (DT the) (NN reduction)))) (VP (AUX was) (VP (VBN rated) (PP (IN by) (S (NP (DT the) (JJ orthopaedic) (NN surgeon)) (VP (VBG treating) (NP (DT the) (NN patient)) (PP (VBG according) (PP (TO to) (NP (NP (NP (DT the) (NNS Children) (POS 's)) (NNP Hospital)) (PP (IN of) (NP (NP (NNP Eastern) (NNP Ontario) (NNP Doc_10901305_1242_1246_Disease) (NNP Scale)) (PRN (-LRB- -LRB-) (NP (NNP CHEOPS)) (-RRB- -RRB-)))))))))))) (. .)))
10901305	7	(S1 (S (S (NP (NP (DT The) (JJ average) (NN time)) (PP (IN from) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_10901305_1324_1332_Chemical))))) (PP (TO to) (NP (NP (NN manipulation)) (PP (IN of) (NP (DT the) (NNP Doc_10901305_1356_1364_Disease) (CC or) (NNP Doc_10901305_1368_1379_Disease)))))) (VP (AUX was) (NP (NP (CD one) (NN minute)) (CC and) (NP (NP (JJ thirty-six) (NNS seconds)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (NP (CD twenty) (NNS seconds)) (PP (TO to) (NP (CD five) (NNS minutes)))) (-RRB- -RRB-)))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ average) (NN time)) (PP (IN from) (NP (JJ intramuscular) (NN administration))) (PP (TO to) (NP (NN manipulation)))) (VP (AUX was) (NP (NP (CD four) (NNS minutes)) (CC and) (NP (NP (JJ forty-two) (NNS seconds)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (NP (CD sixty) (NNS seconds)) (PP (TO to) (NP (JJ fifteen) (NNS minutes)))) (-RRB- -RRB-)))))) (. .)))
10901305	8	(S1 (S (NP (DT The) (JJ average) (NN score)) (PP (VBG according) (PP (TO to) (NP (DT the) (NNP Children) (POS 's)))) (NP (NAC (NNP Hospital) (PP (IN of) (NP (NNP Eastern) (NNP Ontario)))) (NNP Doc_10901305_1686_1690_Disease) (NNP Scale)) (VP (AUX was) (NP (NP (CD 6.4) (NNS points)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (QP (CD 5) (TO to) (CD 10)) (NNS points)) (-RRB- -RRB-))) (, ,) (S (VP (VP (VBG reflecting) (ADJP (JJ minimal))) (CC or) (VP (NP (DT no) (NN Doc_10901305_1762_1766_Disease)) (PP (IN during) (NP (JJ Doc_10901305_1774_1782_Disease) (NN reduction))))))) (. .)))
10901305	9	(S1 (S (NP (JJ Adequate) (NN Doc_10901305_1803_1811_Disease) (NN reduction)) (VP (AUX was) (VP (VBN obtained) (PP (IN in) (NP (NP (CD 111)) (PP (IN of) (NP (DT the) (NNS children))))))) (. .)))
10901305	10	(S1 (S (NP (NP (JJ Ninety-nine) (NN percent)) (PRN (-LRB- -LRB-) (NP (NN sixty-eight)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (DT the) (JJ sixty-nine) (NNS parents)) (ADJP (JJ present) (PP (IN during) (NP (DT the) (NN reduction))))))) (VP (VP (AUX were) (VP (VBN pleased) (PP (IN with) (NP (DT the) (NN sedation))))) (CC and) (VP (MD would) (VP (VB allow) (S (NP (PRP it)) (VP (TO to) (VP (AUX be) (VP (VBN used) (ADVP (RB again)) (PP (IN in) (NP (DT a) (JJ similar) (NN situation)))))))))) (. .)))
10901305	11	(S1 (S (NP (NP (NN Patency)) (PP (IN of) (NP (DT the) (ADJP (JJ airway) (CC and) (JJ independent)) (NN respiration)))) (VP (AUX were) (VP (VBN maintained) (PP (IN in) (NP (NP (DT all)) (PP (IN of) (NP (DT the) (NNS patients))))))) (. .)))
10901305	12	(S1 (S (NP (NP (NN Blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))) (VP (VBD remained) (ADJP (JJ stable))) (. .)))
10901305	13	(S1 (S (NP (JJ Minor) (NN side) (NNS effects)) (VP (VBD included) (NP (NP (NP (NNP Doc_10901305_2204_2210_Disease)) (PRN (-LRB- -LRB-) (NP (JJ thirteen) (NNS patients)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_10901305_2232_2238_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD eight)) (PP (IN of) (NP (NP (DT the) (JJ thirteen) (NNS patients)) (PP (IN with) (NP (NNP Doc_10901305_2276_2282_Disease)))))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10901305_2285_2295_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ evident)) (PP (IN as) (NP (NNP Doc_10901305_2308_2324_Disease))) (PP (IN in) (NP (CD ten) (NNS patients)))) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (NNP Doc_10901305_2347_2365_Disease)) (PRN (-LRB- -LRB-) (NP (CD one) (NN patient)) (-RRB- -RRB-))))) (. .)))
10901305	14	(S1 (S (S (NP (DT No) (JJ long-term) (NNS sequelae)) (VP (AUX were) (VP (VBN noted)))) (, ,) (CC and) (S (NP (DT no) (NNS patients)) (VP (AUX had) (NP (NP (NN Doc_10901305_2435_2449_Disease)) (CC or) (NP (NNS nightmares))))) (. .)))
10901305	15	(S1 (S (VP (VB Doc_10901305_2478_2486_Chemical) (ADVP (RB reliably)) (, ,) (ADVP (RB safely)) (, ,) (CC and) (ADVP (RB quickly)) (VP (VBN provided) (NP (JJ adequate) (NN sedation)) (S (VP (TO to) (VP (ADVP (RB effectively)) (VB facilitate) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (NNS children) (POS 's)) (NNP Doc_10901305_2598_2607_Disease))) (PP (IN in) (NP (NP (DT the) (NN emergency) (NN department)) (PP (IN at) (NP (PRP$ our) (NN institution))))))))))) (. .)))
10901305	16	(S1 (S (NP (NN Doc_10901305_2656_2664_Chemical)) (VP (MD should) (ADVP (RB only)) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (NP (DT an) (NN environment)) (PP (JJ such) (IN as) (NP (NP (DT the) (NN emergency) (NN department)) (, ,) (SBAR (WHADVP (WRB where)) (S (S (NP (JJ proper) (JJ one-on-one) (NN monitoring)) (VP (AUX is) (VP (VBN used)))) (CC and) (S (NP (NP (JJ board-certified) (NNS physicians)) (ADJP (JJ skilled) (PP (IN in) (NP (JJ airway) (NN management))))) (VP (AUX are) (VP (ADVP (RB directly)) (VBN involved) (PP (IN in) (NP (NP (DT the) (NN care)) (PP (IN of) (NP (DT the) (NN patient))))))))))))))))) (. .)))
11007689	0	(S1 (NP (NNP Doc_11007689_0_12_Chemical) (CC and) (NNP Doc_11007689_17_27_Chemical-associated) (NNP Doc_11007689_39_65_Disease) (. .)))
11007689	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NP (NNP Doc_11007689_86_112_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11007689_114_117_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_11007689_146_158_Chemical))))))) (VP (AUX has) (VP (AUX been) (ADVP (RB well)) (VP (VBN documented)))) (. .)))
11007689	2	(S1 (S (NP (NNS Treatments)) (VP (AUX have) (VP (VBN included) (NP (NP (NP (NN discontinuation)) (CC or) (NP (NN reduction))) (PP (IN of) (NP (JJ Doc_11007689_242_254_Chemical) (NN dose)))) (PP (IN with) (CC or) (PP (IN without) (NP (NP (JJ concurrent) (NN plasma) (NN exchange)) (, ,) (NP (NN plasma) (NN infusion)) (, ,) (NP (NN anticoagulation)) (, ,) (CC and) (NP (JJ intravenous) (JJ immunoglobulin) (NNP G) (NN infusion))))))) (. .)))
11007689	3	(S1 (S (ADVP (RB However)) (, ,) (PP (IN for) (NP (NP (NNS recipients)) (PP (IN of) (NP (NN organ) (NN transplantation))))) (, ,) (VP (VBG removing) (NP (DT the) (VBG inciting) (NN agent))) (VP (AUX is) (RB not) (PP (IN without) (NP (NP (DT the) (JJ attendant) (NN risk)) (PP (IN of) (S (VP (VBG precipitating) (NP (NP (JJ acute) (NN rejection)) (CC and) (NP (NN graft) (NN loss))))))))) (. .)))
11007689	4	(S1 (S (NP (DT The) (JJ last) (NN decade)) (VP (AUX has) (VP (VBN seen) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (NNP Doc_11007689_584_594_Chemical)))) (PP (IN as) (NP (NP (DT a) (JJ potent) (NN immunosuppressive) (NN agent)) (PP (IN with) (NP (NP (NNS mechanisms)) (PP (IN of) (NP (NN action))) (ADJP (RB virtually) (JJ identical) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_11007689_689_701_Chemical)))))))))))) (. .)))
11007689	5	(S1 (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (NP (NN switching)) (PP (TO to) (NP (NNP Doc_11007689_729_739_Chemical)))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (NP (DT a) (JJ viable) (JJ therapeutic) (NN option)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (NNP Doc_11007689_810_822_Chemical-induced) (NNP Doc_11007689_831_834_Disease))))))))))) (. .)))
11007689	6	(S1 (S (PP (IN With) (NP (NP (DT the) (ADJP (RBR more) (JJ widespread)) (NN application)) (PP (IN of) (NP (NNP Doc_11007689_876_886_Chemical))) (PP (IN in) (NP (NN organ) (NN transplantation))))) (, ,) (NP (NNP Doc_11007689_913_923_Chemical-associated) (NNP Doc_11007689_935_938_Disease)) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN recognized)))) (. .)))
11007689	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN literature)) (VP (VBG regarding) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_11007689_1030_1033_Disease))))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN exposed) (ADVP (RB sequentially)) (PP (TO to) (NP (NP (NNP Doc_11007689_1070_1082_Chemical)) (CC and) (NP (NNP Doc_11007689_1087_1097_Chemical)))))))))) (VP (AUX is) (VP (VBN limited))) (. .)))
11007689	8	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (VBG living) (NN donor) (JJ renal) (NN transplant) (NN recipient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (JJ Doc_11007689_1186_1198_Chemical-induced) (NN Doc_11007689_1207_1210_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD responded) (PP (TO to) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_11007689_1247_1259_Chemical))))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NNS plasmapheresis)) (CC and) (NP (JJ fresh) (JJ frozen) (NN plasma) (NN replacement) (NN therapy))))))))))))))))) (. .)))
11007689	9	(S1 (S (NP (NP (NN Introduction)) (PP (IN of) (NP (NNP Doc_11007689_1356_1366_Chemical))) (PP (IN as) (NP (DT an) (JJ alternative) (NN immunosuppressive) (NN agent)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_11007689_1439_1442_Disease)))) (CC and) (NP (NP (DT the) (JJ subsequent) (NN loss)) (PP (IN of) (NP (DT the) (JJ renal) (NN allograft))))))) (. .)))
11007689	10	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN switched) (PP (IN from) (NP (NNP Doc_11007689_1522_1534_Chemical))) (PP (TO to) (NP (NP (NNP Doc_11007689_1538_1548_Chemical)) (CC or) (NP (NN vice))))))))) (ADVP (RB versa)) (VP (MD should) (VP (AUX be) (VP (ADVP (RB closely)) (VBN monitored) (PP (IN for) (NP (NP (DT the) (NNS signs) (CC and) (NNS symptoms)) (PP (IN of) (NP (JJ recurrent) (NNP Doc_11007689_1631_1634_Disease)))))))) (. .)))
11027905	0	(S1 (NP (NP (NP (JJ Analgesic) (NN effect)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_11027905_32_40_Chemical))) (PP (IN in) (NP (NNP Doc_11027905_44_50_Disease) (NNS patients))) (PP (IN on) (NP (JJ Doc_11027905_63_71_Chemical) (NN therapy)))) (: :) (NP (DT a) (VBN randomized) (, ,) (VBN controlled) (, ,) (JJ double-blind) (, ,) (JJ crossover) (, ,) (JJ double-dose) (NN study)) (. .)))
11027905	1	(S1 (S (S (NP (NN Doc_11027905_151_155_Disease)) (ADJP (RB not) (JJ responsive) (PP (TO to) (NP (NNP Doc_11027905_174_182_Chemical))))) (VP (AUX is) (ADVP (RB often)) (ADJP (JJ problematic))) (. .)))
11027905	2	(S1 (S (NP (NN Animal) (CC and) (JJ clinical) (NNS studies)) (VP (AUX have) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (NNP Doc_11027905_253_273_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11027905_275_279_Chemical)) (-RRB- -RRB-)) (NNS antagonists)) (, ,) (PP (JJ such) (IN as) (NP (NNP Doc_11027905_302_310_Chemical))) (, ,)) (VP (MD may) (VP (AUX be) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG improving) (NP (JJ opioid) (NN analgesia)) (PP (IN in) (NP (NP (JJ difficult) (JJ Doc_11027905_372_376_Disease) (NNS syndromes)) (, ,) (PP (JJ such) (IN as) (NP (NNP Doc_11027905_396_412_Disease))))))))))))))) (. .)))
11027905	3	(S1 (S (NP (NP (DT A) (JJ slow) (NN bolus)) (PP (IN of) (NP (NP (JJ subhypnotic) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_11027905_451_459_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.25) (NN mg/kg)) (CC or) (NP (CD 0.50) (NN mg/kg))) (-RRB- -RRB-))))))) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NP (CD 10) (JJ Doc_11027905_503_509_Disease) (NNS patients)) (SBAR (WHNP (WP$ whose) (NN Doc_11027905_525_529_Disease)) (S (VP (AUX was) (VP (VBN unrelieved) (PP (IN by) (NP (NNP Doc_11027905_548_556_Chemical))) (PP (IN in) (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ crossover) (, ,) (JJ double-dose) (NN study))))))))))) (. .)))
11027905	4	(S1 (S (NP (NP (JJ Doc_11027905_618_622_Disease) (NN intensity)) (PP (IN on) (NP (NP (NP (NP (DT a) (QP (CD 0) (TO to) (CD 10)) (JJ numerical) (NN scale)) (: ;) (NP (NP (NP (NNP Doc_11027905_663_669_Disease) (CC and) (NNP Doc_11027905_674_682_Disease)) (, ,) (NP (NN drowsiness)) (, ,) (NP (NNP Doc_11027905_696_705_Disease)) (, ,) (CC and) (NP (NNP Doc_11027905_711_720_Disease)) (, ,)) (VP (VBG using) (NP (NP (DT a) (NN scale)) (PP (IN from) (NP (QP (CD 0) (TO to) (CD 3)))) (PRN (-LRB- -LRB-) (ADVP (RB not)) (PP (IN at) (NP (DT all))) (, ,) (NP (NP (JJ slight)) (, ,) (NP (DT a) (NN lot)) (, ,) (NP (JJ awful))) (-RRB- -RRB-))))) (: ;) (NP (NNP Mini-Mental) (NNP State) (NNP Examination))) (-LRB- -LRB-) (NP (NNP MMSE)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD 0-30)) (-RRB- -RRB-)) (: ;) (CC and) (NP (JJ arterial) (NN pressure))))) (VP (AUX were) (VP (VBN recorded) (PP (IN before) (NP (NP (NN administration)) (PP (PP (IN of) (NP (NP (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP T0)) (-RRB- -RRB-)))) (CC and) (PP (IN after) (NP (NP (NP (CD 30) (NNS minutes)) (PRN (-LRB- -LRB-) (NNP T30) (-RRB- -RRB-))) (, ,) (NP (NP (CD 60) (NNS minutes)) (PRN (-LRB- -LRB-) (NNP T60) (-RRB- -RRB-))) (, ,) (NP (NP (CD 120) (NNS minutes)) (PRN (-LRB- -LRB-) (NNP T120) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD 180) (NNS minutes)) (PRN (-LRB- -LRB-) (NNP T180) (-RRB- -RRB-))))))))) (. .)))
11027905	5	(S1 (S (NP (NP (NN Doc_11027905_991_999_Chemical)) (, ,) (CONJP (CC but) (RB not)) (NP (NN saline) (NN solution)) (, ,)) (VP (ADVP (RB significantly)) (VBN reduced) (NP (DT the) (JJ Doc_11027905_1052_1056_Disease) (NN intensity)) (PP (IN in) (NP (RB almost) (PDT all) (DT the) (NNS patients))) (PP (IN at) (NP (DT both) (NNS doses)))) (. .)))
11027905	6	(S1 (S (NP (DT This) (NN effect)) (VP (AUX was) (ADJP (RBR more) (JJ relevant)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (JJR higher) (NNS doses))))))) (. .)))
11027905	7	(S1 (S (S (NP (NN Doc_11027905_1178_1192_Disease)) (VP (VBD occurred) (PP (IN in) (NP (CD 4) (NNS patients))))) (, ,) (CC and) (S (NP (NP (DT an) (JJ unpleasant) (NN sensation)) (PRN (-LRB- -LRB-) (NP (`` ``) (JJ empty) (NN head) ('' '')) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB also)) (VP (VBN reported) (PP (IN by) (NP (CD 2) (NNS patients)))))) (. .)))
11027905	8	(S1 (S (NP (DT These) (NNS episodes)) (VP (VBD reversed) (SBAR (IN after) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_11027905_1345_1353_Chemical) (CD 1)))) (VP (VBD mg) (ADVP (RB intravenously)))))) (. .)))
11027905	9	(S1 (S (NP (NP (JJ Significant) (NNS increases)) (PP (IN in) (NP (NN drowsiness)))) (VP (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11027905_1449_1457_Chemical))) (PP (IN in) (NP (DT both) (NNS groups)))))))) (CC and) (VP (AUX were) (ADJP (RBR more) (JJ marked)) (PP (IN with) (NP (NNP Doc_11027905_1499_1507_Chemical) (CD 0.50) (NN mg/kg))))) (. .)))
11027905	10	(S1 (S (NP (NP (DT A) (JJ significant) (NN difference)) (PP (IN in) (NP (NN MMSE)))) (VP (AUX was) (VP (VBN observed) (PP (IN at) (NP (NNP T30))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (CD 0.50) (NN mg/kg)) (PP (IN of) (NP (NNP Doc_11027905_1612_1620_Chemical))))))))))) (. .)))
11027905	11	(S1 (S (NP (NN Doc_11027905_1622_1630_Chemical)) (VP (MD can) (VP (VB improve) (NP (NP (JJ Doc_11027905_1643_1651_Chemical) (NN analgesia)) (PP (IN in) (NP (NP (JJ difficult) (JJ Doc_11027905_1675_1679_Disease) (NNS syndromes)) (, ,) (PP (JJ such) (IN as) (NP (NNP Doc_11027905_1699_1715_Disease)))))))) (. .)))
11027905	12	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ central) (JJ adverse) (NNS effects)))) (VP (MD should) (VP (AUX be) (VP (VBN taken) (PP (IN into) (NP (NN account))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (VP (VBG using) (NP (JJR higher) (NNS doses)))))))) (. .)))
11027905	13	(S1 (S (NP (DT This) (NN observation)) (VP (MD should) (VP (AUX be) (VP (VBN tested) (PP (IN in) (NP (NP (NNS studies)) (PP (IN of) (NP (VBN prolonged) (NNP Doc_11027905_1892_1900_Chemical) (NN administration)))))))) (. .)))
11135224	0	(S1 (S (NP (NP (NNP Doc_11135224_0_10_Chemical)) (, ,) (NP (NNP Doc_11135224_12_21_Chemical)) (, ,) (CC and) (NP (JJ Doc_11135224_27_38_Chemical) (NN combination))) (VP (VBZ chemotherapy) (PP (IN within) (NP (NP (DT a) (JJ multidisciplinary) (JJ therapeutic) (NN approach)) (PP (IN in) (NP (JJ metastatic) (NNP Doc_11135224_126_154_Disease)))))) (. .)))
11135224	1	(S1 (S (NP (JJ Doc_11135224_168_177_Chemical-based) (JJ chemotherapy) (NNS combinations)) (VP (VBP improve) (NP (NP (NP (NN quality)) (PP (IN of) (NP (NN life)))) (CC and) (NP (NP (NN survival)) (PP (IN in) (NP (NP (JJ advanced) (NNP Doc_11135224_259_287_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11135224_289_294_Disease)) (-RRB- -RRB-))))))) (. .)))
11135224	2	(S1 (S (NP (NP (DT The) (NN emergence)) (PP (IN of) (NP (JJ new) (JJ active) (NNS drugs)))) (VP (MD might) (VP (VB translate) (PP (IN into) (NP (NP (ADJP (RBR more) (JJ effective)) (NNS regimens)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (DT this) (NN disease))))))))) (. .)))
11135224	3	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN feasibility)) (, ,) (NP (NN response) (NN rate)))))) (, ,) (CC and) (S (NP (NP (NNP Doc_11135224_501_509_Disease)) (PP (IN of) (NP (DT a) (NNP Doc_11135224_515_525_Chemical) (, ,) (NNP Doc_11135224_527_536_Chemical) (, ,) (CC and) (NNP Doc_11135224_542_553_Chemical) (NN combination)))) (VP (TO to) (VP (VB treat) (NP (JJ metastatic) (NN Doc_11135224_586_591_Disease))))))) (. .)))
11135224	4	(S1 (S (NP (NP (NP (JJ Thirty-five) (JJ consecutive) (JJ chemotherapy-naive) (NNS patients)) (PP (IN with) (NP (NNP Stage) (NNP IV) (NNP Doc_11135224_659_664_Disease)))) (CC and) (NP (NP (DT an) (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group) (NN performance) (NN status)) (PP (IN of) (NP (JJ 0-2))))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11135224_768_778_Chemical) (PRN (-LRB- -LRB-) (NP (NP (CD 135) (NNS mg/m)) (PRN (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (VP (VBN given) (ADVP (RB intravenously)) (PP (IN in) (NP (CD 3) (NNS hours))))) (-RRB- -RRB-) (PP (IN on) (NP (NNP Day) (CD 1))) (, ,)) (NNP Doc_11135224_834_843_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 120) (NNS mg/m) (PRN (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (VP (VBN given) (ADVP (RB intravenously)) (PP (IN in) (NP (CD 6) (NNS hours)))) (-RRB- -RRB-))) (PP (IN on) (NP (NNP Day) (CD 1)))) (, ,) (CC and) (NNP Doc_11135224_903_914_Chemical) (-LRB- -LRB-) (S (NP (CD 800) (NNS mg/m)) (PRN (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (VP (VBN given) (ADVP (RB intravenously)) (PP (IN in) (NP (CD 30) (NNS minutes))))) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (NNS Days) (CD 1) (CC and) (CD 8)) (, ,) (NP (DT every) (CD 4) (NNS weeks)))))) (. .)))
11135224	5	(S1 (S (SBAR (IN Although) (S (NP (VBG responding) (NNS patients)) (VP (AUX were) (VP (VBN scheduled) (S (VP (TO to) (VP (VB receive) (NP (NP (NN consolidation)) (SBAR (S (NP (NP (NNS radiotherapy)) (CC and) (NP (CD 24) (NNS patients))) (VP (VBD received) (NP (JJ preplanned) (JJ second-line) (NN chemotherapy)) (PP (IN after) (NP (NN disease) (NN progression)))))))))))))) (, ,) (NP (NP (DT the) (NN response) (CC and) (NN Doc_11135224_1182_1190_Disease) (NNS rates)) (VP (VBN reported))) (VP (VBP refer) (ADVP (RB only)) (PP (TO to) (NP (NP (DT the) (JJ chemotherapy) (NN regimen)) (VP (VBN given))))) (. .)))
11135224	6	(S1 (S (S (NP (PDT All) (DT the) (NNS patients)) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (NN Doc_11135224_1296_1304_Disease)))))) (: ;) (S (NP (CD 34)) (VP (AUX were) (ADJP (JJ examinable) (PP (IN for) (NP (NN response)))))) (. .)))
11135224	7	(S1 (S (NP (DT An) (JJ objective) (NN response)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 73.5) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 95) (NN %)) (NN confidence)) (JJ interval) (NN -LSB-CI) (NN -RSB-)) (, ,) (NP (CD 55.6-87.1) (NN %))) (-RRB- -RRB-)))))) (, ,) (PP (VBG including) (NP (NP (CD 4) (JJ complete) (NNS responses)) (PRN (-LRB- -LRB-) (NP (CD 11.7) (NN %)) (-RRB- -RRB-)))))) (. .)))
11135224	8	(S1 (S (PP (VBG According) (PP (TO to) (NP (NN intention-to-treat)))) (, ,) (NP (DT the) (JJ overall) (NN response) (NN rate)) (VP (AUX was) (NP (NP (CD 71.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %) (RB CI)) (, ,) (NP (QP (CD 53.) (CD 7-85.4)) (NN %))) (-RRB- -RRB-)))) (. .)))
11135224	9	(S1 (S (PP (IN After) (NP (NP (CD 154) (NNS courses)) (PP (IN of) (NP (NN therapy))))) (, ,) (NP (DT the) (JJ median) (NN dose) (NN intensity)) (VP (AUX was) (NP (NP (NP (QP (CD 131) (CD mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-) (PP (IN for) (NP (NP (NNP Doc_11135224_1651_1661_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 97.3) (NN %)) (-RRB- -RRB-)))))) (, ,) (NP (QP (CD 117) (CD mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NNP Doc_11135224_1687_1696_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 97.3) (NN %)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (QP (CD 1378) (CD mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NNP Doc_11135224_1727_1738_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 86.2) (NN %)) (-RRB- -RRB-))))))) (. .)))
11135224	10	(S1 (S (NP (NNP World) (NNP Health) (NNP Organization) (NNP Grade) (NN 3-4) (NNP Doc_11135224_1784_1795_Disease) (CC and) (NNP Doc_11135224_1800_1816_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 39.9) (NN %)) (CC and) (NP (NP (CD 11.4) (NN %)) (PP (IN of) (NP (NNS patients)))))) (, ,) (ADVP (RB respectively))) (. .)))
11135224	11	(S1 (S (NP (EX There)) (VP (AUX was) (NP (CD one) (JJ treatment-related) (NN Doc_11135224_1904_1909_Disease))) (. .)))
11135224	12	(S1 (S (NP (NNP Nonhematologic) (NNP Doc_11135224_1926_1936_Disease)) (VP (AUX were) (ADJP (JJ mild))) (. .)))
11135224	13	(S1 (S (PP (IN After) (NP (NP (DT a) (JJ median) (NN follow-up)) (PP (IN of) (NP (CD 22) (NNS months))))) (, ,) (S (NP (DT the) (JJ median) (NN progression) (JJ free) (NN survival) (NN rate)) (VP (AUX was) (NP (CD 7) (NNS months)))) (, ,) (CC and) (S (NP (DT the) (JJ median) (NN survival) (NN time)) (VP (AUX was) (NP (CD 16) (NNS months)))) (. .)))
11135224	14	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11135224_2119_2129_Chemical)) (, ,) (NP (NNP Doc_11135224_2131_2140_Chemical)) (, ,) (CC and) (NP (NNP Doc_11135224_2146_2157_Chemical))))) (VP (VP (AUX is) (ADVP (RB well)) (VP (VBN tolerated))) (CC and) (VP (VBZ shows) (NP (NP (JJ high) (NN activity)) (PP (IN in) (NP (JJ metastatic) (NNP Doc_11135224_2214_2219_Disease)))))) (. .)))
11135224	15	(S1 (S (NP (DT This) (NN treatment)) (VP (NNS merits) (ADVP (RB further)) (NP (NP (NN comparison)) (PP (IN with) (NP (JJ other) (JJ Doc_11135224_2273_2282_Chemical-based) (NNS regimens))))) (. .)))
11147747	0	(S1 (NP (NNP Doc_11147747_0_28_Chemical) (CC and) (NNP Doc_11147747_33_53_Disease) (. .)))
11147747	1	(S1 (S (NP (JJ Many) (JJ new) (JJ Doc_11147747_64_92_Chemical)) (VP (AUX have) (VP (AUX been) (VP (VBN introduced) (PP (IN over) (NP (DT the) (JJ past) (NN decade)))))) (. .)))
11147747	2	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_11147747_145_165_Disease)) (VP (AUX is) (VP (VBN listed) (PP (IN as) (NP (NP (CD one) (NN side) (NN effect)) (PP (IN of) (NP (NP (DT these) (NNS drugs)) (PP (IN in) (NP (PRP$ their) (NN package) (NNS inserts))))))))))) (NP (EX there)) (VP (AUX is) (NP (NP (QP (RB only) (CD one)) (NN report)) (PP (IN in) (NP (DT the) (NN literature))))) (. .)))
11147747	3	(S1 (S (NP (DT This)) (VP (VBZ concerns) (NP (NP (CD 2) (JJ male) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (NNP Doc_11147747_325_337_Disease)) (PP (IN while) (S (VP (VBG taking) (NP (NN Doc_11147747_351_362_Chemical)))))))))) (. .)))
11147747	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN paper))) (NP (DT the) (NNS authors)) (VP (VBP describe) (NP (NP (CD 2) (JJ female) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_11147747_438_450_Disease) (JJ secondary)) (PP (TO to) (NP (NP (DT the) (JJ selective) (NNP Doc_11147747_478_487_Chemical) (NN reuptake) (NNS inhibitors) (NNP Doc_11147747_508_518_Chemical) (CC and) (NNP Doc_11147747_523_533_Chemical)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (JJ third)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT this) (NN side) (NN effect)) (PP (IN on) (NP (NNP Doc_11147747_588_599_Chemical)))))))))))))) (. .)))
11147747	5	(S1 (S (PP (IN In) (NP (NP (CD 2)) (PP (IN of) (NP (DT the) (CD 3) (NNS cases))))) (NP (DT the) (NNS patients)) (VP (AUX were) (ADVP (RB also)) (VP (VBG taking) (NP (NP (NP (NNP Doc_11147747_651_668_Chemical)) (CC and) (NP (NNS beta-blockers))) (, ,) (SBAR (WHNP (DT both) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (MD could) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (DT the) (NNP Doc_11147747_732_744_Disease))))))))))) (. .)))
11147747	6	(S1 (S (NP (NN Animal) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN Doc_11147747_774_786_Disease) (JJ secondary)) (PP (TO to) (NP (NNP Doc_11147747_800_828_Chemical)))) (VP (MD could) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (JJ 5HT4) (NNS receptors)) (VP (VBN found) (PP (IN on) (NP (DT the) (NN bladder)))))))))))) (. .)))
11147747	7	(S1 (S (NP (JJ Further) (NN research)) (VP (AUX is) (VP (VBN needed) (S (VP (TO to) (VP (VB delineate) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (DT this) (JJ troubling) (NN side) (NN effect)))) (SBAR (CC and) (WHADVP (WRB how)) (S (ADVP (RB best)) (VP (TO to) (VP (VB treat) (NP (PRP it))))))))))) (. .)))
11166519	0	(S1 (NP (NP (JJ Acute) (JJ Doc_11166519_6_13_Chemical-induced) (NN Doc_11166519_22_30_Disease)) (: :) (NP (NP (NN differential) (NN sensitivity)) (PP (IN of) (NP (CD six) (JJ inbred) (NN mouse) (NNS strains)))) (. .)))
11166519	1	(S1 (S (NP (NP (JJ Mature) (ADJP (JJ male) (CC and) (JJ female)) (NNS mice)) (PP (IN from) (NP (CD six) (JJ inbred) (NNS stains)))) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (NN susceptibility))) (PP (TO to) (NP (NP (JJ behavioral) (NN Doc_11166519_182_190_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NNP Doc_11166519_224_231_Chemical)))))))))) (. .)))
11166519	2	(S1 (S (S (NP (NN Doc_11166519_233_240_Chemical)) (VP (AUX was) (VP (VBN injected) (ADVP (RB ip)) (PP (IN over) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (NNS doses)) (PRN (-LRB- -LRB-) (NP (CD 50-100) (NNS mg/kg)) (-RRB- -RRB-))))))))) (CC and) (S (NP (NN behavior)) (VP (AUX was) (VP (VBN monitored) (PP (IN for) (NP (CD 20) (NNS minutes)))))) (. .)))
11166519	3	(S1 (S (NP (JJ Doc_11166519_337_344_Disease) (NN end) (NNS points)) (VP (VBD included) (NP (NN latency)) (PP (TO to) (NP (NP (NN forelimb) (CC or) (NN hindlimb) (NN clonus)) (, ,) (NP (NP (NN latency)) (PP (TO to) (NP (JJ clonic) (NN running) (NN Doc_11166519_431_438_Disease)))) (CC and) (NP (NP (NN latency)) (PP (TO to) (NP (NP (VBG jumping)) (VP (VBG bouncing) (NP (NNP Doc_11166519_471_478_Disease))))))))) (. .)))
11166519	4	(S1 (S (NP (NP (DT A) (NN range)) (PP (IN of) (NP (NN strain) (NN specific) (NNS sensitivities)))) (VP (AUX was) (VP (VBN documented) (PP (IN with) (S (NP (NNP A/J) (CC and) (NNP SJL) (NNS mice)) (VP (AUXG being) (ADJP (ADJP (RBS most) (JJ sensitive)) (CC and) (ADJP (JJ C57BL/6J) (RBS most) (JJ resistant)))))))) (. .)))
11166519	5	(S1 (S (NP (NP (NNS DBA/2J)) (, ,) (NP (NNS BALB/cByJ)) (CC and) (NP (JJ NZW/LacJ) (NNS strains))) (VP (VBD exhibited) (NP (JJ intermediate) (NN sensitivity))) (. .)))
11166519	6	(S1 (S (NP (NNP EEG) (NNS recordings)) (VP (AUX were) (VP (VBN made) (PP (IN in) (NP (NP (NNP SJL) (, ,) (NNP A/J) (CC and) (NNP C57BL/6J) (NNS mice)) (VP (VBG revealing) (NP (NP (DT a) (JJ close) (NN correspondence)) (PP (IN between) (NP (NP (JJ electrical) (NN activity)) (CC and) (NP (NN behavior)))))))))) (. .)))
11166519	7	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NP (NNS levels)) (PP (IN of) (NP (NNP Doc_11166519_837_844_Chemical))) (VP (VBN determined) (PP (IN in) (NP (NP (NN hippocampus)) (CC and) (NP (NN cortex)))))) (VP (AUX were) (RB not) (ADJP (JJ different)) (PP (IN between) (NP (ADJP (JJ sensitive) (CC and) (JJ resistant)) (NNS strains)))) (. .)))
11166519	8	(S1 (S (NP (NP (JJ Additional) (NNS studies)) (PP (IN of) (NP (DT these) (JJ murine) (NNS strains)))) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN for) (S (VP (VBG investigating) (NP (JJ genetic) (NNS influences)) (PP (IN on) (NP (NNP Doc_11166519_1039_1046_Chemical-induced) (NNP Doc_11166519_1055_1063_Disease))))))))) (. .)))
11198499	0	(S1 (S (NP (NN Doc_11198499_0_11_Disease)) (VP (VBG following) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_11198499_40_50_Chemical)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NP (DT an) (NNP Doc_11198499_80_91_Chemical) (VBG converting) (JJ enzyme) (NN inhibitor)) (PP (IN for) (NP (JJ chronic) (NNP Doc_11198499_132_144_Disease))))))))) (. .)))
11198499	1	(S1 (S (NP (ADJP (RB Centrally) (JJ acting)) (JJ alpha-2) (NN adrenergic) (NNS agonists)) (VP (AUX are) (NP (NP (CD one)) (PP (IN of) (NP (NP (JJ several) (JJ pharmacologic) (NNS agents)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11198499_256_266_Disease)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_11198499_278_317_Disease))))))))))))) (. .)))
11198499	2	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (PRP$ their) (NNS effects)) (PP (IN on) (NP (NNP Doc_11198499_351_361_Disease))))))) (, ,) (NP (JJ certain) (JJ adverse) (NN cardiorespiratory) (NNS effects)) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))) (. .)))
11198499	3	(S1 (S (NP (NP (NNS Adults)) (VP (ADVP (RB chronically)) (VBN treated) (PP (IN with) (S (NP (NNP Doc_11198499_457_468_Chemical)) (VP (VBG converting) (NP (JJ enzyme) (NNS inhibitors))))))) (VP (MD may) (VP (AUX have) (NP (DT a) (JJ limited) (NN ability) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NNP Doc_11198499_539_550_Disease))))))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ sympathetic) (NN response)) (VP (AUX is) (ADVP (RB simultaneously)) (VP (VBN blocked))))))) (. .)))
11198499	4	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP present) (NP (NP (DT a) (JJ 10-year-old) (NN boy)) (VP (ADVP (RB chronically)) (VBN treated) (PP (IN with) (NP (NP (NNP Doc_11198499_671_681_Chemical)) (, ,) (NP (DT an) (NNP Doc_11198499_686_697_Chemical) (VBG converting) (JJ enzyme) (NN inhibitor)) (, ,))) (S (VP (TO to) (VP (VB control) (NP (NP (NNP Doc_11198499_738_750_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_11198499_765_776_Disease)) (PP (VBG following) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NNP Doc_11198499_803_813_Chemical)) (, ,) (NP (DT an) (JJ alpha-2) (NN agonist))))))))))))) (, ,) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_11198499_856_866_Disease)))))))) (. .)))
11198499	5	(S1 (S (NP (NP (DT The) (JJ possible) (NN interaction)) (PP (IN of) (NP (NP (NNP Doc_11198499_896_906_Chemical)) (CC and) (NP (JJ other) (JJ antihypertensive) (NNS agents))))) (VP (MD should) (VP (AUX be) (VP (VBN kept) (PP (IN in) (NP (NN mind))) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NN therapy)) (S (VP (TO to) (VP (VB treat) (NP (DT either) (NNP Doc_11198499_1005_1017_Disease) (CC or) (NNP Doc_11198499_1021_1031_Disease)) (PP (IN in) (NP (JJ such) (NNS patients)))))))))))) (. .)))
11206082	0	(S1 (S (NP (NP (CD Two) (NN mouse) (NNS lines)) (VP (VBN selected) (PP (IN for) (NP (NP (NN differential) (NNS sensitivities)) (PP (TO to) (NP (NNP Doc_11206082_59_73_Chemical-induced) (NNP Doc_11206082_82_90_Disease))))))) (VP (AUX are) (ADVP (RB also)) (ADJP (RB differentially) (JJ sensitive) (PP (TO to) (NP (NP (JJ various) (JJ pharmacological) (NNS effects)) (PP (IN of) (NP (JJ other) (NNP Doc_11206082_169_173_Chemical) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NN receptor) (NNS ligands))))))) (. .)))
11206082	1	(S1 (S (NP (CD Two) (NN mouse) (NNS lines)) (VP (AUX were) (ADVP (RB selectively)) (VP (VBN bred) (PP (VBG according) (PP (TO to) (NP (NP (NP (PRP$ their) (NN sensitivity)) (PRN (-LRB- -LRB-) (NP (NNP BS) (NN line)) (-RRB- -RRB-))) (CC or) (NP (NP (NN resistance)) (PRN (-LRB- -LRB-) (NP (CD BR) (NN line)) (-RRB- -RRB-)))))) (PP (TO to) (NP (NP (NP (NNP Doc_11206082_301_309_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN i.p.) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11206082_348_383_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11206082_385_393_Chemical)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT an) (JJ inverse) (NN agonist)) (PP (IN of) (NP (DT the) (NNP Doc_11206082_422_426_Chemical)))))) (PRN (-LRB- -LRB-) (DT A) (-RRB- -RRB-)) (S (VP (NN receptor) (NP (JJ Doc_11206082_439_453_Chemical) (NN site)))))) (. .)))
11206082	2	(S1 (S (NP (PRP$ Our) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB characterize) (NP (NP (DT both) (NNS lines) (POS ')) (NNS sensitivities)) (PP (TO to) (NP (NP (JJ various) (JJ physiological) (NNS effects)) (PP (IN of) (NP (NP (JJ other) (NNS ligands)) (PP (IN of) (NP (DT the) (NNP Doc_11206082_571_575_Chemical) (-LRB- -LRB-) (NNP A) (-RRB- -RRB-) (NN receptor))))))))))) (. .)))
11206082	3	(S1 (S (NP (PRP We)) (VP (VP (VBD measured) (NP (JJ Doc_11206082_601_609_Chemical-induced) (NN anxiolysis)) (PP (IN with) (NP (NP (DT the) (JJ elevated) (JJ plus-maze) (NN test)) (, ,) (NP (JJ Doc_11206082_663_671_Chemical-induced) (NN sedation)))) (PP (IN by) (S (VP (VBG recording) (NP (DT the) (JJ vigilance) (NNS states)))))) (, ,) (CC and) (VP (NP (NNP Doc_11206082_728_738_Chemical-) (CC and) (NNP Doc_11206082_744_761_Chemical-induced) (NNP Doc_11206082_770_778_Disease)) (PP (IN after) (S (VP (VBG i.p.) (NP (NNS injections))))))) (. .)))
11206082	4	(S1 (S (NP (NP (NNS Results)) (VP (VBN presented) (ADVP (RB here)))) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN differential) (NNS sensitivities)) (PP (IN of) (NP (NN BS) (CC and) (NN BR) (NNS lines))) (PP (TO to) (NP (NNP Doc_11206082_888_896_Chemical)))) (VP (MD can) (VP (AUX be) (VP (VBN extended) (PP (TO to) (NP (NP (NNP Doc_11206082_916_924_Chemical)) (, ,) (NP (NNP Doc_11206082_926_936_Chemical)) (, ,) (CC and) (NP (NNP Doc_11206082_942_959_Chemical)))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ genetic) (NN selection)) (PP (IN of) (NP (NP (DT a) (JJ general) (NN sensitivity)) (CC and) (NP (NP (NN resistance)) (PP (TO to) (NP (NP (JJ several) (NNS ligands)) (PP (IN of) (NP (DT the) (JJ Doc_11206082_1058_1062_Chemical) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NN receptor))))))))))))))))) (. .)))
11250767	0	(S1 (S (NP (JJ Doc_11250767_0_16_Chemical-induced) (NNS perinuclear-staining)) (VP (VBP antineutrophil) (NP (NP (JJ cytoplasmic) (JJ autoantibody-positive) (NN Doc_11250767_95_105_Disease)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NNP Doc_11250767_126_138_Disease))))))) (. .)))
11250767	1	(S1 (FRAG (S (VP (TO To) (VP (VB describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ Doc_11250767_173_189_Chemical-induced) (JJ Doc_11250767_198_208_Disease) (NN manifesting)) (PP (IN with) (NP (NNP Doc_11250767_226_238_Disease))))))))) (. .)))
11250767	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT the) (JJ first) (NN case) (NN report)) (PP (IN of) (NP (NP (DT a) (NN woman)) (PP (IN with) (NP (NNP Doc_11250767_298_313_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11250767_327_343_Chemical)))))) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (DT a) (NN syndrome)) (PP (IN of) (NP (NP (NNP Doc_11250767_366_378_Disease)) (, ,) (NP (NNP Doc_11250767_380_385_Disease)) (, ,) (CC and) (NP (NNP Doc_11250767_391_409_Disease))))) (VP (VBD developed)))))) (. .)))
11250767	3	(S1 (S (S (NP (NP (JJ Serologic) (NN testing)) (CC and) (NP (JJ immunologic) (NNS studies))) (VP (AUX were) (VP (AUX done)))) (, ,) (CC and) (S (NP (DT a) (JJ pericardial) (NN biopsy)) (VP (AUX was) (VP (VBN performed)))) (. .)))
11250767	4	(S1 (S (NP (NP (DT A) (JJ 25-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_11250767_548_563_Disease)))) (VP (AUX had) (NP (NP (DT a) (NN Doc_11250767_570_585_Disease) (CC and) (NN evidence)) (PP (IN of) (NP (NP (NNP Doc_11250767_602_614_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN confirmed) (PP (IN by) (NP (NN biopsy))))))))))) (. .)))
11250767	5	(S1 (S (NP (JJ Serologic) (NN evaluation)) (VP (VBD revealed) (NP (NP (DT the) (NN presence)) (PP (IN of) (S (VP (VBG perinuclear-staining) (NP (NP (JJ antineutrophil) (JJ cytoplasmic) (NNS autoantibodies)) (PRN (-LRB- -LRB-) (NP (NN pANCA)) (-RRB- -RRB-))) (PP (IN against) (NP (NP (JJ myeloperoxidase)) (PRN (-LRB- -LRB-) (NP (NNP MPO)) (-RRB- -RRB-))))))))) (. .)))
11250767	6	(S1 (S (S (NP (JJ Doc_11250767_795_811_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN withdrawn)))) (, ,) (CC and) (S (NP (PRP she)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ 1-month) (NN course)) (PP (IN of) (NP (NNP Doc_11250767_880_890_Chemical))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD alleviated) (NP (PRP$ her) (NNS symptoms)))))))))) (. .)))
11250767	7	(S1 (S (NP (DT A) (NN literature) (NN review)) (VP (VBD revealed) (NP (NP (DT no) (JJ prior) (NNS reports)) (PP (IN of) (NP (NP (NNP Doc_11250767_972_984_Disease)) (PP (IN in) (NP (NP (JJ anti-MPO) (JJ pANCA-positive) (NN Doc_11250767_1012_1022_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_11250767_1039_1057_Chemical) (NN therapy)))))))))) (. .)))
11250767	8	(S1 (S (NP (NN Doc_11250767_1079_1091_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ initial) (NN manifestation)) (PP (IN of) (NP (NP (JJ drug-induced) (NN Doc_11250767_1141_1151_Disease)) (ADJP (JJ attributable) (PP (TO to) (NP (JJ Doc_11250767_1168_1186_Chemical) (NN therapy))))))))) (. .)))
11256525	0	(S1 (S (VP (VBN Repeated) (NP (JJ transient) (NNP Doc_11256525_19_25_Disease)) (PP (VBG following) (NP (NNP Doc_11256525_36_44_Chemical) (NN administration))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (DT a) (JJ solitary) (NN kidney)))))) (. .)))
11256525	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 70-year-old) (JJ Doc_11256525_133_145_Disease) (NN man)) (PP (IN with) (NP (NP (DT a) (JJ solitary) (NN kidney) (CC and) (NN Doc_11256525_177_204_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (CD two) (NNS episodes)) (PP (IN of) (NP (JJ transient) (NNP Doc_11256525_245_251_Disease)))) (PP (IN after) (NP (NNP Doc_11256525_258_266_Chemical) (NN administration)))))))))))) (. .)))
11256525	2	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN hospitalized) (PP (IN for) (NP (NP (DT a) (NN Doc_11256525_309_330_Disease)) (PP (IN with) (NP (NNP Doc_11256525_336_351_Disease))) (, ,) (VP (VBN treated) (PP (IN with) (NP (JJ high-dose) (NNS diuretics)))))))) (. .)))
11256525	3	(S1 (S (PP (JJ Due) (TO to) (NP (JJ severe))) (NP (NNP Doc_11256525_401_421_Disease) (NNP Doc_11256525_422_430_Chemical)) (VP (AUX was) (VP (VBN prescribed))) (. .)))
11256525	4	(S1 (S (ADVP (RB Surprisingly)) (, ,) (NP (NP (DT the) (JJ first) (NN dose)) (PP (IN of) (NP (NP (CD 50) (NN mg)) (PP (IN of) (NP (NNP Doc_11256525_488_496_Chemical)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ sudden) (NN Doc_11256525_518_524_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD lasted) (NP (CD eight) (NNS hours)) (PP (IN despite) (NP (NP (JJ high-dose) (NN Doc_11256525_569_579_Chemical)) (CC and) (NP (JJ Doc_11256525_584_589_Chemical) (NN infusion)))))))))) (. .)))
11256525	5	(S1 (S (ADVP (NP (CD One) (NN week)) (RB later)) (, ,) (PP (IN by) (NP (NN mistake))) (, ,) (NP (NNP Doc_11256525_628_636_Chemical)) (VP (VP (AUX was) (VP (VBN prescribed) (ADVP (RB again)))) (CC and) (VP (PP (IN after) (NP (NP (DT the) (JJ second) (NN dose)) (PP (IN of) (NP (NP (CD 50) (NNS mg)) (, ,) (NP (DT the) (NN patient)))))) (VBD developed) (NP (NP (DT a) (JJ second) (NN episode)) (PP (IN of) (NP (JJ transient) (NNP Doc_11256525_746_752_Disease))) (VP (VBG lasting) (NP (CD 10) (NNS hours)))))) (. .)))
11256525	6	(S1 (S (PP (IN During) (NP (DT these) (CD two) (NNS episodes))) (, ,) (S (NP (PRP$ his) (NN blood) (NN pressure)) (VP (VBN diminished))) (CC but) (S (NP (DT no) (JJ severe) (NN Doc_11256525_842_853_Disease)) (VP (AUX was) (VP (VBN noted)))) (. .)))
11256525	7	(S1 (S (ADVP (RB Ultimately)) (, ,) (NP (DT an) (NN arteriography)) (VP (VBD showed) (NP (DT a) (ADJP (CD 70-80) (NN %)) (NN Doc_11256525_910_931_Disease))) (. .)))
11256525	8	(S1 (S (PP (IN In) (NP (DT this) (NN patient))) (, ,) (NP (NNP Doc_11256525_950_971_Disease)) (VP (VBN combined) (PP (IN with) (NP (NP (NNP Doc_11256525_986_999_Disease)) (CC and) (NP (NP (JJ diuretic) (NN therapy)) (VP (ADVP (RB certainly)) (VBN resulted) (PP (IN in) (NP (NP (DT a) (JJ strong) (NN activation)) (PP (IN of) (NP (NP (DT the) (JJ renin-Doc_11256525_1076_1087_Chemical) (NN system)) (PRN (-LRB- -LRB-) (NP (NNP RAS)) (-RRB- -RRB-))))))))))) (. .)))
11256525	9	(S1 (S (PP (IN Under) (NP (JJ such) (NNS conditions))) (, ,) (NP (NP (JJ Doc_11256525_1125_1139_Chemical) (NN receptor) (NN blockade)) (PP (IN by) (NP (NNP Doc_11256525_1161_1169_Chemical)))) (ADVP (RB probably)) (VP (VBN induced) (NP (DT a) (JJ critical) (NN fall)) (PP (IN in) (NP (JJ glomerular) (NN filtration) (NN pressure)))) (. .)))
11256525	10	(S1 (S (NP (DT This) (NN case) (NN report)) (VP (VBZ highlights) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (DT the) (NNP Doc_11256525_1284_1298_Chemical) (NN receptor) (NN antagonist) (NN Doc_11256525_1319_1327_Chemical)) (VP (VP (MD can) (VP (VB cause) (NP (JJ serious) (JJ unexpected) (NNS complications)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11256525_1388_1408_Disease))))))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (JJ extreme) (NN caution))) (PP (IN in) (NP (DT this) (NN setting))))))))))) (. .)))
11263551	0	(S1 (NP (NP (NP (JJ Calcineurin-inhibitor) (VBN induced) (JJ Doc_11263551_30_34_Disease) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11263551_45_49_Disease)) (-RRB- -RRB-))) (: :) (NP (NP (DT a) (JJ severe) (VBG disabling) (NN complication)) (PP (IN after) (NP (NN organ) (NN transplantation)))) (. .)))
11263551	1	(S1 (S (NP (NP (NN Bone) (NN Doc_11263551_118_122_Disease)) (PP (IN after) (NP (NN transplantation)))) (VP (AUX is) (NP (NP (DT a) (JJ frequent) (NN complication)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (JJ several) (NNS diseases)))))))))) (. .)))
11263551	2	(S1 (S (NP (NN Treatment) (NNS strategies)) (VP (VBP depend) (PP (IN on) (NP (NP (DT the) (JJ correct) (NN diagnosis)) (PP (IN of) (NP (DT the) (NNP Doc_11263551_272_276_Disease)))))) (. .)))
11263551	3	(S1 (S (NP (NP (NP (CD Nine) (NNS patients)) (PP (IN with) (NP (JJ severe) (NN Doc_11263551_304_308_Disease))) (PP (IN in) (NP (PRP$ their) (NNS feet)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN registered) (PP (IN after) (NP (NN transplantation))))))) (, ,)) (VP (AUX were) (VP (VBN investigated))) (. .)))
11263551	4	(S1 (S (NP (NN Bone) (NNS scans)) (VP (VBD showed) (NP (NP (DT an) (VBN increased) (NNP tracer) (NN uptake)) (PP (IN of) (NP (DT the) (NN foot) (NNS bones))))) (. .)))
11263551	5	(S1 (S (NP (JJ Magnetic) (NN resonance) (NN imaging)) (VP (VBD demonstrated) (NP (NNP Doc_11263551_491_509_Disease)) (PP (IN in) (NP (DT the) (JJ painful) (NNS bones)))) (. .)))
11263551	6	(S1 (S (NP (NN Doc_11263551_532_536_Disease)) (VP (AUX was) (RB not) (VP (VBN explained) (PP (IN by) (NP (NP (JJ other) (NNS diseases)) (VP (VBG causing) (NP (NN foot) (NN Doc_11263551_586_590_Disease)) (, ,) (PP (IN like) (NP (NNP Doc_11263551_597_625_Disease) (, ,) (NNP Doc_11263551_627_641_Disease) (, ,) (NNP Doc_11263551_643_661_Disease) (, ,) (NNP Doc_11263551_663_667_Disease) (, ,) (NNP Doc_11263551_669_681_Disease) (, ,) (NNP Doc_11263551_683_701_Disease) (, ,) (NNP Doc_11263551_703_728_Disease) (, ,) (NP (JJ orthopaedic) (NNP Doc_11263551_742_758_Disease)) (, ,) (NP (NNP Doc_11263551_760_776_Disease)) (, ,) (CC and) (NP (NNP Doc_11263551_782_801_Disease))))))))) (. .)))
11263551	7	(S1 (S (NP (NP (NP (DT The) (NN reduction)) (PP (IN of) (NP (JJ Doc_11263551_820_832_Chemical-) (CC or) (JJ Doc_11263551_837_847_Chemical) (NN trough) (NNS levels)))) (CC and) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (JJ Doc_11263551_888_895_Chemical) (NN channel) (NNS blockers))))) (VP (VBD led) (PP (TO to) (NP (NP (NN relief)) (PP (IN of) (NP (NNP Doc_11263551_930_934_Disease)))))) (. .)))
11263551	8	(S1 (S (NP (NP (DT The) (JJ Calcineurin-inhibitor) (VBN Induced) (NN Doc_11263551_970_974_Disease) (NN Syndrome)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11263551_985_989_Disease)) (-RRB- -RRB-))) (VP (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ severe)) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_11263551_1027_1039_Chemical) (CC or) (NNP Doc_11263551_1043_1053_Chemical))))) (CC and) (VP (AUX is) (ADVP (RB accurately)) (VP (VBN diagnosed) (PP (IN by) (NP (NP (PRP$ its) (JJ typical) (NN presentation)) (, ,) (NP (JJ magnetic) (NN resonance) (NN imaging)) (CC and) (NP (NN bone) (NNS scans))))))) (. .)))
11263551	9	(S1 (S (NP (NP (JJ Incorrect) (NN diagnosis)) (PP (IN of) (NP (DT the) (NN syndrome)))) (VP (MD will) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN of) (NP (NN life) (NN quality))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_11263551_1270_1274_Disease)))))))))) (. .)))
11279304	0	(S1 (S (NP (NN Brain) (JJ natriuretic) (NN peptide)) (VP (AUX is) (NP (NP (DT a) (NN predictor)) (PP (IN of) (NP (NNP Doc_11279304_44_57_Chemical-induced) (NNP Doc_11279304_66_80_Disease))))) (. .)))
11279304	1	(S1 (S (S (NP (NN Doc_11279304_82_96_Chemical)) (VP (AUX are) (NP (JJ effective) (JJ antineoplastic) (NNS drugs)))) (, ,) (CC but) (S (NP (PRP they)) (ADVP (RB frequently)) (VP (VBP cause) (NP (JJ dose-related) (NNP Doc_11279304_172_186_Disease)))) (. .)))
11279304	2	(S1 (S (NP (NP (DT The) (NNP Doc_11279304_192_206_Disease)) (PP (IN of) (NP (JJ conventional) (JJ Doc_11279304_223_236_Chemical) (NN therapy)))) (VP (VBZ highlights) (NP (NP (DT a) (NN need)) (PP (TO to) (NP (NP (NN search)) (PP (IN for) (NP (NP (NNS methods)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (ADJP (RB highly) (JJ sensitive)) (CC and) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG predicting) (NP (NNP Doc_11279304_337_356_Disease)))))))))))))))) (. .)))
11279304	3	(S1 (S (NP (PRP We)) (VP (VBD measured) (NP (NP (DT the) (NN plasma) (NN level)) (PP (IN of) (NP (NP (NN brain) (JJ natriuretic) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NNP BNP)) (-RRB- -RRB-))))) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NNP BNP)) (VP (MD might) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (JJ simple) (JJ diagnostic) (NN indicator)) (PP (IN of) (NP (NP (NNP Doc_11279304_495_508_Chemical-induced) (NNP Doc_11279304_517_531_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11279304_549_563_Disease))) (VP (VBN treated) (PP (IN with) (NP (DT a) (JJ Doc_11279304_579_591_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11279304_593_596_Chemical)) (-RRB- -RRB-)) (JJ -containing) (NN regimen)))))))))))))))))) (. .)))
11279304	4	(S1 (S (NP (NP (JJ Thirteen) (NNS patients)) (PP (IN with) (NP (NNP Doc_11279304_641_655_Disease)))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (DT a) (JJ Doc_11279304_676_679_Chemical-containing) (NN regimen))))) (. .)))
11279304	5	(S1 (S (NP (JJ Cardiac) (NNS functions)) (VP (AUX were) (VP (VBN evaluated) (PP (IN with) (NP (NP (NN radionuclide) (NN angiography)) (PP (IN before) (NP (NNS chemotherapies))))))) (. .)))
11279304	6	(S1 (S (NP (NP (DT The) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NP (JJ atrial) (JJ natriuretic) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NNP ANP)) (-RRB- -RRB-))) (CC and) (NP (NNS BNP))))) (VP (AUX were) (VP (VBN measured) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN radionuclide) (NN angiography))))))) (. .)))
11279304	7	(S1 (S (NP (CD Three) (NNS patients)) (VP (VBD developed) (NP (NN Doc_11279304_928_952_Disease)) (PP (IN after) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (NN chemotherapy)))))) (. .)))
11279304	8	(S1 (S (NP (CD Five) (NNS patients)) (VP (AUX were) (VP (VBN diagnosed) (PP (IN as) (S (VP (AUXG having) (NP (JJ subclinical) (NN Doc_11279304_1042_1055_Disease)) (PP (IN after) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (NN chemotherapy)))))))))) (. .)))
11279304	9	(S1 (S (NP (NP (DT The) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NNS BNP)) (PP (IN in) (NP (PDT all) (DT the) (NNS patients))) (PP (IN with) (NP (ADJP (JJ clinical) (CC and) (JJ subclinical)) (NNP Doc_11279304_1169_1182_Disease)))))) (VP (VBN increased) (PP (IN above) (NP (NP (DT the) (JJ normal) (NN limit)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN pg/ml)) (-RRB- -RRB-)))) (PP (IN before) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (ADJP (JJ clinical) (CC or) (JJ subclinical)) (NNP Doc_11279304_1275_1288_Disease))))) (PP (IN by) (NP (JJ radionuclide) (NN angiography)))) (. .)))
11279304	10	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NNP BNP)) (VP (AUX did) (RB not) (VP (VB increase) (PP (IN in) (NP (DT the) (NNS patients))) (PP (PP (IN without) (NP (NP (NNP Doc_11279304_1382_1395_Disease)) (VP (VBN given) (NP (NNP Doc_11279304_1402_1405_Chemical))))) (, ,) (RB even) (PP (IN at) (NP (NP (QP (JJR more) (IN than) (CD 700) (CD mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))))) (. .)))
11279304	11	(S1 (S (NP (NP (DT The) (NN plasma) (NN level)) (PP (IN of) (NP (NN ANP)))) (VP (AUX did) (RB not) (ADVP (RB always)) (VP (VB increase) (PP (IN in) (NP (PDT all) (DT the) (NNS patients))) (PP (IN with) (NP (ADJP (JJ clinical) (CC and) (JJ subclinical)) (NN Doc_11279304_1536_1549_Disease))))) (. .)))
11279304	12	(S1 (S (NP (DT These) (JJ preliminary) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNS BNP)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN as) (NP (NP (DT an) (JJ early) (CC and) (JJ sensitive) (NN indicator)) (PP (IN of) (NP (JJ Doc_11279304_1647_1660_Chemical-induced) (NN Doc_11279304_1669_1683_Disease))))))))))) (. .)))
1130930	0	(S1 (NP (NP (NN Doc_1130930_0_14_Disease)) (PP (IN of) (NP (JJ combined) (JJ Doc_1130930_27_38_Chemical-Doc_1130930_39_49_Chemical) (NN regimen))) (. .)))
1130930	1	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (NNP Doc_1130930_82_104_Disease)) (, ,) (S (VP (VBN characterized) (ADVP (RB clinically)) (PP (IN by) (NP (JJ acute) (NNP Doc_1130930_140_162_Disease))))) (, ,) (SBAR (IN while) (S (NP (PRP they)) (VP (AUX were) (VP (VBG receiving) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_1130930_207_225_Chemical)) (CC and) (NP (JJ Doc_1130930_230_248_Chemical) (NN therapy)))))))))) (. .)))
1130930	2	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBN given) (NP (DT this) (NN drug) (NN regimen))))))) (VP (MD should) (VP (AUX be) (VP (VBN observed) (ADVP (RB very) (RB carefully)) (PP (IN for) (NP (NP (JJ early) (NNS signs)) (PP (IN of) (NP (NNP Doc_1130930_352_366_Disease)))))))) (. .)))
1130930	3	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (DT this) (JJ antibiotic) (NN combination)))) (VP (MD should) (VP (AUX be) (VP (VBN avoided) (PP (ADVP (RB especially)) (IN in) (NP (JJ elderly) (NNS patients)))))) (. .)))
1130930	4	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_1130930_474_493_Disease)))) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN given) (NP (DT this) (NN regimen))))) (. .)))
11334364	0	(S1 (S (PP (IN In) (NP (NN vivo))) (NP (NP (NN protection)) (PP (IN of) (NP (NN dna) (NN damage)))) (VP (VBN associated) (NP (ADJP (JJ apoptotic) (CC and) (JJ Doc_11334364_58_66_Disease)) (NN cell) (NNS deaths)) (PP (IN during) (NP (NP (NNP Doc_11334364_86_99_Chemical-induced) (NNP Doc_11334364_108_122_Disease)) (, ,) (NP (NNP Doc_11334364_124_134_Chemical-induced) (NNP Doc_11334364_143_156_Disease)) (CC and) (NP (NNP Doc_11334364_161_172_Chemical-induced) (NNP Doc_11334364_181_195_Disease)))) (PP (IN by) (NP (DT a) (JJ novel) (NN Doc_11334364_207_248_Chemical)))) (. .)))
11334364	1	(S1 (S (NP (NP (NNP Doc_11334364_250_268_Chemical)) (, ,) (NP (NP (RB primarily) (DT a) (NN mixture)) (PP (IN of) (NP (NNP Doc_11334364_293_310_Chemical)))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VBP modulate) (NP (NP (DT a) (NN wide-range)) (PP (IN of) (NP (NP (JJ biological) (, ,) (ADJP (JJ pharmacological) (CC and) (JJ toxicological)) (NNS effects)) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (ADVP (RB mainly)) (ADJP (JJ cytoprotective)))))))))))))) (. .)))
11334364	2	(S1 (S (S (NP (DT This) (NN study)) (VP (VBD assessed) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NP (NNP Doc_11334364_477_518_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_520_524_Chemical)) (-RRB- -RRB-)))) (S (VP (TO to) (VP (VB prevent) (NP (NP (NNP Doc_11334364_537_550_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_552_555_Chemical)) (-RRB- -RRB-))))))) (NP (JJ -induced) (NNP Doc_11334364_565_579_Disease)))) (, ,) (S (NP (NP (NNP Doc_11334364_581_591_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_593_596_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (NP (NNP Doc_11334364_606_619_Disease)))) (, ,) (CC and) (S (NP (NP (NNP Doc_11334364_625_636_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_638_641_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (NP (NNP Doc_11334364_651_665_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
11334364	3	(S1 (S (NP (JJ Experimental) (NN design)) (VP (VBD consisted) (PP (IN of) (NP (CD four) (NNS groups))) (: :) (NP (NP (NP (NN control)) (PRN (-LRB- -LRB-) (NP (NN vehicle) (RB alone)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_11334364_746_750_Chemical)) (ADVP (RB alone))) (, ,) (NP (NP (NN drug)) (ADVP (RB alone))) (CC and) (NP (NNP Doc_11334364_773_777_Chemical+drug))))) (. .)))
11334364	4	(S1 (S (PP (IN For) (NP (DT the) (NN cytoprotection) (NN study))) (, ,) (NP (NNS animals)) (VP (AUX were) (ADVP (RB orally)) (VP (VBN gavaged) (NP (QP (CD 100) (CD mg/Kg)) (NN Doc_11334364_852_856_Chemical)) (PP (IN for) (NP (NP (CD 7-10) (NNS days)) (VP (VBN followed) (PP (IN by) (S (VP (VBG i.p.) (NP (NP (NNS injections)) (PP (IN of) (NP (NP (NN organ) (JJ specific) (CD three) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11334364_930_933_Chemical)) (: :) (NP (NP (NP (CD 500) (NNS mg/Kg)) (PP (IN for) (NP (CD 24))) (NP (NP (NNP h)) (: ;) (NP (NNP Doc_11334364_955_958_Chemical)) (: :) (NP (NP (CD 50) (NN mg/Kg/day)) (PP (IN for) (NP (CD four) (NNS days)))) (: ;) (NP (NNP Doc_11334364_988_991_Chemical)) (: :) (NP (NP (CD 20) (NN mg/Kg)) (PP (IN for) (NP (CD 48)))))) (NP (NNP h))) (-RRB- -RRB-))))))))))))) (. .)))
11334364	5	(S1 (S (NP (NP (NNS Parameters)) (PP (IN of) (NP (NN study)))) (VP (VBD included) (NP (NP (NP (NN analysis)) (PP (IN of) (NP (JJ serum) (NN chemistry) (PRN (-LRB- -LRB-) (NP (NNP ALT) (, ,) (NNP BUN) (CC and) (NNP CPK)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (JJ orderly) (NN fragmentation)) (PP (IN of) (NP (NP (JJ genomic) (NN DNA)) (PRN (-LRB- -LRB-) (ADJP (DT both) (JJ endonuclease-dependent) (CC and) (JJ independent)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NN addition))) (PP (TO to) (NP (NP (JJ microscopic) (NN evaluation)) (PP (IN of) (NP (NN damage) (NN and/or) (NN protection))))) (PP (IN in) (NP (NP (JJ corresponding) (NNS PAS)) (VP (VBN stained) (NP (NNS tissues)))))) (. .)))
11334364	6	(S1 (S (NP (NNS Results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_11334364_1303_1307_Chemical)) (VP (VP (VBD preexposure) (ADVP (RB prior) (PP (TO to) (NP (NP (NNP Doc_11334364_1329_1332_Chemical) (, ,) (NNP Doc_11334364_1334_1337_Chemical) (CC and) (NNP Doc_11334364_1342_1345_Chemical)) (, ,) (VP (VBN provided) (PP (IN near) (NP (JJ complete) (NN protection))) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (JJ serum) (NN chemistry) (NNS changes)) (PRN (-LRB- -LRB-) (NP (NNP ALT) (, ,) (NNP BUN) (CC and) (NNP CPK)) (-RRB- -RRB-))))))) (, ,))))) (CC and) (VP (ADVP (RB significantly)) (VBN reduced) (NP (NN DNA) (NN fragmentation))))))) (. .)))
11334364	7	(S1 (S (NP (NP (JJ Histopathological) (NN examination)) (PP (IN of) (NP (NN kidney) (, ,) (NN heart) (CC and) (NN lung) (NNS sections)))) (VP (VBD revealed) (ADJP (JJ moderate)) (PP (TO to) (NP (NP (JJ massive) (NN Doc_11334364_1576_1589_Disease)) (PP (IN with) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ morphological) (NNS aberrations)) (PP (IN by) (NP (NP (PDT all) (DT the) (CD three) (NNS drugs)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ Doc_11334364_1675_1679_Chemical) (NN preexposure)))))))))))) (PP (IN than) (PP (IN in) (NP (PRP$ its) (NN presence)))))) (. .)))
11334364	8	(S1 (S (NP (JJ Doc_11334364_1714_1718_Chemical+drug) (JJ exposed) (NNS tissues)) (VP (VBD exhibited) (NP (NP (JJ minor) (JJ residual) (NN damage)) (CC or) (NP (JJ near) (JJ total) (NN recovery)))) (. .)))
11334364	9	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NN histopathological) (NNS alterations)) (VP (VBD mirrored) (NP (NP (DT both) (JJ serum) (NN chemistry) (NNS changes)) (CC and) (NP (NP (DT the) (NN pattern)) (PP (IN of) (NP (NN DNA) (NN fragmentation)))))) (. .)))
11334364	10	(S1 (S (ADVP (RB Interestingly)) (, ,) (NP (NP (PDT all) (DT the) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (, ,) (NP (NP (NNP Doc_11334364_1955_1958_Chemical)) (, ,) (NP (NNP Doc_11334364_1960_1963_Chemical)) (CC and) (NP (NNP Doc_11334364_1968_1971_Chemical))))) (VP (VBN induced) (NP (JJ apoptotic) (NN death)) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NNP Doc_11334364_2011_2019_Disease))))) (PP (IN in) (NP (NP (DT the) (JJ respective) (NNS organs)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADVP (RB very) (RB effectively)) (VP (VBN blocked) (PP (IN by) (NP (NNP Doc_11334364_2083_2087_Chemical)))))))))) (. .)))
11334364	11	(S1 (S (SBAR (IN Since) (S (NP (NP (NNP Doc_11334364_2095_2098_Chemical)) (, ,) (NP (NNP Doc_11334364_2100_2103_Chemical)) (CC and) (NP (NNP Doc_11334364_2108_2111_Chemical))) (VP (VP (VBP undergo) (NP (NN biotransformation))) (CC and) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (VB produce) (NP (JJ damaging) (NNS radicals)) (PP (IN in) (NP (NN vivo))))))))))) (, ,) (NP (NP (DT the) (NN protection)) (PP (IN by) (NP (NNP Doc_11334364_2208_2212_Chemical)))) (VP (MD may) (VP (AUX be) (VP (VBN linked) (PP (TO to) (NP (NP (DT both) (NN inhibition)) (PP (IN of) (NP (NP (NN metabolism) (NN and/or) (NN detoxification)) (PP (IN of) (NP (JJ cytotoxic) (NNS radicals)))))))))) (. .)))
11334364	12	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (PRP$ its) (POS ') (JJ presumed) (NN contribution)) (PP (TO to) (NP (NN DNA) (NN repair)))) (VP (MD may) (VP (AUX be) (NP (NP (DT another) (JJ important) (NN attribute)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD played) (NP (DT a) (NN role)) (PP (IN in) (NP (DT the) (NN chemoprevention) (NN process))))))))) (. .)))
11334364	13	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (DT this)) (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (NP (DT the) (JJ first) (NN report)) (PP (IN on) (NP (NP (JJ Doc_11334364_2500_2503_Chemical-induced) (JJ apoptotic) (NN death)) (PP (IN in) (NP (DT the) (NN lung) (NN tissue))))))))) (. .)))
11334364	14	(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS events)) (ADVP (RB undoubtedly)) (VP (VB establish) (NP (NP (NP (NNP Doc_11334364_2599_2603_Chemical) (POS 's)) (JJ abundant) (NN bioavailability)) (, ,) (CC and) (NP (DT the) (NN power))) (S (VP (TO to) (VP (VB defend) (NP (JJ multiple) (NN target) (NNS organs)) (PP (IN from) (NP (NP (JJ toxic) (NNS assaults)) (VP (VBN induced) (PP (IN by) (NP (ADJP (ADJP (RB structurally) (JJ diverse)) (CC and) (ADJP (RB functionally) (JJ different))) (NNS entities))) (PP (IN in) (NP (NN vivo)))))))))) (. .)))
11379838	0	(S1 (NP (NP (NP (JJ Doc_11379838_0_14_Chemical-induced) (NN Doc_11379838_23_28_Disease)) (PP (IN in) (NP (NNP Doc_11379838_32_39_Disease) (NNS patients)))) (: :) (NP (NP (NN identification)) (PP (IN of) (NP (NN risk) (NNS factors)))) (. .)))
11379838	1	(S1 (S (NP (NP (NNS Concerns)) (PP (IN about) (NP (NP (JJ possible) (NNS risks)) (PP (IN of) (S (VP (VBG switching) (PP (TO to) (NP (NNP Doc_11379838_140_145_Disease)))))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11379838_162_177_Chemical))))))) (VP (VBP continue) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN establishment)) (PP (IN of) (NP (NP (DT an) (JJ optimal) (NN treatment) (NN paradigm)) (PP (IN for) (NP (NN Doc_11379838_260_278_Disease))))))))))) (. .)))
11379838	2	(S1 (S (NP (NP (DT The) (NN response)) (PP (IN of) (NP (NP (CD 44) (NNS patients)) (VP (VBG meeting) (NP (JJ DSM-IV) (NNS criteria)) (PP (IN for) (NP (NNP Doc_11379838_344_360_Disease)))))) (PP (TO to) (NP (JJ naturalistic) (NN treatment)))) (VP (AUX was) (VP (VBN assessed) (PP (IN for) (NP (NP (QP (IN at) (JJS least) (CD 6)) (NNS weeks)) (VP (VBG using) (NP (NP (DT the) (NNP Montgomery-Asberg) (NNP Depression) (NNP Rating) (NNP Scale)) (CC and) (NP (DT the) (JJ Bech-Rafaelson) (NN Mania) (NNP Rating) (NNP Scale)))))))) (. .)))
11379838	3	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (DT a) (NNP Doc_11379838_543_548_Disease) (CC or) (NNP Doc_11379838_552_561_Disease) (NN switch)))))) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (PP (IN on) (NP (NP (JJ several) (NNS variables)) (VP (VBG including) (NP (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (NP (NP (NP (NN diagnosis)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11379838_658_674_Disease) (FW vs.) (NNP Doc_11379838_679_689_Disease)) (-RRB- -RRB-)) (, ,) (NP (NP (NN number)) (PP (IN of) (NP (JJ previous) (NNP Doc_11379838_711_716_Disease) (NNS episodes)))) (, ,) (NP (NN type))) (PP (IN of) (NP (NNP Doc_11379838_735_749_Chemical) (NN therapy))) (VP (VBN used) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ electroconvulsive) (NN therapy)) (PP (IN vs.) (NP (NNP Doc_11379838_794_808_Chemical) (NNS drugs)))) (CC and) (, ,) (ADVP (RBR more) (RB particularly)) (, ,) (NP (JJ selective) (JJ Doc_11379838_849_878_Chemical) (JJ -LSB-Doc_11379838_880_885_Chemical) (NN -RSB-))) (-RRB- -RRB-)))) (, ,) (NP (NP (NN use) (CC and) (NN type)) (PP (IN of) (NP (NP (NN mood) (NNS stabilizers)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11379838_923_930_Chemical) (FW vs.) (FW anticonvulsants)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (NN temperament)) (PP (IN of) (NP (NP (DT the) (NN patient)) (, ,) (VP (VBN assessed) (PP (IN during) (NP (NP (DT a) (JJ normothymic) (NN period)) (VP (VBG using) (NP (NP (DT the) (NN hyperthymia) (NN component)) (PP (IN of) (NP (DT the) (JJ Semi-structured) (NNP Affective) (NN Temperament) (NN Interview))))))))))))))))))))))) (. .)))
11379838	4	(S1 (S (NP (NP (NNS Switches)) (PP (TO to) (NP (NNP Doc_11379838_1131_1140_Disease) (CC or) (NNP Doc_11379838_1144_1149_Disease)))) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (NP (CD 27) (NN %)) (PP (IN of) (NP (DT all) (NNS patients)))) (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 12)) (-RRB- -RRB-) (-LRB- -LRB-) (CC and) (NP (NP (QP (IN in) (CD 24)) (NN %)) (PP (IN of) (NP (NP (DT the) (NN subgroup)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11379838_1244_1249_Chemical) (CD -LSB-8/33) (NN -RSB-))))))))) (-RRB- -RRB-)) (: ;) (NP (NP (CD 16) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 7)) (-RRB- -RRB-)) (NP (JJ experienced) (JJ Doc_11379838_1283_1288_Disease) (NNS episodes))) (, ,) (CC and) (NP (NP (CD 11) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 5)) (-RRB- -RRB-)) (NP (JJ experienced) (JJ Doc_11379838_1327_1336_Disease) (NNS episodes)))))) (. .)))
11379838	5	(S1 (S (NP (NP (NN Sex)) (, ,) (NP (NN age)) (, ,) (NP (NN diagnosis)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11379838_1368_1377_Disease) (FW vs.) (NNP Doc_11379838_1382_1392_Disease)) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ additional) (NN treatment))) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN switching)))))) (. .)))
11379838	6	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NN mood) (NNS switches)))) (VP (VBD seemed) (S (RB not) (VP (TO to) (VP (VB differ) (PP (IN between) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT an) (NN anticonvulsant)))) (CC and) (NP (NP (DT those)) (VP (VBG receiving) (NP (DT no) (NN mood) (NN stabilizer)))))))))) (. .)))
11379838	7	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NN mood) (NNS switches)) (VP (AUX were) (ADJP (RBR less) (JJ frequent) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_11379838_1663_1670_Chemical)))))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (, ,) (NP (CD 4/26)) (-RRB- -RRB-)) (PP (IN than) (PP (IN in) (NP (NP (NNS patients)) (VP (RB not) (VBN treated) (PP (IN with) (NP (NNP Doc_11379838_1717_1724_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 44) (NN %)) (, ,) (NP (CD 8/18))) (: ;) (NP (NN p)) (X (SYM =)) (CD .04)) (-RRB- -RRB-))))))) (. .)))
11379838	8	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ previous) (NNP Doc_11379838_1770_1775_Disease) (NNS episodes)))) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN probability)) (PP (IN of) (NP (NN switching)))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT a) (JJ high) (NN score)) (PP (IN on) (NP (NP (DT the) (NN hyperthymia) (NN component)) (PP (IN of) (NP (DT the) (JJ Semistructured) (JJ Affective) (NN Temperament) (NN Interview)))))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (S (VP (VBG switching) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD .008)) (-RRB- -RRB-))))))))))))) (. .)))
11379838	9	(S1 (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (NN mood) (NN switching))) (VP (VBN associated) (PP (IN with) (NP (JJ acute) (JJ Doc_11379838_2060_2074_Chemical) (NN therapy))))) (VP (MD may) (VP (AUX be) (VP (VBN reduced) (PP (IN by) (NP (JJ Doc_11379838_2101_2108_Chemical) (NN treatment)))))) (. .)))
11379838	10	(S1 (S (NP (JJ Particular) (NN attention)) (VP (MD should) (VP (AUX be) (VP (VBN paid) (PP (TO to) (NP (NNS patients))) (PP (IN with) (NP (NP (DT a) (JJ hyperthymic) (NN temperament)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX have) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN of) (NP (NN mood) (NNS switches)))))))))))) (. .)))
11391224	0	(S1 (NP (NP (NP (JJ Peritubular) (JJ capillary) (NN basement) (NN membrane) (NN reduplication)) (PP (IN in) (NP (NP (NNS allografts)) (CC and) (NP (JJ native) (NN Doc_11391224_79_93_Disease))))) (: :) (NP (NP (DT a) (JJ clinicopathologic) (NN study)) (PP (IN of) (NP (CD 278) (JJ consecutive) (JJ renal) (NNS specimens)))) (. .)))
11391224	1	(S1 (S (NP (DT An) (NN association)) (VP (AUX has) (VP (AUX been) (VP (VBN found) (PP (IN between) (NP (NP (NP (NNP Doc_11391224_207_232_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11391224_234_236_Disease)) (-RRB- -RRB-))) (CC and) (NP (NP (NN reduplication)) (PP (IN of) (NP (NP (JJ peritubular) (JJ capillary) (NN basement) (NNS membranes)) (PRN (-LRB- -LRB-) (NP (NNP PTCR)) (-RRB- -RRB-)))))))))) (. .)))
11391224	2	(S1 (S (SBAR (IN Although) (S (NP (PDT such) (DT an) (NN association)) (VP (AUX is) (PP (IN of) (NP (ADJP (ADJP (JJ practical)) (CC and) (ADJP (JJ theoretical))) (NN importance)))))) (, ,) (NP (QP (RB only) (CD one)) (JJ prospective) (NN study)) (VP (AUX has) (VP (VBN tried) (S (VP (TO to) (VP (VB confirm) (NP (PRP it))))))) (. .)))
11391224	3	(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (CD 278) (JJ consecutive) (JJ renal) (NNS specimens)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (NP (CD 135) (NNS transplants)) (CC and) (NP (CD 143) (JJ native) (NNS kidneys)))) (-RRB- -RRB-))) (PP (IN for) (NP (NP (JJ ultrastructural) (NN evidence)) (PP (IN of) (NP (NNP PTCR)))))) (. .)))
11391224	4	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (JJ renal) (NNS allografts)) (PP (IN with) (NP (NNP Doc_11391224_607_609_Disease))))))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBD examined) (NP (NP (NNS grafts)) (PP (IN with) (NP (NP (JJ acute) (NN rejection)) (, ,) (NP (JJ recurrent) (NN Doc_11391224_667_685_Disease)) (, ,) (NP (NNP Doc_11391224_687_716_Disease)) (CC and) (NP (NP (JJ stable) (NNS grafts)) (PRN (-LRB- -LRB-) (`` ``) (NP (NN protocol) (NNS biopsies)) ('' '') (-RRB- -RRB-))))))) (. .)))
11391224	5	(S1 (S (NP (JJ Native) (NN kidney) (NNS specimens)) (VP (VBD included) (NP (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (NNP Doc_11391224_807_823_Disease)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_11391224_844_870_Disease)) (, ,) (NP (NNP Doc_11391224_872_894_Disease)) (, ,) (NP (JJ acute) (NNP Doc_11391224_902_924_Disease)) (, ,) (CC and) (NP (NNP Doc_11391224_930_952_Disease))))))) (. .)))
11391224	6	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NNP PTCR)) (PP (PP (IN in) (NP (NP (CD 14)) (PP (IN of) (NP (NP (CD 15) (NNS cases)) (PP (IN of) (NP (NNP Doc_11391224_998_1000_Disease))))))) (, ,) (PP (IN in) (NP (NP (CD 7) (NN transplant) (NN biopsy) (NNS specimens)) (PP (IN without) (NP (NNP Doc_11391224_1043_1045_Disease))))) (, ,) (CC and) (PP (IN in) (NP (NP (CD 13)) (PP (IN of) (NP (CD 143) (JJ native) (NN kidney) (NN biopsy) (NNS specimens))))))) (. .)))
11391224	7	(S1 (S (NP (DT These) (CD 13)) (VP (VBD included) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_11391224_1123_1145_Disease)) (, ,) (NP (NNP Doc_11391224_1147_1173_Disease)) (, ,) (NP (NNP Doc_11391224_1175_1190_Disease)) (, ,) (NP (NNP Doc_11391224_1192_1218_Disease)) (, ,) (NP (JJ crescentic) (NNP Doc_11391224_1231_1249_Disease)) (, ,) (CC and) (NP (JJ Doc_11391224_1255_1262_Chemical-related) (NNP Doc_11391224_1271_1290_Disease)))))) (. .)))
11391224	8	(S1 (S (NP (NP (JJ Mild) (NNS PTCR)) (PP (IN in) (NP (NP (NNS allografts)) (PP (IN without) (NP (NNP Doc_11391224_1324_1326_Disease)))))) (VP (AUX did) (RB not) (VP (VB predict) (NP (NP (NN Doc_11391224_1343_1356_Disease)) (CC or) (NP (JJ significant) (NN Doc_11391224_1372_1383_Disease))) (PP (IN after) (NP (NP (JJ follow-up) (NNS periods)) (PP (IN of) (NP (QP (IN between) (CD 3) (NNS months) (CC and) (CD 1) (NN year)))))))) (. .)))
11391224	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (PP (IN in) (NP (NNS transplants))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (JJ strong) (NN association)) (PP (IN between) (NP (NP (JJ well-developed) (NNP PTCR)) (CC and) (NP (NNP Doc_11391224_1548_1550_Disease))))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NN significance)) (PP (IN of) (NP (NP (JJ mild) (NN PTCR)) (CC and) (NP (PRP$ its) (JJ predictive) (NN value)))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_11391224_1631_1633_Disease)))))) (VP (AUX is) (ADJP (JJ unclear))))))))) (. .)))
11391224	10	(S1 (S (NP (NNP PTCR)) (ADVP (RB also)) (VP (VBZ occurs) (PP (IN in) (NP (JJ certain) (JJ native) (NN Doc_11391224_1681_1696_Disease))) (, ,) (SBAR (IN though) (S (NP (DT the) (NN association)) (VP (AUX is) (RB not) (ADJP (RB as) (JJ strong) (PP (IN as) (NP (NP (DT that)) (PP (IN for) (NP (NNP Doc_11391224_1750_1752_Disease)))))))))) (. .)))
11391224	11	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (S (NP (NP (DT that) (VBN repeated) (NN Doc_11391224_1779_1797_Disease)) (, ,) (PP (VBG including) (NP (NNP Doc_11391224_1809_1827_Disease))) (, ,)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN cause)) (PP (PP (IN of) (NP (DT this) (NN lesion))) (CC both) (PP (IN in) (NP (NP (NNS allografts)) (CC and) (NP (JJ native) (NNS kidneys))))))))))) (. .)))
11419773	0	(S1 (NP (NP (JJ Doc_11419773_0_8_Chemical-induced) (NN Doc_11419773_17_35_Disease)) (: :) (NP (NP (DT an) (JJ unrecognised) (NN danger)) (PP (IN of) (NP (NN healthfood) (NNS products)))) (. .)))
11419773	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ 25-year-old) (NN woman)) (PP (IN with) (NP (JJ pre-existing) (NNP Doc_11419773_134_155_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ intractable) (NN Doc_11419773_182_206_Disease)) (PP (IN after) (NP (NP (NN consuming) (NP (DT a) (`` ``) (JJ natural) (NN energy) ('' '')) (NNP guarana) (NN health) (NN drink)) (VP (VBG containing) (NP (NP (DT a) (JJ high) (NN concentration)) (PP (IN of) (NP (NNP Doc_11419773_298_306_Chemical)))))))))))) (. .)))
11419773	2	(S1 (S (NP (DT This) (NN case)) (VP (VBZ highlights) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (JJ adequate) (NN labelling)) (CC and) (NP (NP (NN regulation)) (PP (IN of) (NP (JJ such) (NNS products)))))))) (. .)))
11426838	0	(S1 (S (NP (NP (NP (ADJP (RB Conformationally) (VBN restricted)) (NNS analogs)) (PP (IN of) (NP (NNP Doc_11426838_39_45_Chemical)))) (CC and) (NP (DT an) (JJ antisense) (JJ Doc_11426838_63_83_Chemical) (VBG targeting) (NN sigma1) (NNS receptors))) (VP (VBP produce) (NP (NP (JJ anti-Doc_11426838_124_131_Chemical) (NNS effects)) (PP (IN in) (NP (NNS mice))))) (. .)))
11426838	1	(S1 (S (NP (NP (NN Doc_11426838_149_156_Chemical) (POS 's)) (NN ability) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NNP sigma) (NNS receptors))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT these) (NNS proteins)) (VP (VB mediate) (NP (NP (DT some)) (PP (IN of) (NP (PRP$ its) (JJ behavioral) (NNS effects)))))))) (. .)))
11426838	2	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (ADJP (CD three) (NN novel)) (NNP sigma) (NN receptor) (NNS ligands)) (PP (IN with) (NP (JJ antagonist) (NN activity)))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNP Swiss) (NNP Webster) (NNS mice)) (: :) (NP (NP (NP (NNP Doc_11426838_378_384_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11426838_386_450_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_11426838_453_459_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11426838_461_511_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_11426838_518_523_Chemical) (PRN (-LRB- -LRB-) (NP (NP (JJ 1R,2S-) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (JJ -cis-N--LSB-2-) (-LRB- -LRB-) (NN 3,4-dichlorophenyl) (-RRB- -RRB-) (NNP ethyl)) (NP (JJ -RSB-) (JJ -2-) (PRN (-LRB- -LRB-) (NP (NN 1-pyrrolidinyl)) (-RRB- -RRB-)) (NN cyclohexylamine))) (-RRB- -RRB-)))))))) (. .)))
11426838	3	(S1 (S (NP (NN Competition) (JJ binding) (NNS assays)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT all) (CD three) (NNS compounds)) (VP (AUX have) (NP (NP (JJ high) (NNS affinities)) (PP (IN for) (NP (JJ sigma1) (NNS receptors)))))))) (. .)))
11426838	4	(S1 (S (NP (DT The) (CD three) (NNS compounds)) (VP (VBP vary) (PP (IN in) (NP (NP (PRP$ their) (NNS affinities)) (PP (IN for) (NP (NP (JJ sigma2) (NNS receptors)) (CC and) (NP (NP (NN exhibit) (JJ negligible) (NNS affinities)) (PP (IN for) (NP (NP (NNP Doc_11426838_819_827_Chemical)) (, ,) (NP (NN opioid)) (, ,) (NP (NP (NNP Doc_11426838_837_841_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP A)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_11426838_849_853_Chemical) (NNS receptors)))))))))) (. .)))
11426838	5	(S1 (S (PP (IN In) (NP (JJ behavioral) (NNS studies))) (, ,) (NP (NP (NN pre-treatment)) (PP (IN of) (NP (NP (NNS mice)) (PP (IN with) (NP (NP (NNP Doc_11426838_915_921_Chemical)) (, ,) (NP (NNP Doc_11426838_923_929_Chemical)) (, ,) (CC or) (NP (NNP Doc_11426838_934_939_Chemical))))))) (VP (ADVP (RB significantly)) (VBD attenuated) (NP (NP (JJ Doc_11426838_965_972_Chemical-induced) (NN Doc_11426838_981_992_Disease)) (CC and) (NP (NN lethality)))) (. .)))
11426838	6	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN post-treatment)) (PP (IN with) (NP (NNP Doc_11426838_1038_1043_Chemical)))) (VP (VBD prevented) (NP (JJ Doc_11426838_1054_1061_Chemical-induced) (NN lethality)) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN proportion)) (PP (IN of) (NP (NNS animals)))))) (. .)))
11426838	7	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (NN protection)) (VP (VBN provided) (PP (IN by) (NP (DT the) (JJ putative) (NNS antagonists)))))))) (, ,) (NP (NP (NP (DT the) (JJ well-characterized) (NNP sigma) (NN receptor) (NN agonist) (NNP Doc_11426838_1234_1253_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11426838_1255_1258_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (DT the) (JJ novel) (NNP sigma) (NN receptor) (NN agonist) (NNP Doc_11426838_1297_1303_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11426838_1305_1369_Chemical)) (-RRB- -RRB-))) (NP (DT each)))) (VP (VBD worsened) (NP (NP (DT the) (JJ behavioral) (NN Doc_11426838_1400_1408_Disease)) (PP (IN of) (NP (NNP Doc_11426838_1412_1419_Chemical))))) (. .)))
11426838	8	(S1 (S (PP (IN At) (NP (NP (NNS doses)) (SBAR (WHADVP (WRB where)) (S (ADVP (RB alone)) (, ,) (NP (PRP they)) (VP (VBD produced) (NP (DT no) (JJ significant) (NNS effects)) (PP (IN on) (NP (NN locomotion)))))))) (, ,) (NP (NNP Doc_11426838_1495_1501_Chemical) (, ,) (NNP Doc_11426838_1503_1509_Chemical) (CC and) (NNP Doc_11426838_1514_1519_Chemical)) (ADVP (RB significantly)) (VP (VBD attenuated) (NP (NP (DT the) (JJ locomotor) (JJ stimulatory) (NNS effects)) (PP (IN of) (NP (NNP Doc_11426838_1582_1589_Chemical))))) (. .)))
11426838	9	(S1 (S (S (VP (TO To) (VP (ADVP (RB further)) (VB validate) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (DT the) (JJ anti-Doc_11426838_1640_1647_Chemical) (NNS effects)) (PP (IN of) (NP (DT the) (JJ novel) (NNS ligands)))) (VP (VBD involved) (NP (NP (NN antagonism)) (PP (IN of) (NP (NNP sigma) (NNS receptors))))))))))) (, ,) (NP (NP (DT an) (JJ antisense) (NN Doc_11426838_1730_1750_Chemical)) (PP (IN against) (NP (JJ sigma1) (NNS receptors)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN shown) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB attenuate) (NP (NP (DT the) (ADJP (JJ Doc_11426838_1822_1832_Disease) (CC and) (JJ locomotor)) (JJ stimulatory) (NNS effects)) (PP (IN of) (NP (NNP Doc_11426838_1870_1877_Chemical))))))))) (. .)))
11426838	10	(S1 (S (ADVP (RB Together)) (, ,) (NP (DT the) (NN data)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (JJ functional) (NN antagonism)) (PP (IN of) (NP (NNP sigma) (NNS receptors)))) (VP (AUX is) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG attenuating) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ Doc_11426838_1991_1998_Chemical-induced) (NNS behaviors)))))))))))) (. .)))
11431197	0	(S1 (NP (NP (JJ Doc_11431197_0_10_Chemical-induced) (JJ acute) (NN Doc_11431197_25_47_Disease)) (PP (IN in) (NP (DT a) (JJ cadaveric) (JJ renal) (NN allograft))) (. .)))
11431197	1	(S1 (S (NP (NN Doc_11431197_80_90_Chemical)) (ADVP (RB frequently)) (VP (AUX is) (VP (VBN used) (PP (IN for) (S (VP (VBG preventing) (NP (JJ peptic) (NN ulceration)) (PP (IN after) (NP (JJ renal) (NN transplantation)))))))) (. .)))
11431197	2	(S1 (S (NP (DT This) (NN drug)) (ADVP (RB occasionally)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ acute) (NN Doc_11431197_226_248_Disease)) (PP (IN in) (NP (JJ native) (NNS kidneys)))))))) (. .)))
11431197	3	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (DT no) (JJ similar) (NNS reports)) (PP (IN with) (NP (JJ renal) (NN transplantation))))) (. .)))
11431197	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ Doc_11431197_345_355_Chemical-induced) (JJ acute) (NN Doc_11431197_370_392_Disease)))) (PP (IN in) (NP (NP (DT a) (NN recipient)) (PP (IN of) (NP (NP (DT a) (JJ cadaveric) (JJ renal) (NN allograft)) (VP (VBG presenting) (PP (IN with) (NP (JJ acute) (NN allograft) (NN dysfunction))) (PP (IN within) (NP (NP (CD 48) (NNS hours)) (PP (IN of) (NP (NP (NN exposure)) (PP (TO to) (NP (DT the) (NN drug))))))))))))) (. .)))
11431197	5	(S1 (S (NP (DT The) (JJ biopsy) (NNS specimen)) (VP (VBD showed) (NP (NP (JJ pathognomonic) (NNS features)) (, ,) (PP (VBG including) (NP (NP (JJ eosinophilic) (NN infiltration)) (PP (IN of) (NP (DT the) (JJ interstitial) (NN compartment))))))) (. .)))
11431197	6	(S1 (S (NP (JJ Allograft) (NN function)) (VP (VP (VBD improved) (ADVP (RB rapidly))) (CC and) (VP (VBD returned) (PP (TO to) (NP (NN baseline))) (PP (IN after) (S (VP (VBG stopping) (NP (DT the) (NN drug))))))) (. .)))
1147734	0	(S1 (S (NP (NN Doc_1147734_0_13_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_1147734_24_40_Chemical)))) (. .)))
1147734	1	(S1 (S (NP (DT This) (NN report)) (VP (VBZ presents) (NP (NP (DT the) (JJ clinical) (, ,) (NN laboratory) (, ,) (CC and) (NN light)) (CC and) (NP (NNP electron) (JJ microscopic) (NNS observations))) (PP (IN on) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_1147734_155_192_Disease))) (VP (VBN caused) (PP (IN by) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_1147734_225_241_Chemical))))))))) (. .)))
1147734	2	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT an) (NN addition)) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD must) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (JJ chronic) (NN Doc_1147734_337_350_Disease)))))))))))))))) (. .)))
11532387	0	(S1 (NP (NP (NN Doc_11532387_0_35_Disease)) (PP (IN during) (NP (NP (NN dose) (NN reduction)) (PP (IN of) (NP (NNP Doc_11532387_61_72_Chemical))))) (. .)))
11532387	1	(S1 (S (NP (NP (NN Doc_11532387_74_89_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11532387_91_93_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ rare) (JJ extrapyramidal) (NN side) (NN effect)) (VP (VBN caused) (PP (IN by) (NP (JJ prolonged) (JJ neuroleptic) (NN medication)))))) (. .)))
11532387	2	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_11532387_202_224_Disease))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT the) (JJ first)) (PP (IN of) (NP (PRP$ its) (NN kind) (S (VP (TO to) (VP (AUX be) (VP (VBN reported))))))))))))) (. .)))
11532387	3	(S1 (S (NP (DT The) (NN patient)) (VP (VBD developed) (NP (NN Doc_11532387_295_297_Disease)) (PP (IN during) (NP (NP (NN dose) (NN reduction)) (PP (IN of) (NP (NNP Doc_11532387_323_334_Chemical)))))) (. .)))
11532387	4	(S1 (S (NP (DT The) (NN symptom)) (VP (AUX was) (VP (VBN treated) (ADVP (RB successfully)) (PP (IN with) (NP (JJ Doc_11532387_378_393_Chemical) (JJ anticholinergic) (NN therapy))))) (. .)))
11532387	5	(S1 (S (NP (NP (DT The) (JJ underlying) (NN mechanism)) (PP (IN of) (NP (NNP Doc_11532387_447_469_Disease))) (PP (IN in) (NP (DT the) (JJ present) (NN case)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (JJ pharmacological) (NN profile)) (PP (IN of) (NP (NP (NNP Doc_11532387_546_557_Chemical)) (, ,) (NP (DT a) (JJ Doc_11532387_561_570_Chemical-Doc_11532387_571_579_Chemical) (NN antagonist))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (JJ pathophysiologic) (NN influence)) (PP (IN of) (NP (DT the) (JJ Doc_11532387_641_650_Chemical) (NN system))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11532387_680_682_Disease))))))))))) (. .)))
11569530	0	(S1 (NP (NP (JJ Pharmacokinetic/pharmacodynamic) (NN assessment)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_11569530_61_66_Chemical) (, ,) (NNP Doc_11569530_68_77_Chemical) (, ,) (NNP Doc_11569530_79_90_Chemical) (CC and) (NNP Doc_11569530_95_105_Chemical))) (PP (IN on) (NP (NP (JJ monophasic) (NN action) (JJ potential) (NN duration)) (PP (IN in) (NP (NNP dog.) (CD 1))))))) (. .)))
11569530	1	(S1 (S (NP (NP (NNP Doc_11569530_157_176_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11569530_178_181_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ fatal)) (NN Doc_11569530_206_229_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (JJ QT) (NN interval)) (CC and) (NP (NP (JJ monophasic) (NN action) (JJ potential) (NN duration)) (PRN (-LRB- -LRB-) (NP (NNP MAPD)) (-RRB- -RRB-)))))))))) (. .)))
11569530	2	(S1 (S (NP (NN Doc_11569530_320_323_Disease)) (VP (AUX is) (NP (NP (DT a) (NN side-effect)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (VBN led) (PP (TO to) (NP (NP (NN withdrawal)) (PP (IN of) (NP (JJ several) (NNS drugs))) (PP (IN from) (NP (NP (DT the) (NN market)) (PRN (-LRB- -LRB-) (NP (NNP e.g.) (NNP Doc_11569530_407_418_Chemical) (CC and) (NNP Doc_11569530_423_433_Chemical)) (-RRB- -RRB-)))) (. .) (CD 2))))))))) (. .)))
11569530	3	(S1 (S (NP (NP (DT The) (NN potential)) (PP (IN of) (NP (NP (NNS compounds)) (SBAR (S (VP (TO to) (VP (VB cause) (NP (NNP Doc_11569530_475_478_Disease))))))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN by) (S (VP (VBG monitoring) (NP (PRP$ their) (NNS effects)) (PP (IN on) (NP (NP (NNP MAPD)) (PP (IN in) (NP (NN dog)))))))))) (. .)))
11569530	4	(S1 (NP (NP (NP (CD Four) (NNS compounds)) (VP (VBN known) (S (VP (TO to) (VP (VP (VB increase) (NP (CD QT) (NN interval))) (CC and) (VP (VB cause) (SBAR (S (NP (NNP Doc_11569530_592_595_Disease)) (VP (AUX were) (VP (VBN investigated))))))))))) (: :) (NP (NNP Doc_11569530_615_626_Chemical) (, ,) (NNP Doc_11569530_628_638_Chemical) (, ,) (NNP Doc_11569530_640_649_Chemical) (CC and) (NNP Doc_11569530_654_659_Chemical)) (. .)))
11569530	5	(S1 (S (PP (IN On) (NP (DT the) (NN basis) (SBAR (IN that) (S (NP (NP (RB only) (JJ free) (NN drug)) (PP (IN in) (NP (DT the) (JJ systemic) (NN circulation)))) (VP (MD will) (VP (VB elicit) (NP (DT a) (JJ pharmacological) (NN response) (NN target)))))))) (, ,) (NP (NP (JJ free) (NNS concentrations)) (PP (IN in) (NP (NN plasma)))) (VP (AUX were) (VP (VBN selected) (S (VP (TO to) (VP (VB mimic) (NP (NP (DT the) (JJ free) (NN drug) (NNS exposures)) (PP (IN in) (NP (NN man))))))))) (. .)))
11569530	6	(S1 (S (NP (NN Infusion) (NNS regimens)) (VP (AUX were) (VP (VBN designed) (SBAR (IN that) (S (NP (NP (NP (ADJP (RB rapidly) (VBN achieved) (CC and) (VBN maintained)) (JJ target-free) (NNS concentrations)) (PP (IN of) (NP (NP (DT these) (NNS drugs)) (PP (IN in) (NP (NN plasma)))))) (CC and) (NP (NP (NNS data)) (PP (IN on) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ free) (NN concentration)) (CC and) (NP (NP (NNS changes)) (PP (IN in) (NP (NNP MAPD)))))))))) (VP (AUX were) (VP (VBN obtained) (PP (IN for) (NP (DT these) (JJ compounds.) (CD 3))))))))) (. .)))
11569530	7	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ free) (CD ED50)) (PP (IN in) (NP (NP (NN plasma)) (PP (IN for) (NP (NP (NP (NNP Doc_11569530_1142_1153_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.9) (NN nM)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_11569530_1164_1174_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 76) (NN nM)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_11569530_1184_1193_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 11) (NN nM)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_11569530_1206_1211_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.9) (NN nM)) (-RRB- -RRB-)))))))) (ADVP (RB closely)) (VP (VB correlate) (PP (IN with) (NP (DT the) (JJ free) (NN concentration))) (PP (IN in) (NP (NP (NN man)) (VP (VBG causing) (NP (JJ QT) (NNS effects))))))))) (. .)))
11569530	8	(S1 (S (PP (IN For) (NP (NP (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (VBN shown) (NP (NNP Doc_11569530_1324_1327_Disease)) (PP (IN in) (NP (DT the) (NN clinic))))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_11569530_1343_1354_Chemical)) (, ,) (NP (NNP Doc_11569530_1356_1366_Chemical)) (, ,) (NP (NNP Doc_11569530_1368_1377_Chemical)) (-RRB- -RRB-)) (NP (EX there)) (VP (AUX is) (NP (NP (JJ little) (NN differentiation)) (PP (IN between) (NP (NP (DT the) (NN dog) (CD ED50)) (CC and) (NP (NP (DT the) (JJ efficacious) (JJ free) (NN plasma) (NNS concentrations)) (PP (IN in) (NP (NP (NN man)) (PRN (-LRB- -LRB-) (NP (NNP <) (JJ 10-fold)) (-RRB- -RRB-)) (VP (VBG reflecting) (NP (PRP$ their) (JJ limited) (NN safety) (NNS margins)))))))))) (. .)))
11569530	9	(S1 (S (NP (DT These) (NNS data)) (VP (VB underline) (NP (NP (DT the) (NN need) (S (VP (TO to) (VP (VB maximize) (NP (DT the) (JJ therapeutic) (NN ratio)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NNP Doc_11569530_1619_1622_Disease)) (PP (IN in) (NP (JJ potential) (NN development) (NNS candidates))))))))))) (CC and) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG using) (NP (NP (JJ free) (NN drug) (NNS concentrations)) (PP (IN in) (NP (JJ pharmacokinetic/pharmacodynamic) (NNS studies)))))))))) (. .)))
11581460	0	(S1 (S (S (NP (NN Bladder)) (VP (VBP Doc_11581460_8_26_Disease) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (JJ continuous) (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NNP Doc_11581460_77_85_Chemical))))))))) (: :) (S (NP (CD 2) (NN case)) (VP (VBZ reports))) (. .)))
11581460	1	(S1 (S (NP (NNP Sedation)) (VP (AUX has) (VP (AUX been) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (DT the) (NN neonate) (S (VP (TO to) (VP (VB decrease) (NP (NP (DT the) (NN stress) (CC and) (NN Doc_11581460_177_181_Disease)) (PP (IN from) (NP (NP (DT the) (NX (NX (JJ noxious) (NNS stimuli)) (CC and) (NX (JJ invasive) (NNS procedures)))) (PP (IN in) (NP (NP (DT the) (JJ neonatal) (JJ intensive) (NN care) (NN unit)) (, ,) (CONJP (RB as) (RB well) (IN as)) (S (VP (TO to) (VP (VB facilitate) (NP (NP (NN synchrony)) (PP (IN between) (NP (NP (NN ventilator)) (CC and) (NP (JJ spontaneous) (NNS breaths))))))))))))))))))))) (. .)))
11581460	2	(S1 (S (NP (NP (NN Doc_11581460_347_355_Chemical)) (, ,) (NP (DT an) (JJ opioid) (JJ analgesic)) (, ,)) (VP (AUX is) (ADVP (RB frequently)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (JJ neonatal) (JJ intensive) (NN care) (NN unit)) (VP (VBG setting) (PP (IN for) (NP (DT these) (JJ very) (NNS purposes)))))))) (. .)))
11581460	3	(S1 (S (NP (NP (JJ Various) (JJ reported) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_11581460_499_507_Chemical) (NN administration)))) (VP (VBP include) (NP (NP (NNP Doc_11581460_531_550_Disease)) (, ,) (NP (NNP Doc_11581460_552_563_Disease)) (, ,) (NP (NNP Doc_11581460_565_587_Disease)) (, ,) (CC and) (NP (NNP Doc_11581460_593_604_Disease)))) (. .)))
11581460	4	(S1 (S (ADVP (RB Here)) (, ,) (NP (NP (CD 2) (NNS cases)) (PP (IN of) (NP (NNP Doc_11581460_623_648_Disease))) (VP (VBG leading) (PP (TO to) (NP (JJ renal) (JJ pelvocalyceal) (NN dilatation) (NN mimicking) (NNP Doc_11581460_701_715_Disease))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NNP Doc_11581460_754_762_Chemical))))))))) (VP (AUX are) (VP (VBN reported))) (. .)))
11587867	0	(S1 (NP (NP (NP (JJ Fatal) (NN Doc_11587867_6_25_Disease)) (ADJP (JJ due) (S (VP (TO to) (VP (VB accidental) (NP (JJ intrathecal) (JJ Doc_11587867_56_66_Chemical) (NN administration))))))) (: :) (NP (NP (DT a) (NN report)) (PP (IN of) (NP (CD two) (NNS cases)))) (. .)))
11587867	1	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (CD two) (JJ fatal) (NNS cases)) (PP (IN of) (NP (NP (JJ accidental) (JJ intrathecal) (JJ Doc_11587867_161_172_Chemical) (NN instillation)) (PP (IN in) (NP (NP (NP (DT a) (JJ 5-year) (JJ old) (NN girl)) (PP (IN with) (NP (JJ recurrent) (NN Doc_11587867_222_250_Disease)))) (CC and) (NP (NP (DT a) (JJ 57-year) (JJ old) (NN man)) (PP (IN with) (NP (NNP Doc_11587867_278_300_Disease))))))))))) (. .)))
11587867	2	(S1 (S (NP (DT The) (NN girl)) (VP (VBD died) (NP (CD seven) (NNS days)) (, ,) (PP (NP (DT the) (NN man) (CD four) (NNS weeks)) (IN after) (NP (NP (JJ intrathecal) (NN injection)) (PP (IN of) (NP (NNP Doc_11587867_378_389_Chemical)))))) (. .)))
11587867	3	(S1 (S (ADVP (RB Clinically)) (, ,) (NP (DT the) (NN onset)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NP (NNP Doc_11587867_447_490_Disease)) (CC and) (NP (VBG ascending) (NNP Doc_11587867_505_514_Disease)))))))) (. .)))
11587867	4	(S1 (S (NP (NP (JJ Histological) (CC and) (JJ immunohistochemical) (NNS investigations)) (PRN (-LRB- -LRB-) (NP (NP (NNP HE-LFB)) (, ,) (NP (CD CD-68))) (, ,) (NP (NNP Neurofilament)) (-RRB- -RRB-))) (VP (VBD revealed) (NP (NP (NNP Doc_11587867_608_640_Disease)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNP Doc_11587867_652_679_Disease)) (PP (IN in) (NP (NP (NNS areas)) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_11587867_700_711_Chemical)))))) (, ,) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ secondary) (NNS changes)) (PP (IN with) (NP (JJ numerous) (JJ prominent) (NNS macrophages))))))))) (. .)))
11587867	5	(S1 (S (NP (NP (DT The) (JJ clinical) (UCP (NN course) (CC and) (JJ histopathological)) (NNS results)) (PP (IN of) (NP (DT the) (CD two) (NNS cases)))) (VP (AUX are) (VP (VBN presented))) (. .)))
11587867	6	(S1 (S (NP (NP (DT A) (NN review)) (PP (IN of) (NP (DT all) (JJ reported) (NNS cases))) (PP (IN in) (NP (DT the) (NN literature)))) (VP (AUX is) (VP (VBN given))) (. .)))
11587867	7	(S1 (S (NP (NP (DT A) (ADJP (RB better) (VBN controlled)) (NN regimen)) (PP (IN for) (S (VP (VBG administering) (NP (JJ Doc_11587867_970_981_Chemical) (CC and) (JJ intrathecal) (NN chemotherapy)))))) (VP (AUX is) (VP (VBN recommended))) (. .)))
11642480	0	(S1 (NP (NP (NN Doc_11642480_0_19_Disease)) (PP (IN in) (NP (DT a) (JJ Doc_11642480_25_34_Disease) (JJ adolescent))) (PP (IN on) (NP (NNP Doc_11642480_49_59_Chemical))) (. .)))
11642480	1	(S1 (S (NP (JJ Current) (NNS estimates)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN between) (NP (NP (CD 0.4) (NN %)) (CC and) (NP (NP (CD 8.3) (NN %)) (PP (IN of) (NP (NP (NNS children)) (CC and) (NP (NNS adolescents))))))) (VP (AUX are) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_11642480_158_174_Disease)))))))) (. .)))
11642480	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ favorable) (NN response)) (PP (TO to) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_11642480_225_235_Chemical)))) (PP (IN by) (NP (NP (DT a) (JJ 15-year-old) (NN boy)) (PP (IN with) (NP (NNP Doc_11642480_262_278_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD exhibited) (NP (NNP Doc_11642480_293_312_Disease)) (PP (IN during) (NP (NP (PRP$ his) (JJ first) (CD 2) (NNS weeks)) (PP (IN of) (NP (NN treatment))))))))))) (. .)))
11642480	3	(S1 (S (NP (DT This)) (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (NP (DT a) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_11642480_388_398_Chemical)))) (SBAR (IN as) (S (NP (PRP it)) (VP (VBD remitted) (PP (IN with) (NP (NP (NN redistribution)) (PP (IN of) (NP (NNS doses))))))))))) (. .)))
11672959	0	(S1 (S (NP (DT The) (JJ 3-week) (JJ Doc_11672959_11_25_Chemical) (NN syndrome)) (VP (VBZ strikes) (ADVP (RB again))) (. .)))
11672959	1	(S1 (S (NP (DT A) (JJ 34-year-old) (NN lady)) (VP (VBD developed) (NP (NP (DT a) (NN constellation)) (PP (IN of) (NP (NNP Doc_11672959_98_108_Disease) (, ,) (NNP Doc_11672959_110_115_Disease) (, ,) (NNP Doc_11672959_117_132_Disease) (CC and) (NNP Doc_11672959_137_146_Disease)))) (, ,) (S (VP (VBG beginning) (PP (IN on) (NP (NP (DT the) (JJ 17th) (NN day)) (PP (IN of) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NP (JJ oral) (NN Doc_11672959_194_208_Chemical)) (PP (IN for) (NP (JJ sero-negative) (NN Doc_11672959_227_247_Disease)))))))))))) (. .)))
11672959	2	(S1 (S (S (NP (JJ Cervical) (CC and) (JJ inguinal) (NN lymph) (NN node) (NNS biopsies)) (VP (VBD showed) (NP (NP (DT the) (NNS features)) (PP (IN of) (NP (JJ severe) (NN necrotising) (NN Doc_11672959_333_346_Disease))) (, ,) (VP (VBN associated) (PP (IN with) (NP (NP (NNS erythrophagocytosis)) (CC and) (NP (JJ prominent) (JJ eosinophilic) (NNS infiltrates))))) (, ,)) (PP (IN without) (NP (JJ viral) (NN inclusion) (NNS bodies))) (, ,) (ADJP (JJ suggestive) (PP (IN of) (NP (DT an) (JJ Doc_11672959_473_494_Disease.A) (NN week)))) (ADVP (RB later)))) (, ,) (NP (NP (JJ fulminant) (NNP Doc_11672959_519_541_Disease)) (, ,) (VP (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ anti-nuclear) (NNS autoantibodies)) (PRN (-LRB- -LRB-) (CC but) (ADVP (RB not)) (PP (IN with) (NP (NP (JJ other) (NNS markers)) (PP (IN of) (NP (NNP Doc_11672959_634_646_Disease))))) (-RRB- -RRB-))))))) (, ,) (CC and) (VP (VBN accompanied) (PP (IN by) (NP (NNP Doc_11672959_668_687_Disease) (CC and) (NNP Doc_11672959_692_698_Disease))))) (, ,)) (VP (VBD supervened)) (. .)))
11672959	3	(S1 (S (NP (PRP She)) (ADVP (RB subsequently)) (VP (VBD died) (SBAR (NP (DT some) (CD 5) (NNS weeks)) (IN after) (S (NP (NP (DT the) (NN commencement)) (PP (IN of) (NP (PRP$ her) (NN drug) (NN therapy.Post-mortem) (NN examination)))) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NNP Doc_11672959_833_864_Disease)) (, ,) (NP (NP (JJ acute) (NN hypersensitivity) (NN Doc_11672959_889_900_Disease)) (, ,) (NP (JJ focal) (JJ acute) (JJ tubulo-interstitial) (NN Doc_11672959_934_943_Disease)) (CC and) (NP (JJ extensive) (NN Doc_11672959_958_978_Disease))) (, ,)))) (PP (IN with) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_11672959_1000_1010_Disease))))))))) (. .)))
11672959	4	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN thought) (SBAR (IN that) (S (NP (NP (DT the) (JJ clinico-pathological) (NNS features)) (CC and) (NP (NP (NN chronology)) (PP (IN of) (NP (DT this) (NN case))))) (VP (VBD bore) (NP (NP (DT the) (NNS hallmarks)) (PP (IN of) (NP (DT the) (JJ so-called) (`` ``) (JJ 3-week) (JJ Doc_11672959_1137_1151_Chemical) (NN syndrome) ('' '')))) (, ,) (NP (NP (DT a) (JJ rare) (PRN (, ,) (CC but) (ADVP (RB often)) (ADJP (JJ fatal)) (, ,)) (JJ immunoallergic) (NN reaction)) (PP (TO to) (NP (NNP Doc_11672959_1215_1229_Chemical))))))))) (. .)))
11679859	0	(S1 (FRAG (S (NP (NP (JJ Intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_11679859_30_46_Chemical))) (PP (IN by) (NP (NP (JJ 15-minute) (NN infusion)) (CC versus) (NP (JJ 2-minute) (NN bolus))))) (VP (AUX does) (RB not) (VP (VB affect) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_11679859_124_133_Disease))))))) (: :) (NP (DT a) (JJ prospective) (, ,) (VBN randomized) (, ,) (VBN controlled) (NN trial)) (. .)))
11679859	1	(S1 (NP (NN STUDY) (NN OBJECTIVE) (: :) (S (NP (PRP We)) (VP (VBD sought) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NNP Doc_11679859_230_239_Disease))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_11679859_276_292_Chemical)))))) (PP (IN as) (NP (NP (DT a) (JJ 2-minute) (NN bolus)) (CC or) (NP (JJ 15-minute) (NN infusion))))))))) (. .)))
11679859	2	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (DT a) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ double-blind) (NN study)) (PP (IN in) (NP (NP (DT the) (NN emergency) (NN department)) (PP (IN of) (NP (DT a) (JJ central-city) (NN teaching) (NN hospital)))))) (. .)))
11679859	3	(S1 (S (NP (NP (NNS Patients)) (VP (VBN aged) (NP (NP (CD 18) (NNS years)) (CC or) (NP (NP (JJR older)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11679859_514_530_Chemical)))))) (PP (IN for) (NP (NP (NNP Doc_11679859_535_543_Disease)) (, ,) (NP (NNP Doc_11679859_545_551_Disease)) (, ,) (CC or) (NP (NNP Doc_11679859_556_564_Disease)))))) (VP (AUX were) (ADJP (JJ eligible) (PP (IN for) (NP (NN inclusion))))) (. .)))
11679859	4	(S1 (S (NP (NN Study) (NNS participants)) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (CD 10) (NN mg)) (PP (IN of) (NP (NNP Doc_11679859_649_665_Chemical))) (VP (VBN administered) (ADVP (RB intravenously)) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (NP (NP (JJ 2-minute) (NN push)) (PRN (-LRB- -LRB-) (NP (JJ bolus) (NN group)) (-RRB- -RRB-))) (CC or) (NP (CD 10) (NN mg))) (VP (VBN diluted) (PP (IN in) (NP (NP (CD 50) (NNS mL)) (PP (IN of) (NP (NP (JJ normal) (NN saline) (NN solution)) (VP (VBN administered) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN during) (NP (NP (DT a) (JJ 15-minute) (NN period)) (PRN (-LRB- -LRB-) (NP (NN infusion) (NN group)) (-RRB- -RRB-))))))))))))))))))))))))) (. .)))
11679859	5	(S1 (S (NP (DT The) (JJ main) (NN outcome)) (VP (AUX was) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN study) (NNS participants))) (VP (VBG experiencing) (NP (NNP Doc_11679859_942_951_Disease)) (PP (IN within) (NP (NP (CD 60) (NNS minutes)) (PP (IN of) (NP (NN administration)))))))) (. .)))
11679859	6	(S1 (S (NP (NNP Akathisia)) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (NP (RB either) (DT a) (JJ spontaneous) (NN report)) (PP (IN of) (NP (NP (NN restlessness)) (CC or) (NP (NNP Doc_11679859_1061_1070_Disease))))) (CC or) (NP (NP (NP (DT a) (NN change)) (PP (IN of) (NP (QP (CD 2) (CC or) (JJR more)))) (PP (IN in) (NP (DT the) (JJ patient-reported) (NNP Doc_11679859_1120_1129_Disease) (NN rating) (NN scale)))) (CC and) (NP (NP (DT a) (NN change)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD 1)))) (PP (IN in) (NP (DT the) (JJ investigator-observed) (NNP Doc_11679859_1199_1208_Disease) (NN rating) (NN scale))))))))) (. .)))
11679859	7	(S1 (S (NP (NP (DT The) (NN intensity)) (PP (IN of) (NP (NP (NNP Doc_11679859_1240_1248_Disease)) (CC and) (NP (NNP Doc_11679859_1253_1259_Disease))))) (VP (AUX was) (VP (VBN measured) (PP (IN with) (NP (DT a) (JJ 100-mm) (JJ visual) (NN analog) (NN scale))))) (. .)))
11679859	8	(S1 (S (NP (QP (CD One) (CD hundred)) (NNS patients)) (VP (AUX were) (VP (VBD enrolled))) (. .)))
11679859	9	(S1 (S (NP (CD One) (NN study) (NN participant)) (VP (AUX was) (VP (VBN excluded) (PP (IN after) (NP (NN protocol) (NN violation))))) (. .)))
11679859	10	(S1 (S (NP (NP (NP (JJ Seventy-three) (NN percent)) (PRN (-LRB- -LRB-) (NP (CD 73/99)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN study) (NNS participants)))) (VP (AUX were) (VP (VBN treated) (PP (IN for) (NP (NP (NN Doc_11679859_1487_1495_Disease)) (CC and) (NP (NP (CD 70) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 70/99)) (-RRB- -RRB-))))) (PP (IN for) (NP (NNP Doc_11679859_1516_1522_Disease))))) (. .)))
11679859	11	(S1 (S (PP (IN In) (NP (DT the) (JJ bolus) (NN group))) (, ,) (NP (NP (CD 26.0) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 13/50)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Doc_11679859_1562_1571_Disease)) (PP (VBN compared) (PP (IN with) (NP (NP (CD 32.7) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 16/49)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (NN infusion) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD Delta=-6.7) (NN %)) (: ;) (NP (NP (CD 95) (NN %) (NN confidence)) (JJ interval) (JJ -LSB-CI) (NN -RSB-) (QP (CD -24.6) (NN %) (TO to) (CD 11.2) (NN %)))) (-RRB- -RRB-))))) (. .)))
11679859	12	(S1 (S (NP (NP (DT The) (NN difference)) (PP (IN between) (NP (DT the) (NN bolus) (CC and) (NN infusion) (NNS groups))) (PP (IN in) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NP (NNS participants)) (SBAR (WHNP (WP who)) (S (VP (VBD saw) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN reduction)) (PP (IN in) (NP (PRP$ their) (NNP Doc_11679859_1803_1811_Disease) (NN intensity)))) (PP (IN within) (NP (CD 30) (NNS minutes))))))))))) (VP (AUX was) (NP (NP (CD 11.8) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %)) (NP (QP (CD CI) (CD -9.6) (NN %) (TO to) (CD 33.3) (NN %)))) (-RRB- -RRB-)))) (. .)))
11679859	13	(S1 (S (NP (NP (DT The) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NNS patients))))) (PP (IN with) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN reduction)) (PP (IN in) (NP (PRP$ their) (NN Doc_11679859_1950_1956_Disease)))))) (VP (AUX was) (NP (NP (CD 12.6) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD -4.6) (NN %) (TO to) (CD 29.8) (NN %))) (-RRB- -RRB-)))) (. .)))
11679859	14	(S1 (S (NP (NP (NP (DT A) (ADJP (CD 50) (NN %)) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_11679859_2040_2049_Disease))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_11679859_2055_2071_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (JJ 15-minute) (JJ intravenous) (NN infusion)))))))))) (CC versus) (NP (DT a) (JJ 2-minute) (JJ intravenous) (NN push))) (VP (AUX was) (RB not) (VP (VBN detected))) (. .)))
11679859	15	(S1 (S (NP (NP (DT The) (NN efficacy)) (PP (IN of) (NP (NNP Doc_11679859_2201_2217_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11679859_2238_2246_Disease)) (CC and) (NP (NNP Doc_11679859_2251_2257_Disease))))))) (ADVP (RB likewise)) (VP (AUX did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (AUX be) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN administration))))))))) (, ,) (SBAR (IN although) (S (NP (DT no) (JJ formal) (JJ statistical) (NNS comparisons)) (VP (AUX were) (VP (VBN made))))))) (. .)))
11706060	0	(S1 (S (NP (VBN Combined) (JJ antiretroviral) (NN therapy)) (VP (VP (VBZ causes) (NP (NN Doc_11706060_39_53_Disease))) (CC and) (VP (VBZ elevates) (NP (NP (NN plasma) (NN Doc_11706060_74_81_Chemical)) (PP (IN in) (NP (NNP transgenic) (NNP Doc_11706060_96_100_Disease) (NNS mice)))))) (. .)))
11706060	1	(S1 (S (NP (NP (ADJP (RB Highly) (JJ active)) (NN antiretroviral) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN HAART)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN implicated) (PP (PP (IN in) (NP (NP (NNP Doc_11706060_169_183_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11706060_185_187_Disease)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (JJ elevated) (NN plasma) (NNP Doc_11706060_212_219_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11706060_221_223_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (NNP Doc_11706060_228_232_Disease))) (PP (IN through) (NP (NP (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_11706060_255_280_Disease))))))) (. .)))
11706060	2	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (JJ mitochondrial) (NNS events)) (PP (IN from) (NP (NNP HAART)))) (PP (IN in) (NP (NN vivo)))))) (, ,) (NP (NP (NP (JJ 8-week-old) (JJ hemizygous) (NNP transgenic) (NNP Doc_11706060_369_373_Disease) (NNS mice)) (PRN (-LRB- -LRB-) (NP (NP (JJ NL4-3Delta) (NN gag/pol)) (: ;) (NP (NNP TG))) (-RRB- -RRB-))) (CC and) (NP (JJ wild-type) (NN FVB/n) (NNS littermates))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT the) (JJ HAART) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11706060_479_489_Chemical)) (, ,) (NP (NNP Doc_11706060_491_501_Chemical)) (, ,) (CC and) (NP (NNP Doc_11706060_507_516_Chemical))))) (CC or) (NP (NN vehicle) (NN control)))) (PP (IN for) (NP (NP (CD 10) (NNS days)) (CC or) (NP (CD 35) (NNS days)))))) (. .)))
11706060	3	(S1 (S (PP (IN At) (NP (NP (NN termination)) (PP (IN of) (NP (DT the) (NNS experiments))))) (, ,) (NP (NNS mice)) (VP (VBD underwent) (NP (NP (NN echocardiography)) (, ,) (NP (NP (NN quantitation)) (PP (IN of) (NP (NP (NN abundance)) (PP (IN of) (NP (NP (JJ molecular) (NNS markers)) (PP (IN of) (NP (NNP Doc_11706060_678_680_Disease))) (PRN (-LRB- -LRB-) (S (NP (JJ ventricular) (NNS mRNA)) (VP (VBG encoding) (NP (JJ atrial) (JJ natriuretic) (NN factor)) (NP (JJ -LSB-ANF) (JJ -RSB-) (CC and) (JJ sarcoplasmic) (NNP Doc_11706060_757_764_Chemical) (NNP ATPase) (JJ -LSB-SERCA2) (NN -RSB-)))) (-RRB- -RRB-))))))) (, ,) (CC and) (NP (NP (NN determination)) (PP (IN of) (NP (NN plasma) (NN Doc_11706060_811_813_Chemical)))))) (. .)))
11706060	4	(S1 (S (S (NP (JJ Myocardial) (JJ histologic) (NNS features)) (VP (AUX were) (VP (VBN analyzed) (ADVP (RB semiquantitatively))))) (CC and) (S (NP (NNS results)) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (NN transmission) (NNP electron) (NN microscopy)))))) (. .)))
11706060	5	(S1 (S (PP (IN After) (NP (NP (CD 35) (NNS days)) (PP (IN in) (NP (DT the) (JJ TG) (NN +) (NN HAART) (NN cohort))))) (, ,) (NP (JJ left) (JJ ventricular) (NN mass)) (VP (VBD increased) (NP (CD 160) (NN %)) (PP (IN by) (NP (NN echocardiography)))) (. .)))
11706060	6	(S1 (S (ADVP (RB Molecularly)) (, ,) (S (NP (NN ANF) (NNS mRNA)) (VP (VBD increased) (NP (CD 250) (NN %)))) (CC and) (S (NP (JJ SERCA2) (NN mRNA)) (VP (VBD decreased) (NP (CD 57) (NN %)))) (. .)))
11706060	7	(S1 (S (ADVP (RB Biochemically)) (, ,) (NP (NNP Doc_11706060_1124_1126_Chemical)) (VP (AUX was) (NP (NP (JJ elevated)) (PRN (-LRB- -LRB-) (NP (CD 8.5) (NN +/-) (CD 2.0) (NN mM)) (-RRB- -RRB-)))) (. .)))
11706060	8	(S1 (S (ADVP (RB Pathologically)) (, ,) (NP (JJ granular) (NN cytoplasmic) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (JJ cardiac) (NNS myocytes))) (, ,) (S (VP (VBG indicating) (NP (JJ enlarged) (, ,) (JJ damaged) (NNS mitochondria)))))) (. .)))
11706060	9	(S1 (S (NP (NNS Findings)) (VP (AUX were) (VP (VBN confirmed) (ADVP (RB ultrastructurally)))) (. .)))
11706060	10	(S1 (S (NP (DT No) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (JJ other) (NNS cohorts))))) (. .)))
11706060	11	(S1 (S (PP (IN After) (NP (CD 10) (NNS days))) (, ,) (NP (JJ only) (NN ANF)) (VP (AUX was) (UCP (ADJP (JJ elevated)) (, ,) (CC and) (PP (ADVP (RB only)) (IN in) (NP (DT the) (NNP TG) (NNP +) (NN HAART) (NN cohort))))) (. .)))
11706060	12	(S1 (S (NP (NNS Results)) (VP (VBP show) (SBAR (IN that) (S (NP (JJ cumulative) (NN HAART)) (VP (VBD caused) (NP (NP (JJ mitochondrial) (NN Doc_11706060_1490_1492_Disease)) (PP (IN with) (NP (JJ elevated) (NN Doc_11706060_1507_1509_Chemical))) (PP (IN in) (NP (NNP Doc_11706060_1513_1517_Disease) (NNP transgenic) (NNS mice)))))))) (. .)))
11745184	0	(S1 (NP (NP (NP (DT A) (NN Phase) (NNP II) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_11745184_20_29_Chemical) (CC plus) (NNP Doc_11745184_35_42_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11745184_44_54_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (JJ metastatic) (NN Doc_11745184_71_87_Disease)))) (: :) (NP (NP (DT an) (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group) (NNP Study)) (PRN (-LRB- -LRB-) (NP (NNP E8188)) (-RRB- -RRB-))) (. .)))
11745184	1	(S1 (S (NP (NN Doc_11745184_154_163_Chemical)) (VP (AUX has) (NP (NP (JJ minimal) (NN antitumor) (NN activity)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN as) (NP (NP (JJ second-) (CC or) (JJ third-line) (NN treatment)) (PP (IN of) (NP (JJ metastatic) (NNP Doc_11745184_254_270_Disease)))))))))) (. .)))
11745184	2	(S1 (S (NP (JJR Older) (NNS reports)) (VP (VBP suggest) (NP (NP (DT an) (JJ objective) (NN response) (NN rate)) (PP (IN of) (NP (CD 8) (NN %)))) (SBAR (WHADVP (WRB when)) (S (NP (NP (CD 60-120) (NN mg/m2)) (PP (IN of) (NP (NNP Doc_11745184_348_357_Chemical)))) (VP (AUX is) (VP (VBN administered) (NP (DT every) (JJ 3-4) (NNS weeks))))))) (. .)))
11745184	3	(S1 (S (SBAR (IN Although) (S (NP (DT a) (JJ dose-response) (NN effect)) (VP (AUX has) (VP (AUX been) (VP (VBN observed) (PP (IN with) (NP (NNP Doc_11745184_446_455_Chemical)))))))) (, ,) (NP (NP (DT the) (JJ dose-limiting) (NNP Doc_11745184_475_485_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_11745184_502_511_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP e.g.)) (, ,) (NP (NNP Doc_11745184_519_533_Disease)) (, ,) (NP (NNP Doc_11745184_535_546_Disease)) (, ,) (CC and) (NP (NNP Doc_11745184_552_565_Disease))) (-RRB- -RRB-)))))) (VP (AUX have) (VP (VBN limited) (NP (PRP$ its) (NN use)) (PP (IN as) (NP (NP (DT a) (NN treatment)) (PP (IN for) (NP (NNP Doc_11745184_607_623_Disease))))))) (. .)))
11745184	4	(S1 (S (NP (NP (NNP Doc_11745184_625_632_Chemical)) (CC or) (NP (NNP Doc_11745184_636_646_Chemical))) (ADVP (RB initially)) (VP (AUX was) (VP (VBN developed) (S (VP (TO to) (VP (VB protect) (NP (JJ military) (NNS personnel)) (PP (IN in) (NP (NP (DT the) (NN event)) (PP (IN of) (NP (JJ nuclear) (NN war)))))))))) (. .)))
11745184	5	(S1 (S (NP (NN Doc_11745184_730_740_Chemical)) (ADVP (RB subsequently)) (VP (AUX was) (VP (VBN shown) (S (VP (TO to) (VP (VB protect) (NP (JJ normal) (NNS tissues)) (PP (IN from) (NP (NP (DT the) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_11745184_816_833_Chemical)) (CC and) (NP (NNP Doc_11745184_838_847_Chemical)))))) (PP (IN without) (S (VP (VBG decreasing) (NP (NP (DT the) (JJ antitumor) (NN effect)) (PP (IN of) (NP (DT the) (NN chemotherapy)))))))))))) (. .)))
11745184	6	(S1 (S (NP (NP (JJ Early) (NNS trials)) (PP (IN of) (NP (NP (NNP Doc_11745184_925_934_Chemical)) (CC and) (NP (NNP Doc_11745184_939_949_Chemical))))) (ADVP (RB also)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_11745184_1000_1009_Chemical-induced) (NNP Doc_11745184_1018_1032_Disease)) (, ,) (NP (NNP Doc_11745184_1034_1045_Disease)) (, ,) (CC and) (NP (NNP Doc_11745184_1051_1061_Disease))))) (VP (AUX were) (VP (VBN reduced)))))) (. .)))
11745184	7	(S1 (S (NP (NP (DT A) (NN Phase) (NNP II) (NN study)) (PP (IN of) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NNP Doc_11745184_1124_1133_Chemical) (CC plus) (NNP Doc_11745184_1139_1149_Chemical)))))) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ progressive) (JJ metastatic) (NNP Doc_11745184_1204_1220_Disease)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN received) (NP (NP (NN one)) (, ,) (CC but) (NP (QP (RB not) (JJR more) (IN than) (CD one))) (, ,) (NP (NP (JJ chemotherapy) (NN regimen)) (PP (IN for) (NP (JJ metastatic) (NN disease))))))))))))))) (. .)))
11745184	8	(S1 (S (NP (NNS Patients)) (VP (VBD received) (NP (NP (NNP Doc_11745184_1329_1339_Chemical)) (, ,) (NP (CD 910) (NN mg/m2))) (ADVP (RB intravenously)) (PP (IN over) (NP (CD 15) (NNS minutes)))) (. .)))
11745184	9	(S1 (S (PP (IN After) (NP (NP (NN completion)) (PP (IN of) (NP (DT the) (JJ Doc_11745184_1406_1416_Chemical) (NN infusion))))) (, ,) (NP (NNP Doc_11745184_1427_1436_Chemical) (CD 120) (NN mg/m2)) (VP (AUX was) (VP (VBN administered) (PP (IN over) (NP (CD 30) (NNS minutes))))) (. .)))
11745184	10	(S1 (S (NP (NP (JJ Intravenous) (NN hydration)) (CC and) (NP (NNP Doc_11745184_1507_1515_Chemical))) (VP (AUX was) (VP (VBN administered) (PP (IN before) (CC and) (IN after) (NP (NNP Doc_11745184_1550_1559_Chemical))))) (. .)))
11745184	11	(S1 (S (NP (NN Treatment)) (VP (AUX was) (VP (VBN administered) (NP (DT every) (CD 3) (NNS weeks)) (PP (IN until) (NP (NN disease) (NN progression))))) (. .)))
11745184	12	(S1 (S (NP (JJ Forty-four) (NNS patients)) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (NP (DT the) (NN study)) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (NP (CD 7)) (PRN (-LRB- -LRB-) (NP (CD 16) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (NP (NN ineligible))))))))) (. .)))
11745184	13	(S1 (S (NP (NP (DT A) (NN median)) (PP (IN of) (NP (NP (CD 2) (NNS cycles)) (PP (IN of) (NP (NN therapy)))))) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (DT the) (CD 37) (NN eligible) (NNS patients))))) (. .)))
11745184	14	(S1 (S (NP (CD Six) (JJ partial) (NNS responses)) (VP (AUX were) (VP (VBN observed) (PP (IN for) (NP (NP (DT an) (JJ overall) (NN response) (NN rate)) (PP (IN of) (NP (CD 16) (NN %))))))) (. .)))
11745184	15	(S1 (S (NP (NP (JJS Most) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 57) (NN %)) (-RRB- -RRB-))) (VP (VBD stopped) (NP (NN treatment)) (PP (IN because) (IN of) (NP (NN disease) (NN progression)))) (. .)))
11745184	16	(S1 (S (NP (NN Doc_11745184_1940_1959_Disease)) (VP (AUX was) (VP (VBN reported) (PP (IN in) (NP (NP (CD 52) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
11745184	17	(S1 (S (NP (CD Seven) (JJ different) (JJ life-threatening) (NN Doc_11745184_2026_2036_Disease)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NNS patients))) (SBAR (IN while) (S (VP (VBG receiving) (NP (NN treatment))))))) (. .)))
11745184	18	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11745184_2122_2131_Chemical)) (CC and) (NP (NNP Doc_11745184_2136_2146_Chemical)))) (PP (IN in) (NP (DT this) (NN study)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ overall) (NN response) (NN rate)) (PP (IN of) (NP (CD 16) (NN %)))))) (. .)))
11745184	19	(S1 (S (NP (CC Neither) (NP (DT a) (JJ Doc_11745184_2216_2221_Disease-protective) (NN effect)) (CC nor) (NP (NP (VBN reduced) (NN Doc_11745184_2252_2260_Disease)) (PP (TO to) (NP (JJ normal) (NNS tissues))))) (VP (AUX was) (VP (VBN observed) (PP (IN with) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_11745184_2313_2323_Chemical))) (PP (TO to) (NP (NNP Doc_11745184_2327_2336_Chemical))))) (PP (IN in) (NP (DT this) (NN trial))))) (. .)))
11752354	0	(S1 (NP (NP (NP (NN Doc_11752354_0_19_Chemical)) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_11752354_36_57_Disease))))) (. .)))
11752354	1	(S1 (S (NP (NP (DT An) (NN association)) (PP (IN between) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_11752354_105_124_Chemical)))) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_11752354_141_162_Disease))))))) (VP (AUX has) (VP (AUX been) (VP (VBN found) (PP (IN in) (NP (NP (DT some)) (, ,) (CC but) (RB not) (NP (DT all)) (, ,) (NP (NNS studies))))))) (. .)))
11752354	2	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (DT this) (NN association)) (, ,) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NN type)) (PP (IN of) (NP (NNP Doc_11752354_268_279_Chemical))) (VP (VBD included) (S (PP (IN in) (NP (NP (NP (NN third-generation)) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (NP (NNP Doc_11752354_316_327_Chemical) (CC or) (NNP Doc_11752354_331_340_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NN second-generation)))) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (NP (NNP Doc_11752354_371_385_Chemical)) (-RRB- -RRB-)) (NP (NNP Doc_11752354_387_406_Chemical)) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_11752354_420_428_Chemical)) (, ,) (CC and) (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (JJ prothrombotic) (NNS mutations) (NNS METHODS))))))) (: :) (PP (IN In) (NP (DT a) (JJ nationwide) (, ,) (JJ population-based) (, ,) (JJ case-control) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBD identified)) (CC and) (VP (VBD enrolled) (NP (CD 248) (NNS women)) (NP (CD 18)) (PP (IN through) (NP (NP (CD 49) (NNS years)) (PP (IN of) (NP (NN age))) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX had) (NP (NP (DT a) (JJ first) (NNP Doc_11752354_633_654_Disease) (ADJP (QP (IN between) (CD 1990) (CC and) (CD 1995) (CC and) (CD 925) (NN control))) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (RB not) (VP (AUX had) (NP (DT a) (NNP Doc_11752354_717_738_Disease))))))))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN matched) (PP (IN for) (NP (NP (NN age)) (, ,) (NP (NP (NN calendar) (NN year)) (PP (IN of) (NP (DT the) (NN index) (NN event)))) (, ,) (CC and) (NP (NP (NN area)) (PP (IN of) (NP (NN residence))))))))))))))))))))) (. .)))
11752354	3	(S1 (S (NP (NNS Subjects)) (VP (VBD supplied) (NP (NN information)) (PP (IN on) (NP (NP (JJ Doc_11752354_859_877_Chemical) (NN use)) (CC and) (NP (JJ major) (JJ cardiovascular) (NN risk) (NNS factors))))) (. .)))
11752354	4	(S1 (S (S (NP (NP (DT An) (NN analysis)) (PP (IN for) (NP (NP (NN factor) (NNP V) (NNP Leiden)) (CC and) (NP (DT the) (NNP G20210A) (NN mutation)))) (PP (IN in) (NP (DT the) (JJ prothrombin) (NN gene)))) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (CD 217) (NNS patients)) (CC and) (NP (CD 763) (NNS controls) (NNS RESULTS))))))) (: :) (S (NP (NP (DT The) (NNS odds) (NN ratio)) (PP (IN for) (NP (NNP Doc_11752354_1077_1098_Disease))) (PP (IN among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NP (DT any) (NN type)) (PP (IN of) (NP (JJ combined) (NNP Doc_11752354_1141_1159_Chemical)))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NNS nonusers))))))))))) (, ,)) (VP (AUX was) (NP (NP (CD 2.0)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 1.5) (TO to) (CD 2.8))) (-RRB- -RRB-))))) (. .)))
11752354	5	(S1 (S (NP (DT The) (VBN adjusted) (NNS odds) (NN ratio)) (VP (AUX was) (NP (NP (CD 2.5)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 1.5) (TO to) (CD 4.1))) (-RRB- -RRB-))) (PP (IN among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NP (JJ second-generation) (NN Doc_11752354_1358_1377_Chemical)) (CC and) (NP (NP (CD 1.3)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 0.7) (TO to) (CD 2.5))) (-RRB- -RRB-)))) (PP (IN among) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (JJ third-generation) (NNP Doc_11752354_1469_1488_Chemical))))))))))))) (. .)))
11752354	6	(S1 (S (S (PP (IN Among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NNP Doc_11752354_1511_1530_Chemical))))))) (, ,) (NP (DT the) (NNS odds) (NN ratio)) (VP (AUX was) (NP (NP (NP (CD 2.1)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 1.5) (TO to) (CD 3.0))) (-RRB- -RRB-)) (PP (IN for) (NP (NP (DT those)) (PP (IN without) (NP (DT a) (JJ prothrombotic) (NN mutation)))))) (CC and) (NP (NP (CD 1.9)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN percent) (NN confidence) (NN interval)) (, ,) (NP (CD 0.6) (TO to) (CD 5.5)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (DT those)) (PP (IN with) (NP (DT a) (NN mutation) (NNS CONCLUSIONS))))))))) (: :) (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_11752354_1747_1768_Disease)))) (VP (AUX was) (VP (VBN increased) (PP (IN among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (JJ second-generation) (NNP Doc_11752354_1822_1841_Chemical)))))))))) (. .)))
11752354	7	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ third-generation) (NNP Doc_11752354_1899_1918_Chemical)))))))) (VP (VP (AUX were) (ADJP (JJ inconclusive))) (CC but) (VP (VBD suggested) (SBAR (IN that) (S (NP (DT the) (NN risk)) (VP (AUX was) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT the) (NN risk)) (VP (VBN associated) (PP (IN with) (NP (JJ second-generation) (NN Doc_11752354_2023_2042_Chemical)))))))))))) (. .)))
11752354	8	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_11752354_2056_2077_Disease)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN among) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NNP Doc_11752354_2111_2130_Chemical)) (SBAR (IN whether) (CC or) (RB not) (S (NP (PRP they)) (VP (AUX had) (NP (DT a) (JJ prothrombotic) (NN mutation))))))))))) (. .)))
11773892	0	(S1 (NP (NP (NP (NN Doc_11773892_0_23_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11773892_25_29_Disease)) (-RRB- -RRB-)) (PP (IN after) (S (NP (NP (JJ orthotopic) (NN liver) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NNP OLTX)) (-RRB- -RRB-))) (VP (VBG using) (NP (JJ calcineurin-based) (NN immunotherapy)))))) (: :) (NP (NP (NN risk)) (PP (IN of) (NP (NP (NN development)) (CC and) (NP (NN treatment))))) (. .)))
11773892	1	(S1 (S (NP (NP (DT The) (JJ calcineurin) (NNS inhibitors)) (ADJP (JJ Doc_11773892_190_202_Chemical) (CC and) (JJ Doc_11773892_207_217_Chemical))) (VP (AUX are) (DT both) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_11773892_239_250_Disease))))))) (. .)))
11773892	2	(S1 (S (NP (NP (PRP$ Their) (NN use)) (PP (IN in) (NP (NP (JJ orthotopic) (NN liver) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NNP OLTX)) (-RRB- -RRB-))))) (VP (AUX has) (ADVP (RB dramatically)) (VP (VBN improved) (NP (NN success) (NNS rates)))) (. .)))
11773892	3	(S1 (S (ADVP (RB Recently)) (, ,) (ADVP (RB however)) (, ,) (NP (PRP we)) (VP (AUX have) (VP (AUX had) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBG presenting) (PP (IN after) (NP (NP (NN OLTX)) (PP (IN with) (NP (NP (NNP Doc_11773892_436_459_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11773892_461_465_Disease)) (-RRB- -RRB-))))))))))))))) (. .)))
11773892	4	(S1 (S (NP (DT This) (NN retrospective) (NN study)) (VP (VBZ examines) (NP (NP (DT the) (NN incidence) (CC and) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_11773892_533_537_Disease)) (CC and) (NP (NP (NNP Doc_11773892_542_563_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11773892_565_568_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (NN OLTX) (NNS patients))))) (. .)))
11773892	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT an) (NN OLTX)) (ADVP (RB only)) (PP (IN from) (NP (NNP June) (CD 1985))) (PP (IN through) (NP (NP (NNP December)) (PP (IN of) (NP (CD 1994)))))) (SBAR (WHNP (WP who)) (S (VP (VBD survived) (ADVP (NP (CD 6) (NNS months)) (RB postoperatively)))))) (VP (AUX were) (VP (VBN studied) (PRN (-LRB- -LRB-) (NP (CD n=834)) (-RRB- -RRB-)))) (. .)))
11773892	6	(S1 (S (NP (PRP$ Our) (ADJP (RB prospectively) (VBN collected)) (NN database)) (VP (AUX was) (NP (NP (DT the) (NN source)) (PP (IN of) (NP (NN information))))) (. .)))
11773892	7	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (CD three) (NNS groups)) (: :) (NP (NP (NNS Controls)) (, ,) (NP (NP (DT no) (NNP Doc_11773892_851_854_Disease) (CC or) (NNP Doc_11773892_858_862_Disease)) (, ,) (NP (CD n=748)) (: ;) (NP (NP (NNP Doc_11773892_871_874_Disease)) (, ,) (NP (NP (JJ sustained) (JJ serum) (NNP Doc_11773892_892_902_Chemical) (CD >2.5) (NN mg/dl)) (, ,) (NP (CD n=41)))) (: ;) (CC and) (NP (NP (NNP Doc_11773892_925_929_Disease)) (, ,) (NP (CD n=45))))))))) (. .)))
11773892	8	(S1 (S (NP (NNS Groups)) (VP (AUX were) (VP (VBN compared) (PP (IN for) (NP (NP (JJ preoperative) (NN laboratory) (NNS variables)) (, ,) (NP (NN diagnosis)) (, ,) (NP (JJ postoperative) (NNS variables)) (, ,) (NP (NN survival)) (, ,) (NP (NP (NN type)) (PP (IN of) (NP (JJ Doc_11773892_1051_1055_Disease) (NN therapy)))) (, ,) (CC and) (NP (NP (NN survival)) (PP (IN from) (NP (NP (NN onset)) (PP (IN of) (NP (NNP Doc_11773892_1092_1096_Disease)))))))))) (. .)))
11773892	9	(S1 (S (PP (IN At) (NP (NP (CD 13) (NNS years)) (PP (IN after) (NP (NN OLTX))))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ severe) (NNP Doc_11773892_1155_1172_Disease)))) (VP (AUX was) (NP (NP (CD 18.1) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_11773892_1184_1187_Disease) (CD 8.6) (NN %)) (CC and) (NP (NNP Doc_11773892_1197_1201_Disease) (CD 9.5) (NN %))) (-RRB- -RRB-)))) (. .)))
11773892	10	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NN control) (NNS patients)))) (, ,) (NP (NNP Doc_11773892_1241_1244_Disease) (CC and) (NNP Doc_11773892_1249_1253_Disease) (NNS patients)) (VP (AUX had) (NP (NP (JJR higher) (JJ preoperative) (NN serum) (NN Doc_11773892_1293_1303_Chemical) (NNS levels)) (, ,) (NP (NP (DT a) (JJR greater) (NN percentage)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_11773892_1350_1370_Disease)) (, ,) (NP (NP (JJR higher) (NN percentage) (NN requirement)) (PP (IN for) (NP (NP (NN dialysis)) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 3) (NNS months)) (ADVP (RB postoperatively))))))) (, ,)))))) (CC and) (NP (DT a) (JJR higher) (JJ 1-year) (NN serum) (NN Doc_11773892_1480_1490_Chemical)))) (. .)))
11773892	11	(S1 (S (S (NP (NP (JJ Multivariate) (JJ stepwise) (JJ logistic) (NN regression) (NN analysis)) (VP (VBG using) (NP (NP (NN preoperative)) (CC and) (NP (JJ postoperative) (NNS variables))))) (VP (VBD identified) (SBAR (IN that) (S (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (JJ serum) (NNP Doc_11773892_1627_1637_Chemical)))) (VP (VBN compared) (PP (IN with) (NP (NN average))) (PP (IN at) (NP (NP (CD 1) (NN year)) (, ,) (NP (CD 3) (NNS months))))))))) (, ,) (CC and) (S (NP (CD 4) (NNS weeks)) (ADVP (RB postoperatively)) (VP (AUX were) (NP (JJ independent) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11773892_1762_1765_Disease) (CC or) (NNP Doc_11773892_1769_1773_Disease))) (PP (IN with) (NP (NP (NNS odds) (NNS ratios)) (PP (IN of) (NP (NP (CD 2.6)) (, ,) (NP (CD 2.2)) (, ,) (CC and) (NP (CD 1.6)) (, ,) (ADVP (RB respectively)))))))))) (. .)))
11773892	12	(S1 (S (S (NP (NP (JJ Overall) (NN survival)) (PP (IN from) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NNS OLTX)))))) (VP (AUX was) (RB not) (ADJP (RB significantly) (JJ different)) (PP (IN among) (NP (NNS groups))))) (, ,) (CC but) (S (PP (IN by) (NP (NN year) (CD 13))) (, ,) (NP (NP (DT the) (NN survival)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NN Doc_11773892_1965_1969_Disease)))))))) (VP (AUX was) (NP (QP (RB only) (CD 28.2)) (NN %)) (PP (VBN compared) (PP (IN with) (NP (NP (CD 54.6) (NN %)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))))) (. .)))
11773892	13	(S1 (S (NP (NP (NNS Patients)) (VP (VBG developing) (NP (NNP Doc_11773892_2047_2051_Disease)))) (VP (AUX had) (NP (DT a) (JJ 6-year) (NN survival)) (PP (IN after) (NP (NP (NN onset)) (PP (IN of) (NP (NP (NNP Doc_11773892_2089_2093_Disease)) (PP (IN of) (NP (CD 27) (NN %))))))) (PP (IN for) (NP (NP (DT the) (NNS patients)) (VP (VBG receiving) (NP (NP (NN hemodialysis)) (CC versus) (NP (CD 71.4) (NN %))) (PP (IN for) (NP (NP (DT the) (NNS patients)) (VP (VBG developing) (NP (NP (NNP Doc_11773892_2182_2186_Disease)) (SBAR (WHNP (WP who)) (S (ADVP (RB subsequently)) (VP (VBD received) (NP (NN kidney) (NNS transplants))))))))))))) (. .)))
11773892	14	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (ADJP (NP (QP (JJR more) (IN than) (CD 10)) (NNS years)) (JJ post-OLTX)))))) (VP (AUX have) (NP (NP (NNP Doc_11773892_2297_2300_Disease)) (CC and) (NP (NNP Doc_11773892_2305_2309_Disease))) (PP (IN at) (NP (DT a) (JJ high) (NN rate)))) (. .)))
11773892	15	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NNP Doc_11773892_2345_2349_Disease)))) (VP (VBZ decreases) (NP (NN survival)) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT those) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN dialysis))) (ADVP (RB only)))))) (. .)))
11773892	16	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP develop) (NP (NNP Doc_11773892_2450_2454_Disease)))))) (VP (VP (AUX have) (NP (NP (DT a) (JJR higher) (NN preoperative)) (CC and) (NP (JJ 1-year) (NN serum) (NN Doc_11773892_2499_2509_Chemical)))) (CC and) (VP (AUX are) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_11773892_2538_2558_Disease)))))))) (. .)))
11773892	17	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (JJ serum) (NNP Doc_11773892_2590_2600_Chemical))) (PP (IN at) (NP (JJ various) (NNS times)))) (ADVP (RB postoperatively)) (VP (AUX is) (ADJP (RBR more) (JJ predictive) (PP (IN of) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_11773892_2675_2678_Disease)) (CC or) (NP (NNP Doc_11773892_2682_2686_Disease)))))))) (. .)))
11773892	18	(S1 (S (NP (NP (JJ New) (NNS strategies)) (PP (IN for) (NP (JJ long-term) (NN immunosuppression)))) (VP (MD may) (VP (AUX be) (VP (VBN needed) (S (VP (TO to) (VP (VB decrease) (NP (DT this) (NN complication)))))))) (. .)))
11807648	0	(S1 (S (VP (VB Doc_11807648_0_18_Disease) (S (VP (VBG following) (NP (NP (JJ cortical) (NN application)) (PP (IN of) (NP (NP (JJ fibrin) (NNS sealants)) (VP (VBG containing) (NP (NNP Doc_11807648_80_95_Chemical))))) (PP (IN in) (NP (NNS rats))))))) (. .)))
11807648	1	(S1 (S (NP (NP (NP (JJ Fibrin) (NNS sealants)) (PRN (-LRB- -LRB-) (NP (NNP FS)) (-RRB- -RRB-))) (VP (VBN derived) (PP (IN from) (NP (JJ human) (NN plasma))))) (VP (AUX are) (ADVP (RB frequently)) (VP (VBN used) (PP (IN in) (NP (NN neurosurgery))))) (. .)))
11807648	2	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB increase) (NP (JJ clot) (NN stability)))))) (, ,) (NP (NNS FS)) (ADVP (RB typically)) (VP (VBP contain) (NP (NP (NN aprotinin)) (, ,) (NP (DT a) (JJ natural) (NN fibrinolysis) (NN inhibitor)))) (. .)))
11807648	3	(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (JJ synthetic) (NN fibrinolysis) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_11807648_356_371_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11807648_373_378_Chemical)) (-RRB- -RRB-))))) (VP (AUX have) (VP (AUX been) (VP (VBN considered) (PP (IN as) (NP (NP (NNS substitutes)) (PP (IN for) (NP (NN aprotinin)))))))) (. .)))
11807648	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_11807648_440_445_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB cause) (NP (NN Doc_11807648_470_488_Disease)))))))) (. .)))
11807648	5	(S1 (S (NP (PRP We)) (VP (VBD wanted) (S (VP (TO to) (VP (VB study) (SBAR (IN whether) (S (NP (NNP Doc_11807648_517_522_Chemical)) (VP (VBZ retains) (NP (PRP$ its) (JJ Doc_11807648_535_545_Disease) (NN action)) (SBAR (IN if) (S (VP (VBN incorporated) (PP (IN into) (NP (DT a) (NN FS))))))))))))) (. .)))
11807648	6	(S1 (S (NP (NP (NP (NP (NNS FS)) (VP (VBG containing) (NP (NN aprotinin)))) (CC or) (NP (NP (JJ different) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_11807648_643_648_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 0.5-47.5) (NNS mg/ml)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN applied) (PP (TO to) (NP (NP (DT the) (JJ pial) (NN surface)) (PP (IN of) (NP (NP (DT the) (NN cortex)) (PP (IN of) (NP (JJ anaesthetized) (NNS rats))))))))) (. .)))
11807648	7	(S1 (S (NP (NP (DT The) (NN response)) (PP (IN of) (NP (DT the) (NNS animals)))) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NN electroencephalography)) (FRAG (CC and) (PP (IN by) (S (VP (VBG monitoring) (NP (NP (DT the) (JJ clinical) (NNS behaviour)) (PP (IN during) (CC and) (IN after) (NP (NP (NN recovery)) (PP (IN from) (NP (NN anaesthesia)))))))))))))) (. .)))
11807648	8	(S1 (S (NP (NP (NNS FS)) (VP (VBG containing) (NP (NNP Doc_11807648_916_921_Chemical)))) (VP (VBD caused) (NP (NP (JJ paroxysmal) (NN brain) (NN activity)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (JJ distinct) (JJ Doc_11807648_990_1000_Disease) (NNS behaviours))))))))) (. .)))
11807648	9	(S1 (S (NP (NP (DT The) (NN degree)) (PP (IN of) (NP (DT these) (NNP Doc_11807648_1033_1041_Disease)))) (VP (VBD increased) (PP (IN with) (NP (NP (JJ increasing) (NN concentration)) (PP (IN of) (NP (NNP Doc_11807648_1085_1090_Chemical)))))) (. .)))
11807648	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NNP FS)) (VP (VBG containing) (NP (NP (CD 47.5) (NN mg/ml)) (SBAR (S (NP (NNP Doc_11807648_1123_1128_Chemical)) (VP (VBD evoked) (NP (NNP Doc_11807648_1136_1156_Disease)) (PP (IN in) (NP (DT all) (VBN tested) (NNS rats))) (PRN (-LRB- -LRB-) (JJ n=6) (-RRB- -RRB-)) (PP (IN while) (NP (NP (DT the) (JJS lowest) (NN concentration)) (PP (IN of) (NP (NNP Doc_11807648_1216_1221_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/ml)) (-RRB- -RRB-)))))))) (ADVP (RB only)) (VP (VBD evoked) (NP (NP (JJ brief) (NNS episodes)) (PP (IN of) (NP (JJ jerk-correlated) (NNP Doc_11807648_1280_1290_Disease) (NNS potentials)))) (PP (IN in) (NP (NP (CD 1)) (PP (IN of) (NP (CD 6) (NNS rats)))))) (. .)))
11807648	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS FS)) (VP (VBG containing) (NP (NN aprotinin)))) (VP (AUX did) (RB not) (VP (VB evoke) (NP (DT any) (JJ paroxysmal) (NN activity)))) (. .)))
11807648	12	(S1 (S (NP (NN Doc_11807648_1410_1425_Chemical)) (VP (VBZ retains) (NP (NP (PRP$ its) (JJ Doc_11807648_1438_1448_Disease) (NN action)) (PP (IN within) (NP (NNS FS))))) (. .)))
11807648	13	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NNS FS)) (VP (VBG containing) (NP (NNP Doc_11807648_1494_1499_Chemical)) (PP (IN for) (NP (NN surgery))) (ADVP (IN within) (CC or) (JJ close)) (PP (TO to) (NP (DT the) (NNS CNS))))))) (VP (MD may) (VP (VB pose) (NP (NP (DT a) (JJ substantial) (NN risk)) (PP (TO to) (NP (DT the) (NN patient)))))) (. .)))
11875660	0	(S1 (NP (NP (NP (JJ Sequential) (NNS observations)) (PP (IN of) (NP (NP (NNP Doc_11875660_27_38_Disease)) (CC and) (NP (JJ subsequent) (JJ morphological) (NNS changes)))) (PP (IN by) (NP (NN mouse) (CD exo) (NN utero) (NN development) (NN system)))) (: :) (NP (NP (NN analysis)) (PP (IN of) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN transformation))))) (PP (PP (IN from) (NP (NNP Doc_11875660_164_175_Disease))) (PP (TO to) (NP (NNP Doc_11875660_179_190_Disease))))) (. .)))
11875660	1	(S1 (S (S (NP (NN Doc_11875660_192_203_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (S (VP (TO to) (VP (VB develop) (PP (IN from) (NP (NNP Doc_11875660_239_250_Disease)))))))))) (: ;) (S (ADVP (RB however)) (, ,) (S (NP (EX there)) (VP (AUX is) (NP (NP (JJ little) (JJ direct) (JJ experimental) (NN evidence)) (SBAR (S (VP (TO to) (VP (VB support) (NP (DT this))))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN transformation)))) (VP (VBZ remains) (ADJP (JJ unclear))))) (. .)))
11875660	2	(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (DT this) (NN theory)) (S (VP (VBG using) (NP (NP (DT the) (JJ exo) (NN utero) (NN development) (NN system)) (SBAR (WHNP (WDT that)) (S (VP (VBZ allows) (NP (NP (JJ direct) (CC and) (JJ sequential) (NNS observations)) (PP (IN of) (NP (NN mid-)))) (PP (TO to) (NP (NN late-gestation) (NN mouse) (NNS embryos)))))))))) (. .)))
11875660	3	(S1 (S (NP (PRP We)) (VP (VP (VBD observed) (S (NP (DT the) (NNP Doc_11875660_543_554_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11875660_566_579_Chemical))) (PP (IN at) (NP (NP (JJ embryonic) (NN day) (CD 13.5)) (PRN (-LRB- -LRB-) (NP (CD E13.5)) (-RRB- -RRB-))))))) (, ,) (VP (VBD let) (S (NP (DT the) (NNS embryos)) (VP (VB develop) (NP (CD exo) (NN utero)) (PP (IN until) (NP (CD E18.5)))))) (, ,) (CC and) (VP (VBD re-observed) (NP (DT the) (JJ same) (NNS embryos)) (PP (IN at) (NP (CD E18.5))))) (. .)))
11875660	4	(S1 (S (NP (PRP We)) (VP (VBD confirmed) (NP (NP (JJ several) (NNS cases)) (PP (IN of) (NP (NN transformation))) (PP (IN from) (NP (NNP Doc_11875660_751_762_Disease)))) (PP (TO to) (NP (NNP Doc_11875660_766_777_Disease)))) (. .)))
11875660	5	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (JJ many) (NNS cases))) (, ,) (NP (DT the) (NNP Doc_11875660_807_819_Disease) (NN brain) (NN tissue)) (VP (AUX was) (VP (VBN preserved) (PP (IN with) (NP (ADJP (JJR more) (CC or) (JJR less)) (NN reduction))) (PP (IN during) (NP (DT this) (NN period))))) (. .)))
11875660	6	(S1 (S (S (VP (TO To) (VP (VB analyze) (NP (DT the) (NN transformation) (NNS patterns))))) (, ,) (NP (PRP we)) (VP (VBD classified) (NP (DT the) (NNP Doc_11875660_953_964_Disease)) (PP (IN by) (NP (NP (NN size) (CC and) (NN shape)) (PP (IN of) (NP (DT the) (NNP Doc_11875660_990_1002_Disease) (NN tissue))))) (PP (IN into) (NP (NP (JJ several) (NNS types)) (PP (IN at) (NP (NP (CD E13.5)) (CC and) (NP (CD E18.5))))))) (. .)))
11875660	7	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN found) (SBAR (IN that) (S (S (NP (NP (DT the) (NN transformation)) (PP (IN of) (NP (NNP Doc_11875660_1089_1101_Disease) (NN tissue)))) (VP (AUX was) (RB not) (ADJP (RB simply) (JJ size-dependent)))) (, ,) (CC and) (S (NP (NP (DT all) (NNS cases)) (PP (IN of) (NP (NNP Doc_11875660_1157_1168_Disease))) (PP (IN at) (NP (CD E18.5)))) (VP (VBD resulted) (PP (IN from) (NP (NP (NNS embryos)) (PP (IN with) (NP (NP (DT a) (JJ large) (NN amount)) (PP (IN of) (NP (NP (JJ Doc_11875660_1223_1235_Disease) (NN tissue)) (PP (IN at) (NP (CD E13.5))))))))))))))) (. .)))
11875660	8	(S1 (S (NP (JJ Microscopic) (NN observation)) (VP (VBD showed) (NP (NP (NP (DT the) (NN configuration)) (PP (IN of) (NP (NNP Doc_11875660_1305_1316_Disease))) (PP (IN at) (NP (CD E13.5)))) (, ,) (NP (NP (JJ frequent) (NN Doc_11875660_1336_1348_Disease) (CC and) (NN detachment)) (PP (IN of) (NP (NP (DT the) (JJ neural) (NN plate)) (PP (IN from) (NP (NP (NN surface) (NN ectoderm)) (PP (IN in) (NP (NP (DT the) (JJ Doc_11875660_1413_1425_Disease) (NN head)) (PP (IN at) (NP (CD E15.5)))))))))) (, ,) (CC and) (NP (NP (JJ multiple) (NNS modes)) (PP (IN of) (NP (NN reduction))))) (PP (IN in) (NP (DT the) (NNP Doc_11875660_1480_1492_Disease) (NN tissue))) (PP (IN at) (NP (CD E18.5)))) (. .)))
11875660	9	(S1 (S (PP (IN From) (NP (NP (NNS observations)) (PP (IN of) (NP (DT the) (NN vasculature))))) (, ,) (NP (NP (VBN altered) (NN distribution) (NNS patterns)) (PP (IN of) (NP (NNS vessels)))) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (DT the) (JJ Doc_11875660_1612_1624_Disease) (NN head))))) (. .)))
11875660	10	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN overgrowth)) (PP (IN of) (NP (DT the) (JJ Doc_11875660_1677_1689_Disease) (JJ neural) (NN tissue)))) (VP (VBZ causes) (NP (NP (DT the) (JJ altered) (NN distribution) (NNS patterns)) (PP (IN of) (NP (NP (NNS vessels)) (, ,) (NP (NP (JJ subsequent) (JJ peripheral) (NNP Doc_11875660_1779_1798_Disease) (FW and/or) (NNP Doc_11875660_1806_1818_Disease)) (PP (IN in) (NP (NP (JJ various) (NNS parts)) (PP (IN of) (NP (DT the) (NNP Doc_11875660_1843_1855_Disease) (NN head)))))) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (JJ multiple) (NNS modes)) (PP (IN of) (NP (NN tissue) (NN reduction))))) (PP (IN during) (NP (NN transformation))) (PP (PP (IN from) (NP (NNP Doc_11875660_1939_1950_Disease))) (PP (TO to) (NP (NNP Doc_11875660_1954_1965_Disease)))))))))))) (. .)))
11897407	0	(S1 (NP (NP (NN Doc_11897407_0_15_Chemical)) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (NP (NNP Doc_11897407_33_46_Chemical-induced) (NNP Doc_11897407_55_76_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
11897407	1	(S1 (S (NP (JJ Doc_11897407_86_93_Disease-avid) (NNS radiopharmaceuticals)) (VP (AUX are) (ADJP (JJ necessary) (PP (IN for) (NP (NP (ADJP (ADJP (JJ rapid)) (CC and) (ADJP (JJ timely))) (NN diagnosis)) (PP (IN of) (NP (JJ acute) (NNP Doc_11897407_174_195_Disease))))))) (. .)))
11897407	2	(S1 (S (NP (NP (DT The) (NN animal) (NN model)) (VP (VBN used) (S (VP (TO to) (VP (VB produce) (NP (NNP Doc_11897407_230_240_Disease))))))) (VP (VBZ implies) (SBAR (S (NP (NP (NN artery) (NN ligation)) (CC but) (NP (NN chemical) (NN induction))) (VP (MD can) (VP (AUX be) (ADVP (RB easily)) (VP (VBN obtained) (PP (IN with) (NP (NNP Doc_11897407_316_329_Chemical))))))))) (. .)))
11897407	3	(S1 (S (NP (NP (DT A) (JJ new) (JJ Doc_11897407_337_344_Disease-avid) (NN radiopharmaceutical)) (VP (VBN based) (PP (IN on) (NP (NNP Doc_11897407_379_392_Chemical))))) (VP (AUX was) (VP (VBN prepared) (SBAR (IN in) (S (NP (NP (DT the) (NN hospital) (NN radiopharmacy)) (PP (IN of) (NP (DT the) (NNP INCMNSZ.) (NNP Doc_11897407_452_467_Chemical)))) (VP (VP (AUX was) (ADJP (ADJP (JJ easy) (SBAR (S (VP (TO to) (VP (VB prepare)))))) (, ,) (ADJP (JJ stable) (PP (IN for) (NP (CD 96))))) (NP (NNP h))) (CC and) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB study) (NP (NP (PRP$ its) (NN biodistribution)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ Doc_11897407_560_573_Chemical-induced) (JJ acute) (NN Doc_11897407_588_609_Disease)))))))))))))))) (. .)))
11897407	4	(S1 (S (NP (NN Histological) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT the) (NNS rats)) (VP (VBD developed) (NP (DT an) (NNP Doc_11897407_672_679_Disease) (CD 18) (NNP h)) (PP (IN after) (NP (NNP Doc_11897407_691_704_Chemical) (NN administration))))))) (. .)))
11897407	5	(S1 (S (NP (DT The) (NN rat) (NN biodistribution) (NNS studies)) (VP (VBD showed) (NP (NP (DT a) (JJ rapid) (NN blood) (NN clearance)) (PP (IN via) (NP (DT the) (NNS kidneys))))) (. .)))
11897407	6	(S1 (S (NP (NP (CD Thirty) (NNS minutes)) (PP (IN after) (NP (NNP Doc_11897407_822_837_Chemical) (NN administration)))) (NP (DT the) (JJ standardised) (NN heart) (NN uptake) (NN value) (NNP S) (PRN (-LRB- -LRB-) (NP (NNP h)) (-RRB- -RRB-)) (NNP UV)) (VP (AUX was) (NP (NP (CD 4.7)) (PP (IN in) (NP (JJ infarcted) (NN rat) (NN heart))) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (ADJP (NP (CD six) (NNS times)) (JJR more)) (PP (IN than) (PP (IN in) (NP (JJ normal) (NNS rats)))))))))) (. .)))
11897407	7	(S1 (S (NP (NP (NNS ROIs)) (VP (VBN drawn) (PP (IN over) (NP (DT the) (NN gamma) (NN camera) (NNS images))))) (VP (VBD showed) (NP (NP (DT a) (NN ratio)) (PP (IN of) (NP (CD 4.4))))) (. .)))
11897407	8	(S1 (S (NP (DT The) (JJ high) (NN image) (NN quality)) (VP (VBZ suggests) (SBAR (IN that) (S (S (NP (JJ high) (NN contrast) (NNS images)) (VP (MD can) (VP (AUX be) (VP (VBN obtained) (PP (IN in) (NP (NNS humans))))))) (CC and) (S (NP (DT the) (CD 96) (NNP h) (NN stability)) (VP (VBZ makes) (S (NP (PRP it)) (NP (NP (DT an) (JJ ideal) (NN agent)) (SBAR (S (VP (TO to) (VP (VB detect) (, ,) (PP (IN in) (NP (NNS patients))) (, ,) (NP (JJ early) (NN Doc_11897407_1196_1214_Disease))))))))))))) (. .)))
11928786	0	(S1 (NP (NNP Doc_11928786_0_9_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_11928786_11_16_Chemical)) (-RRB- -RRB-)) (NNP Doc_11928786_18_26_Disease) (. .)))
11928786	1	(S1 (S (NP (NN Doc_11928786_28_37_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ monocyclic) (NN Doc_11928786_54_68_Chemical)) (VP (ADVP (RB structurally)) (VBN related) (PP (TO to) (NP (NNP Doc_11928786_93_104_Chemical)))))) (. .)))
11928786	2	(S1 (S (NP (NP (NNP Doc_11928786_106_111_Chemical)) (, ,) (NP (NP (DT a) (JJ sustained-release) (NN formulation)) (PP (IN of) (NP (NNP Doc_11928786_148_171_Chemical)))) (, ,)) (VP (AUX was) (ADVP (RB recently)) (VP (VBN released) (PP (IN in) (NP (NNP Ireland))) (, ,) (PP (IN as) (NP (DT a) (NN smoking) (NN cessation) (NN aid))))) (. .)))
11928786	3	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ initial) (CD 6) (NNS months)) (SBAR (WHNP (IN since)) (S (NP (PRP it)) (VP (AUX 's) (NP (NN introduction))))))) (, ,) (NP (CD 12) (JJ Doc_11928786_287_295_Disease) (NNS cases)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (TO to) (NP (NP (DT The) (NNP National) (NNS Poisons) (NNP Information) (NNP Centre.) (CD 8) (NNS patients)) (VP (VBN developed) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_11928786_398_406_Disease)))))))))) (. .)))
11928786	4	(S1 (S (NP (JJ Common) (NNS features)) (VP (VBD included) (NP (NP (NNP Doc_11928786_433_444_Disease)) (, ,) (NP (NNP drowsiness)) (, ,) (NP (NNP Doc_11928786_458_472_Disease)) (CC and) (NP (NNP Doc_11928786_477_488_Disease)))) (. .)))
11928786	5	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (JJ severe) (NN Doc_11928786_520_539_Disease)) (, ,) (PP (VBG including) (NP (NP (CD one) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN resuscitated) (PP (VBG following) (NP (DT a) (NN Doc_11928786_596_610_Disease)))))))))) (. .)))
11928786	6	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD recovered) (PP (IN without) (NP (NN sequelae)))) (. .)))
11928786	7	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (ADJP (CD 31) (NN year)) (JJ old) (NN female)) (SBAR (WHNP (WP who)) (S (VP (VBD required) (NP (NN admission)) (PP (TO to) (NP (DT the) (JJ Intensive) (NN Care) (NN Unit))) (PP (IN for) (NP (NP (NN ventilation)) (CC and) (NP (JJ full) (JJ supportive) (NN therapy)))) (, ,) (PP (VBG following) (NP (NP (NN ingestion)) (PP (IN of) (NP (JJ 13.5g) (NNP Doc_11928786_818_827_Chemical)))))))))))) (. .)))
11928786	8	(S1 (S (S (NP (NNP Recurrent) (NNP Doc_11928786_839_847_Disease)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11928786_866_874_Chemical)))))) (CC and) (S (NP (JJ broad) (JJ complex) (NN Doc_11928786_893_904_Disease)) (VP (AUX was) (ADVP (RB successfully)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_11928786_935_944_Chemical)))))) (. .)))
11928786	9	(S1 (S (NP (NN Doc_11928786_946_951_Chemical)) (VP (VBD caused) (NP (JJ significant) (NN Doc_11928786_971_1011_Disease)) (PP (IN in) (NP (NNP Doc_11928786_1015_1023_Disease)))) (. .)))
11928786	10	(S1 (S (NP (DT The) (JJ potential) (JJ toxic) (NNS effects)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (PRP it)) (PP (IN as) (NP (DT a) (NN smoking) (NN cessation) (NN aid))))))))) (. .)))
11961407	0	(S1 (NP (NP (NP (CD GLEPP1) (NN receptor)) (NP (NP (NNP Doc_11961407_16_24_Chemical) (NNP phosphatase)) (PRN (-LRB- -LRB-) (NP (NNP Ptpro)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN rat) (NNP Doc_11961407_52_55_Chemical) (NNP Doc_11961407_56_65_Disease))) (. .)))
11961407	1	(S1 (NP (NP (DT A) (NN marker)) (PP (IN of) (NP (JJ acute) (NN podocyte) (NN injury))) (. .)))
11961407	2	(S1 (S (NP (NP (NNP Glomerular) (JJ epithelial) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP GLEPP1)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ podocyte) (NN receptor) (NN membrane) (NN protein) (JJ Doc_11961407_183_191_Chemical) (NN phosphatase)) (VP (VBN located) (PP (IN on) (NP (NP (DT the) (JJ apical) (NN cell) (NN membrane)) (PP (IN of) (NP (JJ visceral) (JJ glomerular) (JJ epithelial) (NN cell) (CC and) (NN foot) (NNS processes)))))))) (. .)))
11961407	3	(S1 (S (NP (DT This) (NN receptor)) (VP (VBZ plays) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (NN structure) (CC and) (NN function)) (PP (IN of) (NP (JJ podocyte) (NN foot) (NN process)))))))) (. .)))
11961407	4	(S1 (S (S (VP (TO To) (VP (ADVP (RB better)) (VB understand) (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (NNS GLEPP1)))) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NNP Doc_11961407_451_468_Disease)))))))) (, ,) (NP (NP (DT the) (NX (NX (NN amount)) (CC and) (NX (NN distribution)))) (PP (IN of) (NP (NP (JJ GLEPP1) (NN protein)) (CC and) (NP (NN mRNA))))) (VP (AUX were) (VP (VBN examined) (PP (IN by) (NP (NP (NN immunohistochemistry)) (, ,) (NP (NNP Western) (NNP blot)) (CC and) (NP (JJ RNase) (NN protection) (NN assay)))) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ podocyte) (NN injury))) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
11961407	5	(S1 (S (NP (NNP Doc_11961407_646_671_Chemical) (NNP Doc_11961407_672_681_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (JJ single) (JJ intraperitoneal) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11961407_733_758_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_11961407_760_763_Chemical)) (, ,) (NP (CD 20) (JJ mg/100g) (NNS BW))) (-RRB- -RRB-)))))))) (. .)))
11961407	6	(S1 (S (NP (NNS Tissues)) (VP (AUX were) (VP (VBN analyzed) (ADVP (IN at) (NP (NP (CD 0) (, ,) (CD 5) (, ,) (CD 7) (, ,) (CD 11) (, ,) (CD 21) (, ,) (CD 45) (, ,) (CD 80) (CC and) (CD 126) (NNS days) (IN after)) (NNP Doc_11961407_849_852_Chemical) (NN injection)) (ADVP (RB so) (RB as) (S (VP (TO to) (VP (VB include) (NP (DT both) (NP (NP (DT the) (JJ acute) (NN phase)) (PP (IN of) (NP (NNP Doc_11961407_904_915_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (NN foot) (NN process) (NN effacement)) (PRN (-LRB- -LRB-) (NP (NNS days) (CD 5-11)) (-RRB- -RRB-)))))) (CC and) (NP (NP (DT the) (JJ chronic) (NN phase)) (PP (IN of) (NP (NNP Doc_11961407_993_1004_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11961407_1021_1039_Disease))) (PRN (-LRB- -LRB-) (NP (NNS days) (CD 45-126)) (-RRB- -RRB-)))))))))))) (. .)))
11961407	7	(S1 (S (PP (IN At) (NP (NN day) (CD 5))) (, ,) (NP (NP (CD GLEPP1) (NN protein)) (CC and) (NP (NN mRNA))) (VP (AUX were) (VP (VBN reduced) (PP (IN from) (NP (NP (DT the) (JJ normal) (NN range)) (PRN (-LRB- -LRB-) (NP (QP (CD 265.2) (CD +/-) (CD 79.6) (SYM x) (CD 10) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)) (NN moles/glomerulus) (CC and) (CD 100) (NN %))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 15) (NN %)) (PP (IN of) (NP (NP (JJ normal)) (PRN (-LRB- -LRB-) (NP (NP (CD 41.8) (JJ +/-) (CD 4.8) (NAC (NAC (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (NN moles/glomerulus)) (, ,) (NP (NNP p) (NNP <) (CD 0.005))) (-RRB- -RRB-)))))))) (. .)))
11961407	8	(S1 (S (NP (DT This)) (VP (VBD occurred) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ urinary) (NN protein) (NN content)) (PP (IN from) (NP (NP (NP (QP (CD 1.8) (JJ +/-) (CD 1) (TO to) (CD 99.0)) (NNS +/-)) (NP (CD 61) (NN mg/day))) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.001))) (-RRB- -RRB-))))))))) (. .)))
11961407	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NN podocalyxin)) (VP (AUX did) (RB not) (VP (VB change) (ADVP (RB significantly)) (PP (IN at) (NP (DT this) (NN time))))) (. .)))
11961407	10	(S1 (S (PP (IN By) (NP (NN day) (CD 11))) (, ,) (NP (NP (NN GLEPP1) (NN protein)) (CC and) (NP (NN mRNA))) (VP (AUX had) (VP (VBN begun) (S (VP (TO to) (VP (VB return) (PP (IN towards) (NP (NN baseline)))))))) (. .)))
11961407	11	(S1 (S (PP (IN By) (NP (NN day) (CD 45-126))) (, ,) (PP (IN at) (NP (NP (DT a) (NN time)) (SBAR (WHADVP (WRB when)) (S (NP (JJ glomerular) (NN scarring)) (VP (AUX was) (ADJP (JJ present))))))) (, ,) (NP (NNP GLEPP1)) (VP (AUX was) (ADJP (JJ absent)) (PP (IN from) (NP (JJ glomerulosclerotic) (NNS areas))) (SBAR (IN although) (S (NP (NP (DT the) (JJ total) (NN glomerular) (NN content)) (PP (IN of) (NP (NNS GLEPP1)))) (VP (AUX was) (RB not) (ADJP (JJ different) (PP (IN from) (NP (JJ normal)))))))) (. .)))
11961407	12	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ GLEPP1) (NN expression)) (, ,) (PP (IN unlike) (NP (NN podocalyxin))) (, ,) (VP (VBZ reflects) (NP (NP (JJ podocyte) (NN injury)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11961407_1790_1793_Chemical))))))))) (. .)))
11961407	13	(S1 (S (NP (JJ GLEPP1) (NN expression)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN marker)) (PP (IN of) (NP (JJ podocyte) (NN injury)))))) (. .)))
12041669	0	(S1 (NP (NP (NN Doc_12041669_0_22_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_12041669_43_58_Chemical-induced) (NNP Doc_12041669_67_82_Disease))))) (. .)))
12041669	1	(S1 (S (NP (NP (DT A) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (JJ Doc_12041669_107_129_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_12041669_142_157_Disease)))) (PP (JJ due) (TO to) (NP (JJ Doc_12041669_165_180_Chemical) (NN therapy))))))) (VP (AUX is) (VP (VBN described))) (. .)))
12041669	2	(S1 (S (S (NP (NP (NN Bone) (NN marrow) (NN recovery)) (CC and) (NP (JJ peripheral) (NN blood) (NN recovery))) (VP (AUX were) (ADJP (JJ complete)) (NP (QP (CD 1) (NN month) (CC and) (CD 3)) (NNS months)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN after) (NP (NN treatment))))) (, ,) (CC and) (S (NP (NP (NN blood) (NN transfusion)) (CC or) (NP (JJ other) (NNS therapies))) (VP (AUX were) (RB not) (ADJP (JJ necessary)) (PP (IN in) (NP (NP (DT a) (JJ follow-up) (NN period)) (PP (IN of) (NP (QP (JJR more) (IN than) (CD 2)) (NNS years))))))) (. .)))
12041669	3	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_12041669_432_454_Chemical)))) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ optimal) (NN treatment)) (PP (IN of) (NP (JJ Doc_12041669_487_502_Chemical-induced) (NN Doc_12041669_511_526_Disease)))))) (. .)))
12063090	0	(S1 (S (NP (NN Doc_12063090_0_9_Chemical)) (VP (VP (VBZ potentiates) (NP (JJ Doc_12063090_22_30_Chemical) (NN antinociception))) (CC but) (RB not) (VP (NNP Doc_12063090_55_67_Disease) (PP (IN after) (NP (JJ chronic) (NN treatment))))) (. .)))
12063090	1	(S1 (S (NP (DT This) (NN work)) (VP (VBZ evaluates) (NP (NP (DT the) (UCP (JJ antinociceptive) (CC and) (NNP Doc_12063090_137_149_Disease)) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (CD 3.2) (NN mg/kg) (NNP s.c.) (NNP Doc_12063090_195_203_Chemical))))) (PP (IN with) (NP (NP (CD 177.8) (JJ mg/kg) (NNP s.c.) (NNP Doc_12063090_226_235_Chemical)) (PP (IN in) (NP (ADJP (ADVP (RB acutely) (CC and) (RB chronically)) (VBN treated)) (PRN (-LRB- -LRB-) (ADVP (RB once)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 12) (NNS days)))) (-RRB- -RRB-)) (NNS rats))))))) (. .)))
12063090	2	(S1 (S (PP (IN On) (NP (DT the) (JJ 13th) (NN day))) (, ,) (S (NP (NN antinociceptive) (NNS effects)) (VP (AUX were) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NP (JJ inflammatory) (NN nociception)) (, ,) (NP (JJ Doc_12063090_400_404_Disease-induced) (JJ functional) (NN impairment) (NN model)))))))))) (, ,) (CC and) (S (NP (DT the) (JJ Doc_12063090_450_458_Chemical) (NN meal) (NN test)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (DT the) (JJ intestinal) (NN transit)))))))) (. .)))
12063090	3	(S1 (S (NP (NP (JJ Simultaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_12063090_545_553_Chemical))) (PP (IN with) (NP (NNP Doc_12063090_559_568_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (RB markedly) (JJ antinociceptive)) (NN potentiation)) (CC and) (NP (NP (NP (NP (DT an) (VBG increasing)) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN action))))) (PP (IN after) (NP (NP (DT a) (JJ single)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 298+/-7) (CC vs.) (CD 139+/-36) (NNS units)) (NN area)) (PRN (-LRB- -LRB-) (NP (NN ua)) (-RRB- -RRB-))) (: ;) (NP (NNP P<0.001))) (-RRB- -RRB-))))) (CC and) (NP (VBN repeated) (NN administration))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 280+/-17) (CC vs.) (CD 131+/-22) (NN ua))) (: ;) (NP (NNP P<0.001))) (-RRB- -RRB-)))))) (. .)))
12063090	4	(S1 (S (NP (NP (JJ Antinociceptive) (NN effect)) (PP (IN of) (NP (NNP Doc_12063090_819_827_Chemical)))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (RB chronically) (VBN treated) (NNS rats))) (PRN (-LRB- -LRB-) (NP (QP (CD 39+/-10) (CC vs.) (CD 18+/-5)) (NN au)) (-RRB- -RRB-)) (SBAR (IN while) (S (NP (DT the) (JJ combination-induced) (NN antinociception)) (VP (AUX was) (VP (VBN remained) (ADJP (JJ similar)) (PP (IN as) (NP (NP (DT an) (JJ acute) (NN treatment)) (PRN (-LRB- -LRB-) (NP (QP (CD 298+/-7) (CC vs.) (CD 280+/-17)) (NNS au)) (-RRB- -RRB-)))))))))) (. .)))
12063090	5	(S1 (S (NP (NP (JJ Acute) (JJ antinociceptive) (NNS effects)) (PP (IN of) (NP (DT the) (NN combination)))) (VP (AUX were) (ADVP (RB partially)) (VP (VBN prevented) (PP (IN by) (NP (NP (CD 3.2) (NNS mg/kg)) (NP (NP (NNP Doc_12063090_1095_1103_Chemical) (NNP s.c.)) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (JJ partial) (NN involvement)) (PP (IN of) (NP (DT the) (JJ opioidergic) (NN system))) (PP (IN in) (NP (NP (DT the) (NN synergism)) (VP (VBN observed))))))))) (. .)))
12063090	6	(S1 (S (PP (IN In) (NP (JJ independent) (NNS groups))) (, ,) (NP (NNP Doc_12063090_1230_1238_Chemical)) (VP (VBD inhibited) (NP (DT the) (JJ intestinal) (NN transit)) (PP (IN in) (NP (NP (JJ 48+/-4) (NN %)) (CC and) (NP (JJ 38+/-4) (NN %)))) (PP (IN after) (NP (ADJP (JJ acute) (CC and) (JJ chronic)) (NN treatment))) (, ,) (ADVP (RB respectively)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN tolerance)) (VP (AUX did) (RB not) (VP (VB develop) (PP (TO to) (NP (DT the) (JJ Doc_12063090_1393_1405_Disease) (NNS effects)))))))))) (. .)))
12063090	7	(S1 (S (NP (DT The) (NN combination)) (VP (VBD inhibited) (NP (NP (JJ intestinal) (NN transit)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_12063090_1488_1496_Chemical)))))))) (ADVP (RB regardless) (PP (IN of) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN treatment)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NNP Doc_12063090_1550_1559_Chemical)) (VP (AUX did) (RB not) (VP (VB potentiate) (NP (JJ Doc_12063090_1579_1587_Chemical-induced) (NN Doc_12063090_1596_1608_Disease))))))))) (. .)))
12063090	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP show) (NP (NP (DT a) (JJ significant) (NN interaction)) (PP (IN between) (NP (NP (NP (NNP Doc_12063090_1664_1672_Chemical)) (CC and) (NP (NNP Doc_12063090_1677_1686_Chemical))) (PP (IN in) (NP (RB chronically) (VBN treated) (NNS rats)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT this) (NN combination)) (VP (MD could) (VP (AUX be) (ADJP (JJ useful) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_12063090_1786_1798_Disease))))))))))))) (. .)))
12084448	0	(S1 (S (NP (NNP Doc_12084448_0_10_Chemical) (NNP Doc_12084448_11_25_Disease)) (VP (VBG presenting) (PP (IN with) (NP (NNP Doc_12084448_42_51_Disease)))) (. .)))
12084448	1	(S1 (S (NP (NP (JJ CNS) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ antineoplastic) (NN agent) (NNP Doc_12084448_99_109_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12084448_111_114_Chemical)) (-RRB- -RRB-))))) (VP (VP (AUX are) (ADJP (JJ frequent))) (CC and) (VP (VBP include) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ neurological) (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB limit) (NP (NN drug) (NN use))))))))))) (. .)))
12084448	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 51-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (S (ADJP (JJ severe))) (, ,) (S (VP (VBG disabling) (NP (NP (JJ negative) (NN Doc_12084448_280_289_Disease)) (PP (IN of) (NP (NP (DT the) (JJ upper)) (CC and) (NP (JJR lower) (NNS extremities))))) (PP (IN after) (NP (NP (DT the) (NN infusion)) (PP (IN of) (NP (NNP Doc_12084448_347_357_Chemical))) (PP (IN for) (NP (NNP Doc_12084448_362_374_Disease)))))))))))))) (. .)))
12084448	3	(S1 (S (NP (PRP He)) (VP (AUX was) (ADVP (RB awake)) (, ,) (PP (VBN revealed) (NP (NP (DT no) (NNS changes)) (PP (PP (IN of) (NP (JJ mental) (NN status))) (CC and) (PP (IN at) (NP (NN rest)))) (SBAR (S (NP (EX there)) (VP (AUX were) (NP (DT no) (JJ further) (NN motor) (NNS symptoms)))))))) (. .)))
12084448	4	(S1 (S (NP (NP (JJ Cranial) (JJ magnetic) (NN resonance) (NN imaging)) (CC and) (NP (JJ extensive) (NN laboratory) (NNS studies))) (VP (VBD failed) (S (VP (TO to) (VP (VB reveal) (NP (NP (NNP Doc_12084448_562_593_Disease)) (CC and) (NP (NNP Doc_12084448_598_621_Disease))))))) (. .)))
12084448	5	(S1 (S (NP (DT An) (NN electroencephalogram)) (VP (VBD showed) (NP (NP (JJ continuous) (, ,) (JJ generalized) (JJ irregular) (NN slowing)) (PP (IN with) (NP (NP (JJ admixed) (JJ periodic) (NN triphasic) (NNS waves)) (VP (VBG indicating) (NP (JJ symptomatic) (NNP Doc_12084448_757_771_Disease))))))) (. .)))
12084448	6	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NNP Doc_12084448_795_805_Chemical)))) (VP (VP (AUX was) (VP (VBN discontinued))) (CC and) (VP (PP (IN within) (NP (CD 12) (NNP h) (DT the) (NNP Doc_12084448_843_852_Disease))) (VBD resolved) (ADVP (RB completely)))) (. .)))
12084448	7	(S1 (S (PP (IN In) (NP (NP (DT the) (NN patient)) (VP (VBN described)))) (, ,) (NP (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_12084448_916_925_Disease))) (PP (IN during) (NP (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_12084448_945_955_Chemical)))) (, ,) (NP (JJ normal) (NN laboratory) (NNS findings)) (CC and) (NP (NN imaging) (NNS studies))))) (CC and) (NP (NP (DT the) (NN resolution)) (PP (IN of) (NP (NNS symptoms))) (PP (VBG following) (NP (NP (DT the) (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug))))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ negative) (NN Doc_12084448_1099_1108_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12084448_1139_1142_Chemical)))))))))) (. .)))
12090760	0	(S1 (NP (NP (NN Antagonism)) (PP (IN between) (NP (NP (NN interleukin) (CD 3)) (CC and) (NP (NN erythropoietin)))) (PP (PP (IN in) (NP (NP (NNS mice)) (PP (IN with) (NP (NNP Doc_12090760_65_79_Chemical-induced) (NNP Doc_12090760_88_94_Disease))))) (CC and) (PP (IN in) (NP (NN bone) (NN marrow) (NN endothelial) (NNS cells)))) (. .)))
12090760	1	(S1 (S (NP (NP (JJ Doc_12090760_133_147_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_12090760_149_152_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_12090760_162_168_Disease)) (PP (IN in) (NP (NNS mice)))) (VP (MD can) (VP (AUX be) (VP (VBN reversed) (PP (IN by) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN IGF-IL-3))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NN fusion) (NN protein)) (PP (IN of) (NP (NP (JJ insulin-like) (NN growth) (NN factor) (NNP II)) (PRN (-LRB- -LRB-) (NP (NNP IGF) (NNP II)) (-RRB- -RRB-))))) (CC and) (NP (NN interleukin) (CD 3))) (-RRB- -RRB-))))) (. .)))
12090760	2	(S1 (S (SBAR (IN Although) (S (NP (NP (NP (NN interleukin) (CD 3)) (PRN (-LRB- -LRB-) (JJ IL-3) (-RRB- -RRB-))) (CC and) (NP (NP (NN erythropoietin)) (PRN (-LRB- -LRB-) (NP (NNP EPO)) (-RRB- -RRB-)))) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (VB act) (ADVP (RB synergistically)) (PP (IN on) (NP (NP (JJ hematopoietic) (NN cell) (NN proliferation)) (PP (IN in) (NP (NN vitro)))))))))))) (, ,) (NP (NP (NN injection)) (PP (IN of) (NP (NNP IGF-IL-3) (CC and) (NNP EPO))) (PP (IN in) (NP (JJ Doc_12090760_472_475_Chemical-treated) (NNS mice)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (JJ red) (NNS cells)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NN plasma) (NNP EPO) (NNS levels)))))) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP IGF-IL-3) (CC or) (NNP EPO)) (ADVP (RB alone)))))))))) (. .)))
12090760	3	(S1 (S (NP (PRP We)) (VP (VBD tested) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (DT the) (JJ antagonistic) (NN effect)) (PP (IN of) (NP (NP (NNP IL-3)) (CC and) (NP (NNP EPO)))) (PP (IN on) (NP (JJ erythroid) (NNS cells)))) (VP (MD may) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (JJ endothelial) (NNS cells)))))))))) (. .)))
12090760	4	(S1 (S (NP (JJ Bovine) (NN liver) (NN erythroid) (NNS cells)) (VP (AUX were) (VP (VBN cultured) (PP (IN on) (NP (NP (NNS monolayers)) (PP (IN of) (NP (NP (JJ human) (NN bone) (NN marrow) (NN endothelial) (NNS cells)) (VP (ADVP (RB previously)) (VBN treated) (PP (IN with) (NP (NP (NNP EPO)) (CC and) (NP (NNP IGF-IL-3))))))))))) (. .)))
12090760	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN of) (NP (NP (JJ Doc_12090760_924_933_Chemical) (NN incorporation)) (PP (IN into) (NP (DT both) (JJ erythroid) (CC and) (JJ endothelial) (NNS cells))) (PP (IN in) (NP (NP (NNS cultures)) (VP (VBN pre-treated) (PP (IN with) (NP (NP (NNP IGF-IL-3)) (CC and) (NP (NNP EPO))))))))))) (. .)))
12090760	6	(S1 (S (NP (NP (JJ Endothelial) (NN cell) (NN culture) (NNS supernatants)) (VP (VBN separated) (PP (IN by) (NP (NN ultrafiltration) (CC and) (NN ultracentrifugation))) (PP (IN from) (NP (NNS cells))))) (VP (VP (VBD treated) (PP (IN with) (NP (NNP EPO)))) (CC and) (VP (ADVP (JJ IL-3) (RB significantly)) (VBD reduced) (NP (JJ Doc_12090760_1187_1196_Chemical) (NN incorporation)) (PP (IN into) (NP (JJ erythroid) (NNS cells))) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (NP (JJ identical) (NNS fractions)) (VP (VBN obtained) (PP (IN from) (NP (NP (DT the) (NNS media)) (PP (IN of) (NP (NP (NNS cells)) (VP (VBN cultured) (PP (IN with) (NP (NP (NNP EPO)) (ADVP (RB alone)))))))))))))))) (. .)))
12090760	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ endothelial) (NNS cells)) (VP (VBN treated) (ADVP (RB simultaneously)) (PP (IN with) (NP (NP (NNP EPO)) (CC and) (NP (NNP IL-3)))))) (VP (AUX have) (NP (NP (DT a) (JJ negative) (NN effect)) (PP (IN on) (NP (JJ erythroid) (NN cell) (NN production)))))))) (. .)))
12198388	0	(S1 (S (NP (NP (DT The) (NN relationship)) (PP (IN between) (NP (NP (NP (NP (JJ hippocampal) (JJ Doc_12198388_37_50_Chemical) (NN release)) (CC and) (NP (JJ cholinergic) (JJ convulsant) (NN sensitivity))) (PP (IN in) (NP (NN withdrawal) (NN Doc_12198388_112_119_Disease-prone)))) (CC and) (NP (NN withdrawal) (NN Doc_12198388_141_148_Disease-resistant))))) (VP (VBD selected) (NP (NN mouse) (NNS lines))) (. .)))
12198388	1	(S1 (S (S (NP (DT The) (JJ septo-hippocampal) (NN cholinergic) (NN pathway)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NN epileptogenesis))))))) (, ,) (CC and) (S (NP (JJ genetic) (NNS factors)) (VP (VBP influence) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (JJ cholinergic) (NNS agents)))))) (, ,) (CC but) (S (NP (JJ limited) (NNS data)) (VP (AUX are) (ADJP (JJ available)) (PP (IN on) (NP (NP (JJ cholinergic) (NN involvement)) (PP (IN in) (NP (JJ Doc_12198388_402_409_Chemical) (NN withdrawal) (NN severity))))))) (. .)))
12198388	2	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ cholinergic) (NN activity)) (CC and) (NP (NP (NN responsiveness)) (CC and) (NP (JJ Doc_12198388_506_513_Chemical) (NN withdrawal)))))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NP (DT a) (JJ genetic) (NN animal) (NN model)) (PP (IN of) (NP (JJ Doc_12198388_571_578_Chemical) (NN withdrawal) (NN severity))))))) (. .)))
12198388	3	(S1 (S (NP (JJ Cholinergic) (NN convulsant) (NN sensitivity)) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NNP Doc_12198388_660_667_Chemical-na) (NN ve) (NN Withdrawal) (NNP Doc_12198388_686_693_Disease-Prone) (PRN (-LRB- -LRB-) (NP (NNP WSP)) (-RRB- -RRB-)) (JJ and-Resistant) (PRN (-LRB- -LRB-) (NP (NNP WSR)) (-RRB- -RRB-)) (NNS mice))))) (. .)))
12198388	4	(S1 (S (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN administered) (NP (NP (NNP Doc_12198388_758_766_Chemical)) (, ,) (NP (NNP Doc_12198388_768_777_Chemical)) (, ,) (CC or) (NP (NNP Doc_12198388_782_793_Chemical))) (PP (IN via) (NP (VBN timed) (NN tail) (NN vein) (NN infusion)))))) (, ,) (CC and) (S (NP (NP (DT the) (NNS latencies)) (PP (TO to) (NP (NP (NN onset)) (PP (IN of) (NP (NP (NNP Doc_12198388_854_860_Disease)) (CC and) (NP (NNS clonus))))))) (VP (AUX were) (VP (VBN recorded) (CC and) (VBN converted) (PP (TO to) (NP (NN threshold) (NN dose)))))) (. .)))
12198388	5	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD used) (NP (NN microdialysis)) (S (VP (TO to) (VP (VB measure) (NP (NP (NN basal)) (CC and) (NP (NP (NNP Doc_12198388_967_976_Chemical-stimulated) (NNP Doc_12198388_988_1001_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_12198388_1003_1006_Chemical)) (-RRB- -RRB-)) (NN release)) (PP (IN in) (NP (NP (DT the) (JJ CA1) (NN region)) (PP (IN of) (NP (DT the) (NN hippocampus))))))))))) (. .)))
12198388	6	(S1 (S (NP (NN Doc_12198388_1054_1063_Chemical)) (VP (AUX was) (VP (VP (VBN applied) (PP (IN by) (NP (JJ reverse) (NN dialysis))) (ADVP (RB twice))) (, ,) (VP (VBN separated) (PP (IN by) (NP (CD 75) (NN min)))))) (. .)))
12198388	7	(S1 (S (NP (NNP Hippocampal) (NNP Doc_12198388_1136_1139_Chemical)) (ADVP (RB also)) (VP (AUX was) (VP (VBN measured) (PP (IN during) (NP (NN testing))) (PP (IN for) (NP (JJ handling-induced) (NN Doc_12198388_1194_1205_Disease))))) (. .)))
12198388	8	(S1 (S (NP (NP (NN Sensitivity)) (PP (TO to) (NP (NP (JJ several) (NNP Doc_12198388_1239_1249_Disease) (NNS endpoints)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_12198388_1271_1279_Chemical)) (, ,) (NP (NNP Doc_12198388_1281_1290_Chemical)) (, ,) (CC and) (NP (NNP Doc_12198388_1296_1307_Chemical)))))))) (VP (AUX were) (ADJP (RB significantly) (JJR greater)) (PP (IN in) (NP (NNP WSR) (CC versus) (NNP WSP) (NNS mice)))) (. .)))
12198388	9	(S1 (S (PP (IN In) (NP (NN microdialysis) (NNS experiments))) (, ,) (NP (DT the) (NNS lines)) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN in) (NP (NP (NP (JJ basal) (NN release)) (PP (IN of) (NP (NNP Doc_12198388_1434_1437_Chemical)))) (, ,) (CC and) (NP (ADJP (CD 50) (NN mM)) (JJ Doc_12198388_1449_1452_Chemical) (VBN increased) (JJ Doc_12198388_1463_1466_Chemical) (NN output)))) (PP (IN in) (NP (NP (DT both) (NNS lines)) (PP (IN of) (NP (NNS mice))))))) (. .)))
12198388	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (NN release)) (PP (IN of) (NP (NNP Doc_12198388_1533_1536_Chemical))))) (VP (VBN produced) (PP (IN by) (NP (NP (DT the) (JJ first) (NN application)) (PP (IN of) (NP (NNP Doc_12198388_1574_1577_Chemical))))))) (VP (AUX was) (ADJP (RB 2-fold) (JJR higher)) (PP (IN in) (NP (NNP WSP) (CC versus) (NNP WSR) (NNS mice)))) (. .)))
12198388	11	(S1 (FRAG (SBAR (WHADVP (WRB When)) (S (NP (JJ hippocampal) (NNP Doc_12198388_1637_1640_Chemical)) (VP (AUX was) (VP (VBN measured) (PP (IN during) (S (VP (VBG testing) (SBAR (S (PP (IN for) (NP (JJ handling-induced) (NNP Doc_12198388_1690_1701_Disease))) (, ,) (NP (JJ extracellular) (NNP Doc_12198388_1717_1720_Chemical)) (VP (VP (AUX was) (ADJP (RB significantly) (JJ elevated)) (PRN (-LRB- -LRB-) (NP (CD 192) (NN %)) (-RRB- -RRB-)) (PP (IN in) (NP (NNP WSP) (NNS mice)))) (, ,) (CC but) (VP (AUX was) (ADJP (RB nonsignificantly) (JJ elevated)) (PRN (-LRB- -LRB-) (NP (CD 59) (NN %)) (-RRB- -RRB-)) (PP (IN in) (NP (NNP WSR) (NNS mice)))))))))))))) (. .)))
12198388	12	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ cholinergic) (NN activity)) (CC and) (NP (JJ postsynaptic) (NN sensitivity)))) (PP (TO to) (NP (JJ cholinergic) (NNP Doc_12198388_1941_1952_Disease)))) (VP (MD may) (VP (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_12198388_1976_1983_Chemical) (NN withdrawal) (NN severity))))) (CC and) (VP (VB implicate) (NP (JJ cholinergic) (NNS mechanisms)) (PP (IN in) (NP (JJ Doc_12198388_2044_2051_Chemical) (NN withdrawal))))))))) (. .)))
12198388	13	(S1 (S (ADVP (RB Specifically)) (, ,) (NP (NNP WSP) (NNS mice)) (VP (MD may) (VP (AUX have) (NP (JJR lower) (NN sensitivity)) (S (VP (TO to) (VP (VB cholinergic) (NP (NNP Doc_12198388_2129_2140_Disease)) (PP (VBN compared) (PP (IN with) (NP (NNP WSR)))) (PP (IN because) (IN of) (NP (NP (JJ postsynaptic) (NN receptor) (NN desensitization)) (VP (VBN brought) (PRT (RP on)) (PP (IN by) (NP (NP (JJR higher) (NN activity)) (PP (IN of) (NP (JJ cholinergic) (NNS neurons))))))))))))) (. .)))
12202650	0	(S1 (S (NP (JJ Doc_12202650_0_9_Chemical-induced) (NN Doc_12202650_18_29_Disease)) (VP (VBZ alters) (NP (NP (DT the) (NN excitability)) (PP (IN of) (NP (DT the) (JJ human) (JJ jaw-stretch) (JJ reflex))))) (. .)))
12202650	1	(S1 (S (S (NP (NP (DT The) (NN pathophysiology)) (PP (IN of) (NP (JJ painful) (NNP Doc_12202650_118_145_Disease)))) (VP (AUX is) (RB not) (ADVP (RB fully)) (VP (VBN understood)))) (, ,) (CC but) (S (NP (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_12202650_198_209_Disease)) (VP (VBZ modulates) (NP (NN motor) (NN function)) (PP (IN in) (NP (JJ characteristic) (NNS ways)))))))) (. .)))
12202650	2	(S1 (S (NP (DT This) (NN study)) (VP (VBD tested) (NP (DT the) (NN hypothesis)) (SBAR (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NNP Doc_12202650_311_329_Disease) (NN afferent) (NNS fibers)))) (VP (MD would) (VP (AUX be) (VP (VBN linked) (PP (TO to) (NP (NP (DT an) (VBN increased) (NN excitability)) (PP (IN of) (NP (DT the) (JJ human) (JJ jaw-stretch) (JJ reflex)))))))))) (CC and) (SBAR (IN whether) (S (NP (DT this) (NN process)) (VP (MD would) (VP (AUX be) (ADJP (JJ sensitive) (PP (TO to) (NP (NP (NP (NN length)) (CC and) (NP (NN velocity))) (PP (IN of) (NP (DT the) (NN stretch)))))))))))) (. .)))
12202650	3	(S1 (S (NP (NP (NNP Doc_12202650_506_515_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (JJ micro) (NNP g)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (PP (IN into) (NP (DT the) (NN masseter) (NN muscle))) (S (VP (TO to) (VP (VB induce) (NP (NN Doc_12202650_577_581_Disease)) (PP (IN in) (NP (CD 11) (JJ healthy) (NNS volunteers)))))))) (. .)))
12202650	4	(S1 (S (NP (JJ Short-latency) (JJ reflex) (NNS responses)) (VP (AUX were) (VP (VBN evoked) (PP (IN in) (NP (DT the) (NN masseter) (CC and) (NN temporalis) (NNS muscles))) (PP (IN by) (NP (NP (DT a) (JJ stretch) (NN device)) (PP (IN with) (NP (NP (JJ different) (NNS velocities)) (CC and) (NP (NNS displacements)))) (ADVP (RB before)) (, ,) (PP (PP (IN during)) (, ,) (CC and) (PP (IN after) (NP (DT the) (NNP Doc_12202650_784_788_Disease)))))))) (. .)))
12202650	5	(S1 (S (NP (DT The) (JJ normalized) (JJ reflex) (NN amplitude)) (VP (VP (VBD increased) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN velocity))))) (PP (IN at) (NP (DT a) (VBN given) (NN displacement)))) (, ,) (CC but) (VP (VBD remained) (ADJP (JJ constant)) (PP (IN with) (NP (JJ different) (NNS displacements))) (PP (IN at) (NP (DT a) (VBN given) (NN velocity))))) (. .)))
12202650	6	(S1 (S (NP (DT The) (JJ normalized) (JJ reflex) (NN amplitude)) (VP (AUX was) (ADJP (RB significantly) (JJR higher)) (PP (IN during) (NP (NNP Doc_12202650_1022_1026_Disease))) (, ,) (FRAG (CC but) (ADVP (RB only)) (PP (IN at) (NP (NP (JJR faster) (NNS stretches)) (PP (IN in) (NP (DT the) (NNP Doc_12202650_1064_1078_Disease))))))) (. .)))
12202650	7	(S1 (S (NP (NP (VBN Increased) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN fusimotor) (NN system))) (PP (IN during) (NP (JJ acute) (NN Doc_12202650_1139_1150_Disease)))) (VP (MD could) (VP (AUX be) (NP (NP (CD one) (JJ likely) (NN mechanism)) (SBAR (S (VP (TO to) (VP (VB explain) (NP (DT the) (NNS findings))))))))) (. .)))
12369736	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ 5-HT1B) (NN receptor) (NNS ligands)))) (VP (VBD microinjected) (PP (IN into) (NP (DT the) (NN accumbal) (NN shell) (CC or) (NN core))) (PP (IN on) (NP (NP (DT the) (JJ Doc_12369736_88_95_Chemical-induced) (NN Doc_12369736_104_127_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
12369736	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ 5-HT1B) (NN receptor) (NNS ligands)) (VP (VBN microinjected) (PP (IN into) (NP (NP (DT the) (NNS subregions)) (PP (IN of) (NP (NP (DT the) (NN nucleus) (NNS accumbens)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (NN shell)) (CC and) (NP (DT the) (NN core))) (-RRB- -RRB-))))))))) (PP (IN on) (NP (NP (DT the) (NNP Doc_12369736_308_331_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_12369736_343_350_Chemical))) (PP (IN in) (NP (NNS rats)))))))))))) (. .)))
12369736	2	(S1 (S (S (NP (JJ Male) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VBN implanted) (ADVP (RB bilaterally)) (PP (IN with) (NP (NNS cannulae))) (PP (IN into) (NP (DT the) (NNS accumbens) (NN shell) (CC or) (NN core)))))) (, ,) (CC and) (S (ADVP (RB then)) (VP (AUX were) (ADVP (RB locally)) (VP (VBN injected) (PP (IN with) (NP (NP (NP (NNP Doc_12369736_488_496_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN antagonist)) (PP (IN of) (NP (JJ 5-HT1B) (NNS receptors)))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_12369736_536_544_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN agonist)) (PP (IN of) (NP (JJ 5-HT1B) (NNS receptors)))) (-RRB- -RRB-)))))))) (. .)))
12369736	3	(S1 (S (S (VP (VBN Given) (ADVP (RB alone)) (PP (TO to) (NP (DT any) (JJ accumbal) (NN subregion))))) (, ,) (NP (NP (NP (NNP Doc_12369736_618_626_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.1-10) (NN microg/side)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_12369736_651_659_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.1-10) (NN microg/side)) (-RRB- -RRB-)))) (VP (AUX did) (RB not) (VP (VB change) (NP (JJ basal) (JJ locomotor) (NN activity)))) (. .)))
12369736	4	(S1 (S (NP (NP (JJ Systemic) (NNP Doc_12369736_731_738_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (DT the) (JJ locomotor) (NN activity)) (PP (IN of) (NP (NNS rats))))) (. .)))
12369736	5	(S1 (S (NP (NP (NP (NNP Doc_12369736_806_814_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.1-10) (NN microg/side)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN administered) (JJ intra-accumbens) (NN shell)) (PP (ADVP (RB prior)) (TO to) (NP (NNP Doc_12369736_881_888_Chemical)))) (, ,)) (ADVP (RB dose-dependently)) (VP (VBD attenuated) (NP (DT the) (JJ psychostimulant-induced) (NNP Doc_12369736_946_969_Disease))) (. .)))
12369736	6	(S1 (S (NP (JJ Such) (NN attenuation)) (VP (AUX was) (RB not) (VP (VBN found) (PP (IN in) (NP (NP (NNS animals)) (SBAR (WHNP (WDT which)) (S (VP (AUX had) (VP (AUX been) (VP (VBN injected) (PP (IN with) (NP (NNP Doc_12369736_1042_1050_Chemical))) (PP (IN into) (NP (DT the) (JJ accumbens) (NN core)))))))))))) (. .)))
12369736	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN injected) (PP (IN into) (NP (DT the) (NNS accumbens) (NN shell))) (PRN (-LRB- -LRB-) (CC but) (NP (RB not) (DT the) (NN core)) (-RRB- -RRB-)) (PP (IN before) (NP (NNP Doc_12369736_1141_1148_Chemical)))))) (, ,) (NP (NNP Doc_12369736_1150_1158_Chemical) (PRN (-LRB- -LRB-) (NP (JJ 0.1-10) (NN microg/side)) (-RRB- -RRB-))) (VP (VP (VBD enhanced) (NP (NP (DT the) (JJ locomotor) (NN response)) (PP (TO to) (NP (NNP Doc_12369736_1215_1222_Chemical))))) (: ;) (NP (NP (DT the) (JJ maximum) (NN effect)) (VP (AUXG being) (VP (VBN observed) (PP (IN after) (NP (NP (CD 10) (NN microg/side)) (PP (IN of) (NP (DT the) (NN agonist))))))))) (. .)))
12369736	8	(S1 (S (NP (DT The) (JJ later) (NN enhancement)) (VP (AUX was) (VP (VBN attenuated) (PP (IN after) (NP (NP (JJ intra-accumbens) (NN shell) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_12369736_1375_1383_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN microg/side)) (-RRB- -RRB-)))))))) (. .)))
12369736	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (S (NP (NNP Doc_12369736_1428_1435_Chemical)) (VP (VBN induced) (SBAR (S (NP (NNP Doc_12369736_1444_1459_Disease)) (VP (AUX is) (VP (VBN modified) (PP (IN by) (NP (NP (JJ 5-HT1B) (NN receptor) (NNS ligands)) (VP (VBN microinjected) (PP (IN into) (NP (DT the) (NNS accumbens) (NN shell)))))))))))) (, ,) (CC but) (S (ADJP (RB not) (JJ core)) (, ,) (NP (DT this) (NN modification)) (VP (VBG consisting) (PP (IN in) (NP (NP (JJ inhibitory) (CC and) (JJ facilitatory) (NNS effects)) (PP (IN of) (NP (NP (NP (DT the) (JJ 5-HT1B) (NN receptor) (NN antagonist)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12369736_1656_1664_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NN agonist)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12369736_1679_1687_Chemical)) (-RRB- -RRB-))))))) (, ,) (ADVP (RB respectively))))))) (. .)))
12369736	10	(S1 (S (PP (IN In) (NP (JJ other) (NNS words))) (, ,) (NP (DT the) (JJ present) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (JJ accumbal) (NN shell) (NN 5-HT1B) (NNS receptors)) (VP (VBP play) (NP (DT a) (JJ permissive) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ behavioural) (NN response)) (PP (TO to) (NP (DT the) (NN psychostimulant))))))))) (. .)))
12443032	0	(S1 (S (S (NP (NN Doc_12443032_0_7_Chemical)) (VP (VBD related) (NP (NN Doc_12443032_16_26_Disease)))) (: :) (SQ (AUX are) (NP (PRP we)) (VP (VBG seeing) (NP (NP (DT the) (NN tip)) (PP (IN of) (NP (DT an) (NN iceberg))))) (. ?))))
12443032	1	(S1 (S (NP (NP (DT The) (JJ recreational) (NN use)) (PP (IN of) (NP (NNP Doc_12443032_89_96_Chemical)))) (VP (AUX is) (PP (IN on) (NP (DT the) (NN increase)))) (. .)))
12443032	2	(S1 (S (NP (DT The) (NN emergency) (NN nurse)) (VP (MD ought) (S (VP (TO to) (VP (AUX be) (ADJP (JJ familiar) (PP (IN with) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ cardiovascular) (NNS consequences)) (PP (IN of) (NP (JJ Doc_12443032_206_213_Chemical) (NN use)))))))))))) (. .)))
12443032	3	(S1 (S (PP (IN In) (NP (NN particular))) (, ,) (NP (NP (DT the) (NN tendency)) (PP (IN of) (NP (NNP Doc_12443032_250_257_Chemical)))) (VP (TO to) (VP (VB produce) (SBAR (S (NP (NNP Doc_12443032_269_279_Disease)) (VP (MD ought) (S (VP (TO to) (VP (AUX be) (PP (IN in) (NP (NP (DT the) (NN mind)) (PP (IN of) (NP (DT the) (NN emergency) (NN nurse))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN faced) (PP (IN with) (NP (NP (DT a) (JJ young) (NN victim)) (PP (IN of) (NP (NNP Doc_12443032_361_371_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX is) (ADVP (RB otherwise)) (PP (IN at) (NP (JJ low) (NN risk))))))))))))))))))) (. .)))
12443032	4	(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NNP Doc_12443032_419_429_Disease))) (VP (VBN related) (PP (TO to) (NP (JJ Doc_12443032_441_448_Chemical) (NN use))))) (VP (AUX is) (VP (VBN discussed)))) (CC and) (S (NP (NN treatment) (NNS dilemmas)) (VP (AUX are) (VP (VBN discussed)))) (. .)))
12443032	5	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (JJ moral) (NNS issues)) (VP (VBG relating) (PP (TO to) (NP (NP (DT the) (NN testing)) (PP (IN of) (NP (JJ potential) (JJ Doc_12443032_563_570_Chemical) (NNS users))))))) (VP (MD will) (VP (AUX be) (VP (VBN addressed)))) (. .)))
12464714	0	(S1 (S (NP (NP (NN Crossover) (NN comparison)) (PP (IN of) (NP (NP (NN efficacy) (CC and) (NN preference)) (PP (IN for) (NP (NNP Doc_12464714_52_63_Chemical) (CD 10)))))) (VP (VBD mg) (PP (IN versus) (NP (NNP Doc_12464714_77_87_Chemical/Doc_12464714_88_96_Chemical))) (PP (IN in) (NP (NNP Doc_12464714_100_108_Disease)))) (. .)))
12464714	1	(S1 (S (NP (NNP Doc_12464714_110_121_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ selective) (NNP Doc_12464714_137_141_Chemical) (PRN (-LRB- -LRB-) (NP (NN 1B/1D)) (-RRB- -RRB-)) (NN receptor)) (ADJP (JJ agonist) (PP (IN with) (NP (NP (JJ rapid) (JJ oral) (NN absorption) (CC and) (JJ early) (NN onset)) (PP (IN of) (NP (NN action))) (PP (IN in) (NP (NP (DT the) (JJ acute) (NN treatment)) (PP (IN of) (NP (NNP Doc_12464714_245_253_Disease)))))))))) (. .)))
12464714	2	(S1 (S (NP (DT This) (JJ randomized) (JJ double-) (JJ blind) (NN crossover) (NN outpatient) (NN study)) (VP (VBD assessed) (NP (NP (DT the) (NN preference)) (PP (IN for) (NP (NP (NP (QP (CD 1) (JJ Doc_12464714_342_353_Chemical) (CD 10) (CD mg) (NN tablet) (TO to) (CD 2)) (NNP Doc_12464714_372_382_Chemical) (CD 1) (NN mg/Doc_12464714_388_396_Chemical)) (NP (QP (CD 100) (CD mg)) (NNS tablets))) (PP (IN in) (NP (NP (CD 439) (NNS patients)) (VP (VBG treating) (NP (NP (DT a) (JJ single) (NN Doc_12464714_446_454_Disease) (NN attack)) (PP (IN with) (NP (DT each) (NN therapy))))))))))) (. .)))
12464714	3	(S1 (S (PP (IN Of) (NP (NP (NNS patients)) (VP (VBG expressing) (NP (NP (DT a) (NN preference)) (PRN (-LRB- -LRB-) (NP (CD 89.1) (NN %)) (-RRB- -RRB-)))))) (, ,) (ADVP (RBR more) (IN than) (RB twice) (RB as)) (NP (JJ many)) (VP (VBN preferred) (NP (NNP Doc_12464714_560_571_Chemical)) (PP (TO to) (NP (NP (NNP Doc_12464714_575_585_Chemical/Doc_12464714_586_594_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 69.9)) (CC vs.) (NP (CD 30.1) (NN %))) (, ,) (NP (CD p) (NN <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-))))) (. .)))
12464714	4	(S1 (S (NP (NP (JJR Faster) (NN relief)) (PP (IN of) (NP (NNP Doc_12464714_646_654_Disease)))) (VP (AUX was) (NP (NP (DT the) (ADJP (RBS most) (JJ important)) (NN reason)) (PP (IN for) (NP (NN preference))) (, ,) (VP (VBN cited) (PP (IN by) (NP (NP (NP (CD 67.3) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG preferring) (NP (NNP Doc_12464714_739_750_Chemical)))))) (CC and) (NP (NP (CD 54.2) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD preferred) (NP (NN Doc_12464714_787_797_Chemical/Doc_12464714_798_806_Chemical))))))))))))) (. .)))
12464714	5	(S1 (S (NP (NP (DT The) (JJ co-primary) (NN endpoint)) (PP (IN of) (S (VP (AUXG being) (ADJP (NNP Doc_12464714_841_845_Disease) (JJ free))))) (PP (IN at) (NP (CD 2) (NNP h)))) (VP (AUX was) (ADVP (RB also)) (PP (IN in) (NP (NP (NN favor)) (PP (IN of) (NP (NNP Doc_12464714_879_890_Chemical)))))) (. .)))
12464714	6	(S1 (S (NP (NP (JJ Forty-nine) (NN percent)) (PP (IN of) (NP (NNS patients)))) (VP (AUX were) (ADJP (NNP Doc_12464714_928_932_Disease) (JJ free)) (NP (CD 2) (NNP h)) (PP (IN after) (NP (NNP Doc_12464714_948_959_Chemical))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 24.3) (NN %)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_12464714_994_1004_Chemical/Doc_12464714_1005_1013_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (NNP <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_12464714_1032_1043_Chemical)) (VP (AUXG being) (ADJP (JJ superior)) (PP (IN within) (NP (NP (CD 1) (NNP h)) (PP (IN of) (NP (NN treatment)))))))))))))) (. .)))
12464714	7	(S1 (S (NP (NP (JJ Doc_12464714_1084_1092_Disease) (NN relief)) (PP (IN at) (NP (CD 2) (NNP h)))) (VP (AUX was) (NP (NP (NP (CD 75.9) (NN %)) (PP (IN for) (NP (NNP Doc_12464714_1121_1132_Chemical)))) (CC and) (NP (NP (CD 47.3) (NN %)) (PP (IN for) (NP (NP (NNP Doc_12464714_1147_1157_Chemical/Doc_12464714_1158_1166_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (NNP <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-)))))) (, ,) (PP (IN with) (S (NP (NNP Doc_12464714_1190_1201_Chemical)) (VP (AUXG being) (ADJP (JJ superior) (PP (TO to) (NP (NNP Doc_12464714_1220_1230_Chemical/Doc_12464714_1231_1239_Chemical)))) (PP (IN within) (NP (NP (CD 30) (NN min)) (PP (IN of) (NP (NN dosing))))))))) (. .)))
12464714	8	(S1 (S (NP (NP (QP (RB Almost) (CD 36)) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NNP Doc_12464714_1295_1306_Chemical)))))) (VP (VP (AUX were) (ADJP (NNP Doc_12464714_1312_1316_Disease) (JJ free)) (PP (IN at) (NP (CD 2) (NNP h)))) (CC and) (VP (AUX had) (NP (NP (DT no) (NN recurrence) (CC or) (NN need)) (PP (IN for) (NP (NP (JJ additional) (NN medication)) (PP (IN within) (NP (CD 24)))))) (NP (NNP h))) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (NNP Doc_12464714_1429_1439_Chemical/Doc_12464714_1440_1448_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP p) (NNP <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-)))))))))) (. .)))
12464714	9	(S1 (S (NP (NNP Doc_12464714_1467_1478_Chemical)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ superior) (PP (TO to) (NP (NNP Doc_12464714_1500_1510_Chemical/Doc_12464714_1511_1519_Chemical)))) (PP (PP (IN in) (NP (NP (DT the) (NNS proportions)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (DT no) (NNP Doc_12464714_1559_1565_Disease) (, ,) (NNP Doc_12464714_1567_1575_Disease) (, ,) (NNP Doc_12464714_1577_1588_Disease) (CC or) (NNP Doc_12464714_1592_1603_Disease))))))) (CC and) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ normal) (NN function)) (, 2) (NP (NP (NP (NNP h)) (PP (IN after) (NP (NN drug) (NN intake)))) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CC or) (SYM =) (CD 0.001)) (-RRB- -RRB-))))))))) (. .)))
12464714	10	(S1 (S (NP (JJR More) (NNS patients)) (VP (AUX were) (PRN (-LRB- -LRB-) (ADVP (RB completely)) (, ,) (ADVP (RB very) (CC or) (RB somewhat)) (-RRB- -RRB-)) (VP (VBN satisfied) (NP (CD 2) (NNP h)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_12464714_1767_1778_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 69.8) (NN %)) (-RRB- -RRB-)))) (PP (IN than) (PP (IN at) (NP (NP (CD 2) (NNP h)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_12464714_1820_1830_Chemical/Doc_12464714_1831_1839_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 38.6) (NN %)) (, ,) (NP (JJ p) (NNS <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-))))))))) (. .)))
12464714	11	(S1 (S (NP (NN Recurrence) (NNS rates)) (VP (AUX were) (NP (NP (NP (CD 31.4) (NN %)) (PP (IN with) (NP (NNP Doc_12464714_1898_1909_Chemical)))) (CC and) (NP (NP (CD 15.3) (NN %)) (PP (IN with) (NP (NNP Doc_12464714_1925_1935_Chemical/Doc_12464714_1936_1944_Chemical)))))) (. .)))
12464714	12	(S1 (S (NP (DT Both) (JJ active) (NNS treatments)) (VP (AUX were) (ADVP (RB well)) (VP (VBN tolerated))) (. .)))
12464714	13	(S1 (S (NP (DT The) (JJS most) (JJ common) (JJ adverse) (NNS events)) (-LRB- -LRB-) (NP (NN incidence)) (VP (VBZ >) (CC or) (SYM =) (NP (NP (CD 5) (NN %)) (PP (IN in) (NP (CD one) (NN group)))) (-RRB- -RRB-) (SBAR (S (PP (IN after) (NP (NNP Doc_12464714_2062_2073_Chemical) (CC and) (NNP Doc_12464714_2078_2088_Chemical/Doc_12464714_2089_2097_Chemical))) (, ,) (ADVP (RB respectively)) (, ,) (VP (AUX were) (NP (NP (NNP Doc_12464714_2118_2127_Disease) (PRN (-LRB- -LRB-) (NP (CD 6.7) (CC and) (CD 5.3) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_12464714_2144_2150_Disease) (PRN (-LRB- -LRB-) (NP (CD 4.2) (CC and) (CD 8.5) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_12464714_2170_2180_Disease) (PRN (-LRB- -LRB-) (NP (QP (CD 5.5) (CC and) (CD 2.3)) (NN %)) (-RRB- -RRB-)))))))) (. .)))
12483326	0	(S1 (NP (NP (JJ Severe) (NN Doc_12483326_7_34_Disease)) (PP (IN after) (NP (NP (JJ intracarotid) (NN injection)) (PP (IN of) (NP (NNP Doc_12483326_67_78_Chemical))))) (PP (IN for) (NP (NN recurrent) (NN Doc_12483326_93_106_Disease))) (. .)))
12483326	1	(S1 (S (NP (NN Doc_12483326_120_132_Disease)) (VP (AUX is) (NP (NP (DT a) (NN Doc_12483326_138_153_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBZ occurs) (PP (IN in) (NP (DT the) (NN cerebrum))) (PP (IN during) (NP (NN adulthood)))))))) (. .)))
12483326	2	(S1 (S (PP (IN With) (NP (NP (JJ current) (NN treatment) (NNS regimens)) (PP (VBG including) (NP (NP (JJ combined) (NN surgery)) (, ,) (NP (NN radiation)) (CC and) (NP (NN chemotherapy)))))) (, ,) (NP (NP (DT the) (JJ average) (NN life) (NN expectancy)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX is) (VP (VBN limited) (PP (TO to) (NP (QP (RB approximately) (CD 1)) (NN year))))) (. .)))
12483326	3	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_12483326_393_405_Disease)))) (ADVP (RB sometimes)) (VP (AUX have) (S (NP (NP (NN intracarotid) (NN injection)) (PP (IN of) (NP (NNS carcinostatics)))) (VP (VBN added) (PP (TO to) (NP (DT the) (NN treatment) (NN regimen)))))) (. .)))
12483326	4	(S1 (S (ADVP (RB Generally)) (, ,) (NP (NNP Doc_12483326_505_516_Chemical)) (VP (AUX is) (VP (VBN said) (S (VP (TO to) (VP (AUX have) (NP (NN milder) (NN side) (NNS effects)) (PP (IN than) (NP (NP (NNP Doc_12483326_558_567_Chemical)) (, ,) (SBAR (WHNP (WP$ whose) (NN Doc_12483326_575_602_Disease)) (S (VP (AUX are) (VP (ADVP (RB well)) (VBN known)))))))))))) (. .)))
12483326	5	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP we)) (VP (VBD experienced) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ severe) (NN Doc_12483326_660_687_Disease)))) (PP (IN after) (NP (NP (JJ intracarotid) (NN injection)) (PP (IN of) (NP (NNP Doc_12483326_720_731_Chemical))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB infrequently)) (VP (VBN reported)))))))) (. .)))
12483326	6	(S1 (S (NP (DT A) (JJ 58-year-old) (NN man)) (VP (VBD received) (NP (NP (DT an) (JJ intracarotid) (NN injection)) (PP (IN of) (NP (NNP Doc_12483326_827_838_Chemical))) (PP (IN for) (NP (NP (JJ recurrent) (NN Doc_12483326_853_866_Disease)) (PP (IN in) (NP (PRP$ his) (JJ left) (JJ temporal) (NN lobe))))))) (. .)))
12483326	7	(S1 (S (NP (PRP He)) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_12483326_911_961_Disease) (CD 30))) (NP (NNP h)) (PP (IN after) (NP (DT the) (NN injection)))) (. .)))
12483326	8	(S1 (S (NP (NP (NP (JJ Various) (JJ ocular) (NNS symptoms)) (CC and) (NP (NNS findings))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_12483326_1035_1046_Chemical) (NNP Doc_12483326_1047_1055_Disease))))) (VP (AUX were) (VP (VBN seen))) (. .)))
12483326	9	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNS corticosteroids)))) (CC and) (NP (NP (NNP Doc_12483326_1146_1154_Chemical)) (PP (IN for) (NP (CD 6) (NN days)))))) (PP (IN after) (NP (DT the) (NN injection))))) (. .)))
12483326	10	(S1 (S (SBAR (IN Although) (S (S (NP (NP (DT the) (JJ intraocular) (NN pressure) (NN elevation)) (VP (VBN caused) (PP (IN by) (NP (JJ secondary) (JJ acute) (NN angle-closure) (NN Doc_12483326_1271_1279_Disease))))) (VP (VBD decreased))) (CC and) (S (NP (NNP Doc_12483326_1294_1305_Disease)) (VP (VBD diminished))))) (, ,) (NP (NP (JJ inexorable) (NNP Doc_12483326_1329_1340_Disease)) (CC and) (NP (JJ exudative) (NNP Doc_12483326_1355_1373_Disease))) (VP (VBD continued) (PP (IN for) (NP (CD 3) (NNS weeks)))) (. .)))
12483326	11	(S1 (S (ADVP (RB Finally)) (, ,) (ADVP (NP (CD 6) (NNS weeks)) (RB later)) (, ,) (S (NP (NP (NN diffuse) (NN Doc_12483326_1429_1450_Disease)) (PP (IN with) (NP (NNP Doc_12483326_1456_1469_Disease)))) (VP (VBD occurred))) (CC and) (S (NP (NP (DT the) (NN vision)) (PP (IN in) (NP (PRP$ his) (JJ left) (NN eye)))) (VP (AUX was) (VP (VBN lost)))) (. .)))
12483326	12	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBG performing) (NP (NP (NN intracarotid) (NN injection)) (PP (IN of) (NP (NNP Doc_12483326_1574_1585_Chemical))))))) (, ,) (NP (PRP we)) (VP (MD must) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (PRP$ its) (ADJP (RB potentially) (JJ blinding)) (NN Doc_12483326_1632_1647_Disease)))))) (. .)))
12483326	13	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (JJ further) (NNS studies)) (CC and) (NP (NNS investigations))) (VP (AUX are) (VP (VBN undertaken) (PP (IN in) (NP (DT the) (NN effort) (S (VP (TO to) (VP (VB minimize) (NP (JJ such) (JJ severe) (NN side) (NNS effects))))))))))))) (. .)))
12523465	0	(S1 (S (NP (NN Doc_12523465_0_21_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_12523465_38_48_Chemical)))) (. .)))
12523465	1	(S1 (S (NP (NN Doc_12523465_50_60_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ broad-spectrum) (JJ antiepileptic) (NN drug)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (JJ various) (NNS types)) (PP (IN of) (NP (NN Doc_12523465_131_139_Disease)))))))))) (. .)))
12523465	2	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_12523465_150_171_Disease)) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (DT an) (JJ adverse) (NN effect)) (PP (IN of) (NP (DT this) (NN agent)))))))))) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (CD three) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD experienced) (NP (JJ complex) (NN Doc_12523465_282_303_Disease))) (CC and) (VP (VBD altered) (NP (JJ mental) (NN status)) (SBAR (IN after) (S (S (NP (JJ Doc_12523465_336_346_Chemical) (NN treatment)) (VP (AUX was) (VP (VBN begun)))) (CC or) (S (NP (PRP$ its) (NN dosage)) (VP (VBD increased))))))))))) (. .)))
12523465	3	(S1 (S (S (NP (DT All) (CD three)) (VP (AUX had) (VP (AUX been) (VP (VBN diagnosed) (ADVP (RB earlier)) (PP (IN with) (NP (NNP Doc_12523465_434_442_Disease))))))) (, ,) (CC and) (S (NP (PRP$ their) (NN electroencephalogram) (PRN (-LRB- -LRB-) (NP (NNP EEG)) (-RRB- -RRB-)) (NNS findings)) (VP (AUX were) (ADJP (JJ abnormal)))) (. .)))
12523465	4	(S1 (S (PP (IN During) (NP (NN monitoring))) (, ,) (NP (NNP Doc_12523465_524_545_Disease)) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NNP EEG) (NNS readings))) (, ,) (SBAR (SINV (CC nor) (AUX did) (NP (NN video) (NN recording)) (VP (VB capture) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (VBN described) (NNS events))))))))) (. .)))
12523465	5	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (VP (VBN experienced) (NP (NNP Doc_12523465_681_702_Disease)) (PP (IN before) (NP (DT this) (NN event))))) (. .)))
12523465	6	(S1 (S (NP (NP (DT The) (JJ only) (JJ recent) (NN change)) (PP (IN in) (NP (PRP$ their) (NN treatment)))) (VP (AUX was) (NP (NP (DT the) (NN introduction)) (CC or) (NP (NP (VBN increased) (NN dosage)) (PP (IN of) (NP (NNP Doc_12523465_808_818_Chemical)))))) (. .)))
12523465	7	(S1 (S (PP (IN With) (NP (CC either) (NP (NN discontinuation)) (CC or) (NP (NP (VBN decreased) (NN dosage)) (PP (IN of) (NP (DT the) (NN drug)))))) (NP (DT the) (NNS symptoms)) (VP (VP (VBD disappeared)) (CC and) (VP (AUX did) (RB not) (VP (VB recur)))) (. .)))
12523465	8	(S1 (S (NP (NP (JJ Further) (NNS observations)) (CC and) (NP (NNS reports))) (VP (MD will) (VP (VB help) (S (VP (VB clarify) (NP (DT this) (JJ adverse) (NN effect)))))) (. .)))
12523465	9	(S1 (S (PP (IN Until) (NP (RB then))) (, ,) (NP (NNS clinicians)) (VP (AUX need) (S (VP (TO to) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT this) (JJ possible) (NN complication)) (VP (VBN associated) (PP (IN with) (NP (NN Doc_12523465_1082_1092_Chemical))))))))))) (. .)))
12536034	0	(S1 (NP (JJ Anti-Doc_12536034_5_14_Disease) (JJ drugs-induced) (FW de) (FW novo) (FW Doc_12536034_37_53_Disease) (. .)))
12536034	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP present) (NP (NP (CD three) (NNS patients)) (PP (IN with) (NP (FW de) (FW novo) (NNP Doc_12536034_103_119_Disease)))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_12536034_144_157_Chemical)) (CC and) (NP (NNP Doc_12536034_162_172_Chemical))))))) (. .)))
12536034	2	(S1 (S (PP (IN Despite) (NP (DT the) (JJ underlying) (NNS diseases))) (, ,) (NP (NP (DT the) (NN prognosis)) (PP (IN for) (NP (JJ drug-induced) (JJ de) (NN novo) (NN Doc_12536034_246_261_Disease)))) (VP (AUX is) (ADJP (JJ good)) (SBAR (IN because) (S (NP (PRP it)) (VP (NNS subsides) (ADVP (RB rapidly)) (PP (IN after) (S (VP (VBG discontinuing) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT the) (VBG offending) (NNS drugs))))))))))) (. .)))
12536034	3	(S1 (S (NP (DT The) (JJ Doc_12536034_354_377_Chemical-transmitted) (JJ thalamocortical) (NN circuitry)) (VP (VBZ accounts) (PP (IN for) (NP (NP (DT a) (JJ major) (NN part)) (PP (IN of) (NP (NP (DT the) (JJ underlying) (NN neurophysiology)) (PP (IN of) (NP (DT the) (NNP Doc_12536034_483_499_Disease)))))))) (. .)))
12536034	4	(S1 (S (SBAR (IN Because) (S (NP (JJ drug-induced) (JJ de) (NN novo) (NN Doc_12536034_530_545_Disease)) (VP (AUX is) (ADJP (JJ rare))))) (, ,) (NP (JJ pro-absence) (NNS drugs)) (VP (MD can) (ADVP (RB only)) (VP (AUX be) (VP (VBN considered) (NP (DT a) (VBG promoting) (NN factor))))) (. .)))
12536034	5	(S1 (S (NP (NP (NP (DT The) (JJ underlying) (NN epileptogenecity)) (PP (IN of) (NP (DT the) (NNS patients)))) (CC or) (NP (NP (DT the) (JJ synergistic) (NNS effects)) (PP (IN of) (NP (DT the) (JJ accompanying) (NNS drugs))))) (VP (AUX is) (VP (VBN required) (S (VP (TO to) (VP (VB trigger) (NP (DT the) (JJ de) (NN novo) (NN Doc_12536034_752_767_Disease))))))) (. .)))
12536034	6	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (JJ drug-induced) (NN aggravation)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB whenever)) (S (NP (NP (DT an) (JJ unexpected) (NN increase)) (PP (IN in) (NP (NNP Doc_12536034_869_876_Disease) (NN frequency) (NN and/or) (JJ new) (NN Doc_12536034_898_905_Disease) (NNS types)))) (VP (VBP appear) (PP (VBG following) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NN drug) (NN treatment))))))))))) (. .)))
12536034	7	(S1 (S (PP (IN By) (S (VP (VBG understanding) (NP (NP (DT the) (JJ underlying) (NN mechanism)) (PP (IN of) (NP (NNP Doc_12536034_1002_1018_Disease))))))) (, ,) (NP (PRP we)) (VP (MD can) (VP (VP (VB avoid) (NP (NP (DT the) (JJ inappropriate) (NN use)) (PP (IN of) (NP (NNS anticonvulsants))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_12536034_1091_1099_Disease))))))) (CC and) (VP (VB prevent) (NP (JJ drug-induced) (NN Doc_12536034_1125_1141_Disease))))) (. .)))
12574103	0	(S1 (NP (NP (JJ Prenatal) (JJ Doc_12574103_9_22_Chemical) (NNS programs)) (NP (NP (NP (NNP Doc_12574103_32_44_Disease)) (CC and) (NP (NNP Doc_12574103_49_61_Disease))) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
12574103	1	(S1 (S (NP (NN Dexamethasone)) (VP (AUX is) (ADVP (RB frequently)) (VP (VBN administered) (PP (TO to) (NP (NP (DT the) (VBG developing) (NN fetus)) (SBAR (S (VP (TO to) (VP (VB accelerate) (NP (JJ pulmonary) (NN development)))))))))) (. .)))
12574103	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (JJ prenatal) (NNP Doc_12574103_238_251_Chemical)) (VP (VBN programmed) (NP (NP (DT a) (JJ progressive) (NN Doc_12574103_277_303_Disease)) (CC and) (NP (NP (NNP Doc_12574103_308_320_Disease)) (PP (IN in) (NP (NNS rats)))))))))))) (. .)))
12574103	3	(S1 (S (NP (JJ Pregnant) (NNS rats)) (VP (AUX were) (VP (VBN given) (NP (DT either) (NN vehicle) (CC or) (NP (NP (CD 2) (JJ daily) (JJ intraperitoneal) (NNS injections)) (PP (IN of) (NP (NP (NNP Doc_12574103_411_424_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.2) (CD mg/kg)) (NN body) (NN weight)) (-RRB- -RRB-)))) (PP (IN on) (NP (JJ gestational) (NNS days) (CD 11) (CC and) (CD 12) (, ,) (CD 13) (CC and) (CD 14) (, ,) (CD 15) (CC and) (CD 16) (, ,) (CD 17) (CC and) (CD 18)))) (, ,) (CC or) (NP (CD 19) (CC and) (CD 20))))) (. .)))
12574103	4	(S1 (S (NP (NP (NN Offspring)) (PP (IN of) (NP (NNS rats)))) (VP (VBN administered) (NP (NNP Doc_12574103_558_571_Chemical)) (PP (IN on) (NP (NP (NNS days)) (SBAR (S (NP (QP (CD 15) (CC and) (CD 16)) (NN gestation)) (VP (AUX had) (NP (NP (DT a) (ADJP (CD 20) (NN %)) (NN Doc_12574103_610_640_Disease)) (PP (VBN compared) (PP (IN with) (NP (NP (NN control)) (PP (IN at) (NP (NP (QP (CD 6) (TO to) (CD 9)) (NNS months)) (PP (IN of) (NP (NN age))) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 22) (CD 527+/-509))) (CC versus) (NP (QP (CD 28) (CD 050+/-561)))) (, ,) (NP (NNP P<0.05))) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT the) (NN percent) (NN reduction)) (PP (IN in) (NP (NP (NNS glomeruli)) (VP (VBN measured) (PP (IN at) (NP (NP (CD 3) (NNS weeks)) (PP (IN of) (NP (NN age)))))))))))))))))))))))))) (. .)))
12574103	5	(S1 (S (NP (NP (NNS Six-)) (PP (TO to) (NP (NP (JJ 9-month) (JJ old) (NNS rats)) (VP (VBG receiving) (NP (JJ prenatal) (NNP Doc_12574103_862_875_Chemical)) (PP (IN on) (NP (NP (NNS days) (CD 17) (CC and) (CD 18)) (PP (IN of) (NP (NN gestation))))))))) (VP (AUX had) (NP (NP (DT a) (ADJP (CD 17) (NN %)) (NN reduction)) (PP (IN in) (NP (NP (NNS glomeruli)) (PRN (-LRB- -LRB-) (NP (CD 23) (CD 380+/-587)) (-RRB- -RRB-))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)))))) (. .)))
12574103	6	(S1 (S (S (NP (NP (NP (JJ Male) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (JJ prenatal) (NNP Doc_12574103_1025_1038_Chemical)) (PP (IN on) (NP (NNS days) (CD 15) (CC and) (CD 16) (, ,) (CD 17) (CC and) (CD 18))))))) (, ,) (CC and) (NP (NP (CD 13) (CC and) (CD 14)) (PP (IN of) (NP (NN gestation))))) (VP (AUX had) (NP (NNP Doc_12574103_1100_1124_Disease)) (PP (IN at) (NP (NP (CD 6) (NNS months)) (PP (IN of) (NP (NN age))))))) (: ;) (S (NP (DT the) (JJ latter) (NN group)) (VP (AUX did) (RB not) (VP (AUX have) (NP (DT a) (NNP Doc_12574103_1177_1207_Disease))))) (. .)))
12574103	7	(S1 (S (NP (NP (NN Adult) (NNS rats)) (VP (VBN given) (NP (NNP Doc_12574103_1226_1239_Chemical)) (PP (IN on) (NP (NP (NNS days) (CD 15) (CC and) (CD 16)) (PP (IN of) (NP (NN gestation))))))) (VP (AUX had) (ADJP (ADJP (RBR more) (JJ glomeruli)) (PP (IN with) (NP (NNP Doc_12574103_1295_1313_Disease))) (PP (IN than) (NP (NN control) (NNS rats))))) (. .)))
12574103	8	(S1 (S (NP (DT This) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (JJ prenatal) (NN Doc_12574103_1364_1377_Chemical)) (PP (IN in) (NP (NNS rats)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (NNP Doc_12574103_1399_1429_Disease)) (, ,) (NP (NNP Doc_12574103_1431_1449_Disease)) (, ,) (CC and) (NP (NNP Doc_12574103_1455_1467_Disease)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN at) (NP (NP (JJ specific) (NNS points)) (PP (IN during) (NP (NN gestation)))))))))))) (. .)))
12574103	9	(S1 (S (NP (NN Doc_12574103_1523_1535_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (NP (NP (DT a) (NN reduction)) (PP (PP (IN in) (NP (NNS glomeruli))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (DT a) (NN group)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (AUX have) (NP (DT a) (NN Doc_12574103_1636_1666_Disease)))))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT a) (NN Doc_12574103_1686_1716_Disease)) (VP (AUX is) (RB not) (NP (NP (DT the) (JJ sole) (NN cause)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_12574103_1762_1774_Disease)))))))))))))))))) (. .)))
12584269	0	(S1 (NP (NP (NP (NN Kidney) (NN function)) (CC and) (NP (NN morphology))) (PP (IN after) (NP (NP (JJ short-term) (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_12584269_73_87_Chemical)) (, ,) (NP (NNP Doc_12584269_89_99_Chemical)) (CC and) (NP (NNP Doc_12584269_104_113_Chemical)))) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
12584269	1	(S1 (S (NP (NP (NNP Doc_12584269_138_147_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12584269_149_152_Chemical)) (-RRB- -RRB-))) (VP (MD may) (VP (VB supplement) (NP (NN calcineurin) (NNS inhibitors)) (PP (IN in) (NP (JJ clinical) (NN organ) (NN transplantation))))) (. .)))
12584269	2	(S1 (S (S (NP (DT These)) (VP (AUX are) (ADJP (JJ Doc_12584269_237_248_Disease)))) (, ,) (CC but) (S (NP (NNP Doc_12584269_254_257_Chemical)) (VP (VBZ seems) (S (VP (TO to) (VP (VB act) (ADVP (RB differently)) (S (VP (VBG displaying) (NP (ADJP (RB only) (JJ minor)) (JJ Doc_12584269_305_316_Disease) (NNS effects))))))) (, ,) (SBAR (IN although) (S (NP (DT this) (NN question)) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ open))))))) (. .)))
12584269	3	(S1 (S (PP (IN In) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NN treatment) (NNS protocols))) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_12584269_405_408_Chemical)) (VP (AUX was) (VP (VBN combined) (PP (IN with) (NP (DT a) (JJ calcineurin) (NN inhibitor))))))))) (NP (NP (NNS indications)) (PP (IN of) (NP (DT a) (JJ synergistic) (NN Doc_12584269_480_491_Disease) (NN effect)))) (VP (AUX were) (VP (VBN described))) (. .)))
12584269	4	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (ADVP (RB further)) (NP (NP (DT the) (JJ renal) (NN function)) (, ,) (PP (VBG including) (NP (NP (JJ morphological) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NNS kidneys)) (PP (IN of) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT either) (NNP Doc_12584269_676_690_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12584269_692_695_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_12584269_698_708_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12584269_710_715_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_12584269_720_723_Chemical)))) (PP (PP (IN as) (NP (NNS monotherapies))) (CC or) (PP (IN in) (NP (JJ different) (NNS combinations)))))))))))))))) (. .)))
12584269	5	(S1 (S (PP (IN For) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 2) (NNS weeks))))) (, ,) (NP (NP (NNP Doc_12584269_805_808_Chemical) (CD 15) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (VP (VBN given) (ADVP (RB orally))) (-RRB- -RRB-)) (, ,) (NP (NP (NNP Doc_12584269_838_843_Chemical) (CD 3.0) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (VP (VBN given) (ADVP (RB orally))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_12584269_876_879_Chemical) (CD 0.4) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (VP (VBN given) (ADVP (RB intraperitoneally))) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN administered) (PP (IN once) (NP (DT a) (NN day))) (SBAR (IN as) (S (NP (DT these) (NNS doses)) (VP (AUX have) (ADVP (RB earlier)) (VP (AUX been) (VP (VBN found) (S (VP (TO to) (VP (VB achieve) (NP (NP (DT a) (JJ significant) (JJ immunosuppressive) (NN effect)) (PP (IN in) (NP (NNP Sprague-Dawley) (NNS rats)))))))))))))) (. .)))
12584269	6	(S1 (S (PP (IN In) (NP (DT the))) (: ') (NP (JJ conscious) (JJ catheterized) (NN rat) ('' ') (NN model)) (, ,) (NP (NP (DT the) (JJ glomerular) (NN filtration) (NN rate)) (PRN (-LRB- -LRB-) (NP (NN GFR)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN measured) (PP (IN as) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NNP Cr)) (PRN (-LRB- -LRB-) (NP (NNP EDTA)) (-RRB- -RRB-)))))))) (. .)))
12584269	7	(S1 (S (NP (NP (DT The) (JJ morphological) (NN analysis)) (PP (IN of) (NP (DT the) (NNS kidneys)))) (VP (VBD included) (NP (NP (DT a) (JJ semi-quantitative) (NN scoring) (NN system)) (VP (VBG analysing) (NP (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (JJ striped) (NNP Doc_12584269_1302_1310_Disease)) (, ,) (NP (JJ subcapsular) (NNP Doc_12584269_1324_1332_Disease)) (CC and) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ basophilic) (NNS tubules))))))) (, ,) (CC plus) (NP (NP (DT an) (JJ additional) (JJ stereological) (NN analysis)) (PP (IN of) (NP (NP (DT the) (JJ total) (NN grade)) (PP (IN of) (NP (NNP Doc_12584269_1435_1443_Disease))))))) (PP (IN in) (NP (NP (DT the) (NN cortex)) (VP (VBN stained) (PP (IN with) (NP (NNP Sirius) (NNP Red))))))))) (. .)))
12584269	8	(S1 (S (NP (NP (NNP Doc_12584269_1492_1495_Chemical)) (, ,) (NP (NNP Doc_12584269_1497_1502_Chemical)) (CC and) (NP (NNP Doc_12584269_1507_1510_Chemical))) (VP (ADVP (DT all) (RB significantly)) (VBD decreased) (NP (DT the) (NN GFR))) (. .)))
12584269	9	(S1 (S (NP (DT A) (JJ further) (NN deterioration)) (VP (AUX was) (VP (VBN seen) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_12584269_1586_1589_Chemical)) (VP (AUX was) (VP (VBN combined) (PP (IN with) (NP (DT either) (NNP Doc_12584269_1615_1620_Chemical) (CC or) (NNP Doc_12584269_1624_1627_Chemical))))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (NN GFR)) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_12584269_1690_1695_Chemical)) (CC plus) (NP (NNP Doc_12584269_1701_1704_Chemical))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NN treatment))) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ single) (NNS substances))))))))))))) (. .)))
12584269	10	(S1 (S (NP (DT The) (JJ morphological) (NNS changes)) (VP (VBD presented) (NP (DT a) (JJ similar) (NN pattern))) (. .)))
12584269	11	(S1 (S (S (NP (DT The) (JJ semi-quantitative) (NN scoring)) (VP (AUX was) (ADJP (RB significantly) (JJS worst)) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_12584269_1904_1907_Chemical) (CC plus) (NNP Doc_12584269_1913_1916_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP P<0.001)) (VP (VBN compared) (PP (IN with) (NP (NNS controls))))) (-RRB- -RRB-))))))))) (CC and) (S (NP (NP (DT the) (NN analysis)) (PP (IN of) (NP (NP (DT the) (JJ total) (NN grade)) (PP (IN of) (NP (NNP Doc_12584269_1989_1997_Disease)))))) (ADVP (RB also)) (VP (VP (VBD showed) (NP (DT the) (JJS highest) (NN proportion)) (PP (IN in) (NP (DT the) (JJ same) (NN group)))) (CC and) (VP (AUX was) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P<0.02)) (-RRB- -RRB-)))))))) (. .)))
12584269	12	(S1 (S (NP (DT The) (NNP Doc_12584269_2111_2116_Chemical) (CC plus) (NNP Doc_12584269_2122_2125_Chemical) (NN combination)) (VP (VBD showed) (NP (NP (RB only) (DT a) (ADJP (RB marginally) (JJR higher)) (NN degree)) (PP (IN of) (NP (NNP Doc_12584269_2180_2188_Disease)))) (ADVP (RB as)) (PP (VBN compared) (PP (IN with) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP P=0.05)) (-RRB- -RRB-)))))) (. .)))
12584269	13	(S1 (S (NP (DT This) (NN rat) (NN study)) (VP (VBD demonstrated) (NP (NP (DT a) (JJ synergistic) (JJ Doc_12584269_2279_2290_Disease) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_12584269_2301_2304_Chemical)) (CC plus) (NP (NNP Doc_12584269_2310_2313_Chemical))))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_12584269_2323_2328_Chemical) (CC plus) (NNP Doc_12584269_2334_2337_Chemical)) (VP (AUX was) (ADVP (RB better)) (VP (VBN tolerated)))))) (. .)))
12589964	0	(S1 (NP (NP (NP (NN Evaluation)) (PP (IN of) (NP (NP (JJ cardiac) (NN troponin) (NN I) (CC and) (NN T) (NNS levels)) (PP (IN as) (NP (NP (NNS markers)) (PP (IN of) (NP (NNP Doc_12589964_60_77_Disease))))) (PP (IN in) (NP (JJ Doc_12589964_81_92_Chemical-induced) (NNP Doc_12589964_101_115_Disease) (NNS rats)))))) (, ,) (CC and) (NP (NP (PRP$ their) (NN relationship)) (PP (IN with) (NP (JJ echocardiographic) (CC and) (JJ histological) (NNS findings)))) (. .)))
12589964	1	(S1 (S (NP (NP (NP (NP (JJ Cardiac) (NNS troponins)) (NP (PRP I))) (PRN (-LRB- -LRB-) (NNS cTnI) (-RRB- -RRB-))) (CC and) (NP (NP (NNS T)) (PRN (-LRB- -LRB-) (NP (NN cTnT)) (-RRB- -RRB-)))) (VP (AUX have) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (UCP (ADJP (RB highly) (JJ sensitive)) (CC and) (NP (NP (JJ specific) (NNS markers)) (PP (IN of) (NP (NNP Doc_12589964_310_332_Disease))))))))))) (. .)))
12589964	2	(S1 (S (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (JJ diagnostic) (NN value)) (PP (IN of) (NP (NN cTnI) (CC and) (NN cTnT)))) (PP (IN for) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_12589964_409_426_Disease))))) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NNP Doc_12589964_445_456_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12589964_458_461_Chemical)) (-RRB- -RRB-)))))) (NP (JJ -induced) (NNP Doc_12589964_471_485_Disease)))) (, ,) (CC and) (S (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (JJ serial) (NNS cTnI)) (CC and) (NP (NN cTnT)))) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_12589964_573_590_Disease))) (VP (VBN monitored) (PP (IN by) (NP (NP (JJ echocardiography) (CC and) (JJ histological) (NNS examinations)) (PP (IN in) (NP (DT this) (NN model))))))))))) (. .)))
12589964	3	(S1 (S (NP (JJ Thirty-five) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VBN given) (NP (NP (CD 1.5) (NN mg/kg)) (ADJP (JJ Doc_12589964_720_723_Chemical) (, ,) (JJ i.v.) (, ,) (JJ weekly))) (PP (IN for) (NP (QP (IN up) (TO to) (CD 8)) (NNS weeks))) (PP (IN for) (NP (NP (DT a) (JJ total) (JJ cumulative) (NN dose)) (PP (IN of) (NP (CD 12) (JJ mg/kg) (NNS BW))))))) (. .)))
12589964	4	(S1 (S (NP (CD Ten) (NNS rats)) (VP (VBD received) (NP (NN saline)) (PP (IN as) (NP (DT a) (NN control) (NN group)))) (. .)))
12589964	5	(S1 (S (NP (NNP cTnI)) (VP (AUX was) (VP (VBN measured) (PP (PP (IN with) (NP (NP (NP (NN Access)) (PRN (-LRB- -LRB-) (NP (NN R)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NN ng/ml)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (NN research) (NN immunoassay)) (PRN (-LRB- -LRB-) (NP (NN pg/ml)) (-RRB- -RRB-))))) (, ,) (CC and) (PP (VBN compared) (PP (IN with) (NP (JJ cTnT) (, ,) (JJ CK-MB) (NN mass) (CC and) (NN CK))))))) (. .)))
12589964	6	(S1 (S (PP (IN By) (S (VP (VBG using) (NP (JJ transthoracic) (NN echocardiography))))) (, ,) (NP (NP (NNP anterior)) (CC and) (NP (NP (NP (NN posterior) (NN wall) (NN thickness)) (, ,) (NP (JJ LV) (NNS diameters)) (CC and) (NP (JJ LV) (JJ fractional) (NN shortening))) (PRN (-LRB- -LRB-) (NP (NNP FS)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (DT all) (NNS rats))) (SBAR (IN before) (S (UCP (ADJP (JJ Doc_12589964_1125_1128_Chemical) (CC or) (JJ saline)) (, ,) (CC and) (PP (IN at) (NP (NP (NNS weeks) (CD 6) (CC and) (CD 9)) (PP (IN after) (NP (NP (NN treatment)) (PP (IN in) (NP (DT all) (VBG surviving) (NNS rats)))))))))))) (. .)))
12589964	7	(S1 (S (NP (NN Histology)) (VP (AUX was) (VP (VBN performed) (PP (IN in) (NP (NNP Doc_12589964_1227_1230_Chemical-rats))) (PP (IN at) (NP (NP (QP (CD 6) (CC and) (CD 9)) (NNS weeks)) (PP (PP (IN after) (NP (DT the) (JJ last) (JJ Doc_12589964_1268_1271_Chemical) (NN dose))) (CC and) (PP (IN in) (NP (DT all) (NNS controls)))))))) (. .)))
12589964	8	(S1 (S (NP (NP (CD Eighteen)) (PP (IN of) (NP (DT the) (JJ Doc_12589964_1323_1326_Chemical) (NNS rats)))) (VP (VBD died) (ADVP (RB prematurely)) (PP (IN of) (NP (JJ general) (NN Doc_12589964_1360_1368_Disease))) (PP (IN during) (NP (DT the) (JJ 9-week) (NN period)))) (. .)))
12589964	9	(S1 (S (NP (ADJP (ADJP (JJ End-diastolic)) (PRN (-LRB- -LRB-) (NP (NNP ED)) (-RRB- -RRB-)) (CC and) (ADJP (JJ end-systolic)) (PRN (-LRB- -LRB-) (JJ ES) (-RRB- -RRB-))) (NN LV) (NNS diameters/BW)) (VP (ADVP (RB significantly)) (VBD increased) (, ,) (SBAR (IN whereas) (S (NP (NNP LV) (NNP FS)) (VP (AUX was) (VP (VBN decreased) (PP (IN after) (NP (NP (NP (CD 9) (NNS weeks)) (PP (IN in) (NP (DT the) (NNP Doc_12589964_1526_1529_Chemical) (NN group)))) (PRN (-LRB- -LRB-) (NP (CD p<0.001)) (-RRB- -RRB-))))))))) (. .)))
12589964	10	(S1 (S (NP (DT These) (NNS parameters)) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (NNS controls)))) (. .)))
12589964	11	(S1 (S (NP (NP (JJ Histological) (NN evaluation)) (PP (IN of) (NP (NP (NNS hearts)) (PP (IN from) (NP (NP (DT all) (NNS rats)) (VP (VBN given) (NP (NNP Doc_12589964_1650_1653_Chemical)))))))) (VP (VBD revealed) (NP (NP (JJ significant) (JJ slight) (NNS degrees)) (PP (IN of) (NP (NP (NN perivascular)) (CC and) (NP (JJ interstitial) (NN Doc_12589964_1723_1731_Disease)))))) (. .)))
12589964	12	(S1 (S (PP (IN In) (NP (NP (CD 7)) (PP (IN of) (NP (DT the) (CD 18) (NNS rats))))) (, ,) (NP (NP (NN degeneration)) (CC and) (NP (NN myocyte) (NN vacuolisation))) (VP (AUX were) (VP (VBN found))) (. .)))
12589964	13	(S1 (S (NP (NP (RB Only) (CD five)) (PP (IN of) (NP (DT the) (NNS controls)))) (VP (VBD exhibited) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ very) (JJ slight) (NN perivascular) (NN Doc_12589964_1878_1886_Disease))))) (. .)))
12589964	14	(S1 (S (NP (NP (DT A) (JJ significant) (NN rise)) (PP (IN in) (NP (NN cTnT)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (JJ Doc_12589964_1928_1931_Chemical) (NNS rats))) (PP (IN after) (NP (NP (JJ cumulative) (NNS doses)) (PP (IN of) (NP (CD 7.5) (CC and) (CD 12))) (VP (VBN mg/kg) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (NN baseline)) (PRN (-LRB- -LRB-) (NP (CD p<0.05)) (-RRB- -RRB-))))))))))) (. .)))
12589964	15	(S1 (S (NP (NN cTnT)) (VP (VBD found) (PP (IN in) (NP (NNS rats))) (SBAR (IN after) (S (NP (CD 12) (NNS mg/kg)) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR greater)) (PP (IN than) (NP (NP (DT that)) (VP (VBN found) (PP (IN after) (NP (QP (CD 7.5) (CD mg/kg)) (NN Doc_12589964_2111_2114_Chemical))))))))))) (. .)))
12589964	16	(S1 (S (NP (NP (NP (JJ Maximal) (NNS cTnI)) (PRN (-LRB- -LRB-) (NP (NN pg/ml)) (-RRB- -RRB-))) (CC and) (NP (JJ cTnT) (NNS levels))) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (JJ Doc_12589964_2185_2188_Chemical) (NNS rats))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD p=0.006)) (, ,) (NP (CD 0.007)) (-RRB- -RRB-))))))) (. .)))
12589964	17	(S1 (S (NP (NP (NP (NNP cTnI)) (PRN (-LRB- -LRB-) (NP (NNP ng/ml)) (-RRB- -RRB-))) (, ,) (NP (NN CK-MB) (NN mass)) (CC and) (NP (NNP CK))) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (NP (JJ Doc_12589964_2289_2292_Chemical) (NNS rats)) (PP (VBN compared) (PP (IN with) (NP (NNS controls))))))) (. .)))
12589964	18	(S1 (S (NP (DT All) (NNS markers)) (VP (VBD remained) (ADJP (JJ stable)) (PP (IN in) (NP (NNS controls)))) (. .)))
12589964	19	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NNS data)))) (VP (VBD revealed) (NP (NP (DT a) (JJ significant) (NN correlation)) (PP (IN between) (NP (NP (JJ maximal) (NN cTnT)) (CC and) (NP (NP (NNP ED) (CC and) (NNP ES) (NNP LV) (NNS diameters/BW)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD r=0.81)) (CC and) (NP (CD 0.65))) (: ;) (NP (CD p<0.0001))) (-RRB- -RRB-))))))) (. .)))
12589964	20	(S1 (S (NP (DT A) (JJ significant) (NN relationship)) (VP (AUX was) (VP (VBN observed) (PP (PP (IN between) (NP (NP (JJ maximal) (NN cTnT)) (CC and) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ myocardial) (JJ morphological) (NNS changes)))))) (, ,) (CC and) (PP (IN between) (NP (NP (JJ LV) (NNS diameters/BW)) (CC and) (NP (JJ histological) (NNS findings))))))) (. .)))
12589964	21	(S1 (S (PP (IN Among) (NP (NP (NNS markers)) (PP (IN of) (NP (NNP Doc_12589964_2693_2708_Disease))))) (PP (IN after) (NP (NP (NNP Doc_12589964_2715_2718_Chemical)) (PP (IN in) (NP (NNS rats))))) (, ,) (NP (NN cTnT)) (VP (VBD showed) (NP (NP (DT the) (JJS greatest) (NN ability)) (SBAR (S (VP (TO to) (VP (VB detect) (NP (NP (NN Doc_12589964_2771_2788_Disease)) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ echocardiographic) (NN detection)) (CC and) (NP (JJ histological) (NNS changes)))))))))))) (. .)))
12589964	22	(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN discrepancy)) (PP (IN between) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NN cTnI) (CC and) (NN cTnT)))))) (PP (IN after) (NP (NNP Doc_12589964_2930_2933_Chemical))) (, ,) (PP (ADVP (RB probably)) (JJ due) (PP (TO to) (NP (NP (NN heterogeneity)) (PP (IN in) (NP (NP (NNS cross-reactivities)) (PP (IN of) (NP (NP (NNS mAbs)) (PP (TO to) (NP (JJ various) (NNS cTnI) (CC and) (NN cTnT) (NNS forms))))))))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ likely) (SBAR (SBAR (IN that) (S (NP (NP (NN cTnT)) (PP (IN in) (NP (NNS rats))) (PP (IN after) (NP (NNP Doc_12589964_3064_3067_Chemical)))) (VP (VBZ indicates) (S (NP (NP (NN cell) (NN damage)) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (NN injury))))))) (VP (VBN induced)))))) (CC and) (SBAR (IN that) (S (NP (NN cTnT)) (VP (MD should) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN marker)) (PP (PP (IN for) (NP (NP (DT the) (NN prediction)) (PP (IN of) (NP (ADJP (RB experimentally) (VBN induced)) (NNP Doc_12589964_3221_3235_Disease))))) (CC and) (PP (ADVP (RB possibly)) (IN for) (NP (JJ cardioprotective) (NNS experiments)))))))))))) (. .)))
12596116	0	(S1 (NP (NP (NP (JJ Doc_12596116_0_10_Chemical-induced) (NN Doc_12596116_19_28_Disease)) (CC and) (NP (NNP Doc_12596116_33_55_Disease))) (PP (IN in) (NP (JJ premature) (NNS neonates))) (. .)))
12596116	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP report) (NP (NP (CD 2) (NNS cases)) (PP (IN of) (NP (NP (JJ premature) (NNS neonates)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (JJ enterocutaneous) (JJ Doc_12596116_152_159_Disease) (NN complicating) (NN Doc_12596116_173_198_Disease))))))))) (. .)))
12596116	2	(S1 (S (NP (NN Doc_12596116_200_222_Disease)) (VP (VBD developed) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT a) (NN somatostatin) (NN analogue)) (, ,) (NP (NNP Doc_12596116_282_292_Chemical)) (, ,))))) (S (VP (TO to) (VP (VB enhance) (NP (NP (NN resolution)) (PP (IN of) (NP (DT the) (NNP Doc_12596116_323_330_Disease)))))))) (. .)))
12596116	3	(S1 (S (NP (DT The) (NNS authors)) (VP (VP (VB discuss) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (DT this) (NN complication))))))) (CC and) (VP (VB recommend) (NP (NP (NN caution)) (PP (IN of) (NP (NP (PRP$ its) (NN use)) (PP (IN in) (NP (JJ high-risk) (JJ premature) (NNS neonates)))))))) (. .)))
12615818	0	(S1 (NP (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_12615818_12_34_Disease))) (PP (IN in) (NP (NP (NNS women)) (VP (VBN prescribed) (NP (NNP Doc_12615818_55_74_Chemical)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_12615818_95_112_Chemical))))))))) (: :) (NP (NP (DT a) (JJ nested) (NN cohort) (NN analysis)) (CC and) (NP (JJ case-control) (NN study))) (. .)))
12615818	1	(S1 (S (NP (NP (NN Doc_12615818_175_194_Chemical)) (VP (VBN combined) (PP (IN with) (NP (NP (NNP Doc_12615818_209_226_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12615818_228_231_Chemical/Doc_12615818_232_234_Chemical)) (-RRB- -RRB-)))))) (VP (VP (AUX is) (VP (VBN licensed) (PP (IN in) (NP (DT the) (NNP UK))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS women)) (PP (IN with) (NP (NP (NNP Doc_12615818_290_294_Disease)) (CC and) (NP (NNP Doc_12615818_299_308_Disease)))))))))) (CC and) (VP (AUX is) (ADVP (RB also)) (NP (NP (DT a) (NN treatment) (NN option)) (PP (IN for) (NP (NP (NNP Doc_12615818_344_369_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12615818_371_375_Disease)) (-RRB- -RRB-))))))) (. .)))
12615818	2	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (AUX have) (VP (VBN demonstrated) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_12615818_434_456_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12615818_458_461_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_12615818_479_482_Chemical/Doc_12615818_483_485_Chemical))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ conventional) (JJ combined) (NNP Doc_12615818_522_541_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP COCs)) (-RRB- -RRB-))))))))) (. .)))
12615818	3	(S1 (S (NP (PRP We)) (VP (VBP believe) (SBAR (S (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (DT those) (NNS studies)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (VP (VBN affected) (PP (IN by) (NP (JJ residual) (NN confounding)))))))))) (. .)))
12615818	4	(S1 (S (S (VP (VBG Using) (NP (DT the) (JJ General) (NN Practice) (NN Research) (NN Database)))) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT a) (JJ cohort) (NN analysis) (CC and) (NN case-control) (NN study)) (VP (VBN nested) (PP (IN within) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (NP (NNS women)) (VP (VBN aged) (PP (IN between) (NP (CD 15) (CC and) (CD 39) (NNS years))) (PP (IN with) (NP (NNP Doc_12615818_816_820_Disease) (, ,) (NNP Doc_12615818_822_831_Disease) (CC or) (NNP Doc_12615818_835_839_Disease))) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_12615818_864_867_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_12615818_884_887_Chemical/Doc_12615818_888_890_Chemical)))))))))))))))) (. .)))
12615818	5	(S1 (S (NP (NP (DT The) (JJ age-adjusted) (NN incidence) (NN rate) (NN ratio)) (PP (IN for) (NP (NNP Doc_12615818_943_946_Chemical/Doc_12615818_947_949_Chemical))) (PP (IN versus) (NP (JJ conventional) (NNS COCs)))) (VP (AUX was) (NP (NP (CD 2.20) (ADJP (CD -LSB-95) (NN %)) (NN confidence) (NN interval)) (PRN (-LRB- -LRB-) (NP (NNP CI)) (-RRB- -RRB-)) (NP (CD 1.35-3.58) (NN -RSB-)))) (. .)))
12615818	6	(S1 (S (PP (VBG Using) (PP (IN as) (NP (NP (DT the) (NN reference) (NN group) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (RB not) (VP (VBG using) (NP (JJ oral) (NN contraception))))))))) (, ,) (VP (AUX had) (NP (NP (DT no) (JJ recent) (NN pregnancy)) (CC or) (NP (JJ menopausal) (NNS symptoms))) (, ,) (S (NP (DT the) (JJ case-control) (NN analysis)) (VP (VBD gave) (NP (NP (NP (DT an) (JJ adjusted) (NNS odds) (NN ratio)) (PRN (-LRB- -LRB-) (CC OR) (-LRB- -LRB-) (CD adj) (-RRB- -RRB-) (-RRB- -RRB-)) (PP (IN of) (NP (CD 7.44)))) (-LRB- -LRB-) (NP (CD 95) (NN %) (NNP CI) (CD 3.67-15.08)) (-RRB- -RRB-)) (PP (IN for) (NP (JJ Doc_12615818_1244_1247_Chemical/Doc_12615818_1248_1250_Chemical) (NN use))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (DT an)) (CC OR) (PRN (-LRB- -LRB-) (NP (NN adj)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 2.58)))))) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CI) (NN 1.60-4.18)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NN use)) (PP (IN of) (NP (JJ conventional) (NNS COCs)))))))) (. .)))
12615818	7	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN demonstrated) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_12615818_1392_1395_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12615818_1423_1426_Chemical/Doc_12615818_1427_1429_Chemical))))))) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NP (NNP Doc_12615818_1444_1448_Disease)) (, ,) (NP (NNP Doc_12615818_1450_1459_Disease)) (CC or) (NP (NNP Doc_12615818_1463_1467_Disease)))))) (SBAR (IN although) (S (NP (NP (JJ residual) (NN confounding)) (PP (IN by) (NP (NN indication) (NN cannot)))) (VP (AUX be) (VP (VBN excluded))))))) (. .)))
12617329	0	(S1 (NP (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_12617329_29_39_Chemical))) (PP (IN on) (NP (NP (NNP Doc_12617329_43_53_Chemical) (NNP Doc_12617329_54_68_Disease)) (PP (IN in) (NP (NNS rats)))))) (: :) (NP (DT a) (JJ preliminary) (NN study)) (. .)))
12617329	1	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN work))) (NP (PRP we)) (VP (VBD assessed) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_12617329_168_178_Chemical))))))) (PP (IN on) (NP (NP (NNP Doc_12617329_182_201_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_12617329_213_223_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_12617329_225_227_Chemical)) (-RRB- -RRB-)) (NNP Doc_12617329_229_243_Disease)))))))) (. .)))
12617329	2	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT the) (NN vehicle)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 2) (CD mL/kg))) (PP (IN of) (NP (JJ distilled) (NN water)))) (CC and) (NP (NP (NP (CD 5) (NN %)) (NP (CD w/v) (NN cellulose))) (, ,) (NP (CD 10) (NNS days)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_12617329_340_350_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NN mL/kg)) (PP (IN of) (NP (NP (DT a) (ADJP (CD 10) (NN %)) (JJ w/v) (JJ aqueous) (NN suspension)) (PP (IN of) (NP (NNP Doc_12617329_395_405_Chemical) (NNP powder))))) (, ,) (PP (ADVP (RB orally)) (IN for) (NP (CD 10) (NNS days)))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NNP Doc_12617329_438_448_Chemical)))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NNP Doc_12617329_468_470_Chemical))) (PRN (-LRB- -LRB-) (S (VP (VB 80mg/kg/day) (ADVP (RB intramuscularly)) (, ,) (PP (IN during) (NP (NP (DT the) (JJ last) (CD six) (NNS days)) (PP (IN of) (NP (DT the) (NN treatment) (NN period))))))) (-RRB- -RRB-)))) (. .)))
12617329	3	(S1 (S (NP (NN Doc_12617329_552_566_Disease)) (VP (AUX was) (VP (VBN assessed) (PP (PP (IN by) (S (VP (VBG measuring) (NP (NP (DT the) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_12617329_615_625_Chemical) (CC and) (NNP Doc_12617329_630_634_Chemical)) (PP (IN in) (NP (DT the) (NN plasma)))) (CC and) (NP (NP (JJ reduced) (NNP Doc_12617329_661_672_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12617329_674_677_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN kidney) (NN cortex))))))) (, ,) (CC and) (PP (IN by) (NP (NP (JJ light) (JJ microscopic) (NN examination)) (PP (IN of) (NP (NN kidney) (NNS sections)))))))) (. .)))
12617329	4	(S1 (S (NP (DT The) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NNP Doc_12617329_812_822_Chemical) (CC and) (NNP Doc_12617329_827_829_Chemical)))) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NNP Doc_12617329_854_864_Chemical) (CC and) (NNP Doc_12617329_869_873_Chemical)) (PP (IN by) (NP (NP (QP (IN about) (CD 183) (CC and) (CD 239)) (NN %)) (, ,) (ADVP (RB respectively)))) (PRN (-LRB- -LRB-) (VP (VBN compared) (PP (TO to) (NP (QP (CD 432) (CC and) (CD 346)) (NN %))) (, ,) (ADVP (RB respectively)) (, ,) (SBAR (IN in) (S (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NN cellulose)) (CC and) (NP (NNP Doc_12617329_986_988_Chemical)))))))) (-RRB- -RRB-))) (, ,) (CC and) (VP (VBD decreased) (NP (NP (DT that)) (PP (IN of) (NP (JJ cortical) (NNP Doc_12617329_1022_1025_Chemical)))) (PP (IN by) (NP (CD 21) (NN %))) (PRN (-LRB- -LRB-) (VP (VBN compared) (PP (TO to) (NP (CD 27) (NN %))) (PP (IN in) (NP (DT the) (NN cellulose) (CC plus) (JJ Doc_12617329_1072_1074_Chemical) (NN group)))) (-RRB- -RRB-)) (SBAR (S (NP (DT The) (JJ Doc_12617329_1086_1088_Chemical-induced) (JJ proximal) (NN Doc_12617329_1106_1122_Disease)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (ADJP (RB slightly) (RBR less) (JJ severe)) (PP (IN in) (NP (NP (NP (NNS rats)) (VP (VBN given) (NP (NNP Doc_12617329_1173_1175_Chemical)) (ADVP (RB together)) (PP (IN with) (NP (NNP Doc_12617329_1190_1200_Chemical))) (PP (IN than) (PP (IN in) (NP (DT those) (VBN given) (NNP Doc_12617329_1221_1223_Chemical)))))) (CC and) (NP (NN cellulose))))))))))))))) (. .)))
12617329	5	(S1 (S (NP (PRP It)) (VP (MD could) (VP (AUX be) (VP (VBN inferred) (SBAR (IN that) (S (NP (JJ Doc_12617329_1265_1275_Chemical) (NN treatment)) (VP (AUX has) (VP (VBN induced) (NP (NP (DT a) (JJ modest) (NN amelioration)) (PP (IN of) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ histological) (CC and) (JJ biochemical) (NNS indices)) (PP (IN of) (NP (NNP Doc_12617329_1375_1377_Chemical) (NNP Doc_12617329_1378_1392_Disease))))))))))))))) (. .)))
12617329	6	(S1 (S (NP (JJ Further) (NN work)) (VP (AUX is) (VP (VBN warranted) (PP (IN on) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (NNS treatments))) (PP (PP (IN on) (NP (NP (JJ renal) (JJ functional) (NNS aspects)) (PP (IN in) (NP (NP (NNS models)) (PP (IN of) (NP (NNP Doc_12617329_1493_1514_Disease))))))) (, ,) (CC and) (PP (IN on) (NP (NP (DT the) (NN mechanism)) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-)) (VP (VBN involved))))))))) (. .)))
12627929	0	(S1 (NP (NP (VBN Increased) (NN frequency)) (PP (IN of) (NP (NNP Doc_12627929_23_45_Disease))) (PP (IN with) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_12627929_70_79_Chemical) (CC and) (NNP Doc_12627929_84_95_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ metastatic) (JJ androgen-independent) (NN Doc_12627929_145_160_Disease))))))))) (. .)))
12627929	1	(S1 (NP (NN STUDY) (NN OBJECTIVE) (: :) (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NP (NNP Doc_12627929_208_230_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12627929_232_235_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ advanced) (JJ androgen-independent) (NN Doc_12627929_284_299_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_12627929_322_331_Chemical)) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_12627929_361_372_Chemical))))))))))))))))) (. .)))
12627929	2	(S1 (NP (NP (NN Retrospective) (NN analysis)) (PP (IN of) (NP (DT a) (VBN randomized) (NN phase) (NNP II) (NN trial))) (. .)))
12627929	3	(S1 (NP (NP (NNP National) (NNPS Institutes)) (PP (IN of) (NP (NNP Health) (JJ clinical) (NN research) (NN center))) (. .)))
12627929	4	(S1 (NP (NP (CD Seventy) (NNS men)) (, ,) (VP (VBN aged) (NP (CD 50-80) (NNS years))) (, ,) (PP (IN with) (NP (JJ advanced) (JJ androgen-independent) (NN Doc_12627929_578_593_Disease))) (. .)))
12627929	5	(S1 (S (NP (DT Each) (NN patient)) (VP (VBD received) (NP (DT either) (JJ intravenous) (JJ Doc_12627929_650_659_Chemical) (CD 30) (NN mg/m2/week)) (PP (IN for) (NP (CD 3) (JJ consecutive) (NNS weeks))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (NP (CD 1) (NN week)) (ADJP (RB off))) (, ,) (CC or) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (JJ continuous) (JJ oral) (NNP Doc_12627929_761_772_Chemical) (CD 200) (NNS mg)))))) (NP (NP (DT every) (NN evening)) (PP (CC plus) (NP (DT the) (JJ same) (JJ Doc_12627929_808_817_Chemical) (NN regimen))))))) (. .)))
12627929	6	(S1 (S (NP (DT This) (JJ 4-week) (NN cycle)) (VP (AUX was) (VP (VBN repeated) (SBAR (IN until) (S (NP (EX there)) (VP (AUX was) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (JJ excessive) (NN Doc_12627929_896_904_Disease)) (CC or) (NP (NN disease) (NN progression)))))))))) (. .)))
12627929	7	(S1 (NP (NP (NP (NNS MEASUREMENTS)) (CC AND) (NP (JJ MAIN) (NNS RESULTS))) (: :) (NP (NP (NN None)) (PP (IN of) (NP (NP (CD 23) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (SBAR (S (NP (NNP Doc_12627929_993_1002_Chemical)) (ADVP (RB alone)) (VP (VBD developed) (NP (NNP Doc_12627929_1019_1022_Disease)) (, ,) (SBAR (IN whereas) (S (NP (NP (CD 9)) (PP (IN of) (NP (NP (NP (CD 47) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 19) (NN %)) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (NNP Doc_12627929_1068_1077_Chemical)) (CC plus) (NP (NNP Doc_12627929_1083_1094_Chemical))))))))) (VP (VBD developed) (NP (NP (NNP Doc_12627929_1105_1108_Disease)) (PRN (-LRB- -LRB-) (NP (CD p=0.025)) (-RRB- -RRB-))))))))))))))) (. .)))
12627929	8	(S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NNP Doc_12627929_1148_1159_Chemical))) (PP (TO to) (NP (NNP Doc_12627929_1163_1172_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_12627929_1193_1208_Disease)))))) (ADVP (RB significantly)) (VP (VBZ increases) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_12627929_1250_1253_Disease))))) (. .)))
12627929	9	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (JJ potential) (NN complication)))) (SBAR (WHADVP (WRB when)) (S (VP (VBG adding) (NP (NN Doc_12627929_1325_1336_Chemical)) (PP (TO to) (NP (JJ chemotherapeutic) (NNS regimens)))))))) (. .)))
12639165	0	(S1 (NP (JJ Doc_12639165_0_11_Chemical-induced) (NN Doc_12639165_20_41_Disease) (. .)))
12639165	1	(S1 (FRAG (S (VP (TO To) (VP (VP (VB report) (NP (NP (CD 2) (NNS cases)) (PP (IN of) (NP (NNP Doc_12639165_75_86_Chemical-induced) (NNP Doc_12639165_95_116_Disease))))) (, ,) (VP (VB investigate) (NP (PRP$ its) (NN mechanism))) (, ,) (CC and) (VP (VB compare) (NP (NP (DT the) (JJ observed) (JJ main) (NNS characteristics)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (VBN published) (NNS cases)))))))))) (. .)))
12639165	2	(S1 (NP (NP (NN CASE) (NNS SUMMARIES)) (: :) (NP (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (JJ prolonged) (NNP Doc_12639165_275_296_Disease)) (PP (IN after) (S (VP (VBG receiving) (NP (NNP Doc_12639165_313_324_Chemical)) (PP (VBG following) (NP (JJ percutaneous) (JJ coronary) (NN angioplasty)))))) (, ,) (PP (IN with) (NP (JJ complete) (NN remission))) (PP (IN during) (NP (DT the) (JJ follow-up) (NN period))))) (. .)))
12639165	3	(S1 (S (NP (NP (JJ T-cell) (NN stimulation)) (PP (IN by) (NP (NP (JJ therapeutic) (NN concentration)) (PP (IN of) (NP (NNP Doc_12639165_474_485_Chemical)))))) (VP (AUX was) (VP (VBN demonstrated) (PP (IN in) (NP (NN vitro))) (PP (IN in) (NP (DT the) (NNS patients))) (, ,) (FRAG (CC but) (RB not) (PP (IN in) (NP (JJ healthy) (NNS controls)))))) (. .)))
12639165	4	(S1 (S (S (NP (NN Doc_12639165_570_591_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (PP (IN of) (NP (DT the) (JJ antiplatelet) (NN agent) (NN Doc_12639165_641_652_Chemical)))))) (: ;) (S (NP (JJ several) (NNS cases)) (VP (AUX have) (VP (AUX been) (VP (VP (VBN reported)) (CC but) (VP (ADJP (JJ few)) (PP (IN in) (NP (DT the) (JJ English) (NN literature)))))))) (. .)))
12639165	5	(S1 (S (NP (PRP$ Our) (NNS patients)) (VP (VP (VBD developed) (NP (NP (NNP Doc_12639165_745_753_Disease) (JJ following) (NN treatment)) (PP (IN with) (NP (NNP Doc_12639165_779_790_Chemical))))) (CC and) (VP (VBD showed) (NP (NP (DT the) (JJ clinical) (CC and) (NN laboratory) (NNS characteristics)) (PP (IN of) (NP (NP (NNP Doc_12639165_849_870_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug))))))))))))) (. .)))
12639165	6	(S1 (S (S (NP (NN Doc_12639165_922_931_Disease)) (VP (VP (MD may) (VP (VB develop) (NP (NP (NNS weeks)) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))))) (CC and) (VP (MD may) (VP (VB run) (NP (DT a) (JJ prolonged) (NN course)))))) (, ,) (CC but) (S (NP (JJ complete) (NN remission)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (DT all) (JJ reported) (NNS cases)))))) (. .)))
12639165	7	(S1 (S (NP (DT An) (JJ objective) (NN causality) (NN assessment)) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (JJ adverse) (NN drug) (NN event)) (VP (AUX was) (ADVP (RB probably)) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12639165_1181_1192_Chemical)))))))))) (. .)))
12639165	8	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (PP (IN of) (NP (DT this) (JJ Doc_12639165_1217_1228_Chemical-induced) (NN Doc_12639165_1237_1248_Disease)))) (VP (AUX are) (ADJP (JJ unclear))) (. .)))
12639165	9	(S1 (S (NP (JJ Immune) (NNS mechanisms)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN drug) (POS 's)) (NNP Doc_12639165_1310_1324_Disease))) (, ,) (SBAR (IN as) (S (VP (VBN suggested) (PP (IN by) (NP (NP (DT the) (JJ T-cell) (NN stimulation) (NN study)) (VP (VBN reported) (ADVP (RB here))))))))))) (. .)))
12639165	10	(S1 (S (NP (NN Doc_12639165_1399_1420_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (JJ adverse) (NN effect)) (PP (IN of) (NP (NNP Doc_12639165_1449_1460_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (NP (JJ immune) (NN mediated)))))))) (. .)))
12639165	11	(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (DT the) (NN drug)))) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (PP (IN with) (NP (NN liver) (NN function) (NNS tests))) (ADVP (IN along) (PP (IN with) (NP (JJ complete) (NN blood) (NN cell) (NNS counts))))))) (. .)))
12639165	12	(S1 (S (NP (DT This) (NN complication)) (VP (MD will) (VP (AUX be) (VP (VBN observed) (ADVP (RB even) (RBR less) (RB often)) (PP (IN in) (NP (DT the) (NN future))) (SBAR (IN as) (S (NP (NNP Doc_12639165_1671_1682_Chemical)) (VP (AUX is) (VP (AUXG being) (VP (VBN replaced) (PP (IN by) (NP (DT the) (JJR newer) (NN antiplatelet) (NN agent) (NN Doc_12639165_1733_1744_Chemical))))))))))) (. .)))
12653683	0	(S1 (S (NP (NP (NNP Epithelial) (NNP Doc_12653683_11_17_Chemical) (NNP channel)) (PRN (-LRB- -LRB-) (NP (NNP ENaC)) (-RRB- -RRB-))) (VP (VBD subunit) (NP (NP (NN mRNA)) (CC and) (NP (NN protein) (NN expression))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_12653683_82_107_Chemical-induced) (NNP Doc_12653683_116_134_Disease)))))) (. .)))
12653683	1	(S1 (S (PP (IN In) (NP (JJ experimental) (NNP Doc_12653683_152_170_Disease))) (, ,) (NP (JJ urinary) (JJ Doc_12653683_180_186_Chemical) (NN excretion)) (VP (AUX is) (VP (VBN decreased) (PP (IN during) (NP (NP (DT the) (JJ early) (NN phase)) (PP (IN of) (NP (DT the) (NN disease))))))) (. .)))
12653683	2	(S1 (S (NP (DT The) (JJ molecular) (NN mechanism) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-)) (VP (VBG leading) (PP (TO to) (NP (NN salt) (NN retention))))) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB completely)) (VP (VBN elucidated)))) (. .)))
12653683	3	(S1 (S (NP (NP (DT The) (JJ rate-limiting) (NN constituent)) (PP (IN of) (S (VP (VBG collecting) (NP (JJ duct) (JJ Doc_12653683_387_393_Chemical) (NN transport)))))) (VP (AUX is) (NP (NP (DT the) (JJ epithelial) (NN Doc_12653683_422_428_Chemical) (NN channel)) (PRN (-LRB- -LRB-) (NP (NNP ENaC)) (-RRB- -RRB-)))) (. .)))
12653683	4	(S1 (S (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NN abundance)) (PP (IN of) (NP (NNP ENaC) (NN subunit) (NNS mRNAs)))))) (CC and) (S (NP (NP (NNS proteins)) (PP (IN in) (NP (NP (NNP Doc_12653683_509_534_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12653683_536_539_Chemical)) (-RRB- -RRB-))))) (VP (VBD -induced) (NP (NNP Doc_12653683_549_567_Disease)))) (. .)))
12653683	5	(S1 (S (NP (NP (DT The) (NN time) (NNS courses)) (PP (IN of) (NP (NP (NN urinary) (JJ Doc_12653683_597_603_Chemical) (NN excretion)) (, ,) (NP (NN plasma) (JJ Doc_12653683_622_633_Chemical) (NN concentration)) (CC and) (NP (NNP Doc_12653683_652_663_Disease))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (DT either) (NN Doc_12653683_742_745_Chemical) (CC or) (NN vehicle)))))))))) (. .)))
12653683	6	(S1 (S (NP (NP (DT The) (JJ relative) (NNS amounts)) (PP (IN of) (NP (NN alphaENaC) (, ,) (NN betaENaC) (CC and) (NN gammaENaC) (NNS mRNAs)))) (VP (VP (AUX were) (VP (VBN determined) (PP (IN in) (NP (NP (NNS kidneys)) (PP (IN from) (NP (NP (DT these) (NNS rats)) (PP (IN by) (NP (JJ real-time) (JJ quantitative) (NNP TaqMan) (NNP PCR))))))))) (, ,) (CC and) (VP (NP (NP (DT the) (NNS amounts)) (PP (IN of) (NP (NNS proteins)))) (PP (IN by) (NP (NNP Western) (NNP blot))))) (. .)))
12653683	7	(S1 (S (NP (NP (NP (DT The) (NNS kinetics)) (PP (IN of) (NP (JJ urinary) (JJ Doc_12653683_972_978_Chemical) (NN excretion)))) (CC and) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NNP Doc_12653683_1011_1022_Disease))))) (VP (AUX were) (ADJP (JJ comparable) (PP (IN with) (NP (NP (DT those)) (VP (VBN reported) (ADVP (RB previously))))))) (. .)))
12653683	8	(S1 (S (NP (JJ Doc_12653683_1071_1077_Chemical) (NN retention)) (VP (VBD occurred) (PP (IN on) (NP (NNS days))) (NP (CD 2) (, ,) (CD 3) (CC and) (CD 6)) (PP (IN after) (NP (JJ Doc_12653683_1122_1125_Chemical) (NN injection)))) (. .)))
12653683	9	(S1 (S (NP (NP (DT A) (JJ significant) (NN up-regulation)) (PP (IN of) (NP (NN alphaENaC) (CC and) (NN betaENaC) (NNS mRNA)))) (VP (VBP abundance) (PP (IN on) (NP (NP (NNS days)) (SBAR (S (NP (CD 1) (CC and) (CD 2)) (VP (VBN preceded) (NP (JJ Doc_12653683_1231_1237_Chemical) (NN retention)) (PP (IN on) (NP (NNS days) (CD 2) (CC and) (CD 3))))))))) (. .)))
12653683	10	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NP (NN down-regulation)) (PP (IN of) (NP (NP (NN alphaENaC) (, ,) (NN betaENaC) (CC and) (NN gammaENaC) (NN mRNA) (NN expression)) (PP (IN on) (NP (NN day) (CD 3)))))) (VP (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ high) (NNP Doc_12653683_1388_1399_Chemical) (NNS concentrations)))))) (, ,) (CC and) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (NN return)) (PP (IN of) (NP (NP (JJ Doc_12653683_1448_1454_Chemical) (NN excretion)) (SBAR (S (VP (TO to) (VP (VB control) (NP (NNS values))))))))))))) (. .)))
12653683	11	(S1 (S (NP (NP (DT The) (NNS amounts)) (PP (IN of) (NP (NP (NN alphaENaC)) (, ,) (NP (NN betaENaC)) (CC and) (NP (NN gammaENaC) (NNS proteins))))) (VP (AUX were) (RB not) (VP (VBN increased) (PP (IN during) (NP (JJ Doc_12653683_1568_1571_Chemical-induced) (JJ Doc_12653683_1580_1586_Chemical) (NN retention))))) (. .)))
12653683	12	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (JJ ENaC) (NN mRNA) (NN expression)) (, ,) (ADJP (RB especially) (JJ alphaENaC)) (, ,)) (VP (VP (AUX is) (VP (VBN increased) (PP (IN in) (NP (NP (DT the) (ADJP (RB very) (JJ early)) (NN phase)) (PP (IN of) (NP (NP (DT the) (JJ experimental) (NN model)) (PP (IN of) (NP (JJ Doc_12653683_1723_1726_Chemical-induced) (NNP Doc_12653683_1735_1753_Disease))) (PP (IN in) (NP (NNS rats))))))))) (, ,) (CC but) (VP (VBZ appears) (S (VP (TO to) (VP (VB escape) (PP (IN from) (NP (DT the) (NN regulation))) (PP (IN by) (NP (NNP Doc_12653683_1808_1819_Chemical))) (PP (IN after) (NP (NN day) (CD 3)))))))) (. .)))
12684739	0	(S1 (S (NP (NP (JJ Sub-chronic) (JJ low) (NN dose) (NNP Doc_12684739_21_37_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12684739_39_49_Chemical)) (-RRB- -RRB-))) (VP (VBZ inhibits) (NP (NP (JJ Doc_12684739_60_67_Chemical-induced) (NNS increases)) (PP (IN in) (NP (NN nucleus) (NNS accumbens) (NNP Doc_12684739_107_115_Chemical))))) (. .)))
12684739	1	(S1 (S (NP (NP (NNP Doc_12684739_128_144_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12684739_146_149_Chemical)) (-RRB- -RRB-))) (ADVP (RB irreversibly)) (VP (VBZ inhibits) (NP (NN Doc_12684739_173_177_Chemical-transaminase))) (. .)))
12684739	2	(S1 (S (NP (DT This) (JJ non-receptor) (JJ mediated) (NN inhibition)) (VP (VBZ requires) (NP (NP (JJ de) (NN novo) (NN synthesis)) (PP (IN for) (NP (NP (NN restoration)) (PP (IN of) (NP (JJ functional) (JJ Doc_12684739_287_291_Chemical) (NN catabolism))))))) (. .)))
12684739	3	(S1 (S (PP (VBN Given) (NP (NP (PRP$ its) (JJ preclinical) (NN success)) (PP (IN for) (S (VP (VBG treating) (NP (NP (NNP Doc_12684739_359_374_Disease)) (CC and) (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_12684739_401_421_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12684739_423_426_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (JJ cumulative) (NN lifetime) (NN exposure))))))))))) (, ,) (NP (PRP we)) (VP (VBD explored) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ sub-chronic) (JJ low) (NN dose) (NNP Doc_12684739_522_525_Chemical))) (PP (IN on) (NP (NP (JJ Doc_12684739_529_536_Chemical-induced) (NNS increases)) (PP (IN in) (NP (NP (NP (NN nucleus) (NNS accumbens)) (PRN (-LRB- -LRB-) (NP (NNP NAcc)) (-RRB- -RRB-))) (NP (NP (NNP Doc_12684739_583_591_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12684739_593_595_Chemical)) (-RRB- -RRB-))))))))) (. .)))
12684739	4	(S1 (S (S (VP (VBG Using) (PP (IN in) (NP (NN vivo) (NNS microdialysis))))) (, ,) (NP (PRP we)) (VP (VBD compared) (NP (NP (JJ acute) (NN exposure)) (PRN (-LRB- -LRB-) (NP (CD 450) (NNS mg/kg)) (-RRB- -RRB-))) (PP (TO to) (NP (NP (DT an) (JJ identical) (JJ sub-chronic) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NP (CD 150) (NNS mg/kg)) (PP (IN per) (NP (NN day))) (PP (IN for) (NP (CD 3) (NNS days)))) (-RRB- -RRB-)))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (NN 1-)) (CC or) (NP (JJ 3-day) (NN washout))))))) (. .)))
12684739	5	(S1 (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (JJ low) (NN dose)) (PP (IN of) (NP (NP (CD 150) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NNS mg/kg)) (PP (IN per) (NP (NN day)))) (-RRB- -RRB-))))) (S (VP (VBG using) (NP (DT a) (JJ similar) (NN washout) (NN period))))) (. .)))
12684739	6	(S1 (S (NP (JJ Sub-chronic) (JJ Doc_12684739_896_899_Chemical) (NN exposure)) (VP (VBD inhibited) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_12684739_933_940_Chemical)))) (PP (IN for) (NP (CD 3) (NNS days))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD exceeded) (PP (IN in) (NP (NP (NN magnitude)) (CC and) (NP (NN duration)))) (NP (DT the) (JJ identical) (JJ acute) (NN dose)))))) (. .)))
12684739	7	(S1 (S (NP (JJ Sub-chronic) (JJ low) (NN dose) (NNP Doc_12684739_1054_1057_Chemical)) (VP (VP (VBZ potentiates)) (CC and) (VP (VBZ extends) (NP (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (JJ Doc_12684739_1100_1107_Chemical-induced) (NNS increases)) (PP (IN in) (NP (NP (NNP Doc_12684739_1129_1137_Chemical)) (, ,) (VP (ADVP (RB effectively)) (VBG reducing) (NP (JJ cumulative) (NNS exposures)))))))) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NNS VFDS))))))) (. .)))
12695819	0	(S1 (NP (NP (NNP MR) (NN imaging)) (PP (IN with) (NP (NP (JJ quantitative) (NN diffusion) (NN mapping)) (PP (IN of) (NP (NNP Doc_12695819_50_60_Chemical-induced) (NNP Doc_12695819_69_82_Disease))) (PP (IN in) (NP (NN organ) (NN transplant) (NNS patients))))) (. .)))
12695819	1	(S1 (S (NP (PRP$ Our) (NN objective)) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (NN brain) (NNP MR) (NN imaging) (NNS findings)) (CC and) (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (JJ diffusion-weighted) (PRN (-LRB- -LRB-) (NP (NNP DW)) (-RRB- -RRB-)) (NN imaging))) (PP (IN in) (NP (NP (NN organ) (NN transplant) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ neurologic) (NNS symptoms)) (PP (IN during) (NP (JJ Doc_12695819_293_303_Chemical) (NN therapy)))))))))))))) (. .)))
12695819	2	(S1 (S (NP (NP (NN Brain) (NNP MR) (NNS studies)) (, ,) (PP (VBG including) (NP (CD DW) (NN imaging))) (, ,)) (VP (AUX were) (ADVP (RB prospectively)) (VP (VBN performed) (PP (IN in) (NP (NP (CD 14) (NN organ) (NN transplant) (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_12695819_424_434_Chemical)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_12695819_449_473_Disease))))))))))) (. .)))
12695819	3	(S1 (S (PP (IN In) (NP (NP (DT each) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NNS abnormalities)) (PP (IN on) (NP (DT the) (JJ initial) (NNP MR) (NN study)))))))) (, ,) (NP (DT a) (JJ follow-up) (NNP MR) (NN study)) (VP (AUX was) (VP (VBN performed) (ADVP (NP (CD 1) (NN month)) (RB later)))) (. .)))
12695819	4	(S1 (S (NP (NP (JJ Apparent) (NN diffusion) (NN coefficient)) (PRN (-LRB- -LRB-) (NP (NNP ADC)) (-RRB- -RRB-))) (VP (VBZ values) (PP (IN on) (NP (NP (DT the) (JJ initial) (NNP MR) (NN study)) (SBAR (S (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (NP (NN reversibility)) (PP (IN of) (NP (DT the) (NNS lesions)))))))))))) (. .)))
12695819	5	(S1 (S (PP (IN Of) (NP (DT the) (CD 14) (NNS patients))) (, ,) (S (NP (NP (CD 5)) (PRN (-LRB- -LRB-) (NP (CD 35.7) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Doc_12695819_741_767_Disease)))) (, ,) (S (NP (NP (CD 1)) (PRN (-LRB- -LRB-) (NP (CD 7.1) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Doc_12695819_782_802_Disease)))) (, ,) (CC and) (S (NP (CD 8)) (PRN (-LRB- -LRB-) (NP (CD 57.1) (NN %)) (-RRB- -RRB-)) (VP (AUX had) (NP (JJ normal) (NNS findings)) (PP (IN on) (NP (JJ initial) (NNP MR) (NNS images))))) (. .)))
12695819	6	(S1 (S (PP (IN Among) (NP (NP (DT the) (CD 5) (NNS patients)) (PP (IN with) (NP (NNP Doc_12695819_886_912_Disease))))) (, ,) (NP (NP (CD 4) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 80.0) (NN %)) (-RRB- -RRB-))) (VP (VP (VBD showed) (ADVP (RBR higher) (PP (IN than) (NP (JJ normal) (NN ADC) (NNS values)))) (PP (IN on) (NP (JJ initial) (NNP MR) (NNS images)))) (, ,) (CC and) (VP (ADVP (RB all)) (VBD showed) (NP (JJ complete) (NN resolution)) (PP (IN on) (NP (JJ follow-up) (NNS images))))) (. .)))
12695819	7	(S1 (S (NP (NP (DT The) (VBG remaining) (CD 1) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 20.0) (NN %)) (-RRB- -RRB-))) (VP (VP (VBD showed) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (JJ normal) (NN ADC) (NN value))))) (CC and) (VP (VBD showed) (NP (JJ incomplete) (NN resolution)) (PP (IN with) (NP (NNP Doc_12695819_1153_1178_Disease))))) (. .)))
12695819	8	(S1 (S (NP (JJ Diffusion-weighted) (NN imaging)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG predicting) (NP (NP (DT the) (NNS outcomes)) (PP (IN of) (NP (NP (DT the) (NNS lesions)) (PP (IN of) (NP (NNP Doc_12695819_1266_1276_Chemical-induced) (NNP Doc_12695819_1285_1298_Disease)))))))))))) (. .)))
12707296	0	(S1 (FRAG (NP (JJ Doc_12707296_0_10_Chemical) (NN transport)) (PP (IN in) (NP (NP (NNS humans)) (PP (IN with) (NP (JJ Doc_12707296_36_44_Chemical-induced) (NNP Doc_12707296_53_65_Disease))))) (. .)))
12707296	1	(S1 (S (NP (DT A) (JJ deficient) (JJ Doc_12707296_79_89_Chemical-Doc_12707296_90_102_Chemical) (NN system)) (VP (AUX is) (VP (VBN implicated) (PP (IN in) (NP (NNP Doc_12707296_127_135_Chemical-induced) (NNP Doc_12707296_144_156_Disease))))) (. .)))
12707296	2	(S1 (S (NP (PRP We)) (VP (VB investigate) (SBAR (IN whether) (S (NP (NP (NNS abnormalities)) (PP (IN in) (NP (NNP Doc_12707296_198_208_Chemical)))) (ADVP (RB uptake)) (VP (VBP contribute) (PP (TO to) (NP (DT this) (NN deficiency))))))) (. .)))
12707296	3	(S1 (S (NP (CD Eight) (JJ healthy) (NNS men)) (VP (AUX were) (VP (VBN recruited))) (. .)))
12707296	4	(S1 (S (NP (NP (NN Doc_12707296_281_303_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN given) (NP (QP (RB orally) (DT every) (CD 6)) (NNS hours)) (PP (IN for) (NP (NP (CD 24) (NNS hours)) (PP (IN after) (NP (NP (DT a) (JJ 5-day) (NN fixed-salt) (NN diet)) (PRN (-LRB- -LRB-) (NP (CD 150) (NNS mmol/d)) (-RRB- -RRB-)))))))) (. .)))
12707296	5	(S1 (S (NP (NN Crossover) (NNS studies)) (VP (AUX were) (VP (VBN performed) (ADVP (NP (CD 2) (NNS weeks)) (RB apart)))) (. .)))
12707296	6	(S1 (S (NP (NP (CD Thirty) (NNS milliliters)) (PP (IN of) (NP (NN blood)))) (VP (AUX was) (VP (VBN obtained) (PP (IN for) (NP (NP (NN isolation)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NN mononuclear) (NNS cells))))) (PP (IN after) (NP (DT each) (NN treatment) (NN period))))) (. .)))
12707296	7	(S1 (S (NP (JJ Doc_12707296_570_580_Chemical) (NN uptake)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ mononuclear) (NNS cells)) (VP (VBN incubated) (PP (IN with) (NP (NP (NNP Doc_12707296_637_647_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (TO to) (CD 300)) (NNS micromol/L)) (-RRB- -RRB-))))))) (, ,) (S (VP (VBG incorporating) (NP (QP (CD 100) (CD nmol/L)) (NNP Doc_12707296_696_711_Chemical)) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 5) (NNS minutes))))) (PP (IN at) (NP (NP (CD 37) (NNS degrees)) (SBAR (S (NP (NNP C.) (NNP Forearm) (NNP Doc_12707296_763_778_Chemical) (NN extraction)) (VP (AUX was) (VP (VBN calculated) (PP (IN after) (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_12707296_823_838_Chemical))))) (PP (IN into) (NP (DT the) (JJ brachial) (NN artery))) (PP (IN at) (NP (NP (DT a) (NN rate)) (PP (IN of) (NP (NP (CD 100) (NN nCi/min)) (PP (IN for) (NP (CD 80) (NNS minutes))))))))))))))))) (. .)))
12707296	8	(S1 (S (NP (JJ Deep) (NN forearm) (NN venous) (NNS samples)) (VP (AUX were) (VP (VBN collected) (PP (IN for) (NP (NP (NN determination)) (PP (IN of) (NP (JJ Doc_12707296_969_979_Chemical) (NN extraction))))))) (. .)))
12707296	9	(S1 (S (NP (NN Plasma) (NN Doc_12707296_999_1007_Chemical) (NNS concentrations)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN raised) (PP (IN during) (NP (NP (DT the) (JJ active) (NN phase)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 323+/-43) (TO to) (CD 1082+/-245)) (NN mmol/L)) (, ,) (NP (NNP P<0.05))) (-RRB- -RRB-)))))) (. .)))
12707296	10	(S1 (S (NP (JJ Systolic) (NN blood) (NN pressure)) (VP (AUX was) (ADJP (JJ elevated) (PP (IN by) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (CD 7) (NN mm) (NNP Hg))))))) (. .)))
12707296	11	(S1 (S (S (NP (NP (NP (DT Neither) (JJ Doc_12707296_1185_1195_Chemical) (NN transport)) (PP (IN into) (NP (NP (JJ mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NP (NN placebo)) (ADJP (NNP vs) (JJ active))) (, ,) (NP (NP (CD 26.3+/-3.6) (NNP vs) (CD 29.0+/-2.1) (JJ pmol/10) (CD 000) (NNS cells)) (PP (IN per) (NP (CD 5) (NNS minutes))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN at) (NP (NP (DT an) (JJ Doc_12707296_1327_1337_Chemical) (NN concentration)) (PP (IN of) (NP (CD 300) (NNS micromol/L)))))) (-RRB- -RRB-))))) (CC nor) (NP (NP (JJ Doc_12707296_1375_1385_Chemical) (NN extraction)) (PP (IN in) (NP (DT the) (NN forearm))) (PRN (-LRB- -LRB-) (PP (IN at) (NP (NP (NP (CD 80) (NNS minutes)) (, ,) (NP (NP (NN placebo)) (ADJP (NNP vs) (JJ active)))) (, ,) (NP (CD 1) (CD 868) (CD 904+/-434) (CD 962) (NNP vs)))) (NP (NP (QP (CD 2) (CD 013)) (JJ 910+/-770) (CD 619) (NNS disintegrations)) (PP (IN per) (NP (NN minute)))) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN affected) (PP (IN by) (NP (JJ Doc_12707296_1534_1542_Chemical) (NN treatment)))))) (: ;) (S (ADVP (RB ie)) (, ,) (NP (DT that) (NNP Doc_12707296_1563_1573_Chemical) (NN uptake)) (VP (AUX is) (RB not) (VP (VBN affected) (PP (IN by) (NP (JJ short-term) (JJ Doc_12707296_1611_1619_Chemical) (NN treatment)))))) (. .)))
12707296	12	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_12707296_1648_1656_Chemical-induced) (NNP Doc_12707296_1665_1692_Disease)) (VP (AUX are) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (NNS abnormalities)) (PP (IN in) (NP (DT the) (JJ Doc_12707296_1738_1748_Chemical) (NN transport) (NN system)))))))))) (. .)))
12716030	0	(S1 (S (NP (NP (NN Amount)) (PP (IN of) (NP (NP (NNP Doc_12716030_10_18_Disease)) (CC and) (NP (NNP Doc_12716030_23_31_Disease))))) (VP (VBP size) (PP (IN in) (NP (DT the) (JJ collagenase-induced) (NNP Doc_12716030_64_88_Disease) (NN rat) (NN model)))) (. .)))
12716030	1	(S1 (S (NP (NP (DT The) (VBN aggravated) (NN risk)) (PP (IN on) (NP (NP (NP (NNP Doc_12716030_123_147_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12716030_149_152_Disease)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN used) (PP (IN for) (NP (JJ Doc_12716030_174_180_Disease) (NNS patients))))))))) (VP (MD should) (VP (AUX be) (VP (VBN estimated) (ADVP (RB carefully))))) (. .)))
12716030	2	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VP (VBD established) (NP (JJ sensitive) (NN quantification) (NNS methods))) (CC and) (VP (VBD provided) (NP (NP (DT a) (NN rat) (NNP Doc_12716030_298_301_Disease) (NN model)) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (JJ Doc_12716030_325_328_Disease) (NN deterioration)))))))) (. .)))
12716030	3	(S1 (S (PP (IN In) (NP (NP (NNP Doc_12716030_347_350_Disease)) (VP (ADVP (RB intrastriatally)) (VBN induced) (PP (IN by) (NP (NP (NN 0.014-unit)) (, ,) (NP (NN 0.070-unit)) (, ,) (CC and) (NP (JJ 0.350-unit) (NN collagenase))))))) (, ,) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NNP Doc_12716030_444_452_Disease)))) (VP (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (NP (DT a) (NN hemoglobin) (NN assay)) (VP (VBN developed) (PP (IN in) (NP (DT the) (JJ present) (NN study))))))))) (CC and) (VP (AUX was) (VP (VBN compared) (PP (IN with) (NP (DT the) (ADJP (RB morphologically) (VBN determined)) (NN Doc_12716030_575_583_Disease) (NN volume)))))) (. .)))
12716030	4	(S1 (S (S (NP (NP (DT The) (NN blood) (NNS amounts)) (CC and) (NP (JJ Doc_12716030_614_622_Disease) (NNS volumes))) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN correlated)))) (, ,) (CC and) (S (NP (NP (DT the) (NNP Doc_12716030_670_678_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ 0.014-unit) (NN collagenase))))) (VP (AUX was) (ADJP (JJ adequate) (S (VP (TO to) (VP (VB detect) (NP (JJ Doc_12716030_736_739_Disease) (NN deterioration)))))))) (. .)))
12716030	5	(S1 (S (PP (IN In) (NP (NP (JJ Doc_12716030_758_761_Disease) (NN induction)) (VP (VBG using) (NP (JJ 0.014-unit) (NN collagenase))))) (, ,) (NP (NNP Doc_12716030_802_809_Chemical)) (VP (VBD enhanced) (NP (NP (DT the) (NNP Doc_12716030_823_831_Disease) (NN volume) (NN 3.4-fold)) (PP (IN over) (NP (NP (DT that)) (VP (VBN seen) (PP (IN in) (NP (NP (NN control) (NN Doc_12716030_874_877_Disease) (NNS animals)) (CC and) (NP (DT the) (NNP Doc_12716030_894_902_Disease) (NN 7.6-fold))))))))) (. .)))
12716030	6	(S1 (S (NP (NNS Data)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (DT this) (JJ sensitive) (NN hemoglobin) (NN assay)) (VP (AUX is) (ADJP (JJ useful) (PP (IN for) (NP (JJ Doc_12716030_977_980_Disease) (NN detection))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (DT a) (NN model)) (PP (IN with) (NP (NP (DT a) (JJ small) (NN Doc_12716030_1022_1025_Disease)) (VP (VBN induced) (PP (IN with) (NP (DT a) (JJ low-dose) (NN collagenase))))))) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN for) (NP (NP (NN evaluation)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB affect) (NP (NN Doc_12716030_1117_1120_Disease))))))))))))))))) (. .)))
12757899	0	(S1 (S (NP (NN Doc_12757899_0_9_Chemical)) (VP (VBZ reduces) (NP (JJ Doc_12757899_18_25_Disease-induced) (NN Doc_12757899_34_52_Disease)) (PP (PP (IN in) (NP (JJ ovariectomized) (NN female))) (CC but) (PP (RB not) (IN in) (NP (JJ male) (NNS rats))))) (. .)))
12757899	1	(S1 (S (NP (NNS Estrogens)) (VP (VBP protect) (NP (NP (JJ ovariectomized) (NNS rats)) (PP (IN from) (NP (NP (NNP Doc_12757899_143_161_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_12757899_173_184_Chemical-induced) (NNP Doc_12757899_193_211_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12757899_213_215_Disease)) (-RRB- -RRB-))))))))) (. .)))
12757899	2	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_12757899_245_261_Chemical)))) (PP (IN in) (NP (NP (JJ adult) (ADJP (JJ male) (CC and) (JJ ovariectomized)) (JJ female) (NNS rats)) (VP (VBN subjected) (PP (TO to) (NP (NNP Doc_12757899_320_327_Chemical-Doc_12757899_328_339_Chemical-induced) (NNP Doc_12757899_348_350_Disease))))))) (. .)))
12757899	3	(S1 (S (NP (NNS Rats)) (VP (VBD received) (NP (NP (JJ subcutaneous) (NNS injections)) (PP (IN of) (NP (NP (NP (NNP Doc_12757899_393_409_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN microg/rat)) (-RRB- -RRB-))) (CC or) (NP (NN oil))))) (ADVP (RB once) (RB daily)) (PP (IN for) (NP (CD four) (JJ consecutive) (NNS days)))) (. .)))
12757899	4	(S1 (S (NP (NN Doc_12757899_470_472_Disease)) (VP (AUX was) (VP (VP (VBN induced) (NP (CD 20) (NNP h) (NN following)) (NP (DT the) (JJ second) (NN injection))) (CC and) (VP (VBN terminated) (NP (CD 3) (NNP h)) (ADVP (RB later))))) (. .)))
12757899	5	(S1 (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NP (JJ Doc_12757899_561_567_Chemical-stained) (NN CA3)) (CC and) (NP (JJ CA1) (JJ hippocampal) (NNS neurons))))) (VP (AUX was) (VP (VBN evaluated) (NP (CD 2) (NNS days)) (SBAR (IN after) (S (NP (NNP Doc_12757899_635_637_Disease.) (NNP Doc_12757899_639_655_Chemical)) (VP (VP (AUX did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (JJ first) (NNS clonus)) (PP (IN in) (NP (VBN ovariectomized) (NNS rats)))))))) (CC but) (VP (VBD accelerated) (NP (PRP it)) (PP (IN in) (NP (JJ males.) (NNP Doc_12757899_748_764_Chemical)))) (VP (VBD reduced) (NP (NP (DT the) (JJ argyrophilic) (NNS neurons)) (PP (IN in) (NP (NP (DT the) (NN CA1) (CC and) (NN CA3-C) (NNS sectors)) (PP (IN of) (NP (VBN ovariectomized) (NNS rats)))))))))))) (. .)))
12757899	6	(S1 (S (PP (IN In) (NP (NNS males))) (, ,) (NP (NNP Doc_12757899_861_870_Chemical)) (VP (VBD increased) (NP (DT the) (JJ total) (NN damage) (NN score))) (. .)))
12757899	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_12757899_948_957_Chemical))) (PP (IN on) (NP (NP (JJ Doc_12757899_961_968_Disease) (NN threshold)) (CC and) (NP (NN damage))))) (VP (MD may) (VP (AUX be) (VP (VBN altered) (PP (IN by) (NP (NP (JJ sex-related) (NNS differences)) (PP (IN in) (NP (DT the) (JJ hormonal) (NN environment))))))))))) (. .)))
12789195	0	(S1 (S (NP (NN Doc_12789195_0_16_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ long-term) (NN use)) (PP (IN of) (NP (NNP Doc_12789195_49_58_Chemical)))))) (. .)))
12789195	1	(S1 (S (NP (NN Doc_12789195_60_70_Disease)) (VP (AUX is) (NP (NP (DT an) (NN Doc_12789195_77_95_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ chronic) (JJ excessive) (NN growth) (NN hormone) (NN secretion)) (PP (IN from) (NP (DT the) (NNP anterior) (NN pituitary) (NN gland)))))))) (. .)))
12789195	2	(S1 (S (NP (JJ Significant) (NN disfiguring) (NNS changes)) (VP (VBP occur) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN bone)) (, ,) (NP (NN cartilage)) (, ,) (CC and) (NP (JJ soft) (NN tissue) (NN Doc_12789195_270_281_Disease)) (, ,) (PP (VBG including) (NP (NP (NP (DT the) (NN thickening)) (PP (IN of) (NP (DT the) (NN skin)))) (, ,) (NP (NP (NN coarsening)) (PP (IN of) (NP (JJ facial) (NNS features)))) (, ,) (CC and) (NP (NN Doc_12789195_356_377_Disease))))))))) (. .)))
12789195	3	(S1 (S (NP (NN Doc_12789195_379_395_Disease)) (, ,) (PP (IN on) (NP (DT the) (JJ other) (NN hand))) (, ,) (VP (AUX is) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ similar) (JJ acromegaloid) (NNS features))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ elevated) (NN growth) (NN hormone) (CC or) (JJ insulin-like) (NN growth) (NN factor) (NNS levels))))))) (. .)))
12789195	4	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_12789195_571_587_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN from) (NP (NP (DT the) (JJ long-term) (NN use)) (PP (IN of) (NP (NNP Doc_12789195_628_637_Chemical))) (PP (IN at) (NP (DT an) (ADJP (RB unusually) (JJ high)) (NN dose)))))))))) (. .)))
12789195	5	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case) (NN report)) (PP (IN of) (NP (NNP Doc_12789195_698_714_Disease)))) (PP (IN as) (NP (NP (DT a) (NN side) (NN effect)) (PP (IN of) (NP (JJ Doc_12789195_735_744_Chemical) (NN use)))))) (. .)))
12820454	0	(S1 (S (NP (JJ Combined) (NNS androgen)) (VP (VBD blockade-induced) (NP (NNP Doc_12820454_35_41_Disease)) (PP (IN in) (NP (NNP Doc_12820454_45_60_Disease) (NNS patients))) (PP (IN without) (NP (NN bone) (NN involvement)))) (. .)))
12820454	1	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN onset) (CC and) (NN extent)) (PP (IN of) (NP (NP (JJ combined) (NN androgen) (NN blockade)) (PRN (-LRB- -LRB-) (NP (NN CAB)) (-RRB- -RRB-)))))))) (VP (VBD -induced) (NP (NNP Doc_12820454_186_192_Disease)) (PP (IN in) (NP (NNP Doc_12820454_196_211_Disease) (NNS patients))) (PP (IN without) (NP (NN bone) (NN involvement)))) (. .)))
12820454	2	(S1 (S (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (JJ Forty-two) (NNS patients)) (PP (IN with) (NP (NP (NP (NP (JJ biopsy-proven) (NNP Doc_12820454_307_331_Disease) (CD -LSB-26)) (PP (IN with) (NP (NN stage) (NN C)))) (PRN (-LRB- -LRB-) (NP (NNP T3N0M0)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 16)) (PP (IN with) (NP (NN stage) (NNP D1) (PRN (-LRB- -LRB-) (NP (NNP T3N1M0)) (-RRB- -RRB-)) (NN -RSB-))))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT this) (NN study))))) (. .)))
12820454	3	(S1 (S (NP (DT All) (NNS patients)) (VP (VP (VBD received) (NP (NP (NP (NP (NN CAB) (NN -LSB-Doc_12820454_445_463_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12820454_465_471_Chemical)) (-RRB- -RRB-))) (NP (CD 3.75) (NNS mg)) (, ,) (ADVP (RB intramuscularly))) (, ,) (NP (NP (DT every) (CD 28) (NNS days)) (CC plus) (NP (NP (CD 250) (NNS mg)) (ADJP (NNP Doc_12820454_525_534_Chemical) (, ,) (JJ tid)))) (, ,)) (PP (IN per) (NP (NNP Os) (NN -RSB-)))) (CC and) (VP (AUX were) (VP (VBN evaluated) (PP (IN for) (NP (NP (NP (NNP Doc_12820454_572_578_Disease)) (PP (IN by) (NP (NP (JJ physical) (NN examination)) (CC and) (NP (NN laboratory) (NNS tests)))) (PP (IN at) (NP (NN baseline)))) (CC and) (NP (NP (CD 4) (JJ subsequent) (NNS intervals)) (PRN (-LRB- -LRB-) (ADJP (NP (CD 1) (, ,) (CD 2) (, ,) (CD 3) (CC and) (CD 6) (NNS months)) (JJ post-CAB)) (-RRB- -RRB-)))))))) (. .)))
12820454	4	(S1 (S (NP (NNP Hb) (, ,) (NNP PSA) (CC and) (NNP Doc_12820454_708_720_Chemical) (NNS measurements)) (VP (AUX were) (VP (VBN recorded))) (. .)))
12820454	5	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NN stage) (JJ D2-3) (NN disease)) (, ,) (NP (JJ abnormal) (NN hemoglobin) (NN level)) (CC or) (NP (JJ renal) (CC and) (NN liver) (NN function) (NNS tests)))) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (DT the) (JJ upper) (NNS limits)))))))) (VP (AUX were) (VP (VBN excluded) (PP (IN from) (NP (DT the) (NN study))))) (. .)))
12820454	6	(S1 (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (NP (CD six) (NNS months))) (. .)))
12820454	7	(S1 (S (NP (DT The) (JJ mean) (NN hemoglobin) (PRN (-LRB- -LRB-) (NP (NNP Hb)) (-RRB- -RRB-)) (NNS levels)) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN declined) (PP (IN in) (NP (DT all) (NNS patients))) (PP (IN from) (NP (NP (NN baseline)) (PP (IN of) (NP (NP (QP (CD 14.2) (CD g/dl) (TO to) (CD 14.0)) (NNS g/dl)) (, ,) (NP (NP (CD 13.5) (NN g/dl)) (, ,) (NP (CD 13.2) (NN g/dl)) (CC and) (NP (NP (CD 12.7) (NN g/dl)) (PP (IN at) (NP (CD 1) (, ,) (CD 2) (, ,) (CD 3) (CC and) (CD 6) (NNS months) (NN post-CAB))))) (, ,) (ADVP (RB respectively)))))))) (. .)))
12820454	8	(S1 (S (NP (NP (ADJP (ADJP (JJ Severe)) (CC and) (ADJP (RB clinically) (JJ evident))) (NN Doc_12820454_1193_1199_Disease)) (PP (IN of) (NP (NP (NNP Hb) (NNP <) (CD 11) (NNS g/dl)) (PP (IN with) (NP (JJ clinical) (NNS symptoms)))))) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (NP (CD 6) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 14.3) (NN %)) (-RRB- -RRB-)))))) (. .)))
12820454	9	(S1 (S (NP (DT This) (JJ CAB-induced) (NN Doc_12820454_1292_1298_Disease)) (VP (AUX was) (ADJP (ADJP (JJ normochromic)) (CC and) (ADJP (JJ normocytic)))) (. .)))
12820454	10	(S1 (S (PP (IN At) (ADJP (NP (CD six) (NNS months)) (JJ post-CAB))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (NNP Doc_12820454_1377_1383_Disease)))) (VP (AUX had) (NP (NP (DT a) (JJ Hb) (JJ mean) (NN value)) (PP (IN of) (NP (NP (CD 10.2) (JJ +/-) (CD 0.1) (NNS g/dl)) (PRN (-LRB- -LRB-) (NP (NNP X) (JJ +/-) (FW SE)) (-RRB- -RRB-))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (JJ other) (NNS patients)) (VP (AUX had) (NP (NP (JJ mild) (NAC (NNP Doc_12820454_1473_1479_Disease) (PP (IN with) (NP (NNP Hb)))) (NN mean) (NN value)) (PP (IN of) (NP (NP (NP (CD 13.2) (NN +/-)) (NP (CD 0.17))) (PRN (-LRB- -LRB-) (FRAG (X (SYM X)) (NP (JJ +/-) (FW SE))) (-RRB- -RRB-))))))))) (. .)))
12820454	11	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (JJ severe) (NNP Doc_12820454_1554_1560_Disease))) (PP (IN at) (NP (QP (CD 6) (NNS months)) (NN post-CAB)))) (VP (AUX was) (ADJP (JJ predictable) (PP (IN by) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (NNP Hb) (NN baseline) (NN value)) (PP (IN of) (NP (QP (JJR more) (IN than) (CD 2.5)) (NN g/dl)))))))) (PP (IN after) (NP (NP (CD 3) (NNS months)) (PP (IN of) (NP (NP (NN CAB)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.01)) (-RRB- -RRB-))))))) (. .)))
12820454	12	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NP (JJ severe) (JJ CAB-induced) (NNP Doc_12820454_1730_1736_Disease)) (PP (IN in) (NP (NNP Doc_12820454_1740_1755_Disease) (NNS patients)))))) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (S (VP (VBG T) (NP (NP (NN baseline) (NNS values)) (PRN (-LRB- -LRB-) (NP (NNP T) (QP (CD <) (CD 3) (NN ng/ml) (CC versus) (CD T) (NN >) (CC or) (SYM =) (CD 3) (CD ng/ml))) (-RRB- -RRB-))) (, ,) (PP (IN with) (NP (NP (NP (NN age)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD <) (CD 76) (NNS yrs)) (PP (IN versus) (NP (NNP >)))) (CC or) (NP (NP (SYM =)) (NP (CD 76) (NNS yrs)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ clinical) (NN stage)) (PRN (-LRB- -LRB-) (NP (NN stage) (NN C) (CC versus) (NN stage) (NNPS D1)) (-RRB- -RRB-)))))))))) (. .)))
12820454	13	(S1 (S (NP (ADJP (JJ Severe) (CC and) (ADJP (RB clinically) (JJ evident))) (NNP Doc_12820454_1963_1969_Disease)) (VP (AUX was) (ADVP (RB easily)) (VP (VBN corrected) (PP (IN by) (NP (NP (JJ subcutaneous) (NNS injections)) (PRN (-LRB- -LRB-) (NP (NP (CD 3) (NN times/week)) (PP (IN for) (NP (CD 1) (NN month)))) (-RRB- -RRB-)) (PP (IN of) (NP (NP (JJ recombinant) (NN erythropoietin)) (PRN (-LRB- -LRB-) (NP (NN rHuEPO-beta)) (-RRB- -RRB-)))))))) (. .)))
12820454	14	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ rHuEPO-beta) (JJ correctable) (JJ CAB-induced) (NN Doc_12820454_2160_2166_Disease)) (VP (VBZ occurs) (PP (IN in) (NP (NP (CD 14.3) (NN %)) (PP (IN of) (NP (JJ Doc_12820454_2186_2201_Disease) (NNS patients))))) (PP (IN after) (NP (NP (CD 6) (NNS months)) (PP (IN of) (NP (NN therapy))))))))) (. .)))
12905102	0	(S1 (NP (NP (NP (NN Doc_12905102_0_8_Disease)) (PP (IN during) (NP (JJ Doc_12905102_16_25_Chemical) (NN treatment)))) (: :) (NP (NP (NN incidence)) (CC and) (NP (JJ associated) (NN risk) (NNS factors))) (. .)))
12905102	1	(S1 (S (NP (NP (NN Incidence) (CC and) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_12905102_119_127_Disease) (IN during) (NNP Doc_12905102_135_144_Chemical) (NN treatment)))) (VP (VBP require) (NP (JJ further) (NN clarification))) (. .)))
12905102	2	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (JJ computerized) (NN pharmacy) (NNS records)) (S (VP (TO to) (VP (VB identify) (NP (NP (DT all) (JJ adult) (NNP Doc_12905102_255_266_Disease) (NNS inpatients)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_12905102_291_300_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1995-96)) (-RRB- -RRB-))) (, ,) (VP (VP (VBN reviewed) (NP (PRP$ their) (JJ medical) (NNS records)) (PP (TO to) (NP (NP (NN score) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_12905102_378_386_Disease)))))) (, ,) (CC and) (VP (VBN tested) (NP (NNS associations)) (PP (IN with) (NP (JJ potential) (NN risk) (NNS factors))))))))))))) (. .)))
12905102	3	(S1 (S (S (NP (NP (NNS Subjects)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 139)) (-RRB- -RRB-))) (VP (AUX were) (NP (CD 72) (NNS women)))) (CC and) (S (NP (NP (CD 67) (NNS men)) (, ,) (VP (VP (VBN aged) (NP (CD 40.8) (JJ +/-) (CD 12.1) (NNS years))) (, ,) (VP (VBN hospitalized) (PP (IN for) (NP (CD 24.9) (JJ +/-) (CD 23.3) (NNS days)))) (, ,) (CC and) (VP (VBN given) (NP (NNP Doc_12905102_568_577_Chemical)))) (, ,)) (ADVP (RB gradually)) (VP (VBD increased) (PP (TO to) (NP (NP (DT an) (JJ average) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD 282) (JJ +/-) (CD 203) (NNS mg)) (PRN (-LRB- -LRB-) (NP (CD 3.45) (JJ +/-) (CD 2.45) (NNS mg/kg)) (-RRB- -RRB-)))))) (PP (IN for) (NP (NP (CD 18.9) (NN +/-)) (NP (CD 16.4) (NNS days)))))) (. .)))
12905102	4	(S1 (S (S (NP (NN Doc_12905102_688_696_Disease)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN in) (NP (CD 14))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 10.1) (NN %)) (NN incidence)) (, ,) (CC or) (NP (NP (CD 1.48) (NN cases/person-years)) (PP (IN of) (NP (NN exposure))))) (-RRB- -RRB-))))) (: ;) (S (NP (NP (CD 71.4) (NN %)) (PP (IN of) (NP (NNS cases)))) (VP (AUX were) (ADJP (JJ moderate) (CC or) (JJ severe)))) (. .)))
12905102	5	(S1 (S (S (NP (JJ Associated) (NNS factors)) (VP (AUX were) (ADJP (JJ co-treatment) (PP (IN with) (NP (NP (JJ other) (ADJP (RB centrally) (JJ antimuscarinic)) (NNS agents)) (, ,) (NP (JJ poor) (JJ clinical) (NN outcome)) (, ,) (NP (JJR older) (NN age)) (, ,) (CC and) (NP (JJR longer) (NN hospitalization))))) (PRN (-LRB- -LRB-) (PP (IN by) (NP (NP (CD 17.5) (NNS days)) (, ,) (NP (VBG increasing) (NN cost)))) (-RRB- -RRB-)))) (: ;) (S (NP (NP (NP (NN sex)) (, ,) (NP (NN diagnosis)) (CC or) (NP (JJ medical) (NN co-morbidity))) (, ,) (CC and) (NP (JJ daily) (JJ Doc_12905102_1043_1052_Chemical) (NN dose)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD fell) (PP (IN with) (NP (NN age)))))) (, ,)) (VP (AUX were) (ADJP (JJ unrelated)))) (. .)))
12905102	6	(S1 (S (NP (NN Doc_12905102_1109_1117_Disease)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (JJ Doc_12905102_1139_1148_Chemical-treated) (NNS inpatients))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (JJR older) (NNS patients)) (VP (VBN exposed) (PP (TO to) (NP (JJ other) (JJ central) (NNS anticholinergics)))))))) (. .)))
12905102	7	(S1 (S (NP (NN Doc_12905102_1243_1251_Disease)) (VP (VP (AUX was) (ADVP (RB inconsistently)) (VP (VBN recognized) (ADVP (RB clinically)) (PP (IN in) (NP (JJ milder) (NNS cases))))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN length-of-stay)) (CC and) (NP (JJR higher) (NNS costs)) (, ,) (CC and) (NP (JJ inferior) (JJ clinical) (NN outcome))))))) (. .)))
12907309	0	(S1 (S (NP (NP (JJ Neuroprotective) (NN action)) (PP (IN of) (NP (NP (NNP Doc_12907309_26_30_Chemical)) (, ,) (NP (DT a) (JJ selective) (NN mGluR5) (NN antagonist)) (, ,))) (PP (IN in) (NP (JJ Doc_12907309_66_81_Chemical-induced) (JJ dopaminergic) (NN Doc_12907309_103_116_Disease)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ Doc_12907309_150_158_Chemical) (NN outflow)))) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NNP Doc_12907309_185_197_Disease)) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
12907309	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ metabotropic) (NNP Doc_12907309_269_278_Chemical) (NN receptor) (CD 5)) (PRN (-LRB- -LRB-) (NP (NN mGluR5)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (JJ toxic) (NN action)) (PP (IN of) (NP (NNP Doc_12907309_322_337_Chemical))) (PP (IN on) (NP (NP (JJ dopaminergic) (NNS neurones)) (PP (IN in) (NP (NNS rats)))))))))))) (. .)))
12907309	2	(S1 (S (NP (NP (NNP Doc_12907309_372_387_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg/kg)) (NN sc)) (-RRB- -RRB-)) (, ,) (VP (VBN administered) (NP (CD five) (NNS times))) (, ,)) (VP (VBD reduced) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_12907309_450_458_Chemical)) (CC and) (NP (PRP$ its) (NNS metabolites)))) (PP (IN in) (NP (JJ striatal) (NN tissue)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN measured) (NP (CD 72) (NNP h)) (PP (IN after) (NP (DT the) (JJ last) (NN injection))))))) (. .)))
12907309	3	(S1 (S (NP (NP (DT A) (JJ selective) (NN antagonist)) (PP (IN of) (NP (NP (CD mGluR5)) (, ,) (NP (NP (NNP Doc_12907309_577_611_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_12907309_613_617_Chemical)) (: ;) (NP (QP (CD 5) (CD mg/kg) (NN ip)))) (-RRB- -RRB-))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (NP (CD five) (NNS times)) (PP (ADVP (RB immediately)) (IN before) (NP (DT each) (JJ Doc_12907309_685_700_Chemical) (NN injection))))))))) (VP (VBD reversed) (NP (DT the) (JJ above-mentioned) (JJ Doc_12907309_740_755_Chemical) (NNS effects))) (. .)))
12907309	4	(S1 (S (NP (DT A) (JJ single) (NNP Doc_12907309_774_778_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CD mg/kg)) (NN ip)) (-RRB- -RRB-)) (NN injection)) (VP (VBD reduced) (NP (NP (NP (DT the) (JJ basal) (NN extracellular) (JJ Doc_12907309_834_842_Chemical) (NN level)) (PP (IN in) (NP (DT the) (NN striatum)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ Doc_12907309_877_885_Chemical) (NN release)) (VP (VBN stimulated) (PP (CC either) (PP (IN by) (NP (NP (NNP Doc_12907309_915_930_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg/kg)) (NN sc)) (-RRB- -RRB-)))) (CC or) (PP (IN by) (NP (NP (ADJP (RB intrastriatally) (VBN administered)) (NNP Doc_12907309_980_991_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN microM)) (-RRB- -RRB-))))))))) (. .)))
12907309	5	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (PRP it)) (ADVP (RB transiently)) (VP (VP (VBD diminished) (NP (DT the) (JJ Doc_12907309_1046_1061_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg/kg)) (NN sc)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_12907309_1084_1096_Disease))) (CC and) (VP (VBD reduced) (NP (JJ basal) (NN body) (NN temperature)))) (. .)))
12907309	6	(S1 (S (S (NP (NP (NN Doc_12907309_1133_1137_Chemical)) (VP (VBN administered) (PP (IN into) (NP (DT the) (NN striatum))) (PP (IN at) (NP (NP (JJ high) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN microM)) (-RRB- -RRB-)))))) (VP (VBD increased) (NP (JJ extracellular) (JJ Doc_12907309_1229_1237_Chemical) (NNS levels)))) (, ,) (IN while) (S (NP (NP (JJR lower) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 50-100) (NN microM)) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ devoid) (PP (IN of) (NP (DT any) (NN effect)))))) (. .)))
12907309	7	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN blockade)) (PP (IN of) (NP (NN mGluR5))) (PP (IN by) (NP (NNP Doc_12907309_1381_1385_Chemical)))) (VP (MD may) (VP (VB protect) (NP (JJ dopaminergic) (NNS neurones)) (PP (IN against) (NP (JJ Doc_12907309_1428_1443_Chemical-induced) (NN Doc_12907309_1452_1460_Disease)))))))) (. .)))
12907309	8	(S1 (S (NP (NP (NN Neuroprotection)) (VP (VBN rendered) (PP (IN by) (NP (NNP Doc_12907309_1490_1494_Chemical))))) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (PP (IN with) (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (NP (DT the) (JJ Doc_12907309_1539_1554_Chemical-induced) (JJ Doc_12907309_1563_1571_Chemical) (NN efflux)) (PP (IN in) (NP (NP (DT the) (NN striatum)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN blockade)) (PP (IN of) (NP (JJ extrastriatal) (NNS mGluR5)))))))))))) (, ,) (CC and) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NNP Doc_12907309_1663_1675_Disease))))))))) (. .)))
12921865	0	(S1 (NP (NP (JJ Protective) (NN efficacy)) (PP (IN of) (NP (JJ neuroactive) (NNP Doc_12921865_35_43_Chemical))) (PP (IN against) (NP (NP (JJ Doc_12921865_52_59_Chemical) (NN kindled-Doc_12921865_68_76_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
12921865	1	(S1 (S (NP (NNP Neuroactive) (NNP Doc_12921865_98_106_Chemical)) (VP (VBP demonstrate) (NP (NP (JJ pharmacological) (NNS actions)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (NP (NN relevance)) (PP (IN for) (NP (NP (DT a) (NN host)) (PP (IN of) (NP (NN Doc_12921865_177_215_Disease)))))))))) (. .)))
12921865	2	(S1 (S (NP (PRP They)) (VP (VP (VBP offer) (NP (NP (NN protection)) (PP (IN against) (NP (NNP Doc_12921865_247_255_Disease)))) (PP (IN in) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NNS models)))))) (CC and) (VP (VBP seem) (S (VP (TO to) (VP (VB inhibit) (NP (NP (JJ certain) (NNS stages)) (PP (IN of) (NP (NP (NNP Doc_12921865_315_330_Disease)) (PP (IN in) (NP (JJ preclinical) (NNS assessments))))))))))) (. .)))
12921865	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (NP (CD two) (NNS endogenous)) (CC and) (NP (CD one) (JJ synthetic) (JJ neuroactive) (NN Doc_12921865_447_454_Chemical))) (SBAR (WHNP (WDT that)) (S (ADVP (RB positively)) (VP (VBP modulate) (NP (NP (DT the) (NNP Doc_12921865_484_507_Chemical) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_12921865_509_513_Chemical)) (PRN (-LRB- -LRB-) (DT A) (-RRB- -RRB-))) (-RRB- -RRB-)) (NN receptor)) (PP (IN against) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN sensitivity))) (PP (TO to) (NP (NP (DT the) (JJ convulsant) (NNS effects)) (PP (IN of) (NP (NNP Doc_12921865_592_599_Chemical))) (VP (VBN engendered) (PP (IN by) (NP (NP (VBN repeated) (NNP Doc_12921865_623_630_Chemical) (NN administration)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12921865_647_654_Disease) (NN kindling)) (-RRB- -RRB-))))))))))))))))))) (. .)))
12921865	4	(S1 (S (NP (NP (NP (NNP Doc_12921865_666_682_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12921865_684_720_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_12921865_723_735_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12921865_737_772_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_12921865_778_788_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ synthetic) (NN derivative)) (PP (IN of) (NP (NNP Doc_12921865_816_832_Chemical) (NNP Doc_12921865_833_882_Chemical)))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB suppress) (NP (NP (NP (NP (DT the) (NN expression)) (PRN (-LRB- -LRB-) (NP (JJ anticonvulsant) (NN effect)) (-RRB- -RRB-))) (CC and) (NP (NP (NN development)) (PRN (-LRB- -LRB-) (NP (JJ antiepileptogenic) (NN effect)) (-RRB- -RRB-)))) (PP (IN of) (NP (JJ Doc_12921865_1011_1018_Chemical-kindled) (NNP Doc_12921865_1027_1035_Disease)))) (PP (IN in) (NP (NN male))) (, ,) (NP (NNP Swiss-Webster) (NNS mice))))))))) (. .)))
12921865	5	(S1 (S (NP (VBN Kindled) (NN Doc_12921865_1073_1081_Disease)) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NP (JJ daily) (NN administration)) (PP (IN of) (NP (NP (CD 60) (NNS mg/kg)) (ADJP (JJ Doc_12921865_1131_1138_Chemical) (PP (IN for) (NP (CD 5) (NN days)))))))))) (. .)))
12921865	6	(S1 (S (NP (NP (DT All)) (PP (IN of) (NP (DT these) (JJ positive) (NNP Doc_12921865_1173_1177_Chemical) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NNS modulators)))) (VP (VBD suppressed) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (VBN kindled) (NNP Doc_12921865_1229_1237_Disease)))) (, ,) (SBAR (IN whereas) (RB only) (S (NP (NP (NNP Doc_12921865_1252_1268_Chemical)) (CC and) (NP (NNP Doc_12921865_1273_1283_Chemical))) (VP (VBD inhibited) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN kindling)))))))) (. .)))
12921865	7	(S1 (S (NP (NP (NP (NNP Doc_12921865_1323_1339_Chemical)) (CC and) (NP (NNP Doc_12921865_1344_1356_Chemical))) (, ,) (CONJP (CC but) (RB not)) (NP (NNP Doc_12921865_1366_1376_Chemical)) (, ,)) (ADVP (RB also)) (VP (VBD reduced) (NP (NP (JJ cumulative) (NN lethality)) (VP (VBN associated) (PP (IN with) (NP (NN kindling)))))) (. .)))
12921865	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT some)) (VP (VBP neuroactive) (S (NP (NNP Doc_12921865_1487_1495_Chemical)) (VP (VP (VB attenuate) (NP (NP (NN convulsant) (CC and) (NN sensitizing) (NNS properties)) (PP (IN of) (NP (NNP Doc_12921865_1547_1554_Chemical))))) (CC and) (VP (VB add) (PP (TO to) (NP (NP (DT a) (VBG growing) (NN literature)) (PP (IN on) (NP (NP (PRP$ their) (JJ potential) (NN use)) (PP (IN in) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (NP (NNS effects)) (PP (IN of) (NP (NP (NNS drugs)) (PP (IN of) (NP (NN abuse)))))))))))))))))))) (. .)))
137340	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NP (JJ humoral) (NNS modulators)) (PP (IN of) (NP (NP (NNP Doc_137340_32_40_Chemical-induced) (NNP Doc_137340_49_79_Disease)) (PP (IN of) (NP (NNS mice))))))) (. .)))
137340	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ humoral) (NNS modulators))) (PP (IN on) (NP (NP (DT the) (JJ Doc_137340_129_137_Chemical-induced) (NN Doc_137340_146_176_Disease)) (PP (IN of) (NP (NNS mice)))))) (VP (AUX was) (VP (VBN studied))) (. .)))
137340	2	(S1 (S (NP (NP (DT The) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NP (CD 10) (NN mg/kg)) (PP (IN of) (NP (NNP Doc_137340_245_253_Chemical-HC1)))))) (VP (VBD produced) (NP (NP (DT a) (JJ marked) (NN Doc_137340_276_306_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
137340	3	(S1 (S (NP (DT The) (JJ Doc_137340_320_328_Chemical-induced) (NN Doc_137340_337_350_Disease)) (VP (AUX was) (VP (VP (VBN potentiated) (PP (IN by) (NP (NNP Doc_137340_370_381_Chemical)))) (CC and) (VP (VBN attenuated) (PP (IN by) (NP (NNP Doc_137340_400_413_Chemical)))))) (. .)))
137340	4	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT both) (NP (NNP Doc_137340_433_448_Chemical)) (CC and) (NP (NNP Doc_137340_453_464_Chemical))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX do) (RB not) (VP (VB penetrate) (NP (DT the) (JJ blood-brain) (NN barrier)))))) (, ,)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNP Doc_137340_535_548_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_137340_561_569_Chemical)))))))) (. .)))
137340	5	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NP (NNS mice)) (PP (IN with) (NP (NP (NP (NNP Doc_137340_597_617_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (CD mg/kg) (NN i.p.)) (, ,) (NP (CD one) (NN hour))) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (JJ Doc_137340_661_669_Chemical) (NN hydroxylase)))) (, ,)))))) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NP (DT the) (JJ activity-increasing) (NNS effects)) (PP (IN of) (NP (NNP Doc_137340_742_750_Chemical))))) (. .)))
137340	6	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NP (NNP Doc_137340_789_810_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 3) (SYM X) (CD 320) (CD mg/kg)) (NN i.p.)) (, ,) (NP (CD 24) (NNS hr))) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ Doc_137340_842_851_Chemical) (NN depletor)) (, ,)))) (VP (VBD caused) (NP (NP (DT no) (JJ significant) (NN change)) (PP (IN in) (NP (DT the) (NNP Doc_137340_898_911_Disease))))) (. .)))
137340	7	(S1 (S (NP (DT The) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (JJ activity-increasing) (NNS effects)) (PP (IN of) (NP (NNP Doc_137340_972_980_Chemical)))) (VP (AUX are) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NNP Doc_137340_1012_1026_Chemical))) (PP (IN from) (NP (NP (JJ adrenergic) (NNS neurons)) (PP (IN in) (NP (DT the) (NN brain)))))))))))) (. .)))
137340	8	(S1 (S (CC And) (NP (DT the) (NNS results)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_137340_1121_1129_Chemical)) (VP (VBZ acts) (PP (IN by) (S (VP (VBG retarding) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NNP Doc_137340_1163_1176_Chemical)))) (PP (IN at) (NP (DT some) (JJ central) (JJ cholinergic) (NNS synapses))))))))))))) (. .)))
137340	9	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB also)) (VP (VBN suggested) (PP (IN from) (NP (VBN collected) (NN evidence))) (SBAR (IN that) (S (NP (NP (DT the) (JJ activity-increasing) (NNS effects)) (PP (IN of) (NP (NNP Doc_137340_1300_1308_Chemical))) (PP (IN in) (NP (NNS mice)))) (VP (AUX are) (VP (VBN mediated) (PP (IN by) (NP (NP (NNS mechanisms)) (ADJP (JJ different) (PP (IN from) (NP (NP (DT those)) (SBAR (WHNP (WDT which)) (S (VP (VB mediate) (NP (NP (DT the) (JJ activity-increasing) (NNS effects)) (PP (IN of) (NP (NNP Doc_137340_1414_1422_Chemical))) (PP (IN in) (NP (NNS rats)))))))))))))))))) (. .)))
1378968	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (ADJP (JJ uninephrectomy) (CC and) (JJ high)) (NN protein))) (VP (VBG feeding) (PP (IN on) (NP (NP (JJ Doc_1378968_54_61_Chemical-induced) (NN Doc_1378968_70_91_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
1378968	1	(S1 (S (NP (NP (NNS Rats)) (PP (IN with) (NP (JJ Doc_1378968_111_118_Chemical-induced) (NNP Doc_1378968_127_138_Disease)))) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (NP (NP (JJ high) (NN protein)) (PRN (-LRB- -LRB-) (NP (NNP HP)) (-RRB- -RRB-)) (NP (NN feeding))) (, ,) (NP (NP (NN uninephrectomy)) (PRN (-LRB- -LRB-) (NP (NN NX)) (-RRB- -RRB-))) (CC or) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (DT these)))))) (, ,) (PP (IN in) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ glomerular) (NN hyperfiltration)) (CC and) (NP (NP (JJ further) (NN progression)) (PP (IN of) (NP (NNP Doc_1378968_309_322_Disease)))))))))))) (. .)))
1378968	2	(S1 (S (NP (JJ Newborn) (JJ female) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VP (VBN fed) (NP (NP (DT a) (JJ Doc_1378968_362_369_Chemical-containing) (NN diet)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mmol/kg)) (-RRB- -RRB-))) (PP (IN for) (NP (CD 8) (NNS weeks)))) (CC and) (VP (ADVP (RB then)) (VBN randomized) (PP (TO to) (NP (NP (JJ normal) (NN diet)) (, ,) (NP (NP (NNP HP) (NN diet)) (PRN (-LRB- -LRB-) (NP (NP (CD 40)) (CC vs.) (NP (CD 19) (NN %))) (-RRB- -RRB-))) (, ,) (NP (NNS NX)) (CC or) (NP (NN HP+NX)))) (PP (IN for) (NP (DT another) (CD 8) (NNS weeks)))))) (. .)))
1378968	3	(S1 (S (NP (JJ Corresponding) (JJ non-Doc_1378968_520_527_Chemical) (JJ pretreated) (NNS groups)) (VP (AUX were) (VP (VBN generated))) (. .)))
1378968	4	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBG comparing) (NP (NP (DT all) (NNP Doc_1378968_581_588_Chemical)) (VP (VBN treated) (PP (IN versus) (NP (JJ non-Doc_1378968_608_615_Chemical-treated) (NNS groups)))))))) (, ,) (NP (NNP Doc_1378968_632_639_Chemical)) (VP (VBD caused) (NP (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (JJ glomerular) (NN filtration) (NN rate)) (PRN (-LRB- -LRB-) (NP (SYM GFR)) (-RRB- -RRB-)))) (PP (IN without) (NP (NP (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (JJ effective) (JJ renal) (NN plasma) (NN flow)) (PRN (-LRB- -LRB-) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP (DT a) (NN marker)) (VP (VBN secreted) (PP (IN into) (NP (DT the) (JJ proximal) (NNS tubules))))))))) (-RRB- -RRB-))))))) (CC or) (NP (JJ Doc_1378968_820_827_Chemical) (NN clearance)))) (. .)))
1378968	5	(S1 (S (ADVP (RB Consequently)) (, ,) (NP (JJ Doc_1378968_853_860_Chemical) (NN pretreatment)) (VP (VBD caused) (NP (NP (NP (DT a) (NN fall)) (PP (IN in) (NP (NN filtration) (NN fraction)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ fractional) (JJ Doc_1378968_941_943_Chemical) (NN excretion)))))) (. .)))
1378968	6	(S1 (S (NP (NN Doc_1378968_955_962_Chemical)) (ADVP (RB also)) (VP (VBD caused) (NP (NP (NNP Doc_1378968_975_986_Disease)) (CC and) (NP (JJ systolic) (NNP Doc_1378968_1000_1012_Disease))) (PP (IN in) (NP (NP (NN absence)) (PP (IN of) (NP (NNP Doc_1378968_1027_1045_Disease)))))) (. .)))
1378968	7	(S1 (S (NP (NNP HP)) (VP (VP (VBD failed) (S (VP (TO to) (VP (VB accentuante) (NP (NP (NN progression)) (PP (IN of) (NP (NNP Doc_1378968_1087_1100_Disease)))))))) (CC and) (VP (PP (IN in) (NP (NN fact))) (VBD tended) (S (VP (TO to) (VP (VP (VB increase) (NP (SYM GFR))) (CC and) (VP (VB decrease) (NP (NP (NN plasma) (JJ Doc_1378968_1156_1166_Chemical) (NNS levels)) (PP (IN in) (NP (JJ Doc_1378968_1177_1184_Chemical) (JJ pretreated) (NNS rats)))))))))) (. .)))
1378968	8	(S1 (S (NP (NNS NX)) (VP (VBD caused) (NP (NP (DT an) (JJ additive) (NN deterioration)) (PP (IN in) (NP (NN GFR))) (SBAR (WHNP (WDT which)) (S (, ,) (ADVP (RB however)) (, ,) (VP (AUX was) (VP (VBN ameliorated) (PP (IN by) (NP (NNP HP))))))))) (. .)))
1378968	9	(S1 (S (NP (NNS NX+HP)) (VP (VBD caused) (NP (NP (DT a) (JJ further) (NN rise)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (PP (IN in) (NP (JJ Doc_1378968_1333_1335_Chemical-pretreated) (NNS rats))))))) (. .)))
1378968	10	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNP Doc_1378968_1379_1381_Chemical-induced) (NNP Doc_1378968_1390_1401_Disease)) (, ,) (SBAR (WHADVP (RB even) (WRB when)) (S (NP (DT the) (NN GFR)) (VP (AUX is) (ADVP (RB only) (RB modestly)) (VP (VBN reduced))))) (, ,)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_1378968_1466_1477_Disease)) (CC and) (NP (JJ arterial) (JJ systolic) (NN Doc_1378968_1500_1512_Disease))))))))) (. .)))
1378968	11	(S1 (S (PP (IN In) (NP (NP (DT this) (NN model)) (PP (IN of) (NP (NNP Doc_1378968_1531_1552_Disease))))) (NP (NP (DT the) (NN decline)) (PP (IN in) (NP (NNS GFR)))) (VP (AUX is) (RB not) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ corresponding) (NN fall)) (PP (IN in) (NP (NP (JJ effective) (JJ renal) (NN plasma) (NN flow)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ functional) (NN expression)) (PP (IN of) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ nonfiltrating) (JJ atubular) (NNS glomeruli)))))))))))))))) (. .)))
1378968	12	(S1 (S (NP (NP (DT The) (JJ fractional) (NN reabsorption)) (PP (IN of) (NP (JJ tubular) (NN fluid))) (PP (IN by) (NP (DT the) (JJ proximal) (NNS tubules)))) (VP (AUX is) (VP (VBN reduced) (, ,) (S (VP (VBG leaving) (NP (NP (DT the) (JJ distal) (NN delivery) (NNS unchanged.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))))
1420741	0	(S1 (NP (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_1420741_13_28_Disease))) (PP (IN with) (NP (NNP Doc_1420741_34_46_Chemical)))) (: :) (NP (NP (DT an) (JJ antibiotic)) (PP (IN with) (NP (NP (JJ immunosuppressive) (NNS properties)) (ADJP (JJ similar) (PP (TO to) (NP (NNP Doc_1420741_107_118_Chemical))))))) (. .)))
1420741	1	(S1 (S (NP (JJ Fusidic) (NN acid)) (VP (AUX is) (NP (NP (DT an) (JJ antibiotic)) (PP (IN with) (NP (NP (JJ T-cell) (JJ specific) (JJ immunosuppressive) (NNS effects)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_1420741_217_228_Chemical)))))))))) (. .)))
1420741	2	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ new) (NNS treatments))) (PP (IN for) (NP (NNP Doc_1420741_292_307_Disease))))))) (, ,) (NP (DT a) (NN pilot) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NNS pharmacodynamics) (CC and) (NN tolerability)) (PP (IN of) (NP (JJ Doc_1420741_391_403_Chemical) (NN treatment))) (PP (IN in) (NP (JJ chronic) (JJ active) (, ,) (JJ therapy-resistant) (NNS patients))))))))) (. .)))
1420741	3	(S1 (S (NP (CD Eight) (JJ Doc_1420741_467_482_Disease) (NNS patients)) (VP (AUX were) (VP (VBN included))) (. .)))
1420741	4	(S1 (S (S (NP (NN Doc_1420741_507_519_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB orally)) (PP (IN in) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 500) (JJ mg) (NN t.d.s.)))))))) (CC and) (S (NP (DT the) (NN treatment)) (VP (AUX was) (VP (VBN planned) (S (VP (TO to) (VP (VB last) (NP (CD 8) (NNS weeks)))))))) (. .)))
1420741	5	(S1 (S (NP (DT The) (NN disease) (NN activity)) (VP (AUX was) (ADVP (RB primarily)) (VP (VBN measured) (PP (IN by) (NP (DT a) (VBN modified) (JJ individual) (NN grading) (NN score))))) (. .)))
1420741	6	(S1 (S (NP (NP (CD Five)) (PP (IN of) (NP (NP (CD 8) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-))))) (VP (VBD improved) (PP (IN during) (NP (NP (JJ Doc_1420741_743_755_Chemical) (NN treatment)) (: :) (NP (NP (NP (CD 3)) (PP (IN at) (NP (CD two) (NNS weeks)))) (CC and) (NP (NP (CD 2)) (PP (IN after) (NP (CD four) (NNS weeks)))))))) (. .)))
1420741	7	(S1 (S (S (NP (EX There)) (VP (AUX were) (NP (DT no) (JJ serious) (JJ clinical) (NN side) (NNS effects)))) (, ,) (CC but) (S (NP (NN dose) (NN reduction)) (VP (AUX was) (VP (VBN required) (PP (IN in) (NP (CD two) (NNS patients))) (PP (IN because) (IN of) (NP (NN Doc_1420741_910_916_Disease)))))) (. .)))
1420741	8	(S1 (S (ADVP (RB Biochemically)) (, ,) (S (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ alkaline) (NNS phosphatases)))) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (CD 5)) (PP (IN of) (NP (NP (CD 8) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-))))))))) (, ,) (CC and) (S (NP (DT the) (JJS greatest) (NNS increases)) (VP (AUX were) (VP (VBN seen) (PP (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (JJ elevated) (NNS levels)) (ADVP (RB prior) (PP (TO to) (NP (NN treatment)))))))))))) (. .)))
1420741	9	(S1 (S (NP (DT All)) (VP (VBD reversed) (PP (TO to) (NP (JJ pre-treatment) (NNS levels))) (PP (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (NN treatment)))))) (. .)))
1420741	10	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN pilot) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_1420741_1205_1217_Chemical)) (VP (MD may) (VP (AUX be) (PP (IN of) (NP (NN benefit))) (PP (IN in) (NP (NP (JJ selected) (JJ chronic) (JJ active) (NN Doc_1420741_1263_1278_Disease) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ conventional) (NN treatment)) (VP (AUX is) (ADJP (JJ ineffective)))))))))))) (. .)))
1420741	11	(S1 (S (SBAR (IN Because) (S (NP (EX there)) (VP (VBZ seems) (S (VP (TO to) (VP (VB exist) (NP (NP (DT a) (JJ scientific) (NN rationale)) (PP (IN for) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_1420741_1402_1414_Chemical))) (PP (IN at) (NP (NP (DT the) (JJ cytokine) (NN level)) (PP (IN in) (NP (NNP Doc_1420741_1440_1466_Disease)))))))))))))) (, ,) (NP (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT this) (NN treatment)))) (VP (MD should) (VP (AUX be) (VP (ADVP (RB further)) (VBN investigated))))))) (. .)))
1428568	0	(S1 (NP (NP (NNS Changes)) (PP (IN in) (NP (JJ Doc_1428568_11_21_Disease) (NN status))) (VP (VBN associated) (PP (IN with) (NP (JJ topical) (NNS beta-blockers)))) (. .)))
1428568	1	(S1 (S (NP (NP (NNP Doc_1428568_68_78_Disease)) (CC and) (NP (NNP Doc_1428568_83_101_Disease))) (VP (AUX have) (VP (AUX been) (ADJP (JJ related) (PP (TO to) (NP (NP (JJ side) (NNS effects)) (PP (IN of) (NP (JJ topical) (NNS beta-blockers)))))))) (. .)))
1428568	2	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (DT a) (JJ preliminary) (NN study)) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB determine) (NP (NP (DT any) (NN difference)) (PP (IN between) (NP (NP (NP (NP (DT a) (JJ non) (JJ selective) (NN beta-blocker)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1428568_270_277_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJ selective) (NN beta-blocker)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1428568_309_318_Chemical)) (-RRB- -RRB-)))) (VP (VBG regarding) (NP (NNP CNS) (NN side) (NNS effects)))))))))) (. .)))
1428568	3	(S1 (S (NP (NP (CD Eight) (JJ Doc_1428568_354_366_Disease) (NNS patients)) (VP (ADVP (RB chronically)) (VBN treated) (PP (IN with) (NP (NP (NNP Doc_1428568_401_408_Chemical) (ADJP (CD 0.5) (NN %)) (NNS /12h)) (, ,) (VP (VBG suffering) (PP (IN from) (NP (NP (NNP Doc_1428568_434_444_Disease)) (VP (VBN diagnosed) (PP (IN through) (NP (JJ DMS-III-R) (NNS criteria))))))) (, ,))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN study))))) (. .)))
1428568	4	(S1 (S (PP (IN During) (NP (NP (DT the) (JJ six-month)) (VP (VB follow) (PRT (RP up))))) (, ,) (NP (NNP Doc_1428568_543_553_Disease)) (VP (AUX was) (VP (VBN quantified) (PP (IN through) (NP (DT the) (NNP Beck) (CC and) (NNP Zung-Conde) (NNS scales))) (NP (DT every) (CD two) (NNS months)))) (. .)))
1428568	5	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ double) (JJ blind) (NN cross-over) (NN study)) (PP (IN with) (NP (NN control) (NN group))))) (, ,) (NP (NP (DT the) (NNS patients)) (PP (IN under) (NP (JJ Doc_1428568_700_707_Chemical) (NN treatment)))) (VP (VBD presented) (NP (NP (JJR higher) (NNP Doc_1428568_735_745_Disease) (NNS values)) (VP (VBN measured) (PP (IN through) (NP (NP (DT the) (NNP Beck)) (CC and) (NP (NP (DT the) (JJ Zung-Conde) (NNS scales)) (PRN (-LRB- -LRB-) (NP (CD p) (NN <) (CD 0.001) (NNP vs) (NN control)) (-RRB- -RRB-)))))))) (. .)))
1428568	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_1428568_856_865_Chemical)) (VP (MD could) (VP (AUX be) (NP (NP (JJR less)) (PP (IN of) (NP (DT a) (NN Doc_1428568_885_895_Disease-inducer))) (PP (IN than) (NP (NP (NNP Doc_1428568_909_916_Chemical)) (PP (IN in) (NP (JJ predisposed) (NNS patients))))))))))) (. .)))
1436384	0	(S1 (NP (NP (NN Protection)) (PP (IN against) (NP (NNP Doc_1436384_19_30_Chemical-induced) (NNP Doc_1436384_39_52_Disease))) (PP (IN toward) (NP (NP (JJ striatal) (JJ Doc_1436384_69_77_Chemical) (NNS neurons)) (PP (IN in) (NP (NP (NNS rodents)) (PP (IN by) (NP (NP (NNP Doc_1436384_100_108_Chemical)) (, ,) (NP (DT an) (JJ excitatory) (NNP Doc_1436384_124_134_Chemical) (NN antagonist)))))))) (. .)))
1436384	1	(S1 (S (NP (NP (NNP Doc_1436384_147_155_Chemical)) (, ,) (NP (NNP Doc_1436384_157_235_Chemical)) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (PP (IN as) (NP (NP (DT a) (JJ potent) (NN antagonist)) (PP (IN of) (NP (NP (DT the) (NNP Doc_1436384_286_306_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_1436384_308_312_Chemical)) (-RRB- -RRB-)) (NN subtype)) (PP (IN of) (NP (JJ Doc_1436384_325_334_Chemical) (NN receptor)))))))))) (. .)))
1436384	2	(S1 (S (ADVP (RB Here)) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB antagonize) (NP (NP (DT the) (VBN prolonged) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_403_411_Chemical))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (PP (IN by) (NP (NNP Doc_1436384_431_442_Chemical))) (PP (IN in) (NP (JJ Doc_1436384_446_455_Chemical-treated) (NNS rats)))))))))) (VP (AUX is) (VP (VBN reported))) (. .)))
1436384	3	(S1 (S (NP (NP (DT A) (JJ single) (ADJP (CD 18.4) (NN mg/kg)) (PRN (-LRB- -LRB-) (NP (NN i.p.)) (-RRB- -RRB-)) (NN dose)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (JJ -Doc_1436384_523_534_Chemical) (NN hemisulfate))) (, ,) (VP (VBN given) (PP (TO to) (NP (NNS rats))) (PP (VBN pretreated) (PP (IN with) (NP (NNP Doc_1436384_578_587_Chemical))))) (, ,)) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ persistent) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_625_633_Chemical))))) (PP (IN in) (NP (DT the) (NN striatum))) (ADVP (NP (CD 1) (NN week)) (RB later))) (. .)))
1436384	4	(S1 (S (NP (NP (DT This) (VBN prolonged) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_692_700_Chemical))) (PP (IN in) (NP (DT the) (NN striatum)))) (VP (AUX was) (VP (VBN antagonized) (PP (PP (IN by) (NP (NP (NNP Doc_1436384_736_747_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_1436384_749_755_Chemical)) (, ,) (NP (NP (DT a) (JJ non-competitive) (NN antagonist)) (PP (IN of) (NP (JJ Doc_1436384_789_793_Chemical) (NNS receptors))))) (-RRB- -RRB-)))) (CC or) (PP (IN by) (NP (NP (NNP Doc_1436384_811_819_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ competitive) (NN antagonist)) (PP (IN of) (NP (JJ Doc_1436384_849_853_Chemical) (NNS receptors)))) (-RRB- -RRB-))))))) (. .)))
1436384	5	(S1 (S (NP (NP (DT The) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_1436384_891_899_Chemical)))) (VP (AUX was) (ADJP (JJ dose-dependent)) (, ,) (S (VP (AUXG being) (ADJP (JJ maximum)) (PP (IN at) (NP (NP (JJ 10-40) (NNS mgkg)) (PRN (-LRB- -LRB-) (NP (NN i.p.)) (-RRB- -RRB-))))))) (. .)))
1436384	6	(S1 (S (NP (NP (DT A) (ADJP (CD 10) (NN mg/kg)) (NN dose)) (PP (IN of) (NP (NNP Doc_1436384_975_983_Chemical)))) (VP (AUX was) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG antagonizing) (NP (NP (DT the) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_1031_1039_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (, ,) (SBAR (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (QP (RB as) (JJ long) (IN as) (CD 8)) (NN hr)) (PP (ADVP (RB prior)) (TO to) (NP (NNP Doc_1436384_1093_1104_Chemical)))))) (CC but) (SBAR (WHADVP (RB not) (WRB when)) (S (VP (VBN given) (NP (CD 24) (NN hr)) (PP (RB prior) (PP (TO to) (NP (NNP Doc_1436384_1139_1150_Chemical))))))))))))))) (. .)))
1436384	7	(S1 (S (S (NP (NP (NN Depletion)) (PP (IN of) (NP (NNP Doc_1436384_1165_1173_Chemical))) (PP (IN in) (NP (DT the) (NN striatum)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN antagonized) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_1436384_1216_1224_Chemical)) (VP (AUX was) (VP (VBN given) (PP (IN after) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_1436384_1258_1269_Chemical)))))))))))) (: ;) (S (NP (NNP Doc_1436384_1271_1279_Chemical)) (VP (VBD protected) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PRT (RP up)) (PP (TO to) (NP (QP (CD 4) (CD hr)))) (SBAR (IN after) (FRAG (CC but) (RB not) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (QP (CD 8) (CC or) (CD 24)) (NN hr)) (PP (IN after) (NP (NNP Doc_1436384_1354_1365_Chemical))))))))))))) (. .)))
1436384	8	(S1 (S (NP (NP (DT The) (VBN prolonged) (NN depletion)) (PP (IN of) (NP (NNP Doc_1436384_1394_1402_Chemical))) (PP (IN in) (NP (NP (DT the) (NN striatum)) (PP (IN in) (NP (NNS mice)))))) (, ,) (PP (VBN given) (NP (NP (JJ multiple) (NNS injections)) (PP (IN of) (NP (NNP Doc_1436384_1457_1472_Chemical))))) (, ,) (VP (AUX was) (ADVP (RB also)) (VP (VBN antagonized) (ADVP (RB dose-dependently) (CC and) (RB completely)) (PP (IN by) (NP (NNP Doc_1436384_1530_1538_Chemical))))) (. .)))
1436384	9	(S1 (S (NP (DT The) (NNS data)) (VP (VBP strengthen) (NP (DT the) (NN evidence) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (JJ Doc_1436384_1582_1592_Disease) (NN effect)) (PP (IN of) (NP (NP (UCP (NNP Doc_1436384_1603_1614_Chemical) (CC and) (JJ related)) (NNS compounds)) (PP (IN toward) (NP (JJ nigrostriatal) (NNP Doc_1436384_1658_1666_Chemical) (NNS neurons)))))) (VP (VBZ involves) (NP (JJ Doc_1436384_1684_1688_Chemical) (NNS receptors))))) (CC and) (SBAR (IN that) (S (NP (NNP Doc_1436384_1708_1716_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ Doc_1436384_1723_1727_Chemical) (NN receptor) (NN antagonist)) (PP (IN with) (NP (NP (NN long-lasting)) (PP (IN in) (NP (NP (NN vivo) (NNS effects)) (PP (IN in) (NP (NNS rats)))))))))))))) (. .)))
14513889	0	(S1 (NP (JJ Doc_14513889_0_12_Chemical-induced) (NN Doc_14513889_21_40_Disease) (. .)))
14513889	1	(S1 (S (NP (DT A) (JJ 77-y-old) (NN patient)) (VP (VBD developed) (NP (NNP Doc_14513889_71_94_Disease) (, ,) (NNP Doc_14513889_96_110_Disease) (, ,) (NNP Doc_14513889_112_122_Disease) (CC and) (NNP Doc_14513889_127_133_Disease) (CD 1) (NNP h)) (PP (IN after) (NP (NP (NN ingestion)) (PP (IN of) (NP (QP (CD 200) (CD mg)) (NN Doc_14513889_164_176_Chemical))) (PP (IN for) (NP (NP (DT the) (JJ first) (NN time)) (PP (IN in) (NP (PRP$ his) (NN life)))))))) (. .)))
14513889	2	(S1 (S (S (NP (DT All) (NNS complaints)) (VP (VBN faded) (PRT (RP away)) (PP (IN within) (NP (CD 24) (NNP h.) (JJ Few) (NNS days))) (ADVP (RB later)))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBN used) (NP (DT another) (ADJP (CD 200) (NN mg)) (JJ Doc_14513889_296_308_Chemical) (NN tablet))) (, ,) (CC and) (VP (PP (IN within) (NP (DT an) (NN hour))) (VBD experienced) (NP (NP (DT a) (JJ similar) (JJ clinical) (NN picture)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (ADVP (RB again)) (ADVP (RB spontaneously)) (PP (IN within) (NP (NNS hours))))))))) (. .)))
14513889	3	(S1 (S (NP (NP (NN Laboratory) (NNS evaluations)) (, ,) (PP (VBG including) (S (NP (NN head) (NNS CT)) (VP (VB scan)))) (, ,)) (VP (AUX were) (ADJP (JJ normal))) (. .)))
14513889	4	(S1 (S (NP (DT This) (NN case)) (VP (VBZ illustrates) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (JJ close) (NN vigilance)) (PP (IN in) (NP (NNP Doc_14513889_540_562_Disease)))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (DT the) (JJ elderly)))) (. .)))
14568327	0	(S1 (S (NP (NP (NN Development)) (PP (IN of) (NP (NP (NNP Doc_14568327_15_23_Chemical-induced) (NNP Doc_14568327_32_43_Disease)) (PP (IN in) (NP (JJ Doc_14568327_47_59_Disease) (NNS monkeys)))))) (VP (MD may) (VP (VB depend) (PP (IN upon) (NP (NP (NN rate)) (PP (IN of) (NP (NP (NN symptom) (NN onset) (NN and/or) (NN duration)) (PP (IN of) (NP (NNS symptoms))))))))) (. .)))
14568327	1	(S1 (S (NP (NP (JJ Doc_14568327_135_143_Chemical-induced) (NNP Doc_14568327_152_163_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14568327_165_169_Disease)) (-RRB- -RRB-))) (VP (VBP present) (NP (NP (DT a) (JJ major) (NN problem)) (PP (IN for) (NP (NP (DT the) (JJ long-term) (NN management)) (PP (IN of) (NP (NNP Doc_14568327_227_246_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_14568327_248_250_Disease)) (-RRB- -RRB-)) (NNS patients))))))) (. .)))
14568327	2	(S1 (S (PP (JJ Due) (TO to) (NP (NP (DT the) (NN interdependence)) (PP (IN of) (NP (NN risk) (NNS factors))) (PP (IN in) (NP (JJ clinical) (NNS populations))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (ADVP (RB independently)) (VP (VB examine) (NP (NP (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB influence) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_14568327_417_421_Disease))))))))))))))) (. .)))
14568327	3	(S1 (S (S (VP (VBG Using) (NP (NN macaque) (NNS monkeys)) (PP (IN with) (NP (NP (JJ different) (NNS types)) (PP (IN of) (NP (NNP Doc_14568327_469_473_Chemical-induced) (NNP Doc_14568327_482_494_Disease))))))) (, ,) (NP (DT the) (JJ current) (NN study)) (VP (VBN evaluated) (NP (NP (DT the) (NN degree)) (SBAR (WHPP (TO to) (WHNP (WDT which))) (S (NP (NP (NN rate)) (PP (IN of) (NP (NP (NN symptom) (NN progression)) (, ,) (NP (NN symptom) (NN severity)) (, ,) (CC and) (NP (NP (NN response)) (PP (TO to) (CC and) (NP (NP (NN duration)) (PP (IN of) (NP (JJ Doc_14568327_623_631_Chemical) (NN therapy))))))))) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_14568327_678_682_Disease)))))))))))) (. .)))
14568327	4	(S1 (S (NP (NP (NNS Monkeys)) (PP (IN with) (NP (NP (JJ acute) (PRN (-LRB- -LRB-) (JJ short-term) (-RRB- -RRB-)) (JJ Doc_14568327_716_720_Chemical) (NN exposure)) (, ,) (NP (JJ rapid) (NN symptom) (NN onset)) (CC and) (NP (JJ short) (NN symptom) (NN duration))))) (ADVP (RB prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_14568327_801_809_Chemical) (NN therapy)))))) (VP (VBD developed) (NP (NNP Doc_14568327_828_838_Disease)) (PP (IN between) (NP (NP (CD 11) (CC and) (CD 24) (NNS days)) (PP (IN of) (NP (JJ daily) (JJ Doc_14568327_871_879_Chemical) (NN administration)))))) (. .)))
14568327	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS monkeys)) (PP (IN with) (NP (NP (JJ long-term) (JJ Doc_14568327_932_936_Chemical) (NN exposure)) (, ,) (NP (JJ slow) (NN symptom) (NN progression) (NN and/or) (JJ long) (NN symptom) (NN duration))))) (ADVP (RB prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_14568327_1024_1032_Chemical) (NN therapy)))))) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ resistant)) (PP (TO to) (S (VP (VBG developing) (NP (NP (NNP Doc_14568327_1075_1079_Disease)) (PRN (-LRB- -LRB-) (NP (NNP e.g.)) (, ,) (NP (NP (NNP Doc_14568327_1087_1097_Disease)) (VP (VBD developed) (ADVP (DT no) (RBR sooner)) (PP (IN than) (NP (NP (CD 146) (NNS days)) (PP (IN of) (NP (JJ chronic) (NNP Doc_14568327_1143_1151_Chemical) (NN administration))))))) (-RRB- -RRB-)))))))) (. .)))
14568327	6	(S1 (S (NP (DT All) (NNS animals)) (VP (VP (AUX were) (ADJP (RB similarly) (JJ symptomatic)) (PP (IN at) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (JJ Doc_14568327_1224_1232_Chemical) (NN treatment)))))) (CC and) (VP (AUX had) (NP (NP (JJ similar) (JJ therapeutic) (NNS responses)) (PP (TO to) (NP (DT the) (NN drug)))))) (. .)))
14568327	7	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (JJ distinct) (NNS differences)) (PP (IN in) (NP (DT the) (NN propensity) (S (VP (TO to) (VP (VP (VB develop) (NP (NN Doc_14568327_1363_1367_Disease)) (PP (IN in) (NP (NP (NNS monkeys)) (PP (IN with) (NP (NP (JJ different) (NNS rates)) (PP (IN of) (NP (NN symptom) (NN progression) (CC or) (NN symptom) (NNS durations))))))) (ADVP (RB prior) (PP (TO to) (NP (NNP Doc_14568327_1453_1461_Chemical))))) (CC and) (VP (VB demonstrate) (NP (NP (DT the) (NN value)) (PP (IN of) (NP (DT these) (NNS models)))) (PP (IN for) (S (ADVP (RB further)) (VP (VBG studying) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_14568327_1548_1552_Disease))))))))))))))) (. .)))
14596845	0	(S1 (S (NP (DT A) (NN diet) (VBG promoting) (NN Doc_14596845_17_33_Disease)) (VP (VBZ causes) (NP (NN Doc_14596845_41_71_Disease)) (PP (TO to) (NP (NP (DT a) (JJ low) (NN dose)) (PP (IN of) (NP (NNP Doc_14596845_89_100_Chemical)))))) (. .)))
14596845	1	(S1 (S (NP (NP (JJ Previous) (NN research)) (PP (IN in) (NP (DT this) (NN laboratory)))) (VP (AUX has) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT a) (NN diet)) (PP (IN of) (NP (JJ intermittent) (JJ excessive) (NN sugar) (NN consumption)))) (VP (VBZ produces) (NP (NP (DT a) (NN state)) (PP (IN with) (NP (NP (JJ neurochemical) (CC and) (JJ behavioral) (NNS similarities)) (PP (TO to) (NP (NN Doc_14596845_272_287_Disease))))))))))) (. .)))
14596845	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (JJ female) (NNS rats)) (PP (IN on) (NP (NP (JJ various) (NNS regimens)) (PP (IN of) (NP (NN sugar) (NN access)))))) (VP (MD would) (VP (VB show) (NP (NN Doc_14596845_383_413_Disease)) (PP (TO to) (NP (NP (DT a) (JJ low) (NN dose)) (PP (IN of) (NP (NNP Doc_14596845_431_442_Chemical)))))))))) (. .)))
14596845	3	(S1 (S (PP (IN After) (NP (NP (DT a) (JJ 30-min) (JJ baseline) (NN measure)) (PP (IN of) (NP (NP (NN locomotor) (NN activity)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 0)) (-RRB- -RRB-)))))) (, ,) (NP (NNS animals)) (VP (AUX were) (VP (VBN maintained) (PP (IN on) (NP (NP (DT a) (JJ cyclic) (NN diet)) (PP (IN of) (NP (JJ 12-h) (NN deprivation))) (VP (VBN followed) (PP (IN by) (NP (NP (JJ 12-h) (NN access)) (PP (TO to) (NP (NP (NP (CD 10) (NN %)) (NP (NNP Doc_14596845_599_606_Chemical) (NN solution) (CC and) (NN chow) (NNS pellets))) (PRN (-LRB- -LRB-) (NP (NP (CD 12) (NNP h) (NN access)) (VP (VBG starting) (NP (CD 4) (NNP h)) (PP (IN after) (NP (NP (NN onset)) (PP (IN of) (NP (DT the) (JJ dark) (NN period))))))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 21) (NNS days)))))))))) (. .)))
14596845	4	(S1 (S (NP (NN Locomotor) (NN activity)) (VP (AUX was) (VP (VBN measured) (ADVP (RB again)) (PP (IN for) (NP (CD 30) (NN min))) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NP (NNS days) (CD 1) (CC and) (CD 21)) (PP (IN of) (NP (NN sugar) (NN access))))))))) (. .)))
14596845	5	(S1 (S (PP (VBG Beginning) (PP (IN on) (NP (NN day) (CD 22)))) (, ,) (NP (DT all) (NNS rats)) (VP (AUX were) (VP (VBN maintained) (PP (IN on) (NP (NN ad) (NN libitum) (NN chow))))) (. .)))
14596845	6	(S1 (S (ADVP (NP (CD Nine) (NNS days)) (RB later)) (NP (NN locomotor) (NN activity)) (VP (AUX was) (VP (VBN measured) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT a) (JJ single) (JJ low) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_14596845_954_965_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/kg)) (-RRB- -RRB-)))))))))) (. .)))
14596845	7	(S1 (S (NP (NP (DT The) (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (VBN experienced) (NP (JJ cyclic) (NN Doc_14596845_1019_1026_Chemical) (CC and) (NN chow))))))) (VP (AUX were) (ADJP (JJ Doc_14596845_1041_1052_Disease) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_14596845_1068_1079_Chemical)))))) (PP (VBN compared) (PP (IN with) (NP (NP (CD four) (NN control) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NN ad) (NN libitum)) (NP (CD 10) (NN %))) (ADJP (JJ Doc_14596845_1130_1137_Chemical) (CC and) (JJ chow))) (VP (VBN followed) (PP (IN by) (NP (NP (JJ Doc_14596845_1159_1170_Chemical) (NN injection)) (, ,) (NP (NP (JJ cyclic) (NN chow)) (VP (VBN followed) (PP (IN by) (NP (NP (JJ Doc_14596845_1206_1217_Chemical) (NN injection)) (, ,) (NP (NP (NN ad) (NN libitum) (NN chow)) (PP (IN with) (NP (NNP Doc_14596845_1250_1261_Chemical)))) (, ,) (CC or) (NP (JJ cyclic) (ADJP (CD 10) (NN %)) (NN Doc_14596845_1277_1284_Chemical)))))) (CC and) (NP (NP (NN chow)) (PP (IN with) (NP (DT a) (JJ saline) (NN injection)))))))) (-RRB- -RRB-)))))) (. .)))
14596845	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (NN diet)) (VP (VBN comprised) (PP (IN of) (S (VP (VBG alternating) (NP (NP (NN deprivation) (CC and) (NN access)) (PP (TO to) (NP (NP (DT a) (NN sugar) (NN solution)) (CC and) (NP (NN chow)))))))))) (VP (VBZ produces) (NP (NP (NN bingeing)) (PP (IN on) (NP (NN sugar))) (SBAR (WHNP (WDT that)) (S (VP (VBZ leads) (PP (TO to) (NP (NP (DT a) (JJ long) (JJ lasting) (NN state)) (PP (IN of) (NP (NP (JJ increased) (NN sensitivity)) (PP (TO to) (NP (NNP Doc_14596845_1521_1532_Chemical))))))) (, ,) (PP (ADVP (RB possibly)) (JJ due) (PP (TO to) (NP (NP (DT a) (JJ lasting) (NN alteration)) (PP (IN in) (NP (DT the) (JJ Doc_14596845_1578_1586_Chemical) (NN system)))))))))))))) (. .)))
14657095	0	(S1 (S (NP (JJ Reversible) (NNP Doc_14657095_11_33_Disease)) (VP (VBD related) (PP (TO to) (NP (JJ Doc_14657095_45_59_Chemical) (NN therapy)))) (. .)))
14657095	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NN Doc_14657095_105_127_Disease)) (CC and) (NP (JJ clinical) (JJ congestive) (NN Doc_14657095_152_165_Disease))) (PP (IN after) (NP (NP (CD 2) (NNS months)) (PP (IN of) (NP (NN therapy))))) (PP (IN with) (NP (NP (NNP Doc_14657095_197_211_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14657095_213_216_Chemical)) (-RRB- -RRB-)))))))) (PP (IN for) (NP (VBN disseminated) (NN Doc_14657095_235_253_Disease)))) (. .)))
14657095	2	(S1 (S (NP (NP (PRP$ His) (JJ echocardiographic) (NNS abnormalities)) (CC and) (NP (NNP Doc_14657095_295_308_Disease))) (VP (VBD resolved) (SBAR (IN after) (S (NP (NNP Doc_14657095_324_336_Chemical)) (VP (AUX was) (VP (VBN substituted) (PP (IN for) (NP (NN Doc_14657095_357_360_Chemical)))))))) (. .)))
14657095	3	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB recognize) (NP (NP (DT the) (ADJP (ADJP (JJ rare)) (CC and) (ADJP (RB potentially) (JJ reversible))) (NN Doc_14657095_427_435_Disease)) (PP (IN of) (NP (NNP Doc_14657095_439_442_Chemical)))))))) (. .)))
14659530	0	(S1 (NP (NP (JJ Doc_14659530_0_2_Chemical-induced) (NN Doc_14659530_11_19_Disease) (NN attack)) (: :) (NP (NP (NP (JJ strong) (NN increase)) (PP (IN in) (NP (NN plasma) (NNP Doc_14659530_54_85_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_14659530_87_91_Chemical)) (-RRB- -RRB-)) (NN concentration)))) (CC and) (NP (NP (JJ negative) (NN correlation)) (PP (IN with) (NP (JJ platelet) (JJ Doc_14659530_146_155_Chemical) (NN release))))) (. .)))
14659530	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB investigate) (NP (NP (NNS changes)) (PP (IN in) (NP (DT the) (NN plasma) (NNP Doc_14659530_235_266_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_14659530_268_272_Chemical)) (-RRB- -RRB-)) (NN concentration))))) (CC and) (VP (VB platelet) (NP (NP (NNP Doc_14659530_301_310_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_14659530_312_331_Chemical)) (, ,) (NP (NNP Doc_14659530_333_337_Chemical)) (-RRB- -RRB-)) (NN content)) (PP (IN during) (NP (NP (DT the) (JJ immediate) (NN Doc_14659530_368_376_Disease)) (CC and) (NP (NP (DT the) (VBN delayed) (JJ genuine) (NN Doc_14659530_401_409_Disease) (NN attack)) (VP (VBN provoked) (PP (IN by) (NP (NNP Doc_14659530_429_442_Chemical))))))))))))) (. .)))
14659530	2	(S1 (S (NP (NP (JJ Fifteen) (NN female) (NN Doc_14659530_459_485_Disease)) (CC and) (NP (CD eight) (NNS controls))) (VP (VBD participated) (PP (IN in) (NP (DT the) (NN study)))) (. .)))
14659530	3	(S1 (S (NP (NP (NNP Sublingual) (NNP Doc_14659530_543_556_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered))) (. .)))
14659530	4	(S1 (S (NP (NN Blood)) (VP (AUX was) (VP (VBN collected) (PP (IN from) (NP (DT the) (JJ antecubital) (NN vein))) (NP (NP (CD four) (NNS times)) (: :) (NP (NP (NP (CD 60) (NN min)) (PP (IN before) (CC and) (IN after) (NP (DT the) (NNP Doc_14659530_670_683_Chemical) (NN application)))) (, ,) (CC and) (NP (NP (QP (CD 60) (CC and) (CD 120)) (NN min)) (PP (IN after) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NP (DT the) (JJ Doc_14659530_743_751_Disease) (NN attack)) (PRN (-LRB- -LRB-) (NP (NP (QP (JJ mean) (CD 344) (CC and) (CD 404) (NN min))) (: ;) (NP (CD 12) (NNS subjects))) (-RRB- -RRB-))))))))))) (. .)))
14659530	5	(S1 (S (PP (IN In) (NP (NP (DT those) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (DT no) (JJ Doc_14659530_825_833_Disease) (NN attack))))) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS subjects)) (-RRB- -RRB-)))) (NP (DT a) (JJ similar) (NN time) (NN schedule)) (VP (AUX was) (VP (VBN used))) (. .)))
14659530	6	(S1 (S (NP (NN Plasma) (JJ Doc_14659530_896_900_Chemical) (NN concentration)) (VP (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP P<0.01)) (-RRB- -RRB-)) (PP (IN during) (NP (DT the) (NNP Doc_14659530_959_967_Disease) (NN attack)))) (CC and) (VP (VBD returned) (PP (TO to) (NP (NN baseline))) (PP (IN after) (NP (NP (DT the) (NN cessation)) (PP (IN of) (NP (DT the) (NNP Doc_14659530_1027_1035_Disease))))))) (. .)))
14659530	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT both) (NN change)) (CC and) (NP (NN peak)) (, ,)) (VP (VBD showed) (NP (NP (JJ significant) (JJ positive) (NNS correlations)) (PP (IN with) (NP (NP (NNP Doc_14659530_1118_1126_Disease) (NNP Doc_14659530_1127_1135_Disease) (NN intensity)) (PRN (-LRB- -LRB-) (NP (NNP P<0.001)) (-RRB- -RRB-)))))) (. .)))
14659530	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NN plasma) (NN Doc_14659530_1173_1177_Chemical) (NNS concentrations)) (VP (VBD failed) (S (VP (TO to) (VP (VB change) (PP (PP (IN during) (NP (JJ immediate) (NN Doc_14659530_1227_1235_Disease))) (CC and) (PP (IN in) (NP (NP (DT the) (NNS subjects)) (PP (IN with) (NP (DT no) (JJ Doc_14659530_1264_1272_Disease) (NN attack)))))))))) (. .)))
14659530	9	(S1 (S (S (NP (JJ Basal) (JJ Doc_14659530_1287_1291_Chemical) (NN concentration)) (VP (AUX was) (ADJP (RB significantly) (JJR higher)))) (CC and) (S (NP (NN platelet) (JJ Doc_14659530_1344_1348_Chemical) (NN content)) (VP (VBD tended) (S (VP (TO to) (VP (AUX be) (ADJP (JJR lower)) (PP (IN in) (NP (NP (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (DT a) (JJ Doc_14659530_1406_1414_Disease) (NN attack)))))))))))) (. .)))
14659530	10	(S1 (S (S (NP (NNP Platelet) (NNP Doc_14659530_1432_1441_Chemical) (NN content)) (VP (VBD decreased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP P<0.01)) (-RRB- -RRB-)) (PP (IN after) (NP (NP (NNP Doc_14659530_1489_1502_Chemical)) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN with) (NP (DT no) (NNP Doc_14659530_1523_1531_Disease) (NN attack))))))))) (CC but) (S (NP (DT no) (JJ consistent) (NN change)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_14659530_1594_1602_Disease) (NN attack)))))))) (. .)))
14659530	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NN plasma) (JJ Doc_14659530_1647_1651_Chemical) (NN concentration)) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN timing) (CC and) (NN severity)) (PP (IN of) (NP (DT a) (JJ Doc_14659530_1711_1719_Disease) (NN Doc_14659530_1720_1728_Disease))))))))) (VP (VBZ suggests) (NP (NP (DT a) (JJ direct) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_14659530_1768_1772_Chemical)) (CC and) (NP (NNP Doc_14659530_1777_1785_Disease)))))) (. .)))
14659530	12	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJ Doc_14659530_1800_1809_Chemical) (NN release)) (PP (IN from) (NP (NNS platelets)))) (VP (AUX does) (RB not) (VP (VB provoke) (NP (NNP Doc_14659530_1850_1858_Disease)) (, ,) (SBAR (S (NP (PRP it)) (VP (MD may) (ADVP (RB even)) (VP (VB counteract) (NP (NP (DT the) (NN Doc_14659530_1887_1895_Disease)) (CC and) (NP (DT the) (JJ concomitant) (JJ Doc_14659530_1916_1920_Chemical) (NN release))) (PP (IN in) (NP (DT this) (NN model))))))))) (. .)))
1468485	0	(S1 (NP (NP (JJ Hyperbaric) (JJ Doc_1468485_11_17_Chemical) (NN therapy)) (PP (IN for) (NP (NP (NN control)) (PP (IN of) (NP (JJ intractable) (JJ Doc_1468485_53_69_Chemical-induced) (NN Doc_1468485_78_98_Disease))))) (. .)))
1468485	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ intractable) (NNP Doc_1468485_132_152_Disease)))) (PP (JJ due) (TO to) (NP (NP (JJ Doc_1468485_160_176_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_1468485_189_213_Disease)))))) (. .)))
1468485	2	(S1 (S (NP (NP (JJ Conservative) (NN treatment)) (, ,) (PP (VBG including) (NP (NP (NP (NN bladder) (NN irrigation)) (PP (IN with) (NP (JJ physiological) (NN saline)))) (CC and) (NP (NP (NN instillation)) (PP (IN of) (NP (NNP Doc_1468485_314_336_Chemical)))))) (, ,)) (VP (VBD failed) (S (VP (TO to) (ADVP (RB totally)) (VP (VB control) (NP (NNP Doc_1468485_364_374_Disease)))))) (. .)))
1468485	3	(S1 (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD used) (NP (JJ hyperbaric) (NNP Doc_1468485_400_406_Chemical)) (PP (IN at) (NP (NP (DT an) (JJ absolute) (NN pressure)) (PP (IN of) (NP (NP (CD 2) (NN atm)) (, ,) (NP (NP (CD 5) (NNS days)) (NP (DT a) (NN week))))) (PP (IN for) (NP (CD 8) (JJ consecutive) (NNS weeks)))))) (. .)))
1468485	4	(S1 (S (S (NP (DT The) (NNP Doc_1468485_484_492_Disease)) (VP (VBD ceased) (ADVP (RB completely)) (PP (IN by) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN treatment))))))) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD remained) (ADJP (JJ free) (PP (IN of) (NP (NNP Doc_1468485_568_577_Disease)))) (ADVP (RB thereafter)))) (. .)))
1468485	5	(S1 (S (NP (DT No) (NN side) (NN effect)) (VP (AUX was) (VP (VBN noted) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NN therapy))))))) (. .)))
1468485	6	(S1 (S (PP (IN In) (NP (NN future))) (, ,) (NP (NP (DT this) (NN form)) (PP (IN of) (NP (NN therapy)))) (VP (MD can) (VP (VB offer) (NP (DT a) (JJ safe) (NN alternative)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_1468485_726_742_Chemical-induced) (NNP Doc_1468485_751_771_Disease))))))) (. .)))
14698717	0	(S1 (S (VP (VB Doc_14698717_0_15_Disease) (PP (JJ due) (TO to) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_14698717_38_47_Chemical))) (PP (IN in) (NP (DT a) (JJ nonepileptic) (NN patient)))) (. .)))
14698717	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NNP Doc_14698717_94_103_Disease))) (VP (VBN related) (PP (TO to) (NP (JJ antiepileptic) (NN drug) (NN treatment))))) (VP (AUX is) (ADVP (RB usually)) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (DT the) (JJ Doc_14698717_197_206_Disease) (NN brain) (NN substratum)) (CC and) (NP (DT the) (JJ antiepileptic) (NNS drugs)))))))) (. .)))
14698717	2	(S1 (S (NP (NP (DT The) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ nonepileptic) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_14698717_302_311_Disease)) (PP (VBG following) (NP (NP (JJ Doc_14698717_322_331_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_14698717_346_366_Disease))))))))))) (VP (AUX is) (VP (VBN described))) (. .)))
14698717	3	(S1 (S (NP (DT This) (NN case)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (NN Doc_14698717_409_427_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (VBG following) (NP (NP (JJ Doc_14698717_449_458_Chemical) (NN treatment)) (PP (IN in) (NP (DT some) (JJ Doc_14698717_477_486_Disease) (NNS patients))))))))) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ direct) (NN result)) (PP (IN of) (NP (NN medication))) (, ,) (ADJP (JJ unrelated) (PP (TO to) (NP (NN Doc_14698717_549_557_Disease)))))))))) (. .)))
14765563	0	(S1 (NP (NP (NNS Risks)) (PP (IN of) (NP (NP (DT the) (NN consumption)) (PP (IN of) (NP (NP (NNS beverages)) (VP (VBG containing) (NP (NNP Doc_14765563_49_56_Chemical))))))) (. .)))
14765563	1	(S1 (S (SBAR (IN Although) (S (NP (DT the) (NNP United) (NNP States) (NNP Food) (CC and) (NNP Drug) (NNP Administration)) (VP (VBD banned) (NP (NP (PRP$ its) (NN use)) (PP (IN for) (NP (NNP Doc_14765563_133_153_Disease)))) (PP (JJ due) (TO to) (NP (NP (NN lack)) (PP (IN of) (NP (NP (NN safety)) (CC and) (NP (NN efficacy))))))))) (, ,) (NP (NNP Doc_14765563_190_197_Chemical)) (VP (AUX is) (ADJP (RB widely) (JJ available) (PP (IN in) (NP (NP (NNS beverages)) (PP (VBG including) (NP (NP (NN tonic) (NN water)) (CC and) (NP (JJ bitter) (NNP lemon)))))))) (. .)))
14765563	2	(S1 (S (NP (JJ Numerous) (JJ anecdotal) (NNS reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS products)) (VP (VBG containing) (NP (NNP Doc_14765563_331_338_Chemical)))) (VP (MD may) (VP (VB produce) (NP (NN Doc_14765563_351_377_Disease)) (, ,) (PP (VBG including) (NP (NP (NNP Doc_14765563_389_398_Disease)) (, ,) (NP (JJ altered) (JJ mental) (NN status)) (, ,) (NP (NNP Doc_14765563_423_431_Disease)) (, ,) (CC and) (NP (NNP Doc_14765563_437_441_Disease)))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (JJR older) (NNS women)))))))) (. .)))
14765563	3	(S1 (S (NP (NNS Psychologists)) (VP (AUX need) (S (VP (TO to) (VP (VB inquire) (PP (IN about) (NP (NP (NN consumption)) (PP (IN of) (NP (JJ Doc_14765563_523_530_Chemical-containing) (NNS beverages))))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (DT an) (NN evaluation) (NN process))))))))) (. .)))
14976857	0	(S1 (S (NP (JJ Transient) (NNP Doc_14976857_10_45_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_14976857_57_68_Chemical) (NNP Doc_14976857_69_77_Disease))) (PP (IN in) (NP (NP (DT a) (JJ young) (NN woman)) (PP (IN with) (NP (NNP Doc_14976857_100_117_Disease)))))) (. .)))
14976857	1	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 37-year-old) (JJ white) (NN woman)) (PP (IN with) (NP (NP (NNP Doc_14976857_189_206_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (DT a) (JJ rare) (NN syndrome)) (VP (VBN called) (S (NP (NP (NNP Doc_14976857_245_266_Disease)) (, ,) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ massive) (JJ right-to-left) (JJ interatrial) (NN shunting)) (PP (IN with) (NP (NP (JJ transient) (JJ profound) (NN Doc_14976857_352_359_Disease)) (CC and) (NP (NNP Doc_14976857_364_372_Disease)))))))))))))))))))) (. .)))
14976857	2	(S1 (S (NP (NP (DT This) (NN shunt)) (PP (IN of) (NP (NN blood))) (PP (IN via) (NP (DT a) (NNP Doc_14976857_400_420_Disease)))) (VP (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (JJ normal) (NN pulmonary) (NN artery) (NN pressure)))))) (, ,) (CC and) (VP (AUX was) (ADVP (RB probably)) (VP (VBD precipitated) (PP (IN by) (NP (DT a) (NNP Doc_14976857_520_531_Chemical) (NNP Doc_14976857_532_540_Disease)))))) (. .)))
14976857	3	(S1 (S (NP (DT This) (NN drug)) (VP (VBD caused) (NP (NP (NP (NNP Doc_14976857_559_584_Disease)) (, ,) (ADJP (JJ due) (PP (TO to) (NP (PRP$ its) (JJ negative) (NN inotropic) (NN effect)))) (, ,)) (CC and) (NP (NNP Doc_14976857_628_639_Disease))) (, ,) (PP (JJ due) (PP (TO to) (NP (PRP$ its) (JJ peripheral) (NN vasodilatory) (NN effect))))) (. .)))
14976857	4	(S1 (S (NP (DT These) (NNS effects)) (VP (VBD gave) (NP (NN rise)) (PP (TO to) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (DT the) (JJ right) (NN atrial) (NN pressure)))) (CC and) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (DT the) (NN left) (CD one)))))) (PP (IN with) (NP (NP (NP (DT a) (JJ consequent) (VBG stretching)) (PP (IN of) (NP (DT the) (JJ foramen) (NN ovale)))) (CC and) (NP (NP (DT the) (NN creation)) (PP (IN of) (NP (JJ massive) (JJ right-to-left) (NN shunting))))))) (. .)))
14976857	5	(S1 (S (PP (IN In) (NP (PRP$ our) (NN case))) (NP (DT this) (JJ interatrial) (NN shunt)) (VP (AUX was) (ADVP (RB very) (RB accurately)) (VP (VBN detected) (PP (IN at) (NP (NN bubble) (NN contrast) (NN echocardiography))))) (. .)))
15009014	0	(S1 (S (NP (NP (JJ Noxious) (NN chemical) (NN stimulation)) (PP (IN of) (NP (NN rat) (JJ facial) (NNS mucosa)))) (VP (VBZ increases) (NP (JJ intracranial) (NN blood) (NN flow)) (PP (IN through) (NP (NP (DT a) (JJ trigemino-parasympathetic) (JJ reflex--an) (JJ experimental) (NN model)) (PP (IN for) (NP (NP (NNP Doc_15009014_154_175_Disease)) (PP (IN in) (NP (NNP Doc_15009014_179_195_Disease)))))))) (. .)))
15009014	1	(S1 (S (NP (NN Doc_15009014_197_213_Disease)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ typical) (JJ autonomic) (NNS dysfunctions)) (PP (VBG including) (NP (JJ facial) (CC and) (NNP Doc_15009014_286_320_Disease))))))) (. .)))
15009014	2	(S1 (S (NP (CC Both) (NP (DT the) (NN trigeminal)) (CC and) (NP (DT the) (JJ cranial) (NN parasympathetic) (NNS systems))) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (S (VP (VBG mediating) (NP (DT these) (NNS dysfunctions)))))))) (. .)))
15009014	3	(S1 (S (NP (DT An) (JJ experimental) (NN model)) (VP (AUX was) (VP (VBN developed) (PP (IN in) (NP (DT the) (NN rat) (S (VP (TO to) (VP (VB measure) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (NN lacrimation)))) (CC and) (NP (JJ intracranial) (NN blood) (NN flow))) (PP (VBG following) (NP (NP (JJ noxious) (NN chemical) (NN stimulation)) (PP (IN of) (NP (JJ facial) (NNS mucosa)))))))))))) (. .)))
15009014	4	(S1 (S (NP (NN Blood) (NN flow)) (VP (AUX was) (VP (VBN monitored) (PP (IN in) (NP (NP (NNS arteries)) (PP (IN of) (NP (NP (DT the) (VBN exposed) (NN cranial) (NN dura) (NN mater)) (CC and) (NP (NP (DT the) (JJ parietal) (NN cortex)) (VP (VBG using) (NP (NN laser) (NN Doppler) (NN flowmetry)))))))))) (. .)))
15009014	5	(S1 (S (NP (NP (NN Doc_15009014_723_732_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.01-1) (NN mm)) (-RRB- -RRB-))) (VP (VP (VBD applied) (PP (TO to) (NP (ADJP (JJ oral) (CC or) (JJ nasal)) (ADJP (RB mucosa) (VBN induced)) (NN Doc_15009014_785_827_Disease)))) (CC and) (VP (VBD provoked) (NP (NN lacrimation)))) (. .)))
15009014	6	(S1 (S (NP (DT These) (NNS responses)) (VP (AUX were) (VP (VBN blocked) (PP (IN by) (NP (NP (JJ systemic) (NN pre-administration)) (PP (IN of) (NP (NP (NNP Doc_15009014_917_939_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/kg)) (-RRB- -RRB-)))))))) (. .)))
15009014	7	(S1 (S (NP (DT The) (JJ evoked) (NN Doc_15009014_963_992_Disease)) (VP (AUX were) (ADVP (RB also)) (VP (VBN abolished) (PP (IN by) (NP (NP (JJ topical) (NN pre-administration)) (PP (IN of) (NP (NP (NP (NNP Doc_15009014_1046_1054_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mm)) (-RRB- -RRB-))) (CC and) (NP (NP (NN -LSB-Lys1)) (, ,) (NP (NP (NNP Pro2,5) (, ,) (NNP Arg3,4) (, ,) (NNP Tyr6) (JJ -RSB-) (NN -VIP)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mm)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ vasoactive) (JJ intestinal) (NN polypeptide) (PRN (-LRB- -LRB-) (NNP VIP) (-RRB- -RRB-)) (NN antagonist)) (, ,)))))) (PP (IN onto) (NP (DT the) (VBN exposed) (NN dura) (NN mater))))) (. .)))
15009014	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (JJ noxious) (NN stimulation)) (PP (IN of) (NP (JJ facial) (NNS mucosa)))) (VP (VBZ increases) (NP (NP (JJ intracranial) (NN blood) (NN flow)) (CC and) (NP (NN lacrimation))) (PP (IN via) (NP (DT a) (JJ trigemino-parasympathetic) (JJ reflex))))))) (. .)))
15009014	9	(S1 (S (NP (DT The) (NN blood) (NN flow) (NNS responses)) (VP (VBP seem) (S (VP (TO to) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NP (NNP Doc_15009014_1399_1412_Chemical)) (CC and) (NP (NNP VIP)))) (PP (IN within) (NP (DT the) (NNS meninges)))))))))) (. .)))
15009014	10	(S1 (S (NP (JJ Similar) (NNS mechanisms)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_15009014_1500_1516_Disease)))))))) (. .)))
15036754	0	(S1 (NP (NP (NP (JJ Doc_15036754_0_15_Chemical-induced) (NN Doc_15036754_24_35_Disease)) (CC and) (NP (NN prevention))) (PP (IN of) (NP (NNP Doc_15036754_54_79_Disease))) (. .)))
15036754	1	(S1 (S (NP (NP (JJ Such) (NNP Doc_15036754_86_102_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15036754_104_106_Chemical)) (-RRB- -RRB-)) (NNS compounds)) (PP (IN as) (NP (NP (NP (NNP Doc_15036754_121_147_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15036754_149_152_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_15036754_155_160_Chemical)) (CC and) (NP (NNP Doc_15036754_165_170_Chemical))))) (VP (AUX are) (NP (NP (JJ potent) (NNS inhibitors)) (PP (IN of) (NP (NP (NP (NNS acetylcholinesterases)) (PRN (-LRB- -LRB-) (NP (NNP AChEs)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS butyrylcholinesterases)) (PRN (-LRB- -LRB-) (NP (NNP BChEs)) (-RRB- -RRB-))))))) (. .)))
15036754	2	(S1 (S (NP (NP (DT The) (JJ acute) (NN Doc_15036754_272_280_Disease)) (PP (IN of) (NP (NNP Doc_15036754_284_287_Chemical)))) (VP (AUX is) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (PRP$ their) (JJ irreversible) (ADJP (JJ binding) (PP (IN with) (NP (NP (NNS AChEs)) (PP (IN in) (NP (NP (DT the) (JJ central) (JJ nervous) (NN system)) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ elevates) (NP (NNP Doc_15036754_395_408_Chemical)))))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_15036754_410_413_Chemical)) (-RRB- -RRB-)) (NNS levels))))) (. .)))
15036754	3	(S1 (S (NP (NP (DT The) (JJ protective) (NN action)) (PP (IN of) (NP (NP (RB subcutaneously)) (PRN (-LRB- -LRB-) (NP (NNP SC)) (-RRB- -RRB-)))) (VP (VBN administered) (NP (NP (NNS antidotes)) (CC or) (NP (PRP$ their) (NNS combinations))) (PP (IN in) (NP (NNP Doc_15036754_516_519_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg/kg)) (NN BW)) (-RRB- -RRB-)) (NN intoxication))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (JJ 9-10-weeks-old) (JJ Han-Wistar) (NN male) (NNS rats))))) (. .)))
15036754	4	(S1 (S (NP (DT The) (NNS rats)) (VP (VP (VBD received) (NP (NP (NP (NP (NP (NNP AChE) (NN reactivator) (NNP Doc_15036754_635_657_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_15036754_659_663_Chemical) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (QP (CD 30.0) (CD mg/kg)) (NNS BW)) (-RRB- -RRB-)) (, ,) (NP (JJ anticonvulsant) (NNP Doc_15036754_697_705_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg/kg)) (NN BW)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (DT A) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (JJ -Doc_15036754_727_736_Chemical) (NN receptor) (NN agonist)) (NP (NP (NNP Doc_15036754_754_780_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_15036754_782_785_Chemical) (-RRB- -RRB-)))) (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg/kg)) (NNS BW)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_15036754_803_807_Chemical-receptor) (NN antagonist) (NNP Doc_15036754_828_847_Chemical)) (PRN (-LRB- -LRB-) (NP (CD +-MK801) (NN hydrogen) (NN maleate)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg/kg)) (NNS BW)) (-RRB- -RRB-))) (CC or) (NP (PRP$ their) (NNS combinations))) (PP (IN with) (NP (JJ cholinolytic) (NN drug))) (NP (NNP Doc_15036754_935_951_Chemical)) (-LRB- -LRB-) (NP (QP (CD 50.0) (CD mg/kg)) (NN BW)) (-RRB- -RRB-) (ADVP (RB immediately))) (CC or) (VP (NP (CD 30) (NN min)) (PP (IN after) (NP (NP (DT the) (JJ single) (NN SC) (NN injection)) (PP (IN of) (NP (NNP Doc_15036754_1023_1026_Chemical))))))) (. .)))
15036754	5	(S1 (S (NP (DT The) (NN control) (NNS rats)) (VP (VBD received) (NP (NP (NNP Doc_15036754_1054_1070_Chemical)) (, ,) (CONJP (CC but) (RB also)) (NP (NP (NN saline)) (CC and) (NP (NN olive) (NN oil))) (CONJP (RB instead) (IN of)) (NP (JJ other) (NNS antidotes)) (CC and) (NP (NP (NNP Doc_15036754_1133_1136_Chemical)) (, ,) (ADVP (RB respectively))))) (. .)))
15036754	6	(S1 (S (NP (DT All) (NNS rats)) (VP (AUX were) (VP (VBN terminated) (NP (DT either) (CD 24) (NNP h) (CC or) (NNP 3) (NNS weeks)) (PP (IN after) (NP (DT the) (JJ Doc_15036754_1210_1213_Chemical) (NN injection))))) (. .)))
15036754	7	(S1 (S (NP (NP (DT The) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_15036754_1247_1250_Chemical-Doc_15036754_1251_1259_Chemical))))) (VP (VBD showed) (NP (JJ severe) (JJ typical) (JJ Doc_15036754_1282_1284_Chemical-induced) (NN Doc_15036754_1293_1301_Disease) (NNS signs))) (. .)))
15036754	8	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_15036754_1314_1317_Chemical) (, ,) (NNP Doc_15036754_1319_1327_Chemical) (CC or) (NNP Doc_15036754_1331_1335_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB immediately)) (PP (IN after) (NP (NNP Doc_15036754_1364_1367_Chemical-Doc_15036754_1368_1376_Chemical))))))) (, ,) (NP (DT these) (NNS treatments)) (VP (VP (VBN prevented)) (, ,) (VP (VBN delayed)) (CC or) (VP (VBN shortened) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (JJ serious) (NNS signs)) (PP (IN of) (NP (NNP Doc_15036754_1462_1471_Disease)))))))) (. .)))
15036754	9	(S1 (S (NP (NN Doc_15036754_1473_1481_Chemical-Doc_15036754_1482_1487_Chemical)) (VP (AUX did) (RB not) (VP (VB offer) (NP (NP (DT any) (JJ additional) (NN protection)) (PP (IN against) (NP (NNP Doc_15036754_1536_1539_Chemical) (NNP Doc_15036754_1540_1548_Disease)))))) (. .)))
15036754	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NNP Doc_15036754_1565_1568_Chemical) (, ,) (NNP Doc_15036754_1570_1578_Chemical) (CC and) (NNP Doc_15036754_1583_1587_Chemical)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_15036754_1608_1616_Chemical)))))) (VP (VP (VBD prevented) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (JJ serious) (NNS signs)) (PP (IN of) (NP (NNP Doc_15036754_1662_1671_Disease))))))) (CC and) (VP (ADVP (RB thus)) (VBD reduced) (NP (NP (DT the) (NN Doc_15036754_1693_1701_Disease)) (PP (IN of) (NP (NNP Doc_15036754_1705_1708_Chemical))) (PP (IN in) (NP (NN rat)))))) (. .)))
150790	0	(S1 (S (NP (DT A) (JJ Doc_150790_2_12_Chemical-dependent) (NN Doc_150790_23_42_Disease)) (VP (VBN unmasked) (PP (IN by) (NP (NNP Doc_150790_55_64_Chemical)))) (. .)))
150790	1	(S1 (S (NP (DT A) (JJ 3-year-old) (NN girl)) (VP (AUX had) (NP (NN Doc_150790_88_112_Disease)) (, ,) (PP (IN with) (NP (NP (NNP Doc_150790_119_131_Disease)) (, ,) (NP (NNP Doc_150790_133_145_Disease)) (, ,) (CC and) (NP (NNP Doc_150790_151_172_Disease)))) (PP (IN after) (NP (NP (DT the) (JJ therapeutic) (NN administration)) (PP (IN of) (NP (NNP Doc_150790_213_222_Chemical)))))) (. .)))
150790	2	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ pharmacologic) (NNS doses)) (PP (IN of) (NP (NNP Doc_150790_269_293_Chemical)))))) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (NN disappearance)) (PP (IN of) (NP (NNS symptoms)))))) (. .)))
150790	3	(S1 (S (PP (IN After) (S (VP (VBG discontinuing) (NP (JJ Doc_150790_350_359_Chemical) (NN therapy))))) (NP (NP (DT a) (JJ similar) (NN pattern)) (PP (IN of) (NP (NN behavior)))) (VP (AUX was) (VP (VBN noted) (SBAR (IN that) (S (VP (AUX was) (VP (VBN controlled) (PP (IN by) (NP (NN Doc_150790_431_441_Chemical))))))))) (. .)))
150790	4	(S1 (S (S (NP (DT A) (NN placebo)) (VP (AUX had) (NP (DT no) (NN effect)))) (, ,) (CC but) (S (NP (NNP Doc_150790_472_483_Chemical)) (VP (AUX was) (ADJP (RB as) (JJ effective) (PP (IN as) (NP (NN Doc_150790_504_514_Chemical)))))) (. .)))
150790	5	(S1 (S (NP (NP (JJ Periodic) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_150790_539_549_Chemical)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NN return)) (PP (IN of) (NP (DT the) (NNP Doc_150790_584_596_Disease))))))) (. .)))
150790	6	(S1 (S (NP (NP (DT The) (NN level)) (PP (IN of) (NP (NNP Doc_150790_611_620_Chemical))) (PP (IN in) (NP (DT the) (NN blood)))) (VP (AUX was) (ADVP (RB normal)) (PP (IN during) (NP (NP (DT the) (NNS periods)) (PP (IN of) (NP (NN relapse)))))) (. .)))
150790	7	(S1 (S (NP (JJ Metabolic) (NNS studies)) (VP (VBD suggested) (NP (DT a) (NN block)) (PP (IN in) (NP (NP (DT the) (JJ Doc_150790_719_729_Chemical) (NN pathway)) (PP (IN of) (NP (JJ Doc_150790_741_751_Chemical) (NN metabolism)))))) (. .)))
150790	8	(S1 (S (NP (DT The) (NN patient)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN followed) (PP (IN for) (NP (CD six) (NNS years)))))) (CC and) (VP (AUX has) (VP (VBN required) (NP (NP (JJ pharmacologic) (NNS doses)) (PP (IN of) (NP (NNP Doc_150790_848_858_Chemical)))) (S (VP (TO to) (VP (VB control) (NP (PRP$ her) (NN behavior)))))))) (. .)))
15120741	0	(S1 (NP (NP (NN Recurrent) (NN excitation)) (PP (IN in) (NP (NP (DT the) (JJ dentate) (NN gyrus)) (PP (IN of) (NP (NP (DT a) (JJ murine) (NN model)) (PP (IN of) (NP (NNP Doc_15120741_63_85_Disease))))))) (. .)))
15120741	1	(S1 (S (S (NP (ADJP (JJ Similar) (PP (TO to) (NP (NNS rats)))) (, ,) (JJ systemic) (NNP Doc_15120741_113_124_Chemical) (NN injection)) (VP (VBZ causes) (NP (NP (NP (NNP Doc_15120741_142_160_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15120741_162_164_Disease)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ eventual) (NN development)) (PP (IN of) (NP (NP (NP (JJ spontaneous) (NN Doc_15120741_210_218_Disease)) (CC and) (NP (JJ mossy) (NN fiber))) (VP (VBG sprouting) (PP (IN in) (NP (UCP (NNP C57BL/6) (CC and) (JJ CD1)) (NNS mice)))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ physiological) (NNS correlates)) (PP (IN of) (NP (DT these) (NNS events)))) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN identified) (PP (IN in) (NP (NNS mice))))))) (. .)))
15120741	2	(S1 (S (NP (NP (NN Population) (NNS responses)) (PP (IN in) (NP (NP (JJ granule) (NNS cells)) (PP (IN of) (NP (DT the) (JJ dentate) (NNS gyrus)))))) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (NP (JJ transverse) (NNS slices)) (PP (IN of) (NP (NP (DT the) (JJ ventral) (NNS hippocampus)) (PP (IN from) (NP (ADJP (JJ Doc_15120741_479_490_Chemical-treated) (CC and) (JJ untreated)) (NNS mice))))))))) (. .)))
15120741	3	(S1 (S (PP (IN In) (NP (NP (NNP Doc_15120741_522_524_Chemical) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -free) (NN bathing) (NN medium)) (VP (VBG containing) (NP (NP (NNP Doc_15120741_560_571_Chemical)) (, ,) (NP (NP (NNS conditions)) (VP (VBN designed) (S (VP (TO to) (VP (VB increase) (NP (NN excitability)) (PP (IN in) (NP (DT the) (NNS slices)))))))))))) (, ,) (NP (NP (JJ electrical) (NN stimulation)) (PP (IN of) (NP (DT the) (NN hilus)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ single) (NN population) (NN spike)) (PP (IN in) (NP (NP (JJ granule) (NNS cells)) (PP (IN from) (NP (NP (NN control) (NNS mice)) (CC and) (NP (JJ Doc_15120741_746_757_Chemical-treated) (NNS mice)))) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (VB experience) (NP (NNP Doc_15120741_795_797_Disease))))))))))) (. .)))
15120741	4	(S1 (S (PP (IN In) (NP (JJ Doc_15120741_802_804_Disease) (NNS survivors))) (, ,) (NP (JJ similar) (NN stimulation)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (NN population)) (VP (ADVP (RB spike)) (VBN followed) (, ,) (PP (IN at) (NP (DT a) (JJ variable) (NN latency))) (, ,) (PP (IN by) (NP (NP (JJ negative) (JJ DC) (NNS shifts)) (CC and) (NP (NP (JJ repetitive) (NNS afterdischarges)) (PP (IN of) (NP (NP (CD 3-60) (NNP s) (NN duration)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN blocked) (PP (IN by) (NP (JJ ionotropic) (JJ Doc_15120741_1006_1015_Chemical) (NN receptor) (NNS antagonists)))))))))))))))) (. .)))
15120741	5	(S1 (S (NP (NP (JJ Focal) (JJ Doc_15120741_1044_1053_Chemical) (NN photostimulation)) (PP (IN of) (NP (DT the) (JJ granule) (NN cell) (NN layer))) (PP (IN at) (NP (NP (NNS sites)) (PP (JJ distant) (IN from) (NP (DT the) (NN recording) (NN pipette)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN population) (NNS responses)) (PP (IN of) (NP (NP (CD 1-30) (NNP s) (NN duration)) (PP (IN in) (NP (NP (NNS slices)) (PP (IN from) (NP (NP (NNP Doc_15120741_1208_1210_Disease) (NNS survivors)) (CONJP (CC but) (RB not)) (NP (JJ other) (NNS groups))))))))))) (. .)))
15120741	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (JJ Doc_15120741_1282_1284_Disease-induced) (JJ mossy) (NN fiber) (VBG sprouting)) (CC and) (NP (JJ synaptic) (NN reorganization))) (VP (AUX are) (NP (NP (JJ relevant) (NNS characteristics)) (PP (IN of) (NP (NP (JJ Doc_15120741_1375_1382_Disease) (NN development)) (PP (IN in) (NP (DT these) (JJ murine) (NNS strains)))))) (, ,) (S (VP (VBG resembling) (NP (NP (NN rat) (NNS models)) (PP (IN of) (NP (JJ human) (NNP Doc_15120741_1451_1473_Disease))))))))))) (. .)))
15130900	0	(S1 (NP (NP (NP (NN Doc_15130900_0_22_Disease)) (PP (IN in) (NP (NNP Doc_15130900_26_50_Disease)))) (: :) (NP (NP (NNS risks)) (CC and) (NP (NP (NN relation)) (PP (TO to) (NP (NNP Doc_15130900_74_90_Chemical))))) (. .)))
15130900	1	(S1 (FRAG (S (VP (TO To) (VP (VP (VB assess)) (CC and) (VP (VB characterise) (NP (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_15130900_142_156_Disease)))) (, ,) (CC and) (NP (NP (PRP$ its) (NN relation)) (PP (TO to) (NP (NNP Doc_15130900_178_194_Chemical)))) (, ,)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15130900_213_237_Disease))))))))) (. .)))
15130900	2	(S1 (S (PP (IN In) (NP (NP (DT the) (NN population)) (VP (VBN based)))) (, ,) (NP (NP (JJ nationwide) (NNP Swedish) (NNP Inpatient) (NNP Register)) (NP (NP (DT a) (NN cohort)) (PP (IN of) (NP (CD 1065) (NNS patients))) (PP (IN with) (NP (NP (NNP Doc_15130900_342_366_Disease)) (, ,) (NP (CD 1969-95)) (, ,))))) (VP (AUX was) (VP (VBN identified))) (. .)))
15130900	3	(S1 (S (PP (IN Through) (NP (NP (NN linkage)) (PP (IN with) (NP (DT the) (NNP Swedish) (NNP Doc_15130900_426_432_Disease) (NNP Register))))) (, ,) (NP (NP (DT all) (NNS subjects)) (PP (IN in) (NP (NP (DT this) (NN cohort)) (VP (VBN diagnosed) (PP (IN with) (NP (NNP Doc_15130900_486_500_Disease))))))) (VP (AUX were) (VP (VBN identified))) (. .)))
15130900	4	(S1 (S (PP (VBN Nested) (PP (IN within) (NP (DT the) (NN cohort)))) (, ,) (NP (DT a) (VBN matched) (JJ case-control) (NN study)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NNP Doc_15130900_623_639_Chemical)) (CC and) (NP (NNP Doc_15130900_644_658_Disease))))) (S (VP (VBG using) (NP (NP (NNS odds) (NNS ratios)) (PRN (-LRB- -LRB-) (NP (NNS ORs)) (-RRB- -RRB-))) (PP (IN as) (NP (JJ relative) (NN risk)))))))))) (. .)))
15130900	5	(S1 (S (PP (IN In) (NP (DT the) (NN cohort))) (NP (NP (NP (DT the) (JJ cumulative) (NN risk)) (PP (IN of) (NP (NNP Doc_15130900_738_752_Disease))) (PP (IN after) (NP (NNP Doc_15130900_759_783_Disease)))) (, ,) (CC and) (NP (NP (DT the) (JJ relative) (NN prevalence)) (PP (IN of) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_15130900_829_843_Disease))))) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15130900_872_896_Disease)))))))) (, ,)) (VP (AUX were) (ADVP (RB also)) (VP (VBN estimated))) (. .)))
15130900	6	(S1 (S (NP (NP (DT The) (JJ median) (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NNP Doc_15130900_959_975_Chemical)))) (PP (IN among) (NP (NP (NP (NNS cases)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 11)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 25)) (-RRB- -RRB-))))) (VP (AUX were) (NP (NP (CD 113) (NNP g)) (CC and) (NP (CD 25) (NNP g))) (, ,) (ADVP (RB respectively))) (. .)))
15130900	7	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_15130900_1066_1080_Disease)))) (VP (VBN doubled) (PP (IN for) (NP (DT every) (CD 10) (NNP g) (NN increment))) (PP (IN in) (NP (NNP Doc_15130900_1117_1133_Chemical) (-LRB- -LRB-) (CC OR) (NP (NP (NP (NP (SYM =) (CD 2.0)) (, ,) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval))) (PRN (-LRB- -LRB-) (NP (NNP CI)) (-RRB- -RRB-))) (QP (CD 0.8) (TO to) (CD 4.9))) (-RRB- -RRB-)))) (. .)))
15130900	8	(S1 (S (NP (NP (NN Treatment) (NN duration)) (NP (QP (RBR longer) (IN than) (CD 1)) (NN year))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ eightfold) (VBN increased) (NN risk)) (PRN (-LRB- -LRB-) (NP (QP (CC OR) (SYM =) (CD 7.7) (, ,) (CD 95)) (NN %) (QP (CD CI) (CD 0.9) (TO to) (CD 69))) (-RRB- -RRB-)))))) (. .)))
15130900	9	(S1 (S (S (NP (NP (DT The) (JJ absolute) (NN risk)) (PP (IN for) (NP (NNP Doc_15130900_1325_1339_Disease))) (PP (IN in) (NP (DT the) (NN cohort)))) (VP (VBD reached) (NP (CD 10) (NN %)) (NP (CD 16) (NNS years)) (PP (IN after) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15130900_1394_1418_Disease))))))) (, ,) (CC and) (S (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_15130900_1437_1451_Disease)))) (VP (AUX was) (PRN (-LRB- -LRB-) (ADVP (RB non-significantly)) (-RRB- -RRB-)) (ADVP (RB twice) (IN as) (JJ common)) (SBAR (IN as) (S (VP (VBN expected) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15130900_1532_1556_Disease)))))))))))) (. .)))
15130900	10	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (NP (NP (DT a) (JJ dose-response) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_15130900_1628_1644_Chemical)) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_15130900_1661_1675_Disease) (, ,) (JJ high) (JJ cumulative) (NNS risks)) (PP (IN in) (NP (DT the) (JJ entire) (NN cohort))))))))) (, ,) (S (CC and) (ADVP (RB also)) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NN risk) (NNS factors)))) (VP (VBG operating) (PP (ADVP (RB even)) (IN before) (NP (NNP Doc_15130900_1784_1808_Disease)))))) (. .)))
15145918	0	(S1 (NP (NP (NN Differential) (NN modulation)) (PP (IN by) (NP (NP (NNP Doc_15145918_27_35_Chemical)) (PP (IN of) (NP (NP (JJ alpha2-adrenergic) (CC and) (JJ I1-Doc_15145918_64_75_Chemical) (JJ receptor-mediated) (NN Doc_15145918_94_105_Disease)) (PP (IN in) (NP (JJ female) (NNS rats))))))) (. .)))
15145918	1	(S1 (S (NP (PRP We)) (VP (AUX have) (ADVP (RB recently)) (VP (VBN shown) (SBAR (IN that) (S (NP (NNP Doc_15145918_150_158_Chemical)) (ADVP (RB negatively)) (VP (VP (VBZ modulates) (NP (NP (DT the) (JJ Doc_15145918_184_195_Disease) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_15145918_206_215_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ mixed) (NN alpha2-/I1-receptor) (NN agonist)) (-RRB- -RRB-))))) (PP (IN in) (NP (JJ female) (NNS rats)))) (CC and) (VP (VBZ implicates) (NP (DT the) (JJ cardiovascular) (JJ autonomic) (NN control)) (PP (IN in) (NP (DT this) (NN interaction))))))))) (. .)))
15145918	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (DT this) (NN effect)) (PP (IN of) (NP (NNP Doc_15145918_394_402_Chemical)))) (VP (VBZ involves) (NP (NP (NN interaction)) (PP (IN with) (NP (JJ alpha2-) (NN and/or) (NNS I1-receptors)))))))) (. .)))
15145918	3	(S1 (S (NP (NP (NNS Changes)) (VP (VBN evoked) (PP (IN by) (NP (NP (DT a) (JJ single) (JJ intraperitoneal) (NN injection)) (PP (IN of) (NP (NP (NP (NNP Doc_15145918_514_525_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 600) (NN microg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (NP (NP (NNP Doc_15145918_545_561_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (JJ selective) (NNP I1-)) (CC and) (NP (JJ alpha2-receptor) (NNS agonists))) (, ,) (ADVP (RB respectively)) (, ,)))))) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (JJ hemodynamic) (NN variability)) (, ,) (CC and) (NP (JJ locomotor) (NN activity)))))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ radiotelemetered) (ADJP (JJ sham-operated) (CC and) (JJ ovariectomized)) (PRN (-LRB- -LRB-) (NP (NNP Ovx)) (-RRB- -RRB-)) (NNP Sprague-Dawley) (NN female) (NNS rats)) (PP (IN with) (CC or) (PP (IN without) (NP (NN 12-wk) (NNP Doc_15145918_822_830_Chemical) (NN replacement)))))))) (. .)))
15145918	4	(S1 (S (S (NP (NP (CD Three) (NN time) (NN domain) (NNS indexes)) (PP (IN of) (NP (JJ hemodynamic) (NN variability)))) (VP (AUX were) (VP (VBN employed)))) (: :) (S (NP (NP (NP (DT the) (JJ standard) (NN deviation)) (PP (IN of) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN as) (NP (NP (DT a) (NN measure)) (PP (IN of) (NP (NP (NN blood) (NN pressure) (NN variability)) (CC and) (NP (NP (DT the) (JJ standard) (NN deviation)) (PP (IN of) (NP (JJ beat-to-beat) (NNS intervals))) (PRN (-LRB- -LRB-) (NP (NNP SDRR)) (-RRB- -RRB-)))))))))) (CC and) (NP (DT the) (NN root))) (VP (VBP mean) (NP (NP (NN square)) (PP (IN of) (NP (NP (JJ successive) (NNS differences)) (PP (IN in) (NP (JJ R-wave-to-R-wave) (NNS intervals))) (PP (IN as) (NP (NP (NNS measures)) (PP (IN of) (NP (NN heart) (NN rate) (NN variability)))))))))) (. .)))
15145918	5	(S1 (S (PP (IN In) (NP (JJ sham-operated) (NNS rats))) (, ,) (NP (NP (NNP Doc_15145918_1207_1218_Chemical)) (CC or) (NP (NNP Doc_15145918_1222_1238_Chemical))) (VP (VBD elicited) (NP (NP (JJ similar) (NN Doc_15145918_1256_1267_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBD lasted) (NP (QP (IN at) (JJS least) (CD 5)) (NNP h))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NNS reductions)) (PP (IN in) (NP (NP (JJ standard) (NN deviation)) (PP (IN of) (NP (JJ mean) (JJ arterial) (NN pressure)))))))))))))) (. .)))
15145918	6	(S1 (S (NP (NNP SDRR)) (VP (AUX was) (VP (VBN reduced) (PP (ADVP (RB only)) (IN by) (NP (NNP Doc_15145918_1402_1418_Chemical))))) (. .)))
15145918	7	(S1 (S (NP (NNP Ovx)) (ADVP (RB significantly)) (VP (VBD enhanced) (NP (NP (DT the) (JJ Doc_15145918_1451_1462_Disease) (NN response)) (PP (TO to) (NP (NNP Doc_15145918_1475_1491_Chemical)))) (, ,) (PP (IN in) (NP (NN contrast))) (PP (TO to) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NNP Doc_15145918_1521_1532_Chemical) (NNP Doc_15145918_1533_1544_Disease)))))) (. .)))
15145918	8	(S1 (S (NP (NP (DT The) (VBN enhanced) (NNP Doc_15145918_1559_1575_Chemical) (NNP Doc_15145918_1576_1587_Disease)) (PP (IN in) (NP (NNP Ovx) (NNS rats)))) (VP (AUX was) (VP (VBN paralleled) (PP (IN with) (NP (NP (JJ further) (NN reduction)) (PP (IN in) (NP (NP (NNP SDRR)) (CC and) (NP (NNP Doc_15145918_1650_1678_Disease)))))))) (. .)))
15145918	9	(S1 (S (NP (NP (JJ Estrogen) (NN replacement)) (PRN (-LRB- -LRB-) (NP (NP (JJ Doc_15145918_1702_1718_Chemical) (JJ subcutaneous) (NN pellet)) (, ,) (NP (NP (CD 14.2) (NN microg/day)) (, ,) (NP (CD 12) (NNS wk)))) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Ovx) (NNS rats)))) (VP (VBD restored) (NP (NP (DT the) (JJ hemodynamic) (CC and) (JJ locomotor) (NNS effects)) (PP (IN of) (NP (NNP Doc_15145918_1826_1842_Chemical))) (PP (TO to) (NP (JJ sham-operated) (NNS levels))))) (. .)))
15145918	10	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_15145918_1896_1904_Chemical)) (VP (VP (VBZ downregulates) (NP (ADJP (ADJP (JJ alpha2-)) (CC but) (ADJP (RB not) (JJ I1-receptor-mediated))) (NN Doc_15145918_1956_1967_Disease))) (CC and) (VP (VB highlight) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (DT the) (JJ cardiac) (JJ autonomic) (NN control))) (PP (IN in) (NP (JJ Doc_15145918_2026_2042_Chemical-Doc_15145918_2043_2051_Chemical) (NN interaction))))))))) (. .)))
15188772	0	(S1 (S (NP (NP (JJ Severe) (JJ reversible) (NN Doc_15188772_18_69_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NN accidental))))) (VP (VBP iatrogenic) (NP (NNP Doc_15188772_99_110_Chemical) (NNP Doc_15188772_111_119_Disease))) (. .)))
15188772	1	(S1 (S (NP (NP (JJ Doc_15188772_121_134_Chemical-induced) (NN Doc_15188772_143_157_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN chronic) (NN excess)) (PP (IN of) (NP (JJ endogenous) (NNP Doc_15188772_194_208_Chemical))))))) (VP (AUX has) (VP (AUX been) (VP (VBN recognized) (PP (IN for) (NP (NNS decades))) (PP (IN as) (NP (DT a) (JJ clinical) (NN phenomenon)))))) (. .)))
15188772	2	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS reports)) (PP (IN of) (NP (NNP Doc_15188772_291_313_Disease))) (PP (JJ due) (TO to) (NP (JJ acute) (JJ iatrogenic) (NN Doc_15188772_338_346_Disease)))) (VP (AUX are) (ADJP (JJ rare))) (. .)))
15188772	3	(S1 (S (NP (NP (DT A) (JJ 35-year-old) (NN woman)) (SBAR (WHNP (WP$ whose) (NN cervix) (NN uteri)) (S (VP (AUX was) (VP (ADVP (RB inadvertently)) (VBN injected) (PP (IN with) (NP (NP (CD 8) (NN mg)) (PP (IN of) (NP (NNP Doc_15188772_436_447_Chemical)))))))))) (VP (VP (VBD developed) (NP (NP (NN Doc_15188772_458_477_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ severe) (JJ hemodynamic) (NN compromise)) (, ,) (NP (ADJP (JJ profound) (, ,) (IN albeit) (JJ transient) (, ,)) (NNP Doc_15188772_563_614_Disease)))))))))) (, ,) (CC and) (ADVP (RB only) (RB modestly)) (VP (VBD elevated) (NP (NP (JJ biochemical) (NNS markers)) (PP (IN of) (NP (NNP Doc_15188772_666_685_Disease)))))) (. .)))
15188772	4	(S1 (S (NP (PRP$ Our) (NN case)) (VP (VBZ illustrates) (NP (NP (DT the) (JJ serious) (NNS consequences)) (PP (IN of) (NP (NP (JJ medical) (NNS errors)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN avoided) (PP (IN through) (NP (NP (VBN improved) (NN medication) (VBG labeling)) (CC and) (NP (NN staff) (NN supervision))))))))))))) (. .)))
15233872	0	(S1 (NP (NP (JJ Cardioprotective) (NN effect)) (PP (IN of) (NP (NNP Doc_15233872_27_48_Chemical))) (PP (IN on) (NP (NP (NNP Doc_15233872_52_65_Chemical-induced) (NNP Doc_15233872_74_95_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
15233872	1	(S1 (S (NP (NP (NP (NNP Doc_15233872_105_126_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15233872_128_131_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NNP Doc_15233872_137_181_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15233872_183_202_Chemical)) (-RRB- -RRB-))) (, ,)) (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (ADJP (JJ herbal) (CC and) (JJ homeopathic)) (NN medicine))))) (. .)))
15233872	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (AUX done) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_15233872_316_319_Chemical))) (PP (IN on) (NP (NP (ADJP (RB experimentally) (VBN induced)) (NN Doc_15233872_346_367_Disease)) (PP (IN in) (NP (NNS rats))))))))))) (. .)))
15233872	3	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NNP Doc_15233872_393_396_Chemical)))) (, ,) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (QP (CD 0.5) (CD mL/100)) (NNP g) (NN bodyweight))) (PP (IN per) (NP (NN day))))) (, ,) (ADVP (RB orally) (PP (IN for) (NP (CD 30) (NNS days)))) (, ,) (VP (VBD prevented) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (NN lipid) (NN peroxidation) (CC and) (NN activity)) (PP (IN of) (NP (NP (JJR marker) (NNS enzymes)) (VP (VBN observed) (PP (IN in) (NP (NP (JJ Doc_15233872_552_565_Chemical-induced) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 85) (NN mg) (NN kg) (-LRB- -LRB-) (NN -1) (-RRB- -RRB-) (NNP s.) (NNP c.)) (PP (IN for) (NP (NP (CD 2) (NNS days)) (PP (IN at) (NP (NP (DT an) (NN interval)) (PP (IN of) (NP (CD 24) (NNP h)))))))) (-RRB- -RRB-))))))))))) (. .)))
15233872	4	(S1 (S (NP (NN Doc_15233872_635_638_Chemical)) (VP (VP (VBD prevented) (NP (NP (DT the) (JJ Doc_15233872_653_666_Chemical-induced) (NN decrease)) (PP (IN in) (NP (JJ antioxidant) (NNS enzymes))) (PP (IN in) (NP (DT the) (NN heart))))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (JJ Doc_15233872_746_749_Chemical-stimulated) (JJ Doc_15233872_761_767_Chemical) (NN uptake)) (CC and) (NP (JJ respiratory) (NN coupling) (NN ratio))))))) (. .)))
15233872	5	(S1 (S (NP (NN Doc_15233872_807_810_Chemical)) (VP (VBN protected) (PP (IN against) (NP (NP (JJ pathological) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15233872_861_874_Chemical))) (PP (IN in) (NP (NN rat) (NN heart))))))) (. .)))
15233872	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_15233872_929_932_Chemical)))) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG preventing) (NP (NP (DT the) (NN damage)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15233872_983_996_Chemical))) (PP (IN in) (NP (NN rat) (NN heart)))))))))))))) (. .)))
1527456	0	(S1 (NP (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_1527456_13_21_Disease))) (PP (IN by) (NP (NP (JJ intratympanic) (NN instillation)) (PP (IN of) (NP (NP (NNP Doc_1527456_55_65_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1527456_67_76_Chemical)) (-RRB- -RRB-))))))) (NP (NP (CD 2)) (PP (IN per) (NP (NN cent))) (PP (IN through) (NP (NN ventilation) (NNS tubes)))) (. .)))
1527456	1	(S1 (S (NP (NP (NN Doc_1527456_116_146_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1527456_148_151_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (RBS most) (JJ obscure) (JJ otological) (NNS pathologies))))) (. .)))
1527456	2	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ presents) (NP (NP (DT the) (NNS results)) (PP (IN of) (S (VP (VBG treating) (NP (NNP Doc_1527456_248_251_Disease)) (PP (IN by) (NP (NP (JJ intratympanic) (NN instillation)) (PP (IN of) (NP (NP (NNP Doc_1527456_285_295_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1527456_297_306_Chemical)) (-RRB- -RRB-)) (, 2) (PP (IN per) (NP (NN cent))))))) (PP (IN through) (NP (DT a) (NN grommet))) (, ,) (PP (IN for) (NP (CD five) (JJ weekly) (NNS courses)))))))) (. .)))
1527456	3	(S1 (S (S (NP (NP (JJ Fifty-two) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (JJ intractable) (NNP Doc_1527456_409_417_Disease))))) (VP (VBD entered) (NP (DT this) (JJ therapeutic) (NN trial)))) (, ,) (CC but) (S (NP (QP (RB only) (CD nine))) (VP (VBD finished) (NP (DT all) (CD five) (NNS courses)))) (. .)))
1527456	4	(S1 (S (PP (IN In) (NP (CD one) (NN patient))) (, ,) (S (NP (DT the) (NNP Doc_1527456_511_519_Disease)) (VP (AUX was) (ADVP (RB almost) (RB completely)) (VP (VBN abolished)))) (, ,) (CC but) (S (PP (IN in) (NP (PDT all) (DT the) (CD nine) (NNS patients))) (NP (DT the) (JJ decompensated) (NN Doc_1527456_600_608_Disease)) (VP (VBD changed) (PP (TO to) (NP (DT a) (VBN compensated) (NN one))))) (. .)))
1527456	5	(S1 (S (NP (PRP We)) (VP (VBP suggest) (NP (NP (DT this) (NN mode)) (PP (IN of) (NP (NN treatment))) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADVP (RB previously)) (VP (VBN treated) (PP (IN by) (NP (NP (NNS drugs)) (, ,) (NP (NN acupuncture)) (CC and) (NP (NN biofeedback))))))))))) (, ,) (PP (IN with) (NP (JJ disappointing) (NNS results)))) (. .)))
1527456	6	(S1 (S (NP (NNS Patients)) (VP (MD should) (VP (AUX be) (VP (VBN warned) (PP (IN about) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_1527456_834_841_Disease)) (CC and) (NP (NNP Doc_1527456_846_854_Disease)))) (, ,) (SBAR (WHNP (WDT which)) (S (NP (NNS subsides)) (UCP (PP (ADVP (RB gradually)) (IN with) (NP (DT every) (JJ new) (NN instillation))) (, ,) (CC and) (SBAR (IN that) (S (NP (DT the) (NNP Doc_1527456_923_931_Disease)) (VP (VP (MD may) (RB not) (VP (VB disappear))) (CC but) (VP (MD will) (VP (AUX be) (VP (VBN alleviated) (, ,) (S (VP (VBG enabling) (S (NP (PRP them)) (VP (TO to) (VP (VP (VB cope) (ADVP (RBR more) (RB easily)) (PP (IN with) (NP (DT the) (NN disease)))) (CC and) (VP (VB lead) (NP (DT a) (ADJP (RBR more) (JJ normal)) (NN life)))))))))))))))))))))) (. .)))
15275829	0	(S1 (S (NP (DT The) (ADJP (JJ alpha3) (CC and) (JJ beta4)) (JJ nicotinic) (JJ Doc_15275829_31_44_Chemical) (NN receptor) (NNS subunits)) (VP (AUX are) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NNP Doc_15275829_81_89_Chemical-induced) (NNP Doc_15275829_98_106_Disease) (CC and) (NNP Doc_15275829_111_125_Disease)) (PP (IN in) (NP (NNS mice))))))) (. .)))
15275829	1	(S1 (S (NP (NP (JJ Binding)) (PP (IN of) (NP (NNP Doc_15275829_146_154_Chemical))) (PP (TO to) (NP (NP (JJ nicotinic) (JJ Doc_15275829_168_181_Chemical) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS nAChRs)) (-RRB- -RRB-))))) (VP (VBZ elicits) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (JJ dose-dependent) (NNS behaviors))) (SBAR (WHNP (WDT that)) (S (VP (VBP go) (PP (IN from) (NP (NP (JJ altered) (NN exploration)) (, ,) (NP (NN sedation)) (, ,) (CC and) (NP (NNP Doc_15275829_294_301_Disease)) (, ,))) (PP (TO to) (NP (NNP Doc_15275829_306_314_Disease) (CC and) (NNP Doc_15275829_319_324_Disease)))))))) (. .)))
15275829	2	(S1 (S (NP (NNS nAChRs)) (VP (AUX are) (NP (JJ pentameric) (NN ion) (NNS channels)) (ADVP (RB usually)) (VP (VBN composed) (PP (IN of) (NP (NP (NN alpha)) (CC and) (NP (JJ beta) (NNS subunits)))))) (. .)))
15275829	3	(S1 (S (NP (DT A) (NN gene) (NN cluster)) (VP (VBZ comprises) (NP (NP (DT the) (NN alpha3) (, ,) (NN alpha5) (CC and) (NN beta4) (NNS subunits)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP coassemble) (S (VP (TO to) (VP (VB form) (NP (JJ functional) (NNS receptors)))))))))) (. .)))
15275829	4	(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (JJ beta4) (NNS subunits))) (PP (IN in) (NP (NP (JJ Doc_15275829_563_571_Chemical-induced) (NNP Doc_15275829_580_588_Disease) (CC and) (NNP Doc_15275829_593_607_Disease)) (PP (IN in) (NP (NP (NP (JJ beta4) (JJ homozygous) (NN null)) (PRN (-LRB- -LRB-) (NP (CD beta4) (NN -/-)) (-RRB- -RRB-)) (CC and) (NP (JJ alpha3) (NN heterozygous))) (-LRB- -LRB-) (NP (NN +/-)) (-RRB- -RRB-) (FW mice.) (FW beta4)))))) (SBAR (S (NP (JJ -/-) (NNS mice)) (VP (AUX were) (ADJP (RBR less) (JJ sensitive) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_15275829_734_742_Chemical)))))) (PP (DT both) (PP (IN at) (NP (NP (JJ low) (NNS doses)) (, ,) (VP (VBN measured) (PP (IN as) (NP (NP (VBN decreased) (NN exploration)) (PP (IN in) (NP (DT an) (JJ open) (NN field)))))) (, ,))) (CC and) (PP (IN at) (NP (NP (JJ high) (NNS doses)) (, ,) (VP (VBN measured) (PP (IN as) (NP (NP (NN sensitivity)) (PP (TO to) (NP (JJ Doc_15275829_860_868_Chemical-induced) (NNP Doc_15275829_877_885_Disease))))))))))))) (. .)))
15275829	5	(S1 (S (S (S (VP (VBG Using) (PRT (RP in)) (NP (JJ situ) (NN hybridization) (NNS probes)) (PP (IN for) (NP (DT the) (JJ alpha3) (CC and) (JJ alpha5) (NNS subunits))))) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NN alpha5) (NN mRNA) (NNS levels)) (VP (AUX are) (ADJP (JJ unchanged)) (, ,) (SBAR (IN whereas) (S (NP (JJ alpha3) (NN mRNA) (NNS levels)) (VP (AUX are) (ADVP (RB selectively)) (VP (VBN decreased) (PP (IN in) (NP (NP (DT the) (JJ mitral) (NN cell) (NN layer)) (PP (IN of) (NP (DT the) (JJ olfactory) (NN bulb)))))))))))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ inferior)) (CC and) (NP (NP (DT the) (JJ superior) (NN colliculus)) (PP (IN of) (NP (CD beta4) (JJ -/-) (JJ brains.) (NN alpha3) (NN +/-) (NNS mice))))) (VP (AUX were) (ADJP (RB partially) (JJ resistant) (PP (TO to) (NP (JJ Doc_15275829_1218_1226_Chemical-induced) (NNP Doc_15275829_1235_1243_Disease)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (JJ wild-type) (NNS littermates)))))))) (. .)))
15275829	6	(S1 (S (NP (NP (NN mRNA) (NNS levels)) (PP (IN for) (NP (NP (DT the) (NNS alpha5)) (CC and) (NP (DT the) (JJ beta4) (NNS subunits))))) (VP (AUX were) (ADJP (JJ unchanged)) (PP (IN in) (NP (JJ alpha3) (JJ +/-) (NNS brains)))) (. .)))
15275829	7	(S1 (S (ADVP (RB Together)) (, ,) (NP (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NNS beta4)) (CC and) (NP (DT the) (JJ alpha3) (NNS subunits))) (VP (AUX are) (NP (NP (NNS mediators)) (PP (IN of) (NP (NNP Doc_15275829_1459_1467_Chemical-induced) (NNP Doc_15275829_1476_1484_Disease) (CC and) (NNP Doc_15275829_1489_1503_Disease)))))))) (. .)))
15278670	0	(S1 (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_15278670_15_26_Chemical))) (PP (IN on) (NP (NNP Doc_15278670_30_39_Chemical-induced) (NNP Doc_15278670_48_59_Disease))) (. .)))
15278670	1	(S1 (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NNP Doc_15278670_78_89_Chemical))) (PP (IN on) (NP (NNP Doc_15278670_93_102_Chemical-induced) (NNP Doc_15278670_111_122_Disease)))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NNS cats))))) (. .)))
15278670	2	(S1 (S (NP (NP (DT The) (NNP Doc_15278670_148_158_Disease) (NN threshold)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NN SD)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (CD 41.4) (NN +/-)) (ADJP (CD 6.5) (NN mg.) (NP (NP (NNP l)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (PP (IN with) (NP (NP (NNP Doc_15278670_215_224_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 6) (CD mg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NN .min)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (-RRB- -RRB-))))))) (, ,) (S (VP (VBG increasing) (ADVP (RB significantly)) (PP (TO to) (NP (NP (CD 66.6) (NN +/-)) (NP (NP (QP (CD 10.9) (CD mg.)) (NN l)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-)))))))) (ADVP (WRB when)) (S (NP (NP (DT the) (JJ end-tidal) (NN concentration)) (PP (IN of) (NP (NNP Doc_15278670_345_356_Chemical)))) (VP (AUX was) (NP (CD 0.8) (NN %)))) (. .)))
15278670	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN threshold)) (PRN (-LRB- -LRB-) (NP (NP (CD 61.6) (NN +/-)) (ADJP (CD 8.7) (CD mg.) (NN l) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))) (-RRB- -RRB-)) (PP (IN during) (NP (ADJP (CD 1.6) (NN %)) (NNP Doc_15278670_427_438_Chemical)))) (VP (AUX was) (RB not) (ADJP (JJ significant)) (PP (IN from) (NP (DT that))) (PP (IN during) (NP (ADJP (CD 0.8) (NN %)) (NN Doc_15278670_481_492_Chemical))) (, ,) (S (VP (VBG indicating) (NP (DT a) (VBG celling) (NN effect))))) (. .)))
15278670	4	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (DT the) (NNP Doc_15278670_566_576_Disease) (NN threshold))) (PP (IN between) (NP (NP (NNP Doc_15278670_595_606_Chemical)) (CC and) (NP (NNP Doc_15278670_611_620_Chemical)))))) (. .)))
15278670	5	(S1 (S (NP (NP (DT The) (NN rise)) (PP (IN in) (NP (NN blood) (NN pressure)))) (VP (VBD became) (ADJP (RBR less) (JJ marked)) (SBAR (WHADVP (WRB when)) (S (S (NP (NP (JJR higher) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_15278670_698_709_Chemical)) (CC or) (NP (NNP Doc_15278670_713_722_Chemical))))) (VP (AUX were) (VP (VBN administered)))) (CC and) (S (NP (NP (DT the) (NN blood) (NN pressure)) (PP (IN at) (NP (NNP Doc_15278670_767_778_Disease)))) (VP (VBD decreased) (PP (RB significantly) (PP (IN in) (NP (ADJP (CD 1.6) (NN %)) (NNP Doc_15278670_811_822_Chemical))) (, ,) (CC and) (PP (IN in) (NP (NP (NP (CD 0.8) (NN %)) (CC and) (NP (CD 1.6) (NN %))) (NNP Doc_15278670_845_854_Chemical))))))))) (. .)))
15278670	6	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (JJ Doc_15278670_908_917_Chemical) (NNS concentrations)) (VP (VBN measured) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ systolic) (NN blood) (NN pressure)) (VP (VBD became) (NP (CD 70) (NN mmHg)))))))))) (. .)))
15278670	7	(S1 (S (NP (NP (NNP Doc_15278670_991_997_Chemical)) (, ,) (NP (NP (DT a) (JJ selective) (NN blocker)) (PP (IN of) (NP (JJ Doc_15278670_1022_1029_Chemical-dependent) (NNP Doc_15278670_1040_1049_Chemical) (NNS channels)))) (, ,)) (VP (AUX was) (VP (VBN administered) (ADVP (RB intracerebroventricularly)) (PP (IN in) (NP (NP (NNS rats)) (ADJP (JJ anesthetized) (PP (IN with) (NP (CD 0.8) (NN %)))))) (NP (NNP Doc_15278670_1134_1145_Chemical)) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (DT the) (JJ anticonvulsive) (NNS effects))))))))) (. .)))
15278670	8	(S1 (S (S (NP (NP (NN Doc_15278670_1206_1212_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN ng)) (-RRB- -RRB-))) (VP (AUX had) (NP (DT a) (NN tendency) (S (VP (TO to) (VP (VB decrease) (NP (DT the) (NNP Doc_15278670_1252_1262_Disease) (NN threshold)))))))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 21.6) (JJ +/-) (CD 2.2) (TO to) (CD 19.9)) (NN +/-)) (ADJP (ADJP (QP (CD 2.5) (CD mg.)) (NN l)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))) (-RRB- -RRB-)) (CC but) (S (NP (DT this)) (VP (AUX was) (RB not) (ADJP (RB statistically) (JJ significant)))) (. .)))
15278670	9	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NNP Doc_15278670_1379_1390_Chemical)) (VP (VP (VBZ reduces) (NP (NP (DT the) (JJ Doc_15278670_1403_1413_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_15278670_1424_1433_Chemical) (NNP Doc_15278670_1434_1442_Disease))))) (CC but) (VP (VBZ carries) (NP (NP (DT some) (NN risk)) (ADJP (JJ due) (PP (TO to) (NP (JJ circulatory) (NN Doc_15278670_1484_1494_Disease))))))))))) (. .)))
15325671	0	(S1 (S (NP (NN Doc_15325671_0_16_Disease)) (VP (VBD observed) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (JJ high-dose) (JJ Doc_15325671_56_72_Chemical-based) (NN chemotherapy)) (PP (IN for) (NP (JJ metastatic) (NNP Doc_15325671_107_120_Disease)))))) (. .)))
15325671	1	(S1 (S (NP (NN Doc_15325671_136_152_Chemical)) (VP (AUX is) (NP (NP (DT an) (VBG alkylating) (NN agent)) (VP (VBN given) (ADVP (RB frequently)) (PP (IN as) (NP (NP (DT a) (NN component)) (PP (IN of) (NP (JJ many) (NN conditioning) (NNS regimens)))))))) (. .)))
15325671	2	(S1 (S (PP (IN In) (NP (JJ high) (NNS doses))) (, ,) (NP (PRP$ its) (JJ nonhematological) (NN dose-limiting) (NN Doc_15325671_289_297_Disease)) (VP (AUX is) (ADJP (JJ Doc_15325671_301_315_Disease))) (. .)))
15325671	3	(S1 (NP (NN STUDY) (NN DESIGN) (: :) (S (NP (PRP We)) (VP (VBD combined) (NP (NP (NP (NNP Doc_15325671_343_353_Chemical)) (, ,) (NP (NNP Doc_15325671_355_364_Chemical)) (CC and) (NP (JJ high-dose) (NNP Doc_15325671_379_395_Chemical))) (, ,) (NP (NNP Doc_15325671_397_405_Chemical)) (, ,) (CC and) (NP (NNP Doc_15325671_411_422_Chemical))) (PP (IN in) (NP (NP (DT a) (JJ triple) (JJ sequential) (NN high-dose) (NN regimen)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ metastatic) (NNP Doc_15325671_493_506_Disease))))))))) (. .)))
15325671	4	(S1 (S (NP (NN Analysis)) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (NP (NP (CD 61) (NNS women)) (PP (IN with) (NP (NP (JJ chemotherapy-responsive) (JJ metastatic) (NN Doc_15325671_583_596_Disease)) (VP (VBG receiving) (NP (JJ 96-h) (JJ infusional) (NN Doc_15325671_623_639_Chemical)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJ triple) (JJ sequential) (NN high-dose) (NN regimen)) (SBAR (S (VP (TO to) (VP (VB assess) (NP (NN association)) (PP (IN between) (NP (NP (NN presence)) (PP (IN of) (NP (NP (NP (JJ peritransplant) (NNP Doc_15325671_746_770_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15325671_772_775_Disease)) (-RRB- -RRB-))) (CC and) (NP (DT the) (JJ following) (NN pretreatment) (NNS characteristics)))))))))))))))))) (: :) (NP (NP (NP (NN presence)) (PP (IN of) (NP (NN electrocardiogram) (-LRB- -LRB-) (CD EKG) (-RRB- -RRB-) (NNS abnormalities)))) (, ,) (NP (NN age)) (, ,) (NP (NNP Doc_15325671_881_893_Disease)) (, ,) (NP (JJ prior) (JJ cardiac) (NN history)) (, ,) (NP (NN smoking)) (, ,) (NP (NNP Doc_15325671_927_944_Disease)) (, ,) (NP (NP (JJ prior) (NN use)) (PP (IN of) (NP (NNP Doc_15325671_959_973_Chemical)))) (, ,) (CC and) (NP (JJ left-sided) (NN chest) (NN irradiation))))))) (. .)))
15325671	5	(S1 (S (NP (NP (CD Six)) (PP (IN of) (NP (NP (CD 61) (NNS women)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))))) (VP (VBD developed) (NP (ADJP (RB clinically) (JJ reversible)) (NN grade)) (NP (CD 3) (NN Doc_15325671_1080_1083_Disease)) (PP (VBG following) (NP (NP (JJ infusional) (NN Doc_15325671_1105_1121_Chemical)) (PP (IN with) (NP (NP (DT a) (JJ median) (NN percent) (NN decline)) (PP (IN in) (NP (NP (NN ejection) (NN fraction)) (PP (IN of) (NP (CD 31) (NN %)))))))))) (. .)))
15325671	6	(S1 (S (NP (NP (NN Incidence)) (PP (IN of) (NP (NP (JJ transient) (JJ Doc_15325671_1204_1220_Chemical-related) (NN Doc_15325671_1229_1245_Disease)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))))) (VP (AUX is) (ADJP (JJ comparable) (PP (TO to) (NP (JJ previous) (JJ recorded) (NN literature))))) (. .)))
15325671	7	(S1 (S (NP (JJR Older) (NN age)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN correlated) (PP (PP (IN with) (NP (DT the) (NNP Doc_15325671_1347_1350_Disease) (NN development))) (: ;) (PP (IN with) (NP (NP (JJ median) (NNS ages)) (PP (IN for) (NP (DT the) (JJ entire) (NN group))))) (CC and) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG developing) (NP (NP (NNP Doc_15325671_1430_1433_Disease)) (PP (IN of) (NP (NP (CD 45)) (CC and) (NP (CD 59)))) (, ,) (ADVP (RB respectively))))))))) (. .)))
15325671	8	(S1 (S (NP (DT No) (NN association)) (VP (AUX was) (VP (VBN found) (PP (IN with) (NP (JJ other) (NN pretreatment) (NNS characteristics))))) (. .)))
15325671	9	(S1 (S (PP (IN As) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (DT these) (NNS findings))))) (, ,) (NP (NNS oncologists)) (VP (MD should) (ADVP (RB carefully)) (VP (VB monitor) (NP (NP (NN fluid) (NN balance)) (PP (IN in) (NP (JJR older) (NNS patients)))))) (. .)))
15325671	10	(S1 (S (NP (NP (JJ Routine) (NNS EKG)) (VP (VBG monitoring) (PP (IN during) (NP (JJ infusional) (NNP Doc_15325671_1683_1699_Chemical))))) (VP (AUX did) (RB not) (VP (VB predict) (NP (JJ Doc_15325671_1716_1719_Disease) (NN development)))) (. .)))
15338796	0	(S1 (S (NP (NP (JJ Doc_15338796_0_6_Disease) (JJ side) (NNS effects)) (PP (IN of) (NP (NNP Doc_15338796_23_33_Chemical)))) (, ,) (VP (VBN quantified) (PP (IN by) (NP (DT a) (NN laser) (NN pointer) (NN technique)))) (. .)))
15338796	1	(S1 (S (S (VP (TO To) (VP (VB study) (NP (NP (NNP Doc_15338796_96_102_Disease) (NN side) (NNS effects)) (PP (IN of) (NP (NNP Doc_15338796_119_129_Chemical)))) (NP (DT an) (ADJP (ADJP (RB easily) (JJ applicable)) (, ,) (ADJP (JJ quick)) (CC and) (ADJP (JJ low-priced))) (NN method))))) (VP (AUX is) (VP (VBN needed))) (. .)))
15338796	2	(S1 (S (NP (NP (DT A) (JJ new) (NN method)) (VP (VBG using) (NP (DT a) (ADJP (RB commercially) (JJ available)) (, ,) (JJ pen-shaped) (NN laser) (NN pointer)))) (VP (AUX was) (VP (VBN developed))) (. .)))
15338796	3	(S1 (S (NP (NP (NN Aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (NN sensitivity)) (, ,) (NP (NN reproducibility)) (, ,) (NP (NN reference) (NNS values)) (CC and) (NP (NP (DT the) (NN agreement)) (PP (IN with) (NP (DT a) (NN questionnaire))))))))) (. .)))
15338796	4	(S1 (S (NP (NN Doc_15338796_406_412_Disease)) (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (DT a) (NN laser) (NN pointer) (NN technique)))))) (. .)))
15338796	5	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NN sensitivity))))) (NP (PRP we)) (VP (VBD assessed) (NP (NN Doc_15338796_496_502_Disease)) (PP (IN in) (NP (NP (CD 44) (NNS patients)) (PP (IN with) (NP (NNP Doc_15338796_523_547_Disease))))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ cumulative) (NNS doses)) (PP (IN of) (NP (NNP Doc_15338796_592_602_Chemical)))))))) (. .)))
15338796	6	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (VP (VBN asked) (S (VP (TO to) (VP (VB aim) (PP (IN at) (NP (NP (DT the) (NNP centre)) (PP (IN of) (NP (NP (DT a) (NN target)) (, ,) (VP (VBN subdivided) (PP (IN in) (NP (JJ concentric) (NNS circles))))))))))) (, ,) (PP (IN from) (NP (CD 5) (NNP m) (NN distance))))) (. .)))
15338796	7	(S1 (S (NP (NP (DT The) (NN circle)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN participant)) (VP (VBD succeeded) (PP (TO to) (NP (NN aim))))))) (VP (AUX was) (VP (VBN recorded) (PP (IN in) (NP (JJ millimetres) (NNS radius))))) (. .)))
15338796	8	(S1 (S (PP (IN In) (NP (NP (DT another) (NN series)) (PP (IN of) (NP (NNS measurements))))) (, ,) (NP (NP (NN reproducibility) (CC and) (NN reference) (NNS values)) (PP (IN of) (NP (DT the) (NNP Doc_15338796_879_885_Disease)))) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (CD 65) (JJ healthy) (NNS subjects)) (PP (IN in) (NP (CD three) (NNS sessions))))) (, ,) (PP (IN at) (NP (NP (CD 9) (NN a.m.)) (, ,) (NP (CD 4) (NN p.m.)) (CC and) (NP (NP (CD 9) (NN a.m.)) (, ,) (ADVP (RB respectively))))) (, ,) (ADVP (NP (CD 1) (NN week)) (RB later)))) (. .)))
15338796	9	(S1 (S (S (NP (NNP Postural) (NNP Doc_15338796_1008_1014_Disease)) (VP (AUX was) (VP (VBN measured) (PP (IN with) (NP (NP (DT the) (NN arm) (ADJP (RB horizontally) (VBN outstretched)) (NN rest)) (ADJP (JJ Doc_15338796_1072_1078_Disease) (PP (IN with) (NP (NP (DT the) (NN arm)) (VP (VBN supported) (PP (IN by) (NP (DT an) (NN armrest)))))))))))) (CC and) (S (ADVP (RB finally)) (NP (NNP Doc_15338796_1128_1134_Disease)) (VP (AUX was) (VP (VBN measured) (PP (IN after) (S (VP (VBG holding) (NP (NP (DT a) (JJ 2-kg) (NN weight)) (PP (IN until) (NP (NN exhaustion)))))))))) (. .)))
15338796	10	(S1 (S (NP (JJ Inter-observer) (NN variability)) (VP (AUX was) (VP (VBN measured) (PP (IN in) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (CD 10) (JJ healthy) (NNS subjects))))))) (. .)))
15338796	11	(S1 (S (NP (NN Doc_15338796_1270_1276_Disease)) (VP (AUX was) (VP (VBN measured) (ADVP (RB simultaneously)) (PP (IN by) (NP (CD two) (JJ independent) (NNS observers))))) (. .)))
15338796	12	(S1 (S (NP (NN Doc_15338796_1344_1354_Chemical)) (ADVP (RB significantly)) (VP (VBD increased) (NP (JJ Doc_15338796_1379_1385_Disease) (NN severity)) (PP (IN in) (NP (NNS patients))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN way)))) (. .)))
15338796	13	(S1 (S (PP (IN Within) (NP (JJ healthy) (NNS adults))) (NP (DT no) (NN age-dependency)) (VP (MD could) (VP (AUX be) (VP (VBN found) (PRN (-LRB- -LRB-) (FRAG (NP (NNP b)) (X (SYM =) (ADJP (CD 0.262) (NN mm/year))) (: ;) (NP (NN P)) (X (SYM =)) (NP (CD 0.72))) (-RRB- -RRB-))))) (. .)))
15338796	14	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN agreement)) (PP (IN between) (NP (NP (DT the) (NN questionnaire)) (CC and) (NP (NP (JJ Doc_15338796_1571_1577_Disease) (NN severity)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.093)) (: ;) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.53)))) (-RRB- -RRB-))))))) (. .)))
15338796	15	(S1 (S (NP (NNP Postural) (NNP Doc_15338796_1619_1625_Disease)) (VP (VBD showed) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (DT the) (JJ first) (CC and) (JJ third) (NN session)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.07)))) (-RRB- -RRB-)))))) (. .)))
15338796	16	(S1 (S (S (NP (NP (NN Support)) (PP (IN of) (NP (DT the) (NN arm)))) (VP (VBD decreased) (NP (JJ Doc_15338796_1736_1742_Disease) (NN severity)))) (, ,) (NP (NN exhaustion)) (VP (VBD increased) (NP (JJ Doc_15338796_1774_1780_Disease) (NN severity)) (ADVP (RB significantly))) (. .)))
15338796	17	(S1 (S (NP (DT A) (JJ good) (NN agreement)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (CD two) (JJ independent) (NNS observers)) (PRN (-LRB- -LRB-) (NP (JJ interclass) (NN correlation) (NN coefficient) (NN 0.72)) (-RRB- -RRB-)))))) (. .)))
15338796	18	(S1 (S (S (VP (VBG Quantifying) (NP (NN Doc_15338796_1933_1939_Disease)) (PP (IN by) (S (VP (VBG using) (NP (DT an) (JJ inexpensive) (NN laser) (NN pointer))))))) (VP (AUX is) (, ,) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (NNS children)) (PRN (-LRB- -LRB-) (NP (CD <12) (NNS years)) (-RRB- -RRB-)))))) (NP (DT a) (ADJP (JJ sensitive) (CC and) (JJ reproducible)) (NN method))) (. .)))
15458908	0	(S1 (NP (NP (NP (NP (NN Safety)) (CC and) (NP (JJ adverse) (NNS effects))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_15458908_43_53_Chemical))))) (: :) (NP (NP (JJ multiple) (NNS outcomes)) (PP (IN of) (NP (JJ Doc_15458908_76_86_Chemical) (NN evaluation)))) (. .)))
15458908	1	(S1 (FRAG (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_15458908_135_145_Chemical))) (PP (IN on) (NP (NP (JJ major) (JJ adverse) (NNS events)) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (IN with) (NP (NP (JJ postmenopausal) (JJ Doc_15458908_201_209_Chemical) (NN therapy)) (CC or) (NP (NNP Doc_15458908_221_230_Chemical))))))))))))) (. .)))
15458908	2	(S1 (S (NP (NP (DT The) (JJ Multiple) (NNS Outcomes)) (PP (IN of) (NP (NP (JJ Doc_15458908_266_276_Chemical) (NN Evaluation)) (, ,) (NP (DT a) (NN multicenter)) (, ,) (NP (NN randomized)) (, ,) (NP (JJ double-blind) (NN trial)) (, ,)))) (VP (VBD enrolled) (NP (NP (CD 7,705) (JJ postmenopausal) (NNS women)) (PP (IN with) (NP (NNP Doc_15458908_377_389_Disease))))) (. .)))
15458908	3	(S1 (S (NP (NNS Women)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (NNP Doc_15458908_423_433_Chemical) (CD 60) (NN mg/d)) (CC or) (NP (NP (CD 120) (NN mg/d)) (CC or) (NP (NN placebo))))))) (. .)))
15458908	4	(S1 (S (NP (NNS Outcomes)) (VP (VBD included) (NP (NP (NNP Doc_15458908_484_506_Disease)) (, ,) (NP (NNP Doc_15458908_508_517_Disease)) (, ,) (NP (NNP Doc_15458908_519_538_Disease)) (, ,) (CC and) (NP (NNP Doc_15458908_544_577_Disease)))) (. .)))
15458908	5	(S1 (S (PP (IN During) (NP (NP (DT a) (JJ mean) (NN follow-up)) (PP (IN of) (NP (CD 3.3) (NNS years))))) (, ,) (NP (NNP Doc_15458908_626_636_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN for) (NP (NP (NNP Doc_15458908_679_701_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ relative) (NN risk) (JJ -LSB-RR) (NN -RSB-) (CD 2.1)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (NP (JJ interval) (JJ -LSB-CI) (JJ -RSB-) (NNS 1.2-3.8)))) (-RRB- -RRB-)))))))) (. .)))
15458908	6	(S1 (S (S (NP (DT The) (JJ excess) (NN event) (NN rate)) (VP (AUX was) (NP (NP (QP (CD 1.8) (IN per) (CD 1,000)) (NNS woman-years)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD -0.5-4.1))) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (DT the) (NN number)) (VP (VBD needed) (S (VP (TO to) (VP (VB treat) (S (VP (TO to) (VP (VB cause) (SBAR (S (NP (CD 1) (NN event)) (VP (AUX was) (NP (CD 170)))))))) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD 100-582))) (-RRB- -RRB-)) (PP (IN over) (NP (CD 3.3) (NNS years)))))))) (. .)))
15458908	7	(S1 (S (NP (NP (NN Risk)) (PP (IN in) (NP (DT the) (NNP Doc_15458908_938_948_Chemical) (NN group)))) (VP (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (PP (IN in) (NP (NP (DT the) (NN placebo) (NN group)) (PP (IN for) (NP (DT the) (JJ first) (CD 2) (NNS years)))))))) (, ,) (CC but) (VP (VBD decreased) (PP (TO to) (NP (RB about) (DT the) (JJ same) (NN rate))) (PP (IN as) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (ADVP (RB thereafter)))) (. .)))
15458908	8	(S1 (S (NP (NNP Doc_15458908_1088_1098_Chemical)) (VP (AUX did) (RB not) (VP (VB increase) (NP (NP (NN risk)) (PP (IN for) (NP (NP (NNP Doc_15458908_1125_1134_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN RR) (CD 0.9)) (: ;) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.8-1.1)))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_15458908_1161_1180_Disease)) (PRN (-LRB- -LRB-) (NP (NNP RR) (CD 1.0)) (: ;) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.7-1.3))) (-RRB- -RRB-)) (, ,) (NP (NP (NNP Doc_15458908_1207_1230_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN RR) (CD 1.3)) (: ;) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.4-5.1)))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NNP Doc_15458908_1260_1278_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN RR) (CD 0.9)) (: ;) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.3-2.7)))) (-RRB- -RRB-)))))))) (. .)))
15458908	9	(S1 (S (S (NP (NN Doc_15458908_1317_1327_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN for) (NP (NNP Doc_15458908_1370_1392_Disease)))))))) (, ,) (CC but) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (VBN increased) (NN risk)) (PP (IN for) (NP (NP (NNP Doc_15458908_1430_1439_Disease)) (, ,) (NP (NNP Doc_15458908_1441_1460_Disease)) (, ,) (NP (NNP Doc_15458908_1462_1485_Disease)) (, ,) (CC or) (NP (NNP Doc_15458908_1490_1508_Disease))))))) (. .)))
15458908	10	(S1 (NP (NP (NP (NN LEVEL)) (PP (IN OF) (NP (NN EVIDENCE)))) (: :) (NP (PRP I))))
1549199	0	(S1 (NP (NP (NN Optimization)) (PP (IN of) (NP (JJ Doc_1549199_16_24_Chemical) (NN therapy))) (. .)))
1549199	1	(S1 (S (SBAR (IN While) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (JJ single) (JJ correct) (NN starting) (NN dose)) (PP (IN for) (NP (JJ Doc_1549199_85_93_Chemical) (NN therapy))))))) (, ,) (NP (JJ many) (NNS individuals)) (VP (MD can) (VP (AUX be) (VP (VBN started) (PP (IN on) (NP (CC either) (DT the) (NN 25/100) (CC or) (NN controlled-release) (NN formula))) (, ,) (PP (VBG following) (NP (NP (DT the) (JJ general) (NN rule)) (SBAR (S (RB not) (VP (TO to) (VP (VB attempt) (S (VP (TO to) (VP (VB titrate) (ADJP (JJ Doc_1549199_240_249_Chemical-Doc_1549199_250_258_Chemical) (PP (TO to) (NP (NP (DT the) (NN point)) (PP (IN of) (NP (`` ``) (NP (NN normality)) (, ,) ('' '') (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NNP Doc_1549199_306_314_Disease)))))))))))))))))))))))) (. .)))
1549199	2	(S1 (S (S (NP (DT The) (NN physician)) (VP (MD should) (ADVP (RB also)) (VP (VB determine) (NP (NP (DT the) (JJ proper) (NN use)) (PP (IN of) (NP (DT any) (JJ adjunctive) (NNS medications))))))) (: ;) (S (NP (JJ such) (JJ combined) (NN therapy)) (VP (AUX has) (VP (VBN become) (NP (NP (DT the) (JJ standard) (NN approach)) (PP (TO to) (NP (NN treatment))))))) (. .)))
1549199	3	(S1 (S (PP (VBG Following) (NP (NP (DT the) (JJ initial) (NN period)) (PP (IN of) (NP (NN therapy))))) (, ,) (NP (VBG emerging) (NNS difficulties)) (VP (VBP require) (NP (NP (DT a) (NN reassessment)) (PP (IN of) (NP (NP (JJ therapeutic) (NNS approaches)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN dosage) (NN adjustment) (CC or) (NN introduction)) (PP (IN of) (NP (DT a) (JJ Doc_1549199_627_635_Chemical) (NN agonist))))))))) (. .)))
1549199	4	(S1 (S (NP (NP (JJ Other) (JJ possible) (JJ adverse) (NN effects--such)) (PP (IN as) (NP (NP (NNP Doc_1549199_685_711_Disease)) (, ,) (NP (NNP Doc_1549199_713_736_Disease)) (, ,) (NP (NNP Doc_1549199_738_746_Chemical-induced) (NNP Doc_1549199_755_764_Disease) (, ,) (NNP Doc_1549199_766_784_Disease) (CC or) (NNP Doc_1549199_788_799_Disease)) (, ,) (CC or) (NP (NN drug) (NN interactions--also))))) (VP (VBP require) (NP (ADJP (RB carefully) (VBN monitored)) (JJ individual) (NN treatment))) (. .)))
1549199	5	(S1 (S (NP (JJ Nonpharmacologic) (NNS concerns)) (VP (MD can) (VP (VB help) (S (NP (DT the) (NNP Doc_1549199_917_936_Disease) (NN patient)) (VP (VP (VB achieve)) (CC and) (VP (VB maintain) (NP (NP (JJ optimal) (NN functioning)) (, ,) (PP (VBG including) (NP (NP (JJ daily) (NN exercise)) (, ,) (NP (JJ physical) (NN therapy)) (, ,) (CC and) (NP (NP (NN involvement)) (PP (IN with) (NP (NN support) (NNS groups)))))))))))) (. .)))
15515654	0	(S1 (FRAG (NP (NP (JJ Long) (NN term) (NN audiological) (NN evaluation)) (PP (IN of) (NP (NNP Doc_15515654_37_53_Disease) (NNS patients)))) (. .)))
15515654	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (VP (TO to) (VP (VB identify) (NP (DT the) (NN incidence)))) (CC and) (VP (TO to) (VP (VB monitor) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_15515654_167_179_Disease))) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NP (JJ young) (NNS adults)) (PP (IN with) (NP (NNP Doc_15515654_214_230_Disease) (NN major)))))))))))) (. .)))
15515654	2	(S1 (S (NP (NP (QP (CD One) (CD hundred) (CC and) (CD four)) (PRN (-LRB- -LRB-) (NP (CD 104)) (-RRB- -RRB-)) (NNS patients)) (VP (VBN aged) (NP (NP (CD 6-35) (NNS years)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ 17,2) (NNS years)) (-RRB- -RRB-))))) (VP (VBD participated) (PP (IN in) (NP (DT the) (NN study)))) (. .)))
15515654	3	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (PP (IN on) (NP (NP (DT a) (JJ regular) (NN transfusion-chelation) (NN program)) (VP (VBG maintaining) (NP (NP (DT a) (JJ mean) (NN hemoglobin) (NN level)) (PP (IN of) (NP (CD 9.5) (NN gr/dl)))))))) (. .)))
15515654	4	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (S (VP (VBG receiving) (NP (NP (NNP Doc_15515654_479_494_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15515654_496_499_Chemical)) (-RRB- -RRB-)) (NN chelation) (NN treatment)) (PP (IN with) (NP (NP (DT a) (JJ mean) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD 50-60) (NN mg/kg)) (, ,) (NP (NP (CD 5-6) (NNS days)) (NP (DT a) (NN week)))))))) (PP (IN during) (NP (NP (DT the) (JJ first) (CD six) (NNS years)) (PP (IN of) (NP (NP (DT the) (NN study)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADVP (RB then)) (VP (VBN reduced) (PP (TO to) (NP (QP (CD 40-50) (CD mg/kg)))) (PP (IN for) (NP (DT the) (JJ following) (CD eight) (NNS years)))))))))))))) (. .)))
15515654	5	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN followed) (PP (IN for) (NP (CD 8-14) (NNS years))))) (. .)))
15515654	6	(S1 (S (ADVP (RB Overall)) (, ,) (NP (NP (QP (CD 21) (IN out) (IN of) (CD 104)) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 20.2) (NN %)) (-RRB- -RRB-))) (VP (VP (VBN presented) (PP (IN with) (NP (NP (JJ high) (NN frequency) (NNP Doc_15515654_804_830_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15515654_832_836_Disease)) (-RRB- -RRB-))))) (, ,) (CC either) (VP (ADJP (JJ unilateral) (CC or) (JJ bilateral)))) (. .)))
15515654	7	(S1 (S (NP (NP (DT No) (JJ Doc_15515654_874_882_Disease) (NN factor)) (, ,) (ADJP (JJ other) (PP (IN than) (NP (NNP Doc_15515654_902_905_Chemical)))) (, ,)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NNS patients))))))) (. .)))
15515654	8	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_15515654_957_961_Disease))) (VP (VBN presented) (PP (IN with) (NP (NP (ADJP (RB relatively) (JJR lower)) (NN serum) (NN ferritin) (NNS levels)) (PP (IN than) (NP (NP (DT those)) (PP (IN with) (NP (JJ normal) (NN hearing))))))))) (, ,) (ADVP (RB however)) (, ,) (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NN difference)) (VP (AUX was) (VP (VBN observed))) (. .)))
15515654	9	(S1 (S (NP (NP (NNS Subjects)) (PP (IN with) (NP (NNP Doc_15515654_1125_1129_Disease)))) (VP (AUX were) (VP (VBN submitted) (PP (TO to) (NP (NP (JJ Doc_15515654_1148_1151_Chemical) (NN reduction)) (CC or) (NP (JJ temporary) (NN withdrawal)))))) (. .)))
15515654	10	(S1 (S (PP (VBG Following) (NP (NN intervention))) (, ,) (S (NP (NP (CD 7) (NN out)) (PP (IN of) (NP (CD 21) (JJ affected) (NNS patients)))) (VP (VBD recovered))) (, ,) (S (NP (CD 10)) (VP (VBD remained) (ADJP (JJ stable)))) (CC and) (S (NP (CD 4)) (VP (VBD demonstrated) (NP (NN aggravation)))) (. .)))
15515654	11	(S1 (S (NP (DT The) (NNS findings)) (VP (AUX are) (ADJP (JJ indicative) (PP (IN of) (NP (NP (NP (NNP Doc_15515654_1346_1349_Chemical) (POS 's)) (VBG contributing) (NN role)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_15515654_1392_1410_Disease))))))))) (. .)))
15515654	12	(S1 (S (NP (JJ Regular) (JJ audiologic) (NN evaluation)) (VP (AUX is) (ADJP (JJ imperative)) (PP (IN in) (NP (DT all) (JJ Doc_15515654_1463_1474_Disease) (NNS patients))) (SBAR (IN so) (IN that) (S (S (NP (JJ early) (NNS changes)) (VP (MD may) (VP (AUX be) (VP (VBN recognized))))) (CC and) (S (NP (NN treatment)) (VP (MD may) (VP (AUX be) (VP (ADVP (RB judiciously)) (VBN adjusted) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VP (VB prevent)) (CC or) (VP (VB reverse) (NP (NNP Doc_15515654_1597_1615_Disease)))))))))))))) (. .)))
15572383	0	(S1 (S (NP (NP (JJ Individual) (NNS differences)) (PP (IN in) (NP (NP (JJ renal) (NN ACE) (NN activity)) (PP (IN in) (NP (JJ healthy) (NNS rats)))))) (VP (VBP predict) (NP (NN susceptibility)) (PP (TO to) (NP (JJ Doc_15572383_87_97_Chemical-induced) (NN Doc_15572383_106_118_Disease)))) (. .)))
15572383	1	(S1 (S (PP (IN In) (NP (NN man))) (, ,) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ Doc_15572383_155_166_Chemical-converting) (NN enzyme) (PRN (-LRB- -LRB-) (NP (NNP ACE)) (-RRB- -RRB-)) (NNS levels)) (, ,) (VP (VBN related) (PP (TO to) (NP (NNP ACE) (PRN (-LRB- -LRB-) (NP (NNP I/D)) (-RRB- -RRB-)) (NN genotype)))) (, ,)))) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (JJ renal) (NN prognosis))))) (. .)))
15572383	2	(S1 (S (NP (DT This)) (VP (VBZ raises) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (IN that)) (S (NP (NP (JJ individual) (NNS differences)) (PP (IN in) (NP (JJ renal) (NN ACE) (NN activity)))) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (JJ renal) (NN susceptibility)) (PP (TO to) (NP (VBN inflicted) (NN damage))))))))))) (. .)))
15572383	3	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (JJ predictive) (NN effect)) (PP (IN of) (NP (JJ renal) (NN ACE) (NN activity))) (PP (IN for) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_15572383_488_500_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_15572383_534_544_Chemical)) (PP (IN in) (NP (NNS rats)))))))))))) (. .)))
15572383	4	(S1 (S (NP (NP (JJ Renal) (NN ACE) (NN activity)) (PRN (-LRB- -LRB-) (NP (NP (JJ Doc_15572383_583_594_Chemical) (NN cleavage)) (PP (IN by) (NP (JJ cortical) (NNS homogenates)))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NP (JJ renal) (NN biopsy)) (PP (IN in) (NP (CD 27) (NN adult) (NN male) (JJ Wistar) (NNS rats))))))) (. .)))
15572383	5	(S1 (S (S (PP (IN After) (NP (NP (CD 1) (NN week)) (PP (IN of) (NP (NN recovery))))) (, ,) (NP (NNP Doc_15572383_716_727_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15572383_743_753_Chemical) (CD -LSB-1.5))) (PP (IN mg/kg) (NP (JJ intravenously) (PRN (-LRB- -LRB-) (CD i.v.) (-RRB- -RRB-) (NP (NNP n) (SYM =) (CD 18)) (: ;)) (NNS controls)))))) (, ,) (NP (NN saline) (NN i.v.) (NNP n)) (VP (SYM =) (NP (CD 9) (NN -RSB-))) (. .)))
15572383	6	(S1 (S (NP (NN Doc_15572383_824_835_Disease)) (VP (AUX was) (VP (VBN measured) (NP (DT every) (CD 2) (NNS weeks)))) (. .)))
15572383	7	(S1 (S (PP (IN After) (NP (CD 12) (NNS weeks))) (, ,) (S (NP (NNS rats)) (VP (AUX were) (VP (VBN sacrificed)))) (CC and) (S (NP (PRP$ their) (NNS kidneys)) (VP (VBN harvested))) (. .)))
15572383	8	(S1 (S (SBAR (IN As) (S (VP (VBN anticipated)))) (, ,) (NP (NNP Doc_15572383_955_965_Chemical)) (VP (VBD elicited) (S (NP (NNP Doc_15572383_975_984_Disease)) (VP (VB range) (NP (NP (NNP Doc_15572383_991_1002_Disease)) (, ,) (NP (NNP Doc_15572383_1004_1029_Disease)) (CC and) (NP (JJ mild) (NN Doc_15572383_1039_1063_Disease)))))) (. .)))
15572383	9	(S1 (S (NP (JJ Baseline) (JJ renal) (NN ACE)) (ADVP (RB positively)) (VP (VBD correlated) (PP (IN with) (NP (NP (DT the) (JJ relative) (NN rise)) (PP (IN in) (NP (NNP Doc_15572383_1132_1143_Disease))) (PP (IN after) (NP (NP (NNP Doc_15572383_1150_1160_Chemical)) (PRN (-LRB- -LRB-) (NP (NN r) (SYM =) (CD 0.62) (, ,) (CD P<0.01)) (-RRB- -RRB-)) (, ,) (NP (JJ renal) (JJ interstitial) (JJ alpha-smooth) (NN muscle) (NN actin)) (PRN (-LRB- -LRB-) (NP (NN r) (SYM =) (CD 0.49)) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-)) (, ,) (NP (JJ interstitial) (NN macrophage) (NN influx)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.56)) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (JJ interstitial) (NN collagen) (NNP III)) (PRN (-LRB- -LRB-) (NP (QP (SYM r) (SYM =) (CD 0.53))) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-))) (, ,) (NP (JJ glomerular) (NX (NX (NX (JJ alpha-smooth) (NN muscle) (NN actin)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.74)) (, ,) (NP (NNP P<0.01)) (-RRB- -RRB-))) (CC and) (NX (NX (JJ glomerular) (NN desmin)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.48)) (, ,) (NP (NNP P<0.05)) (-RRB- -RRB-))))))))))) (. .)))
15572383	10	(S1 (S (NP (JJ Baseline) (JJ renal) (NN ACE)) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (NNP Doc_15572383_1483_1507_Disease)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.22)) (, ,) (NP (NNP NS)) (-RRB- -RRB-)))))) (. .)))
15572383	11	(S1 (S (PP (IN In) (NP (NNS controls))) (, ,) (NP (NP (DT no) (JJ predictive) (NNS values)) (PP (IN for) (NP (JJ renal) (NNS parameters)))) (VP (AUX were) (VP (VBN observed))) (. .)))
15572383	12	(S1 (S (NP (NP (JJ Individual) (NNS differences)) (PP (IN in) (NP (JJ renal) (NN ACE) (NN activity)))) (VP (VBP predict) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_15572383_1675_1685_Chemical-induced) (NNP Doc_15572383_1694_1706_Disease))) (PP (IN in) (NP (DT this) (JJ outbred) (NN rat) (NN strain))))) (. .)))
15572383	13	(S1 (S (NP (DT This)) (VP (VBZ supports) (NP (DT the) (NN assumption) (SBAR (IN that) (S (NP (NP (NNS differences)) (PP (IN in) (NP (JJ renal) (NN ACE) (NN activity)))) (VP (VB predispose) (PP (TO to) (NP (NP (DT a) (ADJP (RBR less) (JJ favourable)) (NN course)) (PP (IN of) (NP (NN Doc_15572383_1845_1857_Disease)))))))))) (. .)))
15602202	0	(S1 (S (NP (JJ Recurrent) (JJ acute) (NN Doc_15602202_16_38_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15602202_50_62_Chemical)))) (. .)))
15602202	1	(S1 (S (NP (DT A) (JJ 14-year-old) (NN girl)) (VP (AUX is) (VP (VBN reported) (PP (IN with) (NP (ADJP (JJ recurrent) (, ,) (JJ Doc_15602202_111_123_Chemical-induced) (, ,) (JJ acute)) (NNP Doc_15602202_139_161_Disease))))) (. .)))
15602202	2	(S1 (S (S (NP (DT The) (JJ second) (NN episode)) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ severe)) (PP (IN than) (NP (DT the) (JJ first)))))) (: ;) (S (CC and) (SBAR (IN although) (S (NP (DT both)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (JJ intensive) (JJ corticosteroid) (NN therapy))))))) (, ,) (NP (JJ renal) (NN function)) (VP (VBD remained) (ADJP (JJ impaired)))) (. .)))
15602202	3	(S1 (S (SBAR (IN Although) (S (NP (NP (JJS most) (NNS cases)) (PP (IN of) (NP (JJ antibiotic) (VBN induced) (JJ acute) (NNP Doc_15602202_366_388_Disease)))) (VP (AUX are) (ADJP (ADJP (JJ benign)) (CC and) (ADJP (JJ self-limited)))))) (, ,) (NP (DT some) (NNS patients)) (VP (AUX are) (PP (IN at) (NP (NN risk))) (PP (IN for) (NP (JJ permanent) (NN Doc_15602202_458_470_Disease)))) (. .)))
15632880	0	(S1 (NP (NP (NNP Doc_15632880_0_14_Chemical-induced) (NNP Doc_15632880_23_42_Disease) (CC and) (NNP Doc_15632880_47_59_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15632880_77_90_Disease))))) (. .)))
15632880	1	(S1 (S (NP (NP (DT A) (JJ previous) (JJ randomized) (JJ controlled) (NN trial)) (VP (VBG evaluating) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_15632880_165_179_Chemical))) (PP (IN in) (NP (NNP Doc_15632880_183_196_Disease) (NNS patients)))))) (VP (VBD reported) (NP (NP (DT a) (JJ low) (NN risk)) (PP (IN of) (NP (NP (NP (NNP Doc_15632880_229_241_Disease)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15632880_251_270_Disease)) (PRN (-LRB- -LRB-) (NP (CD 0) (NN %)) (-RRB- -RRB-))))))) (. .)))
15632880	2	(S1 (S (SBAR (IN Because) (S (NP (NP (NNS treatments)) (PP (IN for) (NP (NNP Doc_15632880_300_313_Disease)))) (VP (AUX have) (VP (VBN changed) (SBAR (IN since) (S (NP (NP (DT the) (NNS benefits)) (PP (IN of) (NP (NNP Doc_15632880_349_363_Chemical)))) (VP (AUX were) (VP (VBN reported))))))))) (, ,) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (DT these) (NNS complications)))) (VP (MD may) (VP (VB differ) (PP (IN in) (NP (JJ current) (JJ clinical) (NN practice))))) (. .)))
15632880	3	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBD sought) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ prevalence) (CC and) (JJ clinical) (NNS associations)) (PP (IN of) (NP (NP (NNP Doc_15632880_535_547_Disease)) (CC and) (NP (NNP Doc_15632880_552_571_Disease))))) (PP (IN in) (NP (NP (JJ Doc_15632880_575_588_Disease) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_15632880_611_625_Chemical)))))))))) (. .)))
15632880	4	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (NP (DT a) (NN case) (NN control) (NN study)) (PP (IN of) (NP (NP (JJ Doc_15632880_673_686_Disease) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_15632880_709_723_Chemical))) (PP (IN in) (NP (PRP$ our) (JJ clinical) (NN practice)))))))) (. .)))
15632880	5	(S1 (S (S (NP (NNS Cases)) (VP (AUX were) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NP (NNP Doc_15632880_784_796_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Doc_15632880_798_799_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-))) (NP (CD >5.0) (NN mEq/L))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_15632880_818_837_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15632880_839_841_Chemical) (QP (CD >or=2.5) (CD mg/dL))) (-RRB- -RRB-)))))))))) (, ,) (CC and) (S (NP (PRP they)) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (NP (CD 2) (ADJP (RB randomly) (VBN selected)) (NNS controls)) (PP (IN per) (NP (NN case)))))))) (. .)))
15632880	6	(S1 (S (NP (NP (NP (JJ Clinical) (NNS characteristics)) (, ,) (NP (NNS medications)) (, ,) (CC and) (NP (NN serum) (NNS chemistries))) (PP (IN at) (NP (NP (NN baseline)) (CC and) (NP (JJ follow-up) (NN time) (NNS periods))))) (VP (AUX were) (VP (VBN compared))) (. .)))
15632880	7	(S1 (S (NP (NP (NN Sixty-seven)) (PP (IN of) (NP (NP (CD 926) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 7.2) (NN %)) (-RRB- -RRB-))))) (VP (VBD required) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_15632880_1110_1124_Chemical))) (PP (JJ due) (TO to) (NP (NP (NP (NNP Doc_15632880_1132_1144_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 33)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_15632880_1157_1170_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 34)) (-RRB- -RRB-))))))) (. .)))
15632880	8	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_15632880_1204_1216_Disease)))))) (VP (VP (AUX were) (ADJP (ADJP (JJR older)) (CC and) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX have) (ADJP (JJ Doc_15632880_1252_1260_Disease)))))))) (, ,) (VP (AUX had) (NP (NP (JJR higher) (NN baseline) (NN serum) (JJ Doc_15632880_1288_1297_Chemical) (NNS levels)) (CC and) (NP (JJR lower) (NN baseline) (JJ Doc_15632880_1324_1333_Chemical) (NN supplement) (NNS doses)))) (, ,) (CC and) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX be) (VP (VBN treated) (PP (IN with) (NP (NNS beta-blockers)))))))) (PP (IN than) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 134)) (-RRB- -RRB-))))))) (. .)))
15632880	9	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_15632880_1454_1473_Disease)))))) (VP (VP (AUX had) (NP (NP (JJR lower) (JJ baseline) (NN body) (NN weight)) (CC and) (NP (JJR higher) (JJ baseline) (NN serum) (NN Doc_15632880_1531_1541_Chemical)))) (, ,) (VP (VBN required) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN loop) (NNS diuretics))))) (, ,) (CC and) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX be) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_15632880_1624_1632_Chemical) (NNS diuretics)))))))) (PP (IN than) (NP (NNS controls)))))) (. .)))
15632880	10	(S1 (S (NP (JJ Doc_15632880_1671_1685_Chemical-induced) (NNP Doc_15632880_1694_1706_Disease) (CC and) (NNP Doc_15632880_1711_1730_Disease)) (VP (AUX are) (ADJP (RBR more) (JJ common)) (PP (IN in) (NP (PRP$ our) (JJ clinical) (NN experience))) (SBAR (IN than) (S (VP (VBN reported) (ADVP (RB previously)))))) (. .)))
15632880	11	(S1 (S (NP (DT This) (NN difference)) (VP (AUX is) (VP (VBN explained) (PP (IN by) (NP (NP (JJ patient) (NNS comorbidities)) (CC and) (NP (NP (ADJP (RBR more) (JJ frequent)) (NN use)) (PP (IN of) (NP (NNS beta-blockers)))))))) (. .)))
15649445	0	(S1 (S (NP (JJ Acute) (UCP (NNP Doc_15649445_6_15_Chemical) (CC and) (JJ subchronic)) (JJ Doc_15649445_31_42_Chemical) (NNS treatments)) (VP (VP (VBP change) (NP (JJ synaptosomal) (NN brain) (JJ Doc_15649445_80_89_Chemical) (NN uptake))) (CC and) (VP (VBP elicit) (NP (NP (NN Doc_15649445_108_128_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
15649445	1	(S1 (S (NP (ADJP (JJ Doc_15649445_138_147_Chemical-) (CC and) (JJ Doc_15649445_153_164_Chemical-induced)) (NNP Doc_15649445_173_193_Disease)) (VP (AUX are) (NP (NP (JJ putative) (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_15649445_224_242_Disease) (-LRB- -LRB-) (NNP Doc_15649445_244_246_Disease) (-RRB- -RRB-))) (SBAR (WHNP (WP$ whose) (NN pathophysiology)) (S (VP (AUX has) (VP (AUX been) (VP (VBN related) (PP (TO to) (NP (NP (JJ free) (JJ radical) (NN generation)) (CC and) (NP (JJ oxidative) (NN stress))))))))))) (. .)))
15649445	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (DT the) (NNS authors)) (VP (VBN induced) (NP (NNP Doc_15649445_378_398_Disease)) (PP (IN by) (NP (NP (JJ acute) (JJ Doc_15649445_408_417_Chemical) (CC and) (JJ subchronic) (JJ Doc_15649445_433_444_Chemical) (NN administration)) (PP (TO to) (NP (NNS rats)))))) (. .)))
15649445	3	(S1 (S (NP (NP (JJ Doc_15649445_469_478_Chemical) (NN injection)) (PRN (-LRB- -LRB-) (NP (NP (CD one) (NN dose)) (PP (IN of) (NP (QP (CD 1) (CD mg/kg)))) (NP (NNP s.c.))) (-RRB- -RRB-))) (NP (NP (DT every) (JJ other) (NN day)) (PP (IN for) (NP (CD 3) (NNS days)))) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NN vacuous) (VBG chewing)) (, ,) (NP (NN tongue) (NN protrusion)) (CC and) (NP (NP (NN duration)) (PP (IN of) (NP (JJ facial) (NN twitching))))))) (, ,) (PP (VBN compared) (PP (TO to) (NP (DT the) (NN control))))) (. .)))
15649445	4	(S1 (S (NP (NP (JJ Doc_15649445_670_681_Chemical) (NN administration)) (PRN (-LRB- -LRB-) (NP (NP (CD one) (NN dose)) (PP (IN of) (NP (CD 12) (NNS mg/kg))) (PP (IN once) (NP (DT a) (NN week))) (NP (NNP s.c.))) (-RRB- -RRB-)) (PP (IN for) (NP (CD 4) (NNS weeks)))) (VP (VBD caused) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN vacuous) (VBG chewing)) (, ,) (NP (NN tongue) (NN protrusion)) (CC and) (NP (NP (NN duration)) (PP (IN of) (NP (NP (JJ facial) (NNS twitching)) (VP (VBN observed) (PP (IN in) (NP (CD four) (JJ weekly) (NNS evaluations))))))))))) (. .)))
15649445	5	(S1 (S (PP (IN After) (NP (NP (DT the) (NNS treatments)) (CC and) (NP (JJ behavioral) (NN observation)))) (, ,) (NP (NP (JJ Doc_15649445_925_934_Chemical) (NN uptake)) (PP (IN by) (NP (NP (NNS segments)) (PP (IN of) (NP (DT the) (NN brain)))))) (VP (AUX was) (VP (VBN analyzed))) (. .)))
15649445	6	(S1 (S (NP (DT A) (VBN decreased) (JJ Doc_15649445_993_1002_Chemical) (NN uptake)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (JJ subcortical) (NNS parts)) (PP (IN of) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_15649445_1072_1081_Chemical)) (CC and) (NP (NNP Doc_15649445_1086_1097_Chemical))))))))) (, ,) (PP (VBN compared) (PP (TO to) (NP (DT the) (NN control)))))) (. .)))
15649445	7	(S1 (S (ADVP (RB Importantly)) (, ,) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ Doc_15649445_1151_1160_Chemical) (NN uptake)))) (VP (VBZ correlates) (ADVP (RB negatively)) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_15649445_1227_1247_Disease)))))))) (. .)))
15649445	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ early) (NNS changes)) (PP (IN in) (NP (JJ Doc_15649445_1294_1303_Chemical) (NN transport)))) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ vacuous) (VBG chewing) (NNS movements)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
15737522	0	(S1 (NP (NP (JJ Doc_15737522_0_11_Chemical-associated) (NN Doc_15737522_23_46_Disease)) (PP (IN in) (NP (JJ paediatric) (JJ surgical) (NNS patients))) (. .)))
15737522	1	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB well)) (VP (VBN known) (SBAR (IN that) (S (NP (NNP Doc_15737522_102_113_Chemical)) (VP (VBZ leads) (PP (TO to) (NP (NNP Doc_15737522_123_138_Disease))) (PP (IN in) (NP (DT some) (NNS patients)))))))) (. .)))
15737522	2	(S1 (S (NP (JJ Clinical) (CC and) (JJ experimental) (NNS studies)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS situations)) (VP (VBG causing) (NP (NNP Doc_15737522_228_251_Disease))) (, ,) (PP (JJ such) (IN as) (NP (NN fasting))) (, ,)) (VP (MD may) (VP (AUX have) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_15737522_309_324_Disease))))))))))) (. .)))
15737522	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (NX (NX (NN incidence)) (CC and) (NX (JJ clinical) (NN importance)))) (PP (IN of) (NP (NNP Doc_15737522_409_424_Disease))) (PP (IN in) (NP (NP (JJ paediatric) (JJ surgical) (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_15737522_467_478_Chemical) (NN treatment))) (, ,) (SBAR (WHNP (WP who)) (S (ADVP (RB often)) (VP (AUX had) (S (VP (TO to) (ADVP (RB fast)) (PP (IN in) (NP (DT the) (JJ post-operative) (NN period)))))))))))) (. .)))
15737522	4	(S1 (S (NP (NP (JJ Fifty) (NNS children)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN given) (NP (NNP Doc_15737522_572_583_Chemical))))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN by) (NP (JJ serial) (JJ abdominal) (NNS sonograms))))) (. .)))
15737522	5	(S1 (S (PP (IN Of) (NP (DT those))) (, ,) (NP (NP (CD 13)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (JJ biliary) (NN pathology))) (. .)))
15737522	6	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (DT the) (NNS patients))) (PP (IN with) (CC or) (IN without) (NP (NNP Doc_15737522_721_736_Disease)))) (VP (VBD revealed) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (DT the) (NN treatment) (CC and) (NN starvation) (NNS variables)))))))))) (. .)))
15737522	7	(S1 (S (PP (IN After) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NN treatment))))) (, ,) (NP (NNP Doc_15737522_884_899_Disease)) (VP (VBD resolved) (ADVP (RB spontaneously)) (PP (IN within) (NP (DT a) (JJ short) (NN period)))) (. .)))
15737522	8	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_15737522_963_978_Disease)))) (VP (AUX is) (RB not) (VP (VBN affected) (PP (IN by) (NP (NN fasting))))) (. .)))
15804801	0	(S1 (NP (NP (NN Doc_15804801_0_17_Disease)) (PP (IN after) (NP (NP (NN implantation)) (PP (IN of) (NP (DT a) (JJ Doc_15804801_42_52_Chemical-eluting) (NN stent))))) (. .)))
15804801	1	(S1 (S (S (NP (NP (NN Formation)) (PP (IN of) (NP (NNP Doc_15804801_81_98_Disease)))) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (PP (IN of) (S (VP (VBG stenting) (PP (IN with) (NP (JJ bare) (NN metal) (NNS stents))))))))) (, ,) (CC but) (S (PP (VBN based) (PP (IN on) (NP (JJ experimental) (NNS studies)))) (NP (JJ drug-eluting) (NNS stents)) (VP (MD may) (VP (VB induce) (NP (JJ toxic) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN vessel) (NN wall)) (PP (PP (IN with) (NP (NP (JJ incomplete) (NN stent) (NN apposition)) (, ,) (NP (JJ Doc_15804801_290_298_Disease) (NN formation)))) (CC and) (PP (IN with) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (JJ stent) (NNP Doc_15804801_341_351_Disease) (CC or) (NNP Doc_15804801_355_369_Disease))))))))))) (. .)))
15804801	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ 43-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT a) (NN Doc_15804801_416_433_Disease)) (PP (IN in) (NP (DT the) (JJ right) (JJ coronary) (NN artery))) (PP (NP (CD 6) (NNS months)) (IN after) (S (VP (VBG receiving) (NP (DT a) (JJ Doc_15804801_490_500_Chemical-eluting) (NN stent)))))))))) (. .)))
15804801	3	(S1 (S (S (NP (DT The) (NN patient)) (VP (AUX was) (ADJP (JJ asymptomatic)))) (CC and) (S (NP (DT the) (NNP Doc_15804801_553_561_Disease)) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (DT a) (JJ routine) (NN control)))))) (. .)))
15804801	4	(S1 (S (NP (NN Angiography) (CC and) (NN intracoronary) (NN ultrasound)) (VP (VBD demonstrated) (NP (NP (NN lack)) (PP (IN of) (NP (NN contact))) (PP (IN between) (NP (NN stent) (CC and) (NN vessel) (NN wall)))) (PP (IN in) (NP (DT a) (JJ 15-mm) (JJ long) (NN segment))) (PP (IN with) (NP (NP (JJ maximal) (JJ Doc_15804801_734_742_Disease) (NN diameter)) (PP (IN of) (NP (CD 6.0) (NNS mm)))))) (. .)))
15804801	5	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (ADVP (RB successfully)) (VP (VBN treated) (PP (IN with) (NP (DT a) (NN graft) (NN stent))))) (. .)))
15859940	0	(S1 (NP (NP (NNS Causes)) (PP (IN of) (NP (NP (JJ acute) (NN Doc_15859940_16_42_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN kidney) (NN transplantation))))))) (. .)))
15859940	1	(S1 (S (NP (NN Doc_15859940_101_127_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ well-known) (NN problem)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG following) (NP (JJ renal) (NN transplantation))))))) (. .)))
15859940	2	(S1 (S (PP (IN In) (NP (JJ postrenal) (NN transplantation))) (, ,) (NP (NNP Doc_15859940_227_253_Disease)) (VP (AUX is) (ADVP (RB often)) (NP (NP (DT a) (NN reflection)) (PP (IN of) (NP (NNP Doc_15859940_279_304_Disease))))) (. .)))
15859940	3	(S1 (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VP (VB determine) (NP (NP (DT the) (NNS causes)) (PP (IN of) (NP (NNP Doc_15859940_342_368_Disease))) (PP (IN in) (NP (NP (DT a) (NN population)) (PP (IN of) (NP (JJ renal) (NN transplantation) (NNS recipients))))))) (CC and) (VP (VB discuss) (NP (DT the) (NN literature))))))) (. .)))
15859940	4	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NNS causes)) (PP (IN of) (NP (NNP Doc_15859940_502_528_Disease)))) (PP (IN during) (NP (DT a) (JJ 1-year) (NN period))) (, ,) (PP (IN from) (NP (NNP June) (CD 2003))) (PP (TO to) (NP (NNP June) (CD 2004))) (, ,) (PP (IN at) (NP (NP (DT the) (NNP King) (NNP Fahad) (NNP National) (NNP Guard) (NNP Hospital)) (PP (IN in) (NP (NP (NNP Riyadh)) (, ,) (NP (NNP Saudi) (NNP Arabia)))))) (, ,) (PP (IN by) (S (VP (VBG reviewing) (NP (NP (DT the) (NNS slides)) (PP (IN of) (NP (NP (NP (DT all) (NN transplant) (NNS biopsies)) (PRN (-LRB- -LRB-) (NP (CD n=25)) (-RRB- -RRB-))) (VP (VBN performed) (PP (IN during) (NP (DT this) (NN interval)))))))))))) (. .)))
15859940	5	(S1 (S (NP (NP (NN Pre-)) (CC and) (NP (NN posttransplant) (NN crossmatching))) (VP (AUX was) (VP (AUX done) (SBAR (WHADVP (WRB when)) (FRAG (ADJP (JJ possible)))))) (. .)))
15859940	6	(S1 (S (NP (NP (CD Five) (NNS cases)) (PP (IN of) (NP (NNP Doc_15859940_824_850_Disease)))) (VP (AUX were) (VP (VBN found))) (. .)))
15859940	7	(S1 (S (NP (NP (CD Three)) (PP (IN of) (NP (DT these) (NNS cases)))) (VP (AUX were) (PP (IN from) (NP (NP (DT the) (CD 25) (NNS transplantations)) (VP (VBN performed) (PP (IN at) (NP (NNP King) (NNP Fahad) (NNP National) (NNP Guard) (NNP Hospital)))))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ other) (CD 2) (NNS transplantations)) (VP (VP (AUX had) (VP (AUX been) (VP (VBN performed) (ADVP (RB abroad))))) (CC and) (VP (AUX were) (VP (VBN referred) (PP (TO to) (NP (PRP us))) (PP (IN for) (NP (NN follow-up))))))))) (. .)))
15859940	8	(S1 (S (S (NP (CD Three) (NNS cases)) (VP (AUX were) (VP (VBN related) (PP (TO to) (NP (NNP Doc_15859940_1095_1107_Chemical)))))) (, ,) (CC and) (S (NP (CD 1) (NN case)) (VP (AUX was) (ADJP (JJ secondary) (PP (TO to) (NP (PDT both) (NP (NNP Doc_15859940_1142_1154_Chemical)) (CC and) (NP (NNP Doc_15859940_1159_1169_Chemical))))))) (. .)))
15859940	9	(S1 (S (NP (DT The) (JJ fifth) (NN case)) (VP (AUX had) (NP (NP (NNS features)) (PP (IN of) (NP (NNP Doc_15859940_1202_1228_Disease))) (ADJP (JJ related) (PP (TO to) (NP (NP (DT an) (NN Doc_15859940_1243_1268_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_15859940_1287_1315_Disease)))))))))) (. .)))
15859940	10	(S1 (S (PP (IN In) (NP (DT the) (NN literature))) (, ,) (NP (NP (DT the) (JJ most-frequent) (NN cause)) (PP (IN of) (NP (NNP Doc_15859940_1376_1401_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG following) (NP (JJ renal) (NN transplantation)))))) (VP (AUX is) (NP (NP (NN recurrence)) (PP (IN of) (NP (DT the) (NNP Doc_15859940_1467_1492_Disease))))) (. .)))
15859940	11	(S1 (S (NP (JJ Other) (NNS causes)) (VP (VBP include) (NP (NP (JJ drug-related) (PRN (-LRB- -LRB-) (NP (NNP Doc_15859940_1529_1541_Chemical)) (, ,) (NP (NNP Doc_15859940_1543_1553_Chemical)) (-RRB- -RRB-)) (NNP Doc_15859940_1555_1563_Disease)) (, ,) (NP (JJ procoagulant) (NN status)) (, ,) (CC and) (NP (JJ antibody-mediated) (NN rejection)))) (. .)))
15859940	12	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (DT the) (JJ most-frequent) (NN cause)) (PP (IN of) (NP (NNP Doc_15859940_1660_1686_Disease)))) (VP (AUX was) (ADJP (NN drug) (VBN related)) (, ,) (PP (JJ secondary) (ADVP (RB mainly)) (TO to) (NP (NNP Doc_15859940_1725_1737_Chemical))))))) (. .)))
15859940	13	(S1 (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_15859940_1778_1804_Disease)))) (VP (AUX was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT the) (NN percentage)) (VP (VBN reported) (PP (IN in) (NP (NP (DT the) (NN literature)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-))))))))) (. .)))
15863244	0	(S1 (NP (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (JJ developmental) (NNP Doc_15863244_28_36_Disease)) (PP (IN of) (NP (ADJP (JJ selective) (CC and) (JJ non-selective)) (JJ cyclooxygenase-2) (NNS inhibitors))) (PP (IN in) (NP (NNP CRL)))))) (: :) (NP (PRN (-LRB- -LRB-) (NP (NNP WI)) (-RRB- -RRB-)) (NNP WUBR) (NNP Wistar) (ADJP (JJ rats--Doc_15863244_125_128_Chemical) (CC and) (JJ Doc_15863244_133_142_Chemical)) (NN study)) (. .)))
15863244	1	(S1 (S (NP (JJ Cyclooxygenase) (PRN (-LRB- -LRB-) (NP (NNP COX)) (-RRB- -RRB-)) (NNS inhibitors)) (VP (AUX are) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (ADJP (RBS most) (RB often) (VBN ingested)) (NNS drugs)))) (PP (IN during) (NP (NN pregnancy)))) (. .)))
15863244	2	(S1 (S (PP (IN Unlike) (NP (JJ general) (JJ Doc_15863244_268_276_Disease) (NNS data))) (, ,) (NP (PRP$ their) (JJ prenatal) (JJ toxic) (NNS effects)) (VP (AUX were) (RB not) (VP (ADVP (RB extensively)) (VBN studied) (ADVP (RB before)))) (. .)))
15863244	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN experiment)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ developmental) (NN Doc_15863244_409_417_Disease)) (PP (IN of) (NP (NP (NP (DT the) (JJ non-selective)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15863244_440_449_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ selective) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_15863244_466_469_Chemical)) (: ;) (NP (NNP Doc_15863244_471_545_Chemical))) (-RRB- -RRB-)) (JJ COX-2) (NNS inhibitors))))))))) (. .)))
15863244	4	(S1 (S (NP (NNS Drugs)) (VP (AUX were) (ADVP (RB separately)) (, ,) (SBAR (RB orally) (RB once) (S (ADVP (RB daily)) (VP (VBN dosed) (PP (TO to) (NP (NP (JJ pregnant) (NNS rats)) (PP (PP (IN from) (NP (NN day) (CD 8))) (PP (TO to) (NP (NP (CD 21)) (PRN (-LRB- -LRB-) (NP (JJ GD1=plug) (NN day)) (-RRB- -RRB-))))))))))) (. .)))
15863244	5	(S1 (S (NP (NNS Doses)) (VP (AUX were) (VP (VBN set) (PP (IN at) (NP (CD 0.3) (, ,) (CD 3.0) (CC and) (CD 30.0mg/kg))) (PP (IN for) (NP (NP (NNP Doc_15863244_716_725_Chemical)) (CC and) (NP (NP (CD 0.2)) (, ,) (NP (CD 2.0)) (CC and) (NP (NP (CD 20.0mg/kg)) (PP (IN for) (NP (NNP Doc_15863244_757_760_Chemical))))))))) (. .)))
15863244	6	(S1 (S (NP (NNS Fetuses)) (VP (VP (AUX were) (VP (VBN delivered) (PP (IN on) (NP (NNP GD) (CD 21))))) (CC and) (VP (ADVP (RB routinely)) (VBN examined))) (. .)))
15863244	7	(S1 (S (NP (JJ Comprehensive) (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ developmental))) (NNS measurements)) (VP (AUX were) (VP (AUX done))) (. .)))
15863244	8	(S1 (S (NP (NP (DT The) (VBN pooled) (JJ statistical) (NN analysis)) (PP (IN for) (NP (NNP Doc_15863244_919_968_Disease)))) (VP (AUX was) (VP (VBN performed) (PP (IN for) (NP (NP (NN rat) (NNS fetuses)) (VP (VBN exposed) (PP (TO to) (NP (NP (NNP Doc_15863244_1010_1019_Chemical)) (, ,) (NP (NP (JJ selective) (CC and) (JJ non-selective) (JJ COX-2) (NN inhibitor)) (VP (VBN based) (PP (IN on) (NP (NP (NN present)) (CC and) (NP (JJ historic) (NNS data))))))))))))) (. .)))
15863244	9	(S1 (S (NP (NP (NNP Maternal) (NNP Doc_15863244_1119_1127_Disease)) (, ,) (NP (NNP Doc_15863244_1129_1160_Disease)) (, ,) (CC and) (NP (NNP Doc_15863244_1166_1210_Disease))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (JJS highest) (NN dose)) (PP (IN of) (NP (NNP Doc_15863244_1263_1272_Chemical)))))))))) (. .)))
15863244	10	(S1 (S (NP (NP (NN Decrease)) (PP (IN of) (NP (JJ fetal) (NN length)))) (VP (AUX was) (NP (NP (DT the) (JJ only) (NNS signs)) (PP (IN of) (NP (NP (DT the) (JJ Doc_15863244_1325_1328_Chemical) (NN developmental) (NN Doc_15863244_1343_1351_Disease)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS pups)) (VP (VBN exposed) (PP (TO to) (NP (DT the) (JJS highest) (NN compound) (NN dose))))))))))) (. .)))
15863244	11	(S1 (S (NP (NP (NN Lack)) (PP (IN of) (NP (NN teratogenicity)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (NNP Doc_15863244_1443_1452_Chemical)) (CC and) (NP (JJ Doc_15863244_1457_1460_Chemical-exposed) (NNS groups)))))) (. .)))
15863244	12	(S1 (S (NP (NP (JJ Prenatal) (NN exposure)) (PP (TO to) (NP (JJ non-selective) (NNP COX) (NNS inhibitors)))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP VSD)) (CC and) (NP (NNP MD))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (JJ historic) (NN control)))))) (FRAG (CC but) (RB not) (PP (IN with) (NP (JJ selective) (JJ COX-2) (NNS inhibitors))))) (. .)))
15863244	13	(S1 (S (NP (DT Both) (JJ selective) (CC and) (JJ non-selective) (NN COX-2) (NNS inhibitors)) (VP (AUX were) (ADJP (JJ toxic)) (PP (IN for) (NP (NNS rats) (NNS fetuses))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN in) (NP (DT the) (JJS highest) (NN dose))))))) (. .)))
15863244	14	(S1 (S (PP (IN Unlike) (NP (NNP Doc_15863244_1771_1774_Chemical))) (, ,) (NP (NNP Doc_15863244_1776_1785_Chemical)) (VP (AUX was) (ADVP (RB also)) (ADJP (RB highly) (JJ toxic) (PP (TO to) (NP (DT the) (NNS dams))))) (. .)))
15863244	15	(S1 (S (NP (NP (JJ Prenatal) (NN exposure)) (PP (TO to) (NP (JJ selective) (JJ COX-2) (NNS inhibitors)))) (VP (AUX does) (RB not) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_15863244_1899_1937_Disease))) (PP (IN in) (NP (NN rat)))) (SBAR (WHADVP (WRB when)) (S (VP (VBD compared) (PP (TO to) (NP (NP (JJ non-selective) (NNS drugs)) (CC and) (NP (JJ historic) (NN control))))))))) (. .)))
15899738	0	(S1 (S (NP (NNP Lone) (NNP Doc_15899738_5_24_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_15899738_41_49_Chemical) (NN monohydrate) (NN supplementation)))) (. .)))
15899738	1	(S1 (S (NP (NP (NN Doc_15899738_79_98_Disease)) (PP (IN in) (NP (JJ young) (NNS patients))) (PP (IN without) (NP (JJ structural) (NN Doc_15899738_136_149_Disease)))) (VP (AUX is) (ADJP (JJ rare))) (. .)))
15899738	2	(S1 (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNP Doc_15899738_179_189_Disease)) (VP (AUX is) (ADJP (JJ present)) (PP (IN in) (NP (DT this) (NN population)))))) (, ,) (NP (JJ reversible) (NNS causes)) (VP (MD must) (VP (AUX be) (VP (VP (VBN identified)) (CC and) (VP (VBN resolved))))) (. .)))
15899738	3	(S1 (S (NP (NP (NN Doc_15899738_272_289_Disease)) (, ,) (NP (JJ illicit) (NN drug) (CC or) (NN stimulant) (NN use)) (, ,) (CC and) (NP (NNP Doc_15899738_326_352_Disease))) (VP (AUX are) (PP (IN among) (NP (DT these) (NNS causes)))) (. .)))
15899738	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 30-year-old) (JJ Caucasian) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD came) (PP (TO to) (NP (DT the) (NN emergency) (NN department))) (PP (IN in) (NP (NNP Doc_15899738_467_486_Disease))) (PP (IN with) (NP (JJ rapid) (JJ ventricular) (NN response)))))))))) (. .)))
15899738	5	(S1 (S (NP (PRP$ His) (JJ medical) (NN history)) (VP (AUX was) (ADJP (JJ unremarkable)) (, ,) (PP (IN except) (PP (IN for) (NP (NP (JJ minor) (NN Doc_15899738_575_584_Disease)) (PP (IN of) (NP (DT the) (NNS fingers) (CC and) (NN foot))))))) (. .)))
15899738	6	(S1 (S (S (NP (NP (NP (JJ Thyroid-stimulating) (NN hormone)) (, ,) (NP (NNP Doc_15899738_639_648_Chemical)) (, ,)) (CC and) (NP (JJ Doc_15899738_654_663_Chemical) (NNS levels))) (VP (AUX were) (PP (IN within) (NP (JJ normal) (NNS limits))))) (, ,) (S (NP (NN urine) (NN drug) (NN screen)) (VP (AUX was) (ADJP (JJ negative)))) (, ,) (CC and) (S (NP (JJ Doc_15899738_734_741_Chemical) (NN use)) (VP (AUX was) (VP (VBN denied)))) (. .)))
15899738	7	(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN questioned) (PP (IN about) (NP (NP (NN use)) (PP (IN of) (NP (NP (JJ herbal) (NNS products)) (CC and) (NP (NNS supplements)))))))))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ Doc_15899738_856_864_Chemical) (NN monohydrate)))) (VP (AUX was) (VP (VBN revealed))) (. .)))
15899738	8	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital)))) (, ,) (VP (VBN anticoagulated) (PP (IN with) (NP (JJ unfractionated) (NNP Doc_15899738_968_975_Chemical)))) (, ,) (CC and) (VP (VBN given) (NP (JJ intravenous) (NNP Doc_15899738_999_1008_Chemical)) (PP (IN for) (NP (NP (NN rate) (NN control)) (CC and) (NP (JJ intravenous) (NN Doc_15899738_1042_1052_Chemical)))) (PP (IN for) (NP (NP (NN rate)) (CC and) (NP (NN rhythm) (NN control))))))) (. .)))
15899738	9	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN discharged) (ADVP (NP (QP (JJR less) (IN than) (CD 24)) (NNS hours)) (RB later))))) (, ,) (NP (PRP he)) (VP (AUX was) (VP (VBG receiving) (NP (NP (NNP Doc_15899738_1141_1151_Chemical)) (CC and) (NP (NNP Doc_15899738_1156_1163_Chemical))) (, ,) (PP (IN with) (NP (NP (JJ follow-up) (NNS plans)) (PP (IN for) (NP (NP (NN echocardiography)) (CC and) (NP (JJ nuclear) (NN imaging)))) (S (VP (TO to) (VP (VB assess) (NP (NN perfusion))))))))) (. .)))
15899738	10	(S1 (S (NP (NNP Exogenous) (NNP Doc_15899738_1258_1266_Chemical)) (VP (AUX is) (VP (VBN used) (PP (IN by) (NP (NNS athletes))) (S (VP (TO to) (ADVP (RB theoretically)) (VP (VB improve) (NP (NN exercise) (NN performance))))))) (. .)))
15899738	11	(S1 (S (NP (NNS Vegetarians)) (VP (MD may) (ADVP (RB also)) (VP (VB take) (NP (NNP Doc_15899738_1360_1368_Chemical)) (S (VP (TO to) (VP (VB replace) (SBAR (WHNP (WP what)) (S (NP (PRP they)) (VP (AUX are) (RB not) (NP (NP (NN consuming)) (PP (IN from) (NP (NP (NN meat)) (, ,) (NP (NN fish)) (, ,) (CC and) (NP (JJ other) (NN animal) (NNS products))))))))))))) (. .)))
15899738	12	(S1 (S (NP (JJ Previous) (JJ anecdotal) (NNS reports)) (VP (AUX have) (VP (VBN linked) (NP (NNP Doc_15899738_1491_1499_Chemical)) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_15899738_1522_1532_Disease))))))) (. .)))
15899738	13	(S1 (S (NP (NNS Clinicians)) (VP (MD must) (VP (AUX be) (ADJP (JJ diligent)) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG interviewing) (NP (NNS patients)) (PP (IN about) (NP (PRP$ their) (NN drug) (NN therapy) (NNS histories)))) (CC and) (VP (VBP include) (NP (NP (NNS questions)) (PP (IN about) (NP (NP (PRP$ their) (NN use)) (PP (IN of) (NP (NP (JJ herbal) (NNS products)) (CC and) (NP (JJ dietary) (NNS supplements))))))))))))) (. .)))
15899738	14	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP it)) (VP (AUX is) (UCP (ADJP (JJ important) (S (VP (TO to) (VP (VB report) (NP (NP (JJ adverse) (NNS effects)) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB frequently) (VBN consumed)) (NNS supplements)) (CC and) (NP (JJ herbal) (NNS products)))))) (PP (TO to) (NP (DT the) (NNP Food) (CC and) (NNP Drug) (NNP Administration))))))) (CC and) (PP (IN in) (NP (DT the) (NN literature))))) (. .)))
1592014	0	(S1 (S (NP (NN Doc_1592014_0_8_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ Doc_1592014_24_31_Chemical) (NN metabolite) (NN Doc_1592014_43_58_Chemical)) (PP (IN in) (NP (NNS rats)))))) (. .)))
1592014	1	(S1 (S (S (NP (NP (DT The) (NN half-life)) (PRN (-LRB- -LRB-) (NP (NN t1/2)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_1592014_92_99_Chemical)))) (VP (AUX is) (ADJP (RB relatively) (JJ short)))) (, ,) (CC but) (S (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (NNS consequences)) (PP (IN of) (NP (PRP$ its) (NN use))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_1592014_170_178_Disease)) (CC and) (NP (NNP Doc_1592014_183_190_Disease)))) (, ,)) (VP (MD can) (VP (VB occur) (NP (NP (NNS hours)) (PP (IN after) (NP (NN exposure))))))) (. .)))
1592014	2	(S1 (S (NP (DT This)) (VP (VBD led) (NP (PRP us)) (S (VP (TO to) (VP (VB hypothesize) (SBAR (IN that) (S (NP (NP (DT a) (NN metabolite)) (PP (IN of) (NP (NNP Doc_1592014_272_279_Chemical)))) (VP (MD may) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT some)) (PP (IN of) (NP (DT those) (JJ delayed) (NNS sequelae)))))))))))))) (. .)))
1592014	3	(S1 (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (NP (DT the) (JJ major) (NN metabolite)) (PP (IN of) (NP (NP (NNP Doc_1592014_389_396_Chemical)) (, ,) (NP (NP (NNP Doc_1592014_398_413_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1592014_415_417_Chemical)) (-RRB- -RRB-))) (, ,))))) (S (VP (TO to) (VP (VB cause) (NP (NN Doc_1592014_429_437_Disease))))))) (. .)))
1592014	4	(S1 (S (NP (NP (NP (CD Two) (JJ separate) (NN equimolar) (NNS doses)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.2)) (CC and) (NP (CD 0.4) (NN mumol))) (-RRB- -RRB-))) (PP (IN of) (NP (DT either) (NNP Doc_1592014_498_505_Chemical) (CC or) (NNP Doc_1592014_509_511_Chemical)))) (VP (AUX were) (VP (VBN injected) (ADVP (RB ventricularly)) (PP (IN in) (NP (JJ unanesthetized) (JJ juvenile) (NNS rats))))) (. .)))
1592014	5	(S1 (S (NP (VBN Treated) (NNS rats)) (VP (AUX were) (ADVP (RB then)) (VP (VBN evaluated) (PP (PP (IN for) (NP (NP (NN incidence)) (, ,) (NP (NN latency)) (, ,) (CC and) (NP (JJ Doc_1592014_634_641_Disease) (NN pattern)))) (CC or) (PP (IN for) (NP (NP (NN locomotor) (NN activity)) (PP (IN in) (NP (NP (NNS animals)) (PP (IN without) (NP (NNP Doc_1592014_695_703_Disease)))))))))) (. .)))
1592014	6	(S1 (S (NP (JJ Doc_1592014_705_707_Chemical-Induced) (NN Doc_1592014_716_724_Disease)) (VP (VP (VBD occurred) (ADVP (RBR more) (RB frequently))) (CC and) (VP (AUX had) (ADJP (ADVP (RB significantly) (RBR longer)) (JJ latencies) (PP (IN than) (NP (NP (DT those)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ equimolar) (NNS amounts)) (PP (IN of) (NP (NNP Doc_1592014_832_839_Chemical))))))))))) (. .)))
1592014	7	(S1 (S (SBAR (IN Whereas) (S (NP (NNP Doc_1592014_849_856_Chemical-induced) (NNP Doc_1592014_865_873_Disease)) (VP (VP (AUX were) (ADVP (RB best)) (VP (VBN characterized) (PP (IN as) (NP (NP (NN brief)) (, ,) (NP (NN generalized)) (, ,) (CC and) (NP (NN tonic)))))) (CC and) (VP (VBD resulted) (PP (IN in) (NP (NNP Doc_1592014_947_952_Disease))))))) (, ,) (NP (NP (DT those)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1592014_971_973_Chemical))))) (VP (VP (AUX were) (ADJP (JJ prolonged) (, ,) (RB often) (JJ multiple) (CC and) (JJ mixed)) (PP (IN in) (NP (NN type)))) (, ,) (CC and) (ADVP (RB rarely)) (VP (VBD resulted) (PP (IN in) (NP (NNP Doc_1592014_1047_1052_Disease))))) (. .)))
1592014	8	(S1 (S (NP (NP (JJ Electrical) (NNS recordings)) (PP (IN from) (NP (DT the) (NN hippocampus)))) (VP (VBD showed) (NP (NP (NP (DT a) (JJ rhythmic) (NN progression)) (PP (IN in) (NP (NNP EEG) (NN frequency)))) (CC and) (NP (NP (NN voltage)) (PP (IN with) (NP (JJ clinical) (JJ Doc_1592014_1170_1177_Disease) (NN expression)))))) (. .)))
1592014	9	(S1 (S (NP (NP (JJ Doc_1592014_1190_1192_Chemical-Injected) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (AUX have) (NP (NN Doc_1592014_1225_1233_Disease))))))) (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJR more)) (NN locomotor) (NN activity)) (PP (IN than) (NP (NP (JJ Doc_1592014_1281_1288_Chemical-injected) (NNS animals)) (PP (IN without) (NP (NNP Doc_1592014_1314_1322_Disease))))))) (. .)))
1592014	10	(S1 (S (NP (DT The) (NN finding) (SBAR (IN that) (S (NP (NP (NNP Doc_1592014_1341_1348_Chemical-)) (CC and) (NP (NNP Doc_1592014_1354_1356_Chemical-induced) (NNP Doc_1592014_1365_1373_Disease))) (VP (VBP differ) (PP (IN in) (NP (JJ several) (NNS respects))))))) (VP (VP (VBZ suggests) (NP (NP (QP (JJR more) (IN than) (CD one)) (NN mechanism)) (PP (IN for) (NP (JJ Doc_1592014_1438_1445_Chemical-induced) (NN Doc_1592014_1454_1462_Disease))))) (CC and) (VP (VBZ emphasizes) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (NP (DT a) (JJ Doc_1592014_1498_1505_Chemical) (NN metabolite)) (, ,) (NP (NNP Doc_1592014_1518_1520_Chemical))))))) (. .)))
15957009	0	(S1 (S (NP (DT The) (JJ selective) (JJ 5-HT6) (NN receptor) (NN antagonist) (NN Doc_15957009_40_49_Chemical)) (VP (VBZ restores) (NP (NN memory) (NN performance)) (PP (IN in) (NP (NP (JJ cholinergic) (CC and) (JJ serotonergic) (NNS models)) (PP (IN of) (NP (NP (NNP Doc_15957009_120_137_Disease)) (PP (IN in) (NP (DT the) (NN rat)))))))) (. .)))
15957009	1	(S1 (S (NP (NP (NNS Antagonists)) (PP (IN at) (NP (NNP Doc_15957009_165_174_Chemical) (NN type) (CD 6)))) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_15957009_183_187_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (-RRB- -RRB-)) (NP (NNS receptors)) (VP (VBP show) (NP (NP (NN activity)) (PP (IN in) (NP (NP (NNS models)) (PP (IN of) (NP (NP (NN learning)) (CC and) (NP (NN memory)))))))) (. .)))
15957009	2	(S1 (S (SBAR (IN Although) (S (NP (DT the) (JJ underlying) (NN mechanism) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-))) (VP (AUX are) (RB not) (VP (ADVP (RB well)) (VBN understood))))) (, ,) (NP (DT these) (NNS effects)) (VP (MD may) (VP (VB involve) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_15957009_353_366_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_368_371_Chemical)) (-RRB- -RRB-)) (NNS levels)))))) (. .)))
15957009	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VP (VBD sought) (S (VP (TO to) (VP (VB characterize) (NP (NP (DT the) (JJ cognitive-enhancing) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NNP Doc_15957009_461_465_Chemical) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-)) (NN antagonist)) (NP (NP (NNP Doc_15957009_480_489_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_491_545_Chemical)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (DT a) (NN rat) (NN object) (NN recognition) (NN task)) (VP (VBG employing) (NP (NP (NP (DT a) (JJ cholinergic)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_605_616_Chemical) (NN pretreatment)) (-RRB- -RRB-))) (CC and) (NP (DT a) (JJ serotonergic-) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_652_662_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15957009_664_667_Chemical)) (-RRB- -RRB-)) (NN depletion)) (-RRB- -RRB-)) (NN deficient) (NN model)))))))))) (, ,) (CC and) (VP (VBN compared) (NP (PRP$ its) (NN pattern)) (PP (IN of) (NP (NP (NN action)) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (NN acetylcholinesterase) (NN inhibitor) (NNP Doc_15957009_780_791_Chemical))))))))) (. .)))
15957009	4	(S1 (S (NP (NP (JJ Initial) (NN testing)) (PP (IN in) (NP (NP (DT a) (JJ time-dependent) (VBG forgetting) (NN task)) (VP (VBG employing) (NP (NP (DT a) (JJ 24-h) (NN delay)) (PP (IN between) (NP (NN training) (CC and) (NN testing)))))))) (VP (VBD showed) (NP (NP (DT that) (JJ Doc_15957009_909_920_Chemical) (JJ improved) (NN object) (NN recognition)) (PRN (-LRB- -LRB-) (NP (QP (IN at) (CD 10) (CC and) (CD 30)) (NNS mg/kg)) (, ,) (NP (CD p.o.)) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_15957009_985_994_Chemical)) (VP (AUX was) (ADJP (JJ inactive)))))) (. .)))
15957009	5	(S1 (S (NP (DT Both)) (, ,) (NP (NP (NP (NNP Doc_15957009_1015_1024_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CC and) (CD 10)) (NN mg/kg)) (, ,) (RB intraperitoneally) (PRN (-LRB- -LRB-) (NP (CD i.p.)) (-RRB- -RRB-)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15957009_1072_1083_Chemical)) (PRN (-LRB- -LRB-) (FRAG (NP (CD 10) (NN mg/kg)) (, ,) (NP (NN p.o.)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))) (VP (VBD reversed) (NP (NNP Doc_15957009_1124_1139_Disease)) (S (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_15957009_1151_1162_Chemical) (CC and) (NNP Doc_15957009_1167_1170_Chemical) (NN depletion)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NNS mg/kg)) (, ,) (NP (NNS i.p.)) (, ,) (CC and) (NP (CD 3) (NN mg/kg)) (, ,) (NP (NNS p.o.))) (, ,) (RB respectively) (-RRB- -RRB-))))))) (. .)))
15957009	6	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (SBAR (IN although) (S (NP (NNP Doc_15957009_1256_1265_Chemical)) (VP (AUX did) (RB not) (VP (VB improve) (NP (DT a) (JJ time-related) (NN retention) (NN deficit)))))) (, ,) (NP (PRP it)) (VP (VBD reversed) (NP (NP (DT a) (NN cholinergic)) (CC and) (NP (DT a) (JJ serotonergic) (NN Doc_15957009_1361_1375_Disease))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT both) (NNS mechanisms)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (NP (DT the) (NN facilitation)) (PP (IN of) (NP (NN object) (NN memory))) (PP (IN by) (NP (NNP Doc_15957009_1465_1474_Chemical)))) (CC and) (, ,) (ADVP (RB possibly)) (, ,) (NP (JJ other) (JJ Doc_15957009_1496_1500_Chemical) (PRN (-LRB- -LRB-) (CD 6) (-RRB- -RRB-)) (NN receptor) (NNS antagonists)))))))))))) (. .)))
16005948	0	(S1 (NP (NP (NN Evaluation)) (PP (IN of) (NP (NP (DT the) (JJ anticocaine) (JJ monoclonal) (NN antibody)) (ADJP (JJ Doc_16005948_50_57_Chemical) (PP (IN as) (NP (NP (DT an) (NN immunotherapy)) (PP (IN for) (NP (NNP Doc_16005948_82_98_Disease)))))))) (. .)))
16005948	1	(S1 (S (S (NP (NP (DT The) (JJ illicit) (NN use)) (PP (IN of) (NP (NNP Doc_16005948_119_126_Chemical)))) (VP (VBZ continues) (PP (IN in) (NP (NN epidemic) (NNS proportions))))) (CC and) (S (NP (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_16005948_179_195_Disease)))) (VP (VBZ remains) (ADJP (JJ elusive)))) (. .)))
16005948	2	(S1 (S (NP (JJ Current) (JJ protein-based) (NN technology)) (VP (VBZ offers) (NP (NP (DT a) (JJ new) (JJ therapeutic) (NN venue)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNS antibodies)) (VP (NN bind) (NP (DT the) (NN drug)) (PP (IN in) (NP (DT the) (NN blood) (NN stream))) (, ,) (S (VP (VBG inactivating) (NP (PRP$ its) (JJ toxic) (NNS effects))))))))) (. .)))
16005948	3	(S1 (S (NP (NP (DT The) (JJ therapeutic) (NN potential)) (PP (IN of) (NP (DT the) (JJ anticocaine) (NN antibody) (NN Doc_16005948_418_425_Chemical)))) (VP (AUX was) (VP (VBN examined) (S (VP (VBG using) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_16005948_456_472_Disease)))))))) (. .)))
16005948	4	(S1 (S (NP (NP (JJ Swiss) (NN albino) (NNS mice)) (VP (VBN prepared) (PP (IN with) (NP (JJ intrajugular) (NNS catheters))))) (VP (AUX were) (VP (VBN tested) (PP (IN in) (NP (JJ photocell) (NNS cages))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (CD 93) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (CD LD50)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_16005948_603_610_Chemical) (CC and) (NNP Doc_16005948_615_622_Chemical) (NNS infusions)) (VP (VBG ranging) (PP (PP (IN from) (NP (CD 30))) (PP (TO to) (NP (CD 190) (CD mg/kg))))))))))))) (. .)))
16005948	5	(S1 (S (NP (NN Doc_16005948_663_670_Chemical)) (VP (AUX was) (VP (VP (VBN delivered) (ADVP (NP (CD 30) (NN min)) (RB before)) (, ,) (ADVP (RB concomitantly))) (CC or) (VP (NP (CD 3) (NN min)) (PP (IN after) (NP (JJ Doc_16005948_729_736_Chemical) (NN treatment)))))) (. .)))
16005948	6	(S1 (S (NP (NP (JJ Significant) (NN blockade)) (PP (IN of) (NP (NNP Doc_16005948_772_779_Chemical) (NNP Doc_16005948_780_788_Disease)))) (VP (AUX was) (VP (VBN observed) (PP (IN with) (NP (NP (DT the) (JJR higher) (NN dose)) (PP (IN of) (NP (NP (NP (NNP Doc_16005948_826_833_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 190) (NN mg/kg)) (-RRB- -RRB-)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NN premorbid) (NNS behaviors)) (VP (AUX were) (VP (VBN reduced) (PRT (RP up)) (PP (TO to) (NP (CD 40) (NN %)))))))) (, ,) (NP (NP (NNP Doc_16005948_897_905_Disease)) (PP (IN up) (PP (TO to) (NP (CD 77) (NN %))))) (CC and) (NP (NNP Doc_16005948_920_925_Disease)))))) (PP (IN by) (NP (CD 72) (NN %))))) (. .)))
16005948	7	(S1 (S (ADVP (RB Importantly)) (, ,) (NP (NNP Doc_16005948_947_954_Chemical)) (VP (VBD prevented) (NP (NNP Doc_16005948_965_970_Disease) (ADJP (RB even) (JJ post-Doc_16005948_981_988_Chemical)) (NN injection))) (. .)))
16005948	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP support) (NP (NP (DT the) (JJ important) (NN potential)) (PP (IN of) (NP (NNP Doc_16005948_1047_1054_Chemical)))) (PP (IN as) (NP (NP (DT a) (JJ therapeutic) (NN tool)) (PP (IN against) (NP (NNP Doc_16005948_1085_1101_Disease)))))) (. .)))
1601297	0	(S1 (S (NP (NP (JJ Electrocardiographic) (NN evidence)) (PP (IN of) (NP (NNP Doc_1601297_33_50_Disease))) (PP (IN in) (NP (ADJP (RB psychiatrically) (VBN hospitalized)) (NN Doc_1601297_83_90_Chemical)))) (VP (VBZ abusers)) (. .)))
1601297	1	(S1 (S (NP (NP (NP (DT The) (NNS electrocardiograms)) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 99) (JJ Doc_1601297_135_142_Chemical-abusing) (NNS patients)))) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (DT the) (NNS ECGs)) (PP (IN of) (NP (CD 50) (JJ Doc_1601297_194_207_Disease) (NNS controls))))))) (. .)))
1601297	2	(S1 (S (NP (NP (CD Eleven)) (PP (IN of) (NP (NP (DT the) (JJ Doc_1601297_232_239_Chemical) (NNS abusers)) (CC and) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NNS controls))))))) (VP (AUX had) (NP (NP (JJ ECG) (NN evidence)) (PP (IN of) (NP (NP (JJ significant) (NN Doc_1601297_305_322_Disease)) (VP (VBN defined) (PP (IN as) (NP (NP (NNP Doc_1601297_334_355_Disease)) (, ,) (NP (NNP Doc_1601297_357_365_Disease)) (, ,) (CC and) (NP (NNP Doc_1601297_371_390_Disease))))))))) (. .)))
16160878	0	(S1 (S (NP (NP (JJ Behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_16160878_22_34_Chemical)))) (ADVP (RB centrally)) (VP (VBN administered) (PP (IN in) (NP (NNS mice)))) (. .)))
16160878	1	(S1 (S (NP (JJ Doc_16160878_67_79_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16160878_81_85_Chemical)) (-RRB- -RRB-)) (NNS receptors)) (VP (AUX are) (ADVP (RB widely)) (VP (VBN distributed) (PP (IN in) (NP (DT the) (JJ central) (JJ nervous) (NN system))))) (. .)))
16160878	2	(S1 (S (NP (NP (JJ Intracerebroventricular) (PRN (-LRB- -LRB-) (VBG i.c.v.) (-RRB- -RRB-)) (NN injection)) (PP (IN of) (NP (NNP Doc_16160878_197_201_Chemical)))) (VP (VP (VBZ causes) (NP (NP (NNP Doc_16160878_209_221_Disease)) (CC and) (NP (NNP Doc_16160878_226_237_Disease)))) (CC and) (VP (VBZ stimulates) (NP (NP (NN prolactin)) (CC and) (NP (NN thyrotropin) (NN secretion))))) (. .)))
16160878	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (ADJP (RB centrally) (VBN administered)) (NN Doc_16160878_348_352_Chemical)))) (VP (AUX have) (VP (VBN received) (NP (JJ little) (NN attention)))) (. .)))
16160878	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD tested) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ i.c.v.) (NNS injections)) (PP (IN of) (NP (NNP Doc_16160878_453_457_Chemical))))) (PP (IN on) (NP (NP (ADJP (JJ behavioral) (, ,) (JJ metabolic) (, ,) (CC and) (JJ endocrine)) (NNS responses)) (PP (IN in) (NP (NNS mice))))))) (. .)))
16160878	5	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (JJ graded) (NNS doses)) (PP (IN of) (NP (NNP Doc_16160878_551_555_Chemical) (PRN (-LRB- -LRB-) (NP (CD 1-10,000) (NN ng/mouse)) (-RRB- -RRB-))))))) (VP (VP (VP (VBD provoked) (: :) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NP (DT a) (JJ dose-dependent) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN head) (NNS dips)) (PP (IN in) (NP (DT the) (JJ hole-board) (NN test)))))))) (PRN (: ;) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (NP (NP (DT a) (JJ dose-dependent) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS entries)) (PP (IN in) (NP (NP (DT the) (JJ white) (NN chamber)) (PP (IN in) (NP (DT the) (JJ black-and-white) (NN compartment) (NN test))))))))))) (, ,) (CC and) (PP (IN in) (NP (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS entries)) (PP (IN in) (NP (NP (DT the) (JJ central) (NN platform)) (CC and) (NP (NP (JJ open) (NNS arms)) (PP (IN in) (NP (DT the) (JJ plus-maze) (NN test))))))))) (: ;) (CC and) (NP (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (DT a) (JJ dose-dependent) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN immobility)) (PP (IN in) (NP (DT the) (JJ forced-swimming) (NN test) (CC and) (NN tail) (NN suspension) (NN test))))))))))) (. .)))
16160878	6	(S1 (S (NP (NP (JJ Intracerebroventricular) (NN injection)) (PP (IN of) (NP (NNP Doc_16160878_1031_1035_Chemical)))) (ADVP (RB also)) (VP (VBD caused) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (: :) (NN food) (NN intake))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 100) (CC and) (CD 1,000)) (NN ng/mouse)))))) (, ,) (NP (NP (NN water) (NN intake)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 100-10,000) (NN ng/mouse)))))) (, ,) (CC and) (NP (NP (JJ horizontal) (NN locomotion) (NN activity)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 10,000) (NN ng/mouse)))))))) (. .)))
16160878	7	(S1 (S (SBAR (WHNP (WDT Whatever)) (S (VP (AUX was) (NP (DT the) (NN dose))))) (, ,) (NP (NP (DT the) (JJ central) (NN administration)) (PP (IN of) (NP (NNP Doc_16160878_1276_1280_Chemical)))) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN body) (NN temperature)) (, ,) (NP (NN nociception)) (, ,) (NP (NNP Doc_16160878_1329_1340_Chemical-induced) (NNP Doc_16160878_1349_1364_Disease) (CC and) (VBG climbing) (NN behavior)) (, ,) (CC and) (NP (JJ stress-induced) (NN plasma) (JJ Doc_16160878_1414_1428_Chemical) (NN level)))))) (. .)))
16160878	8	(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT the) (JJ present) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (DT the) (JJ central) (NN injection)) (PP (IN of) (NP (NNP Doc_16160878_1513_1517_Chemical))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 1-10,000) (NN ng/mouse)))))) (VP (VBZ induces) (NP (NP (NN anxiogenic-)) (CC and) (NP (JJ depressant-like) (NNS effects))) (PP (IN in) (NP (NN mouse))))))) (. .)))
16160878	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_16160878_1630_1634_Chemical)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT some) (NNS aspects)) (PP (IN of) (NP (NN Doc_16160878_1670_1691_Disease))))))))))) (. .)))
1616457	0	(S1 (S (NP (NP (NN Learning)) (PP (IN of) (NP (NNS rats))) (PP (IN under) (NP (NNP Doc_1616457_23_30_Disease)))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_1616457_41_54_Chemical)))) (. .)))
1616457	1	(S1 (S (NP (NP (JJ Dissociated) (NN learning)) (PP (IN of) (NP (NP (NNS rats)) (PP (IN in) (NP (NP (DT the) (JJ normal) (NN state)) (CC and) (NP (NP (DT the) (NN state)) (PP (IN of) (NP (NNP Doc_1616457_122_129_Disease)))))) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_1616457_142_155_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg/kg)) (, ,) (NP (NN ip)) (-RRB- -RRB-)))))))) (VP (AUX was) (VP (VBN carried) (PRT (RP out)))) (. .)))
1616457	2	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN trained) (S (VP (TO to) (VP (VB approach) (NP (NP (DT a) (NN shelf)) (SBAR (WHADVP (WRB where)) (S (NP (PRP they)) (VP (VBD received) (NP (NN food) (NN reinforcement))))))))))) (. .)))
1616457	3	(S1 (S (PP (IN In) (NP (NNP Group) (CD 1))) (NP (DT the) (NNS rats)) (VP (AUX were) (VP (VBN trained) (PP (IN under) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NNP Doc_1616457_322_335_Chemical))))) (S (VP (TO to) (VP (VB run) (PP (TO to) (NP (DT the) (JJ same) (NN shelf))) (PP (IN as) (PP (IN in) (NP (DT the) (JJ normal) (NN state))))))))) (. .)))
1616457	4	(S1 (S (PP (IN In) (NP (NNP Group))) (, 2) (NP (DT the) (NNS rats)) (VP (AUX were) (VP (VBN trained) (S (VP (TO to) (VP (VB approach) (NP (JJ different) (NNS shelves)) (PP (IN in) (NP (JJ different) (NN drug) (NNS states)))))))) (. .)))
1616457	5	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN shown) (SBAR (IN that) (S (NP (NNP Doc_1616457_492_511_Disease)) (VP (VBD occurred) (PP (IN in) (NP (DT both) (NNS groups)))))))) (. .)))
1616457	6	(S1 (S (NP (NP (NNS Differences)) (PP (IN in) (NP (NP (DT the) (NNS parameters)) (PP (IN of) (NP (NP (NN training)) (PP (IN under) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NNP Doc_1616457_602_615_Chemical))))))))) (PP (IN between) (NP (NNS Groups) (CD 1) (CC and) (CD 2)))) (VP (AUX were) (VP (VBN revealed))) (. .)))
1616457	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (JJ brain-dissociated) (NN state)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1616457_718_731_Chemical))))) (VP (AUX is) (VP (VBN formed) (PP (IN with) (NP (NP (DT the) (NN participation)) (PP (IN of) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NN information) (NN perception)))))))))))) (. .)))
16167916	0	(S1 (NP (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (JJ short-term) (JJ Doc_16167916_26_36_Chemical) (NN therapy))) (PP (IN on) (NP (NN fibrinolysis) (NNS markers)))) (: :) (NP (NP (NNP TAFI)) (, ,) (NP (NNP tPA)) (, ,) (CC and) (NP (NNP PAI-1))) (. .)))
16167916	1	(S1 (S (NP (NP (NNS Markers)) (PP (IN of) (NP (NP (NNS fibrinolysis)) (, ,) (NP (JJ thrombin-activatable) (NN fibrinolysis) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NNP TAFI)) (-RRB- -RRB-)) (, ,) (NP (JJ tissue-type) (JJ plasminogen) (NN activator)) (PRN (-LRB- -LRB-) (NP (NNP tPA)) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJ plasminogen) (JJ activator) (JJ inhibitor-1) (PRN (-LRB- -LRB-) (JJ PAI-1) (-RRB- -RRB-)) (NNS levels))))) (VP (AUX were) (VP (VBN studied) (PP (IN for) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (NP (JJ short-term) (NNS effects)) (PP (IN of) (NP (NP (JJ Doc_16167916_332_342_Chemical) (NN administration)) (PP (IN in) (NP (JJ postmenopausal) (NNS women))))))))))) (. .)))
16167916	2	(S1 (S (NP (NP (JJ Thirty-nine) (JJ postmenopausal) (NNS women)) (PP (IN with) (NP (NP (NNP Doc_16167916_430_440_Disease)) (CC or) (NP (NNP Doc_16167916_444_456_Disease))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT this) (JJ prospective) (, ,) (JJ controlled) (JJ clinical) (NN study))))) (. .)))
16167916	3	(S1 (S (NP (CD Twenty-five) (NNS women)) (VP (AUX were) (VP (VBN given) (NP (NP (NP (NNP Doc_16167916_548_572_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 60) (NN mg/day)) (-RRB- -RRB-))) (CC plus) (NP (NP (NNP Doc_16167916_590_597_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg/day)) (-RRB- -RRB-)))))) (. .)))
16167916	4	(S1 (S (NP (NP (JJ Age-matched) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 14)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN given) (NP (JJ only) (NNP Doc_16167916_658_665_Chemical)))) (. .)))
16167916	5	(S1 (S (NP (NP (NN Plasma) (NNS TAFI)) (, ,) (NP (NNP tPA)) (, ,) (CC and) (NP (JJ PAI-1) (NN antigen) (NNS levels))) (VP (AUX were) (VP (VBN measured) (PP (PP (IN at) (NP (NN baseline))) (CC and) (PP (IN after) (NP (NP (CD 3) (NNS months)) (PP (IN of) (NP (NN treatment)))))) (PP (IN by) (NP (ADJP (RB commercially) (JJ available)) (NNP ELISA) (NNS kits))))) (. .)))
16167916	6	(S1 (S (NP (NP (NNS Variations)) (PP (IN of) (NP (NNS individuals)))) (VP (AUX were) (VP (VBN assessed) (PP (IN by) (NP (NP (NNP Wilcoxon) (POS 's)) (NN test))))) (. .)))
16167916	7	(S1 (S (NP (NP (NN Relationship)) (PP (IN between) (NP (NP (DT those) (NNS markers)) (CC and) (NP (JJ demographic) (NNS characteristics))))) (VP (AUX were) (VP (VBN investigated))) (. .)))
16167916	8	(S1 (S (NP (NP (CD Three) (NNS months)) (PP (IN of) (NP (JJ Doc_16167916_977_987_Chemical) (NN treatment)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NN TAFI) (NN antigen) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 16) (NN %)) (NN change)) (, ,) (NP (NNP P) (NNP <) (CD 0.01))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NNP tPA) (NN antigen) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 25) (NN %)) (NN change)) (, ,) (NP (NNP P) (NNP <) (CD 0.05))) (-RRB- -RRB-))))))))) (. .)))
16167916	9	(S1 (S (NP (DT A) (JJ significant) (NN correlation)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (JJ baseline) (JJ TAFI) (NN antigen) (NNS concentrations)) (CC and) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NNP Doc_16167916_1289_1299_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP P) (NNP <) (CD 0.05)) (: ;) (NP (SYM r)) (X (SYM =)) (CD 0.33)) (-RRB- -RRB-))))))))) (. .)))
16167916	10	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_16167916_1372_1394_Disease))) (ADJP (JJ due) (PP (TO to) (NP (JJ Doc_16167916_1402_1412_Chemical) (NN treatment))))) (VP (MD may) (VP (AUX be) (UCP (VP (VBN related) (PP (TO to) (NP (VBN increased) (NNP tPA) (NNS levels)))) (, ,) (CC but) (RB not) (NP (JJ TAFI) (NNS levels)))))))) (. .)))
16181582	0	(S1 (NP (JJ Doc_16181582_0_9_Chemical-induced) (NN Doc_16181582_18_32_Disease) (. .)))
16181582	1	(S1 (S (NP (JJ Doc_16181582_34_43_Chemical-induced) (NN Doc_16181582_52_66_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN syndrome)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VBP manifest) (PP (IN in) (NP (ADJP (RB otherwise) (JJ normal)) (NN Doc_16181582_124_133_Disease) (NNS individuals))))))))) (. .)))
16181582	2	(S1 (S (NP (PRP It)) (VP (MD may) (ADVP (RB even)) (VP (VB present) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN tolerated) (NP (DT this) (NN medicine)) (ADVP (RB well)) (PP (IN in) (NP (DT the) (NN past))))))))))) (. .)))
16181582	3	(S1 (S (NP (PRP It)) (VP (AUX is) (UCP (ADVP (RB usually)) (CC but) (VP (RB not) (ADVP (RB necessarily)) (VBN associated) (PP (IN with) (NP (NN Doc_16181582_280_294_Disease)))))) (. .)))
16181582	4	(S1 (S (NP (DT The) (NNP EEG)) (VP (VBZ shows) (NP (NP (JJ characteristic) (JJ triphasic) (NNS waves)) (PP (IN in) (NP (JJS most) (NNS patients))) (PP (IN with) (NP (DT this) (NN complication))))) (. .)))
16181582	5	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_16181582_392_401_Chemical-induced) (NNP Doc_16181582_410_424_Disease)))) (VP (AUX is) (VP (VBN presented))) (. .)))
16181582	6	(S1 (S (NP (NP (DT The) (NNS problems)) (PP (IN in) (S (VP (VBG diagnosing) (NP (DT this) (NN condition)))))) (VP (AUX are) (ADVP (RB subsequently)) (VP (VBN discussed))) (. .)))
16274958	0	(S1 (NP (NNP Recurrent) (NNP Doc_16274958_10_19_Disease) (CC and) (NNP Doc_16274958_24_33_Chemical) (. .)))
16274958	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN woman)) (VP (VBG complaining) (PP (IN of) (NP (NNP Doc_16274958_80_89_Disease))) (SBAR (IN while) (S (NP (PRP she)) (VP (AUX was) (VP (VBN treated) (PP (IN by) (NP (NNP Doc_16274958_115_124_Chemical)))))))))))) (. .)))
16274958	2	(S1 (S (NP (PRP$ Her) (NNS symptoms)) (VP (VP (ADVP (RB totally)) (VBN regressed) (PP (IN after) (NP (NN drug) (NN withdrawal)))) (CC and) (VP (VBD reappeared) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_16274958_199_208_Chemical)) (VP (AUX was) (VP (VBN reintroduced))))))) (. .)))
16274958	3	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (JJ Doc_16274958_271_280_Chemical-induced) (NN Doc_16274958_289_298_Disease))))) (. .)))
16274958	4	(S1 (S (NP (DT This) (NN effect)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (JJ pharmacological) (NN effect)) (PP (IN of) (NP (DT this) (NN drug))) (PP (IN on) (NP (JJ mucous) (NNS membranes)))))))) (. .)))
16298782	0	(S1 (NP (NP (NN Doc_16298782_0_29_Chemical)) (: :) (NP (NP (DT a) (JJ potential) (NN protector)) (PP (IN against) (NP (NNP Doc_16298782_61_71_Chemical) (NNP Doc_16298782_72_83_Disease)))) (. .)))
16298782	1	(S1 (S (S (NP (NP (DT The) (NNP Doc_16298782_89_101_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16298782_103_105_Chemical)) (-RRB- -RRB-)) (NN inhibitor) (NNP Doc_16298782_117_146_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16298782_148_154_Chemical)) (-RRB- -RRB-))) (VP (MD may) (VP (VB act) (PP (IN as) (NP (NP (DT an) (NN otoprotectant)) (PP (IN against) (NP (NNP Doc_16298782_192_219_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_16298782_230_240_Chemical))))))))) (, ,) (CC but) (S (NP (JJ further) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VB confirm) (SBAR (S (NP (NN this.Doc_16298782_289_303_Chemical) (NNS antibiotics)) (VP (AUX are) (ADVP (RB still)) (VP (ADVP (RB widely)) (VBN used) (PP (IN by) (NP (NP (NN virtue)) (PP (IN of) (NP (NP (PRP$ their) (NN efficacy)) (CC and) (NP (JJ low) (NN cost)))))))))))))))) (. .)))
16298782	2	(S1 (S (NP (PRP$ Their) (NN Doc_16298782_386_397_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ serious) (NN health) (NN problem)) (SBAR (S (CC and) (, ,) (SBAR (IN as) (S (NP (PRP$ their) (JJ Doc_16298782_440_448_Disease) (NN mechanism)) (VP (VBZ involves) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NNP Doc_16298782_486_488_Chemical))))))) (, ,) (NP (PRP we)) (VP (AUX need) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ Doc_16298782_519_521_Chemical) (NNS inhibitors))) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (JJ Doc_16298782_555_569_Chemical-induced) (NNP Doc_16298782_578_604_Disease)))))))))))))) (. .)))
16298782	3	(S1 (S (PP (IN In) (NP (DT this) (JJ experimental) (NN study))) (NP (PRP we)) (VP (VBD used) (NP (NP (CD 30) (JJ Sprague-Dawley) (NNS rats)) (, ,) (SBAR (WHNP (CD 27) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX had) (ADVP (RB Doc_16298782_681_691_Chemical)) (VP (VBN instilled) (PP (IN into) (NP (DT the) (JJ middle) (NN ear))))))))) (. .)))
16298782	4	(S1 (S (NP (DT The) (JJ otoprotectant) (NN Doc_16298782_741_747_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB topically)) (PP (TO to) (NP (CD 12/27) (NNS animals))))) (. .)))
16298782	5	(S1 (S (NP (PRP$ Its) (NN effect)) (VP (AUX was) (VP (VBN determined) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN attenuation)) (PP (IN of) (NP (NNP Doc_16298782_846_858_Disease))))) (, ,) (VP (VBN measured) (PP (IN by) (NP (NNS shifts))) (PP (IN in) (NP (DT the) (JJ auditory) (NN brainstem) (NN response) (NN threshold)))))))) (. .)))
16298782	6	(S1 (S (NP (NN Doc_16298782_925_931_Chemical)) (VP (VP (VBD reduced) (NP (JJ Doc_16298782_940_950_Chemical-induced) (NN Doc_16298782_959_971_Disease)) (PP (IN in) (NP (DT the) (JJ high-frequency) (NN range)))) (, ,) (CC but) (VP (VBD gave) (NP (DT no) (NN protection)) (PP (IN in) (NP (NP (DT the) (NN middle)) (CC or) (NP (JJ low) (NNS frequencies)))))) (. .)))
16330293	0	(S1 (NP (NP (NP (NN Safety) (NN profile)) (PP (IN of) (NP (DT a) (JJ Doc_16330293_20_28_Chemical) (NN lozenge))) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ Doc_16330293_59_67_Chemical) (NN gum)) (PP (IN in) (NP (NN adult) (NNS smokers))) (PP (IN with) (NP (JJ underlying) (JJ medical) (NNS conditions))))))))) (: :) (NP (DT a) (JJ 12-week) (, ,) (JJ randomized) (, ,) (JJ open-label) (NN study)) (. .)))
16330293	1	(S1 (S (NP (JJ Doc_16330293_178_186_Chemical) (NN polacrilex) (NNS lozenges)) (VP (VBP deliver) (ADJP (NP (CD 25) (NN %) (TO to) (CD 27) (NN %)) (RBR more) (JJ Doc_16330293_231_239_Chemical)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ equivalent) (NNS doses)) (PP (IN of) (NP (JJ Doc_16330293_274_282_Chemical) (NN polacrilex) (NN gum))))))) (. .)))
16330293	2	(S1 (S (NP (NP (DT The) (VBN increased) (JJ Doc_16330293_313_321_Chemical) (NN exposure)) (PP (IN from) (NP (DT the) (NN lozenge)))) (VP (AUX has) (VP (VBN raised) (NP (NP (NNS questions)) (PP (IN about) (NP (NP (DT the) (JJ relative) (NN safety)) (PP (IN of) (NP (DT the) (NN lozenge) (CC and) (NN gum)))))))) (. .)))
16330293	3	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN safety) (NNS profiles)) (PP (IN of) (NP (NP (DT the) (JJ 4-mg) (NNP Doc_16330293_505_513_Chemical) (NN lozenge)) (CC and) (NP (JJ 4-mg) (JJ Doc_16330293_531_539_Chemical) (NN gum)))) (PP (IN in) (NP (NNS smokers)))) (PP (IN with) (NP (VBN selected) (JJ label-restricted) (NNS diseases))))))) (. .)))
16330293	4	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT a) (JJ multicenter) (, ,) (JJ randomized) (, ,) (JJ open-label) (NN study)) (PP (IN in) (NP (NP (NN adult) (NNS smokers)) (PP (IN with) (NP (NP (NNP Doc_16330293_680_693_Disease)) (, ,) (NP (NP (NNP Doc_16330293_695_707_Disease)) (VP (RB not) (VBN controlled) (PP (IN by) (NP (NN medication))))) (, ,) (NP (NNP and/or) (NNP Doc_16330293_745_762_Disease)))))))) (. .)))
16330293	5	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN randomized) (PP (IN in) (NP (NP (DT a) (CD 1:1) (NN ratio)) (SBAR (S (VP (TO to) (VP (VB receive) (NP (NP (DT the) (JJ 4-mg) (JJ Doc_16330293_824_832_Chemical) (NN lozenge)) (CC or) (NP (JJ 4-mg) (JJ Doc_16330293_849_857_Chemical) (NN gum))))))))))) (. .)))
16330293	6	(S1 (S (NP (NN Safety) (NNS assessments)) (VP (AUX were) (VP (VBN made) (PP (PP (IN at) (NP (NN baseline))) (CC and) (PP (IN at) (NP (NP (CD 2)) (, ,) (NP (CD 4)) (, ,) (NP (CD 6)) (, ,) (CC and) (NP (NP (CD 12) (NNS weeks)) (PP (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NN product) (NN use))))))))))) (. .)))
16330293	7	(S1 (S (NP (CD Nine) (CD hundred) (CD one) (NNS patients)) (VP (AUX were) (VP (VBN randomized) (PP (TO to) (NP (NP (NN treatment)) (, ,) (NP (NP (NP (CD 447)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (DT the) (NN lozenge)))))) (CC and) (NP (NP (CD 454)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (DT the) (NN gum)) (PRN (-LRB- -LRB-) (NP (NN safety) (NN population)) (-RRB- -RRB-)))))))))))) (. .)))
16330293	8	(S1 (S (NP (DT The) (NN majority)) (VP (AUX were) (NP (NP (NNS women)) (PRN (-LRB- -LRB-) (NP (CD 52.7) (NN %)) (-RRB- -RRB-)))) (. .)))
16330293	9	(S1 (S (S (NP (NP (NNS Patients) (POS ')) (JJ mean) (NN age)) (VP (AUX was) (NP (CD 53.9) (NNS years)))) (, ,) (S (NP (PRP$ their) (JJ mean) (NN weight)) (VP (AUX was) (NP (CD 193.9) (NNS pounds)))) (, ,) (CC and) (S (NP (PRP they)) (VP (VBD smoked) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (CD 25.2) (NNS cigarettes))) (PP (IN per) (NP (NN day)))) (PP (IN at) (NP (NN baseline))))) (. .)))
16330293	10	(S1 (S (NP (NP (CD Five) (CD hundred) (JJ fifty-three) (NNS patients)) (, ,) (NP (NP (NP (CD 264)) (VP (VBG taking) (NP (DT the) (NN lozenge)))) (CC and) (NP (NP (CD 289)) (VP (VBG taking) (NP (DT the) (NN gum))))) (, ,)) (VP (VBD used) (NP (NP (DT the) (NN study) (NN product)) (PP (IN for) (NP (QP (CD >) (CC or) (CD =4)) (NNS days))) (PP (IN per) (NP (NN week)))) (PP (IN during) (NP (NP (DT the) (JJ first) (CD 2) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (JJ evaluable) (NN population)) (-RRB- -RRB-))))) (. .)))
16330293	11	(S1 (S (NP (NP (DT The) (JJ Doc_16330293_1460_1468_Chemical) (NN lozenge)) (CC and) (NP (NNP Doc_16330293_1481_1489_Chemical) (NN gum))) (VP (AUX were) (ADJP (RB equally) (RB well) (JJ tolerated)) (, ,) (PP (IN despite) (NP (NP (VBN increased) (JJ Doc_16330293_1541_1549_Chemical) (NN exposure)) (PP (IN from) (NP (DT the) (NN lozenge)))))) (. .)))
16330293	12	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ adverse) (NNS events)) (PP (IN in) (NP (DT the) (CD 2) (NNS groups)))))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN during) (NP (NP (DT the) (JJ first) (CD 2) (NNS weeks)) (PP (IN of) (NP (NP (NN product) (NN use)) (PRN (-LRB- -LRB-) (NP (NP (NN evaluation) (NN population)) (: :) (NP (CD 55.3) (NN %) (NN lozenge))) (, ,) (NP (CD 54.7) (NN %) (NN gum)) (-RRB- -RRB-)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN during) (NP (NP (DT the) (JJ entire) (NN study)) (PRN (-LRB- -LRB-) (NP (NP (NN safety) (NN population)) (: :) (NP (NP (CD 63.8) (NN %)) (CC and) (NP (CD 58.6) (NN %)))) (, ,) (RB respectively) (-RRB- -RRB-))))) (. .)))
16330293	13	(S1 (S (NP (NP (NN Stratification)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN by) (NP (NP (NN sex)) (, ,) (NP (NN age)) (, ,) (NP (NP (NN extent)) (PP (IN of) (NP (JJ concurrent) (NN smoking)))) (, ,) (NP (NP (NN extent)) (PP (IN of) (NP (NN product) (NN use)))) (, ,) (CC and) (NP (NP (NN severity)) (PP (IN of) (NP (JJ adverse) (NNS events))))))))) (VP (VBD revealed) (NP (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NNS differences)) (PP (IN between) (NP (DT the) (NN lozenge) (CC and) (NN gum))))) (. .)))
16330293	14	(S1 (S (NP (DT The) (JJS most) (JJ common) (JJ adverse) (NNS events)) (VP (AUX were) (NP (NP (NP (NNP Doc_16330293_2051_2057_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (QP (CD 17.2) (NN %) (CC and) (CD 16.1) (NN %))) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (QP (CD -3.7) (TO to) (CD 6.0)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_16330293_2098_2105_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (QP (CD 10.7) (NN %) (CC and) (CD 6.6) (NN %))) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (QP (CD 0.5) (TO to) (CD 7.8)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_16330293_2148_2156_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (QP (CD 8.7) (NN %) (CC and) (CD 9.9) (NN %))) (: ;) (NP (CD 95) (NN %))) (NNP Cl)) (, ,) (NP (QP (CD -5.0) (TO to) (CD 2.6)))) (-RRB- -RRB-))))) (. .)))
16330293	15	(S1 (S (NP (JJ Serious) (JJ adverse) (NNS events)) (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (QP (CD 11) (CC and) (CD 13)) (NNS patients))) (PP (IN in) (NP (DT the) (JJ respective) (NNS groups))))) (. .)))
16330293	16	(S1 (S (NP (NP (QP (JJR Fewer) (IN than) (CD 6)) (NN %)) (PP (IN of) (NP (NNS patients))) (PP (IN in) (NP (DT either) (NN group)))) (VP (AUX were) (VP (VBN considered) (PP (IN by) (NP (NP (DT the) (NN investigator)) (SBAR (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (VBG worsening)) (PP (IN of) (NP (PRP$ their) (JJ overall) (NN disease) (NN condition)))) (PP (IN during) (NP (DT the) (NN study))))))))))) (. .)))
16330293	17	(S1 (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD >60) (NN %)) (-RRB- -RRB-))))) (VP (VBD experienced) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (PRP$ their) (NN disease) (NN status)) (PP (IN from) (NP (NN baseline))))))) (. .)))
16330293	18	(S1 (S (NP (DT The) (NP (JJ 4-mg) (JJ Doc_16330293_2545_2553_Chemical) (NN lozenge)) (CC and) (NP (JJ 4-mg) (JJ Doc_16330293_2571_2579_Chemical) (NN gum))) (VP (AUX had) (NP (JJ comparable) (NN safety) (NNS profiles)) (PP (IN in) (NP (DT these) (NNS patients))) (PP (IN with) (NP (JJ label-restricted) (JJ medical) (NNS conditions)))) (. .)))
16330766	0	(S1 (NP (NP (JJ Pharmacological) (NN modulation)) (PP (IN of) (NP (JJ Doc_16330766_30_34_Disease-related) (NN brain) (NN activity))) (PP (IN during) (NP (NP (JJ normal) (CC and) (JJ central) (NN sensitization) (NNS states)) (PP (IN in) (NP (NNS humans))))) (. .)))
16330766	1	(S1 (S (NP (NP (JJ Abnormal) (NN processing)) (PP (IN of) (NP (NP (JJ somatosensory) (NNS inputs)) (PP (IN in) (NP (NP (DT the) (JJ central) (JJ nervous) (NN system)) (PRN (-LRB- -LRB-) (NP (JJ central) (NN sensitization)) (-RRB- -RRB-))))))) (VP (AUX is) (NP (NP (DT the) (NN mechanism)) (PP (VBG accounting) (PP (IN for) (NP (NP (DT the) (JJ enhanced) (JJ Doc_16330766_259_263_Disease) (NN sensitivity)) (PP (IN in) (NP (NP (DT the) (NN skin)) (VP (VBG surrounding) (NP (NP (NNP Doc_16330766_300_313_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16330766_315_337_Disease)) (-RRB- -RRB-))))))))))) (. .)))
16330766	2	(S1 (S (NP (NN Doc_16330766_340_362_Disease)) (VP (VBZ shares) (NP (JJ clinical) (NNS characteristics)) (PP (IN with) (NP (NP (NNP Doc_16330766_400_423_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16330766_441_457_Disease)))))))) (. .)))
16330766	3	(S1 (S (NP (NP (JJ Abnormal) (NN brain) (NNS responses)) (PP (TO to) (NP (JJ somatosensory) (NNS stimuli)))) (VP (AUX have) (VP (AUX been) (VP (VP (VBN found) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16330766_542_554_Disease)))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (JJ normal) (NNS subjects))) (PP (IN during) (NP (JJ experimental) (JJ central) (NN sensitization)))))) (. .)))
16330766	4	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_16330766_679_689_Chemical)) (, ,) (NP (NP (DT a) (NN drug) (NN effective)) (PP (IN in) (NP (NNP Doc_16330766_711_727_Disease) (NNS patients)))) (, ,))) (PP (IN on) (NP (NP (NN brain) (NN processing)) (PP (IN of) (NP (JJ nociceptive) (NN information))) (PP (IN in) (NP (JJ normal) (CC and) (JJ central) (NN sensitization) (NNS states)))))))))) (. .)))
16330766	5	(S1 (S (S (VP (VBG Using) (NP (NP (JJ functional) (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NN fMRI)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ normal) (NNS volunteers))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (JJ Doc_16330766_917_927_Chemical-induced) (NN modulation)) (PP (IN of) (NP (NP (NN brain) (NN activity)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ nociceptive) (JJ mechanical) (NN stimulation)) (PP (IN of) (NP (NP (JJ normal) (NN skin)) (CC and) (NP (JJ Doc_16330766_1034_1043_Chemical-induced) (NN Doc_16330766_1052_1074_Disease)))))))))))) (. .)))
16330766	6	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NNP Doc_16330766_1088_1098_Chemical)))) (VP (AUX was) (NP (CD 1,800) (NN mg)) (PP (IN per) (NP (NN os))) (, ,) (PP (IN in) (NP (DT a) (JJ single) (NN administration)))) (. .)))
16330766	7	(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (S (NP (DT that) (PRN (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-)) (NNP Doc_16330766_1166_1176_Chemical)) (VP (VBD reduced) (NP (DT the) (NNS activations)) (PP (IN in) (NP (DT the) (JJ bilateral) (NN operculoinsular) (NN cortex))) (, ,) (ADVP (RB independently)) (PP (IN of) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ central) (NN sensitization)))))))))) (: ;) (S (NP (PRN (-LRB- -LRB-) (NP (NNP ii)) (-RRB- -RRB-)) (NNP Doc_16330766_1303_1313_Chemical)) (VP (VBD reduced) (NP (DT the) (NN activation)) (PP (IN in) (NP (DT the) (NN brainstem))) (, ,) (ADVP (RB only)) (PP (IN during) (NP (JJ central) (NN sensitization))))) (: ;) (S (NP (PRN (-LRB- -LRB-) (NP (NNP iii)) (-RRB- -RRB-)) (NNP Doc_16330766_1396_1406_Chemical)) (VP (VBD suppressed) (NP (JJ stimulus-induced) (NNS deactivations)) (, ,) (ADVP (RB only)) (PP (IN during) (NP (JJ central) (NN sensitization))))) (: ;) (S (NP (DT this) (NN effect)) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ robust)) (PP (IN than) (NP (NP (DT the) (NN effect)) (PP (IN on) (NP (NN brain) (NN activation)))))))) (. .)))
16330766	8	(S1 (S (NP (DT The) (JJ observed) (JJ drug-induced) (NNS effects)) (VP (AUX were) (RB not) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (DT the) (NN baseline) (NN fMRI) (NN signal))))))) (. .)))
16330766	9	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_16330766_1666_1676_Chemical)) (VP (AUX has) (NP (NP (DT a) (JJ measurable) (NN antinociceptive) (NN effect)) (CC and) (NP (NP (DT a) (JJR stronger) (JJ antihyperalgesic) (NN effect)) (ADJP (RBS most) (JJ evident)))) (PP (IN in) (NP (NP (DT the) (NN brain) (NNS areas)) (VP (VBG undergoing) (NP (NN deactivation)))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG supporting) (NP (NP (DT the) (NN concept)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_16330766_1846_1856_Chemical)) (VP (AUX is) (ADJP (RBR more) (JJ effective) (PP (IN in) (S (VP (VBG modulating) (NP (JJ nociceptive) (NN transmission)) (SBAR (WHADVP (WRB when)) (S (NP (JJ central) (NN sensitization)) (VP (AUX is) (ADJP (JJ present)))))))))))))))) (. .)))
16337777	0	(S1 (NP (NP (NN Investigation)) (PP (IN of) (NP (NP (JJ mitochondrial) (NN involvement)) (PP (IN in) (NP (NP (DT the) (JJ experimental) (NN model)) (PP (IN of) (NP (NNP Doc_16337777_72_80_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_16337777_92_103_Chemical)))))))) (. .)))
16337777	1	(S1 (S (NP (NNP Doc_16337777_105_132_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ several) (NNS aspects)) (PP (IN of) (NP (NN epileptogenesis))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN energy) (NN generation)) (, ,) (NP (NP (NN control)) (PP (IN of) (NP (NN cell) (NN Doc_16337777_238_243_Disease)))) (, ,) (NP (NN neurotransmitter) (NN synthesis)) (, ,) (CC and) (NP (ADJP (JJ free) (JJ radical)) (PRN (-LRB- -LRB-) (NP (NNP FR)) (-RRB- -RRB-)) (NN production))))))))) (. .)))
16337777	2	(S1 (S (NP (NP (VBN Increased) (NN production)) (PP (IN of) (NP (NNS FRs)))) (VP (MD may) (VP (VB cause) (NP (NP (NN mtDNA) (NN damage)) (VP (VBG leading) (PP (TO to) (NP (NP (VBN decreased) (NNS activities)) (PP (IN of) (NP (NP (JJ oxidative) (NN phosphorylation) (NNS complexes)) (VP (VBG containing) (NP (JJ mtDNA-encoded) (NNS subunits))))))))))) (. .)))
16337777	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (VBN increased) (NN generation)) (PP (IN of) (NP (NN FR))) (PP (IN during) (NP (NNP Doc_16337777_537_555_Disease)))) (VP (MD would) (VP (AUX be) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB provoke) (NP (NP (NNS abnormalities)) (PP (PP (IN in) (NP (NN mtDNA))) (CC and) (PP (IN in) (NP (NP (DT the) (NN expression) (CC and) (NN activity)) (PP (IN of) (NP (JJ cytochrome) (NNP c) (NN oxidase))) (PRN (-LRB- -LRB-) (NP (NNP CCO)) (-RRB- -RRB-)) (, ,) (ADJP (JJ complex) (NP (NP (NNP IV)) (PP (IN of) (NP (DT the) (JJ respiratory) (NN chain))))) (, ,) (PP (IN in) (NP (NP (DT the) (JJ chronic) (NN phase)) (PP (IN of) (NP (NP (DT the) (JJ Doc_16337777_741_752_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_16337777_762_784_Disease)))))))))))))))))))) (. .)))
16337777	4	(S1 (S (NP (NN DNA) (NN analysis)) (VP (VBD revealed) (NP (NP (JJ low) (NNS amounts)) (PP (PP (IN of) (NP (DT a) (CD 4.8) (NN kb) (NN mtDNA) (NN deletion))) (CC but) (PP (IN with) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (NN frequency)) (CC or) (NP (NN quantity)))) (PP (IN in) (NP (NP (DT the) (NN control)) (CC and) (NP (JJ experimental) (NNS groups))))))))) (. .)))
16337777	5	(S1 (S (NP (PRP We)) (VP (AUX did) (RB not) (VP (VB find) (NP (NP (NNS abnormalities)) (PP (IN in) (NP (NP (DT the) (NN expression) (CC and) (NN distribution)) (PP (IN of) (NP (NP (NP (DT an) (JJ mtDNA-encoded) (NN subunit)) (PP (IN of) (NP (NP (NNP CCO)) (PRN (-LRB- -LRB-) (NP (NNP CCO-I)) (-RRB- -RRB-))))) (CC or) (NP (NP (DT a) (JJ relative) (NN decrease)) (PP (IN in) (NP (NP (NNS CCO-I)) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (JJ nuclear-encoded) (NNS subunits)) (PRN (-LRB- -LRB-) (ADJP (JJ CCO-IV) (CC and) (JJ SDH-fp)) (-RRB- -RRB-))))))))))))))))) (. .)))
16337777	6	(S1 (S (NP (NP (DT No) (NN abnormality)) (PP (IN in) (NP (NN CCO) (NN activity)))) (VP (AUX was) (VP (VBN observed) (PP (IN through) (NP (NN histochemistry))))) (. .)))
16337777	7	(S1 (S (SBAR (IN Although) (S (NP (NP (NNS evidences)) (PP (IN of) (NP (NNP Doc_16337777_1231_1258_Disease)))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (ADJP (RB previously) (VBN published)) (NNS studies))))))) (, ,) (NP (PRP$ our) (NNS results)) (VP (AUX do) (RB not) (VP (VB suggest) (SBAR (IN that) (S (NP (NP (DT the) (NNS FRs)) (, ,) (VP (VBN generated) (PP (IN during) (NP (DT the) (JJ acute) (NN phase)))) (, ,)) (VP (VBD determined) (NP (NP (JJ important) (NNS abnormalities)) (PP (PP (IN in) (NP (NN mtDNA))) (, ,) (PP (IN in) (NP (NP (NN expression)) (PP (IN of) (NP (NN CCO-I))))) (, ,) (CC and) (PP (IN in) (NP (NN CCO) (NN activity)))))))))) (. .)))
1639466	0	(S1 (S (NP (NP (JJ Adverse) (NN effect)) (PP (IN of) (NP (DT the) (JJ Doc_1639466_22_29_Chemical) (NN channel) (NN blocker)))) (VP (NNP Doc_1639466_46_58_Chemical) (PP (IN on) (NP (NNP Doc_1639466_62_77_Disease))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_1639466_91_116_Disease)))))) (. .)))
1639466	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ 6-week) (NN treatment)) (PP (IN with) (NP (NP (NP (DT the) (JJ Doc_1639466_160_167_Chemical) (NN channel) (NN blocker)) (NP (NNP Doc_1639466_184_196_Chemical))) (CC or) (NP (NP (DT the) (NNP Doc_1639466_204_215_Chemical) (VBG converting) (JJ enzyme) (NN inhibitor)) (NP (NNP Doc_1639466_244_253_Chemical))))))) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (NNP Doc_1639466_273_284_Disease)) (, ,) (NP (JJ renal) (NNS hemodynamics)) (, ,) (CC and) (NP (NP (NN morphology)) (PP (IN of) (NP (DT the) (JJ nonclipped) (NN kidney))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NNS rats))) (PP (IN with) (NP (NP (NN two-kidney)) (, ,) (NP (NP (CD one) (NN clip)) (NP (NNP Doc_1639466_392_417_Disease))))))) (. .)))
1639466	2	(S1 (S (SBAR (NP (CD Six) (NNS weeks)) (IN after) (S (VP (VBG clipping) (PP (IN of) (NP (CD one) (JJ renal) (NN artery)))))) (, ,) (NP (NP (NNP Doc_1639466_465_477_Disease) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 178) (NNS +/-)) (NP (CD 4) (NN mm) (NNP Hg))) (-RRB- -RRB-))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (CD three) (NNS groups)) (: :) (NP (NP (JJ untreated) (JJ Doc_1639466_551_563_Disease) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-))))) (, ,) (ADJP (ADJP (JJ Doc_1639466_582_591_Chemical-treated)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-)) (, ,) (CC or) (ADJP (JJ Doc_1639466_612_624_Chemical-treated)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-))))) (. .)))
1639466	3	(S1 (S (NP (JJ Sham-operated) (NNS rats)) (VP (VBD served) (PP (IN as) (NP (NP (JJ normotensive) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (CD 128) (NN +/-) (CD 3) (NN mm) (NNP Hg)) (, ,) (NP (NNP n) (SYM =) (CD 8))) (-RRB- -RRB-))))) (. .)))
1639466	4	(S1 (S (PP (IN After) (NP (NP (CD 6) (NNS weeks)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (NP (JJ renal) (NNS hemodynamics)) (PRN (-LRB- -LRB-) (NP (NP (JJ glomerular) (NN filtration) (NN rate)) (CC and) (NP (JJ renal) (NN plasma) (NN flow))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (DT the) (JJ anesthetized) (NNS rats))))) (. .)))
1639466	5	(S1 (S (NP (JJ Renal) (NN tissue)) (VP (AUX was) (VP (VBN obtained) (PP (IN for) (NP (NP (NN determination)) (PP (IN of) (NP (NP (JJ glomerular) (NN size)) (CC and) (NP (NN sclerosis)))))))) (. .)))
1639466	6	(S1 (S (S (ADJP (ADJP (JJ Doc_1639466_936_945_Chemical)) (CC but) (ADJP (RB not) (JJ Doc_1639466_954_966_Chemical)))) (VP (VBN reduced) (NP (NN blood) (NN pressure)) (ADVP (RB significantly))) (. .)))
1639466	7	(S1 (S (PP (IN After) (NP (NP (CD 6) (NNS weeks)) (PP (IN of) (NP (NN therapy))))) (, ,) (NP (JJ glomerular) (NN filtration) (NN rate)) (VP (AUX was) (RB not) (ADJP (JJ different)) (PP (IN among) (NP (DT the) (VBN studied) (NNS groups)))) (. .)))
1639466	8	(S1 (S (S (NP (JJ Renal) (NN plasma) (NN flow)) (VP (VBD increased))) (, ,) (CC but) (S (NP (NP (NN albumin) (NN excretion)) (CC and) (NP (NNP Doc_1639466_1157_1175_Disease))) (VP (AUX did) (RB not) (VP (VB change) (PP (IN after) (NP (JJ Doc_1639466_1197_1206_Chemical) (NN treatment)))))) (. .)))
1639466	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (PP (IN in) (NP (DT the) (JJ Doc_1639466_1238_1250_Chemical-treated) (NN group))) (NP (NNP Doc_1639466_1265_1276_Disease)) (VP (VBD increased) (PP (IN from) (NP (CD 12.8) (NN +/-)) (, 2) (ADVP (RB progressively))) (PP (TO to) (NP (QP (CD 163) (CD +/-)) (CD 55))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (CD 19.2) (NN +/-)) (NP (QP (CD 9) (CD mg/24)) (NNS hr))) (PP (IN in) (NP (DT the) (NNP Doc_1639466_1372_1384_Disease) (NNS controls))))))) (. .)))
1639466	10	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_1639466_1408_1426_Disease) (NN index)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ Doc_1639466_1468_1480_Chemical-treated) (NN group))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ Doc_1639466_1513_1525_Disease) (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD 0.38) (JJ +/-) (CD 0.1) (CC versus) (CD 0.13) (NN +/-) (CD 0.04)) (-RRB- -RRB-))))))) (. .)))
1639466	11	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (S (NP (NN glomerular) (NN size)) (VP (AUX was) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (DT the) (JJ Doc_1639466_1619_1631_Chemical-treated) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 14.9) (JJ +/-) (ADJP (QP (CD 0.17) (CD 10))) (PRN (-LRB- -LRB-) (JJ -3) (-RRB- -RRB-)) (NN mm2)) (-RRB- -RRB-))))) (CC but) (ADJP (JJR lower) (PP (IN in) (NP (NP (DT the) (JJ Doc_1639466_1690_1699_Chemical-treated) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 11.5) (JJ +/-) (ADJP (QP (CD 0.15) (CD 10))) (PRN (-LRB- -LRB-) (JJ -3) (-RRB- -RRB-)) (NN mm2)) (-RRB- -RRB-)))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NNP Doc_1639466_1759_1771_Disease) (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD 12.1) (NN +/-)) (NP (CD 0.17) (CD 10) (-LRB- -LRB-) (NN -3) (-RRB- -RRB-) (NN mm2)) (-RRB- -RRB-)))))) (. .)) (PRN (-LRB- -LRB-) (S (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))
16403073	0	(S1 (S (NP (NN Doc_16403073_0_12_Chemical)) (VP (VBN induced) (NP (NNP Doc_16403073_21_40_Disease)) (PP (IN without) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ QT) (JJ interval-prolonging) (NN drug)))))) (. .)))
16403073	1	(S1 (S (NP (NN Doc_16403073_97_109_Chemical)) (VP (AUX is) (RB not) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (ADJP (JJ proarrhythmic)) (PP (IN without) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ QT) (JJ interval-prolonging) (NNS drugs)))))))))) (. .)))
16403073	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN woman)) (PP (IN with) (NP (NNP Doc_16403073_223_246_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (DT a) (ADVP (RB markedly)) (NN Doc_16403073_272_293_Disease)) (CC and) (NP (NP (NNP Doc_16403073_298_317_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16403073_319_322_Disease)) (-RRB- -RRB-)))) (PP (IN after) (S (VP (VBG taking) (NP (NNP Doc_16403073_337_349_Chemical)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_16403073_367_383_Disease))))))))))))) (. .)))
16403073	3	(S1 (S (NP (PRP$ Her) (JJ QT) (NN interval)) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN upon) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_16403073_439_451_Chemical)))))) (. .)))
16403073	4	(S1 (S (NP (JJ Genetic) (NN study)) (VP (AUX did) (RB not) (VP (VB find) (NP (NP (DT any) (NN mutation)) (PP (IN in) (NP (NP (PRP$ her) (NNS genes)) (SBAR (WHNP (WDT that)) (S (VP (VBP encode) (NP (JJ cardiac) (JJ IKr) (NN channel) (NNS proteins)))))))))) (. .)))
16403073	5	(S1 (S (NP (PRP We)) (VP (VBP postulate) (SBAR (IN that) (S (PP (IN by) (NP (NP (NN virtue)) (PP (IN of) (NP (NP (PRP$ its) (JJ direct) (VBG blocking) (NN action)) (PP (IN on) (NP (NN IKr))))))) (, ,) (NP (NNP Doc_16403073_614_626_Chemical)) (ADVP (RB alone)) (VP (MD may) (VP (VP (VB prolong) (NP (CD QT) (NN interval))) (CC and) (VP (VB induce) (NP (NN Doc_16403073_668_671_Disease)))))))) (. .)))
16403073	6	(S1 (S (NP (DT This)) (VP (VBZ calls) (PP (IN for) (NP (NN attention))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_16403073_703_715_Chemical)) (VP (AUX is) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NN risk) (NNS factors))) (PP (IN for) (NP (VBN acquired) (NN Doc_16403073_775_791_Disease)))))))))) (. .)))
16428221	0	(S1 (NP (NP (NP (JJ Doc_16428221_0_19_Disease) (JJ following) (JJ oral) (JJ Doc_16428221_35_50_Chemical) (NN intake)) (PP (IN in) (NP (DT an) (NN adult)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
16428221	1	(S1 (S (NP (NN Doc_16428221_86_101_Chemical)) (VP (AUX is) (ADVP (ADVP (RB structurally)) (CC and) (ADVP (RB functionally))) (ADJP (JJ similar) (PP (TO to) (NP (NNP Doc_16428221_146_157_Chemical))))) (. .)))
16428221	2	(S1 (S (S (NP (NP (NN Doc_16428221_159_178_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_16428221_195_212_Disease))))) (VP (AUX is) (ADVP (RB well)) (VP (VBN documented)))) (, ,) (CC and) (S (PP (IN in) (NP (JJ rare) (NNS cases))) (NP (NNP Doc_16428221_251_267_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN after) (NP (NP (JJ Doc_16428221_292_307_Chemical) (NN intake)) (PP (IN in) (NP (NNS children))))))))) (. .)))
16428221	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 63-year-old) (NN female)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_16428221_392_407_Chemical)) (UCP (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_16428221_415_428_Disease)))) (CC and) (VP (VBN suffered) (PP (IN from) (NP (JJ multiple) (NN Doc_16428221_456_473_Disease))))))))))))))) (. .)))
16428221	4	(S1 (S (NP (PRP We)) (VP (VBP consider) (NP (JJ drug-induced) (NN Doc_16428221_500_519_Disease)) (PP (IN as) (NP (NP (DT the) (ADJP (RBS most) (JJ likely)) (NN cause)) (PP (IN of) (NP (JJ recurrent) (NNP Doc_16428221_558_575_Disease))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT any) (JJ pathological) (NNS findings))))))) (PP (IN during) (NP (DT the) (JJ diagnostic) (NN work-up)))) (. .)))
16428221	5	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (JJ Doc_16428221_668_683_Chemical) (JJ mediated) (NN Doc_16428221_693_703_Disease)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ neurological) (NNS symptoms)) (CC and) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ Doc_16428221_781_796_Chemical) (NN therapy)))))))))))))) (. .)))
16428221	6	(S1 (S (NP (NP (DT This) (JJ potential) (NN side-effect)) (, ,) (SBAR (IN though) (FRAG (ADJP (RB very) (JJ rare)))) (, ,)) (VP (VBZ represents) (NP (NP (CD one) (JJR more) (NN reason)) (SBAR (S (VP (TO to) (VP (AUX be) (ADJP (RB very) (JJ restrictive)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_16428221_916_931_Chemical))))))))))) (. .)))
16574712	0	(S1 (S (NP (JJ Doc_16574712_0_4_Chemical) (NN polydrug) (NNS users)) (VP (VBP show) (NP (NP (JJ process-specific) (JJ central) (NN executive) (NNS impairments)) (VP (VBN coupled) (PP (IN with) (NP (NN Doc_16574712_85_134_Disease)))))) (. .)))
16574712	1	(S1 (S (PP (IN In) (NP (JJ recent) (NNS years))) (NP (JJ working) (NNP Doc_16574712_160_175_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (NP (NNP Doc_16574712_207_211_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16574712_213_246_Chemical)) (, ,) (NP (NNP Doc_16574712_248_255_Chemical)) (-RRB- -RRB-))))))))) (. .)))
16574712	2	(S1 (S (NP (NP (DT The) (JJ current) (NN study)) (VP (VBN aimed) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (JJ Doc_16574712_306_310_Chemical) (NN use))) (PP (PP (IN on) (NP (NP (CD three) (JJ separate) (JJ central) (NN executive) (NNS processes)) (PRN (-LRB- -LRB-) (NP (NP (NN set) (VBG shifting)) (, ,) (NP (NN inhibition)) (CC and) (NP (NN memory))) (VBG updating) (-RRB- -RRB-)))) (CC and) (RB also) (PP (IN on) (`` ``) (ADJP (JJ prefrontal)) ('' ''))))))))) (VP (VBD mediated) (NP (ADJP (JJ social) (CC and) (JJ emotional)) (NN judgement) (NNS processes))) (. .)))
16574712	3	(S1 (S (NP (NNP Fifteen)) (VP (VBD polydrug) (SBAR (S (NP (NP (NNP Doc_16574712_501_508_Chemical) (NNS users)) (CC and) (NP (ADJP (CD 15) (NN polydrug)) (JJ non-Doc_16574712_535_542_Chemical) (NN user) (NNS controls))) (VP (VBD completed) (NP (NP (DT a) (JJ general) (NN drug) (NN use) (NN questionnaire)) (, ,) (NP (NP (DT the) (NNP Brixton) (NNP Spatial) (NN Anticipation) (NN task)) (PRN (-LRB- -LRB-) (NP (VB set) (VBG shifting)) (-RRB- -RRB-))) (, ,) (RB Backward) (NP (NP (NNP Digit) (NNP Span) (NN procedure)) (PRN (-LRB- -LRB-) (NP (NN memory)) (VBG updating) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Inhibition)) (PP (IN of) (NP (NP (NN Return)) (PRN (-LRB- -LRB-) (NP (NN inhibition)) (-RRB- -RRB-))))) (, ,) (NP (DT an) (JJ emotional) (NN intelligence) (NN scale)) (, ,) (NP (DT the) (NNP Tromso) (NNP Social) (NNP Intelligence) (NNP Scale)) (CC and) (NP (NP (DT the) (NNP Dysexecutive) (NN Questionnaire)) (PRN (-LRB- -LRB-) (NP (NNP DEX)) (-RRB- -RRB-)))))))) (. .)))
16574712	4	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (JJ Doc_16574712_865_869_Chemical-free) (NN polydrug) (NNS controls)))) (, ,) (NP (NNP Doc_16574712_894_898_Chemical) (NN polydrug) (NNS users)) (VP (VBD showed) (NP (NNS impairments)) (PP (IN in) (NP (NP (VBN set) (VBG shifting) (CC and) (NN memory)) (UCP (VP (VBG updating)) (, ,) (CC and) (PP (ADVP (RB also)) (IN in) (NP (ADJP (JJ social) (CC and) (JJ emotional)) (NN judgement) (NNS processes))))))) (. .)))
16574712	5	(S1 (S (NP (DT The) (JJ latter) (CD two) (NNS deficits)) (VP (VBD remained) (ADJP (JJ significant)) (PP (IN after) (S (VP (VBG controlling) (PP (IN for) (NP (JJ other) (NN drug) (NN use))))))) (. .)))
16574712	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP lend) (NP (JJ further) (NN support)) (PP (TO to) (NP (DT the) (NN proposal) (SBAR (IN that) (S (NP (NP (JJ cognitive) (NNS processes)) (VP (VBN mediated) (PP (IN by) (NP (DT the) (JJ prefrontal) (NN cortex))))) (VP (MD may) (VP (AUX be) (VP (VBN impaired) (PP (IN by) (NP (JJ recreational) (JJ Doc_16574712_1246_1253_Chemical) (NN use))))))))))) (. .)))
1664218	0	(S1 (NP (NP (NN Phase) (NNP II) (NN study)) (PP (IN of) (NP (NP (DT the) (NNP Doc_1664218_22_31_Chemical) (NN analogue) (NNP Doc_1664218_41_47_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1664218_49_59_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Doc_1664218_64_90_Disease))) (. .)))
1664218	1	(S1 (S (NP (NP (NNP Doc_1664218_92_98_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_1664218_100_110_Chemical)) (: ;) (NP (NNP Doc_1664218_112_202_Chemical))) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ topoisomerase) (NNP II) (NN poison)) (PP (IN with) (NP (JJ high) (JJ experimental) (NN antitumour) (NN activity))))) (. .)))
1664218	2	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN administered) (PP (IN by) (NP (NP (CD 15) (JJ min) (NN infusion)) (PP (TO to) (NP (NP (CD 16) (JJ evaluable) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_1664218_346_372_Disease) (-LRB- -LRB-) (NNP Doc_1664218_374_379_Disease) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 7)) (PP (IN with) (NP (DT no) (JJ prior) (NN treatment)))) (, ,) (NP (NP (CD 9) (NNS patients)) (PP (IN in) (NP (JJ relapse) (JJ following) (NN surgery/radiotherapy))))) (-RRB- -RRB-)))))))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 648) (NNS mg/m2)) (VP (VBN divided) (PP (IN over) (NP (CD 3) (NNS days))))) (, ,) (VP (VBN repeated) (NP (DT every) (CD 3) (NNS weeks))) (-RRB- -RRB-)) (VP (VBN determined) (PP (IN by) (NP (NN phase) (NN I) (NN trial)))))))) (. .)))
1664218	3	(S1 (S (NP (NNS Patients)) (VP (AUX had) (NP (NP (NP (DT a) (JJ median) (NN performance) (NN status)) (PP (IN of) (NP (NP (CD 1)) (PRN (-LRB- -LRB-) (NP (WP WHO)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (JJ median) (NN age)) (PP (IN of) (NP (CD 61) (NNS years)))))) (. .)))
1664218	4	(S1 (S (NP (DT The) (NN histology)) (VP (VBN comprised) (NP (NP (NP (NNP Doc_1664218_663_681_Disease)) (PRN (-LRB- -LRB-) (NP (CD 11)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_1664218_688_702_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ mixed) (NN histology)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_1664218_729_756_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ large) (NN cell) (NNP Doc_1664218_776_802_Disease)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))))) (. .)))
1664218	5	(S1 (S (NP (NP (JJ Doc_1664218_808_819_Disease) (NN grade)) (ADJP (ADJP (JJR greater) (PP (IN than))) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (CD 3)))))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (CD 15) (NNS patients)) (, ,) (NP (NP (NP (NNP Doc_1664218_878_888_Disease)) (PP (IN with) (NP (NP (NN recovery)) (PP (IN in) (NP (NNP 3)))))) (, ,) (CC and) (NP (NP (JJ grand) (JJ mal) (NNP Doc_1664218_923_931_Disease)) (PP (IN in) (NP (CD 1) (NN patient))))))))) (. .)))
1664218	6	(S1 (S (S (NP (NN Grade)) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 2) (NNP Doc_1664218_976_982_Disease) (CC and) (NNP Doc_1664218_987_995_Disease)))) (VP (VP (VBD occurred) (PP (IN in) (NP (ADJP (CD 66) (NN %)) (NNS courses)))) (CC and) (VP (NP (NNP Doc_1664218_1024_1033_Disease)) (PP (IN in) (NP (NP (DT the) (NN infusion) (NN arm)) (PP (IN in) (NP (CD 37) (NN %)))))))) (. .) (NP (NP (CD 1) (NN patient)) (PP (IN with) (NP (NNP Doc_1664218_1077_1100_Disease)))) (VP (VBD achieved) (NP (NP (DT a) (JJ partial) (NN response)) (VP (VBG lasting) (NP (CD 5) (NNS months))))) (. .)))
1664218	7	(S1 (S (NP (NP (JJ Further) (NN testing)) (PP (IN in) (NP (NP (DT this)) (CC and) (NP (JJ other) (NN Doc_1664218_1181_1187_Disease) (NNS types)))) (VP (VBG using) (NP (JJ multiple) (JJ daily) (NNS schedules)))) (VP (AUX is) (VP (VBN warranted))) (. .)))
16680561	0	(S1 (NP (NP (NP (NNS Pharmacokinetics)) (PP (IN of) (NP (NNP Doc_16680561_20_35_Chemical)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NNP Doc_16680561_59_73_Chemical)))))) (. .)))
16680561	1	(S1 (S (PP (IN In) (NP (NN vitro))) (NP (NN work)) (VP (AUX has) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NNP Doc_16680561_122_132_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (JJ cytochrome) (JJ P450) (NN isoenzyme) (PRN (-LRB- -LRB-) (NP (NNP CYP)) (-RRB- -RRB-)) (NNS 2D6))))))))) (. .)))
16680561	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_16680561_251_261_Chemical))) (PP (IN on) (NP (NN CYP2D6) (NN activity)))) (, ,) (S (VP (VBG using) (NP (NNP Doc_16680561_288_299_Chemical)) (PP (IN as) (NP (DT a) (NN probe) (NN substrate))))) (, ,) (PP (IN in) (NP (JJ healthy) (NNS subjects))))))) (. .)))
16680561	3	(S1 (NP (NP (NNP Seventeen) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN genotyped) (PP (IN as) (S (NP (CD CYP2D6) (JJ extensive) (NNS metabolizers)) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (NP (DT this) (JJ randomized) (, ,) (JJ open-label) (, ,) (JJ crossover) (NN study) (S (VP (TO to) (VP (VB receive) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_16680561_518_529_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NNS mg)) (-RRB- -RRB-))))) (PP (IN on) (NP (CD two) (JJ separate) (NNS occasions))))))) (, ,) (UCP (ADVP (RB once) (RB alone)) (CC and) (PP (RB once) (IN after) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_16680561_609_619_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 90) (NNS mg)) (PP (IN for) (NP (CD 7) (NNS days)))) (-RRB- -RRB-))))))))))))))))) (. .)))
16680561	4	(S1 (S (NP (NN Blood) (NNS samples)) (VP (AUX were) (VP (VP (VBN obtained) (NP (NN predose))) (CC and) (VP (ADVP (RB up)) (PP (TO to) (NP (CD 72) (NNP h) (NN postdose)))))) (. .)))
16680561	5	(S1 (S (NP (CD Fourteen) (NNS subjects)) (VP (VBD completed) (NP (DT both) (NN treatment) (NNS arms))) (. .)))
16680561	6	(S1 (S (ADVP (JJ Relative) (PP (TO to) (NP (NP (NNP Doc_16680561_771_782_Chemical)) (ADVP (RB alone))))) (, ,) (VP (VBP mean) (SBAR (S (NP (NP (NP (NNP AUC)) (CC and) (NP (NNP C))) (PRN (-LRB- -LRB-) (NP (NNP max)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_16680561_813_824_Chemical)))) (VP (VBD increased) (ADJP (JJ 3.6-) (CC and) (JJ 1.8-fold)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NNP Doc_16680561_878_888_Chemical)))))))))) (. .)))
16680561	7	(S1 (S (NP (NP (DT The) (NNP t)) (PRN (-LRB- -LRB-) (NP (NNP 1/2)) (, ,) (NP (NNP z)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_16680561_907_918_Chemical)))) (VP (AUX was) (ADVP (RB longer)) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_16680561_935_946_Chemical)) (VP (AUX was) (VP (VBN coadministered) (PP (IN with) (NP (NP (NNP Doc_16680561_971_981_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 21.0) (CC versus) (CD 43.3)) (NNS hs)) (-RRB- -RRB-))))))))) (. .)))
16680561	8	(S1 (S (NP (NP (DT The) (NNP t)) (PRN (-LRB- -LRB-) (NP (NNP max)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN between) (NP (DT the) (NNS regimens)))) (. .)))
16680561	9	(S1 (S (NP (JJR Fewer) (NNS subjects)) (VP (VBD reported) (NP (NP (JJ adverse) (NNS events)) (VP (VBG following) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_16680561_1115_1126_Chemical))) (ADVP (ADVP (RB alone)) (SBAR (IN than) (S (SBAR (WHADVP (WRB when)) (S (VP (VBG receiving) (NP (NNP Doc_16680561_1153_1164_Chemical)) (PP (IN with) (NP (NP (NNP Doc_16680561_1170_1180_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 33) (CC versus) (CD 86)) (NN %)) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT the) (RBS most) (JJ frequent)) (WHPP (IN of) (WHNP (WDT which) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_16680561_1226_1232_Disease)) (CC and) (NP (NNP Doc_16680561_1237_1245_Disease))) (-RRB- -RRB-))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN for) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (DT either) (NNP Doc_16680561_1299_1310_Chemical) (CC or) (NNP Doc_16680561_1314_1324_Chemical))))))))))))))) (. .)))
16680561	10	(S1 (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NNP Doc_16680561_1367_1377_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (NN CYP2D6)))))))) (. .)))
16680561	11	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN during) (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NNP Doc_16680561_1469_1479_Chemical))))) (, ,) (NP (NN dose) (NN adjustment)) (VP (MD may) (VP (AUX be) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP demonstrate) (NP (DT a) (JJ narrow) (JJ therapeutic) (NN index))) (CC and) (VP (AUX are) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP2D6)))))))))))))))) (. .)))
16740173	0	(S1 (NP (NP (NN Case) (NN report)) (: :) (NP (JJ acute) (JJ unintentional) (NN Doc_16740173_33_42_Chemical) (NN intoxication)) (. .)))
16740173	1	(S1 (S (NP (NP (NNS Intoxications)) (PP (IN with) (NP (NP (NNP Doc_16740173_90_99_Chemical)) (, ,) (NP (DT a) (JJ muscarinic) (JJ cholinergic) (NN receptor) (NN agonist))))) (VP (AUX are) (ADJP (JJ rare))) (. .)))
16740173	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT an) (JJ interesting) (NN case)) (VP (VBG investigating) (NP (DT a) (-LRB- -LRB-) (JJ near) (-RRB- -RRB-) (JJ fatal) (NN Doc_16740173_212_221_Disease))))) (. .)))
16740173	3	(S1 (S (NP (NP (DT The) (NN son)) (PP (IN of) (NP (DT an) (JJ 84-year-old) (NN male)))) (VP (VBD discovered) (NP (NP (DT a) (NN newspaper) (NN report)) (VP (VBG stating) (NP (JJ clinical) (NN success)) (PP (IN with) (NP (NP (NN plant) (NNS extracts)) (PP (IN in) (NP (NNP Doc_16740173_341_360_Disease)))))))) (. .)))
16740173	4	(S1 (S (S (NP (NP (DT The) (NN mode)) (PP (IN of) (NP (NN action)))) (VP (AUX was) (VP (VBN said) (S (VP (TO to) (VP (AUX be) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (JJ synthetic) (NN compound) (POS ')) (NX (NNP Doc_16740173_442_456_Chemical) (POS '))))))))))))) (: ;) (S (NP (DT that)) (VP (AUX is) (, ,) (NP (NNP Doc_16740173_468_477_Chemical)))) (. .)))
16740173	5	(S1 (S (S (NP (PRP He)) (VP (VBD bought) (NP (NP (CD 25) (NNP g)) (PP (IN of) (NP (NNP Doc_16740173_497_506_Chemical)))) (PP (IN as) (NP (NP (JJ pure) (NN substance)) (PP (IN in) (NP (DT a) (NN pharmacy))))))) (, ,) (CC and) (S (NP (DT the) (NN father)) (VP (AUX was) (VP (VBN administered) (NP (QP (CD 400) (TO to) (CD 500)) (NNS mg))))) (. .)))
16740173	6	(S1 (S (NP (NP (JJ Doc_16740173_587_596_Chemical) (NNS concentrations)) (PP (IN in) (NP (NP (NP (NP (NN serum)) (CC and) (NP (NN urine))) (PP (IN on) (NP (NN day) (CD 1)))) (CC and) (NP (NP (CD 2)) (PP (IN of) (NP (NN hospital) (NN admission))))))) (VP (AUX were) (VP (VBN analysed) (PP (IN by) (NP (JJ HPLC-mass) (NN spectrometry))))) (. .)))
16740173	7	(S1 (S (PP (NP (NNS Minutes)) (IN after) (NP (JJ oral) (NN administration))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD developed) (NP (NP (NNP Doc_16740173_775_781_Disease)) (, ,) (NP (NP (NN sweating)) (CC and) (NP (NN Doc_16740173_796_807_Disease))) (, ,))) (CC and) (VP (ADVP (RB finally)) (VBD collapsed))) (. .)))
16740173	8	(S1 (S (NP (NP (NN Doc_16740173_832_843_Disease)) (, ,) (NP (JJ cholinergic) (NNS symptoms)) (CC and) (NP (NNP Doc_16740173_870_878_Disease))) (VP (VBD occurred)) (. .)))
16740173	9	(S1 (S (NP (NP (NP (JJ Initial) (JJ cardiopulmonary) (NN resuscitation)) (CC and) (NP (JJ immediate) (NN treatment))) (PP (IN with) (NP (NP (NP (NNP Doc_16740173_956_966_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16740173_968_979_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_16740173_982_990_Chemical)) (CC and) (NP (NNP Doc_16740173_995_1005_Chemical))))) (VP (AUX was) (ADJP (JJ successful))) (. .)))
16740173	10	(S1 (S (PP (IN On) (NP (NN hospital) (NN admission))) (, ,) (NP (NP (NN blood) (NN pressure)) (PP (IN of) (NP (DT the) (VBN intubated) (, ,) (JJ bradyarrhythmic) (NN patient)))) (VP (AUX was) (NP (CD 100/65) (NN mmHg))) (. .)))
16740173	11	(S1 (S (S (NP (JJ Further) (NNS signs)) (VP (AUX were) (NP (NP (NNP Doc_16740173_1138_1151_Disease)) (, ,) (NP (NNP Doc_16740173_1153_1168_Disease)) (, ,) (NP (NNP Doc_16740173_1170_1183_Disease)) (, ,) (CC and) (NP (JJ severe) (NN Doc_16740173_1196_1202_Disease))))) (: ;) (S (NP (DT the) (JJ electrocardiographic) (NN finding)) (VP (AUX was) (ADJP (JJ Doc_16740173_1241_1271_Disease)))) (. .)))
16740173	12	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_16740173_1287_1295_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (IN up) (TO to) (CD 50)) (NN mg)) (PP (IN per) (NP (CD 24) (NNS hours)))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_16740173_1324_1334_Chemical)) (CC and) (NP (NNP Doc_16740173_1339_1347_Chemical))))) (VP (AUX were) (ADJP (JJ necessary))) (. .)))
16740173	13	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN extubated) (ADVP (NP (CD 1) (NN week)) (RB later)))) (. .)))
16740173	14	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (VBN increased) (NN Doc_16740173_1423_1431_Disease)) (CC and) (NP (NNP Doc_16740173_1436_1448_Disease))) (VP (VBD necessitated) (NP (NN reintubation))) (. .)))
16740173	15	(S1 (S (NP (NN Doc_16740173_1476_1501_Disease)) (VP (AUX was) (ADVP (RB further)) (VP (VBN worsened) (PP (IN by) (NP (NP (NN Doc_16740173_1526_1553_Disease)) (CC and) (NP (JJ severe) (NN bronchoconstriction)))))) (. .)))
16740173	16	(S1 (S (ADVP (NP (CD One) (NN week)) (RB later)) (, ,) (NP (DT the) (NN patient)) (VP (VP (AUX was) (ADVP (RB again)) (VP (VBN extubated))) (CC and) (VP (ADVP (NP (CD 3) (NNS days)) (RB later)) (AUX was) (VP (VBN transferred) (PP (TO to) (NP (DT a) (JJ peripheral) (NN ward)))))) (. .)))
16740173	17	(S1 (S (PP (IN On) (NP (DT the) (JJ next) (NN day))) (NP (PRP he)) (VP (VBD died) (, ,) (ADVP (RB probably)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NNP Doc_16740173_1738_1751_Disease)))))) (. .)))
16740173	18	(S1 (S (NP (NP (NN Serum) (NNS samples)) (PP (IN from) (NP (DT the) (JJ first) (CC and) (JJ second) (NNS days)))) (VP (VBD contained) (NP (QP (CD 3.6) (CC and) (CD 1.9) (CD mg/l))) (NP (NNP Doc_16740173_1825_1834_Chemical)) (, ,) (ADVP (RB respectively))) (. .)))
16740173	19	(S1 (S (NP (DT The) (JJ corresponding) (NN urine) (NNS concentrations)) (VP (VBD amounted) (PP (TO to) (NP (QP (CD 374) (CC and) (CD 554)) (NNS mg/l)))) (. .)))
16740173	20	(S1 (S (NP (DT This) (NN case)) (VP (VP (VBD started) (PP (IN with) (NP (DT a) (NNS media) (NN report))) (PP (IN in) (NP (NP (DT a) (JJ popular) (NN newspaper)) (, ,) (VP (VBN initiated) (PP (IN by) (NP (NP (VBN published) (, ,) (JJ peer-reviewed) (NN research)) (PP (IN on) (NP (NNS herbals)))))) (, ,)))) (CC and) (VP (VBD involved) (NP (JJ human) (NN failure)) (PP (IN in) (NP (NP (DT a) (NN case) (NN history)) (, ,) (NP (JJ medical) (NN examination)) (CC and) (NP (JJ clinical) (NN treatment)))))) (. .)))
16740173	21	(S1 (S (PP (IN For) (NP (DT the) (JJ first) (NN time))) (, ,) (NP (NP (DT an) (JJ analytical) (NN method)) (PP (IN for) (NP (NP (DT the) (NN determination)) (PP (IN of) (NP (NNP Doc_16740173_2208_2217_Chemical))) (PP (IN in) (NP (NP (NN plasma)) (CC and) (NP (NN urine))))))) (VP (AUX has) (VP (AUX been) (VP (VBN developed)))) (. .)))
16740173	22	(S1 (S (NP (DT The) (JJ analysed) (JJ Doc_16740173_2271_2280_Chemical) (NN concentration)) (VP (VBD exceeded) (NP (NP (DT the) (JJ supposed) (NN serum) (NN level)) (VP (VBG resulting) (PP (IN from) (NP (DT a) (JJ therapeutic) (NN dose))))) (PP (IN by) (NP (NP (DT a) (NN factor)) (PP (IN of) (NP (QP (CD 130) (TO to) (CD 260))))))) (. .)))
16740173	23	(S1 (S (PP (ADVP (RB Especially)) (IN in) (NP (JJ old) (NNS patients))) (, ,) (NP (NNS intensivists)) (VP (MD should) (VP (VB consider) (NP (NNS intoxications)) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NNS cholinergics))) (-RRB- -RRB-)) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (NNP Doc_16740173_2495_2523_Disease))))))) (. .)))
16755009	0	(S1 (NP (NP (JJ Pharmacological) (NN evidence)) (PP (IN for) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (JJ Daucus) (NNS carota))) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_16755009_81_103_Disease))))))) (. .)))
16755009	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN aimed) (PP (IN at) (S (VP (VBG investigating) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ Daucus) (NN carota) (NNS seeds))) (PP (IN on) (NP (NP (JJ cognitive) (NNS functions)) (, ,) (NP (JJ total) (JJ serum) (JJ Doc_16755009_221_232_Chemical) (NNS levels)) (CC and) (NP (NP (NN brain) (NN cholinesterase) (NN activity)) (PP (IN in) (NP (NNS mice)))))))))))) (. .)))
16755009	2	(S1 (S (NP (NP (DT The) (JJ ethanolic) (NNP Doc_16755009_297_327_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16755009_329_332_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (ADVP (RB orally)) (PP (IN in) (NP (NP (CD three) (NNS doses)) (PRN (-LRB- -LRB-) (NP (CD 100) (, ,) (CD 200) (, ,) (CD 400) (NNS mg/kg)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (CD seven) (JJ successive) (NNS days)) (PP (TO to) (NP (NP (JJ different) (NNS groups)) (PP (IN of) (NP (ADJP (JJ young) (CC and) (VBN aged)) (NNS mice))))))))) (. .)))
16755009	3	(S1 (S (NP (NP (JJ Elevated) (NN plus) (NN maze)) (CC and) (NP (JJ passive) (NN avoidance) (NN apparatus))) (VP (VBD served) (PP (IN as) (NP (NP (DT the) (JJ exteroceptive) (JJ behavioral) (NNS models)) (PP (IN for) (NP (NN testing) (NN memory)))))) (. .)))
16755009	4	(S1 (S (NP (NP (NNP Doc_16755009_582_590_Chemical-)) (, ,) (NP (NNP Doc_16755009_593_604_Chemical-)) (CC and) (NP (JJ ageing-induced) (NNP Doc_16755009_625_632_Disease))) (VP (VBD served) (PP (IN as) (NP (DT the) (JJ interoceptive) (JJ behavioral) (NNS models)))) (. .)))
16755009	5	(S1 (S (NP (NP (NN Doc_16755009_680_683_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 200)) (, ,) (NP (QP (CD 400) (CD mg/kg))) (, ,) (NP (CD p.o.))) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (JJ significant) (NN improvement)) (PP (IN in) (NP (NP (NN memory) (NNS scores)) (PP (IN of) (NP (ADJP (JJ young) (CC and) (VBN aged)) (NNS mice))))))) (. .)))
16755009	6	(S1 (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NP (NN memory) (NN improvement)) (VP (VBN evoked) (PP (IN by) (NP (NNP Doc_16755009_822_825_Chemical))))))) (VP (AUX was) (NP (NP (NP (CD 23) (NN %)) (PP (IN at) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (CD 200) (NN mg/kg)))))) (CC and) (NP (NP (CD 35) (NN %)) (PP (IN at) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (CD 400) (NNS mg/kg)) (PP (IN in) (NP (NP (JJ young) (NNS mice)) (VP (VBG using) (NP (JJ elevated) (JJ plus) (NN maze)))))))))))) (. .)))
16755009	7	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (JJ significant) (NNS improvements)) (PP (IN in) (NP (NN memory) (NNS scores)))) (VP (AUX were) (VP (VBN observed) (S (VP (VBG using) (NP (NP (NN passive) (NN avoidance) (NN apparatus)) (CC and) (NP (VBN aged) (NNS mice))))))) (. .)))
16755009	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_16755009_1061_1064_Chemical)) (VP (VBD reversed) (NP (NP (DT the) (NN Doc_16755009_1078_1085_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NNP Doc_16755009_1097_1108_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.4) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_16755009_1131_1139_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-)))))))) (. .)))
16755009	9	(S1 (S (NP (NP (NN Doc_16755009_1157_1178_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 200)) (, ,) (NP (QP (CD 400) (CD mg/kg))) (, ,) (NP (CD p.o.))) (-RRB- -RRB-))) (VP (VBD reduced) (ADVP (RB significantly)) (NP (NP (DT the) (NN brain) (NN acetylcholinesterase) (NN activity) (CC and) (JJ Doc_16755009_1268_1279_Chemical) (NNS levels)) (PP (IN in) (NP (ADJP (JJ young) (CC and) (VBN aged)) (NNS mice))))) (. .)))
16755009	10	(S1 (S (NP (NP (DT The) (NN extent)) (PP (IN of) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN brain) (NN cholinesterase) (NN activity)) (VP (VBN evoked) (PP (IN by) (NP (NNP Doc_16755009_1379_1382_Chemical))) (PP (IN at) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (QP (CD 400) (CD mg/kg)))))))))))) (VP (AUX was) (NP (NP (NP (CD 22) (NN %)) (PP (IN in) (NP (NN young)))) (CC and) (NP (NP (CD 19) (NN %)) (PP (IN in) (NP (VBN aged) (NNS mice)))))) (. .)))
16755009	11	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ remarkable) (NN reduction)) (PP (IN in) (NP (JJ total) (JJ Doc_16755009_1489_1500_Chemical) (NN level)))) (ADVP (RB as) (RB well)) (, ,) (PP (TO to) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NP (CD 23) (NN %)) (PP (IN in) (NP (NN young)))) (CC and) (NP (NP (CD 21) (NN %)) (PP (IN in) (NP (NP (VBN aged) (NNS animals)) (PP (IN with) (NP (NP (DT this) (NN dose)) (PP (IN of) (NP (NNP Doc_16755009_1588_1591_Chemical))))))))))))) (. .)))
16755009	12	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NNP Doc_16755009_1604_1607_Chemical)) (VP (MD may) (VP (VB prove) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN remedy)) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_16755009_1662_1684_Disease)))))) (PP (IN on) (NP (NP (NN account)) (PP (IN of) (NP (NP (PRP$ its) (JJ multifarious) (JJ beneficial) (NNS effects)) (PP (JJ such) (IN as) (, ,) (NP (NP (NN memory) (VBG improving) (NN property)) (, ,) (NP (JJ Doc_16755009_1771_1782_Chemical) (VBG lowering) (NN property)) (CC and) (NP (JJ anticholinesterase) (NN activity))))))))))))) (. .)))
16787750	0	(S1 (S (NP (NN Doc_16787750_0_13_Chemical)) (VP (VBN induced) (NP (JJ Doc_16787750_22_36_Disease--19) (JJ new) (NNS cases)) (PP (IN in) (NP (NNP Germany))) (PP (PP (IN from) (NP (CD 1994))) (PP (TO to) (NP (NP (JJ 2003--a) (NN side) (NN effect)) (VP (VBN associated) (S (VP (TO to) (VP (VB Doc_16787750_109_112_Chemical-therapy) (ADVP (RB not) (RB only)) (PP (IN in) (NP (JJ young) (NNS children))))))))))) (. .)))
16787750	1	(S1 (S (NP (NP (NNP Doc_16787750_149_162_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16787750_164_167_Chemical)) (-RRB- -RRB-))) (VP (VP (AUX is) (NP (DT a) (JJ broad-spectrum) (JJ antiepileptic) (NN drug))) (CC and) (VP (AUX is) (ADVP (RB usually)) (VP (VBN well-tolerated)))) (. .)))
16787750	2	(S1 (S (NP (JJ Rare) (JJ serious) (NNS complications)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (DT some) (NNS patients))) (, ,) (PP (VBG including) (NP (NP (JJ haemorrhagic) (NNP Doc_16787750_317_329_Disease)) (, ,) (NP (NNP Doc_16787750_331_354_Disease)) (, ,) (NP (NNP Doc_16787750_356_359_Chemical-induced) (NNP Doc_16787750_368_382_Disease)) (CC and) (NP (NNP Doc_16787750_387_390_Chemical-induced) (NNP Doc_16787750_399_413_Disease)))))) (. .)))
16787750	3	(S1 (S (NP (NP (DT The) (JJ typical) (NNS signs)) (PP (IN of) (NP (NNP Doc_16787750_436_439_Chemical-induced) (NNP Doc_16787750_448_462_Disease)))) (VP (AUX are) (NP (NP (NNP Doc_16787750_467_489_Disease)) (, ,) (NP (ADJP (RB sometimes) (JJ marked)) (NNP EEG) (NN background) (NN slowing)) (, ,) (NP (VBN increased) (NNP Doc_16787750_542_549_Disease) (NN frequency))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NNP Doc_16787750_577_591_Disease))))) (. .)))
16787750	4	(S1 (S (NP (EX There)) (VP (AUX is) (ADVP (RB still)) (NP (NP (DT no) (NN proof)) (PP (IN of) (NP (NP (JJ causative) (NN effect)) (PP (IN of) (NP (NNP Doc_16787750_640_643_Chemical))))) (PP (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16787750_661_675_Disease))))) (, ,) (CC but) (ADVP (RB only)) (PP (IN of) (NP (NP (DT an) (NN association)) (PP (IN with) (NP (DT an) (JJ assumed) (JJ causal) (NN relation)))))))) (. .)))
16787750	5	(S1 (S (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 19) (NNS patients)) (PP (IN with) (NP (NNP Doc_16787750_764_767_Chemical-associated) (NNP Doc_16787750_779_793_Disease))) (PP (IN in) (NP (NNP Germany)))) (PP (IN from) (NP (DT the) (NNS years) (CD 1994) (TO to) (CD 2003))))) (, ,) (NP (NP (NN none)) (WHPP (IN of) (WHNP (WP whom)))) (VP (AUX had) (VP (AUX been) (VP (VBN published) (ADVP (RB previously))))) (. .)))
16858720	0	(S1 (NP (NP (NP (NN Doc_16858720_0_20_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_16858720_32_40_Chemical))))) (: -) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (JJ drug-drug) (NNS interactions)))) (. .)))
16858720	1	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN frequency) (, ,) (NN severity) (CC and) (NN preventability)) (PP (IN of) (NP (NNP Doc_16858720_151_159_Chemical-induced) (NNP Doc_16858720_168_189_Disease) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_16858720_197_205_Chemical) (CC and) (NNP Doc_16858720_210_218_Chemical-drug)))) (NNS interactions)))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG living) (PP (IN in) (NP (NP (DT the) (NN county)) (PP (IN of) (NP (NNP Osterg) (NN tland))))))))))) (, ,) (NP (NNP Sweden)) (. .)))
16858720	2	(S1 (S (NP (NP (DT All) (NNS patients)) (PP (IN with) (NP (DT a) (VBN diagnosed) (NN Doc_16858720_335_355_Disease))) (PP (IN at) (NP (CD three) (NNS hospitals))) (PP (IN during) (NP (DT the) (NN period) (CD 2000-2002)))) (VP (AUX were) (VP (VBN identified))) (. .)))
16858720	3	(S1 (S (NP (JJ Medical) (NNS records)) (VP (AUX were) (VP (VBN studied) (ADVP (RB retrospectively)) (S (VP (TO to) (VP (VB evaluate) (SBAR (IN whether) (S (NP (NP (NNP Doc_16858720_485_493_Chemical)) (CC and) (NP (JJ Doc_16858720_498_506_Chemical-drug) (NNS interactions))) (VP (MD could) (VP (AUX have) (VP (VBN caused) (NP (DT the) (NNP Doc_16858720_547_567_Disease)))))))))))) (. .)))
16858720	4	(S1 (S (NP (NP (DT The) (NN proportion)) (PP (IN of) (NP (RB possibly) (JJ avoidable) (NNS cases))) (PP (JJ due) (TO to) (NP (NN drug) (NNS interactions)))) (VP (AUX was) (VP (VBN estimated))) (. .)))
16858720	5	(S1 (S (PP (IN Among) (NP (NP (CD 593) (NNS patients)) (PP (IN with) (NP (NNP Doc_16858720_685_705_Disease))))) (, ,) (NP (NP (CD 59)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN assessed) (SBAR (IN as) (S (VP (VBN related) (PP (TO to) (NP (JJ Doc_16858720_744_752_Chemical) (NN treatment)))))))) (. .)))
16858720	6	(S1 (S (NP (DT This)) (VP (VBP imply) (NP (NP (DT an) (NN incidence)) (PP (IN of) (NP (CD 1.7/100,000) (NN treatment) (NNS years))))) (. .)))
16858720	7	(S1 (S (PP (IN Of) (NP (DT the) (CD 59) (NNS cases))) (, ,) (NP (NP (CD 26)) (PRN (-LRB- -LRB-) (NP (CD 44) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (DT a) (JJ fatal) (NN outcome)) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (NP (CD 136)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-) (PP (IN among) (NP (DT the) (JJ non-Doc_16858720_903_911_Chemical) (NNS patients))))) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
16858720	8	(S1 (S (NP (DT A) (JJ Doc_16858720_935_943_Chemical-drug) (NN interaction)) (VP (MD could) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (DT the) (NNP Doc_16858720_991_1002_Disease))) (PP (PP (IN in) (NP (NP (NP (CD 24)) (PRN (-LRB- -LRB-) (NP (CD 41) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (JJ Doc_16858720_1022_1030_Chemical) (NNS patients))))) (CC and) (PP (IN in) (NP (NP (CD 7)) (PP (IN of) (NP (DT these)))))) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-)) (SBAR (S (NP (DT the) (NNP Doc_16858720_1068_1076_Disease) (NN complication)) (VP (AUX was) (VP (VBN considered) (S (VP (AUXG being) (ADJP (JJ possible) (S (VP (TO to) (VP (VB avoid)))))))))))))) (. .)))
16858720	9	(S1 (S (NP (JJ Doc_16858720_1143_1151_Chemical-induced) (NNP Doc_16858720_1160_1181_Disease)) (VP (AUX are) (NP (NP (DT a) (JJ major) (JJ clinical) (NN problem)) (PP (IN with) (NP (DT a) (JJ high) (NN fatality) (NN rate))))) (. .)))
16858720	10	(S1 (S (NP (NP (RB Almost) (NN half)) (PP (IN of) (NP (DT the) (NNS cases)))) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (DT a) (JJ Doc_16858720_1280_1288_Chemical-drug) (NN interaction))))) (. .)))
16858720	11	(S1 (S (NP (NP (DT A) (JJ significant) (NN proportion)) (PP (IN of) (NP (JJ Doc_16858720_1335_1343_Chemical-related) (NNP Doc_16858720_1352_1373_Disease)))) (VP (MD might) (VP (AUX have) (VP (AUX been) (VP (VBN prevented) (SBAR (IN if) (S (NP (JJR greater) (NN caution)) (VP (AUX had) (VP (AUX been) (VP (VBN taken) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN Doc_16858720_1480_1488_Chemical)))))))))))))))))))) (. .)))
16867021	0	(S1 (NP (NP (NP (JJ Antipsychotic-like) (NN profile)) (PP (IN of) (NP (NNP Doc_16867021_30_42_Chemical)))) (, ,) (NP (NP (DT a) (JJ selective) (JJ H3-receptor) (NN antagonist)) (PP (IN in) (NP (NNS mice)))) (. .)))
16867021	1	(S1 (S (NP (JJ Experimental) (CC and) (JJ clinical) (NN evidence)) (VP (VBZ points) (PP (TO to) (NP (NP (DT a) (NN role)) (PP (IN of) (NP (JJ central) (JJ histaminergic) (NN system))) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_16867021_195_208_Disease)))))))) (. .)))
16867021	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_16867021_264_273_Chemical) (NNP H) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NN -receptor) (NNS ligands))) (PP (IN on) (NP (NP (NP (JJ neuroleptic-induced) (NN Doc_16867021_319_328_Disease)) (, ,) (NP (JJ Doc_16867021_330_341_Chemical-induced) (VBG climbing) (NN behavior)) (CC and) (NP (JJ Doc_16867021_372_383_Chemical-induced) (NN locomotor) (NNS activities))) (PP (IN in) (NP (NNS mice))))))))))) (. .)))
16867021	3	(S1 (S (NP (NN Doc_16867021_422_431_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_16867021_447_458_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg)) (NN p.o.)) (-RRB- -RRB-)))) (, ,) (SBAR (IN while) (S (NP (NP (NP (NNP Doc_16867021_481_492_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1.5) (CD mg/kg)) (NNP s.c.)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_16867021_514_525_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg)) (NNP s.c.)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN used) (PP (IN for) (S (VP (VP (VBG studying) (NP (VBG climbing) (NN behavior) (CC and) (NN locomotor) (NNS activities))) (, ,) (VP (VBG respectively.) (NP (NP (NP (NP (NNP Doc_16867021_622_647_Chemical)) (PRN (-LRB- -LRB-) (NNP Doc_16867021_649_653_Chemical) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN microg) (NN i.c.v.)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_16867021_677_689_Chemical)) (-LRB- -LRB-) (NP (NNP Doc_16867021_691_694_Chemical)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)))) (, ,) (ADVP (FW per) (FW se)) (VP (AUX did) (RB not) (VP (VB cause) (NP (NNP Doc_16867021_734_743_Disease))))))))))))) (. .)))
16867021	4	(S1 (S (NP (NAC (NNP Administration) (PP (IN of) (NP (NNP Doc_16867021_763_766_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 3.75) (, ,) (CD 7.5) (CC and) (CD 15) (NN mg/kg) (NN i.p.)) (-RRB- -RRB-)) (CD 1)) (NNP h)) (ADVP (RB prior) (PP (TO to) (NP (NNP Doc_16867021_810_821_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ dose-dependent) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ Doc_16867021_867_876_Disease) (NNS times)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
16867021	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_16867021_922_926_Chemical)))) (ADVP (RB significantly)) (VP (VBD reversed) (NP (NP (PDT such) (DT an) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_16867021_968_971_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mg/kg)) (NNS i.p.)) (-RRB- -RRB-)))))) (. .)))
16867021	6	(S1 (S (S (NP (NN Doc_16867021_989_993_Chemical)) (ADVP (FW per) (FW se)) (VP (VBD showed) (NP (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (NN locomotor) (NN time)) (, ,) (NP (NP (NN distance)) (VP (VBN traveled))) (CC and) (NP (JJ average) (NN speed)))))) (CC but) (S (NP (NP (NNP Doc_16867021_1089_1092_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-))) (ADVP (FW per) (FW se)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (DT these) (NNS parameters)))))) (. .)))
16867021	7	(S1 (S (PP (IN On) (NP (NNP Doc_16867021_1154_1165_Chemical-induced) (NNP Doc_16867021_1174_1187_Disease))) (, ,) (NP (NP (NNP Doc_16867021_1189_1192_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.75) (CC and) (CD 7.5) (CD mg/kg)) (NNS i.p.)) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NP (NN locomotor) (NN time)) (, ,) (NP (NP (NN distance)) (VP (VBN traveled))) (CC and) (NP (NP (JJ average) (NN speed)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
16867021	8	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NP (NNP Doc_16867021_1309_1313_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN microg) (NN i.c.v.)) (-RRB- -RRB-))))) (VP (MD could) (ADVP (RB partially)) (VP (VB reverse) (NP (NP (JJ such) (NNS effects)) (PP (IN of) (NP (NNP Doc_16867021_1372_1375_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 3.75) (CD mg/kg)) (NNS i.p.)) (-RRB- -RRB-))))) (. .)))
16867021	9	(S1 (S (NP (NP (VBG Climbing) (NN behavior)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_16867021_1424_1435_Chemical))))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16867021_1472_1475_Chemical)))))))) (. .)))
16867021	10	(S1 (S (NP (PDT Such) (DT an) (NN effect)) (VP (AUX was) (, ,) (ADVP (RB however)) (, ,) (ADJP (JJ reversed)) (PP (IN in) (NP (NP (NN presence)) (PP (IN of) (NP (NNP Doc_16867021_1530_1534_Chemical)))))) (. .)))
16867021	11	(S1 (S (NP (NN Doc_16867021_1536_1539_Chemical)) (VP (VBD exhibited) (NP (DT an) (JJ antipsychotic-like) (NN profile)) (PP (IN by) (S (VP (VP (VBG potentiating) (NP (JJ Doc_16867021_1596_1607_Chemical-induced) (NNP Doc_16867021_1616_1625_Disease))) (, ,) (VP (VBG reducing) (NP (JJ Doc_16867021_1636_1647_Chemical-induced) (NNP Doc_16867021_1656_1669_Disease))) (CC and) (VP (VBG reducing) (NP (NP (JJ Doc_16867021_1683_1694_Chemical-induced)) (VP (VBG climbing) (PP (IN in) (NP (NNS mice)))))))))) (. .)))
16867021	12	(S1 (S (NP (NP (JJ Such) (NNS effects)) (PP (IN of) (NP (NNP Doc_16867021_1737_1740_Chemical)))) (VP (AUX were) (VP (VBN reversed) (PP (IN by) (NP (NNP Doc_16867021_1758_1762_Chemical))) (S (VP (VBG indicating) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NNP Doc_16867021_1793_1802_Chemical) (NNP H) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NNS -receptors)))))))) (. .)))
16867021	13	(S1 (S (NP (NNS Findings)) (VP (VBP suggest) (NP (NP (DT a) (NN potential)) (PP (IN for) (NP (NNP H) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NN -receptor) (NNS antagonists)))) (PP (IN in) (S (VP (VBG improving) (NP (NP (DT the) (JJ refractory) (NNS cases)) (PP (IN of) (NP (NN Doc_16867021_1915_1928_Disease)))))))) (. .)))
16904497	0	(S1 (NP (NP (NP (NN Doc_16904497_0_21_Disease)) (PP (IN after) (NP (JJ epidural) (JJ Doc_16904497_37_44_Chemical) (NN injection)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
16904497	1	(S1 (S (NP (NP (JJ Conventional) (NN treatment) (NNS methods)) (PP (IN of) (NP (JJ lumbusacral) (NNP Doc_16904497_128_141_Disease)))) (VP (AUX are) (NP (NP (JJ physical) (NN therapy)) (, ,) (NP (JJ epidural) (JJ Doc_16904497_173_180_Chemical) (NNS injections)) (, ,) (NP (JJ oral) (NNS medications)) (, ,) (CC and) (NP (JJ spinal) (JJ manipulative) (NN therapy)))) (. .)))
16904497	2	(S1 (S (NP (NN Doc_16904497_244_265_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (PP (IN of) (NP (JJ epidural) (NNS anesthesia))))) (. .)))
16904497	3	(S1 (S (NP (DT The) (JJ following) (NN case)) (VP (AUX is) (NP (NP (DT a) (NN report)) (PP (IN of) (NP (NNP Doc_16904497_347_368_Disease))) (VP (ADVP (RB possibly)) (VBN caused) (PP (IN by) (NP (NP (JJ epidural) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_16904497_410_423_Chemical)) (CC and) (NP (NNP Doc_16904497_428_439_Chemical))))))))) (. .)))
16904497	4	(S1 (NP (NP (JJ CLINICAL) (NNS FEATURES)) (: :) (NP (NP (DT A) (JJ 50-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_16904497_485_512_Disease))) (SBAR (S (VP (AUX was) (VP (VBN scheduled) (PP (IN for) (NP (JJ epidural) (JJ Doc_16904497_540_547_Chemical) (NN injection)))))))) (. .)))
16904497	5	(S1 (NP (NP (NP (NN INTERVENTION)) (CC AND) (NP (NN OUTCOME))) (: :) (S (NP (DT An) (JJ 18-gauge) (NNP Touhy) (NN needle)) (VP (AUX was) (VP (VBN inserted) (SBAR (IN until) (S (NP (NP (NN loss)) (PP (IN of) (NP (NN resistance)))) (VP (VBD occurred) (PP (IN at) (NP (DT the) (JJ L4-5) (NN level))))))))) (. .)))
16904497	6	(S1 (S (NP (NP (NN Spread)) (PP (IN of) (NP (NP (DT the) (NN contrast) (NN medium)) (PP (IN within) (NP (DT the) (JJ epidural) (NN space)))))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (JJ radiographic) (NN imaging))))) (. .)))
16904497	7	(S1 (S (PP (IN After) (S (VP (VBG verifying) (NP (DT the) (NN epidural) (NN space))))) (, ,) (NP (NP (NNP Doc_16904497_808_819_Chemical)) (CC and) (NP (NNP Doc_16904497_824_847_Chemical))) (VP (AUX were) (VP (VBN injected))) (. .)))
16904497	8	(S1 (S (PP (IN After) (NP (DT the) (NN injection))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ radicular) (NNS symptoms))))) (. .)))
16904497	9	(S1 (S (ADVP (NP (CD Three) (NNS hours)) (RB later)) (, ,) (NP (PRP she)) (VP (VBD complained) (PP (IN of) (NP (NN perineal))) (NP (NP (NNP Doc_16904497_975_983_Disease)) (CC and) (NP (NNP Doc_16904497_988_1012_Disease)))) (. .)))
16904497	10	(S1 (S (NP (DT The) (JJ neurologic) (NN evaluation)) (VP (VBD revealed) (NP (NP (NP (NN Doc_16904497_1049_1066_Disease)) (PP (IN in) (NP (DT the) (NNP saddle) (NN area)))) (CC and) (NP (NP (JJ medial) (NN aspect)) (PP (IN of) (NP (PRP$ her) (JJ right) (NN leg)))))) (. .)))
16904497	11	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN perception)) (PP (IN of) (NP (NN pinprick) (NN test))))))) (. .)))
16904497	12	(S1 (S (NP (NN Deep-tendon) (NNS reflexes)) (VP (AUX were) (VP (VBN decreased) (ADVP (RB especially)) (PP (IN in) (NP (DT the) (JJ right) (NN leg))))) (. .)))
16904497	13	(S1 (S (NP (PRP She)) (VP (AUX was) (ADJP (JJ unable) (S (VP (TO to) (VP (VB urinate)))))) (. .)))
16904497	14	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (NNS symptoms)) (VP (VBD improved) (ADVP (RB slightly)) (PP (IN over) (NP (DT the) (JJ next) (JJ few) (NNS hours)))) (. .)))
16904497	15	(S1 (S (NP (PRP She)) (VP (AUX had) (NP (NP (NP (DT a) (JJ gradual) (NN return)) (PP (IN of) (NP (NN motor) (NN function)))) (CC and) (NP (NP (NN ability)) (PP (IN of) (S (VP (VBG feeling) (NP (NNP Foley) (NN catheter)))))))) (. .)))
16904497	16	(S1 (S (NP (NP (DT All)) (PP (IN of) (NP (DT the) (NNS symptoms)))) (VP (AUX were) (ADVP (RB completely)) (VP (VBN resolved) (PP (IN over) (NP (DT the) (JJ next) (CD 8) (NNS hours))))) (. .)))
16904497	17	(S1 (S (NP (NP (NNS Complications)) (VP (VBN associated) (PP (IN with) (NP (JJ epidural) (JJ Doc_16904497_1538_1545_Chemical) (NNS injections))))) (VP (AUX are) (ADJP (JJ rare))) (. .)))
16904497	18	(S1 (S (NP (NP (NP (JJ Clinical) (NN examination)) (CC and) (NP (JJ continued) (NN vigilance))) (PP (IN for) (NP (NNP Doc_16904497_1616_1640_Disease))) (PP (IN after) (NP (JJ epidural) (JJ Doc_16904497_1656_1663_Chemical) (NNS injections)))) (VP (AUX is) (ADJP (JJ important))) (. .)))
16938416	0	(S1 (S (NP (NNP High-dose) (NNP Doc_16938416_10_22_Chemical)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_16938416_42_57_Disease)) (PP (IN in) (NP (JJ postmenopausal) (NNS women))))))) (. .)))
16938416	1	(S1 (FRAG (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (JJ long-term) (NNS effects)) (PP (IN of) (NP (JJ androgen) (NN treatment))) (PP (IN on) (NP (NP (NNP Doc_16938416_151_166_Disease)) (PP (IN in) (NP (JJ postmenopausal) (NNS women))))))))) (. .)))
16938416	2	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ population-based) (NN study)) (PP (IN in) (NP (NP (CD 513) (RB naturally) (JJ postmenopausal) (NNS women)) (VP (VBN aged) (NP (JJ 54-67) (NNS years))))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NP (JJ self-reported) (ADJP (RB intramuscularly) (VBN administered)) (NN high-dose) (JJ Doc_16938416_373_381_Chemical-Doc_16938416_382_394_Chemical) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16938416_404_438_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ aortic) (NN Doc_16938416_451_466_Disease)))))) (. .)))
16938416	3	(S1 (S (NP (NNP Aortic) (NNP Doc_16938416_475_490_Disease)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN by) (NP (NP (JJ radiographic) (NN detection)) (PP (IN of) (NP (NP (JJ calcified) (NNS deposits)) (PP (IN in) (NP (NP (DT the) (JJ abdominal) (NN aorta)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX have) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB reflect) (NP (NN intima) (NN Doc_16938416_617_632_Disease)))))))))))))))))) (. .)))
16938416	4	(S1 (S (NP (NN Hormone) (NN therapy) (NNS users)) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (RB never) (NNS users))))) (. .)))
16938416	5	(S1 (S (NP (NP (JJ Intramuscular) (NN hormone) (NN therapy) (NN use)) (PP (IN for) (NP (QP (CD 1) (NN year) (CC or) (JJR longer))))) (VP (AUX was) (VP (VBN reported) (PP (IN by) (NP (CD 25) (NNS women))))) (. .)))
16938416	6	(S1 (S (PP (IN In) (NP (NP (RB almost) (NN half)) (PP (IN of) (NP (DT these) (NNS women))))) (NP (NP (JJ severe) (NNP Doc_16938416_815_830_Disease)) (PP (IN of) (NP (DT the) (NN aorta)))) (VP (AUX was) (ADJP (JJ present)) (PRN (-LRB- -LRB-) (NP (CD n=11)) (-RRB- -RRB-)) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (NNS women))) (PP (IN without) (NP (NN hormone) (NN use))) (NP (NP (JJ severe) (NN Doc_16938416_906_921_Disease)) (PP (IN of) (NP (DT the) (NN aorta)))) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (NP (NP (NP (NP (NP (QP (JJR less) (IN than) (CD 20)) (NN %)) (-LRB- -LRB-) (CC OR) (CD 3.1)) (: ;) (NP (CD 95) (NN %))) (NNS CI)) (, ,) (NP (CD 1.1-8.5)) (, ,)) (VP (VBN adjusted) (PP (IN for) (NP (NN age))))))) (PRN (, ,) (NP (NP (NNS years)) (PP (IN since) (NP (NN menopause) (, ,) (NN smoking) (, ,) (CC and) (NN body) (NN mass) (NN index)))) (-RRB- -RRB-)))))) (. .)))
16938416	7	(S1 (S (NP (DT The) (NN association)) (VP (VBD remained) (PP (IN after) (NP (JJ additional) (NN adjustment))) (PP (IN for) (NP (NP (NNP Doc_16938416_1119_1127_Disease) (, ,) (NNP Doc_16938416_1129_1140_Chemical) (NN level)) (, ,) (NP (JJ systolic) (NN blood) (NN pressure)) (, ,) (CC or) (NP (JJ Doc_16938416_1176_1183_Chemical) (NN use))))) (. .)))
16938416	8	(S1 (S (NP (DT No) (NN association)) (VP (AUX was) (VP (VBN found) (PP (IN for) (NP (NN hormone) (NN use))) (NP (QP (JJR less) (IN than) (CD 1)) (NN year)))) (. .)))
16938416	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ high-dose) (JJ Doc_16938416_1295_1307_Chemical) (NN therapy)) (VP (MD may) (VP (ADVP (RB adversely)) (VB affect) (NP (NNP Doc_16938416_1337_1352_Disease)) (PP (IN in) (NP (JJ postmenopausal) (NNS women)))))))) (CC and) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ androgen) (NN replacement)) (PP (IN in) (NP (DT these) (NNS women)))) (VP (MD may) (RB not) (VP (AUX be) (ADJP (JJ harmless)))))))) (. .)))
17020434	0	(S1 (NP (NP (JJ Optimising) (JJ Doc_17020434_11_17_Disease) (NN prevention)) (PP (IN in) (NP (JJ non-valvular) (NNP Doc_17020434_45_64_Disease))) (. .)))
17020434	1	(S1 (S (NP (NN Doc_17020434_66_85_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ substantial) (NN morbidity)) (CC and) (NP (NN mortality)))))) (. .)))
17020434	2	(S1 (S (NP (NP (VBN Pooled) (NNS data)) (PP (IN from) (NP (NP (NNS trials)) (VP (VBG comparing) (NP (JJ antithrombotic) (NN treatment)) (PP (IN with) (NP (NN placebo))))))) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (S (NP (NNP Doc_17020434_230_238_Chemical)) (VP (VBZ reduces) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_17020434_259_265_Disease)))) (PP (IN by) (NP (CD 62) (NN %))))) (, ,) (CC and) (S (NP (NP (DT that) (NNP Doc_17020434_283_290_Chemical)) (ADVP (RB alone))) (VP (VBZ reduces) (NP (DT the) (NN risk)) (PP (IN by) (NP (CD 22) (NN %))))))))) (. .)))
17020434	3	(S1 (S (ADVP (RB Overall)) (, ,) (PP (IN in) (NP (JJ high-risk) (NNS patients))) (, ,) (NP (NNP Doc_17020434_354_362_Chemical)) (VP (AUX is) (ADJP (JJ superior) (PP (TO to) (NP (NNP Doc_17020434_378_385_Chemical)))) (PP (IN in) (S (VP (VBG preventing) (NP (NNP Doc_17020434_400_407_Disease))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ relative) (NN risk) (NN reduction)) (PP (IN of) (NP (CD 36) (NN %)))))) (. .)))
17020434	4	(S1 (S (NP (NP (NNP Doc_17020434_448_460_Chemical)) (, ,) (NP (DT an) (JJ oral) (JJ direct) (NN thrombin) (NN inhibitor)) (, ,)) (VP (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB as) (JJ efficient) (PP (IN as) (NP (NP (JJ Doc_17020434_529_538_Chemical) (NN antagonist) (NNS drugs)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_17020434_577_591_Disease))))))))))))) (, ,) (CC but) (VP (AUX has) (VP (AUX been) (ADVP (RB recently)) (VP (VBN withdrawn) (PP (IN because) (IN of) (NP (JJ Doc_17020434_636_659_Disease) (NNS tests))))))) (. .)))
17020434	5	(S1 (S (NP (DT The) (JJ ACTIVE-W) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_17020434_681_700_Disease) (NNP Doc_17020434_701_712_Chemical) (NNP Trial)) (PP (IN with) (NP (NNP Doc_17020434_724_734_Chemical))) (PP (IN for) (NP (NP (NNP Prevention)) (PP (IN of) (NP (JJ Vascular) (NNS Events)))))) (-RRB- -RRB-)) (NN study)) (VP (AUX has) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NNP Doc_17020434_798_806_Chemical)) (VP (AUX is) (ADJP (JJ superior) (PP (TO to) (NP (NP (JJ platelet) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17020434_840_851_Chemical) (CC plus) (NNP Doc_17020434_857_864_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN prevention) (NN af) (NN Doc_17020434_887_901_Disease)))))))) (. .)))
17020434	6	(S1 (S (NP (NP (NNP Doc_17020434_903_914_Chemical)) (, ,) (NP (DT a) (NN Factor) (NNP Xa) (NN inhibitor)) (, ,)) (VP (AUX is) (VP (AUXG being) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17020434_975_994_Disease)))))))) (. .)))
17020434	7	(S1 (S (NP (NP (JJ Doc_17020434_996_1007_Chemical-converting) (NN enzyme) (NNS inhibitors)) (CC and) (NP (JJ Doc_17020434_1041_1055_Chemical) (NN receptor-blocking) (NNS drugs))) (VP (VBP hold) (NP (NN promise)) (PP (IN in) (NP (NNP Doc_17020434_1096_1115_Disease))) (PP (IN through) (NP (NNP Doc_17020434_1124_1143_Disease)))) (. .)))
17020434	8	(S1 (S (NP (JJ Preliminary) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_17020434_1178_1185_Chemical)) (VP (MD could) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN recurrence))) (PP (IN after) (NP (JJ electrical) (NN cardioversion)))))))))) (. .)))
17020434	9	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (JJ percutaneous) (NNS methods)) (PP (IN for) (NP (NP (DT the) (NN exclusion)) (PP (IN of) (NP (JJ left) (JJ atrial) (NN appendage)))))) (VP (AUX are) (PP (IN under) (NP (NN investigation))) (PP (IN in) (NP (JJ high-risk) (NNS patients)))) (. .)))
17042910	0	(S1 (S (NP (NP (JJ Anti-oxidant) (NNS effects)) (PP (IN of) (NP (NNP Doc_17042910_24_36_Chemical))) (PP (IN in) (NP (NNP Doc_17042910_40_53_Chemical-induced)))) (VP (VBP Doc_17042910_62_74_Disease) (PP (IN in) (NP (DT the) (NN rat.) (CD 1)))) (. .)))
17042910	1	(S1 (S (NP (NP (NNP Doc_17042910_90_103_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042910_105_108_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (SBAR (S (NP (NNP Doc_17042910_118_130_Disease)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ endothelial) (NN dysfunction)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_17042910_191_203_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042910_205_207_Chemical)) (-RRB- -RRB-)) (NN deficiency)) (CC and) (NP (VBN increased) (NNP Doc_17042910_234_244_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042910_246_249_Chemical)) (-RRB- -RRB-)) (NN production)))))))))))) (. .)))
17042910	2	(S1 (S (NP (NP (NNP Doc_17042910_263_275_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17042910_277_280_Chemical)) (-RRB- -RRB-))) (VP (VBZ possesses) (NP (NP (JJ pleiotropic) (NNS properties)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB improve) (NP (NN endothelial) (NN function)) (PP (IN through) (NP (NP (NP (JJ increased) (NN availability)) (PP (IN of) (NP (NNP Doc_17042910_405_407_Chemical)))) (CC and) (NP (NP (JJ reduced) (NN Doc_17042910_420_423_Chemical) (NN production)) (PP (IN in) (NP (NP (JJ various) (NNS forms)) (PP (IN of) (NP (NNP Doc_17042910_455_467_Disease)))))))))))))))))) (. .)))
17042910	3	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (CD 50) (NNS mg/kg)) (PP (IN per) (NP (NN day)))) (, ,) (ADVP (RB p.o.)) (, ,) (NP (NNP Doc_17042910_539_542_Chemical)) (VP (MD could) (VP (VB prevent) (NP (NP (JJ endothelial) (JJ Doc_17042910_569_571_Chemical) (NN synthase) (PRN (-LRB- -LRB-) (NN eNOS) (-RRB- -RRB-)) (NN downregulation)) (CC and) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NNP Doc_17042910_623_626_Chemical))) (PP (IN in) (NP (NNP Sprague-Dawley) (PRN (-LRB- -LRB-) (NP (NNP SD)) (-RRB- -RRB-)) (NNS rats))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG reducing) (NP (NN blood) (FW pressure.) (CD 2))))))))) (. .)))
17042910	4	(S1 (S (NP (NP (JJ Male) (NN SD) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 30)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17042910_732_735_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NN mg/kg)) (PP (IN per) (NP (NN day))) (PP (IN in) (NP (NN drinking) (NN water)))) (-RRB- -RRB-)) (CC or) (VP (VB tap) (NP (NN water)) (PP (IN for) (NP (CD 15) (NNS days)))))) (. .)))
17042910	5	(S1 (S (NP (NP (NP (NN Doc_17042910_799_812_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 10) (NNS microg/kg)) (PP (IN per) (NP (NN day)))) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-))) (CC or) (NP (NN saline))) (VP (AUX was) (VP (VP (VBN started) (PP (IN after) (NP (NP (CD 4) (NNS days)) (PP (IN in) (NP (ADJP (JJ Doc_17042910_880_883_Chemical-treated) (CC and) (JJ non-treated)) (NNS rats)))))) (CC and) (VP (VBN continued) (PP (IN for) (NP (CD 11-13) (NNS days)))))) (. .)))
17042910	6	(S1 (S (NP (NP (JJ Systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN SBP)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN measured) (PP (IN on) (NP (NP (JJ alternate) (NNS days)) (VP (VBG using) (NP (DT the) (JJ tail-cuff) (NN method))))))) (. .)))
17042910	7	(S1 (S (NP (JJ Endothelial) (NN function)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ Doc_17042910_1069_1082_Chemical-induced) (NN vasorelaxation)) (CC and) (NP (JJ Doc_17042910_1110_1123_Chemical-induced) (NN vasoconstriction)))) (PP (IN in) (NP (JJ aortic) (NNS segments))))) (. .)))
17042910	8	(S1 (S (NP (JJ Vascular) (NN eNOS) (NN mRNA)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ semi-quantitative) (JJ reverse) (NN transcription-polymerase) (NN chain)) (QP (RB reaction.) (CD 3)))))) (. .)))
17042910	9	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_17042910_1295_1298_Chemical)) (ADVP (RB alone))))))) (, ,) (NP (NNP SBP)) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (NP (NP (CD 109) (NN +/-)) (NP (QP (CD 2) (TO to) (CD 133)) (JJ +/-) (CD 2) (NNS mmHg))) (PP (IN on) (NP (NP (NN Days) (CD 4)) (CC and) (NP (NP (NNP Day) (CD 14) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (CD <) (CD 0.001))) (-RRB- -RRB-))))))))) (. .)))
17042910	10	(S1 (S (PP (IN In) (NP (DT the) (NNP Doc_17042910_1412_1415_Chemical) (NNP +) (NNP Doc_17042910_1418_1421_Chemical) (NN group))) (, ,) (NP (NNP SBP)) (VP (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (NP (NP (CD 113) (NN +/-)) (NP (QP (CD 2) (TO to) (CD 119)) (JJ +/-) (CD 2) (NNS mmHg))) (PP (IN on) (NP (NP (NP (NNS Days)) (NP (QP (CD 4) (TO to) (CD 14))) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-)))))))) (, ,) (CC but) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NN SBP)))) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_17042910_1586_1589_Chemical) (RB alone)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-))))))))) (. .)))
17042910	11	(S1 (S (NP (NP (JJ Endothelial-dependent) (NN relaxation)) (CC and) (NP (NN eNOS) (NN mRNA) (NN expression))) (VP (AUX were) (ADJP (ADJP (JJR greater)) (PP (IN in) (NP (DT the) (NNP Doc_17042910_1686_1689_Chemical) (NNP +) (NNP Doc_17042910_1692_1695_Chemical) (NN group))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (JJ Doc_17042910_1714_1717_Chemical) (JJ only) (NN group)) (PRN (-LRB- -LRB-) (VP (VP (VBN P) (NP (NNP <) (CD 0.05))) (CC and) (VP (VBN P) (NP (NNP <) (CD 0.0001)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))) (. .)))
17042910	12	(S1 (S (NP (JJ Aortic) (NN Doc_17042910_1777_1787_Chemical) (NN production)) (VP (AUX was) (ADJP (JJR lower)) (PP (IN in) (NP (DT the) (NNP Doc_17042910_1816_1819_Chemical) (NNP +) (NNP Doc_17042910_1822_1825_Chemical) (NN group))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NN group)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_17042910_1869_1872_Chemical)) (ADVP (RB alone))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (CD <) (CD 0.0001))) (-RRB- -RRB-)) (. .) (CD 4)))))))) (. .)))
17042910	13	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_17042910_1911_1914_Chemical)))) (VP (VBD improved) (NP (NP (JJ endothelial) (NN function)) (, ,) (NP (JJ reduced) (JJ Doc_17042910_1954_1964_Chemical) (NN production)) (CC and) (NP (NP (VBN reduced) (NN SBP)) (PP (IN in) (NP (JJ Doc_17042910_1995_1998_Chemical-treated) (NN SD) (NNS rats)))))) (. .)))
17111419	0	(S1 (S (NP (JJ Severe) (NNP Doc_17111419_7_14_Chemical) (NNP Doc_17111419_15_23_Disease) (NN complicating) (NN volunteer) (NNS apheresis)) (VP (VBP platelet) (NP (NN donation))) (. .)))
17111419	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ severe) (JJ Doc_17111419_103_110_Chemical) (NN Doc_17111419_111_119_Disease)))) (PP (IN during) (NP (NN volunteer) (NN donor) (NN apheresis) (NN platelet) (NN collection)))) (. .)))
17111419	2	(S1 (S (NP (DT The) (NN donor)) (VP (AUX was) (NP (NP (DT a) (JJ 40-year-old) (NN female)) (, ,) (NP (JJ first-time) (NN apheresis) (NN platelet) (NN donor)))) (. .)))
17111419	3	(S1 (S (NP (JJ Past) (JJ medical) (NN history)) (VP (AUX was) (ADJP (JJ remarkable) (PP (IN for) (NP (NP (NNP Doc_17111419_287_299_Disease)) (, ,) (NP (NNP Doc_17111419_301_315_Disease)) (, ,) (CC and) (NP (NNP Doc_17111419_321_331_Disease)))))) (. .)))
17111419	4	(S1 (S (NP (JJ Reported) (NNS medications)) (VP (VBD included) (NP (NP (NNP Doc_17111419_363_373_Chemical)) (, ,) (NP (NNP Doc_17111419_375_386_Chemical)) (, ,) (CC and) (NP (NNP Doc_17111419_392_402_Chemical)))) (. .)))
17111419	5	(S1 (S (NP (NP (CD Thirty) (NNS minutes)) (PP (IN from) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (DT the) (NN procedure)))))) (, ,) (NP (DT the) (NN donor)) (VP (VBD noted) (NP (NN tingling)) (PP (IN around) (NP (DT the) (NN mouth))) (, ,) (NP (NP (NNS hands)) (, ,) (CC and) (NP (NNS feet)))) (. .)))
17111419	6	(S1 (S (NP (PRP She)) (ADVP (RB then)) (ADVP (RB very) (RB rapidly)) (VP (VBD developed) (NP (NP (JJ acute) (NN onset)) (PP (IN of) (NP (JJ severe) (JJ facial) (CC and) (NN extremity) (NN Doc_17111419_587_593_Disease))))) (. .)))
17111419	7	(S1 (S (S (NP (NP (JJ Empirical) (NN treatment)) (PP (IN with) (NP (JJ intravenous) (NNP Doc_17111419_632_649_Chemical)))) (VP (AUX was) (VP (VBN initiated)))) (, ,) (CC and) (S (NP (NNP Doc_17111419_669_688_Disease)) (VP (ADVP (RB slowly)) (VBN subsided) (PP (IN over) (NP (QP (RB approximately) (CD 10) (TO to) (CD 15)) (NNS minutes))))) (. .)))
17111419	8	(S1 (S (NP (DT The) (NNS events)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (JJ severe) (NN reaction)) (PP (TO to) (NP (JJ Doc_17111419_794_801_Chemical) (NN chelation))) (PP (IN by) (NP (NP (JJ Doc_17111419_815_829_Chemical) (NN anticoagulant)) (VP (VBG resulting) (PP (IN in) (NP (JJ symptomatic) (JJ systemic) (NN Doc_17111419_878_890_Disease)))))))))) (. .)))
17111419	9	(S1 (S (PP (IN Upon) (NP (JJ additional) (NN retrospective) (NN analysis))) (, ,) (NP (PRP it)) (VP (AUX was) (VP (VBN noted) (SBAR (IN that) (S (NP (NNP Doc_17111419_950_960_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN Doc_17111419_966_979_Chemical)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB cause) (NP (JJ significant) (NN Doc_17111419_1007_1019_Disease)))))))))))) (. .)))
17111419	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (JJ careful) (NN screening)) (PP (IN for) (NP (NP (NNS medications)) (CC and) (NP (VBG underlying) (NNS conditions)))) (VP (VBG predisposing) (PP (TO to) (NP (NNP Doc_17111419_1114_1126_Disease))))) (VP (AUX is) (VP (VBN recommended) (S (VP (TO to) (VP (VB help) (S (VP (VB prevent) (NP (NP (JJ severe) (NNS reactions)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_17111419_1182_1189_Chemical) (NNP Doc_17111419_1190_1198_Disease))))))))))))))) (. .)))
17111419	11	(S1 (S (NP (NP (NN Laboratory) (NN measurement)) (PP (IN of) (NP (NP (JJ pre-procedure) (NN serum) (NN Doc_17111419_1246_1253_Chemical) (NNS levels)) (PP (IN in) (NP (JJ selected) (NNS donors)))))) (VP (MD may) (VP (VB identify) (NP (NP (NNS cases)) (VP (VBG requiring) (NP (JJ heightened) (NN vigilance)))))) (. .)))
17111419	12	(S1 (S (NP (DT The) (NN case)) (ADVP (RB also)) (VP (VBZ illustrates) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG maintaining) (NP (NN preparedness)) (PP (IN for) (S (VP (VBG managing) (NP (ADJP (JJ rare) (CC but) (JJ serious)) (NNS reactions)) (PP (IN in) (NP (NN volunteer) (NN apheresis) (NN blood) (NNS donors))))))))))) (. .)))
17147461	0	(S1 (NP (JJ Doc_17147461_0_9_Chemical-associated) (NNP Doc_17147461_21_32_Disease) (CC and) (NNP Doc_17147461_37_54_Disease) (. .)))
17147461	1	(S1 (S (NP (NN Doc_17147461_56_65_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ novel) (NN immunosuppressant)) (PP (IN with) (NP (NP (JJ potent) (JJ antiproliferative) (NNS actions)) (PP (IN through) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (JJ raptor-containing) (JJ mammalian) (NN target)) (PP (IN of) (NP (JJ Doc_17147461_206_215_Chemical) (NN protein) (NN kinase))))))))))))) (. .)))
17147461	2	(S1 (S (NP (NN Doc_17147461_232_241_Chemical)) (VP (VBZ represents) (NP (NP (DT a) (JJ major) (JJ therapeutic) (NN advance)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NP (JJ acute) (JJ renal) (NN allograft) (NN rejection)) (CC and) (NP (JJ chronic) (NN allograft) (NN Doc_17147461_356_367_Disease)))))))) (. .)))
17147461	3	(S1 (S (NP (NP (PRP$ Its) (NN role)) (PP (IN in) (NP (NP (DT the) (NN therapy)) (PP (IN of) (NP (NNP Doc_17147461_396_414_Disease) (, ,) (NNP Doc_17147461_416_428_Disease) (, ,) (NNP Doc_17147461_430_451_Disease) (CC and) (NNP Doc_17147461_456_468_Disease)))))) (VP (AUX is) (PP (IN under) (NP (NN investigation)))) (. .)))
17147461	4	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_17147461_501_510_Chemical)) (VP (AUX does) (RB not) (VP (VB share) (NP (NP (DT the) (JJ vasomotor) (JJ renal) (JJ adverse) (NNS effects)) (VP (VBN exhibited) (PP (IN by) (NP (NN calcineurin) (NNS inhibitors))))))))) (, ,) (NP (PRP it)) (VP (AUX has) (VP (AUX been) (VP (VBN designated) (NP (DT a) (: ') (JJ non-Doc_17147461_629_640_Disease) (NN drug) (POS '))))) (. .)))
17147461	5	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ clinical) (NNS reports)) (VP (VBP suggest) (SBAR (IN that) (S (, ,) (PP (IN under) (NP (DT some) (NNS circumstances))) (, ,) (NP (NNP Doc_17147461_714_723_Chemical)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_17147461_743_754_Disease)) (CC and) (NP (NNP Doc_17147461_759_782_Disease))))))))) (. .)))
17147461	6	(S1 (S (NP (DT A) (JJ common) (NN risk) (NN factor)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (NN presence)) (PP (IN of) (NP (JJ pre-existing) (NN Doc_17147461_844_864_Disease)))))))) (. .)))
17147461	7	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_17147461_884_893_Chemical-associated) (NNP Doc_17147461_905_916_Disease)))) (VP (VP (AUX are) (ADJP (JJ multifactorial))) (CC and) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ glomerular) (JJ capillary) (NN pressure)) (VP (VBG following) (NP (JJ calcineurin) (NN inhibitor) (NN withdrawal))))))))))) (. .)))
17147461	8	(S1 (S (S (NP (PRP It)) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN suggested) (SBAR (IN that) (S (NP (NNP Doc_17147461_1075_1084_Chemical)) (ADVP (RB directly)) (VP (VBZ causes) (NP (JJ increased) (JJ glomerular) (NN permeability/injury))))))))) (, ,) (CC but) (S (NP (NP (NN evidence)) (PP (IN for) (NP (DT this) (NN mechanism)))) (VP (AUX is) (ADVP (RB currently)) (ADJP (JJ inconclusive)))) (. .)))
17147461	9	(S1 (S (NP (NP (DT The) (NNP Doc_17147461_1206_1229_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17147461_1246_1255_Chemical))))) (PRN (-LRB- -LRB-) (PP (JJ such) (IN as) (PP (IN in) (NP (JJ delayed) (NN graft) (NN function)))) (-RRB- -RRB-)) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (NN suppression)) (PP (IN of) (NP (NP (JJ compensatory) (JJ renal) (NN cell) (NN proliferation)) (CC and) (NP (JJ survival/repair) (NNS processes))))))))) (. .)))
17147461	10	(S1 (S (SBAR (IN Although) (S (NP (DT these) (JJ adverse) (NNS effects)) (VP (VBP occur) (PP (IN in) (NP (DT some) (NNS patients)))))) (, ,) (NP (PRP$ their) (NN occurrence)) (VP (MD could) (VP (AUX be) (VP (VBN minimised) (PP (IN by) (NP (NP (NP (NN knowledge)) (PP (IN of) (NP (NP (NP (DT the) (JJ molecular) (NNS effects)) (PP (IN of) (NP (NNP Doc_17147461_1522_1531_Chemical))) (PP (IN on) (NP (DT the) (NN kidney)))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17147461_1558_1567_Chemical))) (PP (IN in) (NP (JJ appropriate) (NN patient) (NNS populations)))) (, ,) (NP (NP (JJ close) (NN monitoring)) (PP (IN of) (NP (NNP Doc_17147461_1624_1635_Disease)))) (CC and) (NP (JJ renal) (NN function))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (JJ Doc_17147461_1663_1674_Chemical-converting) (JJ enzyme) (NNS inhibitors)) (CC or) (NP (NP (JJ Doc_17147461_1707_1721_Chemical) (NN receptor) (NNS blockers)) (SBAR (IN if) (S (NP (NNP Doc_17147461_1743_1754_Disease)) (VP (VBZ occurs)))))))) (CC and) (NP (NN withdrawal)))) (SBAR (IN if) (S (VP (VBN needed))))))) (. .)))
17147461	11	(S1 (S (NP (NP (JJ Further) (JJ long-term) (NN analysis)) (PP (IN of) (NP (NP (JJ renal) (JJ allograft) (NNS studies)) (VP (VBG using) (NP (NNP Doc_17147461_1848_1857_Chemical)) (PP (IN as) (NP (NP (JJ de) (NN novo) (NN immunosuppression)) (PP (IN along) (PP (IN with) (NP (JJ clinical) (CC and) (NN laboratory) (NNS studies)))))))))) (VP (MD will) (VP (VB refine) (NP (DT these) (NNS issues)) (PP (IN in) (NP (DT the) (NN future))))) (. .)))
17175308	0	(S1 (S (VP (VB Doc_17175308_0_11_Disease) (PP (IN after) (NP (NN conversion))) (PP (TO to) (NP (NNP Doc_17175308_32_41_Chemical))) (PP (IN in) (NP (JJ renal) (NN transplant) (NNS recipients)))) (. .)))
17175308	1	(S1 (S (NP (NP (NNP Doc_17175308_74_83_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17175308_85_88_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (DT a) (JJ new) (, ,) (JJ potent) (NN immunosuppressive) (NN agent))) (. .)))
17175308	2	(S1 (S (ADVP (RBR More) (RB recently)) (, ,) (NP (NNP Doc_17175308_147_158_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (JJ Doc_17175308_197_206_Chemical) (NN therapy))))) (, ,) (SBAR (IN although) (S (NP (DT the) (NN mechanism)) (VP (AUX has) (VP (VBN remained) (ADJP (JJ unclear))))))))) (. .)))
17175308	3	(S1 (S (NP (PRP We)) (ADVP (RB retrospectively)) (VP (VBD examined) (NP (NP (DT the) (NNS records)) (PP (IN of) (NP (NP (CD 25) (JJ renal) (NN transplant) (NNS patients)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VP (VBD developed)) (CC or) (VP (VBD displayed) (NP (JJ increased) (NN Doc_17175308_371_382_Disease)) (PP (IN after) (NP (JJ Doc_17175308_389_392_Chemical) (NN conversion))))))))))) (. .)))
17175308	4	(S1 (S (NP (NP (DT The) (JJ patient) (NN cohort)) (PRN (-LRB- -LRB-) (NP (CD 14) (NNS men)) (, ,) (NP (CD 11) (NNS women)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17175308_460_463_Chemical))) (PP (IN as) (NP (NN conversion) (NN therapy))) (, ,) (PP (JJ due) (PP (TO to) (NP (NP (NP (NP (NP (NP (NNP Doc_17175308_494_523_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17175308_525_528_Disease)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 15)) (-RRB- -RRB-)) (NP (NP (NNP Doc_17175308_539_548_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-)))) (PRN (: ;) (NP (NP (NNP Doc_17175308_558_574_Disease)) (, ,) (NP (NNP Four) (NNP Doc_17175308_581_593_Disease)) (, ,) (NP (NNP One) (NNP Doc_17175308_599_616_Disease))) (, ,) (NP (NNP One) (NNP Doc_17175308_622_641_Disease)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP BK) (NN virus) (NNP Doc_17175308_655_666_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-)))))))) (. .)))
17175308	5	(S1 (S (NP (NN Doc_17175308_676_679_Chemical)) (VP (AUX was) (VP (VBN started) (PP (IN at) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (NP (NP (CD 78) (NN +/-)) (NP (CD 42) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (TO to) (CD 163))) (-RRB- -RRB-)) (NNS months))) (PP (IN after) (NP (NN transplantation))))))))) (. .)))
17175308	6	(S1 (S (NP (NP (JJ Mean) (NN follow-up)) (PP (IN on) (NP (JJ Doc_17175308_775_778_Chemical) (NN therapy)))) (VP (AUX was) (NP (CD 20) (JJ +/-) (CD 12) (PRN (-LRB- -LRB-) (NP (QP (CD 6) (TO to) (CD 43))) (-RRB- -RRB-)) (NNS months))) (. .)))
17175308	7	(S1 (S (NP (NN Doc_17175308_819_830_Disease)) (VP (VBD increased) (PP (IN from) (NP (NP (CD 0.445)) (PRN (-LRB- -LRB-) (NP (QP (CD 0) (TO to) (CD 1.5))) (-RRB- -RRB-))) (ADVP (RB g/d))) (PP (IN before) (NP (NP (NN conversion)) (PP (TO to) (NP (QP (CD 3.2) (CD g/dL)))))) (PRN (-LRB- -LRB-) (NP (QP (CD 0.2) (TO to) (CD 12))) (-RRB- -RRB-)) (PP (IN after) (NP (NN conversion))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.001)) (-RRB- -RRB-))) (. .)))
17175308	8	(S1 (S (PP (IN Before) (NP (NN conversion) (CD 8))) (PRN (-LRB- -LRB-) (NP (CD 32) (NN %)) (-RRB- -RRB-)) (NP (NNS patients)) (VP (AUX had) (NP (DT no) (NN Doc_17175308_981_992_Disease)) (, ,) (SBAR (IN whereas) (S (ADVP (RB afterwards)) (NP (DT all) (NNS patients)) (VP (AUX had) (NP (NN Doc_17175308_1030_1041_Disease)))))) (. .)))
17175308	9	(S1 (S (PP (IN In) (NP (NP (CD 28) (NN %)) (PP (IN of) (NP (NNS patients))))) (NP (NNP Doc_17175308_1062_1073_Disease)) (VP (VBD remained) (ADJP (JJ unchanged)) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (VBD increased) (PP (IN in) (NP (NP (CD 68) (NN %)) (PP (IN of) (NP (NNS patients))))))))) (. .)))
17175308	10	(S1 (S (PP (IN In) (NP (CD 40) (NN %))) (NP (PRP it)) (VP (VBN increased) (PP (IN by) (NP (QP (JJR more) (IN than) (CD 100)) (NN %)))) (. .)))
17175308	11	(S1 (S (NP (NP (JJ Twenty-eight) (NN percent)) (PP (IN of) (NP (NNS patients)))) (VP (VBD showed) (NP (NP (VBN increased) (NN Doc_17175308_1224_1235_Disease)) (PP (TO to) (NP (DT the) (NNP Doc_17175308_1243_1252_Disease) (NN range))))) (. .)))
17175308	12	(S1 (NP (NP (NP (NNS Biopsies)) (VP (VBN performed) (PP (IN in) (NP (NP (CD five) (NNS patients)) (VP (VBN revealed) (NP (JJ new) (JJ pathological) (NNS changes))))))) (: :) (NP (NP (NNP One) (NNP Doc_17175308_1335_1371_Disease)) (CC and) (NP (NNP Doc_17175308_1376_1398_Disease))) (. .)))
17175308	13	(S1 (S (NP (DT These) (NNS patients)) (VP (VBD showed) (NP (ADJP (RB persistently) (JJ good)) (NN graft) (NN function))) (. .)))
17175308	14	(S1 (S (S (NP (NNP Serum) (NNP Doc_17175308_1462_1472_Chemical) (NNS values)) (VP (AUX did) (RB not) (VP (VB change) (ADVP (RB significantly))))) (: :) (S (NP (NP (CD 1.98) (JJ +/-) (CD 0.8) (NNS mg/dL)) (PP (IN before) (NP (JJ Doc_17175308_1536_1539_Chemical) (NN therapy) (CC and) (CD 2.53) (NN +/-) (CD 1.9)))) (VP (VBD mg/dL) (PP (IN at) (NP (NP (JJ last) (NN follow-up)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .14)) (-RRB- -RRB-)))))) (. .)))
17175308	15	(S1 (S (S (NP (CD Five) (NNS grafts)) (VP (AUX were) (VP (VBN lost)))) (CC and) (S (NP (DT the) (NNS patients)) (VP (VBN returned) (PP (TO to) (NP (NN dialysis))))) (. .)))
17175308	16	(S1 (S (NP (CD Five) (NNS patients)) (VP (VBD displayed) (NP (NP (NNP Doc_17175308_1685_1688_Disease)) (CC and) (NP (NNP Doc_17175308_1693_1709_Disease)))) (. .)))
17175308	17	(S1 (S (NP (NP (JJ Mean) (NN urinary) (NN protein)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD returned) (PP (TO to) (NP (NN dialysis))))))))) (VP (AUX was) (NP (NP (NP (CD 1.26)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.5) (TO to) (CD 3.5))) (-RRB- -RRB-)) (VP (VBG g/d) (ADVP (RB before)))) (CC and) (NP (NP (CD 4.7)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (TO to) (CD 12))) (-RRB- -RRB-)) (VP (VBN g/d) (PP (IN after) (NP (NP (NN conversion)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .01)) (-RRB- -RRB-)))))))) (. .)))
17175308	18	(S1 (S (NP (NP (JJ Mean) (NN serum) (JJ Doc_17175308_1863_1873_Chemical) (NN level)) (PP (IN before) (NP (NN conversion)))) (VP (AUX was) (NP (NP (CD 2.21) (NN mg/dL)) (CC and) (ADVP (RB thereafter)) (, ,) (NP (NP (CD 4.93) (NN mg/dL)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .02)) (-RRB- -RRB-))))) (. .)))
17175308	19	(S1 (S (NP (NNP Heavy) (NNP Doc_17175308_1957_1968_Disease)) (VP (AUX was) (ADJP (JJ common)) (PP (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17175308_1997_2000_Chemical))) (PP (IN as) (NP (NP (NN rescue) (NN therapy)) (PP (IN for) (NP (JJ renal) (NN transplantation)))))))) (. .)))
17175308	20	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NN conversion)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (RB not) (VP (VBN developed) (NP (NNP advanced) (NNP Doc_17175308_2134_2137_Disease) (CC and) (NNP Doc_17175308_2142_2153_Disease))))))))))) (. .)))
17175308	21	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (IN de) (NN novo) (NN glomerular) (NN pathology))) (PP (IN under) (NP (JJ Doc_17175308_2209_2212_Chemical) (NN treatment)))) (VP (VBZ requires) (NP (NP (JJ further) (NN investigation)) (PP (IN by) (NP (JJ renal) (NN biopsy))))) (. .)))
1720453	0	(S1 (NP (NP (NP (JJ Long-term) (NN follow-up)) (PP (IN of) (NP (NNP Doc_1720453_23_33_Chemical) (NNP Doc_1720453_34_48_Disease))) (PP (IN in) (NP (NP (NNS children)) (VP (VBN treated) (PP (IN for) (NP (NNP Doc_1720453_73_101_Disease))))))) (: :) (NP (NP (DT an) (JJ International) (NN Society)) (PP (IN of) (NP (NNP Pediatric) (NNP Oncology) (NN report)))) (. .)))
1720453	1	(S1 (S (NP (NP (DT The) (JJ renal) (NN function)) (PP (IN of) (NP (NP (CD 74) (NNS children)) (PP (IN with) (NP (NNP Doc_1720453_197_225_Disease))))) (PP (IN in) (NP (NP (JJ complete) (NN remission)) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN received) (NP (NP (DT the) (JJ same) (JJ Doc_1720453_279_289_Chemical) (JJ chemotherapy) (NN protocol)) (PRN (-LRB- -LRB-) (NP (NP (NNP International) (NNP Society)) (PP (IN of) (NP (NNP Pediatric) (NNP Oncology) (NNP Doc_1720453_357_384_Disease) (NNP Study)))) (NP (CD 84) (JJ -LSB-SIOP) (NNP MMT) (CD 84) (NN -RSB-)) (-RRB- -RRB-)))))))))) (VP (AUX were) (VP (VBN studied) (NP (CD 1) (NN year)) (PP (IN after) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (NN treatment))))))) (. .)))
1720453	2	(S1 (S (NP (JJ Total) (JJ cumulative) (NNS doses)) (VP (AUX were) (NP (NP (QP (CD 36) (CC or) (CD 60)) (NN g/m2)) (PP (IN of) (NP (NP (NNP Doc_1720453_509_519_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD six) (CC or) (CD 10)) (NNS cycles)) (PP (IN of) (NP (JJ Doc_1720453_541_582_Chemical) (JJ -LSB-Doc_1720453_584_587_Chemical) (NNS -RSB-)))) (-RRB- -RRB-)))))) (. .)))
1720453	3	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (PRP them)))) (VP (AUX had) (VP (VBN received) (NP (NNP Doc_1720453_617_626_Chemical) (CD chemotherapy)))) (. .)))
1720453	4	(S1 (S (S (NP (NNS Ages)) (VP (VBD ranged) (PP (IN from) (NP (QP (CD 4) (NNS months) (TO to) (CD 17)) (NNS years))))) (: ;) (S (NP (CD 58) (NNS patients)) (VP (AUX were) (NP (NNS males) (CC and) (CD 42) (NNS females)))) (. .)))
1720453	5	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ primary) (NN Doc_1720453_743_748_Disease) (NN site)) (VP (AUX was) (NP (DT the) (NP (NN head)) (CC and) (NP (NN neck)))) (. .)))
1720453	6	(S1 (S (NP (JJ Renal) (NN function)) (VP (AUX was) (VP (VBN investigated) (PP (IN by) (S (VP (VBG measuring) (NP (NP (NN plasma) (CC and) (NN urinary) (NNS electrolytes)) (, ,) (NP (NP (NNP Doc_1720453_855_865_Disease)) (, ,) (NP (NP (NAC (NNP Doc_1720453_867_878_Disease) (, ,) (NNP Doc_1720453_880_893_Disease) (, ,)) (NN urinary) (NN pH)) (, ,) (NP (NN osmolarity)) (, ,) (NP (JJ Doc_1720453_919_929_Chemical) (NN clearance)) (, ,) (NP (JJ Doc_1720453_941_950_Chemical) (JJ tubular) (NN reabsorption)) (, ,) (NP (NN beta) (CD 2) (NN microglobulinuria)) (, ,) (CC and) (NP (NN lysozymuria)))))))))) (. .)))
1720453	7	(S1 (S (NP (NP (JJ Fifty-eight) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 78) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (JJ normal) (JJ renal) (NNS tests)) (, ,) (SBAR (IN whereas) (S (NP (NP (CD 16) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NNP Doc_1720453_1097_1116_Disease)))))) (. .)))
1720453	8	(S1 (S (S (NP (NP (CD Two) (NNS subsets)) (PP (IN of) (NP (NNS patients)))) (VP (AUX were) (VP (VBN identified) (PP (IN from) (NP (DT this) (JJ latter) (NN group)))))) (: :) (S (NP (DT the) (JJ first)) (VP (VBN included) (NP (NP (NP (CD four) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NN %)) (PP (IN of) (NP (DT the) (JJ total) (NN population)))) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ major) (NNP Doc_1720453_1264_1272_Disease)) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NNP Doc_1720453_1286_1304_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1720453_1306_1310_Disease)) (-RRB- -RRB-)))))))))))) (: ;) (CC and) (S (NP (DT the) (JJ second) (NN group)) (VP (VBD included) (NP (CD five) (NNS patients)) (PP (IN with) (NP (NP (NP (JJ elevated) (NN beta)) (ADJP (CD 2) (NN microglobulinuria))) (CC and) (NP (JJ low) (JJ Doc_1720453_1404_1413_Chemical) (NN reabsorption)))))) (. .)))
1720453	9	(S1 (S (NP (DT The) (JJ remaining) (CD seven) (NNS patients)) (VP (AUX had) (VP (VBN isolated) (NP (NN beta) (CD 2) (NN microglobulinuria)))) (. .)))
1720453	10	(S1 (S (NP (JJ Severe) (NNP Doc_1720453_1503_1511_Disease)) (VP (AUX was) (VP (VBN correlated) (PP (IN with) (NP (NP (NP (DT the) (JJR higher) (JJ cumulative) (NN dose)) (PP (IN of) (NP (NP (CD 60) (NNS g/m2)) (PP (IN of) (NP (NP (NNP Doc_1720453_1573_1583_Chemical)) (, ,) (NP (NP (DT a) (JJR younger) (NN age)) (PRN (-LRB- -LRB-) (ADJP (NP (QP (JJR less) (IN than) (CD 2) (CD 1/2)) (NNS years)) (JJ old)) (-RRB- -RRB-))) (, ,)))))) (CC and) (NP (NP (DT a) (NN predominance)) (PP (IN of) (NP (JJ vesicoprostatic) (JJ Doc_1720453_1666_1671_Disease) (NN involvement)))))))) (. .)))
1720453	11	(S1 (S (NP (NP (DT This) (JJ low) (NN percentage)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (NNS TDFS)))) (VP (MD must) (VP (AUX be) (VP (VBN evaluated) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_1720453_1768_1778_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_1720453_1799_1817_Disease)) (PP (IN in) (NP (NNS children)))))))))))))) (. .)))
17241784	0	(S1 (S (NP (NP (NNP Progressive) (NNP Doc_17241784_12_20_Disease)) (PP (IN with) (NP (NP (NN up-regulation)) (PP (IN of) (NP (NNS MHC-I)))))) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_17241784_65_71_Chemical) (NN therapy)))) (. .)))
17241784	1	(S1 (S (NP (NN Doc_17241784_81_88_Chemical)) (VP (MD can) (VP (VB cause) (NP (NP (DT a) (JJ necrotizing) (NN Doc_17241784_113_121_Disease) (CC and) (NN Doc_17241784_126_138_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (JJ reversible) (PP (IN on) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NN drug)))))))))))) (. .)))
17241784	2	(S1 (S (SBAR (WHNP (WP What)) (S (VP (AUX is) (ADJP (ADVP (RBR less) (RB well)) (VBN known))))) (VP (AUX is) (NP (NP (DT a) (NN phenomenon)) (SBAR (WHADVP (WRB whereby)) (S (NP (NNP Doc_17241784_233_240_Chemical)) (VP (VP (MD may) (VP (VB induce) (NP (NP (DT a) (NN Doc_17241784_254_262_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ persists))))))) (CC or) (VP (MD may) (VP (VB progress) (PP (IN after) (S (VP (VBG stopping) (NP (DT the) (NN drug)))))))))))) (. .)))
17241784	3	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN muscle) (NN pathology)) (PP (IN in) (NP (CD 8) (JJ such) (NNS cases))))) (. .)))
17241784	4	(S1 (S (S (NP (DT All)) (VP (AUX had) (NP (JJ myofibre) (NN Doc_17241784_391_399_Disease)))) (CC but) (S (NP (QP (RB only) (CD 3))) (VP (AUX had) (NP (DT an) (JJ inflammatory) (VB infiltrate)))) (. .)))
17241784	5	(S1 (S (PP (IN In) (NP (DT all) (NNS cases))) (NP (EX there)) (VP (AUX was) (NP (NP (NN diffuse) (CC or) (NN multifocal) (NN up-regulation)) (PP (IN of) (NP (JJ MHC-I) (NN expression)))) (PP (ADVP (RB even)) (IN in) (NP (JJ non-Doc_17241784_534_542_Disease) (NNS fibres)))) (. .)))
17241784	6	(S1 (S (NP (JJ Progressive) (NN improvement)) (VP (VBD occurred) (PP (IN in) (NP (CD 7) (NNS cases))) (PP (PP (IN after) (NP (NP (NN commencement)) (PP (IN of) (NP (NP (NNP Doc_17241784_617_629_Chemical)) (CC and) (NP (NNP Doc_17241784_634_646_Chemical)))))) (, ,) (CC and) (PP (IN in) (NP (CD one) (NN case)))) (ADVP (RB spontaneously))) (. .)))
17241784	7	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_17241784_711_718_Chemical)) (VP (MD may) (VP (VB initiate) (NP (NP (DT an) (JJ immune-mediated) (NN Doc_17241784_751_759_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ persists) (PP (IN after) (NP (NP (NN withdrawal)) (PP (IN of) (NP (DT the) (NN drug)))))) (CC and) (VP (VBZ responds) (PP (TO to) (NP (JJ immunosuppressive) (NN therapy))))))))))))) (. .)))
17241784	8	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (DT this) (NN Doc_17241784_868_876_Disease)))) (VP (VP (AUX is) (ADJP (JJ uncertain))) (CC but) (VP (MD may) (VP (VB involve) (NP (NP (DT the) (NN induction)) (PP (IN by) (NP (NP (NNP Doc_17241784_923_930_Chemical)) (PP (IN of) (NP (NP (DT an) (JJ endoplasmic) (NN reticulum) (NN stress) (NN response)) (PP (IN with) (NP (NP (VBN associated) (NN up-regulation)) (PP (IN of) (NP (NP (JJ MHC-I) (NN expression)) (CC and) (NP (NN antigen) (NN presentation)))) (PP (IN by) (NP (NN muscle) (NNS fibres))))))))))))) (. .)))
17242861	0	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NN chromosome) (NN substitution) (NNS strains)))) (VP (TO to) (VP (VB identify) (NP (NP (NN Doc_17242861_51_58_Disease) (NN susceptibility) (NNS loci)) (PP (IN in) (NP (NNS mice)))))) (. .)))
17242861	1	(S1 (S (NP (JJ Doc_17242861_88_95_Disease) (NN susceptibility)) (VP (VBZ varies) (PP (IN among) (NP (JJ inbred) (NN mouse) (NNS strains)))) (. .)))
17242861	2	(S1 (S (NP (NP (NP (NN Chromosome) (NN substitution) (NNS strains)) (PRN (-LRB- -LRB-) (NP (NNP CSS)) (-RRB- -RRB-))) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT a) (JJ single) (NN chromosome)) (PP (IN from) (NP (NP (CD one) (JJ inbred) (NN strain)) (PRN (-LRB- -LRB-) (NP (NN donor)) (-RRB- -RRB-))))) (VP (AUX has) (VP (AUX been) (VP (VBN transferred) (PP (IN onto) (NP (NP (DT a) (JJ second) (NN strain)) (PRN (-LRB- -LRB-) (NP (NN host)) (-RRB- -RRB-)))) (PP (IN by) (NP (VBN repeated) (NN backcrossing)))))))) (, ,)) (VP (MD may) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB identify) (NP (NP (JJ quantitative) (NN trait) (NNS loci)) (PRN (-LRB- -LRB-) (NP (NNP QTLs)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBP contribute) (PP (TO to) (NP (NNP Doc_17242861_394_401_Disease) (NN susceptibility))))))))))))) (. .)))
17242861	3	(S1 (S (S (NP (NP (NNS QTLs)) (PP (IN for) (NP (NN susceptibility))) (PP (TO to) (NP (NP (NNP Doc_17242861_445_456_Chemical-induced) (NNP Doc_17242861_465_473_Disease)) (, ,) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_17242861_486_508_Disease)))) (, ,)))) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN reported))))) (, ,) (CC and) (S (NP (NNS CSS)) (VP (AUX have) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB localize) (NP (JJ Doc_17242861_584_591_Disease) (JJ susceptibility) (NNS genes))))))))) (. .)))
17242861	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (NNS QTLs)) (VP (VBN identified) (S (VP (VBG using) (NP (DT a) (NNP B6) (PRN (-LRB- -LRB-) (NP (NN host)) (-RRB- -RRB-)) (NNP x) (NNP A/J) (PRN (-LRB- -LRB-) (NP (NN donor)) (-RRB- -RRB-)) (NN CSS) (NN panel)) (S (VP (TO to) (VP (VB localize) (NP (NP (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_17242861_730_741_Chemical-induced) (NNP Doc_17242861_750_758_Disease))))))))))))))) (. .)))
17242861	5	(S1 (S (NP (NP (CD Three) (CD hundred) (JJ fifty-five) (NN adult) (NN male) (NN CSS) (NNS mice)) (, ,) (NP (CD 58) (NNS B6)) (, ,) (CC and) (NP (CD 39) (NNS A/J))) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (NP (NN susceptibility)) (PP (TO to) (NP (NNP Doc_17242861_858_869_Chemical-induced) (NNP Doc_17242861_878_886_Disease))))))) (. .)))
17242861	6	(S1 (S (S (NP (JJS Highest) (NN stage)) (VP (VBN reached))) (CC and) (S (NP (NP (NN latency)) (PP (TO to) (NP (DT each) (NN stage)))) (VP (AUX were) (VP (VBN recorded) (PP (IN for) (NP (DT all) (NNS mice)))))) (. .)))
17242861	7	(S1 (S (NP (NN B6) (NNS mice)) (VP (AUX were) (ADJP (ADJP (JJ resistant) (PP (TO to) (NP (NNP Doc_17242861_990_998_Disease)))) (CC and) (ADJP (JJR slower) (SBAR (S (VP (TO to) (VP (VB reach) (NP (NNS stages)) (PP (VBN compared) (PP (TO to) (NP (JJ A/J) (NNS mice))))))))))) (. .)))
17242861	8	(S1 (S (NP (NP (DT The) (NN CSS)) (PP (IN for) (NP (NNS Chromosomes) (CD 10) (CC and) (CD 18)))) (VP (VBD progressed) (PP (TO to) (NP (DT the) (RBS most) (JJ severe) (NNS stages))) (, ,) (S (VP (VBG diverging) (ADVP (RB dramatically)) (PP (IN from) (NP (DT the) (NNP B6) (NN phenotype)))))) (. .)))
17242861	9	(S1 (S (NP (NP (NNS Latencies)) (PP (TO to) (NP (NNS stages)))) (VP (AUX were) (ADVP (RB also)) (ADJP (RB significantly) (JJR shorter)) (PP (IN for) (NP (QP (CD CSS10) (CC and) (CD CSS18)) (NNS mice)))) (. .)))
17242861	10	(S1 (S (NP (JJ CSS) (NN mapping)) (VP (VBZ suggests) (NP (NP (JJ Doc_17242861_1265_1272_Disease) (NN susceptibility) (NN loci)) (PP (IN on) (NP (NN mouse) (NNS Chromosomes) (CD 10) (CC and) (CD 18))))) (. .)))
17242861	11	(S1 (S (NP (DT This) (NN approach)) (VP (VBZ provides) (NP (NP (DT a) (NN framework)) (PP (IN for) (S (VP (VBG identifying) (ADJP (RB potentially) (JJ novel)) (ADVP (RB homologous)) (NP (NN candidate) (NNS genes)) (PP (IN for) (NP (JJ human) (NN Doc_17242861_1431_1453_Disease)))))))) (. .)))
17244258	0	(S1 (FRAG (PP (IN In) (NP (NP (NN vitro) (NN characterization)) (PP (IN of) (NP (NP (ADJP (JJ parasympathetic) (CC and) (JJ sympathetic)) (NNS responses)) (PP (IN in) (NP (NP (NNP Doc_17244258_74_90_Chemical-induced) (NNP Doc_17244258_99_107_Disease)) (PP (IN in) (NP (DT the) (NN rat))))))))) (. .)))
17244258	1	(S1 (S (PP (IN In) (NP (NP (NNP Doc_17244258_123_139_Chemical-induced) (NNP Doc_17244258_148_156_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (, ,) (S (NP (NN detrusor) (NN function)) (VP (AUX is) (ADJP (JJ impaired)))) (CC and) (S (NP (NP (DT the) (NN expression) (CC and) (NNS effects)) (PP (IN of) (NP (JJ muscarinic) (NNS receptors)))) (VP (VBD altered))) (. .)))
17244258	2	(S1 (S (SBAR (IN Whether) (S (CC or) (RB not) (NP (DT the) (JJ neuronal) (NN transmission)) (VP (MD may) (VP (AUX be) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_17244258_323_331_Disease)))))))) (VP (AUX was) (ADVP (RB presently)) (VP (VBN investigated))) (. .)))
17244258	3	(S1 (S (NP (NP (NNS Responses)) (PP (IN of) (NP (NP (JJ urinary) (NN strip) (NNS preparations)) (PP (IN from) (NP (NP (NN control)) (CC and) (NP (JJ Doc_17244258_417_433_Chemical-pretreated) (NNS rats)))))) (PP (PP (TO to) (NP (JJ electrical) (NN field) (NN stimulation))) (CC and) (PP (TO to) (NP (NNS agonists))))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (NP (DT the) (NN absence) (CC and) (NN presence)) (PP (IN of) (NP (ADJP (JJ muscarinic) (, ,) (JJ adrenergic) (CC and) (JJ purinergic)) (NN receptor) (NNS antagonists))))))) (. .)))
17244258	4	(S1 (S (S (ADVP (RB Generally)) (, ,) (NP (NNP Doc_17244258_614_622_Chemical)) (VP (VBD reduced) (NP (NNS contractions)))) (, ,) (CC but) (S (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NNS controls))))) (, ,) (NP (PRP it)) (ADVP (RB also)) (VP (VBD reduced) (NP (NP (NNS responses)) (PP (TO to) (NP (NP (JJ low) (JJ electrical) (NN field) (NN stimulation) (NN intensity)) (PRN (-LRB- -LRB-) (NP (CD 1-5) (NN Hz)) (-RRB- -RRB-))))) (PP (IN in) (NP (JJ inflamed) (NNS preparations))))) (. .)))
17244258	5	(S1 (S (PP (IN In) (NP (DT both) (NNS types))) (, ,) (NP (NP (NN purinoceptor) (NN desensitization)) (PP (IN with) (NP (NP (NNP Doc_17244258_830_876_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17244258_878_894_Chemical)) (-RRB- -RRB-))))) (VP (VBD caused) (NP (NP (JJ further) (NNS reductions)) (PP (IN at) (NP (NP (JJ low) (NNS frequencies)) (PRN (-LRB- -LRB-) (NP (CD <10) (NNS Hz)) (-RRB- -RRB-)))))) (. .)))
17244258	6	(S1 (S (NP (DT The) (JJ muscarinic) (NN receptor) (NNS antagonists)) (NP (NP (NP (NNP Doc_17244258_987_995_Chemical)) (, ,) (NP (NNP Doc_17244258_997_1033_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_17244258_1035_1041_Chemical) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (VP (POS ') (NP (NNP M) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (JJ /M) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ /M) (PRN (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (NN -selective) ('' '))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_17244258_1073_1086_Chemical)) (PRN (-LRB- -LRB-) ('' ') (NP (NNP M) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NN -selective) ('' ')) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_17244258_1110_1121_Chemical)) (PRN (-LRB- -LRB-) ('' ') (NP (NNP M) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN -selective) ('' ')) (-RRB- -RRB-)))) (VP (VBD antagonized) (SBAR (S (NP (NP (DT the) (NN tonic) (NN component)) (PP (IN of) (NP (DT the) (JJ electrical) (NN field)))) (VP (VBD stimulation-evoked) (NP (JJ contractile) (NN response)) (ADVP (ADVP (RBR more) (RB potently)) (SBAR (IN than) (S (NP (DT the) (JJ phasic) (NN component.) (NNP Doc_17244258_1278_1284_Chemical)) (VP (VBD inhibited) (NP (NP (DT the) (NN tonic) (NNS contractions)) (PP (IN in) (NP (NNS controls)))) (ADVP (ADVP (RBR more) (RB potently)) (PP (IN than) (NP (NNP Doc_17244258_1349_1362_Chemical) (CC and) (NNP Doc_17244258_1367_1378_Chemical)))))))))))) (. .)))
17244258	7	(S1 (S (PP (IN In) (NP (JJ inflamed) (NNS preparations))) (, ,) (S (NP (NP (DT the) (JJ muscarinic) (NN receptor) (NN antagonism)) (PP (IN on) (NP (NP (DT the) (JJ phasic) (NN component)) (PP (IN of) (NP (DT the) (JJ electrical) (NN field) (JJ stimulation-evoked) (NN contraction)))))) (VP (AUX was) (VP (VBN decreased)))) (CC and) (S (NP (NP (DT the) (ADJP (JJ Doc_17244258_1542_1553_Chemical) (CC and) (JJ Doc_17244258_1558_1564_Chemical)) (NN antagonism)) (PP (IN on) (NP (DT the) (NN tonic) (NN component)))) (VP (AUX was) (ADJP (ADVP (RB much) (RBR less)) (JJ efficient) (PP (IN than) (PP (IN in) (NP (NNS controls))))))) (. .)))
17244258	8	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NNS controls))))) (, ,) (NP (NNP Doc_17244258_1666_1679_Chemical)) (VP (VBD increased) (: --) (CONJP (RB instead) (IN of)) (VP (VBN decreased)) (: --) (NP (NP (DT the) (NN tonic) (NNS responses)) (PP (IN at) (NP (JJ high) (NNS frequencies))))) (. .)))
17244258	9	(S1 (S (SBAR (IN While) (S (NP (NP (NNS contractions)) (PP (TO to) (NP (NNP Doc_17244258_1780_1789_Chemical) (CC and) (NNP Doc_17244258_1794_1797_Chemical)))) (VP (AUX were) (NP (NP (DT the) (JJ same)) (SBAR (SBAR (IN in) (S (VP (VBN inflamed)))) (CC and) (SBAR (IN in) (S (NP (NN control)) (VP (VBZ strips) (SBAR (WHADVP (WRB when)) (S (VP (VBN related) (PP (TO to) (NP (DT a) (NN reference) (JJ Doc_17244258_1874_1883_Chemical) (NN response)))))))))))))) (, ,) (NP (JJ Doc_17244258_1894_1906_Chemical-induced) (NNS relaxations)) (VP (AUX were) (ADJP (JJR smaller)) (PP (IN in) (NP (JJ inflamed) (NNS strips)))) (. .)))
17244258	10	(S1 (S (ADVP (RB Thus)) (, ,) (PP (IN in) (NP (NP (JJ Doc_17244258_1969_1977_Disease) (JJ substantial) (NNS changes)) (PP (IN of) (NP (DT the) (JJ efferent) (JJ functional) (NNS responses))))) (VP (VBP occur)) (. .)))
17244258	11	(S1 (S (SBAR (IN While) (S (NP (JJ postjunctional) (JJ beta-adrenoceptor-mediated) (NNS relaxations)) (VP (AUX are) (VP (VBN reduced))))) (, ,) (NP (NP (NNS effects)) (PP (IN by) (NP (JJ prejunctional) (NN inhibitory) (NN muscarinic) (NNS receptors)))) (VP (MD may) (VP (AUX be) (VP (VBN increased)))) (. .)))
17261653	0	(S1 (NP (NP (JJ Direct) (NN inhibition)) (PP (IN of) (NP (JJ cardiac) (JJ hyperpolarization-activated) (JJ Doc_17261653_57_74_Chemical-gated) (NN pacemaker) (NNS channels))) (PP (IN by) (NP (NNP Doc_17261653_103_112_Chemical))) (. .)))
17261653	1	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ cardiac) (JJ sympathetic) (NN tone)))) (VP (VBZ represents) (NP (NP (DT an) (JJ important) (NN strategy)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_17261653_215_237_Disease))) (, ,) (PP (VBG including) (NP (NP (NNP Doc_17261653_249_259_Disease)) (, ,) (NP (NNP Doc_17261653_261_283_Disease)) (, ,) (CC and) (NP (NN chronic) (NN Doc_17261653_297_310_Disease)))))))) (. .)))
17261653	2	(S1 (S (S (NP (NP (NN Activation)) (PP (IN of) (NP (JJ presynaptic) (NNS alpha2-adrenoceptors)))) (VP (AUX is) (NP (NP (DT the) (ADJP (RBS most) (RB widely) (VBN accepted)) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (DT the) (JJ antisympathetic) (NN drug) (NN Doc_17261653_435_444_Chemical)))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ other) (NN target) (NNS proteins)) (VP (AUX have) (VP (AUX been) (VP (VBN postulated) (S (VP (TO to) (VP (VB contribute) (PP (TO to) (NP (NP (DT the)) (PP (IN in) (NP (NP (JJ vivo) (NNS actions)) (PP (IN of) (NP (NNP Doc_17261653_538_547_Chemical)))))))))))))) (. .)))
17261653	3	(S1 (FRAG (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (S (VP (TO To) (VP (VB test) (SBAR (IN whether) (S (NP (NNP Doc_17261653_586_595_Chemical)) (VP (VBZ elicits) (S (NP (JJ pharmacological) (NNS effects)) (ADJP (JJ independent) (PP (IN of) (NP (NNS alpha2-adrenoceptors))))))))))) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN generated) (NP (NP (NNS mice)) (PP (IN with) (NP (NP (DT a) (JJ targeted) (NN deletion)) (PP (IN of) (NP (NP (DT all) (CD 3) (JJ alpha2-adrenoceptor) (NNS subtypes)) (PRN (-LRB- -LRB-) (JJ alpha2ABC-/-) (-RRB- -RRB-)))))))))) (. .)))
17261653	4	(S1 (S (S (NP (JJ Alpha2ABC-/-) (NNS mice)) (VP (AUX were) (ADJP (RB completely) (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ analgesic) (CC and) (JJ hypnotic) (NNS effects)) (PP (IN of) (NP (NNP Doc_17261653_855_864_Chemical)))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNP Doc_17261653_875_884_Chemical)) (VP (ADVP (RB significantly)) (VBD lowered) (NP (NN heart) (NN rate)) (PP (IN in) (NP (JJ alpha2ABC-/-) (NNS mice))) (PP (IN by) (NP (QP (IN up) (TO to) (CD 150) (CD bpm)))))) (. .)))
17261653	5	(S1 (S (NP (NP (JJ Doc_17261653_957_966_Chemical-induced) (NNP Doc_17261653_975_986_Disease)) (PP (IN in) (NP (JJ conscious) (JJ alpha2ABC-/-) (NNS mice)))) (VP (AUX was) (NP (NP (NP (NP (CD 32.3) (NN %)) (-LRB- -LRB-) (NP (CD 10) (NNS microg/kg)) (-RRB- -RRB-)) (CC and) (NP (NP (CD 26.6) (NN %)) (-LRB- -LRB-) (NP (CD 100) (NNS microg/kg)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN in) (NP (JJ wild-type) (NNS mice))))))) (. .)))
17261653	6	(S1 (S (NP (NP (DT A) (JJ similar) (JJ bradycardic) (NN effect)) (PP (IN of) (NP (NNP Doc_17261653_1134_1143_Chemical)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (VBN isolated) (ADJP (RB spontaneously) (VBG beating)) (JJ right) (NN atria)) (PP (IN from) (NP (NP (NN alpha2ABC-knockout)) (CC and) (NP (JJ wild-type) (NNS mice)))))))) (. .)))
17261653	7	(S1 (S (NP (NNP Doc_17261653_1247_1256_Chemical)) (VP (VBD inhibited) (NP (NP (DT the) (JJ native) (NN pacemaker) (NN current)) (PRN (-LRB- -LRB-) (NP (NP (PRP I)) (PRN (-LRB- -LRB-) (NNP f) (-RRB- -RRB-))) (-RRB- -RRB-)) (PP (IN in) (NP (NP (VBN isolated) (JJ sinoatrial) (NN node) (NN pacemaker) (NNS cells)) (CC and) (NP (NP (NP (NP (NP (DT the) (PRP I)) (PRN (-LRB- -LRB-) (NP (NNP f)) (-RRB- -RRB-))) (JJ -generating) (JJ hyperpolarization-activated) (JJ Doc_17261653_1399_1416_Chemical-gated)) (PRN (-LRB- -LRB-) (NP (NNP HCN)) (-RRB- -RRB-))) (NP (QP (CD 2) (CC and) (CD HCN4)) (NNS channels)) (PP (IN in) (NP (JJ transfected) (CD HEK293) (NNS cells)))))))) (. .)))
17261653	8	(S1 (S (PP (IN As) (NP (NP (DT a) (NN consequence)) (PP (IN of) (S (VP (VBG blocking) (NP (NP (PRP I)) (PRN (-LRB- -LRB-) (NP (NNP f)) (-RRB- -RRB-)))))))) (, ,) (NP (NNP Doc_17261653_1513_1522_Chemical)) (VP (VBD reduced) (NP (NP (NP (DT the) (NN slope)) (PP (IN of) (NP (DT the) (JJ diastolic) (NN depolarization)))) (CC and) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NN pacemaker) (NNS potentials))))) (PP (IN in) (NP (NP (JJ sinoatrial) (NN node) (NNS cells)) (PP (IN from) (NP (ADJP (JJ wild-type) (CC and) (JJ alpha2ABC-knockout)) (NNS mice)))))) (. .)))
17261653	9	(S1 (S (S (NP (NP (JJ Direct) (NN inhibition)) (PP (IN of) (NP (JJ cardiac) (NN HCN) (NN pacemaker) (NNS channels)))) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (JJ bradycardic) (NNS effects)) (PP (IN of) (NP (NP (JJ Doc_17261653_1791_1800_Chemical) (JJ gene-targeted) (NNS mice)) (PP (IN in) (NP (NN vivo))))))))) (, ,) (CC and) (S (ADVP (RB thus)) (, ,) (NP (JJ Doc_17261653_1839_1848_Chemical-like) (NNS drugs)) (VP (VBP represent) (NP (NP (JJ novel) (NNS structures)) (PP (IN for) (NP (JJ future) (NN HCN) (NN channel) (NNS inhibitors)))))) (. .)))
1728522	0	(S1 (NP (NP (NN Doc_1728522_0_23_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_1728522_31_77_Chemical)))) (. .)))
1728522	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_1728522_116_143_Chemical-induced) (NNP Doc_1728522_152_161_Disease))) (PP (IN with) (NP (JJ histologic) (JJ multiple) (NN Doc_1728522_187_197_Disease))))))) (. .)))
1728522	2	(S1 (S (NP (NP (DT This) (NN type)) (PP (IN of) (NP (NN lesion)))) (VP (VBZ broadens) (NP (NP (DT the) (NN spectrum)) (PP (IN of) (NP (NNP Doc_1728522_244_256_Disease))) (ADJP (JJ due) (PP (TO to) (NP (DT this) (NN drug) (NN combination)))) (, ,) (VP (ADVP (RB mainly)) (VBN represented) (PP (IN by) (NP (DT a) (JJ benign) (NN Doc_1728522_318_338_Disease)))))) (. .)))
1728522	3	(S1 (S (NP (NP (DT The) (NN association)) (PP (IN of) (NP (NP (NNP Doc_1728522_359_369_Disease)) (CC and) (NP (NNP Doc_1728522_374_386_Disease))))) (VP (VBP favor) (NP (DT an) (JJ immunoallergic) (NN mechanism))) (. .)))
1728522	4	(S1 (FRAG (SBAR (IN As) (S (NP (NP (JJ Doc_1728522_425_435_Chemical) (NNS derivatives)) (CC and) (NP (NP (NNP Doc_1728522_452_463_Chemical)) (ADVP (RB alone)))) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ such) (NNS types)) (PP (IN of) (NP (NNS lesions))))))))))) (, ,) (NP (DT the) (JJ Doc_1728522_517_528_Chemical) (NN component)) (, ,) (SBAR (IN with) (S (CC or) (PP (IN without) (NP (NP (DT a) (JJ potentiating) (NN effect)) (PP (IN of) (NP (NNP Doc_1728522_581_596_Chemical))))) (, ,) (VP (MD might) (VP (AUX have) (NP (DT a) (JJ major) (NN role)))))) (. .)))
1732369	0	(S1 (NP (NP (JJ Doc_1732369_0_10_Chemical) (NN stress) (NN echocardiography)) (: :) (NP (NP (DT a) (JJ sensitive) (NN indicator)) (PP (IN of) (NP (JJ diminished) (JJ myocardial) (NN function))) (PP (IN in) (NP (NP (JJ asymptomatic) (JJ Doc_1732369_108_119_Chemical-treated) (JJ long-term) (NNS survivors)) (PP (IN of) (NP (NN childhood) (NN Doc_1732369_161_167_Disease)))))) (. .)))
1732369	1	(S1 (S (NP (NNP Doc_1732369_169_180_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN anticancer) (JJ chemotherapeutic) (NN agent)) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (ADJP (ADJP (JJ acute)) (CC and) (ADJP (JJ chronic))) (NN Doc_1732369_264_278_Disease)))))))) (. .)))
1732369	2	(S1 (S (S (VP (TO To) (VP (VB develop) (NP (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (JJ echocardiographic) (NN screening) (NN test)) (PP (IN for) (NP (NNP Doc_1732369_345_359_Disease)))) (PP (JJ due) (TO to) (NP (NNP Doc_1732369_367_378_Chemical)))))) (, ,) (NP (DT a) (NN cohort) (NN study)) (VP (AUX was) (VP (VBN performed) (S (VP (VBG using) (NP (JJ Doc_1732369_415_425_Chemical) (NN infusion)) (S (VP (TO to) (VP (VB differentiate) (NP (NP (JJ asymptomatic) (JJ long-term) (NNS survivors)) (PP (IN of) (NP (NP (NN childhood) (NN Doc_1732369_498_504_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1732369_518_529_Chemical))) (PP (IN from) (NP (JJ healthy) (NN control) (NNS subjects)))))))))))))) (. .)))
1732369	3	(S1 (S (NP (NP (JJ Echocardiographic) (NNS data)) (PP (IN from) (NP (NP (DT the) (JJ experimental) (NN group)) (PP (IN of) (NP (NP (CD 21) (NNS patients)) (PRN (-LRB- -LRB-) (NP (JJ mean) (NN age)) (NP (CD 16) (JJ +/-) (CD 5) (NNS years)) (-RRB- -RRB-)))) (VP (VBN treated) (PP (IN from) (NP (NP (QP (CD 1.6) (TO to) (CD 14.3)) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN median) (CD 5.3)) (-RRB- -RRB-)))) (PP (IN before) (NP (DT this) (NN study))) (PP (IN with) (NP (NP (QP (CD 27) (TO to) (CD 532)) (NNS mg/m2)) (PP (IN of) (NP (NNP Doc_1732369_739_750_Chemical)))))))) (PRN (-LRB- -LRB-) (NP (VB mean) (CD 196)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (JJ echocardiographic) (NNS data)) (PP (IN from) (NP (CD 12) (JJ normal) (JJ age-matched) (NN control) (NNS subjects))))))) (. .)))
1732369	4	(S1 (S (NP (NP (JJ Graded) (JJ Doc_1732369_856_866_Chemical) (NNS infusions)) (PP (IN of) (NP (CD 0.5) (, ,) (CD 2.5) (, ,) (CD 5) (CC and) (CD 10) (NN micrograms/kg))) (PP (IN per) (NP (NN min)))) (VP (AUX were) (VP (VBN administered))) (. .)))
1732369	5	(S1 (S (NP (JJ Echocardiographic) (NNP Doppler) (NNS studies)) (VP (AUX were) (VP (VBN performed) (PP (PP (IN before) (NP (NN infusion))) (CC and) (PP (IN after) (NP (NP (CD 15) (NN min)) (PP (IN of) (NP (NN infusion)))))) (PP (IN at) (NP (DT each) (NN rate))))) (. .)))
1732369	6	(S1 (S (NP (NP (JJ Doc_1732369_1048_1058_Chemical) (NN infusion)) (PP (IN at) (NP (CD 10) (NNS micrograms/kg))) (PP (IN per) (NP (NN min)))) (VP (AUX was) (VP (VBN discontinued) (PP (IN after) (NP (NP (CD six) (NNS studies)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN incidence) (NN rate)) (PP (IN of) (NP (JJ adverse) (NNS symptoms)))))))))) (. .)))
1732369	7	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ important)) (NNS findings)) (VP (AUX were) (SBAR (IN that) (S (S (PP (VBN compared) (PP (IN with) (NP (NP (NNS values)) (PP (IN in) (NP (NN control) (NNS subjects)))))) (, ,) (NP (NP (JJ end-systolic) (JJ left) (JJ ventricular) (NN posterior) (NN wall) (NN dimension) (CC and) (NN percent)) (PP (IN of) (NP (NP (JJ left) (JJ ventricular) (NN posterior) (NN wall)) (VP (VBG thickening) (PP (IN in) (NP (JJ Doc_1732369_1382_1393_Chemical-treated) (NNS patients))))))) (VP (AUX were) (VP (VBN decreased) (PP (IN at) (NP (JJ baseline) (NN study)))))) (CC and) (S (NP (DT these) (NNS findings)) (VP (AUX were) (ADVP (RBR more) (RB clearly)) (VP (VBN delineated) (PP (IN with) (NP (JJ Doc_1732369_1497_1507_Chemical) (NN stimulation))))))))) (. .)))
1732369	8	(S1 (S (NP (NP (JJ End-systolic) (JJ left) (JJ ventricular) (NN posterior) (NN wall) (NN dimension)) (PP (IN at) (NP (NN baseline))) (PP (IN for) (NP (DT the) (JJ Doc_1732369_1596_1607_Chemical-treated) (NN group)))) (VP (AUX was) (NP (NP (CD 11) (NN +/-) (QP (CD 1.9) (CD mm) (CC versus) (CD 13.1) (JJR +/-) (CD 1.5) (CD mm))) (PP (IN for) (NP (NP (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
1732369	9	(S1 (NP (NP (NP (JJ End-systolic) (JJ left) (JJ ventricular) (NN posterior) (NN wall) (NN dimension)) (PP (IN at) (NP (DT the) (NN 5-micrograms/kg)))) (S (NP (NP (FW per) (FW min) (JJ Doc_1732369_1790_1800_Chemical) (NN infusion)) (PP (IN for) (NP (DT the) (JJ Doc_1732369_1818_1829_Chemical-treated) (NN group)))) (VP (AUX was) (NP (NP (NP (CD 14.1) (NN +/-)) (NP (QP (CD 2.4) (CD mm) (CC versus) (CD 19.3)) (JJ +/-) (CD 2.6) (NNS mm))) (PP (IN for) (NP (NP (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))) (. .)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))
17343925	0	(S1 (NP (NP (NN Influence)) (PP (IN of) (NP (NNP Doc_17343925_13_20_Chemical))) (PP (IN on) (S (VP (VBG developing) (NP (NN cochlea))))) (. .)))
17343925	1	(S1 (SQ (AUX Does) (NP (NP (NNP Doc_17343925_49_56_Chemical)) (PP (IN during) (NP (NN pregnancy)))) (VP (VB affect) (NP (NP (DT the) (NNS amplitudes)) (PP (IN of) (NP (NP (JJ transient) (JJ evoked) (NN otoacoustic) (NNS emissions)) (PP (IN in) (NP (NNS newborns))))))) (. ?)))
17343925	2	(S1 (S (NP (JJ Maternal) (NN tobacco) (NN Doc_17343925_179_186_Chemical)) (VP (AUX has) (NP (NP (JJ negative) (NNS effects)) (PP (IN on) (NP (JJ fetal) (NN growth))))) (. .)))
17343925	3	(S1 (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NNP Doc_17343925_242_249_Chemical))) (PP (IN during) (NP (NN pregnancy))) (PP (IN on) (NP (DT the) (VBG developing) (NN cochlea)))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN estimated) (, ,) (SBAR (IN although) (S (NP (NNP Doc_17343925_326_333_Chemical)) (VP (AUX has) (VP (AUX been) (ADVP (RB positively)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_17343925_370_382_Disease)) (PP (IN in) (NP (NNS adults))))))))))))) (. .)))
17343925	4	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ maternal) (NNP Doc_17343925_463_470_Chemical))) (PP (IN on) (NP (NP (NP (JJ transient) (JJ evoked) (NN otoacoustic) (NNS emissions)) (PRN (-LRB- -LRB-) (NP (NNP TEOAEs)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ healthy) (NNS neonates)))))))))) (. .)))
17343925	5	(S1 (S (NP (DT This) (NN study)) (VP (VP (AUX was) (VP (VBN undertaken) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (JJ neonatal) (NN screening)) (PP (IN for) (NP (NNP Doc_17343925_612_630_Disease))))))))) (CC and) (VP (VBD involved) (NP (NP (DT both) (NNS ears)) (PP (IN of) (NP (CD 200) (NNS newborns)))))) (. .)))
17343925	6	(S1 (S (NP (NP (NNS Newborns)) (SBAR (WHNP (WP$ whose) (NNS mothers)) (S (VP (VBD reported) (NP (NNP Doc_17343925_703_710_Chemical)) (PP (IN during) (NP (NN pregnancy)))))) (PRN (-LRB- -LRB-) (NP (CD n=200) (NNS ears)) (-RRB- -RRB-))) (VP (AUX were) (PP (VBN compared) (PP (TO to) (NP (NP (DT a) (NN control) (NN group)) (PP (IN of) (NP (NP (NNS newborns)) (PRN (-LRB- -LRB-) (NP (CD n=200) (NNS ears)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WP$ whose) (NNS mothers)) (S (VP (AUX were) (NP (NNS non-smokers))))))))) (. .)))
17343925	7	(S1 (S (NP (NP (NN Exposure)) (PP (TO to) (NP (NN tobacco)))) (VP (AUX was) (VP (VBN characterized) (PP (IN as) (NP (ADJP (ADJP (JJ low)) (PRN (-LRB- -LRB-) (NP (NP (JJ <5) (NNS cigarettes)) (PP (IN per) (NP (NN day)))) (, ,) (NP (CD n=88) (NNS ears)) (-RRB- -RRB-)) (, ,) (ADJP (JJ moderate)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNS 5<) (CC or) (NNS =cigarettes)) (PP (IN per) (NP (CD day<10)))) (, ,) (NP (CD n=76))) (-RRB- -RRB-)) (CC or) (ADJP (JJ high)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD >) (CC or) (CD =10)) (NNS cigarettes)) (PP (IN per) (NP (NN day)))) (, ,) (NP (CD n=36))) (-RRB- -RRB-))))))) (. .)))
17343925	8	(S1 (S (PP (IN In) (NP (JJ exposed) (NNS neonates))) (, ,) (NP (NNS TEOAEs)) (VP (VBP mean) (SBAR (S (NP (NP (NP (NN response)) (PRN (-LRB- -LRB-) (PP (IN across) (NP (NN frequency))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ mean) (NN amplitude)) (PP (IN at) (NP (NNS 4000Hz))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (PP (IN in) (NP (JJ non-exposed) (NNS neonates))))))))) (. .)))
17343925	9	(S1 (S (NP (NP (NNS Comparisons)) (PP (IN between) (NP (NP (VBN exposed) (NNS newborns) (POS ')) (NNS subgroups)))) (VP (VBD revealed) (NP (DT no) (JJ significant) (NNS differences))) (. .)))
17343925	10	(S1 (S (ADVP (RB However)) (, ,) (PP (IN by) (S (VP (VBG comparing) (NP (DT each) (NN subgroup) (S (VP (TO to) (VP (VB control) (NP (NN group))))))))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (ADJP (RB statistically) (JJ significant)) (NN Doc_17343925_1331_1361_Disease)) (PP (IN at) (NP (NP (NNS 4000Hz)) (PP (IN for) (NP (DT all) (CD three) (NNS groups)))))) (. .)))
17343925	11	(S1 (S (NP (NP (JJ Mean) (JJ TEOAEs) (NNS responses)) (PP (IN of) (NP (ADJP (RB highly) (VBN exposed)) (NNS newborns)))) (VP (AUX were) (ADVP (RB also)) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (PRP$ our) (NN control) (NN group)))))) (. .)))
17343925	12	(S1 (S (PP (IN In) (NP (NN utero))) (, ,) (NP (NP (NN exposure)) (PP (TO to) (NP (NN tobacco) (NN Doc_17343925_1551_1558_Chemical)))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJ small) (NN impact)) (PP (IN on) (NP (JJ outer) (NN hair) (NNS cells)))))))) (. .)))
17343925	13	(S1 (S (NP (DT These) (NNS effects)) (VP (VBP seem) (S (VP (TO to) (VP (AUX be) (ADJP (RB equally) (JJ true) (PP (IN for) (NP (DT all) (VBN exposed) (NNS newborns)))) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN exposure)))))))))) (. .)))
17343925	14	(S1 (S (NP (JJ Further) (NNS studies)) (VP (AUX are) (VP (VBN needed) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB establish) (NP (NP (DT a) (JJ potential) (JJ negative) (NN effect)) (PP (IN of) (NP (JJ maternal) (NNP Doc_17343925_1800_1807_Chemical))) (PP (IN on) (NP (NP (DT the) (NN neonate) (POS 's)) (NN hearing) (NN acuity)))))))))) (. .)))
17344566	0	(S1 (NP (NP (NP (JJ Doc_17344566_0_11_Chemical-induced) (JJ bilateral) (NN leg) (NN Doc_17344566_34_54_Disease)) (CC and) (NP (NNP Doc_17344566_59_70_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17344566_87_101_Disease)))) (. .)))
17344566	1	(S1 (S (NP (NP (DT A) (JJ 54-year-old) (JJ Doc_17344566_117_128_Disease) (NN male)) (VP (VBG taking) (NP (NP (NNP Doc_17344566_141_150_Chemical)) (CC and) (NP (NNP Doc_17344566_155_166_Chemical))))) (VP (VBD presented) (PP (IN with) (NP (JJ bilateral) (NN leg) (NNP Doc_17344566_196_216_Disease) (CC and) (NNP Doc_17344566_221_232_Disease)))) (. .)))
17344566	2	(S1 (S (S (NP (JJ Urgent) (NNS fasciotomies)) (VP (AUX were) (VP (VBN performed)))) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD made) (NP (NP (DT an) (JJ uneventful) (NN recovery)) (PP (IN with) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_17344566_336_347_Chemical)))))))) (. .)))
17344566	3	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ likely)) (SBAR (IN that) (S (NP (DT this) (NN complication)) (VP (MD will) (VP (AUX be) (VP (VBN seen) (ADVP (RBR more) (RB often)) (PP (IN with) (NP (NP (NP (DT the) (VBN increased) (NNP worldwide) (NN use)) (PP (IN of) (NP (DT this) (NN drug)))) (CC and) (NP (NP (PRP$ its) (NN approval)) (PP (IN for) (NP (DT all) (JJ Doc_17344566_480_493_Disease) (NNS patients)))))))))))) (. .)))
17400887	0	(S1 (NP (NP (NP (NP (NNP Doc_17400887_0_17_Disease)) (CC and) (NP (NNP Doc_17400887_22_46_Disease))) (PP (IN after) (NP (NP (JJ neonatal) (JJ Doc_17400887_62_73_Chemical) (NN treatment)) (PP (IN in) (NP (NNS rats)))))) (: :) (NP (NP (NNS implications)) (PP (IN for) (NP (NNP Doc_17400887_110_116_Disease)))) (. .)))
17400887	1	(S1 (S (NP (NN Doc_17400887_118_124_Disease)) (VP (AUX is) (NP (NP (DT a) (NN Doc_17400887_130_157_Disease)) (VP (VBG presenting) (PP (IN before) (NP (NP (CD 3) (NNS years)) (PP (IN of) (NP (NN age))))) (PP (IN with) (NP (NP (NNP Doc_17400887_196_239_Disease)) (CC and) (NP (NNP Doc_17400887_244_264_Disease))))))) (. .)))
17400887	2	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (JJ genetic) (NNS influences))))) (, ,) (NP (JJ recent) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ prenatal) (NN drug) (CC or) (NN chemical) (NNS exposures)) (VP (AUX are) (NP (NN risk) (NNS factors)) (PP (IN for) (NP (NN Doc_17400887_386_392_Disease))))))) (. .)))
17400887	3	(S1 (S (NP (NP (NNP Doc_17400887_394_405_Chemical)) (, ,) (NP (NP (DT a) (JJ beta2-adrenoceptor) (NN agonist)) (VP (VBN used) (S (VP (TO to) (VP (VB arrest) (NP (NNP Doc_17400887_451_464_Disease))))))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN concordance)) (PP (IN for) (NP (NP (NNP Doc_17400887_517_523_Disease)) (PP (IN in) (NP (JJ dizygotic) (NNP twins)))))))))) (. .)))
17400887	4	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_17400887_570_581_Chemical))) (PP (IN on) (NP (NP (JJ microglial) (NN activation)) (PP (IN in) (NP (NP (JJ different) (NN brain) (NNS regions)) (CC and) (NP (NP (JJ behavioral) (NNS outcomes)) (PP (IN in) (NP (VBG developing) (NNS rats)))))))))) (. .)))
17400887	5	(S1 (S (NP (JJ Newborn) (NNS rats)) (VP (AUX were) (VP (VP (VBN given) (NP (NP (NNP Doc_17400887_702_713_Chemical) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)) (NN daily)) (PP (IN on) (NP (JJ postnatal) (NNS days))) (PRN (-LRB- -LRB-) (NP (NNP PN)) (-RRB- -RRB-))) (NP (NP (QP (CD 2) (TO to) (CD 5))) (CC or) (NP (QP (CD PN) (CD 11)))) (PP (TO to) (NP (CD 14)))) (CC and) (VP (VBN examined) (NP (CD 24) (NNP h)) (PP (PP (IN after) (NP (DT the) (JJ last) (NN dose))) (CC and) (PP (IN at) (NP (NNP PN) (CD 30))))))) (. .)))
17400887	6	(S1 (S (NP (JJ Immunohistochemical) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_17400887_886_897_Chemical))) (PP (IN on) (NP (NP (NNP PN)) (QP (CD 2) (TO to) (CD 5))))) (VP (VBD produced) (NP (NP (DT a) (JJ robust) (NN increase)) (PP (IN in) (NP (NP (JJ microglial) (NN activation)) (PP (IN on) (NP (NNP PN) (CD 30))))) (PP (IN in) (NP (DT the) (JJ cerebral) (NN cortex))) (, ,) (PP (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (NN cerebellar)) (CC and) (NP (JJ cerebrocortical) (JJ white) (NN matter)))))))))) (. .)))
17400887	7	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (NNS effects)))) (VP (VBD occurred) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN given) (NP (NNP Doc_17400887_1103_1114_Chemical)) (PP (IN on) (S (VP (VBG PN) (NP (CD 11)) (PP (TO to) (NP (CD 14)))))))))) (. .)))
17400887	8	(S1 (S (PP (IN In) (NP (JJ behavioral) (NNS tests))) (, ,) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17400887_1173_1184_Chemical))) (PP (IN on) (NP (QP (CD PN) (CD 2) (TO to) (CD 5)))))) (VP (VBD showed) (NP (NP (JJ consistent) (NNS patterns)) (PP (IN of) (NP (NN hyper-reactivity)))) (PP (TO to) (NP (NP (NN novelty)) (CC and) (NP (JJ aversive) (NNS stimuli)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN assessed) (PP (PP (IN in) (NP (DT a) (JJ novel) (JJ open) (NN field))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (DT the) (JJ acoustic) (JJ startle) (NN response) (NN test)))))))) (. .)))
17400887	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP indicate) (SBAR (S (NP (NP (DT that) (JJ beta2-adrenoceptor) (NN overstimulation)) (PP (IN during) (NP (DT an) (JJ early) (JJ critical) (NN period)))) (VP (VBZ results) (PP (IN in) (NP (NP (JJ microglial) (NN activation)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ innate) (NN neuroinflammatory) (NNS pathways)) (CC and) (NP (NP (NNP Doc_17400887_1545_1569_Disease)) (, ,) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN described) (PP (IN in) (NP (NNP Doc_17400887_1601_1607_Disease))))))))))))))))) (. .)))
17400887	10	(S1 (S (NP (DT This) (NN study)) (VP (VBZ provides) (NP (NP (DT a) (JJ useful) (NN animal) (NN model)) (PP (IN for) (S (VP (VBG understanding) (NP (NP (DT the) (JJ neuropathological) (NNS processes)) (VP (VBG underlying) (NP (NN Doc_17400887_1712_1737_Disease))))))))) (. .)))
17437408	0	(S1 (S (NP (NP (NN Upregulation)) (PP (IN of) (NP (NP (NN brain) (NN expression)) (PP (IN of) (NP (NNP P-glycoprotein))))) (PP (IN in) (NP (NP (JJ MRP2-deficient) (NNS TR)) (SBAR (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NNS rats))))))) (VP (VBZ resembles) (NP (NP (JJ Doc_17437408_90_97_Disease-induced) (NN up-regulation)) (PP (IN of) (NP (DT this) (NN drug) (NN efflux) (NN transporter))) (PP (IN in) (NP (JJ normal) (NNS rats))))) (. .)))
17437408	1	(S1 (S (NP (NP (NP (DT The) (JJ multidrug) (NN resistance) (NN protein)) (NP (CD 2))) (PRN (-LRB- -LRB-) (NP (NNP MRP2)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (NN drug) (NN efflux) (NN transporter)) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX is) (VP (VBN expressed) (ADVP (RB predominantly)) (PP (IN at) (NP (NP (DT the) (JJ apical) (NN domain)) (PP (IN of) (NP (NNS hepatocytes))))))) (CC but) (VP (VBZ seems) (S (ADVP (RB also)) (VP (TO to) (VP (AUX be) (VP (VBN expressed) (PP (IN at) (NP (NP (DT the) (JJ apical) (NN membrane)) (PP (IN of) (NP (NP (NN brain) (NN capillary) (NN endothelial) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP form) (NP (NP (DT the) (JJ blood-brain) (NN barrier)) (PRN (-LRB- -LRB-) (NP (NNP BBB)) (-RRB- -RRB-)))))))))))))))))))) (. .)))
17437408	2	(S1 (S (NP (NNP MRP2)) (VP (AUX is) (ADJP (JJ absent)) (PP (IN in) (NP (DT the) (NN transport-deficient))) (PRN (-LRB- -LRB-) (NNP TR) (-LRB- -LRB-) (S (NP (LST (: -) (-RRB- -RRB-) (-RRB- -RRB-)) (NNP Wistar) (NN rat)) (ADJP (JJ mutant))) (, ,)) (SBAR (RB so) (IN that) (S (NP (DT this) (NN rat) (NN strain)) (VP (AUX was) (ADJP (RB very) (JJ helpful) (PP (IN in) (S (VP (VBG defining) (NP (NNS substrates)) (PP (IN of) (NP (NNP MRP2))) (PP (IN by) (S (VP (VBG comparing) (NP (NP (NN tissue) (NNS concentrations)) (CC or) (NP (NP (JJ functional) (NNS activities)) (PP (IN of) (NP (NNS compounds))))) (PP (IN in) (NP (NP (JJ MRP2-deficient) (NNS rats)) (PP (IN with) (NP (NP (DT those)) (PP (IN in) (NP (JJ transport-competent) (NNP Wistar) (NNS rats)))))))))))))))))) (. .)))
17437408	3	(S1 (S (PP (IN By) (S (VP (VBG using) (NP (DT this) (NN strategy)) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NN MRP2))) (PP (IN in) (NP (NP (NN brain) (NN access)) (PP (IN of) (NP (NP (JJ antiepileptic) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS AEDs)) (-RRB- -RRB-))))))))))))) (, ,) (NP (PRP we)) (ADVP (RB recently)) (VP (VBD reported) (SBAR (IN that) (S (NP (NNP Doc_17437408_861_870_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NP (NNS MRP2)) (PP (IN in) (NP (DT the) (NNP BBB)))))))))) (. .)))
17437408	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (CD one) (NN drawback)) (PP (IN of) (NP (JJ such) (NNS studies))) (PP (IN in) (NP (ADJP (RB genetically) (JJ deficient)) (NNS rats)))) (VP (AUX is) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NP (JJ compensatory) (NNS changes)) (PP (IN with) (NP (NP (NN upregulation)) (PP (IN of) (NP (JJ other) (NNS transporters)))))) (VP (MD can) (VP (VB occur))))))) (. .)))
17437408	5	(S1 (S (NP (DT This)) (VP (VBD prompted) (NP (PRP us)) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN brain) (NN expression)) (PP (IN of) (NP (NP (NP (NNP P-glycoprotein)) (PRN (-LRB- -LRB-) (NP (NNP Pgp)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ major) (NN drug) (NN efflux) (NN transporter)) (PP (IN in) (NP (JJ many) (NNS tissues))) (, ,) (PP (VBG including) (NP (NP (DT the) (NNP BBB)) (, ,) (PP (IN in) (NP (NNP TR) (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NNS rats)) (PP (VBN compared) (PP (IN with) (NP (JJ nonmutant) (PRN (-LRB- -LRB-) (JJ wild-type) (-RRB- -RRB-)) (NNP Wistar) (NNS rats)))))))))))))))) (. .)))
17437408	6	(S1 (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NNP MRP2)) (CC and) (NP (NNP Pgp)))) (PP (IN in) (NP (NP (NN brain) (CC and) (NN liver) (NNS sections)) (PP (IN of) (NP (NNP TR) (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NNS rats)) (CC and) (NP (JJ normal) (NNP Wistar) (NNS rats))))))) (VP (AUX was) (VP (VBN determined) (PP (IN with) (NP (NN immunohistochemistry))) (, ,) (PP (IN by) (S (VP (VBG using) (NP (NP (DT a) (JJ novel) (, ,) (ADJP (RB highly) (JJ selective)) (JJ monoclonal) (NN MRP2) (NN antibody)) (CC and) (NP (NP (DT the) (JJ monoclonal) (NNP Pgp) (NN antibody)) (NP (NP (CD C219)) (, ,) (ADVP (RB respectively)))))))))) (. .)))
17437408	7	(S1 (S (NP (NP (JJ Immunofluorescence) (NN staining)) (PP (IN with) (NP (DT the) (JJ MRP2) (NN antibody)))) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VB label) (NP (NP (DT a) (JJ high) (NN number)) (PP (IN of) (NP (NNS microvessels)))) (PP (IN throughout) (NP (NP (DT the) (NN brain)) (PP (IN in) (NP (JJ normal) (NNP Wistar) (NNS rats)))))))) (, ,) (SBAR (IN whereas) (S (NP (JJ such) (VBG labeling)) (VP (AUX was) (ADJP (JJ absent) (PP (IN in) (S (VP (VBG TR) (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NNS rats)))))))))))) (. .)))
17437408	8	(S1 (S (NP (NNP TR)) (-LRB- -LRB-) (LST (: -) (-RRB- -RRB-)) (NP (NNS rats)) (VP (VBD exhibited) (NP (NP (DT a) (JJ significant) (NN up-regulation)) (PP (IN of) (NP (NNP Pgp))) (PP (IN in) (NP (NN brain) (NN capillary) (JJ endothelial) (NNS cells)))) (PP (VBN compared) (PP (IN with) (NP (JJ wild-type) (NNS controls))))) (. .)))
17437408	9	(S1 (S (NP (NP (DT No) (JJ such) (JJ obvious) (NN upregulation)) (PP (IN of) (NP (NNP Pgp)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NN liver) (NNS sections))))) (. .)))
17437408	10	(S1 (S (NP (NP (DT A) (JJ comparable) (NN overexpression)) (PP (IN of) (NP (NNP Pgp))) (PP (IN in) (NP (DT the) (NNP BBB)))) (VP (AUX was) (VP (VBN obtained) (PP (IN after) (NP (NP (JJ Doc_17437408_1987_1998_Chemical-induced) (NN Doc_17437408_2007_2015_Disease)) (PP (IN in) (NP (JJ wild-type) (JJ Wistar) (NNS rats))))))) (. .)))
17437408	11	(S1 (S (S (NP (NP (NNS Experiments)) (PP (IN with) (NP (NP (JJ systemic) (NN administration)) (PP (IN of) (NP (DT the) (NNP Pgp)))))) (VP (VBP substrate) (NP (NP (NNP Doc_17437408_2104_2117_Chemical)) (CC and) (NP (DT the) (JJ selective) (NNP Pgp) (FW inhibitor) (NNP Doc_17437408_2150_2160_Chemical))) (PP (IN in) (NP (NNP TR))))) (LST (-LRB- -LRB-) (: -) (-RRB- -RRB-)) (NP (NNS rats)) (VP (VBD substantiated) (SBAR (IN that) (S (NP (NNP Pgp)) (VP (VP (AUX is) (ADJP (JJ functional))) (CC and) (VP (VBZ compensates) (PP (IN for) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (NNS MRP2)) (PP (IN in) (NP (DT the) (NNP BBB)))))))))))) (. .)))
17437408	12	(S1 (S (NP (NP (DT The) (NNS data)) (PP (IN on) (S (VP (VBG TR) (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NNS rats))))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Pgp)) (VP (VBZ plays) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN compensation)) (PP (IN of) (NP (CD MRP2) (NN deficiency))) (PP (IN in) (NP (DT the) (NNP BBB)))))))))) (. .)))
17437408	13	(S1 (S (SBAR (IN Because) (S (NP (PDT such) (DT a) (JJ compensatory) (NN mechanism)) (ADVP (RBS most) (RB likely)) (VP (VBZ occurs) (S (VP (TO to) (VP (VB reduce) (NP (NNP Doc_17437408_2457_2476_Disease)) (PP (IN from) (NP (JJ cytotoxic) (NNS compounds))))))))) (, ,) (NP (DT the) (JJ present) (NNS data)) (VP (VB substantiate) (NP (NP (DT the) (NN concept)) (SBAR (WHNP (WDT that)) (S (ADVP (RB MRP2)) (VP (VBZ performs) (NP (NP (DT a) (JJ protective) (NN role)) (PP (IN in) (NP (DT the) (NNP BBB))))))))) (. .)))
17437408	14	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP$ our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNS TR) (S (LST (-LRB- -LRB-) (: -)) (-RRB- -RRB-) (NP (NNS rats)))) (VP (AUX are) (NP (NP (DT an) (JJ interesting) (NN tool)) (SBAR (S (VP (TO to) (VP (VB study) (NP (NP (NNS consequences)) (PP (IN of) (NP (NP (NN overexpression)) (PP (IN of) (NP (NNP Pgp))) (PP (IN in) (NP (NP (DT the) (NNP BBB)) (PP (IN on) (NP (NP (NN access)) (PP (IN of) (NP (NNS drugs))))) (PP (IN in) (NP (DT the) (NN brain)))))))) (, ,) (PP (IN without) (NP (NP (DT the) (NN need)) (PP (IN of) (S (VP (VBG inducing) (NP (NP (NNP Doc_17437408_2784_2792_Disease)) (CC or) (NP (JJ other) (JJ Pgp-enhancing) (NNS events))) (PP (IN for) (NP (DT this) (NN purpose))))))))))))))))) (. .)))
17439425	0	(S1 (NP (NP (NN Role)) (PP (IN of) (NP (JJ Doc_17439425_8_16_Chemical) (NN oxidase))) (PP (IN in) (NP (NP (NNP Doc_17439425_28_41_Chemical-induced) (NNP Doc_17439425_50_62_Disease)) (PP (IN in) (NP (NNP rats.) (CD 1))))) (. .)))
17439425	1	(S1 (S (NP (NP (NP (JJ Glucocorticoid-induced) (NNP Doc_17439425_98_110_Disease)) (PRN (-LRB- -LRB-) (NP (NNP GC-Doc_17439425_115_117_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN rat)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17439425_149_161_Chemical-redox) (FW imbalance.) (CD 2))))) (. .)))
17439425	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NP (NNP Doc_17439425_205_213_Chemical) (NNP oxidase)) (PRN (-LRB- -LRB-) (NP (NNP XO)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (JJ reactive) (NN oxygen) (NNS species))))))))) (, ,))) (PP (IN in) (NP (NP (NNP Doc_17439425_297_310_Chemical-induced) (NNP Doc_17439425_319_331_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17439425_333_336_Chemical-Doc_17439425_337_339_Disease)) (-RRB- -RRB-)) (. .) (CD 3))))) (. .)))
17439425	3	(S1 (S (NP (CD Thirty) (JJ male) (NNP Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN divided) (ADVP (RB randomly)) (PP (IN into) (NP (NP (CD four) (NN treatment) (NNS groups)) (: :) (NP (NP (NP (NNP saline)) (, ,) (NP (NNP Doc_17439425_435_448_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17439425_450_453_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_17439425_456_467_Chemical)) (CC plus) (NP (NN saline))) (, ,) (CC and) (NP (NNP Doc_17439425_485_496_Chemical)) (CC plus) (NP (NNP Doc_17439425_502_505_Chemical.) (CD 4))))))) (. .)))
17439425	4	(S1 (S (NP (NP (NP (JJ Systolic) (NN blood) (NNS pressures)) (PRN (-LRB- -LRB-) (NP (NNP SBP)) (-RRB- -RRB-))) (CC and) (NP (NNS bodyweights))) (VP (AUX were) (VP (VBN recorded) (NP (DT each) (JJ alternate) (NN day)))) (. .)))
17439425	5	(S1 (S (S (NP (JJ Thymus) (NN weight)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (JJ glucocorticoid) (NN activity)))))))) (, ,) (CC and) (S (NP (NN serum)) (ADJP (JJ Doc_17439425_664_669_Chemical) (S (VP (TO to) (VP (VB assess) (NP (NN XO) (NN inhibition.) (CD 5))))))) (. .)))
17439425	6	(S1 (NP (NP (NP (NP (NNP Doc_17439425_698_701_Chemical) (NNP Doc_17439425_702_715_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 110) (CD +/-)) (JJ 2-126) (JJ +/-) (CD 3) (NN mmHg)) (: ;) (NP (NNP P) (NNP <) (CD 0.001))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_17439425_758_802_Disease))) (PRN (-LRB- -LRB-) (NP (NNP P) ('' '') (NNP <) (CD 0.01)) (-RRB- -RRB-)) (. .)))
17439425	7	(S1 (S (NP (NNP Doc_17439425_816_827_Chemical)) (VP (VBD decreased) (NP (NN serum)) (NP (NNP Doc_17439425_844_849_Chemical)) (PP (PP (IN from) (NP (NP (NP (QP (CD 76) (JJ +/-) (CD 5) (TO to) (CD 30) (NN +/-))) (NP (NP (QP (CD 3) (CD micromol/L))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-)))) (PP (IN in) (NP (NN saline))))) (CC and) (PP (IN from) (NP (NP (NP (CD 84) (NN +/-)) (NP (QP (CD 13) (TO to) (CD 28)) (JJ +/-) (CD 2) (NNS micromol/L))) (PP (IN in) (NP (JJ Doc_17439425_954_957_Chemical-treated) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)) (JJ groups.) (CD 6))))))) (. .)))
17439425	8	(S1 (S (NP (NN Doc_17439425_988_999_Chemical)) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NN Doc_17439425_1016_1019_Chemical-Doc_17439425_1020_1022_Disease)))) (. .)))
17439425	9	(S1 (S (NP (DT This)) (, ,) (PP (ADVP (RB together)) (IN with) (NP (NP (PRP$ our) (JJ previous) (NNS findings)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_17439425_1071_1082_Chemical)) (VP (VBD failed) (S (VP (TO to) (VP (VB prevent) (NP (NP (JJ adrenocorticotrophic) (NN hormone)) (VP (VBN induced) (NP (NNP Doc_17439425_1138_1150_Disease)))))))))))) (, ,) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN XO) (NN activity)) (VP (AUX is) (RB not) (NP (NP (DT a) (JJ major) (NN determinant)) (PP (IN of) (NP (NN GC-Doc_17439425_1211_1213_Disease)))) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
17466854	0	(S1 (NP (NP (JJ Side) (NNS effects)) (PP (IN of) (NP (NP (NN postoperative) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_17466854_48_66_Chemical)) (CC and) (NP (NNP Doc_17466854_71_81_Chemical)))))) (PP (IN into) (NP (NP (DT the) (NN posterior) (NN sub-Tenon) (POS 's)) (NN space))) (. .)))
17466854	1	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ postoperative) (JJ emetic) (NN side) (NNS effects))) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_17466854_218_236_Chemical) (CC and) (NNP Doc_17466854_241_251_Chemical)))))) (PP (IN into) (NP (NP (DT the) (NN posterior) (NN sub-Tenon) (POS 's)) (NN space))) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (JJ routine) (JJ Doc_17466854_311_319_Disease) (NN surgery)))))))) (. .)))
17466854	2	(S1 (S (NP (NNP St.) (NNP Luke)) (VP (AUX 's) (NP (NNP Hospital) (, ,) (NNP Gwardamangia) (, ,) (NNP Malta))) (. .)))
17466854	3	(S1 (S (NP (DT A) (JJ double-blind) (JJ double-armed) (JJ prospective) (NN study)) (VP (VBN comprised) (NP (NP (CD 40) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (JJ uneventful) (NN sutureless) (NN phacoemulsification)) (PP (IN under) (NP (NP (NP (NN sub-Tenon) (POS 's)) (JJ local) (NN infiltration)) (PP (IN of) (NP (NP (CD 3) (NN mL)) (PP (IN of) (NP (JJ plain) (NNP Doc_17466854_561_571_Chemical)))))))))))) (. .)))
17466854	4	(S1 (S (PP (IN At) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN procedure))))) (, ,) (S (NP (NP (NNP Group) (NNP A)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (NP (NP (QP (CD 20) (CD mg/0.5)) (NNS mL)) (PP (IN of) (NP (NNP Doc_17466854_639_657_Chemical)))) (CC and) (NP (NP (QP (CD 10) (CD mg/0.5)) (NNS mL)) (PP (IN of) (NP (NNP Doc_17466854_678_688_Chemical))))) (VP (VBN injected) (PP (IN into) (NP (NP (DT the) (NN posterior) (NN sub-Tenon) (POS 's)) (NN space))))))) (CC and) (S (NP (NP (NNP Group) (NNP B)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (DT the) (JJ same) (NN combination)) (VP (VBN injected) (PP (IN into) (NP (NP (DT the) (NNP anterior) (NN sub-Tenon) (POS 's)) (NN space))))))) (. .)))
17466854	5	(S1 (S (ADVP (RB Postoperatively)) (, ,) (NP (DT all) (NNS patients)) (VP (AUX were) (VP (VBN assessed) (PP (IN for) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NP (NNP Doc_17466854_887_903_Disease)) (, ,) (CC and) (NP (NNP Doc_17466854_909_917_Disease)))))))) (. .)))
17466854	6	(S1 (S (NP (DT A) (JJ chi-square) (NN test)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ statistical) (NN significance)) (PP (IN of) (NP (NNS results))))))))) (. .)))
17466854	7	(S1 (S (S (NP (NP (CD Sixty) (NN percent)) (PP (IN in) (NP (NNP Group) (NNP A)))) (VP (VBD developed) (NP (NP (NN Doc_17466854_1041_1070_Disease)) (, ,) (NP (NN Doc_17466854_1072_1080_Disease)) (, ,) (CC or) (NP (DT both))))) (: ;) (S (NP (NP (CD 1) (NN patient)) (PP (IN in) (NP (NNP Group) (NNP B)))) (VP (VBD developed) (NP (NNS symptoms)))) (. .)))
17466854	8	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_17466854_1167_1185_Chemical)) (CC and) (NP (NNP Doc_17466854_1190_1200_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN posterior) (NN sub-Tenon) (POS 's)) (NN space)))) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (PP (VBG including) (NP (NP (NNP Doc_17466854_1294_1310_Disease)) (, ,) (CC and) (NP (NNP Doc_17466854_1316_1324_Disease)))))))))) (. .)))
17466854	9	(S1 (S (NP (DT All) (JJ adverse) (NNS effects)) (VP (AUX were) (ADJP (JJ self-limiting))) (. .)))
17491223	0	(S1 (NP (NP (NN Assessment)) (PP (IN of) (NP (NP (DT a) (JJ new) (JJ non-invasive) (NN index)) (PP (IN of) (NP (JJ cardiac) (NN performance))))) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (NNP Doc_17491223_79_89_Chemical-induced) (NNP Doc_17491223_98_117_Disease))))) (. .)))
17491223	1	(S1 (S (NP (NN Electrocardiography)) (VP (AUX has) (NP (NP (DT a) (ADJP (RB very) (JJ low)) (NN sensitivity)) (PP (IN in) (S (VP (VBG detecting) (NP (JJ Doc_17491223_191_201_Chemical-induced) (NNP Doc_17491223_210_229_Disease))))))) (. .)))
17491223	2	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (VBN added) (JJ diagnostic) (NN value)) (PP (IN of) (NP (DT a) (JJ new) (JJ cardiac) (NN performance) (NN index) (PRN (-LRB- -LRB-) (JJ dP/dtejc) (-RRB- -RRB-)) (NN measurement))))))) (, ,) (VP (VBN based) (PP (IN on) (NP (JJ brachial) (NN artery) (NN flow) (NNS changes))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (JJ standard) (JJ 12-lead) (NNS ECG))) (, ,) (PP (IN for) (S (VP (VBG detecting) (NP (JJ Doc_17491223_429_439_Chemical-induced) (NNP Doc_17491223_448_467_Disease))))) (, ,) (S (VP (VBG using) (NP (NNP Doc_17491223_475_490_Chemical) (NN single-photon) (NN emission) (JJ computed) (NN tomography)) (PP (IN as) (NP (NP (DT the) (JJ gold) (NN standard)) (PP (IN of) (NP (NN comparison))) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN presence)) (CC or) (NP (NP (NN absence)) (PP (IN of) (NP (NNP Doc_17491223_606_614_Disease)))))))))))))))) (. .)))
17491223	3	(S1 (S (NP (DT The) (NN study) (NN group)) (VP (VBN comprised) (NP (NP (CD 40) (NNS patients)) (VP (VBG undergoing) (NP (JJ Doc_17491223_674_683_Chemical-SPECT/Doc_17491223_690_700_Chemical) (NN stress) (NN test))))) (. .)))
17491223	4	(S1 (S (NP (NP (JJ Simultaneous) (NNS measurements)) (PP (IN of) (NP (NP (NNS ECG)) (CC and) (NP (JJ brachial) (NN artery) (NNS dP/dtejc))))) (VP (AUX were) (VP (VBN performed) (PP (IN at) (NP (DT each) (JJ Doc_17491223_799_809_Chemical) (NN level))))) (. .)))
17491223	5	(S1 (S (NP (NP (QP (IN In) (CD 19))) (PP (IN of) (NP (DT the) (CD 40) (NNS patients)))) (VP (VBP perfusion) (SBAR (S (NP (NP (NNS defects)) (ADJP (JJ compatible) (PP (IN with) (NP (NNP Doc_17491223_876_884_Disease))))) (VP (AUX were) (VP (VBN detected) (PP (IN on) (NP (NN SPECT)))))))) (. .)))
17491223	6	(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN in) (NP (NN dP/dtejc))) (PP (IN during) (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_17491223_953_963_Chemical))))) (PP (IN in) (NP (DT this) (NN group)))) (VP (AUX was) (ADJP (RB severely) (JJ impaired)) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (DT the) (JJ non-ischemic) (NN group))))))) (. .)))
17491223	7	(S1 (S (NP (JJ dP/dtejc) (NN outcome)) (VP (AUX was) (VP (VP (VBN combined) (PP (IN with) (NP (DT the) (JJ ECG) (NNS results))) (, ,) (S (VP (VBG giving) (NP (DT an) (JJ ECG-enhanced) (NN value))))) (, ,) (CC and) (VP (VBN compared) (S (VP (TO to) (VP (VB ECG) (ADVP (RB alone)))))))) (. .)))
17491223	8	(S1 (S (S (NP (DT The) (NN sensitivity)) (VP (VBD improved) (ADVP (RB dramatically) (PP (IN from) (NP (CD 16) (NN %)))) (PP (TO to) (NP (CD 79) (NN %))))) (, ,) (S (NP (JJ positive) (JJ predictive) (NN value)) (VP (VBD increased) (PP (IN from) (NP (NP (QP (CD 60) (NN %) (TO to) (CD 68)) (NN %)) (CC and) (NP (JJ negative) (JJ predictive) (NN value)))) (PP (IN from) (NP (CD 54) (NN %))) (PP (TO to) (NP (CD 78) (NN %))))) (, ,) (CC and) (S (NP (NN specificity)) (VP (VBD decreased) (PP (IN from) (NP (CD 90) (NN %))) (PP (TO to) (NP (CD 67) (NN %))))) (. .)))
17491223	9	(S1 (S (SBAR (IN If) (S (NP (NP (NN ECG)) (ADVP (RB alone))) (VP (AUX is) (VP (VBN used) (PP (IN for) (NP (NN specificity))))))) (, ,) (NP (NP (DT the) (NN combination)) (PP (IN with) (NP (NNS dP/dtejc)))) (VP (VP (VBD improved) (NP (NP (DT the) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN test))))) (CC and) (VP (MD could) (VP (AUX be) (NP (NP (DT a) (JJ cost-savings) (NN alternative)) (PP (TO to) (NP (JJ cardiac) (NN imaging) (CC or) (NN perfusion) (NNS studies)))) (S (VP (TO to) (VP (VB detect) (NP (NNP Doc_17491223_1562_1581_Disease))))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (ADJP (JJ unable) (PP (TO to) (NP (NN exercise))))))))) (. .)))
1749407	0	(S1 (NP (NP (JJ Doc_1749407_0_7_Chemical-induced) (NNP Doc_1749407_16_37_Disease)) (: :) (NP (NP (JJ clinical) (NNS observations)) (CC and) (NP (JJ pathogenetic) (NNS considerations))) (. .)))
1749407	1	(S1 (S (NP (NP (ADJP (ADJP (JJ Clinical)) (CC and) (ADJP (JJ experimental))) (NNS data)) (VP (VBN published) (PP (TO to) (NP (NN date))))) (VP (VBP suggest) (NP (NP (JJ several) (JJ possible) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_1749407_188_195_Chemical)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NNP Doc_1749407_210_237_Disease))))))))) (. .)))
1749407	2	(S1 (S (PP (IN In) (NP (NP (NNS individuals)) (PP (IN with) (NP (NN preexisting))))) (, ,) (NP (NP (JJ high-grade) (JJ coronary) (NN arterial) (NN narrowing)) (, ,) (NP (NNP Doc_1749407_312_339_Disease))) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ myocardial) (JJ Doc_1749407_382_388_Chemical) (NN demand)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_1749407_412_419_Chemical-induced) (NN increase)) (PP (IN in) (NP (JJ rate-pressure) (NN product)))))))))))) (. .)))
1749407	3	(S1 (S (PP (IN In) (NP (NP (JJ other) (NNS individuals)) (PP (IN with) (NP (DT no) (JJ underlying) (NN Doc_1749407_503_530_Disease))))) (, ,) (NP (NNP Doc_1749407_532_550_Disease)) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_1749407_565_570_Disease)) (, ,) (NP (NNP Doc_1749407_572_580_Disease)) (, ,) (CC or) (NP (DT both))))))) (. .)))
1749407	4	(S1 (S (PP (IN With) (NP (NP (NN regard)) (PP (TO to) (NP (NNP Doc_1749407_606_611_Disease))))) (, ,) (S (NP (DT the) (JJ clinical) (NNS findings)) (VP (AUX are) (ADVP (RB largely)) (NP (NN circumstantial)))) (, ,) (CC and) (S (NP (NP (DT the) (NN locus)) (PP (IN of) (NP (JJ Doc_1749407_680_687_Chemical-induced) (NN vasoconstriction)))) (VP (VBZ remains) (ADJP (JJ speculative)))) (. .)))
1749407	5	(S1 (S (SBAR (IN Although) (S (NP (JJ certain) (JJ clinical) (CC and) (JJ experimental) (NNS findings)) (VP (VBP support) (NP (NP (DT the) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_1749407_814_819_Disease)) (VP (VBZ involves) (NP (DT the) (JJ epicardial) (, ,) (JJ medium-size) (NNS vessels))))))))) (, ,) (NP (JJ other) (NNS data)) (VP (VBP suggest) (NP (JJ intramural) (NN vasoconstriction))) (. .)))
1749407	6	(S1 (S (NP (JJ Diffuse) (NN intramural) (NN vasoconstriction)) (VP (AUX is) (RB not) (ADJP (JJ consistent) (PP (IN with) (NP (NP (NNS reports)) (PP (IN of) (NP (JJ segmental) (, ,) (JJ discrete) (NNP Doc_1749407_1004_1014_Disease))))))) (. .)))
1749407	7	(S1 (S (SBAR (IN Whereas) (S (ADJP (JJ certain)) (SBAR (IN in) (S (NP (NN vivo) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT these) (NNS effects)) (VP (AUX are) (ADJP (JJ alpha-mediated)))))))))) (, ,) (NP (JJ other) (ADJP (IN in) (NN vitro)) (NNS data)) (VP (VBP suggest) (NP (DT the) (NN opposite))) (. .)))
1749407	8	(S1 (S (NP (NP (DT The) (NN finding)) (PP (IN of) (NP (JJ Doc_1749407_1149_1156_Chemical-induced) (NN vasoconstriction))) (PP (IN in) (NP (NP (NNS segments)) (PP (IN of) (NP (PRN (-LRB- -LRB-) (JJ noninnervated) (-RRB- -RRB-)) (JJ human) (NN umbilical) (NN artery)))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (JJ intact) (NN innervation)))) (VP (AUX is) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB explain) (NP (NP (DT the) (JJ discrepant) (NNS data)) (VP (VBG involving) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ alpha-mediated) (NNS effects)))))))))))))) (. .)))
1749407	9	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (NP (DT a) (JJ primary) (, ,) (JJ Doc_1749407_1438_1448_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_1749407_1459_1466_Chemical)))))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN excluded)))) (. .)))
17532790	0	(S1 (NP (NP (JJ Proteomic) (NN analysis)) (PP (IN of) (NP (NP (JJ striatal) (NNS proteins)) (PP (IN in) (NP (NP (DT the) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_17532790_60_66_Chemical-induced) (NNP Doc_17532790_75_85_Disease))))))) (. .)))
17532790	1	(S1 (S (NP (NP (JJ Doc_17532790_87_93_Chemical-induced) (NNP Doc_17532790_102_112_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17532790_114_117_Disease)) (-RRB- -RRB-))) (VP (AUX is) (PP (IN among) (NP (NP (DT the) (NN motor) (NNS complications)) (SBAR (WHNP (WDT that)) (S (VP (VBP arise) (PP (IN in) (NP (NNP Doc_17532790_166_185_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_17532790_187_189_Disease)) (-RRB- -RRB-)) (NNS patients))) (PP (IN after) (NP (NP (DT a) (JJ prolonged) (NN treatment)) (PP (IN with) (NP (NNP Doc_17532790_233_239_Chemical))))))))))) (. .)))
17532790	2	(S1 (S (PP (TO To) (NP (DT this) (NN day))) (, ,) (NP (JJ transcriptome) (NN analysis)) (VP (AUX has) (VP (AUX been) (VP (VBN performed) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (JJ Doc_17532790_314_317_Disease) (NN -LSB-Neurobiol)))))))) (. .)))
17532790	3	(S1 (S (NP (NP (NP (NN Dis.)) (, ,) (NP (NP (CD 17)) (PRN (-LRB- -LRB-) (NP (CD 2004)) (-RRB- -RRB-))) (, ,) (NP (CD 219) (NN -RSB-)) (CC but) (NP (NN information))) (VP (VBG regarding) (NP (DT the) (NN proteome)))) (VP (AUX is) (ADVP (RB still)) (VP (VBG lacking))) (. .)))
17532790	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS changes)) (VP (VBG occurring) (PP (IN at) (NP (DT the) (NN protein) (NN level))) (PP (IN in) (NP (NP (JJ striatal) (NNS samples)) (VP (VBN obtained) (PP (IN from) (NP (NP (NP (DT the) (ADJP (RB unilaterally) (JJ Doc_17532790_541_558_Chemical-lesion)) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_17532790_579_581_Disease))) (VP (VBN treated) (PP (IN with) (NP (NN saline))))) (, ,) (NP (NNP Doc_17532790_603_609_Chemical)) (CC or) (NP (NNP Doc_17532790_613_626_Chemical)))) (S (VP (VBG using) (NP (NP (JJ two-dimensional) (NN difference) (NN gel) (NNS electrophoresis)) (CC and) (NP (NP (JJ mass) (NN spectrometry)) (PRN (-LRB- -LRB-) (NP (NNP MS)) (-RRB- -RRB-)))))))))))) (. .)))
17532790	5	(S1 (S (NP (NP (NNS Rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17532790_726_732_Chemical))))) (VP (AUX were) (VP (VBN allocated) (PP (TO to) (NP (NP (CD two) (NNS groups)) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (NN Doc_17532790_798_801_Disease)))))))))) (. .)))
17532790	6	(S1 (S (PP (IN Among) (NP (NP (DT the) (CD 2000) (NNS spots)) (PP (VBN compared) (PP (IN for) (NP (JJ statistical) (NN difference)))))) (, ,) (NP (CD 67) (NNS spots)) (VP (VP (AUX were) (VP (ADVP (RB significantly)) (VBN changed) (PP (IN in) (NP (NN abundance))))) (CC and) (VP (VBN identified) (S (VP (VBG using) (NP (NP (JJ matrix-assisted) (NN laser) (NN desorption/ionization) (NN time-of-flight) (NNS MS)) (, ,) (NP (JJ atmospheric) (NN pressure) (JJ matrix-assisted) (NN laser) (NN desorption/ionization)) (CC and) (NP (NP (JJ HPLC) (VBN coupled) (NN tandem) (NNS MS)) (PRN (-LRB- -LRB-) (NP (NNP LC/MS/MS)) (-RRB- -RRB-)))))))) (. .)))
17532790	7	(S1 (S (PP (IN Out) (PP (IN of) (NP (DT these) (CD 67) (NNS proteins)))) (, ,) (NP (NNP Doc_17532790_1124_1127_Disease)) (ADVP (RB significantly)) (VP (VBD changed) (NP (NP (DT the) (NN expression) (NN level)) (PP (IN of) (NP (NP (CD five) (NNS proteins)) (: :) (NP (NP (NN alphabeta-crystalin)) (, ,) (NP (NN gamma-enolase)) (, ,) (NP (NN guanidoacetate) (NN methyltransferase)) (, ,) (NP (NN vinculin)) (, ,) (CC and) (NP (JJ proteasome) (JJ alpha-2) (NN subunit))))))) (. .)))
17532790	8	(S1 (S (NP (NP (JJ Complementary) (NNS techniques)) (PP (JJ such) (IN as) (NP (NP (JJ western) (NN immunoblotting)) (CC and) (NP (NN immunohistochemistry))))) (VP (AUX were) (VP (VBN performed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN validity)) (PP (IN of) (NP (NP (DT the) (NNS data)) (VP (VBN obtained) (S (VP (VBG using) (NP (DT the) (JJ proteomic) (NN approach))))))))))))) (. .)))
17532790	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT this) (NN study)) (VP (VBZ provides) (NP (NP (JJ new) (NNS insights)) (PP (IN into) (NP (NP (DT the) (NN protein) (NNS changes)) (VP (VBG occurring) (PP (IN in) (NP (NNP Doc_17532790_1562_1565_Disease)))))))) (. .)))
17562951	0	(S1 (NP (NP (NP (NNP Cardiac) (NNP Angiography)) (PP (IN in) (NP (NNP Renally) (JJ Impaired) (NNPS Patients) (PRN (-LRB- -LRB-) (NP (NN CARE)) (-RRB- -RRB-)) (NN study)))) (: :) (NP (NP (DT a) (JJ randomized) (NN double-blind) (NN trial)) (PP (IN of) (NP (JJ contrast-induced) (NNP Doc_17562951_115_126_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17562951_144_166_Disease)))))) (. .)))
17562951	1	(S1 (S (NP (DT No) (JJ direct) (NNS comparisons)) (VP (VBP exist) (PP (IN of) (NP (NP (DT the) (JJ renal) (NN tolerability)) (PP (IN of) (NP (DT the) (JJ low-osmolality) (NNP Doc_17562951_256_271_Chemical) (NNP Doc_17562951_272_281_Chemical))))) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (JJ iso-osmolality) (NNP Doc_17562951_314_329_Chemical) (NNP Doc_17562951_330_339_Chemical)) (PP (IN in) (NP (JJ high-risk) (NNS patients)))))))) (. .)))
17562951	2	(S1 (FRAG (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (NP (DT The) (JJ present) (NN study)) (VP (AUX is) (NP (NP (DT a) (NN multicenter) (, ,) (VBN randomized) (, ,) (JJ double-blind) (NN comparison)) (PP (IN of) (NP (NP (NNP Doc_17562951_459_468_Chemical) (CC and) (NNP Doc_17562951_473_482_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17562951_500_522_Disease))) (PRN (-LRB- -LRB-) (NP (NP (JJ estimated) (JJ glomerular) (NN filtration) (NN rate)) (, ,) (NP (QP (CD 20) (TO to) (CD 59)) (NN mL/min))) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (JJ cardiac) (NN angiography)) (CC or) (NP (JJ percutaneous) (JJ coronary) (NNS interventions))))))))))))) (. .)))
17562951	3	(S1 (S (NP (NP (NNP Serum) (NNP Doc_17562951_659_669_Chemical) (PRN (-LRB- -LRB-) (NP (NNP SCr)) (-RRB- -RRB-)) (NNS levels)) (CC and) (NP (VBN estimated) (JJ glomerular) (NN filtration) (NN rate))) (VP (VP (AUX were) (VP (VBN assessed) (PP (IN at) (NP (NN baseline))))) (CC and) (VP (NP (QP (CD 2) (TO to) (CD 5)) (NNS days)) (PP (IN after) (S (VP (VBG receiving) (NP (NNS medications))))))) (. .)))
17562951	4	(S1 (S (NP (DT The) (JJ primary) (NN outcome)) (VP (AUX was) (NP (NP (DT a) (JJ postdose) (NN SCr) (NN increase)) (VP (VBG >) (NP (QP (CC or) (SYM =) (CD 0.5) (CD mg/dL)) (PRN (-LRB- -LRB-) (NP (CD 44.2) (NNS micromol/L)) (-RRB- -RRB-))) (PP (IN over) (NP (NN baseline)))))) (. .)))
17562951	5	(S1 (S (NP (JJ Secondary) (NNS outcomes)) (VP (AUX were) (NP (NP (NP (DT a) (JJ postdose) (NNP SCr) (NN increase)) (VP (VBG >) (CC or) (SYM =) (NP (CD 25) (NN %)))) (, ,) (NP (NP (DT a) (JJ postdose) (JJ estimated) (JJ glomerular) (NN filtration) (NN rate) (NN decrease)) (PP (IN of) (NP (NP (NNS >)) (CC or) (NP (NP (SYM =)) (NP (CD 25) (NN %)))))) (, ,) (CC and) (NP (NP (DT the) (JJ mean) (JJ peak) (NN change)) (PP (IN in) (NP (NNP SCr)))))) (. .)))
17562951	6	(S1 (S (PP (IN In) (NP (CD 414) (NNS patients))) (, ,) (NP (NP (NN contrast) (NN volume)) (, ,) (NP (NP (NN presence)) (PP (IN of) (NP (NNP Doc_17562951_1104_1121_Disease)))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NNP Doc_17562951_1130_1146_Chemical)) (, ,) (NP (JJ mean) (NN baseline) (NN SCr)) (, ,)))) (CC and) (NP (VBN estimated) (JJ glomerular) (NN filtration) (NN rate))) (VP (AUX were) (ADJP (JJ comparable)) (PP (IN in) (NP (DT the) (CD 2) (NNS groups)))) (. .)))
17562951	7	(S1 (S (NP (NNP SCr) (NNS increases)) (VP (VBG >) (CC or) (SYM =) (S (NP (CD 0.5) (NN mg/dL)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (NP (CD 4.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 9)) (PP (IN of) (NP (CD 204) (NNS patients)))) (-RRB- -RRB-))) (PP (IN after) (NP (NNP Doc_17562951_1315_1324_Chemical)))) (CC and) (NP (NP (CD 6.7) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 14)) (PP (IN of) (NP (CD 210) (NNS patients)))) (-RRB- -RRB-))))) (PP (IN after) (NP (NP (NNP Doc_17562951_1361_1370_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P=0.39)) (-RRB- -RRB-)))) (, ,) (PP (IN whereas) (NP (NP (NNS rates)) (PP (IN of) (NP (NNP SCr) (NNS increases) (NNP >) (CC or) (SYM =) (S (NP (CD 25) (NN %)) (VP (AUX were) (NP (NP (NP (CD 9.8) (NN %)) (CC and) (NP (CD 12.4) (NN %)) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NNP P=0.44)) (-RRB- -RRB-)))))))))))) (. .)))
17562951	8	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17562951_1484_1492_Disease))))) (, ,) (S (NP (NNP SCr) (NNS increases) (NNP >) (CC or) (SYM =)) (NP (CD 0.5) (NN mg/dL)) (VP (AUX were) (NP (NP (NP (NP (CD 5.1) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 4)) (PP (IN of) (NP (CD 78) (NNS patients)))) (-RRB- -RRB-))) (PP (IN with) (NP (NNP Doc_17562951_1559_1568_Chemical)))) (CC and) (NP (NP (NP (CD 13.0) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 12)) (PP (IN of) (NP (CD 92) (NNS patients)))) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NNP Doc_17562951_1604_1613_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P=0.11)) (-RRB- -RRB-)))))))) (, ,) (IN whereas) (S (NP (NNP SCr) (NNS increases) (NNP >) (CC or) (SYM =)) (NP (CD 25) (NN %)) (VP (AUX were) (NP (NP (CD 10.3) (NN %)) (CC and) (NP (CD 15.2) (NN %))) (, ,) (ADVP (RB respectively)) (PRN (-LRB- -LRB-) (NP (NNP P=0.37)) (-RRB- -RRB-)))) (. .)))
17562951	9	(S1 (S (NP (JJ Mean) (NN post-SCr) (NNS increases)) (VP (AUX were) (ADJP (RB significantly) (JJR less)) (PP (IN with) (NP (NP (NNP Doc_17562951_1755_1764_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (DT all) (NNS patients)) (: :) (NP (NP (NP (CD 0.07)) (PP (IN versus) (NP (CD 0.12) (CD mg/dL) (, ,) (CD 6.2) (CC versus) (CD 10.6) (NN micromol/L)))) (, ,) (NP (NNP P=0.03))) (: ;) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17562951_1854_1862_Disease))))) (: :) (NP (NP (CD 0.07)) (CC versus) (NP (CD 0.16) (CD mg/dL) (, ,) (CD 6.2) (CC versus) (CD 14.1) (NN micromol/L)))) (, ,) (NP (NNP P=0.01)) (-RRB- -RRB-))))) (. .)))
17562951	10	(S1 (S (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (JJ contrast-induced) (NNP Doc_17562951_1967_1978_Disease))) (, ,) (VP (VBN defined) (PP (IN by) (NP (JJ multiple) (NN end) (NNS points)))) (, ,)) (VP (AUX is) (RB not) (ADJP (RB statistically) (JJ different)) (PP (IN after) (NP (NP (DT the) (JJ intraarterial) (NN administration)) (PP (IN of) (NP (NNP Doc_17562951_2085_2094_Chemical) (CC or) (NNP Doc_17562951_2098_2107_Chemical))) (PP (TO to) (NP (JJ high-risk) (NNS patients))))) (, ,) (PP (IN with) (CC or) (PP (IN without) (NP (NNP Doc_17562951_2147_2164_Disease))))) (. .)))
17562951	11	(S1 (S (NP (NP (DT Any) (JJ true) (NN difference)) (PP (IN between) (NP (DT the) (NNS agents)))) (VP (VP (AUX is) (ADJP (JJ small))) (CC and) (RB not) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX be) (ADJP (RB clinically) (JJ significant))))))) (. .)))
17600377	0	(S1 (S (NP (NP (DT A) (JJ novel) (NN compound)) (, ,) (NP (NNP Doc_17600377_18_38_Chemical)) (, ,)) (VP (VP (VBZ attenuates) (NP (NNP Doc_17600377_51_69_Disease))) (CC and) (VP (VBZ shows) (NP (NP (JJ neuroprotective) (NNS effects)) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo) (NN Doc_17600377_125_133_Disease) (NNS models))))))) (. .)))
17600377	1	(S1 (S (S (VP (TO To) (VP (VB develop) (NP (NP (DT a) (ADJP (JJ novel) (CC and) (JJ effective)) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB enhance) (NP (NP (JJ cognitive) (NN function)) (CC and) (NP (NN neuroprotection))))))))))) (, ,) (NP (PRP we)) (ADVP (RB newly)) (VP (VBD synthesized) (NP (NNP Doc_17600377_260_280_Chemical)) (PP (IN by) (NP (NP (DT the) (NN esterification)) (PP (IN of) (NP (NP (NNP Doc_17600377_306_312_Chemical)) (CC and) (NP (NNP Doc_17600377_317_332_Chemical))))))) (. .)))
17600377	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NNP Doc_17600377_380_400_Chemical)) (VP (MD could) (VP (VB improve) (NP (NN Doc_17600377_415_432_Disease)) (PP (PP (IN in) (NP (JJ Doc_17600377_436_447_Chemical-injected) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Doc_17600377_469_495_Chemical-infused) (NNS rats))))))))) (. .)))
17600377	3	(S1 (S (NP (NN Doc_17600377_510_530_Chemical)) (VP (AUX was) (VP (VBN found) (S (VP (VP (TO to) (VP (VB attenuate) (NP (NNP Doc_17600377_554_572_Disease)) (PP (IN in) (NP (DT both) (NN rat) (NNS models))) (S (VP (VBG using) (NP (JJ passive) (NN avoidance) (NN test)))))) (CC and) (VP (TO to) (VP (VB reduce) (NP (NP (JJ apoptotic) (NN cell) (NN death)) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN hippocampus)) (PP (IN of) (NP (DT the) (JJ Doc_17600377_691_717_Chemical-infused) (NNS rats))))))))))))) (. .)))
17600377	4	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD examined) (NP (NP (DT the) (JJ neuroprotective) (NNS effects)) (PP (IN of) (NP (NNP Doc_17600377_780_800_Chemical))) (PP (IN in) (NP (NN vitro)))) (S (VP (VBG using) (NP (JJ SH-SY5Y) (NNS cells))))) (. .)))
17600377	5	(S1 (S (NP (NNS Cells)) (VP (AUX were) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_17600377_858_878_Chemical))) (, ,) (SBAR (IN before) (S (VP (VBN exposed) (PP (TO to) (NP (NP (NNP Doc_17600377_898_924_Chemical)) (, ,) (NP (NNP Doc_17600377_926_935_Chemical)) (CC or) (NP (NNP Doc_17600377_939_943_Chemical))))))))) (. .)))
17600377	6	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NNP Doc_17600377_959_979_Chemical)) (VP (VP (ADVP (RB significantly)) (VBD decreased) (NP (JJ apoptotic) (NN cell) (NN death))) (CC and) (VP (VBD reduced) (NP (NP (JJ reactive) (NN oxygen) (NNS species)) (, ,) (NP (NN cytochrome) (NN c) (NN release)) (, ,) (CC and) (NP (NN caspase) (CD 3) (NN activation)))))))) (. .)))
17600377	7	(S1 (S (S (VP (VBG Taking) (NP (DT these)) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NP (NN vivo) (NNS results)) (ADVP (RB together))))))) (, ,) (NP (PRP$ our) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_17600377_1186_1206_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ effective)) (NN candidate)) (PP (IN against) (NP (NNP Doc_17600377_1252_1271_Disease))) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ wide) (NN spread) (NN Doc_17600377_1309_1323_Disease)) (CC and) (NP (JJ progressive) (NN Doc_17600377_1340_1369_Disease))))))))))))) (. .)))
17608141	0	(S1 (NP (NP (NN Attenuation)) (PP (IN of) (NP (NP (JJ Doc_17608141_15_30_Chemical-induced) (JJ nigrostriatal) (JJ dopaminergic) (NN Doc_17608141_66_79_Disease)) (PP (IN in) (NP (NNS mice))))) (PP (IN by) (NP (JJ Doc_17608141_91_109_Chemical) (NN pretreatment))) (. .)))
17608141	1	(S1 (S (NP (JJ Immunological) (NN activation)) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (S (VP (TO to) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (JJ Doc_17608141_185_200_Chemical-induced) (NN Doc_17608141_209_237_Disease))))))))) (. .)))
17608141	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NNS roles)) (PP (IN of) (NP (NP (NNP Doc_17608141_279_297_Chemical)) (, ,) (NP (NP (DT a) (JJ pro-inflammatory) (CC and) (JJ inflammatory) (NN factor)) (, ,) (NP (NN treatment)))))) (PP (IN in) (S (VP (VBG modulating) (NP (DT the) (JJ Doc_17608141_371_386_Chemical-induced) (JJ nigrostriatal) (NNP Doc_17608141_409_417_Chemical) (NNP Doc_17608141_418_431_Disease)))))) (. .)))
17608141	3	(S1 (S (NP (JJ Doc_17608141_433_451_Chemical) (NN pretreatment)) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (JJ basal) (NN body) (NN temperature)) (CC or) (NP (JJ Doc_17608141_510_525_Chemical-elicited) (NNP Doc_17608141_535_547_Disease))) (ADVP (NP (CD three) (NNS days)) (RB later)))) (. .)))
17608141	4	(S1 (S (NP (JJ Such) (JJ systemic) (JJ Doc_17608141_580_598_Chemical) (NN treatment)) (VP (VBD mitigated) (NP (NP (JJ Doc_17608141_619_634_Chemical-induced) (JJ striatal) (NN Doc_17608141_652_660_Chemical)) (CC and) (NP (JJ Doc_17608141_665_695_Chemical) (NNS depletions))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))) (. .)))
17608141	5	(S1 (S (SBAR (IN As) (S (NP (NP (DT the) (ADJP (RBS most) (JJ potent)) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_17608141_772_790_Chemical)))) (VP (AUX was) (VP (VBN administered) (NP (NP (CD two) (NNS weeks)) (, ,) (NP (CD one) (NN day))) (PP (IN before) (CC or) (IN after) (NP (DT the) (JJ Doc_17608141_847_862_Chemical) (NN dosing) (NN regimen))))))) (, ,) (NP (JJ Doc_17608141_879_894_Chemical-induced) (JJ striatal) (UCP (NNP Doc_17608141_912_920_Chemical) (CC and) (NNP Doc_17608141_925_955_Chemical)) (NNS depletions)) (VP (VBD remained) (ADJP (JJ unaltered))) (. .)))
17608141	6	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ systemic) (JJ Doc_17608141_1006_1024_Chemical) (NN pretreatment)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD attenuated) (NP (JJ local) (NNP Doc_17608141_1065_1080_Chemical) (JJ infusion-produced) (NNP Doc_17608141_1099_1107_Chemical) (CC and) (NNP Doc_17608141_1112_1142_Chemical) (NNS depletions)) (PP (IN in) (NP (DT the) (NN striatum))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_17608141_1212_1230_Chemical)))) (VP (AUX is) (ADJP (ADVP (RBR less) (RB likely)) (JJ due) (PP (TO to) (NP (NP (JJ interrupted) (JJ peripheral) (NN distribution)) (CC or) (NP (NP (NN metabolism)) (PP (IN of) (NP (NNP Doc_17608141_1306_1321_Chemical))))))))))))) (. .)))
17608141	7	(S1 (S (NP (PRP We)) (VP (VBD concluded) (NP (NP (DT a) (JJ critical) (NN time) (NN window)) (PP (IN for) (NP (NP (JJ systemic) (JJ Doc_17608141_1372_1390_Chemical) (NN pretreatment)) (PP (IN in) (S (VP (VBG exerting) (NP (JJ effective) (NN protection)) (PP (IN against) (NP (JJ Doc_17608141_1445_1460_Chemical-induced) (NN nigrostriatal) (NNP Doc_17608141_1483_1491_Chemical) (NNP Doc_17608141_1492_1505_Disease)))))))))) (. .)))
17612891	0	(S1 (S (NP (JJ Acute) (NN Doc_17612891_6_17_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17612891_34_43_Chemical)))) (. .)))
17612891	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ acute) (NNP Doc_17612891_72_83_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN commencement)) (PP (IN of) (NP (NNP Doc_17612891_120_129_Chemical))))))) (VP (AUX is) (VP (VBN described) (, ,) (S (VP (VBG highlighting) (NP (NP (DT the) (NN onset)) (, ,) (NP (NN course)) (CC and) (NP (JJ possible) (VBG contributing) (NNS factors))))))) (. .)))
17612891	2	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT an) (JJ urgent) (NN need)) (SBAR (S (VP (TO to) (VP (VB raise) (NP (NP (NN awareness)) (PP (IN about) (NP (NP (DT this) (ADJP (RB potentially) (JJ fatal)) (NN complication)) (PP (IN of) (NP (JJ Doc_17612891_298_307_Chemical) (NN use)))))))))))) (. .)))
17612891	3	(S1 (S (NP (NP (DT A) (JJ 20-year-old) (NN male)) (PP (IN with) (NP (NNP Doc_17612891_346_359_Disease)))) (VP (VBD developed) (NP (NP (DT a) (JJ sudden) (NN onset)) (PP (IN of) (NP (NNP Doc_17612891_388_399_Disease)))) (PP (IN after) (NP (NP (NN commencement)) (PP (IN of) (NP (NNP Doc_17612891_422_431_Chemical)))))) (. .)))
17612891	4	(S1 (S (NP (DT The) (NN patient)) (VP (VBD recovered) (PP (IN with) (NP (JJ intensive) (JJ medical) (NN support)))) (. .)))
17612891	5	(S1 (S (NP (DT The) (NNS symptoms)) (VP (VBD occurred) (PP (IN around) (NP (CD 2) (NNS weeks))) (PP (IN after) (S (VP (VBG starting) (NP (NNP Doc_17612891_539_548_Chemical)) (PP (IN in) (NP (DT an) (JJ inpatient) (NN setting))))))) (. .)))
17612891	6	(S1 (S (NP (JJ Possible) (JJ contributing) (NNS factors)) (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (NP (JJ concomitant) (JJ Doc_17612891_630_644_Chemical) (NN use)) (CC and) (NP (JJ unaccustomed) (JJ physical) (NN activity)))))) (. .)))
17612891	7	(S1 (S (NP (NN Doc_17612891_698_709_Disease)) (VP (AUX is) (NP (NP (DT an) (ADJP (RB increasingly) (VBN recognized)) (NN complication)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17612891_780_789_Chemical)))))))) (. .)))
17612891	8	(S1 (S (NP (PRP It)) (VP (MD can) (VP (AUX be) (ADJP (JJ fatal)) (SBAR (IN if) (S (RB not) (VP (VP (VBN recognized)) (CC and) (VP (VBN treated) (ADVP (RB early)))))))) (. .)))
17612891	9	(S1 (S (PP (VBG Considering) (SBAR (IN that) (S (NP (NNP Doc_17612891_861_870_Chemical)) (VP (VBZ remains) (NP (NP (DT the) (JJ gold) (NN standard)) (PP (IN in) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ resistant) (NNP Doc_17612891_923_932_Disease)))))))))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT an) (JJ urgent) (NN need)) (SBAR (S (VP (TO to) (VP (VB raise) (NP (NP (NN awareness)) (PP (IN among) (NP (NP (JJ medical) (CC and) (JJ paramedical) (NN staff)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN care)) (PP (IN of) (NP (DT these) (NNS patients))))))))))))))) (. .)))
17612891	10	(S1 (S (NP (EX There)) (VP (AUX are) (ADVP (RB also)) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (NP (NNS recommendations)) (CC and) (NP (NNS regulations))) (VP (VBG regarding) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17612891_1138_1147_Chemical))))))))) (. .)))
17615423	0	(S1 (S (NP (JJ Severe) (NNP Doc_17615423_7_21_Disease) (CC and) (NNP Doc_17615423_26_45_Disease)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NNP Doc_17615423_78_89_Chemical)) (, ,) (NP (NNP Doc_17615423_91_101_Chemical)) (, ,) (CC and) (NP (NNP Doc_17615423_107_117_Chemical))))))) (. .)))
17615423	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ severe) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_17615423_179_190_Chemical)) (, ,) (NP (NNP Doc_17615423_192_202_Chemical)) (, ,) (CC and) (NP (NNP Doc_17615423_208_218_Chemical)))))) (VP (VBG resulting) (PP (IN in) (NP (NP (NNP Doc_17615423_232_246_Disease)) (CC and) (NP (NNP Doc_17615423_251_270_Disease))))))))) (. .)))
17615423	2	(S1 (S (NP (NP (DT A) (JJ 72-year-old) (JJ white) (NN man)) (PP (IN with) (NP (NP (JJ underlying) (NNP Doc_17615423_324_352_Disease)) (, ,) (NP (NNP Doc_17615423_354_373_Disease)) (, ,) (NP (NNP Doc_17615423_375_398_Disease)) (, ,) (CC and) (NP (NNP Doc_17615423_404_418_Disease))))) (VP (VBD presented) (SBAR (IN with) (S (VP (VBN generalized) (NP (NP (NNP Doc_17615423_446_450_Disease)) (, ,) (NP (NNP Doc_17615423_452_459_Disease)) (, ,) (CC and) (NP (JJ dark) (NN orange) (NN urine))) (PP (IN for) (NP (CD 3) (NNS days))))))) (. .)))
17615423	3	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBG taking) (NP (QP (CD 80) (CD mg)) (NN Doc_17615423_524_535_Chemical)) (PP (IN at) (NP (NP (NP (NP (NP (NN bedtime)) (PRN (-LRB- -LRB-) (VP (VBN initiated) (ADVP (NP (CD 27) (NNS days)) (RB earlier))) (-RRB- -RRB-)) (: ;) (NP (NNP Doc_17615423_576_586_Chemical)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 400) (NNS mg)) (PP (JJ daily) (IN for) (NP (CD 7) (NNS days)))))))) (, ,) (RB then) (NP (CD 200) (NNS mg)) (JJ daily)) (PRN (-LRB- -LRB-) (VP (VBN initiated) (ADVP (NP (CD 19) (NNS days)) (RB earlier))) (-RRB- -RRB-)) (: ;)) (CC and) (NP (NP (CD 400) (JJ mg) (NNP Doc_17615423_683_693_Chemical) (NN daily)) (PRN (-LRB- -LRB-) (VP (VBN initiated) (ADVP (NP (QP (IN at) (JJS least) (CD 2)) (NNS years)) (RB previously))) (-RRB- -RRB-))))))) (. .)))
17615423	4	(S1 (S (NP (NN Laboratory) (NN evaluation)) (VP (VBD revealed) (NP (NP (CD 66,680) (NNP U/L) (NNP Doc_17615423_783_791_Chemical) (NN kinase)) (, ,) (NP (NP (CD 93) (NN mg/dL)) (NP (NNP Doc_17615423_809_828_Chemical))) (, ,) (NP (NP (CD 4.6) (NN mg/dL)) (NP (NNP Doc_17615423_840_850_Chemical))) (, ,) (NP (CD 1579) (NNP U/L) (NNP Doc_17615423_861_870_Chemical) (NN aminotransferase)) (, ,) (CC and) (NP (CD 738) (NNP U/L) (NNP Doc_17615423_901_908_Chemical) (NN aminotransferase)))) (. .)))
17615423	5	(S1 (S (S (NP (NP (NP (NNP Doc_17615423_927_938_Chemical)) (, ,) (NP (NNP Doc_17615423_940_950_Chemical)) (, ,)) (CC and) (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_17615423_970_998_Disease) (NNS medications))) (VP (AUX were) (ADVP (DT all) (RB temporarily)) (VP (VBN discontinued)))) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VP (VBN given) (NP (JJ forced) (NN alkaline) (NNS diuresis))) (CC and) (VP (VBN started) (PP (IN on) (NP (NN dialysis))))))) (. .)))
17615423	6	(S1 (S (ADVP (NP (CD Nine) (NNS days)) (RB later)) (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_17615423_1151_1159_Chemical) (NN kinase)) (VP (AUX had) (VP (VBN dropped) (PP (TO to) (NP (CD 1695))) (SBAR (S (NP (NP (NNP U/L)) (CC and) (NP (NNP Doc_17615423_1195_1205_Chemical))) (VP (AUX was) (NP (CD 3.3) (NN mg/dL))))))) (. .)))
17615423	7	(S1 (S (NP (DT The) (NN patient)) (VP (VP (AUX was) (VP (VBN discharged))) (CC and) (VP (VBD continued) (NP (NN outpatient) (NN dialysis)) (PP (IN for) (NP (CD 1) (NN month))) (PP (IN until) (NP (NP (PRP$ his) (JJ renal) (NN function)) (VP (VBD recovered)))))) (. .)))
17615423	8	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_17615423_1354_1368_Disease)))) (VP (AUX is) (VP (VBN increased) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ concomitant) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP inhibit) (NP (JJ Doc_17615423_1432_1443_Chemical) (NN metabolism))))))))))) (. .)))
17615423	9	(S1 (S (NP (NN Doc_17615423_1456_1467_Chemical)) (VP (AUX is) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A4))))) (. .)))
17615423	10	(S1 (S (NP (NP (NNP Doc_17615423_1494_1504_Chemical)) (CC and) (NP (NNP Doc_17615423_1509_1519_Chemical))) (VP (AUX are) (VP (VBN recognized) (PP (IN CYP3A4) (NP (NNS inhibitors))))) (. .)))
17615423	11	(S1 (S (NP (NP (JJ Pharmacokinetic) (NNS differences)) (PP (IN in) (NP (NNP Doc_17615423_1598_1605_Chemical)))) (VP (AUX are) (NP (NP (DT an) (JJ important) (NN consideration)) (PP (IN for) (S (VP (VBG assessing) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ potential) (NN drug) (NNS interactions))))))))) (. .)))
17615423	12	(S1 (S (S (PP (IN In) (NP (NP (NNS patients)) (VP (VP (VBG requiring) (NP (NP (DT the) (JJ concurrent) (NN use)) (PP (IN of) (NP (NNP Doc_17615423_1736_1743_Chemical))))) (CC and) (VP (VBG CYP3A4) (NP (NNS inhibitors)))))) (, ,) (NP (NNP Doc_17615423_1767_1778_Chemical) (, ,) (NNP Doc_17615423_1780_1791_Chemical) (, ,) (CC and) (NNP Doc_17615423_1797_1809_Chemical)) (VP (VBP carry) (NP (NP (DT the) (JJS lowest) (NN risk)) (PP (IN of) (NP (NN drug) (NNS interactions)))))) (: ;) (S (NP (NNP Doc_17615423_1854_1866_Chemical)) (VP (VBZ carries) (NP (JJ moderate) (NN risk)) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_17615423_1898_1909_Chemical) (CC and) (NNP Doc_17615423_1914_1924_Chemical)) (VP (VP (AUX have) (NP (DT the) (JJS highest) (NN risk))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN avoided) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (JJ concomitant) (JJ CYP3A4) (NNS inhibitors))))))))))))) (. .)))
17639754	0	(S1 (NP (NP (NP (NN Interaction)) (PP (IN between) (NP (NP (NNP Doc_17639754_20_28_Chemical)) (CC and) (NP (NNP Doc_17639754_33_45_Chemical))))) (: :) (NP (NN case) (NN series)) (. .)))
17639754	1	(S1 (S (NP (NN Doc_17639754_60_68_Chemical)) (VP (VP (AUX is) (NP (DT the) (ADJP (RBS most) (RB widely) (VBN used)) (JJ oral) (NN anticoagulant))) (CC and) (VP (AUX is) (VP (VBN indicated) (PP (IN for) (NP (JJ many) (JJ clinical) (NNS conditions)))))) (. .)))
17639754	2	(S1 (S (NP (NP (NNP Doc_17639754_159_171_Chemical)) (, ,) (NP (DT a) (NN Doc_17639754_175_190_Chemical)) (, ,)) (VP (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (RB commonly) (VBN prescribed)) (NNS antibiotics)) (PP (IN in) (NP (JJ clinical) (NN practice))))))) (CC and) (VP (AUX is) (ADJP (JJ effective) (PP (IN against) (NP (ADJP (ADJP (JJ Gram-positive)) (, ,) (ADJP (JJ Gram-negative)) (, ,) (CC and) (ADJP (JJ atypical))) (NNS bacteria)))))) (. .)))
17639754	3	(S1 (S (SBAR (IN While) (S (NP (JJ small) (JJ prospective) (NNS studies)) (VP (AUX have) (RB not) (VP (VBN revealed) (NP (NP (DT any) (JJ significant) (NN drug-drug) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_17639754_438_446_Chemical)) (CC and) (NP (NNP Doc_17639754_451_463_Chemical))))))))) (, ,) (NP (JJ several) (NN case) (NNS reports)) (VP (AUX have) (VP (VBN indicated) (SBAR (IN that) (S (NP (NNP Doc_17639754_506_518_Chemical)) (VP (MD may) (ADVP (RB significantly)) (VP (VB potentiate) (NP (NP (DT the) (JJ anticoagulation) (NN effect)) (PP (IN of) (NP (NNP Doc_17639754_578_586_Chemical)))))))))) (. .)))
17639754	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 3) (NNS cases)) (PP (IN of) (NP (NP (JJ serious) (JJ Doc_17639754_617_625_Disease) (NNS complications)) (SBAR (WHNP (WDT that)) (S (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_17639754_696_704_Chemical)) (CC and) (NP (NNP Doc_17639754_709_721_Chemical))))))))))))))))) (. .)))
17639754	5	(S1 (S (NP (NNS Physicians)) (VP (MD should) (VP (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (JJ potential) (NN interaction))))) (CC and) (VP (VB use) (NP (NN caution)) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NNP Doc_17639754_813_825_Chemical)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN Doc_17639754_845_853_Chemical))))))))))) (. .)))
17854040	0	(S1 (S (S (NP (NNS Mutations)) (VP (VBN associated) (PP (IN with) (NP (NN Doc_17854040_26_36_Chemical-resistance))) (PP (IN in) (NP (JJ therapy-Doc_17854040_59_61_Chemical) (JJ ve) (NNP Doc_17854040_66_98_Disease) (NNS patients))) (PP (IN with) (CC and) (IN without) (NP (NNP Doc_17854040_125_141_Disease))))) (: :) (S (NP (NNS implications)) (PP (IN for) (NP (NP (JJ antiretroviral) (NN therapy)) (PP (IN in) (NP (NNP Doc_17854040_186_209_Disease) (NNP South) (NNP African) (NNS patients)))))) (. .)))
17854040	1	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT an) (JJ exploratory) (NN study)) (SBAR (S (VP (TO to) (VP (VB investigate) (NP (NP (JJ Doc_17854040_279_289_Chemical-resistant) (JJ Doc_17854040_300_311_Disease) (NN virus) (PRN (-LRB- -LRB-) (NP (NNP HBV)) (-RRB- -RRB-)) (NNS strains)) (PP (IN in) (NP (NP (VBN selected) (JJ Doc_17854040_344_354_Chemical-Doc_17854040_355_357_Chemical) (NN ve) (NN HBV) (NNS carriers)) (PP (IN with) (CC and) (IN without) (NP (NP (NNP Doc_17854040_392_439_Disease)) (PP (IN in) (NP (NNP South) (NNP African) (NNS patients)))))))))))))) (. .)))
17854040	2	(S1 (UCP (S (NP (NP (JJ Thirty-five) (JJ Doc_17854040_479_489_Chemical-Doc_17854040_490_492_Chemical) (JJ ve) (NNP Doc_17854040_497_509_Disease) (NNS patients)) (PP (IN with) (CC or) (IN without) (NP (NNP Doc_17854040_535_551_Disease)))) (VP (AUX were) (VP (VBN studied)))) (: :) (NP (NP (CD 15) (JJ chronic) (NN Doc_17854040_577_594_Disease) (NNS patients)) (CC and) (NP (CD 20) (JJ Doc_17854040_611_630_Disease) (NNS patients))) (. .)))
17854040	3	(S1 (S (NP (DT The) (JJ latter) (NN group)) (VP (AUX was) (ADVP (RB further)) (VP (VBN sub-divided) (PP (IN into) (NP (NP (NP (CD 13) (JJ occult) (NNS HBV)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17854040_702_707_Chemical-negative)) (-RRB- -RRB-))) (CC and) (NP (ADJP (CD 7) (NN overt)) (NN HBV) (PRN (-LRB- -LRB-) (ADJP (NNP Doc_17854040_735_740_Chemical-) (JJ positive)) (-RRB- -RRB-)) (NNS patients)))))) (. .)))
17854040	4	(S1 (S (ADVP (JJ Doc_17854040_762_767_Chemical)) (, ,) (NP (NP (NNS anti-HBs)) (, ,) (NP (NNS anti-HBc)) (, ,) (CC and) (NP (JJ anti-HIV) (NNS 1/2))) (VP (AUX were) (VP (VBN determined) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (JJ routine) (NN diagnosis)) (VP (VBG using) (NP (NP (JJ Axsym) (NNS assays)) (PRN (-LRB- -LRB-) (NP (NP (NNP Abbott) (NNP Laboratories)) (, ,) (NP (NNP North) (NNP Chicago))) (, ,) (NP (NNP IL)) (-RRB- -RRB-)))))))))) (. .)))
17854040	5	(S1 (S (NP (NN Serum) (NNS samples)) (VP (AUX were) (RB PCR) (VP (VBN amplified) (PP (IN with) (NP (NP (JJ HBV) (JJ reverse) (NN transcriptase) (PRN (-LRB- -LRB-) (NP (NNP RT)) (-RRB- -RRB-)) (NNS primers)) (, ,) (VP (VBN followed) (PP (IN by) (NP (NP (JJ direct) (NN sequencing)) (PP (IN across) (NP (NP (DT the) (JJ Doc_17854040_1031_1039_Chemical-Doc_17854040_1040_1050_Chemical-Doc_17854040_1051_1060_Chemical-Doc_17854040_1061_1070_Chemical) (PRN (-LRB- -LRB-) (NP (NNP YMDD)) (-RRB- -RRB-)) (NN motif)) (PP (IN of) (NP (DT the) (JJ major) (JJ catalytic) (NN region))) (PP (IN in) (NP (NP (DT the) (NNP C) (NN domain)) (PP (IN of) (NP (DT the) (NNP HBV) (NNP RT) (NN enzyme)))))))))))))) (. .)))
17854040	6	(S1 (S (NP (CD HBV) (JJ viral) (NN load)) (VP (AUX was) (VP (VBN performed) (PP (IN with) (NP (NP (NNP Amplicor) (NNP HBV) (NNP Monitor) (NN test) (NNS v2.0)) (PRN (-LRB- -LRB-) (NP (NP (NNP Roche) (NNPS Diagnostics)) (, ,) (NP (NNP Penzberg) (, ,) (NNP Germany))) (-RRB- -RRB-)))))) (. .)))
17854040	7	(S1 (S (NP (JJ HBV) (JJ Doc_17854040_1261_1271_Chemical-resistant) (NNS strains)) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (NP (CD 3)) (PP (IN of) (NP (CD 15) (JJ mono-infected) (JJ chronic) (NN Doc_17854040_1337_1348_Disease) (NNS patients)))) (CC and) (NP (NP (CD 10)) (PP (IN of) (NP (CD 20) (NNP Doc_17854040_1371_1390_Disease) (NNS patients)))))))) (. .)))
17854040	8	(S1 (S (PP (TO To) (NP (NP (DT the) (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (, ,) (NP (DT this)) (VP (VBZ constitutes) (NP (NP (DT the) (JJ first) (NN report)) (PP (IN of) (NP (JJ HBV) (JJ Doc_17854040_1472_1482_Chemical-resistant) (NNS strains))) (PP (IN in) (NP (JJ therapy-Doc_17854040_1512_1514_Chemical) (JJ ve) (NNP Doc_17854040_1519_1538_Disease) (NNS patients))))) (. .)))
17854040	9	(S1 (S (NP (NP (DT The) (CD HBV) (JJ viral) (NNS loads)) (PP (IN for) (NP (ADJP (JJ mono-infected) (CC and) (JJ co-infected)) (NNS patients)))) (VP (VBD ranged) (PP (IN from) (NP (NP (CD 3.32) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (TO to) (NP (NP (CD 3.82) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 7)) (-RRB- -RRB-))) (CC and) (NP (NP (QP (CD <200) (TO to) (CD 4.40)) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)))) (ADVP (RB copies/ml))) (, ,) (ADVP (RB respectively))) (. .)))
17854040	10	(S1 (S (NP (PRP It)) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN seen) (SBAR (S (IN whether) (NP (JJ such) (JJ pre-existing) (JJ antiviral) (NNS mutations)) (VP (MD could) (VP (VB result) (PP (IN in) (NP (NP (JJ widespread) (NN emergence)) (PP (IN of) (NP (JJ HBV) (NN resistant) (NNS strains))))) (SBAR (WHADVP (WRB when)) (S (NP (JJ Doc_17854040_1838_1848_Chemical-containing) (ADJP (RB highly) (JJ active)) (NN antiretroviral) (PRN (-LRB- -LRB-) (NP (NNP ARV)) (-RRB- -RRB-)) (NN treatment) (PRN (-LRB- -LRB-) (NP (NNP HAART)) (-RRB- -RRB-)) (NNS regimens)) (VP (VBP become) (ADJP (RB widely) (VBN applied) (PP (IN in) (NP (NNP South) (NNP Africa)))) (, ,) (SBAR (IN as) (S (NP (DT this)) (VP (AUX is) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX have) (NP (JJ potential) (NNS implications)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_17854040_2031_2050_Disease) (NNS patients)))))))))))))))))))))))) (. .)))
1786266	0	(S1 (S (NP (NP (NN Doc_1786266_0_15_Disease)) (, ,) (NP (JJ Doc_1786266_17_31_Chemical) (NN use)) (, ,) (CC and) (NP (JJ cerebral) (NN perfusion))) (VP (VB SPECT) (VP (VB scan) (NP (NNS findings)))) (. .)))
1786266	1	(S1 (S (NP (DT The) (NNP Doc_1786266_85_100_Disease)) (VP (AUX is) (NP (NP (DT an) (JJ extrapyramidal) (NN side) (NN effect)) (VP (VBN associated) (PP (IN with) (NP (JJ chronic) (JJ neuroleptic) (NN therapy)))))) (. .)))
1786266	2	(S1 (S (NP (NP (PRP$ Its) (NN occurrence)) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1786266_226_236_Chemical)))))))) (VP (AUX is) (VP (VBN described) (, ,) (S (VP (VBG representing) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (DT this) (NN syndrome))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NNP Doc_1786266_325_340_Chemical)))))))))) (. .)))
1786266	3	(S1 (S (NP (VBN Repeated) (JJ cerebral) (NN perfusion) (NN SPECT) (NNS scans)) (VP (VBD revealed) (NP (NN Doc_1786266_391_424_Disease)) (SBAR (IN while) (S (NP (DT the) (NNP Doc_1786266_435_452_Disease)) (VP (VP (AUX was) (ADJP (JJ present))) (, ,) (CC and) (VP (NP (NP (DT a) (NN return)) (PP (TO to) (NP (JJ normal) (NN perfusion)))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNP Doc_1786266_508_523_Disease)) (VP (VBD resolved))))))))) (. .)))
17879945	0	(S1 (S (NP (NNP Estrogen)) (VP (VBZ prevents) (NP (NP (JJ Doc_17879945_18_35_Chemical) (NN accumulation)) (PP (IN in) (NP (NP (NNS macrophages)) (VP (VBN induced) (PP (IN by) (NP (DT the) (NNP HIV) (NN protease) (NN inhibitor) (NN Doc_17879945_102_111_Chemical)))))))) (. .)))
17879945	1	(S1 (S (NP (NP (NNS Individuals)) (PP (IN with) (NP (NNP HIV)))) (VP (MD can) (ADVP (RB now)) (VP (VBP live) (NP (NP (JJ long) (NNS lives)) (PP (IN with) (NP (NP (NN drug) (NN therapy)) (SBAR (WHNP (WDT that)) (S (ADVP (RB often)) (VP (VBZ includes) (NP (NP (JJ protease) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NNP Doc_17879945_224_233_Chemical)))))))))))) (. .)))
17879945	2	(S1 (S (NP (JJ Many) (NNS patients)) (, ,) (ADVP (RB however)) (, ,) (VP (VBP develop) (NP (NP (JJ negative) (JJ long-term) (NN side) (NNS effects)) (PP (JJ such) (IN as) (NP (NN Doc_17879945_307_332_Disease))))) (. .)))
17879945	3	(S1 (S (NP (PRP We)) (VP (AUX have) (ADVP (RB previously)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (JJ Doc_17879945_371_380_Chemical) (NN treatment)) (VP (VBZ increases) (NP (NP (JJ Doc_17879945_401_423_Disease) (NN formation)) (PP (IN in) (NP (JJ male) (NNS mice)))) (PP (TO to) (NP (DT a) (JJR greater) (NN extent))) (PP (IN than) (PP (IN in) (NP (JJ female) (NNS mice))))))))) (. .)))
17879945	4	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ peripheral) (NN blood) (NNS monocytes)) (VP (VBN isolated) (PP (IN from) (NP (JJ Doc_17879945_542_551_Chemical-treated) (NNS females))))) (VP (AUX had) (NP (ADJP (RBR less) (JJ Doc_17879945_577_594_Chemical)) (NN accumulation))) (. .)))
17879945	5	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN investigated) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (JJ female) (NNS hormones)) (VP (VBP influence) (NP (NP (JJ Doc_17879945_712_723_Chemical) (NN metabolism)) (PP (IN in) (NP (NNS macrophages)))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NNP HIV) (NN protease) (NN inhibitor) (NNP Doc_17879945_792_801_Chemical))))))))))) (. .)))
17879945	6	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN utilized) (NP (NP (DT the) (JJ human) (JJ monocyte) (NN cell) (NN line)) (, ,) (NP (NN THP-1))) (PP (IN as) (NP (NP (DT a) (NN model)) (SBAR (S (VP (TO to) (VP (VB address) (NP (DT this) (NN question)))))))))) (. .)))
17879945	7	(S1 (S (ADVP (RB Briefly)) (, ,) (NP (NNS cells)) (VP (AUX were) (VP (VBN differentiated) (SBAR (IN for) (S (NP (CD 72) (NAC (NNP h) (PP (IN with) (NP (CD 100) (CD nM)))) (NNP PMA)) (VP (TO to) (VP (VB obtain) (NP (DT a) (JJ macrophage-like) (NN phenotype)) (PP (IN in) (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (NP (NP (QP (CD 1) (CD nM)) (NNP Doc_17879945_1026_1042_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17879945_1044_1046_Chemical)) (-RRB- -RRB-))) (, ,) (NP (CD 100) (JJ nM) (NNP Doc_17879945_1056_1068_Chemical)) (CC or) (NP (NP (NN vehicle)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.01) (NN %)) (NP (NNP Doc_17879945_1087_1094_Chemical))) (-RRB- -RRB-))))))))))))) (. .)))
17879945	8	(S1 (S (S (NP (NNS Cells)) (VP (AUX were) (ADVP (RB then)) (VP (VBN treated) (PP (IN with) (NP (NP (CD 30) (NNS ng/ml)) (UCP (JJ Doc_17879945_1135_1144_Chemical) (CC or) (NN vehicle)))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ aggregated) (NNS LDL))))) (SBAR (IN for) (S (NP (CD 24) (NNP h.) (NN Cell) (NNS extracts)) (VP (AUX were) (VP (VBN harvested)))))))) (, ,) (CC and) (S (NP (NN lipid) (CC or) (JJ total) (NNP RNA)) (VP (AUX was) (VP (VBN isolated)))) (. .)))
17879945	9	(S1 (S (NP (NN Doc_17879945_1267_1269_Chemical)) (VP (VBD decreased) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NNP Doc_17879945_1300_1318_Chemical))) (PP (IN in) (NP (NP (NNS macrophages)) (VP (VBG following) (NP (JJ Doc_17879945_1344_1353_Chemical) (NN treatment))))))) (. .)))
17879945	10	(S1 (S (NP (NN Doc_17879945_1365_1374_Chemical)) (VP (VBD increased) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (NN scavenger) (NN receptor)))) (, ,) (NP (CD CD36) (NN mRNA)) (, ,) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN uptake)) (PP (IN of) (NP (NNP LDL))))))) (. .)))
17879945	11	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (JJ Doc_17879945_1487_1496_Chemical) (NN treatment)) (ADVP (RB selectively)) (VP (VBD increased) (NP (NP (DT the) (JJ relative) (NNS levels)) (PP (IN of) (NP (NP (FW PPARgamma) (FW mRNA)) (, ,) (NP (NP (DT a) (JJ transcription) (NN factor)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (CD CD36) (NN mRNA) (NN expression))))))))))) (. .)))
17879945	12	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_17879945_1662_1664_Chemical)))) (, ,) (ADVP (RB however)) (, ,) (VP (VBD failed) (S (VP (TO to) (VP (VB prevent) (NP (DT these) (NNS increases)) (PP (IN at) (NP (DT the) (JJ mRNA) (NN level))))))) (. .)))
17879945	13	(S1 (S (NP (NNP Doc_17879945_1728_1730_Chemical)) (VP (AUX did) (, ,) (ADVP (RB however)) (, ,) (VP (ADVP (RB significantly)) (VB suppress) (NP (CD CD36) (NN protein) (NNS levels)) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (JJ fluorescent) (NN immunocytochemistry)))))))) (. .)))
17879945	14	(S1 (S (NP (DT This) (NN data)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_17879945_1860_1862_Chemical)) (VP (VBZ modifies) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (CD CD36)))) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN protein) (NN expression))) (PP (IN in) (NP (NP (JJ monocyte-derived) (NNS macrophages)) (VP (VBG resulting) (PP (IN in) (NP (NP (JJ reduced) (JJ Doc_17879945_1983_2000_Chemical) (NN accumulation)) (VP (VBG following) (NP (JJ Doc_17879945_2024_2033_Chemical) (NN treatment)))))))))))))) (. .)))
17919553	0	(S1 (S (NP (JJ Acute) (NNP Doc_17919553_6_15_Disease)) (VP (VBP attack) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NNP Doc_17919553_41_54_Chemical)))))) (. .)))
17919553	1	(S1 (S (NP (JJ Antibiotic-associated) (NN Doc_17919553_92_106_Disease)) (VP (AUX is) (ADJP (JJ rare))) (. .)))
17919553	2	(S1 (S (S (PP (IN With) (NP (NP (JJ widespread) (NN use)) (PP (IN of) (NP (JJ antimicrobial) (NNS agents))))) (, ,) (ADVP (RB however)) (, ,) (NP (NNP Doc_17919553_170_184_Disease)) (VP (VBZ occurs) (ADVP (RB frequently)))) (, ,) (CC and) (S (PP (IN among) (NP (NNP Doc_17919553_214_236_Disease))) (, ,) (NP (JJ idiosyncratic) (NNS reactions)) (VP (AUX are) (NP (DT the) (RBS most) (JJ serious)))) (. .)))
17919553	3	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 25-year-old) (NN male) (NN patient)) (, ,) (PP (IN with) (NP (NP (DT a) (NN height)) (PP (IN of) (NP (NP (CD 175) (NNS cm)) (CC and) (NP (NP (NN weight)) (PP (IN of) (NP (NP (CD 72) (NNS kg)) (VP (VBN presented) (PP (TO to) (NP (NP (NNP Marmara) (NNP University) (NNP Hospital) (NNP Emergency) (NNP Department)) (, ,) (NP (NNP Istanbul)) (, ,) (NP (NNP Turkey)))))))))))) (, ,) (PP (IN with) (NP (NP (NP (CD 5) (NNS days) (POS ')) (NN history)) (PP (IN of) (NP (NP (NNP Doc_17919553_475_483_Disease)) (, ,) (NP (NN malaise)) (, ,) (NP (NNP Doc_17919553_494_500_Disease)) (, ,) (CC and) (NP (NNP Doc_17919553_506_514_Disease))))))) (. .)))
17919553	4	(S1 (S (NP (PRP He)) (VP (AUX had) (VP (AUX been) (VP (VBN prescribed) (NP (NNP Doc_17919553_539_552_Chemical) (CD 400)) (PP (IN mg/d) (S (VP (VBG PO) (S (VP (TO to) (VP (VB treat) (NP (DT an) (NN Doc_17919553_577_610_Disease)) (ADVP (NP (CD 7) (NNS days)) (RB prior))))))))))) (. .)))
17919553	5	(S1 (S (NP (NN Admission) (NN laboratory) (NNS tests)) (VP (AUX were) (UCP (RB as) (S (VP (VBZ follows))) (: :) (NP (NP (NP (JJ Doc_17919553_669_676_Chemical) (NN aminotransferase)) (, ,) (NP (NP (NP (NP (CD 67) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (NP (NN reference) (NN range)) (, ,) (NP (CD 10-37) (NNP U/L))) (-RRB- -RRB-)) (: ;)) (JJ Doc_17919553_732_741_Chemical) (NN aminotransferase)) (, ,) (NP (NP (CD 98) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (JJ 10-40) (NNP U/L)) (-RRB- -RRB-))))) (: ;) (NP (NP (JJ alkaline) (NN phosphatase)) (, ,) (NP (NP (CD 513) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (JJ 0-270) (NNP U/L)) (-RRB- -RRB-)))) (: ;) (NP (NP (NP (NN gamma-glutamyltransferase)) (, ,) (NP (NP (NP (CD 32) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (CD 7-49) (NNP U/L)) (-RRB- -RRB-))) (: ;) (NP (NP (NN amylase)) (, ,) (NP (NP (CD 46) (NNP U/L)) (PRN (-LRB- -LRB-) (NP (CD 0-220) (NNP U/L)) (-RRB- -RRB-)) (: ;) (NP (JJ total) (NNP Doc_17919553_904_913_Chemical)) (, ,) (NP (NP (CD 20.1) (NNS mg/dL)) (PRN (-LRB- -LRB-) (NP (CD 0.2-1.0) (NNS mg/dL)) (-RRB- -RRB-)) (: ;) (NP (JJ direct) (NNP Doc_17919553_950_959_Chemical))) (, ,) (NP (NP (CD 14.8) (NNS mg/dL)) (PRN (-LRB- -LRB-) (NP (CD 0-0.3) (NNS mg/dL)) (-RRB- -RRB-))))) (: ;) (CC and) (NP (NN albumin)))) (, ,) (NP (NP (QP (CD 4.7) (CD mg/dL))) (PRN (-LRB- -LRB-) (NP (CD 3.5-5.4) (NNS mg/dL)) (-RRB- -RRB-))))))) (. .)))
17919553	6	(S1 (S (NP (NP (DT No) (NN toxin)) (, ,) (NP (NN Doc_17919553_1037_1044_Chemical)) (, ,) (CC or) (NP (JJ other) (NNS drugs))) (VP (AUX were) (VP (VBN reported))) (. .)))
17919553	7	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (VP (VBN suffered) (NP (NP (DT a) (JJ previous) (NN episode)) (PP (IN of) (NP (`` ``) (NP (JJ acute) (NN Doc_17919553_1130_1139_Disease)) (PP (IN of) (NP (JJ unknown) (NN origin))) (, ,) ('' '') (SBAR (WHNP (WDT that)) (S (VP (VBD occurred) (PP (IN after) (NP (JJ Doc_17919553_1180_1193_Chemical) (NN usage))))))))))) (. .)))
17919553	8	(S1 (S (NP (DT Both) (NNS incidents)) (VP (VBD occurred) (PP (IN within) (NP (DT a) (NN year)))) (. .)))
17919553	9	(S1 (S (NP (NN Doc_17919553_1252_1265_Chemical)) (VP (AUX is) (NP (NP (DT the) (JJ first)) (PP (IN of) (NP (DT the) (JJ ketolide) (NNS antibacterials))) (SBAR (S (VP (TO to) (VP (VB receive) (NP (NP (NNP US) (NNP Food) (CC and) (NNP Drug) (NNP Administration) (NN approval)) (PP (IN for) (NP (JJ clinical) (NN use)))))))))) (. .)))
17919553	10	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (ADJP (ADJP (JJ infrequent)) (CC and) (ADJP (RB usually) (JJ reversible))) (JJ severe) (NN Doc_17919553_1449_1468_Disease)))))) (. .)))
17919553	11	(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (DT a) (NN score)) (PP (IN of) (NP (CD 8))) (PP (IN on) (NP (DT the) (NNP Naranjo) (NNP Doc_17919553_1507_1528_Disease) (NN probability) (NN scale)))))) (, ,) (S (NP (NNP Doc_17919553_1548_1561_Chemical)) (VP (AUX was) (NP (NP (DT the) (JJ probable) (NN cause)) (PP (IN of) (NP (NP (JJ acute) (NNP Doc_17919553_1594_1603_Disease)) (PP (IN in) (NP (DT this) (NN patient)))))))) (, ,) (CC and) (S (NP (JJ pathological) (NNS findings)) (VP (VBD suggested) (NP (JJ drug-induced) (NNP Doc_17919553_1670_1685_Disease)))) (. .)))
17919553	12	(S1 (S (NP (NP (NN Recurrence)) (PP (IN of) (NP (NN Doc_17919553_1701_1710_Disease) (NN attack)))) (VP (MD might) (VP (AUX have) (VP (AUX been) (VP (VBN avoided) (SBAR (IN if) (S (NP (DT the) (JJ initial) (NN incident)) (VP (AUX had) (VP (AUX been) (VP (VBN communicated) (PP (TO to) (NP (NP (DT the) (VBG attending) (NN physician)) (SBAR (WHNP (WP who)) (S (VP (VBN prescribed) (PP (JJ Doc_17919553_1830_1843_Chemical) (NP (DT the) (JJ second) (NN time))))))))))))))))) (. .)))
17919553	13	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ acute) (NN Doc_17919553_1904_1913_Disease)) (VP (ADVP (RB probably)) (VBN associated) (PP (IN with) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_17919553_1961_1974_Chemical)))))))))) (. .)))
17931375	0	(S1 (NP (NP (DT A) (NN study)) (PP (IN on) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (JJ subcutaneous) (JJ Doc_17931375_54_61_Chemical) (NN injection))) (PP (IN on) (NP (NP (NNP Doc_17931375_75_83_Disease)) (CC and) (NP (NNP Doc_17931375_88_92_Disease)))))))) (. .)))
17931375	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN injection) (NN duration))) (PP (IN on) (NP (NP (NNP Doc_17931375_175_183_Disease)) (CC and) (NP (NNP Doc_17931375_188_192_Disease))))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (DT the) (JJ subcutaneous) (NN injection)) (PP (IN of) (NP (NNP Doc_17931375_255_262_Chemical)))))))))))) (. .)))
17931375	2	(S1 (S (SBAR (IN Although) (S (NP (JJ different) (NNS methods) (S (VP (TO to) (VP (VB prevent) (NP (NP (NNP Doc_17931375_314_322_Disease) (CC and) (NNP Doc_17931375_327_331_Disease)) (VP (VBG following) (NP (NP (DT the) (JJ subcutaneous) (NN injection)) (PP (IN of) (NP (NNP Doc_17931375_372_379_Chemical)))))))))) (VP (AUX have) (VP (AUX been) (ADVP (RB widely)) (VP (VBN studied) (CC and) (VBN described)))))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN injection) (NN duration))) (PP (IN on) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (NNP Doc_17931375_474_482_Disease)) (CC and) (NP (NNP Doc_17931375_487_491_Disease))))))) (VP (AUX is) (ADVP (RB little)) (VP (VBN documented))) (. .)))
17931375	3	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (PP (IN as) (NP (NP (NN within-subject)) (, ,) (NP (JJ quasi-experimental) (NN research)))))) (. .)))
17931375	4	(S1 (S (NP (NP (DT The) (NN sample)) (PP (IN for) (NP (DT the) (NN study)))) (VP (VBD consisted) (PP (IN of) (NP (CD 50) (NNS patients))) (SBAR (WHPP (TO to) (WHNP (WP whom))) (S (NP (JJ subcutaneous) (NN Doc_17931375_673_680_Chemical)) (VP (AUX was) (VP (VBN administered)))))) (. .)))
17931375	5	(S1 (S (NP (NN Doc_17931375_699_706_Chemical)) (VP (AUX was) (VP (VBN injected) (PP (IN over) (NP (NP (NP (CD 10) (NNS seconds)) (PP (IN on) (NP (DT the) (JJ right) (JJ abdominal) (NN site)))) (CC and) (NP (NP (CD 30) (NNS seconds)) (PP (IN on) (NP (DT the) (JJ left) (JJ abdominal) (NN site)))))))) (. .)))
17931375	6	(S1 (S (NP (NNS Injections) (NNS areas)) (VP (AUX were) (VP (VBN assessed) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_17931375_858_866_Disease))))) (PP (IN at) (NP (NP (CD 48) (CC and) (CD 72) (NNS hours)) (PP (IN after) (NP (DT each) (NN injection))))))) (. .)))
17931375	7	(S1 (S (NP (NP (NNS Dimensions)) (PP (IN of) (NP (DT the) (NNP Doc_17931375_926_934_Disease))) (PP (IN on) (NP (DT the) (JJ Doc_17931375_942_949_Chemical) (JJ applied) (NNS areas)))) (VP (AUX were) (VP (VBN measured) (S (VP (VBG using) (NP (JJ transparent) (JJ millimetric) (NN measuring) (NN paper)))))) (. .)))
17931375	8	(S1 (S (S (NP (NP (DT The) (JJ visual) (NN analog) (NN scale)) (PRN (-LRB- -LRB-) (INTJ (UH VAS)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (JJ Doc_17931375_1075_1079_Disease) (NN intensity)))))))) (CC and) (S (NP (DT a) (NN stop-watch)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB time) (NP (DT the) (JJ Doc_17931375_1128_1132_Disease) (NN period)))))))) (. .)))
17931375	9	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN analysed) (S (VP (VBG using) (NP (NP (NN chi-square) (NN test)) (, ,) (NP (NNP Mann-Whitney) (NNP U)) (, ,) (NP (NNP Wilcoxon) (JJ signed) (NNS ranks) (NNS tests)) (CC and) (NP (NN correlation))))))) (. .)))
17931375	10	(S1 (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (JJ Doc_17931375_1271_1279_Disease) (NN occurrence)))) (VP (AUX was) (NP (CD 64) (NN %)) (PP (IN with) (NP (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (CD 10) (NNS seconds) (NN duration)))) (CC and) (NP (NP (CD 42) (NN %)) (PP (IN in) (NP (DT the) (JJ 30-second) (NN injection))))))) (. .)))
17931375	11	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN determined) (SBAR (IN that) (S (NP (NP (DT the) (NN size)) (PP (IN of) (NP (DT the) (NNP Doc_17931375_1416_1424_Disease)))) (VP (AUX was) (ADJP (JJR smaller)) (PP (IN in) (NP (DT the) (JJ 30-second) (NN injection)))))))) (. .)))
17931375	12	(S1 (S (NP (NP (JJ Doc_17931375_1465_1469_Disease) (NN intensity)) (CC and) (NP (JJ Doc_17931375_1484_1488_Disease) (NN period))) (VP (AUX were) (ADJP (ADJP (RB statistically) (RB significantly) (JJR lower)) (PP (IN for) (NP (DT the) (JJ 30-second) (NN injection))) (PP (IN than) (PP (IN for) (NP (DT the) (JJ 10-second) (NN injection)))))) (. .)))
17931375	13	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN determined) (SBAR (IN that) (S (NP (NN injection) (NN duration)) (VP (AUX had) (NP (NP (DT an) (NN effect)) (PP (IN on) (NP (NP (NNP Doc_17931375_1669_1677_Disease)) (CC and) (NP (NNP Doc_17931375_1682_1686_Disease))))) (PP (VBG following) (NP (NP (DT the) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_17931375_1732_1739_Chemical)))))))))) (. .)))
17931375	14	(S1 (S (NP (DT This) (NN study)) (VP (MD should) (VP (AUX be) (VP (VBN repeated) (PP (IN on) (NP (DT a) (JJR larger) (NN sample)))))) (. .)))
17931375	15	(S1 (NP (NP (NP (NN RELEVANCE)) (PP (TO TO) (NP (JJ CLINICAL) (NN PRACTICE)))) (: :) (S (SBAR (WHADVP (WRB When)) (S (VP (VBG administering) (NP (JJ subcutaneous) (JJ Doc_17931375_1855_1862_Chemical) (NNS injections))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB extend) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (DT the) (NN injection))))))))) (. .)))
18004067	0	(S1 (S (NP (NP (NN Doc_18004067_0_19_Disease)) (PP (IN in) (NP (NP (CD two) (NNS patients)) (PP (IN with) (NP (JJ regular) (JJ Doc_18004067_49_56_Chemical) (NN consumption)))))) (VP (VBD ingesting) (NP (NNP Doc_18004067_79_90_Chemical)) (PP (IN at) (NP (JJ therapeutic) (NN dosage)))) (. .)))
18004067	1	(S1 (S (NP (NP (DT The) (JJ possible) (NN role)) (PP (IN of) (NP (NNP Doc_18004067_147_154_Chemical))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_18004067_177_191_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_18004067_229_240_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18004067_242_255_Chemical)) (-RRB- -RRB-)))))))))) (VP (AUX is) (ADVP (RB currently)) (VP (VBN debated))) (. .)))
18004067	2	(S1 (S (S (NP (NN CASE)) (VP (VBP REPORT))) (: :) (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD 2) (NNS patients)) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX were) (NP (NP (JJ regular) (NNS consumers)) (PP (IN of) (NP (NNP Doc_18004067_345_352_Chemical))))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_18004067_371_384_Disease)) (PP (IN within) (NP (CD 3-5) (NNS days))) (PP (IN after) (NP (NP (NN hospitalization)) (CC and) (NP (NN stopping) (JJ Doc_18004067_436_443_Chemical) (NN consumption))))))))) (PP (IN while) (S (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (CD 4) (NNP g) (NNP Doc_18004067_485_496_Chemical/day))))))))) (. .)))
18004067	3	(S1 (S (NP (NP (DT A) (JJ Doc_18004067_504_515_Chemical) (NN serum) (NN level)) (VP (VBN obtained) (PP (IN in) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (NNS patients))))))) (VP (AUX was) (RB not) (PP (IN in) (NP (DT the) (JJ toxic) (NN range)))) (. .)))
18004067	4	(S1 (S (NP (NP (JJ Possible) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_18004067_635_649_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NNP Doc_18004067_696_707_Chemical))))))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
18004067	5	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NN risk) (NNS factors))))) (, ,) (NP (NP (JJ e.g.) (JJ regular) (NN consumption)) (PP (IN of) (NP (NP (NNP Doc_18004067_794_801_Chemical)) (, ,) (NP (NNP Doc_18004067_803_816_Disease))))) (VP (AUX is) (ADJP (JJ possible)) (SBAR (WHADVP (WRB when)) (S (NP (JJ therapeutic) (NNS doses)) (VP (AUX are) (VP (VBN ingested)))))) (. .)))
18004067	6	(S1 (S (NP (PRP We)) (VP (VB propose) (SBAR (SBAR (IN that) (S (NP (DT the) (JJ Doc_18004067_886_897_Chemical) (NN dose)) (VP (MD should) (RB not) (VP (VB exceed) (NP (CD 2) (NN g/day)) (PP (IN in) (NP (JJ such) (NNS patients))))))) (CC and) (SBAR (IN that) (S (NP (PRP$ their) (NN liver) (NN function)) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (ADVP (RB closely)) (SBAR (IN while) (S (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NN Doc_18004067_1029_1040_Chemical)))))))))))))) (. .)))
18020536	0	(S1 (NP (NP (NP (NNS Associations)) (PP (IN between) (NP (NP (NP (NN use)) (PP (IN of) (NP (UCP (NNP Doc_18020536_28_43_Chemical) (CC or) (JJ related)) (NNS drugs)))) (CC and) (NP (NN health) (, ,) (JJ physical) (NNS abilities) (CC and) (NN cognitive) (NN function))))) (: :) (NP (NP (DT a) (JJ non-randomised) (JJ clinical) (NN study)) (PP (IN in) (NP (DT the) (JJ elderly)))) (. .)))
18020536	1	(S1 (S (S (VP (TO To) (VP (VB describe) (NP (NP (NNS associations)) (PP (IN between) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NP (UCP (NNP Doc_18020536_219_234_Chemical) (CC or) (JJ related)) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18020536_253_257_Chemical/RDs)) (-RRB- -RRB-))) (CC and) (NP (NN health)))))))))) (, ,) (NP (NP (JJ functional) (NNS abilities)) (CC and) (NP (NN cognitive))) (VP (VBP function) (PP (IN in) (NP (DT the) (JJ elderly)))) (. .)))
18020536	2	(S1 (S (NP (NP (DT A) (JJ non-randomised) (JJ clinical) (NN study)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN aged) (NP (QP (CD >) (CC or) (CD =65)) (NNS years)))))) (VP (VBD admitted) (PP (TO to) (NP (JJ acute) (NN hospital) (NNS wards))) (SBAR (IN during) (S (NP (NP (QP (CD 1) (CD month.)) (CD 164) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN age) (JJ +/-) (JJ standard) (NN deviation)) (NP (QP (RB -LSB-SD) (CD -RSB-) (CD 81.6)) (JJ +/-) (CD 6.8) (NNS years))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN admitted)))))) (. .)))
18020536	3	(S1 (S (PP (IN Of) (NP (DT these))) (, ,) (S (NP (NP (RB nearly) (NN half)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 78)) (-RRB- -RRB-))) (VP (AUX had) (VP (VBN used) (NP (NNP Doc_18020536_583_587_Chemical/RDs)) (PP (IN before) (NP (NN admission)))))) (, ,) (CC and) (S (NP (NP (DT the) (NN remainder)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 86)) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ non-users)))) (. .)))
18020536	4	(S1 (S (NP (JJ Cognitive) (NN ability)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (DT the) (NNP Mini-Mental) (NNP State) (NNP Examination)) (PRN (-LRB- -LRB-) (NP (NNP MMSE)) (-RRB- -RRB-)))))) (. .)))
18020536	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBG scoring) (NP (QP (CD >) (CC or) (CD =20)) (NN MMSE) (NN sum) (NNS points)))) (VP (VP (AUX were) (VP (VBN interviewed))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 79)) (-RRB- -RRB-)) (CC and) (VP (VBD questioned) (NP (NP (VBG regarding) (NNS symptoms)) (CC and) (NP (JJ functional) (NNS abilities))) (PP (IN during) (NP (NP (DT the) (NN week)) (ADVP (RB prior) (PP (TO to) (NP (NN admission)))))))) (. .)))
18020536	6	(S1 (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_18020536_907_911_Chemical/RDs))) (PP (IN before) (NP (NN admission)))) (, ,) (NP (JJ current) (NNS medications)) (CC and) (NP (NN discharge) (NNS diagnoses))))) (VP (AUX were) (VP (VBN collected) (PP (IN from) (NP (JJ medical) (NNS records))))) (. .)))
18020536	7	(S1 (S (S (NP (NP (NN Health) (, ,) (JJ physical) (NNS abilities)) (CC and) (NP (JJ cognitive) (NN function))) (VP (AUX were) (VP (VBN compared) (PP (IN between) (NP (NP (JJ BZD/RD) (NNS users)) (CC and) (NP (NNS non-users))))))) (, ,) (CC and) (S (NP (NNS adjustments)) (VP (AUX were) (VP (VBN made) (PP (IN for) (NP (JJ confounding) (NNS variables)))))) (. .)))
18020536	8	(S1 (S (NP (NP (DT The) (JJ residual) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_18020536_1205_1213_Chemical)) (, ,) (NP (NNP Doc_18020536_1215_1224_Chemical)) (CC and) (NP (NNP Doc_18020536_1229_1238_Chemical))))) (VP (AUX were) (VP (VBN analysed))) (. .)))
18020536	9	(S1 (S (NP (NP (DT The) (JJ mean) (JJ +/-) (NN SD) (NN duration)) (PP (IN of) (NP (JJ BZD/RD) (NN use)))) (VP (AUX was) (NP (NP (CD 7) (JJ +/-) (CD 7) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 1-31)) (-RRB- -RRB-)))) (. .)))
18020536	10	(S1 (S (S (NP (QP (CD Two) (CC or) (CD three)) (NNS Doc_18020536_1347_1351_Chemical/RDs)) (VP (AUX were) (ADVP (RB concomitantly)) (VP (VBN taken) (PP (IN by) (NP (NP (CD 26) (NN %)) (PP (IN of) (NP (NNS users)))))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-)) (. .)))
18020536	11	(S1 (S (NP (NP (JJ Long-term) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ female) (NN sex)) (CC and) (NP (NP (NN use)) (PP (IN of) (NP (NP (DT a) (JJR higher) (NN number)) (PP (IN of) (NP (NNS drugs))))) (PP (IN with) (NP (NP (NNS effects)) (PP (IN on) (NP (DT the) (NNS CNS))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD tended) (S (VP (TO to) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (VBN diagnosed) (NNP Doc_18020536_1568_1576_Disease))))))))))))))))) (. .)))
18020536	12	(S1 (S (PP (IN After) (NP (NP (NN adjustment)) (PP (IN for) (NP (NP (DT these) (NNS variables)) (PP (IN as) (NP (NNS confounders))))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_18020536_1638_1642_Chemical/RDs)))) (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (JJ cognitive) (NN function))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (DT the) (NN MMSE)))))))) (. .)))
18020536	13	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_18020536_1731_1735_Chemical/RDs)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_18020536_1760_1769_Disease)) (, ,) (NP (NNP Doc_18020536_1771_1789_Disease)))) (PP (IN after) (S (VP (VBG awaking) (PP (IN at) (NP (NP (NN night)) (CC and) (NP (NNP Doc_18020536_1817_1826_Disease)))) (PP (IN in) (NP (DT the) (NNS mornings))) (PP (PP (IN during) (NP (NP (DT the) (NN week)) (ADVP (RB prior) (PP (TO to) (NP (NN admission)))))) (CC and) (PP (IN with) (NP (NP (JJR stronger) (NN Doc_18020536_1896_1915_Disease)) (VP (VBN measured) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (DT the) (NN hospital) (NN stay)))))))))))))) (. .)))
18020536	14	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_18020536_1971_1975_Chemical/RDs)))) (VP (VBD tended) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (VBN reduced) (NN ability) (S (VP (TO to) (VP (VB walk))))) (CC and) (NP (JJR shorter) (JJ night-time) (NN sleep)))) (PP (IN during) (NP (NP (DT the) (NN week)) (ADVP (RB prior) (PP (TO to) (NP (NN admission))))))))))) (. .)))
18020536	15	(S1 (S (NP (NP (DT A) (JJR higher) (JJ residual) (NN serum) (NN concentration)) (PP (IN of) (NP (NNP Doc_18020536_2141_2150_Chemical)))) (VP (VBD correlated) (PP (IN with) (NP (DT a) (JJR lower) (NN MMSE) (NN sum) (NN score))) (PP (IN after) (NP (NP (NN adjustment)) (PP (IN for) (NP (JJ confounding) (NNS variables)))))) (. .)))
18020536	16	(S1 (S (NP (NP (NP (JJ Long-term) (NN use)) (CC and) (NP (JJ concomitant) (NN use))) (PP (IN of) (NP (QP (JJR more) (IN than) (CD one)) (NN BZD/RD)))) (VP (AUX were) (ADJP (JJ common)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (VP (VBN hospitalised) (PP (IN because) (IN of) (NP (JJ acute) (NNS illnesses))))))) (. .)))
18020536	17	(S1 (S (NP (JJ Long-term) (NN use)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (JJ daytime) (CC and) (JJ night-time)) (NNS symptoms)) (UCP (ADJP (JJ indicative) (PP (IN of) (NP (JJR poorer) (NN health)))) (CC and) (VP (ADVP (RB potentially)) (VBN caused) (PP (IN by) (NP (NP (DT the) (JJ adverse) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs))))))))))) (. .)))
18023325	0	(S1 (S (NP (JJ Acute)) (VP (VBP Doc_18023325_6_22_Disease) (PP (IN after) (NP (JJ acute) (JJ Doc_18023325_35_45_Chemical) (NN intoxication)))) (. .)))
18023325	1	(S1 (S (S (NP (NP (JJ Acute) (NN Doc_18023325_66_87_Disease)) (VP (VBN caused) (PP (IN by) (NP (DT a) (JJ Doc_18023325_100_110_Chemical) (NN Doc_18023325_111_119_Disease))))) (VP (AUX is) (ADJP (RB very) (JJ rare)))) (CC and) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (NN report)) (PP (IN of) (NP (NP (PRP it)) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_18023325_173_189_Disease))))))))) (. .)))
18023325	2	(S1 (S (NP (DT A) (JJ 49-year-old) (NN woman)) (VP (AUX was) (VP (VBN transferred) (PP (TO to) (NP (PRP$ our) (NN department))) (PP (IN because) (IN of) (NP (NNP Doc_18023325_256_269_Disease))) (, ,) (S (VP (VBG lancinating) (NP (NP (NNP Doc_18023325_283_287_Disease)) (, ,) (NP (NNP Doc_18023325_289_301_Disease)) (, ,) (CC and) (NP (NP (NNP Doc_18023325_307_318_Disease)) (PP (IN of) (NP (DT the) (JJ distal) (NNS limbs))))))))) (. .)))
18023325	3	(S1 (S (ADVP (NP (CD One) (NN month)) (RB previously)) (, ,) (NP (PRP she)) (VP (AUX had) (VP (VBN taken) (NP (NP (NP (DT a) (JJ single) (JJ high) (NN dose)) (PP (IN of) (NP (NNP Doc_18023325_398_408_Chemical)))) (-LRB- -LRB-) (NP (NP (CD 130) (NNS tablets)) (PP (IN of) (NP (JJ Doc_18023325_425_432_Chemical) (NN STOP) (NN TAB)))) (, ,) (NP (JJ Shin-Poong) (NN Pharm))))) (. .)))
18023325	4	(S1 (NP (NP (NNP Co.)) (, ,) (NP (NP (NP (NNP Ansan)) (PRN (, ,) (NP (NNP Korea)) (-RRB- -RRB-))) (PP (IN in) (NP (DT a) (NN suicide) (NN attempt)))) (. .)))
18023325	5	(S1 (S (NP (PRP She)) (VP (AUX was) (RB not) (NP (DT an) (JJ alcoholic))) (. .)))
18023325	6	(S1 (S (PP (IN For) (NP (NP (DT the) (JJ first) (JJ few) (NNS days)) (PP (IN after) (NP (NN ingestion))))) (, ,) (NP (PRP she)) (VP (VP (AUX was) (PP (IN in) (NP (DT a) (VBN confused) (NN state)))) (CC and) (VP (AUX had) (ADJP (JJ mild) (S (VP (TO to) (VP (VB moderate) (NP (NP (NNP Doc_18023325_621_627_Disease)) (CC and) (NP (NNP Doc_18023325_632_641_Disease))))))))) (. .)))
18023325	7	(S1 (S (NP (PRP She)) (VP (VP (VBD noticed) (NP (NN Doc_18023325_655_665_Disease))) (CC and) (VP (ADVP (RB distally)) (VBD accentuated) (NP (NP (NN motor)) (CC and) (NP (JJ sensory) (NN dysfunction))) (SBAR (IN after) (S (NP (PRP she)) (VP (AUX had) (VP (VBN recovered) (PP (IN from) (NP (DT this) (NN state))))))))) (. .)))
18023325	8	(S1 (S (NP (DT A) (NN nerve) (NN conduction) (NN study)) (VP (AUX was) (ADJP (JJ consistent) (PP (IN with) (NP (JJ severe) (NN sensorimotor) (NN axonal) (NN Doc_18023325_834_848_Disease))))) (. .)))
18023325	9	(S1 (S (NP (NP (JJ Laryngeal) (NN electromyography)) (PRN (-LRB- -LRB-) (NP (JJ thyroarytenoid) (NN muscle)) (-RRB- -RRB-))) (VP (VBD showed) (NP (JJ ample) (NN denervation) (NNS potentials))) (. .)))
18023325	10	(S1 (S (NP (NNP Laryngoscopy)) (VP (VBD revealed) (NP (NN asymmetric) (NN vocal) (VB fold) (NNS movements)) (PP (IN during) (NP (NN phonation)))) (. .)))
18023325	11	(S1 (S (NP (NP (PRP$ Her) (JJ vocal) (NN change)) (CC and) (NP (NN weakness))) (VP (VBD began) (S (VP (TO to) (VP (VB improve) (ADVP (RB spontaneously))))) (PP (NP (QP (RB about) (CD 3)) (NNS weeks)) (IN after) (NP (NN transfer)))) (. .)))
18023325	12	(S1 (S (NP (DT This)) (VP (VP (AUX was) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ acute) (NNP Doc_18023325_1126_1131_Disease)) (PP (IN of) (NP (DT the) (JJ recurrent) (JJ laryngeal) (NN nerve))))))) (CC and) (VP (VBN superimposed) (NP (NP (JJ severe) (JJ acute) (NN sensorimotor) (NN axonal) (NN Doc_18023325_1215_1229_Disease)) (VP (VBN caused) (PP (IN by) (NP (JJ high-dose) (JJ Doc_18023325_1250_1260_Chemical) (NN intoxication))))))) (. .)))
18081909	0	(S1 (S (NP (NP (NN Doc_18081909_0_14_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18081909_26_39_Chemical))))) (VP (VBD added) (PP (TO to) (NP (NNP Doc_18081909_49_58_Chemical)))) (. .)))
18081909	1	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (DT a) (JJ Doc_18081909_108_121_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18081909_123_126_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_18081909_136_150_Disease)))))) (. .)))
18081909	2	(S1 (S (NP (NP (DT A) (JJ 28-year-old) (NN man)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_18081909_195_214_Disease))) (PP (IN with) (NP (JJ generalized) (NNP Doc_18081909_232_240_Disease))))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_18081909_258_261_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3000) (NN mg)) (-RRB- -RRB-)))) (PP (VBN added) (PP (TO to) (NP (NP (NP (NNP Doc_18081909_281_290_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18081909_292_295_Chemical)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 2000) (NN mg)) (-RRB- -RRB-))))))) (. .)))
18081909	3	(S1 (S (NP (NP (NN Frequency)) (PP (IN of) (NP (JJ generalized) (NNP Doc_18081909_333_354_Disease)))) (VP (VBN increased) (PP (IN from) (NP (CD one))) (PP (IN per) (NP (CD 6) (NNS months))) (PP (TO to) (NP (NP (CD two)) (PP (IN per) (NP (NN month)))))) (. .)))
18081909	4	(S1 (S (NP (JJ Neuropsychological) (NN testing)) (VP (VBD showed) (NP (NN Doc_18081909_439_498_Disease))) (. .)))
18081909	5	(S1 (S (NP (NP (DT The) (JJ interictal) (NN electroencephalogram)) (PRN (-LRB- -LRB-) (NP (NNP EEG)) (-RRB- -RRB-))) (VP (VBD showed) (NP (DT a) (JJ generalized) (NN slowing)) (PP (TO to) (NP (NP (CD 5)) (PP (IN per) (NP (NP (JJ second) (JJ theta) (NNS rhythms)) (PP (IN with) (NP (JJ bilateral) (JJ generalized) (NN high-amplitude) (NNS discharges)))))))) (. .)))
18081909	6	(S1 (S (S (NP (NP (JJ Following) (NN discontinuation)) (PP (IN of) (NP (NP (NNP Doc_18081909_693_696_Chemical)) (, ,) (NP (NNP EEG)) (CC and) (NP (JJ neuropsychological) (NNS findings))))) (VP (VBD improved))) (CC and) (S (NP (JJ Doc_18081909_747_754_Disease) (NN frequency)) (VP (VBD decreased))) (. .)))
18083142	0	(S1 (S (NP (NP (NN Doc_18083142_0_14_Chemical)) (VP (VBG signaling) (PP (IN through) (NP (JJ beta-adrenergic) (NNS receptors))))) (VP (AUX is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (NNP Doc_18083142_89_96_Chemical-induced) (NNP Doc_18083142_105_112_Disease))))))) (. .)))
18083142	1	(S1 (S (NP (NN Doc_18083142_126_133_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB widely) (VBN abused)) (NN psychostimulant)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (DT both) (ADJP (ADJP (JJ rewarding)) (CC and) (ADJP (JJ aversive))) (NNS properties))))))) (. .)))
18083142	2	(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (NNP Doc_18083142_250_257_Chemical) (POS 's)) (JJ rewarding) (NNS effects)))) (VP (AUX have) (VP (AUX been) (VP (VBN studied) (ADVP (RB extensively))))))) (, ,) (NP (JJR less) (NN attention)) (VP (AUX has) (VP (AUX been) (VP (VBN paid) (PP (TO to) (NP (NP (DT the) (JJ unpleasant) (JJ behavioral) (NNS states)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18083142_385_392_Chemical)))) (, ,) (PP (JJ such) (IN as) (NP (NN Doc_18083142_402_409_Disease)))))))) (. .)))
18083142	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBN evaluated) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (NP (JJ Doc_18083142_467_475_Chemical) (JJ beta-hydroxylase) (NN knockout) (PRN (-LRB- -LRB-) (NNP Dbh) (NN -/-) (-RRB- -RRB-)) (NNS mice)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP lack) (NP (NP (NNP Doc_18083142_529_543_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18083142_545_547_Chemical)) (-RRB- -RRB-)))))) (, ,)))) (PP (IN in) (NP (DT the) (JJ elevated) (JJ plus) (NN maze) (PRN (-LRB- -LRB-) (NNP EPM) (-RRB- -RRB-)) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (NP (NN noradrenergic)) (VP (VBG signaling) (PP (TO to) (NP (NNP Doc_18083142_640_647_Chemical-induced) (NNP Doc_18083142_656_663_Disease))))))))))))) (. .)))
18083142	4	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NNP Doc_18083142_688_695_Chemical)) (ADVP (RB dose-dependently)) (VP (VBD increased) (NP (JJ Doc_18083142_723_730_Disease-like) (NN behavior)) (PP (IN in) (NP (JJ control) (PRN (-LRB- -LRB-) (NP (NNP Dbh) (CD +/-)) (-RRB- -RRB-)) (NNS mice))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ open) (NN arm) (NN exploration)))))))))))) (. .)))
18083142	5	(S1 (S (NP (DT The) (NNP Dbh) (NN -/-) (NNS mice)) (VP (VP (AUX had) (NP (NP (JJ normal) (NN baseline) (NN performance)) (PP (IN in) (NP (DT the) (NN EPM))))) (CC but) (VP (AUX were) (ADJP (RB completely) (JJ resistant) (PP (TO to) (NP (NP (DT the) (JJ anxiogenic) (NNS effects)) (PP (IN of) (NP (NNP Doc_18083142_942_949_Chemical)))))))) (. .)))
18083142	6	(S1 (S (NP (JJ Doc_18083142_951_958_Chemical-induced) (NN Doc_18083142_967_974_Disease)) (VP (AUX was) (ADVP (RB also)) (VP (VBN attenuated) (PP (IN in) (NP (NNP Dbh) (JJ +/-) (NNS mice))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_18083142_1039_1049_Chemical)) (, ,) (NP (DT a) (JJ Doc_18083142_1053_1061_Chemical) (NN beta-hydroxylase) (PRN (-LRB- -LRB-) (NP (NNP DBH)) (-RRB- -RRB-)) (NN inhibitor)))))))) (. .)))
18083142	7	(S1 (S (PP (IN In) (NP (NP (NNS experiments)) (VP (VBG using) (NP (JJ specific) (JJ adrenergic) (NNS antagonists))))) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (DT the) (JJ beta-adrenergic) (NN receptor) (NN antagonist) (NNP Doc_18083142_1222_1233_Chemical)))) (VP (VBD blocked) (NP (JJ Doc_18083142_1242_1249_Chemical-induced) (JJ Doc_18083142_1258_1265_Disease-like) (NN behavior)) (PP (IN in) (NP (NP (NNP Dbh) (NNS +/-)) (CC and) (NP (JJ wild-type) (NNP C57BL6/J) (NNS mice)))) (, ,) (SBAR (IN while) (S (NP (NP (NP (DT the) (NN alpha) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN antagonist)) (NP (NNP Doc_18083142_1350_1358_Chemical))) (CC and) (NP (NP (DT the) (NN alpha)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)))) (VP (VBP antagonist) (SBAR (S (NP (NNP Doc_18083142_1387_1396_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)))))))))))) (. .)))
18083142	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN noradrenergic)) (VP (VBG signaling) (PP (IN via) (NP (JJ beta-adrenergic) (NNS receptors))))) (VP (AUX is) (VP (VBN required) (PP (IN for) (NP (NP (JJ Doc_18083142_1523_1530_Chemical-induced) (NN Doc_18083142_1539_1546_Disease)) (PP (IN in) (NP (NNS mice)))))))))) (. .)))
18162529	0	(S1 (S (NP (NP (JJ Hypothalamic) (NN prolactin) (NN receptor) (NN messenger) (JJ Doc_18162529_42_58_Chemical) (NNS levels)) (, ,) (NP (NN prolactin) (VBG signaling)) (, ,) (CC and) (NP (NP (JJ Doc_18162529_92_110_Disease) (NN inhibition)) (PP (IN of) (NP (JJ pulsatile) (JJ luteinizing) (NN hormone) (NN secretion))))) (VP (AUX are) (ADJP (JJ dependent) (PP (IN on) (NP (NNP Doc_18162529_182_191_Chemical))))) (. .)))
18162529	1	(S1 (S (NP (NN Doc_18162529_193_211_Disease)) (VP (MD can) (VP (VB reduce) (NP (NP (NN fertility)) (CC and) (NP (NN libido))))) (. .)))
18162529	2	(S1 (S (SBAR (IN Although) (S (NP (JJ central) (NN prolactin) (NNS actions)) (VP (AUX are) (VP (VBN thought) (S (VP (TO to) (VP (VB contribute) (PP (TO to) (NP (DT this)))))))))) (, ,) (NP (DT the) (NNS mechanisms)) (VP (AUX are) (ADVP (RB poorly)) (VP (VBN understood))) (. .)))
18162529	3	(S1 (S (NP (PRP We)) (ADVP (RB first)) (VP (VBD tested) (SBAR (IN whether) (S (NP (JJ chronic) (NNP Doc_18162529_385_403_Disease)) (VP (VBD inhibited) (NP (NP (NP (CD two) (JJ neuroendocrine) (NNS parameters)) (ADJP (JJ necessary) (PP (IN for) (NP (JJ female) (NN fertility))))) (: :) (NP (NP (JJ pulsatile) (NN LH) (NN secretion)) (CC and) (NP (DT the) (JJ Doc_18162529_507_515_Chemical-induced) (NN LH) (NN surge)))))))) (. .)))
18162529	4	(S1 (S (NP (NP (JJ Chronic) (NN Doc_18162529_542_560_Disease)) (VP (VBN induced) (PP (IN by) (NP (DT the) (JJ Doc_18162529_576_584_Chemical) (NN antagonist) (NN Doc_18162529_596_605_Chemical))))) (VP (VBD caused) (NP (NP (DT a) (ADJP (CD 40) (NN %)) (NN reduction)) (VP (VBG LH) (NP (NN pulse) (NN frequency)) (PP (PP (IN in) (NP (VBN ovariectomized) (NNS rats))) (, ,) (CONJP (CC but) (RB only)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ chronic) (JJ low) (NNS levels)) (PP (IN of) (NP (NNP Doc_18162529_722_731_Chemical))))))))))) (. .)))
18162529	5	(S1 (S (NP (NN Doc_18162529_733_742_Chemical)) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (DT a) (JJ Doc_18162529_777_784_Chemical-induced) (NN LH) (NN surge)))) (CC or) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NP (NNP GnRH) (NNS neurons)) (VP (VBN activated) (PP (IN during) (NP (DT the) (NN surge)))))))))) (. .)))
18162529	6	(S1 (S (NP (NN Doc_18162529_864_873_Chemical)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB influence) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ long) (NN form)) (PP (IN of) (NP (NP (NP (JJ prolactin) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP PRL-R)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS components)) (PP (IN of) (NP (NP (NN prolactin) (POS 's)) (VBG signaling) (NN pathway)))))))))))))) (. .)))
18162529	7	(S1 (S (S (VP (TO To) (VP (VB test) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NNP Doc_18162529_1032_1040_Chemical)) (VP (VBZ increases) (NP (NP (JJ PRL-R) (NN expression)) (CC and) (NP (NN sensitivity))) (PP (TO to) (NP (NN prolactin)))))))))) (, ,) (NP (PRP we)) (ADVP (RB next)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NNP Doc_18162529_1124_1133_Chemical)) (ADVP (RB greatly)) (VP (VBZ augments) (NP (JJ prolactin-induced) (NN STAT5) (NN activation)))))) (. .)))
18162529	8	(S1 (S (ADVP (RB Lastly)) (, ,) (NP (PRP we)) (VP (VBD measured) (NP (NP (NN PRL-R) (CC and) (NN suppressor)) (PP (IN of) (NP (NN cytokine)))) (S (VP (VBG signaling) (NP (PRN (-LRB- -LRB-) (NP (NP (NN SOCS-1) (CC and) (NN -3)) (CC and) (NP (NP (NNP CIS)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP reflect) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN prolactin) (VBG signaling))))))))) (-RRB- -RRB-)) (NNS mRNAs)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_18162529_1343_1352_Chemical) (CC and) (NNP Doc_18162529_1357_1366_Chemical)))))))) (. .)))
18162529	9	(S1 (S (S (NP (NN Doc_18162529_1368_1377_Chemical)) (VP (VP (VBN induced) (ADJP (RB only) (JJ SOCS-1)) (PP (PP (IN in) (NP (NP (DT the) (JJ medial) (JJ preoptic) (NN area)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NNP GnRH) (NNS neurons)) (VP (AUX are) (VP (VBN regulated))))) (, ,))) (CC but) (PP (IN in) (NP (DT the) (JJ arcuate) (NN nucleus))))) (CC and) (VP (VBN choroid) (S (ADJP (JJ plexus) (, ,) (JJ PRL-R) (, ,) (JJ SOCS-3)))))) (, ,) (CC and) (S (NP (NN CIS) (NN mRNA) (NNS levels)) (VP (AUX were) (ADVP (RB also)) (VP (VBN induced)))) (. .)))
18162529	10	(S1 (S (NP (NN Doc_18162529_1562_1571_Chemical)) (VP (VBD enhanced) (NP (NP (DT these) (NNS effects)) (PP (IN on) (NP (NP (NN SOCS-3)) (CC and) (NP (NN CIS)))))) (. .)))
18162529	11	(S1 (S (ADVP (RB Interestingly)) (, ,) (NP (NNP Doc_18162529_1629_1638_Chemical)) (ADVP (RB also)) (VP (VBN induced) (NP (NN PRL-R) (, ,) (NN SOCS-3) (, ,) (CC and) (NN CIS) (NN mRNA) (NNS levels)) (ADVP (RB independently))) (. .)))
18162529	12	(S1 (S (NP (DT These) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP GnRH) (NN pulse) (NN frequency)) (VP (AUX is) (VP (VBD inhibited) (PP (IN by) (NP (NN chronic) (NN Doc_18162529_1768_1786_Disease))) (PP (IN in) (NP (DT a) (JJ Doc_18162529_1792_1799_Chemical-dependent) (NN manner)))))))) (. .)))
18162529	13	(S1 (S (NP (PRP They)) (ADVP (RB also)) (VP (VBP provide) (NP (NN evidence)) (PP (IN for) (NP (NP (NN Doc_18162529_1849_1858_Chemical-dependent)) (CC and) (NP (NP (NN brain) (JJ region-specific) (NN regulation)) (PP (IN of) (NP (NP (JJ PRL-R) (NN expression)) (CC and) (NP (VBG signaling) (NNS responses)))) (PP (IN by) (NP (NN prolactin))))))) (. .)))
18182964	0	(S1 (NP (NP (NP (NN Doc_18182964_0_9_Chemical)) (PP (IN for) (NP (NNP Doc_18182964_14_54_Disease)))) (: :) (NP (NNP II)) (. .)))
18182964	1	(S1 (NP (NP (NP (JJ ECG) (NNS changes)) (CC and) (NP (JJ adverse) (NNS events) (NN analysis))) (. .)))
18182964	2	(S1 (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN safety) (CC and) (NN tolerability)) (PP (IN of) (NP (NNP Doc_18182964_154_163_Chemical))))))) (VP (VBD used) (UCP (ADVP (RB alone)) (CC or) (PP (IN with) (NP (NNP Doc_18182964_183_198_Chemical)))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NNP Doc_18182964_216_256_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18182964_258_262_Disease)) (-RRB- -RRB-))))))) (. .)))
18182964	3	(S1 (S (PP (IN In) (NP (DT a) (JJ 16-week) (JJ multicenter) (, ,) (JJ double-blind) (NN trial))) (, ,) (NP (NP (CD 122) (NNS children)) (PP (IN with) (NP (NNP Doc_18182964_337_341_Disease)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (NP (NNP Doc_18182964_368_377_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 31)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_18182964_388_403_Chemical) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 29)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_18182964_414_423_Chemical) (CC and) (NNP Doc_18182964_428_443_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 32)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 30)) (-RRB- -RRB-))))))) (. .)))
18182964	4	(S1 (S (NP (NNS Doses)) (VP (AUX were) (ADVP (RB flexibly)) (VP (VBN titrated) (PRT (RP up)) (PP (TO to) (NP (NP (NP (NP (CD 0.6) (NN mg/day)) (PP (IN for) (NP (NNP Doc_18182964_525_534_Chemical)))) (CC and) (NP (NP (CD 60) (NN mg/day)) (PP (IN for) (NP (NNP Doc_18182964_553_568_Chemical))))) (PRN (-LRB- -LRB-) (NP (NP (DT both)) (PP (IN with) (NP (VBN divided) (NN dosing)))) (-RRB- -RRB-)))))) (. .)))
18182964	5	(S1 (S (NP (NNS Groups)) (VP (AUX were) (VP (VBN compared) (PP (VBG regarding) (NP (NP (JJ adverse) (NNS events)) (CC and) (NP (NP (NNS changes)) (PP (IN from) (NP (NN baseline))) (PP (TO to) (NP (NN week) (CD 16))) (PP (IN in) (NP (NP (NNS electrocardiograms)) (CC and) (NP (JJ vital) (NNS signs))))))))) (. .)))
18182964	6	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (JJR more) (NNS incidents)) (PP (IN of) (NP (NNP Doc_18182964_757_768_Disease)))) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18182964_794_803_Chemical))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (DT those) (ADJP (RB not) (VBN treated))) (PP (IN with) (NP (NP (NNP Doc_18182964_841_850_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 17.5) (NN %)) (CC versus) (NP (CD 3.4) (NN %))) (: ;) (QP (CD p) (CD =.02))) (-RRB- -RRB-))))) (, ,) (CC but) (NP (NP (DT no) (JJ other) (JJ significant) (NN group) (NNS differences)) (VP (VBG regarding) (NP (NP (NN electrocardiogram)) (CC and) (NP (JJ other) (JJ cardiovascular) (NNS outcomes)))))))))))) (. .)))
18182964	7	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS suggestions)) (PP (IN of) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (NNP Doc_18182964_1036_1045_Chemical)) (CC and) (NP (NNP Doc_18182964_1050_1065_Chemical)))) (VP (VBG regarding) (NP (JJ cardiovascular) (NNS outcomes))))))) (. .)))
18182964	8	(S1 (S (NP (ADJP (JJ Moderate) (CC or) (JJ severe)) (JJ adverse) (NNS events)) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ common)) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN on) (NP (NNP Doc_18182964_1167_1176_Chemical)))))) (PRN (-LRB- -LRB-) (NP (NP (CD 79.4) (NN %)) (CC versus) (NP (NP (CD 49.2) (NN %)) (: ;) (NP (NNP p) (CD =.0006)))) (-RRB- -RRB-)) (CC but) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (JJR higher) (NNS rates)) (PP (IN of) (NP (JJ early) (NN study) (NN withdrawal))))))) (. .)))
18182964	9	(S1 (S (S (NP (NN Doc_18182964_1272_1282_Disease)) (VP (AUX was) (ADJP (JJ common)) (PP (IN on) (NP (NNP Doc_18182964_1297_1306_Chemical))))) (, ,) (CC but) (S (ADVP (RB generally)) (VP (VBN resolved) (PP (IN by) (NP (QP (CD 6) (TO to) (CD 8)) (NNS weeks))))) (. .)))
18182964	10	(S1 (S (NP (NP (NN Doc_18182964_1361_1370_Chemical)) (, ,) (VP (VBN used) (UCP (ADVP (RB alone)) (CC or) (PP (IN with) (NP (NNP Doc_18182964_1391_1406_Chemical))))) (, ,)) (VP (VBZ appears) (ADJP (ADJP (JJ safe)) (CC and) (ADJP (RB well) (VBN tolerated) (PP (IN in) (NP (NN childhood) (NN Doc_18182964_1453_1457_Disease)))))) (. .)))
18182964	11	(S1 (S (NP (NP (NNS Physicians)) (VP (VBG prescribing) (NP (NNP Doc_18182964_1482_1491_Chemical)))) (VP (MD should) (VP (VP (VB monitor) (PP (IN for) (NP (NNP Doc_18182964_1511_1522_Disease)))) (CC and) (VP (VB advise) (NP (NNS patients)) (PP (IN about) (NP (NP (DT the) (JJ high) (NN likelihood)) (PP (IN of) (NP (JJ initial) (NN Doc_18182964_1580_1590_Disease)))))))) (. .)))
18186898	0	(S1 (NP (NP (NP (NP (NN Doc_18186898_0_22_Disease)) (CC and) (NP (NN Doc_18186898_27_35_Disease))) (PP (IN after) (NP (NN liver) (NN transplantation)))) (: :) (NP (JJ drug-related) (NNP Doc_18186898_78_101_Disease)) (. ?)))
18186898	1	(S1 (S (NP (NP (NNS Advances)) (PP (IN in) (NP (NP (DT the) (NN field)) (PP (IN of) (NP (NN transplantation)))))) (VP (VP (VBP provide) (NP (NP (DT a) (JJR better) (NN quality)) (PP (IN of) (NP (NN life))))) (CC and) (VP (VBP allow) (NP (NP (RBR more) (JJ favorable) (NNS conditions)) (PP (IN for) (NP (NP (NN growth) (CC and) (NN development)) (PP (IN in) (NP (NNS children)))))))) (. .)))
18186898	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNS combinations)) (PP (IN of) (NP (JJ different) (JJ therapeutic) (NNS regimens)))) (VP (VBP require) (NP (NP (NN consideration)) (PP (IN of) (NP (JJ potential) (JJ adverse) (NNS reactions))))) (. .)))
18186898	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ 15-yr-old) (NN girl)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (JJ orthotopic) (NN liver) (NN transplantation)) (PP (IN because) (IN of) (NP (NN Doc_18186898_444_460_Disease)))))))) (. .)))
18186898	4	(S1 (S (NP (NP (NNP Doc_18186898_462_472_Chemical)) (, ,) (NP (NNP Doc_18186898_474_477_Chemical)) (, ,) (CC and) (NP (NNP Doc_18186898_483_491_Chemical))) (VP (AUX were) (VP (VBN given) (PP (IN as) (NP (NN immunosuppressant))))) (. .)))
18186898	5	(S1 (S (NP (NN Doc_18186898_525_535_Chemical)) (VP (AUX was) (VP (VBN added) (PP (IN because) (IN of) (NP (IN de) (NNP nova) (NNP Doc_18186898_565_586_Disease))) (PP (IN during) (NP (PRP$ her) (NN follow-up))))) (. .)))
18186898	6	(S1 (S (PP (NP (CD Three) (NNS yr)) (IN after) (NP (NN transplantation))) (NP (PRP she)) (VP (VBD developed) (NP (NNP Doc_18186898_654_676_Disease)) (PP (IN with) (NP (NP (JJ severe) (NNP Doc_18186898_689_707_Disease)) (, ,) (NP (NNP Doc_18186898_709_725_Disease)) (, ,) (NP (NNP Doc_18186898_727_737_Disease)) (, ,) (CC and) (NP (NNP Doc_18186898_743_756_Disease))))) (. .)))
18186898	7	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_18186898_767_777_Chemical)) (VP (VP (AUX was) (VP (VBN suspected) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (JJ late) (JJ post-transplant) (JJ renal) (NN Doc_18186898_838_846_Disease))))))))) (CC and) (VP (AUX was) (VP (VBN replaced) (PP (IN by) (NP (NNP Doc_18186898_867_876_Chemical)))))))) (, ,) (NP (NP (NNP Doc_18186898_878_886_Disease)) (, ,) (CC and) (NP (NN electrolyte) (NN imbalance))) (VP (VBD got) (ADJP (JJR worse))) (. .)))
18186898	8	(S1 (S (NP (NNP Proximal) (NNP Doc_18186898_934_949_Disease)) (VP (AUX has) (VP (VBN developed) (PP (IN during) (NP (PRP$ her) (NN follow-up))))) (. .)))
18186898	9	(S1 (S (NP (NP (NN Doc_18186898_986_1002_Disease)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NNP Doc_18186898_1015_1023_Disease)) (, ,)) (VP (AUX is) (ADVP (RB well)) (VP (VP (VBN recognized) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_18186898_1061_1084_Disease)))))) (CC and) (VP (VBN caused) (PP (IN by) (NP (NP (NN depletion)) (PP (IN of) (NP (NN mtDNA)))))))) (. .)))
18186898	10	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (PRP$ our) (NN patient) (POS 's)) (NNP Doc_18186898_1149_1168_Disease) (CC and) (NNP Doc_18186898_1173_1181_Disease)) (VP (MD may) (VP (AUX have) (VP (VBN resulted) (PP (IN from) (NP (NP (NNP Doc_18186898_1205_1230_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VP (VBN triggered) (PP (IN by) (NP (NNP Doc_18186898_1253_1263_Chemical)))) (CC and) (VP (VBN augmented) (PP (IN by) (NP (NN Doc_18186898_1281_1291_Chemical)))))))))))))))) (. .)))
18208574	0	(S1 (S (NP (NP (JJR Higher) (JJ optical) (NN density)) (PP (IN of) (NP (DT an) (NN antigen) (NN assay)))) (VP (VBZ predicts) (NP (NN Doc_18208574_52_62_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_18208574_80_87_Chemical-induced) (NNP Doc_18208574_96_112_Disease)))))) (. .)))
18208574	1	(S1 (S (S (VP (TO To) (VP (VB correlate) (NP (NP (JJ optical) (NN density)) (CC and) (NP (NP (NN percent) (NN inhibition)) (PP (IN of) (NP (NP (DT a) (JJ two-step) (JJ Doc_18208574_192_199_Chemical-induced) (NNP Doc_18208574_208_224_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_18208574_226_229_Disease)) (-RRB- -RRB-)) (NN antigen) (NN assay)) (PP (IN with) (NP (NNP Doc_18208574_250_260_Disease)))))))))) (: ;) (S (NP (DT the) (NN assay)) (VP (VBZ utilizes) (NP (NP (NN reaction) (NN inhibition) (NNS characteristics)) (PP (IN of) (NP (DT a) (JJ high) (JJ Doc_18208574_327_334_Chemical) (NN concentration)))))) (. .)))
18208574	2	(S1 (S (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (NNPS Patients)) (PP (IN with) (NP (NP (NP (QP (JJR more) (IN than) (CD 50)) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (JJ platelet) (NN count)) (CC or) (NP (NP (NNP Doc_18208574_430_446_Disease)) (PRN (-LRB- -LRB-) (NP (CD <150) (NNP x) (CD 10) (-LRB- -LRB-) (CD 9) (-RRB- -RRB-) (NNS /L)) (-RRB- -RRB-))))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NNP Doc_18208574_482_489_Chemical)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (JJ positive) (JJ two-step) (NN antigen) (NN assay) (JJ -LSB-optical) (NN density)) (PRN (-LRB- -LRB-) (NP (NNP OD)) (-RRB- -RRB-)) (NP (QP (CD >0.4) (CC and) (CD >50)) (NN inhibition))) (PP (IN with) (NP (NP (JJ high) (NN concentration)) (PP (IN of) (NP (JJ Doc_18208574_606_613_Chemical) (NNS -RSB-))))))))))))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN study))))) (. .)))
18208574	3	(S1 (S (S (NP (NP (CD Forty)) (PP (IN of) (NP (CD 94) (NNP Doc_18208574_664_667_Disease) (NNS patients)))) (VP (AUX had) (NP (NN Doc_18208574_681_691_Disease)) (PP (IN at) (NP (NN diagnosis))))) (: ;) (S (NP (CD 54/94)) (VP (AUX had) (NP (NN isolated-Doc_18208574_725_728_Disease)) (PP (IN without) (NP (NNP Doc_18208574_737_747_Disease))))) (. .)))
18208574	4	(S1 (S (S (NP (NP (CD Eight)) (PP (IN of) (NP (DT the) (JJ isolated-Doc_18208574_771_774_Disease) (NNS patients)))) (VP (VBD developed) (NP (NN Doc_18208574_794_804_Disease)) (PP (IN within) (NP (NP (DT the) (JJ next) (CD 30)) (NP (NNP d)))))) (: ;) (S (ADVP (RB thus)) (, ,) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 48) (NNS patients)))) (VP (AUX had) (NP (NN Doc_18208574_860_870_Disease)) (PP (IN at) (NP (NN day) (CD 30))))) (. .)))
18208574	5	(S1 (S (PP (IN At) (NP (NN diagnosis))) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NN OD))) (PP (IN between) (NP (NP (NP (JJ Doc_18208574_945_948_Disease) (NNS patients)) (PP (IN with) (NP (NNP Doc_18208574_963_973_Disease)))) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (NN isolated-Doc_18208574_998_1001_Disease)))))))) (. .)))
18208574	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP OD)) (VP (AUX was) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NP (DT all) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_18208574_1061_1071_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 48)) (, ,) (NP (QP (CD 1.34) (CD +/-)) (CD 0.89)) (-RRB- -RRB-)))) (, ,) (PP (VBG including) (NP (NP (JJ isolated-Doc_18208574_1116_1119_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (ADVP (RB later)) (VP (VBD developed) (NP (NNP Doc_18208574_1149_1159_Disease)) (PP (IN within) (NP (NP (CD 30)) (NP (NNP d)))) (PRN (-LRB- -LRB-) (NP (NP (NNP n) (SYM =) (CD 8)) (, ,) (NP (CD 1.84) (JJ +/-) (NN 0.64))) (-RRB- -RRB-)) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ isolated-Doc_18208574_1219_1222_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (VB develop) (NP (NP (NNP Doc_18208574_1252_1262_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.96) (NN +/-) (CD 0.75)) (: ;) (NP (NNP P) (SYM =) (CD 0.011) (CC and) (CD P)) (X (SYM =)) (CD 0.008)) (-RRB- -RRB-)))))))))))))))))))) (. .)))
18208574	7	(S1 (S (NP (DT The) (NN Receiver)) (NP (JJ Operative) (JJ Characteristic) (NN Curve)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNP OD) (CD >1.27)) (PP (IN in) (NP (DT the) (JJ isolated-Doc_18208574_1386_1389_Disease) (NN group)))) (VP (AUX had) (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN chance)) (PP (IN of) (S (VP (VBG developing) (NP (NN Doc_18208574_1444_1454_Disease)) (PP (IN by) (NP (NN day) (CD 30))))))))))) (. .)))
18208574	8	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (NNS groups)))) (VP (VBD showed) (NP (NP (JJ significant) (NN difference)) (PP (IN in) (NP (NN percent) (NN inhibition))))) (. .)))
18208574	9	(S1 (S (NP (JJ Multivariate) (NN analysis)) (VP (VBD showed) (NP (NP (DT a) (JJ 2.8-fold) (JJ increased) (NN risk)) (PP (IN of) (NP (NNP Doc_18208574_1598_1608_Disease))) (PP (IN in) (NP (NNS females))))) (. .)))
18208574	10	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NN Doc_18208574_1632_1642_Disease) (NN risk)) (VP (VBN increased) (PP (IN with) (NP (NP (NN age)) (CC and) (NP (NN OD) (NNS values))))) (. .)))
18208574	11	(S1 (S (S (NP (JJR Higher) (NN OD)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ significant) (NN risk)) (PP (IN of) (NP (NP (JJ subsequent) (NN Doc_18208574_1754_1764_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN isolated-Doc_18208574_1791_1794_Disease)))))))))))) (: ;) (S (NP (NN percent) (NN inhibition)) (, ,) (ADVP (RB however)) (, ,) (VP (AUX was) (RB not) (ADJP (JJ predictive)))) (. .)))
18217897	0	(S1 (S (NP (NNP Doc_18217897_0_11_Chemical)) (VP (AUX has) (NP (NP (NP (JJ limited) (JJ single-agent) (NN activity)) (PP (IN in) (NP (JJ relapsed) (CC or) (JJ refractory) (NN indolent) (NN Doc_18217897_81_102_Disease)))) (: :) (NP (NP (DT a) (NN phase) (NNP II) (NN trial)) (PP (IN of) (NP (NP (DT the) (NNP Doc_18217897_128_134_Disease)) (CC and) (NP (NNP Doc_18217897_139_147_Disease) (NNP Group) (NNP B))))))) (. .)))
18217897	1	(S1 (S (NP (NN Doc_18217897_157_168_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ immunomodulatory) (NN agent)) (PP (IN with) (NP (NP (VBN demonstrated) (NN activity)) (PP (IN in) (NP (NP (NNP Doc_18217897_228_244_Disease)) (, ,) (NP (NNP Doc_18217897_246_266_Disease)) (CC and) (NP (NNP Doc_18217897_271_297_Disease)))))))) (. .)))
18217897	2	(S1 (S (NP (PRP$ Its) (NN activity)) (VP (AUX is) (VP (VBN believed) (S (VP (TO to) (VP (AUX be) (NP (NP (JJ due) (NN modulation)) (PP (IN of) (NP (DT the) (NNP Doc_18217897_352_358_Disease) (NN milieu))))))) (, ,) (PP (VBG including) (NP (NP (NN downregulation)) (PP (IN of) (NP (NP (NNS angiogenesis)) (CC and) (NP (JJ inflammatory) (NNS cytokines)))))))) (. .)))
18217897	3	(S1 (S (PP (IN Between) (NP (NNP July) (CD 2001) (CC and) (NP (NNP April) (CD 2004)))) (, ,) (NP (NP (CD 24) (NNS patients)) (PP (IN with) (NP (JJ relapsed/refractory) (NN indolent) (NN Doc_18217897_516_525_Disease)))) (VP (VBD received) (NP (NP (NNP Doc_18217897_535_546_Chemical) (CD 200) (NNS mg)) (ADJP (JJ daily) (PP (IN with) (NP (NN escalation))))) (PP (IN by) (NP (NP (CD 100) (NNS mg)) (ADVP (RB daily) (NP (DT every) (JJ 1-2) (NNS weeks)) (PP (IN as) (ADJP (JJ tolerated)))))) (, ,) (ADVP (RB up) (PP (TO to) (NP (NP (DT a) (NN maximum)) (PP (IN of) (NP (NP (CD 800) (NNS mg)) (ADVP (RB daily)))))))) (. .)))
18217897	4	(S1 (S (NP (NNS Patients)) (VP (AUX had) (VP (VBN received) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (CD 2) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (NN 1-4)) (-RRB- -RRB-)) (JJ prior) (NNS regimens)))))) (. .)))
18217897	5	(S1 (S (PP (IN Of) (NP (CD 24) (JJ evaluable) (NNS patients))) (, ,) (NP (NP (NP (CD two)) (VP (VBN achieved) (NP (DT a) (JJ complete) (NN remission)))) (CC and) (NP (CD one))) (VP (VBD achieved) (NP (NP (DT a) (JJ partial) (NN remission)) (PP (IN for) (NP (NP (DT an) (JJ overall) (NN response) (NN rate)) (PP (IN of) (NP (CD 12.5) (NN %))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NN confidence) (NN interval)) (: :) (NP (CD 2.6-32.4) (NN %))) (-RRB- -RRB-)))))) (. .)))
18217897	6	(S1 (S (NP (CD Eleven) (NNS patients)) (VP (VBD progressed) (PP (IN during) (NP (NN therapy)))) (. .)))
18217897	7	(S1 (S (NP (NN Grade) (NN 3-4) (JJ adverse) (NNS effects)) (VP (VBD included) (NP (NNP Doc_18217897_971_987_Disease) (, ,) (NNP Doc_18217897_989_996_Disease) (, ,) (NNP Doc_18217897_998_1008_Disease/Doc_18217897_1009_1023_Disease) (, ,) (NNP Doc_18217897_1025_1035_Disease) (CC and) (NNP Doc_18217897_1040_1047_Disease))) (. .)))
18217897	8	(S1 (SINV (PP (IN Of) (NP (NN concern))) (VP (AUX was)) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (CD four) (JJ Doc_18217897_1087_1101_Disease) (NNS events)))) (. .)))
18217897	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBD failed) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (NP (DT an) (JJ important) (NN response) (NN rate)) (PP (TO to) (NP (NP (JJ single) (NN agent) (NNP Doc_18217897_1187_1198_Chemical)) (PP (IN in) (NP (JJ indolent) (NNP Doc_18217897_1211_1220_Disease)))))) (CC and) (NP (NP (NN contrast)) (PP (IN with) (NP (NP (DT the) (JJR higher) (NN activity) (NN level)) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (JJ second) (NN generation) (NN immunomodulatory) (NN agent)) (, ,) (NP (NNP Doc_18217897_1325_1337_Chemical))))))))))))) (. .)))
18221780	0	(S1 (NP (NP (NP (NN Sex) (NNS differences)) (PP (IN in) (NP (NP (JJ Doc_18221780_19_23_Chemical) (NN antagonist) (NN enhancement)) (PP (IN of) (NP (JJ Doc_18221780_50_58_Chemical) (NNS antihyperalgesia))) (PP (IN in) (NP (NP (DT a) (JJ Doc_18221780_81_90_Chemical) (NN model)) (PP (IN of) (NP (JJ persistent) (NNP Doc_18221780_111_115_Disease)))))))) (: :) (NP (NP (NNS comparisons)) (PP (TO to) (NP (NP (CD two) (NNS models)) (PP (IN of) (NP (NNP Doc_18221780_146_156_Disease)))))) (. .)))
18221780	1	(S1 (S (PP (IN In) (NP (NNP Doc_18221780_161_171_Disease) (NNS models))) (, ,) (NP (NNP Doc_18221780_180_200_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18221780_202_206_Chemical)) (-RRB- -RRB-)) (NNS antagonists)) (VP (VB enhance) (NP (NP (DT the) (JJ antinociceptive) (NNS effects)) (PP (IN of) (NP (NNP Doc_18221780_259_267_Chemical)))) (PP (TO to) (NP (DT a) (JJR greater) (NN extent))) (PP (IN in) (NP (NP (NNS males)) (PP (IN than) (NP (NNS females)))))) (. .)))
18221780	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN investigation)))) (VP (AUX was) (S (VP (TO to) (VP (VB extend) (NP (DT these) (NNS findings)) (PP (TO to) (NP (NP (DT a) (JJ persistent) (NN Doc_18221780_390_394_Disease) (NN model)) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX be) (VP (VBN distinguished) (PP (IN from) (NP (NNP Doc_18221780_435_445_Disease) (NNS models))) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NP (DT the) (JJ nociceptive) (NNS fibers)) (VP (VBN activated))) (, ,) (NP (JJ neurochemical) (NNS substrates)) (, ,) (CC and) (NP (NP (NN duration)) (PP (IN of) (NP (DT the) (JJ nociceptive) (NN stimulus))))))))))))))))))) (. .)))
18221780	3	(S1 (S (PP (TO To) (NP (DT this) (NN end))) (, ,) (NP (JJ persistent) (NN Doc_18221780_595_607_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_18221780_641_650_Chemical))))) (PP (IN in) (NP (NP (DT the) (NN tail)) (PP (IN of) (NP (ADJP (RB gonadally) (JJ intact)) (JJ F344) (NNS rats))))) (, ,) (S (VP (VBG following) (SBAR (WHNP (WDT which)) (S (S (NP (DT the) (NN tail)) (VP (AUX was) (VP (VBN immersed) (PP (IN in) (NP (DT a) (ADJP (RB mildly) (JJ noxious)) (JJ thermal) (NN stimulus)))))) (, ,) (CC and) (S (NP (JJ tail-withdrawal) (NNS latencies)) (VP (VBN measured))))))))) (. .)))
18221780	4	(S1 (S (PP (IN For) (NP (NN comparison))) (, ,) (NP (NNS tests)) (VP (AUX were) (VP (VBN conducted) (PP (IN in) (NP (NP (CD two) (JJ Doc_18221780_854_864_Disease) (NNS models)) (, ,) (NP (DT the) (NN hotplate)) (CC and) (NP (JJ warm) (NN water) (NN tail-withdrawal) (NNS procedures)))))) (. .)))
18221780	5	(S1 (S (PP (IN In) (NP (NNS males))) (, ,) (NP (DT the) (JJ non-competitive) (JJ Doc_18221780_959_963_Chemical) (NN antagonist) (NNP Doc_18221780_975_991_Chemical)) (VP (VBD enhanced) (NP (NP (DT the) (JJ antihyperalgesic) (NN effect)) (PP (IN of) (NP (NN low)))) (PP (TO to) (NP (NP (JJ moderate) (NNS doses)) (PP (IN of) (NP (NNP Doc_18221780_1057_1065_Chemical))))) (PP (IN in) (NP (DT a) (JJ dose-and) (JJ time-dependent) (NN manner)))) (. .)))
18221780	6	(S1 (S (PP (IN Across) (NP (NP (DT the) (NNS doses) (CC and) (NN pretreatment) (NNS times)) (VP (VBN examined)))) (, ,) (NP (NN enhancement)) (VP (AUX was) (RB not) (VP (VBN observed) (PP (IN in) (NP (NNS females))))) (. .)))
18221780	7	(S1 (S (NP (NP (NN Enhancement)) (PP (IN of) (NP (JJ Doc_18221780_1209_1217_Chemical) (NN antinociception))) (PP (IN by) (NP (NNP Doc_18221780_1237_1253_Chemical)))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (DT both) (NNS males) (CC and) (NNS females)) (PP (IN in) (NP (DT the) (NNP Doc_18221780_1296_1306_Disease) (NNS models))))) (, ,) (PP (IN with) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (S (NP (DT this) (NN effect)) (VP (AUXG being) (ADJP (JJR greater)) (PP (IN in) (NP (NNS males)))))))))) (. .)))
18221780	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP demonstrate) (NP (NP (DT a) (JJ sexually-dimorphic) (NN interaction)) (PP (IN between) (NP (NP (JJ Doc_18221780_1441_1445_Chemical) (NNS antagonists) (CC and) (NNP Doc_18221780_1462_1470_Chemical)) (PP (IN in) (NP (NP (DT a) (JJ persistent) (NN Doc_18221780_1487_1491_Disease) (NN model)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN distinguished) (PP (IN from) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_18221780_1547_1557_Disease) (NNS models))))))))))))))))) (. .)))
18261172	0	(S1 (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_18261172_15_26_Disease))) (PP (IN after) (NP (NN switch))) (PP (TO to) (NP (NP (JJ Doc_18261172_43_52_Chemical-based) (NN immunosuppression)) (PP (IN in) (NP (JJ long-term) (JJ cardiac) (NN transplant) (NNS patients))))) (. .)))
18261172	1	(S1 (S (NP (JJ Calcineurin-inhibitor) (NN therapy)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (NNP Doc_18261172_161_178_Disease)) (PP (IN in) (NP (NN heart) (NN transplantation) (NNS patients))))))) (. .)))
18261172	2	(S1 (S (S (NP (NP (DT The) (JJ novel) (JJ immunosuppressive) (PRN (-LRB- -LRB-) (NP (AUX IS)) (-RRB- -RRB-)) (NN drug) (NNP Doc_18261172_252_260_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18261172_262_265_Chemical)) (-RRB- -RRB-))) (VP (VBZ lacks) (NP (NNP Doc_18261172_273_284_Disease) (NNS effects)))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (NNP Doc_18261172_303_314_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18261172_331_334_Chemical))))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (VBG following) (NP (JJ renal) (NN transplantation))))))) (. .)))
18261172	3	(S1 (S (PP (IN In) (NP (JJ cardiac) (NN transplantation))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_18261172_431_442_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18261172_459_462_Chemical))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
18261172	4	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (JJ long-term) (JJ cardiac) (NN transplant) (NNS patients)) (VP (AUX were) (VP (VBN switched) (PP (IN from) (NP (NNP Doc_18261172_547_559_Chemical))) (PP (TO to) (NP (JJ Doc_18261172_563_566_Chemical-based) (NNS IS))))) (. .)))
18261172	5	(S1 (S (NP (NN Concomitant)) (VP (AUX IS) (VP (VBN consisted) (PP (IN of) (NP (JJ Doc_18261172_605_626_Chemical) (JJ +/-) (NN Doc_18261172_631_639_Chemical))))) (. .)))
18261172	6	(S1 (S (NP (NNP Proteinuria)) (VP (VBD increased) (ADVP (RB significantly)) (PP (IN from) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (CD 0.13) (JJ g/day) (PRN (-LRB- -LRB-) (NP (NN range) (CD 0-5.7)) (-RRB- -RRB-)) (NN preswitch))))) (PP (TO to) (NP (NP (CD 0.23) (NN g/day)) (PRN (-LRB- -LRB-) (NP (CD 0-9.88)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (CD 24) (NNS months) (JJ postswitch)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0024)) (-RRB- -RRB-))))) (. .)))
18261172	7	(S1 (S (S (PP (IN Before) (NP (DT the) (NN switch))) (, ,) (NP (NP (CD 11.5) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX had) (NP (NP (JJ high-grade) (NN Doc_18261172_842_853_Disease)) (PRN (-LRB- -LRB-) (NP (CD >1.0) (NN g/day)) (-RRB- -RRB-))))) (: ;) (S (NP (DT this)) (VP (VBN increased) (PP (TO to) (NP (ADJP (CD 22.9) (NN %)) (NN postswitch))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.006)))) (-RRB- -RRB-)))) (. .)))
18261172	8	(S1 (S (NP (NP (NN Doc_18261172_916_929_Chemical)) (CC and) (NP (NNP Doc_18261172_934_963_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18261172_965_968_Chemical)) (-RRB- -RRB-)) (NN therapy))) (VP (VBD reduced) (NP (JJ Doc_18261172_986_997_Disease) (NN development))) (. .)))
18261172	9	(S1 (S (NP (NP (NNPS Patients)) (PP (IN without) (NP (NNP Doc_18261172_1028_1039_Disease)))) (VP (AUX had) (VP (VBN increased) (NP (NP (JJ renal) (NN function)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ median) (CD 42.5)) (CC vs.) (NP (CD 64.1))) (, ,) (NP (NNP p) (SYM =) (CD 0.25))) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ high-grade) (NNP Doc_18261172_1145_1156_Disease)))))) (VP (VBD showed) (NP (NP (VBN decreased) (JJ renal) (NN function)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN follow-up))))) (PRN (-LRB- -LRB-) (NP (NP (JJ median) (CD 39.6) (CC vs.) (CD 29.2)) (, ,) (NP (NNP p) (SYM =) (CD 0.125))) (-RRB- -RRB-)))))))) (. .)))
18261172	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_18261172_1254_1265_Disease)) (VP (MD may) (VP (VB develop) (PP (IN in) (NP (JJ cardiac) (NN transplant) (NNS patients))) (PP (IN after) (NP (NN switch))) (PP (TO to) (NP (NP (NNP Doc_18261172_1325_1328_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX have) (NP (NP (DT an) (JJ adverse) (NN effect)) (PP (IN on) (NP (NP (JJ renal) (NN function)) (PP (IN in) (NP (DT these) (NNS patients)))))))))))))) (. .)))
18261172	11	(S1 (S (NP (NNP Doc_18261172_1400_1403_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (NP (JJ Doc_18261172_1424_1428_Chemical/Doc_18261172_1429_1432_Chemical) (NN therapy)) (CC and) (NP (NP (NNS patients)) (VP (VBN monitored) (PP (IN for) (NP (NP (NNP Doc_18261172_1468_1479_Disease)) (CC and) (NP (VBN increased) (NNP Doc_18261172_1494_1511_Disease))))))))))) (. .)))
18308784	0	(S1 (S (NP (NN Doc_18308784_0_15_Chemical)) (VP (VBZ restores) (NP (NP (DT the) (NNP Doc_18308784_29_51_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ chronic) (JJ Doc_18308784_71_79_Chemical) (NN administration)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
18308784	1	(S1 (S (NP (NN Doc_18308784_104_107_Chemical)) (, ,) (PP (IN as) (NP (NP (DT a) (NN Doc_18308784_114_125_Chemical)) (VP (VBN extracted) (PP (IN from) (NP (JJ Panax) (NN ginseng)))))) (, ,) (VP (MD could) (VP (VB ameliorate) (NP (JJ spatial) (NNP Doc_18308784_181_200_Disease)))) (. .)))
18308784	2	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (AUX have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NNP Doc_18308784_242_245_Chemical)) (VP (MD might) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN agent)) (PP (IN for) (NP (NP (DT the) (NN prevention) (CC and) (NN treatment)) (PP (IN of) (NP (NP (DT the) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NN Doc_18308784_329_337_Chemical)))))))))))))) (. .)))
18308784	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_18308784_394_397_Chemical))) (PP (IN on) (NP (NNP Doc_18308784_401_420_Disease)))) (PP (IN by) (NP (NP (JJ chronic) (JJ Doc_18308784_432_440_Chemical) (NN administration)) (CC and) (NP (NP (DT the) (NN mechanism)) (ADJP (JJ responsible) (PP (IN for) (NP (DT this) (NN effect))))))))))) (. .)))
18308784	4	(S1 (S (S (NP (JJ Male) (NNS rats)) (VP (AUX were) (ADVP (RB subcutaneously)) (VP (VBN injected) (PP (IN with) (NP (NP (NNP Doc_18308784_547_555_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)))) (ADVP (RB twice) (NP (DT a) (NN day))) (PP (IN at) (NP (NP (ADJP (CD 12) (NN hour)) (NNS intervals)) (PP (IN for) (NP (CD 10) (NNS days)))))))) (, ,) (CC and) (S (NP (NP (NNP Doc_18308784_617_620_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB intraperitoneally)) (VP (VBN injected) (NP (CD 2) (NNS hours)) (PP (IN after) (NP (NP (DT the) (JJ second) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_18308784_701_709_Chemical)) (ADVP (RB once) (NP (DT a) (NN day)) (PP (IN for) (NP (CD 10) (NNS days))))))))))) (. .)))
18308784	5	(S1 (S (NP (JJ Spatial) (NN learning) (NN capacity)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (DT the) (NNP Morris) (NN water) (NN maze))))) (. .)))
18308784	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNS rats)) (VP (VP (VBD treated) (PP (IN with) (NP (JJ Doc_18308784_841_849_Chemical/Doc_18308784_850_853_Chemical) (VBN decreased) (NN escape) (NN latency)))) (CC and) (VP (VBD increased) (NP (NP (DT the) (NN time)) (VP (VBN spent) (PP (IN in) (NP (NN platform) (UCP (NNP quadrant) (CC and) (VBG entering)) (NN frequency)))))))))) (. .)))
18308784	7	(S1 (S (PP (IN By) (NP (NP (NN implantation)) (PP (IN of) (NP (NP (NNS electrodes)) (CC and) (NP (NN electrophysiological) (NN recording)))) (PP (IN in) (NP (NN vivo))))) (, ,) (NP (DT the) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_18308784_1051_1054_Chemical)) (VP (VBD restored) (NP (NP (DT the) (JJ long-term) (NN potentiation)) (PRN (-LRB- -LRB-) (NP (NNP LTP)) (-RRB- -RRB-)) (VP (VBN impaired) (PP (IN by) (NP (NNP Doc_18308784_1109_1117_Chemical))) (PP (IN in) (NP (DT both) (ADJP (ADJP (RB freely) (JJ moving)) (CC and) (ADJP (JJ anaesthetised))) (NNS rats))))))))) (. .)))
18308784	8	(S1 (S (S (NP (NP (DT The) (JJ electrophysiological) (NN recording)) (PP (IN in) (NP (NN vitro)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_18308784_1220_1223_Chemical)) (VP (VP (VBD restored) (NP (NP (DT the) (NNS LTP)) (PP (IN in) (NP (NNS slices)))) (PP (IN from) (NP (NP (DT the) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18308784_1278_1286_Chemical))))))) (, ,) (CC but) (RB not) (VP (VBD changed) (NP (NN LTP)) (PP (IN in) (NP (NP (DT the) (NNS slices)) (PP (IN from) (NP (JJ normal) (ADJP (JJ saline-) (CC or) (JJ Doc_18308784_1345_1353_Chemical/Doc_18308784_1354_1357_Chemical-treated)) (NNS rats))))))))))) (: ;) (S (NP (DT this) (NN restoration)) (VP (MD could) (VP (AUX be) (VP (VBD inhibited) (PP (IN by) (NP (NNP Doc_18308784_1411_1431_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18308784_1433_1437_Chemical)) (-RRB- -RRB-)) (NN receptor) (NN antagonist) (NNP Doc_18308784_1459_1464_Chemical))))))) (. .)))
18308784	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_18308784_1483_1486_Chemical)) (VP (MD may) (ADVP (RB significantly)) (VP (VP (VB improve) (NP (NP (DT the) (JJ spatial) (NN learning) (NN capacity)) (VP (VBN impaired) (PP (IN by) (NP (JJ chonic) (JJ Doc_18308784_1562_1570_Chemical) (NN administration)))))) (CC and) (VP (VB restore) (NP (DT the) (JJ Doc_18308784_1602_1610_Chemical-inhibited) (NN LTP)))))))) (. .)))
18308784	10	(S1 (S (NP (DT This) (NN effect)) (VP (AUX is) (ADJP (NP (JJ Doc_18308784_1641_1645_Chemical) (NN receptor)) (JJ dependent))) (. .)))
18329269	0	(S1 (NP (NP (NN Synthesis)) (PP (IN of) (NP (NNP Doc_18329269_13_46_Chemical))) (PP (IN as) (NP (NNP Doc_18329269_50_59_Chemical) (NNP A2A) (NN receptor) (NNS antagonists))) (. .)))
18329269	1	(S1 (S (NP (NP (DT A) (NN series)) (PP (IN of) (NP (NNP Doc_18329269_98_130_Chemical) (NNP Doc_18329269_131_140_Chemical) (NNP A) (PRN (-LRB- -LRB-) (NP (NN 2A)) (-RRB- -RRB-)) (NNS antagonists)))) (VP (AUX is) (VP (VBN described))) (. .)))
18329269	2	(S1 (S (NP (NNP SAR) (NNS studies)) (VP (VBD led) (S (VP (TO to) (VP (VB compound) (NP (NP (CD 14)) (PP (IN with) (NP (NP (NP (JJ excellent) (NN potency)) (PRN (-LRB- -LRB-) (NP (NP (NNP K)) (SBAR (S (-LRB- -LRB-) (NP (PRP i)) (-RRB- -RRB-) (VP (SYM =) (NP (CD 0.4) (CD nM)))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN selectivity)) (PRN (-LRB- -LRB-) (NP (DT A) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NN /A) (-LRB- -LRB-) (NN 2A) (-RRB- -RRB-) (NNP >) (CD 100)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN efficacy)) (PRN (-LRB- -LRB-) (VP (VBN MED) (NP (QP (CD 10) (CD mg/kg)) (NNS p.o.))) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NP (DT the) (NN rat)) (JJ Doc_18329269_320_331_Chemical-induced) (NNP Doc_18329269_340_349_Disease) (NN model)) (PP (IN for) (NP (NNP Doc_18329269_360_379_Disease))))))))) (. .)))
1833784	0	(S1 (NP (NP (NN Evidence)) (PP (IN for) (NP (NP (DT an) (NN involvement)) (PP (IN of) (NP (NNP D1) (CC and) (NNP D2) (NNP Doc_1833784_41_49_Chemical) (NNS receptors))) (PP (IN in) (S (VP (VBG mediating) (NP (JJ Doc_1833784_73_81_Chemical-induced) (NNP Doc_1833784_90_103_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
1833784	1	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (AUX have) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (VBN repeated) (NN exposure)) (PP (IN of) (NP (NNS rats))) (PP (PP (TO to) (NP (DT the) (NN drug))) (CC or) (PP (TO to) (NP (DT the) (JJ experimental) (NN environment))))) (VP (AUX is) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB observe) (NP (JJ Doc_1833784_247_255_Chemical-induced) (NN locomotor) (NN stimulation))))))))))) (. .)))
1833784	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN habituation))) (PP (TO to) (NP (DT the) (JJ experimental) (NN environment))) (PP (IN on) (NP (NP (DT the) (NN stimulant) (NN effect)) (PP (IN of) (NP (NNP Doc_1833784_391_399_Chemical))))) (PP (IN in) (NP (NNS rats)))) (VP (AUX was) (VP (VBN examined))) (. .)))
1833784	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ Doc_1833784_447_455_Chemical) (NNS receptors))) (PP (IN in) (S (VP (VBG mediating) (NP (JJ Doc_1833784_479_487_Chemical-induced) (NN locomotor) (NN stimulation)))))) (VP (AUX was) (VP (VBN investigated) (PP (IN by) (S (VP (VBG examining) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ selective) (NNP D1) (CC and) (NNP D2) (NNP Doc_1833784_583_591_Chemical) (NN receptor) (NNS antagonists))) (PP (IN on) (NP (NP (NN activity)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1833784_636_644_Chemical)))))))))))) (. .)))
1833784	4	(S1 (S (NP (NN Locomotor) (NN activity)) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ male) (JJ Sprague-Dawley) (NNS rats)) (VP (VBN tested) (PP (IN in) (NP (JJ photocell) (NNS cages)))))))) (. .)))
1833784	5	(S1 (S (NP (NP (NN Doc_1833784_733_741_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.0) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN Doc_1833784_775_805_Disease)) (PP (IN in) (NP (NNS rats))) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX were) (VP (VBN habituated) (PP (TO to) (NP (DT the) (NN test) (NN environment))))) (, ,) (CC but) (VP (AUX had) (NP (RB only) (DT a) (JJ weak) (CC and) (JJ delayed) (NN stimulant) (NN action)) (PP (IN in) (NP (NP (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ unfamiliar) (PP (IN with) (NP (DT the) (NN test) (NN environment))))))))))))))) (. .)))
1833784	6	(S1 (S (NP (NP (DT The) (NN stimulant) (NN action)) (PP (IN of) (NP (NNP Doc_1833784_989_997_Chemical)))) (VP (AUX was) (VP (VBN blocked) (PP (PP (IN by) (NP (DT the) (JJ central) (JJ nicotinic) (NN antagonist) (NNP Doc_1833784_1046_1058_Chemical))) (CC but) (PP (RB not) (IN by) (NP (NP (DT the) (JJ peripheral) (JJ nicotinic) (NN blocker) (NNP Doc_1833784_1103_1116_Chemical)) (, ,) (VP (VBG indicating) (SBAR (IN that) (S (NP (DT the) (NN response)) (VP (AUX is) (ADVP (RB probably)) (VP (VBN mediated) (PP (IN by) (NP (JJ central) (JJ nicotinic) (NNS receptors))))))))))))) (. .)))
1833784	7	(S1 (S (NP (JJ Doc_1833784_1200_1208_Chemical-induced) (NN Doc_1833784_1217_1230_Disease)) (VP (AUX was) (VP (VBN blocked) (PP (IN by) (NP (NP (DT the) (JJ selective) (NNP D1) (NN antagonist) (NNP Doc_1833784_1274_1283_Chemical)) (, ,) (NP (DT the) (JJ selective) (NNP D2) (NN antagonist) (NNP Doc_1833784_1313_1323_Chemical)) (CC and) (NP (DT the) (NNP D1/D2) (NN antagonist) (NNP Doc_1833784_1349_1361_Chemical)))))) (. .)))
1833784	8	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (DT the) (NNP D2) (NN agonist) (NN Doc_1833784_1396_1400_Chemical)))) (VP (VBD enhanced) (NP (JJ Doc_1833784_1410_1418_Chemical-induced) (NNP Doc_1833784_1427_1440_Disease)) (, ,) (SBAR (IN whereas) (S (NP (DT the) (NNP D1) (NNP agonist) (NNP Doc_1833784_1465_1474_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)))))) (. .)))
1833784	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ acute) (JJ Doc_1833784_1522_1530_Chemical) (NN injection)) (VP (VBZ induces) (NP (NP (DT a) (JJ pronounced) (NN Doc_1833784_1562_1575_Disease)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN habituated) (PP (TO to) (NP (DT the) (NN test) (NN environment))))))))))) (. .)))
1833784	10	(S1 (S (S (NP (DT The) (NN effect)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ central) (JJ Doc_1833784_1665_1673_Chemical) (NNS receptors)) (, ,) (VP (ADVP (RB possibly)) (VBN located) (PP (IN on) (NP (JJ dopaminergic) (NNS neurons)))))))))))) (, ,) (CC and) (S (ADVP (RB also)) (VP (VBZ requires) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT both) (NNP D1) (CC and) (NNP D2) (NNP Doc_1833784_1778_1786_Chemical) (NNS receptors)))))) (. .)))
18343374	0	(S1 (S (NP (NNP Central) (NNP Doc_18343374_8_30_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_18343374_47_57_Chemical-induced) (NN ovulation)))) (. .)))
18343374	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ central) (NN Doc_18343374_116_138_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_18343374_155_173_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18343374_175_177_Chemical)) (-RRB- -RRB-))))))))))) (. .)))
18343374	2	(S1 (FRAG (NP (NN Case) (NN study)) (. .)))
18343374	3	(S1 (NP (NP (NN Ophthalmology) (NN clinic)) (PP (IN of) (NP (DT an) (JJ academic) (NN hospital))) (. .)))
18343374	4	(S1 (NP (NP (NP (NN PATIENT)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (NP (NP (DT A) (JJ 36-year-old) (NN woman)) (VP (VBN referred) (PP (IN from) (NP (NP (DT the) (JJ Doc_18343374_305_316_Disease) (NN clinic)) (PP (IN for) (NP (NNP Doc_18343374_328_342_Disease))))))) (. .)))
18343374	5	(S1 (NP (NP (NP (NN INTERVENTION)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (NP (NP (JJ Ophthalmic) (NN examination)) (PP (IN after) (NP (JJ Doc_18343374_390_392_Chemical) (NN therapy)))) (. .)))
18343374	6	(S1 (NP (NP (NP (JJ MAIN) (NN OUTCOME) (NN MEASURE)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (NP (NP (NNP Central) (NNP Doc_18343374_435_457_Disease)) (PP (IN after) (NP (NP (NN ovulation) (NN induction)) (PP (IN with) (NP (NNP Doc_18343374_489_491_Chemical)))))) (. .)))
18343374	7	(S1 (NP (NP (NP (NN RESULT)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (NP (NP (DT A) (JJ 36-year-old) (JJ Chinese) (NN woman)) (VP (VBN developed) (NP (JJ central) (NNP Doc_18343374_550_572_Disease)) (PP (IN after) (NP (NP (CD eight) (NNS courses)) (PP (IN of) (NP (NNP Doc_18343374_596_598_Chemical))))))) (. .)))
18343374	8	(S1 (S (NP (NP (DT A) (NN search)) (PP (IN of) (NP (NP (DT the) (NN literature)) (PP (IN on) (NP (NP (DT the) (JJ Doc_18343374_634_648_Disease) (NNS complications)) (PP (IN of) (NP (NNP Doc_18343374_666_668_Chemical)))))))) (VP (AUX does) (RB not) (VP (VB include) (NP (DT this) (JJ severe) (JJ ophthalmic) (NN complication)) (, ,) (SBAR (IN although) (S (NP (NP (JJ mild) (NN Doc_18343374_737_755_Disease)) (PP (IN after) (NP (JJ Doc_18343374_762_764_Chemical) (NN intake)))) (VP (AUX is) (RB not) (ADJP (JJ uncommon))))))) (. .)))
18343374	9	(S1 (NP (NP (NP (NN CONCLUSION)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-))) (: :) (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (JJ central) (NNP Doc_18343374_847_869_Disease)))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_18343374_891_893_Chemical))))))) (. .)))
18343374	10	(S1 (S (S (NP (JJ Extra) (NN caution)) (VP (AUX is) (VP (VBN warranted) (PP (IN in) (S (VP (VBG treating) (NP (NNP Doc_18343374_934_945_Disease) (NNS patients)) (PP (IN with) (NP (NNP Doc_18343374_960_962_Chemical))))))))) (, ,) (CC and) (S (NP (NNS patients)) (VP (MD should) (VP (AUX be) (ADVP (RB well)) (VP (VBN informed) (PP (IN of) (NP (DT this) (NN side) (NN effect))) (PP (IN before) (NP (NP (NN commencement)) (PP (IN of) (NP (NN therapy))))))))) (. .)))
1835291	0	(S1 (NP (NP (JJ Acute) (JJ bronchodilating) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_1835291_33_52_Chemical) (CC and) (NNP Doc_1835291_57_69_Chemical)) (PP (IN in) (NP (NNP Doc_1835291_73_110_Disease))))) (. .)))
1835291	1	(S1 (S (NP (NP (DT The) (JJ bronchodilator) (NNS effects)) (PP (IN of) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (JJ Doc_1835291_159_178_Chemical) (NN aerosol)) (PRN (-LRB- -LRB-) (NP (CD 36) (NNS micrograms)) (-RRB- -RRB-))))) (CC and) (NP (JJ short-acting) (JJ Doc_1835291_220_232_Chemical) (NNS tablets))))) (PRN (-LRB- -LRB-) (S (NP (NN dose)) (VP (VBN titrated) (S (VP (TO to) (VP (VB produce) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (CD 10-20) (NNS micrograms/mL))))))))) (-RRB- -RRB-)) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (DT a) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN crossover) (NN study)) (PP (IN in) (NP (NP (CD 21) (NNS patients)) (PP (IN with) (NP (NP (NN stable)) (, ,) (NP (NNP Doc_1835291_400_437_Disease)))))))))) (. .)))
1835291	2	(S1 (S (VP (VB Mean) (S (S (NP (NN peak)) (VP (VBN forced) (NP (NN expiratory) (NN volume)) (PP (IN in) (NP (NP (CD 1) (JJ second) (PRN (-LRB- -LRB-) (NP (NNP FEV1)) (-RRB- -RRB-)) (NNS increases)) (PP (IN over) (NP (NN baseline))))))) (CC and) (S (NP (NP (DT the) (NN proportion)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG attaining) (NP (NP (ADVP (IN at) (JJS least)) (DT a) (ADJP (CD 15) (NN %)) (NN increase)) (PP (IN in) (NP (DT the) (NN FEV1))) (PRN (-LRB- -LRB-) (NP (NNS responders)) (-RRB- -RRB-))))))) (VP (AUX were) (NP (NP (NP (CD 31) (NN %)) (CC and) (NP (CD 90) (NN %)) (, ,) (ADVP (RB respectively)) (, ,)) (PP (IN for) (NP (NP (NNP Doc_1835291_643_654_Chemical)) (CC and) (NP (NP (NP (CD 17) (NN %)) (CC and) (NP (CD 50) (NN %))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN for) (NP (NNP Doc_1835291_690_702_Chemical))))))))))) (. .)))
1835291	3	(S1 (S (NP (DT The) (JJ average) (NN FEV1) (NNS increases)) (PP (IN during) (NP (DT the) (JJ 6-hour) (NN observation) (NN period))) (VP (AUX were) (NP (NP (NP (CD 18) (NN %)) (PP (IN for) (NP (NNP Doc_1835291_781_792_Chemical)))) (CC and) (NP (NP (CD 8) (NN %)) (PP (IN for) (NP (NNP Doc_1835291_804_816_Chemical)))))) (. .)))
1835291	4	(S1 (S (NP (NP (DT The) (JJ mean) (NN duration)) (PP (IN of) (NP (NN action)))) (VP (AUX was) (NP (NP (NP (CD 3.8) (NNS hours)) (PP (IN with) (NP (NNP Doc_1835291_865_876_Chemical)))) (CC and) (NP (NP (CD 2.4) (NNS hours)) (PP (IN with) (NP (NNP Doc_1835291_896_908_Chemical)))))) (. .)))
1835291	5	(S1 (S (SBAR (IN While) (S (NP (NN side) (NNS effects)) (VP (AUX were) (ADJP (JJ rare))))) (, ,) (NP (NP (DT those)) (VP (VBN experienced) (PP (IN after) (NP (JJ Doc_1835291_964_976_Chemical) (NN use))))) (VP (AUX did) (VP (VB involve) (NP (DT the) (NNP Doc_1835291_997_1040_Disease)))) (. .)))
1835291	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP Doc_1835291_1066_1077_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RBR more) (JJ potent)) (NN bronchodilator)) (PP (IN than) (NP (NP (JJ oral) (NN Doc_1835291_1120_1132_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_1835291_1150_1177_Disease)))))))))))) (. .)))
18410508	0	(S1 (S (NP (NP (JJ Doc_18410508_0_15_Chemical-induced) (NN Doc_18410508_24_37_Disease)) (CC and) (NP (JJ microglial) (NN activation))) (VP (AUX are) (RB not) (VP (VBN mediated) (PP (IN by) (NP (JJ fractalkine) (NN receptor) (VBG signaling))))) (. .)))
18410508	1	(S1 (S (S (NP (NP (NNP Doc_18410508_116_131_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18410508_133_137_Chemical)) (-RRB- -RRB-))) (VP (VBZ damages) (NP (NNP Doc_18410508_147_155_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18410508_157_159_Chemical)) (-RRB- -RRB-)) (NN nerve) (NNS endings)) (PP (IN by) (NP (NP (DT a) (NN process)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (AUX been) (VP (VBN linked) (PP (TO to) (NP (JJ microglial) (NN activation)))))))))))) (CC but) (S (NP (NP (DT the) (VBG signaling) (NNS pathways)) (SBAR (WHNP (WDT that)) (S (VP (VB mediate) (NP (DT this) (NN response)))))) (VP (AUX have) (RB not) (ADVP (RB yet)) (VP (AUX been) (VP (VBN delineated))))) (. .)))
18410508	2	(S1 (S (NP (NNS Cardona) (CC et) (NNS al.)) (VP (VBP -LSB-Nat)) (. .)))
18410508	3	(S1 (S (NP (NP (NP (NNP Neurosci.) (CD 9)) (PRN (-LRB- -LRB-) (NP (CD 2006)) (-RRB- -RRB-))) (, ,) (NP (CD 917) (NN -RSB-))) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (DT the) (JJ microglial-specific) (NN fractalkine) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP CX3CR1)) (-RRB- -RRB-))) (PP (IN as) (NP (NP (DT an) (JJ important) (NN mediator)) (PP (IN of) (NP (NP (NNP Doc_18410508_466_470_Chemical-induced) (NNP Doc_18410508_479_496_Disease)) (PP (IN of) (NP (JJ Doc_18410508_500_502_Chemical) (NNS neurons)))))))) (. .)))
18410508	4	(S1 (S (SBAR (IN Because) (S (NP (NP (DT the) (NN Doc_18410508_524_534_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_18410508_545_549_Chemical) (CC and) (NNP Doc_18410508_554_558_Chemical))))) (VP (AUX is) (ADJP (RB highly) (JJ selective) (PP (IN for) (NP (DT the) (JJ Doc_18410508_587_589_Chemical) (JJ neuronal) (NN system)))) (PP (IN in) (NP (NP (NN mouse) (NNS models)) (PP (IN of) (NP (NNP Doc_18410508_625_638_Disease)))))))) (, ,) (NP (PRP we)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (DT the) (NN CX3CR1)) (VP (VBZ plays) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (NP (JJ Doc_18410508_688_692_Chemical-induced) (NN Doc_18410508_701_714_Disease)) (CC and) (NP (JJ microglial) (NN activation))))))))) (. .)))
18410508	5	(S1 (S (NP (NP (NNS Mice)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (JJ CX3CR1) (NN gene)) (VP (AUX has) (VP (AUX been) (VP (VBN deleted) (CC and) (VBN replaced) (PP (IN with) (NP (NP (DT a) (NN cDNA)) (VP (VBG encoding) (NP (NP (JJ enhanced) (JJ green) (NN fluorescent) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN eGFP)) (-RRB- -RRB-)))))))))))) (VP (AUX were) (VP (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18410508_883_887_Chemical)))) (CC and) (VP (VBN examined) (PP (IN for) (NP (JJ striatal) (NNP Doc_18410508_914_927_Disease)))))) (. .)))
18410508	6	(S1 (S (NP (NNP Doc_18410508_929_933_Chemical)) (VP (VP (VBD depleted) (NP (NNP Doc_18410508_943_945_Chemical))) (, ,) (VP (VBD caused) (NP (JJ microglial) (NN activation))) (, ,) (CC and) (VP (VBD increased) (NP (NP (NN body) (NN temperature)) (PP (PP (IN in) (NP (NP (JJ CX3CR1) (NN knockout) (NNS mice)) (PP (TO to) (NP (DT the) (JJ same) (NN extent))))) (CC and) (PP (IN over) (NP (NP (DT the) (JJ same) (NN time) (NN course)) (VP (VBN seen) (PP (IN in) (NP (JJ wild-type) (NNS controls)))))))))) (. .)))
18410508	7	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_18410508_1124_1128_Chemical))) (PP (IN in) (NP (NN CX3CR1) (NN knockout) (NNS mice)))) (VP (VP (AUX were) (RB not) (ADJP (JJ gender-dependent))) (CC and) (VP (AUX did) (RB not) (VP (VB extend) (PP (IN beyond) (NP (DT the) (NN striatum)))))) (. .)))
18410508	8	(S1 (S (NP (NP (JJ Striatal) (NNS microglia)) (VP (VBG expressing) (NP (NNS eGFP)))) (ADVP (RB constitutively)) (VP (VBP show) (NP (NP (JJ morphological) (NNS changes)) (PP (IN after) (NP (NNP Doc_18410508_1302_1306_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (JJ characteristic) (PP (IN of) (NP (NN activation))))))))) (. .)))
18410508	9	(S1 (S (NP (DT This) (NN response)) (VP (VP (AUX was) (VP (VBN restricted) (PP (TO to) (NP (DT the) (NN striatum))))) (CC and) (VP (VBN contrasted) (ADVP (RB sharply)) (PP (IN with) (NP (NP (JJ unresponsive) (NNS eGFP-microglia)) (PP (IN in) (NP (VBG surrounding) (NN brain) (NNS areas))) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (RB not) (VP (VBN damaged) (PP (IN by) (NP (NNP Doc_18410508_1498_1502_Chemical))))))))))) (. .)))
18410508	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (PP (IN from) (NP (NP (DT these) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBZ CX3CR1) (S (VP (VBG signaling) (SBAR (S (VP (AUX does) (RB not) (VP (VBP modulate) (NP (NNP Doc_18410508_1575_1579_Chemical) (NNP Doc_18410508_1580_1593_Disease) (CC or) (JJ microglial) (NN activation)))))))))))))) (. .)))
18410508	11	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP it)) (VP (VBZ appears) (SBAR (IN that) (S (NP (JJ striatal-resident) (NNS microglia)) (VP (VP (VB respond) (PP (TO to) (NP (NNP Doc_18410508_1688_1692_Chemical))) (PP (IN with) (NP (DT an) (NN activation) (NN cascade)))) (CC and) (RB then) (VP (VB return) (PP (TO to) (NP (DT a) (VBG surveying) (NN state))) (PP (IN without) (S (VP (VBG undergoing) (NP (NP (NN apoptosis)) (CC or) (NP (NN migration))))))))))) (. .)))
18417364	0	(S1 (S (NP (NP (JJ Doc_18417364_0_8_Chemical-induced) (JJ Doc_18417364_17_26_Disease) (NNS correlates)) (PP (IN with) (NP (NN midpontine)))) (VP (VBP activation)) (. .)))
18417364	1	(S1 (S (NP (NP (DT The) (NN pathomechanism)) (PP (IN of) (NP (NP (JJ Doc_18417364_88_96_Chemical-induced) (NNP Doc_18417364_105_114_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18417364_116_119_Disease)) (-RRB- -RRB-))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
18417364	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB delineate) (NP (NP (NN brain) (NNS structures)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (JJ Doc_18417364_210_213_Disease) (NN generation)))))))))))) (. .)))
18417364	3	(S1 (S (S (NP (CD Eight) (JJ healthy) (NNS volunteers)) (VP (VBD inhaled) (NP (NNP Doc_18417364_259_267_Chemical)) (PP (IN in) (NP (NN darkness))) (PP (IN during) (NP (DT a) (JJ functional) (JJ magnetic) (NN resonance) (NN imaging) (-LRB- -LRB-) (NN fMRI) (-RRB- -RRB-) (NN experiment))))) (: ;) (S (NP (NN eye) (NNS movements)) (VP (AUX were) (VP (VBN registered) (S (VP (VBG using) (NP (NN video-oculography))))))) (. .)))
18417364	4	(S1 (S (NP (NN Doc_18417364_401_404_Disease)) (VP (VBD correlated) (PP (IN with) (NP (NN blood) (JJ Doc_18417364_427_433_Chemical) (JJ level-dependent) (PRN (-LRB- -LRB-) (JJ BOLD) (-RRB- -RRB-)) (NN activity) (NNS levels))) (PP (IN in) (NP (NP (DT a) (JJ midpontine) (NN site)) (PP (IN in) (NP (DT the) (JJ posterior) (NN basis) (NNS pontis)))))) (. .)))
18417364	5	(S1 (S (NP (JJ Doc_18417364_525_528_Disease-induced) (NN midpontine) (NN activation)) (VP (MD may) (VP (VB correspond) (PP (TO to) (NP (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (JJ dorsomedial) (NN pontine) (NN nuclei)))) (CC and) (NP (NP (DT the) (NN nucleus)) (ADJP (FW reticularis) (FW tegmenti) (FW pontis))))) (, ,) (NP (NP (NNS structures)) (VP (VBN known) (S (VP (TO to) (VP (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (JJ multidirectional) (NNS saccades)))))) (CC and) (VP (VB smooth) (NP (NN pursuit) (NN eye) (NNS movements)))))))))) (. .)))
18439803	0	(S1 (NP (NP (JJ Acute) (NNS effects)) (PP (IN of) (NP (NNP Doc_18439803_17_42_Chemical))) (PP (IN on) (NP (NP (JJ hippocampal) (JJ Doc_18439803_58_68_Chemical) (NNS neurotransmitters)) (PP (IN in) (NP (NP (NNP Doc_18439803_90_101_Chemical-induced) (NNP Doc_18439803_110_117_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
18439803	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ anticonvulsant) (NN activity)) (PP (IN as) (ADVP (RB well) (PP (IN as) (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (JJ hippocampal) (JJ Doc_18439803_245_255_Chemical) (NNS neurotransmitters)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18439803_275_284_Chemical) (, ,) (NNP Doc_18439803_286_295_Chemical) (, ,) (NNP Doc_18439803_297_304_Chemical) (CC and) (NNP Doc_18439803_309_313_Chemical)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_18439803_318_343_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18439803_345_348_Chemical)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NP (PRP$ its) (NN parent) (NN compound)) (, ,) (NP (NP (NNP Doc_18439803_388_401_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18439803_403_406_Chemical)) (-RRB- -RRB-)))))))))))))))))) (. .)))
18439803	2	(S1 (S (NP (NNP Doc_18439803_409_412_Chemical)) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ potent)) (PP (IN than) (NP (NNP Doc_18439803_434_437_Chemical)))) (, ,) (S (VP (VBG exhibiting) (NP (NP (DT the) (JJ median) (JJ effective) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (NNP ED)) (PRN (-LRB- -LRB-) (NP (CD 50)) (-RRB- -RRB-))) (-RRB- -RRB-)) (PP (IN of) (NP (CD 49) (NN mg/kg)))) (PP (IN in) (S (VP (VBG protecting) (NP (NNS rats)) (PP (IN against) (NP (JJ Doc_18439803_524_535_Chemical-induced) (NNP Doc_18439803_544_551_Disease))) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ corresponding) (NN value)) (PP (IN for) (NP (NNP Doc_18439803_588_591_Chemical)))) (VP (AUX was) (NP (CD 322) (NN mg/kg))))))))))) (. .)))
18439803	3	(S1 (S (PP (IN In) (NP (NN vivo))) (NP (NN microdialysis)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT an) (JJ intraperitoneal) (NN administration)) (PP (IN of) (NP (NNP Doc_18439803_684_695_Chemical)))) (VP (VBN induced) (NP (NP (DT a) (JJ pronounced) (NN increment)) (PP (IN of) (NP (JJ hippocampal) (NNP Doc_18439803_742_751_Chemical) (CC and) (NNP Doc_18439803_756_765_Chemical)))) (SBAR (IN whereas) (S (NP (DT no) (JJ significant) (NN change)) (VP (AUX was) (VP (VBN observed) (PP (IN on) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NNP Doc_18439803_825_832_Chemical)) (CC and) (NP (NNP Doc_18439803_837_841_Chemical)))))))))))))) (. .)))
18439803	4	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NP (NP (DT either) (NNP Doc_18439803_868_871_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CC and) (CD 100)) (NNS mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_18439803_894_897_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 300) (CC and) (CD 600)) (NN mg/kg)) (-RRB- -RRB-)))))) (ADVP (RB completely)) (VP (VBD abolished) (NP (NP (JJ Doc_18439803_939_950_Chemical-evoked) (NNS increases)) (PP (IN in) (NP (JJ extracellular) (NNP Doc_18439803_985_994_Chemical) (CC and) (NNP Doc_18439803_999_1008_Chemical))))) (. .)))
18439803	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN reduction)) (VP (AUX was) (ADVP (RB also)) (VP (VBN observed) (PP (IN on) (NP (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NNP Doc_18439803_1095_1099_Chemical)) (CC and) (NP (NNP Doc_18439803_1104_1111_Chemical))))) (CC but) (NP (NP (JJR less)) (PP (IN than) (NP (NP (DT a) (JJ drastic) (NN reduction)) (PP (IN of) (NP (NNP Doc_18439803_1149_1158_Chemical) (CC and) (NNP Doc_18439803_1163_1172_Chemical) (NN level)))))))))) (. .)))
18439803	6	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT the) (NN finding) (SBAR (IN that) (S (NP (NNP Doc_18439803_1206_1209_Chemical) (CC and) (NNP Doc_18439803_1214_1217_Chemical)) (VP (MD could) (VP (VB protect) (NP (DT the) (NNS animals)) (PP (IN against) (NP (NNP Doc_18439803_1252_1263_Chemical-induced) (NNP Doc_18439803_1272_1279_Disease)))))))))) (NP (PRP it)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN reduction)) (PP (IN of) (NP (JJ inhibitory) (JJ Doc_18439803_1329_1339_Chemical) (NNS neurotransmitters)))) (VP (AUX was) (UCP (ADJP (RB comparatively) (JJ minor)) (CC and) (VP (VBN offset) (PP (IN by) (NP (NP (DT a) (JJ pronounced) (NN reduction)) (PP (IN of) (NP (NP (NNP Doc_18439803_1422_1431_Chemical)) (CC and) (NP (NNP Doc_18439803_1436_1445_Chemical))))))))))))) (. .)))
18439803	7	(S1 (S (ADVP (RB Therefore)) (, ,) (PP (IN like) (NP (NNP Doc_18439803_1463_1466_Chemical))) (, ,) (NP (DT the) (NN finding) (SBAR (IN that) (S (NP (NNP Doc_18439803_1485_1488_Chemical)) (VP (MD could) (ADVP (RB drastically)) (VP (VB reduce) (NP (NP (JJ Doc_18439803_1514_1525_Chemical-induced) (NNS increases)) (PP (IN in) (NP (NP (NNP Doc_18439803_1547_1556_Chemical)) (CC and) (NP (NNP Doc_18439803_1561_1570_Chemical)))))))))) (VP (MD should) (VP (VB account) (, ,) (ADVP (ADVP (IN at) (JJS least)) (RB partly)) (, ,) (PP (IN for) (NP (NP (PRP$ its) (JJ anticonvulsant) (NN activity)) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_18439803_1648_1659_Chemical-induced) (NNP Doc_18439803_1668_1675_Disease))) (PP (IN in) (NP (JJ experimental) (NNS animals)))))))) (. .)))
18439803	8	(S1 (S (NP (NP (DT Some) (JJ other) (NN mechanism)) (PP (IN than) (NP (NP (DT those)) (VP (AUXG being) (VP (VBN reported) (NP (NN herein))))))) (VP (MD should) (VP (AUX be) (VP (ADVP (RB further)) (VBN investigated)))) (. .)))
18442015	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NNP Doc_18442015_21_30_Chemical))) (PP (IN on) (NP (NP (NNP Doc_18442015_34_53_Disease) (NNP Doc_18442015_54_60_Disease)) (PP (IN in) (NP (JJ severe) (JJ Doc_18442015_71_86_Disease) (NNS rats))))) (. .)))
18442015	1	(S1 (S (NP (NP (NP (NP (NNS Studies)) (VP (VBG concerning) (PP (IN with) (NP (NP (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_18442015_133_151_Disease))))))) (CC and) (NP (JJ mucosal) (NN ulceration))) (VP (VBN produced) (PP (IN in) (NP (NNP Doc_18442015_187_202_Disease) (NNS rats))))) (VP (AUX are) (VP (VBG lacking))) (. .)))
18442015	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ gastric) (NN acid) (NN back-diffusion)) (, ,) (NP (NN mast) (NN cell) (NNP Doc_18442015_308_317_Chemical) (NN release)) (, ,) (NP (NN lipid) (NN peroxide) (PRN (-LRB- -LRB-) (NNP LPO) (-RRB- -RRB-)) (NN generation)) (CC and) (NP (JJ mucosal) (JJ microvascular) (NN permeability)))) (PP (IN in) (S (VP (VBG modulating) (NP (NNP Doc_18442015_412_430_Disease) (CC and) (NNP Doc_18442015_435_440_Disease)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_18442015_454_469_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NNP Doc_18442015_501_511_Chemical) (CC and) (NNP Doc_18442015_516_527_Chemical)))))))))))))))) (. .)))
18442015	3	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_18442015_568_577_Chemical))) (PP (IN on) (NP (DT this) (NNP Doc_18442015_586_591_Disease) (NN model)))) (VP (AUX was) (VP (VBN evaluated))) (. .)))
18442015	4	(S1 (S (NP (JJ Male) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VBN challenged) (ADVP (RB intragastrically) (RB once) (RB daily)) (PP (IN for) (NP (NP (CD 9) (NNS days)) (PP (IN with) (NP (NP (CD 1.0) (NN ml/kg)) (PP (IN of) (NP (NP (NN corn) (NN oil)) (VP (VBG containing) (NP (NP (NNP Doc_18442015_723_733_Chemical)) (CC and) (NP (NNP Doc_18442015_738_749_Chemical))) (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_18442015_760_775_Disease)))))))))))))) (. .)))
18442015	5	(S1 (S (NP (NN Control) (NNS rats)) (VP (VBD received) (NP (NN corn) (NN oil)) (ADVP (RB only))) (. .)))
18442015	6	(S1 (S (PP (IN After) (NP (NN gastric) (NN surgery))) (, ,) (NP (NN rat) (NNS stomachs)) (VP (AUX were) (VP (VBN irrigated) (PP (IN for) (NP (NP (CD 3) (NNP h)) (PP (IN with) (NP (NP (DT either) (JJ simulated) (JJ gastric) (NN juice)) (CC or) (NP (JJ normal) (NN saline)))))))) (. .)))
18442015	7	(S1 (S (NP (NP (JJ Gastric) (NN acid) (NN back-diffusion)) (, ,) (NP (JJ mucosal) (NN LPO) (NN generation)) (, ,) (NP (JJ Doc_18442015_980_989_Chemical) (NN concentration)) (, ,) (NP (JJ microvascular) (NN permeability)) (, ,) (NP (JJ Doc_18442015_1033_1040_Chemical) (NN hemoglobin) (NN content)) (CC and) (NP (JJ Doc_18442015_1064_1069_Disease) (NNS areas))) (VP (AUX were) (VP (VBN determined))) (. .)))
18442015	8	(S1 (S (NP (NP (JJ Elevated) (JJ Doc_18442015_1102_1117_Disease) (NNS parameters)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN serum) (NN Doc_18442015_1144_1151_Chemical)) (, ,) (NP (JJ total) (NN Doc_18442015_1159_1170_Chemical)) (CC and) (NP (NN low-density) (NN lipoprotein) (NN concentration))))) (VP (AUX were) (VP (VBN obtained) (PP (IN in) (NP (NNP Doc_18442015_1230_1245_Disease) (NNS rats))))) (. .)))
18442015	9	(S1 (S (NP (NP (JJ Severe) (JJ gastric) (NN Doc_18442015_1267_1273_Disease)) (VP (VBN accompanied) (PP (IN with) (NP (NP (JJ increased) (JJ ulcerogenic) (NNS factors)) (, ,) (PP (VBG including) (NP (NP (JJ gastric) (NN acid) (NN back-diffusion)) (, ,) (NP (JJ Doc_18442015_1361_1370_Chemical) (NN release)) (, ,) (NP (JJ LPO) (NN generation)) (CC and) (NP (JJ Doc_18442015_1399_1406_Chemical) (NN hemoglobin) (NN content)))))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN observed) (PP (IN in) (NP (DT these) (NNS rats))))) (. .)))
18442015	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT a) (JJ positive) (NN correlation)) (PP (IN of) (NP (NNP Doc_18442015_1496_1505_Chemical))) (PP (PP (TO to) (NP (NNP Doc_18442015_1509_1527_Disease))) (CC and) (PP (TO to) (NP (NNP Doc_18442015_1535_1540_Disease))))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (DT those) (JJ Doc_18442015_1560_1575_Disease) (NNS rats))))) (. .)))
18442015	11	(S1 (S (NP (NP (DT This) (NNP Doc_18442015_1587_1598_Disease) (NNP Doc_18442015_1599_1604_Disease)) (CC and) (NP (JJ various) (JJ ulcerogenic) (NNS parameters))) (VP (AUX were) (ADVP (RB dose-dependently)) (VP (VBN ameliorated) (PP (IN by) (NP (JJ daily) (JJ intragastric) (NN Doc_18442015_1696_1705_Chemical))))) (. .)))
18442015	12	(S1 (S (NP (NN Doc_18442015_1707_1722_Disease)) (VP (MD could) (VP (VB produce) (NP (NP (NNP Doc_18442015_1737_1756_Disease) (NNP Doc_18442015_1757_1762_Disease)) (PP (IN via) (NP (NP (NN aggravation)) (PP (IN of) (NP (NP (JJ gastric) (NN acid) (NN back-diffusion)) (, ,) (NP (JJ LPO) (NN generation)) (, ,) (NP (JJ Doc_18442015_1827_1836_Chemical) (NN release)) (CC and) (NP (JJ microvascular) (NN permeability)))) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (AUX be) (VP (VBN ameliorated) (PP (IN by) (NP (NNP Doc_18442015_1905_1914_Chemical))) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
18464113	0	(S1 (S (NP (NP (NN Doc_18464113_0_10_Chemical)) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_18464113_33_44_Disease) (NN virus)))))) (VP (VBP reactivation) (PP (IN in) (NP (NP (NNP Doc_18464113_67_94_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18464113_96_101_Chemical)) (-RRB- -RRB-)))) (S (NP (JJ seropositive) (NNP Doc_18464113_116_122_Disease) (NNS patients)) (VP (VBG undergoing) (NP (JJ cytotoxic) (NN chemotherapy))))) (. .)))
18464113	1	(S1 (S (NP (NP (JJ Doc_18464113_167_178_Disease) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HBV)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ major) (NNS causes)) (PP (IN of) (NP (JJ chronic) (NNP Doc_18464113_229_242_Disease) (NNP worldwide))))))) (. .)))
18464113	2	(S1 (S (S (NP (NP (JJ Doc_18464113_254_260_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (NP (NP (JJ chronic) (NNS carriers)) (PP (IN of) (NP (NNS HBV)))))))) (VP (AUX have) (NP (DT a) (JJR higher) (NN Doc_18464113_316_336_Disease) (NN rate)) (SBAR (IN while) (S (VP (VBG receiving) (NP (NP (JJ cytotoxic) (NN chemotherapy)) (PRN (-LRB- -LRB-) (NP (NNP CT)) (-RRB- -RRB-)))))))) (CC and) (S (NP (DT this)) (VP (AUX has) (ADVP (RB mainly)) (VP (AUX been) (VP (VBN attributed) (PP (TO to) (NP (CD HBV) (NN reactivation))))))) (. .)))
18464113	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (JJ Doc_18464113_458_464_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (ADJP (JJ solid) (CC and) (JJ Doc_18464113_493_519_Disease)) (PP (IN with) (NP (JJ chronic) (NNP Doc_18464113_533_546_Disease))))))) (VP (VBD received) (NP (DT the) (JJ antiviral) (NN agent) (NN Doc_18464113_576_586_Chemical)) (UCP (ADVP (RB prior)) (CC and) (PP (IN during) (NP (NP (NNS CT)) (PP (VBN compared) (PP (IN with) (NP (JJ historical) (NN control) (NN group)))) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (VB receive) (NP (NNP Doc_18464113_666_676_Chemical)))))))))) (. .)))
18464113	4	(S1 (S (NP (DT The) (NNS objectives)) (VP (AUX were) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_18464113_724_734_Chemical)))) (PP (IN in) (S (VP (VP (VBG reducing) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (CD HBV) (NN reactivation))))) (, ,) (CC and) (VP (VBG diminishing) (NP (NP (NN morbidity)) (CC and) (NP (NN mortality))) (PP (IN during) (NP (NN CT))))))))))) (. .)))
18464113	5	(S1 (S (NP (CD Two) (NNS groups)) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (DT this) (NN study))))) (. .)))
18464113	6	(S1 (S (NP (DT The) (JJ prophylactic) (JJ Doc_18464113_890_899_Chemical) (NN group)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD 37) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ prophylactic) (JJ Doc_18464113_957_967_Chemical) (NN treatment)))))))) (. .)))
18464113	7	(S1 (S (NP (DT The) (JJ historical) (NNS controls)) (VP (VBD consisted) (PP (IN of) (NP (NP (CD 50) (JJ consecutive) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN CT)) (PP (IN without) (NP (JJ prophylactic) (NN Doc_18464113_1078_1088_Chemical))))))))) (. .)))
18464113	8	(S1 (S (NP (PRP They)) (VP (AUX were) (VP (VBN followed) (PRT (RP up)) (PP (IN during) (NP (QP (CC and) (IN for) (CD 8)) (NNS weeks))) (PP (IN after) (NP (NN CT))))) (. .)))
18464113	9	(S1 (S (NP (DT The) (NNS outcomes)) (VP (AUX were) (VP (VBN compared) (PP (IN for) (NP (DT both) (NNS groups))))) (. .)))
18464113	10	(S1 (S (PP (IN Of) (NP (NP (PRP$ our) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 50)) (-RRB- -RRB-)))) (, ,) (NP (NP (CD 21) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 42) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN established) (NP (NN Doc_18464113_1254_1263_Disease)))) (. .)))
18464113	11	(S1 (S (NP (NP (NP (CD Twelve)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (PRP them)))) (VP (AUX were) (VP (VBN evaluated) (PP (IN as) (NP (JJ severe) (NN Doc_18464113_1311_1320_Disease))))) (. .)))
18464113	12	(S1 (S (PP (IN In) (NP (DT the) (JJ prophylactic) (JJ Doc_18464113_1342_1352_Chemical) (NN group))) (NP (JJ severe) (NNP Doc_18464113_1366_1375_Disease)) (VP (AUX were) (VP (VBN observed) (ADVP (RB only)) (PP (IN in) (NP (NP (NP (CD 1) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 2.7) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (CD 37) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.006))) (-RRB- -RRB-)))))))) (. .)))
18464113	13	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (DT the) (JJ mean) (NN ALT) (NNS values)))) (VP (VBD revealed) (NP (NP (NP (ADJP (RB significantly) (JJR higher)) (JJ mean) (JJ Doc_18464113_1512_1519_Chemical) (NN aminotransferase) (PRN (-LRB- -LRB-) (NP (NNP ALT)) (-RRB- -RRB-)) (NNS values)) (PP (IN in) (NP (NP (DT the) (NN control) (NN group)) (PP (IN than) (NP (DT the) (JJ prophylactic) (JJ Doc_18464113_1593_1603_Chemical) (NN group)))))) (: ;) (NP (NP (CD 154:64)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.32)) (-RRB- -RRB-))))) (. .)))
18464113	14	(S1 (S (NP (PRP$ Our) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ prophylactic) (NNP Doc_18464113_1667_1677_Chemical)) (ADVP (RB significantly)) (VP (VBZ decreases) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJ HBV) (NN reactivation)) (CC and) (NP (JJ overall) (NN morbidity)))) (PP (IN in) (NP (NP (JJ Doc_18464113_1761_1767_Disease) (NNS patients)) (PP (IN during) (CC and) (IN after) (NP (JJ immunosuppressive) (NN therapy)))))))))) (. .)))
18464113	15	(S1 (S (NP (JJ Further) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VB determine) (NP (DT the) (ADJP (RBS most) (JJ appropriate)) (NNP Doc_18464113_1882_1892_Chemical) (CC or) (NNP Doc_18464113_1896_1906_Chemical) (NN analogue)) (PP (IN for) (NP (JJ antiviral) (NNS prophylaxis))) (PP (IN during) (NP (NP (NN CT)) (CC and) (NP (NP (DT the) (JJ optimal) (NN duration)) (PP (IN of) (NP (NN administration))) (PP (IN after) (NP (NP (NN completion)) (PP (IN of) (NP (NNS CT))))))))))))) (. .)))
18503483	0	(S1 (NP (NP (NN Recovery)) (PP (IN of) (NP (NNP Doc_18503483_12_22_Chemical-associated) (NNP Doc_18503483_34_51_Disease))) (PP (IN after) (NP (NP (NN conversion)) (PP (TO to) (NP (NNP Doc_18503483_72_82_Chemical))) (PP (IN in) (NP (NP (DT a) (JJ pediatric) (JJ renal) (NN transplant) (NN recipient--case) (NN report)) (CC and) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature)))))))) (. .)))
18503483	1	(S1 (S (NP (NN Doc_18503483_168_171_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ potent) (NN immunosuppressive) (NN agent)) (PP (IN for) (NP (NP (JJ solid) (NN organ) (NN transplantation)) (PP (IN in) (NP (NNS pediatrics)))))))))))) (. .)))
18503483	2	(S1 (S (NP (NN Doc_18503483_273_286_Disease)) (VP (AUX is) (NP (DT a) (ADJP (RB potentially) (JJ serious)) (NN toxic) (NN effect))) (. .)))
18503483	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (NNP Doc_18503483_349_363_Disease)) (, ,) (NP (NNP Doc_18503483_365_374_Disease)) (, ,) (NP (NNP Doc_18503483_376_384_Disease)) (, ,) (CC or) (NP (NNP Doc_18503483_389_410_Disease)))))) (. .)))
18503483	4	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT an) (JJ eight-and-a-half-yr-old) (JJ male) (JJ renal) (NN transplant) (NN recipient)) (PP (IN with) (NP (JJ right) (NNS BN))))) (. .)))
18503483	5	(S1 (S (NP (NNP MRI)) (VP (VBD demonstrated) (NP (JJ hyperintense) (JJ T2) (NNS signals)) (PP (IN in) (NP (NP (DT the) (JJ cervical) (UCP (NN cord) (CC and) (JJ right)) (JJ brachial) (NN plexus) (NNS roots)) (ADJP (JJ indicative) (PP (IN of) (NP (DT both) (NNP Doc_18503483_617_625_Disease) (CC and) (JJ right) (NNP Doc_18503483_636_653_Disease))))))) (. .)))
18503483	6	(S1 (S (NP (NNS Symptoms)) (VP (VBD persisted) (PP (IN for) (NP (CD three) (NNS months))) (PP (IN despite) (NP (NP (JJ Doc_18503483_699_702_Chemical) (NN dose) (NN reduction)) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN IVIG)))) (CC and) (NP (NP (CD four) (NNS doses)) (PP (IN of) (NP (JJ Doc_18503483_760_778_Chemical) (NN pulse) (NN therapy))))))) (. .)))
18503483	7	(S1 (S (NP (NP (NN Improvement)) (CC and) (NP (ADJP (RB eventually) (JJ full)) (NN recovery))) (ADVP (RB only)) (VP (VBD occurred) (SBAR (IN after) (S (NP (NNP Doc_18503483_855_858_Chemical)) (VP (AUX was) (VP (VP (ADVP (RB completely)) (VBN discontinued)) (CC and) (VP (ADVP (RB successfully)) (VBN replaced) (PP (IN by) (NP (NNP Doc_18503483_916_926_Chemical))))))))) (. .)))
18544179	0	(S1 (S (NP (NNP Omitting) (NNP Doc_18544179_9_17_Chemical)) (VP (VBZ reduces) (NP (NP (NNP Doc_18544179_26_32_Disease)) (CC and) (NP (NNP Doc_18544179_37_45_Disease))) (, ,) (PP (IN without) (S (VP (VBG increasing) (NP (NNP Doc_18544179_66_70_Disease))))) (, ,) (PP (IN after) (NP (NP (NNP Doc_18544179_78_89_Chemical)) (PP (IN for) (NP (NN day) (NN surgery)))))) (. .)))
18544179	1	(S1 (FRAG (NP (NP (NN BACKGROUND)) (CC AND) (NP (NN OBJECTIVE))) (: :) (S (PP (IN Despite) (NP (NP (NNS advantages)) (PP (IN of) (NP (NP (NN induction)) (CC and) (NP (NP (NN maintenance)) (PP (IN of) (NP (NN anaesthesia))) (PP (IN with) (NP (NNP Doc_18544179_201_212_Chemical)))))))) (, ,) (NP (NNP Doc_18544179_214_247_Disease)) (VP (VBZ occurs) (ADVP (RB frequently)))) (. .)))
18544179	2	(S1 (S (NP (NN Doc_18544179_267_275_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN supplement)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (DT this)))))))) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (MD may) (ADVP (RB also)) (VP (VB improve) (NP (NN analgesia))))))) (. .)))
18544179	3	(S1 (S (NP (DT This) (JJ double-blind) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_18544179_447_480_Disease)) (CC and) (NP (NNP Doc_18544179_485_489_Disease))))) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 24) (NAC (NNP h) (PP (IN after) (NP (NNP Doc_18544179_514_525_Chemical)))) (NN anaesthesia)) (PP (IN in) (NP (CD 216) (NN adult) (NN day) (NN surgery) (NNS patients)))))) (. .)))
18544179	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (ADVP (RB either)) (VB receive) (CC or) (RB not) (VB receive) (NP (QP (CD 1) (CD 1)) (NN Doc_18544179_643_651_Chemical))))) (, ,) (SBAR (IN while) (S (NP (DT a) (JJ third) (NN group)) (VP (VBD received) (NP (NNP Doc_18544179_682_695_Chemical)) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NNP Doc_18544179_711_719_Chemical)))))))))) (. .)))
18544179	5	(S1 (S (NP (NP (NN Omission)) (PP (IN of) (NP (NNP Doc_18544179_742_750_Chemical)))) (VP (VP (AUX did) (RB not) (VP (VB reduce) (NP (NP (DT the) (JJ overall) (NN incidence)) (PP (IN of) (NP (NNP Doc_18544179_791_824_Disease)))))) (, ,) (CC but) (VP (AUX did) (VP (VB reduce) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_18544179_858_866_Disease) (NN and/or))) (PP (JJ moderate) (TO to) (NP (JJ severe) (NNP Doc_18544179_893_899_Disease)))) (ADVP (RB prior) (PP (TO to) (NP (NN discharge)))) (PP (PP (IN from) (NP (NP (CD 20) (NN %)) (CC and) (NP (NP (CD 17) (NN %)) (PP (IN with) (NP (NP (NNP Doc_18544179_941_949_Chemical)) (CC and) (NP (NNP Doc_18544179_954_962_Chemical-Doc_18544179_963_976_Chemical))))) (, ,) (ADVP (RB respectively)) (, ,))) (PP (TO to) (NP (CD 5) (NN %)))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.013)) (-RRB- -RRB-))))) (. .)))
18544179	6	(S1 (S (NP (JJ Antiemetic) (NNS requirements)) (VP (AUX were) (VP (VBN reduced) (PP (IN from) (NP (NP (CD 24) (NN %)) (CC and) (NP (CD 31) (NN %)))) (PP (TO to) (NP (NP (CD 7) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.0012)) (-RRB- -RRB-)))))) (. .)))
18544179	7	(S1 (S (NP (NN Doc_18544179_1085_1098_Chemical)) (VP (AUX had) (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN incidence) (CC or) (NN severity)) (PP (IN of) (NP (NNP Doc_18544179_1157_1190_Disease)))))) (. .)))
18544179	8	(S1 (S (S (VP (VBG Combining) (NP (DT the) (CD two) (NNP Doc_18544179_1210_1218_Chemical) (NNS groups)))) (VP (VBD revealed) (NP (JJ further) (JJ significant) (NNS benefits)) (PP (IN from) (NP (NP (DT the) (NN avoidance)) (PP (IN of) (NP (NNS opioids))))) (, ,) (S (VP (VBG reducing) (NP (NNP Doc_18544179_1304_1337_Disease) (CC and) (NNP Doc_18544179_1342_1348_Disease)) (ADVP (RB prior) (PP (TO to) (NP (NP (NN discharge)) (PP (IN from) (NP (NP (NP (QP (CD 35) (NN %) (CC and) (CD 33) (NN %) (TO to) (CD 22) (NN %) (CC and) (CD 19)) (NN %)) (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.049) (CC and) (CD P)) (PRN (FRAG (X (SYM =)) (NP (CD 0.035))) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively))))))))) (, ,) (SBAR (IN while) (S (NP (NAC (NNP Doc_18544179_1447_1453_Disease) (PP (IN in) (NP (DT the) (JJ first) (CD 24)))) (NNP h)) (VP (AUX was) (VP (VBN decreased) (PP (PP (IN from) (NP (CD 42) (NN %))) (PP (TO to) (NP (CD 27) (NN %)))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.034)) (-RRB- -RRB-))))))) (. .)))
18544179	9	(S1 (S (NP (NP (JJ Doc_18544179_1515_1519_Disease) (NN severity)) (CC and) (NP (JJ analgesic) (NNS requirements))) (VP (AUX were) (ADJP (JJ unaffected) (PP (IN by) (NP (NP (DT the) (NN omission)) (PP (IN of) (NP (NNP Doc_18544179_1591_1599_Chemical))))))) (. .)))
18544179	10	(S1 (S (NP (NNP Doc_18544179_1601_1609_Chemical)) (VP (VP (AUX did) (VP (VB reduce) (NP (JJ minor) (NN intraoperative) (NN movement)))) (CC but) (VP (AUX had) (NP (DT no) (JJ Doc_18544179_1662_1673_Chemical-sparing) (NN effect))) (CC and) (VP (VBD increased) (NP (NP (NNP Doc_18544179_1703_1725_Disease)) (, ,) (NP (NNP Doc_18544179_1727_1738_Disease)) (CC and) (NP (NNP Doc_18544179_1743_1754_Disease))))) (. .)))
18544179	11	(S1 (S (SBAR (IN As) (S (NP (NNP Doc_18544179_1771_1779_Chemical)) (VP (VP (VBD exacerbated) (NP (NN Doc_18544179_1792_1825_Disease)) (PP (IN without) (NP (NP (DT an) (NN improvement)) (PP (IN in) (NP (NNP Doc_18544179_1852_1870_Disease)))))) (CC and) (VP (ADVP (RB also)) (AUX had) (NP (JJ adverse) (JJ cardiorespiratory) (NNS effects)))))) (, ,) (NP (PRP it)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (ADJP (ADJP (JJ unnecessary)) (CC and) (ADJP (ADVP (RB possibly)) (JJ detrimental))) (NN supplement)) (PP (TO to) (NP (NNP Doc_18544179_1990_2001_Chemical)))) (PP (IN in) (NP (NN day) (NN surgery))))))) (. .)))
18560792	0	(S1 (NP (NP (NN Doc_18560792_0_22_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_18560792_40_59_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18560792_73_82_Chemical)))))))) (. .)))
18560792	1	(S1 (S (NP (NN Course)) (VP (VBG following) (NP (NN treatment) (NNS modifications))) (. .)))
18560792	2	(S1 (S (NP (NN Doc_18560792_126_154_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (NNP Doc_18560792_191_210_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18560792_212_214_Disease)) (-RRB- -RRB-))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18560792_229_238_Chemical))))))))))) (. .)))
18560792	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (DT these) (NNS abnormalities)))) (VP (VBP vary) (PP (IN from) (NP (NN study))) (PP (TO to) (NP (NP (NN study)) (CC and) (NP (PRP$ their) (NN course)))) (SBAR (IN after) (S (NP (NN drug) (NN withdrawal)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB systematically)) (VP (VBN assessed))))))) (. .)))
18560792	4	(S1 (FRAG (S (VP (TO To) (VP (VB estimate) (NP (NP (NP (DT the) (NN frequency) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_18560792_455_481_Disease)))) (CC and) (NP (NP (PRP$ its) (JJ possible) (NN reversibility)) (PP (IN after) (NP (NN drug) (NN withdrawal))))) (PP (IN in) (NP (DT a) (JJ case-control) (NN study)))))) (. .)))
18560792	5	(S1 (S (NP (NP (DT All) (JJ Doc_18560792_573_575_Disease) (NNS patients)) (PP (IN in) (NP (NP (DT the) (NNP Amiens) (NN area)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18560792_617_626_Chemical))))))) (VP (AUX were) (VP (VBN invited) (S (VP (TO to) (VP (VB attend) (NP (NP (DT a) (JJ cardiologic) (NN assessment)) (PP (VBG including) (NP (JJ transthoracic) (NN echocardiography))))))))) (. .)))
18560792	6	(S1 (S (NP (CD Thirty) (NNP Doc_18560792_724_726_Disease) (NNS patients)) (VP (VBD participated) (PP (IN in) (NP (DT the) (NN study)))) (. .)))
18560792	7	(S1 (S (NP (DT A) (JJ second) (NN echocardiography)) (VP (AUX was) (VP (VBN performed) (PRN (-LRB- -LRB-) (NP (NP (JJ median) (NN interval)) (: :) (NP (CD 13) (NNS months))) (-RRB- -RRB-)) (PP (IN after) (NP (NP (JJ Doc_18560792_838_847_Chemical) (NN withdrawal)) (PRN (-LRB- -LRB-) (NP (CD n=10) (NNS patients)) (-RRB- -RRB-)))))) (. .)))
18560792	8	(S1 (S (NP (NP (NP (NNS Controls)) (SBAR (S (VP (AUX were) (ADJP (JJ age-)))))) (CC and) (NP (JJ sex-matched) (NN non-Doc_18560792_915_917_Disease) (NNS patients))) (VP (VBD referred) (PP (TO to) (NP (DT the) (NN cardiology) (NN department)))) (. .)))
18560792	9	(S1 (S (PP (VBN Compared) (PP (TO to) (NP (NNS controls)))) (, ,) (NP (NP (NP (NNP Doc_18560792_997_1017_Disease)) (PRN (-LRB- -LRB-) (CC OR) (: :) (NP (NP (CD 3.1)) (: ;) (NP (NP (CD 95) (NN %)) (ADVP (RB IC))) (: :) (NP (CD 1.1-8.8))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_18560792_1049_1069_Disease)) (PRN (-LRB- -LRB-) (CC OR) (: :) (NP (NP (CD 10.7)) (: ;) (NP (NP (CD 95) (NN %)) (NP (NNS IC))) (: :) (NP (CD 2.1-53))) (-RRB- -RRB-)))) (VP (AUX were) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (NP (JJ Doc_18560792_1119_1121_Disease) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN tricuspid)) (: :) (NP (NNP NS))) (-RRB- -RRB-))))) (. .)))
18560792	10	(S1 (S (NP (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ affected) (NNS valves))) (PRN (-LRB- -LRB-) (NP (CD n=2.4+/-0.7)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN sum)) (PP (IN of) (NP (NN regurgitation) (NNS grades))) (PRN (-LRB- -LRB-) (NP (CD n=2.8+/-1.09)) (-RRB- -RRB-)))) (VP (AUX were) (ADJP (ADJP (JJR higher)) (PRN (-LRB- -LRB-) (NP (CD p=0.008) (CC and) (CD p=0.006)) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NNP Doc_18560792_1298_1307_Chemical) (NN group)))) (. .)))
18560792	11	(S1 (S (NP (NP (NN Severity)) (PP (IN of) (NP (NN regurgitation)))) (VP (AUX was) (RB not) (VP (VBN correlated) (PP (IN with) (NP (JJ Doc_18560792_1365_1374_Chemical) (JJ cumulative) (NN dose))))) (. .)))
18560792	12	(S1 (S (NP (NP (DT A) (JJ restrictive) (NN pattern)) (PP (IN of) (NP (NP (NNP Doc_18560792_1417_1439_Disease)) (, ,) (NP (NP (NN suggestive)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_18560792_1467_1476_Chemical)))))) (, ,)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (JJ 12/30) (PRN (-LRB- -LRB-) (NP (CD 40) (NN %)) (-RRB- -RRB-)) (NNS patients)) (PP (VBG including) (NP (NP (CD two)) (PP (IN with) (NP (NNP Doc_18560792_1534_1547_Disease))))))))) (. .)))
18560792	13	(S1 (S (S (NP (NN Doc_18560792_1549_1558_Chemical)) (VP (AUX was) (VP (VBN discontinued) (PP (IN in) (NP (NP (CD 10) (NNS patients)) (PP (IN with) (NP (NNP Doc_18560792_1596_1618_Disease))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJR lower) (NN regurgitation) (NN grade)) (PRN (-LRB- -LRB-) (NP (CD p=0.01)) (-RRB- -RRB-))))) (PP (IN at) (NP (DT the) (JJ second) (JJ transthoracic) (NN echocardiography)))))))) (CC and) (S (NP (NP (DT the) (CD two) (NNS patients)) (PP (IN with) (NP (NNP Doc_18560792_1741_1754_Disease)))) (VP (VBD returned) (PP (TO to) (NP (RB nearly) (JJ normal) (JJ clinical) (NN examination))))) (. .)))
18560792	14	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ supports) (NP (NP (DT the) (JJ high) (NN frequency)) (PP (IN of) (NP (JJ restrictive) (NNP Doc_18560792_1857_1876_Disease))) (PP (IN in) (NP (NP (JJ Doc_18560792_1880_1882_Disease) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18560792_1905_1914_Chemical)))))))) (CC and) (VP (VBZ reveals) (SBAR (IN that) (S (NP (DT a) (JJ significant) (NN improvement)) (VP (AUX is) (ADJP (JJ usual)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN treatment)) (VP (AUX is) (VP (VBN converted) (PP (TO to) (NP (JJ non-ergot) (JJ Doc_18560792_2012_2020_Chemical) (NNS agonists)))))))))))) (. .)))
18619688	0	(S1 (S (NP (JJ Doc_18619688_0_10_Chemical-induced) (JJ autophagic) (NN cardiomyocyte) (NN Doc_18619688_44_49_Disease)) (VP (VBZ plays) (NP (DT a) (JJ pathogenic) (NN role)) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_18619688_92_105_Disease)))))) (. .)))
18619688	1	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (NNP Doc_18619688_145_158_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18619688_170_180_Chemical))))))) (VP (AUX are) (ADJP (ADJP (RB very) (JJ complicated)) (CC and) (ADJP (RB still) (JJ unclear)))) (. .)))
18619688	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (SBAR (SBAR (IN whether) (S (NP (NN autophagy)) (VP (AUX was) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_18619688_315_328_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18619688_340_350_Chemical)))))))))) (, ,) (CC so) (SBAR (IN that) (S (NP (PRP we)) (VP (MD can) (VP (VB develop) (NP (NP (DT a) (JJ novel) (NN treatment) (NN strategy)) (PP (IN for) (NP (NNP Doc_18619688_406_419_Disease))))))))))))) (. .)))
18619688	3	(S1 (S (NP (NP (NP (NNP Doc_18619688_430_445_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18619688_447_450_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN on) (NP (NN autophagy))))) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (NP (DT a) (JJ Doc_18619688_501_514_Disease) (NN model)) (PP (IN of) (NP (NP (NNS rats)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18619688_540_550_Chemical)))))))))) (. .)))
18619688	4	(S1 (S (NP (JJ Neonatal) (NNS cardiomyocytes)) (VP (AUX were) (VP (VP (VBN isolated) (PP (IN from) (NP (JJ Sprague-Dawley) (NN rat) (NNS hearts)))) (CC and) (VP (ADVP (RB randomly)) (VBN divided) (PP (IN into) (NP (NP (NNS controls)) (, ,) (NP (NP (DT an) (JJ Doc_18619688_660_670_Chemical-treated) (NN group)) (, ,) (CC and) (NP (DT a) (JJ Doc_18619688_692_695_Chemical) (JJ plus) (JJ Doc_18619688_701_711_Chemical-treated) (NN group)))))))) (. .)))
18619688	5	(S1 (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD examined) (NP (NP (DT the) (NN morphology)) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (NP (QP (RB beclin) (CD 1)) (NN gene)) (, ,) (NP (NP (JJ mitochondrial) (NN permeability) (NN transition)) (PRN (-LRB- -LRB-) (NP (NNP MPT)) (-RRB- -RRB-))) (, ,)))) (CC and) (NP (NP (JJ Na+-Doc_18619688_842_843_Chemical+) (NN ATPase) (NN activity)) (PP (IN in) (NP (NN vivo)))))) (. .)))
18619688	6	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD assessed) (NP (NP (NN cell) (NN viability)) (, ,) (NP (JJ mitochondrial) (JJ membrane) (JJ potential) (NNS changes)) (CC and) (NP (NP (VBN counted) (JJ autophagic) (NNS vacuoles)) (PP (IN in) (NP (JJ cultured) (NNS cardiomyocytes)))))) (. .)))
18619688	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBD analyzed) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN autophagy) (JJ associated) (NN gene)))) (, ,) (S (S (NP (NN beclin) (CD 1)) (VP (VBG using) (NP (NN RT-PCR)))) (CC and) (S (NP (NNP Western)) (VP (VBG blotting) (PP (IN in) (NP (DT an) (NN animal) (NN model))))))) (. .)))
18619688	8	(S1 (S (NP (NN Doc_18619688_1146_1149_Chemical)) (ADVP (RB significantly)) (VP (VBD improved) (NP (NP (JJ cardiac) (NN function)) (CC and) (NP (JJ reduced) (JJ mitochondrial) (NN injury)))) (. .)))
18619688	9	(S1 (S (ADVP (RB Furthermore)) (, ,) (S (NP (NNP Doc_18619688_1237_1247_Chemical)) (VP (VBN induced) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ autophagic) (NNS vacuoles)))))) (, ,) (CC and) (S (NP (NNP Doc_18619688_1298_1301_Chemical)) (ADVP (RB strongly)) (VP (VP (VBD downregulated) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN beclin) (CD 1))) (PP (IN in) (NP (JJ Doc_18619688_1355_1365_Chemical-induced) (VBG failing) (NN heart))))) (CC and) (VP (VBD inhibited) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ autophagic) (NNS vacuoles))))))) (. .)))
18619688	10	(S1 (S (NP (JJ Autophagic) (NN cardiomyocyte) (NNP Doc_18619688_1477_1482_Disease)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NNP Doc_18619688_1530_1543_Disease))) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_18619688_1563_1573_Chemical))))))))) (. .)))
18619688	11	(S1 (S (NP (JJ Mitochondrial) (NN injury)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_18619688_1634_1647_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_18619688_1658_1668_Chemical))) (PP (IN via) (NP (DT the) (JJ autophagy) (NN pathway))))))))) (. .)))
18631865	0	(S1 (NP (NP (NN mToR) (JJ inhibitors-induced) (NN Doc_18631865_24_35_Disease)) (: :) (NP (NP (NNS mechanisms)) (, ,) (NP (NN significance)) (, ,) (CC and) (NP (NN management))) (. .)))
18631865	1	(S1 (S (NP (JJ Massive) (NN urinary) (NN protein) (NN excretion)) (VP (AUX has) (VP (AUX been) (VP (VBN observed) (PP (IN after) (NP (NP (NN conversion)) (PP (IN from) (NP (JJ calcineurin) (NNS inhibitors))) (PP (TO to) (NP (NP (JJ mammalian) (NN target)) (PP (IN of) (NP (NP (NNP Doc_18631865_199_208_Chemical) (-LRB- -LRB-) (NN mToR) (-RRB- -RRB-) (NNS inhibitors)) (, ,) (ADVP (RB especially)) (NP (NNP Doc_18631865_239_248_Chemical)) (, ,))))))) (PP (IN in) (NP (NP (JJ renal) (NN transplant) (NNS recipients)) (PP (IN with) (NP (NNP Doc_18631865_286_315_Disease)))))))) (. .)))
18631865	2	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_18631865_325_336_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (JJ predictive) (NN factor)) (PP (IN of) (NP (JJ poor) (NN transplantation) (NN outcome))))))) (, ,) (NP (JJ many) (NNS studies)) (VP (VBD focused) (PP (IN on) (NP (DT this) (JJ adverse) (NN event))) (PP (IN during) (NP (DT the) (JJ past) (NNS years)))) (. .)))
18631865	3	(S1 (S (SBAR (IN Whether) (S (NP (NNP Doc_18631865_473_484_Disease)) (VP (AUX was) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_18631865_496_505_Chemical)))))) (CC or) (RB only) (S (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (JJ calcineurin) (NNS inhibitors) (NN withdrawal)))) (VP (VBD remained) (NP (NNP unsolved)) (PP (IN until) (NP (JJ high) (NN range)))))) (NP (NNP Doc_18631865_600_611_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN observed) (PP (IN during) (NP (JJ Doc_18631865_637_646_Chemical) (NN therapy))) (PP (PP (IN in) (NP (JJ islet) (NN transplantation))) (CC and) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ Doc_18631865_709_718_Chemical) (JJ de) (NN novo))))))))))) (. .)))
18631865	4	(S1 (S (S (NP (NP (JJ Podocyte) (NN injury)) (CC and) (NP (JJ focal) (JJ segmental) (NN Doc_18631865_764_782_Disease))) (VP (AUX have) (VP (AUX been) (VP (VBN related) (PP (TO to) (NP (NP (NN mToR) (NN inhibition)) (PP (IN in) (NP (DT some) (NNS patients))))))))) (, ,) (CC but) (S (NP (NP (DT the) (NNS pathways)) (VP (VBG underlying) (NP (DT these) (NNS lesions)))) (VP (VBP remain) (ADJP (JJ hypothetic)))) (. .)))
18631865	5	(S1 (S (NP (PRP We)) (VP (VB discuss) (S (VP (VBG herein) (NP (NP (DT the) (JJ possible) (NNS mechanisms)) (CC and) (NP (NP (DT the) (NN significance)) (PP (IN of) (NP (JJ mToR) (JJ blockade-induced) (NN Doc_18631865_987_998_Disease)))))))) (. .)))
1867351	0	(S1 (NP (NP (JJ Neuropsychiatric) (JJ side) (NNS effects)) (PP (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_1867351_47_57_Chemical))))) (. .)))
1867351	1	(S1 (S (NP (DT This) (NN study)) (VP (VBZ describes) (NP (JJ neuropsychiatric) (NN side) (NNS effects)) (PP (IN in) (NP (NNS patients))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_1867351_143_153_Chemical)))))) (. .)))
1867351	2	(S1 (S (NP (NNS Reactions)) (VP (VBD consisted) (ADVP (RB mainly)) (PP (IN of) (NP (NP (ADJP (NNP Doc_1867351_185_193_Disease) (, ,) (JJ acute)) (NNP Doc_1867351_201_210_Disease)) (, ,) (NP (NNP Doc_1867351_212_228_Disease)) (, ,) (CC and) (NP (JJ major) (NNP Doc_1867351_240_273_Disease))))) (. .)))
1867351	3	(S1 (S (NP (NN Side) (NNS effects)) (VP (VP (VBD occurred) (PP (IN after) (NP (DT both) (ADJP (ADJP (JJ therapeutic)) (CC and) (ADJP (JJ prophylactic))) (NN intake)))) (CC and) (VP (AUX were) (VP (VBN graded) (PP (IN from) (ADJP (JJ moderate) (TO to) (JJ severe)))))) (. .)))
1867351	4	(S1 (S (PP (IN In) (NP (NP (DT a) (NN risk) (NN analysis)) (PP (IN of) (NP (NP (JJ neuropsychiatric) (NN side) (NNS effects)) (PP (IN in) (NP (NNP Germany))))))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN estimated) (SBAR (IN that) (S (NP (NP (CD one)) (PP (IN of) (NP (CD 8,000) (JJ Doc_1867351_483_493_Chemical) (NNS users)))) (VP (VBZ suffers) (PP (IN from) (NP (JJ such) (NNS reactions)))))))) (. .)))
1867351	5	(S1 (S (NP (DT The) (NN incidence) (NN calculation)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (CD one)) (PP (IN of) (NP (CD 215) (JJ therapeutic) (NNS users)))) (VP (AUX had) (NP (NNS reactions)) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD one)) (PP (IN of) (NP (CD 13,000)))))) (PP (IN in) (NP (DT the) (NN prophylaxis) (NN group))) (, ,) (S (VP (VBG making) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ neuropsychiatric) (NNS reactions)))) (PP (IN after) (NP (NP (JJ Doc_1867351_719_729_Chemical) (NN treatment)) (ADJP (ADJP (NP (CD 60) (NNS times)) (JJR higher)) (PP (IN than) (PP (IN after) (NP (NN prophylaxis))))))))))))) (. .)))
1867351	6	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (JJ certain) (NNS limitations)) (PP (IN for) (NP (NP (NNP Doc_1867351_815_822_Disease) (NN prophylaxis) (CC and) (NN treatment)) (PP (IN with) (NP (NNP Doc_1867351_854_864_Chemical)))))) (VP (AUX are) (VP (VBN recommended))) (. .)))
18703024	0	(S1 (S (NP (JJ Prenatal) (NN protein) (NN deprivation)) (VP (VBZ alters) (NP (NP (JJ Doc_18703024_36_44_Chemical-mediated) (NNS behaviors)) (CC and) (NP (NP (NN dopaminergic)) (CC and) (NP (JJ glutamatergic) (NN receptor) (VBG binding))))) (. .)))
18703024	1	(S1 (S (NP (JJ Epidemiological) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (JJ prenatal) (JJ nutritional) (NN deprivation)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN Doc_18703024_215_228_Disease))))))))) (. .)))
18703024	2	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (AUX was) (S (VP (TO to) (VP (VB use) (NP (DT an) (NN animal) (NN model)) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ prenatal) (NN protein) (NN deprivation))) (PP (IN on) (NP (NP (NP (NNS behaviors)) (CC and) (NP (NN receptor))) (ADJP (JJ binding) (PP (IN with) (NP (NP (NN relevance)) (PP (TO to) (NP (NNP Doc_18703024_390_403_Disease)))))))))))))))) (. .)))
18703024	3	(S1 (S (NP (PRP We)) (VP (VBP report) (SBAR (IN that) (S (NP (JJ prenatally) (NN protein)) (VP (VBD deprived) (SBAR (S (NP (PRN (-LRB- -LRB-) (NP (NNP PD)) (-RRB- -RRB-)) (JJ female) (NNS rats)) (VP (VBD showed) (NP (NP (NP (DT an) (VBN increased) (JJ stereotypic) (NN response)) (PP (TO to) (NP (NNP Doc_18703024_509_520_Chemical)))) (CC and) (NP (NP (DT an) (VBN increased) (JJ locomotor) (NN response)) (PP (TO to) (NP (NP (NNP Doc_18703024_560_571_Chemical)) (PP (IN in) (NP (NN adulthood)))))))))))))) (. .)))
18703024	4	(S1 (S (NP (DT These) (NNS differences)) (VP (AUX were) (RB not) (VP (VBN observed) (PP (IN during) (NP (NN puberty))))) (. .)))
18703024	5	(S1 (S (NP (NP (DT No) (NNS changes)) (PP (IN in) (NP (NP (JJ Doc_18703024_652_663_Chemical-induced) (NN Doc_18703024_672_681_Disease)) (CC or) (NP (JJ Doc_18703024_685_691_Chemical-induced) (NN locomotion))))) (VP (AUX were) (VP (VBN seen) (PP (VBG following) (NP (NN PD))))) (. .)))
18703024	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ PD) (NN female) (NNS rats)) (VP (VBD showed) (NP (JJ increased) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ Doc_18703024_783_784_Chemical-Doc_18703024_785_791_Chemical) (VBG binding)) (PP (IN in) (NP (DT the) (NN striatum) (CC and) (NN hippocampus))) (, ,) (FRAG (CC but) (RB not) (PP (IN in) (NP (DT the) (NN cortex))))) (. .)))
18703024	7	(S1 (S (NP (JJ PD) (NN female) (NNS rats)) (ADVP (RB also)) (VP (VP (VBD showed) (NP (JJ increased) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ Doc_18703024_896_897_Chemical-Doc_18703024_898_909_Chemical) (VBG binding))) (CC and) (VP (VBD decreased) (NP (NP (JJ Doc_18703024_932_940_Chemical) (NN transporter) (VBG binding)) (PP (IN in) (NP (NN striatum)))))) (. .)))
18703024	8	(S1 (S (NP (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NNS changes)) (PP (IN in) (NP (NP (NN behavior)) (CC or) (NP (NN receptor) (VBG binding))))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (JJ PD) (NNS males)) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NP (JJ increased) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (JJ Doc_18703024_1101_1102_Chemical-Doc_18703024_1103_1109_Chemical) (VBG binding)) (PP (IN in) (NP (NN cortex))))))))))) (. .)))
18703024	9	(S1 (S (NP (DT This) (NN animal) (NN model)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (JJ prenatal) (NNP Doc_18703024_1205_1227_Disease)) (VP (VP (VBZ enhances) (NP (NP (NN risk)) (PP (IN for) (NP (NNP Doc_18703024_1246_1259_Disease))) (PP (IN in) (NP (NNS humans))))) (CC and) (VP (MD may) (ADVP (RB also)) (VP (AUX have) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (JJ developmental) (NNS processes)) (VP (VBG leading) (PP (TO to) (NP (NP (NN differential) (NN sensitivity)) (PP (TO to) (NP (NP (NNS drugs)) (PP (IN of) (NP (NN abuse))))))))))))))))))))))) (. .)))
18726058	0	(S1 (S (NP (NP (JJ Adverse) (NNS effects)) (PP (IN of) (NP (JJ topical) (NNP Doc_18726058_27_37_Chemical))) (PP (IN on) (NP (JJ auditory) (NN nerve)))) (VP (VBP function)) (. .)))
18726058	1	(S1 (S (NP (NN Doc_18726058_78_102_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ direct-acting) (NN vasodilator)) (VP (VBN used) (S (VP (TO to) (VP (VB manage) (NP (NN Doc_18726058_149_158_Disease)) (PP (IN during) (NP (JJ various) (JJ neurosurgical) (NNS operations))))))))) (. .)))
18726058	2	(S1 (S (NP (JJ Transient) (NNP Doc_18726058_210_235_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (PP (IN in) (NP (NP (DT a) (JJ few) (NNS cases)) (PP (IN with) (NP (JJ topical) (NNP Doc_18726058_283_293_Chemical)))))))) (. .)))
18726058	3	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ supports) (NP (JJ previous) (NNS reports))) (CC and) (VP (VBZ provides) (NP (NP (JJ neurophysiological) (NN evidence)) (PP (IN of) (NP (NP (DT an) (JJ adverse) (NN effect)) (PP (IN on) (NP (DT the) (JJ auditory) (NN nerve)))))))) (. .)))
18726058	4	(S1 (S (NP (PRP We)) (VP (VP (VBD conducted) (NP (NP (DT a) (NN retrospective) (NN review)) (PP (IN of) (NP (CD 70) (JJ consecutive) (JJ microvascular) (NN decompression) (NNS operations))))) (CC and) (VP (VBD studied) (NP (NP (DT those) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ topical) (NNP Doc_18726058_567_577_Chemical)) (PP (IN for) (NP (NN Doc_18726058_582_591_Disease))))))))) (. .)))
18726058	5	(S1 (S (NP (JJ Topical) (NNP Doc_18726058_601_611_Chemical)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (JJ direct) (JJ therapeutic) (NN action)) (SBAR (S (VP (TO to) (VP (VB manage) (NP (NN Doc_18726058_662_671_Disease)) (PP (IN in) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 11) (NNS patients))))))))))))) (. .)))
18726058	6	(S1 (S (NP (NP (DT The) (NN timing)) (PP (IN of) (NP (NP (JJ Doc_18726058_713_723_Chemical) (NN application)) (CC and) (NP (JJ ongoing) (JJ operative) (NNS events))))) (VP (AUX was) (VP (VBN reviewed) (ADVP (JJ relative) (PP (TO to) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ neurophysiological) (NNS recordings)))))))) (. .)))
18726058	7	(S1 (S (NP (NP (NNP Brainstem) (JJ auditory) (VBN evoked) (NNS potentials)) (PRN (-LRB- -LRB-) (NP (NNP BAEPs)) (-RRB- -RRB-))) (VP (AUX were) (ADVP (RB routinely)) (VP (VBN used) (S (VP (TO to) (VP (VB monitor) (NP (JJ cochlear) (NN nerve) (NN function)) (PP (IN during) (NP (DT these) (NNS operations)))))))) (. .)))
18726058	8	(S1 (S (NP (DT A) (JJ temporal) (NN relationship)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (JJ topical) (JJ Doc_18726058_1017_1027_Chemical) (CC and) (JJ BAEP) (NNS changes)) (VP (VBG leading) (S (VP (TO to) (VP (VB complete) (NP (JJ waveform) (NN loss)))))))))) (. .)))
18726058	9	(S1 (S (NP (NP (NP (DT The) (JJ average) (JJ temporal) (NN delay)) (PP (IN between) (NP (NNP Doc_18726058_1115_1125_Chemical)))) (CC and) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT an) (JJ adverse) (NN BAEP) (NN change))))) (VP (AUX was) (NP (CD 5) (NN min))) (. .)))
18726058	10	(S1 (S (PP (IN In) (NP (NP (CD 10)) (PP (IN of) (NP (CD 11) (NNS patients))))) (, ,) (NP (NN BAEP) (NNS waves)) (ADVP (RB II/III-V) (RB completely)) (VP (VBD disappeared) (PP (IN within) (NP (QP (CD 2) (TO to) (CD 25)) (NN min))) (PP (IN after) (NP (NNP Doc_18726058_1267_1277_Chemical)))) (. .)))
18726058	11	(S1 (S (NP (NP (CD Eight)) (PP (IN of) (NP (DT these) (CD 10) (NNS patients)))) (VP (AUX had) (NP (NP (JJ complete) (NN loss)) (PP (IN of) (NP (JJ BAEP) (NNS waveforms))) (PP (IN within) (NP (CD 10) (NN min))))) (. .)))
18726058	12	(S1 (S (NP (CD One) (NN patient)) (VP (VBD showed) (NP (NP (NP (DT no) (NN recovery)) (PP (IN of) (NP (JJ later) (NNS waves)))) (CC and) (NP (DT a) (JJ delayed) (JJ profound) (NN Doc_18726058_1426_1452_Disease)))) (. .)))
18726058	13	(S1 (S (NP (NP (DT The) (JJ average) (NN recovery) (NN time)) (PP (IN of) (NP (JJ BAEP) (NNS waveforms))) (PP (TO to) (NP (JJ pre-Doc_18726058_1505_1515_Chemical) (NN baseline) (NNS values)))) (VP (AUX was) (NP (CD 39) (NN min))) (. .)))
18726058	14	(S1 (S (NP (NP (JJ Topical) (NN Doc_18726058_1565_1575_Chemical)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_18726058_1597_1606_Disease)))))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT a) (JJ transient) (NN disturbance))) (PP (IN in) (NP (NP (JJ neurophysiological) (NN function)) (PP (IN of) (NP (DT the) (VBG ascending) (NN auditory) (NN brainstem) (NN pathway))))))))) (. .)))
18726058	15	(S1 (S (NP (NP (DT The) (JJ complete) (NN disappearance)) (PP (IN of) (NP (JJ BAEP) (NNS waveforms))) (PP (IN with) (NP (DT a) (JJ consistent) (JJ temporal) (NN delay)))) (VP (VBZ suggests) (NP (DT a) (JJ possible) (NN Doc_18726058_1838_1881_Disease))) (. .)))
18726058	16	(S1 (S (NP (NP (NNS Recommendations)) (SBAR (S (VP (TO to) (VP (VB avoid) (NP (NP (JJ potential) (NN Doc_18726058_1918_1940_Disease)) (PP (IN from) (NP (NNP Doc_18726058_1946_1956_Chemical))))))))) (VP (AUX are) (VP (VBN provided))) (. .)))
18752389	0	(S1 (S (NP (JJ Doc_18752389_0_21_Chemical-induced) (NNP Doc_18752389_30_45_Disease)) (VP (VBD necessitating) (NP (NN liver) (NN transplantation))) (. .)))
18752389	1	(S1 (S (NP (JJ Abstract) (NNP Serum) (NN aminotransferase) (NNS elevations)) (VP (AUX are) (NP (NP (DT a) (ADJP (RB commonly) (VBN known)) (JJ adverse) (NN effect)) (PP (IN of) (NP (NN 3-hydroxy-3-methylglutaryl)))) (ADVP (RB coenzyme) (NP (DT A) (JJ reductase) (NN inhibitor) (PRN (-LRB- -LRB-) (NP (NNP Doc_18752389_224_230_Chemical)) (-RRB- -RRB-)) (NN therapy)))) (. .)))
18752389	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_18752389_250_261_Disease) (NNS events)) (VP (AUX have) (RB not) (VP (AUX been) (ADVP (RB widely)) (VP (VBN published) (PP (IN with) (NP (NP (NNP Doc_18752389_305_314_Chemical)) (CC or) (NP (DT the) (NN combination) (NN agent) (NNP Doc_18752389_340_361_Chemical))))))) (. .)))
18752389	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ 70-year-old) (JJ Hispanic) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_18752389_418_443_Disease) (JJ necessitating) (NN liver) (NN transplantation)) (PP (NP (CD 10) (NNS weeks)) (IN after) (NP (NP (NN conversion)) (PP (IN from) (NP (NNP Doc_18752389_511_522_Chemical) (CD 40) (NN mg/day))) (PP (TO to) (NP (NNP Doc_18752389_536_569_Chemical/day)))))))))) (. .)))
18752389	4	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (NN lipid) (NN panel)) (VP (AUX had) (VP (AUX been) (VP (VBN maintained) (PP (IN with) (NP (NNP Doc_18752389_626_637_Chemical))) (PP (IN for) (NP (NP (CD 18) (NNS months)) (PP (IN before) (NP (NP (DT the) (NN conversion)) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_18752389_694_708_Disease)))))))))))) (. .)))
18752389	5	(S1 (S (NP (NP (NP (DT A) (JJ routine) (NN laboratory) (NN work-up)) (NP (CD 10) (NNS weeks))) (PP (IN after) (NP (NN conversion)))) (VP (VBD revealed) (NP (JJ elevated) (NN serum) (NN aminotransferase) (NNS levels))) (. .)))
18752389	6	(S1 (S (S (NP (NP (NP (NNP Doc_18752389_814_834_Chemical)) (CC and) (NP (NNP Doc_18752389_839_851_Chemical))) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (NP (PRP she)) (VP (AUX was) (VP (VBG taking) (PP (IN for) (NP (NNP Doc_18752389_878_888_Disease))))))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN discontinued)))) (, ,) (CC and) (S (NP (NP (JJ other) (JJ potential) (NNS causes)) (PP (IN of) (NP (NNP Doc_18752389_939_953_Disease)))) (VP (AUX were) (VP (VBN excluded)))) (. .)))
18752389	7	(S1 (S (S (NP (DT A) (NN repeat) (NN work-up)) (VP (VBD revealed) (NP (JJ further) (NNS elevations)) (PP (IN in) (NP (JJ aminotransferase) (NNS levels))))) (, ,) (CC and) (S (NP (NN liver) (NN biopsy)) (VP (VBD revealed) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ moderate-to-severe) (NN Doc_18752389_1099_1112_Disease)))))) (. .)))
18752389	8	(S1 (S (NP (PRP She)) (VP (VBD underwent) (NP (NN liver) (NN transplantation)) (PP (IN with) (NP (DT an) (JJ uneventful) (NN postoperative) (NN course)))) (. .)))
18752389	9	(S1 (S (S (NP (PRP$ Her) (NN aminotransferase) (NNS levels)) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN by) (NP (NN postoperative) (NN day) (CD 23))))) (, ,) (CC and) (S (NP (PRP$ her) (JJ 2-year) (NN follow-up)) (VP (VBD showed) (NP (DT no) (JJ adverse) (NNS events)))) (. .)))
18752389	10	(S1 (S (NP (NN Doc_18752389_1314_1323_Chemical)) (VP (VP (VBZ undergoes) (NP (NP (JJ extensive) (NN glucuronidation)) (PP (IN by) (NP (NP (JJ Doc_18752389_1363_1382_Chemical) (NNS glucoronosyltransferases)) (PRN (-LRB- -LRB-) (NP (NNP UGT)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN intestine) (CC and) (NN liver)))) (CC and) (VP (MD may) (VP (AUX have) (VP (VBD inhibited) (NP (NP (DT the) (NN glucuronidation)) (PP (IN of) (NP (NNP Doc_18752389_1487_1511_Chemical))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (VBN increased) (JJ Doc_18752389_1536_1547_Chemical) (NN exposure)) (CC and) (NP (JJ subsequent) (NN Doc_18752389_1572_1586_Disease)))))))))) (. .)))
18752389	11	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN case) (NN report)) (PP (IN of) (NP (JJ Doc_18752389_1639_1660_Chemical-induced) (NNP Doc_18752389_1669_1682_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (NN liver) (NN transplantation)))))))) (. .)))
18752389	12	(S1 (S (NP (PRP We)) (VP (VBP postulate) (SBAR (IN that) (S (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (DT the) (JJ Doc_18752389_1762_1782_Chemical-induced) (NN Doc_18752389_1791_1805_Disease)))) (VP (AUX is) (NP (NP (DT the) (VBN increased) (JJ Doc_18752389_1823_1834_Chemical) (NN exposure)) (PP (IN by) (NP (NP (JJ Doc_18752389_1847_1856_Chemical) (NN inhibition)) (PP (IN of) (NP (JJ UGT) (NNS enzymes)))))))))) (. .)))
18752389	13	(S1 (S (NP (NNS Clinicians)) (VP (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (JJ potential) (NN Doc_18752389_1924_1938_Disease)) (PP (IN with) (NP (NNP Doc_18752389_1944_1965_Chemical)))))) (PP (ADVP (RB especially)) (IN in) (NP (JJ elderly) (NNS patients))))) (CC and) (VP (MD should) (ADVP (RB carefully)) (VP (VB monitor) (NP (NN serum) (NN aminotransferase) (NNS levels)) (SBAR (WHADVP (WRB when)) (S (S (VP (VBG starting) (NP (NN therapy)))) (CC and) (S (VP (VBG titrating) (NP (DT the) (NN dosage))))))))) (. .)))
18754075	0	(S1 (NP (NP (NP (JJ Massive) (NN Doc_18754075_8_19_Disease)) (CC and) (NP (NNP Doc_18754075_24_43_Disease))) (PP (IN after) (NP (JJ oral) (NNP Doc_18754075_55_69_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18754075_71_82_Chemical)) (-RRB- -RRB-)) (NN administration))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_18754075_117_151_Disease))))) (. .)))
18754075	1	(S1 (S (NP (NP (DT A) (JJ 61-year-old) (JJ Japanese) (NN man)) (PP (IN with) (NP (NNP Doc_18754075_185_203_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_18754075_211_245_Disease)))) (VP (AUX was) (ADVP (RB initially)) (VP (VBG responding) (ADVP (RB well)) (PP (TO to) (NP (JJ Doc_18754075_279_286_Chemical) (NN therapy))))) (. .)))
18754075	2	(S1 (S (S (NP (NP (DT The) (NN amount)) (PP (IN of) (NP (JJ daily) (JJ urinary) (NN protein)))) (VP (VBD decreased) (PP (IN from) (NP (QP (CD 15.6) (TO to) (CD 2.8)) (NNP g.))) (PP (IN Within) (NP (NP (CD 14) (NNS days)) (PP (IN of) (NP (DT the) (JJ oral) (NNP Doc_18754075_389_403_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18754075_405_423_Chemical)) (-RRB- -RRB-)) (NN administration))))))) (, ,) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (JJ daily) (JJ urinary) (NN protein)))) (VP (VBD increased) (ADVP (RB rapidly)) (ADVP (RB up)) (PP (TO to) (NP (NP (CD 12.8) (NNP g)) (PP (IN with) (NP (NNP Doc_18754075_513_532_Disease)))))) (. .)))
18754075	3	(S1 (S (PP (IN After) (S (VP (VBG discontinuing) (NP (DT the) (JJ oral) (NN Doc_18754075_563_574_Chemical))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD underwent) (NP (NP (NP (CD six) (NNS cycles)) (PP (IN of) (NP (NN hemodialysis)))) (CC and) (NP (NP (CD four) (NNS cycles)) (PP (IN of) (NP (NNP LDL) (NNS apheresis)))))) (. .)))
18754075	4	(S1 (S (NP (NP (JJ Urinary) (NN volume)) (CC and) (NP (NN serum) (NN Doc_18754075_684_694_Chemical) (NNS levels))) (VP (VBD recovered) (PP (TO to) (NP (DT the) (JJ normal) (NN range))) (, ,) (PP (IN with) (NP (NP (JJ urinary) (NN protein)) (VP (VBG disappearing) (ADVP (RB completely)) (PP (IN within) (NP (CD 40) (NNS days))))))) (. .)))
18754075	5	(S1 (S (NP (DT This) (NN report)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (ADJP (ADJP (ADVP (RB not) (RB only)) (JJ intravenous)) (, ,) (CONJP (CC but) (RB also)) (ADJP (JJ oral))) (NNP Doc_18754075_860_875_Chemical)) (VP (MD can) (VP (VB aggravate) (NP (NP (NNP Doc_18754075_890_901_Disease)) (CC and) (NP (NNP Doc_18754075_906_925_Disease)))))))) (. .)))
18768591	0	(S1 (S (NP (NP (NN Serum-)) (CC and) (NP (NN glucocorticoid-inducible))) (VP (VBP kinase) (NP (CD 1)) (PP (IN in) (NP (NNP Doc_18768591_48_59_Chemical-induced) (NNP Doc_18768591_68_86_Disease)))) (. .)))
18768591	1	(S1 (S (NP (JJ Doc_18768591_88_99_Chemical-induced) (NNP Doc_18768591_108_119_Disease)) (VP (VBZ leads) (PP (TO to) (NP (NP (JJ epithelial) (JJ Doc_18768591_140_146_Chemical) (NN channel) (PRN (-LRB- -LRB-) (NNP ENaC) (-RRB- -RRB-)) (NN -dependent) (NN Doc_18768591_172_188_Disease)) (CC and) (NP (JJ renal) (NN Doc_18768591_199_207_Disease))))) (. .)))
18768591	2	(S1 (S (NP (NP (DT The) (JJ Doc_18768591_213_224_Chemical-sensitive) (NN serum-)) (CC and) (NP (JJ glucocorticoid-inducible) (NN kinase) (NN SGK1))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (VP (TO to) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NNP ENaC))))))) (CC and) (VP (TO to) (VP (VB mediate) (NP (JJ renal) (NNP Doc_18768591_361_369_Disease)) (PP (VBG following) (NP (NP (NN mineralocorticoid)) (CC and) (NP (NN salt) (NN excess))))))))))) (. .)))
18768591	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP SGK1)))) (PP (IN in) (NP (DT the) (NNP Doc_18768591_484_500_Disease) (CC and) (NNP Doc_18768591_505_513_Disease))) (PP (IN during) (NP (NN Doc_18768591_521_539_Disease)))))))) (. .)))
18768591	4	(S1 (S (PP (TO To) (NP (DT this) (NN end))) (, ,) (NP (NP (NNP Doc_18768591_554_565_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mug/g)) (NN body) (NN wt)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (ADVP (RB intravenously)) (PP (IN into) (NP (NP (JJ gene-targeted) (NNS mice)) (VP (VBG lacking) (NP (NP (NN SGK1)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD sgk1)) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-) (-RRB- -RRB-))) (CC and) (NP (NP (PRP$ their) (JJ wild-type) (NNS littermates)) (PRN (-LRB- -LRB-) (NN sgk1) (-LRB- -LRB-) (NP (CD +/+)) (-RRB- -RRB-)))) (-RRB- -RRB-)))))))) (. .)))
18768591	5	(S1 (S (NP (JJ Doc_18768591_706_717_Chemical) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ heavy) (NN Doc_18768591_746_757_Disease)) (PRN (-LRB- -LRB-) (NP (QP (CD >100) (CD mg)) (NN protein/mg) (NN crea)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NP (CD 15/44)) (PP (IN of) (NP (NP (NNS sgk1)) (PRN (-LRB- -LRB-) (NP (NN +/+)) (-RRB- -RRB-))))) (CC and) (NP (NP (CD 15/44)) (PP (IN of) (NP (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ severe) (NNP Doc_18768591_852_870_Disease)) (PP (IN with) (NP (NP (NNP Doc_18768591_876_883_Disease)) (, ,) (NP (NNP Doc_18768591_885_894_Disease)) (, ,) (CC and) (NP (NNP Doc_18768591_900_915_Disease)))) (PP (IN in) (NP (DT both) (NNS genotypes)))))))))))) (. .)))
18768591	6	(S1 (S (NP (NN Plasma) (NN Doc_18768591_942_953_Chemical) (NNS levels)) (VP (VP (VBD increased) (PP (IN in) (NP (NP (JJ Doc_18768591_974_983_Disease) (NNS mice)) (PP (IN of) (NP (DT both) (NNS genotypes)))))) (CC and) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (VBN increased) (JJ SGK1) (NN protein) (NN expression)) (PP (IN in) (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ +/+) (-RRB- -RRB-)) (NNS mice)))))))) (. .)))
18768591	7	(S1 (S (NP (JJ Urinary) (JJ Doc_18768591_1088_1094_Chemical) (NN excretion)) (VP (VP (VBD reached) (NP (ADJP (RB signficantly) (JJR lower)) (NNS values)) (PP (IN in) (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ +/+) (-RRB- -RRB-)) (NNS mice))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN +/-)) (NP (QP (CD 5) (CD mumol/mg)) (NN crea)) (-RRB- -RRB-) (PP (IN than) (NP (NP (IN in) (JJ sgk1) (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-) (NNS mice)) (-LRB- -LRB-) (NP (CD 35) (NN +/-)) (QP (CD 5) (CD mumol/mg) (NN crea)))) (-RRB- -RRB-))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN body) (NN Doc_18768591_1282_1293_Disease)) (PP (IN in) (NP (NP (NNS sgk1)) (PRN (-LRB- -LRB-) (NP (CD +/+)) (-RRB- -RRB-)))))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PRN (-LRB- -LRB-) (NP (CD +6.6) (JJ +/-) (NP (CD 0.7) (CC vs.) (CD +4.1) (NN +/-) (CD 0.8)) (NNP g)) (-RRB- -RRB-)))))))) (. .)))
18768591	8	(S1 (S (PP (IN During) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNP Doc_18768591_1392_1410_Disease))))) (, ,) (NP (JJ serum) (NNP Doc_18768591_1418_1422_Chemical) (NNS concentrations)) (VP (VBD increased) (ADVP (RB significantly) (RBR faster)) (PP (IN in) (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice))) (PP (IN than) (PP (IN in) (NP (NP (NP (JJ sgk1) (PRN (-LRB- -LRB-) (CD +/+) (-RRB- -RRB-)) (NNS mice)) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_18768591_1521_1527_Disease))))) (CC and) (NP (NP (DT a) (VBN reduced) (JJ median) (NN survival)) (PP (IN in) (NP (NP (JJ sgk1) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-)) (NNS mice)) (PRN (-LRB- -LRB-) (NP (NP (CD 29) (CC vs.) (CD 40) (NNS days)) (PP (IN in) (NP (JJ sgk1) (PRN (-LRB- -LRB-) (CD +/+) (-RRB- -RRB-)) (NNS mice)))) (-RRB- -RRB-))))))))) (. .)))
18768591	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (JJ gene-targeted) (NNS mice)) (VP (VBG lacking) (NP (NNS SGK1)))) (VP (VP (VBD showed) (VP (VBN blunted) (NP (NNP Doc_18768591_1674_1690_Disease)))) (, ,) (CC yet) (VP (AUX were) (RB not) (VP (VBN protected) (PP (IN against) (NP (JJ renal) (NNP Doc_18768591_1729_1737_Disease))) (PP (IN during) (NP (JJ experimental) (NN Doc_18768591_1758_1776_Disease)))))) (. .)))
18791946	0	(S1 (S (S (NP (NP (JJ Severe) (NN Doc_18791946_7_23_Disease)) (CC and) (NP (NNP Doc_18791946_28_46_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_18791946_63_76_Chemical))))) (: :) (S (NP (DT a) (NN case)) (VP (VBP report) (PP (IN with) (NP (JJ fatal) (NN outcome))))) (. .)))
18791946	1	(S1 (S (NP (NP (JJ Haematological) (JJ adverse) (NNS reactions)) (VP (VBN associated) (PP (IN with) (NP (JJ fatal) (NN outcome))))) (VP (AUX are) (ADJP (JJ rare)) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_18791946_206_219_Chemical)))))) (. .)))
18791946	2	(S1 (S (NP (DT A) (JJ 30-year) (JJ old) (JJ Caucasian) (NN man)) (VP (VBD reported) (PP (IN with) (NP (NP (NNP Doc_18791946_263_277_Disease)) (CC and) (NP (NNP Doc_18791946_282_290_Disease)))) (PP (IN after) (NP (NP (JJ 3-day) (NN administration)) (PP (IN of) (NP (JJ oral) (NNP Doc_18791946_326_339_Chemical))))) (PP (IN for) (NP (NP (DT a) (NN suspect)) (PP (IN of) (NP (NNP Doc_18791946_357_380_Disease)))))) (. .)))
18791946	3	(S1 (S (NP (JJ Clinical) (NNS evaluations)) (VP (VBD suggested) (NP (NP (DT an) (JJ initial) (NN diagnosis)) (PP (IN of) (NP (JJ severe) (NNP Doc_18791946_444_460_Disease) (CC and) (NNP Doc_18791946_465_475_Disease))))) (. .)))
18791946	4	(S1 (S (NP (DT The) (NN patient)) (ADVP (RB progressively)) (VP (VBD developed) (NP (NP (NNP Doc_18791946_513_522_Disease)) (CC and) (NP (NNP Doc_18791946_527_534_Disease))) (PP (IN on) (NP (NP (NN thorax)) (CC and) (NP (JJR lower) (NNS limbs))))) (. .)))
18791946	5	(S1 (S (PP (IN Despite) (NP (ADJP (ADJP (JJ pharmacological)) (CC and) (ADJP (JJ supportive))) (NNS interventions))) (, ,) (S (NP (NN laboratory) (NNS parameters)) (VP (VBD worsened))) (CC and) (S (NP (DT the) (NN patient)) (VP (VBD died) (PP (NP (CD 17) (NNS hours)) (IN after) (NP (NN admission))))) (. .)))
18791946	6	(S1 (S (NP (DT An) (JJ accurate) (NN autopsy)) (VP (VBD revealed) (NP (NP (JJS most) (NNS organs)) (PP (IN with) (NP (JJ diffuse) (JJ petechial) (NN Doc_18791946_758_770_Disease))))) (. .)))
18791946	7	(S1 (S (NP (NP (DT No) (NNS signs)) (PP (IN of) (NP (NNP Doc_18791946_784_806_Disease)))) (VP (AUX were) (VP (VBN found))) (. .)))
18791946	8	(S1 (S (NP (NP (DT No) (NN Doc_18791946_822_829_Disease) (CC or) (NNS signs)) (PP (IN of) (NP (NNP Doc_18791946_842_859_Disease)))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (JJ arterial) (NNS vessels))))) (. .)))
18791946	9	(S1 (S (NP (NN Blood) (CC and) (NN urine) (NNS cultures)) (VP (AUX did) (RB not) (VP (VB show) (NP (DT any) (JJ bacterial) (NN growth)))) (. .)))
18791946	10	(S1 (S (NP (DT This) (NN case) (NN report)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NNP Doc_18791946_983_996_Chemical)) (VP (MD may) (VP (VB precipitate) (ADJP (JJ life-threatening)) (NP (NP (NNP Doc_18791946_1030_1046_Disease)) (CC and) (NP (NNP Doc_18791946_1051_1069_Disease))) (, ,) (PP (RB even) (PP (IN in) (NP (NP (DT the) (JJ early) (NNS phases)) (PP (IN of) (NP (NN treatment))))) (CC and) (PP (IN without) (NP (JJ apparent) (JJ previous) (NNS exposures))))))))) (. .)))
18809400	0	(S1 (S (NP (NN Doc_18809400_0_17_Chemical)) (VP (VBZ prevents) (NP (NP (NNP Doc_18809400_27_47_Disease)) (CC and) (NP (NNP Doc_18809400_52_65_Disease))) (PP (IN in) (NP (JJ experimental) (JJ chemotherapy) (NN Doc_18809400_95_105_Disease)))) (. .)))
18809400	1	(S1 (S (NP (DT The) (NN study)) (VP (VBZ investigates) (SBAR (SBAR (IN if) (S (NP (NNP Doc_18809400_133_150_Chemical)) (VP (AUX is) (ADJP (JJ neuroprotective)) (PP (IN against) (NP (JJ chemotherapy) (VBN induced) (NN Doc_18809400_199_212_Disease)))))) (, ,) (SBAR (IN if) (S (NP (NNP Doc_18809400_217_237_Disease)) (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NNP Doc_18809400_263_294_Disease)))))) (, ,) (CC and) (SBAR (IN if) (S (NP (NP (JJ neuroprotective) (NNS effects)) (PP (IN of) (NP (NNP Doc_18809400_330_347_Chemical)))) (VP (VBP depend) (PP (IN on) (NP (NN mitochondria) (NN protection)))))))) (. .)))
18809400	2	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (DT an)) (PP (IN in) (NP (NP (NN vitro) (NN model)) (PP (IN of) (NP (NP (JJ chemotherapy) (VBN induced) (NN Doc_18809400_433_454_Disease)) (SBAR (WHNP (WDT that)) (S (VP (ADVP (RB closely)) (VBP mimic) (NP (NP (DT the)) (PP (IN in) (NP (NN vivo) (NN condition)))) (PP (IN by) (S (VP (VBG exposing) (NP (NP (JJ primary) (NNS cultures)) (PP (IN of) (NP (NP (JJ dorsal) (NN root) (NN ganglion)) (PRN (-LRB- -LRB-) (NP (NNP DRG)) (-RRB- -RRB-))))) (NP (JJ sensory) (NNS neurons)) (PP (TO to) (NP (NP (NNP Doc_18809400_574_584_Chemical)) (CC and) (NP (NNP Doc_18809400_589_598_Chemical)))) (, ,) (NP (CD two) (ADJP (ADJP (RB widely) (VBN used)) (CC and) (ADJP (RB highly) (JJ effective))) (JJ chemotherapeutic) (NNS drugs))))))))))))) (. .)))
18809400	3	(S1 (S (NP (DT This) (NN approach)) (VP (VBD allowed) (S (VP (VBG investigating) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_18809400_713_730_Chemical)))) (PP (IN in) (S (VP (VBG preventing) (NP (NP (NN Doc_18809400_745_758_Disease) (CC and) (NN apoptosis)) (CC and) (NP (NP (NP (DT the) (NN function)) (CC and) (NP (JJ ultrastructural) (NN morphology))) (PP (IN of) (NP (NN mitochondria))))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (JJ toxic) (NNS agents) (CC and) (NNP Doc_18809400_872_889_Chemical))))))))))) (. .)))
18809400	4	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT both) (NNP Doc_18809400_925_934_Chemical) (CC and) (NNP Doc_18809400_939_949_Chemical)) (VP (VBP cause) (NP (JJ early) (NN Doc_18809400_962_986_Disease)) (PP (IN with) (NP (NP (NP (NN loss)) (PP (IN of) (NP (JJ membrane) (NN potential)))) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (NP (JJ autophagic) (NNS vacuoles)) (PP (IN in) (NP (NNS neurons)))))))))))) (. .)))
18809400	5	(S1 (S (S (NP (NNP Doc_18809400_1068_1085_Chemical)) (VP (VBZ exerts) (NP (NP (JJ neuroprotective) (NNS effects)) (PP (IN against) (NP (NP (JJ chemotherapy) (VBN induced) (NN Doc_18809400_1146_1159_Disease)) (PP (IN in) (NP (JJ sensory) (NNS neurons)))))))) (: :) (S (NP (PRP it)) (VP (VP (VBZ rescues) (NP (DT the) (NNP Doc_18809400_1195_1217_Disease))) (CC and) (VP (VBZ induces) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN frataxin)) (, ,) (NP (NP (DT an) (JJ essential) (JJ mitochondrial) (NN protein)) (PP (IN with) (NP (NN anti-oxidant) (CC and) (NN chaperone) (NNS properties)))))))))) (. .)))
18809400	6	(S1 (S (PP (IN In) (NP (NN conclusion))) (NP (NNP Doc_18809400_1351_1373_Disease)) (VP (AUX is) (NP (DT an) (JJ early) (JJ common) (NN event)) (PP (DT both) (IN in) (NP (NNP Doc_18809400_1407_1417_Chemical) (CC and) (NNP Doc_18809400_1422_1431_Chemical) (VBN induced) (NN Doc_18809400_1440_1453_Disease)))) (. .)))
18809400	7	(S1 (S (NP (NN Doc_18809400_1455_1472_Chemical)) (VP (VBZ protects) (NP (JJ sensory) (NNS neurons)) (PP (IN through) (NP (NP (PRP$ its) (NN anti-oxidant)) (CC and) (NP (JJ mitochondrial) (JJ regulatory) (NNS functions)))) (, ,) (S (ADVP (RB possibly)) (VP (VBG inducing) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN frataxin))))))) (. .)))
18809400	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_18809400_1637_1654_Chemical)) (VP (MD might) (VP (VP (VB reduce) (NP (NP (DT the) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (NN Doc_18809400_1691_1716_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NN chemotherapy))))))))))) (CC and) (VP (VB encourage) (NP (JJ further) (JJ confirmatory) (JJ clinical) (NNS trials)))))))) (. .)))
18821488	0	(S1 (NP (NP (NN Doc_18821488_0_8_Disease)) (PP (IN in) (NP (NP (JJ rhesus) (NNS monkeys)) (VP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT the) (NNP Doc_18821488_59_75_Chemical) (NNP Doc_18821488_76_152_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18821488_154_162_Chemical)) (-RRB- -RRB-)))))))) (. .)))
18821488	1	(S1 (S (NP (NP (JJ Many) (NNS substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP form) (NP (NP (NN methemoglobin)) (PRN (-LRB- -LRB-) (NP (NN MHb)) (-RRB- -RRB-))))))) (ADVP (RB effectively)) (VP (VBP counter) (NP (JJ cyanide) (PRN (-LRB- -LRB-) (NP (NNP CN)) (-RRB- -RRB-)) (NNP Doc_18821488_258_266_Disease))) (. .)))
18821488	2	(S1 (S (SBAR (IN Although) (S (NP (NN MHb) (NNS formers)) (VP (AUX are) (ADVP (RB generally)) (VP (VBN applied) (PP (IN as) (NP (NP (NNS treatments)) (PP (IN for) (NP (NNP CN) (NNP Doc_18821488_332_341_Disease))))))))) (, ,) (NP (PRP it)) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (SBAR (IN that) (S (NP (DT a) (JJ stable) (, ,) (JJ long-acting) (NN MHb) (NN former)) (VP (MD could) (VP (VB serve) (PP (IN as) (NP (DT a) (JJ CN) (NN pretreatment)))))))))) (. .)))
18821488	3	(S1 (S (S (VP (VBG Using) (NP (DT this) (NN rationale)))) (, ,) (NP (NP (DT the) (NNP Doc_18821488_462_478_Chemical) (NNP Doc_18821488_479_487_Chemical)) (, ,) (NP (NP (DT a) (JJ potent) (JJ long-lasting) (NN MHb) (NN former)) (PP (IN in) (NP (NP (NNS rodents)) (CC and) (NP (JJ beagle) (NNS dogs))))) (, ,)) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (DT the) (JJ rhesus) (NN monkey)) (PP (IN for) (NP (JJ advanced) (NN development))))) (PP (IN as) (NP (DT a) (JJ potential) (NN CN) (NN pretreatment))))) (. .)))
18821488	4	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NNP Doc_18821488_664_672_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB intravenously)) (PRN (-LRB- -LRB-) (NP (NNP IV)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (CD 2) (JJ female) (CC and) (CD 4) (JJ male) (JJ rhesus) (NNS monkeys)) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 3.5) (NN and/or) (QP (CD 7.0) (CD mg/kg))) (: ;) (NP (NP (DT a) (JJ single) (NN male)) (SBAR (S (ADVP (RB also)) (VP (VBD received) (NP (NNP Doc_18821488_809_817_Chemical)) (ADVP (RB orally)) (PRN (-LRB- -LRB-) (NP (NNP PO)) (-RRB- -RRB-)) (PP (IN at) (NP (CD 7.0) (CD mg/kg))))))))))))))) (. .)))
18821488	5	(S1 (S (NP (NN Health) (NN status) (CC and) (NN MHb) (NNS levels)) (VP (AUX were) (VP (VBN monitored) (PP (VBG following) (NP (NN exposure))))) (. .)))
18821488	6	(S1 (S (NP (NP (DT The) (VBN selected) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_18821488_939_947_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD produced) (NP (JJ significant) (NN Doc_18821488_976_993_Disease)) (PP (IN in) (NP (JJ beagle) (NNS dogs))) (PP (IN in) (NP (NP (JJR earlier) (NNS studies)) (VP (VBN conducted) (ADVP (RB elsewhere)))))))) (, ,)))) (VP (VBD produced) (NP (ADJP (RB very) (JJ little)) (NN MHb)) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (QP (CD <) (CD 2.0)) (NN %)))) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ rhesus) (NN monkey)))) (. .)))
18821488	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (S (NP (JJ transient) (NNP Doc_18821488_1133_1147_Disease)) (VP (AUX was) (VP (VBN noted) (NP (QP (RB approximately) (CD 60)) (NNS minutes)) (NP (NP (NN postinjection)) (PP (IN of) (NP (NP (NNP Doc_18821488_1200_1208_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.5) (CC or) (CD 7.0)) (NNS mg/kg)) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP (CD 2) (NNS lethalities)) (VP (VBD occurred) (PRN (-LRB- -LRB-) (NP (NP (NP (CD one)) (NP (NNP IV))) (CC and) (NP (CD one) (NN PO))) (-RRB- -RRB-)) (S (VP (VBG following) (NP (DT the) (ADJP (CD 7.0) (NN mg/kg)) (NN dose)))))) (. .)))
18821488	8	(S1 (S (NP (NN Doc_18821488_1306_1319_Disease)) (VP (AUX was) (ADVP (RB also)) (VP (VBN observed) (PP (VBG following) (NP (DT the) (CD 7.0) (NN mg/kg) (NN dose))))) (. .)))
18821488	9	(S1 (S (NP (NP (JJ Histopathology) (NNS analyses)) (PP (IN in) (NP (DT the) (CD 2) (NNS animals))) (SBAR (WHNP (WDT that)) (S (VP (VBD died))))) (VP (VBD revealed) (NP (NN Doc_18821488_1428_1453_Disease)) (, ,) (PP (IN with) (NP (NP (JJR greater) (NN severity)) (PP (IN in) (NP (DT the) (JJ orally-treated) (NN animal)))))) (. .)))
18821488	10	(S1 (S (NP (DT These) (NNS data)) (VP (VBP demonstrate) (NP (JJ direct) (JJ and/or) (JJ indirect) (JJ drug-induced) (NN Doc_18821488_1579_1587_Disease))) (. .)))
18821488	11	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_18821488_1610_1618_Chemical)) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN pursued) (PP (IN as) (NP (NP (DT a) (NN pretreatment)) (PP (IN for) (NP (NNP CN) (NNP Doc_18821488_1666_1675_Disease))))) (SBAR (IN unless) (S (NP (NP (DT the) (JJ anti-CN) (NNS characteristics)) (PP (IN of) (NP (DT this) (NN compound)))) (VP (MD can) (VP (AUX be) (ADVP (RB successfully)) (VP (VBN dissociated) (PP (IN from) (NP (NP (DT those)) (VP (VBG producing) (NP (JJ undesirable) (NN Doc_18821488_1793_1801_Disease))))))))))))))))) (. .)))
18951540	0	(S1 (NP (NP (JJ Repetitive) (JJ transcranial) (JJ magnetic) (NN stimulation)) (PP (IN for) (NP (NP (NNP Doc_18951540_49_57_Chemical-induced) (NNP Doc_18951540_66_77_Disease)) (PP (IN in) (NP (NNP Doc_18951540_81_100_Disease))))) (. .)))
18951540	1	(S1 (S (PP (IN In) (NP (DT a) (JJ placebo-controlled) (, ,) (JJ single-blinded) (, ,) (JJR crossover) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBD assessed) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (`` ``) (JJ real) ('' '') (JJ repetitive) (JJ transcranial) (JJ magnetic) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (NNS rTMS)) (-RRB- -RRB-)))))) (CC versus) (`` ``) (INTJ (UH sham)) ('' '') (SBAR (S (VP (VBZ rTMS) (PRN (-LRB- -LRB-) (NP (NN placebo)) (-RRB- -RRB-)) (PP (IN on) (NP (NP (JJ peak) (NN dose) (NNP Doc_18951540_287_298_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_18951540_316_335_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18951540_337_339_Disease)) (-RRB- -RRB-)))))))))))) (. .)))
18951540	2	(S1 (S (S (NP (NP (CD Ten) (NNS patients)) (PP (IN with) (NP (UCP (NNP Doc_18951540_360_362_Disease) (CC and) (JJ prominent) (SBAR (S (NP (NNP Doc_18951540_377_388_Disease)) (VP (AUX had) (NP (NP (NNS rTMS)) (PRN (-LRB- -LRB-) (NP (CD 1,800) (NNS pulses)) (: ;) (NP (CD 1) (NNP Hz) (NN rate)) (-RRB- -RRB-)) (VP (VBN delivered) (PP (IN over) (NP (DT the) (NN motor) (NN cortex))))) (PP (IN for) (NP (CD 4) (JJ consecutive) (NNS days))) (ADVP (RB twice))))) (, ,) (PP (IN once) (NP (JJ real) (NNS stimuli))) (CC and) (ADVP (RB once))) (NN sham) (NN stimulation)))) (VP (AUX were) (VP (VBN used)))) (: ;) (S (NP (NNS evaluations)) (VP (AUX were) (VP (AUX done) (PP (IN at) (NP (NP (DT the) (NN baseline)) (CC and) (NP (NP (CD 1) (NN day)) (PP (IN after) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (NN treatment) (NN series))))))))))))) (. .)))
18951540	3	(S1 (S (NP (NP (JJ Direct) (NN comparison)) (PP (IN between) (NP (NP (NN sham)) (CC and) (NP (JJ real) (JJ rTMS) (NNS effects))))) (VP (VBD showed) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (JJ clinician-assessed) (JJ Doc_18951540_744_754_Disease) (NN severity))))) (. .)))
18951540	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN comparison)) (PP (IN with) (NP (DT the) (NN baseline)))) (VP (VBD showed) (NP (NP (JJ small) (CC but) (JJ significant) (NN reduction)) (PP (IN in) (NP (NNP Doc_18951540_845_855_Disease) (NN severity)))) (PP (VBG following) (NP (NP (JJ real) (NNS rTMS)) (CONJP (CC but) (RB not)) (NP (NN placebo))))) (. .)))
18951540	5	(S1 (S (NP (DT The) (JJ major) (NN effect)) (VP (AUX was) (PP (IN on) (NP (NNP Doc_18951540_926_934_Disease) (CD subscore)))) (. .)))
18951540	6	(S1 (S (ADVP (RB Similarly)) (, ,) (PP (IN in) (NP (NN patient) (NNS diaries))) (, ,) (SBAR (IN although) (S (NP (DT both) (NNS treatments)) (VP (VBD caused) (NP (NP (NN reduction)) (PP (IN in) (NP (JJ subjective) (JJ Doc_18951540_1032_1042_Disease) (NNS scores)))) (PP (IN during) (NP (NP (DT the) (NNS days)) (PP (IN of) (NP (NN intervention)))))))) (, ,) (NP (DT the) (NN effect)) (VP (AUX was) (VP (VBN sustained) (PP (IN for) (NP (CD 3) (NNS days))) (PP (IN after) (NP (NP (DT the) (NN intervention)) (PP (IN for) (NP (DT the) (JJ real) (NNS rTMS) (RB only))))))) (. .)))
18951540	7	(S1 (S (NP (NP (JJ Following) (NNS rTMS)) (, ,) (NP (DT no) (JJ side) (NNS effects)) (CC and) (NP (NP (DT no) (JJ adverse) (NNS effects)) (PP (IN on) (NP (NP (NN motor) (NN function)) (CC and) (NP (JJ Doc_18951540_1243_1245_Disease) (NNS symptoms)))))) (VP (AUX were) (VP (VBN noted))) (. .)))
18951540	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (JJ residual) (JJ beneficial) (JJ clinical) (NNS aftereffects)) (PP (IN of) (NP (NP (JJ consecutive) (JJ daily) (NNS applications)) (PP (IN of) (NP (NN low-frequency) (NNS rTMS))))) (PP (IN on) (NP (NP (NNP Doc_18951540_1405_1416_Disease)) (PP (IN in) (NP (NNP Doc_18951540_1420_1422_Disease))))))))) (. .)))
18951540	9	(S1 (S (NP (DT The) (NNS effects)) (VP (MD may) (VP (AUX be) (ADVP (RB further)) (VP (VBN exploited) (PP (IN for) (NP (JJ potential) (JJ therapeutic) (NNS uses)))))) (. .)))
18996674	0	(S1 (NP (NP (NNP Intracavernous) (NNP Doc_18996674_15_26_Chemical)) (: :) (NP (NP (DT a) (ADJP (RB minimally) (JJ invasive)) (NN treatment)) (PP (IN for) (NP (NNP Doc_18996674_63_71_Disease))) (PP (IN in) (NP (DT the) (NN emergency) (NN department)))) (. .)))
18996674	1	(S1 (S (NP (NN Doc_18996674_101_109_Disease)) (VP (AUX is) (NP (NP (DT the) (VBN prolonged) (NN erection)) (PP (IN of) (NP (DT the) (NNS penis))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ sexual) (NN arousal))))))) (. .)))
18996674	2	(S1 (S (NP (NP (DT A) (JJ 45-year-old) (NN man)) (, ,) (NP (DT an) (VBN admitted) (JJ frequent) (JJ Doc_18996674_223_230_Chemical) (NN user)) (, ,)) (VP (VBD presented) (PP (TO to) (NP (NP (DT the) (NNP Emergency) (NNP Department)) (PRN (-LRB- -LRB-) (NP (NNP ED)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (CD two) (JJ separate) (NNS occasions)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_18996674_324_332_Disease))) (PP (IN after) (NP (JJ Doc_18996674_339_346_Chemical) (NN use)))))))) (. .)))
18996674	3	(S1 (S (NP (NP (DT The) (NN management) (NNS options)) (PP (IN in) (NP (DT the) (NNP ED)))) (PRN (, ,) (SBAR (IN as) (S (VP (VBN exemplified) (PP (IN by) (NP (CD four) (JJ individual) (NN case) (NNS reports))) (, ,) (PP (IN in) (NP (NP (JJ particular) (DT the) (NN use)) (PP (IN of) (NP (NP (DT a) (ADJP (RB minimally) (JJ invasive)) (NN method)) (PP (IN of) (NP (JJ intracorporal) (JJ Doc_18996674_504_515_Chemical) (NN instillation)))))))))) (, ,)) (VP (AUX are) (VP (VBN discussed))) (. .)))
19037603	0	(S1 (S (NP (NP (JJ Prophylactic) (NN use)) (PP (IN of) (NP (NNP Doc_19037603_20_30_Chemical))) (PP (IN with) (NP (NN chronic)))) (VP (VBP immunosuppressive) (NP (NN therapy)) (PP (IN for) (NP (NNP Doc_19037603_74_97_Disease)))) (. .)))
19037603	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB report) (NP (NP (PRP$ our) (NN experience)) (VP (VBG concerning) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (DT the) (JJ prophylactic) (NN administration)) (PP (IN of) (NP (NNP Doc_19037603_223_233_Chemical)))))) (PP (IN in) (NP (NP (NNP Doc_19037603_237_270_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19037603_272_278_Chemical)) (-RRB- -RRB-)) (JJ positive) (NNS patients)) (PP (IN with) (NP (NNP Doc_19037603_303_324_Disease))))))))))) (. .)))
19037603	2	(S1 (S (PP (PP (IN From) (NP (NNP June) (CD 2004))) (PP (TO to) (NP (NNP October) (CD 2006)))) (, ,) (NP (NP (CD 11) (JJ Doc_19037603_361_367_Chemical) (JJ positive) (NNS patients)) (PP (IN with) (NP (NNP Doc_19037603_391_413_Disease))) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX were) (PP (IN on) (NP (DT both) (JJ immunosuppressive) (CC and) (JJ prophylactic) (JJ Doc_19037603_467_477_Chemical) (NNS therapies)))))) (, ,)) (VP (AUX were) (ADVP (RB retrospectively)) (VP (VBN assessed))) (. .)))
19037603	3	(S1 (S (NP (NP (NN Liver) (NN function) (NNS tests)) (, ,) (NP (JJ Doc_19037603_542_553_Disease) (NN virus) (PRN (-LRB- -LRB-) (NP (NNP HBV)) (-RRB- -RRB-)) (JJ serologic) (NNS markers)) (, ,) (CC and) (NP (NP (NN HBV) (NN DNA) (NNS levels)) (PP (IN of) (NP (DT the) (NNS patients))) (PP (IN during) (NP (NN follow-up))))) (VP (AUX were) (VP (VBN obtained) (PP (IN from) (NP (NN hospital) (NN file) (NNS records))))) (. .)))
19037603	4	(S1 (S (NP (NP (NP (NP (NP (CD Eleven) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD six) (NN male)) (-RRB- -RRB-))) (PP (IN with) (NP (JJ median) (NN age))) (NP (CD 47) (NNS years)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 27-73)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ median) (NN disease) (NN duration)) (NP (NP (CD 50) (NNS months)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 9-178)) (-RRB- -RRB-))))) (CC and) (NP (JJ median) (JJ follow-up) (NN period))) (PP (IN of) (NP (NNS patients))) (NP (CD 13.8) (NNS months)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 5-27)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBD enrolled) (PP (IN in) (NP (DT this) (NN study))))) (. .)))
19037603	5	(S1 (S (NP (JJ Doc_19037603_888_898_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN started) (ADVP (NP (CD 3-7) (NNS days)) (RB prior)) (S (VP (TO to) (VP (VB immunosuppressive) (NP (NN therapy)) (PP (IN in) (NP (DT all) (NNS patients)))))))) (. .)))
19037603	6	(S1 (S (NP (NN Baseline) (, ,) (NN liver) (NN function) (NNS tests)) (VP (AUX were) (ADJP (JJ elevated)) (PP (IN in) (NP (NP (CD two) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (JJ fourth) (NN patient)) (: :) (NP (NP (CD ALT:122) (NN IU/l)) (, ,) (NP (CD AST:111) (NN IU/l)) (, ,) (NP (NN tenth) (NN patient))) (: :) (NP (NP (CD ALT:294) (NN IU/l)) (, ,) (NP (CD AST:274) (NNS IU/l))) (, ,) (PP (IN with) (NP (NP (JJ minimal) (NNS changes)) (PP (IN in) (NP (DT the) (NN liver) (NN biopsy))) (PP (IN in) (NP (DT both)))))) (-RRB- -RRB-))))) (. .)))
19037603	7	(S1 (S (S (PP (ADVP (RB Shortly)) (IN after) (NP (NN treatment))) (NP (PRP$ their) (NNS tests)) (VP (VBD normalized))) (CC and) (S (PP (IN during) (NP (JJ follow-up) (NN period))) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (NP (JJ Doc_19037603_1279_1302_Disease) (NNS tests)))) (. .)))
19037603	8	(S1 (S (PP (IN In) (NP (CD four) (NNS patients))) (NP (NNP HBV) (NN DNA) (NNS levels)) (VP (AUX were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (JJ normal)))) (PP (IN at) (NP (NN baseline)))) (. .)))
19037603	9	(S1 (S (S (NP (NP (CD Two)) (PP (IN of) (NP (DT these)))) (VP (VBD normalized))) (CC and) (S (NP (DT the) (NNS others)) (VP (VBD increased) (ADVP (RB later)))) (. .)))
19037603	10	(S1 (S (PP (IN In) (NP (CD three) (JJ additional) (NNS patients))) (, ,) (NP (NN HBV) (NN DNA) (NNS levels)) (VP (AUX were) (VP (VBN increased) (PP (IN during) (NP (NN follow-up))))) (. .)))
19037603	11	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (NP (NP (JJ significant) (JJ clinical) (VBZ sings)) (PP (IN of) (NP (CD HBV) (NN activation))))) (. .)))
19037603	12	(S1 (S (NP (NN Doc_19037603_1584_1594_Chemical)) (VP (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated))) (CC and) (VP (AUX was) (VP (VBN continued) (PP (IN in) (NP (DT all) (NNS patients)))))) (. .)))
19037603	13	(S1 (S (NP (NP (JJ Prophylactic) (NN administration)) (PP (IN of) (NP (NNP Doc_19037603_1680_1690_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD required) (NP (JJ immunosuppressive) (NN therapy)))))))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (ADJP (JJ safe)) (, ,) (ADJP (RB well) (VBN tolerated)) (CC and) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG preventing) (NP (CD HBV) (NN reactivation))))))))))) (. .)))
19058010	0	(S1 (S (NP (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_19058010_10_19_Chemical)))) (CC and) (NP (NP (JJ Doc_19058010_24_33_Chemical) (NN combination)) (PP (IN in) (NP (NNP Doc_19058010_49_62_Chemical))))) (VP (VBN induced) (NP (NNP Doc_19058010_71_92_Disease)) (PP (IN in) (NP (NNS rats)))) (. .)))
19058010	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (VBN combined) (NNS effects)) (PP (IN of) (NP (NNP Doc_19058010_169_178_Chemical) (CC and) (NNP Doc_19058010_183_192_Chemical))) (PP (IN on) (NP (NP (NN heart) (NN weight)) (, ,) (NP (NN body) (NN weight)) (, ,) (NP (NN serum) (NN marker) (NNS enzymes)) (, ,) (NP (NN lipid) (NN peroxidation)) (, ,) (NP (JJ endogenous) (NNS antioxidants)) (CC and) (NP (NP (NN membrane) (VBN bound) (NNS ATPases)) (PP (IN in) (NP (NP (NNP Doc_19058010_319_332_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19058010_334_337_Chemical)) (-RRB- -RRB-)))) (VP (VBN -induced) (NP (NNP Doc_19058010_347_368_Disease)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
19058010	2	(S1 (NP (NP (JJ Adult) (JJ male) (NN albino) (NNS rats)) (, ,) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_19058010_415_418_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NN mg/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 2) (NNS days))) (PP (IN at) (NP (NP (DT an) (NN interval)) (PP (IN of) (NP (NP (CD 24)) (SBAR (S (NP (NNP h)) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)) (NN elevation)) (PP (IN of) (NP (NP (NN heart) (NN weight)) (, ,) (NP (NN serum) (NN marker) (NNS enzymes)) (, ,) (NP (NN lipid) (NN peroxidation)) (CC and) (NP (NNP Doc_19058010_573_575_Chemical+2) (NNP ATPase) (NN level))))) (SBAR (IN whereas) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)) (NN decrease)) (PP (IN in) (NP (NP (NN body) (NN weight)) (, ,) (NP (JJ endogenous) (NNS antioxidants)) (, ,) (NP (NNP Doc_19058010_682_684_Chemical+/) (NNP Doc_19058010_687_688_Chemical+) (NNP ATPase)) (CC and) (NP (NNP Doc_19058010_701_703_Chemical+2) (NN ATPase) (NNS levels)))))))))))))))) (. .)))
19058010	3	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NP (NNP Doc_19058010_739_748_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NN mg/kg/day)) (, ,) (NP (CD p.o.))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_19058010_775_784_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NN mg/kg/day)) (, ,) (NP (CD p.o.))) (-RRB- -RRB-)))))) (ADVP (RB together) (PP (IN for) (NP (CD 30) (JJ consecutive) (NNS days)))) (VP (CC and) (VP (VBD challenged) (PP (IN with) (NP (NP (NP (NNP Doc_19058010_860_863_Chemical)) (PP (IN on) (NP (NP (DT the) (NN day) (NN 29th)) (CC and) (NP (JJ 30th) (PRN (, ,) (S (VP (VBD showed) (NP (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)) (NN decrease)) (PP (IN in) (NP (NN heart) (NN weight)))) (, ,) (NP (NN serum) (NN marker) (NNS enzymes)) (, ,) (NP (NN lipid) (NN peroxidation)) (, ,) (NP (NNP Doc_19058010_988_990_Chemical+2) (NNP ATPase)) (CC and) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (DT the) (NN body) (NN weight))))))) (, ,)) (JJ endogenous) (NNS antioxidants))))) (, ,) (NP (NNP Doc_19058010_1072_1074_Chemical+/Doc_19058010_1076_1077_Chemical+) (NNP ATPase)) (CC and) (NP (NNP Doc_19058010_1090_1092_Chemical+2) (NNP ATPase)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (SBAR (IN with) (S (NP (NNP Doc_19058010_1121_1124_Chemical)) (VP (VBD treated) (SBAR (S (NP (NP (NN group)) (CC and) (NP (NNP Doc_19058010_1143_1152_Chemical) (CC or) (NNP Doc_19058010_1156_1165_Chemical))) (ADVP (RB alone)) (VP (VBN treated) (NP (NNS groups))))))))))))) (. .)))
19058010	4	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (NP (NP (DT the) (JJ synergistic) (JJ protective) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_19058010_1249_1258_Chemical)) (CC and) (NP (NNP Doc_19058010_1263_1272_Chemical))))) (PP (IN during) (NP (NP (JJ Doc_19058010_1280_1283_Chemical) (VBN induced) (NN Doc_19058010_1292_1313_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
1919871	0	(S1 (NP (NP (JJ Irreversible) (NN damage)) (PP (TO to) (NP (DT the) (JJ medullary) (NN interstitium))) (PP (IN in) (NP (NP (JJ experimental) (JJ analgesic) (NN Doc_1919871_76_87_Disease)) (PP (IN in) (NP (CD F344) (NNS rats))))) (. .)))
1919871	1	(S1 (S (NP (NP (NP (NNP Doc_1919871_102_126_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1919871_128_131_Disease)) (-RRB- -RRB-))) (CC and) (NP (DT a) (VBN decreased) (NN urinary) (VBG concentrating) (NN ability))) (VP (VBD developed) (PP (IN during) (NP (NP (JJ continuous) (JJ long-term) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_1919871_232_239_Chemical)) (CC and) (NP (NNP Doc_1919871_244_255_Chemical)))))) (PP (IN in) (NP (JJ female) (NNP Fischer) (CD 344) (NNS rats)))) (. .)))
1919871	2	(S1 (S (NP (NP (JJ Renal) (NN structure)) (CC and) (NP (VBG concentrating) (NN ability))) (VP (AUX were) (VP (VBN examined) (PP (IN after) (NP (NP (DT a) (NN recovery) (NN period)) (PP (IN of) (NP (QP (IN up) (TO to) (CD 18)) (NNS weeks))))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT no) (NNS analgesics)) (VP (AUX were) (VP (VBN given))))) (, ,) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (DT the) (JJ analgesic-induced) (NNS changes)) (VP (AUX were) (ADJP (JJ reversible)))))))))) (. .)))
1919871	3	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (NN repair)) (PP (TO to) (NP (NP (DT the) (VBN damaged) (NN medullary) (NN interstitial) (NNP matrix) (, ,) (CC or) (NN proliferation)) (PP (IN of) (NP (NP (VBG remaining) (JJ undamaged) (NN type)) (PP (NP (CD 1) (JJ medullary) (NN interstitial) (NNS cells)) (IN after) (NP (NP (DT the) (NN recovery) (NN period)) (VP (VBG following) (NP (JJ analgesic) (NN treatment))))))))))))) (. .)))
1919871	4	(S1 (S (NP (NP (DT The) (NN recovery)) (PP (IN of) (NP (NN urinary) (VBG concentrating) (NN ability)))) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (NP (NP (DT the) (NN length)) (PP (IN of) (NP (JJ analgesic) (NN treatment)))) (CC and) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (DT the) (VBG resulting) (JJ inner) (JJ medullary) (JJ structural) (NN damage)))))))) (. .)))
1919871	5	(S1 (S (S (PP (IN During) (NP (NP (DT the) (JJ early) (NNS stages)) (PP (IN of) (NP (JJ analgesic) (NN treatment))))) (, ,) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NN urinary) (VBG concentrating) (NN ability)))) (VP (AUX were) (ADJP (JJ reversible)))) (, ,) (CC but) (S (PP (IN after) (NP (JJ prolonged) (JJ analgesic) (NN treatment))) (, ,) (NP (NN maximum) (NN urinary) (VBG concentrating) (NN ability)) (VP (VBD failed) (S (VP (TO to) (VP (VB recover)))))) (. .)))
1919871	6	(S1 (S (NP (DT This) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (VBN prolonged) (JJ analgesic) (NN treatment)) (PP (IN in) (NP (NNP Fischer) (CD 344) (NNS rats)))) (VP (VP (VBZ causes) (NP (ADJP (JJ progressive) (CC and) (JJ irreversible)) (NN damage)) (PP (TO to) (NP (DT the) (JJ interstitial) (NNP matrix)))) (CC and) (VP (NN type) (NP (NP (CD 1) (JJ interstitial) (NNS cells)) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_1919871_1248_1251_Disease)))))))))) (. .)))
1919871	7	(S1 (S (NP (DT The) (VBN associated) (NN urinary) (VBG concentrating) (NN defect)) (VP (AUX is) (ADJP (JJ reversible)) (ADVP (RB only)) (PP (IN during) (NP (NP (DT the) (JJ early) (NNS stages)) (PP (IN of) (NP (NP (JJ structural) (NN damage)) (PP (TO to) (NP (DT the) (JJ inner) (NN medulla)))))))) (. .)))
19211690	0	(S1 (NP (NP (NP (JJ Doc_19211690_0_12_Chemical-dependent) (NN Doc_19211690_23_35_Disease)) (CC and) (NP (NN upregulation))) (PP (IN of) (NP (JJ intrarenal) (NNS angiotensinogen))) (PP (IN in) (NP (NNP Dahl) (JJ Doc_19211690_91_95_Chemical-sensitive) (NNS rats))) (. .)))
19211690	1	(S1 (S (NP (NP (NN Blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (VP (AUX is) (ADJP (ADJP (RBR more) (JJ Doc_19211690_140_144_Chemical)) (JJ sensitive)) (PP (IN in) (NP (NNS men))) (PP (IN than) (PP (IN in) (NP (JJ premenopausal) (NNS women))))) (. .)))
19211690	2	(S1 (S (PP (IN In) (NP (NP (NNP Dahl) (JJ Doc_19211690_199_203_Chemical-sensitive) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNS DS)) (-RRB- -RRB-)))) (, ,) (NP (JJ high-Doc_19211690_230_234_Chemical) (-LRB- -LRB-) (NN HS) (-RRB- -RRB-) (NN diet)) (VP (VBZ increases) (NP (NNP BP)) (ADVP (RBR more)) (PP (IN in) (NP (NP (NNS males)) (PP (IN than) (NP (NNS females)))))) (. .)))
19211690	3	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (JJ systemic) (NN renin-Doc_19211690_320_331_Chemical) (NN system)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN suppressed) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (CD HS))))) (PP (IN in) (NP (JJ male) (NNS DS))))))))))) (, ,) (S (NP (JJ intrarenal) (JJ angiotensinogen) (NN expression)) (VP (AUX is) (VP (VBN increased)))) (, ,) (CC and) (S (NP (NP (JJ intrarenal) (NNS levels)) (PP (IN of) (NP (NNP ANG) (NNP II)))) (VP (AUX are) (RB not) (VP (VBN suppressed)))) (. .)))
19211690	4	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (DT the) (NN hypothesis)) (VP (AUX was) (VP (VBN tested) (SBAR (IN that) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (JJ sexual) (NN dimorphism)) (PP (IN in) (NP (NP (JJ HS-induced) (NN upregulation)) (PP (IN of) (NP (NP (JJ intrarenal) (NNS angiotensinogen)) (VP (VBN mediated) (PP (IN by) (NP (NNP Doc_19211690_638_650_Chemical)))))))) (SBAR (WHNP (WDT that)) (S (ADVP (RB also)) (VP (VBZ causes) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NNP BP)) (CC and) (NP (NNP Doc_19211690_688_700_Disease)))))))))))))) (. .)))
19211690	5	(S1 (S (PP (IN On) (NP (DT a) (JJ low-Doc_19211690_711_715_Chemical) (PRN (-LRB- -LRB-) (NP (NNP LS)) (-RRB- -RRB-)) (NN diet))) (, ,) (NP (JJ male) (NNS DS)) (VP (AUX had) (NP (NP (JJR higher) (NNS levels)) (PP (IN of) (NP (JJ intrarenal) (JJ angiotensinogen) (NNS mRNA))) (PP (IN than) (NP (NNS females))))) (. .)))
19211690	6	(S1 (S (NP (NP (JJ HS) (NN diet)) (PP (IN for) (NP (CD 4) (NN wk)))) (VP (VBD increased) (NP (NP (JJ renal) (JJ cortical) (NN angiotensinogen) (NN mRNA)) (CC and) (NP (NN protein))) (PP (ADVP (RB only)) (IN in) (NP (NP (JJ male) (NNS DS)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN prevented) (PP (IN by) (NP (NN castration)))))))))) (. .)))
19211690	7	(S1 (S (NP (NP (NN Ovariectomy)) (PP (IN of) (NP (JJ female) (NNS DS)))) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ intrarenal) (JJ angiotensinogen) (NN expression)) (PP (IN on) (NP (DT either) (NN diet))))))) (. .)))
19211690	8	(S1 (S (NP (NNP Radiotelemetric) (NNP BP)) (VP (AUX was) (ADJP (JJ similar)) (PP (IN between) (NP (NP (NNS males)) (CC and) (NP (JJ castrated) (NNS rats)))) (PP (IN on) (NP (CD LS) (NN diet)))) (. .)))
19211690	9	(S1 (S (NP (NP (JJ HS) (NN diet)) (PP (IN for) (NP (CD 4) (NN wk)))) (VP (VBD caused) (NP (NP (DT a) (JJ progressive) (NN increase)) (PP (IN in) (NP (NP (NP (NNP BP)) (, ,) (NP (NP (NN protein)) (CC and) (NP (NN albumin) (NN excretion))) (, ,)) (CC and) (NP (NNP Doc_19211690_1190_1210_Disease)))) (PP (IN in) (NP (JJ male) (NNS DS) (NNS rats))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN attenuated) (PP (IN by) (NP (NN castration))))))))) (. .)))
19211690	10	(S1 (S (NP (NP (JJ Doc_19211690_1265_1277_Chemical) (NN replacement)) (PP (IN in) (NP (JJ castrated) (NNS DS) (NNS rats)))) (VP (VBD increased) (NP (NP (NNP BP)) (, ,) (NP (NNP Doc_19211690_1325_1337_Disease)) (, ,) (CC and) (NP (NP (NN upregulation)) (PP (IN of) (NP (NP (JJ renal) (NNS angiotensinogen)) (VP (VBN associated) (PP (IN with) (NP (CD HS) (NN diet))))))))) (. .)))
19211690	11	(S1 (S (NP (NNP Doc_19211690_1406_1418_Chemical)) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19211690_1453_1465_Disease) (CC and) (NNP Doc_19211690_1470_1482_Disease))) (PP (IN in) (NP (JJ male) (NNS DS) (NNS rats))) (PP (IN on) (NP (CD HS) (NN diet))))) (ADVP (RB possibly)) (PP (IN through) (NP (NP (NN upregulation)) (PP (IN of) (NP (DT the) (JJ intrarenal) (JJ renin-Doc_19211690_1564_1575_Chemical) (NN system)))))) (. .)))
19269743	0	(S1 (NP (NP (NP (JJ Explicit) (JJ episodic) (NN memory)) (PP (IN for) (NP (NP (JJ sensory-discriminative) (NNS components)) (PP (IN of) (NP (NNP Doc_19269743_66_75_Chemical-induced) (NNP Doc_19269743_84_88_Disease)))))) (: :) (NP (ADJP (JJ immediate) (CC and) (JJ delayed)) (NNS ratings)) (. .)))
19269743	1	(S1 (S (NP (JJ Doc_19269743_121_125_Disease) (NN memory)) (VP (AUX is) (VP (VBN thought) (S (VP (TO to) (VP (VP (VB affect) (NP (JJ future) (JJ Doc_19269743_161_165_Disease) (NN sensitivity))) (CC and) (ADVP (RB thus)) (VP (VB contribute) (PP (TO to) (NP (JJ clinical) (JJ Doc_19269743_210_214_Disease) (NNS conditions))))))))) (. .)))
19269743	2	(S1 (S (NP (NP (JJ Systematic) (NNS investigations)) (PP (IN of) (NP (DT the) (JJ human) (NN capacity) (S (VP (TO to) (VP (VB remember) (NP (NP (JJ sensory) (NNS features)) (PP (IN of) (NP (JJ experimental) (NN Doc_19269743_320_324_Disease)))))))))) (VP (AUX are) (ADJP (JJ sparse))) (. .)))
19269743	3	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB address) (NP (NP (JJ long-term) (JJ Doc_19269743_367_371_Disease) (NN memory)) (, ,) (SBAR (S (NP (CD nine) (JJ healthy) (NN male) (NNS volunteers)) (VP (VBD received) (NP (NP (JJ intradermal) (NNS injections)) (PP (IN of) (NP (NP (CD three) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_19269743_459_468_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.05) (, ,) (CD 1) (CC and) (CD 20) (NN microg)) (, ,) (VP (VBN separated) (PP (IN by) (NP (CD 15) (JJ min) (NNS breaks))))) (-RRB- -RRB-))))))))))))))) (, ,) (NP (DT each)) (VP (VBN given) (NP (CD three) (NNS times)) (PP (IN in) (NP (NP (DT a) (JJ balanced) (NN design)) (PP (IN across) (NP (NP (CD three) (NNS sessions)) (PP (IN at) (NP (CD one) (NN week) (NNS intervals)))))))) (. .)))
19269743	4	(S1 (S (NP (JJ Doc_19269743_611_615_Disease) (NN rating)) (VP (AUX was) (VP (VBN performed) (S (VP (VBG using) (NP (NP (DT a) (JJ computerized) (JJ visual) (NN analogue) (NN scale)) (PRN (-LRB- -LRB-) (NP (CD 0-100)) (-RRB- -RRB-)) (VP (VBN digitized) (PP (IN at) (NP (NP (NN 1/s)) (, ,) (CC either) (ADVP (RB immediately)) (NP (NN online)) (CC or) (NP (NP (NP (CD one) (NN hour)) (CC or) (NP (CD one) (NN day))) (PP (IN after) (NP (NN injection)))))))))))) (. .)))
19269743	5	(S1 (S (NP (NNS Subjects)) (ADVP (RB also)) (VP (VBD recalled) (NP (PRP$ their) (NNP Doc_19269743_801_806_Disease) (CD one) (NN week)) (ADVP (RB later))) (. .)))
19269743	6	(S1 (S (NP (JJ Doc_19269743_823_832_Chemical) (NN injection)) (ADVP (RB reliably)) (VP (VBN induced) (NP (NP (DT a) (JJ dose-dependent) (NN flare)) (PRN (-LRB- -LRB-) (NP (CD p<0.001)) (-RRB- -RRB-))) (PP (IN without) (NP (DT any) (NN difference))) (PP (IN within) (NP (QP (CC or) (IN across)) (NNS sessions)))) (. .)))
19269743	7	(S1 (S (NP (DT The) (JJ strong) (NN burning) (NN Doc_19269743_962_966_Disease)) (VP (VBD decayed) (ADVP (RB exponentially)) (PP (IN within) (NP (DT a) (JJ few) (NNS minutes)))) (. .)))
19269743	8	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (ADJP (JJ able) (PP (TO to) (NP (NP (ADJP (RB reliably) (JJ discriminate)) (NN Doc_19269743_1055_1059_Disease) (NN magnitude)) (CC and) (NP (NN duration))))) (PP (IN across) (NP (NP (JJ Doc_19269743_1090_1099_Chemical) (NNS doses)) (PRN (-LRB- -LRB-) (NP (DT both) (CD p<0.001)) (-RRB- -RRB-)))) (, ,) (ADVP (RB regardless) (PP (IN of) (SBAR (IN whether) (S (NP (JJ first-time) (NNS ratings)) (VP (AUX were) (VP (VBN requested) (ADVP (RB immediately)))))))) (, ,) (PP (PP (IN after) (NP (CD one) (NN hour))) (CC or) (PP (IN after) (NP (CD one) (NN day))))) (. .)))
19269743	9	(S1 (S (NP (NP (JJ Doc_19269743_1224_1228_Disease) (NN recall)) (PP (IN after) (NP (CD one) (NN week)))) (VP (AUX was) (ADJP (ADJP (RB similarly) (JJ precise)) (PRN (-LRB- -LRB-) (NP (NP (NN magnitude)) (: :) (NP (NP (CD p<0.01)) (, ,) (NP (NN duration))) (: :) (NP (CD p<0.05))) (-RRB- -RRB-)))) (. .)))
19269743	10	(S1 (S (NP (NP (NN Correlation)) (PP (IN with) (NP (NN rating) (NN recall))) (PP (IN after) (NP (CD one) (NN week)))) (VP (AUX was) (ADVP (RB best)) (SBAR (WHADVP (WRB when)) (S (NP (JJ first-time) (NNS ratings)) (VP (AUX were) (VP (VBN requested) (ADVP (ADVP (RB as) (RB late)) (PP (IN as) (NP (NP (CD one) (NN day)) (PP (IN after) (NP (NP (NN injection)) (PRN (-LRB- -LRB-) (NP (NP (NN R)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NP (CD =0.79))) (-RRB- -RRB-)) (VP (VBG indicating) (SBAR (IN that) (S (NP (DT both) (NN rating) (NNS retrievals)) (VP (VBD utilized) (NP (JJ similar) (NN memory) (NNS traces)))))))))))))))) (. .)))
19269743	11	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (NP (NP (DT a) (JJ reliable) (NN memory)) (PP (IN for) (NP (NP (NP (NN magnitude)) (CC and) (NP (NN duration))) (PP (IN of) (NP (ADJP (RB experimentally) (VBN induced)) (NN Doc_19269743_1618_1622_Disease))))))) (. .)))
19269743	12	(S1 (S (NP (DT The) (NNS data)) (ADVP (RB further)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN consolidation)) (PP (IN of) (NP (DT this) (NN memory)))) (VP (VP (AUX is) (NP (DT an) (JJ important) (JJ interim) (NN stage))) (, ,) (CC and) (VP (MD may) (VP (VB take) (PRT (RP up)) (PP (TO to) (NP (CD one) (NN day))))))))) (. .)))
19299179	0	(S1 (FRAG (ADJP (JJ Severe) (CC and) (JJ long)) (S (VP (VBG lasting) (NP (NNP Doc_19299179_24_35_Disease)) (PP (IN after) (NP (NP (JJ high-dose) (JJ Doc_19299179_52_66_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_19299179_81_103_Disease))))) (PP (IN in) (NP (NP (JJ Doc_19299179_107_119_Disease) (JJ patients--a) (NN report)) (PP (IN of) (NP (CD two) (NNS cases))))))) (. .)))
19299179	1	(S1 (S (NP (NP (NP (NNP Doc_19299179_153_175_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19299179_177_180_Disease)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ common) (NN Doc_19299179_192_215_Disease)) (PP (IN in) (NP (JJ Doc_19299179_219_231_Disease) (NNS individuals)))) (, ,)) (VP (AUX is) (ADVP (RB generally)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_19299179_285_299_Chemical))))))) (. .)))
19299179	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NN treatment)) (VP (AUX is) (ADVP (RB often)) (VP (VBN limited) (PP (IN by) (NP (JJ adverse) (NNS effects))))) (. .)))
19299179	3	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NP (ADJP (RB severely) (VBN immunocompromised)) (JJ Doc_19299179_413_425_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ severe) (NNP Doc_19299179_456_480_Disease)) (, ,) (CC and) (PP (IN in) (NP (NP (CD one) (JJ patient) (NNS lesions)) (VP (VBG mimicking) (NP (NNP Doc_19299179_519_532_Disease) (NN formation)) (PP (IN on) (NP (JJ radiologic) (NNS exams)))))) (, ,) (PP (IN during) (NP (NP (JJ Doc_19299179_571_585_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_19299179_600_603_Disease)))))))))))) (. .)))
19299179	4	(S1 (S (SBAR (IN Whereas) (S (NP (NN patient) (CD 1)) (VP (VBD showed) (NP (NP (NNS lesions)) (PP (IN of) (NP (QP (IN up) (TO to) (CD 1) (CD cm)))) (ADJP (RB readily) (JJ detectable))) (PP (IN on) (NP (JJ magnetic) (NN resonance) (NN imaging))) (PP (IN under) (NP (JJ prolonged) (JJ Doc_19299179_717_731_Chemical) (NN treatment)))))) (, ,) (NP (NP (NN therapy)) (PP (IN of) (NP (NN patient) (CD 2)))) (VP (AUX was) (VP (VBN switched) (ADVP (RB early)))) (. .)))
19300402	0	(S1 (S (NP (NP (NP (JJ Doc_19300402_0_10_Chemical) (NNS receptors) (NNS antagonists)) (CC and) (NP (JJ Doc_19300402_37_49_Chemical) (NN synthase) (NNS inhibitors))) (PP (IN in) (NP (NP (NNP Doc_19300402_73_84_Chemical)) (CC and) (NP (NNP Doc_19300402_89_103_Chemical))))) (VP (VBN induced) (S (NP (NNP Doc_19300402_112_124_Disease)) (PP (IN in) (NP (ADJP (JJ chemotherapy) (CC and) (JJ Doc_19300402_145_164_Disease)) (NN rat) (NN model))))) (. .)))
19300402	1	(S1 (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NP (DT an) (JJ irreversible) (NN inhibitor)) (PP (IN of) (NP (NP (JJ constitutive) (JJ Doc_19300402_244_246_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNP L-NOArg)) (: ;) (NP (QP (CD 1.0) (CD mg/kg)) (NN ip)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (DT a) (ADJP (RB relatively) (JJ selective)) (NN inhibitor)) (PP (IN of) (NP (NP (JJ inducible) (JJ Doc_19300402_327_329_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNP L-NIL)) (: ;) (NP (QP (CD 1.0) (CD mg/kg)) (NN ip)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (ADJP (RB relatively) (JJ specific)) (NN inhibitor)) (PP (IN of) (NP (JJ neuronal) (JJ Doc_19300402_409_411_Chemical) (NN synthase))))) (PRN (-LRB- -LRB-) (NP (NN 7-NI)) (: ;) (NP (QP (CD 0.1) (CD mg/kg)) (NN ip)) (-RRB- -RRB-)) (, ,) (PP (IN on) (NP (NP (JJ antihyperalgesic) (NN action)) (PP (IN of) (NP (NP (NP (JJ selective) (NNS antagonists)) (PP (IN of) (NP (UCP (JJ B2) (CC and) (NNP B1)) (NNS receptors)))) (: :) (NP (NP (NNP D-Arg--LSB-Hyp3) (, ,) (NNP Thi5) (, ,) (NNP D-Tic7)) (, ,) (NP (NP (NNP Oic8) (NN -RSB-) (NNP Doc_19300402_549_559_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19300402_561_568_Chemical)) (: ;) (NP (QP (CD 70) (CD nmol/kg)) (NN ip)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_19300402_588_605_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 70) (CD nmol/kg)) (NN ip)) (-RRB- -RRB-)))))))))) (ADVP (RB respectively)) (, ,) (PP (IN in) (NP (NP (NN model)) (PP (IN of) (NP (NNP Doc_19300402_648_724_Disease)))))))) (VP (AUX was) (VP (VBN investigated))) (. .)))
19300402	2	(S1 (S (NP (NP (DT The) (NNS changes)) (PP (IN in) (NP (JJ Doc_19300402_767_771_Disease) (NNS thresholds)))) (VP (AUX were) (VP (VBN determined) (S (VP (VBG using) (NP (NP (JJ mechanical) (NN stimuli--the) (NN modification)) (PP (IN of) (NP (NP (DT the) (JJ classic) (NN paw) (NN withdrawal) (NN test)) (VP (VBN described) (PP (IN by) (NP (NNP Randall-Selitto))))))))))) (. .)))
19300402	3	(S1 (S (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN paper)))) (VP (VP (VBP confirm) (NP (NP (DT that) (NN inhibition)) (PP (IN of) (NP (JJ Doc_19300402_969_979_Chemical) (NNS receptors))))) (CC and) (VP (VBP inducible) (NP (JJ Doc_19300402_1004_1006_Chemical) (NN synthase))))) (CC but) (S (NP (RB not) (JJ neuronal) (JJ Doc_19300402_1033_1035_Chemical) (NN synthase) (NN activity)) (VP (VBZ reduces) (NP (NNP Doc_19300402_1062_1083_Disease)))) (. .)))
19300402	4	(S1 (S (NP (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP L-NOArg) (CC and) (NNP L-NIL)))) (CC but) (RB not) (NP (NN 7-NI)) (, ,)) (VP (ADVP (RB significantly)) (VBZ increases) (NP (NP (JJ antihyperalgesic) (NN activity)) (CC both) (NP (NNP Doc_19300402_1190_1197_Chemical) (CC and) (NNP Doc_19300402_1202_1219_Chemical)))) (. .)))
19300402	5	(S1 (S (NP (PRP It)) (VP (AUX was) (ADVP (RB also)) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT both) (NNS products)) (PP (IN of) (NP (NP (NP (JJ inducible) (JJ Doc_19300402_1271_1273_Chemical) (NN synthase)) (CC and) (NP (JJ neuronal) (JJ Doc_19300402_1296_1298_Chemical) (NN synthase) (NN activation))) (CONJP (RB as) (RB well) (IN as)) (NP (NNP Doc_19300402_1330_1340_Chemical))))) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (NNP Doc_19300402_1357_1369_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_19300402_1382_1393_Chemical)))))))))))) (. .)))
19300402	6	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NNP L-NOArg)) (CC and) (NP (NNS 7-NI) (CONJP (CC but) (RB not)) (NNP L-NIL))) (VP (VB intensify) (NP (NP (JJ antihyperalgesic) (NN activity)) (PP (IN of) (NP (NP (NNP Doc_19300402_1475_1482_Chemical)) (CC or) (NP (NNP Doc_19300402_1486_1502_Chemical)))) (PP (IN in) (NP (NNP Doc_19300402_1506_1522_Disease))))) (. .)))
19300402	7	(S1 (S (NP (NP (NNS Results)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (ADJP (JJ B1) (CC and) (JJ B2)) (NNS receptors)) (VP (AUX are) (VP (VBN engaged) (PP (IN in) (NP (NP (NN transmission)) (PP (IN of) (NP (JJ nociceptive) (NNS stimuli))) (PP (IN in) (NP (DT both) (NNP Doc_19300402_1654_1683_Disease)))))))))) (. .)))
19300402	8	(S1 (S (PP (IN In) (NP (NNP Doc_19300402_1688_1702_Chemical-induced) (NNP Doc_19300402_1711_1723_Disease))) (, ,) (NP (JJ inducible) (JJ Doc_19300402_1735_1737_Chemical) (NN synthase)) (VP (VBZ participates) (PP (IN in) (NP (NP (JJ pronociceptive) (NN activity)) (PP (IN of) (NP (NNP Doc_19300402_1790_1800_Chemical))))) (, ,) (SBAR (IN whereas) (S (PP (IN in) (NP (NNP Doc_19300402_1813_1824_Chemical-induced) (NNP Doc_19300402_1833_1845_Disease) (NNP Doc_19300402_1846_1856_Chemical))) (VP (VBD seemed) (S (VP (TO to) (VP (VBP activate) (NP (JJ neuronal) (JJ Doc_19300402_1885_1887_Chemical) (NN synthase) (NN pathway))))))))) (. .)))
19300402	9	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN concomitant) (NN administration)) (PP (IN of) (NP (NP (JJ small) (NNS doses)) (PP (IN of) (NP (NP (JJ Doc_19300402_1962_1972_Chemical) (NN receptor) (NNS antagonists)) (CC and) (NP (JJ Doc_19300402_1998_2000_Chemical) (NN synthase) (NNS inhibitors))))))) (VP (MD can) (VP (AUX be) (ADJP (JJ effective) (PP (IN in) (NP (NP (NN alleviation)) (PP (IN of) (NP (NNP Doc_19300402_2056_2072_Disease)))))) (, ,) (PP (ADVP (RB even)) (IN in) (NP (NN hospital) (NN care))))) (. .)))
19308880	0	(S1 (NP (NP (NN Doc_19308880_0_9_Disease)) (, ,) (NP (NP (DT a) (ADJP (RB rather) (JJ serious)) (JJ adverse) (NN drug) (NN reaction)) (PP (IN with) (NP (NNP Doc_19308880_55_68_Chemical)))) (: :) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (DT the) (JJ French) (NN Pharmacovigilance) (NN database)))) (. .)))
19308880	1	(S1 (S (NP (NN Doc_19308880_135_144_Disease)) (VP (AUX is) (NP (NP (DT an) (JJ adverse) (NN drug) (NN reaction)) (VP (ADVP (RB frequently)) (VBN observed) (PP (IN with) (NP (NNP Doc_19308880_198_211_Chemical)))))) (. .)))
19308880	2	(S1 (S (S (NP (DT Some) (NN case) (NNS reports)) (VP (AUX are) (VP (VBN published) (PP (IN in) (NP (DT the) (NN literature)))))) (CC but) (S (NP (NP (DT no) (JJ systematic) (NN study)) (PP (IN from) (NP (NP (DT a) (NN sample)) (PP (IN of) (NP (NNS patients)))))) (VP (AUX has) (VP (AUX been) (VP (VBN published))))) (. .)))
19308880	3	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (DT this) (NN study)) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB describe) (NP (NP (DT the) (JJ main) (NNS characteristics)) (PP (IN of) (NP (DT this) (JJ adverse) (NN drug) (NN reaction)))))))) (. .)))
19308880	4	(S1 (S (S (VP (VBG Using) (NP (DT the) (JJ French) (NN Pharmacovigilance) (NN database)))) (, ,) (NP (PRP we)) (VP (VBD selected) (NP (NP (DT the) (NNS cases)) (PP (IN of) (NP (NNP Doc_19308880_513_522_Disease))) (VP (VBN reported) (PP (IN since) (NP (CD 1985))) (PP (IN with) (NP (NNP Doc_19308880_548_561_Chemical)))))) (. .)))
19308880	5	(S1 (S (S (NP (NP (CD 272) (NNS cases)) (PP (IN of) (NP (NNP Doc_19308880_585_594_Disease)))) (VP (AUX were) (VP (VBN reported) (PP (IN with) (NP (NNP Doc_19308880_614_627_Chemical)))))) (: :) (FRAG (NP (NP (CD 153) (NNS women)) (CC and) (NP (CD 119) (NNS men)))) (. .)))
19308880	6	(S1 (S (NP (NN Doc_19308880_652_661_Disease)) (ADVP (RB mostly)) (VP (VBD occurred) (PP (IN during) (NP (DT the) (CD two) (JJ first) (NNS weeks))) (PP (VBG following) (NP (NP (JJ Doc_19308880_715_728_Chemical) (NN exposure)) (PRN (-LRB- -LRB-) (NP (CD 39.7) (NN %)) (-RRB- -RRB-))))) (. .)))
19308880	7	(S1 (S (NP (PRP It)) (VP (AUX was) (ADJP (`` ``) (JJ serious) ('' '') (PP (IN for) (NP (NP (NP (QP (RB almost) (CD 2/3))) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 62.5) (NN %)) (-RRB- -RRB-))))) (CC and) (NP (NP (PRP$ its) (NN outcome) (JJ favourable)) (PP (IN in) (NP (NP (JJS most)) (PP (IN of) (NP (NP (DT the) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 82) (NN %)) (-RRB- -RRB-))))))))))) (. .)))
19308880	8	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (DT this) (NN ADR)))) (VP (AUX was) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN aged) (PP (IN between) (NP (CD 61) (CC and) (CD 80) (NNS years))))))) (. .)))
19308880	9	(S1 (S (NP (DT This) (NN work)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (NNP Doc_19308880_978_987_Disease)) (PP (IN with) (NP (NNP Doc_19308880_993_1006_Chemical)))) (VP (AUX is) (NP (DT a) (JJ serious) (, ,) (ADJP (RB rather) (JJ frequent) (CC but) (JJ reversible)) (JJ adverse) (NN drug) (NN reaction)))))) (. .)))
19308880	10	(S1 (S (NP (PRP It)) (VP (VBZ occurs) (PP (ADVP (RB especially)) (PP (IN in) (NP (JJR older) (NNS patients))) (CC and) (PP (IN during) (NP (NP (DT the) (JJ first) (CD two) (NNS weeks)) (PP (IN of) (NP (NN treatment))))))) (. .)))
19346865	0	(S1 (NP (NP (NP (JJ Reversible) (NNP Doc_19346865_11_37_Disease)) (PP (IN in) (NP (NNP Doc_19346865_41_54_Chemical-induced) (NNP Doc_19346865_63_77_Disease)))) (: :) (NP (NP (JJ magnetic) (NN resonance) (NNS findings)) (PP (IN on) (NP (ADJP (JJ diffusion-weighted) (CC and) (JJ fluid)) (JJ attenuated) (NN inversion) (NN recovery) (NN imaging)))) (. .)))
19346865	1	(S1 (S (NP (DT This)) (VP (AUX is) (S (VP (TO to) (VP (VB present) (NP (JJ reversible) (NN Doc_19346865_219_246_Disease)) (PP (IN in) (NP (NNP Doc_19346865_250_263_Chemical-induced) (NNP Doc_19346865_272_286_Disease))) (, ,) (S (VP (TO to) (VP (VB focus) (PP (IN on) (NP (NP (NP (DT the) (JJ diffusion-weighted) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP DWI)) (-RRB- -RRB-))) (CC and) (NP (JJ fluid) (JJ attenuated) (NN inversion) (NN recovery) (PRN (-LRB- -LRB-) (NP (NN FLAIR)) (-RRB- -RRB-)) (NN imaging))))))))))) (. .)))
19346865	2	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (PP (PP (IN From) (NP (NNP November) (CD 2005))) (PP (TO to) (NP (NNP September) (CD 2007)))) (, ,) (NP (NP (CD 8) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NNS men)) (CC and) (NP (CD 3) (NNS women))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN diagnosed) (PP (IN as) (S (VP (AUXG having) (NP (NP (JJ Doc_19346865_511_524_Chemical-induced) (NN Doc_19346865_533_547_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN age) (NN range)) (: ;) (NP (CD 43-78) (NNS years))) (-RRB- -RRB-))))))))) (. .)))
19346865	3	(S1 (S (NP (PRP They)) (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NP (NNP Doc_19346865_595_608_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ total) (NN dosage)) (, ,) (NP (CD 45-120) (NNP g))) (: ;) (NP (NP (NP (NN duration)) (, ,) (NP (CD 30) (NNS days))) (TO to) (NP (CD 2) (NNS months)))) (-RRB- -RRB-))) (S (VP (TO to) (VP (VB treat) (NP (NP (DT the) (NN Doc_19346865_678_687_Disease)) (PP (IN in) (NP (JJ various) (NNS organs)))))))))) (. .)))
19346865	4	(S1 (S (NP (NP (JJ Initial) (NN brain) (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN obtained) (PP (IN after) (NP (DT the) (NN hospitalization))) (, ,) (PP (VBG including) (NP (NP (NNP DWI)) (PRN (-LRB- -LRB-) (NP (CD 8/8)) (-RRB- -RRB-)))) (, ,) (NP (NP (JJ apparent) (NN diffusion) (NN coefficient) (PRN (-LRB- -LRB-) (NNP ADC) (-RRB- -RRB-)) (NN map)) (PRN (-LRB- -LRB-) (NP (CD 4/8)) (-RRB- -RRB-)) (, ,) (NP (NN FLAIR)) (PRN (-LRB- -LRB-) (NP (CD 7/8)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (JJ T2-weighted) (NN image)) (PRN (-LRB- -LRB-) (NP (CD 8/8)) (-RRB- -RRB-)))))) (. .)))
19346865	5	(S1 (S (NP (JJ Follow-up) (NNS MRIs)) (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (QP (CD 5) (NNS patients) (IN from) (JJ third) (TO to) (JJ 14th)) (NNS days))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_19346865_999_1012_Chemical) (NN administration))))))) (. .)))
19346865	6	(S1 (S (NP (NP (NNS Findings)) (PP (IN of) (NP (ADJP (JJ initial) (CC and) (JJ follow-up)) (NNS MRIs)))) (VP (AUX were) (ADVP (RB retrospectively)) (VP (VBN evaluated) (PP (IN by) (NP (CD 2) (NNS neuroradiologists))) (PP (IN by) (NP (NN consensus))) (, ,) (S (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ abnormal) (NN signal) (NNS intensities)) (, ,) (NP (PRP$ their) (NNS locations)) (, ,) (CC and) (NP (NN signal) (NNS changes))))) (PP (IN on) (NP (JJ follow-up) (NNS images)))))))) (. .)))
19346865	7	(S1 (S (NP (JJ Initial) (NN MRIs)) (VP (VBD showed) (NP (NP (NP (JJ abnormal) (JJ high) (NN signal) (NNS intensities)) (PP (IN on) (NP (NP (NNP DWI)) (CC and) (NP (NP (NP (NN FLAIR)) (PRN (-LRB- -LRB-) (CC or) (NP (JJ T2-weighted) (NN image)) (-RRB- -RRB-))) (PP (IN at) (NP (DT the) (JJ dentate) (NN nucleus))) (PRN (-LRB- -LRB-) (NP (CD 8/8)) (-RRB- -RRB-)) (, ,))))) (JJ inferior) (NN colliculus) (PRN (-LRB- -LRB-) (NP (CD 6/8)) (-RRB- -RRB-)) (, ,) (NP (JJ corpus) (NN callosum)) (PRN (-LRB- -LRB-) (NP (CD 2/8)) (-RRB- -RRB-)) (, ,) (NP (NNP pons)) (PRN (-LRB- -LRB-) (CD 2/8) (-RRB- -RRB-)) (, ,) (NP (NP (NN medulla)) (PRN (-LRB- -LRB-) (NP (CD 1/8)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ bilateral) (JJ cerebral) (JJ white) (NN matter)) (PRN (-LRB- -LRB-) (NP (CD 1/8)) (-RRB- -RRB-))))) (. .)))
19346865	8	(S1 (S (S (NP (NP (JJ High-signal) (NN intensity) (NNS lesions)) (PP (IN on) (NP (NNP DWI)))) (VP (VBD tended) (S (VP (TO to) (VP (VB show) (NP (NP (JJ low) (NN signal) (NN intensity)) (PP (IN on) (NP (NP (JJ ADC) (NN map)) (PRN (-LRB- -LRB-) (NP (CD 3/4)) (-RRB- -RRB-)))))))))) (, ,) (CC but) (S (PP (IN in) (NP (CD one) (NN patient))) (, ,) (NP (JJ high) (NN signal) (NN intensity)) (VP (AUX was) (VP (VBN shown) (PP (IN at) (NP (JJ bilateral) (FW dentate) (FW nuclei))) (PP (IN on) (NP (CONJP (RB not) (RB only)) (NP (NN DWI)) (CONJP (CC but) (RB also)) (NP (JJ ADC) (NN map))))))) (. .)))
19346865	9	(S1 (S (S (NP (NP (PDT All) (DT the) (NNS lesions)) (PP (IN in) (NP (NP (NN dentate)) (, ,) (NP (JJ inferior) (NN colliculus)) (, ,) (NP (NNP pons)) (, ,) (CC and) (NP (NNS medullas))))) (VP (AUX had) (VP (AUX been) (VP (VBN resolved) (ADVP (RB completely)) (PP (IN on) (NP (JJ follow-up) (NNS MRIs))) (PP (IN in) (NP (CD 5) (NNS patients))))))) (, ,) (CC but) (S (PP (IN in) (NP (NP (CD 1) (NN patient)) (PP (IN of) (NP (PRP them))))) (, ,) (NP (JJ corpus) (NNP Doc_19346865_1869_1884_Disease)) (VP (VBD persisted))) (. .)))
19346865	10	(S1 (S (NP (JJ Reversible) (NN Doc_19346865_1920_1947_Disease)) (VP (MD could) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (DT the) (NN characteristic)) (PP (IN for) (NP (NP (NNP Doc_19346865_1994_2007_Chemical-induced) (NNP Doc_19346865_2016_2030_Disease)) (, ,) (ADVP (JJ next) (PP (TO to) (NP (DT the) (NN dentate) (NN nucleus) (NN involvement))))))))))) (. .)))
19356053	0	(S1 (FRAG (ADJP (RB Clinically) (JJ significant)) (S (NP (NNP Doc_19356053_23_34_Disease)) (VP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_19356053_67_76_Chemical))) (PP (TO to) (NP (JJ renal) (NN transplant) (NNS recipients)))))) (. .)))
19356053	1	(S1 (S (NP (NN Doc_19356053_121_130_Chemical)) (VP (VP (AUX is) (NP (NP (DT the) (JJS latest) (JJ immunosuppressive) (NN agent)) (VP (VBN used) (S (VP (TO to) (VP (VB prevent) (NP (NN rejection)))))))) (, ,) (CC and) (VP (MD may) (VP (AUX have) (NP (ADJP (ADJP (RBR less) (JJ Doc_19356053_214_228_Disease)) (PP (IN than) (NP (JJ calcineurin) (NN inhibitor)))) (PRN (-LRB- -LRB-) (NP (NNP CNI)) (-RRB- -RRB-)) (JJ -based) (NNS regimens))))) (. .)))
19356053	2	(S1 (S (PP (TO To) (NP (NN date))) (NP (EX there)) (VP (AUX has) (VP (AUX been) (NP (NP (JJ little) (NN documentation)) (PP (IN of) (NP (NP (ADJP (RB clinically) (JJ significant)) (NN Doc_19356053_348_359_Disease)) (VP (VBN linked) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_19356053_383_392_Chemical))))))))))) (. .)))
19356053	3	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN encountered) (NP (NP (JJ several) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (JJ substantial) (NN Doc_19356053_457_468_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_19356053_485_494_Chemical) (NN use))))))))))) (. .)))
19356053	4	(S1 (S (PP (IN In) (NP (DT each) (NN patient))) (, ,) (NP (NP (DT the) (JJ close) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NP (DT the) (NN commencement)) (PP (IN of) (NP (JJ Doc_19356053_576_585_Chemical) (NN therapy)))) (CC and) (NP (NNP Doc_19356053_598_609_Disease))))) (VP (VBN implicated) (NP (NNP Doc_19356053_621_630_Chemical)) (PP (IN as) (NP (NP (DT the) (ADJP (RBS most) (JJ likely)) (NN etiology)) (PP (IN of) (NP (DT the) (NNP Doc_19356053_666_677_Disease)))))) (. .)))
19356053	5	(S1 (S (NP (PRP We)) (VP (VBD analyzed) (S (NP (DT the) (JJ clinical) (CC and) (NN laboratory) (NN information)) (ADJP (JJ available) (PP (IN for) (NP (NP (DT all) (CD 119) (NNS patients)) (VP (VBN transplanted) (PP (IN at) (NP (NP (DT the) (NNP Washington) (NNP Hospital) (NNP Center)) (PP (IN between) (NP (NP (CD 1999-2003)) (SBAR (WHPP (IN for) (WHNP (WP whom))) (S (NP (NNP Doc_19356053_845_854_Chemical)) (VP (AUX was) (NP (NP (DT a) (NN component)) (PP (IN of) (NP (PRP$ their) (JJ immunosuppressant) (NN regimen))))))))))))))))) (. .)))
19356053	6	(S1 (S (PP (IN In) (NP (DT these) (NNS patients))) (, ,) (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (NNP Doc_19356053_943_954_Disease)))) (VP (AUX was) (VP (VBN assessed) (PP (IN on) (NP (NN morning) (NN urine) (NNS samples))) (PP (IN by) (NP (NP (JJ turbidometric) (NN measurement) (CC or) (JJ random) (NN urine) (NN protein)) (: :) (NP (JJ Doc_19356053_1046_1056_Chemical) (NNS ratios)) (, ,) (NP (NP (DT an) (NN estimate)) (PP (IN of) (NP (NP (NNS grams)) (PP (IN of) (NP (NNP Doc_19356053_1089_1100_Disease/day)))))))))) (. .)))
19356053	7	(S1 (S (NP (NN Laboratory) (NNS results)) (VP (AUX were) (VP (VBN compared) (PP (IN between) (NP (NP (RB prior)) (, ,) (NP (IN during)) (CC and) (NP (JJ following) (JJ Doc_19356053_1175_1184_Chemical) (NN use)))))) (. .)))
19356053	8	(S1 (S (NP (NP (JJ Twenty-eight) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (VBN increased) (NN Doc_19356053_1247_1258_Disease)) (PP (IN from) (NP (NN baseline))) (PP (IN during) (NP (PRP$ their) (NN post-transplantation) (NN course)))) (. .)))
19356053	9	(S1 (S (PP (IN In) (NP (CD 21) (NNS patients))) (NP (NP (DT an) (JJ alternative) (NN cause)) (PP (IN of) (NP (NNP Doc_19356053_1354_1365_Disease) (AUX was) (ADJP (DT either) (JJ obvious) (CC or) (JJ insufficient)) (NNS data)))) (VP (AUX was) (ADJP (JJ available) (S (VP (TO to) (VP (AUX be) (ADJP (JJ conclusive))))))) (. .)))
19356053	10	(S1 (S (PP (IN In) (NP (NP (CD 7)) (PP (IN of) (NP (DT the) (CD 28) (NNS patients))))) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ striking) (JJ temporal) (NN association)) (PP (IN between) (NP (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_19356053_1530_1539_Chemical)))) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19356053_1563_1572_Disease-range) (NNP Doc_19356053_1579_1590_Disease)))))))) (. .)))
19356053	11	(S1 (S (NP (NN Doc_19356053_1592_1603_Disease)) (VP (VBD correlated) (ADVP (RBS most) (RB strongly)) (PP (IN with) (NP (JJ Doc_19356053_1634_1643_Chemical) (NN therapy))) (SBAR (WHADVP (WRB when)) (S (VP (VBD compared) (PP (TO to) (NP (JJ other) (ADJP (JJ demographic) (CC and) (JJ clinical)) (NNS variables))))))) (. .)))
19356053	12	(S1 (S (PP (IN In) (NP (JJS most) (NNS patients))) (, ,) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_19356053_1748_1757_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN decrease)) (, ,) (CONJP (CC but) (RB not)) (NP (NN resolution)) (, ,)) (PP (IN of) (NP (NNP Doc_19356053_1805_1816_Disease)))))) (. .)))
19356053	13	(S1 (S (NP (NN Doc_19356053_1831_1840_Chemical)) (VP (VBZ induces) (CC or) (VBZ aggravates) (NP (JJ pre-existing) (NN Doc_19356053_1876_1887_Disease)) (PP (IN in) (NP (NP (DT an) (JJ unpredictable) (NN subset)) (PP (IN of) (NP (JJ renal) (NN allograft) (NNS recipients)))))) (. .)))
19356053	14	(S1 (S (S (NP (NN Doc_19356053_1946_1957_Disease)) (VP (MD may) (VP (VB improve)))) (, ,) (CC but) (S (VP (AUX does) (RB not) (VP (VB resolve) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_19356053_1998_2007_Chemical)) (VP (AUX is) (VP (VBN withdrawn)))))))) (. .)))
19356307	0	(S1 (S (NP (NP (NNS Components)) (PP (IN of) (NP (NNP lemon) (JJ essential) (NN oil)))) (VP (VBP attenuate) (NP (NP (NNP Doc_19356307_44_52_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19356307_64_75_Chemical)))))) (. .)))
19356307	1	(S1 (S (NP (NP (DT The) (JJ anti-Doc_19356307_86_94_Disease) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_19356307_106_116_Chemical)) (CC and) (NP (NNP Doc_19356307_121_139_Chemical))))) (VP (AUX were) (VP (VBN observed) (S (VP (VBG using) (NP (NP (NP (DT the) (JJ passive) (NN avoidance) (NN test)) (PRN (-LRB- -LRB-) (NP (NNP PA)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ open) (NN field) (NN habituation) (NN test)) (PRN (-LRB- -LRB-) (NP (NNP OFH)) (-RRB- -RRB-)))))))) (. .)))
19356307	2	(S1 (S (S (NP (DT These) (NNP lemon) (JJ essential) (NNS oils)) (VP (VBD showed) (NP (JJ strong) (NN ability) (S (VP (TO to) (VP (VB improve) (NP (NNP Doc_19356307_295_310_Disease)) (PP (IN by) (NP (NNP Doc_19356307_314_325_Chemical))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNP Doc_19356307_336_354_Chemical)) (VP (VP (VBD relieved) (NP (DT the) (NNP Doc_19356307_368_397_Disease)) (PP (IN in) (NP (NNP PA))) (ADVP (RB only))) (, ,) (CC and) (VP (AUX did) (RB not) (VP (VB improve) (NP (JJ non-associative) (NN memory)) (ADVP (RB significantly)) (PP (IN in) (NP (NN OFH))))))) (. .)))
19356307	3	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (JJ neurotransmitter) (NN concentration)) (PP (IN in) (NP (DT some) (NN brain) (NNS regions))) (PP (IN on) (NP (DT the) (NN test) (NN day)))))) (VP (VBD showed) (SBAR (IN that) (S (S (NP (NP (JJ Doc_19356307_568_576_Chemical) (NN concentration)) (PP (IN of) (NP (DT the) (JJ vehicle/Doc_19356307_606_617_Chemical) (NN group)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ vehicle/vehicle) (NN group)))))))) (, ,) (CC but) (S (NP (DT this) (NN phenomenon)) (VP (AUX was) (ADJP (JJ reversed)) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNP Doc_19356307_726_736_Chemical)) (CC or) (NP (NNP Doc_19356307_740_758_Chemical))) (VP (AUX were) (VP (VBN administered) (PP (IN before) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_19356307_801_812_Chemical)))))))))))))) (. .)))
19356307	4	(S1 (S (ADVP (RB Simultaneously)) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (DT these) (CD two) (NNP lemon) (JJ essential) (NN oil) (NNS components)) (VP (MD could) (VP (VB inhibit) (NP (NP (NN acetylcholinesterase) (NN activity)) (PP (IN in) (NP (NN vitro)))) (S (VP (VBG using) (NP (DT the) (NNP Ellman) (NN method))))))))) (. .)))
19387625	0	(S1 (NP (NP (JJ Attentional) (NN modulation)) (PP (IN of) (NP (VBN perceived) (NNP Doc_19387625_36_40_Disease) (NN intensity))) (PP (IN in) (NP (JJ Doc_19387625_54_63_Chemical-induced) (JJ secondary) (NN Doc_19387625_82_94_Disease))) (. .)))
19387625	1	(S1 (S (NP (VBN Perceived) (NN Doc_19387625_106_110_Disease) (NN intensity)) (VP (AUX is) (VP (VBN modulated) (PP (IN by) (NP (NN attention))))) (. .)))
19387625	2	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (AUX is) (RB not) (VP (VBN known) (SBAR (IN that) (WHADVP (WRB how)) (S (NP (NNP Doc_19387625_182_186_Disease) (NN intensity) (NNS ratings)) (VP (AUX are) (VP (VBN affected) (PP (IN by) (NP (NN attention))) (PP (IN in) (NP (JJ Doc_19387625_234_243_Chemical-induced) (JJ secondary) (NN Doc_19387625_262_274_Disease))))))))) (. .)))
19387625	3	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (VBN perceived) (JJ Doc_19387625_304_308_Disease) (NN intensity)) (PP (IN in) (NP (JJ secondary) (NNP Doc_19387625_332_344_Disease)))) (VP (AUX is) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (NP (NN attention)) (VP (AUX is) (VP (VBN distracted) (PRT (RP away)) (PP (IN from) (NP (NP (DT the) (JJ painful) (NN pinprick) (NN stimulus)) (PP (IN with) (NP (DT a) (JJ visual) (NN task)))))))))))))) (. .)))
19387625	4	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP it)) (VP (AUX was) (VP (VBN found) (SBAR (IN that) (S (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (JJ attentional) (NN modulation))) (PP (IN in) (NP (JJ secondary) (NNP Doc_19387625_531_543_Disease)))) (VP (AUX is) (ADJP (RB very) (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (JJ Doc_19387625_571_580_Chemical-untreated) (, ,) (JJ control) (NN condition))))))))))) (. .)))
19387625	5	(S1 (S (NP (NP (PRP$ Our) (NNS findings)) (, ,) (VP (VBG showing) (NP (NP (DT no) (NN interaction)) (PP (IN between) (NP (NP (JJ Doc_19387625_656_665_Chemical) (NN treatment)) (CC and) (NP (JJ attentional) (NN modulation))))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ Doc_19387625_716_725_Chemical-induced) (JJ secondary) (NN Doc_19387625_744_756_Disease)) (CC and) (NP (NN attention))) (VP (MD might) (VP (VB affect) (NP (JJ mechanical) (NN Doc_19387625_795_799_Disease)) (PP (IN through) (NP (JJ independent) (NNS mechanisms)))))))) (. .)))
19445921	0	(S1 (NP (NP (JJ Cardioprotective) (NN effect)) (PP (IN of) (NP (NNP Doc_19445921_27_45_Chemical))) (PP (IN on) (NP (NP (NNP Doc_19445921_49_62_Chemical-induced) (NNP Doc_19445921_71_92_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
19445921	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ cardioprotective) (NN potential)) (PP (IN of) (NP (NNP Doc_19445921_179_197_Chemical))) (PP (IN on) (NP (NP (NNP Doc_19445921_201_214_Chemical-induced) (NNP Doc_19445921_223_244_Disease)) (PP (IN in) (NP (NNS rats))))))))))) (. .)))
19445921	2	(S1 (S (NP (NP (JJ Hemodynamic) (NNS parameters)) (CC and) (NP (NN lead) (NNP II) (NN electrocardiograph))) (VP (AUX were) (VP (VP (VBN monitored)) (CC and) (VP (VBN recorded) (ADVP (RB continuously))))) (. .)))
19445921	3	(S1 (S (NP (NP (NP (JJ Cardiac) (NN marker) (NNS enzymes)) (CC and) (NP (JJ antioxidative) (NNS parameters))) (PP (IN in) (NP (NP (NN serum)) (CC and) (NP (NN heart) (NNS tissues))))) (VP (AUX were) (VP (VBN measured))) (. .)))
19445921	4	(S1 (S (NP (NP (NP (NN Assay)) (PP (IN for) (NP (JJ mitochondrial) (NN respiratory) (NN function)))) (CC and) (NP (NP (JJ histopathological) (NN examination)) (PP (IN of) (NP (NN heart) (NNS tissues))))) (VP (AUX were) (VP (VBN performed))) (. .)))
19445921	5	(S1 (S (NP (JJ Doc_19445921_556_569_Chemical-treated) (NNS rats)) (VP (VBD showed) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (JJ Doc_19445921_629_636_Chemical) (NN dehydrogenase)) (, ,) (NP (JJ Doc_19445921_652_661_Chemical) (NN transaminase)) (, ,) (NP (JJ Doc_19445921_676_684_Chemical) (NN kinase)) (CC and) (NP (JJ Doc_19445921_696_711_Chemical) (CC and) (JJ significant) (NNS decreases)))) (PP (IN in) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (NP (JJ Doc_19445921_759_769_Chemical) (NN dismutase)) (, ,) (NP (NN catalase)) (CC and) (NP (NP (JJ Doc_19445921_794_805_Chemical) (NN peroxidase)) (PP (IN in) (NP (NN serum) (CC and) (NN heart)))))))))))) (. .)))
19445921	6	(S1 (S (NP (DT These) (NNS rats)) (ADVP (RB also)) (VP (VBD showed) (NP (NP (NNS declines)) (PP (IN in) (NP (NP (JJ left) (JJ ventricular) (JJ systolic) (NN pressure)) (, ,) (NP (NP (NN maximum) (CC and) (NN minimum) (NN rate)) (PP (IN of) (NP (VBN developed) (JJ left) (NN ventricular) (NN pressure)))) (, ,) (CC and) (NP (NP (NN elevation)) (PP (IN of) (NP (NP (JJ left) (JJ ventricular) (JJ end-diastolic) (NN pressure)) (CC and) (NP (NN ST-segment))))))))) (. .)))
19445921	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (NNP mitochondrial) (NNP Doc_19445921_1073_1096_Disease)) (VP (VBN characterized) (PP (IN by) (NP (VBN decreased) (JJ respiratory) (NN control) (NN ratio))))) (CC and) (NP (NNP Doc_19445921_1154_1157_Chemical/O))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (JJ Doc_19445921_1176_1189_Chemical-treated) (NNS rats))))) (. .)))
19445921	8	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_19445921_1222_1240_Chemical))) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 8) (NN days)))))) (VP (VP (ADVP (RB significantly)) (VBD attenuated) (NP (NNP Doc_19445921_1289_1302_Chemical-induced) (NNP Doc_19445921_1311_1330_Disease) (CC and) (NNP Doc_19445921_1335_1352_Disease))) (CC and) (VP (VBD improved) (NP (JJ mitochondrial) (NN respiratory) (NN function)))) (. .)))
19445921	9	(S1 (S (NP (NP (DT The) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Doc_19445921_1425_1443_Chemical))) (PP (IN against) (NP (NNP Doc_19445921_1452_1465_Chemical-induced) (NNP Doc_19445921_1474_1491_Disease)))) (VP (AUX was) (ADVP (RB further)) (VP (VBN confirmed) (PP (IN by) (NP (JJ histopathological) (NN examination))))) (. .)))
19445921	10	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ Doc_19445921_1586_1604_Chemical) (VBG possessing) (NN antioxidant) (NN activity)) (VP (AUX has) (NP (NP (DT a) (JJ significant) (JJ protective) (NN effect)) (PP (IN against) (NP (NNP Doc_19445921_1681_1694_Chemical-induced) (NNP Doc_19445921_1703_1724_Disease)))))))) (. .)))
19473225	0	(S1 (S (NP (JJ Long-term) (JJ Doc_19473225_10_19_Chemical) (NN supplementation)) (VP (VBD failed) (S (VP (TO to) (VP (VB protect) (PP (IN against) (NP (NP (NNP Doc_19473225_62_86_Disease)) (PP (IN of) (NP (NNP Doc_19473225_90_100_Chemical))))))))) (. .)))
19473225	1	(S1 (S (NP (JJ Toxic) (NN Doc_19473225_108_129_Disease)) (VP (AUX is) (ADVP (RB still)) (NP (NP (DT a) (JJ significant) (VBG limiting) (NN factor)) (PP (IN for) (NP (NP (NN chemotherapy)) (PP (IN with) (NP (NP (NNP Doc_19473225_191_201_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19473225_203_206_Chemical)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN although) (S (NP (NP (NNP Doc_19473225_218_227_Chemical)) (CC and) (NP (PRP$ its) (ADJP (RB closely) (VBN related)) (NNP Doc_19473225_252_262_Chemical) (NNP Doc_19473225_263_272_Chemical))) (VP (AUX were) (VP (VBN claimed) (S (VP (TO to) (VP (VB ameliorate) (NP (NNP Doc_19473225_300_303_Chemical) (NNP Doc_19473225_304_317_Disease)))))))))) (. .)))
19473225	2	(S1 (S (NP (DT This) (NN pilot) (NN trial)) (VP (VBD aimed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ Doc_19473225_366_375_Chemical) (NN supplementation))) (PP (IN for) (S (VP (VBG preventing) (NP (JJ Doc_19473225_407_410_Chemical-induced) (NNP Doc_19473225_419_440_Disease)) (PP (IN in) (NP (DT a) (JJ randomized) (, ,) (JJ placebo-controlled) (, ,) (JJ double-blinded) (ADJP (JJ clinical) (CC and) (JJ electro-diagnostic)) (NN study))))))))))) (. .)))
19473225	3	(S1 (S (S (NP (JJ Forty-three) (NNP Doc_19473225_544_558_Disease) (NNS patients)) (VP (AUX were) (ADJP (JJ available) (PP (IN for) (NP (NN analysis)))) (PP (VBG following) (NP (NP (CD six) (NNS cycles)) (PP (IN of) (NP (DT the) (JJ same) (JJ Doc_19473225_629_632_Chemical-containing) (NN regimen))))))) (: :) (S (NP (CD 23)) (VP (AUX had) (VP (AUX been) (VP (VBN supplemented) (PP (IN by) (NP (NNP Doc_19473225_681_690_Chemical))) (ADVP (RB all)) (PP (IN along) (NP (DT the) (NN treatment) (NN period))) (, ,) (PP (IN at) (NP (NP (DT a) (JJ daily) (NN dose)) (PP (IN of) (NP (NP (CD three) (NNS times)) (NP (NP (CD 500) (NNS mg)) (PRN (-LRB- -LRB-) (NP (NN group) (NNP G)) (-RRB- -RRB-))))))))))) (, ,) (CC and) (S (NP (CD 20)) (VP (AUX had) (VP (VBN received) (NP (NP (DT a) (NN placebo)) (PRN (-LRB- -LRB-) (NP (NN group) (NNS P)) (-RRB- -RRB-)))))) (. .)))
19473225	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN evaluated) (PP (IN by) (NP (NP (JJ neurological) (NNS examinations)) (, ,) (NP (NNS questionnaires)) (CC and) (NP (NN sensory-motor) (NN nerve) (NN conduction) (NNS studies)))))) (. .)))
19473225	5	(S1 (S (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNS signs) (CC or) (NNS symptoms))))) (PP (IN between) (NP (DT the) (CD two) (NNS groups)))) (SBAR (IN although) (S (NP (NNP Doc_19473225_1032_1045_Disease) (NNS symptoms)) (VP (VBD presented) (PP (ADVP (RB mostly)) (IN with) (NP (NP (JJR lower) (NNS scores)) (PP (IN of) (NP (NN severity))))) (PP (IN in) (NP (NN group) (NNP G.))) (ADVP (RB However))))))) (, ,) (NP (DT this) (NN difference)) (VP (VBD reached) (NP (JJ statistical) (NN significance)) (PP (ADVP (RB only)) (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (VBN reported) (JJ Doc_19473225_1201_1205_Disease) (NN sensation)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.011)) (-RRB- -RRB-))))))) (. .)))
19473225	6	(S1 (S (ADVP (RB Also)) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (JJ abnormal) (JJ electro-diagnostic) (NNS findings)))) (VP (VBD showed) (NP (NP (NN similarity)) (PP (IN between) (NP (NP (DT the) (CD two) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP G)) (: :) (NP (NP (NP (CD 7/23)) (VP (SYM =) (NP (CD 30.4) (NN %)))) (: ;) (NP (CD P)) (: :) (NP (QP (CD 6/20) (SYM =) (CD 30)) (NN %))) (-RRB- -RRB-)))))) (. .)))
19473225	7	(S1 (S (NP (DT This) (NN pilot) (NN study)) (VP (VBZ leads) (PP (TO to) (NP (DT the) (NN conclusion) (SBAR (IN that) (S (NP (NP (JJ Doc_19473225_1409_1418_Chemical) (NN supplementation)) (PP (IN at) (NP (DT the) (VBN chosen) (NN regimen)))) (VP (VBZ fails) (S (VP (TO to) (VP (VB protect) (PP (IN against) (NP (NP (NNP Doc_19473225_1482_1506_Disease)) (PP (IN of) (NP (NN Doc_19473225_1510_1513_Chemical)))))))))))))) (. .)))
19581773	0	(S1 (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_19581773_15_32_Disease))) (PP (IN during) (NP (NP (NNP Doc_19581773_40_60_Chemical) (CC and) (NNP Doc_19581773_65_74_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_19581773_89_108_Disease))))) (. .)))
19581773	1	(S1 (S (NP (DT A) (JJ 63-year-old) (NN male)) (VP (VBD experienced) (NP (JJ sudden) (NNP Doc_19581773_148_156_Disease)) (PP (IN after) (NP (NP (CD 9) (NNS weeks)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_19581773_192_227_Chemical)) (CC and) (NP (NNP Doc_19581773_232_241_Chemical)))) (PP (IN for) (NP (NP (NNP Doc_19581773_246_265_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19581773_267_270_Disease)) (-RRB- -RRB-))))))))) (. .)))
19581773	2	(S1 (S (NP (JJ Ophthalmologic) (NNS examinations)) (VP (VBD showed) (NP (NP (NNP Doc_19581773_308_337_Disease)) (CC and) (NP (NNP Doc_19581773_342_371_Disease))) (PP (IN without) (NP (DT any) (JJ other) (JJ neurological) (NNS signs)))) (. .)))
19581773	3	(S1 (S (NP (NP (DT A) (NN brain) (NN imaging) (NN study)) (CC and) (NP (JJ repetitive) (NN nerve) (NN stimulation) (NN test))) (VP (VBD indicated) (NP (DT no) (NN abnormality))) (. .)))
19581773	4	(S1 (S (S (NP (NP (DT The) (JJ Doc_19581773_500_513_Chemical) (NN receptor) (NN antibody) (NN titer)) (CC and) (NP (NP (NN response)) (PP (TO to) (NP (JJ acetylcholinesterase) (NNS inhibitors))))) (VP (AUX were) (ADJP (JJ negative)))) (, ,) (CC and) (S (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (JJ thyroid) (NN function) (NNS tests)))) (VP (AUX were) (ADJP (JJ normal)))) (. .)))
19581773	5	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (JJ ophthalmological) (NNS symptoms)) (VP (VBD improved) (ADVP (RB rapidly) (NP (CD 3) (NNS weeks))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NP (NNP Doc_19581773_746_768_Chemical)) (CC and) (NP (NNP Doc_19581773_773_782_Chemical))))))) (. .)))
19581773	6	(S1 (S (S (NP (NP (DT The) (NN Doc_19581773_788_805_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (NN combination) (NN therapy)) (PP (IN of) (NP (NP (NNP Doc_19581773_845_867_Chemical)) (CC and) (NP (NNP Doc_19581773_872_881_Chemical)))) (PP (IN for) (NP (NNP Doc_19581773_886_889_Disease))))))) (VP (AUX is) (ADVP (RB very) (RB rarely)) (VP (VBN reported)))) (: ;) (S (ADVP (RB therefore)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (DT this) (NN case)) (PP (IN with) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (NP (DT the) (JJ various) (NN eye) (NNS complications)) (PP (IN of) (NP (JJ Doc_19581773_997_1000_Chemical) (NN therapy))))))))) (. .)))
19631624	0	(S1 (NP (NP (NN Doc_19631624_0_28_Disease)) (PP (IN in) (NP (NP (JJ Doc_19631624_32_39_Chemical) (NNS users)) (CC and) (NP (PRP$ their) (JJ neural) (NNS correlates)))) (PP (IN during) (NP (DT a) (JJ face-learning) (NN task))) (. .)))
19631624	1	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (ADVP (RB consistently)) (VP (VBN shown) (SBAR (IN that) (S (NP (JJ Doc_19631624_139_146_Chemical) (NNS users)) (VP (VBP display) (NP (JJ Doc_19631624_161_195_Disease) (NN performance)))))))) (. .)))
19631624	2	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ working) (NN memory) (NN processing)) (PP (IN in) (NP (JJ Doc_19631624_251_258_Chemical) (NNS users)))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (JJ neural) (NNS alterations)) (PP (IN in) (NP (JJ hippocampal) (NN and/or) (NN cortical) (NNS regions))))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (JJ functional) (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NN fMRI)) (-RRB- -RRB-)))))))))))))) (. .)))
19631624	3	(S1 (S (S (VP (VBG Using) (NP (NP (JJ functional) (NN imaging)) (CC and) (NP (DT a) (JJ face-learning) (NN task))))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (JJ neural) (NNS correlates)) (PP (IN of) (S (VP (VP (VBG encoding)) (CC and) (VP (VBG recalling) (NP (JJ face-name) (NNS associations)) (PP (IN in) (NP (NP (CD 20) (JJ recreational) (NN drug) (NNS users)) (SBAR (WHNP (WP$ whose) (NN predominant)) (S (NP (NN drug) (NN use)) (VP (AUX was) (NP (NP (NNP Doc_19631624_616_623_Chemical)) (CC and) (NP (CD 20) (NNS controls)))))))))))))) (. .)))
19631624	4	(S1 (S (S (VP (TO To) (VP (VB address) (NP (NP (DT the) (JJ potential) (JJ confounding) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ Doc_19631624_693_701_Chemical) (NN use)) (PP (IN of) (NP (DT the) (JJ Doc_19631624_713_720_Chemical) (VBG using) (NN group))))))))) (, ,) (NP (DT a) (JJ second) (NN analysis)) (VP (VBD included) (NP (NP (CD 14) (ADJP (RB previously) (VBN tested)) (JJ Doc_19631624_782_790_Chemical) (NNS users)) (PRN (-LRB- -LRB-) (NP (NNP Nestor)) (, ,) (NP (NP (NNP L.) (, ,) (NNP Roberts) (, ,) (NNP G.) (, ,) (NNP Garavan) (, ,) (NNP H.) (, ,) (NNP Hester) (, ,) (NNP R.)) (, ,) (NP (CD 2008)))))) (. .)))
19631624	5	(S1 (NP (NP (NN Doc_19631624_854_885_Disease)) (: :) (NP (NP (NP (JJ parahippocampal) (NN Doc_19631624_903_916_Disease)) (CC and) (NP (JJ frontocortical) (NN hypoactivity))) (PP (IN in) (NP (JJ Doc_19631624_952_960_Chemical) (NNS users)))) (. .)))
19631624	6	(S1 (NP (NNP Neuroimage) (CD 40) (, ,) (CD 1328-1339) (-RRB- -RRB-) (. .)))
19631624	7	(S1 (S (NP (NN Doc_19631624_995_1002_Chemical) (NNS users)) (VP (VBD performed) (ADVP (RB significantly) (RBR worse)) (PP (IN in) (NP (NN learning) (CC and) (NN memory))) (PP (VBN compared) (PP (TO to) (NP (NP (NNS controls)) (CC and) (NP (JJ Doc_19631624_1087_1095_Chemical) (NNS users)))))) (. .)))
19631624	8	(S1 (S (NP (NP (DT A) (NN conjunction) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NN encode) (CC and) (NN recall) (NNS phases)) (PP (IN of) (NP (DT the) (NN task)))))) (VP (VBD revealed) (NP (NNP Doc_19631624_1179_1186_Chemical-specific) (NNP Doc_19631624_1196_1209_Disease)) (PP (IN in) (NP (JJ bilateral) (JJ frontal) (NNS regions))) (, ,) (VP (VBN left) (UCP (ADJP (JJ temporal)) (, ,) (ADJP (JJ right) (JJ parietal)) (, ,) (ADJP (JJ bilateral) (JJ temporal)) (, ,) (CC and) (NP (JJ bilateral) (JJ occipital) (NN brain) (NNS regions))))) (. .)))
19631624	9	(S1 (S (NP (JJ Doc_19631624_1330_1337_Chemical-specific) (NN hypoactivity)) (VP (VP (AUX was) (ADJP (JJ evident) (PP (IN in) (NP (NP (DT the) (ADJP (RB right) (JJ dorsal)) (NNP anterior) (JJ cingulated) (NN cortex)) (PRN (-LRB- -LRB-) (NP (NNP ACC)) (-RRB- -RRB-)))))) (CC and) (VP (VBD left) (NP (JJ posterior) (JJ cingulated) (NN cortex)))) (. .)))
19631624	10	(S1 (S (PP (IN In) (NP (DT both) (NNP Doc_19631624_1471_1478_Chemical) (CC and) (NNP Doc_19631624_1483_1491_Chemical) (NNS groups))) (NP (NN brain) (NN activation)) (VP (AUX was) (VP (VP (VBN decreased) (PP (IN in) (NP (DT the) (JJ right) (JJ medial) (JJ frontal) (NN gyrus)))) (, ,) (VP (VBN left) (NP (JJ parahippocampal) (NN gyrus))) (, ,) (VP (VBN left) (NP (JJ dorsal) (JJ cingulate) (NN gyrus))) (, ,) (CC and) (VP (VBD left) (NP (NN caudate))))) (. .)))
19631624	11	(S1 (S (NP (DT These) (NNS results)) (VP (VBP elucidated) (NP (NP (JJ Doc_19631624_1665_1672_Chemical-related) (NNS deficits)) (, ,) (SBAR (RB only) (WHNP (NP (DT some)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (MD might) (VP (AUX be) (VP (VBN attributed) (PP (TO to) (NP (JJ Doc_19631624_1733_1741_Chemical) (NN use)))))))))) (. .)))
19631624	12	(S1 (S (NP (DT These) (JJ Doc_19631624_1753_1760_Chemical-specific) (NNS effects)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN vulnerability)) (PP (IN of) (NP (JJ isocortical) (CC and) (JJ allocortical) (NNS regions))) (PP (TO to) (NP (NP (DT the) (JJ Doc_19631624_1861_1871_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_19631624_1883_1890_Chemical)))))))))) (. .)))
19657887	0	(S1 (NP (NP (NP (JJ Doc_19657887_0_10_Chemical-like) (NN syndrome)) (PP (IN after) (NP (NNP Doc_19657887_31_49_Chemical) (JJ professional) (NN skin) (NN exposure)))) (: :) (NP (NP (CD two) (NN case) (NNS reports)) (PP (IN in) (NP (NNP France)))) (. .)))
19657887	1	(S1 (S (NP (NN Doc_19657887_106_124_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN plant) (NN growth) (NN regulator)) (VP (VBN used) (PP (IN in) (NP (NN agriculture))) (S (VP (TO to) (VP (VB induce) (NP (NNP bud) (NN break)) (PP (IN in) (NP (NN fruit) (NNS trees))))))))) (. .)))
19657887	2	(S1 (S (NP (NP (NN Contact)) (PP (IN with) (NP (DT the) (NN skin)))) (VP (VP (MD can) (VP (VB result) (PP (IN in) (NP (NP (JJ percutaneous) (NN absorption)) (PP (IN of) (NP (NP (DT the) (NN substance)) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (JJ Doc_19657887_300_308_Chemical) (NN dehydrogenase))))))))))) (CC and) (VP (MD can) (VP (VB induce) (NP (JJ Doc_19657887_338_350_Chemical) (NN syndrome)) (PP (IN in) (NP (NP (NN case)) (PP (IN of) (NP (JJ Doc_19657887_371_378_Chemical) (NN use)))))))) (. .)))
19657887	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN report)))) (VP (AUX is) (S (VP (TO to) (VP (VB describe) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (DT a) (JJ Doc_19657887_441_451_Chemical-like) (NN syndrome)))) (PP (VBG following) (NP (NP (JJ occupational) (NN exposure)) (PP (TO to) (NP (NNP Doc_19657887_501_519_Chemical))))))))) (. .)))
19657887	4	(S1 (S (NP (DT The) (JJ first) (NN case)) (VP (VBD involved) (NP (NP (DT a) (JJ 59-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NP (NNP Doc_19657887_572_578_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ contains) (NP (NNP Doc_19657887_595_613_Chemical))))) (, ,)) (PP (IN without) (NP (NN protection))) (PP (IN after) (NP (NN consuming))) (NP (NP (DT a) (JJ large) (NN amount)) (PP (IN of) (NP (NNP Doc_19657887_668_675_Chemical)))) (PP (IN during) (NP (DT a) (NN meal)))))))) (. .)))
19657887	5	(S1 (S (PP (IN In) (NP (NP (QP (JJR less) (IN than) (CD 1)) (NN hour)) (PP (IN after) (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (NNP Doc_19657887_734_741_Chemical))))))) (, ,) (NP (PRP he)) (VP (VBD developed) (NP (NN malaise)) (PP (IN with) (NP (NP (NNP Doc_19657887_769_789_Disease)) (, ,) (NP (NNP Doc_19657887_791_802_Disease)) (, ,) (CC and) (NP (NNP Doc_19657887_808_815_Disease))))) (. .)))
19657887	6	(S1 (S (NP (NNS Manifestations)) (VP (VBD regressed) (ADVP (RB spontaneously)) (PP (IN under) (NP (NN surveillance))) (PP (IN in) (NP (DT the) (NN hospital)))) (. .)))
19657887	7	(S1 (S (NP (DT The) (JJ second) (NN case)) (VP (VBD occurred) (PP (IN in) (NP (DT a) (JJ 55-year-old) (NN farmer))) (PP (VBG following) (NP (NP (NN cutaneous) (NN contact)) (PP (IN with) (NP (NNP Doc_19657887_974_980_Chemical)))))) (. .)))
19657887	8	(S1 (S (PP (NP (CD Five) (NNS hours)) (IN after) (NP (NN exposure))) (, ,) (NP (PRP he)) (VP (VBD developed) (NP (JJ Doc_19657887_1022_1032_Chemical-like) (NN syndrome)) (PP (IN with) (NP (NP (NNP Doc_19657887_1052_1060_Disease)) (, ,) (NP (NNP Doc_19657887_1062_1073_Disease)) (, ,) (CC and) (NP (NNP Doc_19657887_1079_1099_Disease)))) (PP (IN after) (NP (NP (NN consuming) (CD three) (NNS glasses)) (PP (IN of) (NP (NN wine)))))) (. .)))
19657887	9	(S1 (S (NP (DT The) (NN patient)) (VP (VBD recovered) (ADVP (RB spontaneously)) (PP (IN in) (NP (CD 3) (NNS hours))) (PP (IN under) (NP (NP (NN surveillance)) (PP (IN in) (NP (DT the) (NN hospital)))))) (. .)))
19657887	10	(S1 (S (NP (DT These) (NNS cases)) (VP (VBP confirm) (NP (NP (DT the) (NN necessity)) (PP (IN of) (S (VP (VBG avoiding) (NP (NN Doc_19657887_1268_1275_Chemical) (NN consumption)) (SBAR (IN as) (S (VP (VBN recommended) (PP (IN in) (NP (NP (DT the) (NNS instructions)) (PP (PP (IN for) (NP (NP (NN use)) (PP (IN of) (NP (NNP Doc_19657887_1334_1340_Chemical))))) (CC and) (PP (IN of) (S (VP (VBG preventing) (NP (JJ cutaneous) (NN contact)) (PP (IN during) (NP (NN use))))))))))))))))) (. .)))
1967484	0	(S1 (NP (JJ Doc_1967484_0_9_Chemical-induced) (NN Doc_1967484_18_34_Disease) (. .)))
1967484	1	(S1 (S (NP (NN Doc_1967484_36_45_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ selective) (JJ D2-receptor) (NN antagonist)) (PP (IN with) (NP (UCP (JJ antipsychotic) (CC and) (JJ Doc_1967484_107_121_Chemical)) (NNS properties))))) (. .)))
1967484	2	(S1 (S (SBAR (IN Although) (S (ADVP (RB initially)) (VP (VBD thought) (S (VP (TO to) (VP (AUX be) (ADJP (JJ free) (PP (IN of) (NP (JJ extrapyramidal) (NN side) (NNS effects)))))))))) (, ,) (NP (NNP Doc_1967484_204_213_Chemical-induced) (NNP Doc_1967484_222_240_Disease) (CC and) (NNP Doc_1967484_245_257_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (ADVP (RB occasionally))))) (. .)))
1967484	3	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT a) (JJ 37-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ persistent) (JJ segmental) (NN Doc_1967484_355_363_Disease)) (PP (IN within) (NP (CD 2) (NNS months))) (PP (IN after) (S (VP (VBG starting) (NP (JJ Doc_1967484_395_404_Chemical) (NN therapy)))))))))) (. .)))
1967484	4	(S1 (S (NP (PRP We)) (VP (MD could) (RB not) (VP (VB find) (NP (NP (DT any) (JJ previous) (NNS reports)) (PP (IN of) (NP (NNP Doc_1967484_456_465_Chemical-induced) (NNP Doc_1967484_474_490_Disease)))))) (. .)))
19729346	0	(S1 (NP (NP (NP (JJ Comparative) (NN cognitive)) (CC and) (NP (JJ subjective) (NN side) (NNS effects))) (PP (IN of) (NP (JJ immediate-release) (NNP Doc_19729346_71_80_Chemical))) (PP (IN in) (NP (JJ healthy) (UCP (JJ middle-aged) (CC and) (JJR older)) (NNS adults))) (. .)))
19729346	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD measured) (NP (NP (DT the) (ADJP (JJ objective) (CC and) (JJ subjective)) (JJ neurocognitive) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ single) (JJ 10-mg) (NN dose)) (PP (IN of) (NP (JJ immediate-release) (NNP Doc_19729346_238_247_Chemical))))) (PP (IN in) (NP (NP (JJ healthy) (, ,) (ADJP (ADJP (JJR older)) (PRN (-LRB- -LRB-) (NP (QP (CD >) (CD 65)) (NNS years)) (-RRB- -RRB-)) (, ,) (CC and) (ADJP (JJ middle-aged) (PRN (-LRB- -LRB-) (NP (QP (CD 35) (TO to) (CD 55)) (NNS years)) (-RRB- -RRB-)))) (NNS adults)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (RB not) (VP (VBG suffering) (PP (IN from) (NP (ADJP (JJ chronic) (CC or) (JJ significant)) (JJ daily) (NNP Doc_19729346_377_381_Disease))))))))))) (. .)))
19729346	2	(S1 (S (NP (NN Seventy-one) (NNS participants)) (VP (VP (VBD completed) (NP (CD 2) (JJ separate) (NN study) (NNS days))) (CC and) (VP (AUX were) (ADJP (JJ blind) (PP (TO to) (NP (NP (NN medication) (NN condition)) (PRN (-LRB- -LRB-) (NP (NP (NN placebo)) (, ,) (NP (JJ 10-mg) (NNP Doc_19729346_495_504_Chemical))) (-RRB- -RRB-))))))) (. .)))
19729346	3	(S1 (S (S (NP (NN Plasma) (JJ Doc_19729346_514_523_Chemical) (NN concentration)) (VP (VBD peaked) (PP (IN between) (NP (CD 60) (CC and) (CD 90) (NNS minutes))) (NP (NN postdose)))) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD .01)) (-RRB- -RRB-)) (CC and) (S (NP (NP (NN pupil) (NN size)) (, ,) (NP (NP (DT an) (NN indication)) (PP (IN of) (NP (NP (JJ physiological) (NNS effects)) (PP (IN of) (NP (DT the) (NN medication)))))) (, ,)) (VP (VBD peaked) (PP (IN at) (NP (QP (RB approximately) (CD 90) (TO to) (CD 120)) (NNS minutes))) (NP (NP (NN postdose)) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <)) (CD .01)) (-RRB- -RRB-))))) (. .)))
19729346	4	(S1 (S (NP (JJ Significant) (NNP Doc_19729346_738_815_Disease)) (VP (AUX were) (VP (VBN observed) (PP (IN at) (NP (ADJP (CD 1) (NN hour)) (NN postdose))) (PP (VBN compared) (PP (TO to) (NP (NP (NN baseline)) (PP (IN for) (NP (NP (DT both) (NN age) (NNS groups)) (PP (IN with) (NP (NP (DT a) (NN trend)) (PP (IN toward) (NP (NP (NN return)) (PP (TO to) (NP (NN baseline))))) (PP (IN by) (NP (CD 5) (NNS hours) (NN postdose)))))))))))) (. .)))
19729346	5	(S1 (S (PP (IN For) (NP (RB almost) (DT all) (JJ cognitive) (NNS measures))) (, ,) (NP (EX there)) (VP (AUX were) (NP (DT no) (NN medication)) (PP (IN by) (NP (NP (JJ age-interaction) (NNS effects)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ indicates) (SBAR (IN that) (S (NP (DT the) (CD 2) (NN age) (NNS groups)) (VP (VBD exhibited) (NP (JJ similar) (NNS responses)) (PP (TO to) (NP (DT the) (NN medication) (NN challenge)))))))))))) (. .)))
19729346	6	(S1 (S (NP (DT This) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (PP (IN for) (NP (NP (JJ healthy) (JJR older) (NNS adults)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (RB not) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_19729346_1210_1222_Disease))))))))) (, ,) (NP (NP (JJ neurocognitive) (CC and) (JJ pharmacodynamic) (NNS changes)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT a) (JJ 10-mg) (NN dose)) (PP (IN of) (NP (JJ immediate-release) (NNP Doc_19729346_1316_1325_Chemical)))))))) (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN for) (NP (JJ middle-aged) (NNS adults))))))))))) (. .)))
19729346	7	(S1 (S (NP (NN Study) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN metabolism) (, ,) (JJ neurocognitive) (NNS effects)) (, ,) (CC and) (NP (NP (JJ physical) (JJ side) (NNS effects)) (PP (IN of) (NP (JJ oral) (NNP Doc_19729346_1496_1505_Chemical))))) (VP (AUX are) (ADJP (JJ similar) (PP (IN for) (NP (NP (JJ healthy) (JJ middle-aged)) (CC and) (NP (JJR older) (NNS adults))))))))) (. .)))
19729346	8	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NNS clinicians)) (VP (MD should) (RB not) (VP (VB avoid) (S (VP (VBG prescribing) (NP (JJ oral) (NNS opioids)) (PP (TO to) (NP (NP (JJR older) (NNS adults)) (VP (VBN based) (PP (IN on) (NP (DT the) (NN belief) (SBAR (IN that) (S (NP (JJR older) (NNS adults)) (VP (AUX are) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN for) (NP (NP (JJ side) (NNS effects)) (PP (IN than) (NP (JJR younger) (NNS adults))))))))))))))))))) (. .)))
19759529	0	(S1 (S (NP (DT The) (JJ Doc_19759529_4_11_Chemical) (JJ transporter-1) (NN inhibitor) (NN Doc_19759529_36_45_Chemical)) (VP (VBZ displays) (NP (NP (DT a) (ADJP (JJ selective) (CC and) (JJ specific)) (JJ antipsychotic-like) (NN profile)) (PP (IN in) (NP (UCP (JJ normal) (CC and) (NNP transgenic)) (NNS mice))))) (. .)))
19759529	1	(S1 (S (NP (NN Doc_19759529_138_151_Disease)) (VP (AUX has) (VP (AUX been) (ADVP (RB initially)) (VP (VBN associated) (PP (IN with) (NP (NP (NN dysfunction)) (PP (IN in) (NP (JJ Doc_19759529_202_210_Chemical) (NN neurotransmission)))))))) (. .)))
19759529	2	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (NN observation) (SBAR (IN that) (S (NP (NP (NNS antagonists)) (PP (IN of) (NP (DT the) (NNP Doc_19759529_279_288_Chemical) (NNP Doc_19759529_289_309_Chemical) (-LRB- -LRB-) (NNP Doc_19759529_311_315_Chemical) (-RRB- -RRB-) (NN receptor)))) (VP (VBP produce) (NP (NP (JJ Doc_19759529_334_347_Disease-like) (NNS symptoms)) (PP (IN in) (NP (NNS humans)))))))) (VP (AUX has) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN idea)) (PP (IN of) (NP (NP (DT a) (NN dysfunctioning)) (PP (IN of) (NP (DT the) (JJ glutamatergic) (NN system))) (PP (IN via) (NP (PRP$ its) (JJ Doc_19759529_448_452_Chemical) (NN receptor))))))))) (. .)))
19759529	3	(S1 (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (VBG growing) (NN interest)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ pharmacological) (NNS agents))) (PP (IN with) (NP (NP (JJ potential) (JJ antipsychotic) (NNS properties)) (SBAR (WHNP (WDT that)) (S (VP (VB enhance) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (JJ glutamatergic) (NN system)))) (PP (IN via) (NP (NP (DT a) (NN modulation)) (PP (IN of) (NP (DT the) (JJ Doc_19759529_667_671_Chemical) (NN receptor)))))))))))))) (. .)))
19759529	4	(S1 (SINV (PP (IN Among) (NP (PRP them))) (VP (AUX are) (NP (NP (JJ Doc_19759529_697_704_Chemical) (NN transporter-1)) (PRN (-LRB- -LRB-) (NP (NNP GlyT1)) (-RRB- -RRB-)))) (NP (NP (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_19759529_746_755_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB indirectly)) (VP (VB enhance) (NP (JJ Doc_19759529_782_786_Chemical) (NN receptor) (NN function)) (PP (IN by) (S (VP (VBG increasing) (NP (DT the) (JJ Doc_19759529_823_830_Chemical) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN co-agonist)) (PP (IN for) (NP (DT the) (JJ Doc_19759529_853_857_Chemical) (NN receptor)))) (-RRB- -RRB-)) (NNS levels)) (PP (IN in) (NP (DT the) (NN synapse)))))))))))) (. .)))
19759529	5	(S1 (S (NP (DT This) (NN study)) (VP (VBN aimed) (PP (IN at) (S (VP (VBG investigating) (NP (NP (DT the) (JJ potential) (JJ antipsychotic-like) (NNS properties)) (PP (IN of) (NP (NNP Doc_19759529_972_981_Chemical))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ particular) (NN focus)) (PP (IN on) (NP (NP (NNS models)) (PP (IN of) (NP (NNP Doc_19759529_1020_1033_Disease))))) (, ,) (VP (VBG involving) (NP (NP (NP (DT either) (NN drug) (NN challenge)) (PRN (-LRB- -LRB-) (NP (NN ie)) (, ,) (NP (NNP Doc_19759529_1072_1083_Chemical) (CC and) (NNP Doc_19759529_1088_1094_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP transgenic) (NNS mice)) (PRN (-LRB- -LRB-) (NP (CD ie)) (, ,) (NP (NP (NP (NP (NNP Doc_19759529_1120_1124_Chemical) (NNP Nr1)) (PRN (-LRB- -LRB-) (JJ neo-/-) (-RRB- -RRB-))) (CC and) (NP (NNP DAT))) (PRN (-LRB- -LRB-) (JJ -/-) (-RRB- -RRB-))) (-RRB- -RRB-)))))))))))) (. .)))
19759529	6	(S1 (S (NP (NNS Results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNP Doc_19759529_1172_1181_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-30) (CD mg/kg)) (NN p.o.)) (-RRB- -RRB-))) (VP (VP (VBD blocked) (NP (NP (NNP Doc_19759529_1209_1222_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ non-competitive) (JJ Doc_19759529_1254_1258_Chemical) (NN receptor) (NN antagonist)) (, ,) (NP (NNP Doc_19759529_1280_1286_Chemical))))))) (CC and) (VP (ADVP (RB partially)) (VBD reversed) (NP (NP (JJ spontaneous) (NN Doc_19759529_1322_1335_Disease)) (PP (IN of) (NP (NNP Doc_19759529_1339_1343_Chemical) (NNP Nr1) (PRN (-LRB- -LRB-) (JJ neo-/-) (-RRB- -RRB-)) (NNS mice))))))))) (. .)))
19759529	7	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Doc_19759529_1375_1384_Chemical)) (VP (VBD failed) (S (VP (TO to) (VP (VB affect) (S (NP (NNP Doc_19759529_1402_1415_Disease)) (VP (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19759529_1427_1438_Chemical)))) (CC or) (VP (ADVP (RB naturally)) (VBN observed) (PP (IN in) (NP (NP (JJ Doc_19759529_1464_1472_Chemical) (NN transporter) (PRN (-LRB- -LRB-) (NP (NP (NNP DAT)) (PRN (-LRB- -LRB-) (NP (NN -/-)) (-RRB- -RRB-))) (-RRB- -RRB-)) (NN knockout) (NNS mice)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-30) (CD mg/kg)) (NNS p.o.)) (-RRB- -RRB-))))))))))) (. .)))
19759529	8	(S1 (S (ADVP (RB Importantly)) (, ,) (NP (NP (NP (DT both) (JJ classical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19759529_1559_1570_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ atypical) (PRN (-LRB- -LRB-) (NP (NNP Doc_19759529_1586_1596_Chemical) (, ,) (NNP Doc_19759529_1598_1607_Chemical) (CC and) (NNP Doc_19759529_1612_1624_Chemical)) (-RRB- -RRB-)) (NNS antipsychotics))) (VP (AUX were) (ADJP (JJ effective)) (PP (IN in) (NP (NP (PDT all) (DT these) (NNS models)) (PP (IN of) (NP (NNP Doc_19759529_1679_1692_Disease)))))) (. .)))
19759529	9	(S1 (S (ADVP (RB However)) (, ,) (PP (IN unlike) (NP (DT these) (JJ latter))) (, ,) (NP (NNP Doc_19759529_1724_1733_Chemical)) (VP (AUX did) (RB not) (VP (VB produce) (NP (NP (NNP Doc_19759529_1750_1759_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN retention)) (PP (IN on) (NP (DT the) (NN bar) (NN test)))) (-RRB- -RRB-))) (ADVP (RB up) (PP (TO to) (NP (QP (CD 30) (CD mg/kg)) (NNS p.o.)))) (ADVP (RB Together)) (S (NP (DT these) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (JJ GlyT1) (NN inhibitor)) (, ,) (NP (NNP Doc_19759529_1863_1872_Chemical)) (, ,)) (VP (VBZ produces) (NP (NP (JJ antipsychotic-like) (NNS effects)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP differ) (PP (IN from) (S (NP (DT those)) (VP (VP (VBN observed) (PP (IN with) (NP (NP (NNS compounds)) (VP (ADVP (RB primarily)) (VBG targeting) (NP (DT the) (JJ dopaminergic) (NN system)))))) (, ,) (CC and) (VP (AUX has) (NP (DT a) (JJ reduced) (JJ side-effect) (NN potential)) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (DT these) (JJ latter) (NNS drugs))))))))))))))))))))) (. .)))
19767176	0	(S1 (S (NP (NN Doc_19767176_0_27_Chemical)) (VP (VBZ protects) (NP (NP (DT the) (JJ piriform) (NN cortex)) (PP (IN in) (NP (DT the) (NNP Doc_19767176_64_75_Chemical) (NNP Doc_19767176_76_94_Disease) (NN model))))) (. .)))
19767176	1	(S1 (S (NP (NP (NNP Doc_19767176_102_129_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19767176_131_135_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (NP (NP (DT a) (JJ dual) (NN mechanism)) (PP (IN of) (NP (NN action)))) (PP (IN as) (NP (NP (NP (DT an) (NN antioxidant)) (CC and) (NP (DT an) (NN inhibitor))) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NN kappa-beta)))))) (. .)))
19767176	2	(S1 (S (ADVP (DT Both)) (, ,) (NP (NP (NN production)) (PP (IN of) (NP (NP (JJ reactive) (JJ Doc_19767176_272_278_Chemical) (NNS species)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappaB))))))) (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (JJ severe) (NN Doc_19767176_353_368_Disease)) (PP (IN in) (NP (JJ different) (NNS sub-regions)) (PP (IN of) (NP (DT the) (NN hippocampus))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (DT the) (VBG surrounding) (NNS cortices))))))))) (. .)))
19767176	3	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_19767176_467_471_Chemical))) (PP (IN on) (NP (JJ Doc_19767176_475_493_Disease-associated) (NN cell) (NN loss))) (PP (IN in) (NP (DT the) (ADJP (JJ hippocampus) (CC and) (JJ piriform)) (NN cortex)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NP (DT the) (NN rat)) (VP (VBN fractionated) (NP (JJ Doc_19767176_592_603_Chemical) (NN model))))))) (. .)))
19767176	4	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (CD 150)))) (VP (VP (VBD mg/kg) (NP (NNP Doc_19767176_636_640_Chemical)) (ADVP (RB before))) (CC and) (VP (PP (VBG following) (NP (NNP Doc_19767176_662_680_Disease))) (ADVP (RB significantly)) (VBD increased) (NP (DT the) (NN mortality) (NN rate)) (PP (TO to) (NP (CD 100) (NN %))))) (. .)))
19767176	5	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (CD 50) (NNS mg/kg)) (NP (NP (NNP Doc_19767176_760_764_Chemical)) (PRN (-LRB- -LRB-) (NP (NN low-dose)) (-RRB- -RRB-)))))) (VP (AUX did) (RB not) (VP (VB exert) (NP (NP (JJ major) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (DT a) (NN Doc_19767176_828_846_Disease)) (CC or) (NP (DT the) (NN mortality) (NN rate))))))))) (. .)))
19767176	6	(S1 (S (PP (IN In) (NP (JJ vehicle-treated) (NNS rats))) (, ,) (NP (NNP Doc_19767176_895_913_Disease)) (VP (VBD caused) (NP (JJ pronounced) (NN Doc_19767176_932_947_Disease)) (PP (IN in) (NP (NP (DT the) (JJ piriform) (NN cortex)) (VP (VBG comprising) (NP (NP (DT both) (JJ pyramidal) (NNS cells)) (CC and) (NP (NNS interneurons))))))) (. .)))
19767176	7	(S1 (S (NP (JJ Low-dose) (JJ Doc_19767176_1030_1034_Chemical) (NN treatment)) (ADVP (RB almost) (RB completely)) (VP (VBD protected) (PP (IN from) (NP (NNS lesions))) (PP (IN in) (NP (DT the) (JJ piriform) (NN cortex)))) (. .)))
19767176	8	(S1 (S (NP (NP (DT A) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (JJ neuronal) (NN density)) (PP (IN of) (NP (DT the) (JJ hippocampal) (NN hilar) (NN formation)))))) (VP (AUX was) (VP (VBN identified) (PP (IN in) (NP (NP (JJ vehicle-) (CC and) (JJ Doc_19767176_1219_1223_Chemical-treated) (NNS rats)) (VP (VBG following) (NP (NNP Doc_19767176_1247_1265_Disease))))))) (. .)))
19767176	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT the) (NN NF-kappaB) (NN inhibitor) (CC and) (NN antioxidant) (NN Doc_19767176_1322_1326_Chemical)) (VP (VBD protected) (NP (DT the) (JJ piriform) (NN cortex)) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB affect) (NP (JJ hilar) (NN Doc_19767176_1390_1403_Disease))))))) (. .)))
19767176	10	(S1 (S (NP (DT These) (NNS data)) (VP (MD might) (VP (VB indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NP (JJ reactive) (JJ Doc_19767176_1463_1469_Chemical) (NNS species)) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappaB))))))) (VP (VBZ plays) (NP (NP (DT a) (RBR more) (JJ central) (NN role)) (PP (IN in) (NP (NP (NNP Doc_19767176_1535_1542_Disease-associated) (NNP Doc_19767176_1554_1569_Disease)) (PP (IN in) (NP (DT the) (JJ temporal) (NN cortex)))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (DT the) (JJ hippocampal) (NN hilus))))))))))) (. .)))
19767176	11	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ future) (NNS investigations)) (VP (AUX are) (ADJP (JJ necessary) (S (VP (TO to) (ADVP (RB exactly)) (VP (VB analyze) (NP (NP (DT the) (JJ biochemical) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_19767176_1731_1735_Chemical)) (VP (VBN exerted) (NP (PRP$ its) (JJ beneficial) (NNS effects)) (PP (IN in) (NP (DT the) (JJ piriform) (NN cortex)))))))))))) (. .)))
19803309	0	(S1 (NP (NP (NP (NNS Anaesthetists) (POS ')) (NN nightmare)) (: :) (NP (NP (NN Doc_19803309_26_40_Disease)) (PP (IN after) (NP (NN induction))) (PP (IN in) (NP (NP (DT an) (JJ undiagnosed) (NN case)) (PP (IN of) (NP (NNP Doc_19803309_83_101_Disease)))))) (. .)))
19803309	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT an) (JJ undiagnosed) (NN case)) (PP (IN of) (NP (NNP Doc_19803309_136_154_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ 24-year-old) (ADJP (RB previously) (JJ healthy)) (NN primigravida)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NN life)) (VP (VBG threatening) (NP (NNP Doc_19803309_236_250_Disease)))) (PP (VBG following) (NP (NP (DT a) (JJ standard) (NN dose)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_19803309_292_305_Chemical))) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN anaesthesia))))))))))))) (. .)))
19803309	2	(S1 (S (NP (CC Neither) (NP (DT the) (NN patient)) (CC nor) (NP (DT the) (NN anaesthetist))) (VP (AUX was) (ADJP (JJ aware) (PP (IN of) (NP (DT the) (NN diagnosis)))) (SBAR (IN before) (S (NP (DT this) (ADJP (RB potentially) (JJ lethal)) (NN complication)) (VP (VBD occurred))))) (. .)))
19820426	0	(S1 (NP (NP (JJ Twin) (JJ preterm) (NNS neonates)) (PP (IN with) (NP (NNP Doc_19820426_27_43_Disease))) (VP (VBN related) (PP (TO to) (NP (JJ Doc_19820426_55_74_Chemical) (NN therapy)))) (. .)))
19820426	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ twin) (NNS neonates)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN born) (ADVP (RB prematurely)) (PP (IN at) (NP (NP (CD 32) (NNS weeks)) (PP (IN of) (NP (NN gestation))))) (PP (TO to) (NP (NP (DT a) (NN mother)) (PP (IN with) (NP (NNP Doc_19820426_176_214_Disease))))))))))) (. .)))
19820426	2	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT the) (NNP twins)))) (VP (VBD developed) (ADJP (JJ complete)) (SBAR (S (NP (NNP Doc_19820426_252_263_Disease) (CC and) (NNP Doc_19820426_268_290_Disease)) (VP (VBD related) (PP (TO to) (NP (NP (JJ Doc_19820426_302_321_Chemical) (NN therapy)) (, ,) (NP (DT a) (VBN boosted) (JJ protease-inhibitor) (NN agent)) (, ,))) (SBAR (IN while) (S (NP (DT the) (JJ other) (JJ twin)) (VP (VBD developed) (NP (JJ mild) (NN Doc_19820426_403_414_Disease))))))))) (. .)))
19820426	3	(S1 (S (NP (PRP We)) (VP (VBP recommend) (NP (NN caution)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_19820426_451_470_Chemical))) (PP (IN in) (NP (DT the) (JJ immediate) (JJ neonatal) (NN period)))))) (. .)))
19843802	0	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNS drugs)) (VP (VBP disappear) (PP (IN from) (NP (DT the) (NN patient)))))) (: :) (NP (NP (NN elimination)) (PP (IN of) (NP (JJ intravenous) (NN medication))) (PP (IN by) (NP (NN hemodiafiltration)))) (. .)))
19843802	1	(S1 (S (PP (NP (JJ Twenty-three) (NNS hours)) (IN after) (NP (NN heart) (NN transplantation))) (, ,) (NP (JJ life-threatening) (JJ acute) (NN Doc_19843802_170_189_Disease)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG requiring) (NP (NP (JJ continuous) (JJ venovenous) (NN hemodiafiltration)) (PRN (-LRB- -LRB-) (NP (NNP CVVHDF)) (-RRB- -RRB-)))))))) (. .)))
19843802	2	(S1 (S (NP (NP (NP (NP (JJ Increasing) (NNS doses)) (PP (IN of) (NP (NNP Doc_19843802_297_311_Chemical)))) (, ,) (NP (NNS sedatives)) (, ,) (CC and) (NP (NN muscle) (NNS relaxants))) (VP (VBN administered) (PP (IN through) (NP (DT a) (JJ central) (JJ venous) (NN catheter))))) (VP (AUX were) (ADJP (JJ ineffective))) (. .)))
19843802	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT a) (NN bolus)) (PP (IN of) (NP (NNP Doc_19843802_430_441_Chemical))) (VP (VBN injected) (PP (IN through) (NP (DT an) (JJ alternative) (NN catheter))))) (VP (VBD provoked) (NP (DT a) (JJ Doc_19843802_494_506_Disease) (NN crisis))) (. .)))
19843802	4	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NN interference)) (PP (IN with) (NP (DT the) (JJ central) (JJ venous) (NN infusion))) (PP (IN by) (NP (DT the) (NN dialysis) (NN catheter)))) (VP (AUX was) (VP (VBN suspected))) (. .)))
19843802	5	(S1 (S (S (NP (DT The) (NNS catheters)) (VP (AUX were) (VP (VBN changed)))) (, ,) (CC and) (S (NP (NNS hemodynamics)) (VP (VBD stabilized) (PP (IN at) (NP (JJR lower) (NNP Doc_19843802_672_685_Chemical) (NNS doses))))) (. .)))
19843802	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP IV) (NNS drugs)))) (VP (AUX are) (ADJP (JJ inadequate)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNS CVVHDF)))))))) (, ,) (NP (NP (NN interference)) (PP (IN with) (NP (NP (JJ adjacent) (NNS catheters)) (VP (VBG resulting) (PP (IN in) (NP (NP (NN elimination)) (PP (IN of) (NP (DT the) (NN drug))) (PP (IN by) (NP (NNP CVVHDF))))))))) (VP (MD should) (VP (AUX be) (VP (VBN suspected)))) (. .)))
1987816	0	(S1 (FRAG (NP (NP (ADJP (RBR Less) (JJ frequent)) (JJ Doc_1987816_14_21_Chemical) (NN administration)) (CC and) (NP (JJR lower) (NN urine) (NN volume))) (. .)))
1987816	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NNS patients)) (VP (VBN maintained) (PP (IN on) (NP (NP (DT a) (NN regimen)) (PP (IN of) (NP (NNP Doc_1987816_153_160_Chemical))))) (PP (IN on) (NP (DT a) (JJ once-per-day) (NN schedule))))) (VP (AUX have) (NP (NP (JJR lower) (NN urine) (NNS volumes)) (SBAR (IN than) (SINV (AUX do) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ multiple) (NNS doses)) (PP (IN per) (NP (NN day)))))))))))))))) (. .)))
1987816	2	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT a) (JJ cross-sectional) (NN study)) (PP (IN of) (NP (NP (CD 85) (NNS patients)) (PP (IN from) (NP (NP (DT a) (JJ Doc_1987816_327_334_Chemical) (NN clinic)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ different) (NN dose) (NNS schedules))))))))))) (. .)))
1987816	3	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))) (PP (IN for) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (JJ Doc_1987816_439_446_Chemical) (NN level)) (, ,) (NP (JJ Doc_1987816_454_464_Chemical) (NN clearance)) (, ,) (NP (NN urine) (NN volume)) (, ,) (CC and) (NP (NN maximum) (NN osmolality)))))))) (. .)))
1987816	4	(S1 (S (NP (NP (JJ Multiple) (JJ daily) (NNS doses)) (PP (IN of) (NP (NNP Doc_1987816_547_554_Chemical)))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (JJR higher) (NN urine) (NNS volumes))))) (. .)))
1987816	5	(S1 (S (NP (NP (DT The) (NN dosing) (NN schedule)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (JJ Doc_1987816_631_638_Chemical) (NN treatment)))) (, ,) (CC and) (NP (NP (JJ daily) (NN dose)) (PP (IN of) (NP (NNP Doc_1987816_668_675_Chemical))))) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (JJ maximum) (NN osmolality)) (CC or) (NP (JJ Doc_1987816_713_723_Chemical) (NN clearance))))) (. .)))
1987816	6	(S1 (S (NP (NN Urine) (NN volume)) (VP (MD can) (VP (AUX be) (VP (VBN reduced) (PP (IN by) (S (VP (VBG giving) (NP (NNP Doc_1987816_786_793_Chemical) (ADJP (RB once) (JJ daily)) (NN and/or)) (PP (IN by) (S (VP (VBG lowering) (NP (DT the) (JJ total) (JJ daily) (NN dose))))))))))) (. .)))
1987816	7	(S1 (S (NP (JJ Doc_1987816_846_853_Chemical-induced) (NNP Doc_1987816_862_870_Disease)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (ADJP (JJ related) (PP (TO to) (NP (NN extrarenal)))) (CONJP (RB as) (RB well) (IN as)) (PP (TO to) (NP (JJ renal) (NNS effects)))))))) (. .)))
19884587	0	(S1 (NP (NP (NP (JJ Antibacterial) (NN medication) (NN use)) (PP (IN during) (NP (NP (NN pregnancy)) (CC and) (NP (NN risk)))) (PP (IN of) (NP (NNP Doc_19884587_58_71_Disease)))) (: :) (NP (NNP National) (NNP Doc_19884587_82_95_Disease) (NNP Prevention) (NNP Study)) (. .)))
19884587	1	(S1 (FRAG (S (VP (TO To) (VP (VB estimate) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (JJ antibacterial) (NNS medications)) (CC and) (NP (JJ selected) (NN Doc_19884587_200_213_Disease)))))))) (. .)))
19884587	2	(S1 (NP (NP (NP (NN DESIGN)) (, ,) (NP (NN SETTING)) (, ,) (CC AND) (NP (NNS PARTICIPANTS))) (: :) (NP (NP (JJ Population-based) (, ,) (JJ multisite) (, ,) (JJ case-control) (NN study)) (PP (IN of) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (NNS pregnancies)) (VP (VBN affected) (PP (IN by) (NP (NP (CD 1)) (PP (IN of) (NP (NP (QP (JJR more) (IN than) (CD 30)) (JJ eligible) (JJ major) (NN Doc_19884587_372_385_Disease)) (VP (VBN identified) (PP (IN via) (NP (NP (NNP Doc_19884587_401_413_Disease) (NN surveillance) (NNS programs)) (PP (IN in) (NP (NP (NP (CD 10) (NNS states)) (PRN (-LRB- -LRB-) (NP (NNP n) (QP (SYM =) (CD 13) (CD 155))) (-RRB- -RRB-))) (CC and) (NP (NP (NN control) (NNS women)) (ADJP (RB randomly) (VBN selected)) (PP (IN from) (NP (NP (DT the) (JJ same) (NN geographical) (NNS regions)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4941)) (-RRB- -RRB-)))))))))))))))))))))) (. .)))
19884587	3	(S1 (NP (NP (JJ MAIN) (NN EXPOSURE)) (: :) (NP (NP (JJ Reported) (JJ maternal) (NN use)) (PP (IN of) (NP (NP (NNS antibacterials)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NN month)) (PP (IN before) (NP (NN pregnancy))) (PP (IN through) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (JJ first) (NN trimester)))))) (-RRB- -RRB-))))) (. .)))
19884587	4	(S1 (NP (NP (JJ MAIN) (NN OUTCOME) (NN MEASURE)) (: :) (NP (NP (NP (NNS Odds) (NNS ratios)) (PRN (-LRB- -LRB-) (NP (NNP ORs)) (-RRB- -RRB-))) (VP (VBG measuring) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (JJ antibacterial) (NN use)) (CC and) (NP (NP (VBN selected) (NN Doc_19884587_772_785_Disease)) (VP (VBN adjusted) (PP (IN for) (NP (JJ potential) (NNS confounders)))))))))) (. .)))
19884587	5	(S1 (S (NP (NP (DT The) (VBN reported) (NN use)) (PP (IN of) (NP (NNS antibacterials)))) (VP (VBD increased) (PP (IN during) (NP (NN pregnancy))) (, ,) (S (VP (VBG peaking) (PP (IN during) (NP (DT the) (JJ third) (NN month)))))) (. .)))
19884587	6	(S1 (S (NP (NNP Doc_19884587_926_938_Chemical)) (VP (AUX were) (ADJP (ADJP (JJ associated) (PP (IN with) (NP (NNP Doc_19884587_960_971_Disease)))) (PRN (-LRB- -LRB-) (NP (NP (ADJP (JJ adjusted) (CC OR) (JJ -LSB-AOR)) (JJ -RSB-) (SYM =) (CD 3.4)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (JJ -LSB-CI) (NN -RSB-))) (, ,) (NP (CD 1.3-8.8)) (-RRB- -RRB-)) (, ,) (ADJP (JJ Doc_19884587_1038_1069_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 3.2)) (: ;) (NP (CD 95) (NN %))) (NNS CI)) (, ,) (NP (CD 1.3-7.6))) (-RRB- -RRB-)) (, ,) (ADJP (JJ Doc_19884587_1100_1124_Disease)) (PRN (-LRB- -LRB-) (NP (NNP AOR) (SYM =) (CD 2.7)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NNS CI)) (, ,) (NP (CD 1.3-5.6))) (-RRB- -RRB-)) (, ,) (ADJP (JJ Doc_19884587_1155_1170_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 8.0)) (: ;) (NP (CD 95) (NN %))) (NNS CI)) (, ,) (NP (CD 2.7-23.5))) (-RRB- -RRB-)) (, ,) (ADJP (JJ Doc_19884587_1202_1228_Disease)) (PRN (-LRB- -LRB-) (NP (NNP AOR) (SYM =) (CD 2.5)) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NNS CI)) (, ,) (NP (CD 1.0-5.9))) (-RRB- -RRB-)) (, ,) (CC and) (ADJP (JJ Doc_19884587_1263_1283_Disease))) (PRN (-LRB- -LRB-) (NP (NP (NNP AOR) (SYM =) (CD 2.4)) (: ;) (NP (ADJP (CD 95) (NN %)) (NNS CI))) (, ,) (NP (CD 1.1-5.4)) (-RRB- -RRB-))) (. .)))
19884587	7	(S1 (S (NP (NNP Doc_19884587_1314_1329_Chemical)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NNP Doc_19884587_1351_1363_Disease) (CC or) (NNP Doc_19884587_1367_1381_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 3.7)) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (CD 1.1-12.2))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_19884587_1413_1444_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 4.2)) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (CD 1.9-9.1))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_19884587_1475_1496_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 1.9)) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (CD 1.1-3.4))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_19884587_1531_1540_Disease)))) (PP (IN with) (NP (NP (NNP Doc_19884587_1546_1558_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NNP AOR) (SYM =) (CD 2.1)) (: ;) (NP (CD 95) (NN %))) (NNP CI)) (, ,) (NP (CD 1.2-3.9))) (-RRB- -RRB-)))))) (. .)))
19884587	8	(S1 (NP (NP (JJ Other) (JJ antibacterial) (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBD showed) (SBAR (S (NP (NNS associations)) (VP (VBD included) (NP (NP (NP (NNP Doc_19884587_1650_1663_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2) (NNS defects)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_19884587_1677_1688_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN defect)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_19884587_1701_1715_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN defect)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_19884587_1732_1742_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN defect)) (-RRB- -RRB-)))))))))) (. .)))
19884587	9	(S1 (S (ADVP (RB Reassuringly)) (, ,) (NP (NP (NNP Doc_19884587_1782_1793_Chemical)) (, ,) (NP (NNP Doc_19884587_1795_1808_Chemical)) (, ,) (CC and) (NP (NNP Doc_19884587_1814_1828_Chemical))) (, ,) (SBAR (IN although) (S (VP (VBN used) (ADVP (RB commonly)) (PP (IN by) (NP (JJ pregnant) (NNS women)))))) (, ,) (VP (AUX were) (RB not) (VP (VBN associated) (PP (IN with) (NP (JJ many) (NNP Doc_19884587_1902_1915_Disease))))) (. .)))
19884587	10	(S1 (S (NP (NP (NNP Doc_19884587_1917_1929_Chemical)) (CC and) (NP (NNP Doc_19884587_1934_1949_Chemical))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (JJ several) (NNP Doc_19884587_1979_1992_Disease))) (, ,) (S (VP (VBG indicating) (NP (NP (DT a) (NN need)) (PP (IN for) (NP (JJ additional) (NN scrutiny)))))))) (. .)))
19889778	0	(S1 (NP (NP (NN Differential) (NN impact)) (PP (IN of) (NP (JJ immune) (NN escape) (NNS mutations) (NNP G145R) (CC and) (NNP P120T))) (PP (IN on) (NP (NP (DT the) (NN replication)) (PP (IN of) (NP (JJ Doc_19889778_85_95_Chemical-resistant) (UCP (JJ Doc_19889778_106_133_Chemical-positive) (CC and) (JJ -negative)) (NNS strains))))) (. .)))
19889778	1	(S1 (S (NP (NP (NP (JJ Immune) (NN escape) (NNS variants)) (PP (IN of) (NP (DT the) (NNP Doc_19889778_196_207_Disease) (NN virus)))) (PRN (-LRB- -LRB-) (NP (NNP HBV)) (-RRB- -RRB-))) (VP (VBP represent) (NP (DT an) (VBG emerging) (JJ clinical) (NN challenge)) (, ,) (SBAR (IN because) (S (NP (PRP they)) (VP (MD can) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (NN vaccine) (NN escape)) (, ,) (NP (NN HBV) (NN reactivation)) (, ,) (CC and) (NP (NP (NN failure)) (PP (IN of) (NP (JJ diagnostic) (NNS tests)))))))))))) (. .)))
19889778	2	(S1 (S (NP (JJ Recent) (NNS data)) (VP (VBP suggest) (NP (NP (DT a) (JJ preferential) (NN selection)) (PP (IN of) (NP (JJ immune) (NN escape) (NNS mutants))) (PP (IN in) (NP (NP (JJ distinct) (JJ peripheral) (NN blood) (NN leukocyte) (NNS compartments)) (PP (IN of) (NP (JJ infected) (NNS individuals))))))) (. .)))
19889778	3	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (ADVP (RB systematically)) (VBD analyzed) (NP (NP (DT the) (JJ functional) (NN impact)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ prevalent)) (JJ immune) (NN escape) (NNS variants)) (, ,) (NP (DT the) (NN sG145R) (CC and) (NN sP120T) (NNS mutants)) (, ,))) (PP (IN on) (NP (NP (DT the) (JJ viral) (NN replication) (NN efficacy)) (CC and) (NP (NP (JJ antiviral) (NN drug) (NN susceptibility)) (PP (IN of) (NP (NP (JJ common) (JJ treatment-associated) (NNS mutants)) (PP (IN with) (NP (NP (NN resistance)) (PP (TO to) (NP (NP (NNP Doc_19889778_774_784_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19889778_786_789_Chemical)) (-RRB- -RRB-)) (NP (JJ and/or) (JJ Doc_19889778_798_803_Chemical) (NN negativity))))))))))))) (. .)))
19889778	4	(S1 (S (NP (NP (JJ Replication-competent) (JJ HBV) (NNS strains)) (PP (IN with) (NP (NP (NN sG145R)) (CC or) (NP (NP (ADJP (JJ sP120T) (CC and) (JJ Doc_19889778_876_879_Chemical)) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NN rtM204I) (CC or) (NNS rtL180M/rtM204V)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN generated) (PP (IN on) (NP (NP (DT an) (JJ Doc_19889778_941_946_Chemical-positive)) (CC and) (NP (DT an) (JJ Doc_19889778_963_968_Chemical-negative) (NN background)))) (PP (IN with) (NP (NP (NP (NN precore)) (PRN (-LRB- -LRB-) (NP (NN PC)) (-RRB- -RRB-))) (CC and) (NP (JJ basal) (NN core) (NN promoter) (PRN (-LRB- -LRB-) (NP (NNP BCP)) (-RRB- -RRB-)) (NNS mutants)))))) (. .)))
19889778	5	(S1 (S (S (NP (DT The) (JJ sG145R) (NN mutation)) (VP (VP (ADVP (RB strongly)) (VBD reduced) (NP (JJ Doc_19889778_1083_1088_Chemical) (NNS levels))) (CC and) (VP (AUX was) (ADJP (JJ able) (S (VP (TO to) (VP (ADVP (RB fully)) (VB restore) (NP (NP (DT the) (VBN impaired) (NN replication)) (PP (IN of) (NP (JJ Doc_19889778_1154_1157_Chemical-resistant) (NN HBV) (NNS mutants)))) (PP (TO to) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (JJ wild-type) (NNS HBV)))))))))))) (, ,) (CC and) (S (NP (NNP PC) (CC or) (NNP BCP) (NNS mutations)) (VP (ADVP (RB further)) (VBD enhanced) (NP (JJ viral) (NN replication)))) (. .)))
19889778	6	(S1 (S (SBAR (IN Although) (S (NP (DT the) (JJ sP120T) (NN substitution)) (ADVP (RB also)) (VP (VBN impaired) (NP (JJ Doc_19889778_1319_1324_Chemical) (NN secretion))))) (, ,) (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB enhance) (NP (NP (DT the) (NN replication)) (PP (IN of) (NP (JJ Doc_19889778_1374_1377_Chemical-resistant) (NNS clones)))))) (. .)))
19889778	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ concomitant) (NN occurrence)) (PP (IN of) (NP (NP (NP (JJ Doc_19889778_1435_1440_Chemical) (NN negativity)) (PRN (-LRB- -LRB-) (NP (NNP PC/BCP)) (-RRB- -RRB-))) (, ,) (NP (NN sP120T)) (, ,) (CC and) (NP (JJ Doc_19889778_1474_1477_Chemical) (NN resistance))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN restoration)) (PP (IN of) (NP (NN replication))) (PP (TO to) (NP (NP (NNS levels)) (PP (IN of) (NP (JJ wild-type) (NNS HBV)))))))) (. .)))
19889778	8	(S1 (S (PP (IN In) (NP (NP (DT all) (NNS clones)) (PP (IN with) (NP (NP (JJ combined) (JJ immune) (NN escape)) (CC and) (NP (JJ Doc_19889778_1606_1609_Chemical) (NN resistance) (NNS mutations)))))) (, ,) (NP (DT the) (NNP Doc_19889778_1636_1646_Chemical) (NNS analogues) (NNP Doc_19889778_1657_1665_Chemical) (CC and) (NNP Doc_19889778_1670_1679_Chemical)) (VP (VBD remained) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG suppressing) (NP (JJ viral) (NN replication)) (PP (IN in) (NP (NN vitro)))))))) (. .)))
19889778	9	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP reveal) (NP (NP (DT the) (NN differential) (NN impact)) (PP (IN of) (NP (JJ immune) (NN escape) (NNS variants))) (PP (IN on) (NP (NP (DT the) (NN replication) (CC and) (NN drug) (NN susceptibility)) (PP (IN of) (NP (JJ complex) (NN HBV) (NNS mutants)))))) (, ,) (S (VP (VBG supporting) (NP (NP (DT the) (NN need)) (PP (IN of) (NP (NP (JJ close) (NN surveillance)) (CC and) (NP (NN treatment) (NN adjustment))))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT the) (NN selection)) (PP (IN of) (NP (JJ distinct) (JJ mutational) (NNS patterns)))))))))) (. .)))
1992636	0	(S1 (S (NP (NN Doc_1992636_0_16_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_1992636_44_54_Chemical)))))) (. .)))
1992636	1	(S1 (S (NP (NN Doc_1992636_56_66_Chemical)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN drug)) (VP (VBN designed) (S (VP (TO to) (VP (VB block) (NP (NP (DT the) (JJ final) (NN step)) (PP (IN in) (NP (NP (DT the) (NN acid) (NN secretory) (NN process)) (PP (IN within) (NP (DT the) (JJ parietal) (NN cell)))))))))))) (. .)))
1992636	2	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (ADJP (RB extremely) (JJ effective)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_1992636_238_258_Disease)) (, ,) (NP (NNP Doc_1992636_260_278_Disease)) (, ,) (CC and) (NP (DT the) (NNP Doc_1992636_288_314_Disease)))))))))))) (. .)))
1992636	3	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ clinical) (NN experience)) (PP (IN with) (NP (NNP Doc_1992636_350_360_Chemical)))) (VP (AUX is) (ADVP (RB still)) (VP (VBN limited))))) (, ,) (NP (JJ many) (VBN controlled) (NNS studies)) (VP (AUX have) (VP (VBN established) (NP (NP (DT the) (JJ short-term) (NN safety)) (PP (IN of) (NP (DT this) (NN drug)))))) (. .)))
1992636	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (JJ first) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ serious) (JJ short-term) (JJ adverse) (NN reaction)) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_1992636_538_548_Chemical)) (: :) (NP (NNP Doc_1992636_550_566_Disease)))))))))) (. .)))
1992636	5	(S1 (S (NP (DT The) (NN patient)) (VP (VBD developed) (NP (NP (NN weakness)) (, ,) (NP (NN Doc_1992636_600_608_Disease)) (, ,) (CC and) (NP (NP (NN Doc_1992636_614_633_Disease)) (NP (CD 2) (NNS days)))) (PP (IN after) (S (VP (VBG starting) (NP (NP (NN therapy)) (PP (IN with) (NP (NNP Doc_1992636_669_679_Chemical)))))))) (. .)))
1992636	6	(S1 (S (PP (NP (CD Two) (NNS weeks)) (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN therapy))))) (, ,) (S (NP (PRP$ her) (NN hematocrit)) (VP (AUX had) (VP (VBN decreased) (PP (IN from) (NP (QP (CD 44.1) (NN %) (TO to) (CD 20.4)) (NN %)))))) (, ,) (CC and) (S (NP (PRP she)) (VP (AUX had) (NP (NP (DT a) (JJ positive) (JJ direct) (NNP Coombs) (NN antiglobulin) (NN test)) (CC and) (NP (DT an) (JJ elevated) (JJ indirect) (NN Doc_1992636_854_863_Chemical))))) (. .)))
1992636	7	(S1 (S (SBAR (IN After) (S (NP (PRP she)) (VP (VBN discontinued) (NP (DT the) (NNP Doc_1992636_892_902_Chemical))))) (, ,) (NP (PRP$ her) (NN hemoglobin) (CC and) (NN hematocrit)) (ADVP (RB gradually)) (VP (VBD returned) (PP (TO to) (NP (JJ normal)))) (. .)))
1992636	8	(S1 (NP (DT The) (NN mechanism) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_1992636_987_997_Chemical)) (VP (VBD caused) (SBAR (S (S (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_1992636_1019_1035_Disease)) (VP (AUX is) (ADJP (JJ uncertain)))) (, ,) (CC but) (S (NP (NNS physicians)) (VP (MD should) (VP (AUX be) (VP (VBD alerted) (PP (TO to) (NP (DT this) (JJ possible) (JJ adverse) (NN effect)))))))))))) (. .)))
19957053	0	(S1 (FRAG (NP (NN Doc_19957053_0_13_Chemical)) (CC but) (RB not) (NP (NP (NNP Doc_19957053_22_31_Chemical) (NNP Doc_19957053_32_64_Disease)) (VP (VBG following) (NP (JJ anesthesia-induced) (NNP Doc_19957053_94_105_Disease)))) (. .)))
19957053	1	(S1 (S (NP (NN Vasopressor) (NNS agents)) (VP (AUX are) (VP (VBN used) (S (VP (TO to) (VP (VB correct) (NP (JJ anesthesia-induced) (NN Doc_19957053_177_188_Disease))))))) (. .)))
19957053	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_19957053_216_229_Chemical) (CC and) (NNP Doc_19957053_234_243_Chemical))) (PP (IN on) (NP (NP (JJ frontal) (NN lobe) (NN oxygenation)) (PRN (-LRB- -LRB-) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-RRB- -RRB-))))) (PP (VBG following) (NP (JJ anesthesia-induced) (NNP Doc_19957053_312_323_Disease)))) (. .)))
19957053	3	(S1 (S (S (VP (VBG Following) (NP (NP (NN induction)) (PP (IN of) (NP (NN anesthesia))) (PP (IN by) (NP (NP (NNP Doc_19957053_371_379_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.15) (NNS mg) (NN kg) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-) (-RRB- -RRB-)) (CC and) (NNP Doc_19957053_401_409_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.0) (CD mg)) (NNS kg)) (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (-RRB- -RRB-))))))) (, ,) (NP (CD 13) (NNS patients)) (VP (VBD received) (SBAR (S (NP (NP (NP (NNP Doc_19957053_448_461_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.1) (CD mg)) (NNP iv)) (-RRB- -RRB-))) (CC and) (NP (CD 12) (NNS patients))) (VP (VBD received) (NP (NP (NNP Doc_19957053_499_508_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CD mg)) (NNP iv)) (-RRB- -RRB-))) (S (VP (TO to) (VP (VB restore) (VP (VB mean) (NP (NP (JJ arterial) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))))))))))) (. .)))
19957053	4	(S1 (S (NP (NP (NP (NN Heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP HR)) (-RRB- -RRB-)) (, ,) (NP (NN MAP)) (, ,) (NP (NNP Doc_19957053_583_589_Disease) (NN volume)) (PRN (-LRB- -LRB-) (NP (NNP SV)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ cardiac) (NN output)) (PRN (-LRB- -LRB-) (NP (NNP CO)) (-RRB- -RRB-))) (, ,)) (CC and) (NP (NP (JJ frontal) (NN lobe) (NN oxygenation)) (PRN (-LRB- -LRB-) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN registered))) (. .)))
19957053	5	(S1 (S (NP (NP (NN Induction)) (PP (IN of) (NP (NNS anesthesia)))) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (JJ Doc_19957053_730_763_Disease) (NN concomitant)) (PP (IN with) (NP (NP (DT an) (NN elevation)) (PP (IN in) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)))))))))) (. .)))
19957053	6	(S1 (S (PP (IN After) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_19957053_831_844_Chemical))))) (, ,) (NP (NN MAP)) (VP (VBN increased) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 51) (NN +/-)) (NP (QP (CD 12) (TO to) (CD 81)) (JJ +/-) (CD 13) (NNS mmHg))) (: ;) (NP (NNP P) (NNP <) (CD 0.001)) (: ;) (NP (JJ mean) (JJ +/-) (NN SD))) (-RRB- -RRB-))) (. .)))
19957053	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT a) (ADJP (ADJP (CD 14) (NN %)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (NP (QP (CD 70) (JJ +/-) (CD 8) (NN %) (TO to) (CD 60) (NN +/-))) (NP (CD 7) (NN %)))) (-RRB- -RRB-))) (NN reduction)) (PP (IN in) (NP (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-)))) (VP (VBN followed) (PP (IN with) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (NNP CO)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.7) (NN +/-)) (ADJP (QP (CD 1.1) (TO to) (CD 3.4) (NN +/-)) (NP (NP (CD 0.9) (NNP l) (NN min)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-))))) (-RRB- -RRB-))))))) (. .)))
19957053	8	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NNP Doc_19957053_1085_1094_Chemical)))) (VP (VP (VBD led) (PP (TO to) (NP (NP (DT a) (JJ similar) (NN increase)) (PP (IN in) (NP (NN MAP))) (PRN (-LRB- -LRB-) (NP (NP (CD 53) (NN +/-)) (NP (QP (CD 9) (TO to) (CD 79)) (JJ +/-) (CD 8) (NNS mmHg))) (: ;) (VP (VBG P) (NP (NNP <) (CD 0.001))) (-RRB- -RRB-))))) (, ,) (VP (VBD restored) (NP (NP (NNP CO)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 3.2) (NN +/-) (QP (CD 1.2) (TO to) (CD 5.0))) (JJ +/-) (CD 1.3) (NNP l) (NN min)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (, ,) (CC and) (VP (VBD preserved) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))) (. .)))
19957053	9	(S1 (S (S (NP (NP (DT The) (NN utilization)) (PP (IN of) (NP (NNP Doc_19957053_1276_1289_Chemical)))) (VP (TO to) (VP (VB correct) (NP (NP (NNP Doc_19957053_1301_1312_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNS anesthesia)))))))) (VP (AUX has) (NP (NP (DT a) (JJ negative) (NN impact)) (PP (IN on) (NP (NP (NNP S) (PRN (-LRB- -LRB-) (NP (NNP c)) (-RRB- -RRB-)) (NNP O)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))) (SBAR (IN while) (S (NP (NNP Doc_19957053_1375_1384_Chemical)) (VP (VBZ maintains) (NP (NP (JJ frontal) (NN lobe) (NN oxygenation)) (ADJP (RB potentially) (JJ related) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP CO))))))))))) (. .)))
20003049	0	(S1 (NP (NP (VBN Prolonged) (NN elevation)) (PP (IN of) (NP (NN plasma) (NNP Doc_20003049_30_40_Chemical))) (PP (IN in) (NP (NP (DT a) (JJ cardiac) (NN transplant) (NN patient)) (PP (IN with) (NP (NP (DT a) (VBN suspected) (NN history)) (PP (IN of) (NP (NP (NNP Doc_20003049_101_108_Chemical-induced) (NNP Doc_20003049_117_133_Disease)) (PP (IN with) (NP (NNP Doc_20003049_139_149_Disease))))))))) (. .)))
20003049	1	(S1 (S (NP (NP (JJ Direct) (NN thrombin) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NNP DTIs)) (-RRB- -RRB-))) (VP (VBP provide) (NP (NP (DT an) (JJ alternative) (NN method)) (PP (IN of) (NP (NN anticoagulation)))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NP (JJ Doc_20003049_277_284_Chemical-induced) (NNP Doc_20003049_293_309_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20003049_311_314_Disease)) (-RRB- -RRB-))) (CC or) (NP (NP (NP (NNP Doc_20003049_319_322_Disease)) (PP (IN with) (NP (NNP Doc_20003049_328_338_Disease)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_20003049_340_344_Disease)) (-RRB- -RRB-))))) (VP (VBG undergoing) (NP (NP (JJ cardiopulmonary) (NN bypass)) (PRN (-LRB- -LRB-) (NP (NNP CPB)) (-RRB- -RRB-))))))))) (. .)))
20003049	2	(S1 (S (PP (IN In) (NP (DT the) (JJ following) (NN report))) (, ,) (NP (NP (DT a) (JJ 65-year-old) (NN Doc_20003049_426_440_Disease) (NN patient)) (PP (IN with) (NP (NP (DT a) (VBN suspected) (NN history)) (PP (IN of) (NP (NNP Doc_20003049_477_481_Disease)))))) (VP (AUX was) (VP (VBN administered) (NP (NNP Doc_20003049_499_509_Chemical)) (PP (IN for) (NP (NN anticoagulation))) (PP (IN on) (NP (NN bypass))) (PP (IN during) (NP (NN heart) (NN transplantation))))) (. .)))
20003049	3	(S1 (S (NP (DT The) (NN patient)) (VP (VBD required) (NP (NP (JJ massive) (NN transfusion) (NN support)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 55) (NNS units)) (PP (IN of) (NP (JJ red) (NN blood) (NNS cells)))) (, ,) (NP (NP (CD 42) (NNS units)) (PP (IN of) (NP (NP (JJ fresh-frozen) (NN plasma)) (, ,) (NP (NP (CD 40) (NNS units)) (PP (IN of) (NP (NN cryoprecipitate)))) (, ,) (NP (NP (CD 40) (NNS units)) (PP (IN of) (NP (NNS platelets)))) (, ,) (CC and) (NP (NP (CD three) (NNS doses)) (PP (IN of) (NP (JJ recombinant) (NN Factor) (NNS VIIa)))))))) (-RRB- -RRB-)) (PP (IN for) (NP (JJ severe) (NNP Doc_20003049_789_830_Disease))))) (. .)))
20003049	4	(S1 (S (S (VP (VB STUDY) (NP (NN DESIGN) (CC AND) (NNS METHODS)))) (: :) (S (NP (NP (NN Plasma) (NNS samples)) (PP (IN from) (PP (IN before) (CC and) (IN after) (NP (NN CPB))))) (VP (AUX were) (VP (VBN analyzed) (ADVP (RB postoperatively)) (PP (IN for) (NP (NP (JJ Doc_20003049_933_943_Chemical) (NN concentration)) (VP (VBG using) (NP (DT a) (VBN modified) (NN ecarin) (NN clotting) (NN time) (-LRB- -LRB-) (NN ECT) (-RRB- -RRB-) (NN assay)))))))) (. .)))
20003049	5	(S1 (S (S (NP (NP (RB Unexpectedly) (JJ high) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_20003049_1054_1064_Chemical)))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (DT these) (NNS samples)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 0-32) (NNS microg/mL)) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP (NP (DT a) (JJ prolonged) (NN plasma) (JJ Doc_20003049_1144_1154_Chemical) (NN half) (NN life)) (PRN (-LRB- -LRB-) (NNP t) (-LRB- -LRB-) (NN 1/2) (-RRB- -RRB-) (-RRB- -RRB-)) (PP (IN of) (NP (CD 514) (NNS minutes)))) (VP (AUX was) (ADJP (JJ observed)) (PRN (-LRB- -LRB-) (VP (VBN published) (NP (NP (NP (NN elimination) (NNS t)) (PRN (-LRB- -LRB-) (NP (CD 1/2)) (-RRB- -RRB-)) (VP (AUX is) (ADJP (NP (CD 39-51) (NNS minutes)) (JJ -LSB-<)))) (CC or) (NP (NP (QP (SYM =) (CD 181)) (NNS minutes)) (PP (IN with) (NP (NNP Doc_20003049_1274_1292_Disease) (NNS -RSB-)))))) (-RRB- -RRB-)))) (. .)))
20003049	6	(S1 (S (NP (NP (NP (NN Correlation)) (PP (IN of) (NP (NP (NN plasma) (JJ Doc_20003049_1331_1341_Chemical) (NN concentration)) (CC versus) (NP (NP (DT the) (NN patient) (POS 's)) (JJ coagulation) (NNS variables))))) (CC and) (NP (JJ clinical) (NN course))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ prolonged) (JJ elevated) (NNS levels)) (PP (IN of) (NP (NN plasma) (NN Doc_20003049_1468_1478_Chemical)))) (VP (MD may) (VP (AUX have) (VP (VBN contributed) (PP (TO to) (NP (NP (DT the) (NN patient) (POS 's)) (VBN extended) (NN Doc_20003049_1526_1538_Disease))))))))) (. .)))
20003049	7	(S1 (S (SBAR (IN Because) (S (NP (NNS DTIs)) (VP (AUX do) (RB not) (VP (AUX have) (NP (NN reversal) (NNS agents)))))) (, ,) (NP (NP (JJ surgical) (NNS teams)) (CC and) (NP (NN transfusion) (NNS services))) (VP (MD should) (VP (VB remain) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ massive) (NN transfusion) (NNS events)))))) (PP (IN during) (NP (NP (NN anticoagulation)) (PP (IN with) (NP (DT these) (NNS agents))))))) (. .)))
20003049	8	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN report)) (SBAR (S (VP (TO to) (VP (VB measure) (NP (NP (NN plasma) (JJ Doc_20003049_1776_1786_Chemical) (NN concentration)) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (NN CPB)) (CC and) (NP (JJ extended) (NN Doc_20003049_1836_1848_Disease))))))))))))) (. .)))
20067456	0	(S1 (NP (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (DT the) (JJ adjunctive) (NNP Doc_20067456_30_39_Chemical))) (PP (IN on) (NP (NP (JJ male) (NN Doc_20067456_48_66_Disease)) (VP (VBN induced) (PP (IN by) (NP (DT a) (NNP Doc_20067456_80_118_Chemical))))))) (: :) (NP (DT a) (JJ double-blind) (ADJP (JJ placebo-controlled) (CC and) (JJ randomized)) (NN study)) (. .)))
20067456	1	(S1 (S (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NP (JJ adjunctive) (JJ Doc_20067456_238_247_Chemical) (NN sustained-release)) (PRN (-LRB- -LRB-) (NP (NNP SR)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ male) (NNP Doc_20067456_279_297_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20067456_299_301_Disease)) (-RRB- -RRB-)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (NNP Doc_20067456_316_354_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20067456_356_360_Chemical)) (-RRB- -RRB-)))))))) (, ,) (PP (IN as) (NP (NNP Doc_20067456_366_368_Disease)))))) (VP (AUX is) (NP (NP (DT a) (JJ common) (NN side-effect)) (PP (IN of) (NP (NNP Doc_20067456_396_401_Chemical)))))) (CC and) (S (NP (DT the) (ADJP (RBS most) (JJ effective)) (NNS treatments)) (VP (AUX have) (ADVP (RB yet)) (S (VP (TO to) (VP (AUX be) (VP (VBN determined))))))) (. .)))
20067456	2	(S1 (NP (NP (NP (NNS PATIENTS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (NP (DT The) (JJ randomized) (NN sample)) (VP (VBN consisted) (PP (IN of) (NP (NP (CD 234) (JJ euthymic) (NNS men)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBG receiving) (NP (NP (DT some) (NN type)) (PP (IN of) (NP (NNP Doc_20067456_569_573_Chemical)))))))))))) (. .)))
20067456	3	(S1 (S (NP (DT The) (NNS men)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (NP (NNP Doc_20067456_609_618_Chemical) (NNP SR)) (PRN (-LRB- -LRB-) (NP (QP (CD 150) (CD mg)) (RB twice) (JJ daily)) (, ,) (NP (CD 117)) (-RRB- -RRB-))) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (RB twice) (JJ daily)) (, ,) (NP (CD 117)) (-RRB- -RRB-))))) (PP (IN for) (NP (CD 12) (NNS weeks))))) (. .)))
20067456	4	(S1 (S (NP (NN Efficacy)) (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (DT the) (JJ Clinical) (JJ Global) (JJ Impression-Sexual) (NN Function)) (PRN (-LRB- -LRB-) (NP (NNP CGI-SF)) (: ;) (NP (DT the) (JJ primary) (NN outcome) (NN measure)) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (NNP International) (NNP Index)) (PP (IN of) (NP (NP (NP (NNP Erectile) (NN Function)) (PRN (-LRB- -LRB-) (NP (NN IIEF)) (-RRB- -RRB-)) (, ,) (NP (NNP Arizona) (JJ Sexual) (NN Experience) (NN Scale)) (PRN (-LRB- -LRB-) (NP (NNP ASEX)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NNP Doc_20067456_904_924_Disease) (NN Inventory))) (PP (IN of) (NP (NNP Treatment) (NN Satisfaction))))) (PRN (-LRB- -LRB-) (NP (NNP EDITS)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (JJ secondary) (NN outcome) (NNS measures)) (-RRB- -RRB-))))))) (. .)))
20067456	5	(S1 (S (NP (NNS Participants)) (VP (AUX were) (VP (VBN followed) (ADVP (RB biweekly)) (PP (IN during) (NP (NN study) (NN period))))) (. .)))
20067456	6	(S1 (S (PP (IN After) (NP (NP (CD 12) (NNS weeks)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (NP (DT the) (JJ mean) (PRN (-LRB- -LRB-) (CD sd) (-RRB- -RRB-)) (NNS scores)) (PP (IN for) (NP (NNP CGI-SF)))) (VP (AUX were) (ADJP (RB significantly) (JJR lower)) (, ,) (ADVP (FW i.e.) (JJR better)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NNP Doc_20067456_1180_1189_Chemical) (NNP SR))))) (, ,) (PP (IN at) (NP (NP (NP (CD 2.4)) (PRN (-LRB- -LRB-) (NP (CD 1.2)) (-RRB- -RRB-)) (, ,) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (, ,) (PP (IN at) (NP (CD 3.9)))) (-LRB- -LRB-) (NP (CD 1.1)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (NNP P=) (CD 0.01)) (-RRB- -RRB-)))) (. .)))
20067456	7	(S1 (S (NP (NP (NNS Men)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_20067456_1276_1285_Chemical)))))) (VP (AUX had) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (PP (IN in) (NP (NP (DT the) (JJ total) (NN IIEF) (NN score)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 54.4) (NN %)) (NNP vs) (CD 1.2) (NN %)) (: ;) (NP (NNP P=) (CD 0.003))) (-RRB- -RRB-)))) (, ,) (CC and) (PP (IN in) (NP (NP (DT the) (CD five) (JJ different) (NNS domains)) (PP (IN of) (NP (DT the) (NN IIEF)))))))) (. .)))
20067456	8	(S1 (S (NP (JJ Total) (NN ASEX) (NNS scores)) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR lower)) (PRN (, ,) (PP (FW i.e.) (ADVP (RB better))) (, ,))) (PP (IN among) (NP (NP (NNS men)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_20067456_1491_1500_Chemical)) (PP (IN than) (NP (NN placebo)))))))) (, ,) (PP (IN at) (NP (NP (NP (CD 15.5) (-LRB- -LRB-) (CD 4.3) (-RRB- -RRB-) (NNP vs) (CD 21.5)) (-LRB- -LRB-) (NP (CD 4.7)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP P=) (CD 0.002)) (-RRB- -RRB-))))) (. .)))
20067456	9	(S1 (S (NP (DT The) (JJ EDITS) (NNS scores)) (VP (AUX were) (NP (NP (NP (NP (CD 67.4)) (PRN (-LRB- -LRB-) (NP (CD 10.2)) (-RRB- -RRB-) (PP (IN for) (NP (DT the) (NNP Doc_20067456_1597_1606_Chemical))))) (CC and) (NP (NP (CD 36.3)) (PRN (-LRB- -LRB-) (NP (CD 11.7)) (-RRB- -RRB-)))) (PP (IN for) (NP (DT the) (NN placebo) (NN group))) (PRN (-LRB- -LRB-) (NP (NNP P=) (CD 0.001)) (-RRB- -RRB-)))) (. .)))
20067456	10	(S1 (S (NP (NP (DT The) (NN ASEX) (NN score)) (CC and) (NP (JJ CGI-SF) (NN score))) (VP (AUX were) (VP (VBN correlated) (PRN (-LRB- -LRB-) (NP (NNP P=) (CD 0.003)) (-RRB- -RRB-)))) (. .)))
20067456	11	(S1 (S (PP (IN In) (NP (JJ linear) (JJ regression) (NNS analyses))) (NP (DT the) (JJ CGI-SF) (NN score)) (VP (AUX was) (RB not) (VP (VBN affected) (ADVP (RB significantly)) (PP (IN by) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NNP Doc_20067456_1814_1816_Disease)) (, ,) (NP (NP (NP (NN type)) (PP (IN of) (NP (NNP Doc_20067456_1826_1830_Chemical))) (VP (VBN used))) (CC and) (NP (NN age))))))))) (. .)))
20067456	12	(S1 (S (NP (NN Doc_20067456_1858_1867_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (NP (JJ male) (NN Doc_20067456_1903_1905_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_20067456_1917_1922_Chemical)))))))) (. .)))
20067456	13	(S1 (S (NP (DT These) (NNS results)) (VP (VBP provide) (NP (NP (JJ empirical) (NN support)) (PP (IN for) (S (VP (VBG conducting) (NP (NP (DT a) (JJ further) (NN study)) (PP (IN of) (NP (NN Doc_20067456_1998_2007_Chemical))))))))) (. .)))
20080419	0	(S1 (NP (NP (NP (NP (NN Prevention)) (PP (IN of) (NP (NNP Doc_20080419_14_22_Disease)))) (CC and) (NP (NP (NN reorganization)) (PP (IN of) (NP (JJ hippocampal) (NNS functions))))) (PP (IN by) (NP (NP (NN transplantation)) (PP (IN of) (NP (NP (NN bone) (NN marrow) (NNS cells)) (PP (IN in) (NP (NP (DT the) (JJ acute) (NN phase)) (PP (IN of) (NP (JJ experimental) (NNP Doc_20080419_142_150_Disease))))))))) (. .)))
20080419	1	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (JJ therapeutic) (NN potential)) (PP (IN of) (NP (NP (NN bone) (NN marrow) (NN mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNP BMCs)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_20080419_263_271_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_20080419_283_294_Chemical))) (PP (IN in) (NP (NNS rats))))))) (. .)))
20080419	2	(S1 (S (NP (NP (NNS BMCs)) (VP (VBN obtained) (PP (IN from) (NP (NP (JJ green) (JJ fluorescent) (NN protein) (PRN (-LRB- -LRB-) (NP (NNP GFP)) (-RRB- -RRB-)) (NNP transgenic) (NNS mice)) (CC or) (NP (NNS rats)))))) (VP (AUX were) (VP (VBN transplanted) (ADVP (RB intravenously)) (PP (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (NP (NNP Doc_20080419_430_448_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20080419_450_452_Disease)) (-RRB- -RRB-)))))))) (. .)))
20080419	3	(S1 (S (NP (NP (NNP Doc_20080419_455_485_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20080419_487_490_Disease)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN monitored) (S (VP (VBG using) (NP (NP (NNP Racine) (POS 's)) (NNP Doc_20080419_522_529_Disease) (NN severity) (NN scale)))))) (. .)))
20080419	4	(S1 (S (NP (NP (DT All)) (PP (IN of) (NP (NP (DT the) (NNS rats)) (PP (IN in) (NP (DT the) (JJ saline-treated) (NNP Doc_20080419_584_593_Disease) (NN control) (NN group)))))) (VP (VBD developed) (NP (NNP Doc_20080419_618_621_Disease)) (, ,) (SBAR (IN whereas) (S (NP (NP (NN none)) (PP (IN of) (NP (DT the) (JJ BMC-treated) (JJ Doc_20080419_655_664_Disease) (NNS animals)))) (VP (AUX had) (NP (NNP Doc_20080419_677_685_Disease)) (PP (IN in) (NP (NP (DT the) (JJ short) (NN term)) (PRN (-LRB- -LRB-) (NP (NP (CD 15) (NNS days)) (PP (IN after) (NP (NN transplantation)))) (-RRB- -RRB-)))) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (DT the) (NNP BMC) (NN source)))))))) (. .)))
20080419	5	(S1 (S (PP (IN Over) (NP (NP (DT the) (JJ long-term) (NN chronic) (NN phase)) (PRN (-LRB- -LRB-) (NP (NP (CD 120) (NNS days)) (PP (IN after) (NP (NN transplantation)))) (-RRB- -RRB-)))) (, ,) (NP (NP (QP (RB only) (CD 25)) (NN %)) (PP (IN of) (NP (JJ BMC-treated) (JJ Doc_20080419_858_867_Disease) (NNS animals)))) (VP (VP (AUX had) (NP (NNP Doc_20080419_880_888_Disease))) (, ,) (CC but) (PP (IN with) (NP (NP (DT a) (JJR lower) (NN frequency)) (CC and) (NP (NN duration)))) (PP (VBN compared) (PP (TO to) (NP (DT the) (NNP Doc_20080419_946_955_Disease) (NN control) (NN group))))) (. .)))
20080419	6	(S1 (S (NP (NP (DT The) (NN density)) (PP (IN of) (NP (JJ hippocampal) (NNS neurons))) (PP (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNS BMCs))))))))) (VP (AUX was) (ADVP (RB markedly)) (VP (VBN preserved))) (. .)))
20080419	7	(S1 (S (PP (IN At) (NP (JJ hippocampal) (NNP Schaeffer) (NN collateral-CA1) (NNS synapses))) (, ,) (NP (JJ long-term) (NN potentiation)) (VP (AUX was) (VP (VBN preserved) (PP (IN in) (NP (JJ BMC-transplanted) (NNS rats))) (PP (VBN compared) (PP (TO to) (NP (JJ Doc_20080419_1197_1206_Disease) (NNS controls)))))) (. .)))
20080419	8	(S1 (S (NP (DT The) (JJ donor-derived) (NNP GFP) (PRN (-LRB- -LRB-) (NP (NNP +)) (-RRB- -RRB-)) (NNS cells)) (VP (AUX were) (ADVP (RB rarely)) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (JJ transplanted) (JJ Doc_20080419_1296_1305_Disease) (NNS rats))))))) (. .)))
20080419	9	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NN treatment)) (PP (IN with) (NP (NNS BMCs)))) (VP (MD can) (VP (VP (VB prevent) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ chronic) (NNP Doc_20080419_1386_1394_Disease))))) (, ,) (VP (VB reduce) (NP (NN Doc_20080419_1403_1416_Disease))) (, ,) (CC and) (VP (VB influence) (NP (NP (DT the) (NN reorganization)) (PP (IN of) (NP (DT the) (JJ hippocampal) (JJ neuronal) (NN network))))))) (. .)))
20080983	0	(S1 (NP (NP (JJ Normalizing) (NNS effects)) (PP (IN of) (NP (NNP Doc_20080983_23_32_Chemical))) (PP (IN on) (NP (NP (NN sleep)) (PP (IN in) (NP (JJ chronic) (JJ Doc_20080983_53_60_Chemical) (NNS users))))) (. .)))
20080983	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ morning-dosed) (NNP Doc_20080983_157_166_Chemical))) (PP (IN on) (NP (NN sleep))))) (CC and) (VP (VB Doc_20080983_180_198_Disease) (PP (IN in) (NP (JJ chronic) (JJ Doc_20080983_210_217_Chemical) (NNS users)))))))) (. .)))
20080983	2	(S1 (S (NP (CD Twenty) (JJ Doc_20080983_240_247_Chemical-dependent) (NNS participants)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (S (VP (TO to) (VP (VB receive) (NP (NP (NNP Doc_20080983_305_314_Chemical)) (, ,) (NP (NP (CD 400) (NNS mg)) (PRN (-LRB- -LRB-) (NP (NNP N=10)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NNP N=10)) (-RRB- -RRB-)))) (NP (DT every) (NN morning)) (PP (IN at) (NP (CD 7:30) (RB a.m.))) (PP (IN for) (NP (NP (CD 16) (NNS days)) (PP (IN in) (NP (DT an) (JJ inpatient) (, ,) (JJ double-blind) (JJ randomized) (NN trial)))))))))) (. .)))
20080983	3	(S1 (S (NP (NNS Participants)) (VP (VBD underwent) (NP (JJ polysomnographic) (NN sleep) (NNS recordings)) (PP (IN on) (NP (NNS days))) (NP (NP (QP (CD 1) (TO to) (CD 3))) (, ,) (NP (QP (CD 7) (TO to) (CD 9))) (, ,) (CC and) (NP (NP (QP (CD 14) (TO to) (CD 16))) (PRN (-LRB- -LRB-) (NP (NP (JJ first) (, ,) (ADJP (JJ second) (, ,) (CC and) (JJ third)) (NNS weeks)) (PP (IN of) (NP (NN abstinence)))) (-RRB- -RRB-))))) (. .)))
20080983	4	(S1 (S (NP (DT The) (JJ Multiple) (NNP Sleep) (NNP Latency) (NN Test)) (VP (AUX was) (VP (VBN performed) (PP (IN at) (NP (NP (CD 11:30) (RB a.m.)) (, ,) (NP (CD 2:00) (RB p.m.)) (, ,) (CC and) (NP (CD 4:30) (RB p.m.)))) (PP (IN on) (NP (NNS days))) (NP (NP (CD 2)) (, ,) (NP (CD 8)) (, ,) (CC and) (NP (CD 15))))) (. .)))
20080983	5	(S1 (S (PP (IN For) (NP (NP (NN comparison)) (PP (IN of) (NP (NN sleep) (NN architecture) (NNS variables))))) (, ,) (NP (CD 12) (JJ healthy) (NN comparison) (NNS participants)) (VP (VBD underwent) (NP (NP (DT a) (JJ single) (NN night)) (PP (IN of) (NP (JJ experimental) (NN polysomnography))) (SBAR (WHNP (WDT that)) (S (VP (VBD followed) (NP (NP (CD 1) (NN night)) (PP (IN of) (NP (NN accommodation) (NN polysomnography))))))))) (. .)))
20080983	6	(S1 (S (NP (NP (JJ Progressive) (NN abstinence)) (PP (IN from) (NP (NNP Doc_20080983_919_926_Chemical)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (VBG worsening)) (PP (IN of) (NP (DT all) (JJ measured) (JJ polysomnographic) (NN sleep) (NNS outcomes))))))) (. .)))
20080983	7	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NN placebo)))) (, ,) (NP (NNP Doc_20080983_1029_1038_Chemical)) (VP (VBD decreased) (NP (NP (JJ nighttime) (NN sleep) (NN latency)) (CC and) (NP (VBN increased) (JJ slow-wave) (NN sleep) (NN time))) (PP (IN in) (NP (JJ Doc_20080983_1111_1118_Chemical-dependent) (NNS participants)))) (. .)))
20080983	8	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_20080983_1157_1166_Chemical)))) (VP (VP (VBD interacted) (PP (IN with) (NP (DT the) (NN abstinence) (NN week)))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJR longer) (JJ total) (NN sleep) (NN time)) (CC and) (NP (JJR shorter) (NN REM) (NN sleep) (NN latency)))) (PP (IN in) (NP (NP (DT the) (JJ third) (NN week)) (PP (IN of) (NP (NN abstinence)))))))) (. .)))
20080983	9	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (JJ slow-wave) (NN sleep) (NN time)) (, ,) (NP (JJ total) (NN sleep) (NN time)) (, ,) (CC and) (NP (NP (NN sleep) (NN latency)) (PP (IN in) (NP (NNP Doc_20080983_1389_1396_Chemical-dependent)))) (CC and) (NP (JJ healthy) (NNS participants))))) (VP (VBD revealed) (NP (NP (DT a) (JJ normalizing) (NN effect)) (PP (IN of) (NP (NNP Doc_20080983_1465_1474_Chemical))) (PP (IN in) (NP (JJ Doc_20080983_1478_1485_Chemical-dependent) (NNS participants))))) (. .)))
20080983	10	(S1 (S (NP (NN Doc_20080983_1510_1519_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (JJ daytime) (NN sleep) (NN latency))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NP (DT the) (JJ Multiple) (NNP Sleep) (NNP Latency) (NN Test)) (, ,) (CC and) (NP (NP (DT a) (ADJP (RB nearly) (JJ significant)) (NN decrease)) (PP (IN in) (NP (JJ subjective) (NN Doc_20080983_1669_1687_Disease))))))))))) (. .)))
20080983	11	(S1 (S (NP (JJ Morning-dosed) (NNP Doc_20080983_1716_1725_Chemical)) (VP (VP (VBZ promotes) (NP (JJ nocturnal) (NN sleep))) (, ,) (VP (VBZ normalizes) (NP (NN sleep) (NN architecture))) (, ,) (CC and) (VP (VBZ decreases) (NP (NP (NN Doc_20080983_1797_1815_Disease)) (PP (IN in) (NP (JJ abstinent) (JJ Doc_20080983_1829_1836_Chemical) (NNS users)))))) (. .)))
20080983	12	(S1 (S (NP (DT These) (NNS effects)) (VP (MD may) (VP (AUX be) (ADJP (JJ relevant)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ Doc_20080983_1894_1901_Chemical) (NN dependence))))))) (. .)))
20084309	0	(S1 (NP (NP (NP (NN Safety)) (PP (IN of) (NP (JJ transesophageal) (NN echocardiography))) (PP (IN in) (NP (NNS adults)))) (: :) (NP (NP (NN study)) (PP (IN in) (NP (DT a) (JJ multidisciplinary) (NN hospital)))) (. .)))
20084309	1	(S1 (S (NP (NN TEE)) (VP (AUX is) (NP (NP (NP (DT a) (JJ semi-invasive) (NN tool)) (VP (ADVP (RB broadly)) (VBN used))) (CC and) (NP (NP (PRP$ its) (NN utilization)) (VP (VBN associated) (S (VP (TO to) (VP (VB sedatives) (SBAR (S (NP (NNS drugs)) (VP (MD might) (S (VP (TO to) (VP (VB affect) (NP (DT the) (NN procedure) (NN safety))))))))))))))) (. .)))
20084309	2	(S1 (FRAG (S (VP (TO to) (VP (VB analyze) (NP (NP (NNS aspects)) (PP (IN of) (NP (NP (NN TEE) (NN safety)) (VP (VBN associated) (PP (TO to) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NP (NNP Doc_20084309_303_312_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20084309_314_316_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_20084309_322_332_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20084309_334_336_Chemical)) (-RRB- -RRB-)))))) (CC and) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (DT the) (JJ clinical) (NNS variables)) (PP (IN on) (NP (DT the) (NN event) (NN rate))))))))))))))) (. .)))
20084309	3	(S1 (NP (NP (JJ prospective) (NN study)) (PP (IN with) (NP (NP (CD 137) (NNS patients)) (SBAR (WHNP (WDT that)) (S (VP (VBD underwent) (NP (NN TEE)) (PP (IN with) (NP (NP (NNP Doc_20084309_469_471_Chemical)) (VP (VBN associated) (PP (TO to) (NP (JJ moderate) (NN sedation))))))))))) (. .)))
20084309	4	(S1 (S (S (NP (PRP We)) (VP (VBD analyzed) (NP (DT the) (JJ following) (NNS events)))) (: :) (S (NP (NNS complications)) (VP (VBD related) (PP (PP (IN with) (NP (DT the) (JJ topical) (NN anesthesia))) (, ,) (PP (IN with) (NP (JJ Doc_20084309_595_597_Chemical) (NN use))) (CC and) (PP (IN with) (NP (DT the) (NN procedure)))))) (. .)))
20084309	5	(S1 (S (S (NP (JJ Uni-) (CC and) (JJ multivariate) (NNS analyses)) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB test) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (DT the) (JJ clinical) (NNS variables)))))))))) (: :) (S (NP (NP (NN age) (, ,) (NN sex) (, ,) (NNP Doc_20084309_726_732_Disease) (, ,) (NNP Doc_20084309_734_748_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20084309_750_752_Disease)) (-RRB- -RRB-)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (DT the) (NN test)))) (, ,)) (NP (NP (NP (NNP Doc_20084309_777_797_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20084309_799_801_Disease)) (-RRB- -RRB-))) (CC and) (NP (DT the) (NNP Doc_20084309_811_813_Chemical) (NN dose)))) (. .)))
20084309	6	(S1 (S (NP (NP (DT All) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 65+/-16) (NNS yrs)) (: ;) (NP (ADJP (CD 58) (NN %)) (NNS males))) (-RRB- -RRB-))) (VP (VBD finished) (NP (DT the) (NN examination))) (. .)))
20084309	7	(S1 (S (NP (NP (DT The) (JJ mean) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_20084309_911_913_Chemical)) (CC and) (NP (NNP Doc_20084309_918_920_Chemical))))) (VP (AUX were) (NP (NP (CD 4.3+/-1.9) (NN mg)) (CC and) (NP (CD 0.28+/-0.2) (NN mg))) (, ,) (ADVP (RB respectively))) (. .)))
20084309	8	(S1 (S (NP (NP (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (DT the) (NN examination)))) (CC and) (NP (DT the) (JJ mean) (NN ejection) (NN fraction))) (PRN (-LRB- -LRB-) (NP (NNP EF)) (-RRB- -RRB-))) (VP (AUX were) (NP (NP (CD 16.4+/-6.1) (NNS minutes)) (CC and) (NP (CD 60+/-9) (NN %))) (, ,) (ADVP (RB respectively))) (. .)))
20084309	9	(S1 (S (S (NP (NP (JJ Mild) (NNP Doc_20084309_1096_1103_Disease)) (PRN (-LRB- -LRB-) (NP (CD SO2<90) (NN %)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN event)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS patients)) (-RRB- -RRB-))))) (: ;) (S (NP (NP (CD 3) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 2) (NN %)) (-RRB- -RRB-))) (VP (VBD presented) (NP (NP (JJ transient) (NNP Doc_20084309_1191_1198_Disease) (ADJP (JJ due) (PP (TO to) (NP (JJ upper) (NNP Doc_20084309_1212_1230_Disease))) (PP (IN by) (NP (NP (NN probe) (NN introduction)) (CC and) (NP (NP (CD 8)) (PRN (-LRB- -LRB-) (NP (CD 5.8) (NN %)) (-RRB- -RRB-)))))) (JJ due)) (PP (TO to) (NP (NNP Doc_20084309_1273_1280_Disease))) (VP (VBD caused) (PP (IN by) (NP (NNP Doc_20084309_1291_1293_Chemical) (NN use))))))) (. .)))
20084309	10	(S1 (S (NP (NP (JJ Transient) (NNP Doc_20084309_1309_1320_Disease)) (PRN (-LRB- -LRB-) (NP (NNP SAP<90mmHg)) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 1) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 0.7) (NN %)) (-RRB- -RRB-))))) (. .)))
20084309	11	(S1 (S (NP (DT The) (JJ multivariate) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NP (JJ severe) (NNP Doc_20084309_1409_1411_Disease)) (, ,) (NP (NP (NNP Doc_20084309_1413_1415_Disease)) (PRN (-LRB- -LRB-) (NP (CD EF<45) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_20084309_1443_1445_Chemical))))) (PRN (-LRB- -LRB-) (NP (NNP >5mg)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NNS events)) (PRN (-LRB- -LRB-) (NP (CD p<0.001)) (-RRB- -RRB-))))))))) (. .)))
20084309	12	(S1 (S (S (NP (DT The) (NN EF)) (VP (AUX was) (NP (CD 40) (NN %)) (, ,) (PP (IN in) (NP (NP (NP (DT the) (NN group)) (PP (IN with) (NP (NNP Doc_20084309_1526_1528_Disease)))) (CC and) (NP (NP (CD 44) (NN %)) (PP (IN in) (NP (NP (DT the) (NN group)) (PP (IN with) (NP (JJ severe) (NN Doc_20084309_1562_1564_Disease)))))))))) (CC and) (S (NP (PRP it)) (VP (MD can) (VP (AUX be) (NP (NP (DT a) (NN factor)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ clinical) (NNS events)) (PP (IN in) (NP (DT the) (JJ last) (NN group)))))))))) (. .)))
20084309	13	(S1 (S (NP (NP (NN TEE)) (PP (IN with) (NP (NN sedation)))) (VP (VBZ presents) (NP (NP (DT a) (JJ low) (NN rate)) (PP (IN of) (NP (NNS events))))) (. .)))
20084309	14	(S1 (S (S (NP (EX There)) (VP (AUX were) (NP (DT no) (JJ severe) (NNS events)))) (CC and) (S (NP (EX there)) (VP (AUX was) (NP (DT no) (NN need) (S (VP (TO to) (VP (VB interrupt) (NP (DT the) (NNS examinations)))))))) (. .)))
2008831	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NP (JJ direct) (NN intracoronary) (NN administration)) (PP (IN of) (NP (NNP Doc_2008831_49_65_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (CC and) (IN without) (NP (NNP Doc_2008831_95_109_Disease))))))) (. .)))
2008831	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN intracoronary) (NN administration)) (PP (IN of) (NP (NNP Doc_2008831_158_174_Chemical)))))) (VP (AUX were) (VP (VBN studied) (PP (PP (IN in) (NP (NP (NP (CD 21) (NNS patients)) (PP (IN with) (NP (NNP Doc_2008831_208_222_Disease)))) (CC and) (NP (NP (CD 22) (NNS patients)) (PP (IN with) (NP (JJ atypical) (NNP Doc_2008831_253_263_Disease)))))) (CC and) (PP (IN in) (NP (NP (NNS others)) (PP (IN without) (NP (NP (NNP Doc_2008831_286_301_Disease)) (PRN (-LRB- -LRB-) (NP (NN control) (NN group)) (-RRB- -RRB-))))))))) (. .)))
2008831	2	(S1 (S (NP (NN Doc_2008831_319_335_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB continuously)) (PP (IN at) (NP (NP (DT a) (NN rate)) (PP (IN of) (NP (QP (NP (CD 10) (NN micrograms/min)) (IN up) (TO to) (CD 50)) (NNS micrograms))))))) (. .)))
2008831	3	(S1 (S (PP (IN In) (NP (NP (DT all) (NNS patients)) (PP (IN with) (NP (NNP Doc_2008831_439_453_Disease))))) (, ,) (NP (NNP Doc_2008831_455_469_Disease)) (VP (AUX was) (VP (VBN provoked) (PP (IN at) (NP (NP (DT a) (JJ mean) (NN dose)) (PP (IN of) (NP (NP (CD 28) (JJ +/-) (CD 13) (NNS micrograms)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NNS SD)) (-RRB- -RRB-)))))))) (. .)))
2008831	4	(S1 (S (PP (IN In) (NP (DT the) (NN control) (NN group))) (NP (NP (DT neither) (JJ ischemic) (NNP ST) (NN change)) (CC nor) (NP (VBN localized) (NN Doc_2008831_599_604_Disease))) (VP (VBD occurred)) (. .)))
2008831	5	(S1 (S (NP (NP (DT The) (JJ basal) (NN tone)) (PP (IN of) (NP (DT the) (JJ right) (JJ coronary) (NN artery)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ left) (JJ coronary) (NN artery))))))) (. .)))
2008831	6	(S1 (S (NP (NP (DT The) (NN percentage)) (PP (IN of) (NP (NP (NN vasoconstriction)) (PP (IN of) (NP (DT the) (JJ right) (JJ coronary) (NN artery)))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ left) (JJ coronary) (NN artery))))))) (. .)))
2008831	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (JJ Doc_2008831_877_882_Disease) (NN provocation) (NNS tests)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP use) (NP (NP (DT an) (JJ intracoronary) (NN injection)) (PP (IN of) (NP (NP (DT a) (ADJP (RB relatively) (JJ low)) (NN dose)) (PP (IN of) (NP (NNP Doc_2008831_967_983_Chemical))))))))) (, ,)) (VP (AUX have) (NP (NP (DT a) (JJ high) (NN sensitivity)) (PP (IN in) (NP (NNP Doc_2008831_1012_1026_Disease)))))) (CC and) (S (NP (NP (DT the) (NN vasoreactivity)) (PP (IN of) (NP (DT the) (JJ right) (JJ coronary) (NN artery)))) (VP (MD may) (VP (AUX be) (ADJP (JJR greater) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ other) (JJ coronary) (NNS arteries)))))))))))) (. .)))
20098969	0	(S1 (NP (NP (NP (JJ Oral) (NNS manifestations)) (PP (IN of) (NP (`` ``) (NNP Doc_20098969_24_34_Disease) ('' '')))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
20098969	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (NP (DT the) (NN documentation)) (PP (IN of) (NP (DT this) (JJ clinical) (NN case)))))) (VP (AUX is) (S (VP (TO to) (VP (VB make) (NP (NP (NP (NNS clinicians)) (ADJP (JJ aware) (PP (IN of) (`` ``) (NP (NNP Doc_20098969_140_150_Disease)) ('' '')))) (CC and) (NP (NP (DT the) (JJ medical) (NNS risks)) (VP (VBN associated) (PP (IN with) (NP (DT this) (JJ serious) (NN condition)))))))))) (. .)))
20098969	2	(S1 (S (NP (NN Doc_20098969_226_241_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB very) (JJ addictive)) (, ,) (JJ powerful) (NN stimulant)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ increases) (NP (ADJP (JJ wakefulness) (CC and) (JJ physical)) (NN activity))) (CC and) (VP (MD can) (VP (VB produce) (NP (NP (JJ other) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_20098969_369_389_Disease)) (, ,) (NP (NNP Doc_20098969_391_403_Disease)) (, ,) (NP (NNP Doc_20098969_405_419_Disease)) (, ,) (CC and) (NP (NNP Doc_20098969_425_441_Disease)))))))))))) (. .)))
20098969	3	(S1 (S (NP (NP (JJ Dental) (NNS patients)) (VP (VBG abusing) (NP (NNP Doc_20098969_467_482_Chemical)))) (VP (MD can) (VP (VB present) (PP (IN with) (NP (NP (NP (JJ poor) (JJ oral) (NN hygiene)) (, ,) (NP (NP (NNP Doc_20098969_519_529_Disease)) (, ,) (NP (NP (JJ rampant) (NNP Doc_20098969_539_545_Disease)) (PRN (-LRB- -LRB-) (`` ``) (NP (NNP Doc_20098969_548_558_Disease)) ('' '') (-RRB- -RRB-)))) (, ,)) (CC and) (NP (JJ excessive) (NN Doc_20098969_576_586_Disease)))))) (. .)))
20098969	4	(S1 (S (NP (NP (JJ Oral) (NN rehabilitation)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG using) (NP (NNP Doc_20098969_626_641_Chemical)))))) (VP (MD can) (VP (AUX be) (ADJP (JJ challenging)))) (. .)))
20098969	5	(S1 (NP (NP (NN CASE) (NN DESCRIPTION)) (: :) (NP (NP (DT A) (JJ 30-year-old) (NNP Caucasian) (NN woman)) (VP (VBN presented) (PP (IN with) (NP (NP (JJ dental) (NNP Doc_20098969_732_736_Disease)) (, ,) (NP (NNP Doc_20098969_738_748_Disease)) (, ,) (CC and) (NP (JJ self-reported) (JJ poor) (NNS esthetics)))))) (. .)))
20098969	6	(S1 (S (NP (NP (DT A) (JJ comprehensive) (NN examination)) (PP (VBG including) (NP (NP (PRP$ her) (JJ medical) (NN history)) (, ,) (NP (JJ panoramic) (NN radiograph)) (, ,) (CC and) (NP (JJ intraoral) (NN examination))))) (VP (VBD revealed) (NP (NP (CD 19) (NNP Doc_20098969_903_918_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (RB not) (ADJP (RB very) (JJ common)) (PP (IN for) (NP (DT a) (JJ healthy) (NN adult)))))))) (. .)))
20098969	7	(S1 (S (NP (PRP She)) (VP (VP (VBD reported) (NP (NP (PRP$ her) (NN use)) (PP (IN of) (NP (NNP Doc_20098969_990_1005_Chemical)))) (PP (IN for) (NP (CD five) (NNS years)))) (CC and) (VP (AUX had) (RB not) (VP (VBN experienced) (NP (DT any) (JJ major) (NN Doc_20098969_1055_1071_Disease)) (SBAR (IN before) (S (NP (PRP she)) (VP (VBD started) (S (VP (VBG using) (NP (DT the) (NN drug)))))))))) (. .)))
20098969	8	(S1 (S (NP (NP (NP (DT The) (NN patient) (POS 's)) (JJ medical) (CC and) (JJ dental) (NNS histories)) (PP (IN along) (PP (IN with) (NP (JJ radiographic) (CC and) (JJ clinical) (NNS findings))))) (VP (VBP lead) (PP (TO to) (NP (NP (DT a) (NN diagnosis)) (PP (IN of) (`` ``) (NP (NNP Doc_20098969_1229_1239_Disease)))))) (. .) ('' '')))
20098969	9	(S1 (S (SBAR (IN Although) (S (NP (NP (CD three) (JJ different) (JJ dental) (NN treatment) (NNS modalities)) (PRN (-LRB- -LRB-) (ADVP (RB either)) (ADJP (ADJP (JJ conventional)) (CC or) (ADJP (JJ implant-supported))) (-RRB- -RRB-))) (VP (AUX have) (VP (AUX been) (VP (VBN offered) (PP (TO to) (NP (DT the) (NN patient))) (PP (IN since) (NP (NNP August) (CD 2007)))))))) (, ,) (NP (DT the) (NN patient)) (VP (AUX has) (ADVP (RB yet)) (S (VP (TO to) (VP (VB initiate) (NP (DT any) (NN treatment)))))) (. .)))
20098969	10	(S1 (NP (NP (JJ CLINICAL) (NN SIGNIFICANCE)) (: :) (S (NP (NP (DT This) (JJ clinical) (NN case)) (VP (VBG showing) (NP (NP (JJ oral) (NNS manifestations)) (PP (IN of) (NP (NNP Doc_20098969_1510_1520_Disease)))))) (VP (AUX was) (VP (VBN presented) (S (VP (TO to) (VP (VB help) (S (NP (JJ dental) (NNS practitioners)) (VP (VB recognize) (CC and) (VB manage) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (MD may) (VP (AUX be) (VP (VBG abusing) (NP (NN Doc_20098969_1613_1629_Chemical)))))))))))))))) (. .)))
20098969	11	(S1 (S (NP (JJ Dental) (NNS practitioners)) (ADVP (RB also)) (VP (MD may) (VP (AUX be) (ADJP (JJ skeptical) (PP (IN about) (NP (NP (DT the) (NN reliability)) (PP (IN of) (NP (NP (NN appointment)) (VP (VBG keeping) (PP (IN by) (NP (DT these) (NNS patients))))))))) (, ,) (SBAR (IN as) (S (NP (PRP they)) (ADVP (RB frequently)) (VP (VBP miss) (NP (PRP$ their) (NNS appointments)) (PP (IN without) (NP (JJ reasonable) (NN justification)))))))) (. .)))
20196116	0	(S1 (NP (NP (JJ Doc_20196116_0_16_Chemical) (JJ therapy-induced) (NN Doc_20196116_33_52_Disease)) (: :) (NP (NP (NN magnitude)) (, ,) (NP (NN profile)) (, ,) (NP (NN prognosis)) (, ,) (CC and) (NP (NP (NNS predictors)) (PP (IN of) (NP (NN outcome))))) (. .)))
20196116	1	(S1 (S (NP (NP (JJ Doc_20196116_112_128_Chemical) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP ATT)) (-RRB- -RRB-))) (VP (VBD -associated) (SBAR (S (NP (NP (NNP Doc_20196116_154_173_Disease)) (PRN (-LRB- -LRB-) (NP (NN ATT-Doc_20196116_179_182_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT the) (JJ commonest) (JJ drug-induced) (NN Doc_20196116_214_217_Disease)) (PP (IN in) (NP (NNP South) (NNP Asia)))))))) (. .)))
20196116	2	(S1 (S (NP (NP (JJ Prospective) (NNS studies)) (PP (IN on) (NP (NN ATT-Doc_20196116_260_263_Disease)))) (VP (AUX are) (VP (VBG lacking))) (. .)))
20196116	3	(S1 (S (NP (DT The) (JJ current) (NN study)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (NN magnitude)) (, ,) (NP (JJ clinical) (NN course)) (, ,) (NP (NN outcome)) (, ,) (CC and) (NP (JJ prognostic) (NNS factors))) (PP (IN in) (NP (NN ATT-Doc_20196116_390_393_Disease)))) (. .)))
20196116	4	(S1 (S (S (PP (PP (IN From) (NP (NNP January) (CD 1986))) (PP (TO to) (NP (NNP January) (CD 2009)))) (, ,) (NP (CD 1223) (JJ consecutive) (NNP Doc_20196116_447_450_Disease) (NNS patients)) (VP (AUX were) (VP (VBN evaluated)))) (: :) (S (NP (NP (NNP ATT)) (ADVP (RB alone))) (VP (AUX was) (NP (NP (DT the) (NN cause)) (PP (IN in) (NP (CD 70) (PRN (-LRB- -LRB-) (NP (CD 5.7) (NN %)) (-RRB- -RRB-)) (NNS patients)))))) (. .)))
20196116	5	(S1 (S (NP (NP (DT Another) (CD 15)) (PRN (-LRB- -LRB-) (NP (CD 1.2) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (NN ATT)) (CC and) (NP (JJ simultaneous) (NN Doc_20196116_566_591_Disease)))) (. .)))
20196116	6	(S1 (S (PP (IN In) (NP (CD 44) (PRN (-LRB- -LRB-) (NP (CD 62.8) (NN %)) (-RRB- -RRB-)) (NNS patients))) (, ,) (NP (NNP ATT)) (VP (AUX was) (VP (VBN prescribed) (ADVP (RB empirically)) (PP (IN without) (NP (NP (JJ definitive) (NN evidence)) (PP (IN of) (NP (NNP Doc_20196116_679_691_Disease))))))) (. .)))
20196116	7	(S1 (S (S (NP (JJ ATT-Doc_20196116_697_700_Disease) (NNS patients)) (VP (AUX were) (ADJP (ADJP (JJR younger)) (PRN (-LRB- -LRB-) (NP (QP (CD 32.87) (CD -LSB-+/-15.8)) (JJ -RSB-) (NNS years)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NP (NP (CD 49)) (PRN (-LRB- -LRB-) (NP (CD 70) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (PRP them)))) (VP (AUX were) (NP (NNS women)))) (. .)))
20196116	8	(S1 (S (S (NP (JJS Most)) (VP (AUX had) (NP (JJ hyperacute) (NN presentation)))) (: ;) (S (NP (DT the) (JJ median) (NNP Doc_20196116_826_833_Disease) (NNP Doc_20196116_834_848_Disease) (NN interval)) (VP (AUX was) (NP (CD 4.5) (-LRB- -LRB-) (NN 0-30) (-RRB- -RRB-) (NNS days)))) (. .)))
20196116	9	(S1 (S (NP (NP (DT The) (JJ median) (NN duration)) (PP (IN of) (NP (NNP ATT))) (PP (IN before) (NP (NNP Doc_20196116_913_916_Disease)))) (VP (AUX was) (NP (CD 30) (-LRB- -LRB-) (CD 7-350) (-RRB- -RRB-) (NNS days))) (. .)))
20196116	10	(S1 (S (PP (IN At) (NP (NN presentation))) (, ,) (NP (JJ advanced) (NNP Doc_20196116_964_978_Disease) (CC and) (NNP Doc_20196116_983_997_Disease)) (VP (AUX were) (ADJP (JJ present)) (PP (IN in) (NP (NP (NP (NP (CD 51)) (PRN (-LRB- -LRB-) (NP (CD 76) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 29)) (PRN (-LRB- -LRB-) (NP (CD 41.4) (NN %)) (-RRB- -RRB-)))) (NNS patients))) (, ,) (ADVP (RB respectively))) (. .)))
20196116	11	(S1 (NP (NNP Doc_20196116_1062_1084_Disease) (, ,) (NNP Doc_20196116_1086_1094_Disease) (, ,) (NNP Doc_20196116_1096_1105_Disease) (, ,) (S (CC and) (NP (NNP Doc_20196116_1111_1130_Disease)) (VP (AUX were) (VP (VBN documented) (PP (IN in) (NP (NP (NP (CD seven)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (CD five)) (PRN (-LRB- -LRB-) (NP (CD 7.1) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 26)) (PRN (-LRB- -LRB-) (NP (CD 37.1) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD seven) (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-) (NNS patients)) (, ,) (ADVP (RB respectively)))))) (. .))))
20196116	12	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NP (NP (JJ Doc_20196116_1242_1253_Disease) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP HEV)) (-RRB- -RRB-))) (CC and) (NP (JJ non-A) (JJ non-E-induced) (NN Doc_20196116_1290_1293_Disease))))) (, ,) (NP (JJ ATT-Doc_20196116_1299_1302_Disease) (NNS patients)) (VP (AUX had) (NP (ADJP (RB nearly) (JJ similar)) (NNS presentations)) (PP (IN except) (PP (IN for) (NP (NP (NP (JJR older) (NN age)) (CC and) (NP (JJR less) (NN elevation))) (PP (IN of) (NP (NN liver) (NNS enzymes))))))) (. .)))
20196116	13	(S1 (S (S (NP (NP (DT The) (NN mortality) (NN rate)) (PP (IN among) (NP (NNS patients))) (PP (IN with) (NP (NN ATT-Doc_20196116_1446_1449_Disease)))) (VP (AUX was) (ADJP (JJ high)) (PRN (-LRB- -LRB-) (NP (NP (CD 67.1) (NN %)) (, ,) (NP (NNP n) (SYM =) (CD 47))) (-RRB- -RRB-)))) (, ,) (CC and) (S (NP (QP (RB only) (CD 23)) (PRN (-LRB- -LRB-) (NP (CD 32.9) (NN %)) (-RRB- -RRB-)) (NNS patients)) (VP (VBD recovered) (PP (IN with) (NP (JJ medical) (NN treatment))))) (. .)))
20196116	14	(S1 (S (PP (IN In) (NP (NN multivariate) (NN analysis))) (, ,) (NP (CD three) (NNS factors)) (ADVP (RB independently)) (VP (VBD predicted) (NP (NP (NN mortality)) (: :) (NP (NP (NP (JJ serum) (NNP Doc_20196116_1620_1629_Chemical)) (PRN (-LRB- -LRB-) (NP (CD >or=10.8) (NN mg/dL)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ prothrombin) (NN time) (PRN (-LRB- -LRB-) (NNP PT) (-RRB- -RRB-)) (NN prolongation)) (PRN (-LRB- -LRB-) (NP (CD >or=26) (NNS seconds)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN grade) (NNP III/IV) (NNP Doc_20196116_1718_1732_Disease)))) (PP (IN at) (NP (NN presentation)))) (. .)))
20196116	15	(S1 (S (NP (NN ATT-Doc_20196116_1766_1769_Disease)) (VP (VP (VBD constituted) (NP (NP (CD 5.7) (NN %)) (PP (IN of) (NP (NNP Doc_20196116_1790_1793_Disease)))) (PP (IN at) (NP (PRP$ our) (NN center)))) (CC and) (VP (AUX had) (NP (DT a) (JJ high) (NN mortality) (NN rate)))) (. .)))
20196116	16	(S1 (S (SBAR (IN Because) (S (NP (DT the) (NN mortality) (NN rate)) (VP (AUX is) (ADJP (RB so) (JJ high))))) (, ,) (NP (NP (VBG determining)) (SBAR (WHNP (WDT which) (NNS factors)) (S (VP (AUX are) (NP (NNS predictors)))))) (VP (AUX is) (ADJP (RBR less) (JJ important))) (. .)))
20196116	17	(S1 (S (NP (NP (DT A) (JJ high) (NN proportion)) (PP (IN of) (NP (NNS patients)))) (VP (AUX had) (VP (VBN consumed) (NP (NN ATT)) (ADVP (RB empirically)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX have) (VP (AUX been) (VP (VBN prevented))))))))) (. .)))
2024540	0	(S1 (NP (NP (NP (NP (NN Design)) (CC and) (NP (NN analysis))) (PP (IN of) (NP (DT the) (NN HYPREN-trial)))) (: :) (NP (NP (NN safety)) (PP (IN of) (NP (NNP Doc_2024540_51_60_Chemical) (CC and) (NNP Doc_2024540_65_73_Chemical))) (PP (IN in) (NP (NP (DT the) (JJ initial) (NN treatment) (NN phase)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2024540_122_146_Disease)))))))) (. .)))
2024540	1	(S1 (S (PP (IN Since) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (NNP Doc_2024540_174_220_Chemical))) (PP (IN into) (NP (NP (DT the) (JJ adjunctive) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2024540_268_292_Disease))))))))) (, ,) (NP (NP (NNS cases)) (PP (IN of) (NP (JJ severe) (NNP Doc_2024540_310_321_Disease))) (, ,) (PP (ADVP (RB especially)) (IN on) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (NN treatment))))) (, ,)) (VP (AUX have) (ADVP (RB occasionally)) (VP (AUX been) (VP (VBN reported)))) (. .)))
2024540	2	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (DT the) (NNP Doc_2024540_426_439_Chemical) (NNP Doc_2024540_440_449_Chemical)))) (NP (DT a) (NN multicenter) (, ,) (VBN randomized) (, ,) (JJ Doc_2024540_477_485_Chemical-controlled) (NN trial))))) (VP (AUX was) (VP (VBN designed) (S (NP (DT that)) (VP (VBN compared) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (JJ symptomatic) (NNP Doc_2024540_572_583_Disease)))) (PP (IN on) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (NN treatment))))))))) (. .)))
2024540	3	(S1 (S (NP (NN Trial) (NN medication)) (VP (AUX was) (NP (QP (CD 2.5) (CD mg) (NN Doc_2024540_643_652_Chemical) (CC or) (CD 0.5)) (NN Doc_2024540_660_668_Chemical))) (. .)))
2024540	4	(S1 (S (NP (NNS Subjects)) (VP (AUX were) (NP (NP (JJ 1210) (NNS inpatients)) (PP (IN with) (NP (NP (NNP New) (NNP York) (NNP Heart) (NNP Association)) (PRN (-LRB- -LRB-) (NP (NNP NYHA)) (-RRB- -RRB-)) (NP (JJ functional) (NN class) (NNP II)) (CC and) (NP (NNP III)))))) (. .)))
2024540	5	(S1 (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (SBAR (S (NP (NNP Doc_2024540_790_799_Chemical)) (VP (VBD experienced) (ADVP (RB clinically) (CC and) (RB statistically) (ADVP (RB significantly) (RBR less))) (NP (JJ symptomatic) (NNP Doc_2024540_872_883_Disease)) (PRN (-LRB- -LRB-) (NP (CD 5.2) (NN %)) (-RRB- -RRB-)) (PP (IN than) (NP (NP (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_2024540_922_930_Chemical))))))) (PRN (-LRB- -LRB-) (NP (CD 12.9) (NN %)) (-RRB- -RRB-)))))))) (. .)))
2024540	6	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD recovered)) (. .)))
2024540	7	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_2024540_1001_1010_Chemical)))) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated)))) (CC and) (S (NP (PRP it)) (VP (AUX is) (, ,) (ADVP (RB therefore)) (, ,) (ADJP (JJ unreasonable) (S (VP (TO to) (VP (VB restrict) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_2024540_1110_1119_Chemical)))) (PP (TO to) (NP (NNS inpatients))))))))))))) (. .)))
20470218	0	(S1 (S (VP (VB Doc_20470218_0_36_Disease) (PP (IN during) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_20470218_57_85_Disease))))) (PP (IN in) (NP (DT a) (JJ single) (JJ pediatric) (NN institution)))) (. .)))
20470218	1	(S1 (S (NP (NP (NN Doc_20470218_121_163_Disease)) (PP (IN during) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NN childhood) (NNP Doc_20470218_194_222_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20470218_224_227_Disease)) (-RRB- -RRB-))))))) (VP (VBP remain) (NP (DT a) (JJ challenging) (JJ clinical) (NN problem))) (. .)))
20470218	2	(S1 (S (NP (NP (NN Outcome) (NN improvement)) (PP (IN with) (NP (ADJP (RBR more) (JJ intensive)) (NN chemotherapy)))) (VP (AUX has) (ADVP (RB significantly)) (VP (VBN increased) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (JJ adverse) (NNS events)))))) (. .)))
20470218	3	(S1 (S (NP (DT This) (NN study)) (VP (VBD analyzed) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_20470218_432_458_Disease)))) (PP (IN during) (NP (NP (JJ Doc_20470218_466_469_Disease) (NN treatment)) (PP (IN in) (NP (DT a) (JJ single) (JJ pediatric) (NN institution))))) (, ,) (S (VP (VBG focusing) (PP (IN on) (NP (JJ clinical) (, ,) (ADJP (ADJP (JJ radiological)) (, ,) (CC and) (ADJP (JJ electrophysiological))) (NNS findings)))))) (. .)))
20470218	4	(S1 (S (NP (NN Exclusion) (NNS criteria)) (VP (VBD included) (NP (NNP CNS) (NNP Doc_20470218_618_639_Disease)) (PP (IN at) (NP (NP (NN diagnosis)) (, ,) (NP (JJ therapy-related) (NN Doc_20470218_670_691_Disease)) (, ,) (NP (JJ late-onset) (NN Doc_20470218_704_718_Disease)) (, ,) (CC or) (NP (JJ long-term) (NN Doc_20470218_733_755_Disease))))) (. .)))
20470218	5	(S1 (S (PP (IN During) (NP (DT a) (JJ 9-year) (NN period))) (, ,) (NP (PRP we)) (ADVP (RB retrospectively)) (VP (VBD collected) (NP (NP (CD 27) (JJ neurological) (NNS events)) (PRN (-LRB- -LRB-) (NP (CD 11) (NN %)) (-RRB- -RRB-))) (PP (IN in) (NP (ADJP (RB as) (JJ many)) (NNS patients))) (, ,) (PP (IN from) (NP (NP (CD 253) (NNS children)) (VP (VBD enrolled) (PP (IN in) (NP (DT the) (JJ Doc_20470218_894_897_Disease) (JJ front-line) (NN protocol))))))) (. .)))
20470218	6	(S1 (S (NP (NNS CNS) (NNS complications)) (VP (VBD included) (NP (NP (JJ posterior) (JJ reversible) (NN Doc_20470218_967_986_Disease) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_20470218_1006_1012_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 5)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_20470218_1022_1044_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-)) (, ,) (NP (JJ high-dose) (NNP Doc_20470218_1064_1076_Chemical) (NNP Doc_20470218_1077_1085_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-)) (, ,) (NP (NP (NN syndrome)) (PP (IN of) (NP (NNP Doc_20470218_1107_1151_Disease)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 1)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (JJ other) (JJ unclassified) (NNS events)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-))))) (. .)))
20470218	7	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NNS CNS) (NNS complications)) (VP (VP (AUX are) (NP (JJ frequent) (NNS events)) (PP (IN during) (NP (JJ Doc_20470218_1260_1263_Disease) (NN therapy)))) (, ,) (CC and) (VP (VBP require) (NP (NP (JJ rapid) (NN detection)) (CC and) (NP (JJ prompt) (NN treatment))) (S (VP (TO to) (VP (VB limit) (NP (JJ permanent) (NN damage))))))) (. .)))
20477932	0	(S1 (NP (NP (NP (JJ Doc_20477932_0_7_Chemical) (NNS causes)) (ADJP (JJ Doc_20477932_15_46_Disease) (PP (IN in) (NP (NNS rats))))) (: :) (NP (NP (NP (NN involvement)) (PP (IN of) (NP (JJ nuclear) (UCP (NN factor) (NN kappa) (NNP B) (CC and) (JJ oxidative)) (NN stress)))) (, ,) (CC and) (NP (NP (NN prevention)) (PP (IN by) (NP (NNP Doc_20477932_134_144_Chemical))))) (. .)))
20477932	1	(S1 (S (S (NP (JJ Different) (NNS mechanisms)) (VP (AUX have) (VP (AUX been) (VP (VBN suggested) (PP (IN for) (NP (NNP Doc_20477932_191_198_Chemical) (NNP Doc_20477932_199_207_Disease))) (PP (VBG including) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ oxidative) (NN stress))))))))) (CC but) (S (NP (NP (DT the) (NN association)) (PP (IN between) (NP (JJ oxidative) (NN status))) (PP (IN in) (NP (NP (DT the) (NN brain)) (CC and) (NP (JJ Doc_20477932_312_319_Chemical) (NN induced-behaviour))))) (VP (AUX is) (ADVP (RB poorly)) (VP (VBN understood)))) (. .)))
20477932	2	(S1 (S (NP (NP (JJ Nuclear) (NN factor) (NN kappa) (NNP B)) (PRN (-LRB- -LRB-) (NP (NNP NFkappaB)) (-RRB- -RRB-))) (VP (VP (AUX is) (NP (NP (DT a) (NN sensor)) (PP (IN of) (NP (JJ oxidative) (NN stress))))) (CC and) (VP (VBZ participates) (PP (IN in) (NP (NP (NN memory) (NN formation)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (NN drug) (NN Doc_20477932_494_502_Disease)) (CC and) (NP (NN addiction) (NNS mechanisms))))))))))))) (. .)))
20477932	3	(S1 (S (ADVP (RB Therefore)) (NP (NP (NP (JJ NFkappaB) (NN activity)) (, ,) (NP (JJ oxidative) (NN stress)) (, ,) (NP (JJ neuronal) (JJ Doc_20477932_585_597_Chemical) (FW synthase) (PRN (-LRB- -LRB-) (NP (NN nNOS)) (-RRB- -RRB-)) (NN activity)) (, ,) (NP (JJ spatial) (NN learning)) (CC and) (NP (NN memory))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_20477932_677_687_Chemical)) (, ,) (NP (NP (DT a) (ADJP (RB previously) (VBN proposed)) (NN therapy)) (PP (IN for) (NP (NNP Doc_20477932_723_740_Disease)))) (, ,))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (NP (DT an) (JJ experimental) (NN model)) (PP (IN of) (NP (NNP Doc_20477932_785_792_Chemical) (NN administration))) (PP (IN in) (NP (NNS rats))))))) (. .)))
20477932	4	(S1 (S (NP (NN NFkappaB) (NN activity)) (VP (AUX was) (VP (VBN decreased) (PP (IN in) (NP (NP (NP (DT the) (JJ frontal) (NN cortex)) (PP (IN of) (NP (JJ Doc_20477932_874_881_Chemical) (VBN treated) (NNS rats)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NP (JJ Doc_20477932_907_910_Chemical) (NN concentration)) (CC and) (NP (JJ Doc_20477932_929_940_Chemical) (NN peroxidase) (NN activity))) (PP (IN in) (NP (DT the) (NN hippocampus)))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN nNOS) (NN activity)) (PP (IN in) (NP (DT the) (NN hippocampus)))) (VP (AUX was) (VP (VBN increased))))))) (. .)))
20477932	5	(S1 (S (NP (NP (NN Memory) (NN retrieval)) (PP (IN of) (NP (NP (NNS experiences)) (VP (VBN acquired) (ADVP (RB prior) (PP (TO to) (NP (NNP Doc_20477932_1087_1094_Chemical) (NN administration)))))))) (VP (AUX was) (VP (VP (VBN impaired)) (CC and) (VP (ADVP (RB negatively)) (VBN correlated) (PP (IN with) (NP (NN NFkappaB) (NN activity))) (PP (IN in) (NP (DT the) (JJ frontal) (NN cortex)))))) (. .)))
20477932	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN learning)) (PP (IN of) (NP (JJ new) (NNS tasks)))) (VP (VP (AUX was) (VP (VBN enhanced))) (CC and) (VP (VBD correlated) (PP (IN with) (NP (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (NN nNOS) (NN activity)))) (CC and) (NP (NP (DT the) (NN decrease)) (PP (IN of) (NP (JJ Doc_20477932_1313_1324_Chemical) (NN peroxidase)))))))) (. .)))
20477932	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP provide) (NP (NN evidence)) (PP (IN for) (NP (NP (NP (DT a) (JJ possible) (JJ mechanistic) (NN role)) (PP (IN of) (NP (NN oxidative)))) (CC and) (NP (NP (NP (JJ nitrosative) (NN stress)) (CC and) (NP (NN NFkappaB))) (PP (IN in) (NP (NP (DT the) (NNS alterations)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_20477932_1479_1486_Chemical)))))))))) (. .)))
20477932	8	(S1 (S (NP (NN Doc_20477932_1488_1498_Chemical)) (VP (VBD prevented) (SBAR (S (NP (PDT all) (DT the) (NNS alterations)) (VP (VBD observed)))) (, ,) (S (VP (VBG showing) (NP (JJ novel) (JJ neuroprotective) (NNS properties))))) (. .)))
20520283	0	(S1 (NP (NP (NP (NN Efficacy)) (CC and) (NP (NN safety))) (PP (IN of) (NP (NNP Doc_20520283_23_32_Chemical))) (PP (IN in) (NP (NP (DT a) (ADJP (JJ placebo-) (CC and) (JJ Doc_20520283_51_62_Chemical-controlled)) (NN trial)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ acute) (NN exacerbation)) (PP (IN of) (NP (NNP Doc_20520283_119_132_Disease))))))))) (. .)))
20520283	1	(S1 (S (NP (NNP Doc_20520283_134_143_Chemical)) (VP (AUX is) (VP (VBN approved) (PP (IN by) (NP (DT the) (NNP Food) (CC and) (NNP Drugs) (NNP Administration))) (PP (IN in) (NP (NP (NNS adults)) (PP (PP (IN for) (NP (NP (JJ acute) (NN treatment)) (PP (IN of) (NP (NNP Doc_20520283_226_239_Disease))))) (CC or) (PP (IN of) (NP (NP (UCP (NNP Doc_20520283_246_251_Disease) (CC or) (JJ mixed)) (NNS episodes)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_20520283_286_304_Disease))) (PP (IN with))))) (CC or) (PP (IN without) (NP (JJ Doc_20520283_321_330_Disease) (NNS features)))))))) (. .)))
20520283	2	(S1 (S (PP (IN In) (NP (DT a) (JJ double-blind) (JJ 6-week) (NN trial))) (, ,) (NP (NP (CD 458) (NNS patients)) (PP (IN with) (NP (JJ acute) (NNP Doc_20520283_397_410_Disease)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (JJ fixed-dose) (NN treatment)) (PP (IN with) (NP (NP (NP (NNP Doc_20520283_463_472_Chemical)) (PP (IN at) (NP (CD 5) (CD mg) (RB twice) (JJ daily) (-LRB- -LRB-) (NN BID) (-RRB- -RRB-)))) (, ,) (NP (NP (NNP Doc_20520283_500_509_Chemical)) (PP (IN at) (NP (NP (QP (CD 10) (CD mg)) (NN BID)) (, ,) (NP (NN placebo)) (, ,)))) (CC or) (NP (NP (NNP Doc_20520283_536_547_Chemical)) (PP (IN at) (NP (NP (QP (CD 4) (CD mg)) (NN BID)) (PRN (-LRB- -LRB-) (S (VP (TO to) (VP (VB verify) (NP (JJ assay) (NN sensitivity))))) (-RRB- -RRB-))))))))))) (. .)))
20520283	3	(S1 (FRAG (PP (IN With) (NP (NP (JJ last) (NNS observations)) (VP (VBN carried) (ADVP (RB forward)) (PRN (-LRB- -LRB-) (NN LOCF) (-RRB- -RRB-) (, ,)) (VP (VB mean) (NP (ADJP (JJ Positive) (CC and) (JJ Negative)) (NN Syndrome) (NN Scale)) (NP (JJ total) (NN score) (NNS reductions)) (PP (IN from) (NP (NN baseline))) (S (VP (TO to) (VP (VB endpoint) (SBAR (S (VP (AUX were) (ADJP (ADJP (ADJP (RB significantly) (JJR greater) (PP (IN with) (NP (NP (NP (NNP Doc_20520283_761_770_Chemical)) (PP (IN at) (NP (QP (CD 5) (CD mg)) (NN BID))) (PRN (-LRB- -LRB-) (NP (CD -16.2)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_20520283_795_806_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD -15.4)) (-RRB- -RRB-))) (PP (IN than) (NP (NN placebo)))))))))))))) (PRN (-LRB- -LRB-) (NP (CD -10.7)) (: ;) (NP (DT both) (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-)) (: ;) (S (S (VP (VBG using) (NP (JJ mixed) (NN model)) (PP (IN for) (NP (NP (VBN repeated) (NNS measures)) (PRN (-LRB- -LRB-) (JJ MMRM) (-RRB- -RRB-)))))) (, ,) (NP (NP (NNS changes)) (PP (IN at) (NP (NN day) (CD 42)))) (VP (AUX were) (ADJP (ADJP (ADJP (RB significantly) (JJR greater) (PP (IN with) (NP (NP (NP (NNP Doc_20520283_950_959_Chemical)) (PP (IN at) (NP (NP (QP (CD 5) (CC and) (CD 10) (CD mg)) (NN BID)) (PRN (-LRB- -LRB-) (NP (CD -21.3) (CC and) (CD -19.4)) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))))) (CC and) (NP (NNP Doc_20520283_1015_1026_Chemical))))) (PRN (-LRB- -LRB-) (CD -20.0) (-RRB- -RRB-))) (PP (IN than) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD -14.6)) (: ;) (NP (DT all) (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-))))))) (. .)))
20520283	4	(S1 (S (S (PP (IN On) (NP (DT the) (ADJP (JJ Positive) (CC and) (JJ Negative)) (NN Syndrome) (NNP Scale) (JJ positive) (NN subscale))) (, ,) (NP (DT all) (NNS treatments)) (VP (AUX were) (ADJP (JJ superior) (PP (TO to) (NP (NP (NN placebo)) (PP (IN with) (NP (NNP LOCF) (CC and) (NNP MMRM)))))))) (: ;) (S (NP (NP (NNP Doc_20520283_1194_1203_Chemical)) (PP (IN at) (NP (CD 5) (JJ mg) (NN BID)))) (VP (AUX was) (ADJP (JJ superior) (PP (TO to) (NP (NN placebo)))) (PP (PP (IN on) (NP (NP (DT the) (JJ negative) (NN subscale)) (PP (IN with) (NP (NN MMRM))))) (CC and) (PP (IN on) (NP (NP (DT the) (JJ general) (NN psychopathology) (NN subscale)) (PP (IN with) (NP (NNP LOCF) (CC and) (NNP MMRM)))))))) (. .)))
20520283	5	(S1 (S (NP (NP (JJ Treatment-related) (JJ adverse) (NNS events)) (PRN (-LRB- -LRB-) (NP (NNP AEs)) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 44) (NN %)) (CC and) (NP (CD 52) (NN %)) (, ,) (NP (CD 57) (NN %)) (, ,) (CC and) (NP (NP (CD 41) (NN %)) (PP (IN of) (NP (NP (NP (DT the) (NNP Doc_20520283_1423_1432_Chemical)) (PP (IN at) (NP (QP (CD 5) (CC and) (CD 10) (CD mg)) (NN BID)))) (, ,) (NP (NNP Doc_20520283_1453_1464_Chemical)) (, ,) (CC and) (NP (NN placebo) (NNS groups))))) (, ,) (ADVP (RB respectively))))) (. .)))
20520283	6	(S1 (S (NP (NNP Doc_20520283_1500_1523_Disease)) (VP (VBD reported) (SBAR (IN as) (S (NP (NNS AEs)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 15) (NN %)) (CC and) (NP (CD 18) (NN %)) (, ,) (NP (CD 34) (NN %)) (, ,) (CC and) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (NP (NP (DT the) (NNP Doc_20520283_1585_1594_Chemical)) (PP (IN at) (NP (QP (CD 5) (CC and) (CD 10) (CD mg)) (NN BID)))) (, ,) (NP (NNP Doc_20520283_1615_1626_Chemical)) (, ,) (CC and) (NP (NN placebo) (NNS groups))))) (, ,) (ADVP (RB respectively)))))))) (. .)))
20520283	7	(S1 (S (PP (IN Across) (NP (DT all) (NNS groups))) (, ,) (NP (NP (QP (DT no) (RBR more) (IN than) (CD 5)) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX had) (NP (ADJP (RB clinically) (JJ significant)) (NN weight) (NN change))) (. .)))
20520283	8	(S1 (S (S (NP (ADJP (NN Post) (FW hoc)) (NNS analyses)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NN efficacy)) (VP (AUX was) (ADJP (JJ similar) (PP (IN with) (NP (NP (NNP Doc_20520283_1810_1819_Chemical)) (CC and) (NP (NNP Doc_20520283_1824_1835_Chemical)))))))))) (: ;) (S (NP (JJR greater) (NNS contrasts)) (VP (AUX were) (VP (VBN seen) (PP (IN in) (NP (NP (NNS AEs)) (, ,) (ADVP (RB especially)) (NP (NNP Doc_20520283_1884_1907_Disease))))))) (. .)))
20528871	0	(S1 (S (VP (VB Salvage) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_20528871_21_31_Chemical)) (, ,) (NP (NNP Doc_20528871_33_42_Chemical)) (, ,) (CC and) (NP (NNP Doc_20528871_48_64_Chemical))))) (PP (IN in) (NP (JJ relapsed/refractory) (JJ paediatric) (NN Doc_20528871_99_142_Disease)))) (. .)))
20528871	1	(S1 (S (NP (NP (NP (DT A) (NN combination)) (PP (IN of) (NP (NP (CD 5) (NNP d)) (PP (IN of) (NP (NP (NNP Doc_20528871_168_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20528871_180_184_Chemical)) (-RRB- -RRB-)))))) (PP (IN with) (NP (NP (CD 5) (NNP d)) (PP (IN of) (NP (NP (NP (NNP Doc_20528871_198_207_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20528871_209_211_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_20528871_217_233_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20528871_235_238_Chemical)) (-RRB- -RRB-)))))))) (CC and) (NP (JJ prophylactic) (JJ intrathecal) (NN chemotherapy))) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (NN salvage) (NN therapy)) (PP (IN in) (NP (NP (CD seven) (NNS children)) (PP (IN with) (NP (ADJP (JJ refractory) (CC or) (JJ relapsed)) (NNP Doc_20528871_356_384_Disease))))))))) (. .)))
20528871	2	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ side) (NNS effects)) (ADJP (JJ attributable) (PP (TO to) (NP (DT the) (NNP Doc_20528871_435_439_Chemical))))) (VP (VBD included) (NP (NNP Grade) (CD 2) (CC and) (CD 3)) (UCP (JJ sensory) (CC and) (NN motor) (NNP Doc_20528871_481_491_Disease) (CC and) (NNP Doc_20528871_496_516_Disease))) (. .)))
20528871	3	(S1 (S (NP (NN Doc_20528871_518_541_Disease)) (VP (AUX was) (ADJP (ADJP (JJR greater) (PP (IN for) (NP (DT the) (NN combination)))) (PP (IN than) (NP (NP (NNP Doc_20528871_579_583_Chemical)) (ADVP (RB alone))))) (, ,) (SBAR (IN although) (S (NP (NP (JJ median) (NN time)) (PP (TO to) (NP (NP (NN neutrophil)) (CC and) (NP (NN platelet) (NN recovery))))) (VP (AUX was) (ADJP (JJ consistent) (PP (IN with) (NP (JJ other) (NN salvage) (NNS therapies)))))))) (. .)))
20528871	4	(S1 (S (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (NP (DT some) (NN response)) (PP (TO to) (NP (DT the) (VBN combined) (NN therapy)))))) (CC and) (S (NP (NP (CD five)) (PP (IN of) (NP (DT the) (CD seven)))) (VP (VBD went) (PP (IN into) (NP (JJ complete) (NN remission))) (PP (IN after) (NP (NP (QP (CD one) (CC or) (CD two)) (NNS courses)) (PP (IN of) (NP (NNP Doc_20528871_827_831_Chemical/Doc_20528871_832_834_Chemical/Doc_20528871_835_838_Chemical))))))) (. .)))
20528871	5	(S1 (S (NP (PRP$ Our) (NN experience)) (VP (VBZ supports) (NP (NP (DT the) (NN safety)) (PP (IN of) (S (VP (VBG giving) (NP (NNP Doc_20528871_885_889_Chemical)) (PP (IN as) (NP (NP (NN salvage) (NN therapy)) (PP (IN in) (NP (NN synchrony))) (PP (IN with) (NP (NNP Doc_20528871_927_936_Chemical) (CC and) (NNP Doc_20528871_941_957_Chemical))))))))) (, ,) (SBAR (IN although) (S (NP (NNP Doc_20528871_968_989_Disease)) (VP (MD must) (VP (AUX be) (VP (ADVP (RB closely)) (VBN monitored))))))) (. .)))
2054792	0	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_2054792_10_20_Chemical)))) (VP (VBN combined) (PP (IN with) (NP (NP (JJ whole) (NN body) (NN Doc_2054792_46_58_Disease)) (PP (IN on) (NP (NP (NNP Doc_2054792_62_67_Disease)) (CC and) (NP (JJ normal) (NNS tissues))))))) (. .)))
2054792	1	(S1 (S (NP (NP (JJ Thermal) (NN enhancement)) (PP (IN of) (NP (NP (JJ Doc_2054792_111_121_Chemical-mediated) (NN antitumor) (NN activity)) (CC and) (NP (JJ normal) (NN tissue) (NN Doc_2054792_168_178_Disease)))) (PP (IN by) (NP (JJ whole) (NN body) (NN Doc_2054792_193_205_Disease)))) (VP (AUX were) (VP (VBN compared) (S (VP (VBG using) (NP (DT a) (NNP F344) (NN rat) (NN model)))))) (. .)))
2054792	2	(S1 (S (NP (NN Antitumor) (NN activity)) (VP (AUX was) (VP (VBN studied) (S (VP (VBG using) (NP (DT a) (JJ Doc_2054792_283_288_Disease) (NN growth) (NN delay) (NN assay)))))) (. .)))
2054792	3	(S1 (S (NP (NP (NP (JJ Acute) (JJ normal) (NN tissue) (NNP Doc_2054792_329_339_Disease)) (PRN (-LRB- -LRB-) (NP (FW i.e.)) (, ,) (NP (NP (NNP Doc_2054792_347_357_Disease)) (CC and) (NP (NNP Doc_2054792_362_378_Disease))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ late) (JJ normal) (NN tissue) (NNP Doc_2054792_403_413_Disease)) (PRN (-LRB- -LRB-) (NP (FW i.e.)) (, ,) (NP (NNP Doc_2054792_421_449_Disease)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN evaluated) (PP (PP (IN by) (NP (JJ functional/physiological) (NNS assays))) (CC and) (PP (IN by) (NP (JJ morphological) (NNS techniques)))))) (. .)))
2054792	4	(S1 (S (NP (NP (JJ Whole) (NN body) (NNP Doc_2054792_545_557_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 120) (NN min)) (PP (IN at) (NP (CD 41.5) (NNS degrees))) (X (SYM C))) (-RRB- -RRB-))) (VP (VBD enhanced) (NP (NP (DT both) (JJ Doc_2054792_600_610_Chemical-mediated) (NN antitumor) (NN activity)) (CC and) (NP (JJ toxic) (NN side) (NNS effects)))) (. .)))
2054792	5	(S1 (S (NP (DT The) (JJ thermal) (NN enhancement) (NN ratio)) (VP (VBD calculated) (SBAR (IN for) (S (NP (NN antitumor) (NN activity)) (VP (AUX was) (NP (CD 1.6)))))) (. .)))
2054792	6	(S1 (S (NP (NP (JJ Thermal) (NN enhancement) (NNS ratios)) (VP (VBN estimated) (PP (IN for) (NP (`` ``) (JJ acute) ('' '') (NN hematological) (NNS changes))))) (VP (AUX were) (NP (CD 1.3)) (, ,) (SBAR (IN whereas) (S (NP (DT those)) (VP (VBN estimated) (PP (IN for) (NP (NP (`` ``) (JJ late) ('' '') (NN damage)) (PRN (-LRB- -LRB-) (VP (VBN based) (PP (IN on) (NP (JJ morphological) (NNP Doc_2054792_883_908_Disease)))) (-RRB- -RRB-)) (VP (VBN varied) (PP (IN between) (NP (CD 2.4) (CC and) (CD 4.3)))))))))) (. .)))
2054792	7	(S1 (S (ADVP (RB Thus)) (, ,) (SBAR (IN while) (S (NP (JJ whole) (NN body) (NN Doc_2054792_961_973_Disease)) (VP (VBZ enhances) (NP (JJ Doc_2054792_983_993_Chemical-mediated) (NN antitumor) (NN effect))))) (, ,) (S (NP (JJ normal) (NN tissue) (NN Doc_2054792_1035_1043_Disease)) (VP (AUX is) (ADVP (RB also)) (VP (VBN increased)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ potential) (JJ therapeutic) (NN gain)) (PP (IN of) (NP (DT the) (VBN combined) (NN modality) (NN treatment)))) (VP (AUX is) (VP (VBN eroded)))) (. .)))
20588063	0	(S1 (NP (NP (NN Permeability)) (, ,) (NP (JJ ultrastructural) (NNS changes)) (, ,) (CC and) (NP (NP (NN distribution)) (PP (IN of) (NP (NN novel) (NNS proteins))) (PP (IN in) (NP (NP (DT the) (JJ glomerular) (NN barrier)) (PP (IN in) (NP (JJ early) (NNP Doc_20588063_109_134_Chemical) (NNP Doc_20588063_135_144_Disease)))))) (. .)))
20588063	1	(S1 (NP (NP (NNS BACKGROUND/AIMS)) (: :) (S (NP (PRP It)) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear)) (SBAR (WHNP (WP what)) (S (VP (VBZ happens) (PP (IN in) (NP (DT the) (NN glomerulus))) (SBAR (WHADVP (WRB when)) (S (NP (NN Doc_20588063_219_230_Disease)) (VP (VBZ starts))))))))) (. .)))
20588063	2	(S1 (S (S (S (VP (VBG Using) (NP (NNP Doc_20588063_245_270_Chemical) (NNP Doc_20588063_271_280_Disease) (PRN (-LRB- -LRB-) (NP (NNP PAN)) (-RRB- -RRB-)) (NNS rats)))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (JJ early) (NN ultrastructural)) (CC and) (NP (NP (JJ permeability) (NNS changes)) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ podocyte-associated) (NNS molecules)) (ADJP (JJ nephrin) (, ,) (JJ a-actinin) (, ,) (JJ dendrin)))))))))))) (, ,) (CC and) (S (ADVP (RB plekhh2)) (, ,) (NP (NP (DT the) (JJ last) (CD two)) (PP (IN of) (NP (WDT which)))) (VP (AUX were) (ADVP (RB only) (RB recently)) (VP (VBN discovered) (PP (IN in) (NP (NNS podocytes)))))) (. .)))
20588063	3	(S1 (S (S (VP (VBG Using) (NP (JJ immune) (NNS stainings)))) (, ,) (NP (JJ semiquantitative) (NN measurement)) (VP (AUX was) (VP (VBN performed) (PP (IN under) (NP (DT the) (NNP electron) (NN microscope))))) (. .)))
20588063	4	(S1 (S (NP (NN Permeability)) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (JJ isolated) (NN kidney) (NN perfusion)) (PP (IN with) (NP (NNP tracers))))))) (. .)))
20588063	5	(S1 (S (NP (NP (JJ Possible) (NNS effects)) (PP (IN of) (NP (NN ACE) (NN inhibition)))) (VP (AUX were) (VP (VBN tested))) (. .)))
20588063	6	(S1 (S (PP (IN By) (NP (NN day) (CD 2))) (, ,) (NP (NP (DT some) (JJ patchy) (NN foot) (NN process) (NN effacement)) (, ,) (CC but) (NP (DT no) (NNP Doc_20588063_816_827_Disease)) (, ,)) (VP (VBD appeared)) (. .)))
20588063	7	(S1 (S (NP (NP (DT The) (NN amount)) (PP (IN of) (NP (NN nephrin)))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (DT both) (JJ diseased) (CC and) (JJ normal) (NNS areas))))) (. .)))
20588063	8	(S1 (S (NP (DT The) (JJ other) (NNS proteins)) (VP (VBD showed) (NP (NP (JJ few) (NNS changes)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN limited) (PP (TO to) (NP (JJ diseased) (NNS areas))))))))) (. .)))
20588063	9	(S1 (S (PP (IN By) (NP (NN day) (CD 4))) (, ,) (S (NP (NN foot) (NN process) (NN effacement)) (VP (AUX was) (ADJP (JJ complete)))) (CC and) (S (NP (NNP Doc_20588063_1036_1047_Disease)) (VP (VBD appeared) (PP (IN in) (NP (NN parallel))) (PP (IN with) (NP (NP (NNS signs)) (PP (IN of) (NP (NN size) (NN barrier) (NN damage))))))) (. .)))
20588063	10	(S1 (S (NP (NN Nephrin)) (VP (VBD decreased) (ADVP (RB further)) (, ,) (SBAR (IN while) (S (S (NP (NP (NN dendrin)) (CC and) (NP (NN plekhh2))) (ADVP (RB also)) (VP (VBD decreased))) (CC but) (S (NP (NN a-actinin)) (VP (VBD remained) (ADJP (JJ unchanged))))))) (. .)))
20588063	11	(S1 (S (NP (NN ACE) (NN inhibition)) (VP (AUX had) (NP (DT no) (JJ significant) (JJ protective) (NN effect))) (. .)))
20588063	12	(S1 (S (NP (NNP PAN) (NNS glomeruli)) (ADVP (RB already)) (VP (VBD showed) (NP (JJ significant) (NN pathology)) (PP (IN by) (NP (NN day) (CD 4))) (, ,) (PP (IN despite) (NP (ADJP (RB relatively) (JJ mild)) (NN Doc_20588063_1357_1368_Disease)))) (. .)))
20588063	13	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN preceded) (PP (IN by) (NP (JJ altered) (NN nephrin) (NN expression))) (, ,) (S (VP (VBG supporting) (NP (NP (PRP$ its) (JJ pivotal) (NN role)) (PP (IN in) (NP (JJ podocyte) (NNS morphology)))))))) (. .)))
20588063	14	(S1 (S (NP (NP (DT The) (JJ novel) (NNS proteins)) (VP (VBN dendrin) (CC and) (VBN plekhh2))) (VP (AUX were) (DT both) (VP (VBN reduced) (, ,) (PP (VBG suggesting) (NP (NP (NNS roles)) (PP (IN in) (NP (NNP PAN))))) (, ,) (SBAR (IN whereas) (S (NP (NN a-actinin)) (VP (AUX was) (ADJP (JJ unchanged))))))) (. .)))
20619828	0	(S1 (NP (NP (DT A) (NN novel)) (, ,) (NP (NP (JJ multiple) (NN symptom) (NN model)) (PP (IN of) (NP (NNP Doc_20619828_35_70_Disease))) (PP (IN in) (NP (NNS animals)))) (. .)))
20619828	1	(S1 (S (NP (NP (JJ Current) (NN animal) (NNS models)) (PP (IN of) (NP (NP (NNP Doc_20619828_120_149_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20619828_151_154_Disease)) (-RRB- -RRB-))))) (ADVP (RB typically)) (VP (VBP involve) (NP (NP (JJ acute) (, ,) (JJ drug-induced) (NN symptom) (NN provocation)) (CC or) (NP (NP (DT a) (JJ genetic) (NN association)) (PP (IN with) (NP (NP (NNS stereotypies)) (CC or) (NP (NN Doc_20619828_260_267_Disease))))))) (. .)))
20619828	2	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (JJ current) (NNS models)))) (VP (VBP demonstrate) (NP (JJ multiple) (JJ Doc_20619828_319_322_Disease-like) (NNS behaviors))) (. .)))
20619828	3	(S1 (S (NP (JJ Neonatal) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (JJ tricyclic) (NNP Doc_20619828_394_408_Chemical) (NNP Doc_20619828_409_421_Chemical)) (CC or) (NP (NP (NN vehicle)) (PP (IN between) (NP (NP (NNS days) (CD 9) (CC and) (CD 16)) (ADJP (ADJP (RB twice) (JJ daily)) (CC and) (ADJP (RB behaviorally) (VBN tested) (PP (IN in) (NP (NN adulthood)))))))))))) (. .)))
20619828	4	(S1 (S (NP (NP (JJ Doc_20619828_514_526_Chemical) (NN exposure)) (PP (IN in) (NP (JJ immature) (NNS rats)))) (VP (VBD produced) (NP (NP (JJ significant) (ADJP (JJ behavioral) (CC and) (JJ biochemical)) (NNS changes)) (SBAR (WHNP (WDT that)) (S (VP (VBP include) (NP (NP (NP (JJ enhanced) (NNP Doc_20619828_631_638_Disease)) (PRN (-LRB- -LRB-) (NP (JJ elevated) (CC plus) (NN maze) (CC and) (NN marble)) (VBG burying) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_20619828_680_704_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN perseveration)) (PP (IN in) (NP (DT the) (JJ spontaneous) (NN alternation) (NN task)))) (CC and) (NP (VBN impaired) (NN reversal) (NN learning))) (-RRB- -RRB-))) (, ,) (NP (VBG working) (NNP Doc_20619828_797_814_Disease) (PRN (-LRB- -LRB-) (NP (NN e.g.)) (, ,) (NP (JJ win-shift) (NN paradigm)) (-RRB- -RRB-)) (, ,) (NNP Doc_20619828_843_851_Disease)) (, ,) (CC and) (NP (NNP Doc_20619828_857_884_Disease)))))))) (. .)))
20619828	5	(S1 (S (NP (JJ Doc_20619828_886_894_Chemical) (NNP D2) (NNS receptors)) (VP (AUX were) (ADJP (JJ elevated)) (PP (IN in) (NP (DT the) (NN striatum))) (, ,) (SBAR (IN whereas) (S (NP (NP (JJ Doc_20619828_947_956_Chemical) (NNS 2C)) (, ,) (CONJP (CC but) (RB not)) (NP (JJ Doc_20619828_969_978_Chemical) (NNS 1A)) (, ,) (NP (NNS receptors))) (VP (AUX were) (ADJP (JJ elevated)) (PP (IN in) (NP (DT the) (JJ orbital) (JJ frontal) (NN cortex))))))) (. .)))
20619828	6	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN demonstration)) (PP (IN of) (NP (NP (JJ multiple) (NNS symptoms)) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (JJ Doc_20619828_1123_1126_Disease-like) (NN profile)) (PP (IN in) (NP (NNS animals)))))))))) (. .)))
20619828	7	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (DT these) (NNS behaviors)) (VP (AUX are) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ biochemical) (NNS changes)) (PP (IN in) (NP (NP (NN brain) (NNS regions)) (VP (ADVP (RB previously)) (VBN identified) (PP (IN as) (NP (NP (JJ relevant)) (PP (TO to) (NP (NNP Doc_20619828_1271_1274_Disease)))))))))))) (. .)))
20619828	8	(S1 (S (NP (NP (DT This) (JJ novel) (NN model)) (PP (IN of) (NP (NNP Doc_20619828_1296_1299_Disease)))) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (NN drug) (NN exposure)) (PP (IN during) (NP (DT a) (JJ sensitive) (NN period)))) (VP (MD can) (VP (VB program) (NP (JJ disease-like) (NNS systems)) (ADVP (RB permanently)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX have) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (NN current)) (CC and) (NP (NP (JJ future) (JJ therapeutic) (NNS strategies)) (PP (IN for) (NP (NP (DT this)) (CC and) (NP (JJ other) (NN Doc_20619828_1499_1520_Disease))))))))))))))))) (. .)))
20621845	0	(S1 (S (NP (NP (NN Elevation)) (PP (IN of) (NP (CD ADAM10) (, ,) (CD ADAM17) (, ,) (CD MMP-2) (CC and) (CD MMP-9) (NN expression))) (PP (IN with) (NP (NN media) (NN degeneration)))) (VP (VBZ features) (NP (NP (JJ Doc_20621845_89_94_Chemical-induced) (NN Doc_20621845_103_127_Disease)) (PP (IN in) (NP (DT a) (NN rat) (NN model))))) (. .)))
20621845	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (VP (TO to) (VP (VB establish) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NNP Doc_20621845_205_229_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20621845_231_234_Disease)) (-RRB- -RRB-))))) (PP (IN by) (NP (JJ Doc_20621845_239_255_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20621845_257_264_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_20621845_274_289_Disease))))) (CC and) (VP (TO to) (VP (VB explore) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (NP (NP (DT a) (NN disintegrin) (CC and) (NN metalloproteinase)) (PRN (-LRB- -LRB-) (NP (NNP ADAM)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP matrix) (NNS metalloproteinases)) (PRN (-LRB- -LRB-) (NP (NNP MMPs)) (-RRB- -RRB-))) (CC and) (NP (NP (PRP$ their) (JJ endogenous) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NNP TIMPs)) (-RRB- -RRB-))))) (PP (IN in) (NP (NNP Doc_20621845_447_450_Disease) (NN formation)))))))))) (. .)))
20621845	2	(S1 (S (NP (NP (JJ Thoracic) (NN aorta)) (PP (IN of) (NP (JJ male) (NNP Sprague-Dawley) (NNS rats)))) (VP (AUX was) (VP (VBN exposed) (PP (TO to) (NP (NP (JJ 0.5M) (NN Doc_20621845_534_541_Chemical)) (CC or) (NP (NP (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20621845_560_564_Chemical)) (-RRB- -RRB-))))))) (. .)))
20621845	3	(S1 (S (PP (IN After) (NP (NNS 12weeks))) (, ,) (S (NP (NNS animals)) (VP (AUX were) (VP (VBN euthanized)))) (, ,) (CC and) (S (NP (NP (JJ Doc_20621845_611_618_Chemical-treated)) (, ,) (NP (NP (JJ Doc_20621845_628_635_Chemical-untreated)) (PRN (-LRB- -LRB-) (NP (CD n=12)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_20621845_657_661_Chemical-treated) (JJ aortic) (NNS segments)) (PRN (-LRB- -LRB-) (NP (CD n=12)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN collected) (PP (IN for) (NP (NP (NN histological)) (CC and) (NP (JJ molecular) (NNS assessments))))))) (. .)))
20621845	4	(S1 (S (S (NP (NN MMP-TIMP) (CC and) (NNP ADAM) (NNS mRNAs)) (VP (AUX were) (ADVP (RB semi-quantitatively)) (VP (VBN analyzed)))) (CC and) (S (NP (NN protein) (NNS expressions)) (VP (AUX were) (VP (VBN determined) (PP (IN by) (NP (NN immunohistochemistry)))))) (. .)))
20621845	5	(S1 (S (PP (IN Despite) (NP (NP (JJ similar) (JJ external) (NNS diameters)) (PP (IN among) (NP (ADJP (JJ Doc_20621845_925_932_Chemical-treated) (, ,) (JJ non-Doc_20621845_946_953_Chemical-treated) (CC and) (JJ Doc_20621845_966_970_Chemical-treated)) (NNS segments))))) (, ,) (NP (NP (NP (JJ aneurymal) (NN alteration)) (PRN (-LRB- -LRB-) (NP (NP (NN n=6)) (, ,) (NP (CD 50) (NN %))) (-RRB- -RRB-))) (, ,) (NP (NP (NNS media) (NN degeneration)) (PP (IN with) (NP (JJ regional) (NN disruption)))) (, ,) (NP (NP (NN fragmentation)) (PP (IN of) (NP (JJ elastic) (NN fiber)))) (, ,) (CC and) (NP (VBN increased) (NN collagen) (NN deposition)) (PRN (-LRB- -LRB-) (NP (NP (CD n=12)) (, ,) (NP (CD 100) (NN %))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN demonstrated) (PP (IN in) (NP (JJ Doc_20621845_1167_1174_Chemical-treated) (NNS segments))))) (. .)))
20621845	6	(S1 (S (NP (NN MMP-2) (, ,) (NN MMP-9) (, ,) (NN ADAM-10) (CC and) (NN ADAM-17) (NN mRNA) (NNS levels)) (VP (AUX were) (VP (VBN increased) (PP (IN in) (NP (NP (JJ Doc_20621845_1257_1264_Chemical-treated) (NNS segments)) (PRN (-LRB- -LRB-) (NP (DT all) (CD p<0.01)) (-RRB- -RRB-)))) (, ,) (PP (IN with) (NP (NP (NNS trends)) (PP (IN of) (NP (NP (NN elevation)) (PP (IN in) (NP (JJ Doc_20621845_1324_1331_Chemical-untreated) (NNS segments))))))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (JJ Doc_20621845_1369_1373_Chemical-treated) (NNS segments)))))))) (. .)))
20621845	7	(S1 (S (NP (NN Immunohistochemistry)) (VP (VP (VBD displayed) (ADVP (RB significantly)) (NP (NP (VBN increased) (NNS expressions)) (PP (IN of) (NP (JJ MMP-2) (, ,) (CD MMP-9) (, ,) (CD ADAM-10) (CC and) (CD ADAM-17)))) (PRN (-LRB- -LRB-) (NP (DT all) (CD p<0.01)) (-RRB- -RRB-)) (PP (IN in) (NP (NN intima)))) (CC and) (VP (NNS media) (PP (IN for) (NP (JJ Doc_20621845_1533_1540_Chemical-treated) (NNS segments))))) (. .)))
20621845	8	(S1 (S (NP (NP (NN TIMP) (NNS mRNA)) (CC and) (NP (NN tissue) (NNS levels))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB obviously)) (PP (IN among) (NP (DT the) (CD three) (JJ aortic) (NNS segments))))) (. .)))
20621845	9	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ establishes) (NP (DT a) (JJ Doc_20621845_1682_1685_Disease) (NN model)) (PP (IN by) (NP (NP (JJ periarterial) (JJ Doc_20621845_1708_1715_Chemical) (NN exposure)) (PP (IN in) (NP (NNS rats)))))) (, ,) (CC and) (VP (VBZ demonstrates) (NP (NP (DT a) (JJ significant) (NN elevation)) (PP (IN of) (NP (NN expression))) (PP (IN of) (NP (CD MMP-2) (, ,) (CD MMP-9) (, ,) (CD ADAM10) (CC and) (CD ADAM17)))) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ vascular) (NN remodeling))))))) (. .)))
20633755	0	(S1 (S (NP (NNP Doc_20633755_0_13_Chemical)) (VP (VBN induced) (NP (JJ prolonged) (NNP Doc_20633755_32_37_Disease)) (PP (IN in) (NP (DT a) (JJ patient) (NN receiving) (NN electroconvulsive) (NN therapy)))) (. .)))
20633755	1	(S1 (S (NP (NN Doc_20633755_88_101_Chemical)) (VP (VBZ causes) (NP (JJ prolonged) (NN Doc_20633755_119_124_Disease)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ pseudocholinesterase) (NN enzyme)) (VP (VBZ gets) (VP (VBN deactivated) (PP (IN by) (NP (NNP Doc_20633755_193_222_Chemical)))))))))) (. .)))
20633755	2	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (DT a) (JJ similar) (NN incident)) (PP (IN in) (NP (NP (DT a) (ADJP (RB severely) (JJ Doc_20633755_274_283_Disease)) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (JJ electroconvulsive) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN ECT)) (-RRB- -RRB-))))))))) (. .)))
20633755	3	(S1 (S (NP (NP (JJ Prolonged) (NN Doc_20633755_348_353_Disease)) (PP (IN in) (NP (PRP$ our) (NN case)))) (VP (VBD ensued) (SBAR (IN because) (S (NP (NP (DT the) (NN information)) (PP (IN about) (NP (NP (JJ suicidal) (NN attempt)) (PP (IN by) (NP (NNP Doc_20633755_423_434_Chemical)))))) (VP (AUX was) (VP (VBN concealed) (PP (IN from) (NP (DT the) (VBG treating) (NN team)))))))) (. .)))
20667451	0	(S1 (S (NP (NN Doc_20667451_0_8_Chemical)) (VP (VBZ ameliorates) (NP (NP (NNP Doc_20667451_21_42_Disease)) (CC and) (NP (JJ oxidative) (NN damage))) (PP (IN in) (NP (ADJP (JJ Doc_20667451_67_81_Chemical) (CC and) (JJ Doc_20667451_86_99_Chemical)) (VBN administered) (NNS rats)))) (. .)))
20667451	1	(S1 (S (NP (NP (DT The) (JJ antiepileptic) (NNS drugs)) (, ,) (NP (NP (NNP Doc_20667451_144_158_Chemical)) (CC and) (NP (NNP Doc_20667451_163_176_Chemical)))) (VP (AUX are) (VP (ADVP (RB well)) (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NN Doc_20667451_201_221_Disease)) (PP (IN on) (NP (JJ chronic) (NN use)))))))) (. .)))
20667451	2	(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN in) (NP (JJ free) (JJ radical) (NN generation)))) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN as) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ important) (NNS mechanisms)) (PP (IN of) (NP (NNP Doc_20667451_336_356_Disease))))))) (PP (IN by) (NP (JJ antiepileptic) (NNS drugs)))))) (. .)))
20667451	3	(S1 (S (NP (NN Doc_20667451_381_389_Chemical)) (VP (AUX has) (VP (VBN shown) (NP (NP (NN antioxidant)) (, ,) (NP (NN anti-inflammatory)) (CC and) (NP (JJ neuro-protective) (NNS properties))))) (. .)))
20667451	4	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (DT the) (JJ present) (NN study)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VP (VB investigate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ chronic) (NNP Doc_20667451_546_554_Chemical) (NN administration))) (PP (IN on) (NP (NP (NNP Doc_20667451_573_587_Chemical-)) (CC and) (NP (NNP Doc_20667451_593_606_Chemical-induced) (NNP Doc_20667451_615_635_Disease)))))) (CC and) (VP (VB oxidative) (NP (NP (NN stress)) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
20667451	5	(S1 (S (NP (NP (JJ Pharmacokinetic) (NNS interactions)) (PP (IN of) (NP (NNP Doc_20667451_698_706_Chemical))) (PP (IN with) (NP (NP (NNP Doc_20667451_712_726_Chemical)) (CC and) (NP (NNP Doc_20667451_731_744_Chemical))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN studied))) (. .)))
20667451	6	(S1 (S (NP (NNS Vehicle/drugs)) (VP (AUX were) (VP (VBN administered) (ADVP (RB daily)) (PP (IN for) (NP (NP (NNS 21days)) (PP (TO to) (NP (JJ male) (JJ Wistar) (NNS rats))))))) (. .)))
20667451	7	(S1 (S (NP (NP (JJ Passive) (NN avoidance) (NNS paradigm)) (CC and) (NP (JJ elevated) (CC plus) (NN maze) (NN test))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NN cognitive) (NN function))))))) (. .)))
20667451	8	(S1 (S (PP (IN At) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN study) (NN period))))) (, ,) (NP (NP (NNP serum) (NNP Doc_20667451_963_977_Chemical) (CC and) (NNP Doc_20667451_982_995_Chemical)) (, ,) (NP (JJ whole) (NN brain) (NN Doc_20667451_1009_1024_Chemical)) (CC and) (NP (VBN reduced) (JJ Doc_20667451_1037_1048_Chemical) (NNS levels))) (VP (AUX were) (VP (VBN estimated))) (. .)))
20667451	9	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_20667451_1094_1108_Chemical)) (CC and) (NP (NNP Doc_20667451_1113_1126_Chemical)))) (PP (IN for) (NP (NNS 21days)))) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN Doc_20667451_1159_1192_Disease)) (CONJP (RB as) (RB well) (IN as)) (NP (DT an) (VBN increased) (NN oxidative) (NN stress)))) (. .)))
20667451	10	(S1 (S (NP (JJ Concomitant) (JJ Doc_20667451_1247_1255_Chemical) (NN administration)) (VP (VP (VBD prevented) (NP (DT the) (NNP Doc_20667451_1285_1305_Disease))) (CC and) (VP (VBD decreased) (NP (NP (DT the) (VBN increased) (JJ oxidative) (NN stress)) (VP (VBN induced) (PP (IN by) (NP (DT these) (JJ antiepileptic) (NNS drugs))))))) (. .)))
20667451	11	(S1 (S (NP (JJ Doc_20667451_1389_1397_Chemical) (NN co-administration)) (VP (AUX did) (RB not) (VP (VB cause) (NP (NP (DT any) (JJ significant) (NN alteration)) (PP (IN in) (NP (NP (DT the) (JJ serum) (NNS concentrations)) (PP (IN of) (NP (NP (DT both) (NNP Doc_20667451_1493_1507_Chemical)) (CONJP (RB as) (RB well) (IN as)) (NP (NNP Doc_20667451_1519_1532_Chemical))))))))) (. .)))
20667451	12	(S1 (S (NP (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP Doc_20667451_1558_1566_Chemical)) (VP (AUX has) (NP (JJ beneficial) (NN effect)) (PP (IN in) (S (VP (VBG mitigating) (NP (NP (DT the) (ADJP (JJ Doc_20667451_1607_1643_Disease) (CC and) (JJ oxidative)) (NN damage)) (PP (IN in) (NP (NNS rats))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_20667451_1686_1700_Chemical)) (CC and) (NP (NNP Doc_20667451_1705_1718_Chemical)))))) (PP (IN without) (S (VP (ADVP (RB significantly)) (VBG altering) (NP (PRP$ their) (NN serum) (NNS concentrations)))))))))))) (. .)))
20667451	13	(S1 (S (NP (DT The) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_20667451_1804_1812_Chemical)) (VP (MD can) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (NP (NP (DT a) (JJ potential) (ADJP (JJ safe) (CC and) (JJ effective)) (NN adjuvant)) (PP (TO to) (NP (NNP Doc_20667451_1877_1891_Chemical)))) (CC and) (NP (NP (JJ Doc_20667451_1896_1909_Chemical) (NN therapy)) (PP (IN in) (S (VP (VBG preventing) (NP (NNP Doc_20667451_1932_1952_Disease))))))) (VP (VBN associated) (PP (IN with) (NP (DT these) (NNS drugs)))))))))))) (. .)))
20698227	0	(S1 (SQ (MD Can) (NP (NN angiogenesis)) (VP (AUX be) (NP (NP (DT a) (NN target)) (PP (IN of) (NP (NN treatment)))) (PP (IN for) (NP (NNP Doc_20698227_46_55_Chemical) (NNP associated) (NNP Doc_20698227_67_83_Disease)))) (. ?)))
20698227	1	(S1 (NP (NP (NNS BACKGROUND/AIMS)) (: :) (S (S (ADVP (RB Recently)) (NP (NNP Doc_20698227_111_120_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN found) (S (VP (TO to) (VP (VB inhibit) (NP (NNS angiogenesis))))))))) (CC and) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NN angiogenesis) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_20698227_208_217_Chemical)) (CC and) (NP (NNP Doc_20698227_222_231_Chemical))))))) (VP (AUX have) (VP (AUX been) (VP (VBN found) (S (VP (TO to) (VP (VB cause) (NP (JJ acute) (NNP Doc_20698227_263_272_Disease)))))))))) (. .)))
20698227	2	(S1 (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN relation)) (PP (IN between) (NP (NP (NN hemoglobin) (, ,) (NN haptoglobin) (CC and) (NN angiogenesis) (JJ soluble) (NNS markers)) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX are) (ADJP (JJ modifiable))) (CC and) (VP (MD can) (VP (VB help) (PP (IN in) (S (VP (VBG developing) (NP (NNS strategies)) (PP (IN against) (NP (NNP Doc_20698227_458_464_Disease))))))))))))))))))))) (. .)))
20698227	3	(S1 (S (NP (NP (CD Fourteen) (NNS patients)) (NP (NNP Doc_20698227_493_536_Disease))) (VP (AUX were) (VP (VBN treated) (PP (IN by) (NP (NP (NNP Doc_20698227_553_582_Chemical)) (CC and) (NP (NNP Doc_20698227_587_596_Chemical)))))) (. .)))
20698227	4	(S1 (S (NP (NP (JJ Serum) (NN hemoglobin) (, ,) (NN haptoglobin) (CC and) (NN angiogenesis) (NNS markers)) (PP (IN of) (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (CC and) (NP (NN angiopoetin-2))))) (VP (AUX were) (VP (VBN investigated) (PP (IN before) (CC and) (PP (IN after) (NP (NN therapy)))))) (. .)))
20698227	5	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (JJ haptoglobin) (NNS levels))) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN treatment) (NN period))))))) (. .)))
20698227	6	(S1 (S (NP (NN Hemoglobin) (NNS levels)) (ADVP (RB also)) (VP (VP (VBN decreased)) (CC but) (VP (ADJP (JJ insignificantly)) (PP (IN by) (NP (NN treatment))))) (. .)))
20698227	7	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (IN with) (NP (DT the) (NN literature))))) (, ,) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN angiogenesis) (NNS factors)))) (VP (AUX did) (RB not) (VP (NN change) (ADVP (RB significantly)) (PP (IN by) (NP (NP (NNP Doc_20698227_1024_1044_Chemical)) (CC and) (NP (JJ Doc_20698227_1049_1058_Chemical) (NN therapy)))))) (. .)))
20698227	8	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT no) (NN correlation)) (PP (IN of) (NP (JJ angiogenesis) (JJ soluble) (NNS markers))) (PP (IN with) (NP (DT either) (NN hemoglobin) (CC or) (NN haptoglobin))))) (. .)))
20698227	9	(S1 (S (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN study)) (PP (IN in) (NP (NP (DT the) (NN literature)) (VP (VBG investigating) (NP (NP (DT a) (NN link)) (PP (IN between) (NP (NP (JJ angiogenesis) (JJ soluble) (NNS markers)) (CC and) (NP (NNP Doc_20698227_1279_1288_Chemical)))))))) (VP (VBN induced) (NP (NNP Doc_20698227_1297_1303_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20698227_1321_1332_Disease))))))))) (CC and) (S (NP (PRP we)) (VP (MD could) (RB not) (VP (VB find) (NP (DT any) (NN relation))))) (. .)))
20698227	10	(S1 (S (NP (NP (JJ Future) (NN research)) (PP (IN with) (NP (NP (JJR larger) (NN number)) (PP (IN of) (NP (NNS patients)))))) (VP (AUX is) (VP (VBN needed) (S (VP (TO to) (VP (VB find) (PRT (RP out)) (NP (NP (JJ modifiable) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (MD will) (VP (VB improve) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (JJ Doc_20698227_1489_1498_Chemical) (NN therapy)))))))))))))) (. .)))
2070391	0	(S1 (S (NP (NP (NN Reduction)) (PP (IN in) (NP (NN injection)))) (VP (NNP Doc_2070391_23_27_Disease) (S (VP (VBG using) (NP (JJ buffered) (NN Doc_2070391_43_52_Chemical)) (PP (IN as) (NP (NP (DT a) (JJ local) (NN anesthetic)) (PP (IN before) (NP (JJ cardiac) (NN catheterization)))))))) (. .)))
2070391	1	(S1 (S (NP (JJ Previous) (NNS reports)) (VP (AUX have) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (NN Doc_2070391_144_148_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NNP Doc_2070391_182_191_Chemical))))))) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ acidic) (NN pH)) (PP (IN of) (NP (DT the) (NN solution))))))))))) (. .)))
2070391	2	(S1 (S (S (VP (TO To) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (DT a) (JJ buffering) (NN solution)) (SBAR (S (VP (TO to) (VP (VB adjust) (NP (NP (DT the) (NN pH)) (PP (IN of) (NP (NNP Doc_2070391_310_319_Chemical)))) (PP (IN into) (NP (DT the) (JJ physiologic) (NN range)))))))))) (VP (MD would) (VP (VB reduce) (NP (NNP Doc_2070391_360_364_Disease)) (PP (IN during) (NP (NN injection)))))))))) (, ,) (NP (PRP we)) (VP (VBD performed) (NP (DT a) (JJ blinded) (JJ randomized) (NN study)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (JJ cardiac) (NN catheterization)))))) (. .)))
2070391	3	(S1 (S (NP (CD Twenty) (NNS patients)) (VP (VP (AUX were) (VP (VBN asked) (S (VP (TO to) (VP (VB quantify) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_2070391_526_530_Disease)))) (PP (IN after) (S (VP (VBG receiving) (NP (JJ standard) (NN Doc_2070391_556_565_Chemical)) (PP (IN in) (NP (CD one) (JJ femoral) (NN area))))))))))) (CC and) (VP (VBD buffered) (NP (NNP Doc_2070391_599_608_Chemical)) (PP (IN in) (NP (DT the) (JJ opposite) (JJ femoral) (NN area))))) (. .)))
2070391	4	(S1 (S (NP (NP (DT The) (JJ mean) (JJ Doc_2070391_648_652_Disease) (NN score)) (PP (IN for) (NP (JJ buffered) (NNP Doc_2070391_672_681_Chemical)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NP (DT the) (JJ mean) (NN score)) (PP (IN for) (NP (NP (JJ standard) (NNP Doc_2070391_739_748_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 2.7) (NN +/-) (QP (CD 1.9) (CC vs.) (CD 3.8) (JJR +/-) (CD 2.2))) (, ,) (NP (NNP P) (SYM =) (CD 0.03))) (-RRB- -RRB-)))))))) (. .)))
2070391	5	(S1 (S (NP (NP (DT The) (JJ pH) (NN adjustment)) (PP (IN of) (NP (JJ standard) (NNP Doc_2070391_820_829_Chemical)))) (VP (MD can) (VP (AUX be) (VP (VBN accomplished) (ADVP (RB easily)) (PP (IN in) (NP (DT the) (NN catheterization) (NN laboratory))) (PP (IN before) (NP (NP (NN injection)) (CC and) (NP (NP (NNS results)) (PP (IN in) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NNP Doc_2070391_942_946_Disease)) (VP (VBG occurring) (PP (IN during) (NP (NP (DT the) (NN infiltration)) (PP (IN of) (NP (NNS tissues)))))))))))))))) (. .)))
2071257	0	(S1 (S (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_2071257_10_44_Chemical))) (PP (IN on) (NP (NNP Doc_2071257_48_55_Disease)))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_2071257_66_77_Chemical)))) (. .)))
2071257	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VB test) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_2071257_136_169_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2071257_171_182_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NNP Doc_2071257_187_204_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2071257_216_227_Chemical))) (PP (IN in) (NP (NN man)))))))))))) (. .)))
2071257	2	(S1 (S (NP (JJ Thirty-two) (JJ healthy) (JJ young) (NNS volunteers)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (PP (TO to) (NP (CD four) (JJ different) (NNS groups))))) (. .)))
2071257	3	(S1 (S (NP (PRP They)) (VP (AUX were) (VP (VBN given) (NP (NP (DT a) (ADJP (CD ten) (NN day)) (NN pretreatment)) (PP (IN with) (NP (NP (DT either) (NNP Doc_2071257_373_384_Chemical)) (CC or) (NP (NN placebo) (, ,) (NN p.o.) (, ,) (CC and) (PP (IN on) (NP (NP (DT the) (JJ eleventh) (NN day)) (CC either) (NP (NNP Doc_2071257_434_445_Chemical)) (CC or) (NP (NN placebo)))) (, ,) (NP (NP (NNP i.m.)) (NP (RB Before) (CC and) (CD 0.5) (, ,) (CD 1) (, ,) (CD 2) (, ,) (CD 3))) (, ,)) (CC and) (NP (CD 6) (NNP h))))) (SBAR (IN after) (NN injection) (S (NP (DT the) (NNS subjects)) (VP (AUX were) (VP (VBN given) (NP (NP (NN attention)) (CC and) (NP (JJ mnemonic) (NNS tests))))))))) (. .)))
2071257	4	(S1 (S (NP (NP (DT The) (NNS findings)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT the) (NN drug)) (VP (AUX is) (ADJP (JJ able) (S (VP (TO to) (VP (VB antagonize) (NP (NP (NNP Doc_2071257_638_672_Disease)) (VP (VBN induced) (PP (IN by) (NP (NN Doc_2071257_684_695_Chemical))))))))))))) (. .)))
20722491	0	(S1 (NP (NP (NP (NN Safety)) (PP (IN of) (NP (NNP Doc_20722491_10_22_Chemical)))) (: :) (NP (DT a) (NN review)) (. .)))
20722491	1	(S1 (NP (NP (NP (NN IMPORTANCE)) (PP (IN OF) (NP (DT THE) (NN FIELD)))) (: :) (S (NP (NP (NNP Doc_20722491_59_76_Chemical)) (, ,) (PP (IN in) (NP (NP (JJ particular) (NNP Doc_20722491_92_106_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20722491_108_112_Chemical)) (-RRB- -RRB-)))) (, ,)) (VP (AUX have) (VP (AUX been) (NP (NP (DT the) (NN mainstay)) (PP (IN of) (NP (NN treatment)))) (PP (IN for) (NP (NP (JJ several) (JJ solid) (NN Doc_20722491_169_175_Disease)) (, ,) (PP (VBG including) (NP (NNP Doc_20722491_187_231_Disease))) (, ,))) (PP (IN for) (NP (QP (RB >) (CD 40)) (NNS years)))))) (. .)))
20722491	2	(S1 (S (S (NP (NNS AREAS)) (VP (VBN COVERED) (PP (IN IN) (NP (DT THIS) (NN REVIEW))))) (: :) (S (NP (DT This) (NN article)) (VP (VBZ reviews) (NP (NP (DT the) (NN pharmacology) (CC and) (NN efficacy)) (PP (IN of) (NP (NNP Doc_20722491_333_345_Chemical))) (PP (IN with) (NP (NP (DT a) (JJ special) (NN emphasis)) (PP (IN on) (NP (PRP$ its) (NN safety)))))))) (. .)))
20722491	3	(S1 (SBARQ (WHNP (WP WHAT)) (S (S (NP (DT THE) (NN READER)) (VP (MD WILL) (VP (VB GAIN)))) (: :) (S (NP (DT The) (NN reader)) (VP (MD will) (VP (VB gain) (ADVP (RB better)) (NP (NNP insight)) (PP (IN into) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NP (NNP Doc_20722491_467_479_Chemical)) (PP (IN in) (NP (NP (JJ special) (NNS populations)) (PP (JJ such) (IN as) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ advanced) (NN age)) (, ,) (NP (NNP Doc_20722491_539_563_Disease)))))))))))))))) (. .)))
20722491	4	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VB explore) (NP (NP (NP (JJ different) (NN dosing)) (CC and) (NP (NNS schedules))) (PP (IN of) (NP (NNP Doc_20722491_615_627_Chemical) (NN administration))))) (. .)))
20722491	5	(S1 (S (S (VP (VB TAKE) (NP (NN HOME) (NN MESSAGE)))) (: :) (S (NP (NNP Doc_20722491_663_675_Chemical)) (VP (VP (AUX is) (NP (NP (DT an) (JJ oral) (NN prodrug)) (PP (IN of) (NP (NNP Doc_20722491_698_702_Chemical))))) (CC and) (VP (AUX was) (VP (VBN developed) (S (VP (TO to) (VP (VP (VB fulfill) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (DT a) (ADJP (RBR more) (JJ convenient)) (NN therapy))))) (CC and) (VP (VB provide) (NP (DT an) (JJ improved) (NN safety/efficacy) (NN profile)))))))))) (. .)))
20722491	6	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (VBN shown) (NP (NP (JJ promising) (NNS results)) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (JJ chemotherapeutic) (NNS agents)) (PP (IN in) (NP (NNP Doc_20722491_913_998_Disease))))))))))) (. .)))
20722491	7	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (RB commonly) (VBN reported)) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NNP Doc_20722491_1044_1056_Chemical)))) (VP (AUX are) (NP (NNP Doc_20722491_1061_1069_Disease) (, ,) (NNP Doc_20722491_1071_1077_Disease) (, ,) (NNP Doc_20722491_1079_1087_Disease) (, ,) (NNP Doc_20722491_1089_1099_Disease) (CC and) (NNP Doc_20722491_1104_1122_Disease))) (. .)))
20722491	8	(S1 (S (NP (NN Doc_20722491_1124_1136_Chemical)) (VP (VP (AUX has) (NP (DT a) (JJ well-established) (NN safety) (NN profile))) (CC and) (VP (MD can) (VP (AUX be) (VP (VBN given) (ADVP (RB safely)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ advanced) (NN age)) (, ,) (NP (NNP Doc_20722491_1230_1260_Disease)))))))))) (. .)))
20880751	0	(S1 (NP (NP (NP (JJ Doc_20880751_0_8_Chemical-induced) (NN Doc_20880751_17_28_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20880751_46_65_Disease)))))) (: :) (S (VP (VBG filling) (NP (DT the) (JJ bench-to-bedside) (NN gap)))) (. .)))
20880751	1	(S1 (S (NP (NN Doc_20880751_101_109_Chemical)) (VP (AUX is) (NP (NP (DT the) (ADJP (RBS most) (JJ effective)) (NN drug)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_20880751_158_177_Disease))))))) (. .)))
20880751	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ long-term) (NN use)) (PP (IN of) (NP (DT this) (JJ Doc_20880751_214_222_Chemical) (NN precursor)))) (VP (AUX is) (VP (VBN complicated) (PP (IN by) (NP (NP (RB highly) (VBG disabling) (NNS fluctuations)) (CC and) (NP (NN Doc_20880751_285_296_Disease)))))) (. .)))
20880751	3	(S1 (S (SBAR (IN Although) (S (NP (NP (NN preclinical)) (CC and) (NP (JJ clinical) (NNS findings))) (VP (VBP suggest) (NP (NP (JJ pulsatile) (NN stimulation)) (PP (IN of) (NP (JJ striatal) (JJ postsynaptic) (NNS receptors)))) (PP (IN as) (NP (NP (DT a) (JJ key) (NN mechanism)) (VP (VBG underlying) (NP (JJ Doc_20880751_436_444_Chemical-induced) (NNP Doc_20880751_453_464_Disease)))))))) (, ,) (NP (PRP$ their) (NN pathogenesis)) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ unclear))) (. .)))
20880751	4	(S1 (S (PP (IN In) (NP (JJ recent) (NNS years))) (, ,) (NP (NP (NN evidence)) (PP (IN from) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_20880751_551_570_Disease)))))) (VP (AUX has) (VP (VBN provided) (NP (JJ important) (NN information)) (S (VP (TO to) (VP (VP (VB understand) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ specific) (NN receptor))))) (CC and) (VP (VB post-receptor) (NP (NP (JJ molecular) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_20880751_721_741_Disease)))))))))))) (. .)))
20880751	5	(S1 (S (NP (NP (JJ Recent) (JJ preclinical) (CC and) (JJ clinical) (NNS data)) (PP (IN from) (NP (NP (JJ promising) (NNS lines)) (PP (IN of) (NP (NN research)))))) (VP (VBP focus) (PP (IN on) (NP (NP (DT the) (NN differential) (NN role)) (PP (IN of) (NP (NP (JJ presynaptic) (CC versus) (JJ postsynaptic) (NNS mechanisms)) (, ,) (NP (JJ Doc_20880751_891_899_Chemical) (NN receptor) (NNS subtypes)) (, ,) (NP (ADJP (JJ ionotropic) (CC and) (JJ metabotropic)) (JJ Doc_20880751_947_956_Chemical) (NNS receptors)) (, ,) (CC and) (NP (JJ non-dopaminergic) (NN neurotransmitter) (NNS systems)))) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_20880751_1040_1048_Chemical-induced) (NNP Doc_20880751_1057_1068_Disease)))))))) (. .)))
20882060	0	(S1 (NP (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ pallidal) (NNP Doc_20882060_20_31_Chemical))) (PP (IN on) (NP (NNP Doc_20882060_35_46_Chemical-induced) (NNP Doc_20882060_55_77_Disease)))) (: :) (NP (ADJP (JJ behavioral) (CC and) (JJ electrophysiological)) (NNS studies)) (. .)))
20882060	1	(S1 (S (NP (DT The) (JJ globus) (NN pallidus)) (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NN movement) (NN regulation)))) (. .)))
20882060	2	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (AUX have) (VP (VBN indicated) (SBAR (IN that) (S (S (NP (DT the) (JJ globus) (NN pallidus)) (VP (VBZ receives) (NP (JJ neurotensinergic) (NN innervation)) (PP (IN from) (NP (DT the) (NN striatum))))) (, ,) (CC and) (S (NP (NP (JJ systemic) (NN administration)) (PP (IN of) (NP (DT a) (JJ Doc_20882060_348_359_Chemical) (NN analog)))) (VP (MD could) (VP (VB produce) (NP (JJ antiparkinsonian) (NNS effects))))))))) (. .)))
20882060	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ pallidal) (NNP Doc_20882060_470_481_Chemical))) (PP (IN on) (NP (JJ Doc_20882060_485_496_Chemical-induced) (NN Doc_20882060_505_526_Disease)))))))) (. .)))
20882060	4	(S1 (S (NP (NP (JJ Behavioral) (NNS experiments)) (CC and) (NP (JJ electrophysiological) (NNS recordings))) (VP (AUX were) (VP (VBN performed) (PP (IN in) (NP (DT the) (JJ present) (NN study))))) (. .)))
20882060	5	(S1 (S (NP (NP (JJ Bilateral) (NNS infusions)) (PP (IN of) (NP (NNP Doc_20882060_665_676_Chemical))) (PP (IN into) (NP (DT the) (JJ globus) (NNS pallidus)))) (VP (VBD reversed) (NP (JJ Doc_20882060_711_722_Chemical-induced) (NN Doc_20882060_731_753_Disease)) (PP (IN in) (NP (NNS rats)))) (. .)))
20882060	6	(S1 (S (NP (JJ Electrophysiological) (NNS recordings)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN microinjection)) (PP (IN of) (NP (NNP Doc_20882060_825_836_Chemical)))) (VP (VBN induced) (NP (NP (NN excitation)) (PP (IN of) (NP (JJ pallidal) (NNS neurons)))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ systemic) (JJ Doc_20882060_904_915_Chemical) (NN administration))))))))) (. .)))
20882060	7	(S1 (S (NP (DT The) (NNP Doc_20882060_936_974_Chemical) (NNP Doc_20882060_975_982_Chemical)) (VP (VBD blocked) (NP (CC both) (NP (DT the) (JJ behavioral)) (CC and) (NP (NP (DT the) (JJ electrophysiological) (NNS effects)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_20882060_1059_1070_Chemical))))))) (. .)))
20882060	8	(S1 (S (NP (NP (NN Activation)) (PP (IN of) (NP (JJ pallidal) (JJ Doc_20882060_1107_1118_Chemical) (NNS receptors)))) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (JJ Doc_20882060_1148_1159_Chemical-induced) (NN antiparkinsonian) (NNS effects)))))) (. .)))
2096243	0	(S1 (NP (JJ Doc_2096243_0_8_Chemical-induced) (NN Doc_2096243_17_41_Disease) (. .)))
2096243	1	(S1 (S (NP (NN Doc_2096243_43_66_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT a) (JJ 29-year-old) (NN female)) (PP (IN in) (NP (DT the) (JJ prognostic) (NN period))))) (PP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_2096243_148_156_Chemical-induced) (NNP Doc_2096243_165_184_Disease))))))) (. .)))
2096243	2	(S1 (S (NP (NP (NNS Symptoms)) (PP (JJ such) (IN as) (NP (NP (NN euphoria)) (, ,) (NP (JJ emotional) (NN lability)) (CC and) (NP (JJ puerile) (NN attitude)))) (VP (VBN noted) (PP (IN in) (NP (DT the) (NN patient))))) (VP (AUX were) (VP (VBN diagnosed) (PP (IN as) (NP (NNP Doc_2096243_292_320_Disease))) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NNS criteria)) (VP (VBN defined) (PP (IN in) (NP (DT the) (NN DSM-III-R))))))))) (. .)))
2096243	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP (DT a) (NN Doc_2096243_396_417_Disease))))) (. .)))
2096243	4	(S1 (S (NP (NN Brain) (NNS CT)) (VP (VBD revealed) (NP (DT a) (JJ periventricular) (JJ low) (NN density) (NN area)) (PP (IN in) (NP (NP (NP (DT the) (JJ frontal) (JJ white) (NN matter)) (CC and) (NP (JJ moderate) (NN dilatation))) (PP (IN of) (NP (DT the) (JJ lateral) (NNS ventricles))))) (PP (ADVP (RB especially)) (IN at) (NP (DT the) (JJ bilateral) (NNP anterior) (NNS horns)))) (. .)))
2096243	5	(S1 (S (ADVP (RB Consequently)) (, ,) (NP (NNP Doc_2096243_608_616_Chemical-induced) (NNP Doc_2096243_625_644_Disease)) (VP (MD may) (ADVP (RB uncommonly)) (VP (VB result) (PP (IN in) (NP (NNP Doc_2096243_670_698_Disease))) (PP (IN in) (NP (DT the) (JJ residual) (NN state))))) (. .)))
2096243	6	(S1 (S (NP (PRP It)) (VP (MD may) (VP (AUX be) (VP (VBN attributed) (PP (TO to) (NP (DT the) (NNP Doc_2096243_750_787_Disease)))))) (. .)))
21029050	0	(S1 (S (VP (VB Butyrylcholinesterase) (NP (NN gene) (NNS mutations)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (VBN prolonged) (NN Doc_21029050_64_69_Disease)) (PP (IN after) (NP (NP (NNP Doc_21029050_76_91_Chemical)) (PP (IN for) (NP (JJ electroconvulsive) (NN therapy)))))))))) (. .)))
21029050	1	(S1 (S (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (JJ electroconvulsive) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN ECT)) (-RRB- -RRB-))))) (ADVP (RB often)) (VP (VBP receive) (NP (NNP Doc_21029050_201_216_Chemical)) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (DT the) (JJ anesthetic) (NN procedure)))))) (. .)))
21029050	2	(S1 (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (NN action)))) (VP (MD may) (VP (AUX be) (VP (VBN prolonged) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ genetic) (NNS variants)) (PP (IN of) (NP (NP (DT the) (JJ butyrylcholinesterase) (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NNP BChE)) (-RRB- -RRB-)))))))) (, ,) (S (NP (DT the) (RBS most) (JJ common)) (VP (AUXG being) (NP (NP (DT the) (NNPS K-)) (CC and) (NP (DT the) (NNPS A-variants)))))))) (. .)))
21029050	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (JJ clinical) (NN significance)) (PP (IN of) (NP (NP (JJ genetic) (NNS variants)) (PP (IN in) (NP (NN butyrylcholinesterase) (NN gene))) (PRN (-LRB- -LRB-) (NP (NNP BCHE)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (VBN suspected) (JJ prolonged) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP Doc_21029050_600_615_Chemical))) (PP (IN after) (NP (NN ECT))))))))))))) (. .)))
21029050	4	(S1 (S (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 13) (NNS patients)))) (VP (AUX were) (VP (VBN referred) (PP (TO to) (NP (DT the) (JJ Danish) (NNP Cholinesterase) (NN Research) (NN Unit))) (PP (IN after) (NP (NN ECT))) (PP (IN during) (NP (CD 38) (NNS months))))) (. .)))
21029050	5	(S1 (S (NP (PRP We)) (VP (VBD determined) (SBAR (S (NP (NP (DT the) (NNP BChE) (NN activity)) (CC and) (NP (NP (NP (DT the) (NN BCHE) (NN genotype)) (VP (VBG using) (NP (JJ molecular) (JJ genetic) (NNS methods)))) (, ,) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_21029050_847_852_Disease)))) (, ,) (NP (NP (NN time)) (PP (TO to) (NP (NP (JJ sufficient) (JJ spontaneous) (NN ventilation)) (CC and) (NP (IN whether) (NN neuromuscular) (NN monitoring))))))) (VP (AUX was) (VP (VBN used)))))) (. .)))
21029050	6	(S1 (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (NNP Doc_21029050_960_965_Disease)))) (VP (AUX was) (PP (VBN compared) (PP (IN with) (NP (NP (VBN published) (NNS data)) (PP (IN on) (NP (JJ normal) (NNS subjects))))))) (. .)))
21029050	7	(S1 (S (PP (IN in) (NP (CD 11) (NNS patients))) (, ,) (NP (NNS mutations)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (DT the) (NN BCHE) (NN gene))) (, ,) (S (NP (DT the) (NN K-variant)) (VP (AUXG being) (NP (DT the) (RBS most) (JJ frequent)))))) (. .)))
21029050	8	(S1 (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (NNP Doc_21029050_1138_1143_Disease)))) (VP (AUX was) (NP (CD 5-15) (NN min)) (PP (VBN compared) (PP (IN with) (NP (NP (CD 3-5.3) (NN min)) (PP (IN from) (NP (DT the) (NN literature))))))) (. .)))
21029050	9	(S1 (S (NP (JJ Severe) (NN distress)) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (DT the) (NN recovery) (NN phase)) (PP (IN in) (NP (CD two) (NNS patients))))))) (. .)))
21029050	10	(S1 (S (NP (JJ Neuromuscular) (NN monitoring)) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (CD two) (NNS patients))))) (. .)))
21029050	11	(S1 (S (NP (NP (CD eleven)) (PP (IN of) (NP (NP (CD 13) (NNS patients)) (PP (IN with) (NP (NP (DT a) (VBN prolonged) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP Doc_21029050_1391_1406_Chemical)))))))))) (VP (AUX had) (NP (NNS mutations)) (PP (IN in) (NP (NNP BCHE))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ possible) (NN reason)) (PP (IN for) (NP (NP (DT a) (JJ prolonged) (NN period)) (PP (IN of) (NP (NNP Doc_21029050_1500_1505_Disease)))))))))))) (. .)))
21029050	12	(S1 (S (NP (PRP We)) (VP (VBP recommend) (NP (JJ objective) (JJ neuromuscular) (NN monitoring)) (PP (IN during) (NP (DT the) (JJ first) (NN ECT)))) (. .)))
220563	0	(S1 (NP (NNP Doc_220563_0_19_Chemical) (CC and) (NNP Doc_220563_24_45_Disease) (. .)))
220563	1	(S1 (S (NP (NN Doc_220563_47_68_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN noted) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NP (NNP Doc_220563_118_137_Chemical)) (, ,) (NP (NP (DT a) (NN drug)) (VP (ADVP (RB widely)) (VBN used) (PP (IN in) (NP (NNP France))) (PRN (-LRB- -LRB-) (CC and) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))))) (-RRB- -RRB-)) (PP (IN for) (NP (NP (DT the) (JJ prophylactic) (NN treatment)) (PP (IN of) (NP (NNP Doc_220563_248_263_Disease)))))))))))))) (. .)))
220563	2	(S1 (S (PP (IN In) (NP (NP (CD 24) (NNS patients)) (PP (IN with) (NP (DT this) (NN complication))))) (, ,) (NP (NP (NP (DT the) (JJ marked) (NN slowing)) (PP (IN of) (NP (NN motor) (NN nerve) (NN conduction) (NN velocity)))) (CC and) (NP (DT the) (JJ electromyographic) (NNS changes))) (VP (VBP imply) (ADVP (RB mainly)) (NP (DT a) (NN Doc_220563_407_429_Disease))) (. .)))
220563	3	(S1 (S (NP (NN Improvement)) (VP (AUX was) (VP (VBN noted) (PP (IN with) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy))))))) (. .)))
220563	4	(S1 (S (PP (IN In) (NP (DT a) (JJ few) (NNS cases))) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ active) (NN denervation)))) (VP (VBD signified) (NP (NP (DT a) (JJ poor) (NN prognosis)) (, ,) (PP (IN with) (NP (JJ only) (JJ slight) (NN improvement))))) (. .)))
220563	5	(S1 (S (NP (NP (DT The) (JJ underlying) (NN mechanism)) (VP (VBG causing) (NP (DT the) (NNP Doc_220563_625_635_Disease)))) (VP (AUX is) (ADJP (ADVP (RB not) (CC yet) (RB fully)) (VBN known)) (, ,) (SBAR (IN although) (S (NP (DT some) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (PRP it)) (VP (MD may) (VP (AUX be) (NP (DT a) (NN lipid) (NN storage) (NN process)))))))))) (. .)))
2224762	0	(S1 (NP (NP (DT A) (NN phase)) (NP (NP (PRP I) (NN study)) (PP (IN of) (NP (NNP Doc_2224762_19_51_Chemical)))) (. .)))
2224762	1	(S1 (NP (NP (NP (JJ Clinical) (NNS pharmacology)) (CC and) (NP (NNS pharmacokinetics))) (. .)))
2224762	2	(S1 (S (NP (NP (DT A) (NN Phase) (NN I) (NN study)) (PP (IN of) (NP (NP (JJ intravenous) (PRN (-LRB- -LRB-) (NP (NNP IV)) (-RRB- -RRB-)) (JJ bolus) (NNP Doc_2224762_139_171_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2224762_173_184_Chemical)) (-RRB- -RRB-))))) (VP (AUX was) (VP (AUX done) (PP (IN in) (NP (NP (CD 55) (NNS patients)) (PP (IN in) (NP (NP (JJ good) (NN performance) (NN status)) (PP (IN with) (NP (JJ refractory) (NN Doc_2224762_253_259_Disease))))))))) (. .)))
2224762	3	(S1 (S (S (NP (NN Twenty-six)) (VP (AUX had) (NP (NP (JJ minimal) (JJ prior) (NN therapy)) (PRN (-LRB- -LRB-) (NP (JJ good) (NN risk)) (-RRB- -RRB-))))) (, ,) (S (NP (CD 23)) (VP (AUX had) (NP (NP (JJ extensive) (JJ prior) (NN therapy)) (PRN (-LRB- -LRB-) (NP (JJ poor) (NN risk)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (CD six)) (VP (AUX had) (NP (NN Doc_2224762_367_399_Disease)))) (. .)))
2224762	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 167) (NNS courses))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 15) (TO to) (CD 70)) (NNS mg/m2)))))) (VP (AUX were) (ADJP (JJ evaluable))) (. .)))
2224762	5	(S1 (S (S (NP (NP (JJ Maximum) (JJ tolerated) (NN dose)) (PP (IN in) (NP (JJ good-risk) (NNS patients)))) (VP (AUX was) (NP (CD 70) (NN mg/m2)))) (, ,) (CC and) (S (PP (IN in) (NP (JJ poor-risk) (NNS patients))) (, ,) (NP (CD 60) (NNS mg/m2))) (. .)))
2224762	6	(S1 (S (NP (DT The) (JJ dose-limiting) (NN toxic) (NN effect)) (VP (AUX was) (NP (JJ transient) (JJ noncumulative) (NN Doc_2224762_622_638_Disease))) (. .)))
2224762	7	(S1 (S (S (NP (NNP Granulocyte) (NNP nadir)) (VP (AUX was) (PP (IN on) (NP (NN day) (CD 14))))) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 4-22)) (-RRB- -RRB-)) (. .)))
2224762	8	(S1 (S (NP (ADJP (RBR Less) (JJ frequent)) (JJ toxic) (NNS effects)) (VP (VBD included) (NP (NP (NNP Doc_2224762_724_740_Disease)) (, ,) (NP (NNP Doc_2224762_742_748_Disease)) (, ,) (NP (NNP Doc_2224762_750_756_Disease)) (, ,) (NP (JJ mild) (NNP Doc_2224762_763_771_Disease)) (, ,) (NP (NNP Doc_2224762_773_782_Disease)) (, ,) (CC and) (NP (NNP Doc_2224762_788_797_Disease)))) (. .)))
2224762	9	(S1 (S (NP (NN Doc_2224762_799_815_Disease)) (VP (AUX was) (ADVP (RBR more)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2224762_842_861_Disease)))))) (. .)))
2224762	10	(S1 (S (NP (NP (JJ Pharmacokinetic) (NNS analyses)) (PP (IN in) (NP (CD 21) (NNS patients)))) (VP (VBD revealed) (SBAR (S (NP (NNP Doc_2224762_912_923_Chemical) (NN plasma) (NNS T)) (VP (VBD 1/2) (NP (NP (NN alpha)) (PRN (-LRB- -LRB-) (NP (JJ +/-) (FW SE)) (-RRB- -RRB-)) (PP (IN of) (NP (CD 2.5) (JJ +/-) (CD 0.85) (NNS minutes)))) (, ,) (S (VP (VP (VBG T) (NP (NP (JJ beta) (NNS 1/2)) (PP (IN of) (NP (CD 25.6) (JJ +/-) (CD 6.5) (NNS minutes))))) (, ,) (CC and) (VP (VBG T) (NP (NP (CD 1/2) (NN gamma)) (PP (IN of) (NP (CD 23.6) (JJ +/-) (CD 7.6) (NNS hours))))))))))) (. .)))
2224762	11	(S1 (S (S (NP (NP (DT The) (NN area)) (PP (IN under) (NP (DT the) (NN curve)))) (VP (AUX was) (NP (NP (CD 537) (NN +/-) (CD 149) (NNP ng/ml) (NNP x) (NNS hours)) (, ,) (NP (NP (NP (NP (NN volume)) (PP (IN of) (NP (NP (NN distribution)) (PRN (-LRB- -LRB-) (NP (NNP Vd)) (-RRB- -RRB-))))) (NP (CD 3504) (NNS +/-))) (NP (CD 644) (NNS l/m2)))))) (, ,) (CC and) (S (NP (NP (JJ total) (NN clearance)) (PRN (-LRB- -LRB-) (NP (NNP ClT)) (-RRB- -RRB-))) (VP (AUX was) (NP (QP (CD 204) (CD +)) (QP (CD 39.3) (CD l/hour/m2))))) (. .)))
2224762	12	(S1 (S (S (NP (NP (NNP Doc_2224762_1207_1219_Chemical)) (, ,) (NP (NNP Doc_2224762_1221_1232_Chemical)) (, ,) (NP (NNP Doc_2224762_1234_1247_Chemical)) (, ,) (CC and) (NP (NNP Doc_2224762_1253_1282_Chemical))) (VP (AUX were) (NP (NP (DT the) (NNS metabolites)) (VP (VBN detected) (PP (IN in) (NP (NN plasma))))))) (CC and) (S (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NNP Doc_2224762_1341_1352_Chemical)))) (VP (AUX was) (ADJP (ADJP (JJR less) (PP (IN than))) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (DT the) (JJ total) (NNS metabolites))))))))) (. .)))
2224762	13	(S1 (S (NP (NP (JJ Urinary) (NN excretion)) (PP (IN of) (NP (NNP Doc_2224762_1430_1441_Chemical))) (PP (IN in) (NP (DT the) (JJ first) (CD 24) (NNS hours)))) (VP (AUX was) (UCP (ADVP (RBR less) (IN than)) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (CD 10) (NN %)))))) (. .)))
2224762	14	(S1 (S (NP (NN Activity)) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (NNP Doc_2224762_1517_1529_Disease)) (, ,) (NP (NNP Doc_2224762_1531_1545_Disease)) (, ,) (CC and) (NP (NNP Doc_2224762_1551_1571_Disease)))))) (. .)))
2224762	15	(S1 (S (NP (NP (DT The) (VBN recommended) (NN starting) (NN dose)) (PP (IN for) (NP (NN Phase) (NNP II) (NNS trials)))) (VP (AUX is) (NP (NP (CD 60) (JJ mg/m2) (NNP IV) (NN bolus)) (NP (DT every) (CD 3) (NNS weeks)))) (. .)))
2234245	0	(S1 (NP (NP (NN Doc_2234245_0_28_Disease)) (PP (IN in) (NP (NP (JJ hemodialyzed) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_2234245_64_79_Chemical))))) (. .)))
2234245	1	(S1 (S (PP (IN During) (NP (NP (DT an) (JJ 18-month) (NN period)) (PP (IN of) (NP (NN study))))) (NP (NP (CD 41) (JJ hemodialyzed) (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_2234245_151_166_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 10-40) (NN mg/kg)) (NP (CD BW/3) (NNS times) (JJ weekly))) (-RRB- -RRB-))) (PP (IN for) (NP (DT the) (JJ first) (NN time))))) (VP (AUX were) (VP (VBN monitored) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (NP (NNP Doc_2234245_250_270_Disease.) (CD 6) (NNS patients)) (VP (VBN presented) (NP (NP (JJ clinical) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_2234245_314_341_Disease))))))))))) (. .)))
2234245	2	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ detailed) (NN ophthalmologic)) (CC and) (NP (JJ audiologic) (NNS studies))) (VP (VBD disclosed) (NP (NP (NNS abnormalities)) (PP (IN in) (NP (QP (CD 7) (JJR more)) (JJ asymptomatic) (NNS patients))))) (. .)))
2234245	3	(S1 (S (NP (NN Doc_2234245_457_472_Disease)) (VP (VP (AUX was) (PP (IN of) (NP (JJ retinal) (NN origin)))) (CC and) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (DT a) (JJ tritan-type) (NN Doc_2234245_534_548_Disease)) (, ,) (VP (ADVP (RB sometimes)) (VBN associated) (PP (IN with) (NP (NP (NNP Doc_2234245_576_599_Disease)) (CC and) (NP (NNP Doc_2234245_604_631_Disease)))))))))) (. .)))
2234245	4	(S1 (S (NP (NN Doc_2234245_633_650_Disease)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (DT a) (NN mid-)) (PP (TO to) (NP (JJ high-frequency) (NNP Doc_2234245_697_724_Disease)))) (CC and) (NP (NP (DT the) (NN lesion) (AUX was)) (PP (IN of) (NP (DT the) (JJ cochlear) (NN type)))))))) (. .)))
2234245	5	(S1 (S (NP (JJ Doc_2234245_766_781_Chemical) (NN withdrawal)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ complete) (NN recovery)) (PP (IN of) (NP (JJ visual) (NN function))))) (PP (IN in) (NP (NP (NP (NP (NP (CD 1) (JJ patient) (CC and) (JJ partial) (NN recovery)) (PP (IN in) (NP (NNP 3)))) (, ,) (CC and) (NP (NP (DT a) (JJ complete) (NN reversal)) (PP (IN of) (NP (NNP Doc_2234245_911_923_Disease))))) (PP (IN in) (NP (CD 3) (NNS patients)))) (CC and) (NP (NP (JJ partial) (NN recovery)) (PP (IN in) (NP (NNP 3))))))) (. .)))
2234245	6	(S1 (S (NP (DT This) (NN Doc_2234245_970_978_Disease)) (VP (VP (VBD appeared) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (DT the) (JJR higher) (NNS doses)) (PP (IN of) (NP (NNP Doc_2234245_1030_1045_Chemical)))))))) (CC or) (VP (VBD coincided) (PP (IN with) (NP (NP (DT the) (NN normalization)) (PP (IN of) (NP (JJ ferritin) (CC or) (JJ Doc_2234245_1097_1106_Chemical) (NN serum) (NNS levels))))))) (. .)))
2234245	7	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_2234245_1144_1164_Disease)) (VP (AUX is) (RB not) (NP (NP (DT an) (JJ infrequent) (NN complication)) (PP (IN in) (NP (NP (JJ hemodialyzed) (NNS patients)) (VP (VBG receiving) (NP (NN Doc_2234245_1234_1249_Chemical)))))))))) (. .)))
2234245	8	(S1 (S (NP (JJ Periodical) (NNP audiovisual) (NN monitoring)) (VP (MD should) (VP (AUX be) (VP (VBN performed) (PP (IN on) (NP (NP (JJ hemodialyzed) (NNS patients)) (VP (VBG receiving) (NP (DT the) (NN drug)) (PP (IN in) (NP (NN order)))))) (S (VP (TO to) (VP (VB detect) (NP (JJ adverse) (NNS effects)) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (ADJP (JJ possible)))))))))) (. .)))
2265898	0	(S1 (S (NP (JJ Serial) (NN Doc_2265898_7_15_Disease)) (VP (VBD caused) (PP (IN by) (NP (NNP Doc_2265898_26_44_Chemical) (NN administration))) (PP (IN in) (NP (NP (CD two) (NNS patients)) (PP (IN on) (NP (NN hemodialysis)))))) (. .)))
2265898	1	(S1 (S (S (NP (NP (CD Two) (NNS patients)) (PP (IN with) (NP (JJ similar) (JJ clinical) (NNS features)))) (VP (AUX are) (VP (VBN presented)))) (: :) (S (S (NP (DT both) (NNS patients)) (VP (VP (AUX had) (NP (NNP Doc_2265898_170_191_Disease)) (, ,) (PP (IN on) (NP (NN hemodialysis))) (PP (IN for) (NP (JJ many) (NNS years)))) (CC but) (VP (ADVP (RB recently)) (VBN begun) (PP (IN on) (NP (DT a) (JJ high-flux) (NN dialyzer)))))) (: ;) (S (NP (DT both)) (VP (AUX had) (VP (AUX been) (VP (VBG receiving) (NP (DT a) (JJ Doc_2265898_294_312_Chemical) (NN preparation)))))) (: ;) (CC and) (S (NP (DT both)) (VP (AUX had) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_2265898_352_364_Disease)) (CC and) (NP (NP (JJ recurrent) (NNP Doc_2265898_379_387_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADJP (JJ refractory) (PP (TO to) (NP (NNS anticonvulsants)))))))))))))) (. .)))
2265898	2	(S1 (S (S (NP (DT The) (JJ first) (NN patient)) (VP (VBD died) (PP (IN without) (NP (DT a) (NN diagnosis))))) (: ;) (S (NP (DT the) (JJ second) (NN patient)) (VP (AUX had) (NP (DT a) (JJ dramatic) (NN recovery)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_2265898_550_560_Chemical))))))) (. .)))
2265898	3	(S1 (S (NP (DT Neither) (NN patient)) (VP (AUX was) (VP (VBN considered) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJ renal) (NN state) (ADJP (RB sufficiently) (JJ severe)) (NN enough)) (SBAR (S (VP (TO to) (VP (VB explain) (NP (PRP$ their) (NN presentation)))))))))))) (. .)))
2266990	0	(S1 (NP (NP (NNP Randomized)) (, ,) (NP (NP (JJ double-blind) (NN trial)) (PP (IN of) (NP (NNP Doc_2266990_34_42_Chemical))) (PP (IN in) (NP (NNP Doc_2266990_46_64_Disease)))) (. .)))
2266990	1	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NN evidence) (SBAR (IN that) (S (NP (NN growth) (NN hormone)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_2266990_141_149_Disease))) (PP (IN in) (NP (NNP Doc_2266990_153_171_Disease)))))))))))) (. .)))
2266990	2	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (NP (DT a) (JJ 12-month) (JJ controlled) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_2266990_217_225_Chemical)) (, ,) (NP (DT a) (JJ putative) (NN growth) (NN hormone) (NN secretion) (NN inhibitor)) (, ,))) (PP (IN in) (NP (NP (CD 83) (NNS boys)) (PP (IN with) (NP (NNP Doc_2266990_290_308_Disease))))))) (. .)))
2266990	3	(S1 (S (S (NP (NP (NN Muscle) (NN strength)) (, ,) (NP (NNS contractures)) (, ,) (NP (JJ functional) (NN ability)) (CC and) (NP (JJ pulmonary) (NN function))) (VP (AUX were) (VP (VBN tested) (PP (IN at) (NP (NN baseline)))))) (, ,) (CC and) (S (NP (QP (CD 6) (CC and) (CD 12)) (NNS months)) (PP (IN after) (NP (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_2266990_449_457_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 3) (NN mg/d)) (-RRB- -RRB-))) (CC or) (NP (NN placebo))))) (. .)))
2266990	4	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (NN power)) (PP (IN of) (NP (QP (JJR greater) (IN than) (CD 0.90)))) (SBAR (S (VP (TO to) (VP (VB detect) (NP (DT a) (NN slowing)) (PP (TO to) (NP (NP (CD 25) (NN %)) (PP (IN of) (NP (NP (DT the) (VBN expected) (NN rate)) (PP (IN of) (NP (NP (NN progression)) (PP (IN of) (NP (NNP Doc_2266990_605_613_Disease))))))))) (PP (IN at) (S (VP (VBG P) (NP (QP (JJR less) (IN than) (CD 0.05)))))))))))))))) (. .)))
2266990	5	(S1 (S (NP (NN Doc_2266990_635_643_Chemical)) (VP (AUX did) (RB not) (VP (VB benefit) (NP (NN strength)) (PP (IN at) (NP (NP (DT any) (NN point)) (PP (IN in) (NP (DT the) (NN study))))))) (. .)))
2266990	6	(S1 (S (S (NP (NP (NN Side) (NNS effects)) (ADJP (JJ attributable) (PP (TO to) (NP (NNP Doc_2266990_725_733_Chemical))))) (VP (VBD included) (NP (NP (NNP Doc_2266990_743_761_Disease)) (PRN (-LRB- -LRB-) (NP (CD 36) (NN %)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_2266990_769_778_Disease)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-)) (, ,) (NP (JJ behavioral) (NN change)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NP (NNP Doc_2266990_815_840_Disease) (PRN (-LRB- -LRB-) (NP (CD 18) (NN %)) (-RRB- -RRB-)) (: ;)) (NNP Doc_2266990_848_856_Chemical) (NN dosage)) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (CD 43) (NN %)) (PP (IN of) (NP (NNS patients)))))))) (. .)))
2266990	7	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_2266990_910_918_Chemical))) (PP (IN on) (NP (CD GH) (NN secretion)))) (VP (AUX was) (VP (VBN estimated) (ADVP (RB indirectly)) (PP (IN by) (S (VP (VBG comparing) (NP (NP (NP (DT the) (JJ postabsorptive) (JJ IGF-I) (NNS levels)) (VP (VBN obtained) (NP (NN following) (CD 3) (, ,) (CD 6) (, ,) (CD 9)))) (, ,) (CC and) (NP (CD 12) (NNS months))) (PP (IN in) (NP (NP (DT the) (NNP Doc_2266990_1054_1062_Chemical)) (VP (VBN treated) (PP (TO to) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (NN placebo) (NNS groups))))))))))))) (. .)))
2266990	8	(S1 (S (SBAR (IN Although) (S (NP (JJ Doc_2266990_1112_1120_Chemical-treated) (NNS patients)) (VP (VP (VBD gained) (NP (JJR less) (NN weight))) (CC and) (VP (NP (NN height)) (PP (IN than) (NP (JJ placebo-treated) (NNS patients))))))) (, ,) (NP (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (JJ IGF-I) (NNS levels)))) (VP (AUX was) (VP (VBN observed))) (. .)))
2266990	9	(S1 (S (NP (JJ Doc_2266990_1251_1259_Chemical) (NNS doses)) (VP (RB not) (VB slow) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_2266990_1294_1302_Disease))) (PP (IN in) (NP (NNP Doc_2266990_1306_1324_Disease))))) (. .)))
2273650	0	(S1 (NP (NP (NN Facilitation)) (PP (IN of) (NP (NN memory) (NN retrieval))) (PP (IN by) (NP (NP (JJ pre-test) (NN Doc_2273650_45_53_Chemical)) (CC and) (NP (NP (PRP$ its) (NN state) (NN dependency)) (PP (IN in) (NP (NP (DT the) (JJ step-through) (NN type) (NN passive) (NN avoidance)) (VP (VBG learning) (NP (NN test)) (PP (IN in) (NP (NNS mice))))))))) (. .)))
2273650	1	(S1 (S (S (NP (NP (NN Doc_2273650_145_152_Disease)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_2273650_165_176_Chemical)) (CC and) (NP (NNP Doc_2273650_181_194_Chemical)))))) (VP (AUX were) (VP (VBN reversed) (PP (IN by) (NP (NNP Doc_2273650_212_220_Chemical))) (S (VP (VBN given) (NP (CD 30) (NN min)) (PP (IN before) (NP (NP (DT the) (NN test) (NN trial)) (PRN (-LRB- -LRB-) (NP (NN pre-test)) (-RRB- -RRB-))))))))) (, ,) (CC and) (S (NP (JJ pre-test) (NNP Doc_2273650_281_289_Chemical)) (ADVP (RB also)) (VP (VBD facilitated) (NP (DT the) (NN memory) (NN retrieval)) (PP (IN in) (NP (NP (DT the) (NNS animals)) (VP (VBN administered) (NP (NNP Doc_2273650_356_364_Chemical)) (PP (IN during) (NP (DT the) (NN training) (NN trial)))))))) (. .)))
2273650	2	(S1 (S (S (ADVP (RB Similarly)) (, ,) (NP (JJ pre-test) (NNP Doc_2273650_412_423_Chemical)) (ADVP (RB partially)) (VP (VBD reversed) (NP (DT the) (JJ Doc_2273650_447_458_Chemical-induced) (NNP Doc_2273650_467_474_Disease)) (, ,) (FRAG (CC but) (RB not) (ADVP (RB significantly))))) (: ;) (CC and) (S (NP (JJ pre-test) (NNP Doc_2273650_512_525_Chemical)) (VP (VBD failed) (S (VP (TO to) (VP (VB reverse) (NP (DT the) (JJ Doc_2273650_548_561_Chemical-induced) (NNP Doc_2273650_570_577_Disease))))))) (. .)))
2273650	3	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN facilitation)) (PP (IN of) (NP (NN memory) (NN retrieval))) (PP (IN by) (NP (JJ pre-test) (NNP Doc_2273650_655_663_Chemical)))) (VP (MD might) (VP (AUX be) (NP (NP (DT the) (JJ direct) (NN action)) (PP (IN of) (NP (NNP Doc_2273650_694_702_Chemical)))) (PP (RB rather) (IN than) (NP (DT a) (ADJP (NN state) (JJ dependent)) (NN effect)))))))) (. .)))
227508	0	(S1 (S (NP (NN Doc_227508_0_8_Chemical)) (VP (VBZ reverses) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NNP Doc_227508_49_58_Chemical))))) (. .)))
227508	1	(S1 (S (PP (IN In) (NP (JJ unanesthetized) (, ,) (ADJP (RB spontaneously) (JJ Doc_227508_93_105_Disease)) (NNS rats))) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate)))) (VP (VBN produced) (PP (IN by) (NP (NP (JJ intravenous) (NNP Doc_227508_181_190_Chemical)) (, ,) (NP (QP (CD 5) (TO to) (CD 20)) (NN micrograms/kg)) (, ,))))) (VP (AUX was) (VP (VBD inhibited) (CC or) (VBN reversed) (PP (IN by) (NP (NP (NNP Doc_227508_244_252_Chemical)) (, ,) (NP (QP (CD 0.2) (TO to) (CD 2)) (NN mg/kg)))))) (. .)))
227508	2	(S1 (S (NP (NP (DT The) (JJ Doc_227508_274_285_Disease) (NN effect)) (PP (IN of) (NP (QP (CD 100) (CD mg/kg)) (NN Doc_227508_306_322_Chemical)))) (VP (AUX was) (ADVP (RB also)) (VP (ADVP (RB partially)) (VBN reversed) (PP (IN by) (NP (NNP Doc_227508_354_362_Chemical))))) (. .)))
227508	3	(S1 (S (NP (NN Doc_227508_364_372_Chemical)) (ADVP (RB alone)) (VP (AUX did) (RB not) (VP (VB affect) (ADVP (RB either)) (NP (NP (NN blood) (NN pressure)) (CC or) (NP (NN heart) (NN rate))))) (. .)))
227508	4	(S1 (S (PP (IN In) (NP (NP (NN brain) (NNS membranes)) (PP (IN from) (NP (ADJP (RB spontaneously) (JJ Doc_227508_469_481_Disease)) (NNS rats))))) (NP (NNP Doc_227508_487_496_Chemical)) (, ,) (NP (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (JJ -8) (-RRB- -RRB-)) (TO to) (CD 10)) (PRN (-LRB- -LRB-) (JJ -5) (-RRB- -RRB-)) (NP (NNP M)) (, ,)) (VP (AUX did) (RB not) (VP (VB influence) (S (VP (VP (VB stereoselective) (ADJP (JJ binding) (PP (IN of) (NP (NP (NP (NP (NNP Doc_227508_563_576_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 8) (NNS nM)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_227508_589_597_Chemical))) (, ,) (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (JJ -8) (-RRB- -RRB-)))))) (PP (TO to) (NP (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (JJ -4) (-RRB- -RRB-))) (NP (NNP M))))) (, ,) (VP (AUX did) (RB not) (VP (VB influence) (ADJP (JJ Doc_227508_637_646_Chemical-suppressible) (PP (VBG binding) (PP (IN of) (NP (NP (NNP Doc_227508_671_695_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN nM)) (-RRB- -RRB-)))))))))))) (. .)))
227508	5	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (PP (IN in) (NP (ADJP (RB spontaneously) (JJ Doc_227508_750_762_Disease)) (NNS rats))) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ central) (NN alpha-adrenoceptor) (NN stimulation)))) (VP (VBP involve) (NP (NP (NN activation)) (PP (IN of) (NP (NN opiate) (NNS receptors)))))))) (. .)))
227508	6	(S1 (S (SBAR (IN As) (S (NP (NNP Doc_227508_865_873_Chemical) (CC and) (NNP Doc_227508_878_887_Chemical)) (VP (AUX do) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (DT the) (JJ same) (NN receptor) (NN site)))))))))) (, ,) (NP (DT the) (JJ observed) (JJ functional) (NN antagonism)) (VP (VBZ suggests) (NP (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NP (DT an) (JJ endogenous) (NN opiate)) (PP (IN by) (NP (NNP Doc_227508_1026_1035_Chemical) (CC or) (NNP Doc_227508_1039_1055_Chemical)))))) (CC and) (NP (NP (DT the) (JJ possible) (NN role)) (PP (IN of) (NP (DT the) (NN opiate))) (PP (IN in) (NP (NP (DT the) (JJ central) (NN control)) (PP (IN of) (NP (JJ sympathetic) (NN tone)))))))) (. .)))
230316	0	(S1 (NP (NP (NP (NN Doc_230316_0_13_Disease)) (PP (IN of) (NP (NNP Doc_230316_17_46_Chemical)))) (: :) (NP (NP (JJ clinical) (NN analysis)) (PP (IN of) (NP (NP (NNS cases)) (VP (VBN reported) (PP (IN outside) (NP (NNP Japan))))))) (. .)))
230316	1	(S1 (S (NP (DT An) (NN analysis)) (VP (AUX is) (VP (VBN presented) (PP (IN of) (NP (NP (CD 220) (NNS cases)) (PP (IN of) (NP (JJ possible) (NN Doc_230316_149_159_Disease) (NNS reactions))))) (PP (TO to) (NP (NP (NNP Doc_230316_173_202_Chemical)) (VP (VBN reported) (PP (IN from) (PP (IN outside) (NP (NNP Japan))))))))) (. .)))
230316	2	(S1 (S (PP (PP (IN In) (NP (NP (CD 80) (NNS cases)) (SBAR (S (NP (JJ insufficient) (NN information)) (VP (AUX was) (ADJP (JJ available) (PP (IN for) (NP (JJ adequate) (NN comment))))))))) (CC and) (PP (IN in) (NP (CD 29)))) (NP (NP (DT a) (NN relationship)) (PP (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_230316_354_364_Chemical)))))) (VP (MD could) (VP (AUX be) (VP (VBN excluded)))) (. .)))
230316	3	(S1 (S (PP (IN Of) (NP (DT the) (NN remainder))) (, ,) (NP (NP (DT a) (NN relationship)) (PP (TO to) (NP (NNP Doc_230316_420_430_Chemical)))) (VP (AUX was) (VP (VBN considered) (ADJP (ADJP (JJ probable) (PP (IN in) (NP (CD 42)))) (CC and) (ADJP (JJ possible) (PP (IN in) (NP (CD 69) (NNS cases))))))) (. .)))
230316	4	(S1 (S (PP (IN In) (NP (NP (CD six)) (PP (IN of) (NP (DT the) (JJ probable) (NNS cases))))) (NP (DT the) (NNP Doc_230316_520_544_Disease)) (VP (VBD consisted) (PP (IN of) (NP (NP (DT an) (JJ acute) (JJ reversible) (NN Doc_230316_578_592_Disease)) (VP (ADVP (RB usually)) (VBN related) (PP (TO to) (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (NP (DT a) (JJ high) (NN dose)) (PP (IN of) (NP (NNP Doc_230316_644_654_Chemical))) (PP (IN over) (NP (DT a) (JJ short) (NN period))))))))))) (. .)))
230316	5	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (NN manifestation)) (, ,) (VP (VBN observed) (PP (IN in) (NP (CD 15) (JJ further) (NNS cases)))) (, ,)) (VP (AUX was) (VP (VBN isolated) (NP (NN Doc_230316_750_763_Disease)))) (. .)))
230316	6	(S1 (S (NP (DT This)) (VP (AUX was) (ADVP (RBS most) (RB frequently)) (VP (VBN found) (PP (IN in) (NP (NP (NNS children)) (, ,) (SBAR (WHNP (NP (DT many)) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX had) (VP (VBN received) (NP (NNP Doc_230316_835_845_Chemical)) (PP (IN as) (NP (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_230316_863_891_Disease))))))))))))) (. .)))
230316	7	(S1 (S (PP (IN In) (NP (DT the) (JJ remaining) (NNS cases))) (, ,) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_230316_934_944_Disease)) (, ,) (NP (NNP Doc_230316_946_964_Disease)) (, ,) (CC and) (NP (NNP Doc_230316_970_991_Disease))))) (VP (AUX was) (NP (DT the) (ADJP (RBS most) (JJ common)) (NN manifestation))) (. .)))
230316	8	(S1 (S (NP (NP (JJ Isolated) (NNP Doc_230316_1036_1046_Disease) (CC or) (NNP Doc_230316_1050_1071_Disease)) (, ,) (CC or) (NP (NP (DT these) (NNS manifestations)) (VP (VBG occurring) (ADVP (RB together)))) (, ,)) (VP (AUX were) (ADJP (JJ infrequent))) (. .)))
230316	9	(S1 (S (NP (NP (DT The) (NN onset)) (PP (IN of) (NP (DT all) (NNS manifestations)))) (PRN (-LRB- -LRB-) (PP (IN except) (NP (JJ toxic) (NNP Doc_230316_1180_1194_Disease))) (-RRB- -RRB-)) (VP (AUX was) (ADVP (RB usually)) (NP (NN subacute)) (, ,) (PP (IN with) (NP (JJ subsequent) (JJ partial) (NN recovery)))) (. .)))
230316	10	(S1 (S (NP (JJR Older) (NNS subjects)) (VP (VBD tended) (S (VP (TO to) (VP (VB display) (NP (JJR more) (NN side) (NNS effects)))))) (. .)))
230316	11	(S1 (S (S (NP (NP (DT The) (JJ full) (NN syndrome)) (PP (IN of) (NP (JJ subacute) (NNP Doc_230316_1334_1356_Disease)))) (VP (AUX was) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (NNS women))))) (, ,) (CC but) (S (NP (PRP they)) (VP (VBD tended) (S (VP (TO to) (VP (AUX have) (VP (VBN taken) (NP (NP (JJR greater) (NNS quantities)) (PP (IN of) (NP (DT the) (NN drug)))))))))) (. .)))
2304736	0	(S1 (NP (JJ Doc_2304736_0_8_Chemical-induced) (NN Doc_2304736_17_36_Disease) (. .)))
2304736	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NP (JJ genuine) (NN Doc_2304736_56_75_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_2304736_83_91_Chemical)) (, ,) (NP (DT a) (JJ common) (NN antihypertensive) (NN drug)) (, ,))))))) (VP (AUX is) (VP (VBN presented))) (. .)))
2304736	2	(S1 (S (NP (NN Doc_2304736_139_147_Chemical)) (VP (VBZ exerts) (NP (PRP$ its) (JJ antihypertensive) (NNS effects)) (PP (IN through) (NP (NP (NN vasodilatation)) (VP (VBN caused) (PP (IN by) (NP (NP (JJ selective) (NN blockade)) (PP (IN of) (NP (JJ postsynaptic) (JJ alpha-1) (JJ adrenergic) (NNS receptors))))))))) (. .)))
2304736	3	(S1 (S (PP (IN As) (NP (DT an) (NN alpha-blocker))) (, ,) (NP (PRP it)) (ADVP (RB also)) (VP (VBZ exerts) (NP (NP (DT a) (JJ significant) (JJ relaxant) (NN effect)) (PP (IN on) (NP (DT the) (NN bladder) (NN neck) (CC and) (NN urethra))))) (. .)))
2304736	4	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (JJ clinical) (NN course)) (VP (AUX is) (VP (VP (VBN described)) (CC and) (VP (VBN correlated) (PP (IN with) (NP (NP (JJ initial) (JJ urodynamic) (NNS studies) (NN while)) (PP (IN on) (NP (NP (NNP Doc_2304736_480_488_Chemical)) (CC and) (NP (JJ subsequent) (NNS studies)))))) (SBAR (IN while) (S (VP (VBG taking) (NP (NNP Doc_2304736_525_534_Chemical)))))))) (. .)))
2304736	5	(S1 (S (NP (PRP$ Her) (NNP Doc_2304736_540_552_Disease)) (VP (VBN resolved) (PP (IN with) (NP (NP (DT the) (NN change)) (PP (IN of) (NP (NN medication)))))) (. .)))
2304736	6	(S1 (S (NP (NP (DT The) (NN restoration)) (PP (IN of) (NP (NN continence)))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ substantial) (NN rise)) (PP (IN in) (NP (NP (JJ maximum) (JJ urethral) (NN pressure)) (, ,) (NP (NN maximum) (NN urethral) (NN closure) (NN pressure)) (, ,) (CC and) (NP (JJ functional) (JJ urethral) (NN length)))))))) (. .)))
2304736	7	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP present) (PP (IN with) (NP (NNP Doc_2304736_784_803_Disease))) (SBAR (IN while) (S (VP (VBG taking) (NP (NN Doc_2304736_817_825_Chemical))))))))) (VP (MD should) (VP (VB change) (NP (PRP$ their) (JJ antihypertensive) (NN medication)) (PP (IN before) (S (VP (VBG considering) (NP (NN surgery))))) (, ,) (SBAR (IN because) (S (NP (PRP$ their) (NN Doc_2304736_916_928_Disease)) (VP (MD may) (VP (VB resolve) (ADVP (RB spontaneously)) (PP (IN with) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NN drug) (NN therapy))))))))))) (. .)))
2312209	0	(S1 (S (VP (VB Doc_2312209_0_21_Disease) (S (VP (VBG following) (NP (NP (NN sublingual) (NN administration)) (PP (IN of) (NP (NNP Doc_2312209_61_81_Chemical))))))) (. .)))
2312209	1	(S1 (S (NP (NP (DT A) (NN 78-year-old)) (PP (IN with) (NP (VBN healed) (JJ septal) (NN Doc_2312209_116_124_Disease)))) (VP (VBD suffered) (NP (NP (DT a) (JJ recurrent) (NN Doc_2312209_146_167_Disease)) (PP (IN of) (NP (DT the) (NNP anterior) (NN wall)))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_2312209_221_241_Chemical) (CD 5))) (VP (VBN mg) (ADVP (RB sublingually)))))) (. .)))
2312209	2	(S1 (S (PP (IN After) (S (VP (VBG detailing) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNS events))))))) (, ,) (NP (PRP we)) (VP (VB discuss) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ paradoxical) (JJ coronary) (NNP Doc_2312209_343_348_Disease)) (CC and) (NP (NNP Doc_2312209_353_364_Disease-mediated) (NNP Doc_2312209_374_393_Disease)))) (VP (VBG occurring) (NP (ADJP (JJ downstream) (TO to) (JJ significant)) (NNP Doc_2312209_430_456_Disease)) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NNP Doc_2312209_483_511_Disease)))))))) (. .)))
2334618	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (DT the) (JJ respiratory) (NNS effects)) (PP (IN of) (NP (NP (JJ i.v.) (NNS infusions)) (PP (IN of) (NP (NP (NNP Doc_2334618_59_67_Chemical)) (CC and) (NP (JJ regional) (NNS analgesia)))))))) (PP (IN by) (NP (JJ extradural) (NN block))) (. .)))
2334618	1	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ postoperative) (JJ respiratory) (NN Doc_2334618_155_161_Disease)))) (VP (AUX was) (VP (VBN compared) (PP (IN between) (NP (NP (NP (CD five) (NNS patients)) (VP (VBG receiving) (NP (NP (DT a) (JJ continuous) (JJ i.v.) (NN infusion)) (PP (IN of) (NP (NNP Doc_2334618_237_245_Chemical)))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (CD 73.6) (NN mg)))) (-RRB- -RRB-)))) (CC and) (NP (NP (CD five) (NNS patients)) (VP (VBG receiving) (NP (NP (DT a) (JJ continuous) (JJ extradural) (NN infusion)) (PP (IN of) (NP (ADJP (CD 0.25) (NN %)) (NNP Doc_2334618_331_342_Chemical))) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (CD 192) (NN mg)))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (JJ 24-h) (NN period)) (PP (VBG following) (NP (JJ upper) (JJ abdominal) (NN surgery))))))))))) (. .)))
2334618	2	(S1 (S (S (NP (NN Monitoring)) (VP (VBN consisted) (PP (IN of) (NP (NN airflow) (NN detection))) (PP (IN by) (NP (DT a) (JJ Doc_2334618_458_472_Chemical) (NN analyser))))) (, ,) (S (NP (NN chest) (NN wall) (NN movement)) (VP (VBN detected) (PP (IN by) (NP (JJ pneumatic) (NNS capsules))))) (, ,) (CC and) (S (NP (JJ continuous) (NN electrocardiograph)) (VP (VBD recorded) (PP (IN with) (NP (DT a) (NNP Holter) (JJ ambulatory) (NN monitor))))) (. .)))
2334618	3	(S1 (S (NP (NP (DT Both) (NNP Doc_2334618_617_666_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (VP (VBD occurred) (ADVP (RBR more) (RB frequently)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (DT a) (JJ Doc_2334618_733_741_Chemical) (NN infusion)))))))) (. .)))
2334618	4	(S1 (S (NP (EX There)) (VP (AUX was) (ADVP (RB also)) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (NP (NP (NNP Doc_2334618_789_805_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2334618_829_854_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (JJ Doc_2334618_881_889_Chemical) (NN infusion) (NN group))))) (. .)))
234669	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_234669_11_24_Chemical))) (PP (IN on) (NP (NP (DT the) (NN threshold)) (PP (IN for) (S (VP (VBG initiating) (NP (NNP Doc_234669_57_81_Disease)) (PP (IN during) (NP (NN Doc_234669_89_108_Disease)))))))) (. .)))
234669	1	(S1 (S (NP (NN Doc_234669_110_129_Disease)) (VP (AUX have) (ADVP (RB frequently)) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NNP Doc_234669_180_199_Disease)))))))) (. .)))
234669	2	(S1 (S (NP (NP (DT The) (JJ possible) (JJ additive) (NN role)) (PP (IN of) (NP (JJ pharmacologic) (NNS agents))) (PP (IN in) (S (VP (VBG precipitating) (NP (NN Doc_234669_269_289_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_234669_307_326_Disease))))))))) (VP (AUX has) (ADVP (RB only) (RB recently)) (VP (AUX been) (VP (VBN emphasized)))) (. .)))
234669	3	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_234669_377_390_Chemical))) (PP (IN on) (NP (DT the) (NNP Doc_234669_398_422_Disease) (NN threshold))) (PP (PP (IN during) (NP (JJ normal) (JJ acid-base) (NNS conditions))) (CC and) (PP (IN during) (NP (NNP Doc_234669_479_498_Disease))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (JJ anesthetized) (JJ open) (NN chest) (NNS dogs))))) (. .)))
234669	4	(S1 (S (NP (DT The) (NNP Doc_234669_549_573_Disease) (NN threshold)) (VP (AUX was) (VP (VBN measured) (PP (IN by) (S (VP (VBG passing) (NP (NP (DT a) (JJ gated) (NN train)) (PP (IN of) (NP (CD 12) (JJ constant) (JJ current) (NNS pulses)))) (PP (IN through) (NP (NP (DT the) (JJ ventricular) (NN myocardium)) (PP (IN during) (NP (NP (DT the) (JJ vulnerable) (NN period)) (PP (IN of) (NP (DT the) (JJ cardiac) (NN cycle)))))))))))) (. .)))
234669	5	(S1 (S (PP (IN During) (NP (NP (DT the) (NN infusion)) (PP (IN of) (NP (NNP Doc_234669_761_774_Chemical))))) (, ,) (NP (DT the) (NNP Doc_234669_780_804_Disease) (NN threshold)) (VP (AUX was) (VP (VBN reduced) (PP (IN by) (NP (NP (QP (CD 30) (TO to) (CD 40)) (NN percent)) (PP (IN of) (NP (DT the) (NN control))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ pH) (CC and) (JJ partial) (NNS pressures)) (PP (IN of) (NP (NP (NP (NNP Doc_234669_895_901_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_234669_903_906_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_234669_912_926_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_234669_928_931_Chemical)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN kept) (PP (IN within) (NP (JJ normal) (NNS limits))))))))) (. .)))
234669	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNP Doc_234669_970_989_Disease)) (VP (AUX was) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_234669_1006_1021_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (RB pH) (CD 7.05) (TO to) (CD 7.25))) (: ;) (NP (NP (QP (CD PC02) (CD 70) (TO to) (CD 100)) (NNS mm)) (NP (NNP Hg))) (: :) (NP (NP (QP (CD P02) (CD 20) (TO to) (CD 40)) (NNS mm)) (NP (NNP Hg)))) (-RRB- -RRB-)))))))) (, ,) (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_234669_1095_1108_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (ADJP (RB even) (JJR greater)) (NN decrease)) (PP (IN in) (NP (NP (JJ Doc_234669_1149_1173_Disease) (NN threshold)) (PP (TO to) (NP (NP (CD 60) (NN percent)) (PP (IN of) (NP (DT the) (NN control) (NN level)))))))))) (. .)))
234669	7	(S1 (S (NP (DT These) (NNS experiments)) (VP (VBP suggest) (SBAR (IN that) (S (SBAR (IN although) (S (NP (JJ many) (NNS factors)) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (VBN increased) (NN incidence)) (PP (IN of) (NP (NNP Doc_234669_1318_1341_Disease))) (PP (IN in) (NP (NNP Doc_234669_1345_1364_Disease))))))))) (, ,) (NP (NP (JJ pharmacologic) (NNS agents)) (, ,) (ADJP (RB particularly) (JJ Doc_234669_1401_1414_Chemical)) (, ,)) (VP (MD may) (VP (VB play) (NP (DT a) (JJ significant) (NN role))))))) (. .)))
2348231	0	(S1 (S (S (NP (NP (NNP Doc_2348231_0_14_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2348231_16_23_Chemical)) (-RRB- -RRB-))) (VP (AUX does) (RB not) (VP (VB inhibit) (NP (JJ Doc_2348231_42_54_Chemical-induced) (JJ coronary) (NN Doc_2348231_72_81_Disease))))) (: :) (S (NP (NNS implications)) (PP (IN for) (NP (JJ Doc_2348231_100_112_Chemical-Doc_2348231_113_121_Chemical-201) (JJ myocardial) (NN imaging)))) (. .)))
2348231	1	(S1 (S (NP (CD Doc_2348231_146_158_Chemical-Doc_2348231_159_167_Chemical-201) (NN imaging)) (VP (AUX is) (ADVP (RB often)) (VP (VBN performed) (PP (IN in) (NP (NP (NNS patients)) (ADJP (JJ unable) (S (VP (TO to) (VP (VB exercise) (PP (IN because) (IN of) (NP (NN Doc_2348231_241_268_Disease))))))))))) (. .)))
2348231	2	(S1 (S (NP (NP (DT Many)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (AUX are) (VP (VBG taking) (NP (NP (NP (NNP Doc_2348231_304_318_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2348231_320_327_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ Doc_2348231_332_346_Chemical) (NN derivative)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB improve) (NP (NN Doc_2348231_376_401_Disease)))))))))) (. .)))
2348231	3	(S1 (S (SBAR (IN Whether) (S (NP (NNP Doc_2348231_411_425_Chemical)) (VP (VP (VBZ inhibits) (NP (JJ Doc_2348231_435_447_Chemical-induced) (JJ coronary) (NN Doc_2348231_465_474_Disease)) (PP (IN like) (NP (NP (JJ other) (JJ Doc_2348231_486_501_Chemical)) (PP (JJ such) (IN as) (NP (NNP Doc_2348231_510_522_Chemical)))))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN stopped) (ADVP (RB prior) (PP (TO to) (NP (CD Doc_2348231_554_566_Chemical-Doc_2348231_567_575_Chemical-201) (NN imaging)))))))))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
2348231	4	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (JJ hyperemic) (NN response)) (PP (TO to) (NP (NNP Doc_2348231_648_660_Chemical)))) (PP (IN in) (NP (CD seven) (JJ open-chest) (JJ anesthetized) (NNS dogs))) (PP (IN after) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NP (DT either) (NNP Doc_2348231_730_744_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0)) (, ,) (NP (CD 7.5)) (, ,) (CC or) (NP (CD 15) (JJ mg/kg) (NNS i.v.))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_2348231_775_787_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CD mg/kg)) (NNS i.v.)) (-RRB- -RRB-)))))))) (. .)))
2348231	5	(S1 (S (NP (NN Baseline) (NN circumflex) (JJ coronary) (NN blood) (NNS flows)) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN among) (NP (NN treatment) (NNS groups))))) (. .)))
2348231	6	(S1 (S (NP (NNP Doc_2348231_898_910_Chemical)) (ADVP (RB significantly)) (VP (VBD increased) (NP (JJ coronary) (NN blood) (NN flow)) (PP (IN before) (CC and) (IN after) (NP (NP (QP (CD 7.5) (CC or) (CD 15)) (NN mm/kg)) (PP (IN i.v.) (NP (NP (NNP Doc_2348231_993_1007_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.002))) (-RRB- -RRB-))))))) (. .)))
2348231	7	(S1 (S (CC Neither) (NP (NP (NN dose)) (PP (IN of) (NP (NNP Doc_2348231_1045_1059_Chemical)))) (ADVP (RB significantly)) (VP (VBD decreased) (NP (DT the) (JJ Doc_2348231_1088_1100_Chemical-induced) (NN Doc_2348231_1109_1118_Disease)) (, ,) (SBAR (IN while) (S (NP (JJ peak) (JJ coronary) (NN blood) (NN flow)) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN after) (NP (NP (NNP Doc_2348231_1181_1193_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))))) (. .)))
2348231	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_2348231_1231_1246_Chemical)) (VP (AUX does) (RB not) (VP (VB inhibit) (NP (JJ Doc_2348231_1264_1276_Chemical-induced) (JJ coronary) (NN Doc_2348231_1294_1303_Disease)) (ADVP (RB even)) (PP (IN at) (NP (JJ high) (NNS doses)))))))) (. .)))
2355241	0	(S1 (NP (NP (NP (NN Cause)) (PP (IN of) (NP (NNP Doc_2355241_9_14_Disease))) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2355241_35_54_Disease)))))) (: :) (NP (NP (DT a) (JJ rare) (NN mortality)) (ADJP (JJ due) (PP (TO to) (NP (NN Doc_2355241_80_100_Disease))))) (. .)))
2355241	1	(S1 (S (NP (NP (NNS Causes)) (PP (IN of) (NP (NNP Doc_2355241_112_117_Disease))) (, ,) (PP (IN with) (NP (NP (JJ special) (NN reference)) (PP (TO to) (NP (NNP Doc_2355241_145_165_Disease))))) (, ,)) (PP (IN among) (NP (NP (CD 240) (NNS patients)) (PP (IN with) (NP (ADJP (RB pathologically) (VBN verified)) (NNP Doc_2355241_215_234_Disease))))) (VP (AUX were) (VP (VBN investigated) (S (VP (VBG using) (NP (NP (DT the) (NNS Annuals)) (PP (IN of) (NP (NP (DT the) (JJ Pathological) (NNP Autopsy) (NNS Cases)) (PP (IN in) (NP (NNP Japan))))) (PP (PP (IN from) (NP (CD 1981))) (PP (TO to) (NP (CD 1985))))))))) (. .)))
2355241	2	(S1 (S (NP (NP (DT The) (JJ leading) (NNS causes)) (PP (IN of) (NP (NNP Doc_2355241_355_360_Disease)))) (VP (AUX were) (NP (NP (NP (NNP Doc_2355241_366_375_Disease) (CC and) (NNP Doc_2355241_380_390_Disease)) (PRN (-LRB- -LRB-) (NP (CD 44.1) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ malignant) (NNP Doc_2355241_410_419_Disease) (PRN (-LRB- -LRB-) (NP (CD 11.6) (NN %)) (-RRB- -RRB-) (, ,)) (NNP Doc_2355241_429_443_Disease)) (PRN (-LRB- -LRB-) (NP (CD 4.1) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_2355241_452_471_Disease) (PRN (-LRB- -LRB-) (NP (CD 3.7) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_2355241_483_494_Disease) (PRN (-LRB- -LRB-) (NP (CD 3.3) (NN %)) (-RRB- -RRB-))))) (. .)))
2355241	3	(S1 (S (NP (NN Doc_2355241_503_523_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ 11th) (ADJP (RBS most) (JJ frequent)) (NN cause)) (PP (IN of) (NP (NNP Doc_2355241_560_565_Disease)))) (, ,) (S (VP (VBG accounting) (PP (IN for) (NP (NP (QP (RB only) (CD 0.8)) (NN %)) (PP (IN of) (NP (NNP Doc_2355241_595_601_Disease))))) (PP (IN among) (NP (DT the) (NNS patients))))) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (AUX was) (NP (NP (DT the) (JJ 5th) (ADJP (RBS most) (JJ common)) (NN cause)) (PP (IN of) (NP (NNP Doc_2355241_666_671_Disease)))) (PP (IN among) (NP (NP (DT the) (JJ Japanese) (JJ general) (NN population)) (PP (IN in) (NP (CD 1985))))))))) (. .)))
2355241	4	(S1 (S (NP (NP (DT The) (JJ low) (NN incidence)) (PP (IN of) (NP (NNP Doc_2355241_740_760_Disease))) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (NP (NNP Doc_2355241_775_780_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2355241_798_817_Disease)))))))))) (VP (MD may) (VP (VB reflect) (NP (NP (NP (DT the) (JJ Doc_2355241_834_845_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_2355241_856_864_Chemical)))) (CC and) (NP (NP (DT a) (JJ Doc_2355241_871_882_Disease) (NN mechanism)) (PP (JJ due) (TO to) (NP (NP (VBN reduced) (JJ Doc_2355241_908_921_Chemical) (NNS levels)) (PP (IN in) (NP (DT the) (NNP Doc_2355241_936_948_Disease) (NN brain))))))))) (. .)))
2375138	0	(S1 (NP (JJ Possible) (JJ intramuscular) (JJ Doc_2375138_23_32_Chemical-associated) (NNP Doc_2375138_44_68_Disease) (CC and) (NNP Doc_2375138_73_78_Disease) (. .)))
2375138	1	(S1 (S (NP (NN Doc_2375138_80_103_Chemical)) (VP (AUX is) (ADVP (RB commonly)) (VP (VBN used) (PP (IN for) (NP (UCP (JJ dental) (CC or) (JJ endoscopic)) (NNS procedures))))) (. .)))
2375138	2	(S1 (S (SBAR (IN Although) (S (ADVP (RB generally)) (VP (VBD consisted) (ADJP (JJ safe)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (NP (NN intramuscularly)))))))) (, ,) (NP (JJ intravenous) (NN administration)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NNP Doc_2375138_265_306_Disease))))))) (. .)))
2375138	3	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (DT the) (JJ first) (JJ published) (NN case)) (PP (IN of) (NP (NP (NNP Doc_2375138_358_382_Disease)) (CC and) (NP (NNP Doc_2375138_387_392_Disease)))) (VP (VBN associated) (PP (IN with) (NP (NP (NN intramuscular) (NN administration)) (PP (IN of) (NP (NNP Doc_2375138_441_450_Chemical)))))))) (. .)))
2375138	4	(S1 (S (NP (NP (NN Information)) (VP (VBG regarding) (NP (JJ Doc_2375138_474_483_Chemical) (NN use)))) (VP (AUX is) (VP (VBN reviewed) (S (VP (TO to) (VP (VB provide) (NP (NN recommendation)) (PP (IN for) (NP (JJ safe) (NN administration)))))))) (. .)))
2385256	0	(S1 (S (NP (NN Doc_2385256_0_17_Disease)) (VP (VBG presenting) (PP (IN as) (NP (NN weakness))) (PP (IN after) (NP (NNP Doc_2385256_47_56_Chemical) (NN administration)))) (. .)))
2385256	1	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (DT no) (JJ prior) (NN history)) (PP (IN of) (NP (NNP Doc_2385256_119_140_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD became) (ADJP (RB virtually) (JJ Doc_2385256_162_174_Disease)) (PP (IN after) (NP (NP (JJ parenteral) (JJ Doc_2385256_192_201_Chemical) (NN administration)) (PP (IN for) (NP (NNP Doc_2385256_221_233_Disease)))))))))))) (. .)))
2385256	2	(S1 (S (NP (DT The) (NN serum) (JJ Doc_2385256_245_254_Chemical) (NN concentration)) (VP (AUX was) (NP (NP (CD 3.0) (NN mEq/L)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB usually)) (VP (ADVP (RB well)) (VBN tolerated))))))) (. .)))
2385256	3	(S1 (S (S (NP (DT The) (NNP Doc_2385256_321_330_Chemical)) (VP (AUX was) (VP (VBN stopped)))) (CC and) (S (NP (PRP she)) (VP (VBD recovered) (PP (IN over) (NP (DT a) (JJ few) (NNS days))))) (. .)))
2385256	4	(S1 (S (SBAR (IN While) (S (NP (PRP she)) (VP (AUX was) (ADJP (JJ weak))))) (, ,) (NP (JJ 2-Hz) (JJ repetitive) (NN stimulation)) (VP (VBD revealed) (NP (DT a) (NN decrement)) (PP (IN without) (NP (JJ significant) (NN facilitation))) (PP (PP (IN at) (NP (JJ rapid) (NNS rates))) (CC or) (PP (IN after) (NP (NN exercise)))) (, ,) (S (VP (VBG suggesting) (NP (NN Doc_2385256_525_560_Disease))))) (. .)))
2385256	5	(S1 (S (SBAR (IN After) (S (NP (PRP$ her) (NN strength)) (VP (VBD returned)))) (, ,) (S (NP (JJ repetitive) (NN stimulation)) (VP (AUX was) (ADJP (JJ normal)))) (, ,) (CC but) (S (NP (JJ single) (NN fiber) (NNP EMG)) (VP (VBD revealed) (NP (VBN increased) (NN jitter) (CC and) (VBG blocking)))) (. .)))
2385256	6	(S1 (S (NP (PRP$ Her) (JJ Doc_2385256_691_704_Chemical) (NN receptor) (NN antibody) (NN level)) (VP (AUX was) (ADJP (RB markedly) (JJ elevated))) (. .)))
2385256	7	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_2385256_761_770_Disease) (IN after) (NNP Doc_2385256_777_786_Chemical) (NN administration)) (VP (AUX has) (VP (AUX been) (VP (VBN described) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ known) (NN Doc_2385256_844_861_Disease)))))))))) (, ,) (NP (PRP it)) (VP (AUX has) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ initial) (CC or) (JJ only) (NN manifestation)) (PP (IN of) (NP (DT the) (NN disease)))))))))) (. .)))
2385256	8	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (ADJP (RB unusually) (JJ sensitive) (PP (TO to) (NP (NP (DT the) (JJ neuromuscular) (NNS effects)) (PP (IN of) (NP (NNP Doc_2385256_1024_1033_Chemical)))))))))) (VP (MD should) (VP (AUX be) (VP (VBN suspected) (PP (IN of) (S (VP (AUXG having) (NP (DT an) (JJ underlying) (NN Doc_2385256_1078_1116_Disease)))))))) (. .)))
2396046	0	(S1 (NP (NP (DT No) (NN enhancement)) (PP (IN by) (NP (NP (NNP Doc_2396046_18_31_Chemical)) (PP (IN of) (NP (NP (DT the) (NN hepatocarcinogenicity)) (PP (IN of) (NP (NP (DT a) (JJ Doc_2396046_66_73_Chemical-devoid) (NN diet)) (PP (IN in) (NP (DT the) (NN rat))))))))) (. .)))
2396046	1	(S1 (S (NP (DT An) (NN experiment)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB test) (SBAR (IN whether) (S (NP (NP (NN inclusion)) (PP (IN of) (NP (NNP Doc_2396046_155_168_Chemical))) (PP (IN in) (NP (DT a) (JJ Doc_2396046_174_181_Chemical-devoid) (NN diet)))) (VP (MD would) (VP (VB increase) (NP (NP (DT the) (NN hepatocarcinogenicity)) (PP (IN of) (NP (DT the) (NN diet))))))))))))) (. .)))
2396046	2	(S1 (S (NP (NP (NNS Groups)) (PP (IN of) (NP (JJ 5-week) (JJ old) (NN male) (JJ Fischer-344) (NNS rats)))) (VP (AUX were) (VP (VBN fed) (PP (IN for) (NP (NP (CD 7-25) (NNS months)) (VP (VBN semipurified) (NP (NP (JJ Doc_2396046_329_336_Chemical-devoid) (CC or) (JJ Doc_2396046_347_354_Chemical-supplemented) (NNS diets)) (, ,) (VP (VBG containing) (NP (ADJP (QP (CC or) (RB not) (CD 0.06)) (NN %)) (NNP Doc_2396046_399_412_Chemical))))))))) (. .)))
2396046	3	(S1 (S (NP (NP (DT No) (JJ hepatic) (JJ preneoplastic) (NNS nodules) (CC or) (NN Doc_2396046_450_475_Disease)) (VP (VBN developed) (PP (IN in) (NP (NNS rats))))) (VP (VBN fed) (NP (DT the) (JJ plain) (JJ Doc_2396046_508_515_Chemical-supplemented) (NN diet)) (, ,) (SBAR (IN while) (S (NP (NP (CD one) (JJ preneoplastic) (NN nodule)) (CC and) (NP (CD one) (NN Doc_2396046_574_598_Disease))) (VP (VBD developed) (PP (IN in) (NP (NP (CD two) (NNS rats)) (VP (VBN fed) (NP (NP (DT the) (JJ same) (NN diet)) (VP (VBG containing) (NP (NNP Doc_2396046_650_663_Chemical))))))))))) (. .)))
2396046	4	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (PP (IN of) (NP (JJ preneoplastic) (NNS nodules))) (CC and) (PP (IN of) (NP (NNP Doc_2396046_711_736_Disease))))) (VP (AUX was) (NP (NP (NP (NP (CD 10) (NN %)) (CC and) (NP (CD 37) (NN %)) (, ,) (ADVP (RB respectively)) (, ,)) (PP (IN in) (NP (NNS rats))) (VP (VBN fed) (NP (DT the) (ADJP (RB plain) (JJ Doc_2396046_790_797_Chemical-devoid)) (NN diet)))) (, ,) (CC and) (NP (NP (NP (CD 17) (NN %)) (CC and) (NP (CD 30) (NN %)) (, ,)) (PP (IN in) (NP (NNS rats))) (VP (VBN fed) (NP (DT the) (JJ Doc_2396046_844_857_Chemical-containing) (JJ Doc_2396046_869_876_Chemical-devoid) (NN diet)))))) (. .)))
2396046	5	(S1 (S (NP (DT The) (NNS results)) (VP (VBN evinced) (NP (NP (DT no) (NN enhancement)) (PP (IN of) (NP (NP (DT the) (NN hepatocarcinogenicity)) (PP (IN of) (NP (DT the) (JJ Doc_2396046_961_968_Chemical-devoid) (NN diet)))))) (PP (IN by) (NP (NNP Doc_2396046_984_997_Chemical)))) (. .)))
2396046	6	(S1 (S (NP (JJ Sporadic) (JJ neoplastic) (NNS lesions)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (NNS organs)) (ADJP (JJ other) (PP (IN than) (NP (NP (DT the) (NN liver)) (PP (IN of) (NP (NP (DT some)) (PP (IN of) (NP (DT the) (NNS animals)))))))))) (, ,) (ADVP (RB irrespective) (PP (IN of) (NP (DT the) (NN diet) (NN fed)))))) (. .)))
2425813	0	(S1 (S (PP (IN On) (NP (NP (CD two) (JJ paradoxical) (NNS side-effects)) (PP (IN of) (NP (NP (NNP Doc_2425813_35_47_Chemical)) (PP (IN in) (NP (NNS rats))))))) (, ,) (NP (JJ ribosomal) (NNP RNA)) (VP (VP (VBZ biosyntheses)) (, ,) (CC and) (NP (NP (DT a) (NN mechanism)) (PP (IN of) (NP (NN action))))) (. .)))
2425813	1	(S1 (S (NP (NP (NNP Doc_2425813_112_129_Disease)) (CC and) (NP (NNP Doc_2425813_134_148_Disease))) (VP (VBD occurred) (PP (IN in) (NP (JJ Wistar) (NNS rats))) (PP (VBG following) (NP (NP (DT the) (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_2425813_218_230_Chemical)))))) (. .)))
2425813	2	(S1 (S (PP (IN In) (NP (DT the) (NN liver))) (NP (NP (NP (PDT both) (DT the) (NN content)) (PP (IN of) (NP (NNP RNA)))) (CC and) (NP (NP (DT the) (NN biosynthesis)) (PP (IN of) (NP (JJ ribosomal) (NNP RNA))))) (VP (VBD increased) (SBAR (IN while) (S (NP (DT both) (NP (DT the) (NNP RNA) (NN content)) (CC and) (NP (JJ ribosomal) (NNP RNA)) (NNS biosynthesis)) (VP (AUX were) (VP (VBN reduced) (PP (IN in) (NP (DT the) (JJ gastrocnemius) (NN muscle)))))))) (. .)))
2425813	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT the) (NN drug)) (VP (VBD acted) (PP (IN in) (NP (NP (DT a) (ADJP (JJ selective) (CC and) (JJ tissue-specific)) (NN manner)) (SBAR (S (VP (TO to) (VP (VP (VB enhance) (NP (NP (JJ ribosomal) (NNP RNA)) (NN synthesis)) (PP (IN in) (NP (DT the) (NN liver)))) (CC and) (VP (VB depress) (NP (JJ such) (NN synthesis)) (PP (IN in) (NP (DT the) (NN muscle))))))))))))))) (. .)))
2425813	4	(S1 (S (NP (DT This) (NN view)) (VP (VBZ supports) (NP (DT the) (NN contention) (SBAR (IN that) (S (NP (DT the) (NP (NN liver)) (CC and) (NP (NN muscle))) (VP (AUX are) (NP (NP (JJ independent) (NNS sites)) (PP (IN of) (NP (JJ Doc_2425813_670_682_Chemical) (NN action))))))))) (. .)))
2440413	0	(S1 (NP (NP (NN Differential) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_2440413_24_51_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_53_60_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (JJ pharmacologically-induced) (NNP Doc_2440413_91_99_Disease))) (. .)))
2440413	1	(S1 (S (NP (NP (NP (NNP Doc_2440413_101_128_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_130_139_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ active) (NN ingredient)) (PP (IN of) (NP (DT the) (JJ insecticide) (NNP Doc_2440413_183_190_Chemical)))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VP (VB decrease) (NP (JJ Doc_2440413_219_226_Disease) (NN threshold)) (PP (TO to) (NP (JJ pentylenetrazol) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_257_260_Chemical)) (-RRB- -RRB-)) (NNP 3) (NNP h))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NNP Doc_2440413_284_293_Chemical)))))) (CC and) (VP (ADVP (RB conversely)) (VB increase) (NP (NN threshold)) (PP (TO to) (NP (JJ Doc_2440413_331_334_Chemical-induced) (NX (NNP Doc_2440413_343_351_Disease) (CD 24) (NNP h)))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NNP Doc_2440413_375_384_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Vohland) (FW et) (NNP al.) (CD 1981)) (-RRB- -RRB-))))))))))))) (. .)))
2440413	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NP (NN response)) (PP (TO to) (NP (JJ other) (JJ Doc_2440413_457_464_Disease-inducing) (NNS agents)))))) (VP (AUX was) (VP (VBN tested) (PP (IN in) (NP (NNS mice))) (NP (CD 1) (CC and) (CD 24) (NNP h)) (PP (IN after) (NP (NP (JJ intraperitoneal) (NN administration)) (PP (IN of) (NP (QP (CD 80) (CD mg/kg)) (NN Doc_2440413_560_569_Chemical))))))) (. .)))
2440413	3	(S1 (S (NP (NP (CD One) (NN hour)) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_2440413_608_617_Chemical)))))) (, ,) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ Doc_2440413_635_642_Disease-inducing) (NNS agents)))) (VP (AUX was) (VP (VBN increased) (, ,) (ADVP (RB regardless) (PP (IN of) (NP (PRP$ their) (NN mechanism)))) (, ,) (SBAR (IN while) (S (NP (NP (CD 24) (NNP h) (IN after) (NNP Doc_2440413_722_731_Chemical)) (NP (DT a) (NN differential) (NN response))) (VP (AUX was) (VP (VBN observed))))))) (. .)))
2440413	4	(S1 (S (S (NP (NP (NN Doc_2440413_770_777_Disease) (NN activity)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_2440413_794_797_Chemical)) (CC and) (NP (NP (NNP Doc_2440413_802_812_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_814_817_Chemical)) (-RRB- -RRB-))))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN decreased)))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NNP Doc_2440413_857_864_Disease) (NN activity)) (VP (ADVP (RB due) (PP (TO to) (NP (NP (NP (NP (NNP Doc_2440413_881_905_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_907_910_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_2440413_913_924_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_926_929_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_2440413_932_986_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_988_992_Chemical)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NNP Doc_2440413_998_1008_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_1010_1013_Chemical)) (-RRB- -RRB-))))) (AUX was) (RB not) (ADJP (JJ different) (PP (IN from) (NP (NN control)))))) (. .)))
2440413	5	(S1 (S (PP (IN In) (NP (NN vitro))) (, ,) (NP (NNP Doc_2440413_1057_1066_Chemical) (, ,) (NNP Doc_2440413_1068_1085_Chemical) (CC and) (NNP Doc_2440413_1090_1100_Chemical)) (VP (AUX were) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (NNP Doc_2440413_1123_1130_Chemical) (VBG binding)) (PP (IN in) (NP (NN mouse) (JJ whole) (NN brain))) (, ,) (PP (IN with) (NP (NP (CD IC50) (NNS values)) (PP (IN of) (NP (CD 4.6) (, ,) (CD 404) (CC and) (CD 9.4) (NN microM))))) (, ,) (ADVP (RB respectively))))))) (. .)))
2440413	6	(S1 (S (NP (NP (NNP Doc_2440413_1220_1223_Chemical)) (, ,) (NP (NNP Doc_2440413_1225_1228_Chemical)) (, ,) (NP (NNP Doc_2440413_1230_1234_Chemical)) (, ,) (CC and) (NP (NNP Doc_2440413_1240_1243_Chemical))) (VP (VBD showed) (NP (NP (DT no) (NN inhibition)) (PP (IN of) (NP (NP (NNP Doc_2440413_1268_1275_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2440413_1277_1306_Chemical)) (-RRB- -RRB-))))) (PP (VBG binding) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN of) (NP (CD 100) (NN micron))))))) (. .)))
2440413	7	(S1 (S (NP (DT The) (JJ pharmacological) (NN challenge) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN tolerance)) (VP (MD may) (VP (VB occur) (PP (TO to) (NP (NP (JJ Doc_2440413_1420_1427_Disease) (NN activity)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_2440413_1448_1451_Chemical)) (CC and) (NP (NNP Doc_2440413_1456_1459_Chemical) (CD 24) (NNP h)))) (PP (IN after) (NP (NNP Doc_2440413_1471_1480_Chemical)))))) (, ,) (SBAR (IN since) (S (NP (NP (DT the) (NN response)) (PP (TO to) (NP (RB only) (DT these) (CD two) (JJ Doc_2440413_1519_1526_Disease-inducing) (NNS agents)))) (VP (AUX is) (VP (VBN decreased)))))))))) (. .)))
2440413	8	(S1 (S (NP (NP (DT The)) (PP (IN in) (NP (NN vitro) (NNS data)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN site)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NNP Doc_2440413_1629_1636_Disease) (NN activity) (CD 24))) (NP (NNP h) (IN after) (NNP Doc_2440413_1657_1666_Chemical)))))) (VP (MD may) (VP (AUX be) (NP (DT the) (JJ Doc_2440413_1678_1682_Chemical-A) (JJ receptor-linked) (NN chloride) (NN channel))))))) (. .)))
2445283	0	(S1 (NP (NP (NP (NN Tolerance)) (CC and) (NP (JJ antiviral) (NN effect))) (PP (IN of) (NP (NNP Doc_2445283_34_43_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2445283_61_88_Disease))))) (. .)))
2445283	1	(S1 (S (NP (NP (NN Tolerance)) (CC and) (NP (NP (JJ antiviral) (NN effect)) (PP (IN of) (NP (NNP Doc_2445283_124_133_Chemical))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (CD 6) (NNS patients))) (PP (IN with) (NP (NP (NP (NNP Doc_2445283_165_192_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2445283_194_197_Disease)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (QP (JJR more) (IN than) (CD 8)) (NNS days)) (PP (IN of) (NP (NN evolution))))))))) (. .)))
2445283	2	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_2445283_251_260_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN neutralization)) (PP (IN of) (NP (NNP Doc_2445283_293_300_Disease)))) (CC and) (NP (NP (DT a) (NN drop)) (PP (IN of) (NP (JJ endogenous) (NNP interferon) (NNS titers))))))) (. .)))
2445283	3	(S1 (S (NP (NP (DT The) (JJ average) (NN time)) (PP (IN of) (NP (NNP Doc_2445283_365_370_Disease)))) (VP (AUX was) (VP (VBN delayed))) (. .)))
2445283	4	(S1 (S (NP (DT A) (JJ reversible) (NN Doc_2445283_397_403_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ only) (JJ adverse) (NN effect)) (VP (VBN observed)))) (. .)))
2445283	5	(S1 (S (PP (IN From) (NP (DT these) (NNS results))) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (NNP Doc_2445283_479_488_Chemical)) (VP (AUX has) (NP (NP (DT an) (JJ antiviral) (NN effect)) (PP (IN in) (NP (NP (JJ advanced) (NNS cases)) (PP (IN of) (NP (NNP Doc_2445283_534_537_Disease))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (NNP Doc_2445283_548_554_Disease)) (, ,) (NP (NP (DT the) (JJ only) (JJ secondary) (NN reaction)) (VP (VBN observed))) (, ,)) (VP (MD can) (VP (AUX be) (ADVP (RB easily)) (VP (VBN managed)))))))) (. .)))
2445283	6	(S1 (S (NP (NP (DT The) (JJ possible) (JJ beneficial) (NN effect)) (PP (IN of) (NP (NNP Doc_2445283_651_660_Chemical))) (PP (IN during) (NP (NP (DT the) (JJ initial) (NNS days)) (PP (IN of) (NP (NNP Doc_2445283_688_691_Disease)))))) (VP (AUX is) (VP (VBN discussed))) (. .)))
2476560	0	(S1 (SQ (AUX Is) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_2476560_20_27_Disease)))) (ADJP (JJ hazardous)) (. ?)))
2476560	1	(S1 (S (S (NP (NP (NN Treatment)) (PP (IN for) (NP (NNP Doc_2476560_53_60_Disease)))) (VP (AUX is) (ADVP (RB usually)) (VP (VBN initiated) (PP (IN by) (NP (JJ general) (NNS practitioners)))))) (: ;) (S (NP (JJS most)) (VP (VBP consider) (NP (NP (NNP Doc_2476560_122_129_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2476560_131_157_Chemical)) (-RRB- -RRB-))) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN choice)))))) (. .)))
2476560	2	(S1 (S (S (NP (NN Doc_2476560_184_191_Chemical)) (VP (AUX is) (ADVP (RB also)) (ADVP (RB widely)) (VP (VBN used) (PP (IN as) (NP (DT an) (ADJP (JJ agricultural) (CC and) (JJ industrial)) (NN pesticide)))))) (, ,) (CC and) (S (PP (IN as) (NP (DT a) (NN result))) (NP (NP (DT the) (JJ toxic) (NN profile)) (PP (IN of) (NP (DT this) (NN insecticide)))) (VP (AUX is) (VP (ADVP (RB well)) (VBN understood)))) (. .)))
2476560	3	(S1 (S (NP (NN Evidence)) (VP (AUX is) (VP (VBG accumulating) (SBAR (IN that) (S (NP (NNP Doc_2476560_361_368_Chemical)) (VP (VP (MD can) (VP (AUX be) (ADJP (JJ Doc_2476560_376_411_Disease)))) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NN Doc_2476560_439_455_Disease))))))))))) (. .)))
2476560	4	(S1 (S (NP (NP (NNS Preparations)) (VP (VBG containing) (NP (NNP Doc_2476560_481_488_Chemical)))) (VP (VP (VBP continue) (S (VP (TO to) (VP (AUX be) (VP (VBN sold) (PP (IN over) (NP (DT the) (NN counter)))))))) (CC and) (VP (MD may) (VP (VB represent) (NP (NP (DT a) (NN hazard)) (PP (TO to) (NP (ADJP (RB poorly) (VBN informed)) (NNS patients))))))) (. .)))
2476560	5	(S1 (S (NP (DT This) (NN literature) (NN review)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ general) (NNS practitioners)) (VP (MD should) (VP (VP (VB prescribe) (NP (NP (NNS scabicides)) (PP (IN with) (NP (NP (VBN increased) (NN caution)) (PP (IN for) (NP (JJ certain) (JJ at-risk) (NNS groups))))))) (, ,) (CC and) (VP (VB give) (NP (NP (JJ adequate) (NNS warnings)) (VP (VBG regarding) (NP (JJ potential) (NN Doc_2476560_767_775_Disease)))))))))) (. .)))
2484011	0	(S1 (NP (NP (NN Mouse) (JJ strain-dependent) (NN effect)) (PP (IN of) (NP (NNP Doc_2484011_33_43_Chemical))) (PP (IN on) (NP (NP (NN motility)) (CC and) (NP (NN brain) (JJ biogenic) (NN Doc_2484011_75_81_Chemical)))) (. .)))
2484011	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_2484011_97_121_Chemical)) (, ,) (NP (NP (VBN injected) (NN i.p.)) (PP (IN in) (NP (NP (CD 6) (NNS increments)) (PP (IN of) (NP (NP (CD 100) (NNS mg/kg)) (NP (DT each)))))) (PP (IN over) (NP (CD 30) (NNS hr)))) (, ,))) (PP (IN on) (NP (NP (NN mouse) (NN motility) (CC and) (JJ whole) (NN brain) (NN content)) (PP (IN of) (NP (JJ selected) (JJ biogenic) (JJ Doc_2484011_246_252_Chemical) (CC and) (JJ major) (NNS metabolites)))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (CD 4) (NNS strains)) (PP (IN of) (NP (NNS mice))))))) (. .)))
2484011	2	(S1 (S (NP (DT These)) (VP (AUX were) (NP (NP (DT the) (NNP albino) (NNP Sprague-Dawley) (NNP ICR) (CC and) (NNP BALB/C)) (, ,) (NP (DT the) (JJ black) (NNP C57BL/6)) (CC and) (NP (DT the) (JJ brown) (JJ CDF-I) (NN mouse) (NNS strains)))) (. .)))
2484011	3	(S1 (S (NP (JJ Doc_2484011_415_425_Chemical) (NN treatment)) (VP (VBD produced) (NP (NP (DT a) (JJ biphasic) (NN effect)) (PP (IN on) (NP (NN mouse) (NN motility))))) (. .)))
2484011	4	(S1 (S (NP (NP (DT The) (JJ initial) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_2484011_502_512_Chemical) (NNP Doc_2484011_513_522_Disease) (NN locomotor) (NN activity)) (PP (IN in) (NP (DT all) (NN mouse) (NNS strains)))))) (VP (VBD studied) (PP (IN with) (S (NP (DT the) (CD BALB/C) (NNS mice)) (VP (AUXG being) (NP (DT the) (RBS most) (JJ sensitive)))))) (. .)))
2484011	5	(S1 (S (NP (JJ Subsequent) (NNP Doc_2484011_629_639_Chemical) (NNS treatments)) (VP (VBD produced) (NP (NP (NN enhancement)) (PP (IN of) (NP (NN motility)))) (PP (IN from) (NP (JJ corresponding) (NN control))) (PP (IN in) (NP (DT all) (NN mouse) (NNS strains))) (PP (IN with) (S (NP (DT the) (CD BALB/C) (NNS mice)) (VP (AUXG being) (ADJP (DT the) (JJS least) (JJ sensitive)))))) (. .)))
2484011	6	(S1 (S (NP (DT The) (NN locomotor) (NN activity)) (VP (AUX was) (VP (VBN decreased) (PP (IN from) (NP (NP (JJ corresponding) (NNS controls)) (PP (IN in) (NP (NP (DT all) (NNS strains)) (VP (VBN studied)))) (, ,) (PP (IN except) (PP (IN for) (NP (DT the) (NNP ICR) (NNS mice)))))) (, ,) (PP (IN during) (NP (NP (DT an) (JJ overnight) (JJ drug-free) (NN period)) (PP (VBG following) (NP (DT the) (JJ fourth) (JJ Doc_2484011_952_962_Chemical) (NN treatment))))))) (. .)))
2484011	7	(S1 (S (NP (NP (NN Readministration)) (PP (IN of) (NP (NNP Doc_2484011_994_1004_Chemical)))) (, ,) (PP (IN after) (NP (DT a) (JJ drug-free) (JJ overnight) (NN period))) (, ,) (VP (VBD increased) (NP (NN motility)) (PP (IN from) (NP (JJ respective) (NN saline) (NN control))) (PP (IN in) (NP (NP (DT all) (NNS strains)) (PP (IN with) (NP (NP (NN exception)) (PP (IN of) (NP (NP (DT the) (JJ BALB/C) (NNS mice)) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_2484011_1147_1170_Disease)) (VP (VBD occurred))))))))))) (. .)))
2484011	8	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_2484011_1196_1206_Chemical)))) (VP (VP (AUX did) (RB not) (VP (VB alter) (NP (JJ whole) (NN brain) (NN Doc_2484011_1233_1241_Chemical) (NNS levels)))) (CC but) (VP (VBD decreased) (NP (NP (DT the) (NNS amounts)) (PP (IN of) (NP (NNP Doc_2484011_1278_1308_Chemical)))) (PP (IN in) (NP (NP (DT the) (JJ BALB/C) (NNS mice)) (VP (VBN compared) (S (VP (TO to) (VP (VB saline) (NP (NN control)))))))))) (. .)))
2484011	9	(S1 (S (ADVP (RB Conversely)) (, ,) (NP (NN brain) (JJ Doc_2484011_1374_1389_Chemical) (NN concentration)) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (NN saline) (NN control))) (PP (IN by) (NP (NP (NNP Doc_2484011_1441_1451_Chemical)) (PP (IN in) (NP (DT the) (JJ BALB/C) (NNS mice))))))) (. .)))
2484011	10	(S1 (S (NP (DT The) (NNS results)) (VP (VP (VBP suggest) (NP (NP (DT a) (JJ strain-dependent) (NN effect)) (PP (IN of) (NP (NNP Doc_2484011_1521_1531_Chemical))) (PP (IN on) (NP (NN motility))))) (CC and) (VP (VBP indicate) (NP (NP (DT a) (NN differential) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ acute) (CC and) (JJ multiple) (NN dose) (NNS regimens)) (VP (VBN used))))))) (. .)))
2484011	11	(S1 (S (NP (DT The) (JJ BALB/C) (NN mouse)) (VP (VP (AUX was) (NP (DT the) (ADJP (RBS most) (JJ sensitive)) (NN strain))) (CC and) (VP (MD could) (VP (VB serve) (PP (IN as) (NP (NP (DT the) (NN strain)) (PP (IN of) (NP (NN choice))) (PP (IN for) (S (VP (VBG evaluating) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NNP Doc_2484011_1749_1759_Chemical)))))))))))) (. .)))
2484011	12	(S1 (S (NP (NP (DT The) (JJ biochemical) (NNS results)) (PP (IN of) (NP (NP (NN brain) (NN biogenic) (NNP Doc_2484011_1803_1809_Chemical)) (PP (IN of) (NP (JJ BALB/C) (NN mouse) (NN strain)))))) (VP (VBP suggest) (NP (NP (NP (DT a) (JJ probable) (NN decrease)) (PP (IN of) (NP (NP (JJ Doc_2484011_1864_1877_Chemical) (NN turnover) (NN rate) (NN and/or) (NN metabolism)) (PP (IN by) (NP (JJ monoamine) (NN oxidase)))))) (CC and) (NP (NP (DT a) (VBG resulting) (NN increase)) (PP (IN in) (NP (NP (NNP O-methylation)) (PP (IN of) (NP (NNP Doc_2484011_1976_1990_Chemical))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB account) (PP (IN for) (NP (NP (DT a) (NN Doc_2484011_2015_2036_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP Doc_2484011_2047_2057_Chemical)) (PP (IN in) (NP (DT the) (CD BALB/C) (NNS mice))))))))))))))))) (. .)))
2505783	0	(S1 (NP (NP (NP (NN Doc_2505783_0_18_Chemical)) (CC and) (NP (NP (PRP$ its) (NN contribution)) (PP (TO to) (NP (NN urotoxicity))))) (PP (IN during) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_2505783_77_93_Chemical)) (CC or) (NP (NNP Doc_2505783_97_107_Chemical)))) (. .)))
2505783	1	(S1 (NP (NP (DT An) (JJ experimental) (NN study/short) (NN communication)) (. .)))
2505783	2	(S1 (S (S (VP (VBN Based) (PP (IN on) (NP (JJ clinical) (NNS data))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (NNP Doc_2505783_192_210_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2505783_212_215_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ important) (NN metabolite)) (PP (IN of) (NP (JJ oxazaphosphorine) (NNS cytostatics))))))))))) (, ,) (NP (DT an) (JJ experimental) (NN study)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_2505783_349_352_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_2505783_375_395_Disease)))))))))) (. .)))
2505783	3	(S1 (S (NP (DT The) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NNP Doc_2505783_423_426_Chemical)) (PP (IN after) (NP (CD i.v.) (NN administration))) (VP (AUX does) (RB not) (VP (VB contribute) (PP (TO to) (NP (NN Doc_2505783_476_490_Disease)))))))) (. .)))
2505783	4	(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBN instilled) (ADVP (RB directly)) (PP (IN into) (NP (DT the) (NN bladder)))))) (, ,) (NP (NNP Doc_2505783_534_537_Chemical)) (VP (VBZ exerts) (NP (JJ urotoxic) (NNS effects)))) (, ,) (S (NP (PRP it)) (VP (AUX is) (, ,) (ADVP (RB however)) (, ,) (ADJP (JJ susceptible) (PP (TO to) (NP (NP (NN detoxification)) (PP (IN with) (NP (NNP Doc_2505783_614_619_Chemical)))))))) (. .)))
2515254	0	(S1 (NP (NP (NP (NN Source)) (PP (IN of) (NP (NP (NN Doc_2515254_10_14_Disease)) (CC and) (NP (JJ primitive) (NN dysfunction)))) (PP (IN in) (NP (NNP Doc_2515254_44_52_Disease)))) (: :) (NP (DT an) (JJ identical) (NN site)) (. ?)))
2515254	1	(S1 (S (NP (CD Twenty) (JJ common) (NNP Doc_2515254_87_95_Disease) (NNS patients)) (VP (VBD received) (NP (NP (DT a) (NN one)) (VP (VBN sided) (NP (NP (NP (JJ frontotemporal) (NN application)) (PP (IN of) (NP (NNP Doc_2515254_156_169_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS patients)) (-RRB- -RRB-)) (CC or) (NP (NP (NN placebo) (NN ointment)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS patients)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT a) (JJ double) (JJ blind) (NN study)))))) (. .)))
2515254	2	(S1 (S (NP (JJ Early) (NN onset) (NN Doc_2515254_255_263_Disease) (NNS attacks)) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2515254_288_301_Chemical))) (PP (IN in) (NP (NP (NP (CD seven)) (PP (IN out) (PP (IN of) (NP (CD 10) (NNS patients))))) (CC versus) (NP (NP (DT no) (NN patient)) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))))))) (. .)))
2515254	3	(S1 (S (NP (NP (QP (RB Subsequently) (CD 20)) (JJ Doc_2515254_386_394_Disease) (NNS patients)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (DT an) (JJ early) (NN onset) (NN attack)) (PP (IN with) (NP (JJ frontotemporal) (NNP Doc_2515254_461_474_Chemical))))))) (, ,)) (VP (VBD received) (NP (DT the) (NN drug)) (PP (IN in) (NP (NP (DT a) (JJ second) (NN induction) (NN test)) (PP (IN at) (NP (JJ other) (NN body) (NNS areas)))))) (. .)))
2515254	4	(S1 (S (NP (DT No) (JJ early) (NN onset) (NN Doc_2515254_557_565_Disease)) (VP (AUX was) (VP (VBN observed))) (. .)))
2515254	5	(S1 (S (ADVP (RB Thus)) (NP (NP (DT the) (JJ Doc_2515254_589_597_Disease-inducing) (NN effect)) (PP (IN of) (NP (NNP Doc_2515254_617_630_Chemical)))) (VP (VBZ seems) (S (VP (TO to) (VP (VB depend) (PP (IN on) (NP (NP (JJ direct) (NN stimulation)) (PP (IN of) (NP (NP (DT the) (JJ habitual) (NN site)) (PP (IN of) (NP (NNP Doc_2515254_693_697_Disease))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT the) (JJ frontotemporal) (NN region)) (VP (AUX is) (PP (IN of) (NP (JJ crucial) (NN importance))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT a) (JJ Doc_2515254_790_798_Disease) (NN crisis)))))))))))))) (. .)))
2515254	6	(S1 (S (NP (DT This)) (VP (AUX is) (RB not) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (JJ CNS) (NN origin)) (PP (IN of) (NP (NN Doc_2515254_851_859_Disease) (NN attack))))))) (. .)))
2522601	0	(S1 (S (NP (NP (NN Doc_2522601_0_16_Disease)) (PP (TO to) (NP (NNP Doc_2522601_20_33_Chemical)))) (VP (VBG presenting) (PP (IN with) (NP (NP (DT a) (NNP Doc_2522601_52_70_Disease)) (, ,) (NP (NNP Doc_2522601_72_84_Disease)) (, ,) (NP (NNP Doc_2522601_86_98_Disease)) (, ,) (CC and) (NP (NNP Doc_2522601_104_117_Disease))))) (. .)))
2522601	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN patient)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NNP Doc_2522601_147_163_Disease)) (VP (TO to) (VP (VB Doc_2522601_167_180_Chemical) (VP (VBN presented) (PP (IN with) (NP (NP (JJ generalized) (NNP Doc_2522601_208_220_Disease)) (, ,) (NP (DT a) (JJ severe) (NN Doc_2522601_231_249_Disease)) (, ,) (NP (NNP Doc_2522601_251_263_Disease)) (, ,) (NP (NNP Doc_2522601_265_277_Disease)) (, ,) (CC and) (NP (NNP Doc_2522601_283_296_Disease))))))))))) (. .)))
2522601	2	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN report)) (PP (IN of) (NP (NP (PDT such) (DT an) (JJ unusual) (NN reaction)) (PP (TO to) (NP (NNP Doc_2522601_354_367_Chemical))))))) (. .)))
2549018	0	(S1 (NP (NP (JJ Doc_2549018_0_10_Chemical-induced) (NNP Doc_2549018_19_28_Disease)) (: :) (NP (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ theoretical))) (NNS implications)) (. .)))
2549018	1	(S1 (S (NP (NP (CD Five) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_2549018_93_103_Chemical)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_2549018_125_154_Disease)) (CC or) (NP (NNP Doc_2549018_158_174_Disease)))))))) (VP (VBD developed) (NP (NN Doc_2549018_185_194_Disease))) (. .)))
2549018	2	(S1 (S (NP (NP (DT The) (JJ typical) (JJ Doc_2549018_208_218_Chemical-induced) (NNS symptoms)) (PP (IN of) (NP (NP (NN restlessness)) (, ,) (NP (JJ constant) (NN pacing)) (, ,) (NP (NP (JJ purposeless) (NNS movements)) (PP (IN of) (NP (NP (DT the) (NNS feet)) (CC and) (NP (NNS legs))))) (, ,) (CC and) (NP (JJ marked) (NN Doc_2549018_325_332_Disease))))) (VP (AUX were) (ADJP (JJ indistinguishable) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (JJ neuroleptic-induced) (NNP Doc_2549018_390_399_Disease))))))) (. .)))
2549018	3	(S1 (S (NP (NP (CD Three) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN experienced) (NP (JJ neuroleptic-induced) (NN Doc_2549018_456_465_Disease)) (PP (IN in) (NP (DT the) (NN past)))))))) (VP (VBD reported) (SBAR (IN that) (S (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_2549018_508_518_Chemical-induced) (NNP Doc_2549018_527_536_Disease)))) (VP (AUX were) (ADJP (JJ identical)) (, ,) (SBAR (IN although) (S (ADJP (RB somewhat) (JJR milder)))))))) (. .)))
2549018	4	(S1 (S (NP (NN Doc_2549018_579_588_Disease)) (VP (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ common) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_2549018_628_638_Chemical)))))))) (CC and) (VP (ADVP (RB generally)) (VBD responded) (ADVP (RB well)) (PP (TO to) (NP (NN treatment))) (PP (IN with) (NP (NP (DT the) (JJ beta-adrenergic) (NN antagonist) (NN Doc_2549018_717_728_Chemical)) (, ,) (NP (NN dose) (NN reduction)) (, ,) (CC or) (NP (DT both)))))) (. .)))
2549018	5	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NNP Doc_2549018_780_790_Chemical-induced) (NNP Doc_2549018_799_808_Disease)) (VP (MD may) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (ADJP (RB serotonergically) (VBN mediated)) (NN inhibition)) (PP (IN of) (NP (JJ dopaminergic) (NN neurotransmission)))))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NP (NNP Doc_2549018_929_939_Chemical-induced) (NNP Doc_2549018_948_957_Disease)) (CC and) (NP (JJ tricyclic) (JJ Doc_2549018_972_986_Chemical-induced) (`` ``) (NNS jitteriness) ('' ''))))) (VP (MD may) (VP (AUX be) (ADJP (JJ identical)))))))) (. .)))
2559236	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (S (VP (VBG converting) (NP (JJ enzyme) (NN inhibition)) (PP (IN on) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NNP Doc_2559236_56_66_Chemical-induced) (NNP Doc_2559236_75_86_Disease)))))))) (. .)))
2559236	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (DT the) (VBG converting) (NN enzyme) (NN inhibitor) (-LRB- -LRB-) (NNP CEI) (-RRB- -RRB-) (NNP Doc_2559236_140_149_Chemical)))) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ Munich-Wistar) (NNS rats)) (PP (IN with) (NP (JJ established) (NNP Doc_2559236_202_212_Chemical) (NNP Doc_2559236_213_222_Disease))))))) (. .)))
2559236	2	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VP (VBN given) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_2559236_257_267_Chemical))))) (CC and) (VP (ADVP (NP (CD one) (NN month)) (RB later)) (VBN divided) (PP (IN into) (NP (NP (CD four) (NNS groups)) (VP (VBN matched) (PP (IN for) (NP (NP (NN Doc_2559236_325_336_Disease)) (, ,) (NP (NN blood) (NN pressure)) (, ,) (CC and) (NP (NN plasma) (NN albumin) (NN concentration)))))))))) (. .)))
2559236	3	(S1 (S (NP (NNS Groups) (CD 1) (CC and) (CD 3)) (VP (VBD remained) (ADJP (JJ untreated)) (SBAR (IN while) (S (NP (NNS groups) (CD 2) (CC and) (CD 4)) (VP (VBD received) (NP (NNP Doc_2559236_452_461_Chemical)))))) (. .)))
2559236	4	(S1 (S (NP (NNS Groups) (CD 1) (CC and) (CD 2)) (VP (VBD underwent) (NP (NN micropuncture) (NNS studies)) (PP (IN after) (NP (CD 10) (NNS days)))) (. .)))
2559236	5	(S1 (S (NP (DT These) (JJ short-term) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_2559236_562_571_Chemical)) (VP (VBD reduced) (NP (NP (JJ arterial) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NP (CD 101) (ADJP (JJ +/-) (NP (CD 2) (CC vs.) (CD 124))) (JJ +/-) (CD 3) (NN mm)) (ADJP (NNP Hg) (, ,) (NN group) (CD 2) (CC vs.) (CD 1)) (, ,) (VP (VBG P) (NP (QP (JJR less) (IN than) (CD 0.05))))) (-RRB- -RRB-)) (CC and) (NP (JJ glomerular) (JJ capillary) (NN pressure)) (PRN (-LRB- -LRB-) (NP (QP (CD 54) (JJ +/-) (CD 1) (CC vs.) (CD 61)) (JJ +/-) (CD 2) (JJ mm) (NNP Hg)) (, ,) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (PP (IN without) (S (VP (VBG reducing) (NP (NP (NP (NNP Doc_2559236_768_779_Disease)) (PRN (-LRB- -LRB-) (NP (CD 617) (ADJP (JJ +/-) (NP (CD 50) (CC vs.) (CD 570))) (JJ +/-) (CD 47) (NN mg/day)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP GFR)) (PRN (-LRB- -LRB-) (NP (CD 1.03) (ADJP (JJ +/-) (NP (CD 0.04) (CC vs.) (CD 1.04))) (JJ +/-) (CD 0.11) (NN ml/min)) (-RRB- -RRB-))))))))))) (. .)))
2559236	6	(S1 (S (NP (NNS Groups) (CD 3) (CC and) (CD 4)) (VP (AUX were) (VP (VBN studied) (PP (PP (IN at) (NP (CD four))) (CC and) (PP (IN at) (NP (CD six) (NNS months)))) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_2559236_942_951_Chemical))) (PP (IN on) (NP (NP (NN progression)) (PP (IN of) (NP (NP (NNP Doc_2559236_970_982_Disease)) (PP (IN in) (NP (NNP Doc_2559236_986_996_Chemical) (NNP Doc_2559236_997_1006_Disease))))))))))))) (. .)))
2559236	7	(S1 (S (NP (JJ Chronic) (JJ Doc_2559236_1016_1025_Chemical) (NN treatment)) (VP (VBD reduced) (NP (NN blood) (NN pressure)) (PP (IN without) (S (VP (VBG reducing) (NP (NN Doc_2559236_1076_1087_Disease)) (PP (IN in) (NP (NN group) (CD 4))))))) (. .)))
2559236	8	(S1 (S (NP (NP (JJ Untreated) (NN group)) (NP (CD 3) (NNS rats))) (VP (VBD exhibited) (NP (NP (DT a) (JJ progressive) (NN reduction)) (PP (IN in) (NP (NP (NNP GFR)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 0.35) (NN +/-)) (NP (CD 0.08) (NN ml/min))) (PP (IN at) (NP (CD 4) (NNS months)))) (, ,) (NP (NP (CD 0.27) (NN +/-) (CD 0.07) (NN ml/min)) (NP (QP (IN at) (CD 6)) (NNS months)))) (-RRB- -RRB-)))))) (. .)))
2559236	9	(S1 (S (NP (JJ Doc_2559236_1234_1243_Chemical) (NN treatment)) (VP (VP (VBD blunted)) (CC but) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NNP GFR)) (PP (IN in) (NP (NN group) (CD 4))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 0.86) (NN +/-)) (NP (CD 0.15) (NN ml/min))) (PP (IN at) (NP (CD 4) (NNS months)))) (, ,) (NP (NP (NP (CD 0.69) (NN +/-)) (NP (CD 0.13) (NN ml/min))) (PP (IN at) (NP (CD 6) (NNS months)))) (, ,) (NP (DT both) (JJ P) (QP (JJR less) (IN than) (CD 0.05))) (CC vs.) (NP (NN group) (CD 3))) (-RRB- -RRB-)))))))) (. .)))
2559236	10	(S1 (S (NP (NP (NN Reduction)) (PP (IN in) (NP (NNS GFR)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_2559236_1471_1491_Disease))) (PP (IN in) (NP (NP (DT both) (ADJP (VBN treated) (CC and) (JJ untreated)) (NNS rats.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))))
2572625	0	(S1 (FRAG (NP (JJ Doc_2572625_0_11_Chemical-induced) (JJ acute) (NN Doc_2572625_26_35_Disease)) (. .)))
2572625	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NP (JJ acute) (NN Doc_2572625_89_98_Disease)) (PP (IN with) (NP (NNP Doc_2572625_104_137_Disease)))) (, ,) (NP (CD 7) (NNS months))) (PP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_2572625_185_196_Chemical)) (, ,) (NP (DT a) (JJ Doc_2572625_200_215_Chemical) (NN derivative))))))))))))))) (. .)))
2572625	2	(S1 (S (NP (JJ Doc_2572625_228_239_Chemical) (NN withdrawal)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (JJ prompt) (NN recovery))))) (. .)))
2572625	3	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (JJ several) (NNP Doc_2572625_314_329_Chemical))) (, ,) (VP (ADVP (RB chemically)) (VBN related) (PP (TO to) (NP (NNP Doc_2572625_353_364_Chemical)))) (, ,)) (VP (VP (AUX did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NN recovery))))) (CC and) (VP (AUX did) (RB not) (VP (VB induce) (NP (NP (DT any) (NN relapse)) (PP (IN of) (NP (NNP Doc_2572625_432_441_Disease))))))) (. .)))
2572625	4	(S1 (S (NP (DT This) (NN observation)) (VP (VP (VBZ shows) (SBAR (IN that) (S (NP (NNP Doc_2572625_471_482_Chemical)) (VP (MD can) (VP (VB induce) (NP (JJ acute) (NN Doc_2572625_500_509_Disease))))))) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (JJ cross) (NN Doc_2572625_546_560_Disease)) (PP (IN between) (NP (NP (NNP Doc_2572625_569_580_Chemical)) (CC and) (NP (JJ several) (NNP Doc_2572625_593_608_Chemical)))))))))) (. .)))
2578334	0	(S1 (S (NP (JJ Doc_2578334_0_13_Chemical) (NNS potentiates)) (VP (VBP Doc_2578334_26_59_Disease) (PP (IN in) (NP (NN rat) (NN liver)))) (. .)))
2578334	1	(S1 (S (VP (TO To) (VP (VB test) (NP (NP (DT the) (NN validity)) (PP (IN of) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (NP (NN hypomethylation)) (PP (IN of) (NP (NNP DNA)))) (VP (VBZ plays) (NP (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NP (DT the) (NNP Doc_2578334_172_206_Disease) (PRN (, ,) (S (NP (NP (NNP Doc_2578334_208_221_Chemical) (-LRB- -LRB-) (NNP Doc_2578334_223_228_Chemical) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN DNA) (NN methylation)))) (, ,)) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NP (NNS rats)) (PP (IN during) (NP (NP (DT the) (NN phase)) (PP (IN of) (NP (NN repair) (NN synthesis))) (VP (VBN induced) (PP (IN by) (NP (DT the) (CD three) (NNS carcinogens))))))))))) (, ,)) (NNP Doc_2578334_364_379_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 200) (NNS mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_2578334_393_415_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 60) (NNS mg/kg)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_2578334_431_452_Chemical))))) (-LRB- -LRB-) (NP (NNP Doc_2578334_454_461_Chemical)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD 100) (NNS mg/kg)) (-RRB- -RRB-)))))))))) (. .)))
2578334	2	(S1 (S (NP (NP (DT The) (VBN initiated) (NNS hepatocytes)) (PP (IN in) (NP (DT the) (NN liver)))) (VP (AUX were) (VP (VBN assayed) (PP (IN as) (NP (NP (DT the) (JJ gamma-glutamyltransferase) (-LRB- -LRB-) (NN gamma-GT) (-RRB- -RRB-) (JJ positive) (NN foci)) (VP (VBN formed) (PP (VBG following) (NP (NP (DT a) (JJ 2-week) (NN selection) (NN regimen)) (VP (VBG consisting) (PP (IN of) (NP (NP (JJ dietary) (ADJP (CD 0.02) (NN %)) (NN Doc_2578334_658_679_Chemical)) (VP (VBN coupled) (PP (IN with) (NP (NP (DT a) (JJ necrogenic) (NN dose)) (PP (IN of) (NP (NNP Doc_2578334_714_718_Chemical)))))))))))))))) (. .)))
2578334	3	(S1 (S (NP (NP (DT The) (NNS results)) (VP (VBN obtained))) (VP (VBP indicate) (SBAR (IN that) (S (PP (IN with) (NP (DT all) (CD three) (NNS carcinogens))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_2578334_801_806_Chemical))) (PP (IN during) (NP (NN repair) (NN synthesis)))) (VP (VBD increased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (VBN initiated) (NNS hepatocytes))) (, ,) (PP (IN for) (NP (NN example)))) (NP (CD 10-20) (NN foci/cm2)) (PP (IN in) (NP (NP (JJ Doc_2578334_911_916_Chemical) (CC and) (JJ carcinogen-treated) (NNS rats)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ 3-5) (NNS foci/cm2)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NN carcinogen) (RB only))))))))))))))) (. .)))
2578334	4	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_2578334_1028_1051_Chemical))) (PP (IN during) (NP (NP (DT the) (NN repair) (NN synthesis)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2578334_1091_1098_Chemical))))))) (ADVP (RB further)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (CD 0.019) (JJ mol) (NN %)) (PP (IN of) (NP (NP (JJ Doc_2578334_1134_1142_Chemical) (NNS residues)) (PP (IN in) (NP (NNP DNA)))))) (VP (AUX were) (VP (VBN substituted) (PP (IN by) (NP (DT the) (NN analogue))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (NN incorporation)) (PP (IN of) (NP (NNP Doc_2578334_1226_1231_Chemical)))) (VP (VBZ occurs) (PP (IN during) (NP (NN repair) (NN synthesis))))))))))))) (. .)))
2578334	5	(S1 (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT the) (NN carcinogen))))) (, ,) (NP (NNP Doc_2578334_1298_1303_Chemical)) (VP (VBN given) (PP (IN after) (NP (NP (DT a) (CD two) (NNS thirds)) (SBAR (S (NP (JJ partial) (NN hepatectomy)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (PRP$ its) (NN incorporation)) (VP (MD should) (VP (AUX be) (NP (NN maximum)))))) (, ,) (VP (VBD failed) (S (VP (TO to) (VP (VB induce) (NP (DT any) (JJ gamma-GT) (JJ positive) (NNS foci))))))))))) (. .)))
2578334	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN hypomethylation)) (PP (IN of) (NP (NNP DNA)))) (ADVP (FW per) (FW se)) (VP (MD may) (RB not) (VP (AUX be) (ADJP (JJ sufficient) (PP (IN for) (NP (NN initiation))))))))) (. .)))
2578334	7	(S1 (S (ADVP (RB Perhaps)) (NP (CD two) (NNS events)) (VP (MD might) (VP (AUX be) (ADJP (JJ necessary) (PP (IN for) (NP (NP (NN initiation)) (, ,) (NP (NP (DT the) (JJ first)) (VP (VBN caused) (PP (IN by) (NP (DT the) (NN carcinogen))))) (CC and) (NP (NP (DT a) (NN second)) (VP (VBG involving) (NP (NP (NN hypomethylation)) (PP (IN of) (NP (NN DNA))))))))))) (. .)))
26094	0	(S1 (NP (NP (NP (JJ Antihypertensive) (NNS drugs)) (CC and) (NP (NN Doc_26094_27_37_Disease))) (: :) (NP (DT a) (NN reappraisal)) (. .)))
26094	1	(S1 (S (NP (NP (JJ Eighty-nine) (JJ new) (NN referral) (NN Doc_26094_79_91_Disease) (NNS out-patients)) (CC and) (NP (CD 46) (JJ new) (NN referral) (NN non-Doc_26094_129_141_Disease)) (CONJP (RB chronically) (RB physically)) (NP (JJ ill) (NNS out-patients))) (VP (VBD completed) (NP (DT a) (NN mood) (NN rating) (NN scale)) (PP (IN at) (NP (JJ regular) (NNS intervals))) (PP (IN for) (NP (CD one) (NN year)))) (. .)))
26094	2	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (NP (NP (DT a) (JJ high) (NN prevalence)) (PP (IN of) (NP (NNP Doc_26094_287_297_Disease)))) (PP (IN in) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (NNS patients))))) (, ,) (PP (IN with) (NP (NP (DT no) (NN preponderance)) (PP (IN in) (NP (DT the) (NNP Doc_26094_355_367_Disease) (NN group)))))) (. .)))
26094	3	(S1 (S (NP (NP (JJ Doc_26094_375_387_Disease) (NNS patients)) (PP (IN with) (NP (JJ Doc_26094_402_413_Disease) (NNS histories)))) (VP (AUX had) (NP (NP (DT a) (JJR higher) (NN prevalence)) (PP (IN of) (NP (NNP Doc_26094_451_461_Disease))) (PP (IN than) (NP (DT the) (NN comparison) (NNS patients))))) (. .)))
26094	4	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN accounted) (PP (IN for)) (PP (IN by) (NP (NP (DT a) (JJ significant) (NN number)) (PP (IN of) (NP (NNP Doc_26094_542_553_Disease))) (VP (VBG occurring) (PP (IN in) (NP (NP (JJ Doc_26094_567_578_Chemical) (VBN treated) (NNS patients)) (PP (IN with) (NP (JJ Doc_26094_601_612_Disease) (NNS histories)))))))))) (. .)))
2611118	0	(S1 (S (NP (NN Doc_2611118_0_24_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_2611118_41_58_Chemical) (NN therapy)))) (. .)))
2611118	1	(S1 (S (NP (NP (NNP Doc_2611118_68_85_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2611118_87_95_Chemical)) (, ,) (NP (NNP Geigy) (NNP Pharmaceuticals)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ non-steroidal) (JJ anti-inflammatory) (NN derivative)) (PP (IN of) (NP (NNP Doc_2611118_171_188_Chemical))))) (. .)))
2611118	2	(S1 (S (SBAR (IN Although) (S (ADJP (RB generally) (JJ well-tolerated)))) (, ,) (NP (JJ asymptomatic) (NNP Doc_2611118_238_269_Disease)) (VP (VP (AUX have) (VP (AUX been) (VP (VBN recorded)))) (CC and) (, ,) (ADVP (RBR less) (RB commonly)) (, ,) (S (NP (JJ severe) (NN Doc_2611118_316_325_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2611118_337_347_Chemical)))))) (. .)))
2611118	3	(S1 (S (NP (NP (DT The) (NN patient)) (VP (VBN described))) (VP (VBD developed) (NP (NP (NAC (NNP Doc_2611118_381_405_Disease) (PP (IN after) (NP (CD six) (NNS months)))) (NN therapy)) (PP (IN with) (NP (NP (NP (NNP Doc_2611118_436_453_Chemical)) (SBAR (WHNP (WDT which)) (S (VP (VBD progressed) (PP (IN despite) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (DT the) (NN drug))))))))) (, ,) (NP (NP (DT a) (NN finding)) (VP (RB not) (ADVP (RB previously)) (VBN reported))))))) (. .)))
2632720	0	(S1 (NP (NP (NNP Arterial) (NNP Doc_2632720_9_21_Disease)) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (JJ prolonged) (JJ Doc_2632720_53_65_Chemical) (NN treatment))))) (. .)))
2632720	1	(S1 (S (NP (NP (CD Two)) (PP (IN of) (NP (NP (CD 14) (NNS patients)) (PP (IN with) (NP (NNP Doc_2632720_101_119_Disease))) (VP (VBN treated) (PP (IN on) (NP (DT a) (JJ long-term) (NN basis))) (PP (IN with) (NP (NNP Doc_2632720_154_166_Chemical))))))) (VP (VBD developed) (NP (JJ sustained) (NN Doc_2632720_187_199_Disease))) (. .)))
2632720	2	(S1 (S (S (PP (IN In) (NP (DT both) (NNS cases))) (NP (JJ normal) (UCP (NN plasma) (CC and) (JJ urinary)) (JJ free) (NN Doc_2632720_246_254_Chemical) (NNS levels)) (VP (AUX had) (VP (AUX been) (VP (VBN achieved) (PP (VBG following) (NP (JJ Doc_2632720_290_302_Chemical) (NN therapy))))))) (, ,) (CC yet) (S (NP (JJ continuous) (NN blood) (NN pressure) (NN monitoring)) (VP (VBD demonstrated) (NP (NP (NP (NNP Doc_2632720_366_378_Disease) (CD 31)) (PRN (-LRB- -LRB-) (NP (NN patient) (CD 1)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 52) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (NN patient) (CD 2)) (-RRB- -RRB-)))) (PP (IN after) (NP (NN treatment))))) (. .)))
2632720	3	(S1 (S (PP (IN In) (NP (NN patient) (CD 1))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_2632720_467_486_Chemical)) (CC and) (NP (NNP Doc_2632720_491_507_Chemical))))) (VP (AUX were) (ADJP (JJ elevated))) (. .)))
2632720	4	(S1 (S (PP (IN In) (NP (NN patient) (CD 2))) (, ,) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (DT both) (NNP Doc_2632720_572_591_Chemical) (CC and) (NNP Doc_2632720_596_612_Chemical) (NNS levels))))))) (, ,) (NP (NN plasma) (NN Doc_2632720_628_639_Chemical) (NNS values)) (VP (AUX were) (VP (VBN raised) (, ,) (PP (IN with) (NP (NP (DT a) (JJ concomitant) (NN suppression)) (PP (IN of) (NP (JJ renin) (NNS levels))))))) (. .)))
2632720	5	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (JJ long-term) (NN treatment)) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_2632720_770_782_Chemical)))))) (VP (MD may) (VP (VB induce) (NP (NP (JJ enzyme) (NN blockade)) (VP (VBG leading) (PP (TO to) (NP (JJ mineralocorticoid-related) (NN Doc_2632720_847_859_Disease)))))))))) (. .)))
2670794	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NNP Doc_2670794_27_38_Chemical)))))) (VP (VBG converting) (NP (NP (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2670794_58_67_Chemical)) (-RRB- -RRB-))) (PP (IN on) (NP (NP (NNP Doc_2670794_72_105_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_2670794_113_138_Disease))) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
2670794	1	(S1 (S (NP (NP (NP (NP (NN Induction)) (PP (IN of) (NP (NNP Doc_2670794_164_189_Disease)))) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN fibrinolysis))))) (PP (IN by) (NP (NP (NP (NN injection)) (PP (IN of) (NP (NN thrombin)))) (CC and) (NP (NP (NNP Doc_2670794_250_265_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2670794_267_271_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN rat)))) (VP (VBZ gives) (NP (NN rise)) (PP (TO to) (NP (NNP Doc_2670794_298_331_Disease))) (S (VP (VBG resembling) (SBAR (IN that) (S (VP (VBG occurring) (PP (IN after) (NP (NP (NNP Doc_2670794_364_370_Disease) (CC or) (NNP Doc_2670794_374_380_Disease)) (PP (IN in) (NP (NN man))))))))))) (. .)))
2670794	2	(S1 (S (NP (NP (NN Injection)) (PP (IN of) (NP (NP (NP (NNP Doc_2670794_402_411_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (JJ Doc_2670794_439_450_Chemical) (VBG converting) (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NN ACE)) (-RRB- -RRB-))))) (, ,)))) (VP (VBD reduced) (NP (DT both) (NNP Doc_2670794_489_522_Disease)) (PP (IN in) (NP (DT this) (NN rat) (NN model)))) (. .)))
2670794	3	(S1 (S (S (NP (DT The) (NN lung) (NNS weights)) (VP (AUX were) (ADJP (JJR lower)))) (CC and) (S (NP (NNP PaO2)) (VP (AUX was) (VP (VBN improved) (PP (IN in) (NP (NNS rats))) (PP (VBN given) (NP (DT this) (JJ enzyme-blocking) (NN agent)))))) (. .)))
2670794	4	(S1 (S (NP (NP (DT The) (NNS contents)) (PP (IN of) (NP (NN albumin))) (PP (IN in) (NP (DT the) (NNS lungs)))) (VP (AUX were) (RB not) (VP (VBN changed) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NNP Doc_2670794_705_714_Chemical)) (VP (AUX did) (RB not) (VP (VB influence) (NP (NP (DT the) (NN extravasation)) (PP (IN of) (NP (NN protein)))))))))))) (. .)))
2670794	5	(S1 (S (NP (NN Doc_2670794_763_775_Disease)) (SBAR (IN as) (S (VP (VBN reflected) (PP (IN by) (NP (DT an) (NN increase))) (PP (PP (IN in) (NP (JJ serum) (NNP Doc_2670794_813_817_Chemical))) (CC and) (PP (IN in) (NP (NN kidney) (NN weight))))))) (VP (AUX was) (VP (VBN prevented) (PP (IN by) (NP (NNP Doc_2670794_856_865_Chemical))))) (. .)))
2670794	6	(S1 (S (NP (NP (DT The) (NN amount)) (PP (IN of) (NP (NN fibrin))) (PP (IN in) (NP (DT the) (NNS kidneys)))) (VP (AUX was) (ADVP (RB also)) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN than) (PP (IN in) (NP (NP (NNS animals)) (SBAR (WHNP (WDT which)) (S (VP (VBD received) (NP (NP (NN thrombin)) (CC and) (NP (NP (NNP Doc_2670794_975_979_Chemical)) (ADVP (RB alone)))))))))))) (. .)))
2670794	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_2670794_1023_1032_Chemical))) (PP (IN on) (NP (DT the) (NNS lungs)))) (VP (MD may) (VP (AUX be) (ADJP (JJ attributable) (PP (TO to) (NP (NP (DT a) (JJ vasodilatory) (NN effect)) (ADJP (JJ due) (PP (TO to) (NP (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (VBG circulating) (NN level)) (PP (IN of) (NP (NNP Doc_2670794_1138_1153_Chemical)))))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NNP Doc_2670794_1173_1185_Chemical)) (PRN (-LRB- -LRB-) (ADJP (JJ secondary) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_2670794_1215_1225_Chemical)))))) (-RRB- -RRB-))))))))))))))))) (. .)))
2670794	8	(S1 (S (NP (NNP Doc_2670794_1228_1237_Chemical)) (VP (MD may) (, ,) (PP (IN by) (NP (DT the) (JJ same) (NN mechanism))) (, ,) (VP (VB reduce) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (JJ glomerular) (NN filtration)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB occur) (PP (IN after) (NP (NP (DT an) (NN injection)) (PP (IN of) (NP (NN thrombin))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG diminishing) (NP (NP (DT the) (NN aggregation)) (PP (IN of) (NP (NP (JJ fibrin) (NNS monomers)) (PP (IN in) (NP (DT the) (NNS glomeruli)))))))) (, ,) (PP (IN with) (NP (DT the) (NN result) (SBAR (IN that) (S (S (NP (JJR less) (NN fibrin)) (VP (MD will) (VP (AUX be) (VP (VBD deposited))))) (CC and) (S (ADVP (RB thus) (RBR less)) (NP (NNP Doc_2670794_1504_1517_Disease)) (VP (MD will) (VP (AUX be) (VP (VBN produced))))))))))))))))))))) (. .)))
2673163	0	(S1 (S (NP (NN Doc_2673163_0_6_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_2673163_23_30_Chemical) (NN use)))) (. .)))
2673163	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD eight) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ Doc_2673163_71_78_Chemical) (NN use)) (VP (AUX was) (VP (VBN related) (S (VP (TO to) (VP (VB Doc_2673163_98_104_Disease) (CC and) (VB review) (NP (CD 39) (NNS cases)) (PP (IN from) (NP (DT the) (NN literature)))))))))))) (. .)))
2673163	2	(S1 (S (S (PP (IN Among) (NP (DT these) (CD 47) (NNS patients))) (NP (DT the) (JJ mean) (PRN (-LRB- -LRB-) (NP (JJ +/-) (NN SD)) (-RRB- -RRB-)) (NN age)) (VP (AUX was) (NP (CD 32.5) (JJ +/-) (CD 12.1) (NNS years)))) (: ;) (S (NP (NP (CD 76) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 34/45)) (-RRB- -RRB-))) (VP (AUX were) (NP (NNS men)))) (. .)))
2673163	3	(S1 (S (NP (NN Doc_2673163_239_245_Disease)) (VP (VBD followed) (NP (NP (JJ Doc_2673163_255_262_Chemical) (NN use)) (PP (IN by) (NP (ADJP (JJ inhalation) (, ,) (JJ intranasal) (, ,) (JJ intravenous) (, ,) (CC and) (JJ intramuscular)) (NNS routes))))) (. .)))
2673163	4	(S1 (S (S (NP (NP (NNP Doc_2673163_333_355_Disease)) (CC or) (NP (NNP Doc_2673163_359_386_Disease))) (VP (AUX were) (ADJP (JJ present)) (PP (IN in) (NP (NP (CD 17)) (PP (IN of) (NP (NP (CD 32) (NNS patients)) (VP (VBN studied) (UCP (ADVP (RB angiographically)) (CC or) (PP (IN at) (NP (NN autopsy))))))))))) (: ;) (S (NP (NNP Doc_2673163_461_480_Disease)) (VP (AUX was) (ADJP (JJ present)) (PP (IN in) (NP (CD two) (NNS patients))))) (. .)))
2673163	5	(S1 (S (NP (NN Doc_2673163_510_529_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (CD 10) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 22) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_2673163_561_585_Disease)) (PP (IN in) (NP (CD 22))) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_2673163_603_626_Disease)) (PP (IN in) (NP (CD 13))) (PRN (-LRB- -LRB-) (NP (CD 29) (NN %)) (-RRB- -RRB-))))))) (. .)))
2673163	6	(S1 (S (S (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (NP (DT the) (JJ apparent) (NN incidence)) (PP (IN of) (NP (NNP Doc_2673163_695_701_Disease)))) (VP (VBN related) (PP (TO to) (NP (JJ Doc_2673163_713_720_Chemical) (NN use))))) (VP (AUX is) (VP (VBG increasing))))))) (: ;) (S (NP (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NNP Doc_2673163_744_751_Chemical-associated) (NNP Doc_2673163_763_769_Disease)) (VP (VBZ occurs) (ADVP (RB primarily)) (PP (IN in) (NP (JJ young) (NNS adults))))) (: ;) (S (NP (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NNP Doc_2673163_808_814_Disease)) (VP (MD may) (VP (VB follow) (NP (DT any) (NN route)) (PP (IN of) (NP (NNP Doc_2673163_839_846_Chemical) (NN administration)))))) (: ;) (S (NP (NP (PRN (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-)) (NNP Doc_2673163_867_873_Disease)) (PP (IN after) (NP (JJ Doc_2673163_880_887_Chemical) (NN use)))) (VP (AUX is) (ADVP (RB frequently)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_2673163_922_944_Disease) (CC and) (NNP Doc_2673163_949_976_Disease)))))) (: ;) (CC and) (PRN (-LRB- -LRB-) (NP (CD 5)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ Doc_2673163_989_996_Chemical-associated) (NNP Doc_2673163_1008_1014_Disease)))) (, ,) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_2673163_1033_1056_Disease)))) (VP (VBZ exceeds) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_2673163_1073_1092_Disease))))) (. .)))
2696505	0	(S1 (NP (NP (DT A) (JJ randomized) (NN comparison)) (PP (IN of) (NP (NP (NNP Doc_2696505_27_36_Chemical)) (CC and) (NP (NNP Doc_2696505_41_54_Chemical)))) (PP (IN for) (NP (VBN induced) (NN Doc_2696505_67_78_Disease))) (. .)))
2696505	1	(S1 (S (PP (IN In) (NP (DT a) (JJ randomized) (NN study))) (, ,) (NP (NP (NNP Doc_2696505_103_112_Chemical-induced) (NNP Doc_2696505_121_132_Disease)) (CC and) (NP (NNP Doc_2696505_137_150_Chemical-induced) (NNP Doc_2696505_159_170_Disease))) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (NP (CD 20) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 10)) (PP (IN in) (NP (DT each) (NN group)))) (-RRB- -RRB-))) (VP (VBN scheduled) (PP (IN for) (NP (JJ major) (JJ orthopedic) (NNS procedures)))))))) (. .)))
2696505	2	(S1 (S (NP (DT Each) (NN patient)) (VP (AUX was) (VP (VBN subjected) (PP (TO to) (NP (NP (DT an) (JJ identical) (JJ anesthetic) (NN protocol)) (CC and) (NP (NP (NP (JJ similar) (JJ drug-induced) (NNP Doc_2696505_350_392_Disease)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (TO to) (CD 55)) (NNS mmHg)) (-RRB- -RRB-))))))) (. .)))
2696505	3	(S1 (S (S (NP (JJ Nitroprusside) (NN infusion)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)) (NN Doc_2696505_491_532_Disease)))))) (: ;) (S (NP (NN rebound)) (NP (NNP Doc_2696505_542_554_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (CD three) (NNS patients))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_2696505_611_624_Chemical)))))))) (. .)))
2696505	4	(S1 (S (NP (JJ Doc_2696505_626_635_Chemical) (NN administration)) (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNS findings))))))) (. .)))
2696505	5	(S1 (S (NP (NNP Arterial) (NNP Doc_2696505_707_710_Chemical)) (VP (VBD decreased) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
2696505	6	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_2696505_759_768_Chemical)) (VP (VBZ offers) (NP (NNS advantages)) (PP (IN over) (NP (NN Doc_2696505_792_805_Chemical)))))))) (. .)))
2802551	0	(S1 (S (NP (JJ Doc_2802551_0_6_Chemical) (NN status)) (VP (VBZ influences) (NP (NP (JJ chronic) (JJ Doc_2802551_33_47_Chemical) (NN Doc_2802551_48_62_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
2802551	1	(S1 (S (NP (NP (DT The) (JJ Doc_2802551_76_87_Disease) (NN potential)) (PP (IN of) (NP (NNP Doc_2802551_101_115_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NN mg/kg)) (PP (IN per) (NP (NN day))) (PP (ADVP (RB intraperitoneally)) (IN for) (NP (CD 3) (NNS weeks)))) (-RRB- -RRB-)) (VP (AUX has) (VP (AUX been) (VP (VBN investigated) (PP (IN in) (NP (ADJP (JJ salt-depleted) (, ,) (JJ normal-salt) (, ,) (CC and) (JJ salt-loaded)) (NNS rats)))))) (. .)))
2802551	2	(S1 (S (PP (IN In) (NP (JJ salt-depleted) (NNS rats))) (, ,) (NP (NNP Doc_2802551_262_276_Chemical)) (VP (VBD decreased) (NP (JJ Doc_2802551_287_297_Chemical) (NN clearance)) (ADVP (RB linearly)) (PP (IN with) (NP (NN time))) (, ,) (PP (IN with) (NP (NP (DT an) (ADJP (CD 85) (NN %)) (NN reduction)) (PP (IN by) (NP (NN week) (CD 3)))))) (. .)))
2802551	3	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (PP (IN in) (NP (JJ normal-salt) (NNS rats))) (NP (NNP Doc_2802551_394_404_Chemical) (NN clearance)) (VP (VP (AUX was) (VP (VBN decreased))) (CC but) (VP (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (PP (PP (IN at) (NP (NN week) (CD 2) (CC and) (CD 3))) (, ,) (CC and) (PP (IN in) (NP (NP (JJ salt-loaded) (NNS rats)) (SBAR (S (NP (NNP Doc_2802551_493_503_Chemical) (NN clearance)) (VP (VP (AUX did) (RB not) (VP (VB change) (PP (IN for) (NP (CD 2) (NNS weeks))))) (CC and) (VP (AUX was) (VP (VBN decreased) (PP (IN by) (NP (CD 43) (NN %))) (PP (IN at) (NP (NN week) (CD 3))))))))))))) (. .)))
2802551	4	(S1 (S (NP (NP (DT All) (NNS rats)) (PP (IN in) (NP (DT the) (JJ Doc_2802551_593_599_Chemical-depleted) (NN group)))) (VP (AUX had) (NP (NP (JJ histopathological) (NN evidence)) (PP (IN of) (NP (NP (JJ patchy) (JJ tubular) (JJ cytoplasmic) (NN degeneration)) (PP (IN in) (NP (NP (NNS tubules)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (RB not) (VP (VBN observed) (PP (IN in) (NP (NP (DT any) (NN normal-salt)) (CC or) (NP (JJ salt-loaded) (NN rat)))))))))))))) (. .)))
2802551	5	(S1 (S (NP (NP (NNS Concentrations)) (PP (IN of) (NP (NNP Doc_2802551_779_793_Chemical))) (PP (IN in) (NP (NN plasma)))) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different)) (PP (IN among) (NP (DT the) (CD three) (NNS groups))) (PP (IN at) (NP (DT any) (NN time))) (PP (IN during) (NP (DT the) (NN study)))) (. .)))
2802551	6	(S1 (S (ADVP (RB However)) (, ,) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (CD 3) (NNS weeks))))) (, ,) (NP (NP (JJ Doc_2802551_922_936_Chemical) (NNS levels)) (PP (IN in) (NP (DT the) (NNS kidneys) (CC and) (NN liver)))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR higher) (PP (IN in) (NP (ADJP (JJ salt-depleted) (CC and) (JJ normal-salt)) (NNS rats)))) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (JJ salt-loaded) (NNS rats)))))) (, ,) (PP (IN with) (NP (NP (JJ plasma/kidney) (NNS ratios)) (PP (IN of) (NP (NP (CD 21)) (, ,) (NP (CD 14)) (, ,) (CC and) (NP (NP (CD 8)) (PP (IN in) (NP (UCP (ADJP (JJ salt-depleted)) (, ,) (ADJP (JJ normal-salt)) (, ,) (CC and) (JJ salt-loaded)) (NNS rats)))) (, ,) (ADVP (RB respectively))))))) (. .)))
2802551	7	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NNS reductions)) (PP (IN in) (NP (NP (JJ Doc_2802551_1204_1214_Chemical) (NN clearance)) (CC and) (NP (JJ renal) (JJ Doc_2802551_1235_1249_Chemical) (NN accumulation))))) (PP (IN after) (NP (JJ chronic) (NNP Doc_2802551_1277_1291_Chemical) (NN administration))) (VP (AUX were) (VP (VP (VBN enhanced) (PP (IN by) (NP (NN salt) (NN depletion)))) (CC and) (VP (VBN attenuated) (PP (IN by) (NP (NP (JJ Doc_2802551_1357_1363_Chemical) (NN loading)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
2870085	0	(S1 (NP (NP (NN Doc_2870085_0_9_Chemical)) (: :) (NP (NP (DT an) (JJ ultra-short-acting) (NN beta-adrenergic)) (VP (VBG blocking) (NP (NN agent)))) (. .)))
2870085	1	(S1 (S (NP (NP (NNP Doc_2870085_65_74_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2870085_76_84_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ nonselective) (, ,) (JJ competitive) (, ,) (JJ ultra-short-acting) (JJ beta-adrenergic) (VBG blocking) (NN agent)) (, ,) (PP (IN without) (NP (DT any) (JJ intrinsic) (NN sympathomimetic) (NN activity))))) (. .)))
2870085	2	(S1 (S (NP (NN Doc_2870085_217_226_Chemical)) (VP (VP (AUX is) (VP (VBN metabolized) (PP (IN by) (NP (NN plasma) (NNS esterases))))) (CC and) (VP (AUX has) (NP (NP (DT an) (NN elimination) (NN half-life)) (PP (IN of) (NP (QP (RB approximately) (CD 6.5)) (NNS minutes)))))) (. .)))
2870085	3	(S1 (S (NP (DT This) (NN agent)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN in) (NP (JJ healthy) (NNS volunteers))) (PP (IN at) (NP (QP (NNS doses) (IN up) (TO to) (CD 100)) (NN micrograms/kg/min))))) (. .)))
2870085	4	(S1 (S (PP (IN In) (NP (JJ long-term) (NN infusion) (NNS studies))) (, ,) (NP (NNP Doc_2870085_446_455_Chemical)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN at) (NP (NP (DT the) (JJ effective) (NN beta-blocking) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN micrograms/kg/min)) (-RRB- -RRB-)))) (PP (IN for) (NP (QP (IN up) (TO to) (CD seven)) (NNS days))))) (. .)))
2870085	5	(S1 (S (NP (JJ Doc_2870085_555_564_Chemical) (NN blood) (NNS concentrations)) (VP (VBD increased) (ADVP (RB linearly)) (PP (IN with) (S (VP (VBG increasing) (NP (NP (NN dose) (CC and) (JJ good) (NN correlation) (VBZ exists)) (PP (IN between) (NP (NP (NN blood) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_2870085_686_695_Chemical)) (CC and) (NP (JJ beta-adrenergic) (NN blockade))))))))))) (. .)))
2870085	6	(S1 (S (NP (NN Doc_2870085_726_735_Chemical)) (VP (VBD produced) (NP (NP (DT a) (JJ dose-dependent) (NN attenuation)) (PP (IN of) (NP (NNP Doc_2870085_777_790_Chemical-induced) (NNP Doc_2870085_799_810_Disease))))) (. .)))
2870085	7	(S1 (S (NP (NP (ADJP (ADJP (JJ Electrophysiologic)) (CC and) (ADJP (JJ hemodynamic))) (NNS effects)) (PP (IN of) (NP (NNP Doc_2870085_858_867_Chemical)))) (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (JJ other) (NN beta) (NNS blockers))))))) (. .)))
2870085	8	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (IN with) (NP (JJ other) (NN beta) (NNS blockers))))) (, ,) (NP (JJ Doc_2870085_951_960_Chemical-induced) (NNS effects)) (VP (VBP reverse) (ADVP (RB rapidly)) (PRN (-LRB- -LRB-) (PP (IN within) (NP (CD 30) (NNS minutes))) (-RRB- -RRB-)) (VP (VBG following) (NP (NN discontinuation)) (PP (IN because) (IN of) (NP (PRP$ its) (JJ short) (NN half-life))))) (. .)))
2870085	9	(S1 (S (NP (NN Doc_2870085_1071_1080_Chemical)) (ADVP (RB effectively)) (VP (VBD reduced) (NP (NN heart) (NN rate)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2870085_1129_1161_Disease)))))) (. .)))
2870085	10	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2870085_1180_1195_Disease))))) (, ,) (NP (JJ Doc_2870085_1197_1206_Chemical) (NN infusion)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJ safe) (CC and) (JJ effective)) (PP (IN in) (S (VP (VBG controlling) (NP (NN Doc_2870085_1266_1276_Disease)))))))))) (. .)))
2870085	11	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_2870085_1299_1308_Chemical)) (VP (AUX is) (NP (DT a) (JJ potent) (, ,) (JJ well-tolerated) (, ,) (JJ ultra-short-acting) (JJ beta-adrenergic) (VBG blocking) (NN agent))))))) (. .)))
2870085	12	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_2870085_1396_1405_Chemical))) (PP (IN in) (NP (DT the) (JJ critical) (NN care) (NN setting)))) (VP (AUX is) (ADVP (RB currently)) (VP (VBG undergoing) (NP (NN investigation)))) (. .)))
2887062	0	(S1 (S (ADVP (JJ Immunohistochemical)) (, ,) (NP (NP (NNP electron) (JJ microscopic) (CC and) (JJ morphometric) (NNS studies)) (PP (IN of) (NP (JJ Doc_2887062_70_78_Chemical-induced) (NN rat)))) (VP (VBP Doc_2887062_91_104_Disease) (PP (IN after) (NP (JJ Doc_2887062_111_124_Chemical) (NN treatment)))) (. .)))
2887062	1	(S1 (S (S (VP (TO To) (VP (VB clarify) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_2887062_162_175_Chemical))) (PP (IN on) (NP (NP (JJ Doc_2887062_179_191_Disease) (NNS cells)) (PP (IN in) (NP (NN vivo))))))))) (, ,) (NP (ADJP (JJ immunohistochemical) (, ,) (JJ ultrastructural) (CC and) (JJ morphometrical)) (NNS analyses)) (VP (AUX were) (VP (VBN applied) (PP (TO to) (NP (JJ Doc_2887062_288_296_Chemical-induced) (NN rat) (NN Doc_2887062_309_321_Disease) (NNS cells) (NX (NX (CD 1) (NNP h)) (CC and) (NX (CD 6) (NNP h))))) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NP (NNP Doc_2887062_359_372_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 3) (NN mg/kg)) (PP (IN of) (NP (NN body) (NN weight)))) (-RRB- -RRB-)))))))) (. .)))
2887062	2	(S1 (S (NP (CD One) (NNP h)) (PP (IN after) (NP (NN treatment))) (, ,) (NP (NN serum) (NN prolactin) (NNS levels)) (VP (VBD decreased) (ADVP (RB markedly))) (. .)))
2887062	3	(S1 (S (NP (NNP Electron) (JJ microscopy)) (VP (VBD disclosed) (NP (NP (JJ many) (NN secretory) (NNS granules)) (, ,) (NP (ADJP (RB slightly) (JJ distorted)) (JJ rough) (JJ endoplasmic) (NN reticulum)) (, ,) (CC and) (NP (ADJP (RB partially) (VBN dilated)) (NNP Golgi) (NNS cisternae))) (PP (IN in) (NP (DT the) (JJ Doc_2887062_613_625_Disease) (NNS cells)))) (. .)))
2887062	4	(S1 (S (NP (JJ Morphometric) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (NN volume) (NN density)) (PP (IN of) (NP (JJ secretory) (NNS granules)))) (VP (VBD increased) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NN volume) (NN density)) (PP (IN of) (NP (JJ cytoplasmic) (NNS microtubules)))) (VP (VBD decreased)))))))) (. .)))
2887062	5	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (VBN lowered) (NN serum) (NN prolactin) (NNS levels)) (PP (IN in) (NP (NP (DT the) (JJ early) (NN phase)) (PP (IN of) (NP (JJ Doc_2887062_866_879_Chemical) (NN treatment)))))) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT an) (VBN impaired) (NN secretion)) (PP (IN of) (NP (NN prolactin))) (ADJP (JJ due) (PP (TO to) (NP (NP (VBG decreasing) (NNS numbers)) (PP (IN of) (NP (JJ cytoplasmic) (NNS microtubules))))))))))))) (. .)))
2887062	6	(S1 (S (PP (IN At) (NP (NP (CD 6) (NNP h)) (PP (IN after) (NP (NN injection))))) (, ,) (NP (NN serum) (NN prolactin) (NNS levels)) (VP (AUX were) (ADVP (RB still)) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN than) (PP (IN in) (NP (NNS controls)))))) (. .)))
2887062	7	(S1 (S (NP (NP (DT The) (JJ Doc_2887062_1095_1107_Disease) (NNS cells)) (PP (IN at) (NP (DT this) (NN time)))) (VP (AUX were) (VP (ADVP (RB well)) (VBN granulated) (, ,) (PP (IN with) (NP (NP (JJ vesiculated) (JJ rough) (JJ endoplasmic) (NN reticulum)) (CC and) (NP (ADJP (RB markedly) (VBN dilated)) (NNP Golgi) (NNS cisternae)))))) (. .)))
2887062	8	(S1 (S (NP (NNP Electron) (JJ microscopical) (NN immunohistochemistry)) (VP (VBD revealed) (NP (NP (JJ positive) (NN reaction) (NNS products)) (VP (VBN noted) (PP (IN on) (NP (NP (NP (DT the) (JJ secretory) (NNS granules)) (, ,) (NP (NNP Golgi) (NNS cisternae)) (, ,) (CC and) (NP (JJ endoplasmic) (NN reticulum))) (PP (IN of) (NP (DT the) (JJ untreated) (NN rat) (NN Doc_2887062_1409_1421_Disease) (NNS cells)))))))) (. .)))
2887062	9	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ only) (NN secretory) (NNS granules)) (VP (VBD showed) (NP (NP (DT the) (JJ positive) (NN reaction) (NNS products)) (PP (IN for) (S (VP (VBG prolactin) (NP (CD 6) (NNP h)) (PP (IN after) (NP (NP (JJ Doc_2887062_1524_1537_Chemical) (NN treatment)) (PP (IN of) (NP (DT the) (JJ Doc_2887062_1555_1562_Disease) (NNS cells)))))))))) (. .)))
2887062	10	(S1 (S (NP (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN volume) (NN density)) (PP (IN of) (NP (JJ secretory) (NNS granules)))))) (CC and) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN volume) (NNS densities)) (PP (IN of) (NP (NP (JJ rough) (JJ endoplasmic) (NN reticulum)) (CC and) (NP (NNS microtubules)))))))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (JJ morphometric) (NN analysis))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NNP Doc_2887062_1770_1783_Chemical)) (VP (VBZ inhibits) (NP (NP (NN protein) (NN synthesis)) (CONJP (RB as) (RB well) (IN as)) (NP (NN bringing))) (PP (IN about) (NP (NP (DT a) (NN disturbance)) (PP (IN of) (NP (DT the) (JJ prolactin) (NN secretion)))))))))))) (. .)))
2894766	0	(S1 (NP (JJ Doc_2894766_0_13_Chemical-induced) (NN Doc_2894766_22_41_Disease) (. .)))
2894766	1	(S1 (S (NP (NP (NNP Doc_2894766_43_54_Disease)) (, ,) (NP (JJ bilateral) (NNP Doc_2894766_66_83_Disease)) (, ,) (NP (NP (JJ echocardiographic) (NN evidence)) (PP (IN of) (NP (NNP Doc_2894766_115_132_Disease)))) (, ,) (CC and) (NP (JJ positive) (NNS autoantibodies))) (VP (VBD developed) (PP (IN in) (NP (NP (DT a) (JJ 43-year-old) (NN man)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX was) (S (VP (VBG receiving) (NP (JJ long-term) (JJ Doc_2894766_222_235_Chemical) (NN therapy)) (PP (IN for) (NP (JJ chronic) (NN Doc_2894766_256_274_Disease))))))))))) (. .)))
2894766	2	(S1 (S (PP (IN After) (NP (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NNP Doc_2894766_299_312_Chemical)))) (CC and) (NP (NP (NN completion)) (PP (IN of) (NP (NP (DT a) (JJ six-week) (NN course)) (PP (IN of) (NP (NNS corticosteroids)))))))) (, ,) (NP (DT these) (NNS problems)) (VP (VBN resolved) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (QP (CD four) (TO to) (CD six)) (NNS months)))))) (. .)))
2894766	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (AUX had) (NP (NP (NNP Doc_2894766_467_480_Chemical-induced) (NNP Doc_2894766_489_494_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD manifested) (PP (IN with) (NP (NP (NN Doc_2894766_518_527_Disease)) (CC and) (NP (JJ pulmonary) (JJ parenchymal) (NN involvement)))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ joint) (NNS symptoms)))))))))))))) (. .)))
2894766	4	(S1 (S (NP (NP (NNS Physicians)) (SBAR (WHNP (WP who)) (S (VP (VBP use) (NP (NNP Doc_2894766_619_632_Chemical)) (S (VP (TO to) (VP (VB treat) (NP (NNS patients)) (PP (IN with) (NP (NN Doc_2894766_656_682_Disease)))))))))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NNP Doc_2894766_715_728_Chemical-induced) (NNP Doc_2894766_737_751_Disease)))))))) (. .)))
2924746	0	(S1 (NP (NP (NP (JJ Chronic) (JJ Doc_2924746_8_21_Chemical) (NN treatment)) (PP (IN in) (NP (DT the) (NN rat)))) (: :) (NP (NP (NN efficacy)) (, ,) (NP (NN Doc_2924746_54_62_Disease)) (, ,) (CC and) (NP (NP (NN effect)) (PP (IN on) (NP (NN plasma) (CC and) (NN tissue) (NN Doc_2924746_96_102_Chemical) (NNS concentrations))))) (. .)))
2924746	1	(S1 (S (NP (JJ Doc_2924746_119_125_Chemical) (NN depletion)) (VP (AUX has) (ADVP (RB often)) (VP (AUX been) (NP (NP (DT a) (NN problem)) (PP (IN in) (NP (JJ chronic) (JJ antiepileptic) (NN drug) (PRN (-LRB- -LRB-) (JJ AED) (-RRB- -RRB-)) (NN therapy)))))) (. .)))
2924746	2	(S1 (S (NP (NP (NP (NNP Doc_2924746_206_219_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2924746_221_224_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN AED)) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (DT some) (JJ clinical) (NNS studies)))))) (. .)))
2924746	3	(S1 (S (NP (DT A) (NN rat) (NN model)) (VP (AUX was) (VP (VBN developed) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ chronic) (JJ Doc_2924746_354_357_Chemical) (NN treatment))) (PP (IN on) (NP (NP (JJ Doc_2924746_371_377_Chemical) (NNS concentrations)) (PP (IN in) (NP (DT the) (NN rat))))))))))) (. .)))
2924746	4	(S1 (S (PP (IN In) (NP (NP (DT the) (NN course)) (PP (IN of) (S (VP (VBG developing) (NP (DT this) (NN model))))))) (, ,) (NP (NP (DT a) (JJ common) (NN vehicle)) (, ,) (NP (NNP Doc_2924746_463_479_Chemical)) (, ,) (PP (IN by) (NP (NP (PRP itself)) (PP (IN in) (NP (JJ high) (NNS doses))))) (, ,)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VB exhibit) (NP (JJ protective) (NNS properties)) (PP (IN against) (S (VP (VP (VBN induced) (NP (NNP Doc_2924746_565_573_Disease))) (CC and) (VP (VBD inhibited) (NP (NN Doc_2924746_588_599_Disease))))))))))) (. .)))
2924746	5	(S1 (S (NP (NP (NN Doc_2924746_601_609_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_2924746_621_644_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2924746_646_650_Chemical)) (-RRB- -RRB-)))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (NN measure)) (PP (IN of) (NP (NN protection)))) (PP (IN by) (NP (NNP Doc_2924746_716_719_Chemical))) (SBAR (IN than) (S (NP (NNP Doc_2924746_725_733_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ maximal) (NN electroshock)) (PRN (-LRB- -LRB-) (NP (NNP MES)) (-RRB- -RRB-)))))))))))) (. .)))
2924746	6	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NNP Doc_2924746_796_799_Chemical))) (PP (IN as) (NP (DT an) (JJ aqueous) (NN suspension))) (NP (DT every) (CD 8) (NNP h)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 250) (NNS mg/kg)))))) (VP (VP (AUX was) (ADJP (RB continuously) (JJ protective) (PP (IN against) (NP (JJ Doc_2924746_894_898_Chemical-induced) (NNP Doc_2924746_907_915_Disease))))) (CC and) (VP (AUX was) (ADJP (RB minimally) (JJ toxic) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NNP Doc_2924746_955_966_Disease))) (PP (IN over) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NN treatment))))))))))) (. .)))
2924746	7	(S1 (S (NP (NP (DT The) (JJ Doc_2924746_998_1001_Chemical) (NNS levels)) (VP (VBN measured) (PP (IN in) (NP (NP (NP (NN plasma)) (CC and) (NP (NN brain))) (PP (IN of) (NP (DT these) (NNS animals))))))) (, ,) (ADVP (RB however)) (, ,) (VP (AUX were) (PP (IN below) (NP (NP (DT those)) (VP (ADVP (RB normally)) (VBN considered) (S (ADJP (JJ protective))))))) (. .)))
2924746	8	(S1 (S (NP (NP (DT This) (NN treatment)) (PP (IN with) (NP (NNP Doc_2924746_1134_1137_Chemical)))) (VP (VP (AUX had) (NP (NP (DT no) (JJ apparent) (JJ adverse) (NN effect)) (PP (IN on) (NP (NP (JJ Doc_2924746_1172_1178_Chemical) (NNS concentrations)) (PP (IN in) (NP (DT the) (NN rat))))))) (, ,) (CC and) (, ,) (ADVP (RB indeed)) (, ,) (S (NP (DT the) (NNP Doc_2924746_1223_1229_Chemical) (NN concentration)) (VP (VBN increased) (PP (IN in) (NP (NN liver))) (PP (PP (IN after) (NP (NP (CD 6) (NNS weeks)) (PP (IN of) (NP (NN treatment))))) (CC and) (PP (IN in) (NP (NN plasma)))) (PP (IN at) (NP (NP (CD 8) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))))) (. .)))
2950248	0	(S1 (NP (JJ Doc_2950248_0_12_Chemical-induced) (NN Doc_2950248_21_40_Disease) (. .)))
2950248	1	(S1 (S (NP (NP (NN Doc_2950248_42_48_Disease)) (CC and) (NP (JJ ischemic) (NN electrocardiographic) (NNS changes))) (VP (VBD occurred) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (JJ oral) (NNP Doc_2950248_129_141_Chemical))) (PP (IN in) (NP (NP (CD four) (NNS patients)) (VP (VBG awaiting) (NP (JJ urgent) (JJ myocardial) (NN revascularization) (NNS procedures)))))))) (. .)))
2950248	2	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX has) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (DT a) (NN side) (NN effect)) (PP (IN of) (NP (JJ preoperative) (JJ Doc_2950248_305_317_Chemical) (NN therapy))))) (, ,) (SBAR (IN although) (S (NP (NNP Doc_2950248_336_348_Chemical-induced) (NNP Doc_2950248_357_376_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB occur) (PP (IN in) (NP (NP (NNS animals)) (CC and) (NP (NNS humans)))) (PP (IN with) (NP (NN Doc_2950248_435_458_Disease)))))))))))))) (. .)))
2950248	3	(S1 (S (S (NP (JJ Epicardial) (JJ coronary) (NN collateral) (NNS vessels)) (VP (AUX were) (VP (VBN demonstrated) (PP (IN in) (NP (DT all) (CD four) (NNS patients)))))) (: ;) (S (NP (DT a) (JJ coronary) (`` ``) (VB steal) ('' '') (NN phenomenon)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (DT the) (JJ Doc_2950248_597_609_Chemical-induced) (NN Doc_2950248_618_626_Disease)) (VP (VBN observed)))))))) (. .)))
2951327	0	(S1 (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN sympathoadrenal) (NN activity))) (PP (IN by) (NP (NP (JJ atrial) (JJ natriuretic) (NN factor)) (PP (IN in) (NP (NNS dogs))))) (. .)))
2951327	1	(S1 (S (PP (IN In) (NP (NP (CD six) (JJ conscious) (, ,) (JJ trained) (NNS dogs)) (, ,) (VP (VBN maintained) (PP (IN on) (NP (NP (DT a) (JJ normal) (JJ Doc_2951327_132_138_Chemical) (NN intake)) (PP (IN of) (NP (QP (CD 2) (TO to) (CD 4)) (NN mEq/kg/day)))))))) (, ,) (NP (JJ sympathetic) (NN activity)) (VP (AUX was) (VP (VBN assessed) (PP (IN as) (NP (NP (DT the) (NN release) (NN rate)) (PP (IN of) (NP (NNP Doc_2951327_225_239_Chemical) (CC and) (NNP Doc_2951327_244_255_Chemical))))) (PP (IN during) (NP (NP (JJ 15-minute) (JJ i.v.) (NNS infusions)) (PP (IN of) (NP (JJ human) (JJ alpha-atrial) (NN natriuretic) (NN factor))))))) (. .)))
2951327	2	(S1 (S (NP (NP (JJ Mean) (JJ arterial) (NN pressure)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NP (DT a) (NN percentage)) (PP (IN of) (NP (NN control) (NN +/-) (NN SEM))))) (-RRB- -RRB-)) (PP (IN during) (NP (NP (JJ randomized) (NNS infusions)) (PP (IN of) (NP (CD 0.03))))) (, ,) (CD 0.1) (, ,) (CD 0.3) (, ,) (CC or) (NP (CD 1.0) (NN microgram/kg/min))) (VP (AUX was) (NP (NP (QP (CD 99) (CD +/-)) (CD 1)) (, ,) (NP (NP (CD 95) (NN +/-)) (SBAR (S (NP (NP (NP (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (, ,) (NP (NP (CD 93) (NN +/-)) (NP (NP (NP (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (CD 79) (NN +/-) (CD 6) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively)))) (, ,) (CC but) (NP (DT no) (NNP Doc_2951327_588_599_Disease)) (CC and) (NP (NP (DT no) (NN augmentation)) (PP (IN of) (NP (NP (DT the) (JJ Doc_2951327_627_641_Chemical) (NN release) (NN rate)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 0.3)) (NN microgram/kg/min)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN observed)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (JJ comparable) (NNP Doc_2951327_734_745_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2951327_757_768_Chemical) (CC or) (NNP Doc_2951327_772_785_Chemical))))))))))))) (. .)))
2951327	3	(S1 (S (NP (NP (DT The) (NN release) (NN rate)) (PP (IN of) (NP (NNP Doc_2951327_807_818_Chemical))) (PRN (-LRB- -LRB-) (NP (NN control)) (, ,) (NP (CD 6.7) (NN +/-) (CD 0.6) (NN ng/kg/min)) (-RRB- -RRB-))) (VP (VBD declined) (ADVP (RB immediately)) (PP (IN during) (NP (NP (NNS infusions)) (PP (IN of) (NP (JJ atrial) (JJ natriuretic) (NN factor))))) (PP (TO to) (NP (NP (DT a) (NN minimum)) (PP (IN of) (NP (NP (CD 49) (NN +/-) (CD 5) (NN %)) (PP (IN of) (NP (NP (NN control)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))))))) (PP (IN during) (NP (CD 0.1) (NN microgram/kg/min))) (CC and) (PP (TO to) (NP (NP (NP (NP (CD 63) (NN +/-)) (NP (CD 5) (NN %))) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1) (QP (JJR greater) (IN than) (CD p)) (JJR greater)) (PP (IN than) (NP (CD 0.05)))) (-RRB- -RRB-))) (CC or) (NP (NP (CD 95) (NN +/-)) (ADJP (CD 13) (NN %) (PRN (-LRB- -LRB-) (ADJP (RB not) (JJ significant)) (-RRB- -RRB-)) (PP (IN during) (NP (CD 0.3) (CC or) (CD 1.0) (NN microgram/kg/min))))))))) (. .)))
2951327	4	(S1 (S (NP (NP (JJ Steady) (NN state) (NN arterial) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (JJ atrial) (JJ natriuretic) (NN factor)))) (VP (AUX were) (NP (NP (CD 39) (JJ +/-) (CD 10) (NNS pg/ml)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))) (PP (IN during) (NP (NP (NP (NNS infusions)) (PP (IN of) (NP (NN saline)))) (CC and) (NP (NP (NP (NP (NP (CD 284) (NN +/-)) (NP (CD 24) (NNS pg/ml))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (CD 1520) (NN +/-)) (NP (CD 300) (NNS pg/ml))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 9)) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (QP (CD 0.03) (CC and) (CD 0.1)) (JJ microgram/kg/min) (NNS infusions)) (PP (IN of) (NP (DT the) (NN factor.))) (PRN (-LRB- -LRB-) (VP (ADVP (JJ ABSTRACT)) (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS)))) (-RRB- -RRB-))))))))))
3015567	0	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ immunoreactive) (JJ corticotropin-releasing) (NN factor)))) (VP (VBP secretion) (PP (IN into) (NP (DT the) (JJ hypophysial-portal) (NN circulation))) (PP (IN by) (NP (JJ delayed) (JJ glucocorticoid) (NN feedback)))) (. .)))
3015567	1	(S1 (S (NP (JJ Doc_3015567_146_159_Chemical-induced) (NNP Doc_3015567_168_179_Disease)) (VP (VBZ evokes) (NP (NP (JJ ACTH) (NN secretion)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB primarily)) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ enhanced) (NN secretion)) (PP (IN of) (NP (NP (JJ immunoreactive) (NN corticotropin-releasing) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN irCRF)) (-RRB- -RRB-)))))) (PP (IN into) (NP (DT the) (JJ hypophysial-portal) (NN circulation))))))))) (. .)))
3015567	2	(S1 (S (NP (NP (JJ Portal) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (CC neither) (NP (NNP Doc_3015567_390_410_Chemical)) (CC nor) (NP (NNP Doc_3015567_415_423_Chemical))))) (VP (AUX are) (VP (ADVP (RB significantly)) (VBN altered) (PP (IN in) (NP (DT this) (NN paradigm))))) (. .)))
3015567	3	(S1 (S (NP (NP (NN Application)) (PP (IN of) (NP (DT a) (JJ delayed) (NN feedback) (NN signal)))) (, ,) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NP (DT a) (JJ 2-h) (JJ systemic) (JJ Doc_3015567_540_554_Chemical) (NN infusion)) (PP (IN in) (NP (NP (JJ Doc_3015567_567_575_Chemical-anesthetized) (NNS rats)) (PP (IN with) (NP (NP (JJ pharmacological) (NN blockade)) (PP (IN of) (NP (JJ glucocorticoid) (NN synthesis))))))))))) (, ,) (VP (AUX is) (PP (IN without) (NP (NN effect))) (PP (IN on) (NP (NP (DT the) (JJ resting) (NN secretion)) (PP (IN of) (NP (NNP Doc_3015567_699_719_Chemical) (CC and) (NNP Doc_3015567_724_732_Chemical))))) (PP (IN at) (NP (NP (DT any) (JJ Doc_3015567_740_754_Chemical) (NN feedback)) (SBAR (S (NP (NN dose)) (VP (VBD tested))))))) (. .)))
3015567	4	(S1 (S (NP (NN Resting) (NN irCRF) (NNS levels)) (VP (AUX are) (VP (VBN suppressed) (ADVP (RB only)) (PP (IN at) (NP (NP (DT the) (JJS highest) (JJ Doc_3015567_833_847_Chemical) (NN infusion) (NN rate)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (JJ systemic) (JJ Doc_3015567_890_904_Chemical) (NNS levels)) (PP (IN of) (NP (CD 40) (NN micrograms/dl)))))))))))) (. .)))
3015567	5	(S1 (S (NP (NP (NN Suppression)) (PP (IN of) (NP (NN irCRF) (NN secretion))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ Doc_3015567_979_992_Chemical-induced) (NNP Doc_3015567_1001_1012_Disease)))))) (VP (VP (AUX is) (VP (VBN observed))) (CC and) (VP (VBZ occurs) (PP (IN at) (NP (NP (DT a) (NN plasma) (JJ Doc_3015567_1048_1062_Chemical) (NN level)) (PP (IN between) (NP (CD 8-12) (CD micrograms/dl))))))) (. .)))
3015567	6	(S1 (S (NP (DT These) (NNS studies)) (VP (VBP provide) (NP (NP (JJ further) (NN evidence)) (PP (IN for) (NP (NP (DT a) (JJ strong) (JJ central) (NN component)) (PP (IN of) (NP (NP (DT the) (JJ delayed) (NN feedback) (NN process)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN mediated) (PP (IN by) (NP (NP (NN modulation)) (PP (IN of) (NP (NN irCRF) (NN release))))))))))))))) (. .)))
3031535	0	(S1 (NP (NP (JJ Noradrenergic) (NN involvement)) (PP (IN in) (NP (NNP Doc_3031535_29_38_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3031535_50_78_Chemical)))) (. .)))
3031535	1	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (JJ catecholaminergic) (NN system))) (PP (IN in) (NP (NP (DT the) (JJ cataleptogenic) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_3031535_175_203_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3031535_205_208_Chemical)) (-RRB- -RRB-))))))))))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NN pretreatment)) (PP (PP (IN with) (NP (NP (NNP Doc_3031535_243_260_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3031535_262_268_Chemical)) (-RRB- -RRB-)))) (CC or) (PP (IN with) (NP (NP (NNP Doc_3031535_278_289_Chemical)) (CC and) (NP (NNP Doc_3031535_294_300_Chemical)))))) (CC and) (NP (NP (NNS lesions)) (PP (IN of) (NP (DT the) (JJ locus) (NN coeruleus))))))) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (NNS rats))))) (. .)))
3031535	2	(S1 (S (NP (NP (DT The) (JJ cataleptogenic) (NN effect)) (PP (IN of) (NP (NNP Doc_3031535_392_395_Chemical)))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3031535_443_449_Chemical)))))) (CC and) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNS lesions)) (PP (IN of) (NP (DT the) (JJ locus) (NN coeruleus))))))) (CC but) (PP (RB not) (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_3031535_527_538_Chemical)) (CC and) (NP (NNP Doc_3031535_543_549_Chemical)))))))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NN control) (NNS rats)))))))) (. .)))
3031535	3	(S1 (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (NP (NP (DT the) (JJ cataleptogenic) (NN effect)) (PP (IN of) (NP (NNP Doc_3031535_628_639_Chemical)))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_3031535_687_698_Chemical)) (CC and) (NP (NNP Doc_3031535_703_709_Chemical))))))) (CC but) (RB not) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3031535_739_745_Chemical)))))) (CC or) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NNS lesions)) (PP (IN of) (NP (DT the) (JJ locus) (NNS coeruleus)))))))))) (. .)))
3031535	4	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ noradrenergic) (NNS neurons)) (VP (AUX have) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN manifestation)) (PP (IN of) (NP (NP (NNP Doc_3031535_891_900_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3031535_912_915_Chemical)))))))) (, ,) (SBAR (IN whereas) (S (NP (JJ dopaminergic) (NNS neurons)) (VP (AUX are) (ADJP (JJ important)) (PP (IN in) (NP (NP (NNP Doc_3031535_963_972_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3031535_984_995_Chemical))))))))))))) (. .)))
3070035	0	(S1 (NP (NP (NN Reversibility)) (PP (IN of) (NP (NNP Doc_3070035_17_26_Chemical-induced) (NNP Doc_3070035_35_54_Disease))) (PP (IN after) (NP (NP (VBN prolonged) (NN use)) (PP (IN in) (NP (NP (DT an) (JJ unusual) (NN case)) (PP (IN of) (NP (NNP Doc_3070035_97_122_Disease))))))) (. .)))
3070035	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ severe) (NN Doc_3070035_151_163_Disease)) (PP (IN with) (NP (NP (DT an) (JJ occluded) (JJ renal) (NN artery)) (PP (TO to) (NP (NP (DT a) (JJ solitary) (NN kidney)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_3070035_230_268_Disease)) (PP (VBG following) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_3070035_294_303_Chemical)))))))))))))))) (. .)))
3070035	2	(S1 (S (NP (PRP$ His) (JJ renal) (NN function)) (VP (VP (VBD remained) (ADJP (ADJP (JJ impaired)) (CC but) (ADJP (JJ stable))) (PP (IN during) (NP (NP (NP (CD 2) (NNS years) (POS ')) (NN treatment)) (PP (IN with) (NP (NNP Doc_3070035_384_393_Chemical)))))) (CC but) (VP (VBD returned) (PP (TO to) (NP (JJ pre-treatment) (NNS levels))) (PP (ADVP (RB soon)) (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NN drug))))))) (. .)))
3070035	3	(S1 (S (NP (DT This)) (VP (VP (VBZ indicates) (NP (NP (NN reversibility)) (PP (IN in) (NP (NNP Doc_3070035_497_506_Chemical-induced) (NNP Doc_3070035_515_528_Disease)))) (PP (ADVP (RB even)) (IN after) (NP (PRP$ its) (JJ prolonged) (NN use)))) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT no) (JJ organic) (NN damage)) (VP (VBZ occurs) (PP (TO to) (NP (NP (JJ glomerular) (NNS arterioles)) (VP (VBG following) (NP (JJ chronic) (NN ACE) (NN inhibition)))))))))) (. .)))
3076126	0	(S1 (S (NP (NNP HMG) (NNP CoA) (NN reductase)) (VP (VBZ inhibitors)) (. .)))
3076126	1	(S1 (FRAG (NP (JJ Current) (JJ clinical) (NN experience)) (. .)))
3076126	2	(S1 (S (NP (NP (NNP Doc_3076126_59_69_Chemical)) (CC and) (NP (NNP Doc_3076126_74_85_Chemical))) (VP (AUX are) (NP (NP (DT the) (CD 2) (JJ best-known) (NNS members)) (PP (IN of) (NP (NP (DT the) (NN class)) (PP (IN of) (NP (JJ hypolipidaemic) (NNS agents))) (VP (VBN known) (PP (IN as) (NP (NNP HMG) (NNP CoA) (NN reductase) (NNS inhibitors)))))))) (. .)))
3076126	3	(S1 (S (S (NP (NP (JJ Clinical) (NN experience)) (PP (IN with) (NP (NNP Doc_3076126_217_227_Chemical)))) (VP (VBZ includes) (PP (IN over) (NP (NP (CD 5000) (NNS patients)) (, ,) (SBAR (WHNP (CD 700) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (IN for) (NP (NP (CD 2) (NNS years)) (CC or) (NP (JJR more))))))))))))) (, ,) (CC and) (S (NP (NP (NN experience)) (PP (IN with) (NP (NNP Doc_3076126_328_339_Chemical)))) (VP (VBZ includes) (PP (IN over) (NP (NP (CD 3500) (NNS patients)) (, ,) (SBAR (WHPP (IN of) (WHNP (WP whom))) (S (NP (CD 350)) (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (IN for) (NP (CD 18) (NNS months) (QP (CC or) (JJR more))))))))))))) (. .)))
3076126	4	(S1 (S (NP (NN Doc_3076126_422_432_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN marketed) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))) (PP (IN for) (NP (IN over) (CD 6) (NNS months)))))) (. .)))
3076126	5	(S1 (S (NP (DT Both) (NNS agents)) (VP (VBP show) (NP (JJ substantial) (JJ clinical) (NN efficacy)) (, ,) (PP (IN with) (NP (NP (NNS reductions)) (PP (PP (IN in) (NP (NP (JJ total) (NN Doc_3076126_564_575_Chemical)) (PP (IN of) (NP (QP (IN over) (CD 30)) (NN %))))) (CC and) (PP (IN in) (NP (NP (NN LDL-Doc_3076126_599_610_Chemical)) (PP (IN of) (NP (CD 40) (NN %))) (PP (IN in) (NP (JJ clinical) (NNS studies))))))))) (. .)))
3076126	6	(S1 (S (NP (NP (JJ Modest) (NNS increases)) (PP (IN in) (NP (NP (JJ HDL-Doc_3076126_663_674_Chemical) (NNS levels)) (PP (IN of) (NP (QP (RB about) (CD 10)) (NN %)))))) (VP (AUX are) (ADVP (RB also)) (VP (VBN reported))) (. .)))
3076126	7	(S1 (S (NP (NP (JJ Clinical) (NN tolerability)) (PP (IN of) (NP (DT both) (NNS agents)))) (VP (AUX has) (VP (AUX been) (ADJP (JJ good)) (, ,) (PP (IN with) (NP (NP (QP (JJR fewer) (IN than) (CD 3)) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN withdrawn) (PP (IN from) (NP (NN treatment))) (PP (IN because) (IN of) (NP (JJ clinical) (JJ adverse) (NNS experiences)))))))))) (. .)))
3076126	8	(S1 (S (NP (NP (JJ Ophthalmological) (NNS examinations)) (PP (IN in) (NP (QP (IN over) (CD 1100)) (NNS patients))) (VP (VBN treated) (PP (IN with) (NP (CD one) (CC or) (DT the) (JJ other) (NN agent))))) (VP (AUX have) (VP (VP (VBN revealed) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (JJ significant) (JJ short) (NN term))))) (PRN (-LRB- -LRB-) (NP (QP (RB up) (TO to) (CD 2)) (NNS years)) (-RRB- -RRB-)) (NP (JJ cataractogenic) (NN potential)))) (. .)))
3076126	9	(S1 (S (NP (NP (QP (CD One) (TO to) (CD 2)) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX have) (NP (NP (NNS elevations)) (PP (IN of) (NP (NN serum) (NNS transaminases))) (PP (TO to) (NP (NP (QP (JJR greater) (IN than) (CD 3) (NNS times)) (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (JJ normal))))))) (. .)))
3076126	10	(S1 (S (NP (DT These) (NNS episodes)) (VP (AUX are) (ADJP (ADJP (JJ asymptomatic)) (CC and) (ADJP (JJ reversible))) (SBAR (WHADVP (WRB when)) (S (NP (NN therapy)) (VP (AUX is) (VP (VBN discontinued)))))) (. .)))
3076126	11	(S1 (S (NP (NP (JJ Minor) (NNS elevations)) (PP (IN of) (NP (JJ Doc_3076126_1254_1262_Chemical) (NN kinase) (NNS levels)))) (VP (AUX are) (VP (VBN reported) (PP (IN in) (NP (NP (QP (RB about) (CD 5)) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
3076126	12	(S1 (S (NP (NP (NN Doc_3076126_1315_1323_Disease)) (, ,) (VP (VBN associated) (PP (PP (IN in) (NP (NP (DT some) (NNS cases)) (PP (IN with) (NP (NNP Doc_3076126_1355_1368_Disease))))) (, ,) (CC and) (PP (IN in) (NP (NP (CD 2) (NNS cases)) (PP (IN with) (NP (JJ transient) (NNP Doc_3076126_1400_1413_Disease))))))) (, ,)) (VP (AUX has) (VP (AUX been) (ADVP (RB rarely)) (VP (VBN reported) (PP (IN with) (NP (NNP Doc_3076126_1445_1455_Chemical))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBN treated) (PP (IN with) (NP (NNP Doc_3076126_1507_1518_Chemical) (, ,) (NNP Doc_3076126_1520_1531_Chemical) (CC or) (NNP Doc_3076126_1535_1541_Chemical))))))))) (. .)))
3076126	13	(S1 (S (NP (NP (NNP Doc_3076126_1543_1553_Chemical)) (CC and) (NP (NNP Doc_3076126_1558_1569_Chemical))) (VP (AUX are) (NP (DT both) (JJ effective) (CC and) (JJ well-tolerated) (NNS agents)) (PP (IN for) (S (VP (VBG lowering) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (JJ serum) (NNP Doc_3076126_1653_1664_Chemical)))))))) (. .)))
3076126	14	(S1 (S (SBAR (IN As) (S (NP (JJR wider) (NN use)) (VP (VBZ confirms) (NP (PRP$ their) (NN safety) (NN profile))))) (, ,) (NP (PRP they)) (VP (MD will) (VP (VB gain) (S (VP (VBG increasing) (NP (NN importance)) (PP (IN in) (NP (NP (DT the) (JJ therapeutic) (NN approach)) (PP (TO to) (NP (NP (NNP Doc_3076126_1778_1799_Disease)) (CC and) (NP (PRP$ its) (NNS consequences)))))))))) (. .)))
3101906	0	(S1 (S (NP (JJ Hepatic) (NNS reactions)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_3101906_34_46_Chemical))) (PP (IN in) (NP (DT the) (NNP United) (NNP Kingdom)))) (. .)))
3101906	1	(S1 (S (NP (NN Doc_3101906_70_82_Chemical)) (VP (AUX was) (VP (VBN introduced) (PP (IN in) (NP (NP (DT the) (NNP United) (NNP Kingdom)) (PP (IN in) (NP (CD 1981))))))) (. .)))
3101906	2	(S1 (S (PP (IN By) (NP (NNP November) (CD 1984))) (NP (NP (DT the) (NN Committee)) (PP (IN on) (NP (NP (NNP Safety)) (PP (IN of) (NP (NNP Medicines)))))) (VP (AUX had) (VP (VBN received) (NP (NP (CD 82) (NNS reports)) (PP (IN of) (NP (NP (JJ possible) (NN Doc_3101906_219_233_Disease)) (VP (VBN associated) (PP (IN with) (NP (DT the) (NN drug))))))) (, ,) (PP (VBG including) (NP (CD five) (NN Doc_3101906_275_281_Disease))))) (. .)))
3101906	3	(S1 (S (NP (NP (DT An) (NN analysis)) (PP (IN of) (NP (NP (DT the) (CD 75) (NNS cases)) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (AUX been) (ADVP (RB adequately)) (VP (VBN followed) (PRT (RP up)))))))))) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (CD 16)) (, ,) (PP (VBG including) (NP (CD three) (NN Doc_3101906_383_389_Disease))) (, ,)) (VP (AUX were) (ADVP (RB probably)) (VP (VBN related) (PP (TO to) (NP (NP (NN treatment)) (PP (IN with) (NP (DT the) (NN drug)))))))))) (. .)))
3101906	4	(S1 (S (PP (IN Of) (NP (DT the) (NN remainder))) (, ,) (S (NP (CD 48)) (VP (AUX were) (ADJP (ADVP (RB possibly)) (VBN related) (PP (TO to) (NP (NN treatment)))))) (, ,) (S (NP (CD five)) (VP (AUX were) (ADJP (JJ unlikely) (S (VP (TO to) (VP (AUX be) (ADVP (RB so)))))))) (, ,) (CC and) (S (NP (CD six)) (VP (AUX were) (ADJP (JJ unclassifiable)))) (. .)))
3101906	5	(S1 (S (NP (NP (DT The) (JJ mean) (NN age)) (PP (IN of) (NP (NNS patients))) (PP (IN in) (NP (DT the) (CD 16) (JJ probable) (NNS cases)))) (VP (AUX was) (NP (CD 57.9)) (, ,) (PP (IN with) (S (NP (NNP Doc_3101906_621_635_Disease)) (VP (AUXG being) (ADJP (RBR more) (JJ common)) (PP (IN in) (NP (NNS women))))))) (. .)))
3101906	6	(S1 (S (NP (NP (DT The) (JJ average) (NN duration)) (PP (IN of) (NP (NN treatment))) (PP (IN before) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_3101906_718_726_Disease)))))) (VP (AUX was) (NP (CD 61) (NNS days))) (. .)))
3101906	7	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT these) (ADJP (RB well) (VBN validated)) (NNS cases)))) (VP (VBD occurred) (PP (IN within) (NP (DT the) (JJ first) (CD 10) (NNS days))) (PP (IN after) (NP (NN treatment)))) (. .)))
3101906	8	(S1 (S (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (NN serum) (NN liver) (NN function) (NNS tests)))) (VP (VBD suggested) (NP (NNP Doc_3101906_878_899_Disease)) (PP (IN in) (NP (CD 10))) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-)))) (: ;) (S (NP (DT the) (NN rest)) (VP (VBD showed) (NP (DT a) (JJ mixed) (NN pattern)))) (. .)))
3101906	9	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (JJ histological) (NN examination)) (PP (IN of) (NP (DT the) (NN liver)))))) (ADVP (RB often)) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_3101906_1037_1048_Disease))))) (. .)))
3101906	10	(S1 (S (NP (NP (DT The) (NNS characteristics)) (PP (IN of) (NP (DT the) (CD 48) (NNS patients))) (PP (IN in) (NP (DT the) (JJ possible) (NNS cases)))) (VP (AUX were) (ADJP (JJ similar))) (. .)))
3101906	11	(S1 (S (NP (NP (JJ Allergic) (NNS manifestations)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_3101906_1157_1161_Disease)) (CC and) (NP (NNP Doc_3101906_1166_1178_Disease))))) (VP (AUX were) (ADJP (JJ rare))) (. .)))
3101906	12	(S1 (S (NP (NN Doc_3101906_1190_1199_Disease)) (VP (AUX was) (ADVP (RB usually)) (ADJP (JJ reversible)) (SBAR (WHADVP (WRB when)) (S (NP (NN treatment)) (VP (AUX was) (VP (VBN stopped) (, ,) (PP (IN with) (S (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NN liver) (NN function) (NNS tests)))) (VP (VBG returning) (PP (TO to) (NP (JJ normal))) (PP (IN after) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (CD 3.1) (NNS months))))))))))))) (. .)))
3101906	13	(S1 (S (PP (IN In) (NP (NP (CD two)) (PP (IN of) (NP (NP (DT the) (CD three) (NNP Doc_3101906_1364_1370_Disease)) (VP (ADVP (RB probably)) (VBN associated) (PP (IN with) (NP (JJ Doc_3101906_1396_1408_Chemical) (NN treatment)))))))) (NP (DT the) (NN drug)) (VP (AUX had) (VP (AUX been) (VP (VBN continued) (PP (IN after) (NP (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_3101906_1466_1474_Disease)))) (CC and) (NP (NP (JJ other) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_3101906_1497_1506_Disease))))))))) (. .)))
3101906	14	(S1 (S (NP (NP (ADJP (JJ Clinical) (CC and) (JJ biochemical)) (NN monitoring)) (PP (IN at) (NP (JJ regular) (NNS intervals))) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_3101906_1581_1590_Disease)))))) (VP (AUX is) (VP (VBN advised) (PP (IN during) (NP (NP (JJ long) (NN term) (NN treatment)) (PP (IN with) (NP (NNP Doc_3101906_1634_1646_Chemical))))) (S (VP (TO to) (VP (VB prevent) (NP (JJ possible) (JJ serious) (NN Doc_3101906_1675_1689_Disease))))))) (. .)))
3107448	0	(S1 (NP (JJ Doc_3107448_0_9_Chemical-induced) (NN Doc_3107448_18_27_Disease) (. .)))
3107448	1	(S1 (S (NP (NP (JJ Drug-induced) (NNP Doc_3107448_42_56_Disease)) (, ,) (PP (IN although) (NP (NN common))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (ADVP (RB only) (RB infrequently)) (PP (IN with) (NP (NNP Doc_3107448_116_129_Chemical)))))) (. .)))
3107448	2	(S1 (S (PP (IN For) (NP (NP (NNP Doc_3107448_135_144_Chemical)) (, ,) (NP (DT a) (JJ second-generation) (NN Doc_3107448_166_178_Chemical)))) (, ,) (NP (NP (QP (RB only) (CD two)) (JJ brief) (NNS reports)) (PP (IN of) (NP (NNP Doc_3107448_206_220_Disease)))) (VP (VBP exist)) (. .)))
3107448	3	(S1 (S (NP (NP (CD Two) (NNS patients)) (PP (IN with) (NP (NNP Doc_3107448_246_271_Disease)))) (VP (VBD developed) (NP (DT an) (NN Doc_3107448_285_314_Disease)) (PP (ADVP (RB soon)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_3107448_340_349_Chemical) (NN therapy)))))) (. .)))
3107448	4	(S1 (S (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ serologic) (NN evidence)) (PP (IN of) (NP (NNP Doc_3107448_394_409_Disease)))))) (, ,) (CC and) (S (NP (DT a) (NN liver) (NN biopsy) (NN sample)) (VP (VBD showed) (NP (NP (DT a) (JJ histologic) (NN pattern)) (ADJP (JJ consistent) (PP (IN with) (NP (NN Doc_3107448_481_503_Disease))))))) (. .)))
3107448	5	(S1 (S (CC Both) (NP (NNS patients)) (VP (VP (VBD recovered) (ADVP (RB quickly)) (PP (IN after) (S (VP (VBG stopping) (NP (JJ Doc_3107448_552_561_Chemical) (NN therapy)))))) (CC and) (VP (AUX have) (VP (VBN remained) (ADVP (RB well)) (PP (IN for) (NP (NP (DT a) (JJ follow-up) (NN period)) (PP (IN of) (NP (CD 1) (NN year)))))))) (. .)))
3107448	6	(S1 (S (NP (NN Doc_3107448_627_636_Chemical)) (VP (MD can) (VP (VB produce) (NP (NP (DT an) (NN Doc_3107448_652_680_Disease)) (PP (IN in) (NP (DT some) (NNS persons)))))) (. .)))
3125768	0	(S1 (S (NP (JJ Intracranial) (NN pressure)) (VP (VBZ increases) (PP (IN during) (NP (NNP Doc_3125768_39_49_Chemical-induced) (NNP Doc_3125768_58_66_Disease)))) (. .)))
3125768	1	(S1 (S (NP (NP (JJ Intracranial) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP ICP)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN measured) (PP (IN during) (NP (NP (JJ Doc_3125768_116_126_Chemical-induced) (NN Doc_3125768_135_143_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
3125768	2	(S1 (S (NP (CD Ten) (NNS rats)) (VP (AUX had) (NP (NP (NN arterial)) (, ,) (NP (NP (JJ central) (NNS venous)) (PRN (-LRB- -LRB-) (NP (NNP CVP)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ subdural) (NNS cannulae)) (VP (VBN inserted) (PP (IN under) (NP (JJ Doc_3125768_235_244_Chemical) (NN anesthesia))))))) (. .)))
3125768	3	(S1 (S (NP (DT The) (NNS animals)) (VP (AUX were) (ADJP (RB mechanically) (VBN ventilated) (S (VP (TO to) (VP (VB achieve) (NP (NN normocarbia)))))) (PRN (-LRB- -LRB-) (NP (QP (CD PCO2) (SYM =) (CD 42) (CD +/-) (CD 1)) (NN mmHg)) (, ,) (NP (JJ mean) (FW +/-) (FW SE)) (-RRB- -RRB-))) (. .)))
3125768	4	(S1 (S (PP (VBG Following) (NP (NN instrumentation))) (, ,) (S (NP (NNP Doc_3125768_385_394_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (CC and) (S (NP (NP (NNP Doc_3125768_416_426_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 125) (NN mu/kg)) (-RRB- -RRB-))) (VP (VBN administered) (NP (NNP iv)) (PP (IN during) (NP (NN emergence))) (PP (IN from) (NP (JJ Doc_3125768_477_486_Chemical) (NNS anesthesia))))) (. .)))
3125768	5	(S1 (S (PP (IN In) (NP (NP (DT the) (CD five) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (VBD developed) (NP (NN Doc_3125768_531_547_Disease))))))) (, ,) (NP (NNP ICP) (CC and) (NNP CVP)) (VP (VBD increased) (ADVP (RB significantly)) (PP (IN above) (NP (NN baseline))) (PRN (-LRB- -LRB-) (NP (JJ delta) (NNP ICP) (CD 7.5) (NN +/-) (CD 1.0) (NN mmHg)) (, ,) (NP (NN delta) (NN CVP)) (NP (CD 5.9) (NN +/-) (QP (CD 1.3) (CD mmHg))) (-RRB- -RRB-))) (. .)))
3125768	6	(S1 (S (NP (DT These) (NNS variables)) (VP (VBD returned) (PP (TO to) (NP (NN baseline))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_3125768_700_708_Disease)) (VP (AUX was) (VP (VBN abolished) (PP (IN with) (NP (NN Doc_3125768_728_738_Chemical)))))))) (. .)))
3125768	7	(S1 (S (PP (IN In) (NP (NP (CD five) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (VB become) (ADJP (JJ rigid)))))))) (, ,) (NP (NP (NNP ICP)) (CC and) (NP (NNP CVP))) (VP (AUX did) (RB not) (VP (VB change) (NP (JJ following) (NN Doc_3125768_817_827_Chemical)))) (. .)))
3125768	8	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_3125768_861_869_Disease)) (VP (MD should) (VP (AUX be) (VP (VBN prevented) (SBAR (WHADVP (WRB when)) (S (NP (NP (NNP Doc_3125768_895_905_Chemical)) (, ,) (CC and) (, ,) (ADVP (RB presumably)) (, ,) (NP (JJ other) (NNS opiates)) (, ,)) (VP (AUX are) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (JJ anesthetic) (NN management)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ ICP) (NNS problems))))))))))))))))) (. .)))
3173179	0	(S1 (NP (NP (JJ Doc_3173179_0_9_Chemical) (NN withdrawal)) (PP (IN as) (NP (NP (DT a) (JJ possible) (NN cause)) (PP (IN of) (NP (NNP Doc_3173179_44_65_Disease))) (PP (IN in) (NP (NP (DT a) (NNP Doc_3173179_71_83_Disease) (NN woman)) (PP (IN with) (NP (DT a) (JJ normal) (JJ coronary) (NN angiogram))))))) (. .)))
3173179	1	(S1 (S (NP (NN Doc_3173179_124_133_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective)) (CC and) (NP (JJ relatively-safe) (JJ antihypertensive) (NN drug)))) (. .)))
3173179	2	(S1 (S (NP (JJ Serious) (JJ adverse) (NNS effects)) (VP (VP (AUX are) (ADJP (JJ uncommon))) (CC and) (VP (ADVP (RB mainly)) (AUX have) (VP (AUX been) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NNP Doc_3173179_266_276_Disease)) (PP (IN of) (NP (NP (JJ cardiac) (NN contractility)) (CC and) (NP (NN conduction)))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (AUX is) (VP (VBN combined) (PP (IN with) (NP (JJ beta-blocking) (NNS agents))))))))))))) (. .)))
3173179	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNP Doc_3173179_408_429_Disease)) (VP (VBD coincided) (PP (IN with) (NP (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (NNP Doc_3173179_465_474_Chemical)))) (CC and) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_3173179_497_506_Chemical)))))) (PP (IN in) (NP (NP (DT a) (ADJP (RB previously) (JJ asymptomatic)) (NN woman)) (PP (IN with) (NP (JJ severe) (NN Doc_3173179_554_566_Disease)))))))))) (. .)))
3173179	4	(S1 (S (NP (NP (JJ Possible) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP involve) (NP (NP (DT a) (JJ Doc_3173179_603_612_Chemical-related) (NN increase)) (PP (IN in) (NP (JJ platelet) (NN and/or) (NN vascular) (NN alpha) (NN 2-adrenoreceptor) (NN affinity))) (PP (IN for) (NP (NNP Doc_3173179_694_708_Chemical)))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
3173180	0	(S1 (NP (NP (NN Doc_3173180_0_27_Disease)) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_3173180_49_62_Chemical))))) (. .)))
3173180	1	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ describes) (NP (NP (DT the) (JJ clinical) (NNS features)) (PP (IN of) (NP (CD six) (NNS children))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT the) (NN Doc_3173180_141_168_Disease)) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_3173180_190_203_Chemical)))))))))) (. .)))
3173180	2	(S1 (S (NP (DT These) (NNS children)) (VP (VP (AUX were) (ADJP (JJR older))) (CC and) (VP (AUX were) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (AUX have) (VP (VBN undergone) (NP (NP (JJ recent) (NN bowel) (NN surgery)) (SBAR (WHNP (IN than)) (S (VP (AUX are) (NP (NP (JJ other) (NNS children)) (PP (IN with) (NP (DT this) (NN condition))))))))))))))) (. .)))
3173180	3	(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NNP Doc_3173180_361_374_Chemical))) (PP (IN in) (NP (NP (DT the) (NN aetiology)) (PP (IN of) (NP (DT the) (NNP Doc_3173180_399_426_Disease)))))) (VP (AUX is) (RB not) (VP (VBN established) (ADVP (RB firmly)))))) (, ,) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (DT this) (NN drug))) (PP (IN in) (S (VP (VBG sensitizing) (NP (NNS tissues)) (PP (TO to) (NP (NP (NN oxidation) (NN injury)) (CC and) (NP (NP (DT the) (VBN reported) (NN evidence)) (PP (IN of) (NP (NP (JJ oxidation) (NNS changes)) (PP (IN in) (NP (DT the) (NNP Doc_3173180_575_602_Disease)))))))))))) (VP (VBP suggest) (NP (NP (DT a) (JJ possible) (NN link)) (PP (IN between) (NP (NP (JJ Doc_3173180_635_648_Chemical) (NN treatment)) (CC and) (NP (NP (DT some) (NNS cases)) (PP (IN of) (NP (DT the) (NNP Doc_3173180_681_708_Disease)))))))) (. .)))
3187073	0	(S1 (NP (NP (JJ Adverse) (JJ cardiac) (NNS effects)) (PP (IN during) (NP (NP (JJ induction) (JJ chemotherapy) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_3187073_69_79_Chemical)) (CC and) (NP (NNP Doc_3187073_84_98_Chemical)))))) (. .)))
3187073	1	(S1 (S (NP (NP (NN Survival)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ advanced) (NNP Doc_3187073_136_159_Disease)) (CC and) (NP (NNP Doc_3187073_164_184_Disease))))))) (VP (AUX is) (ADJP (JJ poor) (PP (IN with) (NP (JJ radiotherapy) (NN and/or) (NN surgery))))) (. .)))
3187073	2	(S1 (S (ADVP (RB Obviously)) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN need)) (PP (IN for) (NP (JJ effective) (NN chemotherapy))))) (. .)))
3187073	3	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (NP (NNP Doc_3187073_304_314_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 80-120) (NN mg/m2BSA)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_3187073_337_341_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000) (NN mg/m2BSA)) (PP (JJ daily) (IN as) (NP (DT a) (JJ continuous) (NN infusion))) (PP (IN during) (NP (CD 5) (NNS days)))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN given) (PP (TO to) (NP (NP (CD 76) (NNS patients)) (PP (IN before) (NP (NN radiotherapy) (CC and) (NN surgery))))))) (. .)))
3187073	4	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB clarify) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NP (JJ adverse) (JJ cardiac) (NNS effects)) (PP (TO to) (NP (DT this) (NN treatment)))))))))) (. .)))
3187073	5	(S1 (S (PP (IN Before) (NP (NN treatment))) (NP (DT all) (NNS patients)) (VP (VP (AUX had) (NP (DT a) (JJ cardiac) (NN evaluation))) (CC and) (VP (PP (IN during) (NP (NN treatment) (NN serial) (NN ECG) (NNS recordings))) (AUX were) (VP (VBN performed)))) (. .)))
3187073	6	(S1 (S (PP (IN In) (NP (DT the) (JJ pre-treatment) (NN evaluation))) (, ,) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_3187073_727_749_Disease)))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (CD 33) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 43) (NN %)) (-RRB- -RRB-)))))) (. .)))
3187073	7	(S1 (S (PP (IN During) (NP (NN treatment))) (, ,) (NP (JJ adverse) (JJ cardiac) (NNS effects)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (CD 14) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 18) (NN %)) (-RRB- -RRB-)))))) (. .)))
3187073	8	(S1 (S (NP (NP (DT The) (JJ mean) (NN age)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (AUX was) (NP (NP (NP (DT the) (JJ same)) (PP (IN as) (PP (IN for) (NP (DT the) (JJ entire) (NN group))))) (, ,) (NP (CD 64) (NNS years)))) (. .)))
3187073	9	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_3187073_957_971_Disease)))) (VP (AUX was) (RB not) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_3187073_1013_1035_Disease)))))))) (PP (IN than) (PP (IN in) (NP (NP (DT those)) (ADJP (IN without) (PP (IN in) (NP (DT the) (JJ pre-treatment) (NN evaluation))))))))) (. .)))
3187073	10	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (NNS signs)) (PP (IN of) (NP (NNP Doc_3187073_1116_1130_Disease)))) (VP (AUX were) (NP (NP (NNP Doc_3187073_1136_1146_Disease)) (, ,) (NP (JJ ST-T) (NN wave) (NNS changes)) (CC and) (NP (NNP Doc_3187073_1170_1189_Disease)))) (. .)))
3187073	11	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (NP (NNP Doc_3187073_1212_1236_Disease)) (PP (IN in) (NP (CD one) (NN patient)))) (CC and) (NP (NP (NNP Doc_3187073_1256_1268_Disease)) (PP (IN in) (NP (DT another)))))))) (. .)))
3187073	12	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (SBAR (IN that) (S (NP (NP (NNS patients)) (PP (IN on) (NP (JJ Doc_3187073_1314_1318_Chemical) (NN treatment)))) (VP (MD should) (VP (AUX be) (PP (IN under) (NP (JJ close) (NN supervision))))))) (CC and) (SBAR (IN that) (S (NP (DT the) (NN treatment)) (VP (MD should) (VP (AUX be) (ADJP (JJ discontinued)) (SBAR (IN if) (S (NP (NP (NNP Doc_3187073_1412_1422_Disease)) (CC or) (NP (NNP Doc_3187073_1426_1441_Disease))) (VP (AUX is) (ADJP (JJ observed)))))))))))) (. .)))
3192036	0	(S1 (NP (NP (NN Doc_3192036_0_5_Disease)) (PP (IN from) (NP (NN chemotherapy))) (PP (IN in) (NP (NNP Doc_3192036_27_60_Disease))) (. .)))
3192036	1	(S1 (S (NP (JJ Multiple) (JJ cytotoxic) (NN drug) (NN administration)) (VP (AUX is) (NP (NP (DT the) (ADJP (RB generally) (JJ accepted)) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ high-risk) (NN stage)) (PP (IN of) (NP (NN Doc_3192036_175_190_Disease))))))))) (. .)))
3192036	2	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT this) (NN principle)))) (NP (NP (DT a) (JJ 27-year) (JJ old) (NN woman)) (, ,) (VP (VBN classified) (PP (IN as) (NP (AUXG being))) (PP (IN in) (NP (NP (DT the) (JJ high-risk) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NNP Goldstein) (CC and) (NNP Berkowitz) (NN score)) (: :) (NP (CD 11))) (-RRB- -RRB-))))) (, ,)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (JJ multiple) (JJ cytotoxic) (NNS drugs))))) (. .)))
3192036	3	(S1 (S (NP (DT The) (JJ multiple) (NN drug) (NN schema)) (VP (VBD consisted) (PP (IN of) (: :) (NP (NP (NNP Doc_3192036_399_408_Chemical) (CD 16.213)) (, ,) (NP (NNP Doc_3192036_417_429_Chemical)) (, ,) (NP (NNP Doc_3192036_431_447_Chemical)) (, ,) (NP (NNP Doc_3192036_449_460_Chemical)) (, ,) (CC and) (NP (NNP Doc_3192036_466_475_Chemical))))) (. .)))
3192036	4	(S1 (S (PP (IN On) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (DT the) (NN schedule))))) (, ,) (NP (NP (JJ moderate) (JJ high) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_3192036_534_546_Chemical)) (, ,) (NP (NNP Doc_3192036_548_557_Chemical)) (CC and) (NP (NNP Doc_3192036_562_578_Chemical))))) (VP (AUX were) (VP (VBN administered))) (. .)))
3192036	5	(S1 (S (PP (IN Within) (NP (NP (CD 8) (NNS hours)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NN therapy))))))) (NP (DT the) (NN patient)) (VP (VBD died) (PP (IN with) (NP (NP (DT a) (JJ clinical) (NN picture)) (VP (VBG resembling) (NP (JJ massive) (NNP Doc_3192036_701_722_Disease)) (PP (JJ due) (TO to) (NP (JJ choriocarcinomic) (NN tissue) (NNS plugs)))))) (, ,) (S (ADVP (RB probably)) (VP (VBG originating) (PP (IN from) (NP (DT the) (NN uterus)))))) (. .)))
3192036	6	(S1 (S (S (NP (NP (NN Formation)) (PP (IN of) (NP (DT these) (NNS plugs)))) (VP (AUX was) (ADJP (RB probably) (JJ due) (PP (TO to) (NP (JJ extensive) (NNP Doc_3192036_854_859_Disease) (NNP Doc_3192036_860_868_Disease)))) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (DT the) (NNS walls)) (PP (IN of) (NP (NP (DT the) (JJ major) (NN uterine) (NNS veins)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ open) (NN exchange)) (PP (IN of) (NP (NP (JJ Doc_3192036_961_966_Disease) (NNS plugs)) (PP (TO to) (NP (DT the) (JJ vascular) (NNS spaces)))))))))))))))))) (: ;) (S (NP (NP (NN decrease)) (PP (IN in) (NP (NP (JJ Doc_3192036_1009_1014_Disease) (NN tissue) (NN coherence)) (ADJP (JJ secondary) (TO to) (JJ chemotherapy))))) (VP (MD may) (VP (AUX have) (VP (ADVP (RB further)) (VBN contributed) (PP (TO to) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NNP Doc_3192036_1107_1112_Disease) (NNS emboli))))))))) (. .)))
3192036	7	(S1 (S (PP (IN In) (NP (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (JJ close) (NN time) (NN association)) (PP (IN between) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NN chemotherapy)))))))) (CC and) (NP (NP (DT the) (JJ acute) (NN onset)) (PP (IN of) (NP (JJ massive) (NNP Doc_3192036_1224_1232_Disease)))))) (NP (NP (JJ other) (NNS explanations)) (, ,) (PP (JJ such) (IN as) (NP (JJ spontaneous) (NNP Doc_3192036_1273_1281_Disease))) (, ,)) (VP (MD must) (VP (AUX be) (VP (VBN considered) (S (ADJP (RBR less) (JJ likely)))))) (. .)))
3192036	8	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (JJ large) (NN Doc_3192036_1335_1347_Disease) (NNS loads)))) (VP (AUX are) (, ,) (PP (VBG according) (PP (TO to) (NP (JJ existing) (NNS classifications)))) (, ,) (PP (IN at) (NP (NP (JJ high) (NN risk)) (SBAR (S (VP (VP (TO to) (VP (VB die))) (CC and) (VP (TO to) (VP (VB develop) (NP (NN drug) (NN resistance)))))))))) (. .)))
3192036	9	(S1 (S (PP (IN Notwithstanding) (NP (DT these) (NNS facts))) (NP (PRP$ our) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT these) (NNS patients)) (VP (MD might) (VP (VB benefit) (PP (IN from) (NP (ADJP (RB relatively) (JJ mild)) (JJ initial) (NN treatment))) (, ,) (ADJP (RB especially) (JJ true) (PP (IN for) (NP (NP (NNS patients)) (VP (RB not) (ADVP (RB previously)) (VBN exposed) (PP (TO to) (NP (DT this) (NN drug)))))))))))) (. .)))
3192036	10	(S1 (NP (NP (JJ Close) (NN observation)) (PP (IN of) (NP (DT the) (NN response) (NN status))) (UCP (DT both) (ADVP (RB clinically)) (CC and) (SBAR (IN with) (S (NP (NN beta-hCG) (NNS values)) (VP (MD may) (VP (VB indicate) (SBAR (IN whether) (CC and) (SBAR (WHADVP (WRB when)) (S (NP (JJR more) (JJ agressive) (NN combination) (NN chemotherapy)) (VP (MD should) (VP (AUX be) (VP (VBN started.) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))))))))))
322550	0	(S1 (S (NP (NP (JJ Pulmonary) (NN shunt)) (CC and) (NP (JJ cardiovascular) (NNS responses))) (VP (TO to) (VP (VB CPAP) (PP (IN during) (NP (JJ Doc_322550_60_73_Chemical-induced) (NN Doc_322550_82_93_Disease))))) (. .)))
322550	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ continuous) (JJ positive) (NN airway) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN CPAP)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ cardiovascular) (NNS dynamics)) (CC and) (NP (NP (JJ pulmonary) (NN shunt)) (PRN (-LRB- -LRB-) (NP (NNP QS/QT)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (CD 12) (NNS dogs))) (PP (IN before) (CC and) (IN during) (NP (NP (JJ Doc_322550_255_275_Chemical) (NN infusion)) (SBAR (WHNP (WDT that)) (S (VP (VBD decreased) (NP (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (NP (NP (CD 40-50)) (PP (IN per) (NP (NN cent))))))))))) (. .)))
322550	2	(S1 (S (PP (IN Before) (NP (JJ Doc_322550_352_365_Chemical) (NN infusion))) (, ,) (NP (CD 5) (JJ cm) (NNP Doc_322550_381_384_Chemical) (NN CPAP)) (VP (ADVP (RB significantly)) (, ,) (VP (VBD P) (NP (QP (JJR less) (IN than) (CD .05)))) (, ,) (VP (VBD decreased) (NP (JJ arterial) (NN blood) (NN pressure))) (, ,) (CC but) (VP (AUX did) (RB not) (VP (ADVP (RB significantly)) (VB alter) (NP (NP (NN heart) (NN rate)) (, ,) (NP (JJ cardiac) (NN output)) (, ,) (NP (JJ systemic) (JJ vascular) (NN resistance)) (, ,) (CC or) (NP (NN QS/QT)))))) (. .)))
322550	3	(S1 (S (NP (NP (CD Ten) (JJ cm) (NNP Doc_322550_564_567_Chemical) (NN CPAP)) (PP (IN before) (NP (JJ Doc_322550_580_593_Chemical) (NN infusion)))) (VP (VP (VBD produced) (NP (DT a) (JJ further) (NN Doc_322550_622_657_Disease))) (CC and) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (NN heart) (NN rate)) (CC and) (NP (NP (NNP Doc_322550_701_725_Disease)) (CC and) (NP (NNP QS/QT)))))) (. .)))
322550	4	(S1 (S (S (NP (NN Doc_322550_737_750_Chemical)) (VP (VBD caused) (NP (NP (JJ significant) (NNP Doc_322550_770_806_Disease) (CC and) (JJ systemic) (NN vascular) (NN resistance)) (CC and) (NP (NP (NNS increases)) (PP (IN in) (NP (NN heart) (NN rate))))))) (, ,) (CC but) (S (VP (AUX did) (RB not) (VP (VB change) (NP (JJ cardiac) (NN output) (CC or) (NNS QS/QT))))) (. .)))
322550	5	(S1 (S (NP (NP (CD Five) (JJ cm) (JJ Doc_322550_921_924_Chemical) (NN CPAP)) (PP (IN during) (NP (NNP Doc_322550_937_950_Chemical)))) (VP (AUX did) (RB not) (ADVP (RB further)) (VP (VB alter) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ above-mentioned) (NNS variables)))))) (. .)))
322550	6	(S1 (S (ADVP (RB However)) (, ,) (NP (CD 10) (NN cm) (JJ Doc_322550_1026_1029_Chemical) (NN CPAP)) (VP (VBD decreased) (NP (NP (JJ arterial) (NN blood) (NN pressure)) (, ,) (NP (JJ cardiac) (NN output)) (, ,) (CC and) (NP (NN QS/QT)))) (. .)))
322550	7	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ Doc_322550_1122_1135_Chemical) (NN infusion) (NNS rates)) (SBAR (WHNP (WDT that)) (S (VP (VB decrease) (NP (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (PP (IN by) (NP (NP (CD 40-50)) (PP (IN per) (NP (NN cent))))))))) (VP (AUX do) (RB not) (VP (VB change) (NP (NP (JJ cardiac) (NN output)) (CC or) (NP (NNS QS/QT)))))))) (. .)))
322550	8	(S1 (S (PP (IN During) (NP (JJ Doc_322550_1258_1271_Chemical) (NN infusion))) (NP (NP (JJ low) (NNS levels)) (PP (IN of) (NP (NN CPAP)))) (VP (AUX do) (RB not) (ADVP (RB markedly)) (VP (VB alter) (NP (JJ cardiovascular) (NNS dynamics)))) (, ,) (CC but) (S (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP (NNP CPAP)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN cm) (NNP Doc_322550_1378_1381_Chemical)) (-RRB- -RRB-))))) (, ,) (SBAR (IN while) (S (VP (VBG decreasing) (NP (NN QS/QT))))) (, ,) (VP (VBP produce) (NP (JJ marked) (NN Doc_322550_1423_1478_Disease)))) (. .)))
3341566	0	(S1 (S (NP (JJ Systolic) (NN pressure) (NN variation)) (VP (AUX is) (ADJP (ADJP (JJR greater)) (PP (IN during) (NP (NNP Doc_3341566_46_56_Disease))) (PP (IN than) (PP (IN during) (NP (NP (JJ Doc_3341566_69_89_Chemical-induced) (NN Doc_3341566_98_109_Disease)) (PP (IN in) (NP (VBN ventilated) (NNS dogs)))))))) (. .)))
3341566	1	(S1 (S (NP (NP (DT The) (JJ systolic) (NN pressure) (NN variation)) (PRN (-LRB- -LRB-) (NP (NNP SPV)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT the) (NN difference)) (PP (IN between) (NP (NP (DT the) (JJ maximal) (CC and) (JJ minimal) (NNS values)) (PP (IN of) (NP (DT the) (JJ systolic) (NN blood) (NN pressure)))))) (PRN (-LRB- -LRB-) (NP (NNP SBP)) (-RRB- -RRB-)) (PP (IN after) (NP (CD one) (JJ positive-pressure) (NN breath)))))) (, ,)) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (VBN ventilated) (NNS dogs)) (VP (VBN subjected) (PP (TO to) (NP (NNP Doc_3341566_349_360_Disease)))))))) (. .)))
3341566	2	(S1 (S (NP (JJ Mean) (JJ arterial) (NN pressure)) (VP (AUX was) (VP (VBN decreased) (PP (TO to) (NP (CD 50) (NN mm))) (NP (NNP Hg)) (PP (IN for) (NP (CD 30) (NNS minutes))) (PP (CC either) (PP (IN by) (NP (NP (NNP Doc_3341566_436_446_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_3341566_448_451_Disease)) (, ,) (NP (NNP n) (SYM =) (CD 7))) (-RRB- -RRB-)))) (CC or) (PP (IN by) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_3341566_489_509_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_3341566_511_514_Chemical)) (, ,) (NP (NNP n) (SYM =) (CD 7))) (-RRB- -RRB-))))))))) (. .)))
3341566	3	(S1 (S (PP (IN During) (NP (NNP Doc_3341566_531_534_Disease-induced) (NNP Doc_3341566_543_554_Disease))) (NP (DT the) (JJ cardiac) (NN output)) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (CC and) (ADJP (NP (JJ systemic) (NN vascular) (NN resistance)) (JJR higher))) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN in) (NP (DT the) (NNP Doc_3341566_664_667_Chemical) (NN group))))))) (. .)))
3341566	4	(S1 (S (NP (NP (DT The) (JJ systemic) (, ,) (JJ central) (NNS venous)) (, ,) (NP (NN pulmonary) (NN capillary) (NN wedge) (NNS pressures)) (, ,) (CC and) (NP (NN heart) (NNS rates)) (, ,)) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (DT the) (CD two) (NNS groups)))) (. .)))
3341566	5	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (JJ respiratory) (NNS changes)) (PP (IN in) (NP (DT the) (JJ arterial) (NN pressure) (NN waveform)))))) (VP (VBD enabled) (NP (NP (NN differentiation)) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))) (. .)))
3341566	6	(S1 (S (NP (NP (DT The) (NN SPV)) (PP (IN during) (NP (NNP Doc_3341566_924_935_Disease)))) (VP (AUX was) (NP (QP (CD 15.7) (JJR +/-) (CD 6.7) (CD mm)) (NNP Hg)) (PP (IN in) (NP (DT the) (NNP Doc_3341566_966_969_Disease) (NN group))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 9.1) (NN +/-)) (NP (NP (QP (CD 2.0) (CD mm)) (NNP Hg)) (PP (IN in) (NP (DT the) (NNP Doc_3341566_1016_1019_Chemical) (NN group))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.02))) (-RRB- -RRB-))))))) (. .)))
3341566	7	(S1 (S (NP (NP (DT The) (JJ delta) (NN down)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT the) (NN measure)) (PP (IN of) (NP (NN decrease))) (PP (IN of) (NP (NNP SBP)))) (PP (IN after) (NP (DT a) (JJ mechanical) (NN breath)))))) (, ,)) (VP (AUX was) (NP (NP (NP (QP (CD 20.3) (JJ +/-) (CD 8.4) (CC and) (CD 10.1) (NN +/-))) (NP (CD 3.8) (JJ mm) (NNP Hg))) (PP (IN in) (NP (DT the) (NNP Doc_3341566_1176_1179_Disease) (CC and) (NNP Doc_3341566_1184_1187_Chemical) (NNS groups)))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN during) (NP (NP (NNP Doc_3341566_1217_1228_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.02))) (-RRB- -RRB-))))) (. .)))
3341566	8	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN SPV)) (CC and) (NP (DT the) (NN delta)))) (ADVP (RB down))) (VP (AUX are) (ADJP (JJ characteristic) (PP (IN of) (NP (NP (DT a) (JJ Doc_3341566_1334_1345_Disease) (NN state)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (JJ predominant) (NN decrease)) (PP (IN in) (NP (NN preload)))))))))))))) (. .)))
3341566	9	(S1 (S (NP (PRP They)) (VP (AUX are) (ADVP (RB thus)) (ADJP (RBR more) (JJ important)) (PP (IN during) (NP (JJ absolute) (NN Doc_3341566_1439_1450_Disease))) (PP (IN than) (PP (IN during) (NP (JJ deliberate) (NNP Doc_3341566_1474_1485_Disease))))) (. .)))
3358181	0	(S1 (NP (NP (NP (NN Doc_3358181_0_28_Disease)) (PP (IN during) (NP (JJ cesarean) (NN section))) (PP (IN after) (NP (JJ Doc_3358181_59_68_Chemical) (NN therapy)))) (: :) (NP (NP (NN interaction)) (PP (IN with) (NP (NNS anesthetics)))) (. .)))
3358181	1	(S1 (S (NP (DT This) (NN case)) (VP (VBZ illustrates) (SBAR (IN that) (S (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_3358181_154_163_Chemical)) (PP (IN for) (NP (NNP Doc_3358181_168_181_Disease))))) (VP (MD may) (VP (VB risk) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (NP (DT the) (JJ residual) (JJ betamimetic) (NNS effects)) (PP (IN of) (NP (NNP Doc_3358181_248_257_Chemical)))) (CC and) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNS anesthetics))))))) (PP (IN during) (NP (JJ cesarean) (NN section)))))))) (. .)))
3358181	2	(S1 (S (NP (JJ Such) (NNS interactions)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ serious) (NN Doc_3358181_354_382_Disease))) (PP (ADVP (RB even)) (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (NP (DT an) (NN infusion)) (PP (IN of) (NP (NNP Doc_3358181_422_431_Chemical))))))))) (. .)))
3358181	3	(S1 (S (NP (JJ Preoperative) (NN assessment)) (VP (MD should) (VP (VB focus) (PP (IN on) (NP (NP (JJ cardiovascular) (NN status)) (CC and) (NP (NN serum) (JJ Doc_3358181_505_514_Chemical) (NN level)))))) (. .)))
3358181	4	(S1 (S (NP (NP (NN Delaying) (NN induction)) (PP (IN of) (NP (NN anesthesia)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (SBAR (WHADVP (WRB whenever)) (FRAG (ADJP (JJ possible))))))) (. .)))
3358181	5	(S1 (S (NP (NP (JJ Careful) (NN fluid) (NN administration)) (CC and) (NP (NP (JJ cautious) (NN use)) (PP (IN of) (NP (NP (JJ titrated) (NNS doses)) (PP (IN of) (NP (NNP Doc_3358181_662_671_Chemical))))))) (VP (AUX are) (VP (VBN advised))) (. .)))
3358181	6	(S1 (S (PP (IN After) (NP (NP (NN delivery)) (PP (IN of) (NP (DT the) (NN infant))))) (, ,) (NP (EX there)) (VP (MD should) (VP (AUX be) (NP (NP (DT no) (NN contraindication)) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT an) (JJ alpha-adrenergic) (NN vasopressor)) (PP (JJ such) (IN as) (NP (NNP Doc_3358181_805_818_Chemical))))) (S (VP (TO to) (VP (VB treat) (NP (NNP Doc_3358181_828_839_Disease) (NNS patients)) (PP (IN with) (NP (NN Doc_3358181_854_865_Disease))))))))))) (. .)))
3371379	0	(S1 (NP (NNP Doc_3371379_0_9_Chemical-induced) (NNP Doc_3371379_18_31_Chemical) (NNP Doc_3371379_32_45_Disease) (. .)))
3371379	1	(S1 (NP (NP (NP (DT A) (NN report)) (PP (IN of) (NP (CD two) (NNS cases)))) (. .)))
3371379	2	(S1 (S (NP (NP (CD Two) (NNS patients)) (PP (IN with) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_3371379_97_110_Chemical) (NNP Doc_3371379_111_124_Disease))) (PP (IN after) (NP (NP (JJ combined) (NN treatment)) (PP (IN with) (NP (NNP Doc_3371379_155_164_Chemical)))))))) (VP (VBD showed) (NP (JJ complete) (NN recovery)) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (JJ Doc_3371379_219_226_Chemical) (NN entry) (NN blocker)))))) (. .)))
3371379	3	(S1 (S (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_3371379_249_258_Chemical))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_3371379_279_292_Chemical)))))) (VP (MD should) (VP (CC either) (VP (AUX be) (VP (VBN avoided))) (CC or) (VP (VBN prescribed) (ADVP (RB only)) (PP (IN with) (NP (NP (JJ appropriate) (NN adjustment)) (PP (IN of) (NP (NP (DT the) (JJ Doc_3371379_372_385_Chemical) (NN dose)) (PRN (-LRB- -LRB-) (ADVP (RB usually)) (NP (NP (NN reduction)) (PP (IN of) (NP (DT the) (JJ Doc_3371379_417_430_Chemical) (NN dose))) (PP (IN by) (NP (CD one) (NN half)))) (-RRB- -RRB-))))))))) (. .)))
3403780	0	(S1 (NP (NP (JJ Doc_3403780_0_11_Chemical-associated) (NNP Doc_3403780_23_27_Disease)) (, ,) (NP (NNP Doc_3403780_29_47_Disease)) (, ,) (NP (NNP Doc_3403780_49_74_Disease)) (. .)))
3403780	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NP (NNP Doc_3403780_86_104_Disease)) (, ,) (NP (NNP Doc_3403780_106_145_Disease) (JJ following) (JJ Doc_3403780_156_167_Chemical) (NN ingestion))))) (VP (AUX is) (VP (VBN presented))) (. .)))
3403780	2	(S1 (S (NP (NP (DT The) (JJ diagnostic) (NN difficulty)) (PP (IN at) (NP (NN presentation)))) (VP (AUX is) (VP (VBN highlighted))) (. .)))
3403780	3	(S1 (S (NP (JJ Continuous) (JJ arteriovenous) (NN haemofiltration)) (VP (VBD proved) (NP (NP (DT a) (JJ valuable) (NN means)) (PP (IN of) (S (VP (VBG maintaining) (NP (NP (NN fluid)) (CC and) (NP (NN electrolyte) (NN balance)))))))) (. .)))
3403780	4	(S1 (S (NP (DT The) (NN patient)) (VP (VBD recovered)) (. .)))
3409645	0	(S1 (NP (NP (NN Doc_3409645_0_18_Disease)) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3409645_39_48_Disease))))) (. .)))
3409645	1	(S1 (S (NP (NP (DT The) (NN relationship)) (PP (IN of) (NP (NP (NNP Doc_3409645_70_79_Disease)) (CC and) (NP (NNP Doc_3409645_84_102_Disease))))) (VP (AUX was) (VP (VBN investigated) (PP (IN among) (NP (NP (CD 169) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_3409645_144_164_Disease)) (, ,) (NP (NNP Doc_3409645_166_180_Disease)) (CC and) (NP (NNP Doc_3409645_185_204_Disease)))) (, ,) (SBAR (WHNP (CD 130) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX were) (ADJP (JJ pair-matched) (PP (TO to) (NP (NNS controls))))))))))) (. .)))
3409645	2	(S1 (S (NP (NP (NNS Assessments)) (PP (IN of) (NP (NP (JJ marital) (NN happiness)) (CC and) (NP (NNP Doc_3409645_286_300_Disease))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN made) (S (VP (VBG using) (NP (NP (NP (DT the) (JJ CES-D)) (CC and) (NP (DT the) (NNP Azrin) (JJ Marital) (NN Happiness) (NN Scale))) (PRN (-LRB- -LRB-) (NP (NNP AMHS)) (-RRB- -RRB-))))))) (. .)))
3409645	3	(S1 (S (NP (NNP Doc_3409645_378_397_Disease)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJ common) (PP (IN among) (NP (NP (NP (NNS patients)) (CC and) (NP (NNS controls))) (, ,) (NP (NP (DT the) (NN majority)) (PP (IN in) (S (NP (DT both) (NNS groups)) (VP (VBG reporting) (NP (QP (CD one) (CC or) (JJR more)) (NNS dysfunctions)))))))))))))) (. .)))
3409645	4	(S1 (S (NP (NN Doc_3409645_515_524_Disease)) (VP (VP (AUX was) (ADJP (RBR more) (JJ common)) (PP (IN among) (NP (NP (JJ male) (NNS patients)) (PP (IN than) (NP (NNS controls)))))) (CC and) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (NN co-morbidity)) (CC and) (NP (NP (DT the) (NN taking)) (PP (IN of) (NP (NNP Doc_3409645_642_654_Chemical))))))))))))) (. .)))
3409645	5	(S1 (S (NP (NN Doc_3409645_656_670_Disease)) (VP (VP (AUX was) (ADJP (RBR more) (JJ common)) (PP (IN among) (NP (NNS patients)))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (PP (IN with) (NP (JJ certain) (JJ sexual) (NNS difficulties))) (, ,) (CC but) (RB not) (PP (IN with) (NP (NNP Doc_3409645_768_777_Disease))))))) (. .)))
3409645	6	(S1 (S (NP (JJ Marital) (NN unhappiness)) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (JJ AMHS) (NNS scores)))))) (, ,) (VP (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_3409645_853_862_Disease))))) (CC but) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NN Doc_3409645_887_905_Disease)) (, ,) (NP (JJ sexual) (NN dissatisfaction)) (CC and) (NP (JJ being) (NN female))))))) (. .)))
3412544	0	(S1 (SQ (AUX Does) (NP (NNP Doc_3412544_5_16_Chemical)) (VP (VB cause) (NP (NP (NNP Doc_3412544_23_40_Disease)) (CC or) (NP (NNP Doc_3412544_44_68_Disease)))) (. ?)))
3412544	1	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (NNP Doc_3412544_93_117_Disease)) (CC or) (NP (NNP Doc_3412544_121_166_Disease)))))) (VP (VBN associated) (PP (IN with) (NP (NP (NN consumption)) (PP (IN of) (NP (DT either) (NNP Doc_3412544_205_215_Chemical) (CC or) (NNP Doc_3412544_219_230_Chemical))))))) (VP (AUX was) (VP (VBN calculated) (PP (IN from) (NP (NP (NNS data)) (VP (VBN acquired) (PP (IN by) (NP (NN questionnaire))) (PP (IN from) (NP (NP (CD 381) (NNS cases)) (CC and) (NP (CD 808) (NNS controls))))))))) (. .)))
3412544	2	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_3412544_327_351_Disease)))) (VP (AUX was) (VP (VBN increased) (ADJP (RB nearly) (JJ 20-fold)) (PP (IN by) (NP (NP (NN consumption)) (PP (IN of) (NP (NP (NNP Doc_3412544_399_409_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB also)) (VP (VBD increased) (NP (DT the) (NN risk)) (PP (PP (IN for) (NP (NNP Doc_3412544_445_483_Disease))) (CC but) (RB not) (PP (IN for) (NP (NNP Doc_3412544_496_511_Disease))))))))))))) (. .)))
3412544	3	(S1 (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (PRP we)) (VP (AUX were) (ADJP (JJ unable) (S (VP (TO to) (VP (VB substantiate) (NP (DT an) (VBN increased) (NN risk)) (PP (IN from) (NP (NP (NP (JJ Doc_3412544_580_591_Chemical) (NN consumption)) (PP (IN for) (NP (NNP Doc_3412544_608_632_Disease)))) (CC or) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNP Doc_3412544_649_656_Disease)))))) (SBAR (IN although) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN suggestion)) (PP (IN of) (NP (NP (DT an) (NN association)) (PP (IN with) (NP (NNP Doc_3412544_712_732_Disease)))))))))))))) (. .)))
3425586	0	(S1 (NP (NP (JJ Doc_3425586_0_7_Chemical-associated) (NNP Heinz) (NN body) (NNP Doc_3425586_30_46_Disease)) (PP (IN in) (NP (NP (DT a) (JJ Cambodian) (NN woman)) (PP (IN with) (NP (NN hemoglobin) (NN E) (NN trait))))) (. .)))
3425586	1	(S1 (S (NP (NP (DT A) (JJ Cambodian) (NN woman)) (PP (IN with) (NP (NN hemoglobin) (NN E) (NN trait) (PRN (-LRB- -LRB-) (NP (NNP AE)) (-RRB- -RRB-)) (CC and) (NNP Doc_3425586_144_151_Disease)))) (VP (VBD developed) (NP (DT a) (NNP Heinz) (NN body) (NN Doc_3425586_175_191_Disease)) (SBAR (IN while) (S (VP (VBG taking) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_3425586_215_222_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/day)) (-RRB- -RRB-)))) (VP (ADVP (RB not) (RB usually)) (VBN associated) (PP (IN with) (NP (JJ clinical) (NN Doc_3425586_272_281_Disease))))))))) (. .)))
3425586	2	(S1 (S (NP (NP (PRP$ Her) (JJ red) (NN blood) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNP RBCs)) (-RRB- -RRB-))) (VP (AUX had) (VP (VP (VBN increased) (NP (JJ incubated) (NNP Heinz) (NN body) (NN formation))) (, ,) (VP (VBN decreased) (NP (NP (JJ reduced) (NNP Doc_3425586_374_385_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3425586_387_390_Chemical)) (-RRB- -RRB-)))) (, ,) (CC and) (VP (VBN decreased) (NP (JJ Doc_3425586_407_410_Chemical) (NN stability))))) (. .)))
3425586	3	(S1 (S (NP (NP (DT The) (JJ Doc_3425586_426_443_Chemical) (NN shunt) (NN activity)) (PP (IN of) (NP (DT the) (JJ Doc_3425586_466_473_Chemical-exposed) (NN AE) (NNS RBCs)))) (VP (AUX was) (VP (VBN increased) (PP (VBN compared) (PP (TO to) (NP (JJ normal) (NNS RBCs)))))) (. .)))
3425586	4	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ AE) (NNS RBCs)) (PP (IN from) (NP (DT an) (NN individual))) (VP (RB not) (VBG taking) (NP (NNP Doc_3425586_580_587_Chemical)))) (VP (AUX had) (VP (VBN increased) (NP (JJ incubated) (NNP Heinz) (NN body) (NN formation)))))) (, ,) (NP (NP (DT the) (JJ Doc_3425586_638_641_Chemical) (NN content)) (CC and) (NP (JJ Doc_3425586_654_657_Chemical) (NN stability))) (VP (AUX were) (ADJP (JJ normal))) (. .)))
3425586	5	(S1 (S (NP (NP (DT The) (JJ Doc_3425586_685_702_Chemical) (NN shunt) (NN activity)) (PP (IN of) (NP (DT the) (JJ non-Doc_3425586_729_736_Chemical-exposed) (NN AE) (NNS RBCs)))) (VP (AUX was) (VP (VBN decreased) (PP (VBN compared) (PP (TO to) (NP (JJ normal) (NNS RBCs)))))) (. .)))
3425586	6	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NN AE) (NNS RBCs)) (VP (VBP appear) (S (VP (TO to) (VP (AUX have) (NP (NP (DT an) (VBN increased) (NN sensitivity)) (PP (TO to) (NP (JJ oxidant) (NN stress)))) (PP (DT both) (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo))))))) (, ,) (SBAR (IN since) (S (NP (NNP Doc_3425586_897_904_Chemical)) (VP (AUX does) (RB not) (VP (VB cause) (NP (NNP Doc_3425586_920_936_Disease)) (PP (IN at) (NP (NP (DT this) (NN dose)) (PP (IN in) (NP (ADJP (RB hematologically) (JJ normal)) (NNS individuals)))))))))) (. .)))
3425586	7	(S1 (S (PP (VBN Given) (NP (NP (DT the) (NN influx)) (PP (IN of) (NP (NNP Southeast) (NNPS Asians))) (PP (IN into) (NP (DT the) (NNP United) (NNPS States))))) (, ,) (NP (JJ oxidant) (NNS medications)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (, ,) (SBAR (ADVP (RB especially)) (IN if) (S (NP (DT an) (NN Doc_3425586_1116_1125_Disease)) (VP (AUX is) (ADJP (JJ present))))) (, ,) (PP (IN in) (NP (NP (NNS individuals)) (PP (IN of) (NP (JJ ethnic) (NNS backgrounds))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (NP (NP (DT an) (VBN increased) (NN prevalence)) (PP (IN of) (NP (NN hemoglobin) (NN E)))))))))))) (. .)))
3437726	0	(S1 (NP (NP (JJ Severe) (NNS complications)) (PP (IN of) (NP (JJ antianginal) (NN drug) (NN therapy))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN identified) (PP (IN as) (NP (NP (DT a) (JJ poor) (NN metabolizer)) (PP (IN of) (NP (NP (NNP Doc_3437726_98_108_Chemical)) (, ,) (NP (NNP Doc_3437726_110_121_Chemical)) (, ,) (NP (NNP Doc_3437726_123_132_Chemical)) (, ,) (CC and) (NP (NNP Doc_3437726_138_147_Chemical))))))))) (. .)))
3437726	1	(S1 (S (NP (NP (DT A) (JJ 47-year-old) (NN patient)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_3437726_186_209_Disease))))) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (NP (DT the) (NNS CCU)) (PP (IN in) (NP (NP (NNP Doc_3437726_237_242_Disease)) (PP (IN with) (NP (NNP III))))))))) (. .)))
3437726	2	(S1 (NP (NP (NN Doc_3437726_253_261_Disease)) (, ,) (NP (JJ severe) (NN Doc_3437726_270_281_Disease)) (, ,) (CC and) (NP (NNP Doc_3437726_287_321_Disease)) (. .)))
3437726	3	(S1 (S (NP (NP (ADVP (NP (CD One) (NN week)) (RB prior) (PP (TO to) (NP (NN admission)))) (DT a) (NN therapy)) (PP (IN with) (NP (NP (NP (JJ standard) (NNS doses)) (PP (IN of) (NP (NNP Doc_3437726_384_394_Chemical)))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 100) (CD mg)) (NNS t.i.d.)) (CC and) (NP (QP (RB then) (CD 100) (CD mg)) (NNS b.i.d.))) (-RRB- -RRB-))))) (VP (AUX had) (VP (AUX been) (VP (VBN initiated)))) (. .)))
3437726	4	(S1 (S (NP (NP (CD Two) (NNS days)) (PP (IN before) (NP (NP (NN admission) (NN Doc_3437726_480_489_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 60) (CD mg)) (NNS b.i.d.)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN prescribed) (PP (IN in) (NP (NN addition))))) (. .)))
3437726	5	(S1 (S (NP (NP (NNS Analyses)) (PP (IN of) (NP (DT a) (NN blood) (NN sample)))) (VP (VBD revealed) (NP (NP (ADJP (RB unusually) (JJ high)) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NP (NNP Doc_3437726_609_619_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (JJR greater) (IN than) (CD 3000)) (NN ng/ml)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_3437726_650_659_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 526) (NN ng/ml)) (-RRB- -RRB-))))))) (. .)))
3437726	6	(S1 (S (NP (DT The) (NN patient)) (VP (VBD recovered) (PP (IN within) (NP (CD 1) (NN week))) (PP (VBG following) (NP (NP (NN discontinuation)) (PP (IN of) (NP (JJ antianginal) (NN therapy)))))) (. .)))
3437726	7	(S1 (S (ADVP (NP (CD Three) (NNS months)) (RB later)) (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN exposed) (PP (TO to) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_3437726_822_832_Chemical)) (, ,) (NP (NNP Doc_3437726_834_843_Chemical)) (, ,) (NP (NP (NNP Doc_3437726_845_856_Chemical)) (PRN (-LRB- -LRB-) (SBAR (IN since) (S (NP (PRP he)) (VP (AUX had) (VP (VBN received) (NP (DT this) (NN drug)) (PP (IN in) (NP (DT the) (NN past))))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_3437726_908_917_Chemical)) (PRN (-LRB- -LRB-) (PP (IN as) (NP (NP (DT a) (NN probe)) (PP (IN for) (NP (NP (DT the) (JJ Doc_3437726_938_950_Chemical/Doc_3437726_951_960_Chemical) (NN type) (NN polymorphism)) (PP (IN of) (NP (JJ oxidative) (NN drug) (NN metabolism))))))) (-RRB- -RRB-))))))))) (. .)))
3437726	8	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN found) (SBAR (IN that) (S (NP (PRP he)) (VP (AUX was) (NP (NP (DT a) (JJ poor) (NN metabolizer)) (PP (IN of) (NP (DT all) (CD four) (NNS drugs)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (PRP$ their) (NN metabolism)) (VP (AUX is) (PP (IN under) (NP (DT the) (JJ same) (JJ genetic) (NN control))))))))))))) (. .)))
3437726	9	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS patients)) (VP (VBG belonging) (PP (TO to) (NP (NP (DT the) (JJ poor-metabolizer) (NN phenotype)) (PP (IN of) (NP (JJ Doc_3437726_1208_1217_Chemical/Doc_3437726_1218_1230_Chemical) (NN polymorphism))) (PP (IN in) (NP (NP (NN drug) (NN metabolism)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ constitutes) (NP (NP (CD 6.4) (NN %)) (PP (IN of) (NP (DT the) (JJ German) (NN population))))))) (, ,))))))) (VP (MD may) (VP (VB experience) (NP (NNP Doc_3437726_1328_1350_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN treated) (PP (IN with) (NP (NP (JJ standard) (NNS doses)) (PP (IN of) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT these) (NNS drugs)) (ADVP (RB alone))))))))))))) (. .)))
3437726	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (DT these) (ADJP (RB frequently) (VBN used)) (NNS drugs)))) (VP (AUX is) (VP (VBN expected) (S (VP (TO to) (VP (AUX be) (ADJP (RB especially) (JJ harmful)) (PP (IN in) (NP (NP (DT this) (NN subgroup)) (PP (IN of) (NP (NNS patients)))))))))) (. .)))
347884	0	(S1 (NP (NP (NP (JJ Clinical) (NNS experiences)) (PP (IN in) (NP (NP (DT an) (NN open)) (CC and) (NP (DT a) (JJ double-blind) (NN trial))))) (. .)))
347884	1	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD sixty) (NNS patients)))) (VP (AUX were) (VP (VBN trated) (PP (IN with) (NP (NNP Doc_347884_101_112_Chemical))) (ADVP (RB first)) (PP (IN in) (NP (NP (JJ open) (NNS conditions)) (PRN (-LRB- -LRB-) (NP (CD 20) (NNS patients)) (-RRB- -RRB-)))) (, ,) (ADVP (RB then)) (PP (IN on) (NP (NP (DT a) (JJ double) (JJ blind) (NN basis)) (PRN (-LRB- -LRB-) (NP (CD 40) (NNS patients)) (-RRB- -RRB-)))) (PP (IN with) (NP (NNP Doc_347884_201_212_Chemical))) (PP (IN as) (NP (DT the) (NN reference) (NN substance))))) (. .)))
347884	2	(S1 (S (S (NP (DT The) (JJ open) (NN study)) (VP (VBD lasted) (PP (IN for) (NP (CD four) (NNS weeks))))) (: ;) (S (NP (DT the) (NN drug)) (VP (AUX was) (VP (VBN administrated) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (QP (CD 1) (CD mg)) (NNS tablets)))))))) (. .)))
347884	3	(S1 (S (NP (NP (DT The) (JJ daily) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (JJ initial) (NN dose)) (: :) (NP (CD 1) (NN mg)) (: ;) (NP (NP (JJ mean) (NN dose)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN trial)))))) (: :) (NP (CD 4.47) (NN mg))) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB always)) (VP (VBN administered) (PP (IN in) (NP (CD one) (JJ single) (NN dose))))) (. .)))
347884	4	(S1 (S (S (NP (NN Nineteen) (NNS patients)) (VP (VBD finished) (NP (DT the) (NN trial)))) (, ,) (CC and) (S (PP (IN in) (NP (CD 18) (NNS cases))) (NP (DT the) (JJ therapeutic) (NN result)) (VP (AUX was) (VP (VBN considered) (S (ADJP (RB very) (JJ good) (TO to) (JJ good)))))) (. .)))
347884	5	(S1 (S (NP (DT These) (NNS results)) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (JJ statistical) (NN analysis))))) (. .)))
347884	6	(S1 (S (S (NP (CD Nine) (NNS patients)) (VP (VBD exhibited) (ADJP (JJ mild) (S (VP (TO to) (VP (VB moderate) (NP (NNP Doc_347884_665_700_Disease)))))))) (: ;) (S (NP (DT no) (JJ other) (NN side) (NNS effects)) (VP (AUX were) (VP (VBN observed)))) (. .)))
347884	7	(S1 (S (NP (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (JJ detailed) (NN laboratory) (NNS tests)))) (CC and) (NP (NP (NNS evaluations)) (PP (IN of) (NP (JJ various) (UCP (JJ quantitative) (CC and) (JJ qualitative)) (NN tolerability) (NNS parameters))))) (VP (AUX were) (RB not) (ADJP (JJ indicative) (PP (IN of) (NP (JJ toxic) (NNS effects))))) (. .)))
347884	8	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ double) (JJ blind) (NN study)) (PP (IN with) (NP (NNP Doc_347884_929_940_Chemical))))) (, ,) (NP (DT both) (NNS substances)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (RB highly) (JJ effective) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN Doc_347884_1012_1082_Disease))))))))))) (. .)))
347884	9	(S1 (S (NP (NP (JJ Certain) (NNS clues)) (, ,) (PP (VBG including) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NN action))))) (, ,)) (VP (VBP seem) (S (VP (TO to) (VP (AUX be) (ADJP (JJ indicative) (PP (IN of) (NP (NP (DT the) (NN superiority)) (PP (IN of) (NP (NNP Doc_347884_1174_1185_Chemical)))))))))) (. .)))
347884	10	(S1 (S (NP (DT No) (NNS differences)) (VP (AUX were) (VP (VBN observed) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (JJ side) (NNS effects)) (CC and) (NP (JJ general) (NN tolerability)))))))) (. .)))
3496378	0	(S1 (NP (NP (VBN Prolonged) (NN Doc_3496378_10_21_Disease)) (PP (IN after) (NP (JJ Doc_3496378_28_42_Chemical-induced) (JJ acute) (NN Doc_3496378_57_66_Disease))) (. .)))
3496378	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NNP Doc_3496378_108_122_Chemical-induced) (NNP Doc_3496378_131_140_Disease)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (JJ prolonged) (JJ anicteric) (NN Doc_3496378_177_188_Disease))))))))))) (. .)))
3496378	2	(S1 (S (NP (NN Doc_3496378_190_198_Disease)) (VP (VP (VBD occurred) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_3496378_232_246_Chemical))) (PP (IN for) (NP (CD 7) (NN days)))))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_3496378_282_299_Disease)))))) (. .)))
3496378	3	(S1 (S (NP (NN Doc_3496378_301_309_Disease)) (VP (VP (VBD disappeared) (PP (IN within) (NP (CD 3) (NNS months)))) (CC but) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (VBN prolonged) (JJ anicteric) (NN Doc_3496378_378_389_Disease)) (VP (VBN marked) (PP (IN by) (NP (NP (JJ Doc_3496378_400_408_Disease) (CC and) (JJ high) (NNS levels)) (PP (IN of) (NP (NP (JJ alkaline) (NN phosphatase)) (CC and) (NP (JJ gammaglutamyltransferase) (NNS activities)))))))))))) (. .)))
3496378	4	(S1 (S (ADVP (RB Finally)) (, ,) (S (NP (NNP Doc_3496378_499_507_Disease)) (VP (VBD disappeared) (PP (IN within) (NP (CD 19) (NNS months))))) (, ,) (CC and) (S (NP (NN liver) (NNS tests)) (VP (VBD returned) (PP (TO to) (NP (QP (RB normal) (CD 27)) (NNS months))) (PP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_3496378_602_611_Disease))))))) (. .)))
3496378	5	(S1 (S (NP (DT This) (NN observation)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (JJ prolonged) (NN Doc_3496378_658_669_Disease)) (VP (MD can) (VP (VB follow) (NP (JJ Doc_3496378_681_695_Chemical-induced) (JJ acute) (NN Doc_3496378_710_719_Disease))))))) (. .)))
3503576	0	(S1 (NP (NP (JJ Serial) (NNS studies)) (PP (IN of) (NP (NNP Doc_3503576_18_40_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_3503576_63_75_Chemical) (NN therapy))))) (. .)))
3503576	1	(S1 (S (NP (NN Doc_3503576_85_118_Disease)) (VP (AUX was) (ADVP (RB previously)) (VP (VBN documented) (PP (IN in) (NP (NP (QP (CD 42) (IN of) (CD 89)) (NNS patients)) (PP (IN with) (NP (JJ transfusion-dependent) (NNP Doc_3503576_193_199_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBG receiving) (NP (JJ Doc_3503576_219_223_Chemical) (NN chelation) (NN therapy)) (PP (IN with) (NP (JJ daily) (JJ subcutaneous) (NNP Doc_3503576_266_278_Chemical))))))))))) (. .)))
3503576	2	(S1 (S (NP (NP (JJ Twenty-two) (NNS patients)) (PP (IN in) (NP (DT the) (VBN affected) (NN group)))) (VP (AUX had) (UCP (ADJP (JJ Doc_3503576_326_415_Disease)) (CC and) (PP (IN in) (NP (NP (DT the) (NN hearing) (NN threshold) (NNS levels)) (PP (IN of) (NP (QP (CD 30) (TO to) (CD 100)) (NNS decibels))))))) (. .)))
3503576	3	(S1 (S (SBAR (WHADVP (WRB When)) (S (S (NP (JJ Doc_3503576_480_492_Chemical) (NN therapy)) (VP (AUX was) (VP (VBN discontinued)))) (CC and) (S (NP (JJ serial) (NNS studies)) (VP (AUX were) (VP (VBN performed)))))) (, ,) (S (NP (NP (NNS audiograms)) (PP (IN in) (NP (CD seven) (NNS cases)))) (VP (VBN reverted) (PP (TO to) (ADJP (ADJP (JJ normal)) (CC or) (ADJP (RB near) (JJ normal)))) (PP (IN within) (NP (QP (CD two) (TO to) (CD three)) (NNS weeks))))) (, ,) (CC and) (S (NP (NP (CD nine)) (PP (IN of) (NP (NP (CD 13) (NNS patients)) (PP (IN with) (NP (NNS symptoms)))))) (VP (VBD became) (ADJP (JJ asymptomatic)))) (. .)))
3503576	4	(S1 (S (S (NP (NP (NNS Audiograms)) (PP (IN from) (NP (CD 15) (NNS patients)))) (VP (VBD remained) (ADJP (JJ abnormal)))) (CC and) (S (NP (CD four) (NNS patients)) (VP (VBD required) (NP (NN hearing) (NNS aids)) (PP (IN because) (IN of) (NP (NN Doc_3503576_796_816_Disease))))) (. .)))
3503576	5	(S1 (S (SBAR (IN Since) (S (NP (NP (CD 18)) (PP (IN of) (NP (DT the) (CD 22) (NNS patients)))) (VP (AUX were) (ADVP (RB initially)) (VP (VBG receiving) (NP (JJ Doc_3503576_871_883_Chemical) (NNS doses)) (PP (IN in) (NP (NP (NN excess)) (PP (IN of) (NP (NP (DT the) (RB commonly) (VBN recommended) (CD 50) (NNS mg/kg)) (PP (IN per) (NP (NN dose))))))))))) (, ,) (S (NP (NN therapy)) (VP (AUX was) (VP (VBN restarted) (PP (IN with) (NP (NP (JJR lower) (NNS doses)) (, ,) (NP (NP (QP (RB usually) (CD 50)) (NNS mg/kg)) (PP (IN per) (NP (NN dose)))) (CC or) (NP (JJR less)))) (PP (VBG depending) (PP (IN on) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NNP Doc_3503576_1048_1068_Disease))))))))) (, ,) (CC and) (S (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (CD two) (NNS cases))))) (NP (DT no) (JJ further) (NN Doc_3503576_1117_1125_Disease)) (VP (AUX was) (VP (VBN demonstrated)))) (. .)))
3503576	6	(S1 (S (NP (NP (NP (JJ Auditory) (NN deterioration)) (CC and) (NP (NN improvement))) (, ,) (VP (VBN demonstrated) (ADVP (RB serially)) (PP (IN in) (NP (NP (JJ individual) (NNS patients)) (VP (VP (VBG receiving)) (CC and) (RB not) (VP (VBG receiving) (NP (NP (NNP Doc_3503576_1257_1269_Chemical)) (, ,) (ADVP (RB respectively)))))))) (, ,)) (VP (VBD provided) (NP (JJ convincing) (NN evidence)) (PP (IN for) (NP (NP (DT a) (JJ cause-and-effect) (NN relation)) (PP (IN between) (NP (NP (JJ Doc_3503576_1354_1366_Chemical) (NN administration)) (CC and) (NP (NNP Doc_3503576_1386_1397_Disease))))))) (. .)))
3503576	7	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS data)))) (, ,) (NP (NP (DT a) (NN plan)) (PP (IN of) (NP (NN management)))) (VP (AUX was) (VP (VBN developed) (SBAR (WHNP (WDT that)) (S (VP (VBZ allows) (NP (NP (ADJP (JJ effective) (CC yet) (JJ safe)) (NN administration)) (PP (IN of) (NP (NNP Doc_3503576_1504_1516_Chemical))))))))) (. .)))
3503576	8	(S1 (S (NP (NP (DT A) (NN dose)) (PP (IN of) (NP (CD 50) (NN mg/kg)))) (VP (AUX is) (VP (VBN recommended) (PP (IN in) (NP (NP (DT those)) (PP (IN without) (NP (NN audiogram) (NNS abnormalities))))))) (. .)))
3503576	9	(S1 (S (PP (IN With) (NP (JJ mild) (NN Doc_3503576_1604_1612_Disease))) (, ,) (NP (NP (DT a) (NN reduction)) (PP (TO to) (NP (QP (CD 30) (CC or) (CD 40)) (NNS mg/kg))) (PP (IN per) (NP (NN dose)))) (VP (MD should) (VP (VB result) (PP (IN in) (NP (NP (DT a) (NN reversal)) (PP (IN of) (NP (DT the) (JJ abnormal) (NNS results))) (PP (TO to) (NP (JJ normal))) (PP (IN within) (NP (CD four) (NNS weeks))))))) (. .)))
3503576	10	(S1 (S (NP (JJ Moderate) (NNS abnormalities)) (VP (VBP require) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NNP Doc_3503576_1780_1792_Chemical)))) (PP (TO to) (NP (NP (CD 25) (NNS mg/kg)) (PP (IN per) (NP (NN dose))) (PP (IN with) (NP (JJ careful) (NN monitoring)))))) (. .)))
3503576	11	(S1 (S (PP (IN In) (NP (NP (DT those)) (PP (IN with) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_3503576_1865_1877_Disease))))))) (, ,) (S (NP (DT the) (NN drug)) (VP (MD should) (VP (AUX be) (VP (VBN stopped) (PP (IN for) (NP (CD four) (NNS weeks))))))) (, ,) (CC and) (S (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN audiogram)) (VP (AUX is) (ADJP (ADJP (JJ stable)) (CC or) (ADJP (JJ improved)))))) (, ,) (NP (NN therapy)) (VP (MD should) (VP (AUX be) (VP (VBN restarted) (PP (IN at) (NP (NP (QP (CD 10) (TO to) (CD 25)) (NNS mg/kg)) (PP (IN per) (NP (NN dose))))))))) (. .)))
3503576	12	(S1 (S (NP (JJ Serial) (NNS audiograms)) (VP (MD should) (VP (AUX be) (VP (VP (VBN performed) (NP (DT every) (CD six) (NNS months)) (PP (IN in) (NP (NP (DT those)) (PP (IN without) (NP (NNS problems)))))) (CC and) (VP (ADVP (RBR more) (RB frequently)) (PP (PP (IN in) (NP (NP (JJ young) (NNS patients)) (PP (IN with) (NP (JJ normal) (NN serum) (NN ferritin) (NNS values))))) (CC and) (PP (IN in) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_3503576_2195_2215_Disease)))))))))) (. .)))
354896	0	(S1 (NP (JJ Doc_354896_0_9_Chemical-induced) (NN Doc_354896_18_34_Disease) (. .)))
354896	1	(S1 (S (NP (NP (JJ Intravenous) (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (JJ 50-mg) (NN bolus)) (PP (IN of) (NP (NNP Doc_354896_90_99_Chemical))) (PP (IN in) (NP (DT a) (JJ 67-year-old) (NN man)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ profound) (NN Doc_354896_142_152_Disease)) (PP (IN of) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (JJ sinoatrial) (CC and) (JJ atrioventricular) (JJ nodal) (NNS pacemakers)))))))) (. .)))
354896	2	(S1 (S (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (NP (DT no) (JJ apparent) (VBN associated) (NNS conditions)) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (AUX have) (VP (VBN predisposed) (NP (PRP him)) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_354896_331_347_Disease))))))))))))) (: ;) (S (CC and) (, ,) (ADVP (RB thus)) (, ,) (NP (DT this)) (ADVP (RB probably)) (VP (VBD represented) (NP (NP (DT a) (JJ true) (NN idiosyncrasy)) (PP (TO to) (NP (NNP Doc_354896_409_418_Chemical)))))) (. .)))
3560095	0	(S1 (NP (NP (NN Doc_3560095_0_12_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_3560095_33_62_Disease))))) (. .)))
3560095	1	(S1 (S (NP (NP (CD Thirty-four) (NNS patients)) (PP (IN with) (NP (NNP Doc_3560095_90_119_Disease))) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3560095_143_155_Chemical))) (PP (IN at) (NP (NP (DT a) (JJ maximum) (NN dose)) (PP (IN of) (NP (CD 4) (NN mg/kg/day))))))))) (, ,)) (VP (AUX had) (NP (NP (ADJP (RB statistically) (JJ significant)) (NNS decreases)) (PP (IN from) (NP (NN baseline)))) (PP (IN in) (NP (CD 6) (JJ Doc_3560095_249_258_Disease) (NNS indices))) (PP (IN after) (NP (NP (CD 12) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))) (. .)))
3560095	2	(S1 (S (NP (NNS Improvements)) (VP (AUX were) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNP Doc_3560095_336_349_Disease)) (, ,) (NP (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_3560095_367_375_Disease) (CC and) (NNP Doc_3560095_380_390_Disease)))) (, ,) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN walk) (CD 50) (NNS feet)))) (, ,) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_3560095_434_451_Disease)))) (CC and) (NP (NP (DT the) (NN circumference)) (PP (IN of) (NP (DT the) (JJ left) (NN knee))))))))))) (. .)))
3560095	3	(S1 (S (S (NP (DT The) (ADJP (ADVP (RBS most) (RB frequently)) (JJ observed)) (NN side) (NN effect)) (VP (AUX was) (NP (NP (NNP Doc_3560095_537_555_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 25) (NN %)) (PP (IN of) (NP (NNS patients)))) (-RRB- -RRB-))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ other) (NN evidence)) (PP (IN of) (NP (NNP Doc_3560095_615_645_Disease)))) (PP (IN in) (NP (DT these) (NNS patients))))) (. .)))
3560095	4	(S1 (S (NP (CD One) (NN patient)) (VP (AUX was) (ADVP (RB prematurely)) (VP (VBN discontinued) (PP (IN from) (NP (DT the) (NN study))) (PP (IN for) (NP (JJ severe) (NNP Doc_3560095_732_740_Disease) (CC and) (NNP Doc_3560095_745_759_Disease))))) (. .)))
3560095	5	(S1 (S (NP (JJS Most) (NN side) (NNS effects)) (VP (VP (AUX were) (ADJP (JJ mild))) (CC and) (VP (VBD related) (PP (TO to) (NP (DT the) (JJ GI) (NN tract))))) (. .)))
3560096	0	(S1 (S (NP (NN Doc_3560096_0_12_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_3560096_29_37_Chemical) (NN therapy)))) (. .)))
3560096	1	(S1 (S (NP (NN Doc_3560096_47_59_Disease)) (VP (AUX has) (ADVP (RB recently)) (VP (AUX been) (VP (VBN recognized) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NP (NP (JJ nonsteroidal) (NN antiinflammatory) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NNP NSAID)) (-RRB- -RRB-))) (PP (JJ such) (IN as) (NP (NNP Doc_3560096_163_175_Chemical)))))))))) (. .)))
3560096	2	(S1 (S (NP (JJ Several) (JJ recent) (NNS studies)) (VP (AUX have) (VP (VBN stressed) (NP (NP (DT the) (JJ renal) (NN sparing) (NNS features)) (PP (IN of) (NP (NNP Doc_3560096_244_252_Chemical)))) (, ,) (PP (VBG owing) (PP (TO to) (NP (NP (PRP$ its) (NN lack)) (PP (IN of) (NP (NN interference))) (PP (IN with) (NP (JJ renal) (JJ Doc_3560096_299_311_Chemical) (NN synthesis)))))))) (. .)))
3560096	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD 4) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (NNP Doc_3560096_354_366_Disease)) (VP (VBG ranging) (PP (IN from) (NP (CD 6.1))) (PP (TO to) (NP (QP (CD 6.9) (CD mEq/l)))))) (VP (VBD developed) (PP (IN within) (NP (NP (QP (CD 3) (TO to) (CD 8)) (NNS days)) (PP (IN of) (NP (NNP Doc_3560096_429_437_Chemical) (NN administration)))))))))) (. .)))
3560096	4	(S1 (S (PP (IN In) (NP (NP (DT all)) (PP (IN of) (NP (PRP them))))) (NP (JJ normal) (NN serum) (NN Doc_3560096_482_491_Chemical) (NNS levels)) (VP (VBD reached) (PP (IN within) (NP (NP (QP (CD 2) (TO to) (CD 4)) (NNS days)) (PP (IN of) (NP (NN stopping) (NN Doc_3560096_538_546_Chemical)))))) (. .)))
3560096	5	(S1 (S (PP (IN As) (NP (NP (DT no) (JJ other) (NNS medications)) (VP (VBN known) (S (VP (TO to) (VP (VB effect) (SBAR (S (NP (NN serum) (NNP Doc_3560096_594_603_Chemical)) (VP (AUX had) (VP (AUX been) (VP (VBN given) (ADVP (RB concomitantly))))))))))))) (, ,) (NP (NP (DT this) (NN course)) (PP (IN of) (NP (NNS events)))) (VP (AUX is) (ADJP (JJ suggestive) (PP (IN of) (NP (NP (DT a) (JJ cause-and-effect) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_3560096_713_721_Chemical)) (CC and) (NP (NNP Doc_3560096_726_738_Disease)))))))) (. .)))
3560096	6	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ initial) (NNS hopes)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_3560096_792_800_Chemical)) (VP (MD may) (RB not) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ adverse) (JJ renal) (NNS effects)) (PP (IN of) (NP (JJ other) (NNS NSAID))))))))))) (VP (AUX are) (ADVP (RB probably)) (RB not) (ADJP (JJ justified)))))) (. .)))
3564823	0	(S1 (S (NP (JJ Drug-induced) (NN arterial) (NN Doc_3564823_22_27_Disease)) (VP (VBN relieved) (PP (IN by) (NP (NNP Doc_3564823_40_49_Chemical)))) (. .)))
3564823	1	(S1 (S (NP (NN Case)) (VP (VBP report)) (. .)))
3564823	2	(S1 (S (PP (VBG Following) (NP (NP (JJ major) (NN intracranial) (NN surgery)) (PP (IN in) (NP (DT a) (JJ 35-year-old) (NN man))))) (, ,) (NP (NNP Doc_3564823_123_139_Chemical)) (VP (AUX was) (ADVP (RB intravenously)) (VP (VBN infused) (S (VP (TO to) (VP (VB minimize) (NP (NNP Doc_3564823_178_196_Disease))))))) (. .)))
3564823	3	(S1 (S (NP (NP (JJ Intense) (NN Doc_3564823_206_215_Disease)) (PP (IN with) (NP (VBN threatened) (NNP Doc_3564823_232_240_Disease)))) (VP (VBD arose) (PP (IN in) (NP (NP (DT the) (NN arm)) (VP (VBN used) (PP (IN for) (NP (DT the) (NN infusion))))))) (. .)))
3564823	4	(S1 (S (PP (IN Since) (NP (NP (DT the) (JJ cranial) (NN condition)) (VP (VBN precluded) (NP (NP (NN use)) (PP (IN of) (NP (ADJP (RBR more) (JJ usual)) (NNS methods))))))) (, ,) (NP (NNP Doc_3564823_346_355_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB intra-arterially)) (, ,) (PP (IN with) (NP (NP (JJ careful) (JJ cardiovascular) (NN monitoring)) (, ,) (SBAR (S (VP (TO to) (VP (VB counteract) (NP (DT the) (NNP Doc_3564823_442_451_Disease)))))))))) (. .)))
3564823	5	(S1 (S (NP (DT The) (NN treatment)) (VP (AUX was) (ADVP (RB rapidly)) (ADJP (JJ successful))) (. .)))
3615541	0	(S1 (NP (NP (JJ Regional) (NN localization)) (PP (IN of) (NP (NP (DT the) (NN antagonism)) (PP (IN of) (NP (NNP Doc_3615541_43_54_Chemical-induced) (NNP Doc_3615541_63_76_Disease))))) (PP (IN by) (NP (JJ intracerebral) (JJ Doc_3615541_94_104_Chemical) (NNS injections))) (. .)))
3615541	1	(S1 (S (S (NP (NN Doc_3615541_117_127_Chemical) (NNS receptors)) (VP (AUX are) (VP (VBN found) (PP (IN in) (NP (DT the) (NN brain)))))) (, ,) (CC and) (S (NP (NP (JJ intracerebral) (NNS infusions)) (PP (IN of) (NP (NNP Doc_3615541_193_203_Chemical)))) (VP (MD can) (VP (VB produce) (NP (JJ behavioral) (NNS effects))))) (. .)))
3615541	2	(S1 (FRAG (SBAR (IN Among) (S (NP (DT these) (JJ behavioral) (NNS effects)) (VP (AUX are) (NP (NP (NP (NNS decreases)) (PP (IN in) (NP (NN food) (NN intake)))) (CC and) (NP (NP (NNS decreases)) (PP (IN in) (NP (JJ Doc_3615541_313_324_Chemical-induced) (NN locomotor) (NN activity)))))))) (. .)))
3615541	3	(S1 (S (PP (IN In) (NP (JJ previous) (NNS experiments))) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NNS decreases)) (PP (IN in) (NP (NN food) (NN intake)))) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NP (JJ local) (NN administration)) (PP (IN of) (NP (NNP Doc_3615541_456_466_Chemical))))) (PP (PP (IN into) (NP (JJ several) (JJ hypothalamic) (NNS sites))) (CC and) (PP (IN into) (NP (DT the) (NN nucleus) (NNS accumbens))))))))) (. .)))
3615541	4	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN experiment))) (NP (NNP Doc_3615541_557_567_Chemical)) (VP (VBD decreased) (NP (NN locomotor) (NN activity)) (SBAR (WHADVP (WRB when)) (S (ADVP (RB locally)) (VP (VBN injected) (PP (IN into) (NP (NP (DT the) (JJ same) (NNS sites)) (SBAR (WHADVP (WRB where)) (S (NP (PRP it)) (VP (VBZ decreases) (NP (NN food) (NN intake))))))))))) (. .)))
3615541	5	(S1 (S (NP (NP (DT The) (NNS areas)) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_3615541_687_697_Chemical)) (VP (AUX is) (ADJP (RBS most) (JJ effective) (PP (IN in) (S (VP (VBG decreasing) (NP (NN locomotor) (NN activity)))))))))) (VP (AUX are) (VP (VBN located) (PP (IN in) (NP (DT the) (NN hypothalamus) (CC and) (NN nucleus) (NNS accumbens))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT these) (NNS areas)) (VP (AUX are) (NP (NP (DT the) (JJ major) (NNS sites)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP Doc_3615541_865_875_Chemical)))))) (PP (IN in) (S (VP (VBG inhibiting) (NP (JJ Doc_3615541_890_901_Chemical-induced) (JJ locomotor) (NN activity)))))))))))) (. .)))
3629586	0	(S1 (NP (NP (NP (DT The) (JJ hematologic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_3629586_27_36_Chemical)) (CC and) (NP (NNP Doc_3629586_41_51_Chemical)))) (PP (IN in) (NP (DT the) (NN dog)))) (: :) (NP (NP (DT a) (JJ potential) (NN model)) (PP (IN of) (NP (NNP Doc_3629586_85_98_Chemical) (NNP Doc_3629586_99_113_Disease))) (PP (IN in) (NP (NN man)))) (. .)))
3629586	1	(S1 (S (S (NP (NN Doc_3629586_122_135_Chemical) (NNS antibiotics)) (VP (VBP cause) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNP Doc_3629586_167_191_Disease)))) (PP (IN in) (NP (NN man))))) (, ,) (NP (NP (DT the) (NNS pathogeneses) (CC and) (NNS hematopathology)) (PP (IN of) (NP (WDT which)))) (VP (VBP remain) (ADJP (RB poorly) (VBN characterized))) (. .)))
3629586	2	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (NN need)) (PP (IN for) (NP (NP (DT a) (JJ well-defined) (NN animal) (NN model)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT these) (NNP Doc_3629586_338_354_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN studied)))))))))) (. .)))
3629586	3	(S1 (S (PP (IN In) (NP (CD four) (JJ subacute) (NNP Doc_3629586_388_396_Disease) (NNS studies))) (, ,) (NP (NP (DT the) (JJ intravenous) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_3629586_440_449_Chemical)) (CC or) (NP (NNP Doc_3629586_453_463_Chemical)))) (PP (TO to) (NP (JJ beagle) (NNS dogs)))) (VP (VBD caused) (NP (NP (DT a) (JJ dose-dependent) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_3629586_516_522_Disease)) (, ,) (NP (NNP Doc_3629586_524_535_Disease)) (, ,) (CC and) (NP (NNP Doc_3629586_541_557_Disease)))) (PP (IN after) (NP (NP (JJ 1-3) (NNS months)) (PP (IN of) (NP (NN treatment))))))) (. .)))
3629586	4	(S1 (S (NP (DT A) (JJ nonregenerative) (NN Doc_3629586_607_613_Disease)) (VP (VP (AUX was) (NP (NP (DT the) (ADJP (JJS most) (VBG compromising))) (PP (IN of) (NP (DT the) (NNP Doc_3629586_647_657_Disease))))) (CC and) (VP (VBD occurred) (PP (IN in) (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (PP (IN of) (NP (NP (NNS dogs)) (VP (VBG receiving) (NP (NP (CD 400-500) (NNS mg/kg)) (ADJP (JJ Doc_3629586_724_733_Chemical) (CC or) (JJ 540-840))) (PP (IN mg/kg) (NP (NNP Doc_3629586_751_761_Chemical)))))))))) (. .)))
3629586	5	(S1 (S (S (NP (DT All) (CD three) (NN Doc_3629586_773_783_Disease)) (VP (AUX were) (NP (NP (ADJP (RB completely) (JJ reversible)) (JJ following) (NN cessation)) (PP (IN of) (NP (NN treatment)))))) (: ;) (S (NP (NP (DT the) (NN time)) (VP (VBN required) (PP (IN for) (NP (NP (NN recovery)) (PP (IN of) (NP (DT the) (NN erythron)))))) (PRN (-LRB- -LRB-) (NP (QP (RB approximately) (CD 1)) (NN month)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (ADJP (RB considerably) (JJR longer)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (NNS granulocytes) (CC and) (NNS platelets)) (PRN (-LRB- -LRB-) (NP (NP (NNS hours)) (PP (TO to) (NP (DT a) (JJ few) (NNS days)))) (-RRB- -RRB-))))))))) (. .)))
3629586	6	(S1 (S (S (PP (IN Upon) (NP (NP (NN rechallenge)) (PP (IN with) (NP (DT either) (NNP Doc_3629586_1036_1049_Chemical))))) (, ,) (NP (DT the) (NNP Doc_3629586_1055_1075_Disease)) (VP (AUX was) (VP (VBN reproduced) (PP (IN in) (NP (NP (JJS most) (NNS dogs)) (VP (VBN tested))))))) (: ;) (S (NP (NNP Doc_3629586_1112_1121_Chemical) (PRN (-LRB- -LRB-) (CC but) (ADJP (RB not) (JJ Doc_3629586_1131_1141_Chemical)) (-RRB- -RRB-)) (JJ -treated) (NNS dogs)) (VP (VBD showed) (NP (NP (DT a) (ADJP (RB substantially) (VBN reduced)) (NN induction) (NN period)) (PRN (-LRB- -LRB-) (NP (CD 15) (JJ +/-) (CD 5) (NNS days)) (-RRB- -RRB-))) (PP (VBN compared) (PP (TO to) (NP (DT that)) (PP (IN of) (NP (NP (DT the) (JJ first) (NN exposure)) (PP (TO to) (NP (NP (DT the) (NN drug)) (PRN (-LRB- -LRB-) (NP (CD 61) (JJ +/-) (CD 24) (NNS days)) (-RRB- -RRB-)))))))))) (. .)))
3629586	7	(S1 (S (NP (DT This) (NN observation)) (, ,) (PP (IN along) (PP (IN with) (NP (NP (DT the) (JJ rapid) (NN rate)) (PP (IN of) (NP (NN decline))) (PP (IN in) (NP (NP (JJ red) (NN cell) (NN mass) (NNS parameters)) (PP (IN of) (NP (JJ affected) (NNS dogs)))))))) (, ,) (VP (VBZ suggests) (SBAR (SBAR (IN that) (S (NP (DT a) (NNP Doc_3629586_1406_1415_Disease) (NN component)) (VP (VBD complicated) (NP (DT the) (JJ red) (NN cell) (NN production) (NN problem))))) (CC and) (SBAR (IN that) (S (NP (JJ multiple) (JJ toxicologic) (NNS mechanisms)) (VP (VBD contributed) (PP (TO to) (NP (DT the) (NNP Doc_3629586_1530_1539_Disease)))))))) (. .)))
3629586	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_3629586_1594_1603_Chemical) (CC or) (NNP Doc_3629586_1607_1617_Chemical))) (PP (TO to) (NP (NNS dogs)))))) (VP (MD can) (VP (VB induce) (NP (NP (NN Doc_3629586_1637_1651_Disease)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT the) (JJ Doc_3629586_1667_1680_Chemical-induced) (NNP Doc_3629586_1689_1705_Disease)) (VP (VP (VBN described) (PP (IN in) (NP (NN man)))) (CC and) (ADVP (RB thus)) (VP (VBZ provides) (NP (NP (DT a) (JJ useful) (NN model)) (PP (IN for) (S (VP (VBG studying) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (DT these) (NNS disorders))))))))))))))))))) (. .)))
3676049	0	(S1 (NP (NP (NP (JJ Cerebral) (NN blood) (NN flow)) (CC and) (NP (NN metabolism))) (PP (IN during) (NP (NP (NNP Doc_3676049_42_52_Chemical-induced) (NNP Doc_3676049_61_72_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN subjected) (PP (TO to) (NP (NP (NN surgery)) (PP (IN for) (NP (NNP Doc_3676049_110_128_Disease)))))))))) (. .)))
3676049	1	(S1 (S (NP (NP (JJ Cerebral) (NN blood) (NN flow)) (CC and) (NP (NP (JJ cerebral) (JJ metabolic) (NN rate)) (PP (IN for) (NP (NNP Doc_3676049_182_188_Chemical))))) (VP (AUX were) (VP (VBN measured) (PP (IN during) (NP (NP (JJ Doc_3676049_210_220_Chemical-induced) (NN Doc_3676049_229_240_Disease)) (PP (IN in) (NP (NP (CD 10) (NNS patients)) (VP (VBN subjected) (PP (TO to) (NP (NP (NN craniotomy)) (PP (IN for) (NP (NP (NN clipping)) (PP (IN of) (NP (DT a) (NNP Doc_3676049_298_315_Disease)))))))))))))) (. .)))
3676049	2	(S1 (S (NP (NN Flow) (CC and) (NN metabolism)) (VP (AUX were) (VP (VBN measured) (NP (CD 5-13) (NNS days)) (PP (IN after) (NP (DT the) (NNP Doc_3676049_371_395_Disease))) (PP (IN by) (NP (NP (DT a) (NN modification)) (PP (IN of) (NP (DT the) (JJ classical) (NNP Kety-Schmidt) (NN technique))))) (S (VP (VBG using) (NP (NP (JJ Doc_3676049_460_465_Chemical-133) (NNS i.v.)) (SBAR (S (NP (NNP Anaesthesia)) (VP (AUX was) (VP (VBN maintained) (PP (IN with) (NP (NP (DT an) (VBN inspired) (JJ Doc_3676049_519_529_Chemical) (NN concentration)) (PP (IN of) (NP (NP (NP (CD 0.75) (NN %)) (PRN (-LRB- -LRB-) (CC plus) (NP (NP (NP (CD 67) (NN %)) (NP (NNP Doc_3676049_563_576_Chemical))) (PP (IN in) (NP (NNP Doc_3676049_580_586_Chemical)))) (-RRB- -RRB-)) (, ,) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (NNS CBF) (CC and) (NNS CMRO2)) (VP (AUX were) (NP (NP (CD 34.3) (NN +/-) (QP (CD 2.1) (CD ml/100))) (ADJP (NNP g) (JJ min-1))))))) (CC and) (NP (NP (CD 2.32) (NN +/-)) (NP (NP (CD 0.16) (CD ml/100) (NNP g) (NN min-1)) (PP (IN at) (NP (NP (NNP PaCO2) (CD 4.1) (NN +/-) (CD 0.1) (NN kPa)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NN SEM)) (-RRB- -RRB-))))))))))))))))))) (. .)))
3676049	3	(S1 (S (NP (NP (JJ Controlled) (NN Doc_3676049_734_745_Disease)) (PP (TO to) (NP (NP (DT an) (JJ average) (NN MAP)) (PP (IN of) (NP (CD 50-55) (NN mm) (NNP Doc_3676049_776_778_Chemical)))))) (VP (VP (AUX was) (VP (VBN induced) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_3676049_817_827_Chemical))))))))) (, ,) (CC and) (VP (VBD maintained) (PP (IN at) (NP (NP (DT an) (VBN inspired) (NN concentration)) (PP (IN of) (NP (CD 2.2) (NNS +/-))))) (NP (CD 0.2) (NN %)))) (. .)))
3676049	4	(S1 (S (NP (DT This)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (NNS CMRO2)) (PRN (-LRB- -LRB-) (PP (TO to) (NP (CD 1.73) (NN +/-))) (NP (QP (CD 0.16) (CD ml/100)) (NNP g) (NNS min-1)) (-RRB- -RRB-)))))) (, ,) (SBAR (IN while) (S (NP (NNP CBF)) (VP (AUX was) (ADJP (JJ unchanged)))))) (. .)))
3676049	5	(S1 (S (PP (IN After) (NP (NP (DT the) (NN clipping)) (PP (IN of) (NP (DT the) (NNP Doc_3676049_1025_1033_Disease))))) (NP (DT the) (JJ Doc_3676049_1038_1048_Chemical) (NN concentration)) (VP (AUX was) (VP (VBN reduced) (PP (TO to) (NP (CD 0.75) (NN %))))) (. .)))
3676049	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN CBF)))) (, ,) (SBAR (IN although) (S (NP (NN CMRO2)) (VP (AUX was) (ADJP (JJ unchanged)) (, ,) (PP (VBN compared) (PP (IN with) (NP (JJ pre-Doc_3676049_1174_1185_Disease) (NNS values)))))))) (. .)))
3676049	7	(S1 (S (NP (DT These) (NNS changes)) (VP (MD might) (VP (VB offer) (NP (NN protection)) (PP (TO to) (NP (NN brain) (NN tissue))) (PP (IN during) (NP (NP (NNS periods)) (PP (IN of) (NP (VBN induced) (NNP Doc_3676049_1273_1284_Disease))))))) (. .)))
3693336	0	(S1 (NP (NP (JJ Doc_3693336_0_9_Chemical-induced) (JJ brief) (NNS episodes)) (PP (IN of) (NP (JJ secondary) (NN Doc_3693336_46_51_Disease))) (PP (IN in) (NP (DT a) (JJ Doc_3693336_57_66_Disease) (NN patient))) (. .)))
3693336	1	(S1 (S (NP (NP (JJ Large) (NNS doses)) (PP (IN of) (NP (NNP Doc_3693336_91_100_Chemical)))) (ADVP (RB repeatedly)) (VP (VBN induced) (NP (NP (JJ brief) (NNS episodes)) (PP (IN of) (NP (NNP Doc_3693336_138_143_Disease)))) (PP (IN in) (NP (DT a) (JJ Doc_3693336_149_158_Disease) (JJ elderly) (NN woman)))) (. .)))
3693336	2	(S1 (S (NP (NP (NNS Features)) (PP (IN of) (NP (NP (NNP Doc_3693336_186_209_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3693336_211_219_Disease)) (-RRB- -RRB-))))) (VP (AUX were) (RB not) (ADJP (JJ present))) (. .)))
3693336	3	(S1 (S (NP (JJ Doc_3693336_239_244_Disease) (NN excitement)) (VP (AUX was) (ADJP (JJ coincident) (PP (IN with) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNP Doc_3693336_302_311_Chemical))))))))) (. .)))
3693336	4	(S1 (S (NP (NP (DT The) (JJ possible) (NN contribution)) (PP (IN of) (NP (DT the) (JJ Doc_3693336_346_354_Chemical) (NN group))) (PP (TO to) (NP (NNS changes))) (PP (IN in) (NP (JJ affective) (NN status)))) (VP (AUX is) (VP (VBN discussed))) (. .)))
3714122	0	(S1 (S (NP (NP (DT The) (NN correlation)) (PP (IN between) (NP (NNP Doc_3714122_24_34_Disease)))) (VP (VBP esterase) (NP (NP (NP (NN inhibition)) (CC and) (NP (JJ Doc_3714122_59_66_Chemical-induced) (NN Doc_3714122_75_93_Disease))) (PP (IN in) (NP (NNS rats))))) (. .)))
3714122	1	(S1 (S (NP (NP (DT The) (NN correlation)) (PP (IN between) (NP (NP (NNP Doc_3714122_127_145_Disease)) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NNP Doc_3714122_164_174_Disease) (NN esterase)) (CC or) (NP (NP (JJ Doc_3714122_187_197_Disease) (NN target) (NN enzyme)) (PRN (-LRB- -LRB-) (NP (NNP NTE)) (-RRB- -RRB-))))))))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NP (NNS rats)) (VP (ADVP (RB acutely)) (VBN exposed) (PP (TO to) (NP (NP (NP (NNP Doc_3714122_258_265_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3714122_267_310_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (NNP Doc_3714122_315_325_Disease) (NNP Doc_3714122_326_341_Chemical))))))))) (. .)))
3714122	2	(S1 (S (NP (NN Brain) (CC and) (NN spinal) (NN cord) (NN NTE) (NNS activities)) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (JJ Long-Evans) (JJ male) (NNS rats)) (ADJP (CD 1) (NN hr) (JJ post-exposure) (PP (TO to) (NP (NP (JJ various) (NNS dosages)) (PP (IN of) (NP (NP (NNP Doc_3714122_459_466_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN ip)) (, ,) (NP (CD 1-15) (NNS mg/kg))) (-RRB- -RRB-))))))))))) (. .)))
3714122	3	(S1 (S (NP (DT These) (NNS data)) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (ADJP (RB histologically) (VBN scored)) (JJ cervical) (NN Doc_3714122_548_559_Disease))) (PP (IN in) (NP (NP (DT a) (JJ separate) (NN group)) (PP (IN of) (NP (NP (ADJP (RB similarly) (VBN dosed)) (NNS rats)) (VP (VBN sampled) (ADVP (NP (CD 14-21) (NNS days)) (RB post-exposure))))))))) (. .)))
3714122	4	(S1 (S (NP (NP (DT Those) (NNS dosages)) (PRN (-LRB- -LRB-) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (QP (CD 10) (CD mg/kg))))) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD inhibited))))) (VP (VBP mean) (SBAR (S (NP (NP (JJ NTE) (NN activity)) (PP (IN in) (NP (NP (DT the) (JJ spinal) (NN cord)) (ADJP (ADJP (JJR greater) (PP (IN than))) (CC or) (ADJP (ADJP (JJ equal) (PP (TO to) (NP (CD 73) (NN %)))) (CC and) (ADJP (NP (NN brain)) (JJR greater))))))) (ADVP (IN than) (CC or) (JJ equal) (PP (TO to) (NP (NP (CD 67) (NN %)) (PP (IN of) (NP (NN control) (NNS values)))))) (VP (VBD produced) (NP (JJ severe) (PRN (-LRB- -LRB-) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 3)))) (-RRB- -RRB-)) (JJ cervical) (NN cord) (NN pathology)) (PP (IN in) (NP (NP (CD 85) (NN %)) (PP (IN of) (NP (DT the) (NNS rats))))))))) (. .)))
3714122	5	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS dosages)) (PP (IN of) (NP (NNP Doc_3714122_939_946_Chemical))) (PRN (-LRB- -LRB-) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 5) (NN mg/kg)))) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (VBD inhibited) (NP (NP (JJ mean) (JJ NTE) (NN activity)) (PP (IN in) (NP (JJ spinal) (NN cord)))))))) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (NP (CD 61) (NN %)) (CC and) (NP (NN brain))))) (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 60) (NN %)))) (VP (VBD produced) (NP (NP (DT this) (NN degree)) (PP (IN of) (NP (NNP Doc_3714122_1114_1125_Disease)))) (PP (IN in) (NP (NP (QP (RB only) (CD 9)) (NN %)) (PP (IN of) (NP (DT the) (NNS animals)))))) (. .)))
3714122	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT a) (JJ critical) (NN percentage)) (PP (IN of) (NP (NP (JJ NTE) (NN inhibition)) (PP (IN in) (NP (NP (NN brain) (CC and) (NN spinal) (NN cord)) (VP (VBN sampled) (PP (ADVP (RB shortly)) (IN after) (NP (NNP Doc_3714122_1265_1272_Chemical) (NN exposure))))))))) (VP (MD can) (VP (VB predict) (NP (NNP Doc_3714122_1294_1312_Disease)) (PP (IN in) (NP (NNS rats))) (ADVP (NP (JJ several) (NNS weeks)) (RB later))))))) (. .)))
3719553	0	(S1 (NP (NP (NN Doc_3719553_0_17_Disease)) (PP (TO to) (NP (JJ Doc_3719553_21_35_Chemical) (NN infusion))) (. .)))
3719553	1	(S1 (S (NP (NP (DT An) (NN Doc_3719553_49_66_Disease)) (VP (VBG consisting) (PP (IN of) (NP (NNP Doc_3719553_81_100_Disease) (ADJP (JJ secondary) (TO to) (JJ continuous)) (NN infusion) (NN Doc_3719553_134_148_Chemical))))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ recurrent) (NNP Doc_3719553_186_214_Disease)) (, ,) (NP (NNP Doc_3719553_216_225_Disease)) (, ,) (CC and) (NP (NNP Doc_3719553_231_240_Chemical-induced) (NNP Doc_3719553_249_272_Disease))))))) (. .)))
3719553	2	(S1 (S (NP (DT This) (NN reaction)) (VP (VBD occurred) (PP (IN during) (NP (NP (DT the) (JJ sixth) (CC and) (JJ seventh) (NNS courses)) (PP (IN of) (NP (JJ infusional) (NNS chemotherapy)))))) (. .)))
3719553	3	(S1 (S (NP (NP (JJ Oral) (NNP Doc_3719553_367_382_Chemical)) (CC and) (NP (NNP Doc_3719553_387_397_Chemical))) (VP (AUX were) (ADJP (JJ ineffective)) (PP (IN in) (S (VP (VBG preventing) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (DT the) (NNP Doc_3719553_451_468_Disease)))))))) (. .)))
3719553	4	(S1 (S (NP (NP (NN Discontinuance)) (PP (IN of) (NP (JJ effective) (NN chemotherapy))) (PP (IN in) (NP (DT this) (NN patient))) (PP (IN during) (NP (JJ partial) (NN remission)))) (VP (VBD resulted) (PP (IN in) (NP (JJ fatal) (NN disease) (NN progression)))) (. .)))
3750012	0	(S1 (S (NP (NN Doc_3750012_0_17_Disease)) (VP (VBN caused) (PP (IN by) (NP (NP (NNP Doc_3750012_28_41_Chemical)) (CC and) (NP (NP (JJ Doc_3750012_46_57_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_3750012_70_90_Disease))))))) (. .)))
3750012	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN described) (NP (NP (DT a) (JJ unique) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (ADJP (JJ reversible) (CC and) (JJ dose-related)) (NN Doc_3750012_163_180_Disease)) (PP (IN after) (NP (NP (NNP Doc_3750012_187_200_Chemical) (CC and) (NNP Doc_3750012_205_216_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_3750012_229_249_Disease))))))))))) (. .)))
3750012	2	(S1 (S (SBAR (IN Although) (S (NP (JJ Doc_3750012_260_273_Chemical) (NN receptor) (NNS antibodies)) (VP (AUX were) (RB not) (ADJP (JJ detectable))))) (, ,) (NP (DT the) (NN time) (NN course)) (VP (AUX was) (ADJP (JJ consistent) (PP (IN with) (NP (DT an) (JJ autoimmune) (NN process))))) (. .)))
3780846	0	(S1 (FRAG (PP (IN On) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN tolerance))) (PP (TO to) (NP (NP (DT the) (NNP Doc_3780846_57_74_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3780846_87_95_Chemical))) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
3780846	1	(S1 (S (NP (NP (DT The) (NN development)) (PP (IN of) (NP (NN tolerance))) (PP (TO to) (NP (NP (DT the) (NNP Doc_3780846_141_158_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3780846_171_179_Chemical))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NNS rats))))) (. .)))
3780846	2	(S1 (S (NP (NP (JJ Saline-pretreated) (NNS controls)) (PP (VBN given) (NP (NP (DT a) (NN test) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_3780846_249_257_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (CD mg/kg)) (NNS i.p.)) (-RRB- -RRB-))))))) (VP (VBD showed) (NP (NP (DT a) (JJ pronounced) (NN Doc_3780846_294_302_Disease)) (VP (VBN recorded) (PP (IN as) (NP (NP (NN tonic) (NN activity)) (PP (IN in) (NP (DT the) (NN electromyogram)))))))) (. .)))
3780846	3	(S1 (S (S (NP (NP (NNS Rats)) (VP (VP (VBN treated) (PP (IN for) (NP (NP (CD 11) (NNS days)) (PP (IN with) (NP (NNP Doc_3780846_383_391_Chemical)))))) (CC and) (VP (VBN withdrawn) (PP (IN for) (NP (JJ 36-40) (NNP h)))))) (VP (VBD showed) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN tolerance)))))))) (: :) (S (NP (NP (RB about) (NN half)) (PP (IN of) (NP (DT the) (NNS animals)))) (VP (VBD showed) (NP (NP (DT a) (NN Doc_3780846_505_513_Disease)) (PP (IN after) (NP (NP (DT the) (NN test) (NN dose)) (PP (IN of) (NP (NNP Doc_3780846_537_545_Chemical))))) (SBAR (WHNP (WDT that)) (S (VP (VP (AUX was) (RB not) (ADJP (RB significantly) (JJR less)) (PP (IN than) (PP (IN in) (NP (DT the) (NNS controls))))) (CC and) (VP (AUX were) (ADJP (JJ Doc_3780846_608_616_Disease)) (PRN (-LRB- -LRB-) (NP (DT A) (NN group)) (-RRB- -RRB-))))))))) (. .)))
3780846	4	(S1 (S (NP (DT The) (JJ other) (NNS rats)) (VP (VBD showed) (NP (NP (NP (DT a) (JJ strong) (NN decrease)) (PP (IN in) (NP (DT the) (NNP Doc_3780846_675_683_Disease)))) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (JJ stereotyped)) (PRN (-LRB- -LRB-) (PRP S) (-RRB- -RRB-)))))) (S (VP (VBG licking) (NP (NP (NN and/or) (NN gnawing)) (PP (IN in) (NP (NP (NN presence)) (PP (IN of) (NP (NP (NNP Doc_3780846_760_768_Disease) (CC or) (NNP Doc_3780846_772_784_Disease) (PRN (-LRB- -LRB-) (NP (NNP K)) (-RRB- -RRB-)) (NN behaviour)) (PRN (-LRB- -LRB-) (NP (NNP AS/KS) (NN group)) (-RRB- -RRB-))))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (NNS signs)) (PP (IN of) (NP (JJ dopaminergic) (NN activation))))))) (. .)))
3780846	5	(S1 (S (NP (DT The) (NNP Doc_3780846_863_871_Disease)) (VP (AUX was) (ADVP (RB considerably)) (VP (VBN decreased) (PP (IN in) (NP (DT both) (NNS groups))) (PP (IN after) (NP (NP (CD 20) (NNS days) (POS ')) (NN treatment))))) (. .)))
3780846	6	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ further) (NN series)) (PP (IN of) (NP (NNS experiments))))) (, ,) (NP (NP (NNP Doc_3780846_976_987_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.2) (NN mg/kg) (NN i.p.)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (NN order))) (S (VP (VP (TO to) (VP (VB block) (NP (DT the) (JJ dopaminergic) (NN activation)))) (CC and) (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (JJ real) (NN degree)) (PP (IN of) (NP (DT the) (NN tolerance))) (PP (TO to) (NP (DT the) (NNP Doc_3780846_1116_1124_Disease)))) (PP (IN without) (NP (DT any) (JJ dopaminergic) (NN interference))))))))) (. .)))
3780846	7	(S1 (S (NP (NN Doc_3780846_1164_1175_Chemical)) (VP (VBD enhanced) (NP (DT the) (NN Doc_3780846_1189_1197_Disease)) (PP (IN in) (NP (DT the) (NNP A) (NN group)))) (. .)))
3780846	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN level)) (PP (IN in) (NP (DT the) (NNP AS/KS) (NN group)))) (VP (VBD remained) (ADJP (ADJP (RB considerably) (JJR lower)) (PP (IN than) (PP (IN in) (NP (DT the) (NNP A) (NN group)))))) (. .)))
3780846	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNP Doc_3780846_1326_1334_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN assumed) (S (VP (TO to) (VP (AUX be) (ADVP (RB due) (PP (TO to) (NP (NP (DT an) (NN action)) (PP (IN of) (NP (NNP Doc_3780846_1379_1387_Chemical)))))) (PP (IN in) (NP (DT the) (NN striatum)))))))))) (, ,)) (VP (MD can) (VP (AUX be) (VP (VBN antagonized) (PP (IN by) (NP (NP (DT another) (NN process)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ dopaminergic) (NN activation)) (PP (IN in) (NP (DT the) (NN striatum)))))))))))))) (. .)))
3780846	10	(S1 (S (ADVP (RB Nevertheless)) (, ,) (NP (EX there)) (VP (VBZ occurs) (NP (DT some) (JJ real) (NN tolerance)) (PP (TO to) (NP (DT this) (NN effect)))) (. .)))
3780846	11	(S1 (S (NP (NP (NP (NP (DT The) (JJ rapid) (NNS alternations)) (PP (IN of) (NP (NNP Doc_3780846_1584_1592_Disease)))) (CC and) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (JJ dopaminergic) (NN activation))))) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NNS animals)) (PP (IN of) (NP (DT the) (NNP AS/KS) (NN group))))))) (VP (MD might) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ rapid) (NNS shifts)) (PP (IN in) (NP (NP (DT the) (NN predominance)) (PP (IN of) (NP (JJ various) (JJ DA-innervated) (NNS structures)))))))))) (. .)))
3782049	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ massive) (NNP Doc_3782049_18_32_Disease) (VBG following) (NNP Doc_3782049_43_52_Chemical) (NN administration))) (. .)))
3782049	1	(S1 (S (NP (NN Doc_3782049_69_83_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ lethal)) (NN syndrome)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_3782049_122_133_Disease) (NNS patients)) (VP (VBP seem) (VP (VBN predisposed) (S (VP (TO to) (VP (VB develop)))))))))) (. .)))
3782049	2	(S1 (S (NP (NP (DT The) (JJ clinical) (NNS signs) (CC and) (NNS symptoms)) (, ,) (NP (JJ typical) (NN laboratory) (NNS features)) (, ,) (CC and) (NP (NP (NNS complications)) (PP (IN of) (NP (NNP Doc_3782049_255_269_Disease))))) (VP (AUX are) (VP (VBN presented))) (. .)))
3782049	3	(S1 (S (NP (NP (DT The) (NN case)) (PP (IN of) (NP (DT a) (JJ Doc_3782049_299_312_Disease) (NN patient)))) (VP (AUX is) (VP (VBN reported) (S (VP (TO to) (VP (VB illustrate) (NP (NP (JJ massive) (NN Doc_3782049_355_369_Disease)) (CC and) (NP (JJ subsequent) (NN Doc_3782049_385_404_Disease))) (PP (VBG following) (NP (NNP Doc_3782049_415_424_Chemical) (NN administration)))))))) (. .)))
3782049	4	(S1 (S (NP (NP (NNS Physicians)) (SBAR (WHNP (WP who)) (S (VP (VBP prescribe) (NP (NN Doc_3782049_466_475_Chemical)))))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (NN reaction)))))) (. .)))
3800626	0	(S1 (FRAG (NP (NN Doc_3800626_0_42_Disease)) (PP (JJ due) (TO to) (NP (NNP Doc_3800626_50_61_Chemical-induced) (NNP Doc_3800626_70_86_Disease))) (. .)))
3800626	1	(S1 (S (NP (NN Doc_3800626_88_104_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ common) (, ,) (JJ well-known) (NN side) (NN effect)) (PP (IN of) (NP (JJ repeated) (JJ Doc_3800626_153_164_Chemical) (NN injection))))) (. .)))
3800626	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_3800626_185_207_Disease)) (PP (JJ due) (TO to) (NP (NP (JJ fibrotic) (NN muscle)) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_3800626_243_254_Chemical-induced) (NNP Doc_3800626_263_271_Disease)))))) (VP (AUX has) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN reported)))) (. .)))
3800626	3	(S1 (S (PP (IN In) (NP (NP (NP (DT a) (JJ 37-year-old) (NN woman)) (PP (IN with) (NP (NP (VBN documented) (JJ Doc_3800626_345_356_Chemical-induced) (NN Doc_3800626_365_381_Disease)) (PP (IN of) (NP (NP (NNS triceps)) (CC and) (NP (JJ deltoid) (NNS muscles)))) (ADVP (RB bilaterally))))) (CC and) (NP (NP (DT a) (JJ three-week) (NN history)) (PP (IN of) (NP (JJ right) (NN wrist) (NN drop)))))) (, ,) (NP (JJ electrodiagnostic) (NN examination)) (VP (VBD showed) (NP (NP (DT a) (ADJP (JJ severe) (CC but) (JJ partial)) (NN lesion)) (PP (IN of) (NP (DT the) (JJ right) (JJ radial) (NN nerve) (NN distal))) (PP (TO to) (NP (DT the) (NNS branches)))) (PP (TO to) (NP (DT the) (NNS triceps))) (, ,) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (DT the) (NNP Doc_3800626_620_636_Disease)))))) (. .)))
3800626	4	(S1 (S (NP (NN Surgery)) (VP (VBD revealed) (NP (DT the) (JJ right) (JJ radial) (NN nerve) (S (VP (TO to) (VP (AUX be) (ADVP (RB severely)) (VP (VBN compressed) (PP (IN by) (NP (NP (DT the) (ADJP (RB densely) (JJ fibrotic)) (NN lateral) (NN head)) (PP (IN of) (NP (DT the) (NNS triceps))))))))))) (. .)))
3800626	5	(S1 (S (NP (NP (NN Decompression)) (CC and) (NP (NN neurolysis))) (VP (AUX were) (VP (VBN performed) (PP (IN with) (NP (NP (JJ good) (JJ subsequent) (NN recovery)) (PP (IN of) (NP (NN function))))))) (. .)))
3827439	0	(S1 (NP (NP (JJ Recurrent) (JJ reversible) (NN Doc_3827439_21_40_Disease)) (PP (IN from) (NP (NNP Doc_3827439_46_58_Chemical))) (. .)))
3827439	1	(S1 (S (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NP (JJ cryptogenic) (NN Doc_3827439_87_96_Disease)) (CC and) (NP (VBN disseminated) (NN Doc_3827439_114_128_Disease))))) (VP (VBD developed) (NP (NNP Doc_3827439_139_158_Disease)) (ADVP (RB immediately)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_3827439_203_217_Chemical))) (PP (IN on) (NP (CD four) (JJ separate) (NNS occasions)))))) (. .)))
3827439	2	(S1 (S (NP (NP (NP (DT The) (NN abruptness)) (PP (IN of) (NP (DT the) (NNP Doc_3827439_268_281_Disease)))) (CC and) (NP (NP (PRP$ its) (NN reversibility)) (PP (IN within) (NP (NNS days))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ functional) (NN component)) (PP (TO to) (NP (DT the) (NNP Doc_3827439_370_387_Disease)))))))) (. .)))
3827439	3	(S1 (S (NP (PRP We)) (VP (VB propose) (SBAR (IN that) (S (NP (NNP Doc_3827439_405_417_Chemical)) (, ,) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (JJ reduced) (JJ effective) (NN arterial) (NN volume))))) (, ,) (VP (MD may) (VP (VBP activate) (ADVP (RB tubuloglomerular)) (NP (NN feedback)) (, ,) (S (ADVP (RB thereby)) (VP (VBG contributing) (PP (TO to) (NP (NNP Doc_3827439_536_555_Disease)))))))))) (. .)))
3828020	0	(S1 (NP (NP (NN Doc_3828020_0_19_Disease)) (PP (IN with) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NNP Doc_3828020_47_66_Chemical))))) (. .)))
3828020	1	(S1 (S (NP (NP (NP (NNP Doc_3828020_68_87_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3828020_89_92_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ synthetic) (NN sympathomimetic)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADJP (RB structurally) (JJ similar) (PP (TO to) (NP (NNP Doc_3828020_155_166_Chemical)))))))) (, ,)) (VP (AUX is) (ADJP (JJ available)) (PP (IN over) (NP (NP (DT the) (NN counter)) (PP (IN in) (NP (NP (NNS anorectics)) (, ,) (NP (JJ nasal) (NNS congestants)) (, ,) (CC and) (NP (JJ cold) (NNS preparations))))))) (. .)))
3828020	2	(S1 (S (NP (PRP$ Its) (JJ prolonged) (NN use) (CC or) (NN overuse)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_3828020_309_317_Disease)) (, ,) (NP (NNP Doc_3828020_319_343_Disease)) (, ,) (NP (NNP Doc_3828020_345_370_Disease)) (, ,) (CC and) (NP (JJ nonhemorrhagic) (NNP Doc_3828020_391_410_Disease))))))) (. .)))
3828020	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ young) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD suffered) (NP (DT a) (NN Doc_3828020_463_482_Disease)) (PP (IN after) (S (VP (VBG taking) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (NN Doc_3828020_518_521_Chemical)))))))))))))) (. .)))
3856631	0	(S1 (NP (NP (NN Remission) (NN induction)) (PP (IN of) (NP (NNP Doc_3856631_23_41_Disease))) (PP (IN with) (NP (JJ high-dose) (JJ intravenous) (NNP Doc_3856631_69_81_Chemical))) (. .)))
3856631	1	(S1 (S (NP (NP (CD Twenty) (NNS children)) (PP (IN with) (NP (NNP Doc_3856631_104_132_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_3856631_147_164_Disease)))))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ high-dose) (JJ intravenous) (JJ Doc_3856631_207_219_Chemical) (NN regimen)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB achieve) (CC and) (VB maintain) (NP (NP (NNP CSF) (NNP Doc_3856631_274_286_Chemical) (NNS concentrations)) (PP (IN of) (NP (CD 10) (-LRB- -LRB-) (NN -5) (-RRB- -RRB-) (NNS mol/L)))) (PP (IN without) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (JJ concomitant) (JJ intrathecal) (NN dosing)))))))))))))))) (. .)))
3856631	2	(S1 (S (NP (DT The) (NNP Doc_3856631_375_387_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (NN loading) (NN dose)) (PP (IN of) (NP (CD 6,000) (NNS mg/m2))))) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD one) (NN hour))) (VP (VBN followed) (PP (IN by) (NP (NP (DT an) (NN infusion)) (PP (IN of) (NP (CD 1,200) (NNS mg/m2/h))) (PP (IN for) (NP (CD 23) (NNS hours)))))))))) (. .)))
3856631	3	(S1 (S (NP (JJ Doc_3856631_518_528_Chemical) (NN rescue)) (VP (AUX was) (VP (VBN initiated) (NP (NP (NP (CD 12) (NNS hours)) (PP (IN after) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NP (DT the) (NN infusion)) (PP (IN with) (NP (NP (DT a) (NN loading) (NN dose)) (PP (IN of) (NP (CD 200) (NNS mg/m2))))) (VP (VBN followed) (PP (IN by) (NP (NP (NP (CD 12) (NN mg/m2)) (NP (QP (DT every) (CD three)) (NNS hours))) (PP (IN for) (NP (CD six) (NNS doses))))))))))) (CC and) (RB then) (NP (DT every) (CD six) (NNS hours))) (SBAR (IN until) (S (NP (DT the) (NN plasma) (JJ Doc_3856631_717_729_Chemical) (NN level)) (VP (VBD decreased) (PP (TO to) (NP (QP (JJR less) (IN than) (CD 1)) (NNP X) (CD 10) (-LRB- -LRB-) (NN -7) (-RRB- -RRB-) (NN mol/L)))))))) (. .)))
3856631	4	(S1 (S (NP (NP (DT The) (JJ mean) (JJ steady-state) (NN plasma)) (CC and) (NP (NNP CSF) (NNP Doc_3856631_814_826_Chemical) (NNS concentrations))) (VP (VBD achieved) (SBAR (S (VP (AUX were) (NP (NP (CD 1.1) (NNP X) (CD 10) (-LRB- -LRB-) (NN -3) (-RRB- -RRB-) (NN mol/L)) (CC and) (NP (CD 3.6) (NNP X) (CD 10) (-LRB- -LRB-) (NN -5) (-RRB- -RRB-) (NN mol/L))) (, ,) (ADVP (RB respectively)))))) (. .)))
3856631	5	(S1 (S (NP (DT All) (CD 20) (NNS patients)) (VP (VBD responded) (PP (TO to) (NP (DT this) (NN regimen))) (, ,) (SBAR (S (S (NP (NP (NNS 16/20)) (PRN (-LRB- -LRB-) (NP (CD 80) (NN %)) (-RRB- -RRB-))) (VP (VBD achieved) (NP (DT a) (JJ complete) (NN remission)))) (, ,) (CC and) (S (NP (CD 20) (NN %)) (VP (VBD obtained) (NP (DT a) (JJ partial) (NN remission))))))) (. .)))
3856631	6	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (NN Doc_3856631_1053_1063_Disease)) (VP (VBD encountered) (SBAR (S (VP (AUX were) (NP (NP (JJ transient) (NN serum) (NN transaminase)) (CC and) (NP (NP (JJ Doc_3856631_1114_1123_Chemical) (NNS elevations)) (, ,) (NP (NP (NNP Doc_3856631_1136_1147_Disease)) (, ,) (CC and) (NP (NNP Doc_3856631_1153_1162_Disease))))))))) (. .)))
3856631	7	(S1 (S (NP (CD One) (NN patient)) (VP (VP (AUX had) (NP (NP (JJ focal) (NN Doc_3856631_1186_1194_Disease)) (CC and) (NP (NNP Doc_3856631_1199_1220_Disease)))) (CC but) (VP (VBD recovered) (ADVP (RB completely)))) (. .)))
3856631	8	(S1 (S (NP (JJ High-dose) (JJ intravenous) (NN Doc_3856631_1269_1281_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN remission))) (PP (IN after) (NP (NP (JJ meningeal) (NN relapse)) (PP (IN in) (NP (NNP Doc_3856631_1366_1394_Disease))))))))) (. .)))
3865016	0	(S1 (NP (NP (NN Interaction)) (PP (IN of) (NP (NNP Doc_3865016_15_28_Chemical))) (PP (IN with) (NP (JJ antineoplastic) (NNS agents))) (. .)))
3865016	1	(S1 (S (NP (NP (DT A) (JJ synergistic) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_3865016_81_90_Chemical)) (CC and) (NP (NNP Doc_3865016_95_108_Chemical))))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_3865016_140_168_Disease)) (PP (IN in) (NP (NN relapse))))))))) (. .)))
3865016	2	(S1 (S (NP (NP (DT The) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_3865016_215_224_Chemical)) (CC and) (NP (NNP Doc_3865016_229_242_Chemical))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN eradication)) (PP (IN of) (NP (NP (JJ hitherto) (JJ refractory) (NN Doc_3865016_290_311_Disease)) (PP (IN of) (NP (NN bone) (NN marrow)))))))) (. .)))
3865016	3	(S1 (S (NP (NP (JJ Severe) (JJ side) (NNS effects)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (JJ mental) (NNP Doc_3865016_367_376_Disease)) (CC and) (NP (JJ progressive) (NNP Doc_3865016_393_411_Disease))))))) (, ,) (ADVP (RB however)) (, ,) (VP (VBP point) (PP (TO to) (NP (DT an) (NN enhancement))) (PP (CONJP (RB not) (RB only)) (PP (IN of) (NP (JJ antineoplastic) (NNS effects))) (CONJP (CC but) (RB also)) (PP (IN of) (NP (NP (NNP Doc_3865016_493_501_Disease)) (PP (IN in) (NP (JJ normal) (NNS tissues))))))) (. .)))
3865016	4	(S1 (S (NP (DT This) (NN report)) (VP (VBZ demonstrates) (PP (IN for) (NP (NP (DT the) (JJ first) (NN time)) (SBAR (WHNP (IN that)) (S (NP (NP (DT the) (JJ pharmacodynamic) (NNS properties)) (PP (IN of) (NP (NNP Doc_3865016_604_617_Chemical)))) (VP (MD may) (RB not) (VP (AUX be) (VP (VBN confined) (ADVP (RB strictly)) (PP (TO to) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ normal) (JJ T-cell) (NNS functions))))))))))))) (. .)))
3970039	0	(S1 (S (NP (NP (NN Incidence)) (PP (IN of) (NP (NNP Doc_3970039_13_22_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3970039_40_60_Disease)))))) (VP (VBD exposed) (PP (TO to) (NP (JJ different) (NN treatment) (NNS regimens)))) (. .)))
3970039	1	(S1 (S (NP (JJ Immunosuppressive) (NNS drugs)) (VP (AUX have) (VP (AUX been) (VP (VBN used) (PP (IN during) (NP (NP (DT the) (JJ last) (CD 30) (NNS years)) (PP (IN in) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (NN Doc_3970039_203_223_Disease)))))))))))) (. .)))
3970039	2	(S1 (S (NP (NP (DT The) (NNS drugs)) (ADJP (RB commonly) (VBN used))) (VP (AUX are) (NP (NP (NP (NNP Doc_3970039_253_269_Chemical) (CC and) (NNP Doc_3970039_274_286_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3970039_288_305_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_3970039_308_320_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ Doc_3970039_322_328_Chemical) (NN analogue)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_3970039_344_356_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ Doc_3970039_358_368_Chemical) (NN analogue)) (-RRB- -RRB-))))) (. .)))
3970039	3	(S1 (S (S (NP (EX There)) (VP (AUX is) (NP (NN evidence) (SBAR (IN that) (S (NP (DT all) (CD four) (JJ immunosuppressive) (NNS drugs)) (VP (MD can) (VP (VB reduce) (NP (NN Doc_3970039_447_456_Disease))))))))) (, ,) (CC but) (S (NP (NN disease) (NN activity)) (ADVP (RB almost) (RB always)) (VP (VBZ recurs) (SBAR (IN after) (S (NP (NN therapy)) (VP (AUX is) (VP (VBN stopped))))))) (. .)))
3970039	4	(S1 (S (SBAR (IN Since) (S (NP (JJ adverse) (NNS reactions)) (VP (AUX are) (ADJP (JJ frequent))))) (, ,) (NP (NP (QP (JJR less) (IN than) (CD 50)) (NN percent)) (PP (IN of) (NP (NNS patients)))) (VP (AUX are) (ADJP (JJ able) (S (VP (TO to) (VP (VB continue) (NP (NP (DT a) (JJ particular) (NN drug)) (PP (IN for) (NP (QP (JJR more) (IN than) (CD one)) (NN year))))))))) (. .)))
3970039	5	(S1 (S (SBAR (IN Since) (S (NP (PRP it)) (VP (VBZ takes) (NP (QP (CD three) (TO to) (CD 12)) (NNS months)) (S (VP (TO to) (VP (VB achieve) (NP (JJ maximal) (NNS effects)))))))) (, ,) (NP (NP (DT those) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (ADJP (JJ unable)) (S (VP (TO to) (VP (VB continue) (NP (DT the) (NN drug))))))))) (VP (VBP receive) (NP (NP (JJ little) (NN benefit)) (PP (IN from) (NP (PRP it))))) (. .)))
3970039	6	(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3970039_827_844_Chemical))))) (VP (AUX have) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_3970039_886_915_Disease)))))))) (, ,) (CC and) (S (NP (DT both) (NNP Doc_3970039_926_943_Chemical) (CC and) (NNP Doc_3970039_948_960_Chemical)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_3970039_1000_1022_Disease)))))))) (. .)))
3970039	7	(S1 (S (NP (JJ Doc_3970039_1024_1040_Chemical) (NN therapy)) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_3970039_1071_1095_Disease))))) (. .)))
3970039	8	(S1 (S (S (NP (EX There)) (VP (AUX have) (VP (AUX been) (NP (NP (JJ several) (JJ long-term) (NNS studies)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3970039_1156_1176_Disease))))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_3970039_1190_1202_Chemical)) (CC and) (NP (NNP Doc_3970039_1207_1223_Chemical))))))))) (CC and) (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (JJ common) (NNP Doc_3970039_1264_1271_Disease)))))) (VP (AUX is) (RB not) (VP (VBN increased)))) (. .)))
3970039	9	(S1 (S (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (DT the) (JJ possible) (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_3970039_1329_1339_Disease))))) (PP (IN in) (NP (NNP Doc_3970039_1343_1363_Disease)))) (VP (AUX are) (ADVP (RB still)) (VP (AUXG being) (VP (VBN collected))))) (, ,) (CC and) (S (SBAR (IN until) (S (NP (JJ further) (NN information)) (VP (AUX is) (ADJP (JJ available))))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ immunosuppressive) (NNS drugs)) (, ,) (ADVP (RB particularly)) (NP (NNP Doc_3970039_1484_1501_Chemical)) (, ,))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_3970039_1523_1543_Disease)))))) (VP (MD should) (VP (AUX be) (VP (VBN reserved) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ severe) (JJ progressive) (NN disease)) (CC or) (NP (JJ life-threatening) (NNS complications)))))))))) (. .)))
3985451	0	(S1 (S (NP (JJ Doc_3985451_0_8_Chemical-induced) (NNS iliopsoas)) (VP (VBP Doc_3985451_27_37_Disease) (PP (IN with) (NP (JJ subsequent) (NNP Doc_3985451_54_73_Disease)))) (. .)))
3985451	1	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 28-year-old) (NN man)) (PP (IN on) (NP (NP (JJ chronic) (JJ Doc_3985451_127_135_Chemical) (NN therapy)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD sustained) (NP (DT a) (JJ minor) (NN Doc_3985451_166_177_Disease))) (CC and) (VP (VBD developed) (NP (NP (VBG increasing) (NN Doc_3985451_203_207_Disease)) (CC and) (NP (NP (DT a) (JJ flexure) (NN Doc_3985451_222_233_Disease)) (PP (IN of) (NP (DT the) (JJ right) (NN hip))))))))))))))) (. .)))
3985451	2	(S1 (S (NP (JJ Surgical) (NN exploration)) (VP (VBD revealed) (NP (NP (DT an) (JJ iliopsoas) (NN Doc_3985451_295_303_Disease)) (CC and) (NP (JJ femoral) (NN Doc_3985451_316_332_Disease))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (DT a) (NNP Doc_3985451_349_368_Disease) (CC and) (NNP Doc_3985451_373_409_Disease)))))) (. .)))
3985451	3	(S1 (S (S (NP (JJ Anticoagulant-induced) (NN Doc_3985451_433_452_Disease)) (VP (VBZ represents) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN form)) (PP (IN of) (NP (JJ Doc_3985451_488_496_Chemical-induced) (NNP Doc_3985451_505_526_Disease)))))) (: ;) (S (NP (PRP it)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (NP (JJ severe) (NNP Doc_3985451_558_562_Disease)) (PP (IN in) (NP (DT the) (JJ inguinal) (NN region)))) (, ,) (NP (NP (VBG varying) (NNS degrees)) (PP (IN of) (NP (NNP Doc_3985451_606_634_Disease)))) (, ,) (CC and) (NP (NP (JJ flexure) (NNP Doc_3985451_648_659_Disease)) (PP (IN of) (NP (DT the) (VBN involved) (NN extremity))))))))) (. .)))
3997294	0	(S1 (NP (NP (NN Pneumonitis)) (PP (IN with) (NP (NP (NNP Doc_3997294_17_49_Disease)) (CC and) (NP (NNP Doc_3997294_54_64_Disease)))) (PP (IN during) (NP (JJ Doc_3997294_72_82_Chemical) (NN therapy))) (. .)))
3997294	1	(S1 (S (NP (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NNP Doc_3997294_107_125_Disease)))) (CC and) (NP (VBN implanted) (NN pacemaker))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3997294_167_177_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (NN maximum) (NN dose)) (NP (CD 1000) (NN mg))) (, ,) (NP (NN maintenance) (NN dose)) (NP (QP (CD 800) (CD mg)) (NN daily)) (-RRB- -RRB-)) (PP (IN for) (NP (CD 10) (NNS months))) (, ,) (PP (IN for) (NP (NP (NN control)) (PP (IN of) (NP (NNP Doc_3997294_262_295_Disease))))))) (. .)))
3997294	2	(S1 (S (NP (PRP He)) (VP (VBD developed) (NP (NP (NNP Doc_3997294_310_321_Disease)) (, ,) (NP (NNP Doc_3997294_323_356_Disease)) (, ,) (CC and) (NP (DT a) (ADVP (RB predominantly)) (NN Doc_3997294_378_403_Disease)))) (. .)))
3997294	3	(S1 (S (NP (JJ Immediate) (CC but) (JJ gradual) (NN improvement)) (VP (VBD followed) (NP (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_3997294_462_472_Chemical)))) (CC and) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_3997294_492_504_Chemical)))))) (. .)))
3997294	4	(S1 (S (NP (NP (NN Review)) (PP (IN of) (NP (NP (DT this)) (CC and) (NP (ADJP (RB previously) (VBN reported)) (NNS cases))))) (VP (VBZ indicates) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NP (JJ early) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_3997294_593_603_Chemical) (NNP Doc_3997294_604_615_Disease)))) (, ,) (NP (NP (JJ immediate) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_3997294_641_651_Chemical)))) (, ,) (CC and) (NP (JJ prompt) (CC but) (JJ continued) (JJ Doc_3997294_678_685_Chemical) (NN therapy)))) (S (VP (TO to) (VP (VB ensure) (NP (JJ full) (NN recovery))))))) (. .)))
4008111	0	(S1 (NP (JJ Doc_4008111_0_10_Chemical-induced) (NN Doc_4008111_19_35_Disease) (. .)))
4008111	1	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NNP Doc_4008111_49_65_Disease)) (PP (JJ due) (TO to) (NP (JJ chronic) (NNP Doc_4008111_81_91_Chemical) (NN administration))) (PP (IN in) (NP (NP (DT a) (JJ 5-year-old) (NN boy)) (PP (IN with) (NP (NP (NNP Doc_4008111_132_154_Disease)) (, ,) (NP (NNP Doc_4008111_156_186_Disease)) (CC and) (NP (NNP Doc_4008111_191_219_Disease))))))) (. .)))
4008111	2	(S1 (S (NP (NP (NN Reduction)) (PP (IN in) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NNP Doc_4008111_248_258_Chemical)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT the) (NN disappearance)) (PP (IN of) (NP (DT the) (NNP Doc_4008111_296_312_Disease)))) (CC and) (NP (NP (DT the) (NN persistence)) (PP (IN of) (NP (JJ asymptomatic) (NNP Doc_4008111_349_366_Disease))))))) (. .)))
4027862	0	(S1 (NP (NP (NP (JJ Doc_4027862_0_11_Chemical-induced) (NN Doc_4027862_20_28_Disease)) (PP (IN at) (NP (`` ``) (JJ subtherapeutic) ('' '') (NNS concentrations)))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
4027862	1	(S1 (S (NP (NP (DT An) (JJ elderly) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (JJ low) (NN dose) (NN Doc_4027862_121_132_Chemical))))) (VP (VBD developed) (NP (DT a) (NN Doc_4027862_145_153_Disease)) (SBAR (IN while) (S (NP (PRP$ her) (NN plasma) (NN level)) (VP (AUX was) (PP (IN in) (NP (DT the) (`` ``) (JJ subtherapeutic) ('' '') (NN range))))))) (. .)))
4027862	2	(S1 (S (NP (NP (NN Doc_4027862_212_220_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (VP (VBN induced) (PP (IN by) (NP (JJ tricyclic) (NN drug) (NN therapy))) (PP (IN in) (NP (DT the) (JJ elderly)))))))) (, ,)) (VP (MD can) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (NNS tricyclics)) (PP (IN with) (NP (JJ low) (JJ anticholinergic) (NN potency)))))))) (. .)))
4027862	3	(S1 (S (NP (NP (JJ Therapeutic) (NNS ranges)) (PP (IN for) (NP (NNP Doc_4027862_370_385_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (AUX been) (VP (VBN derived) (PP (IN from) (NP (JJ general) (NN adult) (NN population) (NNS studies))))))))) (VP (MD may) (RB not) (VP (AUX be) (ADJP (JJ appropriate) (PP (IN for) (NP (DT the) (JJ elderly)))))) (. .)))
4027862	4	(S1 (S (NP (NP (JJ Further) (NNS studies)) (PP (IN of) (NP (RB specifically) (JJ elderly) (NNS patients)))) (VP (AUX are) (ADVP (RB now)) (VP (VBN required) (S (VP (TO to) (VP (VB establish) (NP (ADJP (ADJP (JJR safer)) (CC and) (ADJP (RBR more) (JJ appropriate))) (NNS guidelines)) (PP (IN for) (NP (NN drug) (NN therapy)))))))) (. .)))
4071154	0	(S1 (NP (NP (JJ Doc_4071154_0_12_Chemical-induced) (NN Doc_4071154_21_40_Disease)) (: :) (NP (NP (NN recurrence)) (PP (IN on) (NP (NN rechallenge)))) (. .)))
4071154	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN reported) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ acute) (JJ oliguric) (NN Doc_4071154_111_124_Disease)) (PP (IN with) (NP (NNP Doc_4071154_130_142_Disease)))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_4071154_161_170_Disease)) (, ,) (NP (NNP Doc_4071154_172_179_Disease)) (, ,) (CC and) (NP (NNP Doc_4071154_185_198_Disease)))) (PP (IN after) (NP (JJ Doc_4071154_205_217_Chemical) (NN therapy))))))) (. .)))
4071154	2	(S1 (S (NP (NP (JJ Prompt) (NN restoration)) (PP (IN of) (NP (JJ renal) (NN function)))) (VP (VBD followed) (NP (NN drug) (NN withdrawal)) (, ,) (SBAR (IN while) (S (NP (NP (NN re-exposure)) (PP (TO to) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_4071154_328_340_Chemical)))))) (VP (VBD caused) (NP (NP (NN recurrence)) (PP (IN of) (NP (JJ acute) (JJ reversible) (NN Doc_4071154_379_387_Disease)))))))) (. .)))
4071154	3	(S1 (S (NP (PRP$ Our) (NN case)) (VP (VBZ supports) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ endogenous) (JJ renal) (NN Doc_4071154_444_458_Chemical)) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (JJ renal) (NN blood) (NN flow))))) (SBAR (WHADVP (WRB when)) (S (S (VP (VBG circulating) (NP (NN plasma) (NN volume)))) (VP (AUX is) (VP (VBN diminished)))))))))) (. .)))
4071154	4	(S1 (S (SBAR (IN Since) (S (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NNS agents)) (VP (VP (VBP interfere) (PP (IN with) (NP (DT this) (JJ compensatory) (NN mechanism)))) (CC and) (VP (MD may) (VP (VB cause) (NP (NN Doc_4071154_657_676_Disease))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (JJ such) (NNS patients)))))) (. .)))
424937	0	(S1 (NP (NP (NNS Patterns)) (PP (IN of) (NP (NNP Doc_424937_12_26_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_424937_38_48_Chemical)))) (. .)))
424937	1	(S1 (S (NP (NP (CD Twelve) (NNS patients)) (PP (IN with) (NP (NNP Doc_424937_71_84_Disease))) (VP (VBN related) (PP (TO to) (NP (NNP Doc_424937_96_106_Chemical))))) (VP (AUX were) (VP (VBN seen) (PP (IN between) (NP (NP (CD 1967)) (CC and) (NP (CD 1977)))))) (. .)))
424937	2	(S1 (S (NP (NN Illness)) (VP (VBD occurred) (PP (IN within) (NP (NP (JJ 1--9) (NNS weeks)) (PP (IN of) (NP (NP (NN commencement)) (PP (IN of) (NP (NN therapy))))))) (PP (IN in) (NP (NP (CD 9) (NNS patients)) (, ,) (NP (NP (DT the) (JJ remaining) (CD 3) (NNS patients)) (VP (AUXG having) (VP (VBN received) (NP (NP (DT the) (NN drug)) (PP (IN for) (NP (NP (CD 13) (NNS months)) (, ,) (NP (CD 15) (NNS months)) (CC and) (NP (CD 7) (NNS years))))) (PP (IN before) (S (VP (VBG experiencing) (NP (NNS symptoms))))))))))) (. .)))
424937	3	(S1 (S (NP (NP (NN Doc_424937_334_342_Disease)) (PP (IN with) (NP (NN tender) (NN Doc_424937_355_367_Disease)))) (, ,) (S (ADVP (RB usually)) (VP (VP (VBN preceded) (PP (IN by) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NP (NN malaise)) (, ,) (NP (NNP Doc_424937_410_418_Disease) (, ,) (NNP Doc_424937_420_426_Disease) (CC and) (NNP Doc_424937_431_439_Disease)) (, ,)))))) (CC and) (VP (VBN associated) (PP (IN with) (NP (JJ upper) (NNP Doc_424937_467_481_Disease)))))) (, ,) (VP (AUX was) (NP (NP (DT an) (JJ invariable) (NN finding)) (PP (IN in) (NP (DT all) (NNS patients))))) (. .)))
424937	4	(S1 (S (NP (JJ Biochemical) (NN liver) (NN function) (NNS tests)) (VP (VP (VBD indicated) (NP (JJ hepatocellular) (NNP Doc_424937_584_592_Disease))) (CC and) (VP (VBD correlated) (PP (IN with) (NP (NP (JJ histopathological) (NN evidence)) (PP (IN of) (NP (NP (NNP Doc_424937_643_657_Disease)) (, ,) (NP (NP (DT the) (NN spectrum)) (PP (IN of) (SBAR (WHNP (WDT which)) (S (VP (VBD ranged) (PP (IN from) (NP (NP (NNP Doc_424937_693_705_Disease) (CC and) (JJ focal) (JJ hepatocellular) (NN Doc_424937_731_739_Disease)) (PP (TO to) (NP (NNP Doc_424937_743_767_Disease)))))))))))))))) (. .)))
424937	5	(S1 (S (NP (JJS Most) (NNS patients)) (VP (VBD showed) (ADJP (JJ moderate) (TO to) (JJ severe)) (NP (NNP Doc_424937_809_824_Disease) (CC or) (NNP Doc_424937_828_852_Disease)) (PP (IN with) (NP (JJ associated) (NNP Doc_424937_869_880_Disease)))) (. .)))
424937	6	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (VP (VBN withdrawn) (PP (IN on) (NP (NN presentation))) (PP (TO to) (NP (NN hospital))) (PP (IN in) (NP (CD 11) (NNS patients))) (, ,) (PP (IN with) (NP (NP (JJ rapid) (JJ clinical) (NN improvement)) (PP (IN in) (NP (CD 9))))))) (. .)))
424937	7	(S1 (S (S (NP (CD One) (NN patient)) (VP (VBD died) (, ,) (S (VP (AUXG having) (VP (VBN presented) (PP (IN in) (NP (NNP Doc_424937_1025_1040_Disease)))))))) (, ,) (CC and) (S (NP (NP (DT another)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NNP Doc_424937_1075_1085_Chemical)) (PP (IN for) (NP (CD 7) (NNS years)))))))) (, ,)) (VP (VBD showed) (NP (JJR slower) (JJ clinical) (CC and) (JJ biochemical) (NN resolution)) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (JJ several) (NNS months))))))) (. .)))
424937	8	(S1 (S (NP (NP (DT The) (VBG remaining) (NN patient)) (PP (IN in) (NP (DT the) (NN series)))) (VP (VBD developed) (NP (NN Doc_424937_1228_1247_Disease)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (AUX was) (ADVP (RB accidentally)) (VP (VBN recommenced) (NP (CD 1) (NN year)) (PP (IN after) (NP (NP (DT a) (JJ prior) (NN episode)) (PP (IN of) (NP (NNP Doc_424937_1323_1333_Chemical-induced) (NNP Doc_424937_1342_1351_Disease)))))))))) (. .)))
424937	9	(S1 (S (PP (PP (IN In) (NP (DT this) (JJ latter) (NN patient))) (, ,) (CC and) (PP (IN in) (NP (CD 2) (NNS others)))) (, ,) (NP (NP (DT the) (JJ causal) (NN relationship)) (PP (IN between) (NP (NP (NNP Doc_424937_1426_1436_Chemical)) (CC and) (NP (NNP Doc_424937_1441_1460_Disease))))) (VP (AUX was) (VP (VBN proved) (PP (IN with) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_424937_1495_1504_Disease))))) (PP (IN within) (NP (NP (CD 2) (NNS weeks)) (PP (IN of) (NP (NP (NN re-exposure)) (PP (TO to) (NP (DT the) (NN drug))))))))) (. .)))
435349	0	(S1 (FRAG (NP (NP (JJ Doc_435349_0_13_Chemical) (NN infusion) (NN rate)) (CC and) (NP (JJ observed) (NN Doc_435349_41_55_Disease))) (. .)))
435349	1	(S1 (NP (DT A) (JJ dose-response) (NN study) (. .)))
435349	2	(S1 (S (NP (NP (NNP Doc_435349_80_102_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_435349_104_107_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (NP (QP (CD i.v.) (TO to) (CD 36)) (JJ adult) (NNS males)) (PP (IN at) (NP (NP (CD six) (NNS rates)) (: :) (NP (QP (CD 0.25) (CD mg) (NN s-1) (TO to) (CD 20) (CD mg) (NN s-1))))))) (. .)))
435349	3	(S1 (S (NP (DT The) (NN infusion)) (VP (AUX was) (VP (VBN discontinued) (ADVP (RB either)) (SBAR (SBAR (WHADVP (WRB when)) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (JJ muscular) (NN response)) (PP (TO to) (NP (NP (JJ Doc_435349_265_272_Disease) (NN stimulation)) (PP (IN of) (NP (DT the) (JJ ulnar) (NN nerve))))))))) (CC or) (SBAR (WHADVP (WRB when)) (S (NP (JJ Doc_435349_312_315_Chemical) (CD 120) (NN mg)) (VP (AUX was) (VP (VBN exceeded)))))))) (. .)))
435349	4	(S1 (S (NP (CD Six) (JJ additional) (NNS patients)) (VP (VBD received) (NP (DT a) (JJ 30-mg) (NN i.v.) (NN bolus) (NN dose))) (. .)))
435349	5	(S1 (S (NP (NP (NN Doc_435349_395_409_Disease)) (PP (IN in) (NP (NP (CD six) (NNS areas)) (PP (IN of) (NP (DT the) (NN body)))))) (VP (AUX were) (VP (VP (VBN scored) (PP (IN from) (NP (NP (CD 0)) (PP (TO to) (NP (CD 3)))))) (CC and) (VP (VBN summated) (PP (IN as) (NP (DT a) (JJ total) (JJ Doc_435349_483_496_Disease) (NN score)))))) (. .)))
435349	6	(S1 (S (NP (NP (DT The) (NNS times)) (PP (TO to) (NP (NP (JJ first) (NN Doc_435349_523_536_Disease)) (, ,) (NP (JJ Doc_435349_538_544_Disease) (NN suppression)) (CC and) (NP (JJ Doc_435349_561_568_Disease) (NN suppression))))) (VP (AUX were) (ADVP (RB inversely)) (VP (VBN related) (PP (TO to) (NP (DT the) (NN infusion) (NNS rates))))) (. .)))
435349	7	(S1 (S (NP (NP (NP (NN Doc_435349_627_641_Disease)) (PP (IN in) (NP (DT the) (CD six) (NNS areas)))) (CC and) (NP (DT the) (JJ total) (NN Doc_435349_673_686_Disease) (NN score))) (VP (AUX were) (VP (VBN related) (ADVP (RB directly)) (PP (TO to) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN infusion))))))) (. .)))
435349	8	(S1 (S (NP (NP (NP (JJ Total) (JJ Doc_435349_746_759_Disease) (NNS scores)) (PP (IN in) (NP (DT the) (JJ 30-mg) (NN bolus) (NN group)))) (CC and) (NP (DT the) (JJ 5-mg) (ADJP (JJ s-1) (CC and) (JJ 20-mg)) (NN s-1) (NN infusion) (NNS groups))) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different))) (. .)))
4812392	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_4812392_13_22_Disease))) (PP (IN with) (NP (NNP Doc_4812392_28_40_Chemical))) (. .)))
4812392	1	(S1 (S (NP (JJ Doc_4812392_42_54_Chemical) (NN treatment)) (VP (VBD benefited) (NP (CD 19)) (PRN (-LRB- -LRB-) (NP (CD 66) (NN %)) (-RRB- -RRB-)) (PP (IN out) (PP (IN of) (NP (NP (CD 29) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (JJ severe) (NN Doc_4812392_125_134_Disease)))))))) (. .)))
4812392	2	(S1 (S (S (NP (JJ Haematological) (NNS complications)) (VP (AUX were) (RB not) (ADJP (JJ troublesome)))) (CC and) (S (NP (NP (NNS results)) (PP (IN of) (NP (JJ biochemical) (NN liver) (NN function) (NNS tests)))) (VP (VBD remained) (ADJP (JJ normal)))) (. .)))
4812392	3	(S1 (S (NP (JJ Minimal) (NN Doc_4812392_259_270_Disease)) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (NP (CD two) (NNS cases)) (CC and) (NP (JJ portal) (NN Doc_4812392_304_312_Disease))) (PP (IN of) (NP (NP (DT a) (JJ reversible) (NN degree)) (PP (IN in) (NP (CD eight))))))))) (. .)))
4812392	4	(S1 (S (NP (NN Liver) (NNS biopsies)) (VP (MD should) (VP (AUX be) (VP (VBN undertaken) (PP (IN at) (NP (JJ regular) (NNS intervals))) (SBAR (IN if) (S (NP (JJ Doc_4812392_406_418_Chemical) (NN therapy)) (VP (AUX is) (VP (VBN continued) (SBAR (IN so) (S (NP (DT that) (JJ structural) (NN Doc_4812392_459_471_Disease)) (VP (MD may) (VP (AUX be) (VP (VBN detected) (PP (IN at) (NP (DT an) (JJ early) (CC and) (JJ reversible) (NN stage))))))))))))))) (. .)))
567256	0	(S1 (S (NP (NN Doc_567256_0_25_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_567256_42_60_Chemical)))) (. .)))
567256	1	(S1 (S (NP (NN Doc_567256_62_87_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (JJ 76-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN for) (NP (NP (DT a) (JJ well-differentiated) (NN Doc_567256_165_192_Disease)) (PP (IN with) (NP (NNP Doc_567256_198_216_Chemical))) (PP (IN for) (NP (CD 13) (NNS years))))))))))))) (. .)))
567256	2	(S1 (S (NP (NN Doc_567256_231_243_Disease)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ present)) (PP (IN within) (NP (NP (NN pulmonary)) (CC and) (NP (JJ renal) (NN arteries))))) (. .)))
567256	3	(S1 (S (NP (DT The) (NN possibility) (SBAR (IN that) (S (NP (DT the) (NNP Doc_567256_323_344_Disease)) (VP (MD might) (VP (VB represent) (NP (JJ independent) (JJ primary) (NN Doc_567256_381_387_Disease))))))) (VP (AUX is) (VP (VBN considered))) (. .)))
603022	0	(S1 (NP (NP (NNP Doc_603022_0_25_Chemical)) (, ,) (NP (DT a) (ADJP (RBR longer) (JJ acting)) (NN anticholinesterase) (NN drug)) (, ,) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (DT the) (JJ central) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_603022_111_122_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_603022_124_132_Chemical)) (-RRB- -RRB-)))))))) (. .)))
603022	1	(S1 (S (NP (NP (NNP Doc_603022_135_160_Chemical)) (, ,) (NP (NP (DT an) (JJ anticholinesterase) (NN drug)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG penetrating) (NP (DT the) (NN blood-brain) (NN barrier))))))) (, ,)) (VP (AUX was) (VP (VBN used) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG demonstrating) (NP (NP (JJ central) (NNS effects)) (PP (IN of) (NP (NNP Doc_603022_292_303_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_603022_305_313_Chemical)) (-RRB- -RRB-)) (NNP Doc_603022_315_325_Disease))))))))) (. .)))
603022	2	(S1 (S (NP (PRP It)) (VP (VP (AUX is) (ADVP (RB longer)) (VP (VBG acting) (PP (IN than) (NP (NNP Doc_603022_352_365_Chemical))))) (CC and) (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (NN anaesthesia))) (S (VP (TO to) (VP (VB reverse) (NP (DT the) (JJ non-depolarizing) (NN neuromuscular) (NN block)))))))) (. .)))
603022	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNS studies)) (PP (IN into) (NP (NP (DT the) (NN dose)) (ADJP (JJ necessary) (PP (TO to) (S (VP (VBG combating) (NP (JJ Doc_603022_500_511_Chemical) (NN intoxication))))))))) (VP (AUX are) (VP (VBN indicated))) (. .)))
6103707	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (DT the) (JJ subjective) (NNS effects)) (CC and) (NP (NN plasma) (NNS concentrations)))) (VP (VBG following) (NP (NP (JJ oral) (CC and) (NNP i.m.) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6103707_105_118_Chemical)) (PP (IN in) (NP (NNS volunteers))))))) (. .)))
6103707	1	(S1 (S (NP (NP (NNP Doc_6103707_134_147_Chemical) (CD 0.5) (, ,) (CD 1.0)) (CC or) (NP (CD 2.0) (NNS mg))) (VP (AUX was) (VP (VBN given) (PP (IN by) (NP (DT the) (JJ oral) (CC or) (NNP i.m.) (NNS routes))) (PP (TO to) (NP (NP (NP (NNS groups)) (PP (IN of) (NP (NNS volunteers)))) (CC and) (NP (NP (PRP$ its) (NNS effects)) (VP (VBN compared))))))) (. .)))
6103707	2	(S1 (S (NP (NP (NN Plasma) (NNS concentrations)) (PP (IN of) (NP (DT the) (NN drug)))) (VP (AUX were) (VP (VBN estimated) (PP (IN by) (NP (JJ gas-liquid) (NN chromatography))) (, ,) (PP (IN in) (NP (NP (DT a) (JJR smaller) (NN number)) (PP (IN of) (NP (DT the) (NNS subjects))))))) (. .)))
6103707	3	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ striking)) (NN effect)) (VP (AUX was) (NP (NP (NN sedation)) (SBAR (WHNP (WDT which)) (S (VP (VBD increased) (PP (IN with) (NP (DT the) (NN dose))) (, ,) (S (NP (CD 2) (NN mg)) (VP (VBG producing) (NP (JJ deep) (NN sleep)) (SBAR (IN although) (S (NP (DT the) (NNS subjects)) (VP (MD could) (ADVP (RB still)) (VP (AUX be) (VP (VBN aroused))))))))))))) (. .)))
6103707	4	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP i.m.) (NN administration)))) (VP (AUX were) (UCP (ADJP (JJ apparent) (JJR earlier)) (CC and) (VP (ADVP (RB sometimes)) (VBN lasted) (ADVP (RBR longer) (PP (IN than) (NP (NP (DT those)) (VP (VBG following) (NP (JJ oral) (NN administration))))))))) (. .)))
6103707	5	(S1 (S (NP (NN Doc_6103707_638_647_Disease)) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ marked) (PP (IN than) (NP (NN sedation)))) (, ,) (CC but) (ADJP (JJ increased) (PP (IN with) (NP (DT the) (NN dose)))))) (. .)))
6103707	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (NNP Doc_6103707_718_722_Disease) (IN on) (NNP i.m.) (NN injection)) (PP (IN of) (NP (NNP Doc_6103707_744_757_Chemical)))) (ADVP (ADVP (RB significantly) (RBR more) (RB often)) (PP (IN than) (PP (IN with) (NP (JJ isotonic) (NN saline)))))) (. .)))
6103707	7	(S1 (S (NP (NN Plasma) (NNS concentrations)) (VP (VP (VBN varied) (PP (IN with) (NP (NP (NN dose)) (CC and) (NP (NN route))))) (CC and) (VP (VBD corresponded) (ADVP (RB qualitatively)) (PP (IN with) (NP (DT the) (JJ subjective) (NNS effects))))) (. .)))
6103707	8	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (ADVP (RB still)) (ADJP (JJ present)) (PP (IN in) (NP (JJ measurable) (NNS quantities))) (PP (IN after) (NP (NP (CD 24) (NNP h)) (PP (ADVP (RB even)) (IN with) (NP (DT the) (JJS smallest) (NN dose)))))) (. .)))
6133211	0	(S1 (NP (NP (JJ Possible) (NN teratogenicity)) (PP (IN of) (NP (NNP Doc_6133211_27_41_Chemical))) (. .)))
6133211	1	(S1 (S (NP (NP (CD Three) (NNS infants)) (, ,) (VP (VBN born) (PP (IN of) (NP (CD two) (NNS mothers))) (PP (IN with) (NP (NP (NNP Doc_6133211_83_109_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_6133211_138_152_Chemical))) (PP (IN throughout) (NP (NN pregnancy))))))))) (, ,)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (JJ major) (NN Doc_6133211_200_220_Disease))))))) (. .)))
6133211	2	(S1 (S (PP (IN In) (NP (DT the) (NNP singleton) (NN pregnancy))) (, ,) (S (NP (DT the) (NN mother)) (VP (AUX had) (NP (NN Doc_6133211_265_283_Disease)))) (, ,) (CC and) (S (NP (NP (DT the) (NN infant)) (, ,) (NP (DT a) (NN male)) (, ,)) (VP (AUX had) (NP (NP (NN Doc_6133211_313_337_Disease)) (CC and) (NP (DT a) (NN Doc_6133211_344_369_Disease))))) (. .)))
6133211	3	(S1 (S (PP (IN In) (NP (DT the) (JJ twin) (NN pregnancy))) (, ,) (NP (DT the) (NN mother)) (VP (AUX had) (NP (NN Doc_6133211_409_424_Disease))) (. .)))
6133211	4	(S1 (S (NP (NP (DT The) (JJ first) (JJ twin)) (, ,) (NP (DT a) (NN female)) (, ,)) (VP (AUX had) (NP (NP (DT a) (JJ left) (NN Doc_6133211_463_496_Disease)) (CC and) (NP (DT a) (NN Doc_6133211_503_533_Disease)))) (. .)))
6133211	5	(S1 (S (NP (NP (DT The) (JJ second) (JJ twin)) (, ,) (NP (DT a) (NN male)) (, ,)) (VP (AUX had) (NP (NP (DT some) (NNS features)) (PP (IN of) (NP (NP (NNP Doc_6133211_581_596_Disease)) (, ,) (NP (NNP Doc_6133211_598_615_Disease)) (, ,) (NP (NNP Doc_6133211_617_643_Disease)) (, ,) (CC and) (NP (NNP Doc_6133211_649_668_Disease)))))) (. .)))
6133211	6	(S1 (S (PP (IN Despite) (NP (NP (NNS reports)) (PP (TO to) (NP (DT the) (NN contrary))))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NNP Doc_6133211_724_738_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ teratogenic)))))))) (. .)))
6203452	0	(S1 (S (NP (NP (NN Doc_6203452_0_26_Disease)) (CC and) (NP (NN Doc_6203452_31_44_Disease))) (VP (VBN associated) (PP (IN with) (NP (JJ antineoplastic) (NN chemotherapy)))) (. .)))
6203452	1	(S1 (S (NP (NP (CD Five) (NNS patients)) (PP (IN with) (NP (NNP Doc_6203452_109_118_Disease)))) (VP (VBD developed) (NP (NP (NNP Doc_6203452_129_155_Disease)) (PRN (-LRB- -LRB-) (VP (VBN characterized) (PP (IN by) (NP (NP (NNP Doc_6203452_174_193_Disease)) (, ,) (NP (NNP Doc_6203452_195_228_Disease)) (, ,) (CC and) (ADVP (RB usually)) (NP (NNP Doc_6203452_242_258_Disease))))) (-RRB- -RRB-))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_6203452_281_290_Chemical)) (, ,) (NP (NNP Doc_6203452_292_301_Chemical)) (, ,) (CC and) (NP (DT a) (NNP Doc_6203452_309_323_Chemical))))))) (. .)))
6203452	2	(S1 (S (NP (CD One) (NN patient)) (VP (AUX had) (NP (NP (NNP Doc_6203452_341_376_Disease)) (, ,) (NP (NP (NP (CD three)) (NP (DT the) (NNP Doc_6203452_388_413_Disease))) (, ,) (CC and) (NP (NP (CD one)) (NP (NP (DT an) (JJ apparent) (NN forme) (NN fruste)) (PP (IN of) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (NNS disorders)))))))))) (. .)))
6203452	3	(S1 (S (NP (NP (JJ Histologic) (NN examination)) (PP (IN of) (NP (DT the) (JJ renal) (NN tissue)))) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_6203452_537_562_Disease)))) (, ,) (S (ADVP (RB primarily)) (VP (VBG affecting) (NP (NP (DT the) (JJ small) (NNS arteries)) (, ,) (NP (NNS arterioles)) (, ,) (CC and) (NP (NNS glomeruli)))))) (. .)))
6203452	4	(S1 (S (SBAR (IN Because) (S (NP (DT each) (NN patient)) (VP (VP (AUX was) (ADJP (JJ Doc_6203452_656_661_Disease-free))) (CC or) (VP (AUX had) (NP (RB only) (DT a) (JJ small) (NN Doc_6203452_687_692_Disease)) (PP (IN at) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT this) (NN syndrome))))))))) (, ,) (NP (DT the) (NNP Doc_6203452_728_754_Disease)) (VP (MD may) (VP (AUX have) (VP (AUX been) (VP (VBN induced) (PP (IN by) (NP (NN chemotherapy))))))) (. .)))
6203452	5	(S1 (S (NP (NP (NN Diagnosis)) (PP (IN of) (NP (DT this) (ADJP (RB potentially) (JJ fatal)) (NN complication)))) (VP (MD may) (VP (AUX be) (VP (VBN delayed) (CC or) (VBN missed) (SBAR (IN if) (S (NP (NP (JJ renal) (NN tissue)) (CC or) (NP (DT the) (JJ peripheral) (NN blood) (NN smear))) (VP (AUX is) (RB not) (VP (VBN examined))))) (, ,) (SBAR (IN because) (S (NP (NNP Doc_6203452_939_952_Disease)) (VP (MD may) (VP (AUX be) (VP (VBN ascribed) (PP (TO to) (NP (NNP Doc_6203452_972_981_Chemical) (NNP Doc_6203452_982_996_Disease) (CC and) (DT the) (NNP Doc_6203452_1005_1011_Disease) (CC and) (NNP Doc_6203452_1016_1032_Disease))) (PP (TO to) (NP (JJ drug-induced) (NN Doc_6203452_1049_1072_Disease))))))))))) (. .)))
6209318	0	(S1 (NP (NP (NP (NNP International) (NNP Doc_6209318_14_24_Chemical)) (CC and) (NP (NN placebo) (NN antiarrhythmic) (JJ coronary) (NN trial))) (: :) (NP (NP (NNP I.) (NNP Report)) (PP (IN on) (NP (NP (NNP Doc_6209318_81_91_Disease)) (CC and) (NP (JJ other) (NNS findings))))) (. .)))
6209318	1	(S1 (NP (NNP Impact) (NNP Research) (NNP Group) (. .)))
6209318	2	(S1 (S (NP (NP (DT The) (JJ antiarrhythmic) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ sustained) (NN release) (NN form)) (PP (IN of) (NP (NP (NNP Doc_6209318_195_205_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6209318_207_225_Chemical)) (-RRB- -RRB-))))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN in) (NP (NP (DT a) (JJ double-blind) (NN placebo) (NN trial)) (PP (IN in) (NP (CD 630) (NNS patients))) (PP (IN with) (NP (JJ recent) (VBN documented) (NN Doc_6209318_313_334_Disease))))))) (. .)))
6209318	3	(S1 (S (NP (DT The) (JJ primary) (NN response) (NN variable)) (VP (VP (AUX was) (VP (VBN based) (PP (IN on) (NP (NP (JJ central) (NN reading)) (PP (IN of) (NP (ADJP (CD 24) (NN hour)) (JJ ambulatory) (JJ electrocardiographic) (NNS recordings))))))) (CC and) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (QP (CD 30) (CC or) (JJR more)) (JJ single) (JJ premature) (NN ventricular) (NNS complexes))) (PP (IN in) (NP (QP (DT any) (CD two)) (JJ consecutive) (CD 30) (JJ minute) (NNS blocks)))) (CC or) (NP (NP (QP (CD one) (CC or) (JJR more)) (NNS runs)) (PP (IN of) (NP (QP (CD two) (CC or) (JJR more)) (JJ premature) (NN ventricular) (NNS complexes))) (PP (IN in) (NP (DT the) (JJ entire) (ADJP (CD 24) (NN hour)) (JJ electrocardiographic) (NN recording))))))))) (. .)))
6209318	4	(S1 (S (S (NP (NP (JJ Large) (NNS differences)) (, ,) (VP (VBN regarded) (PP (IN as) (ADJP (RB statistically) (JJ significant)))) (, ,) (PP (IN between) (NP (DT the) (JJ Doc_6209318_767_777_Chemical) (CC and) (NN placebo) (NNS groups)))) (VP (AUX were) (VP (VBN noted) (PP (IN in) (NP (DT that) (NN end) (NN point))) (PP (IN at) (NP (NP (NNS months)) (CD 1) (CC and) (CD 4)))))) (, ,) (CC but) (S (NP (JJ only) (NNS trends)) (VP (AUX were) (VP (VBN observed) (PP (IN at) (NP (NN month) (CD 12)))))) (. .)))
6209318	5	(S1 (S (NP (DT These) (NNS differences)) (VP (AUX were) (VP (VBN observed) (SBAR (RB even) (IN though) (S (NP (NP (DT the) (JJ serum) (JJ Doc_6209318_942_952_Chemical) (NNS levels)) (VP (VBN obtained) (PP (IN in) (NP (DT this) (NN study))))) (VP (AUX were) (ADJP (ADJP (RB generally) (JJR lower)) (PP (IN than) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (VP (VBN used) (NP (NP (DT the) (JJ regular) (NN form)) (PP (IN of) (NP (DT the) (NN drug))))))))))))))))))) (. .)))
6209318	6	(S1 (S (S (NP (EX There)) (VP (AUX were) (ADJP (RBR more) (JJ Doc_6209318_1096_1102_Disease)) (PP (IN in) (NP (DT the) (NNP Doc_6209318_1110_1120_Chemical) (NN group))) (PRN (-LRB- -LRB-) (NP (CD 7.6) (NN %)) (-RRB- -RRB-)) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (PRN (-LRB- -LRB-) (NP (CD 4.8) (NN %)) (-RRB- -RRB-)))) (: ;) (S (NP (DT the) (NN difference)) (VP (AUX was) (RB not) (ADJP (RB statistically) (JJ significant)))) (. .)))
6209318	7	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ coronary) (NNS events)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
6209318	8	(S1 (S (NP (NP (ADJP (RB Previously) (VBN recognized)) (NN side) (NNS effects)) (, ,) (ADVP (RB particularly)) (NP (NP (NNP Doc_6209318_1328_1334_Disease)) (CC and) (NP (NNP Doc_6209318_1339_1364_Disease))) (, ,)) (VP (AUX were) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (DT the) (NNP Doc_6209318_1392_1402_Chemical) (NN group))) (PP (IN than) (PP (IN in) (NP (DT the) (NN placebo) (NN group))))) (. .)))
6229975	0	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NN heart)))) (VP (VBP size) (PP (IN during) (NP (NP (JJ long-term) (JJ Doc_6229975_39_46_Chemical) (NN treatment)) (PP (IN after) (NP (NNP Doc_6229975_63_84_Disease)))))) (. .)))
6229975	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ long-term) (JJ Doc_6229975_110_117_Chemical) (NN treatment))) (PP (IN on) (NP (NN heart) (NN size))) (PP (IN after) (NP (NNP Doc_6229975_148_169_Disease)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN by) (NP (NN X-ray))) (PP (IN in) (NP (NP (DT a) (JJ double-blind) (NN study)) (PP (VBG including) (NP (NP (CD 241) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN placebo) (CD 126)) (, ,) (NP (NNP Doc_6229975_254_261_Chemical) (CD 115))) (-RRB- -RRB-)))))))) (. .)))
6229975	2	(S1 (S (NP (DT The) (JJ follow-up) (NN period)) (VP (AUX was) (NP (CD 12) (NNS months))) (. .)))
6229975	3	(S1 (S (NP (DT The) (JJ Doc_6229975_308_315_Chemical-treated) (NNS patients)) (VP (VBD showed) (NP (NP (DT a) (ADJP (JJ small) (CC but) (JJ significant)) (NN increase)) (PP (IN in) (NP (NN heart) (NN size))) (PP (IN from) (NP (NN baseline))) (PP (IN in) (NP (NN contrast))) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (DT the) (NN placebo) (NN group))))))) (. .)))
6229975	4	(S1 (S (NP (DT These) (NNS differences)) (VP (MD may) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (JJ Doc_6229975_484_491_Chemical-induced) (NN Doc_6229975_500_511_Disease)) (CC and) (NP (NP (DT a) (JJ compensatory) (NN increase)) (PP (IN in) (NP (JJ end-diastolic) (NN volume))))))))) (. .)))
6229975	5	(S1 (S (NP (NP (DT The) (JJ Doc_6229975_569_576_Chemical-related) (NN increase)) (PP (IN in) (NP (NN heart) (NN size)))) (VP (AUX was) (VP (VBN observed) (ADVP (RB only)) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (JJ normal) (CC and) (JJ borderline) (NN heart) (NN size))))) (. .)))
6229975	6	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_6229975_694_706_Disease))))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN heart) (NN size)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
6229975	7	(S1 (S (PP (IN After) (NP (NN re-Doc_6229975_772_782_Disease))) (, ,) (NP (NN heart) (NN size)) (VP (VP (VBD increased) (PP (IN in) (NP (DT the) (NN placebo) (NN group)))) (CC and) (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN in) (NP (DT the) (NNP Doc_6229975_856_863_Chemical) (NN group))))) (. .)))
6286738	0	(S1 (NP (NP (NNP Doc_6286738_0_10_Chemical) (NNP Doc_6286738_11_19_Disease)) (PP (IN in) (NP (NN dairy) (NNS cows))) (. .)))
6286738	1	(S1 (S (NP (NP (JJ Large) (JJ parenteral) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_6286738_61_71_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (TO to) (CD 17.5)) (NNP x) (CD 10) (-LRB- -LRB-) (CD 6) (-RRB- -RRB-) (NNP IU) (NNP Doc_6286738_95_105_Chemical)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (JJ prolonged) (NNP Doc_6286738_138_151_Disease) (, ,) (NNP Doc_6286738_153_170_Disease) (, ,) (CC and) (JJ large) (NNS increases)) (PP (IN of) (NP (NNP Doc_6286738_195_205_Chemical)))) (CC and) (NP (NP (PRP$ its) (NNS metabolites)) (PP (IN in) (NP (NP (DT the) (NN blood) (NN plasma)) (PP (IN of) (NP (NP (JJ nonlactating) (NN nonpregnant)) (CC and) (NP (JJ pregnant) (NNP Jersey) (NNS cows))))))))))) (. .)))
6286738	2	(S1 (S (NP (JJ Doc_6286738_300_307_Chemical) (NNS concentrations)) (NP (CD 1) (NN day) (NN postpartum)) (VP (AUX were) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (NNS cows)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6286738_373_383_Chemical))) (PP (IN about) (NP (NP (CD 32) (NNS days)) (ADJP (ADJP (JJ prepartum)) (PRN (-LRB- -LRB-) (NP (QP (CD 8.8) (CD mg/100)) (NNS ml)) (-RRB- -RRB-))))))))) (PP (IN than) (PP (IN in) (NP (NP (NN control) (NNS cows)) (PRN (-LRB- -LRB-) (NP (QP (CD 5.5) (CD mg/100)) (NNS ml)) (-RRB- -RRB-))))))) (. .)))
6286738	3	(S1 (S (S (NP (NP (NN None)) (PP (IN of) (NP (NP (DT the) (NNS cows)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6286738_492_502_Chemical))))))) (VP (VBD showed) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_6286738_519_529_Disease)))) (PP (IN during) (NP (DT the) (JJ peripartal) (NN period))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (CD 22) (NN %)) (PP (IN of) (NP (DT the) (NN control) (NNS cows)))) (VP (VBD developed) (NP (NP (JJ clinical) (NNS signs)) (PP (IN of) (NP (NNP Doc_6286738_621_631_Disease)))) (PP (IN during) (NP (DT this) (NN period))))) (. .)))
6286738	4	(S1 (S (S (NP (NP (NNS Signs)) (PP (IN of) (NP (NNP Doc_6286738_661_671_Chemical) (NNP Doc_6286738_672_680_Disease)))) (VP (AUX were) (RB not) (VP (VBN observed) (PP (IN in) (S (VP (VBG nonlactating) (NP (JJ nonpregnant) (NNS cows)))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (JJ pregnant) (NNS cows)) (VP (ADVP (RB commonly)) (VBN developed) (NP (NP (JJ severe) (NNS signs)) (PP (IN of) (NP (NP (NNP Doc_6286738_791_801_Chemical) (NNP Doc_6286738_802_810_Disease)) (CC and) (NP (NP (CD 10)) (PP (IN of) (NP (CD 17) (NNS cows))))))))) (VP (VBD died))) (. .)))
6286738	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (JJ widespread) (JJ metastatic) (NN calcification)) (PP (IN in) (NP (NP (DT the) (NNS cows)) (SBAR (WHNP (WDT that)) (S (VP (VBD died)))))))) (. .)))
6286738	6	(S1 (S (PP (IN Because) (IN of) (NP (NP (NP (DT the) (JJ extreme) (NN Doc_6286738_927_935_Disease)) (PP (IN of) (NP (NNP Doc_6286738_939_949_Chemical))) (PP (IN in) (NP (JJ pregnant) (NNP Jersey) (NNS cows)))) (CC and) (NP (NP (DT the) (JJ low) (NN margin)) (PP (IN of) (NP (NN safety))) (PP (IN between) (NP (NP (NNS doses)) (PP (IN of) (NP (NNP Doc_6286738_1020_1030_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBP prevent) (NP (NNP Doc_6286738_1044_1054_Disease) (CC and) (NNS doses)) (SBAR (IN that) (S (VP (VB induce) (NP (NNP Doc_6286738_1077_1087_Disease))))))))))))) (, ,) (NP (PRP we)) (VP (VBD concluded) (SBAR (IN that) (S (NP (JJ Doc_6286738_1107_1117_Chemical) (NN cannot)) (VP (AUX be) (VP (VBN used) (ADVP (RB practically)) (S (VP (TO to) (VP (VB prevent) (NP (NNP Doc_6286738_1156_1166_Disease)) (SBAR (WHADVP (WRB when)) (S (VP (VBN injected) (NP (JJ several) (NNS weeks)) (NP (NN prepartum))))))))))))) (. .)))
6287825	0	(S1 (S (NP (NN Doc_6287825_0_29_Disease)) (ADVP (RB as)) (VP (VBN seen) (PP (IN in) (NP (DT the) (NNP Nigerian) (NNP African)))) (. .)))
6287825	1	(S1 (S (NP (NP (DT The) (JJ anatomical) (CC and) (JJ aetiological) (NNS diagnoses)) (PP (IN of) (NP (NNP Doc_6287825_108_132_Disease))) (PP (VBG excluding) (NP (NP (PRP$ its) (JJ primary) (JJ benign) (CC and) (JJ malignant) (NNS disorders)) (, ,) (VP (ADVP (RB as)) (VBN seen) (PP (IN in) (NP (CD 358) (NNS Nigerians))))))) (VP (AUX are) (VP (VBN presented))) (. .)))
6287825	2	(S1 (S (S (NP (EX There)) (VP (AUX is) (NP (DT a) (JJ male) (NN preponderance)))) (CC and) (S (NP (DT the) (JJ peak) (NN incidence)) (VP (AUX is) (PP (IN in) (NP (DT the) (JJ fourth) (NN decade))))) (. .)))
6287825	3	(S1 (S (NP (NN Doc_6287825_305_329_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ commonest) (NN presentation)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN %)) (-RRB- -RRB-)))) (. .)))
6287825	4	(S1 (S (NP (NN Doc_6287825_368_392_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ commonest) (JJ identifiable) (NN cause)) (PRN (-LRB- -LRB-) (NP (CD 15.6) (NN %)) (-RRB- -RRB-))) (, ,) (S (VP (VBG accounting) (PP (IN for) (NP (NP (NN half)) (PP (IN of) (NP (NP (DT the) (NNS cases)) (PP (IN with) (NP (NNP Doc_6287825_477_493_Disease)))))))))) (. .)))
6287825	5	(S1 (S (NP (NP (NN Doc_6287825_495_516_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_6287825_524_546_Disease)) (PP (IN of) (NP (NNP Doc_6287825_550_558_Chemical) (CC and) (NNP Doc_6287825_563_573_Chemical))))))) (VP (VP (AUX was) (ADJP (JJ common)) (PRN (-LRB- -LRB-) (NP (CD 10.1) (NN %)) (-RRB- -RRB-))) (CC and) (VP (VBD presented) (ADVP (RB mainly)) (PP (IN as) (NP (JJ sensory) (CC and) (NNP Doc_6287825_629_653_Disease))))) (. .)))
6287825	6	(S1 (S (NP (NN Doc_6287825_655_672_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NNP Doc_6287825_696_716_Disease))))) (. .)))
6287825	7	(S1 (S (NP (NN Doc_6287825_718_727_Chemical)) (VP (AUX was) (NP (NP (DT the) (ADJP (RBS most) (JJ frequent)) (NN agent)) (PP (IN in) (NP (JJ drug-induced) (NNP Doc_6287825_772_782_Disease))))) (. .)))
6287825	8	(S1 (S (S (NP (NP (NNP Doc_6287825_784_792_Disease)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-))) (VP (AUX was) (RB not) (NP (NP (DT an) (JJ uncommon) (NN cause)) (PP (IN of) (NP (NNP Doc_6287825_828_846_Disease))) (PP (IN although) (NP (NP (NNP Doc_6287825_856_868_Disease)) (VP (VBG arising) (PP (IN from) (NP (DT the) (JJ reticuloendothelial) (NN system))))))))) (CC or) (S (NP (NP (VBN related) (NNS structures)) (PP (IN of) (NP (DT the) (NN head) (CC and) (NN neck)))) (VP (AUX were) (ADJP (RBR more) (JJ frequent)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN %)) (-RRB- -RRB-)))) (. .)))
6287825	9	(S1 (S (PP (IN In) (NP (NP (CD 26.5) (NN %)) (PP (IN of) (NP (PDT all) (DT the) (NNS cases))))) (, ,) (NP (NP (DT the) (NN aetiology)) (PP (IN of) (NP (DT the) (NNP Doc_6287825_1030_1040_Disease)))) (VP (AUX was) (ADJP (JJ undetermined))) (. .)))
6287825	10	(S1 (S (NP (NP (NN Heredofamilial)) (CC and) (NP (NN Doc_6287825_1078_1105_Disease))) (VP (AUX were) (ADJP (JJ rare))) (. .)))
6287825	11	(S1 (S (NP (NP (DT Some)) (PP (IN of) (NP (DT the) (NNS factors))) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ clinical) (NN presentation) (CC and) (NN pathogenesis)) (PP (IN of) (NP (DT the) (NNP Doc_6287825_1198_1210_Disease))))))) (VP (AUX are) (ADVP (RB briefly)) (VP (VBN discussed))) (. .)))
6308277	0	(S1 (NP (NP (NN Reduction)) (PP (IN in) (NP (NNP Doc_6308277_13_21_Chemical) (NNP Doc_6308277_22_30_Disease))) (PP (IN by) (NP (NNP Doc_6308277_34_47_Chemical))) (. .)))
6308277	1	(S1 (S (NP (NP (DT A) (NN patient)) (SBAR (WHNP (WP who)) (S (ADVP (RB allegedly)) (VP (VBD consumed) (NP (NP (CD 100) (NNS tablets)) (PP (IN of) (NP (NP (DT an) (JJ over-the-counter) (JJ analgesic)) (VP (VBG containing) (NP (NP (NNP Doc_6308277_138_161_Chemical)) (, ,) (NP (NNP Doc_6308277_163_171_Chemical)) (, ,) (CC and) (NP (NNP Doc_6308277_177_190_Chemical))))))))))) (VP (VBD displayed) (NP (DT no) (JJ significant) (NNS CNS) (NN stimulation)) (PP (IN despite) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (CD 175) (NNS micrograms)) (PP (IN of) (NP (NNP Doc_6308277_274_282_Chemical))) (PP (IN per) (NP (NP (NN mL)) (PP (IN of) (NP (NN serum)))))))))) (. .)))
6308277	2	(S1 (S (SBAR (IN Because) (S (NP (NNS salicylates)) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB augment) (NP (NP (DT the) (JJ stimulatory) (NNS effects)) (PP (IN of) (NP (NNP Doc_6308277_377_385_Chemical))) (PP (IN on) (NP (DT the) (NNS CNS)))))))))))) (, ,) (NP (NN attention)) (VP (AUX was) (VP (VBN focused) (PP (IN on) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNP Doc_6308277_460_473_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 52) (NN micrograms/mL)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NP (DT the) (NNS CNS) (NN Doc_6308277_509_517_Disease)) (PP (IN of) (NP (NNP Doc_6308277_521_529_Chemical))))))))))) (. .)))
6308277	3	(S1 (S (NP (NP (NNS Studies)) (PP (IN in) (NP (JJ DBA/2J) (NNS mice)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (: :) (S (LST (LS 1)) (-RRB- -RRB-) (VP (VBP pretreatment) (SBAR (IN with) (S (NP (NP (NNP Doc_6308277_588_601_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBN increased) (NP (NP (DT the) (NN interval)) (PP (IN between) (NP (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6308277_667_675_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 300) (TO to) (CD 450) (CD mg/kg)) (NN IP)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (JJ fatal) (NNP Doc_6308277_721_732_Disease))))))) (PP (IN by) (NP (NP (DT a) (NN factor)) (PP (IN of) (NP (QP (RB about) (CD two))))))))))) (PRN (: ;) (CC and) (NP (CD 2)) (-RRB- -RRB-)) (NN pretreatment)) (PP (IN with) (NP (NNP Doc_6308277_784_797_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 75) (NNS mg/kg)) (-RRB- -RRB-))) (VP (VBD reduced) (SBAR (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ audiogenic) (NNP Doc_6308277_845_853_Disease)))) (VP (VBD produced) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNP Doc_6308277_882_890_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 12.5) (TO to) (CD 75) (CD mg/kg)) (NNS IP)) (-RRB- -RRB-))))))))))))) (. .)))
6308277	4	(S1 (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (JJ sound-induced) (NNP Doc_6308277_945_953_Disease))) (PP (IN after) (NP (CD 12.5) (CC or) (CD 25)))) (VP (VBD mg/kg) (SBAR (S (NP (NNP Doc_6308277_977_985_Chemical)) (VP (AUX was) (VP (VBN reduced) (PP (IN from) (NP (QP (CD 50) (TO to) (CD 5)) (NN %))) (PP (IN by) (NP (NNP Doc_6308277_1015_1028_Chemical)))))))) (. .)))
6308277	5	(S1 (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_6308277_1048_1056_Chemical))))) (, ,) (NP (NP (NNP Doc_6308277_1058_1071_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 300)) (NN mg/kg)) (-RRB- -RRB-))) (VP (VP (AUX did) (RB not) (VP (VB modify) (NP (NP (DT the) (NN Doc_6308277_1109_1117_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ maximal) (NN electroshock))))))) (CC and) (VP (AUX did) (RB not) (VP (VB alter) (NP (NP (DT the) (JJ convulsant) (NN dose)) (PP (IN of) (NP (NNP Doc_6308277_1191_1208_Chemical))) (PP (IN in) (NP (NP (NNS mice)) (PRN (-LRB- -LRB-) (NP (NP (NNS tests)) (VP (VBN performed) (PP (IN by) (NP (NP (DT the) (JJ Anticonvulsant) (NN Screening) (NN Project)) (PP (IN of) (NP (NNS NINCDS))))))) (-RRB- -RRB-)))))))) (. .)))
6308277	6	(S1 (S (NP (NP (NN Doc_6308277_1286_1299_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 150)) (NN micrograms/mL)) (-RRB- -RRB-))) (VP (AUX did) (RB not) (VP (VB retard) (NP (NP (DT the) (NN incorporation)) (PP (IN of) (NP (JJ radioactive) (NNP Doc_6308277_1374_1383_Chemical)))) (PP (IN into) (NP (NNP Doc_6308277_1389_1392_Chemical))) (PP (IN in) (NP (NP (NNS slices)) (PP (IN of) (NP (NN rat) (NN cerebral) (NN cortex))))))) (. .)))
6308277	7	(S1 (S (ADVP (RB Thus)) (NP (NP (DT the) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_6308277_1455_1468_Chemical)) (VP (VBZ antagonizes) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NNP Doc_6308277_1496_1504_Chemical)))) (PP (IN in) (NP (DT the) (NNS CNS))))))) (VP (VBZ remains) (ADJP (JJ unknown))) (. .)))
6386793	0	(S1 (NP (NP (DT A) (JJ double-blind) (NN study)) (PP (IN of) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_6386793_51_74_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ major) (NN Doc_6386793_101_120_Disease))))))) (. .)))
6386793	1	(S1 (S (PP (IN In) (NP (DT a) (JJ 6-week) (JJ double-blind) (JJ parallel) (NN treatment) (NN study))) (, ,) (NP (NP (NNP Doc_6386793_173_182_Chemical)) (CC and) (NP (NNP Doc_6386793_187_200_Chemical))) (VP (AUX were) (VP (VBN compared) (PP (TO to) (NP (NP (NN placebo)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (CD 33) (JJ Doc_6386793_249_258_Disease) (NNS outpatients))))))))) (. .)))
6386793	2	(S1 (S (S (NP (NP (NNP Doc_6386793_272_281_Chemical)) (CC and) (NP (NNP Doc_6386793_286_299_Chemical))) (VP (AUX were) (ADJP (RB equally) (JJ effective) (PP (IN in) (S (VP (VBG alleviating) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_6386793_354_372_Disease)))))))))) (, ,) (CC and) (S (NP (DT both)) (VP (AUX were) (ADJP (RB significantly) (JJ superior) (PP (TO to) (NP (NN placebo)))))) (. .)))
6386793	3	(S1 (S (NP (NP (NP (DT The) (JJ overall) (NN incidence)) (PP (IN of) (NP (NN side) (NNS effects)))) (CC and) (NP (NP (DT the) (NN frequency) (CC and) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_6386793_495_509_Disease)) (, ,) (NP (NNP Doc_6386793_511_520_Disease)) (, ,) (CC and) (NP (NN drowsiness)))))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR less) (PP (IN with) (NP (NNP Doc_6386793_566_575_Chemical)))) (PP (IN than) (PP (IN with) (NP (NNP Doc_6386793_586_599_Chemical)))))) (. .)))
6386793	4	(S1 (S (NP (NN Doc_6386793_601_610_Chemical)) (ADVP (RB also)) (VP (VBD produced) (NP (NP (JJR fewer) (NNS CNS)) (CC and) (NP (JJ cardiovascular) (NNS effects)))) (. .)))
6386793	5	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (ADJP (RB clinically) (JJ important)) (NNS changes)) (PP (IN in) (NP (NN laboratory) (NNS parameters))))) (. .)))
6386793	6	(S1 (S (NP (NN Doc_6386793_732_741_Chemical)) (ADVP (RB thus)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ effective) (JJ Doc_6386793_776_790_Chemical) (NN drug)) (VP (VBN associated) (PP (IN with) (NP (NP (JJR fewer) (NN side) (NNS effects)) (PP (IN than) (NP (NP (NNP Doc_6386793_836_849_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ Doc_6386793_870_879_Disease) (NNS outpatients)))))))))))))))) (. .)))
6387529	0	(S1 (NP (NP (JJ Behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_6387529_22_30_Chemical) (CC and) (NNP Doc_6387529_35_46_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_6387529_64_78_Disease)) (CC and) (NP (NNP Doc_6387529_83_94_Disease)))))) (. .)))
6387529	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ oral) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_6387529_125_133_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ single) (NN dose)) (PP (IN of) (NP (NP (CD 10) (NNS mg)) (CC and) (NP (NP (DT a) (JJ median) (NN dose)) (PP (IN of) (NP (CD 30) (NN mg/day)))))) (PP (IN for) (NP (CD 2) (NNS weeks)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_6387529_204_215_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ single) (NN dose)) (PP (IN of) (NP (NP (CD 80) (NNS mg)) (CC and) (NP (NP (DT a) (JJ median) (NN dose)) (PP (IN of) (NP (CD 240) (NN mg/day)))))) (PP (IN for) (NP (CD 2) (NNS weeks)))) (-RRB- -RRB-))))))) (PP (IN on) (NP (NP (JJ psychological) (NN performance)) (PP (IN of) (NP (NNS patients))) (PP (IN with) (NP (NNP Doc_6387529_329_344_Disease) (CC and) (NNP Doc_6387529_349_360_Disease)))))) (VP (AUX were) (VP (VBN investigated) (PP (IN in) (NP (DT a) (JJ double-blind) (, ,) (JJ randomized) (CC and) (NN crossover) (NN design))))) (. .)))
6387529	2	(S1 (S (S (NP (DT Both) (NNS drugs)) (VP (VBP Doc_6387529_442_472_Disease))) (CC but) (S (NP (DT the) (NN decrease)) (VP (AUX was) (ADJP (JJR greater) (PP (IN for) (NP (NNP Doc_6387529_506_514_Chemical))) (PP (IN than) (NP (NNP Doc_6387529_520_531_Chemical)))))) (. .)))
6387529	3	(S1 (S (NP (NP (NN Doc_6387529_533_570_Disease)) (CC but) (NP (DT the) (CD two) (NNS drugs))) (VP (AUX did) (RB not) (VP (VB differ))) (. .)))
6387529	4	(S1 (S (NP (NNS Patients)) (VP (VBD tapped) (ADVP (RBR faster)) (PP (IN after) (NP (NNP Doc_6387529_634_645_Chemical))) (SBAR (IN than) (S (NP (NNP Doc_6387529_651_659_Chemical) (CC and) (PRP they)) (VP (AUX were) (ADJP (RBR more) (JJ sedated)) (PP (IN after) (NP (NP (NNP Doc_6387529_693_701_Chemical)) (PP (IN than) (NP (NNP Doc_6387529_707_718_Chemical))))))))) (. .)))
6387529	5	(S1 (S (PP (IN After) (NP (NP (CD 2) (NNS weeks)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (NNS patients)) (VP (VBD tested) (NP (JJ 5-8) (NNP h)) (SBAR (IN after) (S (NP (NP (DT the) (JJ last) (NN dose)) (PP (IN of) (NP (NN medication)))) (VP (AUX did) (RB not) (VP (VB show) (NP (NP (DT any) (NN decrement)) (PP (IN of) (NP (NN performance))))))))) (. .)))
6387529	6	(S1 (S (NP (DT These) (NNS results)) (VP (AUX are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (ADVP (RB previously)) (VBN found) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))))) (. .)))
6387529	7	(S1 (S (NP (NP (NN Accumulation)) (PP (IN of) (NP (NNS drugs)))) (VP (AUX was) (RB not) (VP (VBN reflected) (PP (IN in) (NP (JJ prolonged) (NNP Doc_6387529_973_994_Disease))))) (. .)))
6466532	0	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (NNP i.v.) (NNP Doc_6466532_19_33_Chemical) (CC and) (NNP Doc_6466532_38_46_Chemical)) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_6466532_68_79_Disease) (CC and) (NNP Doc_6466532_84_95_Disease) (NN following)))))))) (VP (VBD repeated) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_6466532_124_137_Chemical)) (PP (IN in) (NP (NNS children))))))) (. .)))
6466532	1	(S1 (S (NP (NP (DT The) (NN effectiveness)) (PP (IN of) (NP (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_6466532_190_204_Chemical) (CD 5)))) (CC and) (NP (NP (ADJP (ADJP (NP (CD 10) (NNS micrograms)) (JJ kg-1)) (CC and) (ADJP (NP (QP (JJ Doc_6466532_234_242_Chemical) (CD 10) (CC and) (CD 20)) (NNS micrograms)) (JJ kg-1))) (NNS i.v.)) (PP (ADVP (RB immediately)) (IN before) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN anaesthesia)))))))) (, ,) (SBAR (S (VP (TO to) (VP (VB prevent) (NP (NP (NNP Doc_6466532_334_344_Disease) (CC and) (NNP Doc_6466532_349_360_Disease) (JJ following) (VBN repeated) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_6466532_389_402_Chemical)) (PP (IN in) (NP (NNS children)))))))))) (, ,)) (VP (AUX was) (VP (VBN studied))) (. .)))
6466532	2	(S1 (S (NP (DT A) (NN control) (NN group)) (VP (AUX was) (VP (VBN included) (PP (IN for) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (DT the) (JJR lower) (NN dose) (NN range)) (PP (IN of) (NP (NP (NNP Doc_6466532_502_516_Chemical)) (CC and) (NP (NNP Doc_6466532_521_529_Chemical)))))))))) (. .)))
6466532	3	(S1 (S (S (NP (NP (DT A) (NN frequency)) (PP (IN of) (NP (NP (NNP Doc_6466532_546_557_Disease)) (PP (IN of) (NP (CD 50) (NN %)))))) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (DT the) (NN control) (NN group)))))) (, ,) (CC but) (S (NP (DT this)) (VP (AUX was) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (DT the) (NN frequency))) (PP (IN with) (NP (DT the) (JJ active) (NNS drugs)))))) (. .)))
6466532	4	(S1 (S (NP (NP (NN Doc_6466532_680_691_Disease)) (PRN (-LRB- -LRB-) (VP (VBN defined) (PP (IN as) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN heart) (NN rate))) (PP (TO to) (NP (QP (JJR less) (IN than) (CD 50)) (NN beat) (NN min-1)))))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN prevented) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (JJR larger) (NN dose)) (PP (IN of) (NP (DT either) (JJ active) (NN drug)))) (VP (AUX was) (VP (VBN used))))))) (. .)))
6466532	5	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN recommended) (SBAR (IN that) (S (S (NP (DT either) (NNP Doc_6466532_854_868_Chemical) (CD 10)) (VP (VBZ micrograms) (ADJP (JJ kg-1)))) (CC or) (S (NP (NNP Doc_6466532_891_899_Chemical) (CD 20)) (VP (VBZ micrograms) (SBAR (S (NP (JJ kg-1) (NNS i.v.)) (VP (MD should) (ADVP (RB immediately)) (VP (VB precede) (NP (NP (NN induction)) (PP (IN of) (NP (NN anaesthesia))) (, ,) (PP (IN in) (NP (NNS children)))) (, ,) (SBAR (IN if) (S (NP (NP (DT the) (VBN repeated) (NN administration)) (PP (IN of) (NP (NNP Doc_6466532_1024_1037_Chemical)))) (VP (AUX is) (VP (VBN anticipated))))))))))))))) (. .)))
6503301	0	(S1 (NP (NP (NN Doc_6503301_0_28_Disease)) (PP (IN after) (NP (NP (JJ Doc_6503301_35_46_Chemical) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6503301_56_60_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (NNP Doc_6503301_66_74_Disease))) (. .)))
6503301	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_6503301_86_121_Disease))) (PP (IN with) (NP (JJ fatal) (NN outcome))) (PP (IN after) (NP (NNP Doc_6503301_147_158_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_6503301_160_164_Chemical)) (-RRB- -RRB-)) (NN therapy))) (PP (IN for) (NP (NNP Doc_6503301_178_186_Disease)))) (VP (AUX is) (VP (VBN reported))) (. .)))
6503301	2	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ fulminant) (JJ clinical) (NN course)) (PP (IN from) (NP (NP (NN start)) (PP (IN of) (NP (NP (NNS symptoms)) (PP (IN until) (NP (NNP Doc_6503301_267_272_Disease))))))))) (. .)))
6503301	3	(S1 (S (PP (IN At) (NP (NN autopsy))) (NP (DT the) (NN liver)) (VP (AUX was) (ADJP (ADJP (JJ enlarged)) (CC and) (ADJP (JJ firm))) (PP (IN with) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_6503301_331_348_Disease)))))) (. .)))
6503301	4	(S1 (S (NP (ADJP (JJ Small-) (CC and) (JJ medium-sized)) (JJ hepatic) (NNS veins)) (VP (AUX were) (VP (VBN blocked) (PP (IN by) (NP (NNP Doc_6503301_404_414_Disease))))) (. .)))
6503301	5	(S1 (S (NP (JJ Eosinophilic) (NNS infiltrations)) (VP (AUX were) (VP (VBN found) (PP (IN around) (NP (DT the) (NNS vessels))))) (. .)))
6503301	6	(S1 (S (S (NP (NP (JJ Published) (NNS cases)) (PP (IN from) (NP (DT the) (NN literature)))) (VP (AUX are) (VP (VBN reviewed)))) (CC and) (S (NP (JJ pertinent) (NNS features)) (VP (VBN discussed))) (. .)))
6518066	0	(S1 (NP (NP (NP (JJ Maternal) (NN Doc_6518066_9_16_Chemical)) (CC and) (NP (JJ neonatal) (NN Doc_6518066_30_47_Disease))) (: :) (NP (NP (NN evaluation)) (PP (IN with) (NP (JJ cross-sectional) (NN echocardiography)))) (. .)))
6518066	1	(S1 (S (NP (JJ Cross-sectional) (NN echocardiography)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (CD two) (NNS neonates)) (SBAR (WHNP (WP$ whose) (NNS mothers)) (S (VP (VBD ingested) (NP (NNP Doc_6518066_189_196_Chemical)) (PP (IN during) (NP (NN pregnancy)))))))))))) (. .)))
6518066	2	(S1 (S (PP (IN In) (NP (CD one) (NN infant))) (, ,) (NP (NP (NNP Doc_6518066_230_247_Disease)) (PP (IN of) (NP (DT the) (JJ tricuspid) (NN valve)))) (VP (AUX was) (VP (VBN identified))) (. .)))
6518066	3	(S1 (S (PP (IN In) (NP (DT the) (JJ other) (NN infant))) (NP (JJ cross-sectional) (NN echocardiography)) (VP (VBD provided) (NP (NN reassurance)) (SBAR (IN that) (S (NP (DT the) (NN infant)) (VP (AUX did) (RB not) (VP (AUX have) (NP (NN Doc_6518066_390_407_Disease))))))) (. .)))
6518066	4	(S1 (S (NP (NP (JJ Cross-sectional) (JJ echocardiographic) (NN screening)) (PP (IN of) (NP (NP (NNS newborns)) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_6518066_476_483_Chemical))) (PP (IN during) (NP (NN gestation))))))) (VP (MD can) (VP (VB provide) (NP (NP (ADJP (RB highly) (JJ accurate)) (, ,) (JJ noninvasive) (NN assessment)) (PP (IN of) (NP (NP (DT the) (NN presence) (CC or) (NN absence)) (PP (IN of) (NP (NNP Doc_6518066_583_590_Chemical-induced) (NNP Doc_6518066_599_620_Disease)))))))) (. .)))
6534871	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NN training))) (PP (IN on) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (JJ experimental) (NNP Doc_6534871_50_71_Disease)) (PP (IN in) (NP (VBG aging) (NNS rats))))))) (. .)))
6534871	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN exercise))) (PP (IN on) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_6534871_130_143_Chemical-induced) (NNP Doc_6534871_152_173_Disease)))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (NP (JJ female) (NN albino) (NNS rats)) (PP (IN of) (NP (CD 20,40,60)))) (CC and) (NP (NP (CD 80) (NNS weeks)) (PP (IN of) (NP (NN age)))))))) (. .)))
6534871	2	(S1 (S (NP (DT The) (NNS rats)) (VP (AUX were) (VP (VBN trained) (S (VP (TO to) (VP (VBP swim) (PP (PP (IN for) (NP (DT a) (JJ specific) (NN duration))) (CC and) (PP (IN for) (NP (DT a) (JJ particular) (NN period))))))))) (. .)))
6534871	3	(S1 (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NNP Doc_6534871_343_351_Disease)))) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (JJ histological) (NNS methods))))) (. .)))
6534871	4	(S1 (S (NP (NP (NNS Elevations)) (PP (IN in) (NP (DT the) (NN serum)))) (VP (VP (VBD GOT)) (CC and) (VP (VBD GPT) (SBAR (S (VP (AUX were) (ADJP (JJ maximum)) (PP (IN in) (NP (NP (DT the) (NN sedentary-Doc_6534871_458_472_Chemical) (CC and) (NN minimum)) (PP (IN in) (NP (DT the) (NNS exercise-controls)))))))))) (. .)))
6534871	5	(S1 (S (NP (NP (DT These) (NNS changes)) (PP (IN in) (NP (DT the) (JJ serum) (NNS transaminases)))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (JJ corresponding) (NNS depletions)) (PP (IN in) (NP (DT the) (JJ cardiac) (NNP GOT) (CC and) (NNP GPT))))))) (. .)))
6534871	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NN age)) (VP (AUX was) (VP (VBN seen) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NNS responses)) (VP (VBN exhibited) (PP (IN by) (NP (DT the) (JJ young) (CC and) (JJ old) (NNS rats))))))))))) (. .)))
6534871	7	(S1 (S (NP (NP (NNS Studies)) (VP (VBG dealing) (PP (IN with) (NP (NNP Doc_6534871_738_759_Disease))))) (VP (AUX are) (ADJP (RBR more) (JJ informative)) (SBAR (WHADVP (WRB when)) (S (VP (VBN dealt) (PP (IN with) (NP (NN age))))))) (. .)))
6538499	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_6538499_10_33_Chemical))) (PP (IN on) (NP (NP (NNP Doc_6538499_37_47_Chemical) (NNP Doc_6538499_48_56_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
6538499	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (DT a) (ADJP (RB widely) (VBN used)) (JJ organic) (JJ solvent)) (, ,) (NP (NP (NNP Doc_6538499_111_134_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6538499_136_143_Chemical)) (-RRB- -RRB-))) (, ,))) (PP (IN on) (NP (NP (DT the) (JJ toxic) (NN action)) (PP (IN of) (NP (NP (DT an) (ADJP (ADJP (JJ acute)) (CC or) (ADJP (JJ chronic))) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_6538499_204_214_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6538499_216_219_Chemical)) (-RRB- -RRB-))))))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NNS mice))))) (. .)))
6538499	2	(S1 (S (NP (NN Doc_6538499_244_251_Chemical)) (ADVP (RB impressively)) (VP (VBD decreased) (NP (NP (DT both) (JJ acute) (NN high-dose)) (CC and) (NP (JJ chronic) (JJ low-dose-Doc_6538499_317_320_Chemical-associated) (NN lethality)))) (. .)))
6538499	3	(S1 (S (NP (JJ Light) (JJ microscopic) (NN analysis)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN protection)) (PP (IN against) (NP (NNP Doc_6538499_410_413_Chemical-induced) (NNP Doc_6538499_422_455_Disease))))) (. .)))
6538499	4	(S1 (S (NP (JJ Such) (NN treatment)) (VP (AUX did) (RB not) (VP (VB diminish) (NP (NP (DT the) (JJ Doc_6538499_493_496_Chemical) (NN antitumor) (NN activity)) (PP (PP (IN in) (NP (NNP Doc_6538499_519_533_Disease))) (CC and) (PP (IN in) (NP (NNP Doc_6538499_541_562_Disease))))))) (. .)))
6634932	0	(S1 (NP (NP (NP (JJ Sublingual) (NN absorption)) (PP (IN of) (NP (DT the) (JJ Doc_6634932_29_48_Chemical) (JJ antiarrhythmic) (NN agent)))) (, ,) (NP (NNP Doc_6634932_71_77_Chemical)) (. .)))
6634932	1	(S1 (S (NP (NP (NP (NNP Doc_6634932_79_85_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6634932_87_110_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ quaternary) (JJ antiarrhythmic) (NN agent)) (, ,)) (VP (AUX was) (VP (VBN administered) (ADVP (RB sublingually)) (PP (TO to) (NP (NP (NNS dogs)) (PP (IN with) (NP (NNP Doc_6634932_191_198_Chemical-induced) (NNP Doc_6634932_207_231_Disease))))))) (. .)))
6634932	2	(S1 (S (NP (CC Both) (NP (JJ anti-arrhythmic) (NN efficacy)) (CC and) (NP (NN bioavailability))) (VP (AUX were) (PP (VBN compared) (PP (TO to) (NP (JJ oral) (NN drug))))) (. .)))
6634932	3	(S1 (S (NP (NNP Sublingual) (NNP Doc_6634932_322_328_Chemical)) (VP (VBD converted) (NP (NNP Doc_6634932_339_362_Disease)) (PP (TO to) (NP (JJ sinus) (NN rhythm))) (PP (IN in) (NP (DT all) (CD 5) (NNS dogs)))) (. .)))
6634932	4	(S1 (S (NP (NP (DT The) (NN area)) (PP (IN under) (NP (DT the) (NN plasma) (NN concentration) (NN time) (NN curve))) (PP (IN at) (NP (CD 90) (NN min)))) (VP (AUX was) (ADJP (ADJP (QP (CD 4-12) (NNS times)) (JJR greater)) (PP (IN than) (PP (IN for) (NP (JJ oral) (NN drug))))) (, ,) (S (VP (VP (VBG suggesting) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT an) (JJ absorption-limiting) (NN process)) (PP (IN in) (NP (DT the) (NN intestine))))))) (, ,) (CC and) (VP (VBG providing) (NP (NP (DT an) (JJ alternate) (NN form)) (PP (IN of) (NP (NP (NN administration)) (PP (IN for) (NP (JJ quaternary) (NNS drugs)))))))))) (. .)))
6640832	0	(S1 (S (NP (JJ Early) (NN adjuvant)) (VP (NNP Doc_6640832_15_25_Chemical) (PP (IN in) (NP (JJ superficial) (NNP Doc_6640832_41_58_Disease)))) (. .)))
6640832	1	(S1 (S (NP (DT A) (NN multicenter) (NN study)) (VP (AUX was) (VP (VBN performed) (PP (IN in) (NP (CD 110) (NNS patients))) (PP (IN with) (NP (JJ superficial) (JJ transitional) (NN cell) (NN Doc_6640832_145_169_Disease))))) (. .)))
6640832	2	(S1 (S (NP (NP (NN Doc_6640832_171_181_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CD mg/50)) (NN ml)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (ADVP (RB intravesically)) (PP (IN within) (NP (NP (CD 24) (NNP h)) (PP (IN after) (NP (NP (JJ transurethral) (NN resection)) (PP (IN of) (NP (NNP TA-T1) (PRN (-LRB- -LRB-) (NP (NNP O-A)) (-RRB- -RRB-)) (NNP Doc_6640832_285_299_Disease))))))))) (. .)))
6640832	3	(S1 (S (NP (NN Instillation)) (VP (AUX was) (VP (VP (VBN repeated) (ADVP (RB twice)) (PP (IN during) (NP (DT the) (JJ first) (NN week)))) (, ,) (VP (ADVP (RB then)) (JJ weekly) (PP (IN during) (NP (DT the) (JJ first) (NN month)))) (CC and) (VP (ADVP (RB afterwards)) (JJ monthly) (PP (IN for) (NP (CD 1) (NN year)))))) (. .)))
6640832	4	(S1 (S (S (NP (DT The) (NN tolerance)) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (DT these) (CD 110) (NNS patients)))))) (, ,) (CC and) (S (NP (CD 29) (NNS patients)) (VP (VBD presented) (PP (IN with) (NP (JJ local) (NNS side-effects))))) (. .)))
6640832	5	(S1 (S (PP (IN In) (NP (NP (CD 24)) (PP (IN of) (NP (DT these) (NNS patients))))) (NP (JJ chemical) (NNP Doc_6640832_561_569_Disease)) (VP (AUX was) (ADJP (JJ severe) (RB enough) (SBAR (IN for) (S (NP (PRP them)) (VP (TO to) (VP (VB drop) (PP (IN out) (PP (IN of) (NP (DT the) (NN study)))))))))) (. .)))
6640832	6	(S1 (S (NP (DT No) (JJ systemic) (NNS side-effects)) (VP (AUX were) (VP (VBN observed))) (. .)))
6640832	7	(S1 (S (NP (NN Recurrence)) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (CD 82) (JJ evaluable) (NNS patients))) (PP (PP (IN after) (NP (NP (CD 1) (NN year)) (PP (IN of) (NP (NN follow-up))))) (CC and) (PP (IN in) (NP (NP (CD 72) (NNS patients)) (VP (VBN followed) (PP (IN for) (NP (NP (CD 2-3) (NNS years)) (PRN (-LRB- -LRB-) (NP (JJ mean) (CD 32) (NNS months)) (-RRB- -RRB-)))))))))) (. .)))
6640832	8	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 82) (NNS patients)) (VP (VBN studied) (PP (IN after) (NP (CD 1) (NN year)))))) (, ,) (NP (CD 23)) (VP (AUX had) (NP (NP (NN primary)) (CC and) (NP (CD 59) (NN recurrent) (NN disease)))) (. .)))
6640832	9	(S1 (S (PP (IN Of) (NP (DT the) (CD 82) (JJ evaluable) (NNS patients))) (, ,) (NP (CD 50)) (VP (AUX did) (RB not) (VP (VB show) (NP (DT any) (NN recurrence)) (PP (IN after) (NP (NP (CD 1) (NN year)) (PRN (-LRB- -LRB-) (NP (CD 61) (NN %)) (-RRB- -RRB-)))) (, ,) (PP (IN while) (NP (NP (CD 32)) (VP (VBN presented) (PP (IN with) (NP (NP (QP (CD one) (CC or) (JJR more)) (NNS recurrences)) (PRN (-LRB- -LRB-) (NP (CD 39) (NN %)) (-RRB- -RRB-))))))))) (. .)))
6640832	10	(S1 (S (PP (IN Of) (NP (DT these) (NNS recurrences))) (, ,) (NP (CD 27)) (VP (AUX were) (NP (NNP T1) (NNP Doc_6640832_1048_1054_Disease)) (SBAR (IN while) (S (NP (CD five)) (VP (VBD progressed) (PP (TO to) (NP (RBR more) (ADJP (RB highly) (JJ invasive)) (NNS lesions))))))) (. .)))
6640832	11	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ free) (PP (IN of) (NP (NN recurrence)))) (PP (IN during) (NP (DT the) (JJ first) (NN year)))))))) (, ,) (NP (CD 80) (NN %)) (VP (VBD remained) (ADJP (JJ Doc_6640832_1187_1192_Disease-free)) (PP (IN during) (NP (DT the) (ADJP (JJ 2-) (TO to) (JJ 3-year)) (JJ follow-up) (NN period)))) (. .)))
6640832	12	(S1 (S (PP (IN Of) (NP (NP (DT the) (NNS patients)) (VP (VBG developing) (NP (QP (CD one) (CC or) (JJR more)) (NNS recurrences)) (PP (IN during) (NP (DT the) (JJ first) (NN year)))))) (, ,) (NP (QP (RB only) (CD 50)) (NN %)) (VP (VBD presented) (PP (IN with) (NP (JJ further) (NN recurrence))) (SBAR (IN once) (S (NP (DT the) (NNS instillations)) (VP (AUX were) (VP (VBN stopped)))))) (. .)))
6640832	13	(S1 (S (NP (NP (DT The) (JJ beneficial) (NN effect)) (PP (IN of) (NP (NNP Doc_6640832_1419_1429_Chemical)))) (VP (VP (VBZ appears) (ADJP (JJ obvious))) (CC and) (VP (MD might) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (NP (DT the) (NN drug)) (NP (PRP itself))) (, ,) (NP (NP (DT the) (JJ early) (CC and) (JJ repeated) (NNS instillations)) (PP (IN after) (NP (NN TUR)))) (, ,) (CC or) (NP (DT both)))))))) (. .)))
6666578	0	(S1 (NP (NP (JJ Doc_6666578_0_15_Chemical-induced) (NN Doc_6666578_24_34_Disease)) (PP (IN in) (NP (NNS rats))) (. .)))
6666578	1	(S1 (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ high) (NN dose) (NN Doc_6666578_68_83_Chemical) (NN treatment))) (PP (PP (IN on) (NP (NP (JJ aortic) (NN permeability)) (PP (TO to) (NP (NN albumin))))) (CC and) (PP (IN on) (NP (NP (DT the) (NN ultrastructure)) (PP (IN of) (NP (DT the) (NN vessel)))))) (. .)))
6666578	2	(S1 (S (NP (JJ Male) (JJ Sprague-Dawley) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_6666578_212_227_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6666578_229_234_Chemical)) (-RRB- -RRB-)))) (NP (CD 500) (NN mg/kg/day)) (PP (IN for) (NP (QP (CD 10) (CC or) (CD 42)) (NNS days))))) (. .)))
6666578	3	(S1 (S (NP (NN Pair) (NN fed) (NNS rats)) (VP (VBD served) (PP (IN as) (NP (NNS controls)))) (. .)))
6666578	4	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (JJ aortic) (NNS morphology)))) (VP (AUX were) (VP (VBN examined) (PP (IN by) (NP (NP (NN light-)) (CC and) (NP (NP (JJ transmission-electron) (NN microscopy)) (PRN (-LRB- -LRB-) (NP (NNP TEM)) (-RRB- -RRB-))))))) (. .)))
6666578	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (JJ endothelial) (NN permeability)) (CC and) (NP (NP (DT the) (NN penetration)) (PP (IN through) (NP (NP (DT the) (JJ aortic) (NN wall)) (PP (IN of) (NP (NN albumin))))))) (VP (AUX were) (VP (VBN studied) (NP (NP (CD 10) (NNS minutes)) (, ,) (NP (CD 24) (CC and) (CD 48) (NNS hours))) (PP (IN after) (NP (NP (NN i.) (CC v.) (NN injection)) (PP (IN of) (NP (JJ human) (NN serum) (NN 131I-albumin))))) (PRN (-LRB- -LRB-) (FW 131I-HSA) (-RRB- -RRB-)))) (. .)))
6666578	6	(S1 (S (NP (NN TEM)) (VP (VBD revealed) (NP (NP (JJ extensive) (NN elastolysis)) (PP (IN in) (NP (NP (DT the) (JJ arterial) (NN wall)) (PP (IN of) (NP (JJ Doc_6666578_659_664_Chemical-treated) (NNS rats))))) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT an) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NN crosslink) (NN formation)))))))) (. .)))
6666578	7	(S1 (S (PP (IN In) (NP (JJ experimental) (NNS animals))) (NP (NP (JJ excess) (NN deposition)) (PP (IN of) (NP (NN collagen) (CC and) (NNS glycoaminoglycans)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (ADJP (JJ subendothelial) (CC and) (JJ medial)) (NN layer)) (PP (IN of) (NP (DT the) (JJ aortic) (NN wall))))) (, ,) (PP (ADVP (RB together)) (IN with) (NP (NP (JJ prominent) (JJ basal) (NN membrane) (NN substance)) (PP (IN around) (NP (JJ aortic) (JJ smooth) (NN muscle) (NNS cells))))))) (. .)))
6666578	8	(S1 (S (NP (NP (DT The) (NN aorta/serum-ratio)) (CC and) (NP (NP (DT the) (JJ radioactive) (NN build-up)) (PP (NP (CD 24) (CC and) (CD 48) (NNS hours)) (IN after) (NP (NN injection))) (PP (IN of) (NP (FW 131I-HSA))))) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6666578_1103_1108_Chemical))) (PP (IN for) (NP (CD 42) (NNS days)))))) (, ,) (S (VP (VBG indicating) (NP (NP (DT an) (VBN impeded) (JJ transmural) (NN transport)) (PP (IN of) (NP (NNP tracer))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (NP (DT a) (JJ steric) (NN exclusion) (NN effect)) (PP (IN of) (NP (JJ abundant) (NNP Doc_6666578_1236_1247_Chemical))))))))))))))) (. .)))
6666578	9	(S1 (S (S (NP (DT The) (JJ endothelial) (NN ultrastructure)) (VP (AUX was) (ADJP (JJ unaffected)) (PP (IN by) (NP (NNP Doc_6666578_1298_1303_Chemical))))) (, ,) (CC and) (S (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (JJ aortic) (JJ 131I-HSA) (NN radioactivity)) (CC or) (NP (NN aorta/serum-ratio))))) (VP (AUX were) (VP (VBN recorded) (PP (IN between) (NP (UCP (JJ experimental) (CC and) (NN control)) (NNS groups))) (SBAR (NP (CD 10) (NNS minutes)) (IN after) (S (NP (NNP tracer)) (VP (NN injection) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (DT the) (NN permeability)) (PP (IN of) (NP (NP (DT the) (JJ endothelial) (NN barrier)) (PP (TO to) (NP (NN albumin)))))) (VP (VBD remained) (ADJP (JJ unaffected)) (PP (IN by) (NP (JJ Doc_6666578_1561_1566_Chemical) (NN treatment)))))))))))))) (. .)))
6666578	10	(S1 (S (NP (DT These) (NNS observations)) (VP (VBP support) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_6666578_1654_1659_Chemical)))))) (VP (MD may) (VP (VB induce) (NP (DT a) (JJ fibroproliferative) (NN response)) (PP (IN in) (NP (NN rat) (NN aorta))) (, ,) (PP (ADVP (RB possibly)) (IN by) (NP (NP (DT an) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN cross-linking)) (PP (IN of) (NP (NN collagen) (CC and) (NN elastin))))))))))))) (. .)))
6692345	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_6692345_10_17_Chemical))) (PP (IN on) (NP (NP (JJ Doc_6692345_21_66_Chemical-induced) (JJ epithelial) (NN proliferation)) (PP (IN in) (NP (NP (DT the) (JJ urinary) (NN bladder) (CC and) (NN forestomach)) (PP (IN of) (NP (DT the) (NN rat))))))) (. .)))
6692345	1	(S1 (S (NP (NP (DT The) (NN co-administration)) (PP (IN of) (NP (NNP Doc_6692345_176_183_Chemical))) (PP (IN with) (NP (NP (NNP Doc_6692345_189_234_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6692345_236_241_Chemical)) (-RRB- -RRB-)))) (PP (TO to) (NP (NNS rats)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (VBN reduced) (NN incidence)) (PP (IN of) (NP (JJ Doc_6692345_286_291_Chemical-induced) (NN Doc_6692345_300_318_Disease)))) (CC but) (NP (NP (DT a) (JJ concomitant) (NN induction)) (PP (IN of) (NP (NNP Doc_6692345_350_368_Disease))))))) (. .)))
6692345	2	(S1 (S (NP (DT An) (JJ autoradiographic) (NN study)) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (NP (JJ male) (JJ F-344) (NNS rats)) (VP (VBN fed) (NP (NP (NN diet)) (VP (VBG containing) (NP (NNP Doc_6692345_449_454_Chemical)) (PP (IN at) (NP (NP (DT a) (NN level)) (PP (IN of) (NP (ADJP (CD 0.2) (NN %)) (NN and/or) (NN Doc_6692345_481_488_Chemical))))))) (PP (IN at) (NP (NP (DT a) (NN level)) (PP (IN of) (NP (CD 0.5) (NN %))))) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_6692345_534_541_Chemical)))) (PP (IN on) (NP (NP (DT the) (VBN increased) (NN cell) (NN proliferation)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6692345_589_594_Chemical))) (PP (IN in) (NP (DT the) (NN forestomach) (CC and) (NN bladder)))))))))))))) (. .)))
6692345	3	(S1 (S (NP (NP (JJ Doc_6692345_627_632_Chemical-induced) (NN cell) (NN proliferation)) (PP (IN in) (NP (DT the) (NN bladder)))) (VP (AUX was) (UCP (VP (ADVP (RB significantly)) (VBN suppressed) (PP (IN by) (NP (JJ Doc_6692345_707_714_Chemical) (NN co-administration))) (PP (IN after) (NP (CD 4) (NNS weeks)))) (CC but) (RB not) (PP (IN after) (NP (CD 12) (NNS weeks))))) (. .)))
6692345	4	(S1 (S (PP (PP (IN In) (NP (DT the) (NN forestomach))) (, ,) (CC and) (ADVP (RB also)) (PP (IN in) (NP (DT the) (NN liver)))) (, ,) (NP (NNP Doc_6692345_814_821_Chemical)) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (JJ Doc_6692345_841_846_Chemical-induced) (NN increase)) (PP (IN in) (S (VP (VBG labeling) (NP (NN index)))))))) (. .)))
6692345	5	(S1 (S (NP (DT The) (JJ present) (NNS results)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NN carcinogenicity) (NN experiment)) (VP (VBG suggesting) (SBAR (SBAR (IN that) (S (NP (JJ different) (NNS mechanisms)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (NNP Doc_6692345_1007_1012_Chemical) (NNP Doc_6692345_1013_1027_Disease)) (PP (IN in) (NP (DT the) (NN bladder) (CC and) (NN forestomach))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (NP (NNP Doc_6692345_1069_1076_Chemical) (POS 's)) (NN effect)) (PP (IN on) (NP (NP (NNP Doc_6692345_1089_1094_Chemical)) (PP (IN in) (NP (DT the) (NN forestomach)))))) (VP (AUX is) (RB not) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (JJ irritant) (NN effect)) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (NN cell) (NN proliferation)))))))))))))))) (. .)))
6692345	6	(S1 (S (ADVP (RB Also)) (, ,) (NP (EX there)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (NN adaptation)) (PP (IN by) (NP (NP (DT the) (NNS rats)) (PP (TO to) (NP (NP (DT the) (JJ chronic) (NN ingestion)) (PP (IN of) (NP (NN Doc_6692345_1273_1280_Chemical)))))))))))) (. .)))
6727060	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_6727060_10_28_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_6727060_39_53_Chemical)))) (. .)))
6727060	1	(S1 (S (NP (NN Doc_6727060_55_85_Disease)) (VP (VBD appeared) (PP (IN in) (NP (NP (DT the) (NN mouth) (, ,) (NN tongue) (, ,) (NN neck) (CC and) (NN abdomen)) (PP (IN of) (NP (DT a) (JJ 64-year-old) (JJ male) (NN patient))))) (SBAR (IN after) (S (NP (PRP he)) (VP (VBD took) (NP (NNP Doc_6727060_178_192_Chemical)) (PP (IN for) (NP (NNP Doc_6727060_197_222_Disease))) (PP (IN in) (NP (NP (DT a) (NN regimen)) (PP (IN of) (NP (NP (CD 30) (NNS mg)) (PP (IN per) (NP (NN day))))) (PP (IN for) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (QP (RB about) (CD 260)) (NNS days))))))))))) (. .)))
6727060	2	(S1 (S (NP (DT The) (NNS symptoms)) (VP (VBD exacerbated) (PP (TO to) (NP (DT a) (NN maximum))) (PP (IN in) (NP (DT a) (NN month)))) (. .)))
6727060	3	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (NNP Doc_6727060_343_357_Chemical) (NN administration)) (VP (AUX was) (VP (VBN discontinued))))) (, ,) (NP (DT the) (NN Doc_6727060_395_413_Disease)) (ADVP (RB gradually)) (VP (VBD improved) (PP (TO to) (NP (DT a) (JJ considerable) (NN extent)))) (. .)))
6727060	4	(S1 (S (NP (NP (NN Attention)) (PP (TO to) (NP (NP (DT the) (JJ possible) (NN induction)) (PP (IN of) (NP (JJ specific) (NNP Doc_6727060_507_525_Disease)))))) (VP (AUX is) (VP (VBN called) (PP (IN for)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (NN drug))))))) (. .)))
6747681	0	(S1 (S (NP (JJ Intra-arterial) (NNP Doc_6747681_15_19_Chemical)) (VP (VBZ chemotherapy) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_6747681_50_67_Disease)) (PP (IN of) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))) (. .)))
6747681	1	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (JJ rapid) (JJ systemic) (NN clearance)) (PP (IN of) (NP (NP (NNP Doc_6747681_142_146_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6747681_148_185_Chemical)) (-RRB- -RRB-)))))) (, ,) (NP (JJ intra-arterial) (NN administration)) (VP (MD should) (VP (VB provide) (NP (NP (DT a) (JJ substantial) (NN advantage)) (PP (IN over) (NP (NP (JJ intravenous) (NN administration)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_6747681_310_327_Disease)))))))))) (. .)))
6747681	2	(S1 (S (NP (JJ Thirty-six) (NNS patients)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_6747681_367_371_Chemical) (QP (DT every) (CD 6) (TO to) (CD 8)) (NNS weeks))) (, ,) (PP (CC either) (PP (IN by) (NP (NP (JJ transfemoral) (NN catheterization)) (PP (IN of) (NP (NP (DT the) (JJ internal) (NN carotid)) (CC or) (NP (JJ vertebral) (NN artery)))))) (CC or) (PP (IN through) (NP (DT a) (ADJP (RB fully) (JJ implantable)) (NN intracarotid) (NN drug) (NN delivery) (NN system)))) (, ,) (PP (VBG beginning) (PP (IN with) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 200) (JJ mg/sq) (NNP m) (NN body) (NN surface) (NN area)))))))) (. .)))
6747681	3	(S1 (S (NP (NP (CD Twelve) (NNS patients)) (PP (IN with) (NP (NP (NNP Grade) (NNP III)) (CC or) (NP (NNP IV) (NNP Doc_6747681_634_646_Disease))))) (VP (AUX were) (VP (VBN treated) (PP (IN after) (NP (NP (JJ partial) (NN resection)) (PP (IN of) (NP (DT the) (NNP Doc_6747681_691_696_Disease))))) (PP (IN without) (NP (JJ prior) (NN radiation) (NN therapy))))) (. .)))
6747681	4	(S1 (S (PP (IN After) (NP (NP (QP (CD two) (TO to) (CD seven)) (NNS cycles)) (PP (IN of) (NP (NN chemotherapy))))) (, ,) (NP (CD nine) (NNS patients)) (VP (VBD showed) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ Doc_6747681_808_813_Disease) (NN size)) (CC and) (NP (VBG surrounding) (NN Doc_6747681_835_840_Disease)))) (PP (IN on) (NP (JJ contrast-enhanced) (JJ computerized) (NN tomography) (NNS scans))))) (. .)))
6747681	5	(S1 (S (PP (IN In) (NP (DT the) (CD nine) (NNS responders))) (, ,) (NP (NP (JJ median) (NN duration)) (PP (IN of) (NP (JJ chemotherapy) (NN response))) (PP (IN from) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN operation)))))) (VP (AUX was) (NP (NP (CD 25) (NNS weeks)) (PRN (-LRB- -LRB-) (VP (VBP range) (NP (CD 12)) (PP (TO to) (NP (QP (JJR more) (IN than) (CD 91)) (NNS weeks)))) (-RRB- -RRB-)))) (. .)))
6747681	6	(S1 (S (NP (NP (DT The) (JJ median) (NN duration)) (PP (IN of) (NP (NN survival))) (PP (IN in) (NP (DT the) (CD 12) (NNS patients)))) (VP (AUX was) (NP (NP (CD 54) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (NP (NN range) (CD 21)) (PP (TO to) (NP (QP (JJR more) (IN than) (CD 156)) (NNS weeks)))) (-RRB- -RRB-))) (, ,) (PP (IN with) (NP (NP (DT an) (JJ 18-month) (NN survival) (NN rate)) (PP (IN of) (NP (CD 42) (NN %)))))) (. .)))
6747681	7	(S1 (S (NP (NP (JJ Twenty-four) (NNS patients)) (PP (IN with) (NP (JJ recurrent) (NNP Grade) (NNP I))) (PP (TO to) (NP (NP (NNP IV) (NNP Doc_6747681_1220_1232_Disease)) (, ,) (SBAR (WHNP (WP$ whose) (NN resection) (CC and) (NN irradiation) (NN therapy)) (S (VP (AUX had) (VP (VBN failed))))) (, ,)))) (VP (VBD received) (NP (NP (QP (CD two) (TO to) (CD eight)) (NNS courses)) (PP (IN of) (NP (JJ intra-arterial) (JJ Doc_6747681_1334_1338_Chemical) (NN therapy))))) (. .)))
6747681	8	(S1 (S (NP (NP (CD Seventeen)) (PP (IN of) (NP (DT these)))) (VP (VP (AUX had) (NP (DT a) (NN response))) (CC or) (VP (AUX were) (ADJP (JJ stable)) (PP (IN for) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (NP (CD 20) (NNS weeks)) (PRN (-LRB- -LRB-) (VP (VBP range) (NP (CD 6)) (PP (TO to) (NP (QP (JJR more) (IN than) (CD 66)) (NNS weeks)))) (-RRB- -RRB-)))))))) (. .)))
6747681	9	(S1 (S (NP (DT The) (NN catheterization) (NN procedure)) (VP (AUX is) (ADJP (JJ safe)) (, ,) (PP (IN with) (NP (NP (DT no) (JJ immediate) (NN complication)) (PP (IN in) (NP (NP (CD 111) (NNS infusions)) (PP (IN of) (NP (NNP Doc_6747681_1545_1549_Chemical)))))))) (. .)))
6747681	10	(S1 (S (NP (NP (DT A) (JJ delayed) (NN complication)) (PP (IN in) (NP (CD nine) (NNS patients)))) (VP (AUX has) (VP (AUX been) (NP (NP (JJ unilateral) (NN Doc_6747681_1611_1625_Disease)) (ADJP (JJ secondary) (PP (TO to) (NP (DT a) (NN Doc_6747681_1641_1659_Disease))))))) (. .)))
6747681	11	(S1 (S (NP (NP (DT The) (NN frequency)) (PP (IN of) (NP (NNP Doc_6747681_1678_1689_Disease)))) (VP (VBD decreased) (SBAR (IN after) (S (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (DT the) (JJ Doc_6747681_1731_1738_Chemical) (NN diluent)))) (VP (AUX was) (VP (VBN lowered)))))) (. .)))
6773726	0	(S1 (NP (NP (NN Provocation)) (PP (IN of) (NP (JJ postural) (NNP Doc_6773726_24_35_Disease))) (PP (IN by) (NP (NP (NNP Doc_6773726_39_52_Chemical)) (PP (IN in) (NP (NNP Doc_6773726_56_85_Disease))))) (. ?)))
6773726	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_6773726_101_114_Chemical))) (PP (IN on) (NP (NP (NN heart) (NN rate)) (CC and) (NP (JJ systolic) (NN blood) (NN pressure))))) (VP (AUX was) (VP (VBN compared) (PP (IN in) (NP (NP (CD 5) (JJ normal) (NNS subjects)) (, ,) (NP (NP (CD 12) (JJ Doc_6773726_195_203_Disease) (NNS subjects)) (PP (IN without) (NP (NNP Doc_6773726_221_241_Disease)))) (, ,) (CC and) (NP (NP (CD 5) (JJ Doc_6773726_249_257_Disease) (NNS subjects)) (PP (IN with) (NP (NNP Doc_6773726_272_292_Disease)))))))) (. .)))
6773726	2	(S1 (S (NP (NP (DT The) (NN magnitude) (CC and) (NN time) (NN course)) (PP (IN of) (NP (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN heart) (NN rate)))) (CC and) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (JJ systolic) (NN blood) (NN pressure)))))) (PP (IN after) (NP (NNP Doc_6773726_404_417_Chemical)))) (VP (AUX were) (ADJP (JJ similar) (PP (IN in) (NP (NP (DT the) (JJ normal) (CC and) (JJ Doc_6773726_449_457_Disease) (NNS subjects)) (PP (IN without) (NP (NNP Doc_6773726_475_495_Disease)))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (DT a) (JJR lesser) (NN increase)) (PP (IN in) (NP (NN heart) (NN rate)))) (CC and) (NP (NP (DT a) (JJR greater) (NN decrease)) (PP (IN in) (NP (JJ systolic) (NN blood) (NN pressure))))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (JJ Doc_6773726_603_611_Disease) (NNS subjects)) (PP (IN with) (NP (NNP Doc_6773726_626_646_Disease))))))))) (. .)))
6773726	3	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB therefore)) (VP (VBN suggested) (SBAR (IN that) (S (NP (NN caution)) (VP (MD should) (VP (AUX be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NN vasodilator) (NNS drugs)) (PP (IN in) (NP (NP (JJ Doc_6773726_745_753_Disease) (NNS patients)) (, ,) (ADVP (RB particularly)) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_6773726_788_808_Disease)))))))))))))))) (. .)))
6861444	0	(S1 (S (NP (NN Blood)) (VP (VBP pressure) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ chronic) (JJ low-dose) (JJ intrarenal) (JJ Doc_6861444_55_68_Chemical) (NN infusion)) (PP (IN in) (NP (JJ conscious) (NNS rats))))))) (. .)))
6861444	1	(S1 (S (NP (NP (JJ Doc_6861444_97_112_Chemical) (NN solution)) (PRN (-LRB- -LRB-) (NP (CD 0.9) (NN %)) (-RRB- -RRB-)) (CC or) (NP (NP (NNP Doc_6861444_132_145_Chemical)) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 4) (, ,) (CD 12) (CC and) (CD 36) (NNS micrograms)))))) (JJ h-1) (JJ kg-1)) (VP (AUX was) (VP (VBN infused) (PP (IN for) (NP (CD five) (JJ consecutive) (NNS days))) (, ,) (ADVP (ADVP (RB either) (RB intrarenally) (-LRB- -LRB-) (PP (IN by) (NP (DT a) (JJ new) (NN technique))) (-RRB- -RRB-)) (CC or) (ADVP (RB intravenously))) (PP (IN into) (NP (NNS rats))) (PP (IN with) (NP (NP (CD one) (NN kidney)) (VP (VBN removed)))))) (. .)))
6861444	2	(S1 (S (NP (NP (JJ Intrarenal) (NN infusion)) (PP (IN of) (NP (NNP Doc_6861444_346_359_Chemical)))) (VP (VBD caused) (NP (NN Doc_6861444_367_379_Disease)) (PP (IN at) (NP (NP (NNS doses)) (SBAR (WHNP (WDT which)) (S (VP (AUX did) (RB not) (VP (AUX do) (ADVP (RB so)))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN infused) (ADVP (RB intravenously)))))) (. .)))
6861444	3	(S1 (S (NP (NP (NN Intrarenal)) (VP (VBN compared) (PP (IN with) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NNP Doc_6861444_486_499_Chemical))))))) (VP (VBD caused) (NP (NP (JJR higher) (NN plasma) (NN Doc_6861444_521_534_Chemical) (NNS concentrations)) (CC and) (NP (NP (DT a) (NN shift)) (PP (IN of) (NP (DT the) (NN plasma) (JJ Doc_6861444_576_589_Chemical) (NN concentration-blood) (NN pressure) (NN effect) (NN curve))) (PP (IN towards) (NP (JJR lower) (NN plasma) (JJ Doc_6861444_653_666_Chemical) (NNS levels)))))) (. .)))
6861444	4	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN Doc_6861444_702_714_Disease)) (PP (IN after) (NP (JJ chronic) (JJ intrarenal) (JJ Doc_6861444_740_753_Chemical) (NN infusion)))) (VP (AUX is) (VP (VBN produced) (PP (PP (IN by) (NP (NP (ADJP (RB relatively) (JJR higher)) (NNS levels)) (PP (IN of) (NP (VBG circulating) (NNP Doc_6861444_818_831_Chemical))))) (CC and) (PP (IN by) (NP (NP (VBG triggering)) (PP (IN of) (NP (DT an) (JJ additional) (NN intrarenal) (NN pressor) (NN mechanism))))))))))) (. .)))
6888657	0	(S1 (NP (NP (NN Characterization)) (PP (IN of) (NP (NP (NNP Doc_6888657_20_28_Chemical-induced) (NNP Doc_6888657_37_60_Disease)) (PP (IN in) (NP (DT the) (NNP Fischer) (CD 344) (NN rat))))) (. .)))
6888657	1	(S1 (S (NP (NN Doc_6888657_85_101_Disease)) (VP (AUX were) (VP (VBN induced) (PP (IN in) (NP (CD F344) (JJ female) (NNS rats))) (PP (IN by) (NP (NP (JJ chronic) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_6888657_161_179_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_6888657_181_184_Chemical)) (, ,) (NP (CD 8-10) (NN mg))) (-RRB- -RRB-)))) (VP (VBN implanted) (ADVP (RB subcutaneously)) (PP (IN in) (NP (JJ silastic) (NNS capsules)))))))) (. .)))
6888657	2	(S1 (S (PP (IN Over) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (CD 1-150) (NNS days)) (PP (IN of) (NP (JJ Doc_6888657_272_275_Chemical) (NN treatment))))))) (, ,) (S (NP (NP (NNS pairs)) (PP (IN of) (NP (NP (NN control)) (CC and) (NP (JJ Doc_6888657_308_311_Chemical-treated) (NNS rats))))) (VP (AUX were) (VP (VBN sacrificed)))) (, ,) (CC and) (S (NP (PRP$ their) (NNS pituitaries)) (VP (VBD dissociated) (ADVP (RB enzymatically)) (PP (IN into) (NP (JJ single-cell) (NNS preparations))))) (. .)))
6888657	3	(S1 (S (NP (DT The) (NN cell) (NNS populations)) (VP (AUX were) (VP (VBN examined) (PP (VBG regarding) (NP (NP (JJ total) (NN cell) (NN recovery)) (VP (VBN correlated) (PP (IN with) (NP (NP (JJ gland) (NN weight)) (, ,) (NP (JJ intracellular) (NN prolactin) (PRN (-LRB- -LRB-) (NNP PRL) (-RRB- -RRB-)) (NN content)) (CC and) (NP (NP (JJ subsequent) (NN release)) (PP (IN in) (NP (NP (JJ primary) (NN culture)) (, ,) (NP (JJ immunocytochemical) (NN PRL) (NN staining)) (, ,) (NP (NP (NN density) (NN and/or) (NN size) (NNS alterations)) (PP (IN via) (NP (NP (NN separation)) (PP (PP (IN on) (NP (NNP Ficoll-Hypaque))) (CC and) (PP (IN by) (NP (NN unit) (NN gravity) (NN sedimentation))))))) (, ,) (CC and) (NP (NN cell) (NN cycle) (NN analysis)) (, ,)))))) (PP (IN after) (NP (JJ Doc_6888657_761_772_Chemical) (NN DNA) (NN staining))) (, ,) (PP (IN by) (NP (NN laser) (NN flow) (NN cytometry)))))))) (. .)))
6888657	4	(S1 (S (NP (NP (JJ Total) (NN cell) (NNS yields)) (PP (IN from) (NP (JJ Doc_6888657_835_838_Chemical-treated) (NNS pituitaries)))) (VP (VBN increased) (PP (IN from) (NP (QP (CD 1.3) (NNS times)) (NN control) (NNS yields))) (PP (IN at) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NN treatment))))) (PP (TO to) (NP (QP (CD 58.9) (NNS times)) (NN control) (NNS values))) (PP (IN by) (NP (NN day) (CD 150)))) (. .)))
6888657	5	(S1 (S (S (NP (JJ Intracellular) (NN PRL) (NN content)) (VP (VBN ranged) (PP (IN from) (NP (QP (CD 1.9) (TO to) (CD 9.4) (NNS times)) (NN control) (NNS levels))))) (, ,) (CC and) (S (NP (NP (NN PRL) (NN release)) (PP (IN in) (NP (NN vitro)))) (VP (AUX was) (ADVP (RB significantly) (CC and) (RB consistently)) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NNS controls)))) (, ,) (PP (IN after) (NP (NP (QP (IN at) (JJS least) (CD 8)) (NNS days)) (PP (IN of) (NP (NNP Doc_6888657_1141_1144_Chemical) (NN exposure))))))) (. .)))
6888657	6	(S1 (S (PP (IN Beyond) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NNP Doc_6888657_1172_1175_Chemical) (NN exposure))))) (, ,) (NP (NP (DT the) (ADJP (RB immunochemically) (JJ PRL-positive)) (NN proportion)) (PP (IN of) (NP (NNS cells)))) (VP (VBD increased) (PP (TO to) (NP (NP (QP (IN over) (CD 50)) (NN %)) (PP (IN of) (NP (DT the) (JJ total) (NN population)))))) (. .)))
6888657	7	(S1 (S (NP (NP (VBN Increased) (NN density) (NN and/or) (NN size)) (CC and) (NP (NN PRL) (NN content))) (VP (AUX were) (VP (VBN indicated) (PP (IN for) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (DT the) (NN PRL) (NN cell) (NN population))) (PP (IN in) (NP (NP (DT both) (NNS types)) (PP (IN of) (NP (NN separation) (NNS protocols))))))))) (. .)))
6888657	8	(S1 (S (NP (NP (PDT All) (DT these) (NNS effects)) (PP (IN of) (NP (NNP Doc_6888657_1452_1455_Chemical)))) (VP (AUX were) (ADJP (RBR more) (JJ pronounced)) (PP (IN among) (NP (ADJP (RB previously) (VBN ovariectomized)) (NNS animals)))) (. .)))
6888657	9	(S1 (S (NP (DT The) (NNS data)) (VP (VBP extend) (NP (NP (DT the) (NNS findings)) (PP (IN of) (NP (JJ other) (NNS investigators)))) (, ,) (S (ADVP (RB further)) (VP (VBG establishing) (NP (DT the) (JJ Doc_6888657_1596_1599_Chemical-induced) (NN Doc_6888657_1608_1613_Disease)) (PP (IN as) (NP (NP (DT a) (NN model)) (PP (IN for) (NP (NP (NN study)) (PP (IN of) (NP (NNP PRL) (JJ cellular) (NN control) (NNS mechanisms)))))))))) (. .)))
7053303	0	(S1 (NP (NP (NP (NN Age)) (CC and) (NP (JJ renal) (NN clearance))) (PP (IN of) (NP (NNP Doc_7053303_27_37_Chemical))) (. .)))
7053303	1	(S1 (S (PP (IN In) (NP (NP (NP (CD 35) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NNS ages)) (NP (QP (CD 20) (TO to) (CD 86)) (NN yr))) (-RRB- -RRB-))) (VP (VBG receiving) (NP (NNP Doc_7053303_83_93_Chemical)) (ADVP (RB therapeutically))))) (NP (NP (CD two) (NN serum) (NNS samples)) (CC and) (NP (NP (DT all) (NN urine)) (VP (VBN formed) (PP (IN in) (NP (DT the) (NN interim)))))) (VP (AUX were) (VP (VBN collected) (PP (IN for) (NP (NP (NN analysis)) (PP (IN of) (NP (NNP Doc_7053303_195_205_Chemical))))) (PP (PP (IN by) (NP (JJ high-pressure) (NN liquid) (NN chromatography))) (CC and) (PP (IN for) (NP (NNP Doc_7053303_253_263_Chemical)))))) (. .)))
7053303	2	(S1 (S (NP (JJ Doc_7053303_265_275_Chemical) (NN clearance)) (VP (VBD decreased) (PP (IN with) (NP (NN age)))) (. .)))
7053303	3	(S1 (S (NP (NP (DT The) (VBN extrapolated) (JJ 6-hr) (NN serum) (NN concentration)) (PP (IN of) (NP (NNP Doc_7053303_351_361_Chemical))) (PP (IN per) (NP (NN unit) (NN dose)))) (, ,) (PP (IN after) (NP (JJ intravenous) (NNP Doc_7053303_395_405_Chemical))) (, ,) (VP (VBD increased) (PP (IN with) (NP (NP (NN age)) (PP (IN of) (NP (DT the) (NNS patients)))))) (. .)))
7053303	4	(S1 (S (NP (NP (DT The) (NN ratio)) (PP (IN of) (NP (JJ Doc_7053303_456_466_Chemical) (NN clearance))) (PP (TO to) (NP (NP (JJ Doc_7053303_480_490_Chemical) (NN clearance)) (PRN (-LRB- -LRB-) (NP (NNP Rc)) (-RRB- -RRB-))))) (VP (VBD averaged) (NP (QP (CD 4.8) (CD +/-)) (CD 2.0)) (, ,) (S (VP (VBG indicating) (NP (NP (JJ net) (JJ tubular) (NN secretion)) (PP (IN for) (NP (NNP Doc_7053303_565_575_Chemical))))))) (. .)))
7053303	5	(S1 (S (NP (NNP Rc)) (VP (VBD seemed) (S (VP (TO to) (VP (AUX be) (UCP (ADJP (JJ independent) (PP (IN of) (NP (NN age)))) (CC and) (VP (VBN decreased) (PP (IN with) (S (VP (VBG increasing) (NP (NP (NN serum) (NN concentration)) (PP (IN of) (NP (NNP Doc_7053303_665_675_Chemical)))))))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (NN secretion)) (PP (IN of) (NP (NNP Doc_7053303_706_716_Chemical)))) (VP (AUX is) (NP (DT a) (JJ saturable) (NN process)))))))) (. .)))
7053303	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (QP (RB only) (CD one)) (NN case)) (PP (IN of) (NP (NNP Doc_7053303_768_776_Disease)))) (PP (ADVP (RB possibly)) (JJ due) (PP (TO to) (NP (NP (NNP Doc_7053303_793_803_Chemical)) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (DT a) (NN drug) (NN level)) (PP (IN of) (NP (CD 1.9) (NNS microgram/ml))))) (NP (NP (CD 6) (NN hr)) (PP (IN after) (NP (DT a) (NN dose)))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NP (CD 13) (NNS patients)) (PP (IN without) (NP (NNP Doc_7053303_896_919_Disease)))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (JJ Doc_7053303_928_938_Chemical) (NNS levels)) (PP (IN above) (NP (CD 1.25) (CD microgram/ml))))))))))))) (. .)))
7053303	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (JJ high) (JJ Doc_7053303_982_992_Chemical) (NNS levels)) (ADVP (RB alone))) (VP (AUX do) (RB not) (ADVP (RB always)) (VP (VB induce) (NP (NN Doc_7053303_1027_1035_Disease)))) (. .)))
7083920	0	(S1 (NP (NP (JJ Further) (NNS observations)) (PP (IN on) (NP (NP (DT the) (JJ electrophysiologic) (NNS effects)) (PP (IN of) (NP (JJ oral) (JJ Doc_7083920_63_73_Chemical) (NN therapy))))) (. .)))
7083920	1	(S1 (S (NP (DT A) (NN case)) (VP (AUX is) (VP (VBN presented) (PP (IN of) (NP (NP (DT a) (JJ reversible) (NN Doc_7083920_119_137_Disease)) (VP (VBG occurring) (PP (IN under) (NP (NP (JJ Doc_7083920_154_164_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_7083920_179_197_Disease))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN without) (NP (JJ clear) (NN Doc_7083920_225_266_Disease)))))))))) (. .)))
7083920	2	(S1 (S (NP (PRP$ His) (NN bundle) (NNS recordings)) (VP (VBD showed) (NP (DT an) (NN Doc_7083920_300_318_Disease)) (PP (IN with) (NP (NP (JJ intermittent) (NN exit) (NN block)) (CC and) (NP (NP (NP (ADJP (RB greatly) (VBN prolonged)) (NN BH)) (CC and) (NP (JJ HV) (NNS intervals))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 40) (CC and) (CD 100) (NN msec))) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))))) (. .)))
7083920	3	(S1 (S (PP (NP (CD Thirty) (NNS days)) (IN after) (NP (JJ Doc_7083920_441_451_Chemical) (NN discontinuation))) (, ,) (NP (PRP$ His) (NN bundle) (NNS electrograms)) (VP (VBD showed) (NP (NN Doc_7083920_500_514_Disease)) (PP (IN without) (NP (NP (NN intra-Hisian)) (CC or) (NP (JJ infra-Hisian) (NN delay))))) (. .)))
7083920	4	(S1 (S (NP (NNP Doc_7083920_559_569_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN during) (NP (NP (JJ long-term) (JJ oral) (NN therapy)) (PP (IN in) (NP (NNS patients))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ clear) (JJ intraventricular) (NN conduction) (NNS defects))))))))) (. .)))
7088431	0	(S1 (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_7088431_15_40_Disease))) (PP (IN in) (NP (NP (JJ Doc_7088431_44_47_Chemical-exposed) (NN offspring)) (PP (IN under) (NP (NN observation))))) (. .)))
7088431	1	(S1 (S (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (NNP Doc_7088431_98_137_Disease))) (VP (VBN detected) (PP (IN at) (NP (NN follow-up))) (PP (IN in) (NP (NP (JJ young) (NNS women)) (VP (VBN exposed) (PP (IN in) (NP (NN utero))) (PP (TO to) (NP (NNP Doc_7088431_195_213_Chemical)))))))) (VP (AUX are) (VP (VBN reported))) (. .)))
7088431	2	(S1 (S (S (NP (NP (CD One) (NN patient)) (, ,) (VP (VBN aged) (NP (CD 23))) (, ,)) (VP (AUX had) (VP (AUX been) (VP (VBN followed) (PP (IN for) (NP (CD 2) (NNS years))) (SBAR (IN before) (S (NP (NNP Doc_7088431_287_296_Disease)) (VP (AUX was) (VP (VBN diagnosed))))))))) (: ;) (S (NP (NP (DT the) (JJ second) (NN patient)) (, ,) (VP (VBN aged) (NP (CD 22))) (, ,)) (VP (AUX had) (VP (AUX been) (VP (VBN seen) (PP (IN on) (NP (NP (DT a) (JJ regular) (NN basis)) (PP (IN for) (NP (NP (CD 5) (NNS years)) (, ,) (NP (CD 8) (NNS months)))))))))) (. .)))
7088431	3	(S1 (S (PP (IN In) (NP (DT both) (NNS instances))) (, ,) (NP (NP (NN suspicion)) (PP (IN of) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_7088431_445_454_Disease)))))) (VP (AUX was) (VP (VBN aroused) (PP (IN by) (NP (NP (DT the) (NN palpation)) (PP (IN of) (NP (DT a) (JJ small) (NN nodule))) (PP (IN in) (NP (DT the) (JJ vaginal) (NN fornix))))))) (. .)))
7088431	4	(S1 (S (S (NP (NN Hysterosalpingography)) (VP (AUX was) (VP (VBN performed) (PP (IN on) (NP (DT both) (NNS patients)))))) (CC and) (, ,) (S (PP (IN in) (NP (CD 1) (NN instance))) (, ,) (NP (DT an) (JJ abnormal) (NN x-ray) (NN film)) (VP (AUX was) (VP (VBN reflected) (PP (IN by) (NP (NP (DT the) (JJ gross) (NN appearance)) (PP (IN of) (NP (NP (DT the) (JJ uterine) (NN cavity)) (VP (VBN found) (PP (IN in) (NP (DT the) (JJ surgical) (NNS specimen))))))))))) (. .)))
7199841	0	(S1 (S (NP (NP (JJ Neurologic) (NNS effects)) (PP (IN of) (NP (NP (NN subarachnoid) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_7199841_53_72_Chemical)) (, ,) (NP (NNP Doc_7199841_74_85_Chemical)) (, ,) (CC and) (NP (JJ low) (NNS pH))))))) (ADVP (RB normal)) (VP (VBP saline) (PP (IN in) (NP (NNS dogs)))) (. .)))
7199841	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ neurologic) (NNS consequences)) (PP (IN of) (NP (NP (JJ deliberate) (NN subarachnoid) (NN injection)) (PP (IN of) (NP (NP (JJ large) (NNS volumes)) (PP (IN of) (NP (NP (NNP Doc_7199841_248_267_Chemical)) (PP (IN in) (NP (JJ experimental) (NNS animals)))))))))))))) (. .)))
7199841	2	(S1 (S (NP (NP (DT The) (JJ possible) (NN role)) (PP (IN of) (NP (NP (JJ low) (NNS pH)) (CONJP (RB as) (RB well) (IN as)) (NP (JJ total) (NN volume)))) (PP (IN as) (NP (JJ potential) (NNS factors))) (PP (IN in) (S (VP (VBG causing) (NP (NN Doc_7199841_377_390_Disease)))))) (VP (AUX was) (VP (VBN evaluated))) (. .)))
7199841	3	(S1 (S (NP (NP (DT The) (CD 65) (NNS dogs)) (PP (IN in) (NP (DT the) (NN study)))) (VP (VBD received) (NP (NP (NNS injections)) (PP (IN in) (NP (DT the) (JJ subarachnoid) (NN space)))) (SBAR (IN as) (S (VP (VBZ follows) (: :) (NP (NP (NP (QP (CD 6) (TO to) (CD 8) (NN ml))) (PP (IN of) (NP (NNP Doc_7199841_502_513_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 15)) (-RRB- -RRB-)) (, ,) (NP (NP (NNP Doc_7199841_524_543_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 20)) (-RRB- -RRB-)))) (, ,) (NP (NP (NP (JJ low) (JJ pH) (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 3.0)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 20)) (-RRB- -RRB-)) (, ,) (CC or) (NP (NP (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (CD 10)) (-RRB- -RRB-)))))))) (. .)))
7199841	4	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 20) (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (JJ subarachnoid) (NN injection)) (PP (IN of) (NP (NNP Doc_7199841_679_698_Chemical) (CD seven))))))))) (PRN (-LRB- -LRB-) (NP (CD 35) (NN %)) (-RRB- -RRB-)) (VP (VBD developed) (NP (JJ hind-limb) (NN Doc_7199841_731_740_Disease))) (. .)))
7199841	5	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (NP (DT the) (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NNP Doc_7199841_776_787_Chemical)) (, ,) (NP (NP (JJ normal) (NN saline)) (, ,) (CC or) (NP (JJ normal) (NN saline)))))))))) (VP (VBD titrated) (PP (TO to) (NP (DT a) (NN pH) (CD 3.0) (VBN developed) (NN hind-limb) (NN Doc_7199841_862_871_Disease)))) (. .)))
7199841	6	(S1 (S (S (PP (IN Of) (NP (NP (DT the) (CD 15) (JJ spinal) (NNS cords)) (PP (IN of) (NP (NP (DT the) (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NNP Doc_7199841_925_944_Chemical))))))))) (, ,) (NP (CD 13)) (VP (VBD showed) (NP (NNP Doc_7199841_956_972_Disease)))) (: ;) (S (NP (DT the) (NX (NX (NN nerve) (NNS roots)) (CC and) (NX (NN subarachnoid) (NNS vessels)))) (VP (AUX were) (ADJP (JJ normal)))) (. .)))
7199841	7	(S1 (S (NP (NP (DT The) (JJ spinal) (NNS cords)) (PP (IN of) (NP (DT the) (NNS animals))) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NP (NNP Doc_7199841_1074_1085_Chemical) (, ,) (JJ low) (JJ pH) (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN pH) (CD 3.0)) (-RRB- -RRB-))) (, ,) (CC or) (NP (JJ normal) (NN saline))))))) (VP (AUX did) (RB not) (VP (VB show) (NP (JJ abnormal) (NNS findings)))) (. .)))
7234705	0	(S1 (S (NP (JJ Doc_7234705_0_12_Chemical-induced) (NNS polymorphous)) (VP (VBP Doc_7234705_34_57_Disease)) (. .)))
7234705	1	(S1 (S (NP (NP (CD Seven) (NNS cases)) (PP (IN of) (NP (JJ Doc_7234705_74_86_Chemical-induced) (JJ polymorphous) (NN Doc_7234705_108_131_Disease)))) (VP (AUX are) (VP (VBN presented))) (. .)))
7234705	2	(S1 (S (PP (IN In) (NP (CD four) (NNS patients))) (, ,) (NP (JJ polymorphous) (NNP Doc_7234705_178_201_Disease)) (VP (VBD appeared) (PP (IN after) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NP (QP (CD 200) (TO to) (CD 400)) (NNS mg)) (PP (IN of) (NP (NNP Doc_7234705_264_276_Chemical))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ sustained) (NNP Doc_7234705_308_331_Disease)))))))))) (. .)))
7234705	3	(S1 (S (PP (IN In) (NP (DT the) (JJ remaining) (CD three) (NNS patients))) (, ,) (NP (NNP Doc_7234705_366_378_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB orally)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ chronic) (NNP Doc_7234705_428_462_Disease) (CC or) (NNP Doc_7234705_466_480_Disease))))))) (. .)))
7234705	4	(S1 (S (NP (DT These) (NNS patients)) (VP (AUX had) (NP (NP (NN Doc_7234705_501_517_Disease) (CC and) (NN recurrent) (NN Doc_7234705_532_539_Disease)) (ADJP (JJ due) (PP (TO to) (NP (JJ polymorphous) (NNP Doc_7234705_560_583_Disease)))))) (. .)))
7234705	5	(S1 (S (PP (IN In) (NP (CD four) (NNS patients))) (, ,) (NP (DT the) (NNP Doc_7234705_607_617_Disease)) (VP (VP (AUX was) (ADVP (RB rapidly)) (VP (VBN diagnosed))) (CC and) (VP (VBN treated) (PP (IN with) (NP (NP (NN disappearance)) (PP (IN of) (NP (NP (JJ further) (NNS episodes)) (PP (IN of) (NP (DT the) (NNP Doc_7234705_698_708_Disease))))))))) (. .)))
7234705	6	(S1 (S (PP (IN In) (NP (CD two) (NNS patients))) (, ,) (NP (NP (DT the) (NNP Doc_7234705_731_741_Disease)) (VP (VBN degenerated) (PP (IN into) (NP (NP (JJ irreversible) (NN Doc_7234705_772_796_Disease)) (CC and) (NP (DT both) (NNS patients)))))) (VP (VBD died)) (. .)))
7234705	7	(S1 (S (S (PP (IN In) (NP (DT the) (JJ seventh) (NN patient))) (, ,) (NP (DT a) (JJ permanent) (NN ventricular) (NN pacemaker)) (VP (AUX was) (VP (VBN inserted)))) (CC and) (, ,) (S (PP (IN despite) (NP (NP (NN continuation)) (PP (IN of) (NP (JJ Doc_7234705_921_933_Chemical) (NN therapy))))) (, ,) (NP (JJ polymorphous) (NN Doc_7234705_956_979_Disease)) (VP (AUX did) (RB not) (VP (VB reoccur)))) (. .)))
7234705	8	(S1 (S (NP (DT These) (CD seven) (NNS cases)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NNP Doc_7234705_1032_1044_Chemical)) (VP (MD can) (VP (VB produce) (NP (NP (DT an) (VBN acquired) (NN Doc_7234705_1069_1091_Disease)) (PP (IN with) (NP (JJ polymorphous) (NN Doc_7234705_1110_1133_Disease))))))))) (. .)))
7248170	0	(S1 (NP (NP (NP (JJ Doc_7248170_0_14_Chemical-induced) (NN Doc_7248170_23_47_Disease)) (PP (IN in) (NP (DT the) (NN rat)))) (: :) (NP (NP (PRP$ its) (NN relationship)) (PP (TO to) (NP (NNP Doc_7248170_80_100_Chemical-induced) (NNP Doc_7248170_109_118_Disease)))) (. .)))
7248170	1	(S1 (S (NP (NP (DT The) (NN yield)) (PP (IN of) (NP (JJ severe) (NNP Doc_7248170_140_162_Disease) (PRN (-LRB- -LRB-) (VP (VBN defined) (PP (IN as) (NP (NP (DT a) (JJ shrunken) (ADJP (RB finely) (JJ nodular)) (NN liver)) (PP (IN with) (NP (JJ micronodular) (NN histology)))))) (, ,)) (NNP Doc_7248170_236_243_Disease)))) (NP (NP (QP (JJR greater) (IN than) (CD 30)) (NN ml)) (, ,) (NP (NP (NN plasma) (NN albumin)) (QP (JJR less) (IN than) (CD 2.2) (CD g/dl))) (, ,) (NP (NP (NNP Doc_7248170_299_311_Disease) (CD 2-3) (NNS times)) (ADJP (JJ normal))) (, ,) (CC and) (NP (NP (NP (JJ testicular) (NN Doc_7248170_345_352_Disease)) (PRN (ADVP (RB approximately)) (NP (DT half) (JJ normal) (NN weight)) (-RRB- -RRB-))) (PP (IN after) (NP (NP (CD 12) (NNS doses)) (PP (IN of) (NP (NNP Doc_7248170_405_425_Chemical))))) (VP (VBN given) (ADVP (RB intragastrically)) (PP (IN in) (NP (DT the) (JJ Doc_7248170_456_470_Chemical-primed) (NN rat)))))) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (CD 25) (NN %))) (PP (TO to) (NP (CD 56) (NN %))) (PP (IN by) (S (VP (VBG giving) (NP (NP (DT the) (JJ initial) (`` ``) (JJ calibrating) ('' '') (NN dose)) (PP (IN of) (NP (NNP Doc_7248170_556_576_Chemical)))) (PP (IN at) (NP (NP (DT the) (NN peak)) (PP (IN of) (NP (DT the) (JJ Doc_7248170_596_610_Chemical-induced) (NNP Doc_7248170_619_643_Disease)))))))))) (. .)))
7248170	2	(S1 (S (PP (IN At) (NP (DT this) (NN point))) (NP (PRP it)) (VP (AUX was) (VP (VBN assumed) (SBAR (IN that) (S (NP (DT the) (JJ cytochrome) (JJ P450/Doc_7248170_699_703_Chemical) (JJ toxic) (NN state)) (VP (AUX was) (ADJP (DT both) (ADJP (JJ maximal)) (CC and) (ADJP (JJ stable)))))))) (. .)))
7248170	3	(S1 (S (S (NP (NP (DT The) (JJ optimal) (NN rat) (NN size)) (SBAR (S (VP (TO to) (VP (VB begin) (NP (NNP Doc_7248170_775_789_Chemical))))))) (VP (AUX was) (VP (VBN determined) (PP (IN as) (NP (NP (CD 100)) (NP (NNP g))))))) (, ,) (CC and) (S (NP (NP (DT this) (NN size)) (PP (IN as) (NP (DT a) (NN group)))) (VP (AUX had) (NP (NP (DT a) (JJ mean) (JJ maximum) (JJ relative) (NN liver) (NN weight) (NN increase)) (ADJP (ADJP (NP (CD 47) (NN %)) (JJR greater)) (PP (IN than) (NP (NP (JJ normal) (NNS rats)) (PP (IN of) (NP (DT the) (JJ same) (NN body) (NN weight))))))))) (. .)))
7248170	4	(S1 (S (NP (NP (DT The) (JJ optimal) (NN time)) (PP (IN for) (NP (NP (DT the) (JJ initial) (NN dose)) (PP (IN of) (NP (NNP Doc_7248170_985_1005_Chemical)))))) (VP (AUX was) (PP (IN after) (NP (NP (CD 14) (NNS days)) (PP (IN on) (NP (NNP Doc_7248170_1027_1041_Chemical)))))) (. .)))
7265370	0	(S1 (S (NP (NNP Doc_7265370_0_11_Chemical) (NNP Doc_7265370_12_27_Disease)) (VP (VBD complicating) (NP (JJ Doc_7265370_41_48_Chemical) (NN therapy))) (. .)))
7265370	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_7265370_68_79_Chemical) (NNP Doc_7265370_80_95_Disease)))) (VP (AUX is) (VP (VBN reported) (PP (IN in) (NP (DT a) (NN man))) (PP (IN after) (NP (NP (CD 4) (NNS years)) (PP (IN of) (NP (NP (JJ Doc_7265370_134_165_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_7265370_178_190_Disease))))))))) (. .)))
7265370	2	(S1 (S (NP (DT The) (NN stone)) (VP (VP (VBD passed) (ADVP (RB spontaneously))) (CC and) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VB contain) (NP (NP (DT a) (JJ Doc_7265370_250_261_Chemical) (NN metabolite)) (VP (VBN admixed) (PP (IN with) (NP (NN Doc_7265370_286_301_Chemical))))))))))) (. .)))
7265370	3	(S1 (S (S (NP (NP (NNS Factors)) (VP (VBG affecting) (NP (NNP Doc_7265370_321_332_Chemical) (NNP Doc_7265370_333_348_Disease)))) (VP (AUX are) (VP (VBN discussed)))) (CC and) (S (NP (CD 2) (ADJP (RB previously) (VBN reported)) (NNS cases)) (VP (AUX are) (VP (VBN reviewed)))) (. .)))
7269015	0	(S1 (NP (JJ Doc_7269015_0_8_Chemical-induced) (NN Doc_7269015_17_37_Disease) (. .)))
7269015	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (DT a) (JJ Doc_7269015_51_59_Chemical-induced) (NN Doc_7269015_68_87_Disease)))) (VP (AUX is) (VP (VBN reported))) (. .)))
7269015	2	(S1 (S (NP (JJ Spontaneous) (NN resolution)) (VP (VBD occurred) (PP (VBG following) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (NN drug)))))) (. .)))
7269015	3	(S1 (S (S (NP (NP (DT The) (NN similarity)) (PP (IN between) (NP (NP (DT the) (JJ histologic) (NNS appearances)) (PP (IN of) (NP (NP (NNP Doc_7269015_219_227_Chemical) (NNP Doc_7269015_228_236_Disease)) (CC and) (NP (UCP (DT both) (NN radiation) (CC and) (JJ Doc_7269015_260_276_Chemical-induced)) (NNP Doc_7269015_285_293_Disease))))))) (VP (AUX is) (VP (VBN discussed)))) (CC and) (S (NP (DT the) (NN world) (NN literature)) (VP (VBN reviewed))) (. .)))
7269015	4	(S1 (S (PP (IN In) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (JJ known) (NN tendency)) (PP (IN of) (NP (NNP Doc_7269015_375_383_Chemical))) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ cellular) (NN atypia)) (CC and) (NP (NNP Doc_7269015_414_423_Disease))) (PP (IN in) (NP (JJ other) (NNS sites)))))))))) (, ,) (NP (JJ periodic) (NN urinary) (NN cytology)) (VP (AUX is) (VP (VBN suggested) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ long-term) (NN therapy))))))) (. .)))
7292072	0	(S1 (NP (NP (NNP Variant) (NNP Doc_7292072_8_31_Disease)) (PP (IN in) (NP (NNP Doc_7292072_35_46_Chemical) (NNP Doc_7292072_47_55_Disease))) (. .)))
7292072	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ variant) (NN Doc_7292072_85_108_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7292072_120_131_Chemical) (NNP Doc_7292072_132_140_Disease)))))))) (. .)))
7292072	2	(S1 (S (NP (NP (JJ Unusual) (NNS features)) (PP (IN of) (NP (DT the) (NNP Doc_7292072_166_176_Disease)))) (VP (AUX are) (NP (NP (JJ repetitive) (NN group) (NN beating)) (, ,) (NP (NP (JJ progressive) (NN shortening)) (PP (IN of) (NP (DT the) (JJ R-R) (NN interval)))) (, ,) (NP (NP (JJ progressive) (NN widening)) (PP (IN of) (NP (NP (DT the) (NNS QRS)) (ADJP (JJ complex) (PP (IN with) (NP (NP (JJ eventual) (NN failure)) (PP (IN of) (NP (NN intraventricular) (NN conduction))))))))) (, ,) (CC and) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN direction)) (PP (IN of) (NP (DT the) (NNP QRS) (NN axis)))))))) (. .)))
7292072	3	(S1 (S (NP (NP (NN Recognition)) (PP (IN of) (NP (JJ variant) (NNP Doc_7292072_410_433_Disease)))) (VP (AUX is) (ADJP (JJ important)) (SBAR (IN because) (S (NP (NN therapy)) (VP (VBZ differs) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (JJ classic) (NN Doc_7292072_492_515_Disease))))))))) (. .)))
7352670	0	(S1 (S (NP (NN Rebound)) (VP (VBP Doc_7352670_8_20_Disease) (SBAR (IN after) (S (NP (NNP Doc_7352670_27_47_Chemical)) (VP (VBD prevented) (PP (IN by) (NP (NNP Doc_7352670_61_70_Chemical))) (PP (IN in) (NP (NNS rats))))))) (. .)))
7352670	1	(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (DT the) (JJ renin--Doc_7352670_103_114_Chemical) (NN system))) (PP (IN in) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NP (NN blood) (NN pressure)) (PP (IN during) (NP (NP (NNP Doc_7352670_166_175_Chemical) (NNP anesthesia)) (CC and) (NP (NP (NNP Doc_7352670_191_211_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7352670_213_216_Chemical)) (-RRB- -RRB-)))))))))) (VP (VBD -induced) (SBAR (S (NP (NNP Doc_7352670_226_237_Disease)) (VP (AUX was) (VP (VBN evaluated)))))) (. .)))
7352670	2	(S1 (S (NP (NN Control) (NNS rats)) (VP (VBD received) (NP (NP (JJ Doc_7352670_275_284_Chemical) (NNS anesthesia)) (PRN (-LRB- -LRB-) (NP (CD 1) (NNP MAC)) (-RRB- -RRB-)) (PP (IN for) (NP (CD one) (NN hour))) (, ,) (VP (VBN followed) (PP (IN by) (NP (JJ Doc_7352670_330_333_Chemical) (NN infusion)))) (, ,)) (NP (CD 40) (NN microgram/kg/min)) (, ,) (PP (IN for) (NP (CD 30) (NN min))) (, ,) (VP (VBN followed) (PP (IN by) (NP (DT a) (JJ 30-min) (NN recovery) (NN period))))) (. .)))
7352670	3	(S1 (S (NP (NP (DT A) (JJ second) (NN group)) (PP (IN of) (NP (NNS rats)))) (VP (VP (AUX was) (VP (VBN treated) (ADVP (RB identically)))) (CC and) (PRN (, ,) (PP (IN in) (NP (NN addition))) (, ,)) (VP (VBD received) (NP (NP (DT an) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_7352670_504_513_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ competitive) (NN inhibitor)) (PP (IN of) (NP (NNP Doc_7352670_542_556_Chemical)))) (-RRB- -RRB-))))) (PP (IN throughout) (NP (DT the) (JJ experimental) (NN period))))) (. .)))
7352670	4	(S1 (S (PP (IN In) (NP (DT each) (NN group))) (, ,) (NP (JJ Doc_7352670_609_612_Chemical) (NN infusion)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ initial) (NN decrease)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (PP (IN from) (NP (NP (CD 86) (NNS torr)) (CC and) (NP (CD 83) (NNS torr)))))))) (, ,) (ADVP (RB respectively)) (, ,) (PP (TO to) (NP (CD 48) (NN torr)))) (. .)))
7352670	5	(S1 (S (PP (IN During) (NP (DT the) (JJ Doc_7352670_735_738_Chemical) (NN infusion))) (NP (DT the) (NN control) (NNS animals)) (VP (VBD demonstrated) (NP (DT a) (JJ progressive) (NN Doc_7352670_795_821_Disease)) (PP (TO to) (NP (QP (CD 61) (CD torr)))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (JJ Doc_7352670_846_855_Chemical-treated) (NNS animals)) (VP (VBD showed) (NP (DT no) (NN change)))))) (. .)))
7352670	6	(S1 (S (PP (VBG Following) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_7352670_919_922_Chemical))))) (, ,) (NP (NP (NN blood) (NN pressure)) (PP (IN in) (NP (DT the) (NN control) (NNS animals)))) (VP (VBD rebounded) (PP (TO to) (NP (CD 94) (CD torr))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (CD 78) (NN torr)) (PP (IN in) (NP (DT the) (JJ Doc_7352670_1016_1025_Chemical-treated) (NNS rats))))))))) (. .)))
7352670	7	(S1 (S (NP (DT This) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (PP (IN with) (NP (JJ stable) (JJ Doc_7352670_1078_1087_Chemical) (NN anesthesia))) (, ,) (NP (NP (NP (DT the) (JJ partial) (NN recovery)) (PP (IN of) (NP (NP (NN blood) (NN pressure)) (PP (IN during) (NP (JJ Doc_7352670_1146_1149_Chemical) (NN infusion)))))) (CC and) (NP (NP (DT the) (JJ post-Doc_7352670_1172_1175_Chemical) (NN rebound)) (PP (IN of) (NP (NN blood) (NN pressure))))) (VP (MD can) (VP (AUX be) (VP (ADVP (RB completely)) (VBN blocked) (PP (IN by) (NP (NNP Doc_7352670_1231_1240_Chemical))))))))) (. .)))
7352670	8	(S1 (S (NP (DT This)) (VP (VBZ demonstrates) (NP (NP (DT the) (NN participation)) (PP (IN of) (NP (DT the) (JJ renin--Doc_7352670_1292_1303_Chemical) (NN system))) (PP (IN in) (S (VP (VBG antagonizing) (NP (NP (DT the) (VBN combined) (JJ Doc_7352670_1340_1351_Disease) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_7352670_1363_1372_Chemical)) (CC and) (NP (NNP Doc_7352670_1377_1380_Chemical)))))))))) (. .)))
7420681	0	(S1 (NP (NP (JJ Clinical) (NNP Doc_7420681_9_23_Disease)) (PP (IN of) (NP (NP (NNP Doc_7420681_27_37_Chemical)) (CC and) (NP (NNP Doc_7420681_42_52_Chemical)))) (. .)))
7420681	1	(S1 (NP (DT A) (JJ prospective) (NN study) (. .)))
7420681	2	(S1 (S (NP (NP (QP (RB Nearly) (CD 3.2) (CD million)) (NNS people)) (PP (IN in) (NP (DT this) (NN country)))) (VP (VBP receive) (NP (JJ Doc_7420681_125_139_Chemical) (NNS antibiotics)) (ADVP (RB annually))) (. .)))
7420681	3	(S1 (S (NP (NP (NNP Doc_7420681_162_180_Chemical)) (CC and) (NP (NNP Doc_7420681_185_203_Chemical))) (VP (VBP continue) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (NNP Doc_7420681_228_239_Disease)) (CC and) (NP (NNP Doc_7420681_244_258_Disease))) (PP (IN in) (NP (DT both) (ADJP (JJ animal) (CC and) (JJ clinical)) (NNS studies))))))) (. .)))
7420681	4	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (CD 62) (NNS patients)) (SBAR (WHNP (IN with)) (S (VP (VP (VBN confirmed) (NP (JJ initial) (JJ normal) (JJ renal) (NN function))) (CC and) (VP (VBN treated) (PP (IN with) (NP (NP (QP (CD 2) (TO to) (CD 5)) (NN mg/kg/day)) (PP (IN of) (NP (NNP Doc_7420681_405_423_Chemical) (CC or) (NNP Doc_7420681_427_445_Chemical))))) (PP (IN for) (NP (NP (DT a) (NN minimum)) (PP (IN of) (NP (CD seven) (NNS days)))))))))) (VP (AUX were) (VP (VBN followed) (PRT (RP up)) (ADVP (RB prospectively)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_7420681_528_542_Chemical-related) (NNP Doc_7420681_551_564_Disease)) (, ,) (VP (VBN defined) (PP (IN as) (NP (NP (ADVP (IN at) (JJS least)) (DT a) (JJ one-third) (NN reduction)) (PP (IN in) (NP (JJ renal) (NN function)))))))))))) (. .)))
7420681	5	(S1 (S (PP (IN In) (NP (DT these) (CD 62) (NNS patients))) (, ,) (NP (NP (DT no) (JJ other) (NNS causes)) (PP (IN for) (NP (NNP Doc_7420681_669_682_Disease)))) (VP (MD could) (VP (AUX be) (VP (VBN identified)))) (. .)))
7420681	6	(S1 (S (NP (NP (NP (NP (CD Five)) (PP (IN of) (NP (CD 33))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (DT the) (JJ Doc_7420681_728_738_Chemical-treated) (NNS patients)))) (CC and) (NP (NP (CD 16)) (PP (IN of) (NP (CD 29))) (PRN (-LRB- -LRB-) (NP (CD 55.2) (NN %)) (-RRB- -RRB-)))) (PP (IN of) (NP (DT the) (JJ Doc_7420681_784_794_Chemical-treated) (NNS patients)))) (VP (AUX had) (NP (NNP Doc_7420681_816_829_Disease))) (. .)))
7420681	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_7420681_837_847_Chemical)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_7420681_868_881_Disease))) (ADVP (QP (JJR more) (IN than) (CD three) (NNS times)) (RB as) (RB often) (SBAR (IN as) (S (VP (AUX was) (ADJP (JJ Doc_7420681_920_930_Chemical)))))))) (. .)))
7423039	0	(S1 (NP (NP (JJ Metabolic) (NN involvement)) (PP (IN in) (NP (NNP Doc_7423039_25_35_Chemical) (NNP Doc_7423039_36_50_Disease))) (. .)))
7423039	1	(S1 (S (NP (NP (DT The) (JJ Doc_7423039_56_67_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_7423039_79_89_Chemical)))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (JJ mammalian) (JJ myocardial) (NNS cells)) (PP (IN in) (NP (NN culture))))) (PP (IN as) (NP (DT a) (NN model) (NN system))))) (. .)))
7423039	2	(S1 (S (NP (NN Doc_7423039_163_173_Chemical)) (VP (VBD inhibited) (NP (NP (NN cell) (NN growth)) (CC and) (NP (NP (DT the) (JJ rhythmic) (NNS contractions) (NN characteristic)) (PP (IN of) (NP (JJ myocardial) (NNS cells))) (PP (IN in) (NP (NN culture)))))) (. .)))
7423039	3	(S1 (S (S (NP (NP (DT A) (JJ possible) (NN involvement)) (PP (IN of) (NP (NN energy) (NN metabolism)))) (VP (AUX was) (VP (VBN suggested) (ADVP (RB previously))))) (, ,) (CC and) (S (PP (IN in) (NP (DT this) (NN study))) (NP (NP (DT the) (JJ adenylate) (NN energy) (NN charge)) (CC and) (NP (JJ Doc_7423039_393_411_Chemical) (JJ mole) (NN fraction))) (VP (AUX were) (VP (VBN determined) (PP (IN in) (NP (DT the) (JJ Doc_7423039_449_459_Chemical-treated) (NNS cells)))))) (. .)))
7423039	4	(S1 (S (NP (DT The) (NN adenylate) (NN energy) (NN charge)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (VP (ADVP (RB significantly)) (VBN decreased))))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ Doc_7423039_554_571_Chemical) (NN mole) (NN fraction)) (VP (AUX was) (ADJP (JJ unchanged))))))) (. .)))
7423039	5	(S1 (S (NP (JJ Such) (NN disparity)) (VP (VBZ suggests) (NP (NP (DT an) (NN inhibition)) (PP (IN of) (NP (JJ Doc_7423039_642_650_Chemical) (NN phosphokinase))))) (. .)))
7423039	6	(S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (QP (CD 1) (CD mM)) (ADJP (JJ Doc_7423039_687_696_Chemical) (PP (TO to) (NP (DT the) (JJ myocardial) (NN cell)))) (NNS cultures)))) (ADVP (RB markedly)) (VP (VBZ increases) (NP (DT the) (JJ Doc_7423039_752_755_Chemical) (NN concentration)) (PP (IN through) (NP (NP (DT a) (NN pathway)) (VP (ADVP (RB reportedly)) (VBG leading) (PP (TO to) (NP (DT a) (JJ compartmentalized) (NN Doc_7423039_830_833_Chemical) (NN pool))))))) (. .)))
7423039	7	(S1 (S (PP (IN In) (NP (DT the) (JJ Doc_7423039_847_857_Chemical-treated) (NNS cells))) (, ,) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_7423039_889_898_Chemical)))) (VP (VP (VBD increased) (NP (DT the) (JJ adenylate) (NN charge))) (CC and) (VP (, ,) (ADVP (JJ concomitant) (PP (IN with) (NP (NP (DT this) (NN inrcease)) (, ,) (NP (NP (DT the) (NNS cells) (POS ')) (JJ functional) (NN integrity))))) (, ,) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NP (NN percentage)) (PP (IN of) (NP (NN beating) (NNS cells)))) (CC and) (NP (NP (NN rate)) (PP (IN of) (NP (NNS contractions)))))))) (, ,) (AUX was) (VP (VBN maintained)))) (. .)))
7444978	0	(S1 (NP (NP (JJ Age-dependent) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN rat))) (PP (TO to) (NP (NP (JJ Doc_7444978_40_50_Disease) (NNS effects)) (PP (IN of) (NP (NNP Doc_7444978_62_74_Chemical))))) (. .)))
7444978	1	(S1 (S (NP (NP (JJ Doc_7444978_76_88_Chemical) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NP (CD 300) (NN mg/kg)) (NP (NNP s.c.))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (PP (IN for) (NP (JJ various) (NNS periods))) (PP (PP (IN into) (NP (JJ preweanling) (NNS rats))) (CC and) (PP (IN for) (NP (CD 3) (NNS weeks)))) (PP (IN into) (NP (VBG weanling) (NNS rats))))) (. .)))
7444978	2	(S1 (S (PP (VBG Beginning) (PP (IN at) (NP (NP (CD 8) (NNS days)) (PP (IN of) (NP (NN age)))))) (, ,) (NP (NP (NN body) (NN movement)) (CC and) (NP (NN hearing))) (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (QP (CD 6) (CC and) (RB up) (TO to) (CD 17)) (NNS weeks))) (, ,) (ADVP (RB respectively)))) (. .)))
7444978	3	(S1 (S (S (NP (NNP Doc_7444978_313_331_Disease) (CC and) (NNP Doc_7444978_336_344_Disease)) (VP (VBD occurred) (ADVP (RB only)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN during) (NP (DT the) (JJ preweaning) (NN period)))))))) (: ;) (S (PP (IN within) (NP (DT this) (NN period))) (NP (DT the) (JJS greatest) (NNS sensitivities)) (PP (IN for) (NP (DT these) (NNS abnormalities))) (VP (VBD occurred) (PP (IN from) (NP (NP (QP (CD 2) (TO to) (CD 11-17))) (CC and) (NP (NP (QP (CD 5) (TO to) (CD 11)) (NNS days)) (PP (IN of) (NP (NN age)))))) (, ,) (ADVP (RB respectively)) (, ,) (S (VP (VBG indicating) (SBAR (S (IN that) (NP (DT the) (NN cochlea)) (VP (AUX is) (ADJP (ADJP (RBR more) (JJ sensitive) (PP (TO to) (NP (NNP Doc_7444978_588_600_Chemical)))) (PP (IN than) (NP (NP (DT the) (NN site)) (ADJP (PRN (-LRB- -LRB-) (ADJP (JJ vestibular) (CC or) (JJ central)) (-RRB- -RRB-)) (JJ responsible) (PP (IN for) (NP (DT the) (NNP Doc_7444978_659_670_Disease)))))))))))))) (. .)))
7449470	0	(S1 (NP (NP (JJ Late) (, ,) (JJ late) (NNP Doc_7449470_11_22_Chemical) (NNP Doc_7449470_23_37_Disease)) (. .)))
7449470	1	(S1 (S (NP (NN Doc_7449470_39_55_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN complication)) (SBAR (WHNP (WDT which)) (S (VP (VBZ limits) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_7449470_104_114_Chemical)))) (PP (IN as) (NP (DT a) (JJ chemotherapeutic) (NN agent)))))))) (. .)))
7449470	2	(S1 (S (NP (NN Doc_7449470_144_158_Disease)) (VP (AUX is) (ADJP (JJ frequent)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ total) (NN dose)) (VP (VP (VBZ exceeds) (NP (CD 600) (NN mg/m2))) (CC and) (VP (VBZ occurs) (PP (IN within) (NP (QP (CD one) (TO to) (CD six)) (NNS months))) (PP (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy)))))))))) (. .)))
7449470	3	(S1 (S (NP (DT A) (NN patient)) (VP (AUX is) (VP (VBN reported) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ progressive) (UCP (NNP Doc_7449470_321_335_Disease) (CD two) (CC and) (JJ one-half)) (NNS years)) (PP (IN after) (S (VP (VBG receiving) (NP (NP (CD 580) (NN mg/m2)) (SBAR (WHNP (WDT which)) (S (ADVP (RB apparently)) (VP (VBZ represents) (NP (JJ late) (, ,) (JJ late) (NNP Doc_7449470_424_438_Disease)))))))))))))) (. .)))
7453952	0	(S1 (NP (NP (NN Attenuation)) (PP (IN of) (NP (DT the) (JJ Doc_7453952_19_26_Chemical-induced) (NN Doc_7453952_35_67_Disease))) (PP (IN by) (NP (NP (NNP Doc_7453952_71_80_Chemical)) (PP (IN in) (NP (NNS rats))))) (. .)))
7453952	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_7453952_104_113_Chemical))) (PP (PP (IN on) (NP (NNP Doc_7453952_117_124_Chemical-induced) (NNP Doc_7453952_133_143_Disease) (CC and) (NNP Doc_7453952_148_156_Disease))) (CC and) (PP (IN on) (NP (NP (DT the) (JJ Doc_7453952_168_175_Chemical) (NN concentration)) (PP (IN in) (NP (DT the) (NN plasma) (, ,) (NN brain) (, ,) (NN kidney) (, ,) (NN thyroid) (CC and) (JJ red) (NN blood) (NNS cells))))))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NP (NNS rats)) (, ,) (VP (ADVP (RB chronically)) (VBN treated) (PP (IN with) (NP (NNP Doc_7453952_299_303_Chemical)))))))) (. .)))
7453952	2	(S1 (S (S (NP (NNP Doc_7453952_305_314_Chemical)) (VP (VBD reduced) (NP (NP (DT the) (NN drinking) (CC and) (NN urine) (NN volume)) (PP (IN of) (NP (NNS rats)))) (PP (IN in) (NP (NP (NP (DT an) (JJ acute)) (PRN (-LRB- -LRB-) (NP (QP (CD 6) (CC or) (CD 12)) (NNP h)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (DT a) (NN subacute)) (-LRB- -LRB-) (NP (CD 3) (NNS days)) (-RRB- -RRB-)) (NP (NN experiment.) (CD 6) (NNP h))))) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_7453952_453_462_Chemical))))))) (, ,) (NP (DT a) (NN reduction)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (JJ Doc_7453952_496_503_Chemical) (NN content)) (PP (PP (IN of) (NP (DT the) (JJ renal) (NN medulla))) (CC but) (RB not) (PP (IN in) (NP (NP (DT the) (JJ other) (NNS organs)) (VP (VBN studied))))))))) (. .)))
7453952	3	(S1 (S (PP (IN At) (NP (CD 12) (NNP h))) (, ,) (NP (PDT all) (DT the) (NNS tissues)) (VP (VBD showed) (NP (NP (DT a) (JJ slight) (NN increase)) (PP (IN in) (NP (JJ Doc_7453952_623_630_Chemical) (NNS levels))))) (. .)))
7453952	4	(S1 (S (PP (IN After) (NP (NP (CD 3) (NNS days)) (PP (IN of) (NP (VBN combined) (NN treatment))))) (, ,) (NP (NP (DT a) (JJ marked) (NN elevation)) (PP (IN in) (NP (UCP (NN plasma) (CC and) (NN tissue)) (JJ Doc_7453952_715_722_Chemical) (NNS levels)))) (VP (VBD accompanied) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN water) (NN intake))))) (. .)))
7453952	5	(S1 (S (PP (IN In) (NP (PDT all) (DT the) (NNS experiments))) (, ,) (NP (NP (DT the) (NN attenuation)) (PP (IN of) (NP (DT the) (JJ Doc_7453952_818_825_Chemical-induced) (NNP Doc_7453952_834_866_Disease))) (PP (IN by) (NP (NNP Doc_7453952_870_879_Chemical)))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NN ratio)) (PP (IN between) (NP (NP (NP (DT the) (JJ Doc_7453952_936_943_Chemical) (NN concentration)) (PP (IN in) (NP (DT the) (JJ renal) (NN medulla)))) (CC and) (NP (NP (PRP$ its) (NNS levels)) (PP (IN in) (NP (DT the) (NN blood))))))))) (CC and) (NP (NP (DT an) (NN elevation)) (PP (IN in) (NP (DT the) (NN plasma) (NN Doc_7453952_1038_1047_Chemical) (NN level)))))))) (. .)))
7453952	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (NP (JJ acute) (NNP Doc_7453952_1082_1091_Chemical) (NN administration)) (PP (TO to) (NP (NP (JJ Doc_7453952_1110_1117_Chemical-treated) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NP (NNP Doc_7453952_1150_1160_Disease)) (CC and) (NP (NNP Doc_7453952_1165_1173_Disease)))))))) (VP (MD might) (VP (VB relieve) (NP (DT these) (NNS patients))))) (CC but) (S (NP (VBN prolonged) (NNP Doc_7453952_1217_1226_Chemical) (NN supplementation)) (VP (VP (MD would) (VP (VB result) (PP (IN in) (NP (JJ elevated) (JJ Doc_7453952_1268_1275_Chemical) (NNS levels))))) (CC and) (VP (MD might) (VP (AUX be) (ADJP (JJ hazardous)))))))))) (. .)))
7468724	0	(S1 (S (NP (NN Doc_7468724_0_28_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_7468724_45_56_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_7468724_71_84_Disease)))))) (. .)))
7468724	1	(S1 (S (NP (JJ Severe) (NN Doc_7468724_93_121_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (QP (CD eight) (IN of) (CD 160)) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7468724_169_180_Chemical))) (PP (IN for) (NP (NN Doc_7468724_185_198_Disease))))))) (. .)))
7468724	2	(S1 (S (NP (JJ Associated) (JJ corticosteroid) (NN therapy) (CC and) (JJ twin) (NNS gestations)) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (VP (VBG predisposing) (NP (NNS factors))))))) (. .)))
7468724	3	(S1 (S (NP (NP (JJ Potential) (NNS mechanisms)) (PP (IN of) (NP (DT the) (NN pathophysiology)))) (VP (AUX are) (ADVP (RB briefly)) (VP (VBN discussed))) (. .)))
7504976	0	(S1 (S (S (NP (NNP Doc_7504976_0_15_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ antithyroid) (NNS drugs))))) (: :) (S (NP (CD four) (NNS cases)) (VP (VBG including) (NP (CD one)) (PP (IN with) (NP (NP (NN cross-reactivity)) (PP (IN between) (NP (NP (NNP Doc_7504976_101_112_Chemical)) (CC and) (NP (NNP Doc_7504976_117_133_Chemical)))))))) (. .)))
7504976	1	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_7504976_199_222_Disease)))) (PP (VBN encountered) (PP (IN with) (NP (JJ antithyroid) (NNS drugs))))))))) (. .)))
7504976	2	(S1 (S (NP (NP (NN Retrospective) (NN review)) (PP (IN of) (NP (NP (JJ medical) (NNS records)) (PP (IN of) (NP (NP (CD 236) (NNS patients)) (PP (IN with) (NP (NNP Doc_7504976_329_344_Disease)))))))) (VP (VBD admitted) (PP (IN in) (NP (NP (PRP$ our) (NN department)) (PRN (-LRB- -LRB-) (NP (NP (NNS in-)) (CC or) (NP (NNS out-patients))) (-RRB- -RRB-)))) (PP (IN from) (NP (CD 1986))) (PP (TO to) (NP (CD 1992)))) (. .)))
7504976	3	(S1 (S (NP (NP (CD Four) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 1.7) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN identified) (PP (IN with) (NP (NP (NNP Doc_7504976_464_479_Disease)) (SBAR (WHNP (WDT which)) (S (VP (MD could) (ADVP (RB reasonably)) (VP (AUX be) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ antithyroid) (NN agent)))))))))))))) (. .)))
7504976	4	(S1 (S (NP (CD Two) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (NN Doc_7504976_569_590_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_7504976_602_613_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7504976_615_628_Chemical)) (-RRB- -RRB-))))))) (. .)))
7504976	5	(S1 (S (NP (CD Two) (NNS others)) (VP (AUX had) (NP (DT a) (JJ mixed) (PRN (-LRB- -LRB-) (ADJP (JJ Doc_7504976_655_666_Disease) (CC and) (JJ cytolytic)) (-RRB- -RRB-)) (NN Doc_7504976_682_691_Disease)) (PP (VBG following) (NP (NN Doc_7504976_702_713_Chemical)))) (. .)))
7504976	6	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (DT the) (JJ latter) (CD two) (NNS patients)))) (ADVP (RB further)) (VP (VBD experienced) (NP (NP (DT a) (JJ cytolytic) (NN Doc_7504976_778_787_Disease)) (SBAR (WHNP (WDT which)) (S (VP (VBD appeared) (SBAR (IN after) (S (NP (NP (NNP Doc_7504976_809_825_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7504976_827_835_Chemical)) (-RRB- -RRB-))) (VP (AUX had) (VP (VBN replaced) (NP (NNP Doc_7504976_850_861_Chemical))))))))))) (. .)))
7504976	7	(S1 (S (NP (NP (JJ Biological) (NNS features)) (PP (IN of) (NP (NNP Doc_7504976_886_895_Disease)))) (VP (VBD disappeared) (PP (IN in) (NP (DT all) (NNS cases))) (PP (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (VBN incriminated) (NN drug))))) (, ,) (SBAR (IN while) (S (NP (JJ biliary) (, ,) (JJ viral) (CC and) (JJ immunological) (NNS searches)) (VP (AUX were) (ADJP (JJ negative)))))) (. .)))
7504976	8	(S1 (S (NP (NP (QP (RB Only) (CD 2)) (NNS patients)) (PP (IN of) (NP (PRP$ our) (NN retrospective) (NN study)))) (VP (VBD experienced) (NP (DT a) (ADJP (ADJP (JJ mild)) (CC or) (ADJP (JJ severe))) (NN Doc_7504976_1098_1109_Disease))) (. .)))
7504976	9	(S1 (S (NP (NN Doc_7504976_1123_1138_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ potential) (JJ adverse) (NN effect)) (PP (IN of) (NP (JJ antithyroid) (NNS drugs))) (SBAR (WHNP (WDT which)) (S (VP (VBZ warrants) (, ,) (PP (IN as) (PP (IN for) (NP (NP (JJ haematological) (NNS disturbances)) (, ,) (NP (DT a) (JJ pre-therapeutic) (NN determination)) (CC and) (NP (NP (DT a) (JJ careful) (NN follow-up)) (PP (IN of) (NP (JJ relevant) (JJ biological) (NNS markers)))))))))))) (. .)))
7504976	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NNP Doc_7504976_1340_1354_Disease)) (VP (MD may) (RB not) (VP (AUX be) (VP (VBN restricted) (PP (TO to) (NP (NP (CD one) (NN class)) (PP (IN of) (NP (JJ antithyroid) (NNS agents)))))))) (. .)))
7516729	0	(S1 (S (NP (NP (JJ Interactive) (NNS effects)) (PP (IN of) (NP (NP (NNS variations)) (PP (IN in) (NP (NP (JJ -LSB-Doc_7516729_38_40_Chemical) (JJ -RSB-) (NNS o)) (CC and) (NP (JJ -LSB-Doc_7516729_48_50_Chemical) (NNS -RSB-))))))) (VP (VBP o) (PP (IN on) (NP (NN rat) (JJ atrial) (JJ spontaneous) (NN frequency)))) (. .)))
7516729	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (S (VP (VBG varying) (NP (NP (DT the) (JJ extracellular) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_7516729_149_151_Chemical) (CC and) (NNP Doc_7516729_156_158_Chemical)))))) (PRN (-LRB- -LRB-) (NP (NP (JJ -LSB-Doc_7516729_161_163_Chemical) (JJ -RSB-) (NNS o)) (CC and) (NP (JJ -LSB-Doc_7516729_171_173_Chemical) (JJ -RSB-) (NNS o))) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT both)) (, ,) (NP (NP (NP (DT the) (JJ spontaneous) (NN beating)) (CC and) (NP (DT the) (JJ negative) (JJ chronotropic) (NN action))) (PP (IN of) (NP (NNP Doc_7516729_250_259_Chemical)))) (, ,)))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (DT the) (VBN isolated) (NN rat) (NN atria))))) (. .)))
7516729	2	(S1 (S (NP (NP (JJ Basal) (NN frequency)) (PRN (-LRB- -LRB-) (NP (NN BF)) (-RRB- -RRB-)) (VP (VBN evaluated) (PP (IN by) (NP (NN surface) (NN electrogram))))) (VP (AUX was) (NP (NP (CD 223) (NN +/-) (QP (CD 4) (CD beats/min.))) (PP (IN in) (NP (NP (NN control) (NN Krebs-Ringer)) (VP (VBG containing) (NP (QP (CD 137) (CD mM)) (NX (NX (NNP Doc_7516729_422_424_Chemical)) (CC and) (NX (NX (CD 1.35) (JJ mM) (NNP Doc_7516729_437_439_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP N)) (-RRB- -RRB-)))))))))) (. .)))
7516729	3	(S1 (S (NP (PRP It)) (VP (VBD decreased) (PP (IN by) (NP (CD 16) (NN +/-))) (NP (CD 3) (NN %)) (PP (IN by) (S (VP (VBG lowering) (NP (JJ -LSB-Doc_7516729_484_486_Chemical) (JJ -RSB-) (NNS o)) (PP (TO to) (NP (NP (CD 78) (NNS mM)) (PRN (-LRB- -LRB-) (NP (NNP LNa)) (-RRB- -RRB-)) (, ,) (NP (NP (CD 23) (NN +/-)) (NP (CD 2) (NN %))))) (PP (IN by) (S (VP (VBG lowering) (NP (NP (ADJP (RB simultaneously) (JJ -LSB-Doc_7516729_543_545_Chemical)) (JJ -RSB-) (NNS o)) (PP (TO to) (NP (NP (CD 78) (NNS mM)) (CC and) (NP (JJ -LSB-Doc_7516729_562_564_Chemical) (JJ -RSB-) (NNS o))))) (PP (TO to) (NP (NP (NP (CD 0.675) (NNS mM)) (PRN (-LRB- -LRB-) (NP (NNP LNa+LCa)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 31) (NNS +/-)) (NP (CD 5) (NN %))))) (PP (IN by) (S (VP (VP (VBG lowering) (NP (JJ -LSB-Doc_7516729_616_618_Chemical) (JJ -RSB-) (NNS o)) (PP (TO to) (NP (CD 78) (NN mM)))) (CC plus) (VP (VBG increasing) (NP (JJ -LSB-Doc_7516729_647_649_Chemical) (JJ -RSB-) (NNS o)) (PP (TO to) (NP (NP (QP (CD 3.6) (CD mM))) (PRN (-LRB- -LRB-) (NP (NNP LNa+HCa)) (-RRB- -RRB-))))))))))))))) (. .)))
7516729	4	(S1 (S (S (PP (IN At) (NP (JJ normal) (JJ -LSB-Doc_7516729_684_686_Chemical) (JJ -RSB-) (NN o))) (, ,) (NP (NP (NP (NP (NN decrease)) (PRN (-LRB- -LRB-) (NP (CD 0.675) (NNS mM)) (-RRB- -RRB-))) (CC or) (NP (NP (NN increase)) (PRN (-LRB- -LRB-) (NP (CD 3.6) (NNS mM)) (-RRB- -RRB-)))) (PP (IN of) (NP (JJ -LSB-Doc_7516729_735_737_Chemical) (JJ -RSB-) (NNS o)))) (VP (AUX did) (RB not) (VP (VB modify) (NP (NN BF))))) (: ;) (S (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (CD ten) (NNS times)) (-LRB- -LRB-) (NP (CD 0.135) (NNS mM)) (PP (IN of) (NP (JJ normal) (JJ -LSB-Doc_7516729_805_807_Chemical) (JJ -RSB-) (NNS o)))))) (VP (AUX was) (ADJP (JJ effective) (S (VP (TO to) (VP (VB reduce) (NP (NN BF)) (PP (IN by) (NP (NP (CD 40) (NN +/-)) (NP (CD 13) (NN %)))))))))) (. .)))
7516729	5	(S1 (S (NP (DT All) (JJ negative) (JJ chronotropic) (NNS effects)) (VP (AUX were) (ADJP (JJ BF-dependent))) (. .)))
7516729	6	(S1 (S (NP (NP (JJ Dose-dependent) (NN Doc_7516729_920_931_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7516729_943_952_Chemical))))) (VP (AUX was) (VP (VBN potentiated) (PP (IN by) (NP (NP (NNP LNa)) (, ,) (NP (NNP LCa)) (, ,) (CC and) (NP (NNP HCa)))))) (. .)))
7516729	7	(S1 (S (NP (NP (ADJP (ADJP (JJ Independent)) (CC but) (ADJP (RB not) (JJ additive))) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_7516729_1031_1033_Chemical)) (CC and) (NP (NNP Doc_7516729_1038_1040_Chemical))))) (VP (AUX are) (VP (VBN shown) (PP (IN by) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (NP (DT the) (NNS values)) (PP (IN of) (NP (NP (JJ -LSB-Doc_7516729_1082_1091_Chemical) (JJ -RSB-) (NNS o)) (VP (VBN needed) (S (VP (TO to) (VP (VB reduce) (NP (NN BF)) (PP (IN by) (NP (NP (CD 30) (NN %)) (PRN (-LRB- -LRB-) (NP (CD IC30)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (DT the) (JJ following) (NN order)) (PP (IN of) (NP (JJ inhibitory) (NN potency)))))))))))) (: :) (NP (NNP LNa) (NNP >) (NNP LCa) (NNP >) (NNP HCa) (NNP >) (NNP N)))))) (, ,) (S (VP (VBG resulting) (NP (NP (NN LNa+HCa)) (ADJP (JJ similar) (PP (TO to) (NP (NNP LNa))))))))) (. .)))
7516729	8	(S1 (S (NP (DT The) (JJ -LSB-Doc_7516729_1236_1245_Chemical) (NN -RSB-)) (VP (VBD o) (SBAR (IN that) (S (NP (NP (VBN arrested) (JJ atrial) (NN beating)) (PRN (-LRB- -LRB-) (NP (NNP AC)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB also)) (VP (VBN potentiated) (PP (IN with) (NP (NP (DT the) (NN order) (NN LNa)) (X (SYM =) (X (NP (NNP LNa+LCa) (SYM =) (NNP LNa+HCa) (SYM =) (NNP LCa) (NNPS >) (NNP HCa)) (SYM =)) (NP (NNP N)))))))))) (. .)))
7516729	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (S (VP (VB rat) (NP (JJ atrial) (JJ spontaneous) (NN beating)))) (VP (AUX is) (ADJP (ADJP (RBR more) (JJ dependent)) (PP (IN on) (NP (JJ -LSB-Doc_7516729_1438_1440_Chemical) (JJ -RSB-) (NNS o))) (PP (IN than) (PP (IN on) (NP (NP (JJ -LSB-Doc_7516729_1452_1454_Chemical) (JJ -RSB-) (NNS o)) (PP (IN in) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (QP (CD +/-) (CD 50)) (NN %)) (PP (IN of) (NP (PRP$ their) (JJ normal) (NN concentration))))))))))))))) (. .)))
7516729	10	(S1 (S (ADVP (RB Also)) (NP (NP (DT the) (NN enhancement)) (PP (IN of) (NP (JJ Doc_7516729_1534_1543_Chemical) (NNS effects))) (PP (IN on) (NP (JJ atrial) (NN beating)))) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ pronounced)) (PP (IN at) (NP (NNP LNa))) (PP (IN than) (PP (IN at) (NP (NNP LCa.))))) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))
7582165	0	(S1 (NP (NP (NP (NN Pseudo-Doc_7582165_7_25_Disease)) (PP (TO to) (NP (NNP Doc_7582165_29_44_Chemical)))) (: :) (NP (NP (NN diagnosis)) (CC and) (NP (NNS alternatives))) (. .)))
7582165	1	(S1 (S (NP (NP (CD Two) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (JJ parenteral) (NNP Doc_7582165_111_124_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Triniol)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7582165_139_152_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Sedionbel)) (-RRB- -RRB-))))))) (VP (AUX are) (VP (VBN described))) (. .)))
7582165	2	(S1 (S (NP (NP (DT A) (JJ few) (NNS minutes)) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NNS drugs)))))) (, ,) (NP (PRP they)) (VP (VBD presented) (NP (NP (NP (NNP Doc_7582165_244_253_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNS patients)) (CD 1) (CC and) (CD 2)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7582165_277_291_Disease)) (PRN (-LRB- -LRB-) (NP (NN patient) (CD 1)) (-RRB- -RRB-))))) (. .)))
7582165	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NP (NP (DT the) (NNS patients) (POS ')) (NNS reactions)) (, ,) (SBAR (SBAR (S (NP (DT the) (JJ immunological) (NNS mechanisms)) (VP (VBN involved)))) (CC and) (SBAR (IN whether) (S (NP (DT these) (NNS patients)) (VP (MD would) (VP (AUX be) (ADJP (JJ able) (S (VP (TO to) (VP (VB tolerate) (NP (NP (DT any) (NN kind)) (PP (IN of) (NP (NN corticoid)))))))))))))))))))) (. .)))
7582165	4	(S1 (S (NP (NP (NP (JJ Clinical) (NNS examinations)) (CC and) (NP (ADJP (NN skin) (, ,) (JJ oral) (CC and) (JJ parenteral)) (NNS challenges))) (PP (IN with) (NP (JJ different) (NNP Doc_7582165_577_592_Chemical) (CC and) (NNP ELISA) (NNS tests)))) (VP (AUX were) (VP (VBN performed))) (. .)))
7582165	5	(S1 (S (PP (IN In) (NP (DT the) (CD two) (NNS patients))) (, ,) (NP (NP (NN skin) (CC and) (NNP ELISA) (NNS tests)) (PP (IN with) (NP (NNP Doc_7582165_672_685_Chemical)))) (VP (AUX were) (ADJP (JJ negative)) (, ,) (SBAR (IN as) (S (VP (AUX was) (NP (DT the) (JJ prick) (NN test)) (PP (IN with) (NP (NP (DT each)) (PP (IN of) (NP (PRP$ its) (NNS excipients))))))))) (. .)))
7582165	6	(S1 (S (NP (NP (DT A) (JJ single-blind) (JJ parenteral) (NN challenge)) (PP (IN with) (NP (NNP Triniol)))) (VP (AUX was) (ADJP (ADJP (JJ positive) (PP (IN in) (NP (NP (DT both) (NNS patients)) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (CD 1) (NN ml)) (PP (IN of) (NP (DT the) (NN drug)))))))))) (, ,) (CC and) (ADJP (JJ negative) (PP (IN with) (NP (PRP$ its) (NNS excipients)))))) (. .)))
7582165	7	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VP (VBD carried) (PRT (RP out)) (NP (NP (JJ oral) (CC and) (JJ parenteral) (NNS challenges)) (PP (IN with) (NP (JJ other) (NNP Doc_7582165_973_988_Chemical))))) (CC and) (VP (VBD found) (NP (NN intolerance)) (PP (TO to) (NP (NP (DT some)) (PP (IN of) (NP (PRP them))))))) (. .)))
7582165	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_7582165_1055_1068_Chemical)) (VP (VBD caused) (NP (JJ pseudoallergic) (NNS reactions)) (PP (IN in) (NP (PRP$ our) (NNS patients))))))) (. .)))
7582165	9	(S1 (S (S (NP (NP (NNS Corticosteroids)) (ADJP (JJ different) (PP (IN from) (NP (NNP Doc_7582165_1149_1162_Chemical))))) (ADVP (RB also)) (VP (VBD produced) (NP (NNP Doc_7582165_1177_1193_Disease) (NNS reactions)) (PP (IN in) (NP (DT these) (NNS patients))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (DT a) (JJ few)) (PP (IN of) (NP (PRP them)))) (VP (AUX were) (VP (VBN tolerated)))) (. .)))
7582165	10	(S1 (S (NP (NP (DT The) (JJ basic) (NNS mechanisms)) (PP (IN of) (NP (DT those) (NNS reactions)))) (VP (AUX are) (RB not) (ADVP (RB yet)) (ADVP (RB fully)) (VP (VBN understood))) (. .)))
7582165	11	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN report)) (PP (IN of) (NP (NP (DT a) (NN pseudo-Doc_7582165_1387_1394_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7582165_1405_1418_Chemical)))))))) (. .)))
7628595	0	(S1 (S (NP (NP (NN Study)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NNP Doc_7628595_21_32_Chemical)) (CC and) (NP (NNP Doc_7628595_37_49_Chemical))))))) (VP (VBP supplementation) (PP (IN in) (S (VP (VBG preventing) (NP (NP (JJ hematologic) (NN Doc_7628595_92_100_Disease)) (PP (IN of) (NP (NNP Doc_7628595_104_114_Chemical)))))))) (. .)))
7628595	1	(S1 (S (NP (DT A) (JJ prospective) (, ,) (JJ randomized) (NN study)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_7628595_186_197_Chemical) (CC and) (NNP Doc_7628595_202_214_Chemical) (NN supplementation))) (PP (IN in) (S (VP (VBG preventing) (NP (JJ Doc_7628595_245_255_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_7628595_257_260_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_7628595_270_293_Disease))))))))))) (. .)))
7628595	2	(S1 (S (NP (NP (JJ Seventy-five) (JJ Doc_7628595_308_351_Disease) (NNS patients)) (PP (IN with) (NP (CD CD4+) (NN cell) (NNS counts)))) (VP (VBD <) (SBAR (S (NP (NNS 500/mm3)) (VP (AUX were) (VP (VBN randomized) (UCP (S (VP (TO to) (VP (VB receive) (NP (NP (DT either) (NNP Doc_7628595_427_430_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 500) (CD mg)) (NN daily)) (-RRB- -RRB-))) (ADVP (RB alone)) (PRN (-LRB- -LRB-) (NP (NP (NN group) (NN I)) (, ,) (NP (NNP n) (SYM =) (CD 38))) (-RRB- -RRB-))))) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (NNP Doc_7628595_493_505_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CD mg)) (NN daily)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ intramascular) (NNP Doc_7628595_538_549_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1000) (NNS micrograms) (JJ monthly)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NN group) (NNP II)) (, ,) (NP (NNP n) (SYM =) (CD 37)) (-RRB- -RRB-))))))))))))) (. .)))
7628595	3	(S1 (S (S (ADVP (RB Finally)) (, ,) (NP (CD 15) (NNS patients)) (VP (AUX were) (VP (VBN excluded) (PP (IN from) (NP (DT the) (NN study))) (PRN (-LRB- -LRB-) (NP (NP (NN noncompliance) (CD 14)) (, ,) (NP (NNP Doc_7628595_665_670_Disease) (CD 1))) (-RRB- -RRB-))))) (: ;) (S (ADVP (RB thus)) (, ,) (NP (NP (CD 60) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 31)) (PP (IN in) (NP (NN group) (NN I)))) (CC and) (NP (NP (CD 29)) (PP (IN in) (NP (NN group) (NNP II))))) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ eligible) (PP (IN for) (NP (NN analysis)))))) (. .)))
7628595	4	(S1 (S (NP (NP (DT No) (JJ significant) (NNS differences)) (PP (IN between) (NP (NNS groups)))) (VP (AUX were) (VP (VBN found) (PP (IN at) (NP (NN enrollment))))) (. .)))
7628595	5	(S1 (S (S (PP (IN During) (NP (DT the) (NN study))) (, ,) (NP (NNP Doc_7628595_842_853_Chemical) (CC and) (NNP Doc_7628595_858_864_Chemical) (NNS levels)) (VP (AUX were) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NN group) (NNP II) (NNS patients))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (NN hemoglobin)) (, ,) (NP (JJ hematocrit) (, ,) (JJ mean) (NN corpuscular) (NN volume)) (, ,) (CC and) (NP (NN white-cell) (, ,) (NN neutrophil) (CC and) (NN platelet) (NNS counts))))) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (NP (NNS groups)) (PP (IN at) (NP (CD 3) (, ,) (CD 6) (, ,) (CD 9) (CC and) (CD 12) (NNS months)))))))) (. .)))
7628595	6	(S1 (S (NP (NP (JJ Severe) (JJ hematologic) (NN Doc_7628595_1117_1125_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN neutrophil) (NN count) (NNP <) (JJ 1000/mm3) (NN and/or) (NN hemoglobin) (NN <)) (NP (CD 8) (NN g/dl))) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 4) (NNS patients)) (VP (VBN assigned) (PP (TO to) (NP (NP (NN group) (NN I)) (CC and) (NP (NP (CD 7)) (VP (VBN assigned) (PP (TO to) (NP (NN group) (NNP II))))))))))) (. .)))
7628595	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN correlation)) (PP (IN between) (NP (NP (NNP Doc_7628595_1287_1298_Chemical) (CC or) (NNP Doc_7628595_1302_1308_Chemical) (NNS levels)) (CC and) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_7628595_1335_1351_Disease)))))))) (. .)))
7628595	8	(S1 (S (NP (NP (ADJP (JJ Doc_7628595_1353_1364_Chemical) (CC and) (JJ Doc_7628595_1369_1381_Chemical)) (NN supplementation)) (PP (IN of) (NP (JJ Doc_7628595_1401_1404_Chemical) (NN therapy)))) (VP (AUX does) (RB not) (VP (VB seem) (ADJP (JJ useful) (PP (IN in) (S (VP (VP (VBG preventing)) (CC or) (VP (VBG reducing) (NP (NP (JJ Doc_7628595_1460_1463_Chemical-induced) (NN Doc_7628595_1472_1485_Disease)) (PP (IN in) (NP (DT the) (JJ overall) (VBN treated) (NN population))))))))) (, ,) (SBAR (IN although) (S (NP (NP (DT a) (JJ beneficial) (NN effect)) (PP (IN in) (NP (NP (JJ certain) (NNS subgroups)) (PP (IN of) (NP (NNS patients)))))) (ADVP (RB cannot)) (VP (AUX be) (VP (VBN excluded))))))) (. .)))
7802851	0	(S1 (NP (NP (NP (NN Safety)) (CC and) (NP (NN side-effects))) (PP (IN of) (NP (NNP Doc_7802851_27_37_Chemical))) (. .)))
7802851	1	(S1 (NP (NP (VBN Controlled) (NN study)) (PP (IN in) (NP (NP (NNP Doc_7802851_59_70_Disease)) (PP (IN with) (NP (NNP Doc_7802851_76_90_Disease))))) (. .)))
7802851	2	(S1 (S (NP (NP (DT The) (JJ widespread) (NN use)) (PP (IN of) (NP (NNP Doc_7802851_126_141_Chemical)))) (VP (AUX has) (VP (VBN led) (PP (TO to) (NP (NP (JJ increasing) (NN recognition)) (PP (IN of) (NP (PRP$ their) (JJ unwanted) (NNS effects))))))) (. .)))
7802851	3	(S1 (S (NP (NP (NP (DT The) (NN efficacy)) (PP (IN of) (NP (NP (NNP Doc_7802851_219_229_Chemical)) (CC and) (NP (NP (NN placebo)) (PP (IN in) (NP (NNP Doc_7802851_245_259_Disease))) (PP (IN with) (NP (NNP Doc_7802851_265_276_Disease))))))) (, ,) (CC and) (NP (DT the) (JJ side-effect) (CC and) (JJ adverse) (NN effect) (NNS profiles)) (PP (IN of) (NP (DT both) (NN drug) (NNS groups)))) (VP (AUX were) (VP (VBN measured))) (. .)))
7802851	4	(S1 (S (PP (IN In) (NP (NNP London) (CC and) (NNP Toronto))) (NP (NP (CD 154) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD met) (NP (NP (JJ DSM-III) (NNS criteria)) (PP (IN for) (NP (NNP Doc_7802851_433_447_Disease)))) (PP (IN with) (NP (NNP Doc_7802851_453_464_Disease))))))) (VP (AUX were) (VP (VBN randomised) (PP (TO to) (NP (NP (NN Doc_7802851_484_494_Chemical)) (CC or) (NP (NN placebo)))))) (. .)))
7802851	5	(S1 (S (NP (NP (NNS Subjects)) (PP (IN in) (NP (DT each) (NN drug) (NN group)))) (ADVP (RB also)) (VP (VBD received) (ADVP (RB either)) (NP (NP (NN exposure)) (CC or) (NP (NN relaxation)))) (. .)))
7802851	6	(S1 (S (NP (NN Treatment)) (VP (VP (AUX was) (PP (IN from) (NP (NNS weeks))) (ADVP (CD 0) (TO to) (CD 8))) (CC and) (VP (AUX was) (ADVP (RB then)) (ADJP (JJ tapered) (PP (IN from) (NP (NNS weeks) (QP (CD 8) (TO to) (CD 16))))))) (. .)))
7802851	7	(S1 (S (NP (JJ Mean) (JJ Doc_7802851_667_677_Chemical) (NN dose)) (VP (AUX was) (NP (CD 5) (NN mg)) (ADVP (RB daily))) (. .)))
7802851	8	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NN placebo) (NNS subjects)))) (, ,) (NP (NNP Doc_7802851_731_741_Chemical) (NNS patients)) (VP (VBD developed) (NP (NP (JJR more) (JJ adverse) (NNS reactions)) (PRN (-LRB- -LRB-) (NP (NP (CD 21) (NN %)) (CC v.) (NP (CD 0) (NN %))) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_7802851_799_809_Disease)) (, ,) (NP (NNP Doc_7802851_811_819_Disease)) (, ,) (NP (NN disinhibition)) (CC and) (NP (NNP Doc_7802851_839_849_Disease)))) (: ;) (CC and) (NP (JJR more) (NNS side-effects)) (, ,) (ADVP (RB particularly)) (NP (NP (NN sedation)) (, ,) (NP (NNP Doc_7802851_897_909_Disease) (, ,) (NNP Doc_7802851_911_926_Disease) (, ,) (NNP Doc_7802851_928_939_Disease) (CC and) (NNP Doc_7802851_944_950_Disease))))) (. .)))
7802851	9	(S1 (S (NP (NNS Side-effects)) (VP (VP (VBD tended) (S (VP (TO to) (VP (VB diminish) (PP (IN during) (NP (NN treatment))))))) (CC but) (VP (VBD remained) (ADJP (JJ significant)) (PP (IN at) (NP (NN week) (CD 8))))) (. .)))
7802851	10	(S1 (S (PP (IN Despite) (NP (DT this))) (, ,) (NP (DT the) (JJ drop-out) (NN rate)) (VP (AUX was) (ADJP (JJ low))) (. .)))
7802851	11	(S1 (S (S (NP (NN Doc_7802851_1091_1101_Chemical)) (VP (VBD caused) (NP (NP (NNS side-effects)) (CC and) (NP (JJ adverse) (NNS effects))) (PP (IN during) (NP (NN treatment))))) (CC but) (S (NP (JJ many) (NNS patients)) (VP (AUX were) (ADJP (JJ willing) (S (VP (TO to) (VP (VB accept) (NP (DT these)))))))) (. .)))
7834920	0	(S1 (S (NP (JJ Crescentic) (NN fibrillary) (NN Doc_7834920_22_40_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ intermittent) (JJ Doc_7834920_70_78_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_7834920_91_113_Disease)))))) (. .)))
7834920	1	(S1 (S (NP (DT This) (NN case) (NN study)) (VP (VBZ reveals) (NP (NP (DT an) (JJ unusual) (NN finding)) (PP (IN of) (NP (NP (RB rapidly) (JJ proliferative) (JJ crescentic) (NN Doc_7834920_194_212_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_7834920_239_247_Chemical)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (DT no) (JJ other) (JJ identifiable) (NNS causes)) (PP (IN for) (S (VP (VBG developing) (NP (DT this) (NN disease))))))))))))))))) (. .)))
7834920	2	(S1 (S (NP (DT This) (NN patient)) (VP (VP (VBD underwent) (NP (NP (DT a) (JJ 10-month) (NN regimen)) (PP (IN of) (NP (NP (NNP Doc_7834920_359_367_Chemical)) (CC and) (NP (NNP Doc_7834920_372_381_Chemical)))) (PP (IN for) (NP (NNP Doc_7834920_386_408_Disease))))) (CC and) (VP (AUX was) (VP (VBN discovered) (S (VP (TO to) (VP (AUX have) (VP (VBN developed) (NP (NP (NNS signs)) (PP (IN of) (NP (JJ severe) (NNP Doc_7834920_462_475_Disease) (CD five) (NNS weeks)))) (PP (IN after) (NP (NP (NN completion)) (PP (IN of) (NP (NN therapy)))))))))))) (. .)))
7834920	3	(S1 (S (NP (JJ Renal) (NN biopsy)) (VP (VBD revealed) (NP (NP (JJ severe) (NN Doc_7834920_545_563_Disease)) (PP (IN with) (NP (NP (NNS crescents)) (, ,) (NP (NNP electron) (JJ dense) (NN fibrillar) (NNS deposits)) (CC and) (NP (JJ moderate) (JJ lymphocytic) (NN interstitial) (VB infiltrate)))))) (. .)))
7834920	4	(S1 (S (NP (NP (JJ Other) (JJ possible) (NNS causes)) (PP (IN of) (NP (ADJP (RB rapidly) (JJ progressive)) (NN Doc_7834920_709_727_Disease)))) (VP (AUX were) (VP (VP (VBN investigated)) (CC and) (VP (VBD ruled) (PRT (RP out))))) (. .)))
7834920	5	(S1 (S (NP (DT This) (NN report)) (VP (VBZ documents) (NP (NP (DT the) (JJ unusual) (NN occurrence)) (PP (IN of) (NP (RB rapidly) (JJ progressive) (NNP Doc_7834920_829_847_Disease))) (PP (IN with) (NP (NP (NNS crescents)) (CC and) (NP (JJ fibrillar) (NN Doc_7834920_877_895_Disease))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7834920_922_930_Chemical))))))) (. .)))
7858459	0	(S1 (S (NP (JJ Acute) (NN Doc_7858459_6_15_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ high-dose) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_7858459_51_65_Chemical)) (CC and) (NP (NNP Doc_7858459_70_82_Chemical))))))) (. .)))
7858459	1	(S1 (S (NP (DT A) (JJ 61-year-old) (NN man)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NN combination) (NNS chemotherapy)) (VP (VBG incorporating) (NP (NP (NNP Doc_7858459_158_169_Chemical)) (, ,) (NP (NNP Doc_7858459_171_180_Chemical)) (, ,) (NP (NP (JJ high-dose) (NNP Doc_7858459_192_206_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2,250) (CD mg/m2/24)) (NNS hours)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_7858459_234_246_Chemical))) (PP (IN for) (NP (DT an) (JJ inoperable) (NN Doc_7858459_265_287_Disease)))))))) (. .)))
7858459	2	(S1 (S (NP (PRP He)) (VP (VP (VBD developed) (NP (NP (JJ acute) (JJ neurologic) (NNS symptoms)) (PP (IN of) (NP (JJ mental) (NNP Doc_7858459_338_347_Disease) (, ,) (NNP Doc_7858459_349_363_Disease) (CC and) (NNP Doc_7858459_368_380_Disease))))) (, ,) (CC and) (ADVP (RB then)) (VP (VBN lapsed) (PP (IN into) (NP (NP (DT a) (JJ deep) (NN Doc_7858459_410_414_Disease)) (, ,) (VP (VBG lasting) (PP (IN for) (NP (QP (RB approximately) (CD 40)) (NNS hours))) (PP (IN during) (NP (NP (DT the) (JJ first) (NN dose)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 2)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_7858459_484_498_Chemical) (CC and) (NNP Doc_7858459_503_515_Chemical) (NN infusion)))))))))) (. .)))
7858459	3	(S1 (S (NP (DT This) (NN complication)) (VP (VBD reappeared) (PP (IN on) (NP (NN day) (CD 25))) (PP (IN during) (NP (NP (DT the) (JJ second) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_7858459_591_605_Chemical)) (CC and) (NP (NNP Doc_7858459_610_622_Chemical)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADVP (RB then)) (NP (NP (DT the) (JJ only) (NNS drugs)) (VP (VBN given))))))))) (. .)))
7858459	4	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_7858459_670_682_Chemical)) (VP (AUX was) (ADJP (JJ unlikely) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (DT this) (NN condition))))))))))) (, ,) (NP (NNP Doc_7858459_734_747_Disease)) (PP (JJ due) (TO to) (NP (JJ high-dose) (NNP Doc_7858459_765_779_Chemical))) (VP (AUX was) (ADJP (RB highly) (VBN suspected))) (. .)))
7858459	5	(S1 (S (NP (NP (DT The) (NN pathogenesis)) (PP (IN of) (NP (NNP Doc_7858459_822_836_Chemical) (NNP Doc_7858459_837_850_Disease)))) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (NP (DT a) (NNP Krebs) (NN cycle) (NN blockade)) (PP (IN by) (NP (NP (NNP Doc_7858459_891_904_Chemical)) (CC and) (NP (NNP Doc_7858459_909_922_Chemical))))) (, ,) (NP (JJ Doc_7858459_924_932_Chemical) (NN deficiency)) (, ,) (CC or) (NP (JJ Doc_7858459_948_961_Chemical) (NN dehydrogenase) (NN deficiency))))))) (. .)))
7858459	6	(S1 (S (NP (JJ High-dose) (JJ Doc_7858459_998_1012_Chemical/Doc_7858459_1013_1025_Chemical) (NN infusion) (NN therapy)) (VP (AUX has) (ADVP (RB recently)) (VP (VBN become) (NP (NP (DT a) (JJ popular) (NN regimen)) (PP (IN for) (NP (JJ various) (NNP Doc_7858459_1093_1100_Disease)))))) (. .)))
7858459	7	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ necessary)) (SBAR (IN that) (S (NP (DT both) (NNS oncologists) (CC and) (NNS neurologists)) (VP (AUX be) (ADJP (RB fully) (JJ aware) (PP (IN of) (NP (DT this) (JJ unusual) (NN complication)))))))) (. .)))
7862923	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (S (VP (VBG switching) (NP (NN Doc_7862923_20_33_Chemical)) (PP (TO to) (NP (NNP Doc_7862923_37_50_Chemical)))))) (PP (IN on) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (NNS neuroleptics))))) (. .)))
7862923	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
7862923	2	(S1 (S (NP (NN Doc_7862923_104_117_Chemical)) (VP (AUX was) (VP (VBN switched) (PP (TO to) (NP (NP (PRP$ its) (JJ 10-keto) (NN analogue) (NN Doc_7862923_155_168_Chemical)) (PP (IN among) (NP (NP (CD six) (JJ difficult-to-treat) (NNP Doc_7862923_198_211_Disease) (CC or) (NNP Doc_7862923_215_232_Disease) (NNS patients)) (VP (VBG using) (NP (RB concomitantly) (NNP Doc_7862923_262_273_Chemical) (, ,) (NNP Doc_7862923_275_289_Chemical) (CC or) (NNP Doc_7862923_293_302_Chemical))))))))) (. .)))
7862923	3	(S1 (S (NP (DT This) (NN change)) (VP (VBD resulted) (PP (IN within) (NP (JJ 2-4) (NNS weeks))) (PP (IN in) (NP (NP (NP (DT the) (ADJP (CD 50-200) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NNS levels)) (PP (IN of) (NP (DT these) (NNS neuroleptics)))))) (CC and) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NNP Doc_7862923_431_454_Disease))))))) (. .)))
7862923	4	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD showed) (NP (DT any) (JJ clinical) (NN deteriotation)) (PP (IN during) (NP (DT the) (JJ following) (JJ 3-6) (NNS months)))) (. .)))
7862923	5	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN case)))) (VP (VBP report) (SBAR (S (VP (VBP support) (NP (NP (DT the) (NN idea)) (SBAR (WHNP (WDT that)) (S (PP (IN in) (NP (NP (NN contrast)) (PP (IN with) (NP (NNP Doc_7862923_615_628_Chemical) (NNP Doc_7862923_629_642_Chemical))))) (VP (AUX does) (RB not) (VP (VB induce) (NP (NP (DT the) (JJ hepatic) (JJ microsomal) (NN enzyme) (NNS systems)) (VP (VBG regulating) (NP (NP (DT the) (NN inactivation)) (PP (IN of) (NP (JJ antipsychotic) (NNS drugs))))))))))))))) (. .)))
7881871	0	(S1 (NP (NP (NN Time) (NN course)) (PP (IN of) (NP (NN lipid) (NN peroxidation))) (PP (IN in) (NP (NNP Doc_7881871_37_62_Chemical-induced) (NNP Doc_7881871_71_82_Disease))) (. .)))
7881871	1	(S1 (S (NP (JJ Reactive) (JJ Doc_7881871_93_99_Chemical) (NNS species)) (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (JJ acute) (NNP Doc_7881871_158_183_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_7881871_185_188_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_7881871_198_209_Disease))))) (, ,) (PP (IN with) (NP (NP (NNS antioxidants)) (VP (ADVP (RB significantly)) (VBG reducing) (NP (DT the) (NNP Doc_7881871_256_267_Disease)))))))) (. .)))
7881871	2	(S1 (S (NP (NP (DT The) (JJ temporal) (NN relationship)) (PP (IN between) (NP (NP (NP (NN lipid) (NN peroxidation)) (PP (IN in) (NP (DT the) (NN kidney)))) (CC and) (NP (NNP Doc_7881871_340_351_Disease))))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (DT this) (NN study))))) (. .)))
7881871	3	(S1 (S (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ single) (NNP IV) (NN injection)) (PP (IN of) (NP (NNP Doc_7881871_428_453_Chemical))))) (, ,) (PRN (-LRB- -LRB-) (NP (NNP Doc_7881871_456_459_Chemical)) (, ,) (NP (CD 7.5) (NN mg/kg)) (-RRB- -RRB-))))) (CC and) (S (NP (CD 24) (NN hour) (NN urine) (NNS samples)) (VP (AUX were) (VP (VBN obtained) (ADVP (RB prior)) (S (VP (TO to) (VP (VB sacrifice) (PP (IN on) (NP (NP (NNS days) (CD 3,5,7,10,17,27,41)) (PRN (-LRB- -LRB-) (NP (NNP N) (SYM =) (PP (JJ 5-10) (IN per) (NP (NN group)))) (-RRB- -RRB-)))))))))) (. .)))
7881871	4	(S1 (S (NP (DT The) (NNS kidneys)) (VP (AUX were) (VP (VBN removed) (, ,) (PP (VBN flushed) (PP (IN with) (NP (NN ice) (JJ cold) (NN TRIS) (NN buffer)))))) (. .)))
7881871	5	(S1 (S (NP (NP (NN Kidney) (NNS cortices)) (PP (IN from) (NP (DT each) (NN animal)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB prepare) (NP (NNS homogenates))))))) (. .)))
7881871	6	(S1 (S (NP (NN Tissue) (NN lipid) (NN peroxidation)) (VP (AUX was) (VP (VBN measured) (PP (IN in) (NP (JJ whole) (NNS homogenates))) (PP (CONJP (RB as) (RB well) (IN as)) (IN in) (NP (NP (NN lipid) (NNS extracts)) (PP (IN from) (NP (NP (NNS homogenates)) (PP (IN as) (NP (JJ Doc_7881871_816_835_Chemical) (JJ reactive) (NNS substances))))))))) (. .)))
7881871	7	(S1 (S (S (NP (NN Doc_7881871_857_868_Disease)) (VP (AUX was) (ADJP (JJ evident)) (PP (IN at) (NP (NN day) (CD 5))))) (, ,) (VP (VP (VBD peaked) (PP (IN at) (NP (NN day) (CD 7)))) (CC and) (VP (VBD persisted) (PP (TO to) (NP (NN day) (CD 27))))) (. .)))
7881871	8	(S1 (S (NP (NP (NN Lipid) (NN peroxidation)) (PP (IN in) (NP (NNS homogenates)))) (VP (VP (AUX was) (ADVP (RB maximal)) (PP (IN at) (NP (NN day) (CD 3)))) (CC and) (VP (VBD declined) (ADVP (RB rapidly)) (S (VP (TO to) (VP (VB control) (NP (NNS levels)) (PP (IN by) (NP (NN day) (CD 17)))))))) (. .)))
7881871	9	(S1 (S (NP (DT This) (NN study)) (VP (VBZ supports) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN lipid) (NN peroxidation))) (PP (IN in) (S (VP (VBG mediating) (NP (NP (DT the) (NN Doc_7881871_1105_1123_Disease)) (PP (IN in) (NP (NNP Doc_7881871_1127_1130_Chemical) (NNP Doc_7881871_1131_1142_Disease))))))))) (. .)))
7890216	0	(S1 (NP (NP (NP (NN Composition)) (PP (IN of) (NP (NNP Doc_7890216_15_34_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_7890216_51_61_Chemical))))) (: :) (NP (NP (NN response)) (PP (TO to) (NP (JJ oral) (NNP Doc_7890216_80_100_Chemical)))) (. .)))
7890216	1	(S1 (S (NP (NP (NNP Doc_7890216_102_112_Chemical)) (, ,) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (NNP Doc_7890216_141_151_Disease)))) (, ,)) (VP (VBZ induces) (NP (NN Doc_7890216_161_180_Disease)) (PP (IN in) (NP (NP (CD 13-60) (NN %)) (PP (IN of) (NP (NNS patients)))))) (. .)))
7890216	2	(S1 (S (SBAR (IN Because) (S (NP (NP (NN knowledge)) (PP (IN of) (NP (NN stone) (NN composition)))) (VP (AUX is) (ADJP (JJ essential) (PP (IN for) (NP (NP (NNS studies)) (PP (IN of) (NP (PRP$ their) (NN pathogenesis) (, ,) (NN treatment) (, ,) (CC and) (NN prevention))))))))) (, ,) (NP (DT this)) (VP (AUX was) (VP (VBN investigated) (PP (IN by) (NP (NP (JJ direct) (CC and) (JJ indirect) (NNS methods)) (PP (IN in) (NP (NP (CD 14) (JJ Doc_7890216_377_387_Chemical) (VBN treated) (JJ Doc_7890216_396_407_Disease) (NNS patients)) (PP (IN with) (NP (NNP Doc_7890216_422_433_Disease))))))))) (. .)))
7890216	3	(S1 (S (S (NP (NP (JJ Chemical) (NN analysis)) (PP (IN of) (NP (NNP Doc_7890216_456_467_Disease)))) (VP (VBD retrieved) (PP (IN at) (NP (NN cholecystectomy))) (PP (IN from) (NP (CD two) (NNS patients))))) (, ,) (VP (VBD showed) (SBAR (IN that) (S (NP (PRP they)) (VP (VBD contained) (NP (NP (CD 71) (NN %)) (CC and) (NP (CD 87) (NN %))) (NP (NNP Doc_7890216_555_566_Chemical)) (PP (IN by) (NP (NN weight))))))) (. .)))
7890216	4	(S1 (S (PP (IN In) (NP (DT the) (JJ remaining) (CD 12) (NNS patients))) (, ,) (NP (NP (JJ localised) (JJ computed) (NN tomography)) (PP (IN of) (NP (DT the) (NN gall) (NN bladder)))) (VP (VBD showed) (SBAR (IN that) (S (NP (CD eight)) (VP (AUX had) (NP (NNS stones)) (PP (IN with) (NP (NP (JJ maximum) (JJ attenuation) (NNS scores)) (PP (IN of) (NP (NP (QP (CD <) (CD 100)) (NNP Hounsfield) (NNS units)) (PRN (-LRB- -LRB-) (S (NP (NP (NNS values)) (PP (IN of) (NP (QP (CD <) (CD 100)) (NNS HU)))) (VP (VBP predict) (NP (JJ Doc_7890216_773_784_Chemical) (JJ rich) (, ,) (JJ dissolvable) (NNS stones)))) (-RRB- -RRB-)))))))))) (. .)))
7890216	5	(S1 (S (NP (NN Gall) (NN bladder) (NN bile)) (VP (AUX was) (VP (VBN obtained) (PP (IN by) (NP (NP (NN ultrasound)) (VP (VBN guided)))) (, ,) (NP (NP (JJ fine) (NN needle) (NN puncture)) (PP (IN from) (NP (CD six) (NNS patients)))))) (. .)))
7890216	6	(S1 (S (S (NP (DT All) (CD six) (NNS patients)) (VP (AUX had) (VP (VBN supersaturated) (NP (JJ bile) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (NP (NP (NP (PRN (-LRB- -LRB-) (NP (NNP SEM)) (-RRB- -RRB-)) (NNP Doc_7890216_958_969_Chemical) (NN saturation) (NN index)) (PP (IN of) (NP (CD 1.19)))) (-LRB- -LRB-) (NP (CD 0.08)) (-RRB- -RRB-)) (-LRB- -LRB-) (NP (NN range) (CD 1.01-1.53)) (-RRB- -RRB-)))) (-RRB- -RRB-) (S (CC and) (NP (DT all)) (VP (AUX had) (NP (NP (ADJP (RB abnormally) (JJ rapid)) (JJ Doc_7890216_1050_1061_Chemical) (JJ microcrystal) (NN nucleation) (NNS times)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD <) (CD 4)) (NNS days)) (PRN (-LRB- -LRB-) (NN range) (NN 1-4) (-RRB- -RRB-))) (-RRB- -RRB-))))) (, ,)) (NN whilst)) (PP (IN in) (NP (CD four)))))) (, ,) (NP (DT the) (NN bile)) (VP (VBD contained) (NP (JJ Doc_7890216_1151_1162_Chemical) (NNS microcrystals)) (ADVP (RB immediately)) (PP (IN after) (S (VP (VBG sampling))))) (. .)))
7890216	7	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 12) (NNS patients)) (VP (VBN considered) (PP (IN for) (NP (JJ oral) (NNP Doc_7890216_1244_1264_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_7890216_1266_1270_Chemical)) (-RRB- -RRB-)) (NN treatment)))))) (, ,) (NP (CD two)) (VP (VP (AUX had) (NP (DT a) (VBN blocked) (JJ cystic) (NN duct))) (CC and) (VP (AUX were) (RB not) (VP (VBD started) (PP (IN on) (NP (NNP Doc_7890216_1337_1341_Chemical))) (SBAR (IN while) (S (NP (PRP one)) (VP (AUX was) (VP (VBN lost) (S (VP (TO to) (VP (VB follow) (PRT (RP up)))))))))))) (. .)))
7890216	8	(S1 (S (PP (IN After) (NP (NP (CD one) (NN year)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (NP (CD five)) (PP (IN of) (NP (DT the) (JJ remaining) (CD nine) (NNS patients)))) (VP (VBD showed) (NP (DT either) (ADJP (ADJP (ADJP (JJ partial)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-))) (CC or) (ADJP (ADJP (JJ complete)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 2)) (-RRB- -RRB-)))) (NNP Doc_7890216_1490_1500_Disease) (NN dissolution)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (PRP$ their) (NNS stones)) (VP (AUX were) (ADJP (NNP Doc_7890216_1548_1559_Chemical) (JJ rich)))))))) (. .)))
7890216	9	(S1 (NP (NP (NP (DT This) (NNS corresponds)) (, ,) (PP (IN by) (NP (JJ actuarial) (PRN (-LRB- -LRB-) (NP (NN life) (NN table)) (-RRB- -RRB-)) (NN analysis))) (, ,)) (PP (TO to) (NP (NP (DT a) (JJ combined) (JJ Doc_7890216_1634_1644_Disease) (NN dissolution) (NN rate)) (PP (IN of) (NP (CD 58.3))) (PRN (-LRB- -LRB-) (NP (CD 15.9) (NN %)) (-RRB- -RRB-)))) (. .)))
7890216	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NNP Doc_7890216_1694_1704_Chemical)) (VP (VBN induced) (NP (NNP Doc_7890216_1713_1724_Disease)))) (VP (AUX are) (ADJP (ADJP (RB generally) (JJ small)) (, ,) (ADJP (JJ multiple)) (, ,) (CC and) (ADJP (JJ Doc_7890216_1760_1771_Chemical) (JJ rich))) (SBAR (IN although) (S (, ,) (PP (IN in) (NP (NP (NN common)) (PP (IN with) (NP (JJ spontaneous) (NNP Doc_7890216_1814_1832_Disease))))) (, ,) (PP (IN at) (NP (NN presentation))) (NP (DT some) (NNS patients)) (VP (MD will) (VP (AUX have) (NP (NP (DT a) (VBN blocked) (JJ cystic) (NN duct)) (CC and) (NP (NP (DT some) (NN Doc_7890216_1905_1916_Disease)) (VP (VBG containing) (NP (NNP Doc_7890216_1928_1935_Chemical)))))))))) (. .)))
7919560	0	(S1 (S (NP (NP (NN Doc_7919560_0_19_Disease)) (CC and) (NP (NN Doc_7919560_24_52_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7919560_63_73_Chemical)))) (. .)))
7919560	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_7919560_106_125_Disease)) (CC and) (NP (NNP Doc_7919560_130_158_Disease)))))))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7919560_169_179_Chemical)))) (. .)))
7919560	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (S (NP (DT A) (JJ 13-year-old) (NN boy)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_7919560_230_240_Chemical)) (CC and) (NP (NNP Doc_7919560_245_255_Chemical)))) (PP (IN because) (IN of) (NP (VBN suspected) (NN Doc_7919560_277_287_Disease)))))) (. .)))
7919560	3	(S1 (S (NP (NNS Medications)) (VP (AUX were) (VP (VBN discontinued) (SBAR (WHADVP (WRB when)) (S (NP (NP (NP (NNP Doc_7919560_324_343_Disease)) (CC and) (NP (NNP Doc_7919560_348_372_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_7919560_383_394_Disease))))) (VP (VBD occurred)))))) (. .)))
7919560	4	(S1 (S (NP (DT The) (NN patient)) (VP (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_7919560_434_452_Chemical))))) (CC and) (VP (ADVP (RB gradually)) (VBN improved))) (. .)))
7919560	5	(S1 (S (NP (NP (JJ Macrophage-migration) (NN inhibition) (PRN (-LRB- -LRB-) (NP (NNP MIF)) (-RRB- -RRB-)) (NN test)) (PP (IN with) (NP (NNP Doc_7919560_525_535_Chemical)))) (VP (AUX was) (ADJP (JJ positive))) (. .)))
7919560	6	(S1 (S (SBAR (IN After) (S (NP (NP (RBS most) (JJ Doc_7919560_573_583_Disease)) (PP (VBG causing) (NP (NP (NNP Doc_7919560_592_611_Disease)) (CC and) (NP (NNP Doc_7919560_616_627_Disease))))) (VP (AUX were) (VP (VBN ruled) (PRT (RP out)))))) (, ,) (NP (DT a) (NN Doc_7919560_646_676_Disease)) (VP (AUX was) (VP (VBN suspected))) (. .)))
7919560	7	(S1 (S (NP (NP (JJ Positive) (NN MIF) (NN test)) (PP (IN for) (NP (NNP Doc_7919560_714_724_Chemical)))) (VP (VBD showed) (NP (NP (NN sensitization)) (PP (IN of) (NP (NP (DT the) (NN patient) (POS 's)) (NNS lymphocytes))) (PP (TO to) (NP (NNP Doc_7919560_778_788_Chemical))))) (. .)))
7919560	8	(S1 (S (NP (NN Doc_7919560_803_831_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC and) (JJ dangerous)) (NN manifestation)) (PP (IN of) (NP (NNP Doc_7919560_873_880_Disease))) (PP (TO to) (NP (NNP Doc_7919560_884_895_Chemical))))) (. .)))
7930386	0	(S1 (S (NP (JJ Doc_7930386_0_12_Chemical-induced) (NNP Doc_7930386_21_38_Disease)) (VP (AUX does) (RB not) (VP (VB impair) (NP (PRP$ its) (JJ prolactin-releasing) (NN action)))) (. .)))
7930386	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NNP Doc_7930386_143_160_Disease)) (, ,) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7930386_173_185_Chemical) (NN administration)))) (, ,)))) (PP (IN on) (NP (NP (DT the) (JJ secretory) (NN rate)) (PP (IN of) (NP (NP (NN prolactin)) (PRN (-LRB- -LRB-) (NP (NN PRL)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (DT the) (JJ direct) (NN drug) (NN effect)))))))))))) (. .)))
7930386	2	(S1 (S (NP (NP (CD Two) (NNS groups)) (PP (IN of) (NP (JJ supine) (NNS subjects)))) (VP (AUX were) (VP (VBN studied) (PP (IN under) (NP (NP (JJ placebo-controlled) (NNS conditions)) (, ,) (NP (NP (NP (CD one)) (PP (IN during) (NP (NP (DT the) (NN night)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG sleeping) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-)))))))) (CC and) (NP (NP (DT the) (JJ other)) (PP (IN at) (NP (JJ daytime))))) (, ,))) (FRAG (WHADVP (WRB when) (RB awake))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-)))) (. .)))
7930386	3	(S1 (S (NP (DT Each) (NN subject)) (VP (VBD received) (NP (NP (DT a) (JJ single) (CD 50) (JJ mg) (NN dose)) (PP (IN of) (NP (NNP Doc_7930386_497_509_Chemical)))) (S (VP (VBN given) (NP (QP (RB orally) (CD 2)) (NNS hours)) (PP (IN before) (NP (NN blood) (NN collection)))))) (. .)))
7930386	4	(S1 (S (NP (NN Plasma) (NN PRL) (NNS concentrations)) (VP (AUX were) (VP (VBN analysed) (PP (IN at) (NP (NP (NP (CD 10) (JJ min) (NNS intervals)) (CC and) (NP (JJ underlying) (NN secretory) (NNS rates))) (VP (VBN calculated) (PP (IN by) (NP (DT a) (JJ deconvolution) (NN procedure)))))))) (. .)))
7930386	5	(S1 (S (PP (IN For) (NP (DT both) (NNS experiments))) (NP (DT the) (NN drug) (NN intake)) (VP (VBD led) (PP (TO to) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (NN PRL) (NN secretion))))) (, ,) (S (VP (VBG acting) (ADVP (RB preferentially)) (PP (IN on) (NP (NN tonic) (NN secretion))) (SBAR (IN as) (S (NP (NP (NN pulse) (NN amplitude)) (CC and) (NP (NN frequency))) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN from) (S (VP (VBG corresponding) (NP (NN control) (NNS values)))))))))))) (. .)))
7930386	6	(S1 (S (PP (IN During) (NP (DT the) (NN night))) (NP (NNP Doc_7930386_927_939_Chemical) (NN ingestion)) (VP (VBD altered) (NP (DT the) (JJ complete) (NN sleep) (NN architecture)) (SBAR (IN in) (IN that) (S (NP (PRP it)) (VP (VP (VBD suppressed) (NP (NP (NN REM) (NN sleep)) (CC and) (NP (DT the) (NN sleep) (NNS cycles)))) (CC and) (VP (VBN induced) (NP (JJ increased) (NN wakefulness))))))) (. .)))
7930386	7	(S1 (S (SBAR (IN As) (S (NP (NP (DT the) (JJ relative) (NN increase)) (PP (IN in) (NP (NP (NN PRL) (NN secretion)) (VP (VBN expressed) (PP (IN as) (NP (NP (DT a) (NN percentage)) (PP (IN of) (NP (DT the) (NN mean))))))))) (VP (AUX did) (RB not) (ADVP (RB significantly)) (VP (VB differ) (PP (IN between) (NP (NP (DT the) (NN night) (CC and) (NN day) (NN time) (NNS studies)) (PRN (-LRB- -LRB-) (NP (CD 46) (JJ +/-) (NP (CD 19) (NN %)) (NNP vs) (CD 34) (NN +/-) (CD 10) (NN %)) (-RRB- -RRB-)))))))) (, ,) (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN concluded) (SBAR (IN that) (S (NP (DT the) (JJ observed) (NNP Doc_7930386_1292_1309_Disease)) (VP (AUX did) (RB not) (VP (VB interfere) (PP (IN with) (NP (DT the) (NN drug) (NN action))) (ADVP (FW per) (FW se))))))))) (. .)))
7930386	8	(S1 (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NN REM) (NN sleep)))) (VP (AUX was) (VP (VBN shown) (S (RB not) (VP (TO to) (VP (AUX be) (NP (DT a) (VBG determining) (NN factor)) (ADVP (RB either)) (PP (IN for) (NP (NP (JJ secretory) (NN pulse) (NN amplitude)) (CC and) (NP (NN frequency)))) (PRN (, ,) (ADVP (RB as)) (, ,)) (SBAR (IN for) (S (NP (DT both)) (, ,) (VP (VBP mean) (SBAR (S (NP (NN nocturnal) (NNS values)) (VP (AUX were) (UCP (ADJP (JJ similar) (PP (IN with))) (CC and) (PP (IN without) (NP (JJ prior) (JJ Doc_7930386_1548_1560_Chemical) (NN ingestion))))))))))))))) (. .)))
7977601	0	(S1 (NP (NP (NN Survey)) (PP (IN of) (NP (NP (NNS complications)) (PP (IN of) (NP (NP (JJ Doc_7977601_27_44_Chemical) (NN angiography)) (PP (IN in) (NP (NNP Japan))))))) (. .)))
7977601	1	(S1 (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NNP Doc_7977601_103_120_Chemical)))) (PP (IN for) (NP (NN use))) (PP (IN in) (NP (JJ fundus) (NN angiography)))) (. .)))
7977601	2	(S1 (S (NP (PRP We)) (VP (VBD sent) (NP (NP (DT a) (NN questionnaire)) (VP (VBG concerning) (NP (NP (NNS complications)) (PP (IN of) (NP (NNP Doc_7977601_213_230_Chemical)))))) (PP (TO to) (NP (CD 32) (NNS institutions))) (PP (IN in) (NP (NP (NNP Japan)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN selected) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (DT the) (NN client) (NN list)) (PP (IN from) (NP (NP (DT the) (NNP Topcon) (NN Company)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ manufactures) (NP (DT the) (JJ Doc_7977601_360_377_Chemical) (JJ fundus) (NN camera)))))))))))))))))) (. .)))
7977601	3	(S1 (S (NP (NP (NNS Ophthalmologists)) (PP (IN at) (NP (CD 15) (NNS institutions)))) (VP (VBD responded) (, ,) (S (VP (VBG reporting) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 3,774) (JJ Doc_7977601_476_493_Chemical) (NNS angiograms)) (VP (VBN performed) (PP (IN on) (NP (NP (CD 2,820) (NNS patients)) (PP (IN between) (NP (NP (NNP June) (CD 1984)) (CC and) (NP (NNP September) (CD 1992))))))))))))) (. .)))
7977601	4	(S1 (S (PP (IN Before) (NP (NP (NN angiography)) (, ,) (NP (NN intradermal)) (CC or) (NP (JJ intravenous) (JJ Doc_7977601_618_635_Chemical) (NN testing)))) (, ,) (CC or) (S (NP (DT both)) (VP (AUX was) (VP (VBN performed) (PP (IN at) (NP (NP (CD 13)) (PP (IN of) (NP (CD 15) (NNS institutions)))))))) (. .)))
7977601	5	(S1 (S (PP (IN For) (NP (CD three) (NNS patients))) (, ,) (NP (DT the) (NN decision)) (VP (AUX was) (VP (VBN made) (S (RB not) (VP (TO to) (VP (VB proceed) (PP (IN with) (NP (NN angiography))) (PP (IN after) (NP (JJ positive) (JJ preangiographic) (NN testing)))))))) (. .)))
7977601	6	(S1 (S (NP (NP (DT The) (NN dosage)) (PP (IN of) (NP (NNP Doc_7977601_821_838_Chemical))) (VP (VBN used) (PP (IN for) (NP (NN angiography))))) (VP (VBN varied) (PP (IN from) (NP (QP (CD 25) (TO to) (CD 75)) (NN mg))) (, ,) (PP (VBG depending) (PP (IN upon) (NP (DT the) (NN institution))))) (. .)))
7977601	7	(S1 (S (NP (EX There)) (VP (VP (AUX were) (NP (NP (CD 13) (NNS cases)) (PP (IN of) (NP (NP (JJ adverse) (NNS reactions)) (PRN (-LRB- -LRB-) (NP (CD 0.34) (NN %)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (CD ten) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX were) (NP (NP (JJ mild) (NNS reactions)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_7977601_1008_1014_Disease) (, ,) (NNP Doc_7977601_1016_1025_Disease) (, ,) (NNP Doc_7977601_1027_1037_Disease) (, ,) (NNP Doc_7977601_1039_1048_Disease) (, ,) (CC and) (NN urgency)) (PP (TO to) (NP (VB defecate))))))))))) (, ,) (CC and) (VP (AUX did) (RB not) (VP (VB require) (NP (NN treatment))))) (. .)))
7977601	8	(S1 (S (S (ADVP (RB Also)) (VP (VBN recorded))) (VP (AUX were) (NP (NP (NP (CD one) (NN case)) (PP (IN of) (NP (NP (NNP Doc_7977601_1137_1141_Disease)) (PP (IN of) (NP (DT the) (NN vein))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD required) (NP (NN treatment)))))))) (, ,) (CC and) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NNP Doc_7977601_1198_1209_Disease)))))) (. .)))
7977601	9	(S1 (S (NP (DT The) (CD two) (JJ Doc_7977601_1219_1230_Disease) (NNS patients)) (VP (VBD required) (NP (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_7977601_1263_1268_Disease))))) (. .)))
7977601	10	(S1 (S (NP (NP (DT A) (NN comparison)) (PP (IN of) (NP (NP (NN frequency)) (PP (IN of) (NP (NP (JJ adverse) (NNS reactions)) (PP (TO to) (NP (NNP Doc_7977601_1333_1350_Chemical))))) (PP (IN with) (NP (NP (DT the) (ADJP (RB previously) (VBN reported)) (NN frequency)) (PP (IN of) (NP (NP (JJ such) (NNS reactions)) (PP (TO to) (NP (NNP Doc_7977601_1411_1429_Chemical)))))))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (NNP Doc_7977601_1445_1462_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ safe)) (PP (IN as) (NP (NNP Doc_7977601_1476_1487_Chemical)))) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (NN angiography))))))))) (. .)))
7988234	0	(S1 (S (NP (NN Doc_7988234_0_10_Disease)) (VP (VBG following) (NP (NP (DT the) (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_7988234_55_65_Chemical))))) (. .)))
7988234	1	(S1 (S (NP (DT A) (JJ 72-year-old) (NN woman)) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))) (PP (IN with) (NP (NP (`` ``) (NN flash) ('' '') (NN Doc_7988234_129_144_Disease)) (, ,) (VP (VBN preceded) (PP (IN by) (NP (NNP Doc_7988234_158_168_Disease)))) (, ,) (VP (VBG requiring) (NP (NN intubation))))))) (. .)))
7988234	2	(S1 (S (NP (PRP$ Her) (JJ medical) (NN history)) (VP (VBD included) (NP (NNP Doc_7988234_221_244_Disease)) (PP (IN with) (NP (NP (JJ previous) (NNP Doc_7988234_259_281_Disease)) (, ,) (NP (NNP Doc_7988234_283_295_Disease)) (, ,) (CC and) (NP (NNP Doc_7988234_301_318_Disease))))) (. .)))
7988234	3	(S1 (S (NP (NP (DT A) (NN history)) (PP (IN of) (NP (NNP Doc_7988234_333_343_Disease) (JJ secondary))) (PP (TO to) (NP (JJ Doc_7988234_357_367_Chemical) (NN therapy)))) (VP (AUX was) (VP (VBN elicited))) (. .)))
7988234	4	(S1 (S (NP (JJ Current) (NNS medications)) (VP (AUX did) (RB not) (VP (VB include) (NP (NP (JJ Doc_7988234_426_437_Chemical-converting) (NN enzyme) (NNS inhibitors)) (CC or) (NP (NNS beta-blockers))))) (. .)))
7988234	5	(S1 (S (NP (PRP She)) (VP (AUX had) (NP (DT no) (JJ previous) (JJ beta-blocking) (NN drug) (NN exposure))) (. .)))
7988234	6	(S1 (S (PP (IN During) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (NP (NN hospitalization)) (PRN (-LRB- -LRB-) (PP (IN while) (NP (NN intubated))) (-RRB- -RRB-)))))) (, ,) (NP (JJ intravenous) (NNP Doc_7988234_605_615_Chemical)) (VP (AUX was) (VP (VBN given) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (JJ severe) (NN Doc_7988234_647_657_Disease))))))) (. .)))
7988234	7	(S1 (S (NP (DT The) (NNP Doc_7988234_663_673_Disease)) (VP (VBD resolved) (PP (IN after) (NP (NN therapy))) (PP (IN with) (NP (NP (JJ intravenous) (NN Doc_7988234_714_722_Chemical)) (CC and) (NP (JJ Doc_7988234_727_742_Chemical) (NN hydrochloride))))) (. .)))
8073369	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_8073369_10_17_Chemical))) (PP (IN on) (NP (DT the) (JJ developing) (NN chick) (NN embryo))) (. .)))
8073369	1	(S1 (S (NP (NP (NNP Doc_8073369_50_57_Chemical)) (, ,) (NP (NP (DT an) (NN alkaloid)) (PP (IN from) (NP (NP (JJ Conium) (NN maculatum)) (PRN (-LRB- -LRB-) (NP (NN poison) (NN hemlock)) (-RRB- -RRB-))))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (ADJP (JJ teratogenic)) (PP (IN in) (NP (NN livestock))))))))) (. .)))
8073369	2	(S1 (S (NP (DT The) (JJ major) (JJ teratogenic) (NN outcome)) (VP (AUX is) (ADJP (JJ Doc_8073369_191_205_Disease)) (, ,) (PP (ADVP (RB presumably)) (JJ due) (PP (TO to) (NP (JJ nicotinic) (NN receptor) (NN blockade))))) (. .)))
8073369	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_8073369_263_270_Chemical)) (VP (VP (AUX has) (VP (VBN failed) (S (VP (TO to) (VP (VB produce) (NP (NP (NN Doc_8073369_293_307_Disease)) (PP (IN in) (NP (NNS rats) (CC or) (NNS mice))))))))) (CC and) (VP (AUX is) (ADVP (RB only)) (ADJP (RB weakly) (JJ teratogenic) (PP (IN in) (NP (NNS rabbits)))))) (. .)))
8073369	4	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB evaluate)) (CC and) (VP (VB compare) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_8073369_436_443_Chemical)) (CC and) (NP (NNP Doc_8073369_448_456_Chemical)))) (PP (IN in) (NP (DT the) (VBG developing) (NN chick))))))))) (. .)))
8073369	5	(S1 (S (NP (NP (NNS Concentrations)) (PP (IN of) (NP (NNP Doc_8073369_500_507_Chemical) (CC and) (NNP Doc_8073369_512_520_Chemical) (NN sulfate)))) (VP (AUX were) (ADVP (NP (NP (CD 0.015) (NN %)) (, ,) (NP (CD 0.03) (NN %)) (, ,) (NP (CD 0.075) (NN %)) (, ,) (NP (CD 0.15) (NN %)) (, ,) (NP (CD 0.75) (NN %)) (, ,) (NP (CD 1.5) (NN %)) (, ,) (NP (CD 3) (NN %)) (, ,) (CC and) (NP (CD 6) (NN %)) (CC and) (NP (CD 1) (NN %)) (, ,) (NP (CD 5) (NN %)) (, ,) (CC and) (NP (CD 10) (NN %)) (, ,)) (RB respectively))) (. .)))
8073369	6	(S1 (S (NP (DT Both) (NNS compounds)) (VP (VBD caused) (NP (NP (NN Doc_8073369_645_657_Disease)) (CC and) (NP (NN lethality))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))) (. .)))
8073369	7	(S1 (S (S (NP (NP (DT All) (NNS concentrations)) (PP (IN of) (NP (JJ Doc_8073369_722_730_Chemical) (NN sulfate)))) (VP (VBD caused) (NP (DT some) (NN lethality)))) (CC but) (S (NP (NP (DT a) (ADJP (RB no) (NN effect)) (NN level)) (PP (IN for) (NP (NNP Doc_8073369_787_794_Chemical) (CD lethality)))) (VP (AUX was) (NP (CD 0.75) (NN %)))) (. .)))
8073369	8	(S1 (S (NP (NP (DT The) (NNP Doc_8073369_820_832_Disease)) (VP (VBN caused) (PP (IN by) (NP (DT both) (NNP Doc_8073369_848_855_Chemical) (CC and) (NNP Doc_8073369_860_868_Chemical) (NN sulfate))))) (VP (AUX were) (ADJP (JJ Doc_8073369_882_932_Disease))) (. .)))
8073369	9	(S1 (S (S (NP (NP (DT No) (JJ histopathological) (NNS alterations)) (CC or) (NP (NP (NNS differences)) (PP (IN in) (NP (NN bone) (NN formation))))) (VP (AUX were) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (NNS limbs) (CC or) (NNS toes)) (PP (IN of) (NP (NP (DT any) (NNS chicks)) (PP (IN from) (NP (DT any) (NN group)))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ extensive) (NN Doc_8073369_1080_1098_Disease)) (VP (VBD occurred) (PP (IN in) (NP (DT all) (JJ Doc_8073369_1115_1123_Chemical) (JJ sulfate-treated) (NNS chicks))))) (. .)))
8073369	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (ADJP (ADJP (RB statistically) (JJ significant)) (PRN (-LRB- -LRB-) (NP (NP (JJ P) (NNS <)) (CC or) (NP (SYM =) (CD 0.01))) (-RRB- -RRB-))) (NN decrease)) (PP (IN in) (NP (NN movement))) (PP (IN in) (NP (NP (NNP Doc_8073369_1226_1233_Chemical)) (CC and) (NP (JJ Doc_8073369_1238_1246_Chemical) (JJ sulfate) (VBN treated) (NNS chicks))))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NN ultrasound))))))) (. .)))
8073369	11	(S1 (S (S (NP (NN Control) (NNS chicks)) (VP (AUX were) (PP (IN in) (NP (NN motion))) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (CD 33.67) (NN %)) (PP (IN of) (NP (DT the) (NN time)))))) (, ,) (SBAR (IN while) (S (NP (JJ Doc_8073369_1369_1376_Chemical-treated) (NNS chicks)) (VP (AUX were) (ADVP (RB only)) (VP (VBG moving) (NP (NP (CD 8.95) (NN %)) (PP (IN of) (NP (DT a) (JJ 5-min) (NN interval)))))))))) (, ,) (CC and) (S (NP (DT no) (NN movement)) (VP (AUX was) (VP (VBN observed) (PP (IN for) (NP (JJ Doc_8073369_1469_1477_Chemical) (JJ sulfate) (VBN treated) (NNS chicks)))))) (. .)))
8073369	12	(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (NP (DT the) (JJ chick) (NN embryo)) (VP (VBZ provides) (NP (NP (DT a) (ADJP (ADJP (JJ reliable)) (CC and) (ADJP (JJ simple))) (JJ experimental) (NN animal) (NN model)) (PP (IN of) (NP (JJ Doc_8073369_1591_1598_Chemical-induced) (NN Doc_8073369_1607_1621_Disease))))) (. .)))
8073369	13	(S1 (S (NP (NP (NNS Data)) (PP (IN from) (NP (DT this) (NN model)))) (VP (VBP support) (NP (NP (DT a) (NN mechanism)) (VP (VBG involving) (NP (NP (JJ nicotinic) (NN receptor) (NN blockade)) (PP (IN with) (NP (JJ subsequent) (VBN decreased) (JJ fetal) (NN movement))))))) (. .)))
8092427	0	(S1 (NP (NP (JJ Immediate) (NN Doc_8092427_10_28_Disease)) (PP (TO to) (NP (NNP Doc_8092427_32_43_Chemical))) (. .)))
8092427	1	(S1 (S (NP (NP (DT A) (JJ large) (NN group)) (PP (IN of) (NP (NNS patients))) (PP (IN with) (NP (VBN suspected) (NNP Doc_8092427_86_104_Disease))) (PP (TO to) (NP (JJ Doc_8092427_108_119_Chemical) (NNS antibiotics)))) (VP (AUX was) (VP (VBN evaluated))) (. .)))
8092427	2	(S1 (S (NP (DT A) (VBN detailed) (JJ clinical) (NN history)) (, ,) (ADVP (RB together) (PP (IN with) (NP (NN skin) (NNS tests)))) (, ,) (NP (NP (NP (NN RAST)) (PRN (-LRB- -LRB-) (NP (JJ radioallergosorbent) (NN test)) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ controlled) (NN challenge) (NNS tests)) (, ,)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB establish) (SBAR (IN whether) (S (NP (NP (NNS patients)) (ADJP (JJ Doc_8092427_306_314_Disease) (PP (TO to) (NP (JJ Doc_8092427_318_329_Chemical) (NNS antibiotics))))) (VP (VP (AUX had) (NP (NP (JJ selective) (JJ immediate) (NNP Doc_8092427_366_374_Disease) (NNS responses)) (PP (TO to) (NP (NP (NNP Doc_8092427_388_399_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8092427_401_403_Chemical)) (-RRB- -RRB-)))))) (CC or) (VP (AUX were) (ADJP (JJ cross-reacting) (PP (IN with) (NP (JJ other) (JJ Doc_8092427_439_449_Chemical) (NNS derivatives))))))))))))) (. .)))
8092427	3	(S1 (S (NP (NN Skin) (NNS tests)) (VP (AUX were) (VP (VBN performed) (PP (IN with) (NP (NP (NP (NNP Doc_8092427_494_525_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8092427_527_534_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_8092427_537_555_Chemical)) (, ,) (NP (NP (NNP Doc_8092427_557_573_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8092427_575_577_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_8092427_580_590_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8092427_592_595_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_8092427_602_604_Chemical)))))) (. .)))
8092427	4	(S1 (S (NP (NP (NN RAST)) (PP (IN for) (NP (NP (NNP Doc_8092427_615_622_Chemical)) (CC and) (NP (NNP Doc_8092427_627_629_Chemical-PLL))))) (VP (AUX was) (VP (AUX done))) (. .)))
8092427	5	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT both) (NN skin) (NN test) (CC and) (NN RAST)) (PP (IN for) (NP (NNP Doc_8092427_677_680_Chemical)))) (VP (AUX were) (ADJP (JJ negative))))) (, ,) (NP (JJ single-blind) (, ,) (JJ placebo-controlled) (NN challenge) (NNS tests)) (VP (AUX were) (ADVP (RB done)) (S (VP (TO to) (VP (VB ensure) (NP (NP (NP (NN tolerance)) (PP (IN of) (NP (NNP Doc_8092427_778_780_Chemical)))) (CC or) (NP (NP (NN sensitivity)) (PP (TO to) (NP (NNP Doc_8092427_799_801_Chemical))))))))) (. .)))
8092427	6	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 177) (NNS patients)))) (VP (AUX were) (VP (VBN diagnosed) (PP (IN as) (NP (NNP Doc_8092427_845_853_Disease))) (PP (TO to) (NP (JJ Doc_8092427_857_868_Chemical) (NNS antibiotics))))) (. .)))
8092427	7	(S1 (S (NP (PRP We)) (VP (VBD selected) (NP (NP (DT the) (CD 54) (ADJP (-LRB- -LRB-) (NP (CD 30.5) (NN %)) (-RRB- -RRB-)) (NNS cases)) (PP (IN of) (NP (JJ immediate) (JJ Doc_8092427_928_930_Chemical) (NN Doc_8092427_931_938_Disease))) (PP (IN with) (NP (NP (JJ good) (NN tolerance)) (PP (IN of) (NP (NNP Doc_8092427_962_964_Chemical))))))) (. .)))
8092427	8	(S1 (S (NP (NN Doc_8092427_966_977_Disease)) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (NP (CD 37) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 69) (NN %)) (-RRB- -RRB-)) (, ,) (NP (DT the) (JJ other) (CD 17)) (PRN (-LRB- -LRB-) (NP (CD 31) (NN %)) (-RRB- -RRB-))) (VP (AUXG having) (NP (JJ Doc_8092427_1035_1044_Disease) (NN and/or) (NN Doc_8092427_1052_1062_Disease))))))) (. .)))
8092427	9	(S1 (S (S (NP (PDT All) (DT the) (NNS patients)) (VP (AUX were) (NP (NP (NN skin) (NN test) (NN negative)) (PP (TO to) (NP (NNP Doc_8092427_1108_1111_Chemical)))))) (: ;) (S (NP (NP (CD 49)) (PP (IN of) (NP (CD 51))) (PRN (-LRB- -LRB-) (NP (CD 96) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (ADJP (RB also) (JJ negative) (PP (TO to) (NP (NP (NNP Doc_8092427_1150_1153_Disease)) (, ,) (CC and) (NP (NP (QP (CD 44) (IN of) (CD 46))) (PRN (-LRB- -LRB-) (NP (CD 96) (NN %)) (-RRB- -RRB-)))))) (PP (TO to) (NP (NNP Doc_8092427_1177_1179_Chemical))))) (. .)))
8092427	10	(S1 (S (NP (NP (NN Skin) (NNS tests)) (PP (IN with) (NP (NNP Doc_8092427_1197_1199_Chemical)))) (VP (AUX were) (ADJP (JJ positive)) (PP (IN in) (NP (CD 34) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (. .)))
8092427	11	(S1 (S (NP (JJS RAST)) (VP (AUX was) (ADJP (JJ positive)) (PP (IN for) (NP (NNP Doc_8092427_1258_1260_Chemical))) (PP (PP (IN in) (NP (NP (CD 22) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 41) (NN %)) (-RRB- -RRB-)))) (CC and) (PP (TO to) (NP (NNP Doc_8092427_1289_1292_Chemical)) (PP (IN in) (NP (NP (QP (RB just) (CD 5))) (PRN (-LRB- -LRB-) (NP (CD 9) (NN %)) (-RRB- -RRB-))))))) (. .)))
8092427	12	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NN sera))) (PP (IN with) (NP (NP (JJ negative) (NN RAST)) (PP (IN for) (NP (NNP Doc_8092427_1349_1351_Chemical)))))) (VP (AUX were) (ADJP (JJ positive) (TO to) (JJ Doc_8092427_1369_1372_Chemical))) (. .)))
8092427	13	(S1 (S (S (NP (NP (NN Challenge) (NNS tests)) (PP (IN with) (NP (NNP Doc_8092427_1395_1397_Chemical)))) (VP (AUX were) (VP (VBN performed) (PP (IN in) (NP (CD 23) (NNS subjects))) (PRN (-LRB- -LRB-) (NP (CD 43) (NN %)) (-RRB- -RRB-)) (S (VP (TO to) (VP (VB establish) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NP (JJ immediate) (NN Doc_8092427_1474_1491_Disease)) (PP (TO to) (NP (NNP Doc_8092427_1495_1497_Chemical)))))))))))) (, ,) (CC and) (S (PP (IN in) (NP (NP (CD 15) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 28) (NN %)) (-RRB- -RRB-)))) (NP (NP (DT both) (NN skin) (NN test) (CC and) (NN RAST)) (PP (IN for) (NP (NNP Doc_8092427_1549_1551_Chemical)))) (VP (AUX were) (ADJP (JJ negative)))) (. .)))
8092427	14	(S1 (S (NP (NN Doc_8092427_1567_1569_Chemical)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN by) (NP (DT all) (CD 54) (NNS patients))))) (. .)))
8092427	15	(S1 (S (NP (PRP We)) (VP (VBP describe) (SBAR (S (NP (NP (DT the) (JJS largest) (NN group)) (PP (IN of) (NP (NP (JJ Doc_8092427_1642_1644_Chemical-Doc_8092427_1645_1653_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN tolerated) (NP (NNP Doc_8092427_1682_1684_Chemical))))))))) (VP (VBD reported) (ADVP (RB so) (RB far)))))) (. .)))
8092427	16	(S1 (S (NP (NP (NN Diagnosis)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (MD can) (VP (AUX be) (VP (VBN achieved) (SBAR (RB only) (IN if) (S (NP (JJ specific) (JJ Doc_8092427_1763_1765_Chemical-related) (NNS reagents)) (VP (AUX are) (VP (VBN employed)))))))) (. .)))
8092427	17	(S1 (S (NP (JJ Further) (NNS studies)) (VP (AUX are) (ADJP (JJ necessary) (S (VP (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ exact) (NN extent)) (PP (IN of) (NP (DT this) (NN problem)))))) (CC and) (VP (TO to) (VP (VB improve) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (JJ diagnostic) (NNS methods)))))))))) (. .)))
809711	0	(S1 (NP (NP (NN Reversal)) (PP (IN by) (NP (NP (NNP Doc_809711_12_25_Chemical)) (PP (IN of) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_809711_67_80_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_809711_98_125_Disease))))))))) (. .)))
809711	1	(S1 (S (NP (NN Doc_809711_127_140_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB reduce) (NP (JJ ST-segment) (NN elevation)) (PP (IN during) (NP (NP (NNP Doc_809711_194_221_Disease)) (, ,) (NP (NP (DT an) (NN effect)) (VP (VBN potentiated) (PP (IN in) (NP (DT the) (NN dog))) (PP (IN by) (NP (NP (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP reverse) (NP (JJ Doc_809711_279_292_Chemical-induced) (NN Doc_809711_301_312_Disease))))))))))))))))) (. .)))
809711	2	(S1 (S (NP (PRP$ Our) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ combined) (NN Doc_809711_374_387_Chemical)) (CC and) (NP (JJ Doc_809711_392_405_Chemical) (NN therapy)))))))))) (. .)))
809711	3	(S1 (S (NP (NP (CD Ten) (NNS patients)) (PP (IN with) (NP (JJ acute) (JJ transmural) (NNP Doc_809711_450_472_Disease)))) (VP (VBD received) (NP (NP (JJ intravenous) (NNP Doc_809711_494_507_Chemical)) (, ,) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB reduce) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN from) (NP (NP (QP (CD 107) (JJ +/-) (CD 6) (TO to) (CD 85)) (JJ +/-) (CD 6) (NNS mm)) (NP (NP (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))))))))) (, ,)) (PP (IN for) (NP (CD 60) (NNS minutes)))) (. .)))
809711	4	(S1 (S (NP (NN Left) (NN ventricular) (VBG filling) (NN pressure)) (VP (VBD decreased) (PP (IN from) (NP (CD 19) (NN +/-))) (, 2) (PP (TO to) (NP (NP (CD 11) (NNS +/-)) (NP (NP (QP (CD 2) (CD mm)) (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))))) (. .)))
809711	5	(S1 (S (NP (NP (NNP SigmaST)) (, ,) (NP (NP (DT the) (NN sum)) (PP (IN of) (NP (JJ ST-segment) (NNS elevations))) (PP (IN in) (NP (CD 16) (JJ precordial) (NNS leads)))) (, ,)) (VP (VBD decreased) (PRN (-LRB- -LRB-) (PP (FW P) (NP (QP (JJR less) (IN than) (CD 0.02)))) (-RRB- -RRB-)) (PP (IN with) (NP (JJ intravenous) (NNP Doc_809711_832_845_Chemical)))) (. .)))
809711	6	(S1 (S (NP (NP (JJ Subsequent) (NN addition)) (PP (IN of) (NP (NP (JJ Doc_809711_870_883_Chemical) (NN infusion)) (, ,) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB re-elevate) (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (TO to) (NP (NP (CD 106) (NNS +/-)) (NP (NP (QP (CD 4) (CD mm)) (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))))) (PP (IN for) (NP (CD 30) (NNS minutes))))))) (, ,)))) (VP (VBD increased) (NP (JJ left) (NN ventricular) (VBG filling) (NN pressure)) (PP (TO to) (NP (CD 17) (NN +/-))) (, 2) (S (VP (VP (VBG mm) (NP (NP (NNP Hg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))) (CC and) (ADVP (RB also)) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (JJS sigmaST)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
809711	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN addition)) (PP (IN of) (NP (NNP Doc_809711_1176_1189_Chemical))) (PP (TO to) (NP (NNP Doc_809711_1193_1206_Chemical)))) (VP (AUX is) (RB not) (ADJP (JJ beneficial)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_809711_1259_1286_Disease))))))))))) (. .)))
8170551	0	(S1 (NP (NP (JJ Doc_8170551_0_13_Chemical-induced) (NNP Doc_8170551_22_37_Disease)) (: :) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NNP Doc_8170551_69_92_Disease)))))) (. .)))
8170551	1	(S1 (S (NP (JJ Carbonic) (NN anhydrase) (NNS inhibitors)) (VP (MD can) (VP (VB cause) (NP (NN Doc_8170551_134_149_Disease)))) (. .)))
8170551	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (CD 20) (NNS patients)) (VP (VBG receiving) (NP (JJ long-term) (JJ carbonic) (NN anhydrase) (NN inhibitor) (NN treatment)) (PP (IN for) (NP (JJ periodic) (NNP Doc_8170551_246_255_Disease) (CC and) (NNP Doc_8170551_260_268_Disease)))))) (. .)))
8170551	3	(S1 (S (NP (NP (CD Three) (NNS patients)) (PP (IN on) (NP (NNP Doc_8170551_288_301_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NN Doc_8170551_318_331_Disease))) (. .)))
8170551	4	(S1 (S (S (NP (JJ Extracorporeal) (NN lithotripsy)) (ADVP (RB successfully)) (VP (VBD removed) (NP (DT a) (NN Doc_8170551_383_397_Disease)) (PP (IN in) (NP (CD one) (NN patient))))) (CC and) (S (NP (NN surgery)) (VP (VBD removed) (NP (DT a) (JJ staghorn) (NN Doc_8170551_444_452_Disease)) (PP (IN in) (NP (DT another))) (, ,) (S (VP (VBG permitting) (NP (JJ continued) (NN treatment)))))) (. .)))
8170551	5	(S1 (S (NP (JJ Renal) (NN function)) (VP (VBD remained) (ADJP (JJ normal)) (PP (IN in) (NP (DT all) (NNS patients)))) (. .)))
8170551	6	(S1 (S (NP (NN Doc_8170551_545_560_Disease)) (VP (VP (AUX is) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NNP Doc_8170551_582_595_Chemical))))) (CC but) (VP (AUX does) (RB not) (VP (VB preclude) (NP (PRP$ its) (NN use))))) (. .)))
8231633	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (JJ Doc_8231633_11_18_Chemical) (NN channel) (NNS blockers))) (PP (IN on) (NP (NNP Doc_8231633_39_50_Chemical-induced) (NNP Doc_8231633_59_67_Disease))) (. .)))
8231633	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (JJ Doc_8231633_131_138_Chemical) (NN channel) (NNS blockers))) (PP (IN on) (NP (JJ Doc_8231633_159_170_Chemical-induced) (JJ acute) (NN Doc_8231633_185_193_Disease)))))))) (. .)))
8231633	2	(S1 (S (PP (IN For) (NP (NP (DT each)) (PP (IN of) (NP (NP (NP (DT the) (CD three) (VBN tested) (NNP Doc_8231633_224_231_Chemical) (NN channel) (NNS blockers)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8231633_250_259_Chemical) (, ,) (NNP Doc_8231633_261_270_Chemical) (CC and) (NNP Doc_8231633_275_283_Chemical)) (-RRB- -RRB-)) (SBAR (S (NP (NP (CD 6) (NNS groups)) (PP (IN of) (NP (NNS mice)))) (VP (AUX were) (VP (VBN treated) (PP (IN by) (NP (NP (NP (CD two) (JJ different) (NNS doses)) (, ,) (PP (FW i.e.) (NP (CD 2) (CC and) (CD 10) (NNS mg/kg/i.p.))) (, ,)) (CC or) (NP (NP (DT an) (JJ equal) (NN volume)) (PP (IN of) (NP (NN saline)))))) (PP (IN for) (NP (NP (DT the) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 20)) (-RRB- -RRB-))))))))) (: ;) (NP (CD 15) (NNS minutes)))))) (ADVP (RB later)) (, ,) (NP (PDT all) (DT the) (NNS animals)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (NP (DT a) (JJ single) (CD 50) (JJ mg/kg/i.p.) (NN dose)) (PP (IN of) (NP (NNP Doc_8231633_510_521_Chemical))))))) (. .)))
8231633	3	(S1 (S (NP (NP (DT The) (JJ convulsant) (NN activity)) (, ,) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN latency))) (PP (TO to) (NP (NN convulse)))) (CC and) (NP (DT the) (NN mortality) (NN rate))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (DT each) (NN group))))) (. .)))
8231633	4	(S1 (S (NP (DT The) (JJ local) (JJ anesthetic-induced) (NN mortality)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN by) (NP (DT the) (CD three) (JJ different) (JJ Doc_8231633_722_729_Chemical) (NN channel) (NNS blockers))))) (. .)))
8231633	5	(S1 (S (S (NP (NP (DT The) (JJ convulsant) (NN activity)) (PP (IN of) (NP (NNP Doc_8231633_775_786_Chemical)))) (VP (AUX was) (RB not) (ADVP (RB significantly)) (VP (VBN modified)))) (CC but) (S (NP (NNP Doc_8231633_822_829_Chemical) (NN channel) (NNS blockers)) (VP (VBD decreased) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN latency))) (SBAR (S (VP (TO to) (VP (VB obtain) (NP (JJ Doc_8231633_887_898_Chemical-induced) (NNP Doc_8231633_907_918_Disease))))))))) (: ;) (S (NP (DT this) (NN effect)) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ pronounced)) (PP (IN with) (NP (NNP Doc_8231633_957_965_Chemical)))))) (. .)))
8302922	0	(S1 (S (NP (NP (JJ Epidural) (NN blood) (NN flow)) (PP (IN during) (NP (NP (NNP Doc_8302922_27_43_Chemical)) (CC or) (NP (NNP Doc_8302922_47_59_Chemical))))) (VP (VBN induced) (NP (NNP Doc_8302922_68_79_Disease))) (. .)))
8302922	1	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NNP Doc_8302922_107_123_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8302922_125_129_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_8302922_134_146_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8302922_148_151_Chemical)) (-RRB- -RRB-))))) (VP (VBN induced) (NP (NNP Doc_8302922_161_172_Disease))) (PP (IN on) (NP (NP (JJ epidural) (NN blood) (NN flow)) (PRN (-LRB- -LRB-) (NP (NNP EBF)) (-RRB- -RRB-))))) (PP (IN during) (NP (NN spinal) (NN surgery)))))) (, ,) (NP (NNP EBF)) (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (NP (DT the) (NN heat) (NN clearance) (NN method)) (PP (IN in) (NP (NP (CD 30) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ postero-lateral) (NN interbody) (NN fusion)) (PP (IN under) (NP (JJ Doc_8302922_342_352_Chemical) (NN anaesthesia))))))))))))) (. .)))
8302922	2	(S1 (S (S (NP (NP (DT An) (JJ initial) (NN dose)) (PP (IN of) (NP (NP (NP (CD 0.1) (NN microgram.kg-1.min-1)) (PP (IN of) (NP (NP (NNP Doc_8302922_413_417_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NNS patients)) (-RRB- -RRB-))))) (, ,) (CC or) (NP (NP (CD 10) (NN micrograms.kg-1.min-1)) (PP (IN of) (NP (NP (NNP Doc_8302922_464_467_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NNS patients)) (-RRB- -RRB-)))))))) (VP (AUX was) (VP (VBN administered) (ADVP (RB intravenously)) (PP (IN after) (NP (DT the) (JJ dural) (NN opening)))))) (CC and) (S (NP (DT the) (NN dose)) (VP (AUX was) (VP (VBN adjusted) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT the) (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))) (PP (IN at) (NP (QP (RB about) (CD 60)) (NN mmHg))))))))) (. .)))
8302922	3	(S1 (S (NP (DT The) (NNP Doc_8302922_636_647_Disease) (NN drug)) (VP (AUX was) (VP (VBN discontinued) (PP (IN at) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (DT the) (JJ operative) (NN procedure))))))) (. .)))
8302922	4	(S1 (S (PP (IN After) (S (VP (VBG starting) (NP (NNP Doc_8302922_731_735_Chemical) (CC or) (NNP Doc_8302922_739_742_Chemical))))) (, ,) (S (NP (NP (NP (NN MAP)) (CC and) (NP (NN rate) (NN pressure) (NN product))) (PRN (-LRB- -LRB-) (NP (NNP RPP)) (-RRB- -RRB-))) (VP (VBD decreased) (ADVP (RB significantly)) (PP (VBN compared) (PP (IN with) (NP (NP (NN preinfusion) (NNS values)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.01)) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NNP Doc_8302922_867_878_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_8302922_886_890_Chemical))))))) (VP (VBD remained) (ADJP (JJ constant)) (PP (IN until) (NP (CD 60) (NN min))) (PP (IN after) (NP (PRP$ its) (NN discontinuation))))) (. .)))
8302922	5	(S1 (S (NP (NP (NN Heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NN HR)) (-RRB- -RRB-))) (VP (AUX did) (RB not) (VP (VB change) (PP (IN in) (NP (DT either) (NN group))))) (. .)))
8302922	6	(S1 (S (NP (NNP EBFF)) (VP (AUX did) (RB not) (VP (VB change) (PP (IN during) (NP (JJ Doc_8302922_1024_1028_Chemical) (NN infusion))) (SBAR (IN whereas) (S (PP (IN in) (NP (DT the) (NNP Doc_8302922_1053_1056_Chemical) (NN group))) (, ,) (NP (NNP EBF)) (VP (VBD decreased) (ADVP (RB significantly) (NP (QP (IN at) (CD 30) (CC and) (CD 60) (NN min)))) (PP (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NNP Doc_8302922_1128_1131_Chemical))))) (PRN (-LRB- -LRB-) (NP (NP (NN preinfusion)) (: :) (NP (NP (CD 45.9) (JJ +/-) (CD 13.9) (NNS ml/100g/min.)) (ADJP (CD 30) (NN min))) (: :) (NP (NP (NP (CD 32.3) (NN +/-)) (NP (QP (CD 9.9) (CD ml/100)) (NN g/min))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-))) (. .)) (NP (NP (CD 60) (NN min)) (: :) (NP (NP (NP (CD 30) (NN +/-)) (NP (CD 7.5) (CD ml/100) (NN g/min))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-)))) (-RRB- -RRB-))))))) (. .)))
8302922	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_8302922_1291_1295_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ preferable) (PP (TO to) (NP (NNP Doc_8302922_1317_1320_Chemical)))) (PP (IN for) (NP (NP (JJ Doc_8302922_1325_1336_Disease) (NNS anaesthesia)) (PP (IN in) (NP (NN spinal) (NN surgery))))) (SBAR (IN because) (S (NP (NNP Doc_8302922_1375_1378_Chemical)) (VP (VBD decreased) (NP (NN EBF)))))))))) (. .)))
8319760	0	(S1 (S (NP (NN Doc_8319760_0_7_Chemical)) (VP (VBZ prevents) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_8319760_36_61_Chemical-induced) (NNP Doc_8319760_70_79_Disease))))) (. .)))
8319760	1	(S1 (S (NP (NP (DT The) (NN appearance)) (PP (IN of) (NP (NNP Doc_8319760_99_118_Disease))) (PP (JJ such) (IN as) (NP (NP (NNP Doc_8319760_127_138_Disease)) (, ,) (NP (NNP Doc_8319760_140_155_Disease)) (, ,) (NP (NNP Doc_8319760_157_177_Disease)) (CC and) (NP (NP (NN increase)) (PP (IN in) (NP (NNP Doc_8319760_194_213_Chemical))))))) (, ,) (S (VP (VBN induced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NP (NN injection)) (PP (IN of) (NP (NNP Doc_8319760_247_272_Chemical))))))) (VP (AUX was) (RB markedly) (VP (VBD inhibited) (PP (IN by) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (NNP Doc_8319760_322_329_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8319760_331_339_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ novel) (JJ Doc_8319760_350_364_Chemical) (NN receptor) (NN antagonist)) (, ,))))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (QP (CD 1) (CC or) (CD 2) (CD mg/kg))) (PP (IN per) (NP (NN day))))))))) (. .)))
8319760	2	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (NP (NP (DT a) (JJ possible) (NN involvement)) (PP (IN of) (NP (DT the) (JJ renin-Doc_8319760_477_488_Chemical) (NN system))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_8319760_518_543_Chemical-induced) (NN Doc_8319760_552_561_Disease))))))) (. .)))
8372922	0	(S1 (S (NP (NP (NN Neuroplasticity)) (PP (IN of) (NP (DT the) (NN adult)))) (VP (VBP primate) (NP (NN auditory) (NN cortex)) (PP (VBG following) (NP (JJ cochlear) (NN Doc_8372922_72_84_Disease)))) (. .)))
8372922	1	(S1 (S (NP (JJ Tonotopic) (NN organization)) (VP (AUX is) (NP (NP (DT an) (JJ essential) (NN feature)) (PP (IN of) (NP (NP (DT the) (JJ primary) (NN auditory) (NN area)) (PRN (-LRB- -LRB-) (NP (NNP A1)) (-RRB- -RRB-)) (PP (IN of) (NP (JJ primate) (NN cortex))))))) (. .)))
8372922	2	(S1 (S (PP (IN In) (NP (NP (NNP A1)) (PP (IN of) (NP (NN macaque) (NNS monkeys))))) (, ,) (S (NP (JJ low) (NNS frequencies)) (VP (AUX are) (VP (VBN represented) (ADVP (RB rostrolaterally))))) (CC and) (S (NP (JJ high) (NNS frequencies)) (VP (AUX are) (VP (VBN represented) (ADVP (RB caudomedially))))) (. .)))
8372922	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NNS changes)) (VP (VBP occur) (PP (IN in) (NP (NP (DT this) (JJ tonotopic) (NN organization)) (VP (VBG following) (NP (JJ cochlear) (NN Doc_8372922_422_434_Disease)))))))))))) (. .)))
8372922	4	(S1 (S (PP (IN Under) (NP (NN anesthesia))) (, ,) (S (NP (NP (DT the) (JJ superior) (JJ temporal) (NN gyrus)) (PP (IN of) (NP (NN adult) (NN macaque) (NNS monkeys)))) (VP (AUX was) (VP (VBN exposed)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ tonotopic) (NN organization)) (PP (IN of) (NP (NNP A1)))) (VP (AUX was) (VP (VBN mapped) (S (VP (VBG using) (NP (JJ conventional) (NN microelectrode) (NN recording) (NNS techniques))))))) (. .)))
8372922	5	(S1 (S (PP (VBG Following) (NP (NN recovery))) (, ,) (NP (DT the) (NNS monkeys)) (VP (AUX were) (ADVP (RB selectively)) (VP (VBN deafened) (PP (IN for) (NP (NP (JJ high) (NNS frequencies)) (VP (VBG using) (NP (NP (NNP Doc_8372922_709_718_Chemical)) (CC and) (NP (NNP Doc_8372922_723_733_Chemical)))))))) (. .)))
8372922	6	(S1 (S (NP (NP (DT The) (JJ actual) (NNS frequencies)) (VP (VBN deafened))) (VP (AUX were) (VP (VBN determined) (PP (IN by) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (JJ tone-burst) (JJ elicited) (NN auditory) (NN brainstem) (NNS responses))))))) (. .)))
8372922	7	(S1 (S (PP (NP (CD Three) (NNS months)) (IN after) (NP (NN deafening))) (, ,) (NP (NNP A1)) (VP (AUX was) (VP (VBN remapped))) (. .)))
8372922	8	(S1 (S (NP (NP (NN Postmortem) (NN cytoarchitectural) (NNS features)) (VP (VBG identifying) (NP (NNP A1)))) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (DT the) (JJ electrophysiologic) (NNS data))))) (. .)))
8372922	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (VBN deprived) (NN area)) (PP (IN of) (NP (NNP A1)))) (VP (VP (VBZ undergoes) (NP (JJ extensive) (NN reorganization))) (CC and) (VP (VBZ becomes) (ADJP (JJ responsive) (PP (TO to) (NP (JJ intact) (JJ cochlear) (NNS frequencies))))))))) (. .)))
8372922	10	(S1 (S (NP (NP (DT The) (NN region)) (PP (IN of) (NP (NN cortex))) (SBAR (WHNP (WDT that)) (S (VP (VBZ represents) (NP (DT the) (JJ low) (NNS frequencies)))))) (VP (AUX was) (RB not) (ADVP (RB obviously)) (VP (VBN affected) (PP (IN by) (NP (DT the) (JJ cochlear) (NN Doc_8372922_1238_1250_Disease))))) (. .)))
8386779	0	(S1 (S (NP (JJ Doc_8386779_0_18_Chemical) (NNS alleviates)) (VP (VBP Doc_8386779_30_41_Disease) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intracavernous) (NNS injections)) (PP (IN for) (NP (NNP Doc_8386779_83_103_Disease))))))) (. .)))
8386779	1	(S1 (S (PP (IN In) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NNP Doc_8386779_140_151_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ intracorporeal) (NNS injections))))) (VP (MD could) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN acidity)) (PP (IN of) (NP (DT the) (NN medication))))))))))))))) (, ,) (NP (PRP we)) (VP (VBD performed) (NP (NP (DT a) (JJ randomized) (NN study)) (VP (VBG comparing) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_8386779_300_311_Disease))) (PP (VBG following) (NP (JJ intracorporeal) (NNS injections)))) (PP (IN with) (CC or) (PP (IN without) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_8386779_380_398_Chemical))) (PP (TO to) (NP (DT the) (JJ intracorporeal) (NNS medications))))))))) (. .)))
8386779	2	(S1 (NP (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 38) (JJ consecutive) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (TO to) (NP (PRP$ our) (NN clinic))) (SBAR (IN with) (S (NP (NNP Doc_8386779_502_511_Disease)) (VP (VBD received) (NP (NP (CD 0.2) (NN ml.)) (PP (IN of) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (CD 3) (NNS drugs))))))))))))))) (: :) (NP (NP (CD 6) (NN mg.)) (NP (NP (NP (NNP Doc_8386779_564_574_Chemical)) (, ,) (NP (CD 100) (JJ micrograms.) (NNP Doc_8386779_592_604_Chemical)) (CC and) (NP (CD 10) (JJ micrograms.) (NNP Doc_8386779_624_640_Chemical))) (PP (IN with) (PRN (-LRB- -LRB-) (NP (CD pH) (CD 7.05)) (-RRB- -RRB-)) (CC or) (PP (IN without) (PRN (-LRB- -LRB-) (NP (QP (CD pH) (CD 4.17))) (-RRB- -RRB-)) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_8386779_693_711_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 0.03) (CD mEq) (. .)) (-RRB- -RRB-))))) (. .)))
8386779	3	(S1 (S (IN Of) (NP (NP (DT the) (CD 19) (NNS patients)) (PP (IN without) (NP (NNP Doc_8386779_752_770_Chemical)))) (VP (VBD added) (PP (TO to) (NP (DT the) (NN medication) (CD 11))) (SBAR (S (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_8386779_818_829_Disease))) (ADVP (JJ due) (PP (TO to) (NP (DT the) (NN medication)))) (, ,) (SBAR (IN while) (S (NP (NP (QP (RB only) (CD 1))) (PP (IN of) (NP (NP (DT the) (CD 19) (NNS men)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (SBAR (S (NP (NNP Doc_8386779_898_916_Chemical)) (VP (VBD complained) (PP (IN of) (NP (NNP Doc_8386779_931_942_Disease)))))))))))))))))) (. .)))
8386779	4	(S1 (S (PP (IN From) (NP (DT these) (NNS data))) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (NNP Doc_8386779_981_992_Disease) (JJ following) (NN intracorporeal) (NNS injections)) (VP (AUX is) (ADVP (RBS most) (JJ likely)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (NN acidity)) (PP (IN of) (NP (NP (DT the) (NN medication)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (AUX be) (VP (VBN overcome) (PP (IN by) (S (VP (VBG elevating) (NP (DT the) (NN pH)) (PP (TO to) (NP (DT a) (JJ neutral) (NN level)))))))))))))))))))) (. .)))
8387218	0	(S1 (NP (NP (DT The) (NN use) (CC and) (NN Doc_8387218_12_20_Disease)) (PP (IN of) (NP (NP (NNP Doc_8387218_24_34_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8387218_36_39_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Doc_8387218_44_65_Disease) (NNS individuals) (NN intolerant))) (PP (TO to) (NP (NNP Doc_8387218_92_102_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP Doc_8387218_104_107_Chemical)) (-RRB- -RRB-))))
8387218	1	(S1 (S (NP (NP (QP (CD One) (CD hundred))) (CC and) (NP (NP (JJ fifty-one) (NNS patients)) (ADJP (JJ intolerant) (PP (TO to) (NP (NP (NNP Doc_8387218_158_168_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8387218_170_173_Chemical)) (-RRB- -RRB-))))))) (VP (VBD received) (NP (NP (NNP Doc_8387218_184_194_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8387218_196_199_Chemical)) (-RRB- -RRB-))) (PP (TO to) (NP (NP (DT a) (JJ maximum) (NN dose)) (PP (IN of) (NP (CD 12.5) (NN mg/kg/day)))))) (. .)))
8387218	2	(S1 (S (NP (JJ Patient) (NN response)) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ CD4+) (JJ lymphocyte) (NN subset) (NN count)) (, ,) (NP (NNP HIV) (CD p24) (NN antigen)) (, ,) (NP (NN weight)) (, ,) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))))))))))) (. .)))
8387218	3	(S1 (S (S (NP (CD Seventy) (NNS patients)) (VP (VBD developed) (NP (JJ major) (JJ Doc_8387218_394_418_Disease) (NN whilst)) (PP (IN on) (NP (NN therapy))))) (: ;) (S (NP (DT this)) (VP (AUX was) (NP (NP (DT the) (JJ first) (JJ Doc_8387218_457_461_Disease) (NN diagnosis)) (PP (IN in) (NP (CD 17)))))) (. .)))
8387218	4	(S1 (S (NP (NP (ADJP (RB Only) (JJ minor)) (NNS changes)) (PP (IN in) (NP (JJ CD4+) (JJ lymphocyte) (NN subset) (NN count)))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (JJ Doc_8387218_547_551_Disease) (NNS patients))) (, ,) (SBAR (IN although) (S (NP (DT a) (ADJP (RBR more) (JJ significant)) (NN rise)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT those)) (PP (IN with) (NP (NP (JJR earlier) (NNS stages)) (PP (IN of) (NP (NN disease)))))))))))) (. .)))
8387218	5	(S1 (S (S (NP (NP (IN Of) (DT those) (JJ positive)) (PP (IN for) (NP (NP (CD p24) (NN antigen)) (PP (IN at) (NP (NP (DT the) (NN commencement)) (PP (IN of) (NP (DT the) (NN study))))) (NP (CD 67) (NN %))))) (VP (VBD showed) (NP (DT a) (JJ positive) (NN response)))) (, ,) (CC and) (S (NP (DT this)) (VP (AUX was) (ADJP (RBS most) (JJ likely) (PP (IN in) (NP (NP (DT those)) (PP (IN with) (NP (NP (JJ CD4+) (JJ lymphocyte) (NN subset) (NNS counts)) (PP (IN above) (NP (CD 100) (CD mm3)))))))))) (. .)))
8387218	6	(S1 (S (NP (DT A) (JJ positive) (NN weight) (NN response)) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (CD 16) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
8387218	7	(S1 (S (NP (JJS Most) (NNS patients)) (VP (VBD showed) (NP (NP (NP (NN improvement)) (PP (IN in) (NP (JJ individual) (NNS parameters)))) (CC and) (NP (NP (JJ global) (NN score)) (PP (IN of) (NP (NP (NN quality)) (PP (IN of) (NP (NN life)))))))) (. .)))
8387218	8	(S1 (S (NP (NP (JJ Adverse) (NNS reactions)) (ADJP (ADVP (RB possibly)) (JJ attributable) (PP (TO to) (NP (NNP Doc_8387218_1022_1032_Chemical))))) (VP (AUX were) (ADJP (JJ common))) (. .)))
8387218	9	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ common)) (NN side-effect)) (VP (AUX was) (NP (NP (NNP Doc_8387218_1078_1087_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy))) (PP (IN in) (NP (CD 19) (NNS individuals)))))))))) (. .)))
8387218	10	(S1 (S (NP (NN Doc_8387218_1147_1168_Disease)) (VP (VP (VBD occurred) (PP (IN in) (NP (CD 12) (NNS patients)))) (CC and) (VP (NP (NNP Doc_8387218_1197_1209_Disease)) (PP (IN in) (NP (CD six))))) (. .)))
8387218	11	(S1 (S (NP (JJ Thirteen) (NNS patients)) (VP (VBD developed) (NP (NP (DT a) (VBN raised) (NN serum) (NN amylase)) (PP (IN without) (NP (NN Doc_8387218_1277_1291_Disease))))) (. .)))
8387218	12	(S1 (S (S (NP (CD Seven) (NNS patients)) (VP (VBD developed) (NP (NP (JJ Doc_8387218_1318_1342_Disease) (NN characteristic)) (PP (IN of) (NP (NNP Doc_8387218_1361_1369_Disease)))))) (CC but) (S (NP (DT these)) (VP (VP (AUX were) (ADJP (JJ mild))) (, ,) (VP (AUX did) (RB not) (VP (VB require) (NP (NN treatment)))) (CC and) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN on) (S (VP (VBG ceasing) (NP (NNP Doc_8387218_1451_1461_Chemical)))))))) (. .)))
8410052	0	(S1 (NP (NP (JJ Immunohistochemical) (NNS studies)) (PP (IN with) (NP (NNS antibodies))) (PP (TO to) (NP (JJ neurofilament) (NNS proteins))) (PP (IN on) (NP (NP (NNP Doc_8410052_73_86_Disease)) (PP (IN in) (NP (NP (JJ experimental) (JJ focal) (NNS lesions)) (PP (IN in) (NP (NN rat))))))) (. .)))
8410052	1	(S1 (S (NP (NP (NN Immunohistochemistry)) (PP (IN with) (NP (NP (JJ monoclonal) (NNS antibodies)) (PP (IN against) (NP (NP (JJ neurofilament) (PRN (-LRB- -LRB-) (NP (NNP NF)) (-RRB- -RRB-)) (NNS proteins)) (PP (IN of) (NP (NP (JJ middle) (CC and) (JJ high) (JJ molecular) (NN weight) (NN class)) (, ,) (ADJP (JJ NF-M) (CC and) (JJ NF-H)) (, ,)))))))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB study) (NP (NP (NN Doc_8410052_285_298_Disease)) (PP (IN in) (NP (NP (DT the) (NN borderzone)) (PP (IN of) (NP (NP (JJ focal) (NNS lesions)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
8410052	2	(S1 (S (NP (JJ Focal) (NN Doc_8410052_349_369_Disease)) (VP (AUX was) (VP (VBN produced) (PP (IN by) (NP (NP (NN infusion)) (PP (IN of) (NP (NNP Doc_8410052_398_405_Chemical))) (PP (PP (IN at) (NP (NN acid) (NN pH))) (CC or) (PP (IN by) (NP (NP (NN stab)) (VP (VBN caused) (PP (IN by) (NP (NN needle) (NN insertion))))))))))) (. .)))
8410052	3	(S1 (S (NP (NN Doc_8410052_456_500_Disease)) (VP (AUX were) (VP (VBN evoked) (PP (IN by) (NP (JJ prolonged) (JJ Doc_8410052_526_537_Chemical-induced) (NN Doc_8410052_546_564_Disease))))) (. .)))
8410052	4	(S1 (S (NP (NP (JJ Immunohistochemical) (NN staining)) (PP (IN for) (NP (NNS NFs)))) (VP (VBD showed) (NP (NP (JJ characteristic) (NN terminal) (NNS clubs)) (PP (IN of) (NP (NNS axons)))) (PP (IN in) (NP (NP (DT the) (NN borderzone)) (PP (IN of) (NP (NNS lesions)))))) (. .)))
8410052	5	(S1 (S (NP (NP (NNS Differences)) (PP (IN in) (NP (DT the) (VBG labelling) (NN pattern)))) (VP (VBD occurred) (PP (IN with) (NP (NP (JJ different) (NNS antibodies)) (SBAR (WHNP (WDT which)) (S (ADVP (RB apparently)) (VP (VBD depended) (PP (IN on) (NP (NP (JJ molecular) (NN weight) (NN class)) (PP (IN of) (NP (NP (NNS NFs)) (CC and) (NP (NN phosphorylation) (NN state)))))))))))) (. .)))
8410052	6	(S1 (S (NP (NP (DT These) (JJ immunohistochemical) (NNS changes)) (PP (IN of) (NP (NNS NFs)))) (VP (MD can) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN for) (NP (NP (NNP Doc_8410052_904_917_Disease)) (PP (IN in) (NP (NP (JJ various) (JJ experimental) (NN Doc_8410052_942_951_Disease)) (CC or) (NP (JJ ischemic) (NNS lesions)))))))))) (. .)))
84204	0	(S1 (S (NP (NP (JJ Pharmacokinetic) (CC and) (JJ clinical) (NNS studies)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ Doc_84204_54_64_Chemical-associated) (JJ mental) (NNP Doc_84204_83_92_Disease.) (CD 15) (NNS cases)) (PP (IN of) (NP (JJ Doc_84204_106_116_Chemical-associated) (JJ mental) (NN Doc_84204_135_144_Disease)))))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))) (. .)))
84204	1	(S1 (S (PP (IN In) (NP (NN order) (SBAR (IN that) (S (NP (DT this) (NN syndrome)) (VP (MD might) (VP (AUX be) (VP (VBN investigated) (SBAR (S (NP (NP (NNS changes)) (PP (IN in) (NP (JJ mental) (NN status))) (PRN (-LRB- -LRB-) (NP (NNP M.S.)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (NP (NN serum) (NNS concentrations)) (CC and) (NP (JJ renal) (CC and) (JJ hepatic) (NN function)))) (PP (IN in) (NP (CD 36) (NNS patients)))))))))))))) (, ,) (S (NP (CD 30) (NNS patients)) (VP (AUX had) (NP (DT no) (JJ M.S.) (NN change)) (PP (IN on) (NP (NNP Doc_84204_370_380_Chemical))))) (CC and) (S (NP (CD 6)) (VP (AUX had) (ADJP (JJ moderate) (PP (TO to) (NP (JJ severe) (NNS changes)))))) (. .)))
84204	2	(S1 (S (NP (DT These) (CD 6) (NNS patients)) (VP (AUX had) (NP (NP (NP (DT both) (NNP Doc_84204_445_472_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ Doc_84204_504_514_Chemical) (NNS trough-concentrations)) (PP (IN of) (NP (QP (JJR more) (IN than) (CD 1.25)) (NNS microgram/ml)))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))) (. .)))
84204	3	(S1 (S (NP (NP (DT The) (NN severity)) (PP (IN of) (NP (JJ M.S.) (NNS changes)))) (VP (VBD increased) (SBAR (IN as) (S (NP (NNS trough-concentrations)) (VP (VBD rose) (, ,) (SBAR (S (NP (CD 5) (NNS patients)) (VP (AUX had) (NP (JJ lumbar) (NN puncture))))))))) (. .)))
84204	4	(S1 (S (S (NP (NP (DT The) (JJ cerebrospinal) (JJ fluid) (: :) (NN serum) (NN ratio)) (PP (IN of) (NP (NNP Doc_84204_730_740_Chemical) (NNS concentrations)))) (VP (VP (AUX was) (VP (VBN 0.24:1))) (CC and) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NNP Doc_84204_786_796_Chemical)) (VP (VBZ passes) (NP (DT the) (JJ blood-brain) (NN barrier)))))))) (: ;) (S (NP (PRP it)) (ADVP (RB also)) (VP (VBZ raises) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NNP M.S.) (NNS changes)) (VP (AUX are) (ADJP (JJ due) (PP (TO to) (NP (NP (NN blockade)) (PP (IN of) (NP (NP (NNP Doc_84204_901_910_Chemical) (NNP H2-receptors)) (PP (IN in) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))))))))) (. .)))
84204	5	(S1 (S (NP (NP (NP (NNS Patients)) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX have) (NP (DT both) (VBN raised) (NNS trough-concentrations))))))) (CC and) (NP (JJ mental) (NN Doc_84204_1024_1033_Disease))) (VP (AUX are) (NP (NP (DT those)) (PP (IN with) (NP (DT both) (JJ severe) (NNP Doc_84204_1061_1090_Disease))))) (. .)))
84204	6	(S1 (S (NP (PRP They)) (VP (VP (MD should) (VP (AUX be) (VP (ADVP (RB closely)) (VBN observed)))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN given) (NP (NP (JJ reduced) (NNS doses)) (PP (IN of) (NP (NNP Doc_84204_1161_1171_Chemical)))))))) (. .)))
8421099	0	(S1 (NP (NP (JJ Prospective) (NN study)) (PP (IN of) (NP (NP (DT the) (JJ long-term) (NNS effects)) (PP (IN of) (NP (NP (NN somatostatin) (NN analog)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8421099_67_77_Chemical)) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (JJ gallbladder) (NN function)) (CC and) (NP (NP (NNP Doc_8421099_107_116_Disease) (NN formation)) (PP (IN in) (NP (JJ Chinese) (NNP Doc_8421099_138_149_Disease) (NNS patients)))))) (. .)))
8421099	1	(S1 (S (NP (DT This) (NN article)) (VP (VBZ reports) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (JJR gallbladder) (NN function)) (VP (VBN examined) (PP (IN by) (NP (NN ultrasonography))) (PP (IN in) (NP (NP (CD 20) (JJ Chinese) (NNS patients)) (PP (IN with) (NP (JJ active) (NNP Doc_8421099_280_290_Disease))) (VP (VBN treated) (PP (IN with) (NP (NP (CD sc) (NN injection)) (PP (IN of) (NP (DT the) (NN somatostatin) (NN analog) (NNP Doc_8421099_344_354_Chemical))))) (PP (IN in) (NP (NP (NNS dosages)) (PP (IN of) (NP (NP (CD 300-1500) (NN micrograms/day)) (PP (IN for) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (NP (CD 24.2) (NN +/-)) (NP (CD 13.9) (NNS months)))))))))))))))))) (. .)))
8421099	2	(S1 (S (PP (IN During) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_8421099_451_461_Chemical))))) (, ,) (S (NP (CD 17) (NNS patients)) (VP (VBD developed) (NP (NN sludge)))) (, ,) (S (NP (CD 10)) (VP (AUX had) (NP (NN Doc_8421099_500_510_Disease)))) (, ,) (CC and) (S (NP (CD 1)) (VP (VBD developed) (NP (NP (NN Doc_8421099_528_547_Disease)) (VP (VBG requiring) (NP (NN surgery)))))) (. .)))
8421099	3	(S1 (S (PP (IN In) (NP (NP (DT all)) (PP (IN of) (NP (NP (CD 7) (NNS patients)) (VP (VBN examined) (ADVP (RB acutely))))))) (, ,) (NP (NN gallbladder) (NN contractility)) (VP (AUX was) (VP (VBD inhibited) (PP (IN after) (NP (DT a) (JJ single) (JJ 100-micrograms) (NN injection))))) (. .)))
8421099	4	(S1 (S (PP (IN In) (NP (NP (CD 8) (NNS patients)) (VP (VBN followed) (PP (IN for) (NP (CD 24) (NNS weeks)))))) (, ,) (NP (JJ gallbladder) (NN contractility)) (VP (VBD remained) (NP (NNP Doc_8421099_759_768_Disease)) (PP (IN throughout) (NP (NN therapy)))) (. .)))
8421099	5	(S1 (S (PP (IN After) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_8421099_809_819_Chemical))) (PP (IN in) (NP (NP (CD 10) (NNS patients)) (PP (IN without) (NP (NNP Doc_8421099_843_853_Disease))))))) (, ,) (NP (NP (CD 8) (NNS patients)) (VP (VBN assessed))) (VP (AUX had) (NP (NP (NN return)) (PP (IN of) (NP (JJ normal) (NN gallbladder) (NN contractility))) (PP (IN within) (NP (CD 1) (NN month))))) (. .)))
8421099	6	(S1 (S (PP (IN In) (NP (NP (CD 8)) (PP (IN of) (NP (NP (DT the) (JJ remaining) (CD 10) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_8421099_986_996_Disease)) (PP (IN during) (NP (NN treatment)))))))))) (, ,) (NP (JJ gallbladder) (NN contractility)) (VP (VP (VBD normalized) (PP (IN in) (NP (NP (CD 5) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 3)) (SBAR (WHPP (IN of) (WHNP (WP whom))) (S (VP (AUX has) (NP (NP (NN disappearance)) (PP (IN of) (NP (PRP$ their) (NNS stones)))) (PP (IN within) (NP (CD 3) (NNS weeks))))))) (-RRB- -RRB-))))) (, ,) (CC and) (VP (VBD remained) (NP (NNP Doc_8421099_1141_1150_Disease)) (PP (IN in) (NP (NP (CD 3)) (PRN (-LRB- -LRB-) (NP (NP (CD 2)) (PP (IN of) (SBAR (WHNP (WP whom)) (S (VP (AUX had) (NP (NP (NNS stones)) (ADJP (JJ present) (PP (IN at) (NP (CD 6) (NNS months)))))))))) (-RRB- -RRB-)))))) (. .)))
8421099	7	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN suppression)) (PP (IN of) (NP (NN gallbladder) (NN contractility)))) (VP (AUX is) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NP (DT the) (JJ successive) (NN formation)) (PP (IN of) (NP (JJ bile) (NN sludge) (, ,) (NNP Doc_8421099_1327_1337_Disease) (, ,) (CC and) (NNP Doc_8421099_1343_1356_Disease)))))) (PP (IN during) (NP (NP (JJ Doc_8421099_1364_1374_Chemical) (NN therapy)) (PP (IN in) (NP (JJ Chinese) (NNP Doc_8421099_1394_1405_Disease) (NNS patients))))))))) (. .)))
8421099	8	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB therefore)) (ADJP (RB very) (JJ important) (S (VP (TO to) (VP (VB follow) (NP (NP (DT the) (NNS changes)) (PP (IN of) (NP (NN gallbladder) (NN function)))) (PP (IN during) (NP (NP (JJ long-term) (JJ Doc_8421099_1510_1520_Chemical) (NN therapy)) (PP (IN of) (NP (JJ Doc_8421099_1532_1543_Disease) (NNS patients)))))))))) (. .)))
8423889	0	(S1 (NP (NP (NN Increase)) (PP (IN of) (NP (NNP Doc_8423889_12_32_Disease))) (PP (IN after) (NP (JJ Doc_8423889_39_49_Chemical) (NN medication))) (. .)))
8423889	1	(S1 (S (NP (NN Doc_8423889_62_72_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ major) (JJ clinical) (NN feature)) (PP (IN of) (NP (NNP Doc_8423889_104_123_Disease))))) (. .)))
8423889	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (VBN increased) (NN amount)) (PP (IN of) (NP (NNP Doc_8423889_159_175_Disease))) (PP (IN in) (NP (CD four) (NNS patients)))) (PP (IN with) (NP (NNP Doc_8423889_198_228_Disease))) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (DT the) (NNP Doc_8423889_251_265_Chemical) (NNP Doc_8423889_266_276_Chemical)))))) (. .)))
8423889	3	(S1 (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NP (DT a) (ADJP (RB clinically) (JJ relevant)) (JJ Doc_8423889_319_327_Chemical-antagonistic) (NN capacity)) (PP (IN of) (NP (NNP Doc_8423889_353_363_Chemical))) (PP (IN in) (NP (NNP Doc_8423889_367_386_Disease) (NNS patients)))))) (VP (MD must) (VP (AUX be) (VP (VBN considered)))) (. .)))
8437969	0	(S1 (S (NP (NN Doc_8437969_0_12_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ continuous-infusion) (NNP Doc_8437969_49_59_Chemical)))) (. .)))
8437969	1	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (JJ intermittent) (JJ intravenous) (NNS infusions)) (PP (IN of) (NP (NNP Doc_8437969_121_131_Chemical)))))) (VP (AUX is) (ADVP (RB infrequently)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_8437969_183_199_Disease))))))) (. .)))
8437969	2	(S1 (S (NP (NP (NP (DT A) (JJ 40-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_8437969_224_232_Disease)))) (CC and) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (NNP Doc_8437969_251_266_Disease))))) (VP (VBD developed) (NP (NP (JJ recurrent) (, ,) (JJ brief) (NNS episodes)) (PP (IN of) (NP (JJ apparent) (NN Doc_8437969_315_327_Disease)))) (SBAR (IN while) (S (VP (VBG receiving) (NP (JJ continuous-infusion) (NNP Doc_8437969_364_374_Chemical) (CD 50) (NN mg/hour)))))) (. .)))
8437969	3	(S1 (S (NP (DT The) (NNP Doc_8437969_391_402_Disease)) (VP (AUX were) (ADVP (RB temporally)) (VP (VP (VBN related) (PP (TO to) (NP (NNP Doc_8437969_430_440_Chemical) (NN administration)))) (, ,) (VP (VBN disappeared) (PP (IN after) (NP (NN dechallenge)))) (, ,) (CC and) (VP (AUX did) (RB not) (VP (VB recur) (PP (IN during) (NP (JJ Doc_8437969_513_523_Chemical) (NN treatment))))))) (. .)))
8437969	4	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8437969_570_582_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ continuous-infusion) (NN Doc_8437969_619_629_Chemical)))))))) (. .)))
8558192	0	(S1 (NP (NP (NN Phase) (NNP II) (NN trial)) (PP (IN of) (NP (NNP Doc_8558192_18_29_Chemical))) (PP (IN in) (NP (JJ metastatic) (NNP Doc_8558192_44_78_Disease))) (. .)))
8558192	1	(S1 (S (NP (NP (NNP European) (NNP Organization)) (PP (IN for) (NP (NP (NP (NNP Research)) (CC and) (NP (NNP Treatment))) (PP (IN of) (NP (NNP Doc_8558192_132_138_Disease) (NNP Gastrointestinal)))))) (VP (VBP Treat) (NP (NNP Doc_8558192_162_168_Disease) (NNP Cooperative) (NNP Group))) (. .)))
8558192	2	(S1 (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN response) (NN rate)) (CC and) (NP (NP (JJ toxic) (NNS effects)) (PP (IN of) (NP (NNP Doc_8558192_248_259_Chemical)))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_8558192_261_264_Chemical)) (-RRB- -RRB-)) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (JJ single) (NN agent)) (PP (IN in) (NP (JJ metastatic) (NNP Doc_8558192_311_345_Disease)))))) (. .)))
8558192	3	(S1 (S (NP (NP (NNS PATIENTS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (NP (JJ Forty-six) (NN eligible) (NNS patients)) (PP (IN with) (NP (JJ measurable) (NNS lesions)))) (VP (VP (AUX were) (VP (VBN included))) (CC and) (VP (AUX were) (ADJP (JJ stratified)) (PP (VBG according) (PP (TO to) (NP (JJ previous) (NN chemotherapy)))))) (. .)))
8558192	4	(S1 (S (NP (NP (NP (CD Thirty) (NNS patients)) (PP (IN without) (NP (JJ prior) (NN chemotherapy)))) (CC and) (NP (NP (CD 16)) (VP (VBN pretreated) (PP (IN with) (NP (JJ Doc_8558192_557_566_Chemical-based) (NN chemotherapy)))))) (VP (AUX were) (ADJP (JJ assessable) (PP (IN for) (NP (NP (NN Doc_8558192_606_614_Disease)) (CC and) (NP (NN response)))))) (. .)))
8558192	5	(S1 (S (NP (NN Doc_8558192_629_632_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB weekly)) (PP (IN as) (NP (DT a) (JJ 25-mg/m2) (JJ short) (JJ intravenous) (-LRB- -LRB-) (NN i.v.) (-RRB- -RRB-) (NN infusion))))) (. .)))
8558192	6	(S1 (S (NP (NP (CD Six)) (PP (IN of) (NP (NP (CD 30) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-)))) (PP (IN without) (NP (JJ prior) (NN chemotherapy)))) (VP (VBD achieved) (NP (NP (DT a) (JJ partial) (NN response)) (-LRB- -LRB-) (NP (NNP PR)) (-RRB- -RRB-) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 95) (NN %)) (NN confidence)) (JJ interval) (JJ -LSB-CI) (NN -RSB-)) (, ,) (NP (QP (CD 8) (NN %) (TO to) (CD 39) (NN %)))) (-RRB- -RRB-)))) (. .)))
8558192	7	(S1 (S (NP (NP (DT The) (JJ median) (NN duration)) (PP (IN of) (NP (NN response)))) (VP (AUX was) (NP (NP (CD 21) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (QP (CD 17) (TO to) (CD 28))) (-RRB- -RRB-)))) (. .)))
8558192	8	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (NP (NP (CD 16) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 6) (NN %)) (-RRB- -RRB-))) (PP (IN with) (NP (JJ prior) (NN chemotherapy)))))) (VP (AUX had) (NP (NP (DT a) (JJ complete) (NN response)) (PRN (-LRB- -LRB-) (NP (NNP CR)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NP (CD 31) (NNS weeks) (POS ')) (NN duration)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NN CI)) (, ,) (NP (QP (CD 0) (NN %) (TO to) (CD 30) (NN %)))) (-RRB- -RRB-)))))) (. .)))
8558192	9	(S1 (S (NP (NP (DT The) (JJ overall) (NN response) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP World) (NNP Health) (NNP Organization)) (NP (JJ -LSB-WHO) (JJ -RSB-) (NNS criteria)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (CD 15) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN CR)) (, ,) (NP (NP (NP (CD 2) (NN %)) (: ;) (NP (NNP PR) (CD 13) (NN %)) (: ;) (NP (ADJP (CD 95) (NN %)) (NNS CI))) (, ,) (NP (QP (CD 6) (NN %) (TO to) (CD 29) (NN %))))) (-RRB- -RRB-)))) (. .)))
8558192	10	(S1 (S (NP (NP (DT The) (JJ median) (NN dose-intensity)) (PRN (-LRB- -LRB-) (NP (NNP DI)) (-RRB- -RRB-))) (VP (AUX was) (NP (CD 20) (NN mg/m2/wk))) (. .)))
8558192	11	(S1 (S (S (NP (NN Doc_8558192_1189_1192_Chemical)) (VP (AUX was) (VP (ADVP (RB well)) (VBN tolerated)))) (CC and) (S (NP (NP (CD zero) (NNS instances)) (PP (IN of) (NP (WP WHO) (NN grade))) (NP (CD 4) (JJ nonhematologic) (NNP Doc_8558192_1261_1269_Disease))) (VP (VBD occurred))) (. .)))
8558192	12	(S1 (S (NP (NP (NP (QP (IN At) (JJS least) (CD one)) (NN episode)) (PP (IN of) (NP (NN grade) (CD 3)))) (CC or) (NP (CD 4) (NN Doc_8558192_1317_1333_Disease))) (VP (AUX was) (VP (VBN seen) (PP (IN in) (NP (NP (CD 59) (NN %)) (PP (IN of) (NP (NNS patients))))))) (. .)))
8558192	13	(S1 (S (S (NP (NP (DT A) (NN grade)) (NP (QP (CD 2) (CC or) (CD 3)) (NN Doc_8558192_1378_1387_Disease))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 16) (NN %)) (PP (IN of) (NP (NNS patients))))))) (, ,) (CC but) (S (NP (DT no) (JJ toxic) (NN Doc_8558192_1430_1436_Disease)) (VP (VBD occurred))) (. .)))
8558192	14	(S1 (S (S (NP (JJ Other) (NN side) (NNS effects)) (VP (AUX were) (ADJP (JJ rare)))) (, ,) (CC and) (S (NP (NNP Doc_8558192_1481_1505_Disease)) (VP (AUX has) (VP (AUX been) (ADJP (JJ minor)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN %) (NN grade) (CD 1)) (-RRB- -RRB-))))) (. .)))
8558192	15	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_8558192_1573_1576_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ active) (NN agent)) (PP (IN in) (NP (JJ metastatic) (NN Doc_8558192_1610_1644_Disease)))))))) (. .)))
8558192	16	(S1 (S (PP (VBN Given) (NP (NP (PRP$ its) (JJ excellent) (NN tolerance) (NN profile)) (CC and) (NP (JJ low) (NN Doc_8558192_1692_1700_Disease)))) (, ,) (NP (NP (JJ further) (NN evaluation)) (PP (IN of) (NP (NNP Doc_8558192_1724_1727_Chemical))) (PP (IN in) (NP (NN combination) (NN therapy)))) (VP (AUX is) (VP (VBN warranted))) (. .)))
8590259	0	(S1 (NP (NP (NN Evaluation)) (PP (IN of) (NP (NP (JJ adverse) (NNS reactions)) (PP (IN of) (NP (JJ Doc_8590259_35_58_Chemical) (JJ ophthalmic) (NN solution))))) (. .)))
8590259	1	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (JJ adverse) (NNS reactions)) (PP (IN of) (NP (NNP Doc_8590259_132_145_Chemical)))) (PP (IN in) (NP (CD 20) (JJ normal) (NNS volunteers))) (PP (IN by) (S (VP (VBG instilling) (NP (NP (DT a) (JJ single) (NN drop)) (PP (IN of) (NP (ADJP (CD 1) (NN %)) (NN Doc_8590259_204_217_Chemical))) (PP (IN in) (NP (PRP$ their) (JJ right) (NNS eyes)))))))) (. .)))
8590259	2	(S1 (S (NP (NP (NNS Examinations)) (, ,) (PP (VBG including) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (NN pulse) (NN rate)) (, ,) (NP (FW conjunctiva)) (CC and) (NP (NP (NP (NN cornea)) (, ,) (NP (NN intraocular) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP IOP)) (-RRB- -RRB-)) (, ,) (NP (NN pupil) (NN diameter)) (, ,)) (NN basal) (S (VP (VB tear) (NP (NP (NP (NN secretion)) (CC and) (NP (NN margin) (JJ reflex) (NN distance))) (PP (IN of) (NP (DT both) (ADJP (JJ upper) (CC and) (JJR lower)) (NNS eyelids))))))))) (, ,)) (VP (VP (AUX were) (VP (VBN performed) (ADVP (RB prior)) (PP (TO to) (NP (NN entry))))) (CC and) (VP (PP (IN at) (NP (NP (CD 1) (, ,) (CD 3) (, ,) (CD 5) (CC and) (CD 7) (NNS hours)) (PP (IN after) (NP (NN instillation))))))) (. .)))
8590259	3	(S1 (S (NP (DT The) (JJ Doc_8590259_521_539_Disease) (NNS effects)) (VP (VP (AUX were) (ADJP (RB statistically) (JJ significant)) (PP (IN for) (NP (NP (JJ Doc_8590259_583_596_Chemical-treated) (NNS eyes)) (PP (IN throughout) (NP (DT the) (NN study)))))) (CC and) (ADVP (RB also)) (VP (ADJP (RB statistically) (JJ significant)) (PP (IN for) (NP (NP (JJ contralateral) (NNS eyes)) (PP (IN from) (NP (NP (CD three) (NNS hours)) (PP (IN after) (NP (NP (JJ topical) (NN administration)) (PP (IN of) (NP (ADJP (CD 1) (NN %)) (NNP Doc_8590259_741_754_Chemical))))))))))) (. .)))
8590259	4	(S1 (S (NP (NN Doc_8590259_756_792_Disease)) (VP (AUX were) (UCP (ADVP (RB statistically)) (, ,) (CC but) (RB not) (ADJP (RB clinically) (, ,) (JJ significant)))) (. .)))
8590259	5	(S1 (S (S (NP (NP (DT No) (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (JJ diastolic) (NN blood) (NN pressure)) (, ,) (NP (NN pulse) (NN rate)) (CC and) (NP (NN basal))))) (VP (VB tear) (NP (NN secretion)))) (VP (AUX were) (VP (VBN noted))) (. .)))
8590259	6	(S1 (S (NP (NP (NN Doc_8590259_946_968_Disease)) (CC and) (NP (NN Doc_8590259_973_982_Disease))) (VP (AUX were) (ADVP (RB commonly)) (VP (VBN found))) (. .)))
8590259	7	(S1 (S (NP (JJ Upper) (NN lid) (NN retraction)) (VP (AUX was) (ADVP (RB frequently)) (VP (VBN noted))) (. .)))
8590259	8	(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NNS elevations)) (PP (IN of) (NP (DT the) (JJ upper) (NN lid) (NN margin))) (PP (IN in) (NP (JJS most) (NNS subjects)))) (VP (VP (AUX were) (RB not) (NP (QP (JJR more) (IN than) (CD 2)) (NN mm))) (CC and) (VP (AUX did) (RB not) (VP (VB cause) (NP (NP (JJ noticeable) (NN change)) (PP (IN in) (NP (NN appearance))))))))) (, ,) (NP (CD one) (NN subject)) (VP (VP (VBD suffered) (PP (IN from) (NP (JJ mechanical) (NNP Doc_8590259_1221_1230_Disease)))) (CC and) (VP (VBD marked) (NP (NNP Doc_8590259_1242_1258_Disease) (CD 3) (NNS hours)) (PP (IN after) (NP (NP (NN instillation)) (PP (IN of) (NP (DT the) (NN medication))))))) (. .)))
8590259	9	(S1 (S (NP (DT This)) (VP (MD may) (ADVP (RB well)) (VP (AUX be) (NP (NP (DT a) (ADJP (RB particularly) (JJ notable)) (NN finding)) (PP (IN in) (NP (JJ Asian) (NNS people)))))) (. .)))
8595686	0	(S1 (NP (NP (JJ Doc_8595686_0_11_Chemical) (NN pretreatment)) (PP (IN for) (NP (NP (NNP Doc_8595686_29_37_Chemical) (NN injection) (NNP Doc_8595686_48_52_Disease)) (PP (IN in) (NP (JJ ambulatory) (NNS patients))))) (. .)))
8595686	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD investigated) (NP (NP (JJ Doc_8595686_101_109_Chemical) (NN injection) (NN Doc_8595686_120_124_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (JJ ambulatory) (NN anaesthesia))))))) (. .)))
8595686	2	(S1 (S (PP (IN In) (NP (DT a) (JJ randomized) (, ,) (JJ double-blind) (NN trial))) (, ,) (NP (CD 90) (NNS women)) (VP (AUX were) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (NN one)) (PP (IN of) (NP (CD three) (NNS treatments)))) (ADVP (RB prior) (PP (TO to) (NP (NP (NN induction)) (PP (IN of) (NP (NN anaesthesia))) (PP (IN with) (NP (NNP Doc_8595686_307_315_Chemical))))))))))) (. .)))
8595686	3	(S1 (S (NP (NP (NNS Patients)) (PP (IN in) (NP (NNP Group) (NNP C)))) (VP (VBD received) (NP (NP (QP (CD 2) (CD ml)) (JJ normal) (NN saline)) (, ,) (NP (NP (NNP Group) (NNP L)) (, ,) (NP (NP (CD 2) (NN ml)) (, ,) (NP (NP (NNP Doc_8595686_381_390_Chemical) (CD 2) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN mg)) (-RRB- -RRB-)))) (CC and) (NP (NP (NNP Group) (NNP T)) (, ,) (NP (NP (QP (CD 2) (CD ml)) (NNP Doc_8595686_420_431_Chemical) (CD 2.5) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg)) (-RRB- -RRB-))))))) (. .)))
8595686	4	(S1 (S (NP (JJ Venous) (NN discomfort)) (VP (AUX was) (VP (VBN assessed) (PP (IN with) (NP (NP (DT a) (JJ visual) (NN analogue) (NN scale)) (PRN (-LRB- -LRB-) (INTJ (UH VAS)) (-RRB- -RRB-)))) (NP (JJ 5-15) (NNP sec)) (PP (IN after) (S (VP (VBG commencing) (NP (NP (JJ Doc_8595686_538_546_Chemical) (NN administration)) (VP (VBG using) (NP (NP (DT an) (NN infusion) (NN pump)) (PRN (-LRB- -LRB-) (NP (NN rate) (CD 1000) (NN micrograms.kg-1.min-1)) (-RRB- -RRB-)))))))))) (. .)))
8595686	5	(S1 (S (NP (NN Doc_8595686_620_641_Disease)) (VP (VBD occurred) (PP (IN in) (NP (JJ 60-90) (NNP sec)))) (. .)))
8595686	6	(S1 (S (S (NP (NP (NP (JJ Visual) (JJ analogue) (NNS scores)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NNS SD)) (-RRB- -RRB-))) (PP (IN during) (NP (NN induction)))) (VP (AUX were) (ADJP (ADJP (JJR lower) (PP (IN in) (NP (NP (NNS Groups)) (NX (NX (NX (NNP L)) (PRN (-LRB- -LRB-) (NP (QP (CD 3.3) (CD +/-)) (CD 2.5)) (-RRB- -RRB-))) (CC and) (NX (NX (NNP T)) (PRN (-LRB- -LRB-) (NP (QP (CD 4.1) (CD +/-)) (CD 2.7)) (-RRB- -RRB-))))))) (PP (IN than) (PP (IN in) (NP (NNP Group) (NNP C))))) (PRN (-LRB- -LRB-) (NP (QP (CD 5.6) (CD +/-)) (CD 2.3)) (-RRB- -RRB-)))) (: ;) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.0031)))) (. .)))
8595686	7	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ venous) (NN discomfort)))) (VP (VP (AUX was) (ADJP (ADJP (ADJP (JJR lower) (PP (IN in) (NP (NNP Group) (NNP L)))) (PRN (-LRB- -LRB-) (NP (NP (CD 76.6) (NN %)) (: ;) (NP (CD P) (NNS <))) (NP (CD 0.05)) (-RRB- -RRB-))) (PP (IN than) (PP (IN in) (NP (NNP Group) (NNP C))))) (PRN (-LRB- -LRB-) (NP (CD 100) (NN %)) (-RRB- -RRB-))) (CC but) (RB not) (ADJP (JJ different) (PP (IN from) (NP (NP (NNP Group) (NNP T)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %)) (-RRB- -RRB-)))))) (. .)))
8595686	8	(S1 (S (NP (NP (DT The) (JJ VAS) (NNS scores)) (PP (IN for) (NP (NP (NN recall)) (PP (IN of) (NP (NNP Doc_8595686_983_987_Disease))))) (PP (IN in) (NP (DT the) (NN recovery) (NN room)))) (VP (AUX were) (VP (VBN correlated) (PP (IN with) (NP (DT the) (NNP VAS) (NNS scores))) (PP (IN during) (NP (NP (NN induction)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.7045)) (: ;) (NP (QP ($ P) (CD <) (CD 0.0001))) (-RRB- -RRB-)))))) (. .)))
8595686	9	(S1 (S (NP (NN Recovery) (NN room) (NN discharge) (NNS times)) (VP (AUX were) (ADJP (JJ similar)) (: :) (NP (NP (NP (NNP C)) (PRN (-LRB- -LRB-) (NP (NP (CD 75.9) (NN +/-)) (NP (CD 19.4) (NN min))) (-RRB- -RRB-))) (: ;) (NP (NP (NNP L) (CD 73.6)) (PRN (NP (QP (CD +/-) (CD 21.6)) (NN min)) (-RRB- -RRB-))) (: ;) (NP (NP (NNP T)) (PRN (-LRB- -LRB-) (NP (CD 77.1) (NN +/-) (CD 18.9) (NN min)) (-RRB- -RRB-))))) (. .)))
8595686	10	(S1 (S (S (VP (VBG Assessing) (NP (PRP$ their) (JJ overall) (NN satisfaction)))) (, ,) (NP (CD 89.7) (NN %)) (VP (MD would) (VP (VB choose) (NP (JJ Doc_8595686_1257_1265_Chemical) (NN anaesthesia)) (ADVP (RB again)))) (. .)))
8595686	11	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_8595686_1302_1311_Chemical)) (VP (VBZ reduces) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_8595686_1350_1358_Chemical) (NN injection) (NNP Doc_8595686_1369_1373_Disease))) (PP (IN in) (NP (JJ ambulatory) (NNS patients)))) (SBAR (IN whereas) (S (NP (NNP Doc_8595686_1405_1416_Chemical)) (ADVP (RB only)) (VP (VBZ reduces) (NP (PRP$ its) (NN severity))))))))) (. .)))
8638206	0	(S1 (NP (NP (JJ Persistent) (NN Doc_8638206_11_20_Disease)) (PP (IN after) (NP (NP (VBN prolonged) (NN use)) (PP (IN of) (NP (NNP Doc_8638206_44_54_Chemical))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNS corticosteroids))))))) (. .)))
8638206	1	(S1 (S (NP (NP (JJ Neuromuscular) (VBG blocking) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NNP NMBAs)) (-RRB- -RRB-))) (VP (AUX are) (ADVP (RB often)) (VP (VBN used) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG requiring) (NP (JJ prolonged) (JJ mechanical) (NN ventilation))))))) (. .)))
8638206	2	(S1 (S (NP (NP (NNS Reports)) (PP (IN of) (NP (JJ persistent) (NN Doc_8638206_222_231_Disease))) (PP (IN after) (NP (NP (DT the) (NN discontinuance)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (VP (AUX have) (ADVP (RBS most) (RB often)) (VP (VBN involved) (NP (NP (JJ aminosteroid-based) (NNS NMBAs)) (PP (JJ such) (IN as) (NP (NNP Doc_8638206_330_348_Chemical)))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NNS corticosteroids)))))))))) (. .)))
8638206	3	(S1 (S (NP (NP (NNP Doc_8638206_408_427_Chemical)) (, ,) (NP (NP (NP (DT a) (NN short-acting)) (NP (NNP Doc_8638206_444_464_Chemical) (NNP NMBA))) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN eliminated) (ADVP (RB independently) (PP (IN of) (NP (JJ renal) (CC or) (JJ hepatic) (NN function))))))))) (, ,)) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (JJ persistent) (NN Doc_8638206_574_583_Disease))) (, ,) (FRAG (CC but) (RB only) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN with) (NP (NNS corticosteroids)))))))))) (. .)))
8638206	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8638206_646_656_Chemical-related) (NNP Doc_8638206_665_674_Disease)) (VP (VBG persisting) (PP (IN for) (NP (QP (RB approximately) (CD 50)) (NNS hours))) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (RB not) (VP (VBN treated) (PP (IN with) (NP (NNS corticosteroids)))))))))))))) (. .)))
8643971	0	(S1 (NP (NP (NP (DT A) (NN phase) (NNP I/II) (NN study)) (PP (IN of) (NP (NP (NNP Doc_8643971_22_32_Chemical)) (CC plus) (NP (NNP Doc_8643971_38_47_Chemical)))) (PP (IN as) (NP (JJ first-line) (NN therapy))) (PP (IN for) (NP (NNP Doc_8643971_74_95_Disease)))) (: :) (NP (JJ preliminary) (NNS results)) (. .)))
8643971	1	(S1 (S (NP (NP (JJ Improved) (NNS outcomes)) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_8643971_156_180_Disease)))))) (VP (VBP require) (NP (NP (NNS investigations)) (PP (IN of) (NP (JJ new) (NNS drugs))) (PP (IN for) (NP (JJ induction) (NN therapy))))) (. .)))
8643971	2	(S1 (S (S (NP (NP (JJ Preliminary) (NNS results)) (PP (IN of) (NP (NP (DT an) (NNP Eastern) (NNP Cooperative) (NNP Oncology) (NNP Group) (NN study)) (PP (IN of) (NP (NP (JJ single-agent) (NNP Doc_8643971_323_333_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8643971_335_340_Chemical)) (: ;) (NP (NP (NNP Bristol-Myers) (NNP Squibb) (NNP Company)) (, ,) (NP (NNP Princeton))) (, ,) (NP (NNP NJ)) (-RRB- -RRB-))))))) (VP (VBD reported) (NP (DT a) (ADJP (CD 37) (NN %)) (NN response) (NN rate)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_8643971_433_453_Disease))))))) (, ,) (CC and) (S (NP (DT the) (JJ Doc_8643971_463_473_Chemical/Doc_8643971_474_483_Chemical) (NN combination)) (VP (VP (AUX has) (VP (AUX been) (VP (VBN used) (ADVP (RB successfully))))) (CC and) (VP (AUX has) (VP (ADVP (RB significantly)) (VBN improved) (NP (NP (JJ median) (NN response) (NN duration)) (PP (IN in) (NP (NNP Doc_8643971_582_596_Disease) (NNS patients)))))))) (. .)))
8643971	3	(S1 (S (NP (PRP We)) (VP (VBD initiated) (NP (NP (DT a) (NN phase) (NNP I/II) (NN trial)) (SBAR (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN response) (CC and) (NN Doc_8643971_669_677_Disease)) (PP (IN of) (S (VP (VBG escalating) (NP (NP (JJ Doc_8643971_692_702_Chemical) (NNS doses)) (VP (VBN combined) (PP (IN with) (NP (JJ fixed-dose) (NNP Doc_8643971_734_743_Chemical))) (PP (IN with) (NP (NP (JJ granulocyte) (JJ colony-stimulating) (NN factor) (NN support)) (PP (IN in) (NP (NNS patients))))) (PP (IN with) (NP (JJ untreated) (ADJP (RB locally) (VBN advanced)) (JJ inoperable) (NN Doc_8643971_850_873_Disease))))))))))))))) (. .)))
8643971	4	(S1 (S (PP (TO To) (NP (NN date))) (, ,) (NP (NP (CD 23) (NNS men)) (PP (IN with) (NP (NP (DT a) (JJ median) (NN age)) (PP (IN of) (NP (NP (CD 50) (NNS years)) (CC and) (NP (JJ good) (NN performance) (NN status))))))) (VP (AUX have) (VP (VBN entered) (NP (DT the) (NN trial)))) (. .)))
8643971	5	(S1 (S (NP (JJ Primary) (NN Doc_8643971_981_986_Disease) (NNS sites)) (VP (AUX were) (NP (NP (NP (NP (NN oropharynx)) (, ,) (NP (CD 10) (NNS patients))) (: ;) (NP (NP (NN hypopharynx)) (, ,) (NP (CD four))) (: ;) (NP (NP (NN larynx)) (, ,) (NP (CD two))) (: ;) (NP (NP (JJ oral) (NN cavity)) (, ,) (NP (CD three))) (: ;) (NP (NP (JJ unknown) (NN primary)) (, ,) (NP (CD two))) (: ;) (CC and) (NP (NP (JJ nasal) (NN cavity)) (CC and) (NP (JJ parotid) (NN gland)))) (, ,) (NP (NP (CD one)) (NP (DT each))))) (. .)))
8643971	6	(S1 (S (NP (QP (IN Of) (CD 20)) (NNS patients)) (VP (VBP evaluable) (PP (IN for) (NP (NNP Doc_8643971_1172_1180_Disease))) (, ,) (SBAR (S (S (NP (CD four)) (VP (AUX had) (VP (VB stage) (NP (NNP III))))) (CC and) (S (NP (CD 16)) (VP (AUX had) (VP (VB stage) (NP (NNP IV) (NN disease)))))))) (. .)))
8643971	7	(S1 (S (NP (NP (NN Treatment)) (, ,) (VP (VBN given) (NP (NP (DT every) (CD 21) (NNS days)) (PP (IN for) (NP (NP (DT a) (NN maximum)) (PP (IN of) (NP (CD three) (NNS cycles))))))) (, ,) (VP (VBN consisted) (PP (IN of) (NP (NNP Doc_8643971_1305_1315_Chemical))) (PP (IN by) (NP (JJ 3-hour) (NN infusion))))) (VP (VBD followed) (NP (DT the) (JJ next) (NN day)) (PP (IN by) (NP (NP (DT a) (JJ fixed) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_8643971_1376_1385_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 75) (NN mg/m2)) (-RRB- -RRB-))))))) (. .)))
8643971	8	(S1 (S (S (NP (DT The) (NN dose) (NNS levels)) (VP (VB incorporate) (S (VP (VBG escalating) (NP (JJ Doc_8643971_1437_1447_Chemical) (NNS doses)))))) (, ,) (CC and) (S (NP (NP (JJ intrapatient) (NNS escalations)) (PP (IN within) (NP (DT a) (VBN given) (NN dose) (NN level)))) (VP (AUX are) (VP (VBN permitted) (SBAR (IN if) (S (NP (NNP Doc_8643971_1527_1535_Disease)) (VP (VBZ permits))))))) (. .)))
8643971	9	(S1 (S (S (PP (IN At) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT this) (NN writing))))) (, ,) (NP (NP (NN dose) (NN level) (CD 4)) (PRN (-LRB- -LRB-) (NP (NP (CD 260)) (, ,) (NP (CD 270)) (, ,) (CC and) (NP (CD 280) (NN mg/m2))) (-RRB- -RRB-))) (VP (AUX is) (VP (AUXG being) (VP (VBN evaluated))))) (: ;) (S (NP (NP (CD three) (NNS patients)) (PP (IN from) (NP (DT this) (NN level)))) (VP (AUX are) (ADJP (JJ evaluable)))) (. .)))
8643971	10	(S1 (S (PP (IN With) (NP (NP (JJ Doc_8643971_1684_1694_Chemical) (NNS doses)) (PP (IN of) (NP (NP (CD 200) (NNS mg/m2)) (CC and) (NP (JJR higher)))))) (, ,) (NP (NP (JJ granulocyte) (JJ colony-stimulating) (NN factor)) (NP (CD 5) (NN micrograms/kg/d))) (VP (AUX is) (VP (VBN given) (PRN (-LRB- -LRB-) (NP (NNS days) (CD 4) (IN through) (CD 12)) (-RRB- -RRB-)))) (. .)))
8643971	11	(S1 (S (PP (IN Of) (NP (NP (CD 18) (NNS patients)) (ADJP (JJ evaluable) (PP (IN for) (NP (NN response)))))) (, ,) (NP (NP (CD seven)) (PRN (-LRB- -LRB-) (NP (CD 39) (NN %)) (-RRB- -RRB-))) (VP (VBD achieved) (SBAR (S (NP (NP (DT a) (JJ complete) (NN response)) (CC and) (NP (NP (CD six)) (PRN (-LRB- -LRB-) (NP (CD 33) (NN %)) (-RRB- -RRB-)))) (VP (VBD achieved) (NP (DT a) (JJ partial) (NN response)))))) (. .)))
8643971	12	(S1 (S (S (NP (CD Three) (NNS patients)) (VP (AUX had) (NP (DT no) (NN change)))) (CC and) (S (NP (NN disease)) (VP (VBD progressed) (PP (IN in) (NP (CD two))))) (. .)))
8643971	13	(S1 (S (NP (DT The) (JJ overall) (NN response) (NN rate)) (VP (AUX is) (NP (CD 72) (NN %))) (. .)))
8643971	14	(S1 (S (NP (CD Eleven) (VBG responding) (NNS patients)) (VP (AUX had) (NP (NP (JJ subsequent) (NN surgery/radiotherapy)) (CC or) (NP (JJ radical) (NN radiotherapy)))) (. .)))
8643971	15	(S1 (S (NP (CD Two) (JJ pathologic) (JJ complete) (NNS responses)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN achieved) (NP (JJ clinical) (JJ complete) (NNS responses)))))))))) (. .)))
8643971	16	(S1 (S (S (NP (NP (NNP Doc_8643971_2223_2231_Disease)) (, ,) (NP (NNP Doc_8643971_2233_2245_Disease)) (, ,) (CC and) (NP (NNP Doc_8643971_2251_2262_Disease/Doc_8643971_2263_2271_Disease))) (VP (AUX have) (VP (VBN occurred) (ADVP (RB frequently))))) (, ,) (CC but) (S (PP (IN with) (NP (NP (CD one) (NN exception)) (-LRB- -LRB-) (NP (DT a) (NN grade) (CD 3) (NNP Doc_8643971_2332_2339_Disease)) (-RRB- -RRB-))) (NP (PRP they)) (VP (AUX have) (VP (AUX been) (NP (NN grade)) (NP (CD 1) (CC or) (CD 2))))) (. .)))
8643971	17	(S1 (S (NP (DT No) (JJ dose-limiting) (JJ hematologic) (NN Doc_8643971_2399_2407_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN seen)))) (. .)))
8643971	18	(S1 (S (S (NP (NN Doc_8643971_2423_2433_Chemical/Doc_8643971_2434_2443_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN first-line) (NN regimen)) (PP (IN for) (NP (ADJP (RB locoregionally) (VBN advanced)) (NNP Doc_8643971_2507_2527_Disease)))))) (CC and) (S (NP (VBN continued) (NN study)) (VP (AUX is) (VP (VBN warranted)))) (. .)))
8643971	19	(S1 (S (NP (NNS Results)) (ADVP (RB thus) (RB far)) (VP (VBP suggest) (NP (NP (DT no) (JJ dose-response) (NN effect)) (PP (IN for) (NP (NP (JJ Doc_8643971_2615_2625_Chemical) (NNS doses)) (PP (IN above) (NP (QP (CD 200) (CD mg/m2)))))))) (. .)))
8649546	0	(S1 (NP (NP (NN Improvement)) (PP (IN of) (NP (NNP Doc_8649546_15_23_Chemical-induced) (NNP Doc_8649546_32_42_Disease))) (PP (IN by) (NP (NP (NNP Doc_8649546_46_57_Chemical)) (PP (IN in) (NP (NNP Doc_8649546_61_80_Disease))))) (. .)))
8649546	1	(S1 (S (NP (NP (CD Seven) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NP (NNP Doc_8649546_112_131_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8649546_133_135_Disease)) (-RRB- -RRB-)))) (PP (IN with) (NP (ADJP (RB severely) (VBG disabling)) (NNP Doc_8649546_161_171_Disease))))) (VP (VBD received) (NP (JJ low-dose) (NN Doc_8649546_190_201_Chemical)) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (DT the) (ADJP (RB currently) (JJ used)) (JJ medical) (NN treatment)))))) (. .)))
8649546	2	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (ADJP (CD 40) (NN %)) (NN improvement)) (PP (IN in) (NP (NP (DT the) (JJ Doc_8649546_304_314_Disease) (NN score)) (PP (IN without) (NP (NP (NN increase)) (PP (IN of) (NP (NNP Doc_8649546_341_353_Disease) (NNP Doc_8649546_354_370_Disease))))))))) (. .)))
8649546	3	(S1 (S (NP (ADJP (JJ Ballistic) (CC and) (JJ choreic)) (NNP Doc_8649546_394_404_Disease)) (VP (AUX were) (ADVP (RB markedly)) (VP (VBN ameliorated) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_8649546_440_448_Disease)) (VP (AUX was) (RB not)))))) (. .)))
8649546	4	(S1 (S (NP (DT This) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NN administration)) (PP (IN of) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NNS beta-blockers)))))) (VP (MD may) (VP (VB improve) (NP (JJ Doc_8649546_540_548_Chemical-induced) (JJ ballistic) (CC and) (JJ choreic) (NN Doc_8649546_579_589_Disease)) (PP (IN in) (NP (NN Doc_8649546_593_595_Disease)))))))) (. .)))
8669433	0	(S1 (NP (NP (NP (JJ Habitual) (NN use)) (PP (IN of) (NP (NNP Doc_8669433_16_29_Chemical))) (PP (IN as) (NP (DT a) (NN risk) (NN factor))) (PP (IN for) (NP (NNP Doc_8669433_51_72_Disease)))) (: :) (NP (NP (DT a) (NN comparison)) (PP (IN with) (NP (NNP Doc_8669433_92_102_Chemical)))) (. .)))
8669433	1	(S1 (S (NP (NP (CD Six) (JJ epidemiologic) (NNS studies)) (PP (IN in) (NP (NP (DT the) (NNP United) (NNPS States)) (CC and) (NP (NNP Europe))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ habitual) (NN use)) (PP (IN of) (NP (NNP Doc_8669433_192_202_Chemical)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_8669433_241_262_Disease)) (CC and) (NP (NP (NNP Doc_8669433_267_290_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8669433_292_296_Disease)) (-RRB- -RRB-))))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ relative) (NN risk)) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (QP (CD 4) (TO to) (CD 19))))))))))))) (. .)))
8669433	2	(S1 (S (PP (IN As) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT these)) (CC and) (NP (JJ other) (NNS studies)))))) (, ,) (NP (NNP Doc_8669433_385_395_Chemical)) (VP (AUX has) (ADVP (RB now)) (VP (AUX been) (VP (VBN withdrawn) (PP (IN from) (NP (NP (DT the) (NN market)) (PP (IN in) (NP (JJS most) (NNS countries)))))))) (. .)))
8669433	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (CD three) (NN case) (NN control) (NNS studies)) (, ,) (NP (NP (CD one) (DT each)) (PP (IN in) (NP (NP (NNP North) (NNP Carolina)) (, ,) (NP (JJ northern) (NNP Maryland)) (, ,) (CC and) (NP (NP (NNP West) (NNP Berlin)) (, ,) (NP (NNP Germany)))))) (, ,)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ habitual) (NN use)) (PP (IN of) (NP (NNP Doc_8669433_592_605_Chemical)))) (VP (AUX is) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_8669433_630_651_Disease)) (CC and) (NP (NNP Doc_8669433_656_660_Disease)))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ relative) (NN risk)) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (QP (CD 2) (TO to) (CD 4))))))))))))) (. .)))
8669433	4	(S1 (S (NP (DT These) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT both) (NP (NNP Doc_8669433_739_749_Chemical)) (CC and) (NP (NNP Doc_8669433_754_767_Chemical))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN burden)) (PP (IN of) (NP (NNP Doc_8669433_800_804_Disease))))) (, ,) (PP (IN with) (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (DT the) (JJ latter)))) (VP (AUXG being) (ADJP (ADJP (RB somewhat) (JJR less)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ former)))))))))))))) (. .)))
8669433	5	(S1 (S (NP (NP (DT This) (JJ apparent) (NN difference)) (PP (IN in) (NP (NN risk)))) (VP (MD may) (RB not) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ Doc_8669433_945_956_Disease) (NN potential)) (PP (IN of) (NP (NP (DT the) (NNS drugs)) (NP (PRP themselves))))))))))) (. .)))
8669433	6	(S1 (S (NP (DT A) (ADJP (RBR lower) (JJ relative)) (NN risk)) (VP (MD would) (VP (AUX be) (VP (VBN expected) (PP (IN for) (NP (NNP Doc_8669433_1036_1049_Chemical))) (SBAR (IN if) (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (DT both) (NNS drugs)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS analgesics)))))))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (DT either) (NN agent)) (ADVP (RB alone))))))))))))) (. .)))
8669433	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_8669433_1167_1180_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (PP (DT both) (PP (IN as) (NP (DT a) (JJ single) (NN agent))) (CC and) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS analgesics)))))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_8669433_1268_1278_Chemical)) (VP (AUX was) (ADJP (JJ available)) (PP (ADVP (RB only)) (IN in) (NP (NNS combinations))))))))) (. .)))
8669433	8	(S1 (S (S (NP (NP (DT The) (NN possibility)) (SBAR (WHNP (IN that)) (S (NP (NP (JJ habitual) (NN use)) (PP (IN of) (NP (NNP Doc_8669433_1352_1365_Chemical)))) (ADVP (RB alone)) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_8669433_1394_1398_Disease)))))))) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB clearly)) (VP (VBN demonstrated))))) (, ,) (CC but) (S (NP (NN cannot)) (VP (AUX be) (VP (VBN dismissed)))) (. .)))
8682684	0	(S1 (NP (JJ Doc_8682684_0_13_Chemical-induced) (NN Doc_8682684_22_33_Disease) (. .)))
8682684	1	(S1 (S (PP (IN Through) (NP (NP (CD 30) (NNS years)) (PP (IN of) (NP (JJ widespread) (NN use))))) (, ,) (NP (NNP Doc_8682684_71_84_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (ADJP (RB remarkably) (JJ safe)) (NN medication)) (PP (IN in) (NP (JJ therapeutic) (NNS dosages)))))))))) (. .)))
8682684	2	(S1 (S (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (NNP Doc_8682684_177_190_Chemical))) (SBAR (S (VP (TO to) (VP (VB produce) (NP (NN Doc_8682684_202_227_Disease))))))) (VP (AUX is) (ADJP (RB very) (JJ low))) (. .)))
8682684	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_8682684_250_263_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB produce) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_8682684_309_320_Disease))) (, ,) (PP (VBG including) (NP (NNP Doc_8682684_332_343_Disease))))))) (, ,) (PP (IN in) (NP (JJ sensitive) (NNS individuals)))))) (. .)))
8682684	4	(S1 (S (NP (DT This) (NN article)) (VP (VBZ describes) (NP (NP (CD two) (JJ Doc_8682684_398_412_Disease) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (JJ transient) (NNS episodes)) (PP (IN of) (NP (NNP Doc_8682684_452_463_Disease)))) (ADVP (RB reproducibly)) (VP (VBD developed) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_8682684_511_524_Chemical)))))))))) (. .)))
8682684	5	(S1 (S (NP (NP (JJ Other) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_8682684_544_562_Disease)))) (VP (AUX were) (RB not) (ADJP (RB clinically) (JJ detectable))) (. .)))
8682684	6	(S1 (S (NP (DT The) (NNP Doc_8682684_599_610_Disease) (NNS episodes)) (VP (AUX were) (ADJP (JJ severe) (RB enough) (S (VP (TO to) (VP (VB require) (NP (NN vasopressor) (NN administration))))))) (. .)))
8682684	7	(S1 (S (NP (DT The) (NNS reports)) (VP (VBP illustrate) (NP (DT the) (NN need) (SBAR (IN for) (S (NP (NNS clinicians)) (VP (TO to) (VP (VB consider) (NP (NNP Doc_8682684_737_750_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_8682684_768_779_Disease)) (PP (IN of) (NP (JJ unknown) (NN origin))))))))))))) (. .)))
8690168	0	(S1 (NP (NP (NN Reduction)) (PP (IN of) (NP (NP (JJ Doc_8690168_13_29_Chemical-associated) (JJ anionic) (NNS sites)) (PP (IN in) (NP (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)) (PP (IN of) (NP (NNS rats))) (PP (IN with) (NP (NNP Doc_8690168_104_118_Chemical-induced) (NNP Doc_8690168_127_147_Disease))))))) (. .)))
8690168	1	(S1 (S (NP (NP (JJ Doc_8690168_149_165_Chemical-associated) (JJ anionic) (NNS sites)) (PP (IN in) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NNS rats))) (PP (NP (CD 8) (NNS months)) (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (NNP Doc_8690168_276_284_Disease))))) (PP (PP (IN by) (NP (NNP Doc_8690168_288_302_Chemical))) (CC and) (PP (IN in) (NP (JJ age-) (NNP adn) (JJ sex-matched) (NN control) (NNS rats)))) (, ,) (S (VP (VBG employing) (NP (DT the) (JJ cationic) (NN dye) (NN Doc_8690168_372_387_Chemical)))))) (. .)))
8690168	2	(S1 (S (NP (NP (JJ Morphometric) (NN analysis)) (PP (IN at) (NP (DT the) (JJ ultrastructural) (NN level)))) (VP (AUX was) (VP (VBN performed) (S (VP (VBG using) (NP (DT a) (JJ computerized) (NN image) (NN processor)))))) (. .)))
8690168	3	(S1 (S (NP (NP (DT The) (JJ Doc_8690168_496_512_Chemical) (NN specificity)) (PP (IN of) (NP (DT the) (JJ Doc_8690168_532_547_Chemical) (NN staining)))) (VP (AUX was) (VP (VBN demonstrated) (PP (IN by) (NP (NP (JJ Doc_8690168_577_594_Chemical-degrading) (NNS enzymes)) (, ,) (VP (VBG showing) (SBAR (IN that) (S (NP (NP (NN pretreatment)) (PP (IN of) (NP (NP (DT the) (NNS sections)) (PP (IN with) (NP (NN heparitinase)))))) (VP (VBD abolished) (NP (DT all) (NN staining)) (, ,) (SBAR (IN whereas) (S (NP (NNP chondroitinase) (NNP ABC)) (VP (AUX had) (NP (DT no) (NN effect))))))))))))) (. .)))
8690168	4	(S1 (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (NP (JJ anionic) (NNS sites)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 74) (NN %)) (PP (IN in) (NP (NNP Doc_8690168_778_786_Disease)))) (CC and) (NP (NP (CD 81) (NN %)) (PP (IN in) (NP (NN control) (NNS rats))))) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN found) (PP (IN within) (NP (NP (DT the) (JJ lamina) (NN rara) (NN externa)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane))))))) (. .)))
8690168	5	(S1 (S (NP (NP (DT A) (NN minority)) (PP (IN of) (NP (JJ anionic) (NNS sites)))) (VP (VP (AUX were) (VP (VBN scattered) (PP (IN throughout) (NP (DT the) (FW lamina) (FW densa) (CC and) (FW lamina) (FW rara) (FW interna))))) (, ,) (CC and) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR smaller)) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (NP (DT the) (FW lamina) (FW rara) (FW externa)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD p<0.001) (CC and) (CD p<0.01)) (PP (IN for) (NP (NP (NNP Doc_8690168_1116_1124_Disease)) (CC and) (NP (NN control) (NNS rats))))) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))) (. .)))
8690168	6	(S1 (S (NP (NN Doc_8690168_1158_1166_Disease) (NNS rats)) (ADVP (RB progressively)) (VP (VBD developed) (NP (NNP Doc_8690168_1196_1207_Disease)) (S (VP (VBG reaching) (NP (NP (CD 40.3)) (PRN (-LRB- -LRB-) (NP (CD 32.2-62.0)) (-RRB- -RRB-))) (NP (CD mg/24) (NNP h)) (PP (IN after) (NP (CD 8) (NNS months))) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (NN control) (NNS animals)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0.8)) (PRN (-LRB- -LRB-) (NP (CD 0.2-0.9)) (-RRB- -RRB-)) (NP (CD mg/24) (NNP h))) (, ,) (NP (CD p<0.002))) (-RRB- -RRB-))))))))) (. .)))
8690168	7	(S1 (S (PP (IN At) (NP (DT the) (JJ same) (NN time))) (, ,) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ Doc_8690168_1358_1374_Chemical) (JJ anionic) (NNS sites)) (CC and) (NP (NP (DT the) (JJ total) (JJ anionic) (NN site) (NN surface)) (PRN (-LRB- -LRB-) (S (NP (NP (NN number)) (PP (IN of) (NP (JJ anionic) (NNS sites)))) (VP (SYM x) (VP (VB mean) (NP (JJ anionic) (NN site) (NN surface))))) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (FW lamina) (FW rara) (FW externa)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))))) (VP (AUX was) (VP (VBN reduced) (PP (PP (IN by) (NP (NP (CD 19) (NN %)) (PRN (-LRB- -LRB-) (NP (CD p<0.021)) (-RRB- -RRB-)))) (CC and) (PP (IN by) (NP (NP (CD 26) (NN %)) (PRN (-LRB- -LRB-) (NP (CD p<0.02)) (-RRB- -RRB-))))) (, ,) (ADVP (RB respectively)))) (. .)))
8690168	8	(S1 (S (NP (NP (NP (NP (NN Number)) (CC and) (NP (JJ total) (JJ anionic) (NN site) (NN surface))) (PP (IN in) (NP (NP (DT the) (VBG remaining) (NN part)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))))) (-LRB- -LRB-) (NP (FW lamina) (FW densa) (CC and) (FW lamina) (FW rara) (FW interna)) (-RRB- -RRB-)) (VP (AUX were) (RB not) (ADJP (RB significantly) (VBN changed))) (. .)))
8690168	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (PP (IN in) (NP (NP (JJ Doc_8690168_1792_1806_Chemical-Doc_8690168_1807_1815_Disease) (NNS rats)) (PP (IN with) (NP (DT an) (VBN increased) (NN urinary) (NN albumin) (NN excretion))))) (, ,) (NP (DT a) (VBN reduced) (JJ Doc_8690168_1876_1892_Chemical) (NN charge) (NN barrier/density)) (VP (AUX is) (VP (VBN found) (PP (IN at) (NP (NP (DT the) (FW lamina) (FW rara) (NNS externa)) (PP (IN of) (NP (DT the) (JJ glomerular) (NN basement) (NN membrane)))))))))) (. .)))
869641	0	(S1 (NP (NP (NN Mediation)) (PP (IN of) (NP (JJ enhanced) (JJ reflex) (NN vagal) (NN Doc_869641_35_46_Disease))) (PP (IN by) (NP (NNP Doc_869641_50_56_Chemical))) (PP (IN via) (NP (NP (JJ central) (JJ Doc_869641_69_77_Chemical) (NN formation)) (PP (IN in) (NP (NNS dogs))))) (. .)))
869641	1	(S1 (S (NP (NP (NN Doc_869641_97_103_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-))) (VP (VBD decreased) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))) (PP (IN after) (NP (NP (JJ extracerebral) (NN decarboxylase) (NN inhibition)) (PP (IN with) (NP (NP (NNP Doc_869641_209_215_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 25) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-)))))) (PP (IN in) (NP (JJ anesthetize) (JJ Doc_869641_247_250_Chemical-inhibited) (NNS dogs)))) (. .)))
869641	2	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ reflex) (NN Doc_869641_287_298_Disease)) (VP (VBN caused) (PP (IN by) (NP (VBN injected) (NNP Doc_869641_318_332_Chemical))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN enhanced) (PP (IN by) (NP (NNP Doc_869641_363_369_Chemical))) (, ,) (SBAR (S (NP (NNP Doc_869641_371_401_Chemical)) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (, ,) (NP (NN heart) (NN rate)) (CC or) (NP (NP (JJ reflex) (NNS responses)) (PP (TO to) (NP (NNP Doc_869641_469_483_Chemical))))))))))) (. .)))
869641	3	(S1 (S (NP (NP (NNP Doc_869641_485_491_Chemical)) (, ,) (NP (DT a) (JJ Doc_869641_495_503_Chemical-beta-oxidase) (NN inhibitor)) (, ,)) (VP (AUX did) (RB not) (VP (AUX have) (NP (DT any) (NN effect)) (PP (IN on) (NP (NP (DT the) (ADJP (JJ Doc_869641_559_570_Disease) (, ,) (JJ Doc_869641_572_583_Disease) (CC or) (JJ reflex-enhancing)) (NN effect)) (PP (IN of) (NP (NNP Doc_869641_614_620_Chemical))))))) (. .)))
869641	4	(S1 (S (S (NP (NN Doc_869641_622_630_Chemical)) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NNP Doc_869641_661_667_Chemical)))) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))))))) (CC but) (S (NP (RB completely)) (VP (VBD blocked) (NP (NP (DT the) (NN enhancement)) (PP (IN of) (NP (NNS reflexes)))))) (. .)))
869641	5	(S1 (S (NP (NP (NN Removal)) (PP (IN of) (NP (DT the) (JJ carotid) (NNS sinuses)))) (VP (VP (VBD caused) (NP (NP (DT an) (JJ elevation) (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate)))) (CC and) (VP (VBD abolished) (NP (NP (DT the) (JJ negative) (JJ chronotropic) (NN effect)) (PP (IN of) (NP (NN Doc_869641_884_898_Chemical)))))) (. .)))
869641	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_869641_909_915_Chemical)) (VP (VBD restored) (SBAR (S (NP (NP (DT the) (NN Doc_869641_929_940_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_869641_951_965_Chemical))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (S (VP (VBG decreasing) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NP (NN heart)) (PP (FW rate.) (NP (NNP Doc_869641_1023_1028_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CD mg/kg)) (NNS i.v.)) (-RRB- -RRB-))))))))))) (VP (VP (VBD decreased) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate)))) (CC and) (VP (VBD decreased) (NP (DT the) (JJ reflex) (NN Doc_869641_1109_1120_Disease)) (PP (TO to) (NP (NNP Doc_869641_1124_1138_Chemical)))))))) (. .)))
869641	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_869641_1161_1167_Chemical)) (VP (VBZ enhances) (NP (JJ reflex) (NN Doc_869641_1184_1195_Disease)) (PP (IN through) (NP (JJ central) (JJ alpha-receptor) (NN stimulation)))))))) (. .)))
869641	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (DT the) (NNS effects)) (VP (VP (AUX are) (VP (VBN mediated) (PP (IN through) (NP (NNP Doc_869641_1286_1294_Chemical) (CONJP (RB rather) (IN than)) (NNP Doc_869641_1307_1321_Chemical))))) (CC and) (VP (AUX do) (RB not) (VP (VB require) (NP (DT the) (JJ carotid) (JJ sinus) (NNS baroreceptors))))) (. .)))
8701950	0	(S1 (S (NP (NN Doc_8701950_0_33_Disease)) (VP (VBD complicating) (NP (NNP Doc_8701950_47_52_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8701950_54_64_Chemical)) (-RRB- -RRB-)) (NN therapy))) (. .)))
8701950	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD 3) (NNS episodes)) (PP (IN of) (NP (NP (NNP Doc_8701950_101_134_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8701950_136_140_Disease)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (CD 2) (JJ solid) (NN organ) (NNS recipients)) (PP (IN under) (NP (NNP Doc_8701950_176_181_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8701950_183_193_Chemical)) (-RRB- -RRB-)) (NN therapy)))))) (. .)))
8701950	2	(S1 (S (PP (IN In) (NP (DT both) (NNS cases))) (, ,) (NP (NP (NP (NN discontinuation)) (PP (IN of) (NP (NNP Doc_8701950_238_243_Chemical)))) (CC and) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NN plasma) (NN exchange)) (, ,) (NP (JJ fresh) (JJ frozen) (NN plasma) (NN replacement)) (, ,) (NP (NNP Doc_8701950_313_328_Chemical)) (, ,) (NP (NNP Doc_8701950_330_337_Chemical)) (, ,) (CC and) (NP (NNP Doc_8701950_343_355_Chemical)))))) (VP (VBD led) (PP (TO to) (NP (NP (NN resolution)) (PP (IN of) (NP (NNP Doc_8701950_377_381_Disease)))))) (. .)))
8701950	3	(S1 (S (PP (IN In) (NP (CD one) (NN patient))) (, ,) (NP (NP (NN reintroduction)) (PP (IN of) (NP (NNP Doc_8701950_417_422_Chemical)))) (VP (VBD led) (PP (TO to) (NP (NP (JJ rapid) (NN recurrence)) (PP (IN of) (NP (NNP Doc_8701950_450_454_Disease)))))) (. .)))
8701950	4	(S1 (S (S (NP (JJ Doc_8701950_456_461_Chemical-associated) (NN Doc_8701950_473_477_Disease)) (VP (AUX is) (ADVP (RB probably)) (ADJP (JJ rare)))) (CC but) (S (NP (NNS physicians)) (VP (MD must) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (JJ severe) (NN complication))))))) (. .)))
8701950	5	(S1 (S (PP (PP (IN In) (NP (PRP$ our) (NN experience))) (CC and) (PP (VBG according) (PP (TO to) (NP (DT the) (NN literature))))) (, ,) (NP (NNP Doc_8701950_604_609_Chemical)) (VP (AUX does) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB cross-react) (PP (IN with) (NP (NP (NP (NNP Doc_8701950_644_657_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8701950_659_662_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (JJ immuno-suppressive) (NN drug)) (VP (ADVP (RB already)) (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NN Doc_8701950_716_720_Disease)))))))))))))) (. .)))
8739323	0	(S1 (FRAG (NP (NP (NP (NN Effect)) (PP (IN of) (NP (DT some) (JJ anticancer) (NNS drugs)))) (CC and) (NP (NP (VBN combined) (NN chemotherapy)) (PP (IN on) (NP (NNP Doc_8739323_61_75_Disease))))) (. .)))
8739323	1	(S1 (S (NP (NP (DT The) (NNP Doc_8739323_81_92_Disease) (NN action)) (PP (IN of) (NP (NP (NN anticancer) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NP (NP (NP (NNP Doc_8739323_128_143_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8739323_145_147_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_8739323_150_162_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8739323_164_167_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_8739323_170_184_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8739323_186_190_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_8739323_196_212_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP Doc_8739323_214_216_Chemical)) (-RRB- -RRB-)))))) (VP (VBN administered) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NN combination) (JJ -LSB-Doc_8739323_256_259_Chemical) (NN +) (NNP Doc_8739323_262_266_Chemical) (NNP +) (NNP Doc_8739323_269_271_Chemical) (PRN (-LRB- -LRB-) (NP (NNP CMF)) (-RRB- -RRB-)) (NN -RSB-)))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NP (NNS experiments)) (PP (IN on) (NP (NNP Wistar) (NNS rats))))))) (. .)))
8739323	2	(S1 (S (PP (IN After) (NP (NN drug) (NN administration))) (, ,) (NP (NP (JJ Doc_8739323_351_361_Chemical) (NNS concentrations)) (PP (PP (IN in) (NP (DT the) (NN plasma))) (CC and) (PP (IN in) (NP (NP (DT the) (NN urine)) (PP (IN of) (NP (DT the) (NNS rats))))))) (VP (AUX were) (VP (VP (VBN determined)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ Doc_8739323_448_458_Chemical) (NN clearance)))) (. .)))
8739323	3	(S1 (S (NP (NP (JJ Histopathologic) (NN evaluation)) (PP (IN of) (NP (DT the) (NNS kidneys)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN performed))) (. .)))
8739323	4	(S1 (S (PP (IN After) (NP (NNP Doc_8739323_538_541_Chemical) (NN administration))) (NP (NP (NP (NP (DT a) (JJ significant) (NN increase)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0228)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN plasma) (NN Doc_8739323_607_617_Chemical) (NN concentration)))) (CC and) (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0001)) (-RRB- -RRB-)) (NN decrease)) (PP (IN in) (NP (JJ Doc_8739323_675_685_Chemical) (NN clearance))))) (VP (AUX was) (VP (VBN noted) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))))) (. .)))
8739323	5	(S1 (S (PP (IN After) (NP (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_8739323_756_758_Chemical) (, ,) (NNP Doc_8739323_760_764_Chemical) (CC and) (NNP Doc_8739323_769_771_Chemical)))) (CC neither) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN increase)) (PP (IN in) (NP (JJ Doc_8739323_820_830_Chemical) (NN concentration)))) (CC nor) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_8739323_864_874_Chemical)))))) (NP (NN clearance)) (VP (AUX was) (VP (VBN observed) (PP (VBN compared) (PP (TO to) (NP (NP (DT the) (NN group)) (VP (VBG receiving) (NP (DT no) (NNS cytostatics)))))))) (. .)))
8739323	6	(S1 (S (PP (VBG Following) (NP (NP (NN polytherapy)) (PP (VBG according) (PP (TO to) (NP (DT the) (NN CMF) (NN regimen)))))) (, ,) (S (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN decrease)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.0343)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ Doc_8739323_1051_1061_Chemical) (NN clearance)))) (VP (AUX was) (VP (VBN found)))) (, ,) (CC but) (S (NP (JJ Doc_8739323_1087_1097_Chemical) (NN concentration)) (VP (AUX did) (RB not) (VP (VB increase) (ADVP (RB significantly)) (PP (VBN compared) (PP (TO to) (NP (NNS controls))))))) (. .)))
8739323	7	(S1 (S (S (NP (NN Doc_8739323_1165_1167_Chemical)) (VP (VBD caused) (NP (NN Doc_8739323_1175_1195_Disease)) (PP (IN in) (NP (NP (CD 40) (NN %)) (PP (IN of) (NP (NNS rats))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB cause) (NP (DT this) (NN complication)) (SBAR (WHADVP (WRB when)) (S (VP (VBN combined) (PP (IN with) (NP (NP (NNP Doc_8739323_1270_1274_Chemical)) (CC and) (NP (NNP Doc_8739323_1279_1282_Chemical)))))))))) (. .)))
8739323	8	(S1 (S (NP (JJ Histologic) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NN rat) (NNS kidneys))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_8739323_1353_1356_Chemical) (, ,) (NNP Doc_8739323_1358_1360_Chemical) (CC and) (NNP Doc_8739323_1365_1367_Chemical))))) (, ,) (SBAR (IN while) (S (NP (DT no) (JJ such) (NN change)) (VP (AUX was) (VP (VBN observed) (PP (IN after) (NP (NP (JJ Doc_8739323_1409_1413_Chemical) (CC and) (JJ joint) (NN administration)) (PP (IN of) (NP (NNP Doc_8739323_1442_1445_Chemical) (NNP +) (NNP Doc_8739323_1448_1452_Chemical) (NNP +) (NNP Doc_8739323_1455_1457_Chemical))) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))))))))))) (. .)))
8739323	9	(S1 (S (NP (PRP$ Our) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN Doc_8739323_1506_1520_Disease)) (PP (IN of) (NP (NNP Doc_8739323_1524_1527_Chemical) (NNP +) (NNP Doc_8739323_1530_1534_Chemical) (NNP +) (NNP Doc_8739323_1537_1539_Chemical))) (VP (VBN administered) (ADVP (RB jointly)))) (VP (AUX is) (ADJP (ADJP (JJR lower)) (PP (IN than) (PP (IN in) (NP (NN monotherapy))))))))) (. .)))
8741744	0	(S1 (S (NP (DT The) (JJ interpeduncular) (NN nucleus)) (VP (VBZ regulates) (NP (NP (NP (NNP Doc_8741744_38_46_Chemical) (POS 's)) (NNS effects)) (PP (IN on) (NP (JJ free-field) (NN activity))))) (. .)))
8741744	1	(S1 (S (NP (JJ Partial) (NNS lesions)) (VP (AUX were) (VP (VBN made) (PP (IN with) (NP (NNP Doc_8741744_112_123_Chemical))) (PP (IN in) (NP (NP (DT the) (JJ interpeduncular) (NN nucleus)) (PP (IN of) (NP (NP (DT the) (JJ ventral) (NN midbrain)) (PP (IN of) (NP (DT the) (NN rat))))))))) (. .)))
8741744	2	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (JJ sham-operated) (NNS controls)))) (, ,) (NP (NNS lesions)) (ADVP (RB significantly)) (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.25)) (-RRB- -RRB-) (VP (VBD blunted) (SBAR (S (NP (DT the) (JJ early) (PRN (-LRB- -LRB-) (NP (CD <60) (NN min)) (-RRB- -RRB-)) (JJ free-field) (NN Doc_8741744_301_323_Disease)) (VP (VP (VBD caused) (PP (IN by) (NP (NP (NNP Doc_8741744_334_342_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 0.5) (CD mg)) (NNS kg)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-))) (, ,) (NP (NNP i.m.))) (-RRB- -RRB-))))) (, ,) (VP (VBD enhanced) (NP (DT the) (JJ later) (PRN (-LRB- -LRB-) (NP (CD 60-120) (NN min)) (-RRB- -RRB-)) (JJ Doc_8741744_398_406_Chemical-induced) (NNP Doc_8741744_415_428_Disease))) (, ,) (CC and) (VP (VBD raised) (NP (JJ spontaneous) (JJ nocturnal) (NN activity))))))) (. .)))
8741744	3	(S1 (S (NP (NNS Lesions)) (VP (VBD reduced) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ immunohistological) (NN staining)))) (PP (PP (IN for) (NP (NP (JJ Doc_8741744_535_542_Chemical) (NN acetyltransferase)) (PP (IN in) (NP (NP (DT the) (JJ interpeduncular) (NN nucleus)) (PRN (-LRB- -LRB-) (NP (NNP p) (CD <0.025)) (-RRB- -RRB-)))))) (, ,) (CC but) (RB not) (PP (IN for) (NP (NP (JJ Doc_8741744_616_624_Chemical) (NN hydroxylase)) (PP (IN in) (NP (DT the) (VBG surrounding) (JJ catecholaminergic) (JJ A10) (NN region))))))) (. .)))
8741744	4	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (JJ interpeduncular) (NN nucleus)) (VP (VP (VBZ mediates) (NP (NP (JJ nicotinic) (NN Doc_8741744_750_760_Disease)) (PP (IN of) (NP (NN locomotor) (NN activity))))) (CC and) (VP (VBZ dampens) (NP (NP (JJ nicotinic) (JJ arousal) (NNS mechanisms)) (VP (VBN located) (ADVP (RB elsewhere)) (PP (IN in) (NP (DT the) (NN brain)))))))))) (. .)))
8752018	0	(S1 (NP (NP (NP (JJ Doc_8752018_0_7_Chemical-associated) (NN Doc_8752018_19_52_Disease)) (VP (VBN reduced) (PP (IN by) (NP (NP (DT a) (NN switch)) (PP (TO to) (NP (NNP Doc_8752018_76_93_Chemical))))))) (: :) (NP (DT a) (NN case) (NN series)) (. .)))
8752018	1	(S1 (S (NP (NN Doc_8752018_122_129_Chemical)) (VP (VBZ remains) (NP (NP (DT a) (JJ first-line) (NN treatment)) (PP (IN for) (NP (NP (DT the) (JJ acute) (CC and) (NN maintenance) (NN treatment)) (PP (IN of) (NP (NNP Doc_8752018_204_220_Disease))))))) (. .)))
8752018	2	(S1 (S (SBAR (IN Although) (S (NP (JJ much)) (VP (AUX has) (VP (AUX been) (VP (VBN written) (PP (IN about) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (DT the) (ADJP (RBR more) (JJ common)) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NNP Doc_8752018_312_319_Chemical))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_8752018_329_337_Disease)) (CC and) (NP (NNP Doc_8752018_342_348_Disease))))))))))))) (, ,) (NP (NP (ADJP (RBR more) (JJ subtle)) (JJ Doc_8752018_362_369_Chemical) (JJ side) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_8752018_391_409_Disease)) (, ,) (NP (NNP Doc_8752018_411_429_Disease)) (, ,) (CC and) (NP (NNP Doc_8752018_435_457_Disease))))) (VP (VBP remain) (ADJP (JJ understudied))) (. .)))
8752018	3	(S1 (S (NP (DT This) (NN report)) (VP (VBZ summarizes) (NP (PRP$ our) (NN experience)) (PP (IN in) (S (VP (VBG switching) (NP (NNP Doc_8752018_530_537_Disease) (NNS patients)) (PP (IN from) (NP (NNP Doc_8752018_552_559_Chemical))) (PP (TO to) (NP (NNP Doc_8752018_563_580_Chemical))) (S (VP (TO to) (VP (VB alleviate) (NP (JJ such) (NN Doc_8752018_599_635_Disease))))))))) (. .)))
8752018	4	(S1 (FRAG (ADJP (JJ Open)) (, ,) (NP (NN case) (NN series) (NN design)) (. .)))
8752018	5	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD seven) (NNS cases)) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN substitution)) (PP (IN of) (NP (NNP Doc_8752018_724_731_Chemical))) (PRN (, ,) (ADVP (DT either) (RB fully) (CC or) (RB partially)) (, ,)) (PP (IN with) (NP (NNP Doc_8752018_765_782_Chemical)))) (VP (AUX was) (ADJP (RB extremely) (JJ helpful)) (PP (IN in) (S (VP (VBG reducing) (NP (NP (DT the) (NN Doc_8752018_821_866_Disease)) (VP (VBN attributed) (PP (TO to) (NP (NNP Doc_8752018_881_888_Chemical))) (PP (IN in) (NP (PRP$ our) (NNP Doc_8752018_896_903_Disease) (NNS patients))))))))))))) (. .)))
8752018	6	(S1 (S (PP (IN In) (NP (DT this) (JJ preliminary) (NN report))) (, ,) (NP (NNP Doc_8752018_954_971_Chemical)) (VP (AUX was) (NP (NP (DT a) (JJ superior) (NN alternative)) (PP (TO to) (NP (NNP Doc_8752018_1002_1009_Chemical))) (PP (IN in) (NP (NP (JJ Doc_8752018_1013_1020_Disease) (NNS patients)) (VP (VBG experiencing) (NP (NP (NNP Doc_8752018_1043_1061_Disease)) (, ,) (NP (NNP Doc_8752018_1063_1081_Disease)) (, ,) (CC and) (NP (NNP Doc_8752018_1087_1109_Disease)))))))) (. .)))
8829025	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_8829025_10_20_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN function)) (PP (IN in) (NP (NP (NN liver) (NN transplant) (NNS recipients)) (VP (VBG receiving) (NP (NNP Doc_8829025_80_90_Chemical))))))) (. .)))
8829025	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_8829025_106_116_Chemical))) (PP (IN on) (NP (NP (JJ renal) (NN function)) (PP (IN in) (NP (NP (NN liver) (NN transplant) (NNS recipients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBG receiving) (NP (NN Doc_8829025_185_195_Chemical))))))))))) (VP (AUX was) (VP (VBN evaluated) (PP (IN between) (NP (NP (NNP January) (CD 1992)) (CC and) (NP (NNP January) (CD 1996)))))) (. .)))
8829025	2	(S1 (S (NP (NP (CD Two) (NNS groups)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_8829025_282_292_Chemical)))))) (VP (AUX were) (VP (VBN compared) (PP (IN over) (NP (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 1) (NN year)))) (, ,) (NP (NP (CD one) (NN group)) (VP (VBG comprising) (NP (NP (NP (JJ Doc_8829025_353_365_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBG receiving) (NP (NNP Doc_8829025_394_404_Chemical))))))) (, ,) (CC and) (NP (NP (DT the) (JJ other) (VBG comprising) (NN nonhypertensive) (NNS patients)) (VP (RB not) (VBG receiving) (NP (NNP Doc_8829025_470_480_Chemical))))))))))) (. .)))
8829025	3	(S1 (S (NP (NP (DT The) (NN time)) (PP (IN from) (NP (NN transplant))) (PP (TO to) (NP (NN baseline)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN in) (NP (DT all) (NNS patients)))) (. .)))
8829025	4	(S1 (S (NP (NN Doc_8829025_548_558_Chemical)) (ADVP (RB significantly)) (VP (VBD improved) (NP (NN kidney) (NN function)) (SBAR (IN as) (S (VP (VBN indicated) (PP (IN by) (NP (NP (DT a) (JJ significant) (VBG lowering)) (PP (IN of) (NP (JJ serum) (JJ Doc_8829025_646_656_Chemical) (NNS levels))))) (PP (IN at) (NP (QP (CD 6) (CC and) (CD 12)) (NNS months))))))) (. .)))
8829025	5	(S1 (S (NP (NP (DT The) (ADJP (JJ observed) (JJ positive)) (NN impact)) (PP (IN of) (NP (NNP Doc_8829025_716_726_Chemical))) (PP (IN on) (S (VP (VBG reducing) (NP (NP (DT the) (NN Doc_8829025_743_757_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8829025_774_784_Chemical))) (PP (IN in) (NP (NN liver) (NN transplant) (NNS recipients))))))))) (VP (MD should) (VP (AUX be) (NP (NP (DT an) (JJ important) (NN factor)) (PP (IN in) (S (VP (VBG selecting) (NP (NP (DT an) (NN agent)) (SBAR (S (VP (TO to) (VP (VB treat) (NP (NNP Doc_8829025_877_889_Disease)) (PP (IN in) (NP (DT this) (NN population)))))))))))))) (. .)))
88336	0	(S1 (S (NP (NP (NP (NN Alpha)) (CC and) (NP (NN beta) (NN Doc_88336_15_19_Disease))) (PP (IN in) (NP (NN drug) (NN intoxication)))) (VP (JJ uncomplicated) (PP (IN by) (NP (NNP Doc_88336_58_74_Disease)))) (. .)))
88336	1	(S1 (S (NP (NP (CD Four) (NNS patients)) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN rendered) (NP (NP (NNP Doc_88336_108_116_Disease)) (CC or) (NP (NNP Doc_88336_120_129_Disease))) (PP (IN by) (NP (NN drug) (NN intoxication))))))) (, ,) (CC but) (SBAR (WHNP (WP who)) (S (VP (AUX were) (RB not) (ADJP (JJ hypoxic))))) (, ,))) (VP (AUX are) (VP (VBN described))) (. .)))
88336	2	(S1 (S (S (NP (CD Three) (NNS patients)) (VP (VBD received) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_88336_231_246_Chemical)))) (PP (IN for) (NP (NNP Doc_88336_251_258_Chemical) (NNP Doc_88336_259_278_Disease))))) (, ,) (CC and) (S (NP (CD one)) (VP (VBD took) (NP (NP (DT a) (JJ suicidal) (NN Doc_88336_304_312_Disease)) (PP (IN of) (NP (NNP Doc_88336_316_326_Chemical)))))) (. .)))
88336	3	(S1 (S (NP (NP (NP (DT The) (NN patient)) (PP (IN with) (NP (NNP Doc_88336_345_355_Chemical) (NNP Doc_88336_356_364_Disease)))) (CC and) (NP (NP (CD two)) (PP (IN of) (NP (NP (DT those)) (PP (IN with) (NP (JJ Doc_88336_387_402_Chemical) (NN intoxication))))))) (VP (VBD conformed) (PP (TO to) (NP (NP (DT the) (NNS criteria)) (PP (IN of) ('' ') (NP (NN alpha))) (NP (NNP Doc_88336_452_456_Disease) (POS ')))) (, ,) (S (VP (VBG showing) (NP (NP (JJ non-reactive) (JJ generalized) (CC or) (JJ frontally) (NN predominant) (NN alpha) (NN activity)) (PP (IN in) (NP (DT the) (NNP EEG))))))) (. .)))
88336	4	(S1 (S (NP (NP (DT The) (JJ fourth) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (ADJP (JJ unconscious)) (PP (IN after) (NP (NNP Doc_88336_589_604_Chemical) (NN administration))))))) (VP (VBP exhibite) (NP (NP (JJ generalized) (JJ non-reactive) (NN activity)) (PP (IN in) (NP (DT the) (JJ slow) (NN beta) (NN range))))) (. .)))
88336	5	(S1 (S (NP (DT All) (CD four)) (VP (VBD recovered) (ADVP (RB completely)) (PP (IN without) (NP (NNP Doc_88336_725_746_Disease))) (PP (VBG following) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (DT the) (VBG offending) (NNS agents)))))) (. .)))
88336	6	(S1 (S (NP (NP (DT The) (NNS similarities)) (PP (IN between) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ structural) (NNS lesions)))) (CC and) (NP (NP (JJ pharmacological) (NN Doc_88336_876_886_Disease)) (PP (IN of) (NP (DT the) (NN brain))))))) (VP (VBP stem) (SBAR (S (NP (JJ reticular) (NN formation)) (VP (AUX are) (VP (VBN discussed)))))) (. .)))
88336	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (PP (IN in) (NP (DT both) (NNS situations))) (NP (JJ disturbed) (JJ reticulo-thalamic) (NNS interactions)) (VP (AUX are) (ADJP (JJ important)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN alpha) (NN Doc_88336_1064_1068_Disease)))))))))) (. .)))
88336	8	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (NP (DT this) (ADJP (ADJP (JJ electroencephalographic)) (CC and) (ADJP (JJ behavioural))) (NN picture)) (VP (AUX is) (VP (VBN seen) (PP (IN in) (NP (NN drug) (NN intoxication))) (, ,) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ significant) (NNP Doc_88336_1209_1219_Disease))))))))) (, ,) (NP (DT a) (JJ favourable) (NN outcome)) (VP (MD may) (VP (AUX be) (VP (VBN anticipated)))))))) (. .)))
8864707	0	(S1 (NP (NP (JJ Magnetic) (NN resonance) (NN volumetry)) (PP (IN of) (NP (DT the) (NN cerebellum))) (PP (IN in) (NP (NP (JJ Doc_8864707_50_59_Disease) (NNS patients)) (PP (IN after) (NP (NNP Doc_8864707_75_84_Chemical) (NNP Doc_8864707_85_96_Disease))))) (. .)))
8864707	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NP (JJ Doc_8864707_161_170_Chemical) (NN medication)) (CC and) (NP (NN Doc_8864707_186_204_Disease))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN experienced) (NP (JJ clinical) (NN intoxication))))))))))))))) (. .)))
8864707	2	(S1 (S (NP (NP (NP (CD Five) (NNS females)) (CC and) (NP (CD 6) (NNS males))) (, ,) (NP (NP (CD 21-59) (NNS years)) (PP (IN of) (NP (NN age)))) (, ,)) (VP (AUX were) (VP (VBN examined) (PP (IN with) (NP (NP (DT a) (JJ 1.5-T) (NN whole-body) (NN system)) (VP (VBG using) (NP (DT a) (JJ circular) (JJ polarized) (NN head) (NN coil))))))) (. .)))
8864707	3	(S1 (S (NP (JJ Conventional) (NN spin) (VB echo) (NNS images)) (VP (AUX were) (VP (VBN acquired) (PP (IN in) (NP (DT the) (NN sagittal) (CC and) (NN transverse) (NN orientation))))) (. .)))
8864707	4	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBD performed) (SBAR (S (S (NP (DT a) (JJ high-resolution) (NN 3D) (NN gradient)) (VP (VBP echo))) (, ,) (S (NP (NP (JJ T1-weighted) (NNS sequences)) (PP (IN at) (NP (DT a) (NN 1-mm)))) (VP (VBP slice) (NP (NN thickness))))))) (. .)))
8864707	5	(S1 (S (NP (DT The) (NNS images)) (VP (AUX were) (ADVP (RB subsequently)) (VP (VBN processed) (S (VP (TO to) (VP (VB obtain) (NP (JJ volumetric) (NNS data)) (PP (IN for) (NP (DT the) (NN cerebellum)))))))) (. .)))
8864707	6	(S1 (S (NP (NP (JJ Cerebellar) (NN volume)) (PP (IN for) (NP (DT the) (JJ patient) (NN group)))) (VP (VBD ranged) (PP (IN between) (NP (NP (CD 67.66)) (CC and) (NP (NP (QP (CD 131.08) (CD ml))) (PRN (-LRB- -LRB-) (NP (JJ mean) (CD 108.9) (NNS ml)) (-RRB- -RRB-)))))) (. .)))
8864707	7	(S1 (S (PP (IN In) (NP (NN addition))) (NP (CD 3D) (NN gradient)) (VP (VBP echo) (SBAR (S (NP (NP (NN data) (NNS sets)) (PP (IN from) (NP (CD 10) (JJ healthy) (NN male) (CC and) (CD 10) (JJ healthy) (JJ female) (JJ age-matched) (NNS volunteers)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB compare) (NP (JJ cerebellar) (NNS volumes)))))))))) (. .)))
8864707	8	(S1 (S (S (VP (VBG Using) (NP (JJ linear) (NN regression)))) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (DT no) (NN correlation)) (VP (VBZ exists) (PP (IN between) (NP (NP (JJ Doc_8864707_979_986_Disease) (NN duration)) (, ,) (NP (NP (NN elevation)) (PP (IN of) (NP (JJ Doc_8864707_1010_1019_Chemical) (NN serum) (NNS levels)))) (CC and) (NP (JJ cerebellar) (NN volume)))))))) (. .)))
8864707	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ multiple) (NN regression)) (PP (IN for) (NP (NP (DT the) (JJ daily) (NN dosage)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (NP (JJ Doc_8864707_1119_1128_Chemical) (NN treatment)) (CC and) (NP (JJ cerebellar) (NN volume)))))))) (VP (VBD revealed) (NP (NP (DT a) (NN correlation)) (PP (IN of) (NP (DT these) (NNS parameters))))) (. .)))
8864707	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (S (NP (NNP Doc_8864707_1222_1231_Chemical) (NNP Doc_8864707_1232_1242_Disease)) (VP (AUX does) (RB not) (ADVP (RB necessarily)) (VP (VB result) (PP (IN in) (NP (NNP Doc_8864707_1274_1292_Disease)))))) (CC and) (S (NP (PRP it)) (VP (AUX is) (ADJP (JJ unlikely) (SBAR (IN that) (S (NP (JJ Doc_8864707_1317_1326_Chemical) (NN medication)) (VP (AUX was) (NP (NP (DT the) (JJ only) (NN cause)) (PP (IN of) (NP (NNP Doc_8864707_1360_1378_Disease)))) (PP (IN in) (NP (DT the) (VBG remaining) (NNS patients)))))))))))) (. .)))
8864707	11	(S1 (S (NP (NP (JJ Quantitative) (JJ morphometric) (NNS studies)) (PP (IN of) (NP (DT the) (NN cerebellum)))) (VP (VBP provide) (NP (NP (JJ valuable) (NNS insights)) (PP (IN into) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (NNP Doc_8864707_1509_1529_Disease))))))) (. .)))
891050	0	(S1 (NP (NP (JJ Late) (NN recovery)) (PP (IN of) (NP (JJ renal) (NN function))) (PP (IN in) (NP (NP (DT a) (NN woman)) (PP (IN with) (NP (DT the) (NNP Doc_891050_52_77_Disease))))) (. .)))
891050	1	(S1 (S (NP (DT A) (NN case)) (VP (AUX is) (VP (VBN reported) (PP (IN of) (NP (NP (DT the) (NNP Doc_891050_105_130_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_891050_132_135_Disease)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT a) (NN woman)) (VP (VBG taking) (NP (NNP Doc_891050_155_174_Chemical))))))) (. .)))
891050	2	(S1 (S (S (NP (PRP She)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_891050_197_204_Chemical)) (, ,) (NP (NNP Doc_891050_206_218_Chemical)) (CC and) (NP (NNS hemodialysis))))))) (: ;) (CC and) (S (PP (IN after) (NP (QP (JJR more) (IN than) (CD three)) (NNS months))) (, ,) (S (NP (PRP$ her) (JJ urinary) (NN output)) (VP (VBD rose) (PP (IN above) (NP (NP (CD 500) (NN ml)) (: ;) (CC and) (NP (CD six) (NNS months)))) (PP (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_891050_343_349_Disease))))))) (, ,) (NP (NN dialysis) (NN treatment)) (VP (AUX was) (VP (VBN stopped)))) (. .)))
891050	3	(S1 (S (NP (DT This) (NN case)) (VP (VBZ emphasizes) (NP (DT the) (NN possibility) (SBAR (SBAR (IN that) (S (NP (NP (NN Doc_891050_425_428_Disease)) (PP (IN in) (NP (NNS adults)))) (VP (AUX is) (RB not) (ADJP (RB invariably) (JJ irreversible))))) (CC and) (SBAR (IN that) (S (, ,) (PP (IN despite) (NP (JJ prolonged) (NN Doc_891050_498_506_Disease))) (, ,) (NP (NP (NN recovery)) (PP (IN of) (NP (JJ renal) (NN function)))) (VP (MD can) (VP (AUX be) (VP (VBN obtained))))))))) (. .)))
891050	4	(S1 (S (S (ADVP (RB Therefore)) (, ,) (PP (IN in) (NP (NP (NN adult) (NNS patients)) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_891050_593_596_Disease)))))) (, ,) (NP (NN dialysis)) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN discontinued) (ADVP (RB prematurely)))))) (: ;) (S (ADVP (RB moreover)) (, ,) (NP (NP (JJ bilateral) (NN nephrectomy)) (, ,) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (JJ severe) (NNP Doc_891050_704_716_Disease)) (CC and) (NP (NNP Doc_891050_721_754_Disease)))))) (, ,)) (VP (MD should) (VP (AUX be) (VP (VBN performed) (PP (IN with) (NP (NN caution))))))) (. .)))
8919272	0	(S1 (NP (NP (JJ Morphological) (NNS features)) (PP (IN of) (NP (NNP Doc_8919272_26_40_Disease))) (PP (IN after) (NP (NP (NN chronic) (NN administration)) (PP (IN of) (NP (NP (DT the) (JJ antiepileptic) (NN drug) (NN Doc_8919272_96_105_Chemical)) (PP (TO to) (NP (NNS rats))))))) (. .)))
8919272	1	(S1 (NP (NP (DT A) (NN transmission) (NNP electron) (JJ microscopic) (NN study)) (PP (IN of) (NP (NNS capillaries))) (PP (IN in) (NP (DT the) (JJ cerebellar) (NN cortex))) (. .)))
8919272	2	(S1 (S (NP (NP (JJ Long-term) (JJ intragastric) (NN application)) (PP (IN of) (NP (NP (DT the) (JJ antiepileptic) (NN drug)) (NP (NNP Doc_8919272_259_275_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Vupral) (`` ``) (NNP Polfa) ('' '')) (-RRB- -RRB-)) (PP (IN at) (NP (NP (DT the) (JJ effective) (NN dose)) (PP (IN of) (NP (QP (CD 200) (CD mg/kg)) (NNP b.) (NNP w.) (ADJP (RB once) (JJ daily) (PP (TO to) (NP (NP (NNS rats)) (PP (IN for) (NP (CD 1) (, ,) (CD 3) (, ,) (CD 6) (, ,) (CD 9) (CC and) (CD 12) (NNS months)))))))))))))) (VP (VBD revealed) (NP (NP (NNP Doc_8919272_391_413_Disease)) (VP (VBG indicating) (NP (NP (NNP Doc_8919272_425_442_Disease)) (PRN (-LRB- -LRB-) (NP (`` ``) (NP (NNP Doc_8919272_445_454_Chemical) (NNP Doc_8919272_455_469_Disease)) ('' '')) (-RRB- -RRB-)))))) (. .)))
8919272	3	(S1 (S (NP (NP (DT The) (JJ first) (JJ ultrastructural) (NNS changes)) (PP (IN in) (NP (NP (JJ structural) (NNS elements)) (PP (IN of) (NP (NP (DT the) (JJ blood-brain-barrier)) (PRN (-LRB- -LRB-) (NP (NNP BBB)) (-RRB- -RRB-)))))) (PP (IN in) (NP (DT the) (JJ cerebellar) (NN cortex)))) (VP (AUX were) (ADJP (JJ detectable)) (PP (IN after) (NP (NP (CD 3) (NNS months)) (PP (IN of) (NP (DT the) (NN experiment)))))) (. .)))
8919272	4	(S1 (S (NP (PRP They)) (VP (VP (VBD became) (ADJP (RBR more) (JJ severe)) (PP (IN in) (NP (NP (DT the) (JJ later) (NNS months)) (PP (IN of) (NP (DT the) (NN experiment)))))) (, ,) (CC and) (VP (AUX were) (ADJP (RBS most) (JJ severe)) (PP (IN after) (NP (CD 12) (NNS months))) (, ,) (VP (VBN located) (ADVP (RB mainly)) (PP (IN in) (NP (NP (DT the) (JJ molecular) (NN layer)) (PP (IN of) (NP (DT the) (JJ cerebellar) (NN cortex)))))))) (. .)))
8919272	5	(S1 (S (NP (NP (NNS Lesions)) (PP (IN of) (NP (DT the) (NN capillary)))) (VP (VBD included) (NP (NP (NN Doc_8919272_837_845_Disease)) (PP (IN of) (NP (JJ endothelial) (NNS cells))))) (. .)))
8919272	6	(S1 (S (NP (NP (NNS Organelles)) (PP (IN of) (NP (NP (NP (DT these) (NNS cells)) (, ,) (PP (IN in) (NP (NP (JJ particular) (DT the) (NN mitochondria)) (PRN (-LRB- -LRB-) (NP (VBN increased) (NN number) (CC and) (NN size)) (, ,) (NP (NP (JJ distinct) (NN degeneration)) (PP (IN of) (NP (PRP$ their) (NNP matrix) (CC and) (NNS cristae)))) (-RRB- -RRB-))))) (CC and) (NP (NNP Golgi) (NN apparatus))))) (VP (AUX were) (VP (VBN altered))) (. .)))
8919272	7	(S1 (S (NP (NP (JJ Reduced) (NN size)) (PP (IN of) (NP (NP (JJ capillary) (NNS lumen)) (CC and) (NP (NN occlusion))))) (VP (AUX were) (VP (VBN caused) (PP (IN by) (NP (NP (JJ swollen) (JJ endothelial) (NNS cells)) (SBAR (WHNP (WDT which)) (S (VP (AUX had) (NP (NP (JJ Doc_8919272_1136_1143_Chemical) (NNS protrusions)) (CC and) (NP (JJ swollen) (NNS microvilli)))))))))) (. .)))
8919272	8	(S1 (S (NP (NP (NN Pressure)) (PP (IN on) (NP (DT the) (NN vessel) (NN wall)))) (VP (AUX was) (VP (VBN produced) (PP (IN by) (NP (JJ enlarged) (JJ perivascular) (NN astrocytic) (NNS processes))))) (. .)))
8919272	9	(S1 (S (NP (NP (NNS Fragments)) (PP (IN of) (NP (JJ Doc_8919272_1281_1289_Disease) (NN endothelial) (NNS cells)))) (VP (AUX were) (UCP (PP (IN in) (NP (DT the) (JJ vascular) (NNS lumens))) (CC and) (SBAR (IN in) (S (NP (DT these) (EX there)) (VP (AUX was) (NP (NP (NP (NN loosening)) (CC and) (NP (NN breaking))) (PP (IN of) (NP (JJ tight) (JJ cellular) (NNS junctions))))))))) (. .)))
8919272	10	(S1 (S (NP (NP (NN Damage)) (PP (TO to) (NP (DT the) (JJ vascular) (NN basement) (NNS lamina)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN observed))) (. .)))
8919272	11	(S1 (S (NP (NP (NN Damage)) (PP (TO to) (NP (DT the) (NN capillary)))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ marked) (NN damage)) (PP (TO to) (NP (JJ neuroglial) (NNS cells))))) (, ,) (ADVP (RB mainly)) (S (VP (TO to) (VP (VB perivascular) (NP (NP (NNS processes)) (PP (IN of) (NP (NNS astrocytes))))))))) (. .)))
8919272	12	(S1 (S (NP (NP (NP (DT The) (NN proliferation)) (PP (IN of) (NP (NP (NNS astrocytes)) (PRN (-LRB- -LRB-) (NP (NP (NNP Bergmann) (POS 's)) (PP (IN in) (NP (JJ particular)))) (-RRB- -RRB-))))) (CC and) (NP (NP (RB occasionally)) (PP (IN of) (NP (NNS oligodendrocytes))))) (VP (AUX was) (VP (VBN found))) (. .)))
8919272	13	(S1 (S (NP (NP (NNS Alterations)) (PP (IN in) (NP (NP (DT the) (JJ structural) (NNS elements)) (PP (IN of) (NP (DT the) (NNP BBB)))))) (VP (VBD coexisted) (PP (IN with) (NP (NP (JJ marked) (NNS lesions)) (PP (IN of) (NP (NP (NNS neurons)) (PP (IN of) (NP (NP (DT the) (NN cerebellum)) (PRN (-LRB- -LRB-) (S (NP (NNP Purkinje) (NNS cells)) (VP (AUX are) (NP (JJS earliest)))) (-RRB- -RRB-))))))))) (. .)))
8919272	14	(S1 (S (PP (IN In) (NP (NNP electron) (NNS micrographs))) (NP (NP (DT both) (ADJP (ADJP (JJ Doc_8919272_1871_1878_Chemical)) (CC and) (ADJP (JJ antiluminal))) (NNS sides)) (PP (IN of) (NP (NP (DT the) (NNP BBB)) (PP (IN of) (NP (DT the) (JJ cerebellar) (NN cortex)))))) (VP (AUX had) (NP (JJ similar) (NNS lesions))) (. .)))
8919272	15	(S1 (S (NP (NP (DT The) (JJ possible) (NN influence)) (PP (IN of) (NP (NP (DT the) (NNP Doc_8919272_1988_2002_Disease)) (PRN (, ,) (ADVP (RB mainly)) (NP (NNP Doc_8919272_2011_2025_Disease)) (, ,)))) (PP (IN upon) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_8919272_2051_2060_Chemical) (NNP Doc_8919272_2061_2075_Disease)))))) (VP (AUX is) (VP (VBN discussed))) (. .)))
8953972	0	(S1 (S (NP (JJ Fatal) (NN Doc_8953972_6_27_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prehospital) (NN use)) (PP (IN of) (NP (NNP Doc_8953972_63_74_Chemical)))))) (. .)))
8953972	1	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ paramedic) (NN misjudgment)) (PP (IN in) (NP (NP (DT the) (NN execution)) (PP (IN of) (NP (NP (DT a) (NN protocol)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_8953972_171_188_Disease))))))) (PP (IN in) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8953972_202_217_Disease)) (PP (IN with) (NP (NNP Doc_8953972_223_231_Disease))))))))))))) (. .)))
8953972	2	(S1 (S (NP (NP (NP (DT The) (JJ sudden) (NN onset)) (PP (IN of) (NP (NP (NNP Doc_8953972_253_273_Disease)) (, ,) (NP (NNP Doc_8953972_275_279_Disease)) (, ,)))) (CC and) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (DT a) (JJ new) (NN medicine))))) (VP (VBD led) (NP (NP (DT the) (CD two) (NNS paramedics)) (PP (IN on) (NP (DT the) (NN scene)))) (S (VP (TO to) (VP (VB administer) (NP (JJ subcutaneous) (NNP Doc_8953972_376_387_Chemical)))))) (. .)))
8953972	3	(S1 (S (ADVP (RB Subsequently)) (, ,) (NP (NP (JJ acute) (NN Doc_8953972_409_423_Disease)) (CC and) (NP (JJ fatal) (NN Doc_8953972_434_457_Disease))) (VP (VBD occurred)) (. .)))
8953972	4	(S1 (S (S (NP (NNP Doc_8953972_468_479_Chemical)) (VP (AUX has) (NP (NP (DT a) (VBN proven) (NN role)) (PP (IN in) (NP (NNP Doc_8953972_501_515_Disease))) (PP (IN in) (NP (JJ prehospital) (NN care)))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (NN use)) (PP (IN by) (NP (NNS paramedics))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ suspected) (NNP Doc_8953972_591_608_Disease)) (CC and) (NP (JJ severe) (NNP Doc_8953972_620_632_Disease))))))) (VP (MD should) (VP (AUX be) (VP (VBN viewed) (PP (IN with) (NP (NN caution))))))) (. .)))
8955532	0	(S1 (NP (NP (NN Role)) (PP (IN of) (NP (NP (NN activation)) (PP (IN of) (NP (JJ Doc_8955532_22_32_Chemical) (JJ B2) (NNS receptors))))) (PP (IN in) (NP (NP (NN disruption)) (PP (IN of) (NP (NP (DT the) (JJ blood-brain) (NN barrier)) (PP (IN during) (NP (JJ acute) (NNP Doc_8955532_100_112_Disease))))))) (. .)))
8955532	1	(S1 (S (NP (NP (JJ Cellular) (NNS mechanisms)) (SBAR (WHNP (WDT which)) (S (VP (VBP account) (PP (IN for) (NP (NN disruption))) (NP (DT the) (JJ blood-brain) (NN barrier)) (PP (IN during) (NP (JJ acute) (NN Doc_8955532_200_212_Disease))))))) (VP (AUX are) (RB not) (ADJP (JJ clear))) (. .)))
8955532	2	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NN synthesis/release)) (PP (IN of) (NP (NNP Doc_8955532_301_311_Chemical)))))) (S (VP (TO to) (VP (VBP activate) (NP (JJ B2) (NNS receptors)) (PP (IN in) (NP (NP (NN disruption)) (PP (IN of) (NP (NP (DT the) (JJ blood-brain) (NN barrier)) (PP (IN during) (NP (JJ acute) (NN Doc_8955532_391_403_Disease)))))))))))))) (. .)))
8955532	3	(S1 (S (NP (NP (NN Permeability)) (PP (IN of) (NP (DT the) (JJ blood-brain) (NN barrier)))) (VP (AUX was) (VP (VBN quantitated) (PP (IN by) (NP (NP (NN clearance)) (PP (IN of) (NP (JJ fluorescent-labeled) (NNP Doc_8955532_497_504_Chemical))))) (PP (IN before) (CC and) (IN during) (NP (NP (JJ Doc_8955532_523_536_Chemical-induced) (JJ acute) (NN Doc_8955532_551_563_Disease)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NN vehicle)) (CC and) (NP (NP (NNP Doc_8955532_597_604_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN microM)) (-RRB- -RRB-)))))))))))) (. .)))
8955532	4	(S1 (S (NP (JJ Doc_8955532_619_632_Chemical) (NN infusion)) (VP (VBD increased) (NP (NP (JJ arterial) (NN pressure)) (, ,) (NP (JJ arteriolar) (NN diameter)) (CC and) (NP (NP (NN clearance)) (PP (IN of) (NP (JJ fluorescent) (NNP Doc_8955532_720_727_Chemical))))) (PP (IN by) (NP (DT a) (JJ similar) (NN magnitude))) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
8955532	5	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN disruption)) (PP (IN of) (NP (DT the) (JJ blood-brain) (NN barrier))) (PP (IN during) (NP (JJ acute) (NNP Doc_8955532_846_858_Disease)))) (VP (AUX is) (RB not) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN synthesis/release)) (PP (IN of) (NP (NNP Doc_8955532_902_912_Chemical))) (S (VP (TO to) (VP (VBP activate) (NP (JJ B2) (NNS receptors)))))))))))) (. .)))
8996652	0	(S1 (NP (NP (NN Risk) (NNS factors)) (PP (IN of) (NP (NP (NNP Doc_8996652_16_42_Disease)) (PP (IN in) (NP (JJ preterm) (NNS infants))))) (. .)))
8996652	1	(S1 (S (PP (IN Among) (NP (NP (CD 547) (JJ preterm) (NNS infants)) (PP (IN of) (NP (QP (CD <) (CC or) (SYM =) (CD 34) (NNS weeks)) (NN gestation))) (VP (VBN born) (PP (IN between) (NP (NP (CD 1987)) (CC and) (NP (CD 1991))))))) (, ,) (NP (NP (CD 8) (NNS children)) (PRN (-LRB- -LRB-) (NP (CD 1.46) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (JJ severe) (JJ progressive) (CC and) (JJ bilateral) (NN Doc_8996652_208_234_Disease))) (. .)))
8996652	2	(S1 (S (NP (NP (JJ Perinatal) (NN risk) (NNS factors)) (PP (IN of) (NP (NP (NNS infants)) (PP (IN with) (NP (NNP Doc_8996652_275_287_Disease)))))) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (CD two) (NN control) (NNS groups))) (VP (VBN matched) (PP (PP (IN for) (NP (NP (NN gestation)) (CC and) (NP (NN birth) (NN weight)))) (CC and) (PP (IN for) (NP (JJ perinatal) (NNS complications))))))))) (. .)))
8996652	3	(S1 (S (NP (PRP$ Our) (NNS observations)) (VP (VBD demonstrated) (NP (NP (DT an) (NN association)) (PP (IN of) (NP (NNP Doc_8996652_455_467_Disease))) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (JJ perinatal) (NNS complications))))))) (. .)))
8996652	4	(S1 (S (NP (NN Doc_8996652_520_531_Disease)) (VP (VBD appeared) (ADJP (RB closely) (VBN related) (PP (TO to) (NP (NP (DT a) (VBN prolonged) (NN administration)) (CC and) (NP (NP (JJR higher) (JJ total) (NN dose)) (PP (IN of) (NP (NP (JJ Doc_8996652_612_620_Disease) (NNS drugs)) (, ,) (ADVP (RB particularly)) (NP (NP (NNP Doc_8996652_641_656_Chemical)) (CC and) (NP (NNP Doc_8996652_661_671_Chemical)))))))))) (. .)))
8996652	5	(S1 (S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (ADVP (RB strongly)) (VP (VBP recommend) (S (VP (TO to) (VP (ADVP (RB prospectively) (CC and) (RB regularly)) (VB perform) (NP (NP (JJ audiologic) (NN assessment)) (PP (IN in) (NP (JJ sick) (JJ preterm) (NNS children)))) (SBAR (IN as) (S (NP (NNP Doc_8996652_793_805_Disease)) (VP (AUX is) (PP (PP (IN of) (NP (JJ delayed) (NN onset))) (CC and) (PP (IN in) (NP (JJS most) (NNS cases)))) (ADJP (JJ bilateral) (CC and) (JJ severe))))))))) (. .)))
9034419	0	(S1 (S (NP (NN Doc_9034419_0_7_Disease)) (VP (VBG resulting) (PP (IN from) (NP (DT a) (JJ Doc_9034419_25_36_Chemical) (NN Doc_9034419_37_45_Disease)))) (. .)))
9034419	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_9034419_78_89_Chemical) (NNP Doc_9034419_90_98_Disease))))))) (. .)))
9034419	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 40-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_9034419_139_155_Disease))) (SBAR (S (VP (VBD took) (NP (NP (DT an) (NN Doc_9034419_164_172_Disease)) (PP (IN of) (NP (NNP Doc_9034419_176_187_Chemical)))) (PP (IN in) (NP (DT an) (JJ apparent) (NN suicide) (NN attempt))))))) (. .)))
9034419	3	(S1 (S (PP (IN After) (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (CD 26) (JJ Doc_9034419_246_257_Chemical) (NN 50-mg) (NNS tablets))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD experienced) (NP (DT a) (VBN witnessed) (JJ generalized) (NN Doc_9034419_321_328_Disease))) (. .)))
9034419	4	(S1 (S (S (NP (PRP She)) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (DT the) (JJ medical) (JJ intensive) (NN care) (NN unit)))))) (, ,) (S (NP (NNP Doc_9034419_383_394_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (, ,) (CC and) (S (NP (DT no) (JJ further) (NNS sequelae)) (VP (AUX were) (VP (VBN seen)))) (. .)))
9034419	5	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NNP Doc_9034419_513_524_Chemical) (NNP Doc_9034419_525_533_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD resulted) (PP (IN in) (NP (DT a) (JJ generalized) (NN Doc_9034419_565_572_Disease)))))))) (. .)))
9034419	6	(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (NP (NP (JJ nonoverdose) (NNS pharmacokinetics)) (CC and) (NP (NNS pharmacodynamics))) (PP (IN of) (NP (NNP Doc_9034419_636_647_Chemical)))) (CC and) (NP (NP (DT the) (JJ potential) (NNS risks)) (PP (IN of) (NP (JJ available) (NNS interventions))))))) (, ,) (NP (DT no) (JJ emergent) (NN therapy)) (VP (AUX was) (VP (VBN instituted))) (. .)))
9034419	7	(S1 (S (NP (NP (DT The) (JJ Doc_9034419_753_764_Chemical) (NN Doc_9034419_765_773_Disease)) (PP (IN in) (NP (PRP$ our) (NN patient)))) (VP (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ single) (NN episode)) (PP (IN of) (NP (JJ generalized) (NNP Doc_9034419_833_840_Disease)))))) (CC but) (VP (VBD elicited) (NP (DT no) (JJ further) (NNS sequelae)))) (. .)))
9088814	0	(S1 (S (NP (NP (JJ Combined) (NNS effects)) (PP (IN of) (NP (NP (JJ prolonged) (JJ Doc_9088814_30_46_Chemical-induced) (NN Doc_9088814_55_66_Disease)) (CC and) (NP (NNP Doc_9088814_71_84_Disease)))) (PP (IN on) (NP (JJ human) (NN hepatic)))) (VP (VBP function)) (. .)))
9088814	1	(S1 (S (NP (NP (JJ Combined) (NNS effects)) (PP (IN of) (NP (JJ prolonged) (NNP Doc_9088814_142_158_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9088814_160_164_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_9088814_174_185_Disease) (CC and) (NNP Doc_9088814_190_203_Disease))) (PP (IN on) (NP (JJ hepatic) (NN function)))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (CD 30) (NNS patients)) (VP (VBG undergoing) (NP (NN hip) (NN surgery))))))) (. .)))
9088814	2	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (PP (TO to) (NP (NP (CD one)) (PP (IN of) (NP (NP (CD three) (NNS groups)) (: ;) (NP (NP (NP (DT those)) (SBAR (IN in) (S (NP (NP (NN group) (DT A)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (NP (JJ controlled) (NNP Doc_9088814_392_403_Disease)) (ADVP (RB alone))))))))) (, ,) (NP (NP (DT those)) (PP (IN in) (NP (NP (NN group) (NNP B)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-)) (TO to) (NP (NNP Doc_9088814_440_453_Disease)) (ADVP (RB alone))))) (CC and) (NP (NP (DT those)) (PP (IN in) (NP (NN group) (NN C))))))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-)) (PP (TO to) (NP (DT both) (JJ controlled) (NNP Doc_9088814_509_520_Disease) (CC and) (NNP Doc_9088814_525_538_Disease))))) (. .)))
9088814	3	(S1 (S (S (NP (NP (NN Doc_9088814_540_553_Disease)) (PP (IN in) (NP (NNS groups) (NNP B) (CC and) (NNP C)))) (VP (AUX was) (VP (VBN produced) (PP (IN by) (S (VP (VP (VBG withdrawing) (NP (NP (QP (RB approximately) (CD 1000)) (NNS mL)) (PP (IN of) (NP (NN blood))))) (CC and) (VP (VBG replacing) (NP (PRP it)) (PP (IN with) (NP (NP (DT the) (JJ same) (NN amount)) (PP (IN of) (NP (JJ Doc_9088814_672_679_Chemical) (NN solution)))))))))))) (, ,) (CC and) (S (NP (JJ final) (NN haematocrit) (NNS values)) (VP (AUX were) (NP (QP (CD 21) (CC or) (CD 22)) (NN %)))) (. .)))
9088814	4	(S1 (S (NP (NP (JJ Controlled) (NN Doc_9088814_746_757_Disease)) (PP (IN in) (NP (NP (NNS groups)) (X (DT A) (CC and) (SYM C))))) (VP (AUX was) (VP (VBN induced) (PP (IN with) (NP (NNP Doc_9088814_793_797_Chemical))) (S (VP (TO to) (VP (VB maintain) (NP (JJ mean) (JJ arterial) (NN blood) (NN pressure)) (PP (IN at) (NP (CD 55) (NN mmHg))) (PP (IN for) (NP (CD 180) (NN min)))))))) (. .)))
9088814	5	(S1 (S (NP (NNS Measurements)) (VP (VBD included) (NP (NP (NP (JJ arterial) (JJ ketone) (NN body) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NNP AKBR)) (, ,) (NP (NNP Doc_9088814_919_932_Chemical/Doc_9088814_933_950_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ clinical) (JJ hepatic) (NN function) (NNS parameters)))) (. .)))
9088814	6	(S1 (S (NP (JJ AKBR) (CC and) (JJ biological) (JJ hepatic) (NN function) (NNS tests)) (VP (VBD showed) (NP (DT no) (NN change)) (PP (IN throughout) (NP (NP (DT the) (NN time) (NN course)) (PP (IN in) (NP (NP (NNS groups)) (X (DT A) (CC and) (SYM B))))))) (. .)))
9088814	7	(S1 (S (PP (IN In) (NP (NN group) (NN C))) (, ,) (NP (NNP AKBR)) (VP (VBD showed) (SBAR (S (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (PP (IN at) (NP (NP (CD 120) (NN min)) (PRN (-LRB- -LRB-) (NP (JJ -40) (NN %)) (-RRB- -RRB-)))) (CC and) (PP (IN at) (NP (CD 180) (NN min)))) (PRN (-LRB- -LRB-) (NP (CD -49) (NN %)) (-RRB- -RRB-)) (PP (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NNP Doc_9088814_1206_1217_Disease) (CC and) (PP (IN at) (NP (NP (NP (CD 60) (NN min)) (PRN (-LRB- -LRB-) (NP (CD -32) (NN %)) (-RRB- -RRB-) (PP (IN after) (NP (NP (NN recovery)) (PP (IN of) (NP (NN normotension))))) (, ,))) (CC and) (NP (NNP SGOT)))) (, ,) (NN SGPT) (, ,) (NN LDH) (CC and) (JJ total) (NNP Doc_9088814_1301_1310_Chemical)))))) (VP (VBD showed) (NP (JJ significant) (NNS increases)) (PP (IN after) (NP (NN operation))))))) (. .)))
9088814	8	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (VBN prolonged) (NN combination)) (PP (IN of) (NP (NP (QP (JJR more) (IN than) (CD 120)) (NN min)) (PP (IN of) (NP (NP (JJ Doc_9088814_1430_1434_Chemical-induced) (NNP Doc_9088814_1443_1454_Disease)) (CC and) (NP (JJ moderate) (NNP Doc_9088814_1468_1481_Disease))))))) (VP (MD would) (VP (VB cause) (NP (NN Doc_9088814_1494_1524_Disease))))))) (. .)))
9100294	0	(S1 (S (NP (NP (NN Doc_9100294_0_26_Disease)) (PP (IN in) (NP (NN rat) (NNS fetuses)))) (VP (VBD exposed) (PP (TO to) (NP (JJ Doc_9100294_53_60_Chemical) (NN channel) (NNS blockers)))) (. .)))
9100294	1	(S1 (S (NP (JJ Preclinical) (JJ toxicologic) (NN investigation)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (DT a) (JJ new) (JJ Doc_9100294_138_145_Chemical) (NN channel) (NN blocker)) (, ,) (NP (NNP Doc_9100294_163_173_Chemical)) (, ,)) (VP (VBN induced) (NP (NNP Doc_9100294_183_209_Disease)) (PP (IN in) (NP (NP (NN rat) (NNS fetuses)) (VP (VBN exposed) (PP (TO to) (NP (DT this) (NN agent))) (PP (IN during) (NP (NN organogenesis)))))))))) (. .)))
9100294	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (JJ Doc_9100294_335_342_Chemical) (NN channel) (NNS blockers)) (PP (IN in) (NP (NN general)))) (VP (VB induce) (NP (NNP Doc_9100294_378_406_Disease)) (S (VP (VBG indicating) (NP (DT a) (JJ pharmacologic) (NN class) (NN effect))))))))))))) (. .)))
9100294	3	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (CD three) (JJ Doc_9100294_465_472_Chemical) (NN channel) (NNS blockers)) (PP (IN of) (NP (NP (JJ different) (NN structure)) (, ,) (NP (NP (NNP Doc_9100294_514_524_Chemical)) (, ,) (NP (NNP Doc_9100294_526_535_Chemical)) (, ,) (CC and) (NP (NNP Doc_9100294_541_550_Chemical))) (, ,)))) (PP (IN along) (PP (IN with) (NP (DT the) (JJ new) (NN agent))))) (. .)))
9100294	4	(S1 (S (S (NP (JJ Pregnant) (NNS rats)) (VP (AUX were) (VP (VBN administered) (NP (NP (CD one)) (PP (IN of) (NP (DT these) (JJ Doc_9100294_623_630_Chemical) (NN channel) (NNS blockers)))) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (JJ cardiac) (NNS morphogenesis)))))))) (CC and) (S (NP (DT the) (NN offspring)) (VP (VBD examined) (PP (IN on) (NP (NP (NN day) (CD 20)) (PP (IN of) (NP (NP (NN gestation)) (PP (IN for) (NP (NNP Doc_9100294_745_773_Disease))))))))) (. .)))
9100294	5	(S1 (S (S (NP (NP (DT A) (JJ low) (NN incidence)) (PP (IN of) (NP (NNP Doc_9100294_794_822_Disease)))) (VP (AUX was) (VP (VBN observed) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (CD four) (JJ Doc_9100294_871_878_Chemical) (NN channel) (NNS blockers)))))))))) (, ,) (CC but) (S (NP (DT this) (NN incidence)) (VP (AUX was) (ADJP (RB statistically) (JJ significant)) (ADVP (RB only)) (PP (IN for) (NP (NP (NNP Doc_9100294_955_964_Chemical)) (CC and) (NP (NNP Doc_9100294_969_979_Chemical)))))) (. .)))
9100294	6	(S1 (S (NP (DT All) (CD four) (NNS agents)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NN aortic) (NN arch) (VBG branching) (NNS variants))) (, ,) (SBAR (IN although) (S (VP (ADVP (RB significantly)) (VBD increased) (ADVP (RB only)) (PP (IN for) (NP (NP (NNP Doc_9100294_1092_1102_Chemical)) (CC and) (NP (NNP Doc_9100294_1107_1116_Chemical))))))))) (. .)))
9195768	0	(S1 (NP (NP (DT The) (NN site)) (PP (IN of) (NP (NP (JJ common) (JJ side) (NNS effects)) (PP (IN of) (NP (NNP Doc_9195768_35_46_Chemical))))) (. .)))
9195768	1	(S1 (S (S (NP (NP (NN Doc_9195768_48_67_Disease)) (VP (VBG following) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ subcutaneous) (NNP Doc_9195768_102_113_Chemical)))))) (VP (AUX are) (ADJP (JJ common)))) (, ,) (CC but) (S (PP (IN of) (NP (JJ uncertain) (NN origin)))) (. .)))
9195768	2	(S1 (S (NP (PRP They)) (VP (VP (AUX are) (ADJP (ADVP (RB almost) (RB always)) (JJ benign))) (, ,) (CC but) (VP (MD can) (VP (AUX be) (VP (VBN mistaken) (PP (IN for) (NP (NP (DT a) (JJ serious) (JJ adverse) (NN event)) (PP (IN by) (NP (DT the) (NN patient))))))))) (. .)))
9195768	3	(S1 (S (NP (CD Two) (NNS patients)) (VP (AUX are) (VP (VBN presented) (PP (IN with) (NP (NNP Doc_9195768_278_308_Disease))) (PP (VBN limited) (PP (TO to) (NP (NP (NNS areas)) (PP (IN of) (NP (NP (NN heat) (NN exposure)) (CC or) (NP (NN Doc_9195768_346_353_Disease))))))))) (. .)))
9195768	4	(S1 (S (PP (IN In) (NP (DT these) (NNS individuals))) (, ,) (NP (NN side) (NNS effects)) (VP (AUX are) (ADVP (RBS most) (JJ likely)) (VP (VBN generated) (ADVP (RB superficially)) (PP (IN in) (NP (DT the) (NN skin))))) (. .)))
9199746	0	(S1 (NP (NP (NNP Macula) (NNP Doc_9199746_7_15_Disease)) (PP (IN after) (NP (JJ intravitreal) (NNP Doc_9199746_35_43_Chemical))) (. .)))
9199746	1	(S1 (S (SBAR (IN Although) (S (NP (JJ intravitreal) (NNP Doc_9199746_79_94_Chemical)) (VP (AUX have) (NP (ADJP (RB substantially) (VBN improved)) (JJ visual) (NN prognosis)) (PP (IN in) (NP (NNP Doc_9199746_143_158_Disease)))))) (, ,) (ADVP (RB macular)) (NP (NNP Doc_9199746_168_178_Disease)) (VP (MD may) (VP (VB impair) (NP (JJ full) (JJ visual) (NN recovery)))) (. .)))
9199746	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ presumed) (NNP Doc_9199746_251_259_Chemical) (NNP Doc_9199746_260_276_Disease)))) (PP (VBG following) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_9199746_302_310_Chemical)) (CC and) (NP (NNP Doc_9199746_315_325_Chemical)))) (PP (IN for) (NP (JJ alpha-haemolytic) (NNP Doc_9199746_347_376_Disease)))))) (. .)))
9199746	3	(S1 (S (NP (NN Doc_9199746_387_402_Disease)) (VP (VBN resolved) (PP (IN with) (NP (NN improvement))) (PP (IN in) (NP (NP (JJ visual) (NN acuity)) (PP (TO to) (NP (CD 6/24))))) (PP (IN at) (NP (CD three) (NNS months)))) (. .)))
9199746	4	(S1 (S (NP (JJ Fundus) (JJ Doc_9199746_478_489_Chemical) (NN angiography)) (VP (VBD confirmed) (NP (NP (JJ macular) (JJ capillary) (NN closure)) (CC and) (NP (NN Doc_9199746_542_556_Disease)))) (. .)))
9199746	5	(S1 (S (ADVP (RB Currently)) (NP (JJ accepted) (JJ intravitreal) (JJ antibiotic) (NNS regimens)) (VP (MD may) (VP (VP (VB cause) (NP (NN Doc_9199746_633_649_Disease))) (CC and) (VP (VB macular) (NP (NNP Doc_9199746_662_671_Disease))))) (. .)))
9199746	6	(S1 (S (NP (NP (NN Treatment) (NNS strategies)) (VP (VBN aimed) (PP (IN at) (S (VP (VBG avoiding) (NP (NN Doc_9199746_712_728_Disease))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
9245658	0	(S1 (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NNP Doc_9245658_12_20_Chemical))) (PP (IN in) (NP (JJ smoking-related) (NNP Doc_9245658_40_62_Disease))) (. .)))
9245658	1	(S1 (S (NP (NN Doc_9245658_64_72_Chemical)) (VP (VP (VBZ activates) (NP (DT the) (JJ sympathetic) (JJ nervous) (NN system))) (CC and) (VP (PP (IN in) (NP (DT this) (NN way))) (MD could) (VP (VB contribute) (PP (TO to) (NP (NN Doc_9245658_150_172_Disease)))))) (. .)))
9245658	2	(S1 (S (S (NP (NP (NN Animal) (NNS studies)) (CC and) (NP (JJ mechanistic) (NNS studies))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_9245658_227_235_Chemical)) (VP (MD could) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG accelerating) (NP (NNP Doc_9245658_270_285_Disease))))))))))) (, ,) (CC but) (S (NP (NP (NN evidence)) (PP (IN among) (NP (NNS humans)))) (VP (AUX is) (ADJP (RB too) (JJ inadequate) (S (VP (TO to) (VP (AUX be) (ADJP (JJ definitive) (PP (IN about) (NP (PDT such) (DT an) (NN effect)))))))))) (. .)))
9245658	3	(S1 (S (ADVP (RB Almost) (RB certainly)) (, ,) (NP (NP (NNP Doc_9245658_388_396_Chemical)) (PP (IN via) (NP (PRP$ its) (JJ hemodynamic) (NNS effects)))) (VP (VBZ contributes) (PP (TO to) (NP (JJ acute) (JJ cardiovascular) (NNS events))) (, ,) (SBAR (IN although) (S (NP (JJ current) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_9245658_524_532_Chemical)))) (VP (AUX are) (ADJP (ADVP (RB much) (RBR less)) (JJ important)) (SBAR (IN than) (S (VP (AUX are) (NP (NP (NP (DT the) (JJ prothrombotic) (NNS effects)) (PP (IN of) (NP (NN cigarette) (NN smoking)))) (CC or) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_9245658_631_646_Chemical))))))))))))))) (. .)))
9245658	4	(S1 (S (NP (NN Doc_9245658_648_656_Chemical)) (VP (AUX does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB enhance) (NP (NP (NN Doc_9245658_684_694_Disease)) (PP (IN among) (NP (NNS humans))))))))) (. .)))
9245658	5	(S1 (S (NP (NP (JJ Clinical) (NNS studies)) (PP (IN of) (NP (NP (NP (NN pipe) (NNS smokers)) (CC and) (NP (NNS people))) (VP (VBG using) (NP (JJ transdermal) (NNP Doc_9245658_771_779_Chemical)))))) (VP (VBP support) (NP (DT the) (NN idea) (SBAR (IN that) (S (NP (NP (NNS toxins)) (ADJP (JJ other) (PP (IN than) (NP (NNP Doc_9245658_820_828_Chemical))))) (VP (AUX are) (NP (NP (DT the) (ADJP (RBS most) (JJ important)) (NNS causes)) (PP (IN of) (NP (JJ acute) (JJ cardiovascular) (NNS events))))))))) (. .)))
9245658	6	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (DT the) (NN dose) (NN response)) (PP (IN for) (NP (NP (JJ cardiovascular) (NNS events)) (PP (IN of) (NP (NNP Doc_9245658_947_955_Chemical)))))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (JJ flat))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (SBAR (IN if) (S (NP (NNP Doc_9245658_995_1003_Chemical)) (VP (AUX is) (VP (VBN involved))))) (, ,) (NP (JJ adverse) (NNS effects)) (VP (MD might) (VP (AUX be) (VP (VBN seen) (PP (IN with) (NP (ADJP (RB relatively) (JJ low-level)) (NN cigarette) (NNS exposures))))))))))) (. .)))
9249847	0	(S1 (S (VP (ADVP (RB Iatrogenically)) (VBN induced) (NP (JJ intractable) (NNP Doc_9249847_35_73_Disease)) (PP (IN after) (NP (NP (NNP Doc_9249847_80_89_Chemical)) (CC and) (NP (NN catheter) (NN ablation)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_9249847_130_160_Disease)) (CC and) (NP (NNP Doc_9249847_165_198_Disease))))))) (. .)))
9249847	1	(S1 (S (PP (IN In) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_9249847_218_230_Disease)) (CC and) (NP (NNP Doc_9249847_235_268_Disease)))))) (, ,) (NP (NP (JJ intractable) (NNP Doc_9249847_282_320_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9249847_322_326_Disease)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB iatrogenically)) (VP (VBN induced))) (. .)))
9249847	2	(S1 (S (NP (NP (NNS QRS)) (PP (IN without) (NP (NN preexcitation))) (, ,) (VP (VBN caused) (PP (IN by) (NP (JJ junctional) (NN escape) (NNS beats))) (PP (IN after) (NP (NP (JJ Doc_9249847_423_432_Chemical) (CC or) (JJ unidirectional) (NN antegrade) (NN block)) (PP (IN of) (NP (JJ accessory) (NN pathway))))) (PP (IN after) (NP (NN catheter) (NN ablation)))) (, ,)) (VP (VBD established) (NP (JJ frequent) (JJ Doc_9249847_534_538_Disease) (NN attack))) (. .)))
9284778	0	(S1 (S (NP (NP (NN Epidemic)) (PP (IN of) (NP (NNP Doc_9284778_12_25_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_9284778_36_60_Chemical))))) (VP (VBD used) (PP (IN as) (NP (NP (JJ Doc_9284778_69_74_Chemical-sparing) (NNS substitutes)) (PP (IN of) (NP (NNP Doc_9284778_98_117_Chemical)))))) (. .)))
9284778	1	(S1 (S (NP (NP (NNP Doc_9284778_131_155_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_157_162_Chemical)) (-RRB- -RRB-))) (VP (AUX are) (VP (VBN used) (ADVP (RB increasingly)) (PP (IN in) (NP (NN industry))) (PP (IN as) (NP (NP (NNS substitutes)) (PP (IN for) (NP (NP (NNP Doc_9284778_217_222_Chemical-depleting) (NNP Doc_9284778_233_252_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_254_258_Chemical)) (-RRB- -RRB-)))))))) (. .)))
9284778	2	(S1 (S (NP (NP (JJ Limited) (NNS studies)) (PP (IN in) (NP (NNS animals)))) (VP (VBP indicate) (NP (NP (JJ potential) (NN Doc_9284778_307_321_Disease)) (PP (IN of) (NP (NP (DT some)) (PP (IN of) (NP (DT these) (NNS compounds))))))) (. .)))
9284778	3	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT an) (NN epidemic)) (PP (IN of) (NP (NNP Doc_9284778_381_394_Disease))) (PP (IN in) (NP (NP (CD nine) (JJ industrial) (NNS workers)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX had) (VP (VBN repeated) (NP (JJ accidental) (NN exposure)) (PP (TO to) (NP (NP (DT a) (NN mixture)) (PP (IN of) (NP (NP (NP (NNP Doc_9284778_479_513_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_515_523_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9284778_529_563_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_565_573_Chemical)) (-RRB- -RRB-)))))))))))))))) (. .)))
9284778	4	(S1 (S (NP (DT All) (CD nine) (JJ exposed) (NNS workers)) (VP (AUX were) (VP (VBN affected) (PP (TO to) (NP (JJ various) (NNS degrees))))) (. .)))
9284778	5	(S1 (S (NP (DT Both) (NNS compounds)) (VP (AUX are) (VP (VBN metabolised) (PP (IN in) (NP (DT the) (JJ same) (NN way))) (PP (IN as) (NP (NP (NP (NNP Doc_9284778_685_723_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9284778_725_734_Chemical)) (-RRB- -RRB-)) (SBAR (S (VP (TO to) (VP (VB form) (NP (JJ reactive) (JJ Doc_9284778_753_768_Chemical) (NN halide) (NNS intermediates))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NNP Doc_9284778_825_839_Disease)) (PP (IN of) (NP (NNP Doc_9284778_843_852_Chemical)))))))))))))) (. .)))
9284778	6	(S1 (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VB test) (SBAR (IN whether) (S (NP (NNP Doc_9284778_879_896_Chemical)) (VP (MD can) (VP (VB result) (PP (IN in) (NP (JJ serious) (NN Doc_9284778_919_932_Disease))))))))))) (. .)))
9284778	7	(S1 (S (PP (IN For) (NP (CD one))) (NP (NP (ADJP (RB severely) (VBN affected)) (NN worker) (NN liver) (NN biopsy) (CC and) (JJ immunohistochemical) (NNS stainings)) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ Doc_9284778_1043_1058_Chemical) (NN protein) (NNS adducts)))))) (VP (AUX were) (VP (AUX done))) (. .)))
9284778	8	(S1 (S (NP (NP (DT The) (NN serum)) (PP (IN of) (NP (NP (CD six) (JJ affected) (NNS workers)) (CC and) (NP (CD five) (NNS controls))))) (VP (AUX was) (VP (VBN tested) (PP (IN for) (NP (NP (NNS autoantibodies)) (SBAR (WHNP (WDT that)) (S (VP (VBP react) (PP (IN with) (NP (NP (NP (JJ human) (NN liver) (JJ cytochrome-P450) (NNS 2E1)) (PRN (-LRB- -LRB-) (NP (CD P450) (NNS 2E1)) (-RRB- -RRB-))) (CC and) (NP (NP (ADJP (CD P58) (NN protein)) (JJ disulphide) (JJ isomerase) (NN isoform)) (PRN (-LRB- -LRB-) (NP (NNP P58)) (-RRB- -RRB-)))))))))))) (. .)))
9284778	9	(S1 (S (NP (DT The) (NN liver) (NN biopsy) (NN sample)) (VP (VBD showed) (NP (NP (JJ hepatocellular) (NN Doc_9284778_1335_1343_Disease)) (SBAR (WHNP (WDT which)) (S (VP (VP (AUX was) (ADJP (JJ prominent)) (PP (IN in) (NP (NN perivenular) (NN zone) (CD three)))) (CC and) (VP (VBD extended) (ADVP (RB focally) (PP (IN from) (NP (JJ portal) (NNS tracts)))) (PP (TO to) (NP (NP (NP (JJ portal) (NNS tracts)) (CC and) (NP (JJ centrilobular) (NNS areas))) (PRN (-LRB- -LRB-) (PP (VBG bridging) (NP (NNP Doc_9284778_1481_1489_Disease))) (-RRB- -RRB-)))))))))) (. .)))
9284778	10	(S1 (S (NP (JJ Doc_9284778_1492_1507_Chemical-adducted) (NNS proteins)) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (VBG surviving) (NNS hepatocytes))))) (. .)))
9284778	11	(S1 (S (NP (NP (NNS Autoantibodies)) (PP (IN against) (NP (NNP P450) (CD 2E1) (CC or) (CD P58))) (, ,) (VP (ADVP (RB previously)) (VBN associated) (PP (IN with) (NP (NNP Doc_9284778_1633_1652_Disease)))) (, ,)) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (NN serum)) (PP (IN of) (NP (CD five) (JJ affected) (NNS workers))))))) (. .)))
9284778	12	(S1 (S (NP (NP (VBN Repeated) (NN exposure)) (PP (IN of) (NP (JJ human) (NNS beings))) (PP (TO to) (NP (NNP Doc_9284778_1760_1777_Chemical)))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (JJ serious) (NN Doc_9284778_1800_1812_Disease))) (PP (IN in) (NP (NP (DT a) (JJ large) (NN proportion)) (PP (IN of) (NP (DT the) (VBN exposed) (NN population))))))) (. .)))
9284778	13	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ exact) (NN mechanism)) (PP (IN of) (NP (NP (NNP Doc_9284778_1894_1908_Disease)) (PP (IN of) (NP (DT these) (NNS agents)))))) (VP (AUX is) (RB not) (VP (VBN known))))) (, ,) (NP (DT the) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ Doc_9284778_1964_1979_Chemical-altered) (NN liver) (NNS proteins)) (VP (AUX are) (VP (VBN involved)))))) (. .)))
9284778	14	(S1 (S (PP (IN In) (NP (NP (NN view)) (PP (IN of) (NP (NP (DT the) (ADJP (RB potentially) (JJ widespread)) (NN use)) (PP (IN of) (NP (DT these) (NNS compounds))))))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT an) (JJ urgent) (NN need)) (SBAR (S (VP (TO to) (VP (VB develop) (NP (JJR safer) (NNS alternatives)))))))) (. .)))
9293063	0	(S1 (S (NP (NN Doc_9293063_0_19_Disease)) (VP (VBG occurring) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (JJ long-term) (NN treatment)) (PP (IN with) (NP (NNP Doc_9293063_75_82_Chemical)))))) (. .)))
9293063	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_9293063_104_123_Disease))) (SBAR (WHNP (WDT which)) (S (VP (VBD developed) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (PP (IN on) (NP (JJ long-term) (JJ Doc_9293063_179_186_Chemical) (NN treatment)))))))))))))) (. .)))
9293063	2	(S1 (S (NP (JJ Such) (NNS patients)) (VP (MD should) (VP (AUX be) (PP (IN under) (NP (JJ close) (NN follow-up))) (, ,) (PP (ADVP (RB preferably)) (IN with) (NP (NP (JJ periodic) (NN ultrasound) (NN examination)) (PP (IN of) (NP (DT the) (NN liver))))))) (. .)))
9293063	3	(S1 (S (SBAR (IN If) (S (NP (DT the) (NN patient)) (VP (VBZ develops) (NP (DT a) (NN Doc_9293063_333_343_Disease))))) (, ,) (PP (IN because) (IN of) (NP (NP (JJ non-specific) (JJ clinical) (NNS features)) (CC and) (NP (NN imaging) (NNS appearances)))) (, ,) (NP (NN biopsy)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ only) (NN way)) (SBAR (S (VP (TO to) (VP (VB achieve) (NP (DT a) (JJ definitive) (NN diagnosis))))))))) (. .)))
9334596	0	(S1 (NP (NP (NP (JJ Endocrine) (NN screening)) (PP (IN in) (NP (CD 1,022) (NNS men))) (PP (IN with) (NP (NNP Doc_9334596_38_58_Disease)))) (: :) (NP (NP (JJ clinical) (NN significance)) (CC and) (NP (JJ cost-effective) (NN strategy))) (. .)))
9334596	1	(S1 (S (NP (PRP We)) (VP (VP (VBN reviewed) (NP (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (JJ serum) (NNP Doc_9334596_153_165_Chemical)))) (CC and) (NP (NN prolactin) (NN determination))) (PP (IN in) (NP (NP (CD 1,022) (NNS patients)) (VP (VBN referred) (PP (IN because) (IN of) (NP (NNP Doc_9334596_232_252_Disease))))))) (CC and) (VP (VBN compared) (NP (DT the) (NNS data)) (PP (IN with) (NP (NP (NN history)) (, ,) (NP (NP (NNS results)) (PP (IN of) (NP (JJ physical) (NN examination)))) (, ,) (NP (JJ other) (JJ etiological) (NNS investigations)) (CC and) (NP (NP (NNS effects)) (PP (IN of) (NP (JJ endocrine) (NN therapy))))))) (S (VP (VP (TO to) (VP (VB refine) (NP (NP (DT the) (NNS rules)) (PP (IN of) (NP (JJ cost-effective) (NN endocrine) (NN screening)))))) (CC and) (VP (TO to) (VP (VB pinpoint) (NP (NP (JJ actual) (NN responsibility)) (PP (IN for) (NP (JJ hormonal) (NNS abnormalities))))))))) (. .)))
9334596	2	(S1 (S (NP (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (NP (NP (NNP Doc_9334596_535_547_Chemical)) (CC and) (NP (NNP prolactin)))) (VP (AUX were) (VP (VBN determined) (PP (IN by) (NP (NN radioimmunoassay))))) (. .)))
9334596	3	(S1 (S (S (NP (DT Every) (NN patient)) (VP (AUX was) (VP (VBN screened) (PP (IN for) (NP (NNP Doc_9334596_630_642_Chemical)))))) (CC and) (S (NP (CD 451)) (VP (AUX were) (VP (VBN screened) (PP (IN for) (NP (NN prolactin))) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NNP Doc_9334596_695_712_Disease)) (, ,) (NP (NNP Doc_9334596_714_726_Disease)) (CC or) (NP (NNP Doc_9334596_730_742_Chemical)))))) (NP (QP (JJR less) (IN than) (CD 4)) (NN ng./ml))))) (. .)))
9334596	4	(S1 (S (NP (NN Determination)) (VP (AUX was) (VP (VBN repeated) (PP (IN in) (NP (NP (NN case)) (PP (IN of) (NP (JJ abnormal) (JJ first) (NNS results))))))) (. .)))
9334596	5	(S1 (S (NP (NNP Prolactin) (NNS results)) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT a) (JJ previous) (JJ personal) (NN cohort)) (PP (IN of) (NP (NP (JJ 1,340) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9334596_921_941_Disease)) (CC and) (NP (JJ systematic) (NN prolactin) (NN determination)))))))))))) (. .)))
9334596	6	(S1 (S (NP (NP (JJ Main) (JJ clinical) (NNS criteria)) (VP (VBN tested) (PP (VBG regarding) (NP (NN efficiency))) (PP (IN in) (NP (NN hormone) (NN determination))))) (VP (AUX were) (NP (NP (NNP Doc_9334596_1063_1080_Disease)) (, ,) (NP (JJ small) (NNS testes)) (CC and) (NP (NNP Doc_9334596_1099_1111_Disease)))) (. .)))
9334596	7	(S1 (S (NP (JJ Endocrine) (NN therapy)) (VP (VBD consisted) (PP (IN of) (NP (NP (NNP Doc_9334596_1144_1166_Chemical) (CC or) (JJ human) (JJ chorionic) (NN gonadotropin)) (PP (IN for) (NP (NP (NNP Doc_9334596_1203_1215_Disease)) (CC and) (NP (NNP Doc_9334596_1220_1233_Chemical)))) (PP (IN for) (NP (NNP Doc_9334596_1238_1256_Disease)))))) (. .)))
9334596	8	(S1 (S (NP (NN Doc_9334596_1267_1279_Chemical)) (VP (AUX was) (UCP (NP (NP (QP (JJR less) (IN than) (CD 3)) (NN ng./ml.)) (PP (IN in) (NP (CD 107) (NNS patients)))) (CC but) (ADJP (JJ normal) (PP (IN in) (NP (CD 40) (NN %))) (PP (IN at) (NP (NN repeat) (NN determination)))))) (. .)))
9334596	9	(S1 (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (ADJP (RB repeatedly) (JJ low)) (NNP Doc_9334596_1396_1408_Chemical)))) (VP (VBN increased) (PP (IN with) (NP (NN age))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 4) (NN %)) (PP (IN before) (NP (NN age)))) (NP (CD 50) (NNS years))) (CC and) (NP (NP (CD 9) (NN %)) (NP (CD 50) (NNS years) (QP (CC or) (JJR older))))) (-RRB- -RRB-))) (. .)))
9334596	10	(S1 (S (NP (CD Two) (NNP Doc_9334596_1483_1499_Disease)) (VP (AUX were) (VP (VBN discovered) (PP (IN after) (NP (JJ Doc_9334596_1522_1534_Chemical) (NN determination))))) (. .)))
9334596	11	(S1 (S (NP (NP (JJS Most)) (PP (IN of) (NP (DT the) (JJ other) (JJ low) (NNP Doc_9334596_1572_1584_Chemical) (NNS levels)))) (VP (VBD seemed) (S (VP (TO to) (VP (VB result) (PP (IN from) (NP (JJ nonorganic) (NNP Doc_9334596_1625_1649_Disease))) (PP (IN because) (IN of) (NP (NP (JJ normal) (NN serum) (NN luteinizing) (NN hormone) (CC and) (NN prolactin)) (CC and) (S (VP (TO to) (VP (AUX have) (NP (NP (RB only) (DT a) (JJ small) (NN role)) (PP (IN in) (NP (NP (NNP Doc_9334596_1741_1761_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ definite) (NN improvement)) (PP (IN in) (NP (NP (NP (NP (QP (RB only) (CD 16) (IN of) (CD 44) (CD -LSB-36)) (NN %)) (NN -RSB-)) (PP (IN after) (NP (JJ androgen) (NN therapy)))) (, ,) (NP (NP (JJ normal) (UCP (NN morning) (CC or) (JJ nocturnal)) (NNS erections)) (PP (IN in) (NP (CD 30) (NN %)))) (CC and) (NP (JJ definite) (JJ vasculogenic) (NNS contributions)))) (PP (IN in) (NP (CD 42) (NN %)))) (-RRB- -RRB-)))))))))))))) (. .)))
9334596	12	(S1 (S (S (VP (VBG Determining) (NP (NN Doc_9334596_1937_1949_Chemical)) (PP (ADVP (RB only)) (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (NNP Doc_9334596_1967_1984_Disease) (CC or) (JJ abnormal) (JJ physical) (NN examination))))))) (VP (MD would) (VP (AUX have) (VP (VBN missed) (NP (NP (CD 40) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS cases)) (PP (IN with) (NP (JJ low) (NNP Doc_9334596_2062_2074_Chemical))) (, ,) (PP (VBG including) (NP (NP (CD 37) (NN %)) (PP (IN of) (NP (NP (DT those)) (VP (ADVP (RB subsequently)) (VBN improved) (PP (IN by) (NP (JJ androgen) (NN therapy)))))))))))))) (. .)))
9334596	13	(S1 (S (NP (NN Prolactin)) (VP (VP (VBD exceeded) (NP (CD 20) (NN ng./ml.)) (PP (IN in) (NP (CD 5) (NN men)))) (CC and) (VP (AUX was) (ADJP (JJ normal) (PP (IN in) (NP (CD 2)))) (PP (IN at) (NP (NN repeat) (NN determination))))) (. .)))
9334596	14	(S1 (S (NP (QP (RB Only) (CD 1)) (NN Doc_9334596_2233_2245_Disease)) (VP (AUX was) (VP (VBN discovered))) (. .)))
9334596	15	(S1 (S (NP (DT These) (NNS data)) (VP (AUX are) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT those)) (SBAR (S (NP (PRP we)) (VP (VBD found) (PP (IN during) (NP (NP (DT the) (JJ last) (CD 2) (NNS decades)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ overall) (NN prolactin)) (NP (QP (JJR greater) (IN than) (CD 20)) (NNS ng./ml.))) (PP (IN in) (NP (NP (CD 1.86) (NN %)) (PP (IN of) (NP (CD 1,821) (NNS patients)))))) (, ,) (NP (NP (NNP Doc_9334596_2400_2413_Disease)) (PP (IN in) (NP (CD 7)))) (, ,) (NP (CD 0.38) (NN %)) (-RRB- -RRB-))))))))))) (. .)))
9334596	16	(S1 (S (NP (NNP Doc_9334596_2428_2441_Chemical)) (VP (AUX was) (ADVP (RB definitely)) (ADJP (JJ effective)) (PP (IN in) (NP (NP (NNS cases)) (PP (IN with) (NP (NP (NP (NN prolactin)) (NP (QP (JJR greater) (IN than) (CD 35)) (NNS ng./ml)) (. .)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 8) (IN of) (CD 12))) (VP (VBN compared) (PP (TO to) (NP (QP (RB only) (CD 9) (IN of) (CD 22)) (NNS cases))) (PP (IN with) (NP (NP (NN prolactin)) (PP (IN between) (NP (CD 20) (CC and) (CD 35) (NNS ng./ml)))))) (. .)) (-RRB- -RRB-))))))) (. .)))
9334596	17	(S1 (S (NP (NN Doc_9334596_2598_2610_Chemical)) (VP (AUX was) (ADJP (JJ low)) (PP (IN in) (NP (NP (QP (JJR less) (IN than) (CD 50)) (NN %)) (PP (IN of) (NP (NNS cases))))) (PP (IN with) (S (VP (VBG prolactin) (NP (QP (JJR greater) (IN than) (CD 35)) (NN ng./ml)))))) (. .)))
9334596	18	(S1 (S (NP (NP (JJ Low) (NNS prevalences) (CC and) (NNS effects)) (PP (IN of) (NP (NP (NP (JJ low) (NN Doc_9334596_2732_2744_Chemical)) (CC and) (NP (JJ high) (NN prolactin))) (PP (IN in) (NP (NNP Doc_9334596_2767_2787_Disease)))))) (VP (VBP cannot) (S (VP (VB justify) (NP (PRP$ their) (JJ routine) (NN determination))))) (. .)))
9334596	19	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ cost-effective) (NN screening) (NNS strategies)) (VP (VBD recommended) (SBAR (S (ADVP (RB so) (RB far)) (VP (VBD missed) (NP (NP (QP (CD 40) (TO to) (CD 50)) (NN %)) (PP (IN of) (NP (NNS cases)))) (PP (VBN improved) (PP (IN with) (NP (NP (JJ endocrine) (NN therapy)) (CC and) (NP (DT the) (NNP Doc_9334596_2962_2978_Disease))))))))) (. .)))
9334596	20	(S1 (S (NP (PRP We)) (ADVP (RB now)) (VP (VBP advocate) (SBAR (SBAR (IN that) (S (NP (NP (RB before) (NN age)) (ADJP (NP (CD 50) (NNS years)) (JJ Doc_9334596_3021_3033_Chemical))) (VP (AUX be) (VP (VBN determined) (ADVP (RB only)) (PP (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_9334596_3065_3082_Disease)) (CC and) (NP (JJ abnormal) (JJ physical) (NN examination)))))))))) (CC but) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX be) (VP (VBN measured) (PP (IN in) (NP (DT all) (NN men) (QP (JJR older) (IN than) (CD 50)) (NNS years))))))))) (. .)))
9334596	21	(S1 (S (NP (NNP Prolactin)) (VP (MD should) (VP (AUX be) (VP (VBN determined) (PP (ADVP (RB only)) (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_9334596_3221_3238_Disease)) (, ,) (NP (NNP Doc_9334596_3240_3252_Disease) (NN and/or) (NNP Doc_9334596_3260_3272_Chemical)))))) (ADVP (RBR less) (PP (IN than) (NP (CD 4) (NN ng./ml))))))) (. .)))
9351491	0	(S1 (NP (NP (JJ Extrapyramidal) (JJ side) (NNS effects)) (PP (IN with) (NP (NP (NNP Doc_9351491_33_44_Chemical)) (CC and) (NP (NNP Doc_9351491_49_60_Chemical)))) (PP (IN at) (NP (JJ comparable) (NNP D2) (NN receptor) (NN occupancy) (NNS levels))) (. .)))
9351491	1	(S1 (S (NP (NN Doc_9351491_105_116_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ antipsychotic) (NN drug)) (PP (IN with) (NP (NP (JJ high) (NN affinity)) (PP (IN at) (NP (NNP Doc_9351491_164_172_Chemical) (NNP D2) (CC and) (NNP Doc_9351491_180_195_Chemical) (NNS receptors))))))) (. .)))
9351491	2	(S1 (S (S (NP (JJ Previous) (JJ clinical) (NNS studies)) (VP (AUX have) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (NNP Doc_9351491_252_263_Chemical) (POS 's)) (JJ pharmacologic) (NN profile)) (VP (MD may) (VP (VB produce) (NP (NP (NP (VBN improved) (NN efficacy)) (PP (IN for) (NP (JJ negative) (NNP Doc_9351491_331_349_Disease)))) (CC and) (NP (NP (VBN decreased) (NN propensity)) (PP (IN for) (NP (JJ extrapyramidal) (NN side) (NNS effects)))))))))))) (: ;) (S (NP (NNS features)) (VP (VBN shared) (PP (IN by) (NP (NP (NN so-called) (POS ')) (JJ atypical) ('' ') (NNS neuroleptics))))) (. .)))
9351491	3	(S1 (S (S (VP (TO To) (VP (VB determine) (SBAR (IN if) (S (NP (JJ routine) (JJ Doc_9351491_486_497_Chemical) (NN treatment)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ unique) (NN degree)) (PP (IN of) (NP (NP (NNP D2) (NN receptor) (NN occupancy)) (CC and) (NP (NP (NN pattern)) (PP (IN of) (NP (JJ clinical) (NNS effects))))))))))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (JJ -LSB-123I) (JJ -RSB-) (NN IBZM) (NN SPECT)) (S (VP (TO to) (VP (VB determine) (NP (JJ D2) (NN occupancy)) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ routine) (JJ clinical) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_9351491_703_714_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 12)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_9351491_727_738_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-)))))))))))))) (. .)))
9351491	4	(S1 (S (NP (DT Both) (NNP Doc_9351491_753_764_Chemical) (CC and) (NNP Doc_9351491_769_780_Chemical)) (VP (VBD produced) (NP (NP (NNP D2) (NN occupancy) (NNS levels)) (PP (IN between) (NP (QP (RB approximately) (CD 60) (CC and) (CD 90)) (NN %)))) (PP (IN at) (NP (JJ standard) (JJ clinical) (NNS doses)))) (. .)))
9351491	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (NN occupancy) (NNS levels)) (VP (VBN obtained) (PP (IN with) (NP (NP (NNP Doc_9351491_946_957_Chemical)) (CC or) (NP (NNP Doc_9351491_961_972_Chemical))))))))) (. .)))
9351491	6	(S1 (S (NP (NN Doc_9351491_974_999_Disease)) (VP (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_9351491_1038_1049_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 42) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9351491_1060_1071_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 29) (NN %)) (-RRB- -RRB-)))))))))) (CC and) (VP (AUX was) (VP (VBN observed) (PP (IN at) (NP (NP (NN occupancy) (NNS levels)) (PP (IN above) (NP (CD 60) (NN %)))))))) (. .)))
9351491	7	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS observations)))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN concluded) (SBAR (SBAR (IN that) (S (NP (JJ 5-HT2) (NN blockade)) (VP (VBD obtained) (PP (IN with) (NP (NNP Doc_9351491_1205_1216_Chemical))) (PP (IN at) (NP (NP (JJ D2) (NN occupancy) (NNS rates)) (PP (IN of) (NP (CD 60) (NN %)))))))) (CC and) (SBAR (IN above) (S (VP (AUX does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB protect) (PP (IN against) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (JJ extrapyramidal) (NN side) (NNS effects))))))))))))))) (. .)))
9390208	0	(S1 (NP (NP (NP (NP (NP (NN Treatment)) (PP (IN of) (NP (ADJP (RB previously) (VBN treated)) (NN metastatic) (NNP Doc_9390208_43_56_Disease))) (PP (IN by) (NP (NNP Doc_9390208_60_72_Chemical)))) (CC and) (NP (JJ 48-hour) (JJ continuous) (NN infusion))) (PP (IN of) (NP (NP (JJ high-dose) (NNP Doc_9390208_118_122_Chemical)) (CC and) (NP (NP (NNP Doc_9390208_127_137_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9390208_139_142_Chemical)) (-RRB- -RRB-)))))) (: :) (NP (NP (JJ low) (JJ palliative) (NN benefit)) (CC and) (NP (JJ high) (JJ treatment-related) (NN Doc_9390208_195_203_Disease))) (. .)))
9390208	1	(S1 (S (PP (IN For) (NP (ADJP (RB previously) (VBN treated)) (JJ advanced) (NN Doc_9390208_237_250_Disease))) (, ,) (NP (EX there)) (VP (AUX is) (NP (DT no) (JJ standard) (NN second-line) (NN therapy))) (. .)))
9390208	2	(S1 (S (NP (NP (NN Combination) (NNS chemotherapy)) (PP (IN with) (NP (NP (NNP Doc_9390208_324_336_Chemical)) (, ,) (NP (NP (JJ high-dose) (NNP Doc_9390208_348_362_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9390208_364_368_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9390208_374_384_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9390208_386_397_Chemical)) (-RRB- -RRB-)))))) (VP (AUX had) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (DT an) (ADJP (ADJP (JJ effective)) (CC and) (ADJP (RB well) (JJ tolerated))) (NN regimen)))))) (. .)))
9390208	3	(S1 (S (PP (PP (IN From) (NP (NNP October) (CD 1993))) (PP (TO to) (NP (NNP November) (CD 1995)))) (, ,) (NP (PRP we)) (VP (VBD treated) (NP (NP (CD 13) (NNS patients)) (PP (IN with) (NP (NP (NP (ADJP (RB previously) (JJ chemotherapy-treated)) (JJ metastatic) (NN Doc_9390208_568_581_Disease)) (PP (IN by) (NP (NP (NNP Doc_9390208_585_597_Chemical)) (, ,) (NP (CD 12) (NN mg/m2)) (, ,))) (PP (IN on) (NP (NN day) (CD 1)))) (CC and) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_9390208_645_649_Chemical)) (, ,) (NP (CD 3000) (NN mg/m2)) (, ,))))))) (ADVP (RB together)) (PP (IN with) (NP (NP (NNP Doc_9390208_677_687_Chemical)) (, ,) (NP (CD 300) (NN mg/m2)) (, ,))) (PP (IN for) (NP (CD 48))) (NP (NNP h)) (PP (PP (IN from) (NP (NN day) (CD 1))) (PP (TO to) (NP (CD 2))))) (. .)))
9390208	4	(S1 (S (NP (NP (DT Each) (NN course)) (PP (IN of) (NP (NN chemotherapy)))) (VP (AUX was) (VP (VBN given) (NP (DT every) (CD 4) (NNS weeks)))) (. .)))
9390208	5	(S1 (S (NP (NP (JJS Most)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (AUX had) (NP (NP (JJR more)) (PP (IN than) (NP (CD two) (JJ metastatic) (NNS sites)))) (, ,) (PP (IN with) (NP (NN lung) (NN metastasis) (NN predominant)))) (. .)))
9390208	6	(S1 (S (NP (CD Seven) (NNS patients)) (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9390208_909_922_Chemical)))))) (. .)))
9390208	7	(S1 (S (S (NP (CD Seven) (NNS patients)) (VP (AUX had) (ADVP (RB previously)) (VP (VBN received) (NP (NN radiotherapy))))) (CC and) (S (NP (CD seven)) (VP (AUX had) (VP (VBN received) (NP (NN hormone) (NN therapy))))) (. .)))
9390208	8	(S1 (S (S (NP (NP (JJ Median) (NN number)) (PP (IN of) (NP (NP (NNS courses)) (PP (IN of) (NP (NNP Doc_9390208_1044_1055_Chemical))))) (VP (VBN given))) (VP (AUX was) (NP (CD six)))) (CC and) (S (NP (NP (DT the) (JJ median) (JJ cumulative) (NN dose)) (PP (IN of) (NP (NNP Doc_9390208_1104_1116_Chemical)))) (VP (AUX was) (NP (CD 68.35) (NN mg/m2)))) (. .)))
9390208	9	(S1 (S (S (NP (CD One) (NN patient)) (VP (AUX had) (NP (JJ complete) (NN response)))) (, ,) (S (NP (CD seven)) (VP (AUX had) (NP (NN stable) (NN disease)))) (, ,) (S (NP (NN none)) (VP (AUX had) (NP (JJ partial) (NN response)))) (CC and) (S (NP (CD five)) (VP (AUX had) (NP (JJ progressive) (NN disease)))) (. .)))
9390208	10	(S1 (S (NP (DT The) (JJ overall) (JJ objective) (NN response) (NN rate)) (VP (AUX was) (NP (CD 7.6) (NN %))) (. .)))
9390208	11	(S1 (S (NP (DT The) (JJ median) (NN follow-up) (NN period)) (VP (AUX was) (NP (CD 14) (NNS months))) (. .)))
9390208	12	(S1 (S (NP (JJ Median) (NN survival)) (VP (AUX was) (NP (CD 16) (NNS months))) (. .)))
9390208	13	(S1 (S (NP (JJ Median) (NN progression-free) (NN survival)) (VP (AUX was) (NP (CD 5) (NNS months))) (. .)))
9390208	14	(S1 (S (NP (DT A) (JJ complete) (NN responder)) (VP (AUX had) (NP (JJ relapse-free) (NN survival)) (PP (IN up) (PP (TO to) (NP (CD 17) (NNS months))))) (. .)))
9390208	15	(S1 (S (NP (JJ Major) (NN Doc_9390208_1492_1502_Disease)) (VP (AUX were) (NP (NP (NNP Doc_9390208_1508_1522_Disease)) (CC and) (NP (NNP Doc_9390208_1527_1537_Disease)))) (. .)))
9390208	16	(S1 (S (S (NP (CD Eight) (NNS patients)) (VP (AUX were) (ADJP (JJ dead)) (PP (IN in) (NP (DT the) (JJ last) (NN follow-up))))) (: ;) (S (NP (NP (CD two)) (PP (IN of) (NP (PRP them)))) (VP (VBD died) (PP (IN of) (NP (JJ treatment-related) (NNP Doc_9390208_1625_1633_Disease))))) (. .)))
9390208	17	(S1 (S (NP (DT The) (NNP Doc_9390208_1639_1650_Chemical)) (VP (VP (VBZ achieves) (NP (JJ little) (JJ palliative) (NN benefit))) (CC and) (VP (VBZ induces) (NP (JJ severe) (NN Doc_9390208_1705_1713_Disease)) (PP (IN at) (NP (DT a) (ADJP (RB fairly) (JJ high)) (NN rate))))) (. .)))
9390208	18	(S1 (S (NP (NP (NP (NN Administration)) (PP (IN of) (NP (NP (DT this) (NN regimen)) (PP (TO to) (NP (NP (JJ Doc_9390208_1771_1784_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (IN by) (NP (NN chemotherapy))))))))))))) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_9390208_1847_1870_Disease))))) (VP (VBZ requires) (NP (JJ careful) (NN attention))) (. .)))
9401499	0	(S1 (NP (NP (JJ Doc_9401499_0_11_Chemical-induced) (NN Doc_9401499_20_35_Disease)) (: :) (NP (NP (NP (NN report)) (PP (IN of) (NP (CD three) (JJ Chinese) (NNS patients)))) (CC and) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature))))) (. .)))
9401499	1	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (S (NP (NP (CD three) (JJ Chinese) (NNS patients)) (PP (IN with) (NP (NNP Doc_9401499_143_154_Chemical-induced) (NNP Doc_9401499_163_178_Disease)))) (VP (AUX were) (VP (VBN reported)))) (CC and) (S (NP (NP (DT another) (CD 13) (NNS patients)) (PP (IN in) (NP (DT the) (JJ English) (NN literature)))) (VP (AUX were) (VP (VBN reviewed)))) (. .)))
9401499	2	(S1 (S (NP (PRP We)) (VP (VBD attempted) (S (VP (TO to) (VP (VP (VB find) (NP (VBG underlying) (NNS similarities))) (, ,) (VP (VB evaluate) (NP (DT the) (NN risk) (NNS factors))) (, ,) (CC and) (VP (VB identify) (NP (NP (JJ appropriate) (NN treatment)) (PP (IN for) (NP (DT this) (NN complication))))))))) (. .)))
9401499	3	(S1 (S (S (NP (NP (DT All)) (CC but) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (NNS patients))))) (VP (AUX were) (ADVP (RB over)) (ADJP (NP (CD 60) (NNS years)) (JJ old)))) (, ,) (CC and) (S (NP (NP (DT the) (CD 6)) (SBAR (WHNP (WP who)) (S (VP (VBD died))))) (VP (AUX were) (ADJP (ADJP (NP (DT all)) (JJR older)) (PP (IN than) (NP (CD 65)))))) (. .)))
9401499	4	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (JJ old) (NN age)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (NN risk) (NN factor)) (PP (IN for) (S (VP (VBG developing) (NP (DT this) (NN complication)))))))) (. .)))
9401499	5	(S1 (S (NP (NN Doc_9401499_558_573_Disease)) (VP (VBD occurred) (SBAR (NP (CD 3-20) (NNS weeks)) (IN after) (S (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NNP Doc_9401499_614_625_Chemical)) (, ,) (NP (NP (ADJP (RB so) (JJ frequent)) (NN examination)) (PP (IN of) (NP (JJ white) (NN cell) (NN count)))))) (PP (IN during) (NP (NN treatment)))) (VP (AUX is) (VP (VBN recommended)))))) (. .)))
9401499	6	(S1 (S (NP (EX There)) (VP (VBD seemed) (S (VP (TO to) (VP (AUX be) (NP (NP (DT no) (JJ direct) (NN correlation)) (PP (IN between) (NP (NP (NP (DT the) (NN dose) (CC or) (NN duration)) (VP (VBN used))) (CC and) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NN Doc_9401499_799_822_Disease))))))))))) (. .)))
9401499	7	(S1 (S (NP (NP (NN Treatment)) (PP (IN for) (NP (NP (JJ Doc_9401499_838_849_Chemical-induced) (NN Doc_9401499_858_873_Disease)) (PP (IN with) (NP (JJ colony-stimulating) (NNS factors)))))) (VP (VBD seemed) (S (VP (TO to) (VP (AUX have) (NP (JJ little) (NN effect)))))) (. .)))
9401499	8	(S1 (S (NP (DT The) (NN fact) (SBAR (IN that) (S (NP (NP (CD 5)) (PP (IN of) (NP (NP (DT the) (CD 6) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ concurrent) (JJ Doc_9401499_994_1001_Chemical) (NN channel) (NNS blockers)))))))) (VP (VBD died))))) (, ,) (VP (MD should) (VP (VB alert) (NP (NP (NNS clinicians)) (SBAR (S (VP (TO to) (VP (AUX be) (ADJP (RBR more) (JJ cautious)) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (DT these) (CD two) (NNS drugs)))))))))) (ADVP (RB simultaneously)))) (. .)))
9406968	0	(S1 (NP (NP (NN Upregulation)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ Doc_9406968_34_45_Chemical) (NN gene))))) (PP (IN in) (NP (NP (DT the) (ADJP (JJ paraventricular) (CC and) (JJ supraoptic)) (NN nuclei)) (PP (IN of) (NP (DT the) (JJ Doc_9406968_103_110_Chemical-induced) (JJ Doc_9406968_119_137_Disease) (NN rat))))) (. .)))
9406968	1	(S1 (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NNP Doc_9406968_161_181_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9406968_183_186_Chemical)) (-RRB- -RRB-)) (NN gene))) (PP (IN in) (NP (NP (NP (DT the) (NN paraventricular)) (PRN (-LRB- -LRB-) (NP (NNP PVN)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ supraoptic) (NNS nuclei)) (PRN (-LRB- -LRB-) (NP (NN SON)) (-RRB- -RRB-)))))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NNS rats))) (PP (IN with) (NP (NP (NNP Doc_9406968_280_287_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9406968_289_291_Chemical)) (-RRB- -RRB-)))) (NP (JJ -induced) (NNP Doc_9406968_301_309_Disease)) (, ,) (S (VP (VBG using) (PP (IN in) (NP (NP (JJ situ) (NN hybridization) (NN histochemistry)) (CC and) (NP (NN radioimmunoassay)))))))) (. .)))
9406968	2	(S1 (S (NP (NP (DT The) (JJ male) (NNP Wistar) (NNS rats) (NN consuming)) (NP (DT a) (NN diet)) (SBAR (WHNP (WDT that)) (S (VP (VBD contained) (NP (NP (NNP Doc_9406968_429_433_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 60) (NN mmol/kg)) (-RRB- -RRB-))) (PP (IN for) (NP (CD 4) (NNS weeks))))))) (VP (VBD developed) (NP (JJ marked) (NN Doc_9406968_476_484_Disease))) (. .)))
9406968	3	(S1 (S (NP (DT The) (JJ Doc_9406968_490_492_Chemical-treated) (NNS rats)) (VP (VBD produced) (NP (NP (DT a) (JJ large) (NN volume)) (PP (IN of) (NP (JJ hypotonic) (NN urine))) (PP (IN with) (NP (JJ low) (JJ ionic) (NNS concentrations))))) (. .)))
9406968	4	(S1 (S (NP (NN Plasma) (NN Doc_9406968_587_593_Chemical) (NNS concentrations)) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADVP (RB slightly)) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ Doc_9406968_652_654_Chemical-treated) (NNS rats))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN in) (NP (NNS controls)))))))))))) (. .)))
9406968	5	(S1 (S (NP (NP (NP (NN Plasma) (NN concentration)) (PP (IN of) (NP (NNP Doc_9406968_725_728_Chemical)))) (CC and) (NP (NP (NNS transcripts)) (PP (IN of) (NP (JJ Doc_9406968_748_751_Chemical) (NN gene))) (PP (IN in) (NP (DT the) (NNP PVN) (CC and) (NNP SON))))) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (DT the) (JJ Doc_9406968_812_814_Chemical-treated) (NNS rats))) (PP (VBN compared) (PP (IN with) (NP (NNS controls)))))) (. .)))
9406968	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_9406968_879_890_Disease)) (VP (VBP and/or) (SBAR (S (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ visceral) (NN afferent) (NNS inputs)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (NP (NN plasma) (NN Doc_9406968_983_986_Chemical)) (CC and) (NP (NP (DT the) (NN upregulation)) (PP (IN of) (NP (NP (JJ Doc_9406968_1011_1014_Chemical) (NN gene) (NN expression)) (PP (IN in) (NP (DT the) (NNP PVN))))))))) (CC and) (NP (NP (DT the) (NN SON)) (PP (IN of) (NP (DT the) (JJ Doc_9406968_1061_1063_Chemical-induced) (NNP Doc_9406968_1072_1090_Disease) (NN rat)))))))))))))) (. .)))
9495837	0	(S1 (NP (NP (NP (NN Antinociceptive)) (CC and) (NP (JJ antiamnesic) (NNS properties))) (PP (IN of) (NP (DT the) (JJ presynaptic) (JJ cholinergic) (NN amplifier) (NNP Doc_9495837_84_88_Chemical))) (. .)))
9495837	1	(S1 (S (NP (NP (DT The) (JJ antinociceptive) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_9495837_120_162_Chemical) (JJ -LSB-) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (JJ -Doc_9495837_170_174_Chemical) (NNS -RSB-)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-40) (CD mg)) (JJ kg-1) (NNP s.c.)) (: ;) (NP (NP (QP (CD 30-60) (CD mg)) (JJ kg-1) (NNS p.o.)) (: ;) (NP (QP (CD 10-30) (CD mg)) (JJ kg-1) (NNS i.v.)) (: ;) (NP (CD 10-30) (JJ micrograms/mouse) (NNS i.c.v.))) (-RRB- -RRB-))))) (VP (AUX was) (VP (VP (VBN examined) (PP (IN in) (NP (NP (NP (NNS mice) (, ,) (NNS rats) (CC and) (NN guinea) (NNS pigs)) (PP (IN by) (NP (NN use))) (PP (IN of) (NP (DT the) (JJ hot-plate) (, ,) (JJ abdominal-constriction) (, ,) (JJ tail-flick) (CC and) (JJ paw-pressure) (NNS tests))) (. .)) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NP (JJ -Doc_9495837_401_405_Chemical) (NN antinociception)) (VP (VBD peaked) (NP (CD 15) (NN min)) (PP (IN after) (NP (NN injection))))))) (CC and) (ADVP (RB then)) (VP (ADVP (RB slowly)) (VBN diminished)))) (. .)))
9495837	2	(S1 (S (NP (NP (DT The) (NN antinociception)) (VP (VBN produced) (PP (IN by) (NP (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NN -Doc_9495837_518_522_Chemical))))) (VP (AUX was) (UCP (VP (VBN prevented) (PP (IN by) (NP (NP (DT the) (JJ unselective) (JJ muscarinic) (NN antagonist) (NNP Doc_9495837_578_586_Chemical)) (, ,) (NP (DT the) (JJ M1-selective) (NNS antagonists) (NNP Doc_9495837_617_628_Chemical) (CC and) (NNP Doc_9495837_633_644_Chemical)) (CC and) (NP (DT the) (JJ Doc_9495837_653_666_Chemical) (NN depletor) (NNP Doc_9495837_676_691_Chemical))))) (, ,) (CC but) (PP (RB not) (IN by) (NP (NP (DT the) (JJ opioid) (NN antagonist) (NNP Doc_9495837_726_734_Chemical)) (, ,) (NP (DT the) (NNP Doc_9495837_740_764_Chemical) (NN antagonist) (NNP Doc_9495837_776_821_Chemical)) (, ,) (NP (DT the) (NNP H3) (NN agonist) (NNP Doc_9495837_838_863_Chemical)) (, ,) (NP (DT the) (NNP D2) (NN antagonist) (NNP Doc_9495837_883_893_Chemical)) (, ,) (NP (DT the) (JJ Doc_9495837_899_919_Chemical) (JJ antagonist) (NNP Doc_9495837_931_997_Chemical) (NN hydrochloride)) (, ,) (NP (DT the) (JJ Doc_9495837_1017_1037_Chemical) (JJ antagonist) (NNP Doc_9495837_1049_1105_Chemical) (NN hydrobromide)) (CC and) (NP (DT the) (NNS polyamines) (NN depletor) (NNP Doc_9495837_1147_1156_Chemical)))))) (. .)))
9495837	3	(S1 (S (NP (NP (S (PP (VBN Based) (PP (IN on) (NP (DT these) (NNS data)))) (, ,) (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN postulated) (PP (IN that) (NP (NP (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-) (NN -Doc_9495837_1211_1215_Chemical)) (VP (VBN exerted) (NP (NP (DT an) (JJ antinociceptive) (NN effect)) (VP (VBD mediated) (PP (IN by) (NP (NP (DT a) (JJ central) (NN potentiation)) (PP (IN of) (NP (JJ cholinergic) (NN transmission))))))))))))) (. .)) (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (JJ -Doc_9495837_1320_1324_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10-40) (CD mg)) (JJ kg-1) (NNS i.p.)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (JJ able) (S (VP (TO to) (VP (VB prevent) (S (VP (NNP Doc_9495837_1366_1373_Disease) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NNP Doc_9495837_1385_1396_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg)) (JJ kg-1) (NNS i.p.)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9495837_1418_1429_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg)) (JJ kg-1) (NNS i.p.)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN mouse) (NN passive-avoidance) (NN test))))))))))) (. .)))
9495837	4	(S1 (S (NP (NP (JJ Affinity) (NNS profiles)) (PP (IN of) (NP (NP (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-) (NN -Doc_9495837_1511_1515_Chemical)) (PP (IN for) (NP (JJ muscarinic) (NN receptor) (NNS subtypes))))) (, ,) (VP (VBN determined) (PP (IN by) (NP (NP (JJ functional) (NNS studies)) (PRN (-LRB- -LRB-) (NP (NP (NN rabbit) (NN vas) (NNS deferens)) (PP (IN for) (NP (NP (NNP M1)) (, ,) (NP (NP (NN guinea) (NN pig) (NN atrium)) (PP (IN for) (NP (NNP M2))))))) (, ,) (NP (NP (NN guinea) (NN pig) (NN ileum)) (PP (IN for) (NP (NP (NNP M3)) (CC and) (NP (NP (JJ immature) (NN guinea) (NN pig) (NN uterus)) (PP (IN for) (NP (JJ putative) (NNP M4))))))) (-RRB- -RRB-))))) (, ,)) (VP (AUX have) (VP (VBN shown) (NP (NP (DT an) (NNP M4/M1) (NN selectivity) (NN ratio)) (PP (IN of) (NP (CD 10.2))) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN antinociception)) (CC and) (NP (NP (DT the) (JJ anti-Doc_9495837_1820_1827_Disease) (NN effect)) (VP (VBN induced) (PP (IN by) (NP (PRN (-LRB- -LRB-) (JJ +/-) (-RRB- -RRB-)) (NN -Doc_9495837_1852_1856_Chemical))) (PP (IN through) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ Doc_9495837_1880_1893_Chemical) (JJ extracellular) (NNS levels))))))))))))))))) (. .)))
9495837	5	(S1 (S (PP (IN In) (NP (DT the) (ADJP (JJ antinociceptive) (CC and) (JJ antiamnesic)) (NN dose) (NN range))) (, ,) (NP (-LRB- -LRB-) (NN +/-) (-RRB- -RRB-) (NN -Doc_9495837_1973_1977_Chemical)) (VP (AUX did) (RB not) (VP (VB impair) (NP (NP (NN mouse) (NN performance)) (VP (VBN evaluated) (PP (IN by) (NP (NP (DT the) (JJ rota-rod) (NN test)) (CC and) (NP (NNP Animex) (NN apparatus)))))))) (. .)))
9522143	0	(S1 (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ different) (JJ anaesthetic) (NNS agents))) (PP (IN in) (NP (NP (NNP Doc_9522143_46_58_Disease)) (VP (VBG following) (NP (JJ spinal) (NN anaesthesia))))) (. .)))
9522143	1	(S1 (S (NP (NP (DT The) (NN cause)) (PP (IN of) (NP (NNP Doc_9522143_102_114_Disease))) (PP (IN after) (NP (JJ spinal) (NNS anaesthesia)))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
9522143	2	(S1 (S (PP (IN Up) (PP (IN until) (NP (RB now)))) (, ,) (NP (NP (DT the) (JJ only) (NN factor)) (VP (VBN studied))) (VP (AUX has) (VP (AUX been) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT the) (NN diameter)) (PP (IN of) (NP (DT the) (JJ spinal) (NN needle))))) (PP (IN on) (NP (JJ post-operative) (NN Doc_9522143_265_291_Disease)))))) (. .)))
9522143	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (VP (TO to) (VP (VB describe) (NP (DT this) (NN Doc_9522143_336_348_Disease)))) (CC and) (VP (TO to) (VP (VB investigate) (NP (NP (JJ other) (NNS factors)) (VP (VBG influencing) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN Doc_9522143_408_420_Disease))))))))))) (. .)))
9522143	4	(S1 (S (S (NP (NP (CD Two) (NNS groups)) (PP (IN of) (NP (CD 22) (JJ similar) (NNS patients)))) (VP (AUX were) (VP (VBN studied)))) (: :) (S (NP (CD one) (NN group)) (VP (VBD received) (NP (NP (CD 6) (JJ mL) (NNP Doc_9522143_494_504_Chemical) (CD 2) (NN %)) (: ;) (CC and) (NP (DT the) (JJ other) (VBN received) (ADJP (CD 3) (NN mL)) (JJ Doc_9522143_537_548_Chemical) (CD 0.5) (NN %))))) (. .)))
9522143	5	(S1 (S (NP (NP (NNS Patients)) (VP (VBN given) (NP (NNP Doc_9522143_570_580_Chemical)))) (VP (AUX were) (ADJP (ADJP (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (VB develop) (NP (NNP Doc_9522143_609_621_Disease)))))) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (IN out) (IN of) (CD 22))) (-RRB- -RRB-))) (PP (IN than) (NP (NP (DT those)) (VP (VBN given) (NP (NNP Doc_9522143_654_665_Chemical))) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (IN out) (IN of) (CD 22))) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.05))) (-RRB- -RRB-)))))) (. .)))
9522143	6	(S1 (S (NP (NP (DT The) (JJ average) (NN Doc_9522143_704_716_Disease)) (PP (IN for) (NP (NN speech) (NNS frequencies)))) (VP (AUX was) (NP (QP (RB about) (CD 10)) (NN dB)) (PP (IN after) (NP (NP (NNP Doc_9522143_762_772_Chemical)) (CC and) (NP (NP (CD 15)) (VP (VBN dB) (PP (IN after) (NP (NNP Doc_9522143_789_800_Chemical)))))))) (. .)))
9522143	7	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD complained) (PP (IN of) (NP (JJ subjective) (NNP Doc_9522143_848_860_Disease)))) (. .)))
9522143	8	(S1 (S (NP (NP (JJ Long-term) (NN follow-up)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX was) (RB not) (ADJP (JJ possible))) (. .)))
9522152	0	(S1 (S (NP (NP (DT A) (JJ transient) (JJ Doc_9522152_12_32_Disease) (JJ following) (NN intrathecal) (NN injection)) (PP (IN of) (NP (CD 1) (NN %)))) (VP (VBP hyperbaric) (NP (NNP Doc_9522152_82_93_Chemical)) (PP (IN for) (NP (JJ unilateral) (NN spinal) (NN anaesthesia)))) (. .)))
9522152	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ transient) (NNP Doc_9522152_161_181_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD occurred) (PP (IN after) (NP (NP (JJ unilateral) (JJ spinal) (NNS anaesthesia)) (PP (IN with) (NP (NP (CD 8) (NN mg)) (PP (IN of) (NP (NP (ADJP (CD 1) (NN %)) (JJ hyperbaric) (NN Doc_9522152_259_270_Chemical)) (VP (ADVP (RB slowly)) (VBN injected) (PP (IN through) (NP (DT a) (JJ 25-gauge) (JJ pencil-point) (NN spinal) (NN needle))))))))))))))) (. .)))
9522152	2	(S1 (S (S (NP (DT The) (NN surgery) (CC and) (NNS anaesthesia)) (VP (VP (AUX were) (ADJP (JJ uneventful))) (, ,) (CC but) (VP (NP (CD 3) (NNS days)) (PP (IN after) (NP (NN surgery)))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD reported) (NP (NP (DT an) (NN area)) (PP (IN of) (NP (NN hypoaesthesia)))) (PP (IN over) (NP (NP (JJ L3-L4) (NNS dermatomes)) (PP (IN of) (NP (NP (DT the) (NN leg)) (SBAR (WHNP (WDT which)) (S (VP (AUX had) (VP (AUX been) (VP (VBN operated) (PRT (RP on)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9522152_512_538_Disease)) (-RRB- -RRB-)) (PP (IN without) (NP (NP (NN reduction)) (PP (IN in) (NP (JJ muscular) (NN strength))))))))))))))) (. .)))
9522152	3	(S1 (S (NP (NP (NN Sensation)) (PP (IN in) (NP (DT this) (NN area)))) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN over) (NP (DT the) (JJ following) (CD 2) (NNS weeks)))) (. .)))
9522152	4	(S1 (S (NP (NP (JJ Prospective) (JJ multicentre) (NNS studies)) (PP (IN with) (NP (NP (DT a) (JJ large) (NN population)) (CC and) (NP (DT a) (JJ long) (NN follow-up))))) (VP (MD should) (VP (AUX be) (VP (VBN performed) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (DT this) (JJ unusual) (NN side) (NN effect)))))))))) (. .)))
9522152	5	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT a) (JJ low) (NN solution) (NN concentration)) (VP (MD should) (VP (AUX be) (VP (VBN preferred) (PP (IN for) (NP (NP (JJ unilateral) (JJ spinal) (NNS anaesthesia)) (PP (IN with) (NP (NP (DT a) (JJ hyperbaric) (JJ anaesthetic) (NN solution)) (PRN (-LRB- -LRB-) (SBAR (IN if) (S (NP (NP (JJ pencil-point) (NN needle)) (CC and) (NP (JJ slow) (NN injection) (NN rate))) (VP (AUX are) (VP (VBN employed))))) (-RRB- -RRB-)))))) (, ,) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB minimize) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (DT a) (VBN localized) (JJ high) (JJ peak) (JJ anaesthetic) (NN concentration)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (VB lead) (PP (TO to) (NP (DT a) (JJ transient) (NN Doc_9522152_1135_1155_Disease)))))))))))))))))))) (. .)))
9523805	0	(S1 (NP (NP (NP (NN Doc_9523805_0_29_Disease)) (PP (IN after) (NP (JJ spinal) (NNS anesthesia)))) (: :) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN with) (NP (NP (NNP Doc_9523805_78_88_Chemical)) (CC and) (NP (NNP Doc_9523805_93_104_Chemical)))) (PP (IN than) (PP (IN with) (NP (NNP Doc_9523805_115_124_Chemical))))) (. .)))
9523805	1	(S1 (S (NP (JJ Recent) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NNP Doc_9523805_168_197_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9523805_199_203_Disease)) (-RRB- -RRB-))) (ADVP (RB frequently)) (VP (VP (VBP follow) (NP (JJ Doc_9523805_223_232_Chemical) (JJ spinal) (NNS anesthesia))) (CC but) (VP (AUX are) (ADJP (JJ infrequent) (PP (IN with) (NP (NNP Doc_9523805_275_286_Chemical))))))))) (. .)))
9523805	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN identification)) (PP (IN of) (NP (NP (DT a) (JJ short-acting) (JJ local) (NN anesthetic)) (SBAR (S (VP (TO to) (VP (VB substitute) (PP (IN for) (NP (NNP Doc_9523805_365_374_Chemical))) (PP (IN for) (NP (JJ brief) (JJ surgical) (NNS procedures)))))))))) (VP (VBZ remains) (NP (DT an) (JJ important) (NN goal))) (. .)))
9523805	3	(S1 (S (NP (NN Doc_9523805_432_442_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ amide) (JJ local) (NN anesthetic)) (PP (IN with) (NP (NP (DT a) (NN duration)) (PP (IN of) (NP (NN action))) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_9523805_517_526_Chemical)))))))))) (. .)))
9523805	4	(S1 (S (ADVP (RB Accordingly)) (, ,) (NP (DT the) (JJ present) (, ,) (JJ prospective) (JJ double-blind) (NN study)) (VP (VBZ compares) (NP (NNP Doc_9523805_594_604_Chemical)) (PP (IN with) (NP (NP (NNP Doc_9523805_610_619_Chemical)) (CC and) (NP (NNP Doc_9523805_624_635_Chemical)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NP (NN duration)) (PP (IN of) (NP (NN action)))) (CC and) (NP (NP (JJ relative) (NN risk)) (PP (IN of) (NP (NNP Doc_9523805_692_696_Disease))))))))) (. .)))
9523805	5	(S1 (S (NP (NP (CD Ninety) (NNS patients)) (PP (JJ classified) (IN as) (NP (NP (NP (NNP American) (NNP Society)) (PP (IN of) (NP (NNP Anesthesiologists) (JJ physical) (NN status) (NN I)))) (CC or) (NP (NNP II)))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN scheduled) (PP (IN for) (NP (JJ short) (JJ gynecologic) (NNS procedures))) (PP (IN under) (NP (JJ spinal) (NN anesthesia)))))))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (S (VP (TO to) (VP (VB receive) (NP (NP (CD 2.5) (NNS ml)) (NP (NP (NP (NP (CD 2) (NN %)) (NP (NNP Doc_9523805_920_929_Chemical))) (PP (IN in) (NP (ADJP (CD 7.5) (NN %)) (NNP Doc_9523805_938_945_Chemical)))) (, ,) (NP (NP (NP (CD 2) (NN %)) (NP (NNP Doc_9523805_950_960_Chemical))) (PP (IN in) (NP (ADJP (CD 7.5) (NN %)) (NNP Doc_9523805_969_976_Chemical)))) (, ,) (CC or) (NP (NP (NP (CD 0.5) (NN %)) (NP (NNP Doc_9523805_986_997_Chemical))) (PP (IN in) (NP (ADJP (CD 7.5) (NN %)) (NNP Doc_9523805_1006_1013_Chemical))))))))))) (. .)))
9523805	6	(S1 (S (NP (DT All) (NNS solutions)) (VP (AUX were) (VP (VBN provided) (PP (IN in) (NP (JJ blinded) (NNS vials))) (PP (IN by) (NP (DT the) (NN hospital) (NN pharmacy))))) (. .)))
9523805	7	(S1 (S (NP (NP (NNS Details)) (PP (IN of) (NP (NP (JJ spinal) (NN puncture)) (, ,) (NP (NP (NP (NN extension)) (CC and) (NP (NN regression))) (PP (IN of) (NP (NN spinal) (NN block)))) (, ,) (CC and) (NP (NP (DT the) (NNS times)) (SBAR (S (VP (TO to) (VP (VB reach) (NP (NN discharge) (NNS criteria)))))))))) (VP (AUX were) (VP (VBN noted))) (. .)))
9523805	8	(S1 (S (PP (IN In) (NP (NP (DT the) (NN evening)) (PP (IN of) (NP (NN postoperative) (NN day) (CD 1))))) (, ,) (NP (NNS patients)) (VP (AUX were) (VP (VBN evaluated) (PP (IN for) (NP (NN Doc_9523805_1277_1281_Disease))) (PP (IN by) (NP (NP (NP (DT a) (NN physician)) (ADJP (JJ unaware) (PP (IN of) (NP (NP (DT the) (NN drug)) (VP (VBN administered)))))) (CC and) (NP (NP (DT the) (NNS details)) (PP (IN of) (NP (DT the) (JJ anesthetic) (NN procedure)))))))) (. .)))
9523805	9	(S1 (S (NP (NP (CD Nine)) (PP (IN of) (NP (NP (CD 30) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_9523805_1414_1423_Chemical)))))) (VP (VBD experienced) (NP (NP (NNP Doc_9523805_1436_1440_Disease)) (, ,) (NP (NP (CD 1)) (PP (IN of) (NP (NP (CD 30) (NNS patients)) (VP (VBG receiving) (SBAR (S (S (NP (NP (NNP Doc_9523805_1469_1479_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.03)) (-RRB- -RRB-))) (VP (AUX had) (NP (PRP them)))) (, ,) (CC and) (S (NP (NP (NN none)) (PP (IN of) (NP (NP (CD 30) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_9523805_1535_1546_Chemical)))))) (VP (AUX had) (NP (NN Doc_9523805_1551_1555_Disease)))))))))))) (. .)))
9523805	10	(S1 (S (NP (NP (NNS Times)) (VP (VP (TO to) (VP (VB ambulate))) (CC and) (VP (TO to) (VP (VB void))))) (VP (VP (AUX were) (ADJP (JJ similar)) (PP (IN after) (NP (NP (NNP Doc_9523805_1606_1615_Chemical)) (CC and) (NP (NP (NNP Doc_9523805_1620_1630_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 150) (CC vs.) (CD 165) (NN min) (CC and) (CD 238) (CC vs.) (CD 253)) (NN min)) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))))) (CC but) (VP (VBN prolonged) (PP (IN after) (NP (NP (NNP Doc_9523805_1703_1714_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 200) (CC and) (CD 299)) (NN min)) (, ,) (ADVP (RB respectively))) (: ;) (NP (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))) (. .)))
9523805	11	(S1 (S (NP (NN Doc_9523805_1771_1781_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ preferable) (TO to) (JJ Doc_9523805_1803_1812_Chemical)) (PP (IN for) (NP (JJ short) (JJ surgical) (NNS procedures))) (SBAR (IN because) (S (NP (PRP it)) (VP (AUX has) (NP (NP (NP (DT a) (JJ similar) (NN duration)) (PP (IN of) (NP (NN action)))) (CC but) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN of) (NP (NNP Doc_9523805_1912_1916_Disease)))))))))) (. .)))
9587734	0	(S1 (S (NP (JJ Doc_9587734_0_13_Chemical-induced) (NNP Doc_9587734_22_36_Disease) (CC and) (NNP Doc_9587734_41_46_Disease)) (VP (VBG following) (NP (NP (CD 5) (NNS days)) (PP (IN of) (NP (NN immobilization))))) (. .)))
9587734	1	(S1 (S (NP (DT The) (JJ present) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_9587734_122_136_Disease)) (CC and) (NP (JJ subsequent) (NNP Doc_9587734_152_157_Disease))))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NNP Doc_9587734_173_186_Disease))) (PP (VBG following) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_9587734_208_221_Chemical))) (PP (IN in) (NP (DT a) (JJ 23-year-old) (JJ Malawian) (NN woman)))))))) (. .)))
9587734	2	(S1 (S (PP (NP (CD Five) (NNS days)) (IN after) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_9587734_300_310_Disease))))))) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD aspirated) (NP (NN stomach) (NNS contents))) (CC and) (VP (VBD needed) (NP (JJ endotracheal) (NN intubation)))) (. .)))
9587734	3	(S1 (S (NP (NP (CD Forty) (NNS seconds)) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NP (NNP Doc_9587734_420_433_Chemical)) (, ,) (NP (NNP Doc_9587734_435_446_Disease)) (CC and) (NP (NNP Doc_9587734_451_465_Disease))))))) (VP (VBD occurred)) (. .)))
9587734	4	(S1 (S (NP (NP (NNS Attempts)) (SBAR (S (VP (TO to) (VP (VB resuscitate) (NP (DT the) (NN patient))))))) (VP (AUX were) (RB not) (ADJP (JJ successful))) (. .)))
9587734	5	(S1 (S (NP (NP (DT The) (NN serum) (NN level)) (PP (IN of) (NP (NNP Doc_9587734_552_561_Chemical)))) (VP (AUX was) (VP (VBN observed) (S (VP (TO to) (VP (AUX be) (ADJP (CD 8.4) (NN mequiv) (JJ L-1))))))) (. .)))
9587734	6	(S1 (S (ADVP (RB Apart) (PP (IN from) (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NP (NP (DT the) (NN patient) (POS 's)) (NN level)) (PP (IN of) (NP (NN consciousness)))))))) (, ,) (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (NNS signs)) (PP (PP (IN of) (NP (NN motor) (NN neurone) (NN damage))) (CC or) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (JJ other) (JJ known) (NN predisposing) (NNS conditions)) (PP (IN for) (NP (NNP Doc_9587734_764_777_Disease))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_9587734_810_823_Chemical)))))))))))) (. .)))
9587734	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN postulated) (SBAR (IN that) (S (NP (PRP$ her) (NN Doc_9587734_851_856_Disease)) (VP (AUX was) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_9587734_871_887_Disease))) (PP (TO to) (NP (NP (NNP Doc_9587734_891_904_Chemical)) (, ,) (VP (VBN associated) (PP (IN with) (NP (PRP$ her) (JJ 5-day) (NN immobilization)))))))))))) (. .)))
9625142	0	(S1 (S (NP (NP (JJ Acute) (NNP Doc_9625142_6_15_Disease)) (, ,) (NP (NNP Doc_9625142_17_44_Disease)) (, ,) (CC and) (NP (NNP Doc_9625142_50_72_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_9625142_84_95_Chemical)))) (. .)))
9625142	1	(S1 (S (NP (DT An) (JJ 80-yr-old) (NN man)) (VP (VBD developed) (NP (JJ acute) (NN Doc_9625142_130_139_Disease)) (PP (ADVP (RB shortly)) (IN after) (S (VP (VBG ingesting) (NP (JJ oral) (NNP Doc_9625142_169_180_Chemical)))))) (. .)))
9625142	2	(S1 (S (SBAR (IN Although) (S (NP (DT the) (NNS transaminases)) (ADVP (RB gradually)) (VP (VBD returned) (PP (TO to) (NP (NN baseline))) (PP (IN after) (S (VP (VBG withholding) (NP (DT the) (JJ Doc_9625142_262_273_Chemical) (JJ antibiotic)))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (NP (DT a) (JJ gradual) (NN increase)) (PP (IN in) (NP (JJ serum) (NNP Doc_9625142_324_333_Chemical)))) (CC and) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN hemoglobin) (NN concentration)) (VP (VBN caused) (PP (IN by) (NP (DT an) (NNP Doc_9625142_390_417_Disease) (CC and) (NNP Doc_9625142_422_444_Disease))))))))) (. .)))
9625142	3	(S1 (S (NP (DT These)) (VP (VBD responded) (PP (TO to) (NP (NP (JJ systemic) (NN Doc_9625142_474_482_Chemical)) (CC and) (NP (NNS immunoglobulins))))) (. .)))
9625142	4	(S1 (S (PP (IN Despite) (NP (NP (DT the) (JJ widespread) (NN use)) (PP (IN of) (NP (DT these) (NNS agents))))) (NP (NP (DT this) (NNP triad)) (PP (IN of) (NP (NN side) (NNS effects)))) (VP (AUX has) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NN connection)) (PP (IN with) (NP (JJ Doc_9625142_626_637_Chemical) (NNS antibiotics)))))))) (. .)))
9653867	0	(S1 (NP (NP (JJ Doc_9653867_0_9_Chemical) (NN abuse)) (: :) (NP (NP (DT an) (JJ unusual) (NN case)) (PP (IN of) (NP (NNP Doc_9653867_36_50_Disease))) (PP (IN in) (NP (NN pregnancy)))) (. .)))
9653867	1	(S1 (S (NP (NP (NP (NN Doc_9653867_65_81_Disease)) (CC and) (NP (DT the) (JJ associated) (NN behavioural) (NNS problems))) (CC and) (NP (NNP Doc_9653867_126_136_Disease))) (VP (AUX are) (ADJP (JJ uncommon)) (PP (IN in) (NP (NN pregnancy)))) (. .)))
9653867	2	(S1 (FRAG (SBAR (SBAR (WHADVP (WRB When)) (S (NP (PRP they)) (VP (AUX do) (VP (VB occur) (SBAR (S (NP (PRP they)) (VP (AUX are) (ADVP (RB often)) (ADJP (JJ unrecognized)) (PP (IN because) (IN of) (NP (NN denial)))))))))) (CC but) (SBAR (WHADVP (WRB when)) (S (NP (JJ significant)) (VP (MD may) (VP (VB pose) (NP (DT a) (NN risk)) (PP (TO to) (NP (NP (PDT both) (DT the) (NN mother)) (CC and) (NP (PRP her) (NN fetus))))))))) (. .)))
9653867	3	(S1 (S (NP (DT This) (NN case)) (VP (VBZ illustrates) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS problems))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (VP (VBN encountered) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NP (NNP Doc_9653867_381_397_Disease)) (PP (IN in) (NP (NN pregnancy))))) (, ,) (PP (VBG including) (NP (NP (ADJP (JJ prolonged) (CC and) (JJ recurrent)) (JJ metabolic) (NNS disturbances)) (CC and) (NP (JJ diuretic) (NN abuse))))))))))))) (. .)))
9653867	4	(S1 (S (PP (IN In) (NP (NN particular))) (NP (PRP it)) (VP (VP (VBZ illustrates) (NP (NP (DT the) (NNS derangements)) (PP (IN of) (NP (NP (JJ thyroid) (NN function)) (VP (VBN seen) (PP (IN in) (NP (NP (JJ pregnant) (NNS women)) (PP (IN with) (NP (NNP Doc_9653867_583_599_Disease)))))))))) (CC and) (VP (VBZ reminds) (NP (PRP us)) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (NP (NP (DT a) (NN cause)) (PP (IN for) (NP (NNP Doc_9653867_637_651_Disease)))) (VP (VBZ remains) (ADJP (JJ obscure))))) (, ,) (NP (JJ Doc_9653867_669_678_Chemical) (NN abuse)) (VP (MD should) (VP (AUX be) (VP (VP (VBN considered)) (CC and) (VP (VBN explored))))))))) (. .)))
9660111	0	(S1 (S (NP (JJ Repeated) (NNP Doc_9660111_9_21_Chemical)) (VP (VBZ induces) (NP (NP (JJ Doc_9660111_30_38_Chemical) (NN D2/D3)) (CC and) (NP (JJ alpha1-adrenergic) (NN up-regulation)))) (. .)))
9660111	1	(S1 (SINV (S (NP (NP (NP (NNP Doc_9660111_82_94_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9660111_96_99_Chemical)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ shows) (NP (DT a) (JJ clinical) (JJ Doc_9660111_125_139_Chemical) (NN activity))))) (, ,)) (VP (VP (AUX is) (ADVP (RB chemically)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_9660111_175_185_Chemical))))) (CC but) (VP (AUX does) (RB not) (VP (VB inhibit) (NP (NP (DT the) (NN reuptake)) (PP (IN of) (NP (NP (NNP Doc_9660111_223_236_Chemical)) (CC and) (NP (NNP Doc_9660111_241_260_Chemical))))))))) (, ,) (CC nor) (AUX does) (NP (PRP it)) (VP (VB induce) (NP (JJ beta-adrenergic) (NN down-regulation))) (. .)))
9660111	2	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (PRP$ its) (JJ Doc_9660111_335_349_Chemical) (NN activity)))) (VP (AUX is) (ADVP (RB still)) (NP (NN unknown))) (. .)))
9660111	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB find) (PRT (RP out)) (SBAR (IN whether) (S (S (NP (NNP Doc_9660111_430_433_Chemical)) (VP (VBN given) (ADVP (RB repeatedly)))) (VP (AUX was) (ADJP (JJ able) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ adaptive) (NNS changes)) (PP (IN in) (NP (DT the) (JJ dopaminergic) (CC and) (JJ alpha1-adrenergic) (NNS systems))) (, ,) (VP (VBN demonstrated) (PP (IN by) (NP (PRP us))))) (ADVP (RB previously)) (PP (IN for) (NP (JJ various) (NNP Doc_9660111_580_595_Chemical)))))))))))))) (. .)))
9660111	4	(S1 (S (NP (NNP Doc_9660111_597_600_Chemical)) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NP (JJ male) (JJ Wistar) (NNS rats)) (CC and) (NP (JJ male) (NNP Albino) (NNP Swiss) (NNS mice)))) (ADVP (RB perorally)) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 14) (NNS days))))) (. .)))
9660111	5	(S1 (S (PP (IN In) (NP (DT the) (JJ acute) (NN experiment))) (NP (NP (NNP Doc_9660111_717_720_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ given) (NN i.p.)) (-RRB- -RRB-))) (VP (VP (AUX does) (RB not) (VP (VB antagonize) (NP (NP (DT the) (NNP Doc_9660111_758_767_Chemical) (NNP Doc_9660111_768_779_Disease)) (PP (IN in) (NP (NNS mice)))))) (CC and) (VP (AUX does) (RB not) (VP (VB potentiate) (NP (NP (DT the) (JJ Doc_9660111_816_835_Chemical) (NN head) (NNS twitches)) (PP (IN in) (NP (NNS rats))))))) (. .)))
9660111	6	(S1 (S (NP (NP (NN Doc_9660111_859_862_Chemical)) (VP (VBN given) (ADVP (RB repeatedly)) (PP (TO to) (NP (NNS rats))))) (VP (VBZ increases) (NP (NP (DT the) (NN locomotor) (NN Doc_9660111_912_925_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9660111_937_950_Chemical)) (, ,) (NP (NNP Doc_9660111_952_962_Chemical)) (CC and) (NP (NP (-LRB- -LRB-) (NNP +) (-RRB- -RRB-) (NN -7-hydroxy-dipropyloaminotetralin)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9660111_1005_1013_Chemical) (NNP D2) (CC and) (NNP D3) (NNS effects)) (-RRB- -RRB-)))))))) (. .)))
9660111	7	(S1 (S (NP (NP (DT The) (NNS stereotypies)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_9660111_1062_1075_Chemical)) (CC or) (NP (NNP Doc_9660111_1079_1090_Chemical)))))) (VP (AUX are) (RB not) (VP (VBN potentiated) (PP (IN by) (NP (NNP Doc_9660111_1114_1117_Chemical))))) (. .)))
9660111	8	(S1 (S (NP (PRP It)) (VP (VBZ increases) (NP (NP (DT the) (JJ behaviour) (NN stimulation)) (VP (VBN evoked) (PP (IN by) (NP (NNP Doc_9660111_1168_1181_Chemical)))) (PRN (-LRB- -LRB-) (VP (VBN given) (ADVP (RB intraventricularly))) (-RRB- -RRB-)) (PP (IN in) (NP (NNS rats))) (, ,) (VP (VBN evaluated) (PP (IN in) (NP (NP (DT the) (JJ open) (NN field) (NN test)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NNP Doc_9660111_1266_1280_Disease)) (VP (VBN evoked) (PP (IN by) (NP (NNP Doc_9660111_1291_1300_Chemical))) (PP (IN in) (NP (NNS mice))))) (, ,) (CC both) (NP (NP (DT these) (NNS effects)) (VP (AUXG being) (VP (VBN mediated) (PP (IN by) (NP (DT an) (JJ alpha1-adrenergic) (NN receptor))))))))))) (. .)))
9660111	9	(S1 (S (NP (PRP It)) (VP (MD may) (VP (AUX be) (VP (VBN concluded) (SBAR (IN that) (S (, ,) (PP (IN like) (NP (NP (JJ other) (JJ tricyclic) (NN Doc_9660111_1425_1440_Chemical)) (VP (VBN studied) (ADVP (RB previously))))) (, ,) (S (NP (NNP Doc_9660111_1461_1464_Chemical)) (VP (VBN given) (ADVP (RB repeatedly)))) (VP (VBZ increases) (NP (NP (NP (DT the) (NN responsiveness)) (PP (IN of) (NP (NP (NN brain) (NNP Doc_9660111_1520_1528_Chemical) (NNP D2)) (CC and) (NP (NP (NNP D3)) (PRN (-LRB- -LRB-) (NP (NP (JJ locomotor) (NN activity)) (CC but) (NP (RB not) (JJ stereotypy))) (-RRB- -RRB-)))))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ alpha1-adrenergic) (NNS receptors))) (PP (TO to) (NP (PRP$ their) (NNS agonists))))))))) (. .)))
9660111	10	(S1 (S (NP (DT A) (NN question)) (VP (VBZ arises) (SBAR (IN whether) (S (NP (DT the) (JJ reuptake) (NN inhibition)) (VP (AUX is) (PP (IN of) (NP (NP (DT any) (NN importance)) (PP (TO to) (NP (NP (DT the) (JJ adaptive) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (JJ repeated) (NNP Doc_9660111_1752_1767_Chemical)))))))) (, ,) (S (VP (VBN suggested) (S (VP (TO to) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (JJ Doc_9660111_1805_1819_Chemical) (NN activity))))))))))))) (. .)))
9672936	0	(S1 (NP (NP (JJ Doc_9672936_0_9_Chemical-associated) (NNP Doc_9672936_21_28_Disease)) (PP (IN in) (NP (NP (DT a) (JJ healthy) (JJ adolescent) (NN receiving) (NN Doc_9672936_63_72_Chemical)) (PP (IN for) (NP (JJ Doc_9672936_77_95_Disease) (NN control))))) (. .)))
9672936	1	(S1 (S (NP (DT A) (JJ healthy) (JJ 17-year-old) (NN male)) (VP (VBD received) (NP (NP (JJ standard) (JJ intermittent) (NNS doses)) (PP (IN of) (NP (NNP Doc_9672936_172_181_Chemical)))) (PP (IN via) (NP (NP (DT a) (JJ patient-controlled) (NN analgesia) (PRN (-LRB- -LRB-) (NP (NNP PCA)) (-RRB- -RRB-)) (NN pump)) (PP (IN for) (NP (NP (NN management)) (PP (IN of) (NP (JJ Doc_9672936_246_264_Disease) (NN control)))))))) (. .)))
9672936	2	(S1 (S (NP (NNP Twenty-three) (NNP h)) (ADVP (RB postoperatively)) (NP (PRP he)) (VP (VBD developed) (NP (DT a) (JJ brief) (JJ self-limited) (NN Doc_9672936_339_346_Disease))) (. .)))
9672936	3	(S1 (S (NP (DT Both) (NN plasma) (NNP Doc_9672936_360_369_Chemical) (CC and) (NNP Doc_9672936_374_386_Chemical)) (VP (AUX were) (ADJP (JJ elevated)) (PP (IN in) (NP (NP (DT the) (NN range)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ clinical) (NNS manifestations)) (PP (IN of) (NP (JJ central) (JJ nervous) (NN system) (NN excitation))))))))) (. .)))
9672936	4	(S1 (S (NP (NP (DT No) (JJ other) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP CNS) (NNP Doc_9672936_522_530_Disease)))) (VP (AUX were) (VP (VBN identified))) (. .)))
9672936	5	(S1 (S (NP (DT This) (NN method)) (VP (VBD allowed) (NP (NP (JJ frequent) (NN self-dosing)) (PP (IN of) (NP (NNP Doc_9672936_592_601_Chemical))) (PP (IN at) (NP (NP (JJ short) (NN time) (NNS intervals)) (CC and) (NP (NP (JJ rapid) (NN accumulation)) (PP (IN of) (NP (NP (NNP Doc_9672936_652_661_Chemical)) (CC and) (NP (NNP Doc_9672936_666_678_Chemical))))))))) (. .)))
9672936	6	(S1 (S (NP (NP (DT The) (JJ routine) (NN use)) (PP (IN of) (NP (NNP Doc_9672936_699_708_Chemical))) (PP (IN via) (NP (NP (NNP PCA) (RB even)) (PP (IN for) (NP (DT a) (JJ brief) (NN postoperative) (NN analgesia)))))) (VP (MD should) (VP (AUX be) (VP (VBN reconsidered)))) (. .)))
9698967	0	(S1 (S (NP (NP (DT An) (JJ unusual) (JJ toxic) (NN reaction)) (PP (TO to) (NP (NN axillary)))) (VP (VBP block) (PP (IN by) (NP (NP (NNP Doc_9698967_47_58_Chemical)) (PP (IN with) (NP (NNP Doc_9698967_64_74_Chemical)))))) (. .)))
9698967	1	(S1 (S (NP (NP (DT An) (NN Doc_9698967_79_105_Disease)) (, ,) (VP (VBN accompanied) (PP (IN by) (NP (NNP Doc_9698967_122_141_Disease) (, ,) (NNP Doc_9698967_143_152_Disease) (, ,) (NNP Doc_9698967_154_177_Disease) (CC and) (NNP Doc_9698967_182_203_Disease)))) (, ,)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT an) (JJ elderly)) (, ,) (NP (NNP ASA) (NN classification) (NN group) (NNP II)) (, ,) (NP (ADJP (RB cardiovascularly) (VBN medicated)) (JJ male)) (, ,) (NP (NP (CD 12) (NN min)) (PP (IN after) (NP (NP (NN performance)) (PP (IN of) (NP (JJ axillary) (NN block))) (PP (IN with) (NP (NP (NNP Doc_9698967_343_354_Chemical) (CD 850) (NNS mg)) (VP (VBG containing) (NP (NNP Doc_9698967_373_383_Chemical) (CD 0.225)) (ADVP (RB mg)) (, ,) (PP (IN for) (NP (NP (NN correction)) (PP (IN of) (NP (NNP Doc_9698967_412_435_Disease))))))))))))))) (. .)))
9698967	2	(S1 (S (S (PP (IN After) (NP (NP (JJ intravenous) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_9698967_473_482_Chemical)) (, ,) (NP (NNP Doc_9698967_484_494_Chemical)) (CC and) (NP (NNP Doc_9698967_499_508_Chemical)))))) (NP (NP (DT the) (NN patient) (POS 's)) (NN condition)) (VP (VBD improved))) (, ,) (CC and) (S (ADVP (NP (CD 15) (NN min)) (RB later)) (NP (PRP he)) (VP (VBD woke) (PRT (RP up)))) (. .)))
9698967	3	(S1 (S (S (NP (DT The) (NN block)) (VP (AUX was) (ADJP (JJ successful)))) (CC and) (S (NP (NN surgery)) (VP (AUX was) (VP (VBN conducted) (SBAR (IN as) (S (VP (VBN scheduled) (PP (IN despite) (S (VP (VBG persisting) (NP (NN Doc_9698967_655_674_Disease))))))))))) (. .)))
9698967	4	(S1 (S (ADVP (RB Postoperatively)) (, ,) (NP (DT the) (NN patient)) (VP (VP (VBD refused) (NP (CD DC) (NN cardioversion))) (CC and) (VP (AUX was) (VP (VBN treated) (ADVP (RB medically))))) (. .)))
9698967	5	(S1 (S (NP (NP (NP (PDT Both) (DT the) (JJ temporal) (NN relationship)) (PP (IN of) (NP (NNS events)))) (CC and) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NN treatment))))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT a) (JJ rapid) (JJ systemic) (NN absorption)) (PP (IN of) (NP (NNP Doc_9698967_872_883_Chemical))) (PP (IN with) (NP (NP (JJ Doc_9698967_889_899_Chemical) (NN and/or) (NN interaction)) (PP (IN of) (NP (DT these) (NNS drugs))) (PP (IN with) (NP (NP (DT the) (NN patient) (POS 's)) (JJ cardiovascular) (NNS medications)))))) (VP (AUX were) (ADJP (JJ responsible) (PP (IN for) (NP (DT the) (JJ perioperative) (NNS complications)))))))) (. .)))
9721172	0	(S1 (NP (NP (NP (JJ Drug-associated) (JJ acute-onset) (NN Doc_9721172_28_47_Disease)) (CC and) (NP (NNP Doc_9721172_52_77_Disease))) (PP (IN in) (NP (DT a) (NN child))) (. .)))
9721172	1	(S1 (S (NP (JJ Acute) (NN Doc_9721172_96_115_Disease) (NN syndrome)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ established)) (NN cause)) (PP (IN of) (NP (NP (JJ progressive) (NNP Doc_9721172_172_183_Disease)) (PP (IN in) (NP (NNS adults)))))) (, ,) (VP (AUX is) (ADVP (RBS most) (RB often)) (ADJP (NN drug) (CC or) (NN toxin) (VBN related))) (, ,) (CC and) (VP (AUX is) (PP (IN of) (NP (JJ unknown) (NNS pathogenesis))))) (. .)))
9721172	2	(S1 (S (NP (PRP It)) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN reported) (ADVP (RB previously)) (PP (IN in) (NP (NNS children)))))) (. .)))
9721172	3	(S1 (S (NP (NN Doc_9721172_313_337_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ well-recognized) (JJ immune) (JJ complex-mediated) (NN Doc_9721172_383_399_Disease) (NN reaction)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ affects) (NP (DT all) (NN age) (NNS groups))) (, ,) (VP (AUX is) (NP (NP (NN drug) (CC or) (NN Doc_9721172_449_458_Disease)) (VP (VBN induced)))) (, ,) (CC and) (VP (AUX has) (NP (JJ classic) (ADJP (JJ systemic) (, ,) (JJ mucosal) (, ,) (CC and) (JJ dermatologic)) (NNS manifestations)))))))) (. .)))
9721172	4	(S1 (S (S (NP (NP (DT A) (ADJP (RB previously) (JJ healthy)) (NN child)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ acute) (, ,) (JJ severe) (, ,) (RB rapidly) (JJ progressive) (NNP Doc_9721172_612_640_Disease)) (PP (ADVP (RB shortly)) (IN after) (NP (NN Doc_9721172_655_679_Disease))))))) (VP (AUX is) (VP (VBN described)))) (: ;) (S (NP (DT this)) (VP (AUX was) (ADVP (RB temporally)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_9721172_730_739_Chemical) (NN use)))))) (. .)))
9721172	5	(S1 (S (PP (IN Despite) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_9721172_766_786_Chemical)) (, ,) (NP (NNP Doc_9721172_788_798_Chemical)) (, ,) (CC and) (ADVP (RB then)) (NP (NNP Doc_9721172_809_819_Chemical)))))) (, ,) (NP (PRP$ her) (NN Doc_9721172_825_844_Disease)) (VP (AUX was) (VP (VBG unrelenting) (, ,) (SBAR (IN with) (S (NP (NNP Doc_9721172_867_876_Disease)) (VP (VBN shown) (PP (IN by) (NP (NN biopsy))) (PP (NP (CD 6) (NNS months)) (IN after) (NP (NN presentation)))))))) (. .)))
9721172	6	(S1 (S (NP (DT This) (NN case)) (VP (VP (VBZ documents) (NP (NP (JJ acute) (JJ drug-related) (NN Doc_9721172_961_989_Disease)) (PP (IN in) (NP (DT the) (JJ pediatric) (NN age) (NN group))))) (CC and) (VP (VBZ suggests) (NP (NP (JJ shared) (JJ immune) (NNS mechanisms)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT both) (NNP Doc_9721172_1083_1107_Disease) (CC and) (NNP Doc_9721172_1112_1140_Disease)))))))) (. .)))
9727773	0	(S1 (S (NP (NP (JJ High) (NN incidence)) (PP (IN of) (NP (NNP Doc_9727773_18_48_Disease)))) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_9727773_65_86_Chemical)) (PP (IN in) (NP (NNP Belgium)))))) (. .)))
9727773	1	(S1 (S (NP (NN Doc_9727773_99_129_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (, ,) (JJ progressive) (CC and) (JJ incurable)) (NN disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN intake)) (PP (IN of) (NP (JJ Doc_9727773_221_241_Chemical) (NNS drugs)))))))))))) (. .)))
9727773	2	(S1 (S (NP (NP (DT The) (NN importance)) (PP (IN of) (NP (DT this) (NN association)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN in) (NP (NNP Belgium))) (SBAR (IN while) (S (NP (DT this) (NN country)) (ADVP (RB still)) (VP (AUX had) (NP (DT no) (NN restriction)) (PP (IN on) (NP (NP (DT the) (NN prescription)) (PP (IN of) (NP (NNP Doc_9727773_376_397_Chemical)))))))))) (. .)))
9727773	3	(S1 (S (NP (NP (NP (JJ Thirty-five) (NNS patients)) (PP (IN with) (NP (NNP Doc_9727773_425_455_Disease)))) (CC and) (NP (CD 85) (VBN matched) (NNS controls))) (VP (AUX were) (VP (VBN recruited) (PP (IN over) (NP (NP (CD 32) (NNS months)) (PRN (-LRB- -LRB-) (JJ 1992-1994) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Belgium))))) (. .)))
9727773	4	(S1 (S (NP (NP (NN Exposure)) (PP (TO to) (NP (NNP Doc_9727773_546_567_Chemical)))) (VP (AUX was) (VP (VBN assessed) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (NN hospital) (NNS records)) (CC and) (NP (JJ standardized) (NN interview)))))))) (. .)))
9727773	5	(S1 (S (NP (NP (NN Twenty-three)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (ADVP (RB previously)) (VP (VBN taken) (ADJP (JJ Doc_9727773_692_713_Chemical) (, ,) (RB mainly) (JJ Doc_9727773_722_735_Chemical) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (QP (RB only) (CD 5))) (PP (IN of) (NP (NP (DT the) (NNS controls)) (PRN (-LRB- -LRB-) (NP (QP (CD 66) (CC versus) (CD 6)) (NN %)) (, ,) (NP (CD p<0.0001)) (-RRB- -RRB-)))))))))))) (. .)))
9727773	6	(S1 (S (NP (NP (NP (CD Five) (NNS patients)) (VP (VBN died) (PP (IN before) (NP (DT the) (NN interview))))) (, ,) (NP (NP (DT all)) (PP (IN of) (NP (PRP them))))) (VP (AUX had) (VP (VBN taken) (NP (NNP Doc_9727773_866_887_Chemical)))) (. .)))
9727773	7	(S1 (S (PP (IN In) (NP (NP (CD 8) (NNS patients)) (SBAR (S (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_9727773_920_950_Disease)))) (VP (AUX was) (ADJP (JJ uncertain))))))) (, ,) (NP (NP (CD 5)) (PP (IN of) (NP (PRP them)))) (VP (AUX had) (VP (VBN taken) (NP (NN Doc_9727773_986_1007_Chemical)))) (. .)))
9727773	8	(S1 (S (NP (NP (DT The) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_9727773_1046_1067_Chemical))))))))) (VP (VBD tended) (S (VP (VP (TO to) (VP (AUX be) (PP (IN on) (NP (NN average))) (ADVP (ADVP (RBR more) (RB severely)) (JJ ill)))) (, ,) (CC and) (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJR shorter) (JJ median) (NN delay)) (PP (IN between) (NP (NP (NN onset)) (PP (IN of) (NP (NP (NNS symptoms)) (CC and) (NP (NN diagnosis)))))))))))) (. .)))
9727773	9	(S1 (S (NP (NP (DT A) (NN policy)) (PP (IN of) (NP (NP (JJ unrestricted) (NN prescription)) (PP (IN of) (NP (NNP Doc_9727773_1228_1249_Chemical)))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (JJ associated) (NNP Doc_9727773_1293_1323_Disease))))))) (. .)))
9727773	10	(S1 (S (NP (NP (NN Intake)) (PP (IN of) (NP (NNP Doc_9727773_1335_1356_Chemical)))) (VP (MD may) (VP (VB accelerate) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (DT the) (NN disease)))))) (. .)))
9746003	0	(S1 (NP (NP (JJ Inappropriate) (NN use)) (PP (IN of) (NP (NP (NNP Doc_9746003_21_34_Chemical)) (CC and) (NP (NNP Doc_9746003_39_49_Chemical)))) (PP (IN in) (NP (JJ typical) (NNP Doc_9746003_61_77_Disease))) (. .)))
9746003	1	(S1 (S (NP (NP (NNP Doc_9746003_79_92_Chemical)) (CC and) (NP (NNP Doc_9746003_97_107_Chemical))) (VP (AUX are) (VP (VBN contraindicated) (PP (IN in) (NP (JJ typical) (NN Doc_9746003_139_155_Disease))))) (. .)))
9746003	2	(S1 (S (PP (IN Of) (NP (NP (CD 18) (JJ consecutive) (NNS referrals)) (PP (IN of) (NP (NP (NNS children)) (PP (IN with) (NP (JJ resistant) (JJ typical) (NNS absences))))))) (ADVP (RB only)) (, ,) (NP (CD eight)) (VP (AUX were) (UCP (VP (ADVP (RB erroneously)) (VBN treated) (PP (IN with) (NP (NNP Doc_9746003_271_284_Chemical)))) (CC either) (RB as) (ADJP (JJ monotherapy)) (CC or) (PP (IN as) (NP (DT an) (JJ add-on))))) (. .)))
9746003	3	(S1 (S (NP (NN Doc_9746003_324_334_Chemical)) (VP (AUX was) (ADVP (RB also)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (CD two) (NNS children))))))) (. .)))
9746003	4	(S1 (S (S (NP (NP (NN Frequency)) (PP (IN of) (NP (NNS absences)))) (VP (VBD increased) (PP (IN in) (NP (CD four) (NNS children))) (PP (VBN treated) (PP (IN with) (NP (NNP Doc_9746003_445_458_Chemical)))))) (CC and) (S (NP (NP (CD two)) (PP (IN of) (NP (DT these)))) (VP (VBD developed) (NP (NP (NNP Doc_9746003_486_501_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (PP (IN on) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_9746003_535_548_Chemical))))))))))) (. .)))
9746003	5	(S1 (S (NP (NNS Absences)) (VP (AUX were) (VP (VBN aggravated) (PP (IN in) (NP (NP (DT both) (NNS cases)) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_9746003_595_605_Chemical)) (VP (AUX was) (VP (VBN added) (PRT (RP on)) (PP (TO to) (NP (JJ concurrent) (NN treatment))))))))))) (. .)))
9746003	6	(S1 (S (NP (NP (JJ Optimal) (NN control)) (PP (IN of) (NP (DT the) (NNS absences)))) (VP (AUX was) (VP (VBN achieved) (PP (IN with) (NP (NP (NP (NNP Doc_9746003_694_710_Chemical)) (, ,) (NP (NNP Doc_9746003_712_723_Chemical)) (, ,) (CC or) (NP (NNP Doc_9746003_728_740_Chemical))) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NN combination)))))))) (. .)))
9754849	0	(S1 (S (NP (NN Doc_9754849_0_24_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ rapid) (NN adjustment)) (PP (TO to) (NP (NNP Doc_9754849_61_70_Chemical)))))) (. .)))
9754849	1	(S1 (S (NP (NN Doc_9754849_72_98_Disease)) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (NP (JJ occasional) (NNP Doc_9754849_126_148_Disease)) (PP (IN during) (NP (NP (NNS intoxications)) (PP (IN with) (NP (UCP (JJ Doc_9754849_175_182_Chemical) (CC but) (RB not)) (NNS opiates)))))))))) (. .)))
9754849	2	(S1 (S (S (NP (DT This)) (VP (AUX is) (NP (NP (DT a) (NN case) (NN report)) (PP (IN of) (NP (NN euphoria)))))) (CC and) (S (NP (NNP Doc_9754849_238_262_Disease)) (VP (ADVP (DT both) (RB transiently)) (VBN induced) (PP (IN by) (NP (NP (JJ rapid) (NN adjustment)) (PP (TO to) (NP (NP (DT the) (JJ selective) (JJ mu-opioid) (NN receptor) (NN agonist) (NNP Doc_9754849_352_361_Chemical)) (PP (IN in) (NP (NP (DT an) (NN inpatient)) (VP (ADVP (RB previously)) (VBG abusing) (NP (NP (NNP Doc_9754849_397_404_Chemical)) (CC and) (NP (NNP Doc_9754849_409_416_Chemical)))))))))))) (. .)))
9754849	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ minor) (NNP EEG) (NNS abnormalities)) (VP (VBD occurred)) (. .)))
9754849	4	(S1 (S (NP (JJ Possible) (JJ underlying) (NN neurobiological) (NNS phenomena)) (VP (AUX are) (VP (VBN discussed))) (. .)))
9766615	0	(S1 (NP (NP (JJ Adverse) (NNS effects)) (PP (IN of) (NP (DT the) (JJ atypical) (NNS antipsychotics))) (. .)))
9766615	1	(S1 (NP (NP (NNP Collaborative) (NNP Working) (NNP Group)) (PP (IN on) (NP (JJ Clinical) (NN Trial) (NNS Evaluations))) (. .)))
9766615	2	(S1 (S (NP (NP (JJ Adverse) (NNS effects)) (PP (IN of) (NP (NNS antipsychotics)))) (ADVP (RB often)) (VP (VBP lead) (S (VP (TO to) (VP (VB noncompliance))))) (. .)))
9766615	3	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNS clinicians)) (VP (MD should) (VP (VP (VB address) (NP (NP (NP (NNS patients) (POS ')) (NNS concerns)) (PP (IN about) (NP (JJ adverse) (NNS effects))))) (CC and) (VP (VB attempt) (S (VP (TO to) (VP (VB choose) (NP (NP (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (MD will) (VP (VB improve) (NP (NP (NP (NP (PRP$ their) (NNS patients) (POS ')) (NN quality)) (PP (IN of) (NP (NN life)))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ overall) (NN health)))))))))))))) (. .)))
9766615	4	(S1 (S (NP (NP (DT The) (JJ side) (NN effect) (NNS profiles)) (PP (IN of) (NP (DT the) (JJ atypical) (NNS antipsychotics)))) (VP (AUX are) (ADJP (ADJP (RBR more) (JJ advantageous)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (JJ conventional) (NNS neuroleptics))))))) (. .)))
9766615	5	(S1 (S (NP (JJ Conventional) (NNS agents)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (NP (JJ unwanted) (JJ central) (JJ nervous) (NN system) (NNS effects)) (, ,) (PP (VBG including) (NP (NP (NP (NNP Doc_9766615_568_591_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9766615_593_596_Disease)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_9766615_599_617_Disease)) (, ,) (NP (NP (NN sedation)) (, ,) (CC and) (NP (NP (JJ possible) (NN impairment)) (PP (IN of) (NP (DT some) (JJ cognitive) (NNS measures)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ cardiac) (NNS effects))) (, ,) (NP (NNP Doc_9766615_709_732_Disease)) (, ,) (NP (JJ hepatic) (NNS changes)) (, ,) (NP (NN anticholinergic) (NN side) (NNS effects)) (, ,) (NP (NNP Doc_9766615_781_799_Disease)) (, ,) (CC and) (NP (NNP Doc_9766615_805_816_Disease)))))))) (. .)))
9766615	6	(S1 (S (S (NP (DT The) (JJR newer) (JJ atypical) (NNS agents)) (VP (VP (AUX have) (NP (NP (DT a) (JJR lower) (NN risk)) (PP (IN of) (NP (NNP Doc_9766615_865_868_Disease))))) (, ,) (CC but) (VP (AUX are) (VP (VBN associated) (PP (IN in) (NP (VBG varying) (NNS degrees))) (PP (IN with) (NP (NP (NN sedation)) (, ,) (NP (JJ cardiovascular) (NNS effects)) (, ,) (NP (JJ anticholinergic) (NNS effects)))))))) (, ,) (NP (NP (NNP Doc_9766615_972_983_Disease)) (, ,) (NP (NNP Doc_9766615_985_1003_Disease)) (, ,) (NP (JJ hepatic) (NNS effects)) (, ,)) (VP (VBD lowered) (NP (NP (NP (JJ Doc_9766615_1030_1037_Disease) (NN threshold)) (PRN (-LRB- -LRB-) (ADVP (RB primarily)) (NP (NNP Doc_9766615_1059_1068_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_9766615_1075_1090_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9766615_1092_1101_Chemical) (RB only)) (-RRB- -RRB-))))) (. .)))
9766615	7	(S1 (S (SBAR (IN Since) (S (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (JJ specific) (JJ adverse) (NNS effects)))) (VP (VBP differ) (PP (IN among) (NP (DT the) (JJ various) (NNS atypicals)))))) (, ,) (NP (DT the) (NN clinician)) (VP (MD should) (ADVP (RB carefully)) (VP (VB consider) (SBAR (WHNP (WDT which)) (S (NP (NN side) (NNS effects)) (VP (AUX are) (ADJP (RBS most) (JJ likely) (S (VP (TO to) (VP (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN individual) (POS 's)) (NN dissatisfaction)))) (CC and) (VP (VB noncompliance) (PP (IN before) (S (VP (VBG choosing) (NP (NP (DT an) (NN antipsychotic)) (PP (IN for) (NP (DT a) (JJ particular) (NN patient))))))))))))))))) (. .)))
9812111	0	(S1 (NP (NP (DT A) (JJ randomized) (, ,) (JJ placebo-controlled) (NN dose-comparison) (NN trial)) (PP (IN of) (NP (NNP Doc_9812111_58_69_Chemical))) (PP (IN for) (NP (NP (NP (NNP Doc_9812111_74_83_Disease)) (CC and) (NP (NNP Doc_9812111_88_108_Disease))) (PP (IN in) (NP (NNP Doc_9812111_112_131_Disease))))) (. .)))
9812111	1	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN efficacy) (CC and) (NN side) (NNS effects)) (PP (IN of) (NP (NP (NP (CD two) (NNS doses)) (PP (IN of) (NP (NNP Doc_9812111_228_239_Chemical)))) (CC and) (NP (NP (NN placebo)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_9812111_272_281_Disease) (CC and) (NNP Doc_9812111_286_306_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9812111_324_343_Disease))))))))))))))))) (. .)))
9812111	2	(S1 (S (PP (IN In) (NP (DT a) (JJ 6-week) (NN random-assignment))) (, ,) (NP (NP (NP (JJ double-blind) (, ,) (JJ placebo-controlled) (NN trial)) (PRN (-LRB- -LRB-) (NP (NN phase)) (NP (DT A)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_9812111_434_445_Chemical)) (, ,) (NP (NP (CD 2-3) (NN mg/day)) (PRN (-LRB- -LRB-) (NP (JJ standard) (NN dose)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_9812111_479_490_Chemical)) (, ,) (NP (NP (CD 0.50-0.75) (NN mg/day)) (PRN (-LRB- -LRB-) (NP (JJ low) (NN dose)) (-RRB- -RRB-))) (, ,)) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (CD 71) (NNS outpatients)) (PP (IN with) (NP (NNP Doc_9812111_558_577_Disease))))))) (. .)))
9812111	3	(S1 (S (PP (IN For) (NP (NP (DT the) (JJ subsequent) (JJ 6-week) (NN double-blind) (NN crossover) (NN phase)) (PRN (-LRB- -LRB-) (NP (NN phase) (NN B)) (-RRB- -RRB-)))) (, ,) (S (NP (NP (NNS patients)) (VP (VBG taking) (NP (ADJP (JJ standard-) (CC or) (JJ low-dose)) (NNP Doc_9812111_683_694_Chemical)))) (VP (AUX were) (VP (VBN switched) (PP (TO to) (NP (NN placebo)))))) (, ,) (CC and) (S (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN placebo)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (ADJP (JJ standard-) (CC or) (JJ low-dose)) (NNP Doc_9812111_797_808_Chemical)))))) (. .)))
9812111	4	(S1 (S (PP (IN For) (NP (NP (DT the) (CD 60) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD completed) (NP (NN phase) (DT A))))))) (, ,) (NP (JJ standard-dose) (NNP Doc_9812111_876_887_Chemical)) (VP (AUX was) (ADJP (ADJP (JJ efficacious)) (CC and) (ADJP (JJ superior) (PP (TO to) (NP (NP (DT both) (JJ low-dose) (NN Doc_9812111_934_945_Chemical) (CC and) (NN placebo)) (PP (IN for) (NP (NP (NNS scores)) (PP (PP (IN on) (NP (DT the) (JJ Brief) (NNP Psychiatric) (NNP Rating) (NNP Scale) (NNP Doc_9812111_1007_1016_Disease) (NN factor))) (CC and) (PP (IN on) (NP (NNP Doc_9812111_1031_1052_Disease))))))))))) (. .)))
9812111	5	(S1 (S (NP (NP (NN Response) (NNS rates)) (VP (VBG according) (PP (TO to) (NP (NP (CD three) (NNS sets)) (PP (IN of) (NP (NNS criteria))))))) (VP (AUX were) (ADJP (ADJP (JJR greater)) (PP (IN with) (NP (NP (DT the) (JJ standard) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 55) (NN %)) (NP (CD -60) (NN %))) (-RRB- -RRB-)))) (PP (IN than) (NP (NP (NP (DT the) (JJ low) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 25) (NN %)) (NP (CD -35) (NN %))) (-RRB- -RRB-))) (CC and) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (CD 25) (NN %)) (NP (CD -30) (NN %))) (-RRB- -RRB-))))))) (. .)))
9812111	6	(S1 (S (NP (NP (DT The) (NN advantage)) (PP (IN of) (NP (JJ standard) (NN dose))) (PP (IN over) (NP (JJ low) (NN dose)))) (VP (AUX was) (VP (VBN replicated) (PP (IN in) (NP (NN phase) (NN B))))) (. .)))
9812111	7	(S1 (S (PP (IN In) (NP (NN phase) (DT A))) (, ,) (NP (NNP Doc_9812111_1286_1306_Disease)) (VP (VBD tended) (S (VP (TO to) (VP (AUX be) (ADJP (JJR greater) (PP (IN with) (NP (DT the) (JJ standard) (NN dose))) (PP (IN than) (PP (IN in) (NP (DT the) (JJ other) (CD two) (NNS conditions)))))))) (, ,) (PP (ADVP (RB primarily)) (IN because) (IN of) (NP (NP (DT a) (NN subgroup)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (ADJP (JJ moderate) (TO to) (JJ severe)) (NNS signs)))))))) (. .)))
9812111	8	(S1 (S (NP (NNP Low-dose) (NNP Doc_9812111_1472_1483_Chemical)) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN from) (NP (NN placebo))) (PP (IN on) (NP (NP (DT any) (NN measure)) (PP (IN of) (NP (NP (NN efficacy)) (CC or) (NP (NN side) (NNS effects)))))))) (. .)))
9812111	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBD indicated) (NP (NP (DT a) (JJ favorable) (JJ therapeutic) (NN profile)) (PP (IN for) (NP (NNP Doc_9812111_1627_1638_Chemical)))) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 2-3) (NN mg/day))))) (, ,) (SBAR (IN although) (S (NP (DT a) (NN subgroup)) (VP (VBD developed) (ADVP (JJ moderate) (PP (TO to) (NP (JJ severe) (NN Doc_9812111_1712_1732_Disease)))))))) (. .)))
9812111	10	(S1 (S (NP (NP (DT A) (JJ starting) (NN dose)) (PP (IN of) (NP (CD 1) (NN mg/day))) (PP (IN with) (NP (JJ gradual) (, ,) (JJ upward) (NN dose) (NN titration)))) (VP (AUX is) (VP (VBN recommended))) (. .)))
9812111	11	(S1 (S (NP (NP (DT The) (JJ narrow) (JJ therapeutic) (NN window)) (VP (VBN observed) (PP (IN with) (NP (NNP Doc_9812111_1858_1869_Chemical))))) (VP (MD may) (ADVP (RB also)) (VP (VB apply) (PP (TO to) (NP (NP (JJ other) (NNS neuroleptics)) (VP (VBN used) (PP (IN in) (NP (NP (JJ Doc_9812111_1915_1934_Disease) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9812111_1949_1958_Disease)) (CC and) (NP (NNP Doc_9812111_1963_1983_Disease))))))))))) (. .)))
983936	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (NNP Doc_983936_11_31_Chemical)) (, ,) (NP (NNP Doc_983936_33_45_Chemical)) (, ,) (CC and) (NP (NNP Doc_983936_51_65_Chemical)))) (PP (IN on) (NP (NP (NNP Doc_983936_69_80_Chemical-induced) (NNP Doc_983936_89_106_Disease)) (PP (IN in) (NP (NNS dogs))))) (. .)))
983936	1	(S1 (S (NP (NP (DT A) (JJ reproducible) (NN model)) (PP (IN for) (S (VP (VBG producing) (NP (JJ diffuse) (NN Doc_983936_159_176_Disease)))))) (PRN (-LRB- -LRB-) (NP (JJ Doc_983936_178_189_Chemical) (NN infusion)) (-RRB- -RRB-)) (VP (AUX has) (VP (AUX been) (VP (VBN developed) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (JJ cardioprotective) (NNS effects)) (PP (IN of) (NP (NP (NNS agents)) (CC or) (NP (NNS maneuvers)))) (SBAR (WHNP (WDT which)) (S (VP (MD might) (VP (VB alter) (NP (NP (DT the) (NN evolution)) (PP (IN of) (NP (JJ acute) (NNP Doc_983936_321_342_Disease))))))))))))))) (. .)))
983936	2	(S1 (S (NP (NP (NNS Infusions)) (PP (IN of) (NP (NNP Doc_983936_357_368_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 4) (NN mug)) (PP (IN per) (NP (FW kilogram) (FW per) (NN minute))) (PP (IN for) (NP (CD 6) (NNS hours)))) (-RRB- -RRB-))) (VP (VBD increased) (NP (JJ Doc_983936_423_435_Chemical) (NNS uptakes)) (PP (IN into) (NP (NP (JJ intact) (NN myocardium)) (CC and) (NP (NP (DT each)) (PP (IN of) (NP (PRP$ its) (JJ subcellular) (NNS components)))))) (PP (IN with) (S (NP (DT the) (JJ mitochondrial) (NN fraction)) (VP (VBG showing) (NP (DT the) (ADJP (RBS most) (JJ consistent)) (NNS changes)) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ saline-infused) (NN control) (NNS animals)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 4,957) (CC vs.) (CD 827)) (NNS counts)) (PP (IN per) (NP (NN minute))) (PP (IN per) (NP (NP (NN gram)) (PP (IN of) (NP (VBN dried) (NN tissue) (CC or) (NN fraction)))))) (-RRB- -RRB-))))))))))) (. .)))
983936	3	(S1 (S (NP (NP (JJ Myocardial) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_983936_723_730_Chemical)))) (ADVP (RB also)) (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 12.0) (CC vs.) (CD 5.0) (JJR mg.per) (CD 100)) (NNP Gm.)) (PP (IN of) (NP (JJ fat-free) (JJ dry) (NN weight)))) (-RRB- -RRB-))) (. .)))
983936	4	(S1 (S (NP (NP (NP (NNS Infusions)) (PP (IN of) (NP (NNP Doc_983936_827_843_Chemical))) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB raise) (NP (JJ serum) (JJ Doc_983936_870_877_Chemical) (NNS concentrations)))))) (QP (CD 2) (CD mEq.))) (PP (IN per) (NP (NN liter)))) (VP (VBD failed) (S (VP (TO to) (VP (VB increase) (NP (JJ Doc_983936_929_936_Chemical) (NN influx)) (PP (IN into) (NP (DT the) (JJ myocardial) (NN cell))))))) (. .)))
983936	5	(S1 (S (NP (JJ Mitochondrial) (JJ Doc_983936_984_996_Chemical) (NNS uptakes)) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN decreased) (UCP (PP (IN in) (NP (NP (NNS animals)) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_983936_1061_1081_Chemical) (CC or) (NNP Doc_983936_1085_1097_Chemical)))))) (CC or) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_983936_1106_1120_Chemical)) (VP (AUX was) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (JJ Doc_983936_1138_1149_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (NP (CD 2,682,2,803) (, ,) (CC and) (CD 3,424) (NNS counts)) (PP (IN per) (NP (NN minute))) (PP (IN per) (NP (NP (NN gram)) (PP (IN of) (NP (VBN dried) (NN fraction)))))) (, ,) (RB respectively) (-RRB- -RRB-))))))))))) (. .)))
983936	6	(S1 (S (NP (JJ Myocardial) (JJ Doc_983936_1255_1262_Chemical) (NNS concentrations)) (ADVP (RB also)) (VP (AUX were) (ADJP (VBN decreased) (PRN (-LRB- -LRB-) (NP (NP (CD 11.2)) (, ,) (NP (CD 8.3)) (, ,) (CC and) (NP (NP (CD 8.9) (NN mg.)) (PP (IN per) (NP (NP (CD 100) (NNP Gm.)) (PP (IN of) (NP (JJ fat-free) (JJ dry) (NN weight)))))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (CD three) (NN treatment) (NNS groups))) (, ,) (S (VP (AUXG being) (VP (ADVP (RB significantly)) (VBN decreased) (PP (ADVP (RB only)) (IN in) (NP (DT the) (JJ last) (CD two))))))) (. .)))
983936	7	(S1 (S (NP (NP (NN Evidence)) (PP (IN of) (NP (JJ microscopic) (NN damage)))) (VP (AUX was) (VP (VBN graded) (PP (IN as) (ADJP (RBR less) (JJ severe))) (PP (IN in) (NP (DT the) (CD three) (NN treatment) (NNS groups))))) (. .)))
983936	8	(S1 (S (NP (NP (NNP Doc_983936_1543_1563_Chemical)) (, ,) (NP (NNP Doc_983936_1565_1577_Chemical)) (, ,) (CC and) (NP (NNP Doc_983936_1583_1597_Chemical))) (DT all) (VP (VBP appear) (S (VP (TO to) (VP (AUX have) (NP (JJ cardioprotective) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN tested) (PP (IN in) (NP (DT this) (NN model)))))))))) (. .)))
9855119	0	(S1 (S (NP (NP (ADJP (JJ Clinical) (CC and) (JJ histopathologic)) (NN examination)) (PP (IN of) (NP (JJ renal) (NNS allografts)))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_9855119_74_84_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9855119_86_91_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (QP (IN at) (JJS least) (CD one)) (NN year)))) (. .)))
9855119	1	(S1 (S (NP (PRP We)) (ADVP (RB clinically) (CC and) (RB pathologically)) (VP (VBD analyzed) (NP (NP (JJ renal) (NNS allografts)) (PP (IN from) (NP (NP (QP (CD 1) (CD 9)) (JJ renal) (NN transplant) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_9855119_235_245_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9855119_247_252_Chemical)) (-RRB- -RRB-)))) (PP (IN for) (NP (QP (JJR more) (IN than) (CD 1)) (NN year)))))))) (. .)))
9855119	2	(S1 (S (NP (NP (JJ Twenty-six) (JJ renal) (NN allograft) (NN biopsy) (NNS specimens)) (PP (IN from) (NP (NP (QP (CD 1) (CD 9)) (JJ renal) (NN transplant) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NNS transplantations)) (PP (IN between) (NP (NP (CD 1991)) (CC and) (NP (CD 1993)))))))))) (VP (AUX were) (VP (VBN evaluated))) (. .)))
9855119	3	(S1 (S (S (NP (JJ Thirteen) (NNS biopsies)) (VP (AUX were) (VP (VBN performed) (PP (IN from) (NP (JJ stable) (VBG functioning) (JJ renal) (NNS allografts))) (PP (IN with) (NP (NP (JJ informed) (NN consent)) (PRN (-LRB- -LRB-) (NP (JJ nonepisode) (NN biopsy)) (-RRB- -RRB-))))))) (CC and) (S (NP (DT the) (JJ other) (CD 13)) (VP (AUX were) (PP (IN from) (NP (NP (JJ dysfunctional) (JJ renal) (NNS allografts)) (PP (IN with) (NP (NP (DT a) (JJ clinical) (NN indication)) (PP (IN for) (NP (NP (NN biopsy)) (PRN (-LRB- -LRB-) (NP (NN episode) (NN biopsy)) (-RRB- -RRB-)))))))))) (. .)))
9855119	4	(S1 (S (NP (NP (DT The) (JJ main) (JJ pathologic) (NNS diagnoses)) (PRN (-LRB- -LRB-) (S (NP (DT some)) (VP (VBP overlap))) (-RRB- -RRB-))) (VP (AUX were) (NP (NP (JJ acute) (NN rejection)) (PRN (-LRB- -LRB-) (NP (NNP AR)) (: ;) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)) (, ,) (NP (NN chronic) (NN rejection)) (PRN (-LRB- -LRB-) (NP (NNP CR)) (: ;) (NP (CD n=5)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NNP AR+CR)) (PRN (-LRB- -LRB-) (NP (NNP n) (CD =4)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (JJ recurrent) (NNP Doc_9855119_804_819_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (CD =5)) (-RRB- -RRB-))) (, ,) (NP (JJ normal) (NNS findings)) (PRN (-LRB- -LRB-) (NP (NNP n) (CD =2)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ minimal-type) (NN chronic) (NNP Doc_9855119_873_878_Chemical) (NNP Doc_9855119_879_890_Disease)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 9)) (-RRB- -RRB-)))) (, ,) (CC and) (NP (JJ mild-type) (NNP Doc_9855119_914_919_Chemical) (NNP Doc_9855119_920_931_Disease))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 11)) (-RRB- -RRB-)))) (. .)))
9855119	5	(S1 (S (PP (IN Of) (NP (DT the) (JJ nonepisode) (NNS biopsies))) (, ,) (NP (QP (CD 7) (CC and) (CD 4)) (NNS biopsies)) (VP (VBD showed) (NP (NP (NN minimal-type)) (CC and) (NP (JJ mild-type) (NN chronic) (NNP Doc_9855119_1029_1034_Chemical) (NNP Doc_9855119_1035_1046_Disease))) (, ,) (ADVP (RB respectively))) (. .)))
9855119	6	(S1 (S (NP (JJ Chronic) (NNP Doc_9855119_1070_1075_Chemical) (NNP Doc_9855119_1076_1087_Disease)) (VP (VBD consisted) (PP (IN of) (NP (NP (NP (JJ rough) (CC and) (JJ foamy) (JJ tubular) (NN vacuolization)) (PRN (-LRB- -LRB-) (NP (CD 5) (NNS biopsies)) (-RRB- -RRB-))) (, ,) (NP (NP (NN arteriolopathy)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN angiodegeneration)) (PP (IN of) (NP (DT the) (JJ arteriolar) (NN wall)))) (: ;) (NP (CD 20) (NNS biopsies))) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_9855119_1225_1259_Disease) (PRN (-LRB- -LRB-) (NP (CD 4) (NNS biopsies)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ striped) (NN form)) (PP (IN of) (NP (NP (NNP Doc_9855119_1297_1318_Disease)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS biopsies)) (-RRB- -RRB-)))))))) (. .)))
9855119	7	(S1 (S (NP (NP (DT The) (JJ serum) (JJ Doc_9855119_1344_1354_Chemical) (NNS levels)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (JJ mild-type) (NN chronic) (NNP Doc_9855119_1399_1404_Chemical) (NNP Doc_9855119_1405_1416_Disease) (NN group))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD included) (NP (ADJP (CD 7) (NN episode)) (NNS biopsies))))) (, ,)) (VP (AUX were) (ADJP (ADJP (RB statistically) (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (JJ minimum-type) (NN chronic) (NN Doc_9855119_1524_1529_Chemical-Doc_9855119_1530_1541_Disease) (NN group)))))) (PRN (-LRB- -LRB-) (NP (NNP P<) (CD 0.001)) (-RRB- -RRB-))) (. .)))
9855119	8	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NN chronic) (NNP Doc_9855119_1610_1615_Chemical) (NNP Doc_9855119_1616_1627_Disease)) (VP (VBZ consists) (ADVP (RB primarily)) (PP (IN of) (NP (NP (NN arteriolopathy)) (VP (VBG manifesting) (PP (IN as) (NP (NP (JJ insudative) (NN hyalinosis)) (PP (IN of) (NP (DT the) (JJ arteriolar) (NN wall)))))))))))) (, ,) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN mild-type) (NN chronic) (NNP Doc_9855119_1762_1767_Chemical) (NNP Doc_9855119_1768_1779_Disease)) (VP (AUX is) (NP (NP (DT a) (NN condition)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NN deterioration)) (PP (IN of) (NP (JJ renal) (NN allograft) (NN function))))))))))))))) (. .)))
9862868	0	(S1 (NP (NP (JJ Different) (NN lobular) (NNS distributions)) (PP (IN of) (NP (NP (JJ altered) (JJ hepatocyte) (JJ tight) (NNS junctions)) (PP (IN in) (NP (NP (NN rat) (NNS models)) (PP (IN of) (NP (NNP Doc_9862868_87_128_Disease))))))) (. .)))
9862868	1	(S1 (S (NP (NP (NP (JJ Hepatocyte) (JJ tight) (NNS junctions)) (PRN (-LRB- -LRB-) (NP (NNP TJs)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (RB only) (JJ intercellular) (NN barrier)) (PP (IN between) (NP (NP (DT the) (NN sinusoidal)) (CC and) (NP (DT the) (JJ canalicular) (NNS spaces))))) (, ,)) (VP (VBP play) (NP (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (NN bile) (NN formation))))) (. .)))
9862868	2	(S1 (S (SBAR (IN Although) (S (NP (NN hepatocyte) (NNS TJs)) (VP (AUX are) (VP (VBN impaired) (PP (IN in) (NP (NNP Doc_9862868_321_332_Disease))))))) (, ,) (NP (NP (NNS attempts)) (SBAR (S (VP (TO to) (VP (VB localize) (NP (NP (DT the) (JJ precise) (NN site)) (PP (IN of) (NP (JJ hepatocyte) (JJ TJ) (NN damage)))) (PP (IN by) (NP (JJ freeze-fracture) (NNP electron) (NN microscopy)))))))) (VP (AUX have) (VP (VBN produced) (NP (JJ limited) (NN information)))) (. .)))
9862868	3	(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (JJ several) (JJ TJ-associated) (NNS proteins)) (PP (IN like) (NP (NP (NN ZO-1)) (CC and) (NP (NN 7H6))))) (VP (AUX have) (VP (AUX been) (VP (VP (VBN identified)) (CC and) (VP (VBN characterized))))) (. .)))
9862868	4	(S1 (S (NP (NP (NN Immunolocalization)) (PP (IN of) (NP (NNS 7H6)))) (VP (VBZ appears) (S (VP (TO to) (ADVP (RB closely)) (VP (VB correlate) (PP (IN with) (NP (JJ paracellular) (NN permeability))))))) (. .)))
9862868	5	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (NP (NN rat) (NNS models)) (PP (IN of) (NP (NP (NP (NNP Doc_9862868_678_702_Disease)) (PP (IN by) (NP (NNP Doc_9862868_706_723_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9862868_725_727_Chemical)) (-RRB- -RRB-)) (NN treatment)))) (CC and) (NP (NP (NP (NNP Doc_9862868_743_767_Disease)) (PP (IN by) (NP (JJ bile) (NN duct) (NN ligation)))) (PRN (-LRB- -LRB-) (NP (NNP BDL)) (-RRB- -RRB-)))))) (S (VP (TO to) (ADVP (RB precisely)) (VP (VB determine) (NP (NP (DT the) (NN site)) (PP (IN of) (NP (JJ TJ) (NN damage)))))))) (. .)))
9862868	6	(S1 (S (NP (NP (NNS Alterations)) (PP (IN in) (NP (JJ hepatocyte) (NNS TJs)))) (VP (AUX were) (VP (VBN assessed) (PP (IN by) (S (VP (VP (VBG double-immunolabeling) (PP (IN for) (NP (NN 7H6)))) (CC and) (VP (ADVP (JJ ZO-1)) (VBG using) (NP (DT a) (JJ confocal) (NN laser) (VBG scanning) (NN microscope)))))))) (. .)))
9862868	7	(S1 (S (PP (IN In) (NP (NN control) (NNS rats))) (, ,) (NP (NP (NN immunostaining)) (PP (IN for) (NP (NP (NN 7H6)) (CC and) (NP (NN ZO-1))))) (VP (VBD colocalized) (S (VP (TO to) (VP (VB outline) (NP (JJ bile) (NNS canaliculi)) (PP (IN in) (NP (DT a) (JJ continuous) (NN fashion))))))) (. .)))
9862868	8	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NN 7H6)) (CC and) (NP (JJ ZO-1) (NN immunostaining))) (VP (AUX was) (ADJP (RBR more) (JJ discontinuous)) (, ,) (S (VP (VBG outlining) (NP (DT the) (JJ bile) (NNS canaliculi)) (PP (IN after) (NP (NN BDL)))))) (. .)))
9862868	9	(S1 (S (NP (NP (NN Immunostaining)) (PP (IN for) (NP (NN 7H6))) (, ,) (ADJP (RB not) (JJ ZO-1)) (, ,)) (VP (VP (VBD decreased)) (CC and) (ADVP (RB predominantly)) (VP (VBD appeared) (PP (IN as) (NP (JJ discrete) (NNS signals))) (PP (IN in) (NP (NP (DT the) (JJ submembranous) (NN cytoplasm)) (PP (IN of) (NP (JJ periportal) (NNS hepatocytes))) (PP (IN after) (NP (NNP BDL))))))) (. .)))
9862868	10	(S1 (S (PP (IN After) (NP (JJ Doc_9862868_1356_1358_Chemical) (NN treatment))) (, ,) (NP (NP (NNS changes)) (PP (IN in) (S (VP (VBG immunostaining) (PP (IN for) (NP (NP (NN 7H6)) (CC and) (NP (NN ZO-1)))))))) (VP (VP (AUX were) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN seen) (PP (IN in) (NP (JJ periportal) (NNS hepatocytes))))))) (PP (IN after) (NP (NNP BDL)))) (, ,) (CC but) (VP (VBN distributed) (ADVP (RBR more) (RB diffusely)) (PP (IN throughout) (NP (DT the) (NN lobule))))) (. .)))
9862868	11	(S1 (S (NP (DT This) (NN study)) (VP (AUX is) (NP (NP (DT the) (JJ first)) (SBAR (S (VP (TO to) (VP (VB demonstrate) (SBAR (IN that) (S (NP (NP (NN impairment)) (PP (IN of) (NP (JJ hepatocyte) (NNS TJs)))) (VP (VP (VBZ occurs) (ADVP (RB heterogenously)) (PP (IN in) (NP (DT the) (NN liver) (NN lobule))) (PP (IN after) (NP (NN BDL)))) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP BDL) (CC and) (NNP Doc_9862868_1682_1684_Chemical) (NNS treatments)) (VP (VBP produce) (NP (NP (JJ different) (NN lobular) (NNS distributions)) (PP (IN of) (NP (VBN increased) (JJ paracellular) (NN permeability))))))))))))))))) (. .)))
9869257	0	(S1 (S (NP (NP (NN Memory) (NN facilitation) (CC and) (NN stimulation)) (PP (IN of) (NP (JJ endogenous) (NN nerve) (NN growth)))) (VP (VB factor) (NP (NN synthesis)) (PP (IN by) (NP (DT the) (NNP Doc_9869257_87_100_Chemical) (NNP releaser) (NNP Doc_9869257_110_114_Chemical)))) (. .)))
9869257	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_9869257_131_135_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9869257_137_178_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT the) (NNP Doc_9869257_185_198_Chemical) (NN releaser)) (, ,))) (PP (IN on) (NP (NP (NN memory) (NNS processes)) (CC and) (NP (NN nerve) (NN growth) (NN factor) (-LRB- -LRB-) (NN NGF) (-RRB- -RRB-) (NN synthesis))))) (VP (AUX were) (VP (VBN evaluated))) (. .)))
9869257	2	(S1 (S (PP (IN In) (NP (DT the) (NN mouse) (NN passive-avoidance) (NN test))) (, ,) (NP (NP (NP (NNP Doc_9869257_322_326_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10-30) (NNS mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN administered) (CD 20) (NN min)) (PP (IN before) (NP (DT the) (NN training) (NN session)))) (, ,)) (VP (VBD prevented) (NP (NNP Doc_9869257_407_414_Disease)) (S (VP (VBN induced) (PP (IN by) (NP (NP (PDT both) (DT the) (JJ non) (JJ selective) (JJ antimuscarinic) (NN drug) (NNP Doc_9869257_469_480_Chemical)) (CC and) (NP (DT the) (JJ M1-selective) (JJ antagonist) (NNP Doc_9869257_513_525_Chemical))))))) (. .)))
9869257	3	(S1 (S (PP (IN In) (NP (DT the) (JJ same) (JJ experimental) (NNS conditions))) (, ,) (NP (NP (NNP Doc_9869257_564_568_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 5-20) (NN microg)) (PP (IN per) (NP (NN mouse)))) (, ,) (NP (NNP i.c.v.)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ able) (S (VP (TO to) (VP (VB prevent) (NP (JJ antimuscarine-induced) (NNP Doc_9869257_648_655_Disease)))))) (, ,) (S (VP (VBG demonstrating) (NP (NP (DT a) (JJ central) (NN localization)) (PP (IN of) (NP (DT the) (NN activity))))))) (. .)))
9869257	4	(S1 (S (PP (IN At) (NP (DT the) (JJS highest) (JJ effective) (NNS doses))) (, ,) (S (NP (NNP Doc_9869257_743_747_Chemical)) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT any) (JJ collateral) (NNS symptoms)) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN by) (NP (DT the) (NNP Irwin) (NN test))))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB modify) (NP (JJ spontaneous) (NN motility) (CC and) (NN inspection) (NN activity)) (, ,) (SBAR (IN as) (S (VP (VBN revealed) (PP (IN by) (NP (DT the) (JJ hole-board) (NN test))))))))) (. .)))
9869257	5	(S1 (S (NP (NN Doc_9869257_923_927_Chemical)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ able) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NNS NGF)) (VP (VBN secreted) (PP (IN in) (NP (NN vitro))) (PP (IN by) (NP (NNS astrocytes))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))))))))))) (. .)))
9869257	6	(S1 (S (NP (NP (DT The) (JJ maximal) (CD NGF) (NNS contents)) (VP (VBN obtained) (PP (IN by) (NP (NNP Doc_9869257_1069_1073_Chemical))))) (VP (AUX were) (ADJP (JJ 17.6-fold) (PP (IN of) (NP (DT the) (NN control) (NN value))))) (. .)))
9869257	7	(S1 (S (PP (IN During) (NP (NN culture))) (, ,) (NP (DT no) (JJ morphological) (NNS changes)) (VP (AUX were) (VP (VBN found) (PP (IN at) (NP (NP (JJ effective) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_9869257_1194_1198_Chemical))))))) (. .)))
9869257	8	(S1 (S (NP (DT The) (JJ current) (NN work)) (VP (VBZ indicates) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP Doc_9869257_1242_1246_Chemical))) (S (VP (TO to) (VP (VP (VB induce) (NP (NP (JJ beneficial) (NNS effects)) (PP (IN on) (NP (JJ cognitive) (NNS processes))))) (CC and) (VP (VB stimulate) (NP (NP (NN activity)) (PP (IN of) (NP (NN NGF) (NN synthesis))) (PP (IN in) (NP (JJ astroglial) (NNS cells)))))))))) (. .)))
9869257	9	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NNP Doc_9869257_1371_1375_Chemical)) (VP (MD could) (VP (VB represent) (NP (NP (DT a) (JJ potential) (JJ useful) (NN drug)) (ADJP (JJ able) (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (JJ impaired) (JJ cognitive) (NNS processes))))))))))) (. .)))
9931093	0	(S1 (S (NP (NP (NNS Mechanisms)) (PP (IN of) (NP (NP (NP (NNP Doc_9931093_14_20_Chemical-induced) (NNP Doc_9931093_29_41_Disease)) (PP (IN in) (NP (DT the) (NN rat.) (NN -Doc_9931093_55_65_Chemical)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_9931093_67_73_Chemical)) (-RRB- -RRB-))))) (VP (AUX is) (NP (DT a) (JJ powerful) (, ,) (ADJP (RB widely) (VBN used)) (NN immunosuppressant))) (. .)))
9931093	1	(S1 (S (NP (NP (DT The) (JJ clinical) (NN utility)) (PP (IN of) (NP (NNP Doc_9931093_145_151_Chemical)))) (VP (AUX is) (VP (VBN complicated) (PP (IN by) (NP (NP (JJ substantial) (NN Doc_9931093_182_194_Disease)) (CC and) (NP (NN Doc_9931093_199_213_Disease)))))) (. .)))
9931093	2	(S1 (S (S (VP (TO To) (VP (VB clarify) (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (JJ Doc_9931093_244_250_Chemical-induced) (NNP Doc_9931093_259_271_Disease)))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (JJ chronic) (NNS effects)) (PP (IN of) (NP (NNP Doc_9931093_307_313_Chemical))) (PP (IN on) (NP (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (JJ endothelin-1) (PRN (-LRB- -LRB-) (JJ ET-1) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN mRNA)) (PP (IN of) (NP (NP (JJ ET-1) (CC and) (JJ endothelin-converting) (NN enzyme-1)) (PRN (-LRB- -LRB-) (JJ ECE-1) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT the) (JJ endothelial) (NNP Doc_9931093_446_458_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNS eNOS)) (-RRB- -RRB-))) (NN activity)))) (, ,) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN mRNA)) (PP (IN of) (NP (NP (NNS eNOS)) (CC and) (NP (JJ C-type) (JJ natriuretic) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NNP CNP)) (-RRB- -RRB-)) (PP (IN in) (NP (NN rat) (NN blood) (NNS vessels)))))))))))) (. .)))
9931093	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (JJ specific) (NN endothelin) (NN type)))) (NP (NP (DT A) (NN receptor) (NN antagonist) (NN Doc_9931093_657_666_Chemical)) (PP (IN on) (NP (NP (NNP Doc_9931093_670_676_Chemical-induced) (NNP Doc_9931093_685_697_Disease)) (PP (IN in) (NP (NNS rats)))))) (VP (AUX was) (VP (VBN studied))) (. .)))
9931093	4	(S1 (S (NP (NP (NNP Doc_9931093_719_725_Chemical)) (, ,) (NP (NP (CD 5) (JJ mg.) (JJ kg-1.) (NN d-1)) (VP (VBN given) (PP (IN for) (NP (CD 4) (NNS weeks))))) (, ,)) (VP (VP (VBD elevated) (NP (NP (NN blood) (NN pressure)) (PP (IN from) (NP (QP (CD 102+/-13) (TO to) (CD 152+/-15)) (NNS mm)))) (NP (NNP Hg))) (CC and) (VP (VBD increased) (NP (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (NN ET-1)))) (CC and) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (JJ ET-1) (NNS mRNA))) (PP (IN in) (NP (NP (DT the) (JJ mesenteric) (NN artery)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 240) (NN %) (CC and) (CD 230) (NN %))) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))))))) (. .)))
9931093	5	(S1 (S (NP (JJ Little) (NN change)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ ECE-1) (NN mRNA)) (CC and) (NP (JJ CNP) (NN mRNA)))))))) (. .)))
9931093	6	(S1 (S (NP (NN Doc_9931093_1011_1017_Chemical)) (VP (VBD decreased) (NP (NP (NN eNOS) (NN activity)) (CC and) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NN eNOS) (NNS mRNA))) (PP (IN in) (NP (NP (DT the) (NN aorta)) (PRN (-LRB- -LRB-) (NP (NP (CD 48) (NN %)) (CC and) (NP (CD 55) (NN %))) (, ,) (RB respectively) (-RRB- -RRB-))))))) (. .)))
9931093	7	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_9931093_1134_1143_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg.) (NN kg-1.) (NN d-1)) (-RRB- -RRB-))))) (VP (VBD prevented) (NP (JJ Doc_9931093_1173_1179_Chemical-induced) (NNP Doc_9931093_1188_1200_Disease)) (PP (IN in) (NP (NNS rats)))) (. .)))
9931093	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_9931093_1238_1244_Chemical)) (VP (MD may) (VP (VB increase) (NP (NN blood) (NN pressure)) (PP (CONJP (RB not) (RB only)) (PP (IN by) (S (VP (VBG increasing) (NP (JJ ET-1) (NN production))))) (CONJP (CC but) (RB also)) (PP (IN by) (S (VP (VBG decreasing) (NP (JJ Doc_9931093_1335_1337_Chemical) (NN synthesis)) (PP (IN in) (NP (DT the) (NN vasculature)))))))))))) (. .)))
